Date,open,close,Price Change %,Article_title,Textrank_summary
2023-12-28,109.8499984741211,110.4000015258789,,,
2023-12-27,109.04000091552734,109.79000091552734,0.5006855342718867,,
2023-12-26,108.51000213623048,109.2300033569336,0.6878209773503402,,
2023-12-22,108.86000061035156,109.02999877929688,0.6635344268071939,,
2023-12-21,107.41999816894533,108.4800033569336,0.15616219731046674,,
2023-12-20,107.8499984741211,107.4000015258789,0.9867857066252586,,
2023-12-19,108.1500015258789,108.41999816894533,-0.4172433515148964,,
2023-12-18,107.63999938964844,108.05999755859376,0.24965015187892875,,
2023-12-15,107.86000061035156,107.29000091552734,0.3901878217454888,,
2023-12-14,107.83000183105467,108.5999984741211,-0.5284625362495265,"ABT Quantitative Stock Analysis - Peter Lynch | Top Stock Reports for JPMorgan, Abbott, Qualcomm & Others","Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Buyouts, Rates & Loans Aid JPMorgan (JPM), Fee Income Ails Market Share Gain, EPD Business Growth Aid Abbott (ABT) Qualcomm (QCOM) Rides on 5G Traction, Portfolio Strength Featured Reports J&J's (JNJ) Innovative Medicine & MedTech Units Drive Growth J&J's Innovative Medicine sales are being driven by existing key drugs and new products. Click to get this free report JPMorgan Chase & Co. (JPM) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report QUALCOMM Incorporated (QCOM) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report BHP Group Limited Sponsored ADR (BHP) : Free Stock Analysis Report Fomento Economico Mexicano S.A.B. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT) and Qualcomm Inc. (QCOM)."
2023-12-13,106.01000213623048,107.25,0.7140838634806218,3 No-Brainer Healthcare Stocks to Buy Right Now,"Coronavirus testing giant Abbott Laboratories (NYSE: ABT) and vaccine leaders Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE). Moderna Moderna took center stage as it brought its coronavirus vaccine from the drawing board to market in less than a year -- and the vaccine generated billions of dollars in earnings as the biotech's first and only product. Pfizer Like Moderna, Pfizer sells one of the leading coronavirus vaccines -- and Pfizer sells a billion-dollar coronavirus treatment, Paxlovid."
2023-12-12,106.37000274658205,106.68000030517578,1.1696989329139251,"Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know | ABT Quantitative Stock Analysis - Peter Lynch | ABT August 2024 Options Begin Trading | MDT, ABT: 2 Healthcare Dividend Aristocrat Stocks Hedge Funds are Bullish On | Guru Fundamental Report for ABT - Peter Lynch","Abbott (ABT) has recently been on Zacks.com's list of the most searched stocks. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Below is a chart showing ABT's trailing twelve month trading history, with the $110.00 strike highlighted in red: Considering the fact that the $110.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the August 2024 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new August 2024 contracts and identified one put and one call contract of particular interest. | Among these stocks, Medtronic (NYSE:MDT) and Abbott Laboratories (NYSE:ABT) stand out due to their status as Dividend Aristocrats (companies that have increased their dividends for over 25 consecutive years). Abbott Laboratories ABT has raised its dividend payout for 51 consecutive years, making it a perfect choice for income investors. Our data shows that Echo Street Capital Management’s Greg Poole and Bridgewater Associates’ Ray Dalio were among the hedge fund managers who increased their exposure to ABT stock. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT)."
2023-12-11,104.20999908447266,106.22000122070312,0.29143325241071955,Abbott (ABT) Advances But Underperforms Market: Key Facts,"Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. The most recent trading session ended with Abbott (ABT) standing at $106.68, reflecting a +0.43% shift from the previouse trading day's closing. Also, we should mention that ABT has a PEG ratio of 2.66."
2023-12-08,104.12000274658205,104.51000213623048,1.9287996870637723,2 Healthcare Stocks to Buy Hand Over Fist in December | Peter Lynch Detailed Fundamental Analysis - ABT,"Two great examples in the healthcare sector are Abbott Laboratories (NYSE: ABT) and Intuitive Surgical (NASDAQ: ISRG). Abbott Laboratories Shares of medical device specialist Abbott Laboratories have failed to keep pace with the market this year. Intuitive Surgical Intuitive Surgical has performed more or less in line with the broader market this year despite lingering issues related to the pandemic, which also slowed down its business. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT)."
2023-12-07,105.19000244140624,104.0500030517578,0.37456721029642887,"VIG, UNH, JPM, ABT: ETF Inflow Alert | Looking for Dividend Growth in the New Year? 3 Magnificent Stocks to Buy Now.","Among the largest underlying components of VIG, in trading today UnitedHealth Group Inc (Symbol: UNH) is off about 0.5%, JPMorgan Chase & Co (Symbol: JPM) is up about 0.5%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $619.0 million dollar inflow -- that's a 0.9% increase week over week in outstanding units (from 428,308,525 to 432,067,546). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $146.17 per share, with $167.33 as the 52 week high point — that compares with a last trade of $165.12. | The company now pays a dividend of $6.20 per share, which represents a dividend yield of 4.29%, surpassing the 1.62% yield of the S&P 500. Medtronic Medtronic, with 46 years of dividend increases, is just a few years away from becoming a Dividend King -- a company that's lifted its dividend for at least 50 consecutive years. Pfizer shares have dropped 40% this year, and valuation metrics don't reflect the level of revenue the company may deliver several years down the road."
2023-12-06,104.62999725341795,104.94000244140624,-1.0837526030892992,PETQ vs. ABT: Which Stock Is the Better Value Option? | Abbott (ABT) Advances While Market Declines: Some Information for Investors,"Based on these metrics and many more, PETQ holds a Value grade of A, while ABT has a Value grade of C. PETQ is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. Click to get this free report PetIQ, Inc. (PETQ) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Investors interested in Medical - Products stocks are likely familiar with PetIQ (PETQ) and Abbott (ABT). | Abbott (ABT) closed the latest trading day at $104.94, indicating a +0.57% change from the previous session's end. Also, we should mention that ABT has a PEG ratio of 2.61. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here."
2023-12-05,105.0,104.3499984741211,0.29628710324577046,,
2023-12-04,104.41000366210938,105.19000244140624,-0.619049072265625,Peter Lynch Detailed Fundamental Analysis - ABT,"Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT)."
2023-12-01,104.22000122070312,104.87999725341795,0.7470536844544946,Peter Lynch Detailed Fundamental Analysis - ABT,"Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT)."
2023-11-30,103.75,104.29000091552734,0.6332719487473221,Abbott (ABT) Rises Higher Than Market: Key Facts,"Abbott (ABT) closed the most recent trading day at $104.29, moving +0.64% from the previous trading session. One should further note that ABT currently holds a PEG ratio of 2.59. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here."
2023-11-29,102.31999969482422,103.62999725341795,0.5204828101468374,"Wall Street Bulls Look Optimistic About Abbott (ABT): Should You Buy? | Should You Invest in the iShares U.S. Medical Devices ETF (IHI)? | Notable ETF Inflow Detected - OEF, UNH, ABT, NEE","Let's take a look at what these Wall Street heavyweights have to say about Abbott (ABT) before we discuss the reliability of brokerage recommendations and how to use them to your advantage. Brokerage Recommendation Trends for ABT Is ABT Worth Investing In? | Click to get this free report iShares U.S. Medical Devices ETF (IHI): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report SPDR S&P Health Care Equipment ETF (XHE): ETF Research Reports First Trust Indxx Medical Devices ETF (MDEV): ETF Research Reports To read this article on Zacks.com click here. Looking at individual holdings, Abbott Laboratories (ABT) accounts for about 17.58% of total assets, followed by Intuitive Surgical Inc (ISRG) and Medtronic Plc (MDT). First Trust Indxx Medical Devices ETF (MDEV) tracks INDXX GLOBAL MEDICAL EQUIPMENT INDEX and the SPDR S&P Health Care Equipment ETF (XHE) tracks S&P Health Care Equipment Select Industry Index. | Among the largest underlying components of OEF, in trading today UnitedHealth Group Inc (Symbol: UNH) is off about 0.8%, Abbott Laboratories (Symbol: ABT) is up about 1.1%, and NextEra Energy Inc (Symbol: NEE) is higher by about 1.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 100 ETF (Symbol: OEF) where we have detected an approximate $107.8 million dollar inflow -- that's a 0.9% increase week over week in outstanding units (from 54,950,000 to 55,450,000). For a complete list of holdings, visit the OEF Holdings page » The chart below shows the one year price performance of OEF, versus its 200 day moving average: Looking at the chart above, OEF's low point in its 52 week range is $167.20 per share, with $217 as the 52 week high point — that compares with a last trade of $216.01."
2023-11-28,102.45999908447266,102.05999755859376,1.280294724883586,ABT Quantitative Stock Analysis - Peter Lynch | 3 Defensive Dividend Stocks to Protect Your Portfolio | ABT Dividend Yield Pushes Past 2%,"Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | www.barchart.com AbbVie Chicago-based AbbVie Inc. (ABBV) started out as a spin-off from Abbott Laboratories (ABT) in 2013. Looking ahead, analysts are targeting 15% EPS growth for this fiscal year, followed by roughly 9% for FY 2024. www.barchart.com Domino's Pizza has an average ""Moderate Buy"" rating from 25 analysts, with 14 of those calling it a “Strong Buy."" On average, Wall Street expects HD to return to EPS growth in fiscal 2025. www.barchart.com The stock is a ""Moderate Buy"" among the 27 analysts in coverage, with 15 “Strong Buys,” 1 “Moderate Buy,” and 11 “Holds.” The average 12-month price target of $336.32 represents a premium of 8% to current levels. | Looking at the universe of stocks we cover at Dividend Channel, in trading on Tuesday, shares of Abbott Laboratories (Symbol: ABT) were yielding above the 2% mark based on its quarterly dividend (annualized to $2.04), with the stock changing hands as low as $101.35 on the day. Abbott Laboratories (Symbol: ABT) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index. In the case of Abbott Laboratories, looking at the history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2% annual yield."
2023-11-27,102.5999984741211,102.70999908447266,-0.39039774492786466,Here's Why Investors Should Retain Abbott (ABT) Stock Now,"Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DaVita Inc. (DVA) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Biodesix, Inc. (BDSX) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT is well-poised for growth in the coming quarters, driven by the expansion of its global presence to address the unmet demand for advanced medical technologies. Image Source: Zacks Investment Research Abbott projects full-year 2023 organic sales growth, excluding COVID-19 testing-related sales, in the low double digits (unchanged from the previous outlook) and COVID-19 testing-related sales of around $1.5 billion (earlier $1.3 billion)."
2023-11-24,102.68000030517578,102.87000274658205,0.10721307211257715,Peter Lynch Detailed Fundamental Analysis - ABT,"Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT)."
2023-11-22,102.27999877929688,102.6999969482422,0.18504328091308622,Abbott (ABT) Benefits From Innovation Amid FX Headwinds | Bullish Two Hundred Day Moving Average Cross - ABT,"Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott’s ABT new product launches and geographic expansion should boost sales. Although, over the past few quarters, there has been a significant decline in demand for Abbott’s rapid diagnostic tests to detect COVID-19 as compared to the year-ago period, it is largely being offset by higher growth across other businesses. | In trading on Wednesday, shares of Abbott Laboratories (Symbol: ABT) crossed above their 200 day moving average of $103.10, changing hands as high as $103.22 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $89.674 per share, with $115.83 as the 52 week high point — that compares with a last trade of $102.85. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average » Also see: • Top Ranked Dividend Stocks With Insider Buying • DTLK Options Chain • SRK Historical Stock Prices The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2023-11-21,101.47000122070312,101.91000366210938,0.4106356804438495,"Top Analyst Reports for Novo Nordisk, Bank of America & Netflix | Medical device maker Medtronic raises fiscal 2024 profit view","Click to get this free report Bank of America Corporation (BAC) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Netflix, Inc. (NFLX) : Free Stock Analysis Report TotalEnergies SE Sponsored ADR (TTE) : Free Stock Analysis Report To read this article on Zacks.com click here. Other noteworthy reports we are featuring today include Johnson & Johnson (JNJ), Abbott Laboratories (ABT) and TotalEnergies SE (TTE). Market Share Gain, EPD Business Growth Aid Abbott (ABT) The Zacks analyst is impressed with Abbott's strong market share gains in core businesses. | Medtronic joins medical device makers including Abbott Laboratories ABT.N and Boston ScientificBSX.N that have benefited from soaring demand for non-urgent surgeries. Adds background in paragraphs 2 and 3, profit in paragraph 5 Nov 21 (Reuters) - Medtronic MDT.N raised its annual profit forecast for the second time this year on Tuesdayafter beating second-quarter earnings estimates, as a post-pandemic pickup in surgical volumes boosted demand for its medical devices. Medical device makers are seeing higher demand for their products due to a steady recovery in surgical procedures that were deferred during the pandemic, especially by older adults, as well as easing staff shortages at hospitals."
2023-11-20,98.9499969482422,101.1999969482422,0.43362810299885507,Validea's Top Health Care Stocks Based On Martin Zweig - 11/20/2023 | Ozempic Might Be Helping Abbott Laboratories and DexCom Stock. Here's How. | PETQ vs. ABT: Which Stock Should Value Investors Buy Now? | After A 6% Rise This Month Should You Pick Medtronic Stock Ahead of Its Q2?,"Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis Martin Zweig Portfolio About Martin Zweig: During the 15 years that it was monitored, Zweig's stock recommendation newsletter returned an average of 15.9 percent per year, during which time it was ranked number one based on risk-adjusted returns by Hulbert Financial Digest. Detailed Analysis of BOSTON SCIENTIFIC CORPORATION BSX Guru Analysis BSX Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. | But at least two device companies, Abbott Laboratories (NYSE: ABT) and DexCom, (NASDAQ: DXCM) are actually anticipating that Ozempic and its peer medicines will give their businesses a boost. Therapies made by Novo Nordisk and Eli Lilly like Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound treat diabetes and also obesity by prompting the patient's body to produce more insulin after they eat food, thereby lowering their blood glucose level after meals to within healthy ranges. Medical device businesses like Abbott Labs and DexCom, both of which make continuous glucose monitors (CGMs) and heavily rely on the segment to drive growth, are particularly exposed to this risk. | Investors with an interest in Medical - Products stocks have likely encountered both PetIQ (PETQ) and Abbott (ABT). These are just a few of the metrics contributing to PETQ's Value grade of A and ABT's Value grade of C. PETQ sticks out from ABT in both our Zacks Rank and Style Scores models, so value investors will likely feel that PETQ is the better option right now. Click to get this free report PetIQ, Inc. (PETQ) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | (1) Diabetes Segment To Drive Sales Trefis estimates Medtronic’s Q2 fiscal 2024 total revenues to be around $7.8 billion, reflecting a low single-digit y-o-y rise but marginally below the $7.9 billion consensus estimate. (3) MDT stock is undervalued We estimate Medtronic’s Valuation to be $97 per share, reflecting a solid 30% upside from its current market price of around $75. Total [2] MDT Return 6% -4% 5% S&P 500 Return 7% 17% 101% Trefis Reinforced Value Portfolio 6% 25% 541% [1] Month-to-date and year-to-date as of 11/17/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2023-11-17,100.43000030517578,99.5500030517578,2.273875764924892,"Peter Lynch Detailed Fundamental Analysis - ABT | Abbott (ABT) Up 5.1% Since Last Earnings Report: Can It Continue? | UPRO, LIN, CMCSA, ABT: Large Outflows Detected at ETF","Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | It has been about a month since the last earnings report for Abbott (ABT). Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Neogen Corporation (NEOG) : Free Stock Analysis Report To read this article on Zacks.com click here. The Diabetes Care division reported organic sales growth of 24.5% year over year, led by FreeStyle Libre, which contributed $1.4 billion to revenues in the reported quarter. | Among the largest underlying components of UPRO, in trading today Linde PLC (Symbol: LIN) is off about 0.3%, Comcast Corp (Symbol: CMCSA) is up about 0.2%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $131.2 million dollar outflow -- that's a 4.7% decrease week over week (from 59,650,000 to 56,850,000). For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $30.89 per share, with $52.2214 as the 52 week high point — that compares with a last trade of $46.86."
2023-11-16,97.72000122070312,100.26000213623048,-0.8762294640485342,"QIAGEN (QGEN) Expands Sample Technologies Line With New Launch | Notable Thursday Option Activity: DVN, ABT, KMX","Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report QIAGEN N.V. (QGEN) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | That number of contracts represents approximately 3.4 million underlying shares, working out to a sizeable 52.6% of ABT's average daily trading volume over the past month, of 6.5 million shares. Particularly high volume was seen for the $110 strike put option expiring November 17, 2023, with 12,196 contracts trading so far today, representing approximately 1.2 million underlying shares of ABT. Below is a chart showing DVN's trailing twelve month trading history, with the $44 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) options are showing a volume of 33,950 contracts thus far today."
2023-11-15,97.37000274658205,98.0,2.599264105401207,"Alcon (ALC) Q3 Earnings Miss Estimates, Margins Increase | Abbott (ABT) Just Overtook the 50-Day Moving Average | Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It","Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Alcon (ALC) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Investors should think about putting ABT on their watchlist given the ultra-important technical indicator and positive move in earnings estimate revisions. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. After reaching an important support level, Abbott (ABT) could be a good stock pick from a technical perspective. | Abbott (ABT) has recently been on Zacks.com's list of the most searched stocks. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions."
2023-11-14,96.31999969482422,97.08000183105467,0.6470136958479947,"Charles River (CRL) to Advance AI Drug Discovery With New Pact | 3 Dividend Giants to Grow Wealth no Matter What the Market Is Doing | Here's Why You Should Retain Penumbra (PEN) Stock for Now | Bio-Rad (BIO) Hurt by Macroeconomic Woes, Margin Pressure","Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Charles River Laboratories International, Inc. (CRL) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Growth stocks are known to stand out in bull markets, while stocks that are considered safer -- like a pharma company promising steady earnings -- generally excel in more difficult markets. Johnson & Johnson Johnson & Johnson (NYSE: JNJ) also is a Dividend King, offering evidence of its commitment to dividend growth. Right now, AbbVie pays an annual dividend of $6.20 at a yield of 4.47%, making it another dividend stock that tops the yield of the S&P 500. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Key Picks Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Key Picks Some better-ranked stocks in the broader medical space are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%."
2023-11-13,95.66999816894533,95.79000091552734,0.7890387651976847,"Here's Why You Should Retain CVS Health (CVS) Stock for Now | Validea's Top Health Care Stocks Based On Peter Lynch - 11/13/2023 | US STOCKS-Wall St falls as megacaps drag ahead of inflation data | Medical device makers rise on relief after Wegovy obesity trial data | Quest Diagnostics (DGX) Introduces Mobile Phlebotomy Service | Abbott Says Aspirin-free Medication Regimen Benefits People With HeartMate 3 Heart Pump | Medical device stocks rise in relief after Wegovy heart benefits data | US STOCKS-Wall Street wavers after rally, focus on inflation data | US STOCKS-S&P 500 takes a pause ahead of U.S inflation data | US STOCKS-S&P 500 takes a pause ahead of U.S inflation data","Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Key Picks Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Detailed Analysis of CIGNA GROUP CI Guru Analysis CI Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Carelon Services offers a broad array of healthcare-related services and capabilities to internal and external customers including integrated care delivery, behavioral health, palliative care, utilization management, payment integrity services and subrogation services, as well as health and wellness programs. | Medtech companies such as Dexcom DXCM.O, Abbott ABT.N and Insulet PODD.O rose between 2% and 5% as analysts said data for cardiovascular benefits for Novo Nordisk's NOVOb.CO weight-loss drug Wegovy is better than feared for the companies. By Sruthi Shankar and Amruta Khandekar Nov 13 (Reuters) - Wall Street's main indexes slipped on Monday as investors awaited a crucial inflation reading and other economic data this week that could shape expectations around how long the Federal Reserve will keep interest rates elevated. This week's economic data as well as speeches from Fed officials will provide clues on the trajectory of interest rates amid growing expectations that the Fed is done hiking borrowing costs. | Shares of diabetes care device makers Abbott Laboratories ABT.N, Dexcom DXCM.O, Insulet PODD.O, Tandem TNDM.O and Medtronic rose between 2% and 8%. Corrects syntax in paragraph 1 Nov 13 (Reuters) - Shares of U.S. medical device makers climbed in early trading on Monday as a potential hit from the cardiac benefits of Novo Nordisk's NOVOb.CO Wegovy was seen as more moderate than initially feared by investors. Heart device maker Penumbra PEN.N was the biggest gainer, up 19%, after the data showed the reduction in risk of non-fatal stroke was not statistically significant over the length of the trial. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | (RTTNews) - Abbott's (ABT) new data show that an Aspirin-free medication regimen benefits people with its HeartMate 3 heart pump. According to Abbott, the new late-breaking data show advanced heart failure patients living with its HeartMate 3 heart pump who didn't receive aspirin as part of their blood-thinning medication regimen experienced fewer complications from bleeding and were associated with reduced hospital visits compared to patients who took aspirin daily following their implant. The ARIES trial studied more than 600 patients and found that HeartMate 3 patients who didn't receive aspirin but continued using the standard post-implant vitamin-K antagonist (VKA) treatment regimen met the primary endpoint by showing non-inferiority of no aspirin to aspirin. | Shares of diabetes care device makers Abbott Laboratories ABT.N, Dexcom DXCM.O, Insulet PODD.O, Tandem TNDM.O and Medtronic MDT.N gained between 2% and 8%. Adds fresh analyst comments in paragraphs 3, 10; updates share movement Nov 13 (Reuters) - Shares of U.S. medical device makers rose on Monday as a potential hit from the cardiac benefits of Novo Nordisk's NOVOb.CO weight-loss drug Wegovy was seen as more moderate for the battered sector than initially feared by investors. Monday's moves are the latest sign that investors across industries are closely looking at developments with the popular new class of weight-loss and diabetes drugs called GLP-1s such as Wegovy and Eli Lilly's LLY.N Mounjaro and Zepbound. | Medtech companies were rising with Dexcom DXCM.O adding 5%, Insulet PODD.O climbing more than 6% and Abbott ABT.N rising 2% as analysts commented on data about the cardiovascular benefits for Novo Nordisk's NOVOb.CO weight-loss drug Wegovy. By Sinéad Carew and Sruthi Shankar Nov 13 (Reuters) - Wall Street's three main stock indexes were making little progress in either direction on Monday as investors awaited a crucial inflation reading that could shape expectations around how long the U.S. Federal Reserve will keep interest rates elevated. After the indexes enjoyed a rally on Friday investors turned their focus to Consumer Price Index (CPI) data, due out Tuesday morning. | Other medtech companies rallying included Insulet PODD.O, which added 5.6% and Dexcom DXCM.O, up 4.6%, along with Abbott's ABT.N 1.9% gain as analysts reacted to data about the cardiovascular benefits for Novo Nordisk's NOVOb.CO weight-loss drug Wegovy. By Sinéad Carew and Sruthi Shankar Nov 13 (Reuters) - The S&P 500 closed Monday's session slightly lower as investors held their breath before a crucial inflation reading that could provide clues as to how long the U.S. Federal Reserve will keep interest rates elevated. After the indexes enjoyed a solid rally on Friday, the market turned its focus on Monday to Consumer Price Index (CPI) data, due out Tuesday morning. | Medtech companies including Dexcom DXCM.O, Insulet PODD.O and Abbott ABT.N rose as analysts discussed data about the cardiovascular benefits for Novo Nordisk's NOVOb.CO weight-loss drug Wegovy. By Sinéad Carew and Sruthi Shankar Nov 13 (Reuters) - The S&P 500 closed Monday's session slightly down as investors held their breath before a crucial inflation reading that could provide clues as to how long the U.S. Federal Reserve will keep interest rates elevated. After the indexes enjoyed a solid rally on Friday, the market turned its focus on Monday to Consumer Price Index (CPI) data, due out Tuesday morning."
2023-11-10,93.6999969482422,93.97000122070312,0.12543404293799829,"Hologic's (HOLX) Q4 Earnings Beat Estimates, Gross Margin Down","Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%."
2023-11-09,94.87999725341795,93.5500030517578,0.2881582510723748,"Wall Street Analysts See a 25.28% Upside in Abbott (ABT): Can the Stock Really Move This High? | IVV, GOOG, XOM, ABT: ETF Inflow Alert | Here's Why You Should Retain Boston Scientific (BSX) Now | Alcon (ALC) Unveils New Progress in Presbyopia Correcting IOLs | Surmodics (SRDX) Q4 Earnings Top Estimates, Revenues Up Y/Y | BD (BDX) Q4 Earnings In-Line With Estimates, Margins Contract | What's Next For Boston Scientific Stock After 5% Gains In A Week? | Inspire Medical (INSP) Q3 Earnings Top Estimates, Revenues Lag | 2 No-Brainer Stocks to Buy for Forever Dividend Growth | Abbott India's Q2 profit climbs on strong sales | BD beats quarterly revenue estimates on strong demand for medical devices","You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Therefore, while the consensus price target may not be a reliable indicator of how much ABT could gain, the direction of price movement it implies does appear to be a good guide. Abbott (ABT) closed the last trading session at $94.74, gaining 2.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. But, for ABT, an impressive average price target is not the only indicator of a potential upside. | Among the largest underlying components of IVV, in trading today Alphabet Inc (Symbol: GOOG) is down about 0.2%, Exxon Mobil Corp (Symbol: XOM) is up about 0.7%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P 500 ETF (Symbol: IVV) where we have detected an approximate $812.4 million dollar inflow -- that's a 0.2% increase week over week in outstanding units (from 812,050,000 to 813,900,000). For a complete list of holdings, visit the IVV Holdings page » The chart below shows the one year price performance of IVV, versus its 200 day moving average: Looking at the chart above, IVV's low point in its 52 week range is $376.49 per share, with $461.88 as the 52 week high point — that compares with a last trade of $438.43. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inari Medical, Inc. (NARI) : Free Stock Analysis Report To read this article on Zacks.com click here. Key Picks Some better-ranked stocks in the broader medical space are Abbott Laboratories ABT, Inari Medical NARI and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Alcon (ALC) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inari Medical, Inc. (NARI) : Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked stocks in the broader medical space are Abbott Laboratories ABT, Inari Medical NARI and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Surmodics, Inc. (SRDX) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. A few other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Boston Scientific (NYSE: BSX) reported its Q3 results last month, with revenues and earnings beating the street estimates. While BSX stock looks like it has little room for growth, it is helpful to see how Boston Scientific’s Peers fare on metrics that matter. Total [2] BSX Return 3% 14% 144% S&P 500 Return 4% 14% 95% Trefis Reinforced Value Portfolio 4% 22% 525% [1] Month-to-date and year-to-date as of 11/7/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inspire Medical Systems, Inc. (INSP) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) has also placed an important focus on dividends, lifting its payments for 51 straight years. Nothing is 100% certain, of course, but you can increase your chances of long-term dividend growth by choosing companies with a track record of dividend increases. This classic dividend stock offers a total annual payment of $1.84 per share, which amounts to a dividend yield of 3.23% at the current share price. | BENGALURU, Nov 9 (Reuters) - Abbott India ABOT.NS, the local unit of U.S. healthcare firm Abbott Laboratories ABT.N, reported a 17.7% rise in second-quarter profit on Thursday, driven by strong sales in its mainstay pharmaceuticals segment. Peers Cipla CIPL.NS and Dr Reddy's REDY.NS beat analysts' profit estimates while Gland Pharma GLAD.NS missed profit estimates. Revenue growth profit growth Mean rating* # of analysts Stock to price target** Div yield (%) Abbott India Ltd | BD joined a list of companies that have benefited from a recent boost to medical technology businesses, including larger rivals Abbott Laboratories ABT.N and Boston Scientific BSX.N, as more people, especially older patients, opted for surgeries they put off during the pandemic. The company reported a 6.8% rise in quarterly revenue to $5.09 billion, marginally ahead of analysts' average estimate of $5.02 billion, according to LSEG data. The company's interventional unit, through which it offers surgical and critical care devices, recorded sales of $1.20 billion, beating estimates of $1.16 billion."
2023-11-08,95.22000122070312,94.73999786376952,-1.4017645870159894,"Globus Medical (GMED) Q3 Earnings Top Estimates, Margins Down | Analysts Anticipate USMV Will Reach $83 | Here's Why You Should Retain Align Technology (ALGN) Stock Now | Inogen (INGN) Q3 Earnings Miss Estimates, Revenues Down Y/Y | Masimo (MASI) Q3 Earnings Beat Estimates, Margins Fall | 2 Medical Device Companies Experiencing Strong Demand Even as Weight-Loss Drugs Rise in Popularity | DaVita (DVA) Q3 Earnings & Revenues Top Estimates, Margins Up | Accuray (ARAY) Q1 Earnings In-Line With Estimates, Revenues Top","Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Globus Medical, Inc. (GMED) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inari Medical, Inc. (NARI) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Inari Medical NARI and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Three of USMV's underlying holdings with notable upside to their analyst target prices are Abbott Laboratories (Symbol: ABT), American Financial Group Inc (Symbol: AFG), and Exxon Mobil Corp (Symbol: XOM). Although ABT has traded at a recent price of $94.80/share, the average analyst target is 25.20% higher at $118.69/share. Below is a twelve month price history chart comparing the stock performance of ABT, AFG, and XOM: Below is a summary table of the current analyst target prices discussed above: | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Align Technology, Inc. (ALGN) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inari Medical, Inc. (NARI) : Free Stock Analysis Report To read this article on Zacks.com click here. Other Key Picks Some better-ranked stocks in the broader medical space are Abbott Laboratories ABT, Inari Medical NARI and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Inogen, Inc (INGN) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Masimo Corporation (MASI) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom DXCM and Integer Holdings ITGR. ABT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.76%. | DexCom (NASDAQ: DXCM) and Abbott Laboratories (NYSE: ABT) are two businesses that are still doing well. DexCom DexCom makes continuous glucose monitoring (CGM) devices that help people with diabetes track their glucose levels. Trading at 33 times its trailing earnings, Abbott is the more modestly priced stock of the two right now -- DexCom's price-to-earnings multiple is at more than 100, but that should come down as the business continues to grow over the years. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DaVita Inc. (DVA) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. A few other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Accuray Incorporated (ARAY) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%."
2023-11-07,94.93000030517578,94.8000030517578,-0.5040992971855199,"Medical device maker Zimmer cuts revenue growth forecast as profit beats | OPKO Health (OPK) Q3 Earnings Lag Estimates, Revenues Top | Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q3 | Shockwave Medical (SWAV) Q3 Earnings Beat, Revenues Rise Y/Y","Larger peers Abbott LaboratoriesABT.N and Boston Scientific BSX.N had also topped quarterly profit estimates on easing staffing shortages and a surge in hospital admissions for elective procedures deferred during the pandemic. Adds comments from conference call in paragraphs 3,4 Nov 7 (Reuters) - Zimmer Biomet Holdings Inc ZBH.N on Tuesday trimmed its annual revenue growth forecast due to a stronger dollar after topping analysts' estimates for third-quarter profit on robust performance in the medical device maker's knee unit. ""Once the (knee) cartilage is damaged, there is no recovery...And a drop in weight is not going to cure osteoarthritis,"" CEO Ivan Tornos said on anearnings call On an adjusted basis, the company reported a profit of $1.65 per share, compared with analysts' average estimate of $1.60, according to LSEG data. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report OPKO Health, Inc. (OPK) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Myriad Genetics, Inc. (MYGN) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inari Medical, Inc. (NARI) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Inari Medical NARI and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report ShockWave Medical, Inc. (SWAV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom DXCM and Integer Holdings ITGR. ABT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.76%."
2023-11-06,95.5500030517578,95.0,-0.13694011692834182,"Validea's Top Health Care Stocks Based On Peter Lynch - 11/6/2023 | Insulet (PODD) Q3 Earnings Beat, 2023 Sales Growth View Up | 3 Dividend Kings to Buy for Royal Returns","Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Detailed Analysis of ELEVANCE HEALTH INC ELV Guru Analysis ELV Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of PFIZER INC. PFE Guru Analysis PFE Fundamental Analysis ELEVANCE HEALTH INC (ELV) is a large-cap growth stock in the Insurance (Accident & Health) industry. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inari Medical, Inc. (NARI) : Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Inari Medical NARI and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Abbott Laboratories (ABT) Source: Sundry Photography/Shutterstock.com Abbott Laboratories (NYSE:ABT) stands resilient despite falling 12.5% year-to-date. Despite a decrease in cash from operations to $1.88 billion, Abbott’s $1.03 billion in free cash flow solidly underpins its ability to fund growth and dividends. The dividend narrative continues to be a draw, with McCormick maintaining its dividend payout, reinforcing its stature among dividend stocks to buy."
2023-11-03,97.0,95.83999633789062,-0.5756180368302773,"Stryker (SYK) Q3 Earnings Beat on Strong Segmental Result | Peter Lynch Detailed Fundamental Analysis - ABT | Penumbra (PEN) Q3 Earnings Top Estimates, Margins Increase | Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know | Fresenius Medical (FMS) Q3 Earnings Miss, Operating Margin Up | Cardinal Health (CAH) Beats on Q1 Earnings, Ups '24 EPS View | AMN Healthcare (AMN) Q3 Earnings and Revenues Beat Estimates","Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Stryker Corporation (SYK) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Other Key Picks Some other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom DXCM and Integer Holdings ITGR. ABT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.76%. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inari Medical, Inc. (NARI) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Inari Medical NARI and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Abbott (ABT) has recently been on Zacks.com's list of the most searched stocks. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Fresenius Medical Care AG & Co. KGaA (FMS) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom DXCM and Integer Holdings ITGR. ABT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.76%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom DXCM and Integer Holdings ITGR. ABT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.76%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report AMN Healthcare Services Inc (AMN) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%."
2023-11-02,94.9800033569336,95.95999908447266,-1.1958800640302836,"DENTSPLY SIRONA (XRAY) Beats on Q3 Earnings, Lowers '23 Guidance | Exact Sciences (EXAS) Q3 Earnings Beat, Gross Margin Rises | 3 Dividend Stocks That Are Investor Safe Havens | QuidelOrtho (QDEL) Q3 Earnings Top Estimates, Margins Down | Baxter (BAX) Beats on Q3 Earnings, Divests BioPharma Business | Nevro (NVRO) Q3 Earnings Top Estimates, FY23 Revenue View Up | Teleflex beats profit estimates on strong demand for medical devices | Cencora (COR) Q4 Earnings Top, GLP-1 Drugs Boost Sales | 1 Stock Down 15% This Year to Buy and Hold Forever | Abbott Obtains FDA Approval For HPV Test To Run On Alinity M | Baxter International beats Q3 profit estimates on strong demand for medical devices | Glaukos (GKOS) Q3 Earnings Beat Estimates, Revenues Rise Y/Y | McKesson (MCK) Beats on Q2 Earnings, Raises '23 EPS View","Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DENTSPLY SIRONA Inc. (XRAY) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom DXCM and Integer Holdings ITGR. ABT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.76%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inari Medical, Inc. (NARI) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Inari Medical NARI and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | AbbVie (ABBV) AbbVie (NYSE:ABBV) hasn’t paid dividends for as long as either NextEra or Aflac — it was spun off from Abbott Laboratories (NYSE:ABT) in 2012. By the site’s definition, these stocks have a reasonably high yield; the quarterly dividend is accelerating, they’ve never missed or lowered dividends and they have paid dividends for at least 20 years. The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors The post 3 Dividend Stocks That Are Investor Safe Havens appeared first on InvestorPlace. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report QuidelOrtho Corporation (QDEL) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Baxter International Inc. (BAX) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom DXCM and Integer Holdings ITGR. ABT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.76%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Nevro Corp. (NVRO) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom, Inc. DXCM and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Teleflex joined a list of companies that have benefited from a recent boost to medical technology businesses, including larger rivals Abbott LaboratoriesABT.N and Boston Scientific BSX.N that also beat profit expectations driven by the post-pandemic demand for medical devices. The manufacturer for hospital supplies and single-use medical devices reported an 8.7% rise in revenue to $746.4 million for the quarter ended Oct. 1, higher than analysts' estimate of $733.6 million, according to LSEG data. Teleflex's interventional segment, which focuses on heart and medical imaging devices, reported sales of $134.1 million, beating estimates of $120 million. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Cencora, Inc. (COR) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Other Stocks to Consider Some other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom DXCM and Integer Holdings ITGR. ABT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.76%. | The past three years have been a roller coaster for Abbott Laboratories (NYSE: ABT). ABT data by YCharts. Medical devices, Abbott's largest segment by revenue, saw the most significant sales growth at 16.6% year over year. | (RTTNews) - Abbott (ABT) said it has received U.S. Food and Drug Administration approval for its molecular human papillomavirus or HPV screening solution, adding a powerful cancer screening tool for detecting high-risk HPV infections to the Alinity m family of diagnostic assays. The Alinity m high risk (HR) HPV assay is approved as a test for HPV detection and for use in routine cervical cancer screening as per professional medical guidelines. The Alinity m HR HPV assay delivers information on five risk groups covering the 14 different potentially cancer-causing genotypes of the virus, helping physicians identify not just if a patient has an HPV infection but whether that infection is caused by one (or more) of the types that may cause cancer. | Larger peers Abbott Laboratories ABT.N and Boston Scientific BSX.N also topped quarterly profit estimates on easing staffing shortages and a surge in hospital admissions for elective procedures, which were deferred during the pandemic. Baxter, which manufactures dialysis products and infusion pumps, reported a 3% year-on-year rise in quarterly revenue to $3.71 billion, beating analysts' average estimate of $3.69 billion, according to LSEG data. The healthcare products company expects its full-year adjusted profit, before special items, to range between $2.57 per share and $2.60 per share. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Glaukos Corporation (GKOS) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom DXCM and Integer Holdings ITGR. ABT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.76%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report McKesson Corporation (MCK) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, DexCom DXCM and Integer Holdings ITGR. ABT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.76%."
2023-11-01,94.8499984741211,95.01000213623048,1.0317916328727128,"CVS Health (CVS) Q3 Earnings Surpass Estimates, Margins Up | Unusual Put Option Trade in Abbott Laboratories (ABT) Worth $4,312.00K","Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inari Medical, Inc. (NARI) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Inari Medical NARI and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | On November 1, 2023 at 15:02:13 ET an unusually large $4,312.00K block of Put contracts in Abbott Laboratories (ABT) was bought, with a strike price of $115.00 / share, expiring in 79 day(s) (on January 19, 2024). Fintel tracks all large options trades, and the premium spent on this trade was 2.16 sigmas above the mean, placing it in the 98.93th percentile of all recent large trades made in ABT options. Average portfolio weight of all funds dedicated to ABT is 0.56%, a decrease of 1.65%."
2023-10-31,93.9000015258789,94.5500030517578,0.16869126482173288,"Ecolab (ECL) Q3 Earnings Surpass Estimates, Margins Rise | GE HealthCare beats quarterly profit estimates on imaging device demand | PacBio (PACB) Tops on Q3 Earnings, Raises FY23 Revenue View","Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Ecolab Inc. (ECL) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Boston Scientific Corporation BSX and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Larger peer Abbott Laboratories ABT.N also topped its quarterly profit estimates, aided by a recovery in sales of its medical devices such as heart valves and pacemakers. Oct 31 (Reuters) - GE HealthCare Technologies Inc GEHC.O on Tuesday beat Wall Street expectations for third-quarter profit as a continued recovery in demand for surgical procedures boosted sales of its medical devices. On Oct. 16, U.S. health officials had lifted curbs on reimbursement of a non-invasive imaging test called amyloid PET used to diagnose Alzheimer's, providing broader access to PET scanners made by companies like GE HealthCare that were only accessible for use in limited spaces like clinical trials. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Pacific Biosciences of California, Inc. (PACB) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Boston Scientific Corporation BSX and Integer Holdings Corporation ITGR. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%."
2023-10-30,93.52999877929688,93.0,0.6922273858533976,"Top Stock Reports for JPMorgan Chase, Home Depot & Salesforce | Revvity (RVTY) Misses on Q3 Earnings, Lowers '23 EPS View | 2 No-Brainer Dividend Stocks to Buy This Week | Is Abbott Stock Undervalued At $95? | Avantor (AVTR) Q3 Earnings In-Line With Estimates, Revenues Top","If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Buyouts, High Rates, Modest Loan Demand Aid JPMorgan (JPM) Home Depot's (HD) Interconnected Strategy to Boost Sales Salesforce (CRM) Rides on Partnership Wins & Acquisitions Featured Reports Organic Sales Gain, EPD Business Growth Aid Abbott (ABT) The Zacks analyst is impressed with Abbott's strong market share gains in organic base business. Click to get this free report JPMorgan Chase & Co. (JPM) : Free Stock Analysis Report Intel Corporation (INTC) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Advanced Micro Devices, Inc. (AMD) : Free Stock Analysis Report Salesforce Inc. (CRM) : Free Stock Analysis Report The Home Depot, Inc. (HD) : Free Stock Analysis Report To read this article on Zacks.com click here. Other noteworthy reports we are featuring today include Abbott Laboratories (ABT), Advanced Micro Devices, Inc. (AMD) and Intel Corporation (INTC). | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Medpace Holdings, Inc. (MEDP) : Free Stock Analysis Report Revvity Inc. (RVTY) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Medpace MEDP and Boston Scientific BSX. ABT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.76%. | So with AbbVie's stock trading a paltry 12.8 times projected earnings, it might be a good idea to start to build a position in this Dividend King or add to an already existing position. Third, Altria is an extremely shareholder-friendly company, evinced by its sky-high dividend year of almost 10%, its 54-year history of consecutive dividend raises, and regular share buybacks. See the 10 stocks *Stock Advisor returns as of October 23, 2023 George Budwell has no position in any of the stocks mentioned. | Abbott (NYSE: ABT) reported its Q3 results last week, with revenues and earnings beating the street estimates. Total [2] ABT Return -3% -15% 144% S&P 500 Return -2% 9% 87% Trefis Reinforced Value Portfolio -5% 18% 504% [1] Month-to-date and year-to-date as of 10/26/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ABT stock is trading at 4.0x sales compared to the last five-year average of 5.4x, and we believe investors will likely be better off picking ABT for robust gains in the long run. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report Avantor, Inc. (AVTR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Boston Scientific Corporation BSX and West Pharmaceutical Services, Inc. WST. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%."
2023-10-27,94.75,92.8499984741211,-0.5666618049974697,"Integer Holdings (ITGR) Q3 Earnings Top Estimates, FY23 View Up | Merit Medical (MMSI) Q3 Earnings Top Estimates, FY23 View Revised | Peter Lynch Detailed Fundamental Analysis - ABT | DexCom (DXCM) Beats on Q3 Earnings, Raises Sales Outlook","Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Boston Scientific Corporation BSX and West Pharmaceutical Services, Inc. WST. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Boston Scientific Corporation BSX and West Pharmaceutical Services, Inc. WST. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 6.8%. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Edwards Lifesciences EW. ABT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.76%."
2023-10-26,93.05999755859376,93.9800033569336,-2.0052786552811677,"Got $1,000? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond | Dexcom lifts 2023 revenue view on strong demand for diabetes devices | Boston Scientific raises profit forecast on strength in heart devices unit | CONMED (CNMD) Beats on Q3 Earnings, Ups '23 EPS View | West Pharmaceutical (WST) Beats on Q3 Earnings, HVP Drives Sales","Two stocks in that category are AbbVie (NYSE: ABBV) and Tandem Diabetes Care (NASDAQ: TNDM). That's why AbbVie is down 9.9% this year, and at these levels, the company looks like a good pick, especially for investors on the market for blue chip dividend stocks. Overall, given the vast market opportunity, Tandem Diabetes Care's innovative devices, and the company's efforts to bring down costs, its stock could eventually rebound from its terrible performance this year. | Dexcom joined larger peer Abbott ABT.Nin saying the use of GLP-1 drugs among diabetes patients could end up increasing demand for CGMs, which track blood sugar levels throughout the day and can transmit glucose readings as frequently as five minutes. Adds comment for conference call in paragraph 3-4 Oct 26 (Reuters) - Medical device maker Dexcom DXCM.O on Thursday raised its annual revenue forecast and beat quarterly estimates on strong demand for its continuous glucose monitoring (CGM) devices, sending its shares more than 14% higher in extended trading. Makers of medical products such as bariatric surgery devices and CGM systemshave been trying to ease investor concerns over a potential hit to demand from the rising popularity of new GLP-1 diabetes drugs such as Novo Nordisk's Ozempic and Eli Lilly's Mounjaro. | Rival Abbott Laboratories ABT.N also topped quarterly profit estimates earlier this month on upbeat sales of its glucose monitoring and heart devices. Adds details in paragraph 4, analyst comment in paragraph 6 Oct 26 (Reuters) - Medical equipment maker Boston Scientific BSX.N raised its annual profit forecast and beat estimates for third-quarter profit on Thursday as a post-pandemic rebound in elective surgeries boosts demand for its heart devices. Analysts have also pointed to increasing demand for the company's heart product to prevent stroke — Watchman Left Atrial Appendage Closure Device — which is expected to become a blockbuster offering in the next few years. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report CONMED Corporation (CNMD) : Free Stock Analysis Report Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Edwards Lifesciences EW. ABT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.76%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Edwards Lifesciences EW. ABT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.76%."
2023-10-25,94.55999755859376,93.56999969482422,0.9886157559380574,5 Stocks to Watch on Solid Revenues in Last Reported Quarter | FDA Approves New Therapy For Rare Blood Cancers | Are These 3 Dividend Aristocrats Undervalued Hidden Gems? | Teladoc Health (TDOC) Q3 Loss Narrows on Integrated Care Strength | PREVIEW-Boston Scientific may be shielded from weight-loss drugs hit by procedure recovery | ZBH or ABT: Which Is the Better Value Stock Right Now? | Edwards Lifesciences posts lower-than-expected sales of heart device; shares fall,"Click to get this free report JPMorgan Chase & Co. (JPM) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report Freeport-McMoRan Inc. (FCX) : Free Stock Analysis Report Procter & Gamble Company (The) (PG) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT reported second-quarter fiscal 2023 global revenues of $9.98 billion, outpacing the Zacks Consensus Estimate by 2.9%. ABT projects full-year 2023 organic sales growth, excluding COVID-19 testing-related sales, in the low double digits (from the earlier projection of at least high single digits) and COVID-19 testing-related sales of around $1.5 billion. | MDS are a rare form of blood cancers that can occur when the mutations in the bone marrow progenitor cells, i.e., cells that form blood, lead to insufficient numbers of healthy blood cells. Richard Pazdur, director of the FDA's Oncology Center of Excellence, said, ""Today's approval represents an important treatment advancement for rare blood cancers, and more specifically, patients with relapsed or refractory MDS who have an IDH1 mutation. The Abbott RealTime IDH1 Assay was also approved earlier as a companion diagnostic to identify AML patients with an IDH1 mutation for treatment with Tibsovo or Rezlidhia (olutasidenib). | That list is stacked with plenty of familiar large caps, such as Lowe's Companies Inc. (NYSE: LOW), Target Corp. (NYSE: TGT),  Abbott Laboratories (NYSE: ABT), McDonald's Corp. (NYSE: MCD), PepsiCo Inc. (NASDAQ: PEP), Johnson & Johnson (NYSE: JNJ), Coca-Cola Co. (NYSE: KO) and Exxon Mobil Corp. (NYSE: XOM), among many others. If you look at MarketBeat's list of dividend aristocrats, you'll see a select group of publicly traded companies that have an outstanding track record of consistently increasing their dividend payouts for at least 25 consecutive years. MarketBeat's NextEra analyst forecasts show a consensus view of ""moderate buy"" with a price target of $75.23, an upside of 36.58%, suggesting that the stock is undervalued relative to its price potential in the next 12 to 18 months. | Other Medical Sector Releases Of the Medical sector players that have reported third-quarter 2023 results so far, the bottom-line results of Elevance Health, Inc. ELV, Quest Diagnostics Incorporated DGX and Abbott Laboratories ABT beat the respective Zacks Consensus Estimate. ABT reported an adjusted operating profit of $2.14 billion in the quarter under review, down 5.5% year over year. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report Teladoc Health, Inc. (TDOC) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. | Boston Scientific, which makes a major chunk of its revenue from sales of its heart devices, also makes devices to diagnose and treat a range of gastrointestinal and pulmonary conditions. ** 24 analysts, on average, forecast Boston Scientific's third-quarter revenue to be $3.48 billion, according to LSEG, compared with $3.17 billion reported a year earlier ** 20 analysts, on average, estimated third-quarter net profit to be $702.6 million, compared with $620 million in the year-ago quarter Boston Scientific's Watchman heart device sales https://tmsnrt.rs/3ShcMvN Boston Scientific's full-year revenue https://tmsnrt.rs/46K8VM7 (Reporting by Khushi Mandowara and Mariam Sunny in Bengaluru; Editing by Sriraj Kalluvila) ((Khushi.Mandowara@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | These are just a few of the metrics contributing to ZBH's Value grade of B and ABT's Value grade of C. Both ZBH and ABT are impressive stocks with solid earnings outlooks, but based on these valuation figures, we feel that ZBH is the superior value option right now. Click to get this free report Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Investors looking for stocks in the Medical - Products sector might want to consider either Zimmer Biomet (ZBH) or Abbott (ABT). | TAVR, which is Edward Lifesciences' lead product segment, is facing an increased competition from rivals like Abbott ABT.N, Boston Scientific BSX.N and Medtronic MDT.N. Adds share movement in paragraph 1, CFO comment in paragraph 6 Oct 25 (Reuters) - Edwards Lifesciences Corp EW.N on Wednesday reported a rise in third-quarter sales, but lower-than-expected sales of the company's artificial heart valves pushed the device maker's shares down 7% after the bell. Sales of Edward's transcatheter aortic valve replacement (TAVR), a device used to perform minimally invasive surgery for people with heart valve disease, rose 11% to $960.9 million in the third quarter."
2023-10-24,95.4000015258789,94.80999755859376,-1.0469520826246814,HCA Healthcare's (HCA) Q3 Earnings Miss on High Expense Level | Shockwave Medical (SWAV) Announces IVL Studies' Positive Results | Abbott : Data Showcase Benefits Of Minimally Invasive Devices For People With Leaky Heart Valves | Is Intuitive Surgical Stock A Pick After A 9% Fall In A Month Amid Mixed Q3?,"ABT reported an adjusted operating profit of $2.14 billion in the quarter under review, down 5.5% year over year. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report To read this article on Zacks.com click here. Other Medical Sector Releases Of the Medical sector players that have reported third-quarter 2023 results so far, the bottom-line results of UnitedHealth Group Incorporated UNH, Intuitive Surgical, Inc. ISRG and Abbott Laboratories ABT beat the respective Zacks Consensus Estimate. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report ShockWave Medical, Inc. (SWAV) : Free Stock Analysis Report To read this article on Zacks.com click here. Another notable name in the niche space is Abbott Laboratories ABT, which is also Shockwave Medical’s peer. This month, ABT reported its third-quarter 2023 results, wherein it registered broad-based growth in the underlying base business. | (RTTNews) - Abbott (ABT) announced data from late-breaking presentations showing the impact of its minimally invasive heart devices in treating mitral and tricuspid valve disease. Data include findings from the Triluminate pivotal trial that reinforce the safety and effectiveness of the TriClip transcatheter edge-to-edge repair or TEER system for patients with symptomatic, severe tricuspid regurgitation or TR despite optimal medical therapy. The company also presented late-breaking data from the MitraClip EXPAND G4 real-world registry that highlights the device's benefits across a broad group of patients with mitral regurgitation or MR. Leaky valves in people with MR and TR can reduce the amount of blood being pumped through the body and make the heart work harder than it should. | Intuitive Surgical (NASDAQ: ISRG) recently reported its Q3 results, with revenues lower but earnings beating our estimates. As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index, less of a roller-coaster ride, as evident in HQ Portfolio performance metrics. Total [2] ISRG Return -9% 1% 279% S&P 500 Return -1% 10% 89% Trefis Reinforced Value Portfolio -2% 21% 520% [1] Month-to-date and year-to-date as of 10/23/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2023-10-23,96.87999725341795,95.77999877929688,-0.6184527860045088,Validea's Top Health Care Stocks Based On Martin Zweig - 10/23/2023 | The Value Deepens for Medtech Stocks: Reversal Imminent | Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock | 5 Dividend Aristocrats Where Analysts See Capital Gains,"Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis Martin Zweig Portfolio About Martin Zweig: During the 15 years that it was monitored, Zweig's stock recommendation newsletter returned an average of 15.9 percent per year, during which time it was ranked number one based on risk-adjusted returns by Hulbert Financial Digest. Detailed Analysis of CENCORA INC COR Guru Analysis COR Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of HUMANA INC HUM Guru Analysis HUM Fundamental Analysis VERTEX PHARMACEUTICALS INCORPORATED (VRTX) is a large-cap growth stock in the Biotechnology & Drugs industry. | Results from Johnson & Johnson (NYSE: JNJ) and Abbott Laboratories (NYSE: ABT) foreshadow good news for MedTech investors. Intuitive Surgical Pulls Back on Tepid Comps Despite Business Strength Intuitive Surgical (NASDAQ: ISRG) already reported for Q3 compared to Baxter International (NYSE: BAX), Medtronic (NYSE: MDT), and Stryker (NYSE: SYK), which are slated to report in November. Stryker has a Low Bar to Hurdle Stryker reports in early November and has a low bar to beat despite most analysts raising their revenue and EPS targets. | Abbott (ABT) is one of the stocks most watched by Zacks.com visitors lately. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. | Smucker Co. (Symbol: SJM) $112.73 $141.36 25.40% Abbott Laboratories (Symbol: ABT) $96.78 $120.38 24.38% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Smucker Co. (Symbol: SJM) 3.76% 25.40% 29.16% Abbott Laboratories (Symbol: ABT) 2.11% 24.38% 26.49% Another consideration with dividend growth stocks is just how much the dividend is growing. Smucker Co. (Symbol: SJM) $3.99 $4.12 3.26% Abbott Laboratories (Symbol: ABT) $1.88 $2.04 8.51% These five stocks are part of our full Dividend Aristocrats List."
2023-10-20,95.25,96.77999877929688,-1.135423725543377,"Peter Lynch Detailed Fundamental Analysis - ABT | Friday Sector Leaders: Healthcare, Consumer Products","Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Within that group, Merck & Co Inc (Symbol: MRK) and Abbott Laboratories (Symbol: ABT) are two large stocks leading the way, showing a gain of 2.8% and 2.2%, respectively. Combined, MRK and ABT make up approximately 8.9% of the underlying holdings of XLV. Among healthcare ETFs, one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is up 0.2% on the day, and down 3.76% year-to-date."
2023-10-19,96.54000091552734,95.44000244140624,1.6062979310203414,"Company News for Oct 19, 2023 | See Which Of The Latest 13F Filers Holds Abbott Laboratories | Wells Fargo Maintains Abbott Laboratories (ABT) Overweight Recommendation | 7 Blue-Chip Stocks to Buy on the Dip | Morgan Stanley Maintains Abbott Laboratories (ABT) Equal-Weight Recommendation | Raymond James Maintains Abbott Laboratories (ABT) Outperform Recommendation | Noteworthy Thursday Option Activity: ABT, DFS, DLR","Abbott Laboratories’ (ABT) shares climbed 3.7% after the company reported third-quarter 2023 adjusted earnings per share of $1.14, outpacing the Zacks Consensus Estimate of $1.10. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Procter & Gamble Company (The) (PG) : Free Stock Analysis Report State Street Corporation (STT) : Free Stock Analysis Report U.S. Bancorp (USB) : Free Stock Analysis Report To read this article on Zacks.com click here. Shares of State Street Corp. (STT) advanced 2% after the company posted third-quarter 2023 adjusted earnings per share of $1.93, beating the Zacks Consensus Estimate of $1.77. | Existing -18,885 -$5,402 Measured Wealth Private Client Group LLC Existing -475 -$110 Gemmer Asset Management LLC Existing -5 -$34 Lesa Sroufe & Co Existing UNCH -$33 Spirit of America Management Corp NY Existing UNCH -$38 Powers Advisory Group LLC Existing +54 -$25 Aggregate Change: -51,257 -$10,660 In terms of shares owned, we count 3 of the above funds having increased existing ABT positions from 06/30/2023 to 09/30/2023, with 5 having decreased their positions. DAVENPORT & Co LLC 955,567 4-10 Find out the full Top 10 Hedge Funds Holding ABT » We'll keep following the latest 13F filings by hedge fund managers and bring you interesting stories derived from a look at the aggregate information across groups of managers between filing periods. At Holdings Channel, we have reviewed the latest batch of the 20 most recent 13F filings for the 09/30/2023 reporting period, and noticed that Abbott Laboratories (Symbol: ABT) was held by 11 of these funds. | Fintel reports that on October 19, 2023, Wells Fargo maintained coverage of Abbott Laboratories (NYSE:ABT) with a Overweight recommendation. Average portfolio weight of all funds dedicated to ABT is 0.56%, a decrease of 0.38%. The put/call ratio of ABT is 0.73, indicating a bullish outlook. | Abbott Laboratories (ABT) Source: Sundry Photography/Shutterstock.com A medical devices and healthcare company, Abbott Laboratories (NYSE:ABT) primarily focuses on diagnostics, branded generic medicines and nutritional products. While it offers myriad relevancies, the market has been unkind to ABT. Since the beginning of the year, ABT surrendered almost 13% of equity value. | Fintel reports that on October 19, 2023, Morgan Stanley maintained coverage of Abbott Laboratories (NYSE:ABT) with a Equal-Weight recommendation. Average portfolio weight of all funds dedicated to ABT is 0.56%, a decrease of 0.38%. The put/call ratio of ABT is 0.73, indicating a bullish outlook. | Fintel reports that on October 19, 2023, Raymond James maintained coverage of Abbott Laboratories (NYSE:ABT) with a Outperform recommendation. Average portfolio weight of all funds dedicated to ABT is 0.56%, a decrease of 0.38%. The put/call ratio of ABT is 0.73, indicating a bullish outlook. | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Abbott Laboratories (Symbol: ABT), where a total of 27,107 contracts have traded so far, representing approximately 2.7 million underlying shares. Below is a chart showing ABT's trailing twelve month trading history, with the $105 strike highlighted in orange: Discover Financial Services (Symbol: DFS) saw options trading volume of 10,967 contracts, representing approximately 1.1 million underlying shares or approximately 43.9% of DFS's average daily trading volume over the past month, of 2.5 million shares. That amounts to about 45.7% of ABT's average daily trading volume over the past month of 5.9 million shares."
2023-10-18,96.0,95.55999755859376,-1.1394224815510499,"Abbott (ABT) Q3 Earnings and Revenues Surpass, Margins Dip | Geopolitical Conflicts in Middle-East in Focus | Health Care Sector Update for 10/18/2023: ABT, ARDX, TNGX, XLV, IBB | Abbott (ABT) Reports Q3 Earnings: What Key Metrics Have to Say | Pre-Markets in Red on Mid-East Concerns, Q3 Earnings in Focus | Oversold and Overextended, Abbott Laboratories is a Great Buy | Stocks Tumble on Renewed Middle East Risks | US STOCKS-Wall St falls as Middle East tensions drive risk-off mood | Stocks Close Lower on Heightened Geopolitical Risks and Soaring Bond Yields | Abbott Laboratories (ABT) Q3 2023 Earnings Call Transcript | S&P Futures Plunge as Middle East Fears Weigh on Sentiment, Tesla and Netflix Earnings on Tap | Abbott Laboratories Q3 Profit Beats Estimates | Markets Today: Stocks Slip on Set-Back in Diplomatic Efforts to Contain Israel-Hamas Conflict | Abbott Laboratories Lifts Midpoint Of FY23 Earnings Outlook Range - Update | Pre-Market Most Active for Oct 18, 2023 : ARDX, SQQQ, NKTX, TQQQ, QQQ, NVDA, ABT, PLTR, MS, NCLH, SPR, NIO | Abbott profit beats on strong sales of medical devices, diagnostics | ABB matches Q3 earnings forecasts, dampens expectations for next quarter | US STOCKS-Wall St set for lower open as Middle East tensions drive risk-off mood | Abbott beats profit estimates on strong sales of devices, diagnostics | US STOCKS-Futures down on Middle East worries as earnings get into full swing | S&P Futures Drop as Middle East Fears Weigh on Sentiment, Tesla and Netflix Earnings on Tap | Abbott Laboratories Q3 23 Earnings Conference Call At 9:00 AM ET","Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT reported third-quarter 2023 adjusted earnings of $1.14 per share, which topped the Zacks Consensus Estimate by 3.6%. Abbott Laboratories Price, Consensus and EPS Surprise Abbott Laboratories price-consensus-eps-surprise-chart | Abbott Laboratories Quote The Medical Devices segment’s sales rose 16.6% year over year on a reported basis (up 14.7% on an organic basis) to $4.25 billion. | Abbott Laboratories ABT came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $1.10 per share. Click to get this free report Morgan Stanley (MS) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Procter & Gamble Company (The) (PG) : Free Stock Analysis Report To read this article on Zacks.com click here. Procter & Gamble Co. PG came out with quarterly earnings of $1.83 per share, beating the Zacks Consensus Estimate of $1.71 per share. | Abbott Laboratories (ABT) was climbing almost 3% after it reported Q3 adjusted earnings of $1.14 per diluted share, down from $1.15 a year earlier but still beating the $1.10 forecast from analysts polled by Capital IQ. Health care stocks were steady premarket Wednesday with the iShares Biotechnology ETF (IBB) inactive and the Health Care Select Sector SPDR Fund (XLV) marginally higher. Ardelyx (ARDX) was gaining nearly 13% in value after the US Food and Drug Administration approved Xphozah as an add-on therapy to reduce serum phosphorus in adults with chronic kidney disease on dialysis who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. | Abbott (ABT) reported $10.14 billion in revenue for the quarter ended September 2023, representing a year-over-year decline of 2.6%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Here is how Abbott performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net sales- Diagnostics- U.S. $1.01 billion compared to the $1.01 billion average estimate based on four analysts. | Abbott Laboratories ABT came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $1.10 per share. Click to get this free report Morgan Stanley (MS) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Procter & Gamble Company (The) (PG) : Free Stock Analysis Report To read this article on Zacks.com click here. Procter & Gamble Co. PG came out with quarterly earnings of $1.83 per share, beating the Zacks Consensus Estimate of $1.71 per share. | The Technical Outlook: Abbott Laboratories is at the Bottom The technical outlook favored a rebound in ABT shares going into the Q3 report, and the report provided the expected catalyst. Abbott Laboratories (NYSE: ABT) share price has trended lower for nearly 2 years, but that trend is over. Assuming the market follows through on this signal, shares of ABT should continue to rebound and may move up to the $103 to $105 region before hitting significant resistance. | Abbott Laboratories (ABT) is up more than +3% after reporting Q3 net sales of $10.14 billion, better than the consensus of $9.81 billion. Also, the White House today said that the “current” U.S. intelligence assessment is that Israel was “not responsible” for the Gaza hospital blast based on “overhead imagery, intercepts and open source information.” Airline stocks are lower after Unite Airlines Holdings warned that the Israeli-Hamas war and higher jet fuel costs would weigh on earnings. A jump in the 10-year T-note yield to a new 16-year high today is bearish for stocks. | Abbott LaboratoriesABT.N advanced 2.8% after beating third-quarter profit estimates on strong sales of devices, diagnostics products. By Ankika Biswas and Shashwat Chauhan Oct 18 (Reuters) - Wall Street's main indexes fell on Wednesday as growing tensions in the Middle East dented risk sentiment, with investors also focused on earnings to gauge the impact of inflation and high interest rates on businesses. Long-dated Treasury yields hit multi-year highs after a sharp rebound in U.S. homebuilding added to earlier data pointing to a resilient economy, fueling concerns the Federal Reserve would not cut rates anytime soon. | Abbott Laboratories (ABT) rallied +3.71% after reporting Q3 net sales of $10.14 billion, better than the consensus of $9.81 billion. What you need to know… The S&P 500 Index ($SPX) (SPY) on Wednesday closed down -1.34%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.98%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -1.41%. Across the markets… December 10-year T-notes (ZNZ23) Wednesday closed down -11 ticks, and the 10-year T-note yield rose +6.6 bp to 4.900%. | Operator [Operator signoff] Duration: 0 minutes Call participants: Mike Comilla -- Vice President, Investor Relations Robert Ford -- Chairman and Chief Executive Officer Phil Boudreau -- Senior Vice President, Finance, and Chief Financial Officer Josh Jennings -- TD Cowen -- Analyst Larry Biegelsen -- Wells Fargo Securities -- Analyst Robbie Marcus -- JPMorgan Chase and Company -- Analyst Danielle Antalffy -- UBS -- Analyst Joanne Wuensch -- Citi -- Analyst Vijay Kumar -- Evercore ISI -- Analyst Matt Miksic -- Barclays -- Analyst Jayson Bedford -- Raymond James -- Analyst More ABT analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Abbott Laboratories (NYSE: ABT) Q3 2023 Earnings Call Oct 18, 2023, 9:00 a.m. For the fourth quarter, we forecast total underlying base business organic sales growth, excluding COVID testing sales, to be in the low double digits and exchange to have an unfavorable impact of a little more than 1% on fourth quarter reported sales. | You can see more pre-market stock movers here Today’s U.S. Earnings Spotlight: Wednesday - October 18th Tesla (TSLA), Procter & Gamble (PG), Abbott Labs (ABT), Netflix (NFLX), Morgan Stanley (MS), Elevance Health (ELV), Lam Research (LRCX), U.S. Bancorp (USB), Crown Castle (CCI), Travelers (TRV), Kinder Morgan (KMI), Las Vegas Sands (LVS), PPG Industries (PPG), Nasdaq Inc (NDAQ), Discover (DFS), Equifax (EFX), State Street (STT), M&T Bank (MTB), Steel Dynamics (STLD), Northern Trust (NTRS), Citizens Financial Group Inc (CFG), Rexford Inl Rty (REXR), Ally Financial Inc (ALLY), First Industrial RT (FR), Commerce Bancshares (CBSH), First Horizon National (FHN), Zions (ZION), Alcoa (AA), Columbia Banking (COLB), Synovus (SNV), FNB (FNB), Liberty Oilfield (LBRT), United Community Banks (UCBI), Unifirst (UNF), SL Green (SLG), Winnebago Industries (WGO), Marten Transport (MRTN), Stepan (SCL), Banner (BANR), Monarch (MCRI). Third-quarter earnings season picks up steam, with investors awaiting fresh reports from major global companies today, including Tesla (TSLA), Netflix (NFLX), Procter & Gamble (PG), Abbott Labs (ABT), and Morgan Stanley (MS). Japan’s Nikkei 225 Stock Index closed just above the flatline today as investors digested better-than-expected Chinese economic data, while anxieties about a more hawkish Federal Reserve and uncertainties related to the Gaza conflict continued to weigh on sentiment. | (RTTNews) - Abbott Laboratories (ABT) announced a profit for third quarter that beat the Street estimates. Excluding items, Abbott Laboratories reported adjusted earnings of $2.00 billion or $1.14 per share for the period. The company's revenue for the quarter fell 2.6% to $10.14 billion from $10.41 billion last year. | Earnings Reports (10/18/2023) Abbott Laboratories (ABT), Citizens Financial Group Inc (CFG), Crown Castle Inc (CCI), Discover Financial Services (DFS), Elevance Health Inc (ELV), Equifax Inc (EFX), Kinder Morgan Inc (KMI), Lam Research Corp (LRCX), Las Vegas Sands Corp (LVS), M&T Bank Corp (MTB), Morgan Stanley (MS), Nasdaq Inc (NDAQ), Netflix Inc (NFLX), Northern Trust Corp (NTRS), PPG Industries Inc (PPG), Procter & Gamble Co/The (PG), State Street Corp (STT), Steel Dynamics Inc (STLD), Tesla Inc (TSLA), Travelers Cos Inc/The (TRV), US Bancorp (USB), Zions Bancorp NA (ZION). Abbott Laboratories (ABT) climbed more than +2% in pre-market trading after reporting Q3 net sales of $10.14 billion, better than the consensus of $9.81 billion. Strength in bank stocks led the overall market higher today after the 10-year Jan JGB bond yield climbed to a new 10-year high. | (RTTNews) - Biopharmaceutical major Abbott Laboratories (ABT), while announcing flat earnings and weak revenues in its third quarter, on Wednesday raised the midpoint of its fiscal 2023 earnings guidance on a reported and adjusted basis. For the year, the company now expects earnings per share of $3.14 to $3.18 and adjusted earnings per share of $4.42 to $4.46. The company previously expected earnings per share of $3.02 to $3.22 and adjusted earnings per share of $4.30 to $4.50 for the full-year 2023. | Abbott Laboratories (ABT) is +2.24 at $94.38, with 639,471 shares traded. The total Pre-Market volume is currently 89,913,341 shares traded. ProShares UltraPro Short QQQ (SQQQ) is +0.28 at $19.11, with 3,387,490 shares traded. | Adds details on earnings throughout Oct 18 (Reuters) - Abbott Laboratories ABT.N on Wednesday tightened its profit forecast for the year after beating estimates for third-quarter earnings on strong demand for its medical devices and diagnostics products. The company is seeing a recovery in sales of its medical devices such as heart valve devices and pacemakers as more older people opt for surgeries that were put off due to the pandemic. Abbott posted a near 17% rise in quarterly sales of its medical devices to $4.25 billion, beating analysts' estimates of $4.16 billion. | Adds details ZURICH, Oct 18 (Reuters) - Swiss engineering group ABB ABBN.S matched forecasts with its third-quarter operating profit on Wednesday and dampened expectations for the fourth quarter while reporting continued decline in orders from China. The group said its order intake fell 2% during the quarter with double-digit growth in the United States, its biggest market, partially helping to offset a decline in China, ABB's second-largest market. For the full year 2023, the group said it expected comparable revenue growth to be in the low double-digit percentage range, and an operational margin to be in the range of 16.5% to 17.0%. | Abbott LaboratoriesABT.N advanced 2.4% after beating third-quarter profit estimates on strong sales of devices, diagnostics products. By Ankika Biswas and Shashwat Chauhan Oct 18 (Reuters) - Wall Street's main indexes were set to open lower on Wednesday as growing tensions in the Middle East spurred safe-haven demand, with investors also focused on earnings to gauge the impact of inflation and high interest rates on businesses. Interactive Brokers GroupIBKR.O fell 3.6% after reporting third-quarter results, with brokerages reducing their price targets on the online broker, citing the company's lowered account growth targets. | Oct 18 (Reuters) - Abbott Laboratories ABT.N on Wednesday tightened its profit forecast for the year after beating estimates for third-quarter earnings due to strong demand for its medical devices and diagnostics products. On an adjusted basis, the company now expects annual profit of $4.42 to $4.46 per share, compared with its previous forecast of $4.30-$4.50 per share. (Reporting by Pratik Jain and Leroy Leo in Bengaluru; Editing by Anil D'Silva) ((Pratik.Jain@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investors would lookout for quarterly updates from U.S. bank Morgan Stanley MS.N, custodian bank State Street STT.N and medical device maker Abbott Laboratories ABT.N before the opening bell. By Ankika Biswas and Shashwat Chauhan Oct 18 (Reuters) - Futures for Wall Street's main indexes dipped on Wednesday as growing tensions in the Middle East spurred demand for safe-haven assets, with investors also focused on earnings to gauge the impact of inflation and high interest rates on businesses. ET, Dow e-minis 1YMcv1 were down 93 points, or 0.27%, S&P 500 e-minis EScv1 were down 18.5 points, or 0.42%, and Nasdaq 100 e-minis NQcv1 were down 88.25 points, or 0.58%. | You can see more pre-market stock movers here Today’s U.S. Earnings Spotlight: Wednesday - October 18th Tesla (TSLA), Procter & Gamble (PG), Abbott Labs (ABT), Netflix (NFLX), Morgan Stanley (MS), Elevance Health (ELV), Lam Research (LRCX), U.S. Bancorp (USB), Crown Castle (CCI), Travelers (TRV), Kinder Morgan (KMI), Las Vegas Sands (LVS), PPG Industries (PPG), Nasdaq Inc (NDAQ), Discover (DFS), Equifax (EFX), State Street (STT), M&T Bank (MTB), Steel Dynamics (STLD), Northern Trust (NTRS), Citizens Financial Group Inc (CFG), Rexford Inl Rty (REXR), Ally Financial Inc (ALLY), First Industrial RT (FR), Commerce Bancshares (CBSH), First Horizon National (FHN), Zions (ZION), Alcoa (AA), Columbia Banking (COLB), Synovus (SNV), FNB (FNB), Liberty Oilfield (LBRT), United Community Banks (UCBI), Unifirst (UNF), SL Green (SLG), Winnebago Industries (WGO), Marten Transport (MRTN), Stepan (SCL), Banner (BANR), Monarch (MCRI). Third-quarter earnings season picks up steam, with investors awaiting fresh reports from major global companies today, including Tesla (TSLA), Netflix (NFLX), Procter & Gamble (PG), Abbott Labs (ABT), and Morgan Stanley (MS). Separately, data showed that the country’s industrial output grew more than expected in September from a year earlier, remaining consistent with the August growth rate, signifying that policy support measures are beginning to stabilize segments of the world’s second-largest economy. | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on Oct. 18, 2023, to discuss Q3 23 earnings results. To access the live webcast, log on to https://www.abbottinvestor.com/news-and-events?c=94004&p=irol-calall The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2023-10-17,91.9499969482422,92.13999938964844,-0.45833587646482893,"Pre-Market Earnings Report for October 18, 2023 : PG, ASML, ABT, MS, ELV, USB, TRV, NDAQ, STT, MTB, NTRS, CFG | Intuitive Surgical (ISRG) to Post Q3 Earnings: What's in Store? | Notable ETF Outflow Detected - SPY, XOM, ABT, DIS | Which Is A Better Pick – Abbott Stock Or Amgen? | Should You Pick MGM Resorts Over Boston Scientific Stock For Better Returns? | Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now?","Zacks Investment Research reports that the 2023 Price to Earnings ratio for ABT is 20.95 vs. an industry ratio of -2.00, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories (ABT)is reporting for the quarter ending September 30, 2023. In the past year ABT has beat the expectations every quarter. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report IQVIA Holdings Inc. (IQV) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT has an Earnings ESP of +1.62% and a Zacks Rank of 3. ABT’s earnings beat estimates in the last reported quarter. | Among the largest underlying components of SPY, in trading today Exxon Mobil Corp (Symbol: XOM) is up about 1%, Abbott Laboratories (Symbol: ABT) is up about 0.2%, and Walt Disney Co. (Symbol: DIS) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P 500 ETF Trust (Symbol: SPY) where we have detected an approximate $4.9 billion dollar outflow -- that's a 1.2% decrease week over week (from 932,180,000 to 921,030,000). For a complete list of holdings, visit the SPY Holdings page » The chart below shows the one year price performance of SPY, versus its 200 day moving average: Looking at the chart above, SPY's low point in its 52 week range is $363.54 per share, with $459.44 as the 52 week high point — that compares with a last trade of $434.69. | Given its better prospects, we believe Abbott stock (NYSE: ABT) is a better healthcare pick than Amgen stock (NASDAQ: AMGN). AMGN trades at a higher valuation multiple of 5.7x revenues vs. 3.9x for ABT due to its superior profitability. There is more to the comparison, and in the sections below, we discuss why we believe ABT will offer better returns than AMGN in the next three years. | MGM Resorts’ Revenue Growth Is Better MGM Resorts’ revenue growth has been better, with a 21.1% average annual growth rate in the last three years, compared to 6.3% for Boston Scientific. MGM Resorts’ 51% debt as a percentage of equity is higher than 13% for Boston Scientific, but its 9% cash as a percentage of assets is higher than 1% for the latter, implying that Boston Scientific has a better debt position and MGM Resorts has more cash cushion. The table below summarizes our revenue and return expectations for both companies over the next three years and points to an expected return of 20% for Boston Scientific over this period vs. a 24% expected return for MGM Resorts stock, implying that investors will likely be better off picking MGM over BSX, based on Trefis Machine Learning analysis – Boston Scientific vs. MGM Resort – which also provides more details on how we arrive at these numbers. | Click to get this free report ProShares S&P 500 Dividend Aristocrats ETF (NOBL): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Aflac Incorporated (AFL) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Dividend Appreciation ETF (VIG): ETF Research Reports iShares Core Dividend Growth ETF (DGRO): ETF Research Reports To read this article on Zacks.com click here. Launched on 10/09/2013, the ProShares S&P 500 Dividend Aristocrats ETF (NOBL) is a smart beta exchange traded fund offering broad exposure to the Style Box - Large Cap Value category of the market. IShares Core Dividend Growth ETF (DGRO) tracks Morningstar US Dividend Growth Index and the Vanguard Dividend Appreciation ETF (VIG) tracks NASDAQ US Dividend Achievers Select Index."
2023-10-16,91.0999984741211,92.18000030517578,0.20663670224283573,Should You Buy Abbott (ABT) Ahead of Earnings?,"This suggests that analysts have very recently bumped up their estimates for ABT, giving the stock a Zacks Earnings ESP of 1.62% heading into earnings season. Given that ABT has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Investors are always looking for stocks that are poised to beat at earnings season and Abbott Laboratories ABT, may be one such company."
2023-10-13,89.87999725341797,90.87000274658205,1.1855124578970055,Abbott (ABT) Gains As Market Dips: What You Should Know | Will Abbott (ABT) Beat Estimates Again in Its Next Earnings Report? | Abbott Laboratories a Top Ranked SAFE Dividend Stock With 2.3% Yield (ABT),"Abbott (ABT) ended the recent trading session at $90.87, demonstrating a +0.75% swing from the preceding day's closing price. Meanwhile, ABT's PEG ratio is currently 4.03. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Abbott (ABT). Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the company is positive, which is a great sign of an earnings beat, especially when you combine this metric with its nice Zacks Rank. | According to the ETF Finder at ETF Channel, Abbott Laboratories is a member of the iShares S&P 1500 Index ETF (ITOT), and is also an underlying holding representing 0.86% of the SPDR S&P Dividend ETF (SDY), which holds $172,340,337 worth of ABT shares. Abbott Laboratories (Symbol: ABT) has been named to the Dividend Channel ''S.A.F.E. Abbott Laboratories (Symbol: ABT) made the ""Dividend Channel S.A.F.E."
2023-10-12,92.25,90.19000244140624,1.101474770156859,CGDV: An Outperforming Dividend ETF with Lots to Like,"Other well-known, high-quality dividend-paying stocks within CGDV’s top holdings include the likes of Microsoft (NASDAQ:MSFT), Carrier Global (NYSE:CARR), Raytheon Technologies (NYSE:RTX), and Abbott Laboratories (NYSE:ABT). With a dividend yield of 1.74%, the Capital Group Dividend Value ETF (NYSEARCA:CGDV) may not seem like the type of ETF that would be of interest to dividend investors at first glance. According to fund sponsor Capital Group, CGDV’s strategy is to “produce income exceeding the average yield on U.S. stocks generally and to provide an opportunity for growth of principal consistent with sound common stock investing.” CGDV invests in “dividend-paying stocks of larger established U.S. companies.” The fund can also invest up to 10% of its assets in larger international companies."
2023-10-11,97.16000366210938,92.63999938964844,-2.2330596841124817,3 Reasons to Buy Abbott Laboratories Stock | Abbott Laboratories Enters Oversold Territory,"Medical device giant Abbott Laboratories (NYSE: ABT) hasn't performed well in the past year. ABT data by YCharts 1. Bigfoot Biomedical's claim to fame is its innovative insulin pen cap that can be paired with Abbott's FreeStyle Libre and uses data from the CGM device to guide insulin dosing recommendations for diabetes patients. | Abbott Laboratories (Symbol: ABT) presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most ""interesting"" ideas that merit further research by investors. But making Abbott Laboratories an even more interesting and timely stock to look at, is the fact that in trading on Wednesday, shares of ABT entered into oversold territory, changing hands as low as $92.05 per share. Indeed, ABT's recent annualized dividend of 2.04/share (currently paid in quarterly installments) works out to an annual yield of 2.09% based upon the recent $97.56 share price."
2023-10-10,96.81999969482422,97.55999755859376,-4.652124436079717,"Lumentum Lights Up on the AI and ML Surge | Worried About a Recession? Protect Your Portfolio With These 3 Resilient Stocks | What's in Store for Abbott Laboratories (ABT) in Q3 Earnings? | 3 Dividend Kings Every Investor Should Own to Survive a Market Crash | Ex-Dividend Reminder: Abbott Laboratories, American Financial Group and Bank OZK","Lumentum CEO Alan Lowe commented, ""With generational upgrades in the network's backbone and increased customer activity for AI in the data center, we expect year-over-year Telecom and Datacom growth in calendar 2024… We believe that the current customer inventory correction cycle will continue through the balance of the calendar year, and therefore, our shipments will be below end-market demand. Lowered Guidance Lumentum lowered its fiscal Q1 2024 EPS of 20 to 30 cents versus 55 cents consensus analyst estimates. The increased AI activity for datacom translates into more shipments for its chip-level products for 800-gig transceivers and continuous wave (CW) lasers to connect server racks and AI clusters, which require higher data rates but low power. | www.barchart.com Abbott Laboratories We conclude our list with pharmaceutical giant Abbott Laboratories (ABT). Out of 13 analysts covering the stock, 6 have a “Strong Buy” rating, 1 has a “Moderate Buy” rating, and 6 have a “Hold” rating. Out of 28 analysts covering the stock, 18 have a “Strong Buy” rating, 3 have a “Moderate Buy” rating, and 7 have a “Hold” rating. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Cencora, Inc. (COR) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT is slated to report its third-quarter 2023 results on Oct 18, before market open. Q3 Estimates The Zacks Consensus Estimate for ABT’s third quarter 2023 revenues is pegged at $9.78 billion. | It earned the title by riding the coattails of Abbott Labs (NYSE:ABT) which spun it off. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Dividend stocks have proved time and again to be a superior investing strategy. AbbVie (ABBV) Source: Valeriya Zankovych / Shutterstock.com Pharmaceutical stock AbbVie (NYSE:ABBV) isn’t your typical Dividend King. | Looking at the universe of stocks we cover at Dividend Channel, on 10/12/23, Abbott Laboratories (Symbol: ABT), American Financial Group Inc (Symbol: AFG), and Bank OZK (Symbol: OZK) will all trade ex-dividend for their respective upcoming dividends. Abbott Laboratories (Symbol: ABT): American Financial Group Inc (Symbol: AFG): Bank OZK (Symbol: OZK): In general, dividends are not always predictable, following the ups and downs of company profits over time. As a percentage of ABT's recent stock price of $96.92, this dividend works out to approximately 0.53%, so look for shares of Abbott Laboratories to trade 0.53% lower — all else being equal — when ABT shares open for trading on 10/12/23."
2023-10-09,96.41000366210938,96.76000213623048,0.7643026916980089,2 Magnificent Dividend Stocks to Buy Hand Over Fist in October | Implied VOOG Analyst Target Price: $292,"After all, most stocks outside the areas of artificial intelligence and weight-loss care have lost ground over the last two years because of various economic and geopolitical factors, along with a wide swath of investors opting for safer alternatives to stocks like high-yield savings accounts and fixed rate CDs. That may not be the most convincing outlook for a dividend stock (analysts usually prefer a competitive advantage that lasts for at least 20 years), but it should be enough to make AbbVie's shares a valuable part of a diversified income portfolio. See the 10 stocks *Stock Advisor returns as of October 2, 2023 George Budwell has no position in any of the stocks mentioned. | Similarly, ABT has 26.83% upside from the recent share price of $96.88 if the average analyst target price of $122.88/share is reached, and analysts on average are expecting TMO to reach a target price of $629.53/share, which is 26.27% above the recent price of $498.55. Three of VOOG's underlying holdings with notable upside to their analyst target prices are Keurig Dr Pepper Inc (Symbol: KDP), Abbott Laboratories (Symbol: ABT), and Thermo Fisher Scientific Inc (Symbol: TMO). Below is a twelve month price history chart comparing the stock performance of KDP, ABT, and TMO: Below is a summary table of the current analyst target prices discussed above:"
2023-10-06,95.80999755859376,96.87999725341795,0.3630312839192047,HLN vs. ABT: Which Stock Is the Better Value Option?,"These metrics, and several others, help HLN earn a Value grade of B, while ABT has been given a Value grade of C. HLN is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. Click to get this free report Haleon PLC Sponsored ADR (HLN) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Investors interested in stocks from the Medical - Products sector have probably already heard of Haleon PLC Sponsored ADR (HLN) and Abbott (ABT)."
2023-10-05,95.76000213623048,96.1999969482422,1.1167933640430572,"(ABT) Ascends While Market Falls: Some Facts to Note | Notable ETF Inflow Detected - VTV, BAC, ABT, BMY","Abbott (ABT) closed the most recent trading day at $96.20, moving +0.58% from the previous trading session. We can additionally observe that ABT currently boasts a PEG ratio of 4.27. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | Among the largest underlying components of VTV, in trading today Bank of America Corp (Symbol: BAC) is off about 0.5%, Abbott Laboratories (Symbol: ABT) is up about 0.4%, and Bristol Myers Squibb Co. (Symbol: BMY) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Value ETF (Symbol: VTV) where we have detected an approximate $610.7 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 707,610,267 to 712,114,313). For a complete list of holdings, visit the VTV Holdings page » The chart below shows the one year price performance of VTV, versus its 200 day moving average: Looking at the chart above, VTV's low point in its 52 week range is $122.54 per share, with $147.725 as the 52 week high point — that compares with a last trade of $135.25."
2023-10-04,95.88999938964844,95.6500015258789,0.4594766104806175,,
2023-10-03,95.5199966430664,95.79000091552734,-0.25028456074371364,"The Zacks Analyst Blog Highlights Abbott Laboratories, Koninklijke Philips and Smith & Nephew","Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Koninklijke Philips N.V. (PHG) : Free Stock Analysis Report Smith & Nephew SNATS, Inc. (SNN) : Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include: Abbott Laboratories ABT, Koninklijke Philips PHG and Smith & Nephew SNATS SNN. During the first half of 2023, ABT repurchased approximately 7 million shares for a total cost of $725 million."
2023-10-02,95.76000213623048,95.7300033569336,0.28266779936129377,3 Medical Product Stocks With Solid Dividend Yield: ABT & Others,"Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Koninklijke Philips N.V. (PHG) : Free Stock Analysis Report Smith & Nephew SNATS, Inc. (SNN) : Free Stock Analysis Report To read this article on Zacks.com click here. Owing to the rising market volatility, it would be a wise decision to focus on some dividend-paying companies like Abbott Laboratories ABT, Koninklijke Philips PHG and Smith & Nephew SNATS SNN from the Medical - Products industry to create a steady income source. During the first half of 2023, ABT repurchased approximately 7 million shares for a total cost of $725 million."
2023-09-29,98.4499969482422,96.8499984741211,-0.03132704535053396,"Want $500 in Passive Income? Invest $3,500 Into These 3 Dividend Stocks and Wait 4 Years","Including the years prior to the split from Abbott Laboratories (NYSE: ABT) in 2013, AbbVie is a Dividend King. A dividend stock for energy bulls Lee Samaha (Diamondback Energy): I don't know what Diamondback's dividend will be next year, nor does the investment community at large -- and, for that matter, neither does its management. The reason is that the company returns capital to investors through a combination of a base dividend (which it intends to maintain), a variable dividend whose amount fluctuates with the price of energy and Diamondback's production, and opportunistic share buybacks."
2023-09-28,96.27999877929688,98.12000274658205,-1.6251889524814003,"The Zacks Analyst Blog Highlights Alphabet, Exxon Mobil, Merck, Abbott Laboratories and NextEra Energy | Abbott (ABT) Rides on Nutrition Recovery Amid Low Testing Sales | After Plunging -8.5% in 4 Weeks, Here's Why the Trend Might Reverse for Abbott (ABT)","Click to get this free report NextEra Energy, Inc. (NEE) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Exxon Mobil Corporation (XOM) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report Alphabet Inc. (GOOGL) : Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include: Alphabet Inc. GOOGL, Exxon Mobil Corp. XOM, Merck & Co., Inc. MRK, Abbott Laboratories ABT and NextEra Energy, Inc. NEE. Here are highlights from Wednesday’s Analyst Blog: Top Stock Reports for Alphabet, Exxon Mobil and Merck The Zacks Research Daily presents the best research output of our analyst team. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report Quanterix Corporation (QTRX) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott’s ABT branded generics and international diabetes businesses continue to drive growth for the company. The withdrawal of business from the Chinese market, which holds a significant share of Abbott’s pediatric nutrition sales, is going to significantly impact Abbott’s overall Nutrition business in the coming period. | Why a Trend Reversal is Due for ABT The RSI reading of 22.54 for ABT is an indication that the heavy selling could be in the process of exhausting itself, so the stock could bounce back in a quest for reaching the old equilibrium of supply and demand. A downtrend has been apparent in Abbott (ABT) lately with too much selling pressure. A strong agreement among sell-side analysts covering ABT in raising earnings estimates for the current year has led to an increase in the consensus EPS estimate by 0% over the last 30 days."
2023-09-27,96.58999633789062,95.52999877929688,1.9110967912484302,"IWB, BAC, LIN, ABT: ETF Outflow Alert | Abbott (ABT) Stock Sinks As Market Gains: What You Should Know | Top Stock Reports for Alphabet, Exxon Mobil & Merck","Among the largest underlying components of IWB, in trading today Bank of America Corp (Symbol: BAC) is up about 0.7%, Linde PLC (Symbol: LIN) is up about 0.5%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $257.5 million dollar outflow -- that's a 0.9% decrease week over week (from 125,150,000 to 124,050,000). For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $192.01 per share, with $252.935 as the 52 week high point — that compares with a last trade of $234.60. | In the latest trading session, Abbott (ABT) closed at $95.53, marking a -0.73% move from the previous day. It is also worth noting that ABT currently has a PEG ratio of 4.3. ABT's industry had an average PEG ratio of 2.62 as of yesterday's close. | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Solid Momentum in Cloud Business Benefits Alphabet (GOOGL) ExxonMobil (XOM) Banks on Oil-Rich Offshore Guyana Assets Keytruda to Remain Merck's (MRK) Key Top-Line Driver Featured Reports Organic Sales Gain, EPD Business Growth Aid Abbott (ABT) The Zacks analyst is impressed with Abbott's strong market share gains in organic base business. Click to get this free report NextEra Energy, Inc. (NEE) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Exxon Mobil Corporation (XOM) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report Intuit Inc. (INTU) : Free Stock Analysis Report Alphabet Inc. (GOOGL) : Free Stock Analysis Report To read this article on Zacks.com click here. Other noteworthy reports we are featuring today include Abbott Laboratories (ABT), Intuit Inc. (INTU) and NextEra Energy, Inc. (NEE)."
2023-09-26,97.0500030517578,96.2300033569336,-1.0974196073946125,Will Insulet (PODD) Stock Recover To Its Pre-Inflation Shock Highs of $300? | Prestige Consumer (PBH) Stock Rallies 20% in a Year: Here's Why | Here's Why Investors Should Invest in Abbott (ABT) Stock Now | EXCLUSIVE-Edwards Lifesciences cooperating with EU antitrust regulators | 5 Dividend Aristocrats to Buy as Things Look Dicey for Wall Street | EXCLUSIVE-Edwards Lifesciences targeted in EU antitrust raid last week - sources | 2 Stocks to Benefit from the Aging Population,"Insulet stock (NASDAQ: PODD) currently trades at $156 per share, about 29% lower than the level seen in early June 2022, just before the Fed started increasing rates, compared to 14% gains for the S&P 500 during this period. July – September 2022: Fed hikes interest rates aggressively – resulting in an initial recovery in the S&P 500 followed by another sharp decline October 2022 – July 2023: Fed continues rate hike process; improving market sentiments help S&P500 recoup some of its losses Since August 2023: Fed keeps interest rates unchanged to quell fears of a recession, although another rate hike remains on the cards. Insulet And S&P500 Performance During 2007-08 Financial Crisis PODD stock saw a 70% decline from $21 in September 2007 (pre-crisis peak) to $6 in March 2009 (as the markets bottomed out). | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Koninklijke Philips N.V. (PHG) : Free Stock Analysis Report Prestige Consumer Healthcare Inc. (PBH) : Free Stock Analysis Report LeMaitre Vascular, Inc. (LMAT) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT, a healthcare product company, currently carries a Zacks Rank #2. ABT has a trailing four-quarter earnings surprise of 12.4%, on average. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DaVita Inc. (DVA) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT is gaining from its strategic global expansion to address the unmet demand for advanced medical technologies. In the past few quarters, there has been a decline in demand for Abbott’s rapid diagnostic tests to detect COVID-19, primarily offset by higher growth across other businesses. | According to analysts, Edwards Lifesciences competes with Abbot Laboratories ABT.N, Medtronic MDT.N, Zimmer Biomet ZBH.N and Boston Scientific Corp BSX.N, among others. By Foo Yun Chee BRUSSELS, Sept 26 (Reuters) - Edwards Lifesciences EW.N is working with EU antitrust regulators after they raided one of its facilities in an EU country a week ago, the U.S. medical device maker said on Tuesday. The European Commission on Sept. 19 said it raided a cardiovascular medical device company in an EU country on concerns that it may have abused its market power in breach of the bloc's antitrust rules. | Thus, with the government shutdown and rate hike concerns looming and the stock market subjected to bouts of volatility, it’s prudent for investors to place bets on dividend aristocrats like Caterpillar CAT, Abbott Laboratories ABT, McDonald's MCD, Aflac AFL and Automatic Data Processing ADP for steady income. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Caterpillar Inc. (CAT) : Free Stock Analysis Report Automatic Data Processing, Inc. (ADP) : Free Stock Analysis Report McDonald's Corporation (MCD) : Free Stock Analysis Report Aflac Incorporated (AFL) : Free Stock Analysis Report To read this article on Zacks.com click here. In the past five years, ABT’s payout has advanced by 14%. | According to analysts, Edwards Lifesciences competes with Abbot Laboratories ABT.N, Medtronic MDT.N, Zimmer Biomet ZBH.N and Boston Scientific Corp BSX.N, among others. By Foo Yun Chee BRUSSELS, Sept 26 (Reuters) - Edwards Lifesciences EW.N was raided by EU antitrust regulators at one of its facilities in an EU country a week ago, two people with direct knowledge of the matter told Reuters on Tuesday. The European Commission on Sept. 19 said it raided a cardiovascular medical device company in an EU country on concerns that it may have abused its market power in breach of the bloc's antitrust rules. | Abbott Laboratories Inc.  (NYSE: ABT) Abbott Labs is a diversified global healthcare company that treats chronic illnesses with products catering to the entire life cycle. ABT shares are trading down 10.4% YTD, paying a 2.08% annual dividend yield. ABT fell to a low of $95.45 in March 2023 to establish the lower trendline of the rectangle."
2023-09-25,97.97000122070312,97.47000122070312,-0.8449249552180744,Market Heat Check: Top 10 Stocks Riding High on Implied Volatility | Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?,"Intuitive Surgical (ISRG) Phillip Morris International (PM) Proctor & Gamble (PG) Aboot Laboratories (ABT) Novo Nordisk (NVO) RTX Corp (RTX) Charles Schwab (SCHW) Pepsico (PEP) Here is the full list of stocks showing IV Percentile and earnings dates. IV Percentile is a measure of implied volatility where current implied volatility is compared to the range of implied volatilities in this past. Using The Stock Screener To Find High Volatility Stocks With the VIX index jumping back above 17, there are quite a few stocks showing high implied volatility. | Click to get this free report iShares U.S. Medical Devices ETF (IHI): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report SPDR S&P Health Care Equipment ETF (XHE): ETF Research Reports First Trust Indxx Medical Devices ETF (MDEV): ETF Research Reports To read this article on Zacks.com click here. Looking at individual holdings, Thermo Fisher Scientific Inc (TMO) accounts for about 16.55% of total assets, followed by Abbott Laboratories (ABT) and Medtronic Plc (MDT). First Trust Indxx Medical Devices ETF (MDEV) tracks INDXX GLOBAL MEDICAL EQUIPMENT INDEX and the SPDR S&P Health Care Equipment ETF (XHE) tracks S&P Health Care Equipment Select Industry Index."
2023-09-22,98.9000015258789,98.1500015258789,-0.5103603080228802,"Abbott India warns of laxatives shortage in tussle with Goa regulator | Daily Dividend Report: SCVL,ABT,TXN,WKC,BFS","By Rishika Sadam HYDERABAD, Sept 22 (Reuters) - Abbott Laboratories' ABT.N Indian unit has warned of potential supply shortages of two popular laxative syrups after production was prohibited in India's Goa state, where drug inspectors have found lapses at a company factory, a letter shows. Goa, where Abbott has one of its two India plants, asked the company to halt production of Cremaffin and Duphalac syrups last month. In a letter to Goa's Directorate of Food and Drugs Administration dated Sept. 18, which is not public and has not previously been reported on, Abbott ABOT.NS pushed state regulators to allow it to restart manufacturing the two medicines. | VIDEO: Daily Dividend Report: SCVL,ABT,TXN,WKC,BFS The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The increased quarterly cash dividend of $0.12 per share will be paid on October 17, 2023, to shareholders of record as of the close of business on October 3, 2023. Abbott has increased its dividend payout for 51 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years."
2023-09-21,100.0,98.93000030517578,-0.758341747652804,Abbott (ABT) Stock Moves -1.35%: What You Should Know | Abbott (ABT) to Commercialize Biosimilars in Emerging Markets,"Abbott (ABT) closed at $98.93 in the latest trading session, marking a -1.35% move from the prior day. Also, we should mention that ABT has a PEG ratio of 4.48. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report Quanterix Corporation (QTRX) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT recently announced an agreement with the leading international biopharmaceutical company, mAbxience Holdings S.L. It will help introduce life-saving treatments in key oncology, women's health and respiratory diseases for the first time in some countries at a fraction of the cost of originator biologics, making it more accessible and affordable for healthcare systems in these countries by leveraging ABT's broad in-country footprint."
2023-09-20,101.19000244140624,100.27999877929688,-1.0699996948242188,All You Need to Know About Abbott (ABT) Rating Upgrade to Buy | Abbott (ABT) Broadens Electrophysiology Footprint With TactiFlex | Abbott (ABT) Unveils Connected Diabetes App With New Pact | Abbott Inks Deal With MAbxience To Commercialize Biosimilar Molecules In Emerging Markets,"Abbott (ABT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Most Powerful Force Impacting Stock Prices The change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report Quanterix Corporation (QTRX) : Free Stock Analysis Report SiBone (SIBN) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT has taken a significant step in the field of electrophysiology with the introduction of its TactiFlex Ablation Catheter, Sensor Enabled. In the face of rising demand to treat AFib, Abbott's TactiFlex SE catheter launch offers numerous advantages over conventional treatments. | Abbott Laboratories, Inc. ABT and WW International WW announced the release of a linked app to help patients with diabetes understand how food and activity affect their glucose levels. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report SiBone (SIBN) : Free Stock Analysis Report WW International, Inc. (WW) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories Price Abbott Laboratories price | Abbott Laboratories Quote In June 2023, Abbott partnered with the American Diabetes Association (“ADA”) to launch a therapeutic nutrition program for people with diabetes. | (RTTNews) - Abbott Laboratories (ABT) announced Wednesday an agreement with Spain-based global biotech firm mAbxience Holdings S.L. Abbott will register and commercialize the biosimilars in key emerging countries in Latin America, Southeast Asia, the Middle East and Africa, leveraging the company's broad in-country footprint to make these cutting-edge medicines available to more people in emerging countries. mAbxience, with majority ownership from Fresenius Kabi and partial ownership from Insud Pharma, will manufacture the biosimilars in one of its two state-of-the art and Good Manufacturing Practices (GMP)-approved facilities in Spain and Argentina."
2023-09-19,101.37999725341795,100.66999816894533,-0.8993019469846298,"Noteworthy ETF Inflows: IWB, MCD, BAC, ABT | EXCLUSIVE-India's Torrent in talks with Apollo to borrow up to $1 bln for Cipla bid, sources say","Among the largest underlying components of IWB, in trading today McDonald's Corp (Symbol: MCD) is up about 0.1%, Bank of America Corp (Symbol: BAC) is trading flat, and Abbott Laboratories (Symbol: ABT) is up by about 824.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $159.1 million dollar inflow -- that's a 0.5% increase week over week in outstanding units (from 124,500,000 to 125,150,000). For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $192.01 per share, with $252.935 as the 52 week high point — that compares with a last trade of $243.68. | It competes with global majors Pfizer PFE.N and Abbott ABT.N, among others, in the world's most populous nation where the pharmaceutical market is expected to be worth $130 billion by 2030 from $50 billion currently. By M. Sriram and Aditya Kalra MUMBAI/NEW DELHI, Sept 19 (Reuters) - India's Torrent Pharmaceutical TORP.NS is in preliminary talks with Apollo Global Management APO.N to secure a loan of up to $1 billion to help fund a planned bid for Cipla CIPL.NS, two people briefed on the discussions said. Torrent has also been in talks with CVC Capital Partners and Bain Capital who might become equity partners in a consortium and contribute as much as a combined $1.5 billion to the deal, sources have said."
2023-09-18,102.06999969482422,101.0,-0.7003344877765725,"India's Torrent Pharma in talks with CVC, Bain Capital for Cipla bid- sources","It competes with global majors Pfizer PFE.N and Abbott ABT.N, among others, in the world's most populous nation whose pharmaceutical market is expected to reach $130 billion by 2030, from $50 billion currently. By Aditya Kalra and M. Sriram DELHI/MUMBAI, Sept 18 (Reuters) - India's Torrent Pharmaceuticals TORP.NS is in talks with private equity funds CVC Capital Partners and Bain Capital to raise up to $1.5 billion to bid for India's Cipla CIPL.NS, according to three sources with direct knowledge of the matter. Bain and Blackstone declined to comment while Cipla, Torrent and CVC did not respond to comments."
2023-09-15,102.8499984741211,101.73999786376952,-1.0482998902942844,S&P 500 Analyst Moves: ABT | December 15th Options Now Available For Abbott Laboratories (ABT) | 2 Dividend Kings to Buy on the Dip and Hold Forever | Could Abbott Laboratories Stock Help You Become a Millionaire?,"VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories is now the #106 analyst pick, moving up by 3 spots. This rank is formed by averaging the analyst opinions for each component from each broker, and then ranking the 500 components by those average opinion values. | Below is a chart showing ABT's trailing twelve month trading history, with the $105.00 strike highlighted in red: Considering the fact that the $105.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the December 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new December 15th contracts and identified one put and one call contract of particular interest. | Let's look at two Dividend Kings that are lagging the market this year but are still worth investing in for the long term: Abbott Laboratories (NYSE: ABT) and AbbVie (NYSE: ABBV). ABT Revenue (Quarterly) data by YCharts The company owes it to an internal culture dedicated to innovation, its expertise in navigating the highly regulated healthcare industry, and a brand name that inspires confidence in the physicians and patients who use its products. Abbott Laboratories Medical devices expert Abbott Laboratories has delivered somewhat inconsistent financial results over the past three years. | Abbott Laboratories (NYSE: ABT) is a leading healthcare company with a global presence. Here's how the company's quarterly growth rate has fluctuated over the past decade: ABT Revenue (Quarterly YoY Growth) data by YCharts Through the first half of 2023, only one of its segments generated more than the 9% growth the company has averaged over the past decade, and that's medical devices. The table below shows the annual return the stock would need to average for it to grow to a value of $1 million, based on investment years and the initial investment amount:"
2023-09-14,103.22000122070312,102.6500015258789,-1.0792422234511485,ABT May 2024 Options Begin Trading | Goa state warns Abbott India on antacid Digene license suspension,"Below is a chart showing ABT's trailing twelve month trading history, with the $105.00 strike highlighted in red: Considering the fact that the $105.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the May 2024 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new May 2024 contracts and identified one put and one call contract of particular interest. | By Rishika Sadam HYDERABAD, India, Sept 14 (Reuters) - India's Goa state has warned the local unit of Abbott Laboratories ABT.N it plans to suspend the manufacturing license of its popular antacid medicine after inspectors flagged contamination risks and sanitization issues at its factory, government documents show. The Goa plant is one of Abbott's two factories in India, where Digene has a 7% share of the market for so-called antiflatulent medicines, according to Pharmarack, which estimated annual Digene syrup sales at $11 million, with 8 million units sold. Following the recall, inspectors conducted four inspections at Abbott's Goa factory between Aug. 24 and Sept. 2 and flagged issues such as water stagnation in tanks and pipes, saying: ""This may lead to the contamination and microbial growth,"" confidential inspection reports reviewed by Reuters showed."
2023-09-13,102.06999969482422,102.69000244140624,-0.552218260107802,,
2023-09-12,102.37000274658205,102.4000015258789,0.6074289687819566,Is Abbott Laboratories a Buy? | This Proven 200% Dividend Growth Strategy Is a Peter Lynch Favorite,"Despite its formidable market capitalization of $174 billion and more than 100 years in operation, Abbott Laboratories (NYSE: ABT) is a stock that can sometimes be overlooked. Good things come to those who wait The catch with Abbott Laboratories is that it isn't a growth stock per se. See the 10 stocks *Stock Advisor returns as of September 5, 2023 Alex Carchidi has no position in any of the stocks mentioned. | JNJ/Kenvue ""Prequel"" Shows How to Tap Spinoffs for Max Gains, Divs To see what I'm getting at, consider the split of medical-equipment maker Abbott Labs (ABT) from pharmaceutical firm AbbVie (ABBV), which occurred back in 2013. Moreover, as JNJ offered to exchange its shares for shares of the new firm under the spinoff, the resulting drop in the share count cuts JNJ's shares outstanding. On the day of the split, Abbott investors were handed one share of AbbVie for every Abbott share they owned, and the new firm set its payout at $0.40 a share quarterly."
2023-09-11,100.8000030517578,102.4499969482422,0.029304267355665763,"Abbott (ABT) Outpaces Stock Market Gains: What You Should Know | Noteworthy Monday Option Activity: SAM, TWNK, ABT | Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know | With 2x Potential Returns Is DexCom A Better Pick Over Intuitive Surgical?","Abbott (ABT) closed at $102.45 in the latest trading session, marking a +1.71% move from the prior day. It is also worth noting that ABT currently has a PEG ratio of 4.5. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | Below is a chart showing TWNK's trailing twelve month trading history, with the $30 strike highlighted in orange: And Abbott Laboratories (Symbol: ABT) saw options trading volume of 16,363 contracts, representing approximately 1.6 million underlying shares or approximately 41.9% of ABT's average daily trading volume over the past month, of 3.9 million shares. Especially high volume was seen for the $104 strike call option expiring September 15, 2023, with 1,359 contracts trading so far today, representing approximately 135,900 underlying shares of ABT. Below is a chart showing ABT's trailing twelve month trading history, with the $104 strike highlighted in orange: For the various different available expirations for SAM options, TWNK options, or ABT options, visit StockOptionsChannel.com. | Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. | DexCom’s Revenue Growth Is Better DexCom’s revenue growth has been better, with a 25.5% average annual growth rate in the last three years, compared to 12.4% for Intuitive Surgical. Intuitive Surgical stock trades at 16x revenues compared to its last five-year average of 21x, and DexCom stock trades at 13x revenues vs. the last five-year average of 21x. The table below summarizes our revenue and return expectations for Intuitive Surgical and DexCom over the next three years and points to an expected return of 45% for ISRG over this period vs. a 98% expected return for DXCM stock, implying that both stocks offer excellent buying opportunity at current levels."
2023-09-08,100.5999984741211,100.7300033569336,1.6368986572720445,"VTV, ABT, WFC, NEE: ETF Inflow Alert | The 3 Best Pharma Stocks to Buy Now: September 2023","Among the largest underlying components of VTV, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.1%, Wells Fargo & Co (Symbol: WFC) is up about 0.6%, and NextEra Energy Inc (Symbol: NEE) is up by about 1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Value ETF (Symbol: VTV) where we have detected an approximate $235.7 million dollar inflow -- that's a 0.2% increase week over week in outstanding units (from 705,954,364 to 707,610,267). For a complete list of holdings, visit the VTV Holdings page » The chart below shows the one year price performance of VTV, versus its 200 day moving average: Looking at the chart above, VTV's low point in its 52 week range is $122.54 per share, with $147.725 as the 52 week high point — that compares with a last trade of $142.71. | Abbott (ABT) Source: Sisacorn / Shutterstock.com Abbott Laboratories (NYSE:ABT) has recently demonstrated its prowess in pharmaceuticals and healthcare. As technology advances, the companies that make life in this sector will always be applying it, as well as implementing new processes, new combinations, and new formulas, always with the aim of being able to make medicines and treatments much more effective and efficient for all of us. In an era when cell therapies are gaining momentum in the pharmaceutical sector, this collaboration aims to develop innovative technologies that improve the consistency of clinical outcomes for patients and address the manufacturing challenges associated with advanced engineered cellular products."
2023-09-07,101.98999786376952,100.66999816894533,0.12922950773795805,Relative Strength Alert For Abbott Laboratories | Abbott Laboratories a Top 25 Dividend Giant With 2.01% Yield (ABT) | Is Abbott Stock A Better Healthcare Pick Over Thermo Fisher Scientific?,"Abbott Laboratories (Symbol: ABT) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most ""interesting"" ideas that merit further research by investors. But making Abbott Laboratories an even more interesting and timely stock to look at, is the fact that in trading on Thursday, shares of ABT entered into oversold territory, changing hands as low as $100.80 per share. Indeed, ABT's recent annualized dividend of 2.04/share (currently paid in quarterly installments) works out to an annual yield of 2.01% based upon the recent $101.56 share price. | Abbott Laboratories (Symbol: ABT) has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a stunning $22.58B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 2.01% yield, according to the most recent Dividend Channel ''DividendRank'' report. Below is a long-term dividend history chart for ABT, which the report stressed as being of key importance. The annualized dividend paid by Abbott Laboratories is $2.04/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 07/13/2023. | We believe Thermo Fisher Scientific stock (NYSE: TMO) is a better pick than its sector peer, Abbott stock (NYSE: ABT), given its better prospects. TMO trades at a slightly higher valuation multiple of 4.9x revenues vs. 4.4x for ABT due to its superior revenue growth. While ABT is down 6% this year, TMO is up 1%, and the S&P500 index is up 18%."
2023-09-06,101.01000213623048,101.55999755859376,-1.2942442616650955,Abbott (ABT) to Advance Diabetes Care With New Acquisition,"Abbott Laboratories, Inc. ABT recently entered into a definitive agreement to acquire Bigfoot -- a developer of smart insulin management systems for people with diabetes. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report Quanterix Corporation (QTRX) : Free Stock Analysis Report SiBone (SIBN) : Free Stock Analysis Report To read this article on Zacks.com click here. The FDA has approved ABT’s TactiFlex Ablation Catheter to treat abnormal heart rhythms."
2023-09-05,102.77999877929688,100.87999725341795,0.544496001120277,"Abbott (ABT) Dips More Than Broader Markets: What You Should Know | What's Next For DexCom Stock After A 17% Fall In A Month? | Down 10.3%, Is Abbott Laboratories Stock a Buy on the Dip?","Abbott (ABT) closed at $100.88 in the latest trading session, marking a -1.92% move from the prior day. Meanwhile, ABT's PEG ratio is currently 4.59. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | DexCom stock (NASDAQ: DXCM) has seen a 17% fall in a month, compared to a 2% fall for the broader S&P500 index. DexCom’s revenue growth of 117% to $3.2 billion over the last twelve months, compared to $1.5 billion in 2019, partly offset by 2. the company’s P/S ratio falling 9% to 12.5x revenues vs. 13.7x in 2019, and 3. a 5% rise in its total shares outstanding to 388 million. Total [2] DXCM Return -17% -9% 593% S&P 500 Return -2% 18% 102% Trefis Reinforced Value Portfolio -4% 32% 576% [1] Month-to-date and year-to-date as of 8/31/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | If you're trying to build a passive income stream to eventually fuel your dream retirement, Abbott Laboratories (NYSE: ABT) is a stock you probably want to know more about. In addition to its recent rapid dividend growth, cautious long-term investors love the stock because they know Abbott has raised its dividend payout for 50 consecutive years. Reasons to buy Abbott Laboratories stock right now COVID-19 test sales are tanking as expected, but sales of its other diagnostics, nutrition products, and medical devices are soaring."
2023-09-01,103.4000015258789,102.8499984741211,-1.8486101852937955,"The 3 Most Promising Healthcare Stocks to Own Now | The Zacks Analyst Blog Highlights Oracle, Abbott Laboratories, Sanofi, Realty Income and Hilton Worldwide Holdings","Furthermore, its IVL solution faces limited competition with Abbott Laboratories (NYSE:ABT) products, not expected until 2026. InvestorPlace - Stock Market News, Stock Advice & Trading Tips The healthcare sector has underperformed this year, with the Health Care Select Sector SPDR (NYSEARCA:XLV) down 1%. Shockwave Medical (SWAV) Source: metamorworks / Shutterstock Despite Shockwave Medical’s (NASDAQ:SWAV) decline since May 11, it’s one of my top healthcare stock picks. | Click to get this free report Sanofi (SNY) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Oracle Corporation (ORCL) : Free Stock Analysis Report Realty Income Corporation (O) : Free Stock Analysis Report Hilton Worldwide Holdings Inc. (HLT) : Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include: Oracle Corp. ORCL, Abbott Laboratories ABT, Sanofi SNY, Realty Income Corp. O and Hilton Worldwide Holdings Inc. HLT. Here are highlights from Thursday’s Analyst Blog: Top Stock Reports for Oracle, Abbott and Sanofi The Zacks Research Daily presents the best research output of our analyst team."
2023-08-31,104.5199966430664,102.9000015258789,-0.5319178371773602,"Top Stock Reports for Oracle, Abbott & Sanofi | Wall Street Analysts Think Abbott (ABT) Is a Good Investment: Is It? | 2 Unstoppable Growth Stocks to Buy in 2023 and Beyond","If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Oracle (ORCL) Gains from Cloud Suite Adoption & Partnerships Organic Sales Gain, EPD Business Growth Aid Abbott (ABT) Dupixent to Remain Sanofi's (SNY) Key Top-Line Driver Featured Reports Business Separation & Regulated Investment Aid Exelon (EXC) Per the Zacks analyst, Exelon's separation from Constellation Energy will allow former to focus on transmission & distribution operations. Click to get this free report Sanofi (SNY) : Free Stock Analysis Report Exelon Corporation (EXC) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Oracle Corporation (ORCL) : Free Stock Analysis Report Realty Income Corporation (O) : Free Stock Analysis Report Hilton Worldwide Holdings Inc. (HLT) : Free Stock Analysis Report To read this article on Zacks.com click here. Today's Research Daily features new research reports on 15 major stocks, including Oracle Corporation (ORCL), Abbott Laboratories (ABT) and Sanofi (SNY). | Let's take a look at what these Wall Street heavyweights have to say about Abbott (ABT) before we discuss the reliability of brokerage recommendations and how to use them to your advantage. Brokerage Recommendation Trends for ABT Is ABT Worth Investing In? | Medical device makers Abbott Laboratories (NYSE: ABT) and Medtronic (NYSE: MDT) are two such businesses that could provide investors with a reliable source of income while they wait for their investments to grow in value. ABT Revenue (Annual) data by YCharts. The stock market has rebounded after a disastrous 2022, with the S&P 500 up 15% so far this year -- such volatility in the stock market is unavoidable."
2023-08-30,104.08000183105467,104.41000366210938,-1.5499379728452818,"Abbott (ABT) Outpaces Stock Market Gains: What You Should Know | IWD, PG, WMT, ABT: Large Inflows Detected at ETF | A Significant Reversal is in Sight for These 5 Med Tech Companies | Will Edwards Lifesciences Stock Recover To Its Pre-Inflation Shock Highs of $130?","ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.40 per share and revenue of $39.77 billion. Abbott (ABT) closed at $104.41 in the latest trading session, marking a +0.52% move from the prior day. Investors should also note that ABT has a PEG ratio of 4.64 right now. | Among the largest underlying components of IWD, in trading today Procter & Gamble Company (Symbol: PG) is up about 0.2%, Walmart Inc (Symbol: WMT) is up about 0.1%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $119.4 million dollar inflow -- that's a 0.2% increase week over week in outstanding units (from 318,400,000 to 319,150,000). For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $134.09 per share, with $164.18 as the 52 week high point — that compares with a last trade of $159.21. | Abbott Laboratories for Diversification in Health Care Products Abbott Laboratories (NYSE: ABT) is no pure play on medtech but offers diversification for med tech investors. The salient point is that the med tech and med tech stocks market has normalized and presents a healthy opportunity for investors. Intuitive Surgical is The Growth Stock in Med Tech Med tech is growing, and Intuitive Surgical (NYSE: ISRG) is outpacing the group. | Edwards Lifesciences (NYSE: EW), a medical technology company specializing in artificial heart valves, currently trades at $76 per share, about 10% lower than the level seen in March 2021, and it can see higher levels over time. EW stock was trading at around $95 in early June 2022, just before the Fed started increasing rates, and is now 20% below that level, compared to 16% gains for the S&P 500 during this period. Timeline of 2007-08 Crisis 10/1/2007: Approximate pre-crisis peak in S&P 500 index 9/1/2008 – 10/1/2008: Accelerated market decline corresponding to Lehman bankruptcy filing (9/15/08) 3/1/2009: Approximate bottoming out of S&P 500 index 12/31/2009: Initial recovery to levels before accelerated decline (around 9/1/2008) EW and S&P 500 Performance During 2007-08 Crisis EW stock saw a marginal decline of 5% between August 2008 (pre-crisis peak for EW) and March 2009 (as the markets bottomed out)."
2023-08-29,103.23999786376952,103.87000274658205,0.31706555077734255,Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know,"Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions."
2023-08-28,105.06999969482422,102.79000091552734,0.6102333357695844,ABT Dividend Yield Pushes Past 2% | 1 Stock-Split Stock Billionaires Are Buying Hand Over Fist and 1 Unexpected Stock-Split Stock They're Selling,"Looking at the universe of stocks we cover at Dividend Channel, in trading on Monday, shares of Abbott Laboratories (Symbol: ABT) were yielding above the 2% mark based on its quarterly dividend (annualized to $2.04), with the stock changing hands as low as $101.89 on the day. Abbott Laboratories (Symbol: ABT) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index. In the case of Abbott Laboratories, looking at the history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2% annual yield. | Stock splits allow companies to lower their stock prices to levels within reach of everyday investors by turning one share into 10, for example. Nvidia is a stock-split stock billionaires are buying with both hands During the three months that ended June 30, billionaire money managers were tripping over each other on their way to buy shares of Nvidia. Stock-split stock that billionaires sold heavily in the second quarter: Dexcom One stock-split stock that saw aggressive selling from billionaire fund managers in the second quarter was Dexcom, the manufacturer of continuous blood-glucose monitors."
2023-08-25,104.0199966430664,104.20999908447266,-2.1699807613201965,Wall St Week Ahead-Historically stormy month of September may test US stock rally | Which Is A Better Buy – Boston Scientific Stock Or Abbott?,"By David Randall NEW YORK, Aug 25 (Reuters) - U.S. stock investors are bracing for a potentially volatile September as the market faces key economic data reports, a Federal Reserve meeting and worries over a possible government shutdown during a month of historically muted equity performance. The Fed’s monetary policy meeting on Sep. 20 stands as another potential source of volatility: Friday’s speech from Fed Chairman Jerome Powell in Jackson Hole fueled expectations of another rate increase this year, though a move in September was seen as less likely. Some investors believe further gains could come from a resilient economy and continued excitement over the business potential of artificial intelligence, fanned this week by chip maker Nvidia’s strong earnings report and $25 billion stock buyback announcement. | The table below summarizes our revenue and return expectations for both companies over the next three years and points to an expected return of 18% for Boston Scientific over this period vs. a 9% expected return for Abbott stock, implying that investors will likely be better off picking BSX over ABT, based on Trefis Machine Learning analysis – Boston Scientific vs. Abbott – which also provides more details on how we arrive at these numbers. We believe Boston Scientific stock  (NYSE: BSX) will likely offer better returns over Abbott stock (NYSE: ABT) in the next three years. Investors have assigned a lower multiple to ABT due to a significant fall in its Diagnostics sales amid lower Covid-19 testing demand."
2023-08-24,104.91000366210938,103.75,0.182659534260728,Abbott (ABT) Stock Moves -1.31%: What You Should Know,"In the latest trading session, Abbott (ABT) closed at $103.75, marking a -1.31% move from the previous day. Investors should also note that ABT has a PEG ratio of 4.7 right now. ABT's industry had an average PEG ratio of 2.58 as of yesterday's close."
2023-08-23,105.6999969482422,105.12999725341795,-1.1057131080134892,US FDA taps EPA veteran James Jones to oversee food division after formula crisis | Want Growing Passive Income? This Dividend King Could Be a Smart Buy,"In last year's outbreak, five infants were sickened and two died after consuming formula from an Abbott Laboratories ABT.N plant. By Leah Douglas Aug 23 (Reuters) - The U.S. Food and Drug Administration has selected James ""Jim"" Jones, a 30-year veteran of the Environmental Protection Agency (EPA), to direct its food division as part of a broader reorganization, the agency said on Wednesday. The FDA in January said it would reorganize its food program after being slammed for its slow response to issues at an infant formula plant that resulted in an outbreak of illness and a national formula shortage. | But for COVID-19 test makers like Abbott Laboratories (NYSE: ABT), a drop in test demand has weighed on the stock so far in 2023. ABT Dividend data by YCharts. However, when viewed within the proper context, Abbott's results are, arguably, just fine; the company posted net sales growth in each of its four segments, except diagnostics."
2023-08-22,103.87999725341795,105.1500015258789,-0.5392617892915902,ABT Quantitative Stock Analysis - Peter Lynch | Medtronic raises annual forecast as demand for medical procedures picks up,"Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Medtronic becomes the latest in line of medical device makers, including Abbott Laboratories ABT.N, Stryker SYK.N and Boston Scientific BSX.N, that are benefitting from a flurry of demand for non-urgent surgeries, after reaching a trough during the pandemic. Adds details on forecast in paragraphs 1,2,3 Aug 22 (Reuters) - Medtronic MDT.N on Tuesday raised its annual profit forecast, banking on higher demand for its medical devices as surgical procedure volumes pick up pace. It now expects profit to be between $5.08 per share and $5.16 per share for the fiscal year 2024, above the range of $5 to $5.10 per share previously expected."
2023-08-21,103.77999877929688,103.87000274658205,1.222568642702929,5 Dividend Growth Stocks With Upside To Analyst Targets,"Royal Gold Inc (Symbol: RGLD) $106.99 $140.50 31.32% NU Skin Enterprises, Inc. (Symbol: NUS) $24.34 $31.50 29.42% Abbott Laboratories (Symbol: ABT) $103.71 $123.88 19.44% Chevron Corporation (Symbol: CVX) $160.90 $188.39 17.08% Colgate-Palmolive Co. (Symbol: CL) $74.55 $87.08 16.81% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Royal Gold Inc (Symbol: RGLD) 1.40% 31.32% 32.72% NU Skin Enterprises, Inc. (Symbol: NUS) 6.41% 29.42% 35.83% Abbott Laboratories (Symbol: ABT) 1.97% 19.44% 21.41% Chevron Corporation (Symbol: CVX) 3.75% 17.08% 20.83% Colgate-Palmolive Co. (Symbol: CL) 2.58% 16.81% 19.39% Another consideration with dividend growth stocks is just how much the dividend is growing. Royal Gold Inc (Symbol: RGLD) $1.35 $1.475 9.26% NU Skin Enterprises, Inc. (Symbol: NUS) $1.53 $1.55 1.31% Abbott Laboratories (Symbol: ABT) $1.86 $2 7.53% Chevron Corporation (Symbol: CVX) $5.6 $5.95 6.25% Colgate-Palmolive Co. (Symbol: CL) $1.84 $1.9 3.26% These five stocks are part of our full Dividend Aristocrats List."
2023-08-18,104.55999755859376,103.70999908447266,0.08672573554040684,,
2023-08-17,105.1999969482422,104.93000030517578,-0.8129289345524155,"Alcon (ALC) Q2 Earnings Surpass Estimates, Margins Increase","Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Alcon (ALC) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%."
2023-08-16,104.45999908447266,104.52999877929688,-0.2566508088391459,Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It,"Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions."
2023-08-15,106.1500015258789,104.94000244140624,0.06701100463117253,"Abbott (ABT) Gains in Core Diagnostics With FDA Nod for Alinity H | Notable ETF Inflow Detected - IOO, ABT, PM, NKE | Boston Scientific's (BSX) POLARx System Gets FDA Approval","Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Danaher Corporation (DHR) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT, a global leader in healthcare solutions, recently achieved a significant milestone with the FDA approval of its cutting-edge Alinity h-series hematology system. More on the News The Alinity h-series is based on Alinity hq, an automated hematology analyzer, and Alinity hs, an integrated slide maker and stainer. | Among the largest underlying components of IOO, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.2%, Philip Morris International Inc (Symbol: PM) is down about 1.2%, and Nike (Symbol: NKE) is lower by about 1.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Global 100 ETF (Symbol: IOO) where we have detected an approximate $208.8 million dollar inflow -- that's a 5.2% increase week over week in outstanding units (from 52,700,000 to 55,450,000). For a complete list of holdings, visit the IOO Holdings page » The chart below shows the one year price performance of IOO, versus its 200 day moving average: Looking at the chart above, IOO's low point in its 52 week range is $58.45 per share, with $78.3499 as the 52 week high point — that compares with a last trade of $75.22. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report To read this article on Zacks.com click here. Peers Developments within Cardiac Segment Within cardiac ablation treatment, companies like Johnson & Johnson JNJ, Abbott Laboratories ABT and Medtronic plc MDT are also making significant progress. Significance of POLARx Cryoablation System The expandable cryoballoon catheter in particular, part of the new POLARx Cryoablation System, is an exciting advancement for the successful treatment of AF since it enables medical professionals to better customise care for individual patients without compromising safety or effectiveness."
2023-08-14,105.13999938964844,106.0999984741211,-1.1398954941867598,"Validea's Top Health Care Stocks Based On Peter Lynch - 8/14/2023 | 2 Best Healthcare Stocks to Buy Right Now | 2 Blue Chip Dividend Stocks That Are Top Buys in August | Abbott (ABT) EPD Arm Grows, Low Testing Sales Play Spoilsport","Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis THERMO FISHER SCIENTIFIC INC (TMO) is a large-cap growth stock in the Medical Equipment & Supplies industry. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. | Abbott Laboratories: A balanced healthcare play Investors seeking a company with a multi-faceted presence within healthcare would do well to consider Abbott Laboratories (NYSE: ABT). To top it off, Abbott's valuation is cheap when you consider its reputation as a highly reliable dividend grower: The stock's forward price-to-earnings (P/E) ratio of 22.9 is below the medical devices industry peer average valuation multiple of 24.4. But with its above-average growth prospects and a dividend payout ratio positioned to be approximately 12% in 2023, the company's payout growth profile could balance out the lower starting income. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a global leader in healthcare products and services, with a diversified portfolio of medical devices, diagnostics, nutrition, and branded generic drugs. The one knock against Abbott is that its stock trades at almost 24 times projected earnings, which qualifies as a premium valuation for a large-cap healthcare stock. 10 stocks we like better than Abbott Laboratories When our analyst team has a stock tip, it can pay to listen. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott’s ABT branded generics and international diabetes businesses continue to drive growth for the company. Abbott Laboratories Price Abbott Laboratories price | Abbott Laboratories Quote Following the massive setback related to the voluntary recall and production stoppage of certain infant powder formula products manufactured at its facility in Sturgis, MI last year, Abbott’s Nutrition business has started showing signs of recovery since the beginning of 2023."
2023-08-11,104.22000122070312,105.30999755859376,0.9130674244298815,"Asensus Surgical (ASXC) Q2 Loss Widens, Revenues In Line | Peter Lynch Detailed Fundamental Analysis - ABT | National Vision (EYE) Q2 Earnings Top Estimates, Margins Down | The Zacks Analyst Blog Highlights JPMorgan Chase, Salesforce, Abbott Laboratories, HCA Healthcare and General Motors","Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Asensus Surgical, Inc. (ASXC) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report National Vision Holdings, Inc. (EYE) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%. | Click to get this free report JPMorgan Chase & Co. (JPM) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Salesforce Inc. (CRM) : Free Stock Analysis Report General Motors Company (GM) : Free Stock Analysis Report HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include: JPMorgan Chase & Co. JPM, Salesforce, Inc. CRM, Abbott Laboratories ABT, HCA Healthcare, Inc. HCA and General Motors Co. GM. Here are highlights from Thursday’s Analyst Blog: Top Stock Reports for JPMorgan, Salesforce and Abbott Labs The Zacks Research Daily presents the best research output of our analyst team."
2023-08-10,105.4800033569336,104.73999786376952,1.045860991291289,"Top Stock Reports for JPMorgan Chase, Salesforce & Abbott Laboratories","Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Salesforce, Inc. (CRM) and Abbott Laboratories (ABT). If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Acquisitions, High Rates Aid JPMorgan (JPM), Fee Income Hurt Salesforce (CRM) Rides on Portfolio Strength and Buyouts Organic Sales Gain, Growing EPD Business Aid Abbott (ABT) Featured Reports Buyouts Support Morgan Stanley (MS), Capital Markets A Woe Per the Zacks analyst, acquisitions with an aim to be less capital-markets dependent, high rates and solid balance sheet aid Morgan Stanley. Click to get this free report JPMorgan Chase & Co. (JPM) : Free Stock Analysis Report Morgan Stanley (MS) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Salesforce Inc. (CRM) : Free Stock Analysis Report General Motors Company (GM) : Free Stock Analysis Report HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report To read this article on Zacks.com click here."
2023-08-09,105.5,105.3000030517578,-0.7015599825684243,"QIAGEN (QGEN) Q2 Earnings and Revenues Top, '23 View Slashed | SmileDirectClub (SDC) Q2 Earnings Miss Estimates, '23 View Up | Charles River (CRL) Q2 Earnings Top, 2023 View Narrowed | Insulet (PODD) Q2 Earnings Beat, Sales Growth View Raised | Abbott India posts 41% rise in Q1 profit on strong sales","Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report QIAGEN N.V. (QGEN) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report SmileDirectClub, Inc. (SDC) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Charles River Laboratories International, Inc. (CRL) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%. | BENGALURU, Aug 9 (Reuters) - Abbott India ABOT.NS, the Indian arm of U.S. healthcare firm Abbott Laboratories ABT.N, reported a 41% rise in its first-quarter profit on Wednesday, driven by strong sales in its mainstay pharmaceuticals segment. Revenue growth Profit growth Mean rating* # of analysts Stock to price target** Div yield (%) Abbott India Ltd 24.69 15.76 10.82 19.32 Buy 38 1.09 0.67 * Mean of analysts' ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell ** Ratio of the stock's last close to analysts' mean price target; a ratio above 1 means the stock is trading above the PT"
2023-08-08,107.5999984741211,105.58000183105467,-0.18957056705421962,Abbott Laboratories (ABT) Shares Cross Below 200 DMA | Is AbbVie Still a Good Dividend Stock to Buy?,"In trading on Tuesday, shares of Abbott Laboratories (Symbol: ABT) crossed below their 200 day moving average of $105.94, changing hands as low as $104.05 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $93.25 per share, with $115.83 as the 52 week high point — that compares with a last trade of $104.92. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other dividend stocks recently crossed below their 200 day moving average » Also see: • Historical Stock Price • ALL market cap history • TWX Options Chain The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie (NYSE: ABBV) shares offer an above-average dividend yield of 4% at recent prices, but some cautious investors were turned off by earnings that fell by 58% to $2.3 billion in the first half of the year. Earlier this year, AbbVie said it expected combined sales of Skyrizi and Rinvoq to exceed peak Humira sales by 2027. With additional growth drivers like Epkinly and Vraylar pushing the company's needle, AbbVie should have no problem raising its dividend payout at a pace that exceeds inflation over the long run."
2023-08-07,107.98999786376952,108.4499969482422,-1.8773203268699399,"Henry Schein (HSIC) Q2 Earnings Top, Operating Margin Dips | Analysts See 10% Upside For The Holdings of SDY","Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Henry Schein, Inc. (HSIC) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%. | Similarly, ABT has 14.69% upside from the recent share price of $107.65 if the average analyst target price of $123.47/share is reached, and analysts on average are expecting FUL to reach a target price of $82.50/share, which is 13.95% above the recent price of $72.40. Three of SDY's underlying holdings with notable upside to their analyst target prices are Realty Income Corp (Symbol: O), Abbott Laboratories (Symbol: ABT), and Fuller Company (Symbol: FUL). Below is a twelve month price history chart comparing the stock performance of O, ABT, and FUL: Below is a summary table of the current analyst target prices discussed above:"
2023-08-04,107.31999969482422,107.6500015258789,0.42596452780097116,"Globus Medical (GMED) Q2 Earnings Beat Estimates, Margins Dip | ResMed's (RMD) Q4 Earnings Miss, Revenues Beat Estimates | Peter Lynch Detailed Fundamental Analysis - ABT | Tandem Diabetes (TNDM) Reports Narrower Q2 Loss, Trims '23 View | Does Abbott Laboratories' Dividend Make It a Buy? | Inari Medical (NARI) Q2 Earnings Top, Revenues Rise Y/Y","Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Globus Medical, Inc. (GMED) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report ResMed Inc. (RMD) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Tandem Diabetes Care, Inc. (TNDM) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%. | On the other hand, seasoned businesses like medical devices maker Abbott Laboratories (NYSE: ABT) have a track record of paying investors for decades on end without flinching. Hard to find a payout with a stronger track record There are two crucial factors for determining whether Abbott is worth buying for its dividend income: growth and sustainability. But if it doesn't bother you that you'll need to invest consistently in this company over time to build up a decent base of dividend income, and if it doesn't bother you that rapid growth is probably never coming, Abbott is a decent option to buy. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Inari Medical, Inc. (NARI) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 12.4%."
2023-08-03,107.70999908447266,107.54000091552734,0.3074933209029842,"Cigna (CI) Q2 Earnings Beat on Strong U.S. Commercial Unit | PacBio (PACB) Tops on Q2 Earnings, Raises FY23 Revenue View | Glaukos (GKOS) Q2 Earnings Beat Estimates, Revenues Rise Y/Y | Stryker lifts annual profit forecast as demand for its devices picks up | Surmodics (SRDX) Q3 Earnings Top Estimates, FY23 View Up | BD (BDX) Q3 Earnings Surpass Estimates, Margins Contract | McKesson (MCK) Q1 Earnings Beat Estimates, U.S. Sales Strong | Fresenius Medical (FMS) Q2 Earnings and Revenues Beat Estimates | NuVasive (NUVA) Q2 Earnings Meet Estimates, Margins Down | STERIS (STE) Q1 Earnings Beat Estimates, Gross Margin Falls | DENTSPLY SIRONA (XRAY) Beats on Q2 Earnings, Ups '23 EPS View | Noteworthy ETF Inflows: DGRO, C, ABT, MDT","Other Medical Sector Releases Of the Medical sector players that have reported second-quarter 2023 results so far, the bottom-line results of Elevance Health, Inc. ELV, Intuitive Surgical, Inc. ISRG and Abbott Laboratories ABT beat the respective Zacks Consensus Estimate. ABT reported an adjusted operating profit of $2.04 billion in the quarter under review, down 29.2% year over year. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Cigna Group (CI) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Pacific Biosciences of California, Inc. (PACB) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Integer Holdings Corporation ITGR and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Glaukos Corporation (GKOS) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 12.4%. | Larger rivals like Abbott LaboratoriesABT.N and Johnson & JohnsonJNJ.N have also beaten expectations, driven by the demand for medical devices after the pandemic. Aug 3 (Reuters) - Stryker SYK.N raised its annual profit forecast on Thursday as the medtech company sees strong demand for its medical and surgical devices, aided by a post-pandemic pickup in surgical procedure volumes at hospitals. In the second quarter, sales at Stryker's medical surgery and neurotechnology unit rose 12.2%, to $2.9 billion, while sales in the orthopedics and spine segment rose nearly 10%, to $2.14 billion. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Surmodics, Inc. (SRDX) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. A few other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Integer Holdings Corporation ITGR and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. A few other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Integer Holdings Corporation ITGR and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report McKesson Corporation (MCK) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 12.4%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Fresenius Medical Care AG & Co. KGaA (FMS) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 12.4%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report NuVasive, Inc. (NUVA) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report STERIS plc (STE) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report DENTSPLY SIRONA Inc. (XRAY) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 12.4%. | Among the largest underlying components of DGRO, in trading today Citigroup Inc (Symbol: C) is off about 0.9%, Abbott Laboratories (Symbol: ABT) is down about 0.7%, and Medtronic PLC (Symbol: MDT) is lower by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core Dividend Growth ETF (Symbol: DGRO) where we have detected an approximate $87.0 million dollar inflow -- that's a 0.4% increase week over week in outstanding units (from 462,150,000 to 463,800,000). For a complete list of holdings, visit the DGRO Holdings page » The chart below shows the one year price performance of DGRO, versus its 200 day moving average: Looking at the chart above, DGRO's low point in its 52 week range is $43.67 per share, with $53.55 as the 52 week high point — that compares with a last trade of $52.40."
2023-08-02,110.0199966430664,108.62000274658205,-0.1578295147992618,"Inspire Medical (INSP) Q2 Earnings & Revenues Top Estimates | CVS Health (CVS) Q2 Earnings Surpass Estimates, Margins Up | Penumbra (PEN) Q2 Earnings Top Estimates, Sales View Raised | AmerisourceBergen (ABC) Beats on Q3 Earnings, Ups '23 EPS View | Nevro (NVRO) Q2 Earnings Lag Estimates, FY23 View Cut | Revvity (RVTY) Beats on Q2 Earnings, Lowers '23 EPS View | Exact Sciences (EXAS) Beats on Q2 Earnings, Ups '23 Sales View","Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Inspire Medical Systems, Inc. (INSP) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Integer Holdings Corporation ITGR and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report AmerisourceBergen Corporation (ABC) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Other Stocks to Consider Some other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 12.4%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Nevro Corp. (NVRO) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Integer Holdings Corporation ITGR and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report Revvity Inc. (RVTY) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 12.4%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%."
2023-08-01,110.70999908447266,110.52999877929688,-1.2724904010189224,"Hologic's (HOLX) Q3 Earnings Beat Estimates, 2023 View Up | Zimmer Biomet's downbeat 2024 view hits shares after forecast raise | Tenet Healthcare (THC) Q2 Earnings Beat on Solid Hospital Unit | Ecolab (ECL) Q2 Earnings Surpass Estimates, Margins Rise | Zimmer Biomet (ZBH) Q2 Earnings Match Estimates, View Raised | Medical device maker Zimmer Biomet lifts profit forecast as surgeries rebound | Longreach sells stake in medical device firm Quasar to Boyu Capital | IDEXX (IDXX) Q2 Earnings and Revenues Beat Estimates, View Up","Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%. | Expectations were high heading into the results following strong reports from Abbott Laboratories ABT.N and Johnson & Johnson JNJ.N as a resumption of non-urgent procedures and easing staffing shortages at hospitals boosted demand. By Mariam Sunny Aug 1 (Reuters) - Zimmer Biomet Holdings ZBH.N on Tuesday raised its full-year profit forecast after beating second-quarter estimates on demand for its medical devices but shares fell more than 5% as investors focused on the company's comments for 2024. Combined sales at Zimmer's hips and knees units rose 7% to $1.28 billion in the second quarter, compared to the average $1.21 billion estimated by four analysts according to Refinitiv data. | Other Medical Sector Releases Of the Medical sector players that have reported second-quarter 2023 results so far, the bottom-line results of Elevance Health, Inc. ELV, Intuitive Surgical, Inc. ISRG and Abbott Laboratories ABT beat the Zacks Consensus Estimate. ABT reported an adjusted operating profit of $2.04 billion in the quarter under review, down 29.2% year over year. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Tenet Healthcare Corporation (THC) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Ecolab Inc. (ECL) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report To read this article on Zacks.com click here. A few other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Integer Holdings Corporation ITGR and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%. | Abbott LaboratoriesABT.N attributed its strong quarter to hospitals addressing bottlenecks from the pandemic while Johnson & JohnsonJNJ.N said it expected to top profit estimates with surgeries bouncing back. Corrects paragraph 3 to remove reference to Abbott's hips and knees unit Aug 1 (Reuters) - Zimmer Biomet Holdings Inc ZBH.N on Tuesday raised its full-year profit forecast, anticipating demand to hold up for its medical devices following a rebound in knee and hip replacement procedures. The company also beat estimates for profit to extend a strong second quarter for the industry that is benefiting from patients resuming non-urgent procedures and surgeries postponed during the pandemic and staffing shortages easing at hospitals. | Established in 1988 and headquartered in Hong Kong, Quasar is a leading contract development and manufacturing organisation of advanced medical devices and counts Johnson & Johnson JNJ.N, Medtronic MDT.N and Abbott Laboratories ABT.N as their clients, the company's website showed. Updates with Longreach's response in paragraph 4 Aug 1 (Reuters) - Private equity firm Longreach Group said it has sold its majority stake in Hong Kong-based medical device manufacturing solution provider Quasar Medical to Boyu Capital Partner. Longreach, which bought a 86% majority interest in Quasar in April 2019, said in a statement late on Monday that it and the minority shareholders from Quasar's founding family have sold all the issued and outstanding shares in the company, without disclosing the value of the transaction. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%."
2023-07-31,112.8499984741211,111.33000183105467,-0.1625872158470885,"Avantor (AVTR) Q2 Earnings Lag Estimates, FY23 View Revised | Glucose Monitor Maker DexCom In Buy Zone After Gapping Higher | 4 Medical Product Stocks to Buy Amid Recovering Prospects","Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Avantor, Inc. (AVTR) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%. | Rivals in the space include Abbott Laboratories (NYSE: ABT) and Medtronic plc (NYSE: MDT). In its investors’ day presentation, DexCom guided toward $4 billion to $4.5 billion in revenue for 2024, and $4.6 billion to $5.1 billion for 2025. Wall Street expects the company to grow earnings by 40% this year, to $1.22 a share, with earnings growth of 30% next year, to $1.58 per share. | Meanwhile, industry players like Abbott Laboratories ABT, Stryker SYK, Zimmer Biomet ZBH and Haemonetics HAE have adapted well to changing consumer preferences and are still witnessing an uptrend in their share prices. Price and Consensus: ABT Stryker: It is one of the world’s largest medical device companies operating in the global orthopedic market. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Stryker Corporation (SYK) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report To read this article on Zacks.com click here."
2023-07-28,113.18000030517578,112.7300033569336,-1.3469177347086878,"Integer Holdings (ITGR) Q2 Earnings Top Estimates, FY23 View Up | Amedisys (AMED) Q2 Earnings Beat Estimates, Margins Dip | Integra's (IART) Q2 Earnings Top Estimates, 2023 View Cut | DexCom (DXCM) Q2 Earnings Beat Estimates, Volumes Remain Strong | Neogen (NEOG) Q4 Earnings Beat Estimates, Gross Margin Up","Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. A few other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Amedisys, Inc. (AMED) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all of the trailing four quarters, the average surprise being 12.4%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Integra LifeSciences Holdings Corporation (IART) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 12.4%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Neogen Corporation (NEOG) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%."
2023-07-27,114.45999908447266,112.6500015258789,-0.3975940510945633,"Boston Scientific (BSX) Q2 Earnings Beat, Margins Improve | LabCorp (LH) Q2 Earnings Miss Estimates, Margins Decline | Edwards Lifesciences (EW) Q2 Earnings Top Estimates, View Up | Baxter (BAX) Beats on Q2 Earnings, Revises 2023 EPS Guidance | Align Technology (ALGN) Q2 Earnings Beat, Gross Margin Up | HCA Healthcare raises 2023 profit view as surgical procedure volumes rebound | CONMED (CNMD) Beats on Q2 Earnings, Ups '23 EPS View","Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Laboratory Corporation of America Holdings (LH) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Baxter International Inc. (BAX) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 12.4%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%. | The recovery in demand for surgical procedures has also boosted margins for others including medical device makers such as Johnson & Johnson JNJ.N and Abbott Laboratories ABT.N, which topped second-quarter profit estimates last week. Adds background in paragraph 2-3 July 27 (Reuters) - Hospital operator HCA Healthcare Inc HCA.N on Thursday raised its annual profit forecast, betting on a recovery in surgical procedure volumes. (Reporting by Khushi Mandowara and Vaibhav Sadhamta in Bengaluru; Editing by Shinjini Ganguli) ((Khushi.Mandowara@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report CONMED Corporation (CNMD) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 12.4%."
2023-07-26,112.5,114.08000183105467,-1.5813363385211572,"Edwards Lifesciences shares fall as slow heart-valve growth dulls forecast raise | Merit Medical (MMSI) Q2 Earnings & Revenues Beat Estimates | Universal Health (UHS) Q2 Earnings Beat, Boosts '23 EPS View | Thermo Fisher (TMO) Q2 Earnings Miss Estimates, Margins Down | Medical Device Stocks' Q2 Earnings on Jul 27: BSX, LH & IART | Quest Diagnostics (DGX) Q2 Earnings Beat Estimates, FY View Up | Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know | Quest Diagnostics beats profit estimates as routine testing picks up | Should You Invest in the iShares U.S. Medical Devices ETF (IHI)? | Reckitt beats quarterly like-for-like sales estimates, raises HY dividend","Edwards lifted its 2023 sales forecast to between $5.9 billion and $6.1 billion, from $5.6 billion to $6.0 billion estimated earlier. It expects 2023 sales for its TAVR devices to be between $3.85 billion and $4 billion, compared with its prior forecast of $3.8 billion to $4 billion. In the quarter ended June 30, Edwards' revenue rose 11% to $1.53 billion, above estimates of $1.50 billion. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. A few other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Universal Health Services, Inc. (UHS) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Other Medical Sector Releases Of the Medical sector players that have reported second-quarter 2023 results so far, the bottom-line results of Elevance Health, Inc. ELV, Intuitive Surgical, Inc. ISRG and Abbott Laboratories ABT beat the respective Zacks Consensus Estimate. ABT reported an adjusted operating profit of $2.04 billion in the quarter under review, down 29.2% year over year. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Laboratory Corporation of America Holdings (LH) : Free Stock Analysis Report Integra LifeSciences Holdings Corporation (IART) : Free Stock Analysis Report To read this article on Zacks.com click here. The second-quarter 2023 reporting cycle for the Medical Device space has started with Abbott ABT reporting better-than-expected earnings and sales. Boston Scientific Corporation Price and EPS Surprise Boston Scientific Corporation price-eps-surprise | Boston Scientific Corporation Quote LabCorp: Similar to the past few quarters, LabCorp is expected to have benefited from an ongoing sales rebound in its legacy Diagnostics business, driven by routine and esoteric testing and a benefit from hospital deals. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%. | Abbott (ABT) is one of the stocks most watched by Zacks.com visitors lately. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. | Last week, medical device maker Abbott Laboratories ABT.N also reported an increase in demand for its diagnostic products, excluding COVID-related sales. Non-COVID testing at companies such as Quest and rival Labcorp LH.N was hit as people delayed routine health check-ups following pandemic-led lockdowns, but that demand has now started to normalize while COVID testing sales have fallen. The company has raised its 2023 sales forecast for its base business to $8.92 billion to $9.02 billion, from a previous view of $8.78 billion to $8.88 billion. | Click to get this free report iShares U.S. Medical Devices ETF (IHI): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report SPDR S&P Health Care Equipment ETF (XHE): ETF Research Reports First Trust Indxx Medical Devices ETF (MDEV): ETF Research Reports To read this article on Zacks.com click here. Looking at individual holdings, Thermo Fisher Scientific Inc (TMO) accounts for about 17.24% of total assets, followed by Abbott Laboratories (ABT) and Medtronic Plc (MDT). First Trust Indxx Medical Devices ETF (MDEV) tracks INDXX GLOBAL MEDICAL EQUIPMENT INDEX and the SPDR S&P Health Care Equipment ETF (XHE) tracks S&P Health Care Equipment Select Industry Index. | During the same period last year, Reckitt's sales benefited from a baby formula shortage in the United States, after market leader Abbott Laboratories ABT.L recalled dozens of brands. Updates with details on 2023 outlook, HY revenue growth and CEO comment July 26 (Reuters) - Reckitt Benckiser RKT.L on Wednesday forecast its full-year adjusted operating margins to be slightly above 2022 levels after the British company beat quarterly like-for-like (LFL) net revenue estimates, helped by its hygiene and health businesses. The company retained its 2023 target range of 3% to 5% for group LFL net revenue growth and expects adjusted operating margins to be slightly above 2022 levels, excluding last year's one-off benefit of about 80 basis points related to an infant formula supply disruption in the U.S. ""The strong first-half performance gives us confidence in our full-year targets, despite some tough comparatives in our OTC portfolio and an expected tougher competitive environment in US Nutrition in H2,"" CEO Nicandro Durante said."
2023-07-25,113.11000061035156,112.93000030517578,1.4044460720485985,"2 Top Dividend Stocks to Buy and Hold Forever | NextGen (NXGN) Q1 Earnings Top Estimates, Revenues Surge Y/Y | GE HealthCare raises 2023 profit forecast as supply chain woes ease | Column: Here’s what AbbVie doesn’t want you to know about its sham AndroGel patent case | Barclays Maintains Abbott Laboratories (ABT) Overweight Recommendation","Let's consider two of them: Johnson & Johnson (NYSE: JNJ) and Abbott Laboratories (NYSE: ABT). ABT Revenue (Annual) data by YCharts. Johnson & Johnson Over the years, Johnson & Johnson has certainly been the precise kind of company dividend seekers gravitate toward. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report NEXTGEN HEALTHCARE, INC (NXGN) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. A few other top-ranked stocks in the broader medical space that have announced quarterly results are Abbott Laboratories ABT, Elevance Health, Inc. ELV and Intuitive Surgical, Inc. ISRG. ABT’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 12.4%. | Johnson & Johnson JNJ.N and Abbott Laboratories ABT.N, which make medical devices like heart stents and implants, surpassed quarterly profit estimates last week as patients underwent their delayed procedures. July 25 (Reuters) - GE HealthCare Technologies Inc GEHC.O raised its annual profit forecast on Tuesday, after beating quarterly earnings estimates due to easing supply chain issues that had largely impacted electronic components during the pandemic. The healthcare equipment firm operates four medical device businesses - imaging and ultrasound devices, patient care solutions and pharmaceutical diagnostics - with imaging being the largest. | By Alison Frankel (Reuters) - Any way you look at it, AbbVie ABBV.N predecessor Abbott Laboratories ABT.N made a bad decision when it sued generic drug maker Perrigo PRGO.N in 2011, as Perrigo geared up to bring a generic version of AbbVie’s testosterone replacement product AndroGel to market. And now we know that AbbVie’s own lawyers were so skeptical about their case that they discussed the prospect of facing Rule 11 sanctions for filing the suit – and that even before the case hit the docket, AbbVie in-house lawyers debated how much their company would have to pay Perrigo in a settlement. “Thus, the distinction between attorney and client is conflated in this case.” The judge proceeded to explain why he concluded that specific documents reflected the lawyers’ “furtherance of fraud.” (Among Bartle's points: AbbVie lawyers talked about why their preferred venue for the Perrigo suit was New Jersey federal court, where, in their view, judges take a long time to resolve patent litigation.) | Fintel reports that on July 24, 2023, Barclays maintained coverage of Abbott Laboratories (NYSE:ABT) with a Overweight recommendation. Average portfolio weight of all funds dedicated to ABT is 0.56%, an increase of 14.17%. The put/call ratio of ABT is 0.94, indicating a bullish outlook."
2023-07-24,113.83999633789062,114.62000274658205,-0.15913739210015354,3 Ultrareliable Dividend Stocks to Buy and Hold for Decades | Peter Lynch Detailed Fundamental Analysis - ABT,"Abbott Laboratories: A 1.8% yield Abbott Laboratories (NYSE: ABT) offers investors a less-than-thrilling yield at the moment, but it's rising fast. You could aim for stocks that offer a high yield upfront, but dividend payers generally don't offer high yields unless investors are worried about their ability to continue raising their payouts. 10 stocks we like better than Johnson & Johnson When our analyst team has a stock tip, it can pay to listen. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT)."
2023-07-21,112.8499984741211,114.29000091552734,0.6851778230704337,"Is ACADIA Pharmaceuticals (ACAD) Stock Outpacing Its Medical Peers This Year? | Company News for Jul 21, 2023","Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Another stock in the Medical sector, Abbott (ABT), has outperformed the sector so far this year. Acadia Pharmaceuticals is a member of our Medical group, which includes 1119 different companies and currently sits at #8 in the Zacks Sector Rank. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report International Business Machines Corporation (IBM) : Free Stock Analysis Report United Airlines Holdings Inc (UAL) : Free Stock Analysis Report Kinder Morgan, Inc. (KMI) : Free Stock Analysis Report To read this article on Zacks.com click here. Shares of Abbott Laboratories (ABT) climbed 4.2% after posting second-quarter 2023 adjusted earnings per share of $1.08, exceeding the Zacks Consensus Estimate of $1.04. Kinder Morgan, Inc.’s (KMI) shares rose 2% after the company reported second-quarter 2023 adjusted earnings per share of $0.24, outpacing the Zacks Consensus Estimate of $0.23 Shares of United Airlines Holdings Inc. (UAL) advanced 3.2% after reporting second-quarter 2023 adjusted earnings per share of $5.03, beating the Zacks Consensus Estimate of $3.99."
2023-07-20,108.0999984741211,111.83000183105467,1.2760323091510481,"Health Care Sector Update for 07/20/2023: ABT, JNJ, VIR, GOSS | Intuitive Surgical beats profit, revenue estimates | Broader Market Falls on Disappointing Tech Earnings from Tesla and Netflix | Abbott (ABT) Q2 Earnings & Revenues Beat Estimates, Down Y/Y | Slump in Netflix and Tesla Weighs on Tech Stocks | Abbott Laboratories (ABT) Q2 2023 Earnings Call Transcript | Thursday's ETF Movers: XLV, ARKK | J&J upbeat on 2023 as devices rebound post-COVID, shares jump | Thursday Sector Leaders: Utilities, Healthcare | Nasdaq Futures Plunge as Disappointing Tesla and Netflix Results Weigh on Sentiment | Johnson & Johnson's Inflection Point: What it Means for Investors | Abbott Laboratories Has the Prescription for Higher Share Prices | Abbott Laboratories Reaffirms FY23 Adj. EPS Outlook - Update | 5 Dividend Growth Stocks With Upside To Analyst Targets | Abbott (ABT) Q2 Earnings and Revenues Surpass Estimates | Abbott (ABT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates | Abbott beats quarterly profit estimates on demand for medical devices | Abbott beats quarterly profit estimates on demand for medical devices | Abbott Laboratories Q2 Profit Decreases, but beats estimates","In company news, Abbott Laboratories (ABT) shares rose 4.2% after the company posted better-than-expected Q2 results. Health care stocks were higher late Thursday, with the NYSE Health Care Index rising 2% and the Health Care Select Sector SPDR Fund (XLV) up 1.7%. Vir Biotechnology (VIR) shares plunged nearly 45% after the company said Thursday that a phase 2 trial assessing VIR-2482 to prevent influenza A illness didn't meet its primary and secondary efficacy endpoints. | Larger peer Abbott Laboratories ABT.N earlier on Thursday also reported a better-than-expected quarter as a rebound in surgical procedure volumes drove demand for medical devices despite high inflation-driven costs. July 20 (Reuters) - Intuitive Surgical Inc ISRG.O beat Wall Street estimates for quarterly sales and profit on Thursday, boosted by a rise in total procedures volume of its surgical robot da Vinci. A market leader for surgical robots, Intuitive's worldwide da Vinci procedure volumes rose about 22% from a year earlier, benefiting from higher patient admissions as they catch up with treatment that was delayed during the pandemic. | Abbott Laboratories (ABT) closed up more than +4% after reporting Q2 net sales of $10.0 billion, better than the consensus of $9.73 billion. Netflix (NFLX) closed down more than -8% after reporting Q2 revenue of $8.19 billion, weaker than the consensus of $8.30 billion and forecast Q3 revenue of $8.50 billion, below the consensus of $8.67 billion. Equifax (EFX) closed down more than -8% after reporting Q2 operating revenue of $1.32 billion, below the consensus of $1.33 billion, and forecast Q3 revenue of $1.32 billion-$1.34 billion, weaker than the consensus of $1.35 billion. | Abbott Laboratories ABT reported second-quarter 2023 adjusted earnings of $1.08 per share, which topped the Zacks Consensus Estimate by 3.8%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report McKesson Corporation (MCK) : Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report To read this article on Zacks.com click here. On an organic basis (excluding the impact of foreign exchange, the Cardiovascular Systems acquisition, the impact of business exit and the impact of COVID-19 testing sales), sales rose 11.5% year over year in the reported quarter. | Abbott Laboratories (ABT) is up more than +4% after reporting Q2 net sales of $10.0 billion, better than the consensus of $9.73 billion. Equifax (EFX) is down more than -9% after reporting Q2 operating revenue of $1.32 billion, below the consensus of $1.33 billion, and forecast Q3 revenue of $1.32 billion-$1.34 billion, weaker than the consensus of $1.35 billion. Netflix (NFLX) is down more than -8% to lead losers in the Nasdaq 100 after reporting Q2 revenue of $8.19 billion, weaker than the consensus of $8.30 billion, and forecast Q3 revenue of $8.50 billion, below the consensus of $8.67 billion. | Operator [Operator signoff] Duration: 0 minutes Call participants: Mike Comilla -- Vice President, Investor Relations Robert Ford -- Chairman and Chief Executive Officer Bob Funck -- Executive Vice President, Finance, and Chief Financial Officer Josh Jennings -- TD Cowen -- Analyst Larry Biegelsen -- Wells Fargo Securities -- Analyst Danielle Antalffy -- UBS -- Analyst Vijay Kumar -- Evercore ISI -- Analyst Joanne Wuensch -- Citi -- Analyst Marie Thibault -- BTIG -- Analyst Matt Miksic -- Barclays -- Analyst Jayson Bedford -- Raymond James -- Analyst More ABT analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Abbott Laboratories (NYSE: ABT) Q2 2023 Earnings Call Jul 20, 2023, 9:30 a.m. Turning to our outlook for the full year, we now forecast total underlying base business organic sales growth, excluding COVID testing sales, to be in the low double digits. | In trading on Thursday, the The Health Care Select Sector SPDR Fund ETF is outperforming other ETFs, up about 1.7% on the day. Components of that ETF showing particular strength include shares of Johnson & Johnson, up about 5.9% and shares of Abbott Laboratories, up about 3.9% on the day. Among components of that ETF with the weakest showing on Thursday were shares of Ginkgo Bioworks Holdings, lower by about 9.8%, and shares of Twist Bioscience, lower by about 9.5% on the day. | Shares of other medical device makers such as Medtronic MDT.N and Abbott Laboratories ABT.N, which also posted upbeat results, gained more than 3%. J&J is trying to bolster growth at its pandemic-hit medical devices business while placing huge bets on its newer cancer drugs and seeking to counter a potential slowdown in sales of its Stelara arthritis drug when biosimilars hit as soon as 2025. Wolk told Reuters that J&J's patent litigation settlement with Amgen <AMGN.O> over arthritis drug Stelara, which met expectations with sales of $2.8 billion in the second quarter,boosted confidence about hitting its target of $57 billion in pharmaceuticals sales by 2025. | Among large Healthcare stocks, Johnson & Johnson (Symbol: JNJ) and Abbott Laboratories (Symbol: ABT) are the most notable, showing a gain of 6.2% and 3.9%, respectively. Combined, JNJ and ABT make up approximately 12.4% of the underlying holdings of XLV. Among utilities ETFs, one ETF following the sector is the Utilities Select Sector SPDR ETF (Symbol: XLU), which is up 1.4% on the day, and down 3.32% year-to-date. | You can see more pre-market stock movers here Today’s U.S. Earnings Spotlight: Thursday - July 20th J&J (JNJ), Abbott Labs (ABT), Philip Morris (PM), Blackstone Group (BX), Intuitive Surgical (ISRG), Marsh McLennan (MMC), CSX (CSX), Freeport-McMoran (FCX), Kenvue (KVUE), Truist Financial Corp (TFC), Capital One Financial (COF), DR Horton (DHI), Travelers (TRV), Newmont Goldcorp (NEM), PPG Industries (PPG), Nidec (NJDCY), Genuine Parts (GPC), Fifth Third (FITB), WR Berkley (WRB), Snap-On (SNA), Pool (POOL), American Airlines (AAL), KeyCorp (KEY), MarketAxesss (MKTX), Knight Transportation (KNX), East West Bancorp (EWBC), Webster Financial (WBS), Synovus (SNV), Bank Ozk (OZK), Home BancShares (HOMB), ManpowerGroup (MAN), Badger Meter (BMI), Glacier (GBCI), WNS Holdings (WNS), Texas Capital (TCBI), Associated Banc-Corp (ASB), ServisFirst Bancshares (SFBS), First Financial Bancorp (FFBC), Triumph Bancorp (TFIN), OFG Bancorp (OFG), Scholastic (SCHL), S&T Bancorp (STBA), Forestar (FOR), 1st Source (SRCE), OceanFirst (OCFC), Berkshire Hills Bancorp (BHLB), Foreign Trade Bank of Latin America (BLX), Amerant Bancorp A (AMTB), Heritage Financial Co (HFWA), Insteel Industries (IIIN), Sify (SIFY), Metropolitan Bank (MCB), Five Point (FPH), Capstar Financial (CSTR), Alpine Income (PINE). Second-quarter earnings season kicks into full gear, and investors anticipate new reports from major global companies today, including J&J (JNJ), Abbott Labs (ABT), and Philip Morris (PM). The trade data released by the Ministry of Finance on Thursday revealed that Japan’s annual exports grew much less than expected in June, while imports declined more than expected, indicating a sluggish global demand. | Not only is Johnson & Johnson's business sound but results from competitors like Abbott Laboratories (NYSE: ABT) and trends within the consumer health market suggest strength will continue. The stock trades at only 15x earnings compared to nearly 17x for the broad market and 25x for ABT stock. Johnson & Johnson also has a more favorable yield at 3% compared to only 1.9% at ABT. | Abbott Laboratories (NYSE: ABT) is a tale of two stories. Abbott Laboratories Outperforms in Q2 Abbott Laboratories had a great Q2 quarter despite the impact of COVID-19 testing sales on the top and bottom lines. Sales are up 22% compared to 2019 on an ex-COVID-19 basis; organic sales are up 11.5% this quarter due to strength in all segments except diagnostic. | (RTTNews) - While reporting financial results for the second quarter on Thursday, Abbott Laboratories (ABT) reaffirmed its adjusted earnings guidance for the full-year 2023. For fiscal 2023, the company now projects earnings in a range of $3.02 to $3.22 per share and adjusted earnings in a range of $4.30 to $4.50 per share. Previously, the company expected earnings in the range of $3.05 to $3.25 per share and adjusted earnings in the range of $4.30 to $4.50 per share. | NU Skin Enterprises, Inc. (Symbol: NUS) $29.48 $40.25 36.53% Chevron Corporation (Symbol: CVX) $154.69 $191.06 23.51% Royal Gold Inc (Symbol: RGLD) $122.00 $141.25 15.78% Abbott Laboratories (Symbol: ABT) $107.28 $123.12 14.77% Johnson & Johnson (Symbol: JNJ) $158.74 $181.57 14.38% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. NU Skin Enterprises, Inc. (Symbol: NUS) 5.29% 36.53% 41.82% Chevron Corporation (Symbol: CVX) 3.90% 23.51% 27.41% Royal Gold Inc (Symbol: RGLD) 1.23% 15.78% 17.01% Abbott Laboratories (Symbol: ABT) 1.90% 14.77% 16.67% Johnson & Johnson (Symbol: JNJ) 3.00% 14.38% 17.38% Another consideration with dividend growth stocks is just how much the dividend is growing. NU Skin Enterprises, Inc. (Symbol: NUS) $1.53 $1.55 1.31% Chevron Corporation (Symbol: CVX) $5.52 $5.86 6.16% Royal Gold Inc (Symbol: RGLD) $1.35 $1.475 9.26% Abbott Laboratories (Symbol: ABT) $1.86 $2 7.53% Johnson & Johnson (Symbol: JNJ) $4.31 $4.58 6.26% These five stocks are part of our full Dividend Aristocrats List. | Abbott (ABT) came out with quarterly earnings of $1.08 per share, beating the Zacks Consensus Estimate of $1.04 per share. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report ICU Medical, Inc. (ICUI) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $9.98 billion for the quarter ended June 2023, surpassing the Zacks Consensus Estimate by 2.84%. | Abbott (ABT) reported $9.98 billion in revenue for the quarter ended June 2023, representing a year-over-year decline of 11.4%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Here is how Abbott performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net sales- Diagnostics- U.S. $961 million versus $1.07 billion estimated by four analysts on average. | Adds diagnostic sales in paragraphs 4, 5, forecast in paragraph 7 July 20 (Reuters) - Abbott Laboratories ABT.N on Thursday reported second-quarter profit above expectations, due to recovery in surgical procedure volumes and demand for its diabetes care devices. Rival J&J's medical device segment also topped estimates earlier in the day, helped by a recovery in demand for medical procedures which were delayed during the pandemic. Abbott clocked quarterly sales for its medical devices at $4.3 billion, with $1.3 billion coming from continuous-glucose-monitoring device Freestyle Libre, beating analysts' estimates of $4.10 billion. | July 20 (Reuters) - Abbott Laboratories ABT.N on Thursday reported second-quarter profit above expectations, due to recovery in surgical procedure volumes and demand for its diabetes care devices. Demand for medical devices is expected to rise this year, tracking a recovery in non-urgent surgical procedures across the U.S. as older adults in particular get more comfortable visiting hospitals and staffing shortages at those facilities ease. Abbott clocked quarterly sales for its medical devices at $4.3 billion, with $1.3 billion coming from continuous-glucose-monitoring device Freestyle Libre, beating analysts' estimates of $4.10 billion. | (RTTNews) - Abbott Laboratories (ABT) released earnings for second quarter that decreased from last year but beat the Street estimates. The company's revenue for the quarter fell 11.4% to $9.98 billion from $11.26 billion last year. -Analyst Estimates: $1.05 -Revenue (Q2): $9.98 Bln vs. $11.26 Bln last year."
2023-07-19,107.06999969482422,107.27999877929688,3.450511942261067,"Pre-Market Earnings Report for July 20, 2023 : JNJ, ABT, PM, TSM, MMC, BX, FCX, TFC, DHI, TRV, NEM, GPC | 5 Big Cap Earnings Charts to Watch This Week | Validea's Top Health Care Stocks Based On Peter Lynch - 7/19/2023","Zacks Investment Research reports that the 2023 Price to Earnings ratio for ABT is 24.36 vs. an industry ratio of 5.10, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories (ABT)is reporting for the quarter ending June 30, 2023. In the past year ABT has beat the expectations every quarter. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Halliburton Company (HAL) : Free Stock Analysis Report Netflix, Inc. (NFLX) : Free Stock Analysis Report Taiwan Semiconductor Manufacturing Company Ltd. (TSM) : Free Stock Analysis Report Tesla, Inc. (TSLA) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories (ABT) has beat 8 quarters in a row. In addition to regional banks, we will get some of the big growth stocks like Netflix and Tesla along with dozens of large cap companies in a variety of industries including energy, big pharma, the semiconductors, paint, homebuilders, railroads and car parts. | Detailed Analysis of CIGNA GROUP CI Guru Analysis CI Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis INTEGRA LIFESCIENCES HOLDINGS CORP (IART) is a mid-cap growth stock in the Scientific & Technical Instr. Evernorth Health Services includes a range of coordinated and point solution health services and capabilities, as well as those from partners across the health care system, in pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions, which are provided to health plans, employers, government organizations and health care providers."
2023-07-18,106.80999755859376,106.9499969482422,0.19613251617745883,"XLV, ABT, DHR, BMY: Large Outflows Detected at ETF | Why Abbott (ABT) Might Surprise This Earnings Season | Here's Why You Should Add BD (BDX) Stock in Your Portfolio | 2 Medical Stocks to Buy as Earnings Approach","Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.3%, Danaher Corp (Symbol: DHR) is up about 1%, and Bristol Myers Squibb Co. (Symbol: BMY) is up by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $753.8 million dollar outflow -- that's a 1.8% decrease week over week (from 310,820,000 to 305,070,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $119.95 per share, with $141.77 as the 52 week high point — that compares with a last trade of $132.10. | This suggests that analysts have very recently bumped up their estimates for ABT, giving the stock a Zacks Earnings ESP of +0.64% heading into earnings season. Given that ABT has a Zacks Rank #2 (Buy) and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Investors are always looking for stocks that are poised to beat at earnings season and Abbott Laboratories ABT may be one such company. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report To read this article on Zacks.com click here. Other Key Picks A few other top-ranked stocks in the broader medical space are Abbott Laboratories ABT, HealthEquity, Inc. HQY and Boston Scientific Corporation BSX. ABT’s earnings surpassed estimates in all the trailing four quarters, with an average of 19.3%. | Among the broader healthcare space, Abbott Laboratories (ABT) and Intuitive Surgical (ISRG) are two medical stocks that will highlight this week’s earnings lineup. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report To read this article on Zacks.com click here. Image Source: Zacks Investment Research EPS Outlook Following a very tough to compete against year Abbott Laboratories earnings are now forecasted to decline -18% in fiscal 2023 at $4.39 per share compared to EPS of $5.34 in 2022."
2023-07-17,107.54000091552734,107.0,0.13107330104715778,See Which Of The Latest 13F Filers Holds Abbott Laboratories,"We then compared that number to the sum total of ABT shares those same funds held back at the 03/31/2023 period, to see how the aggregate share count held by hedge funds has moved for ABT. Gateway Investment Advisers LLC 563,786 4-10 Find out the full Top 10 Hedge Funds Holding ABT » We'll keep following the latest 13F filings by hedge fund managers and bring you interesting stories derived from a look at the aggregate information across groups of managers between filing periods. At Holdings Channel, we have reviewed the latest batch of the 21 most recent 13F filings for the 06/30/2023 reporting period, and noticed that Abbott Laboratories (Symbol: ABT) was held by 10 of these funds."
2023-07-14,108.0,107.93000030517578,-0.5021395861355017,Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It | Here's What To Expect From Intuitive Surgical's Q2,"Abbott (ABT) is one of the stocks most watched by Zacks.com visitors lately. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. | See our interactive dashboard analysis on  Intuitive Surgical Earnings Preview for more details on how the company’s revenues and earnings will likely trend for the quarter. Note: P/E Multiples are based on Share Price at the end of the year and reported (or expected) Adjusted Earnings for the full year While ISRG stock looks appropriately priced, it is helpful to see how Intuitive Surgical’s Peers fare on metrics that matter. Total [2] ISRG Return -1% 28% 381% S&P 500 Return 0% 16% 98% Trefis Multi-Strategy Portfolio 3% 22% 291% [1] Month-to-date and year-to-date as of 7/12/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2023-07-13,106.69000244140624,107.73999786376952,-0.06481453224464699,Abbott (ABT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? | 5 Stocks to Buy Ahead of Q2 Earnings Next Week | September 1st Options Now Available For Abbott Laboratories (ABT),"Abbott (ABT) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2023. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Genuine Parts Company (GPC) : Free Stock Analysis Report Snap-On Incorporated (SNA) : Free Stock Analysis Report PPG Industries, Inc. (PPG) : Free Stock Analysis Report AutoNation, Inc. (AN) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT exited the first quarter of 2023 with better-than-expected earnings and revenues. The Medical Device segment of ABT registered strong sales led by double-digit organic growth in Diabetes Care, Structural Heart, Heart Failure and Neuromodulation. | Below is a chart showing ABT's trailing twelve month trading history, with the $110.00 strike highlighted in red: Considering the fact that the $110.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the September 1st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new September 1st contracts and identified one put and one call contract of particular interest."
2023-07-12,108.05999755859376,106.8499984741211,0.9841554019458711,What's in Store for Abbott Laboratories (ABT) in Q2 Earnings? | ABT vs. LMAT: Which Stock Should Value Investors Buy Now? | Validea's Top Health Care Stocks Based On Peter Lynch - 7/12/2023,"Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Neogen Corporation (NEOG) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT is slated to report second-quarter 2023 results on July 20 before market open. The addition of CSI to ABT's vascular portfolio is a part of a larger investment that will improve the company's capacity to treat patients with peripheral and coronary artery disease. | The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that ABT has an improving earnings outlook. These are just a few of the metrics contributing to ABT's Value grade of B and LMAT's Value grade of D. ABT sticks out from LMAT in both our Zacks Rank and Style Scores models, so value investors will likely feel that ABT is the better option right now. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report LeMaitre Vascular, Inc. (LMAT) : Free Stock Analysis Report To read this article on Zacks.com click here. | ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis APOLLO MEDICAL HOLDINGS INC (AMEH) is a small-cap growth stock in the Healthcare Facilities industry. The following are the top rated Health Care stocks according to Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch."
2023-07-11,107.0199966430664,107.5,-1.1197474660468767,"Abbott (ABT) Gains But Lags Market: What You Should Know | Ex-Dividend Reminder: Buckle, AbbVie and Abbott Laboratories | AngioDynamics (ANGO) to Report Q4 Earnings: What's in the Cards? | September 15th Options Now Available For Abbott Laboratories (ABT)","Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. In the latest trading session, Abbott (ABT) closed at $107.50, marking a +0.45% move from the previous day. Investors should also note that ABT has a PEG ratio of 4.79 right now. | Looking at the universe of stocks we cover at Dividend Channel, on 7/13/23, Buckle, Inc. (Symbol: BKE), AbbVie Inc (Symbol: ABBV), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Buckle, Inc. (Symbol: BKE): AbbVie Inc (Symbol: ABBV): Abbott Laboratories (Symbol: ABT): In general, dividends are not always predictable, following the ups and downs of company profits over time. Similarly, investors should look for ABBV to open 1.10% lower in price and for ABT to open 0.48% lower, all else being equal. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report McKesson Corporation (MCK) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT has an Earnings ESP of +0.86% and a Zacks Rank of 2. ABT has an estimated long-term growth rate of 5.1%. | Below is a chart showing ABT's trailing twelve month trading history, with the $110.00 strike highlighted in red: Considering the fact that the $110.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the September 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new September 15th contracts and identified one put and one call contract of particular interest."
2023-07-10,106.58000183105467,107.0199966430664,0.4485174471968105,,
2023-07-07,106.3000030517578,106.3499984741211,0.4128305539994181,"Noteworthy ETF Inflows: VTI, MRK, ACN, ABT | Wall St Week Ahead-As earnings loom, investors weigh recession resilience","Among the largest underlying components of VTI, in trading today Merck & Co Inc (Symbol: MRK) is down about 1.4%, Accenture plc (Symbol: ACN) is trading flat, and Abbott Laboratories (Symbol: ABT) is higher by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Total Stock Market ETF (Symbol: VTI) where we have detected an approximate $2.3 billion dollar inflow -- that's a 0.8% increase week over week in outstanding units (from 1,394,762,430 to 1,405,309,167). For a complete list of holdings, visit the VTI Holdings page » The chart below shows the one year price performance of VTI, versus its 200 day moving average: Looking at the chart above, VTI's low point in its 52 week range is $174.84 per share, with $221.42 as the 52 week high point — that compares with a last trade of $218.50. | He is bullish on companies such as Abbott Laboratories ABT.N, which is down nearly 3% year to date. Global fund managers increased their allocations to healthcare and banks by about 5 percentage points in June, while cutting holdings of popular recession plays such as cash and consumer staples companies, BofA Global said. Despite that dim picture, ""cheap"" valuations and stable healthcare earnings make the sector increasingly attractive to invest in if the economy does slow in the second half, said Sameer Samana, seniorglobal marketstrategist for Wells Fargo Investment Institute."
2023-07-06,106.75,107.1999969482422,0.047032380929427194,RDVY's Holdings Could Mean 12% Gain Potential | Abbott (ABT) Gets FDA Approval for AVEIR DR Leadless Pacemaker,"Similarly, ABT has 14.67% upside from the recent share price of $107.37 if the average analyst target price of $123.12/share is reached, and analysts on average are expecting SYF to reach a target price of $37.95/share, which is 12.47% above the recent price of $33.74. Three of RDVY's underlying holdings with notable upside to their analyst target prices are Mueller Industries Inc (Symbol: MLI), Abbott Laboratories (Symbol: ABT), and Synchrony Financial (Symbol: SYF). Below is a twelve month price history chart comparing the stock performance of MLI, ABT, and SYF: Combined, MLI, ABT, and SYF represent 6.14% of the First Trust Rising Dividend Achievers ETF. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report SiBone (SIBN) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT recently received FDA approval for its pioneering AVEIR dual chamber (DR) leadless pacemaker system. During the same month, ABT’s FreeStyle Libre 2 system became the first and only CGM system to be nationally reimbursed in France for people who use basal insulin."
2023-07-05,106.72000122070312,107.37000274658205,0.4215428086578002,Validea's Top 5 Health Care Stocks Based On Joel Greenblatt - 7/5/2023 | Abbott's Minimally Invasive Dual Chamber Leadless Pacemaker System Gets FDA Approval,"Detailed Analysis of BOSTON SCIENTIFIC CORPORATION BSX Guru Analysis BSX Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis COMMUNITY HEALTH SYSTEMS INC (CYH) is a small-cap growth stock in the Healthcare Facilities industry. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. | (RTTNews) - Abbott Laboratories (ABT) a biopharmaceutical major, announced on Wednesday that it has received FDA approval for its dual chamber (DR) leadless pacemaker system dubbed AVEIR. As per the company, more than 80 percent of the people need a pacemaker pacing in two chambers of the heart and the approval increases the access leadless pacing for millions of people across the U.S. The previously-approved AVEIR VR single chamber device paces the right ventricle, and the now-approved AVEIR AR single chamber device paces the right atrium."
2023-07-03,108.25,107.22000122070312,0.6090718875974147,Abbott (ABT) Stock Sinks As Market Gains: What You Should Know,"Abbott (ABT) closed at $107.22 in the latest trading session, marking a -1.65% move from the prior day. We can also see that ABT currently has a PEG ratio of 4.88. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here."
2023-06-30,108.0,109.0199966430664,-0.9515000270640877,Abbott (ABT) Teams Up With the ADA to Evaluate CGM Systems,"Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT recently teamed up with the American Diabetes Association (“ADA”) to launch a therapeutic nutrition program for people with diabetes. ABT’s TactiFlex Ablation Catheter has been approved by the FDA for the treatment of abnormal heart rhythm."
2023-06-29,107.02999877929688,107.66000366210938,0.9444413361725983,,
2023-06-28,107.95999908447266,107.61000061035156,0.5886245818909265,Validea's Top 5 Health Care Stocks Based On Benjamin Graham - 6/28/2023,"Detailed Analysis of OWENS & MINOR, INC. OMI Guru Analysis OMI Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis CORVEL CORPORATION (CRVL) is a mid-cap growth stock in the Healthcare Facilities industry. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices."
2023-06-27,108.88999938964844,107.79000091552734,-0.3241927353549156,Abbott (ABT) Stock Sinks As Market Gains: What You Should Know | Abbott (ABT) EPD Sales Aid Growth Amid Currency Headwind | Here's How Much a $1000 Investment in Abbott Made 10 Years Ago Would Be Worth Today | How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings,"ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.39 per share and revenue of $39.38 billion. Abbott (ABT) closed at $107.79 in the latest trading session, marking a -0.66% move from the prior day. Also, we should mention that ABT has a PEG ratio of 4.86. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott’s ABT new product launches and acquisitions are expected to boost its sales. Abbott Laboratories Price Abbott Laboratories price | Abbott Laboratories Quote Within Diagnostics, excluding COVID testing, organic sales growth was led by mid-to-high single-digit growth in Core Lab, Rapid and Point of Care Diagnostics. | What if you'd invested in Abbott (ABT) ten years ago? It may not have been easy to hold on to ABT for all that time, but if you did, how much would your investment be worth today? Analysts are anticipating more upside for ABT. | BAX is part of a big group of Medical stocks that boast a positive ESP, and investors may want to take a look at Abbott (ABT) as well. It's Most Accurate Estimate is currently $1.04 a share, and ABT is 22 days out from its next earnings report. BAX and ABT's positive ESP figures tell us that both stocks have a good chance at beating analyst expectations in their next earnings report."
2023-06-26,108.0999984741211,108.51000213623048,-1.010192377892202,Here's Why Investors Should Retain Abbott (ABT) Stock Now | The Health Care Select Sector SPDR Fund Experiences Big Outflow,"Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT is well-poised for growth in the coming quarters, courtesy of the continued growth in the Diabetes business. Progress With Diabetes Business: This business achieved organic sales growth of 21% in the first quarter of 2023, led by a more than 25% growth in FreeStyle Libre, including approximately 50% growth in the United States and mid-teens internationally. | Among the largest underlying components of XLV, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is down about 0.7%, Abbott Laboratories (Symbol: ABT) is down about 0.3%, and Danaher Corp (Symbol: DHR) is lower by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $198.0 million dollar outflow -- that's a 0.5% decrease week over week (from 310,420,000 to 308,920,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $119.95 per share, with $141.77 as the 52 week high point — that compares with a last trade of $130.78."
2023-06-23,108.1999969482422,108.0500030517578,0.3792818389424336,Abbott (ABT) Just Overtook the 50-Day Moving Average,"Given this move in earnings estimate revisions and the positive technical factor, investors may want to keep their eye on ABT for more gains in the near future. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott (ABT) is looking like an interesting pick from a technical perspective, as the company reached a key level of support."
2023-06-22,106.69000244140624,108.25,-0.13862652561455566,Will Abbott Stock Rebound To Its 2022 Highs?,"Abbott stock (NYSE: ABT) currently trades at $106 per share, over 10% below its level in March 2021, and it has the potential for sizable gains. Timeline of 2007-08 Crisis 10/1/2007: Approximate pre-crisis peak in S&P 500 index 9/1/2008 – 10/1/2008: Accelerated market decline corresponding to Lehman bankruptcy filing (9/15/08) 3/1/2009: Approximate bottoming out of S&P 500 index 12/31/2009: Initial recovery to levels before accelerated decline (around 9/1/2008) ABT and S&P 500 Performance During 2007-08 Crisis ABT stock rose from $26 in September 2007 to $28 in August 2008 (pre-crisis peak) before falling to around $22 in March 2009 (as the markets bottomed out), implying ABT stock lost nearly 20% of its pre-crisis value. Conclusion With the Fed’s efforts to tame runaway inflation rates helping market sentiments, we believe Abbott (ABT) stock has the potential for solid gains once fears of a potential recession are allayed."
2023-06-21,106.62000274658205,106.25,1.4621778263155532,"DexCom Clears Base, Wall Street Eyes Double-Digit Earnings Growth | Surmodics (SRDX) Rallies on FDA Approval for SurVeil DCB | Agilent Technologies Stock: Ready to Rise off the Floor | Validea's Top 5 Health Care Stocks Based On Peter Lynch - 6/21/2023 | Abbott (ABT) Stock Moves -0.42%: What You Should Know","DexCom says its CGM competitors include the Diabetes Care division of Abbott Laboratories (NYSE: ABT), Medtronic’s Diabetes Group; Roche Holding AG’s (OTCMKTS: RHHVF) Diabetes Care unit, and privately-held LifeScan and Ascensia DiabetesCare. “We currently intend to retain any future earnings to finance the operation and expansion of our business,” it said in regulatory filings, adding, “As a result, stockholders … may only receive a return on their investment in our common stock if the market price of our common stock increases.” That’s the company throwing down and raising the stakes, acknowledging that it will only reward shareholders with price appreciation, not reward share owners with that comfortable, cozy feeling of getting a dividend payout, even when the stock’s price languishes. Fellow S&P 500 components with good recent price gains include  Medtronic plc (NYSE: MDT), Stryker Corp. (NYSE: SYK), Boston Scientific Corp. (NYSE: BSX), and Zimmer Biomet Holdings Inc. (NYSE: ZBH) Using MarketBeat’s DexCom analyst ratings, you can see that five analysts boosted their price targets on DexCom after the company’s most recent earnings report on April 27. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report Surmodics, Inc. (SRDX) : Free Stock Analysis Report To read this article on Zacks.com click here. Commercialization Plan Surmodics has a deal in place with Abbott Laboratories ABT for commercialization of SurVeil DCB. The company will receive a share of profit on third-party sales made by ABT. | It counts some of the most well-known biotechnology, healthcare, diagnostic and applied materials companies in the world as clients, including Abbott Laboratories (NYSE: ABT), Thermo Fisher Scientific Inc. (NYSE: TMO) and Roche Holding AG (OTCMKTS: RHHBY). Revenues rose 6.8% year-over-year (YoY) to $1.72 billion, beating analyst estimates of $1.67 billion. Fiscal full-year 2023 EPS is expected between $5.60 to $5.65 versus $5.69 consensus analyst estimates on revenues between $6.93 billion to $7.03 billion versus $7.09 billion consensus analyst estimates. | ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis INTEGRA LIFESCIENCES HOLDINGS CORP (IART) is a mid-cap growth stock in the Scientific & Technical Instr. Its Established Pharmaceutical Products segment includes gastroenterology products, women's health products, cardiovascular and metabolic products, pain and central nervous system products and respiratory drugs and vaccines. | Abbott (ABT) closed at $106.25 in the latest trading session, marking a -0.42% move from the prior day. Investors should also note that ABT has a PEG ratio of 4.78 right now. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here."
2023-06-20,105.1999969482422,106.6999969482422,-0.34702939134364896,3 Passive Income Stocks to Hold for the Next 20 Years,"Abbott Labs Abbott Laboratories (NYSE: ABT) is a healthcare company with a wide portfolio of products spanning the diagnostics, medical devices, and nutrition segments. The company has reported steadily improving financials over the past three years, with revenue rising from $34.6 billion in 2020 to $43.7 billion in 2022. Net income climbed from $4.5 billion to $6.9 billion over the same period, and the company generated an average free cash flow of $7.4 billion over the three years."
2023-06-16,105.44000244140624,106.1999969482422,1.4258555546707776,,
2023-06-15,103.26000213623048,105.0199966430664,0.7207838479122762,ABT February 2024 Options Begin Trading | ABT Crosses Above Key Moving Average Level,"Below is a chart showing ABT's trailing twelve month trading history, with the $105.00 strike highlighted in red: Considering the fact that the $105.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the February 2024 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new February 2024 contracts and identified one put and one call contract of particular interest. | In trading on Thursday, shares of Abbott Laboratories (Symbol: ABT) crossed above their 200 day moving average of $104.83, changing hands as high as $105.11 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $93.25 per share, with $115.69 as the 52 week high point — that compares with a last trade of $105.05. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average » Also see: • Top Ten Hedge Funds Holding NIB • Top Ten Hedge Funds Holding HWAY • TM Stock Predictions The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2023-06-14,103.30999755859376,103.25,1.7044300507702586,Validea's Top 5 Health Care Stocks Based On Benjamin Graham - 6/14/2023,"Detailed Analysis of APOLLO MEDICAL HOLDINGS INC AMEH Guru Analysis AMEH Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis KURA ONCOLOGY INC (KURA) is a small-cap growth stock in the Biotechnology & Drugs industry. The Company's clinical diagnostic business offers molecular diagnostic testing services, genetic testing, and anatomic pathology laboratory services designed to provide physicians and patients with clinically actionable diagnostic information."
2023-06-13,101.48999786376952,101.86000061035156,-0.058075268620285975,Abbott (ABT) Gains But Lags Market: What You Should Know,"Abbott (ABT) closed at $101.86 in the latest trading session, marking a +0.45% move from the prior day. Meanwhile, ABT's PEG ratio is currently 4.54. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here."
2023-06-12,101.83999633789062,101.4000015258789,0.3645706516603753,"Health Care Sector Update for 06/12/2023: ME, BIIB, ABT, BNTX | Health Care Sector Update for 06/12/2023: BIIB, ABT, BNTX | Abbott (ABT) EPD Sales Gain Traction, Margin Pressure Lingers | What's Next For Boston Scientific Stock After Outperforming During The 2022 Inflation Shock?","Abbott Laboratories (ABT) said in a regulatory filing on Monday that it has named Philip Boudreau as chief financial officer. Health care stocks were mostly higher late Monday, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) both up about 0.3%. The company's shares were down 2.6%. | Abbott Laboratories (ABT) said in a regulatory filing on Monday that it has named Philip Boudreau as chief financial officer. In company news, Biogen (BIIB) and partner Eisai said Saturday that a US Food and Drug Administration advisory committee supported the approval of Leqembi to treat Alzheimer's disease. A court hearing over a lawsuit against BioNTech (BNTX) in Germany seeking damages for alleged side effects of its COVID-19 vaccine was postponed on Monday after the plaintiff's lawyer requested the case to be heard by different judges, Reuters reported. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH) : Free Stock Analysis Report Neuronetics, Inc. (STIM) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott’s ABT Established Pharmaceuticals and Nutrition businesses should drive growth in the coming quarters. In Diabetes Care, sales of FreeStyle Libre grew more than 25% on an organic basis in the quarter, including approximately 50% growth in the United States and mid-teens growth internationally. | Timeline of 2007-08 Crisis 10/1/2007: Approximate pre-crisis peak in S&P 500 index 9/1/2008 – 10/1/2008: Accelerated market decline corresponding to Lehman bankruptcy filing (9/15/08) 3/1/2009: Approximate bottoming out of S&P 500 index 12/31/2009: Initial recovery to levels before accelerated decline (around 9/1/2008) BSX and S&P 500 Performance During 2007-08 Crisis BSX stock declined from $14 in September 2007 (pre-crisis peak) to around $7 in March 2009 (as the markets bottomed out), implying it lost nearly 50% of its pre-crisis value. Conclusion With the Fed’s efforts to tame runaway inflation rates helping market sentiments, we believe Boston Scientific (BSX) stock has little room for growth even once fears of a potential recession are allayed, given its rich valuation. Total [2] BSX Return -2% 10% 134% S&P 500 Return 2% 11% 91% Trefis Multi-Strategy Portfolio 4% 14% 259% [1] Month-to-date and year-to-date as of 6/8/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2023-06-09,100.97000122070312,101.69000244140624,-0.4320451962231799,"Daily Dividend Report: ODC,AMAT,CL,ABT,PM","VIDEO: Daily Dividend Report: ODC,AMAT,CL,ABT,PM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The Board of Directors of Oil-Dri Corporation of America yesterday declared quarterly cash dividends of $0.29 per share of the Company's Common Stock and $0.218 per share of the Company's Class B Stock, an approximate 4% increase for both classes of stock. The Board of Directors of Colgate-Palmolive today declared a quarterly cash dividend of $0.48 per common share, payable on August 15, 2023, to shareholders of record on July 21, 2023."
2023-06-08,101.25,100.77999877929688,0.7130842943433382,"Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now? | Top Stock Reports for Procter & Gamble, Bank of America & Abbott Laboratories","Click to get this free report ProShares S&P 500 Dividend Aristocrats ETF (NOBL): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Aflac Incorporated (AFL) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Dividend Appreciation ETF (VIG): ETF Research Reports iShares Core Dividend Growth ETF (DGRO): ETF Research Reports To read this article on Zacks.com click here. A smart beta exchange traded fund, the ProShares S&P 500 Dividend Aristocrats ETF (NOBL) debuted on 10/09/2013, and offers broad exposure to the Style Box - Large Cap Value category of the market. IShares Core Dividend Growth ETF (DGRO) tracks Morningstar US Dividend Growth Index and the Vanguard Dividend Appreciation ETF (VIG) tracks NASDAQ US Dividend Achievers Select Index. | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read P&G's (PG) Productivity & Cost Savings Plan to Aid Margins Higher Rates, Loans Support BofA (BAC) Amid Fee Income Woes Organic Sales Gain, Growing EPD Business Aid Abbott (ABT) Featured Reports Cisco (CSCO) Benefits From Strong Security Products Adoption Per Zacks analyst, Cisco is benefiting from a rapidly growing security market driven by robust adoption of identity and access, advanced threat and unified threat management security solutions. Click to get this free report Bank of America Corporation (BAC) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Duke Energy Corporation (DUK) : Free Stock Analysis Report Procter & Gamble Company (The) (PG) : Free Stock Analysis Report Cisco Systems, Inc. (CSCO) : Free Stock Analysis Report Sony Corporation (SONY) : Free Stock Analysis Report To read this article on Zacks.com click here. Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), Bank of America Corporation (BAC) and Abbott Laboratories (ABT)."
2023-06-07,102.41999816894533,101.66000366210938,-0.46419873649691357,Relative Strength Alert For Abbott Laboratories | Abbott (ABT) Is Considered a Good Investment by Brokers: Is That True? | Abbott (ABT) Dips More Than Broader Markets: What You Should Know | Validea's Top 5 Health Care Stocks Based On Benjamin Graham - 6/7/2023,"In trading on Wednesday, shares of Abbott Laboratories (Symbol: ABT) entered into oversold territory, hitting an RSI reading of 29.98, after changing hands as low as $101.25 per share. The chart below shows the one year performance of ABT shares: Looking at the chart above, ABT's low point in its 52 week range is $93.25 per share, with $116.15 as the 52 week high point — that compares with a last trade of $101.69. A bullish investor could look at ABT's 29.98 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. | Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Abbott (ABT). Brokerage Recommendation Trends for ABT Is ABT Worth Investing In? | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott (ABT) closed the most recent trading day at $101.66, moving -0.94% from the previous trading session. ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.38 per share and revenue of $39.38 billion. | Detailed Analysis of GRIFOLS SA - ADR GRFS Guru Analysis GRFS Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis EXACT SCIENCES CORP (EXAS) is a large-cap growth stock in the Biotechnology & Drugs industry. Its Diagnostic Products segment includes core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion medicine; molecular diagnostics polymerase chain reaction (PCR) instrument systems; point of care systems; rapid diagnostics lateral flow testing products, and informatics and automation solutions."
2023-06-06,103.87000274658205,102.62000274658205,-0.7420372197061695,"Noteworthy ETF Inflows: VT, WMT, BAC, ABT","Among the largest underlying components of VT, in trading today Walmart Inc (Symbol: WMT) is down about 0.2%, Bank of America Corp (Symbol: BAC) is up about 2%, and Abbott Laboratories (Symbol: ABT) is lower by about 1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Total World Stock ETF (Symbol: VT) where we have detected an approximate $615.1 million dollar inflow -- that's a 2.3% increase week over week in outstanding units (from 286,847,202 to 293,352,298). For a complete list of holdings, visit the VT Holdings page » The chart below shows the one year price performance of VT, versus its 200 day moving average: Looking at the chart above, VT's low point in its 52 week range is $76.80 per share, with $95.04 as the 52 week high point — that compares with a last trade of $94.80."
2023-06-05,104.05999755859376,103.76000213623048,-1.2034273293028603,Should You Pick Stryker Stock Over BAX For Better Returns?,"Baxter’s Revenue Growth Is Better Baxter’s revenue growth has been slightly better, with a 10.2% average annual growth rate in the last three years, compared to 7.8% for Stryker. However, Baxter’s  5.9% cash as a percentage of assets is marginally higher than 4.8% for Stryker, implying that Stryker has a better debt position and Baxter has more cash cushion. The table below summarizes our revenue and return expectations for Stryker and Baxter over the next three years and points to an expected return of 20% for Stryker over this period vs. an 11% expected return for Baxter, based on Trefis Machine Learning analysis – Stryker vs. Baxter – which also provides more details on how we arrive at these numbers."
2023-06-02,103.30999755859376,104.1999969482422,-0.2882908220273221,,
2023-06-01,101.91000366210938,102.81999969482422,0.8614842809803199,Abbott (ABT) Gains But Lags Market: What You Should Know | Abbott (ABT) Gains But Lags Market: What You Should Know,"ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.38 per share and revenue of $39.36 billion. Abbott (ABT) closed the most recent trading day at $102.82, moving +0.8% from the previous trading session. We can also see that ABT currently has a PEG ratio of 4.57. | Abbott (ABT) closed the most recent trading day at $102.82, moving +0.8% from the previous trading session. ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.38 per share and revenue of $39.36 billion. We can also see that ABT currently has a PEG ratio of 4.57."
2023-05-31,101.5,102.0,0.8929408301583495,What's Next For Medtronic Stock After A 9% Fall In A Week? | Abbott (ABT) Gains As Market Dips: What You Should Know | Peter Lynch Detailed Fundamental Analysis - ABT,"Medtronic reported adjusted earnings of $1.57 on a per share and adjusted basis, up 5% y-o-y, and it compares with our forecast of $1.56. At its current levels, Medtronic stock is trading at 16x its expected forward earnings of $5.11 on a per share and adjusted basis for fiscal 2024, compared to the last three-year average of around 21x. Total [2] MDT Return -10% 5% 14% S&P 500 Return 1% 10% 88% Trefis Multi-Strategy Portfolio 1% 10% 245% [1] Month-to-date and year-to-date as of 5/30/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott (ABT) closed the most recent trading day at $102, moving +0.29% from the previous trading session. We can also see that ABT currently has a PEG ratio of 4.56. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT)."
2023-05-30,102.25,101.70999908447266,0.49261083743842365,Abbott (ABT) Reports Upbeat Cardiomems Sensor Study Result | Intuitive Surgical Gives Buying Opportunity Off Its 52 Week Highs,"Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report Perrigo Company plc (PRGO) : Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories, Inc. ABT presented new data from an investigator-sponsored European study — MONITOR-HF. The study revealed that Abbott's CardioMEMS HF System led to a significant improvement in quality-of-life scores in patients with indicated heart failures as early as three months. | The company has dominated the robot-assisted surgery market for over two decades and remained king of the hill despite any competition from other medical device makers like Microbot Medical Inc. (NASDAQ: MBOT),  Boston Scientific Co. (NYSE: BSX), Abbott Laboratories (NYSE: ABT), Stryker Co. (NYSE: SYK), Becton Dickinson& Co.  (NYSE: BDX), and Medtronic plc (NYSE: MDT). Intuitive Surgical (NASDAQ: ISRG) manufactures the revolutionary da Vinci Surgical System, the leader in robotic-assisted surgery systems. Each installed robotic system sets the Intuitive Surgical ecosystem in place as the healthcare company continues to generate revenues from surgeries, equipment, training,  and support."
2023-05-26,102.1500015258789,102.87000274658205,-0.5281182547944683,"Should You Invest in the iShares U.S. Medical Devices ETF (IHI)? | Is Illumina Stock A Better Pick Over TMO? | ESGU, PEG, GIS, ABT: Large Outflows Detected at ETF","Click to get this free report iShares U.S. Medical Devices ETF (IHI): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report SPDR S&P Health Care Equipment ETF (XHE): ETF Research Reports First Trust Indxx Medical Devices ETF (MDEV): ETF Research Reports To read this article on Zacks.com click here. Looking at individual holdings, Thermo Fisher Scientific Inc (TMO) accounts for about 17.24% of total assets, followed by Abbott Laboratories (ABT) and Medtronic Plc (MDT). First Trust Indxx Medical Devices ETF (MDEV) tracks INDXX GLOBAL MEDICAL EQUIPMENT INDEX and the SPDR S&P Health Care Equipment ETF (XHE) tracks S&P Health Care Equipment Select Industry Index. | Thermo Fisher Scientific’s Revenue Growth Is Better Thermo Fisher Scientific’s revenue growth has been much better, with a 20.8% average annual growth rate in the last three years, compared to 10.8% for Illumina. Thermo Fisher Scientific Is More Profitable But Comes With Higher Risk Illumina’s operating margin has slid from 29.3% in 2019 to -90.6% in 2022, while Thermo Fisher Scientific’s operating margin declined marginally from 20.6% to 20.3% over this period. The table below summarizes our revenue and return expectations for Illumina and Thermo Fisher Scientific over the next three years and points to an expected return of 31% for ILMN over this period vs. a 36% expected return for TMO, based on Trefis Machine Learning analysis – Illumina vs. Thermo Fisher Scientific – which also provides more details on how we arrive at these numbers. | Among the largest underlying components of ESGU, in trading today Public Service Enterprise Group Inc (Symbol: PEG) is off about 0.5%, General Mills Inc (Symbol: GIS) is up about 0.1%, and Abbott Laboratories (Symbol: ABT) is higher by about 1.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares ESG Aware MSCI USA ETF (Symbol: ESGU) where we have detected an approximate $73.0 million dollar outflow -- that's a 0.5% decrease week over week (from 147,450,000 to 146,650,000). For a complete list of holdings, visit the ESGU Holdings page » The chart below shows the one year price performance of ESGU, versus its 200 day moving average: Looking at the chart above, ESGU's low point in its 52 week range is $77.2839 per share, with $96.41 as the 52 week high point — that compares with a last trade of $92.24."
2023-05-25,103.2699966430664,102.13999938964844,0.7048469994596451,Abbott Laboratories (ABT) Shares Cross 2% Yield Mark,"Looking at the universe of stocks we cover at Dividend Channel, in trading on Thursday, shares of Abbott Laboratories (Symbol: ABT) were yielding above the 2% mark based on its quarterly dividend (annualized to $2.04), with the stock changing hands as low as $101.34 on the day. Abbott Laboratories (Symbol: ABT) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index. In the case of Abbott Laboratories, looking at the history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2% annual yield."
2023-05-24,105.6500015258789,104.04000091552734,-1.0942164134308967,"Abbott (ABT) Unveils Late-Breaking Data on Leadless Pacemaker | Abbott, other formula makers face FTC investigation for collusion - WSJ | Abbott: MONITOR-HF Trial With CardioMEMS Sensor Meets Primary Endpoint | ABT Makes Notable Cross Below Critical Moving Average | What To Expect From Medtronic's Q4? | Guru Fundamental Report for ABT - Peter Lynch","Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT announced a favorable outcome on its leadless pacemaker. Image Source: Zacks Investment Research Here's How AVEIR DR is Better According to Abbott, unlike traditional pacemakers, leadless pacemakers are implanted directly into the heart through a minimally invasive, catheter-based procedure. | The FTC is looking into whether Abbott Laboratories ABT.N and other formula manufacturers have ""engaged in collusion or coordination with any other market participant regarding the bidding"", the WSJ report said, citing documents posted to FTC's website. Adds details from WSJ report and background May 24 (Reuters) - The U.S. Federal Trade Commission is investigating whether baby-formula makers colluded on bids for attractive state contracts, the Wall Street Journal reported on Wednesday. The FTC has sought information from Nestle NESN.S, which makes the Good Start line of infant formulas, a company spokeswoman told the Journal, adding that the Swiss manufacturer has responded to the FTC. | (RTTNews) - Abbott (ABT) said data from an investigator-sponsored European trial found managing indicated heart failure patients with CardioMEMS HF System resulted in a significant improvement in patient-reported quality-of-life scores as early as three months after use with the remote monitoring sensor. The MONITOR-HF trial is the third randomized, controlled trial globally, funded by the Dutch Ministry of Health with clinical research organization costs paid by Abbott. The MONITOR-HF trial also resulted in a significant 44% reduction in heart failure-related hospitalizations among chronic heart failure patients who used guideline-directed medical therapy. | In trading on Wednesday, shares of Abbott Laboratories (Symbol: ABT) crossed below their 200 day moving average of $105.29, changing hands as low as $104.60 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $93.25 per share, with $118.23 as the 52 week high point — that compares with a last trade of $104.84. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other dividend stocks recently crossed below their 200 day moving average » Also see: • WBT Options Chain • Institutional Holders of ESDI • MANT Options Chain The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (1) Better Pricing To Aid Sales Trefis estimates Medtronic’s Q4 fiscal 2023 total revenues to be around $8.2 billion, reflecting a low single-digit y-o-y rise but marginally below the $8.3 billion consensus estimate. (2) EPS expected to align with the consensus estimates Medtronic’s Q4 fiscal 2023 earnings per share (EPS) is expected to be $1.56 per Trefis analysis, in line with the consensus estimate. Total [2] MDT Return -4% 12% 22% S&P 500 Return -1% 8% 85% Trefis Multi-Strategy Portfolio 0% 9% 243% [1] Month-to-date and year-to-date as of 5/24/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT)."
2023-05-23,107.3000030517578,105.73999786376952,-1.523900224419016,,
2023-05-22,108.68000030517578,108.25,-1.4538724544451214,Judge tosses out some claims in Abbott baby formula litigation | Judge tosses some claims in Abbott baby formula litigation | Abbott (ABT) Expands in Electrophysiology With New FDA Nod,"By Jonathan Stempel May 22 (Reuters) - Abbott Laboratories ABT.N persuaded a federal judge to dismiss some claims in nationwide litigation over recalled baby formula. In a decision on Monday, U.S. District Judge Matthew Kennelly in Chicago dismissed claims by parents pursuing only ""economic loss"" claims related to Similac and other formula that they said had a ""substantial risk"" of bacteria contamination. The litigation followed Abbott's February 2022 closure of a baby formula plant in Sturgis, Michigan and subsequent recalls, which together caused a nationwide shortage of formula. | By Jonathan Stempel May 22 (Reuters) - Abbott Laboratories ABT.N persuaded a federal judge to dismiss some claims in nationwide litigation over recalled baby formula. The litigation followed Abbott's February 2022 closure of a baby formula plant in Sturgis, Michigan and subsequent recalls, which together caused a nationwide shortage of formula. Separate nationwide litigation before a different Chicago judge involves claims that Abbott's formula caused a deadly illness in preterm infants. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DaVita Inc. (DVA) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report Addus HomeCare Corporation (ADUS) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott's ABT catheter line of products advanced after it received regulatory approval. How TactiFlex is Superior to Other Catheters According to Abbott, unlike other available catheters, the TactiFlex catheter is facilitated by a tip design with a laser-cut pattern."
2023-05-19,108.9800033569336,108.93000030517578,-0.39565725429548326,Abbott's (ABT) Assert-IQ Cardiac Monitor Receives FDA Approval | Abbott (ABT) Down 1.7% Since Last Earnings Report: Can It Rebound? | Abbott Announces FDA Approval For TactiFlex Ablation Catheter,"Abbott Laboratories, Inc. ABT recently announced the receipt of the FDA approval for its Assert-IQTM insertable cardiac monitor (ICM), giving doctors a new choice for the diagnostic assessment and ongoing monitoring of patients with irregular heartbeats. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DaVita Inc. (DVA) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report Addus HomeCare Corporation (ADUS) : Free Stock Analysis Report To read this article on Zacks.com click here. More on Assert-IQ Abbott's Assert-IQ ICM uses Bluetooth® technology to stay linked to a transmitter, typically the patient's own cell phone, where it continuously monitors heart rhythms and sends real-time results to the clinic's portal. | A month has gone by since the last earnings report for Abbott (ABT). Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. The Medical Devices business sales rose 8.5% year over year on a reported basis (up 12.4% on an organic basis) at $3.90 billion. | (RTTNews) - Abbott (ABT) announced the FDA has approved the company's TactiFlex Ablation Catheter, Sensor Enabled, an ablation catheter with a flexible tip and contact force technology. Used to perform an ablation procedure to treat atrial fibrillation, the TactiFlex catheter can result in reduced procedure times and better safety when compared to the company's previous generation catheters. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2023-05-18,108.7300033569336,108.47000122070312,-0.04588277685589846,5 Dividend Growth Stocks With Upside To Analyst Targets | iShares Core S&P Total U.S. Stock Market ETF Experiences Big Inflow | Abbott Laboratories Says FDA Approves Assert-IQ Insertable Cardiac Monitor,"Chevron Corporation (Symbol: CVX) $155.71 $190.39 22.27% Nucor Corp. (Symbol: NUE) $139.64 $161.17 15.42% Johnson & Johnson (Symbol: JNJ) $158.99 $183.31 15.30% California Water Service Group (Symbol: CWT) $56.09 $64.67 15.29% Abbott Laboratories (Symbol: ABT) $108.82 $124.44 14.35% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Chevron Corporation (Symbol: CVX) 3.88% 22.27% 26.15% Nucor Corp. (Symbol: NUE) 1.46% 15.42% 16.88% Johnson & Johnson (Symbol: JNJ) 2.99% 15.30% 18.29% California Water Service Group (Symbol: CWT) 1.85% 15.29% 17.14% Abbott Laboratories (Symbol: ABT) 1.87% 14.35% 16.22% Another consideration with dividend growth stocks is just how much the dividend is growing. Chevron Corporation (Symbol: CVX) $5.44 $5.77 6.07% Nucor Corp. (Symbol: NUE) $1.81 $2.02 11.60% Johnson & Johnson (Symbol: JNJ) $4.24 $4.52 6.60% California Water Service Group (Symbol: CWT) $0.96 $1.02 6.25% Abbott Laboratories (Symbol: ABT) $1.84 $1.96 6.52% These five stocks are part of our full Dividend Aristocrats List. | Among the largest underlying components of ITOT, in trading today McDonald's Corp (Symbol: MCD) is down about 0.1%, Thermo Fisher Scientific Inc (Symbol: TMO) is down about 0.2%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P Total U.S. Stock Market ETF (Symbol: ITOT) where we have detected an approximate $96.0 million dollar inflow -- that's a 0.2% increase week over week in outstanding units (from 455,200,000 to 456,250,000). For a complete list of holdings, visit the ITOT Holdings page » The chart below shows the one year price performance of ITOT, versus its 200 day moving average: Looking at the chart above, ITOT's low point in its 52 week range is $77.44 per share, with $96.36 as the 52 week high point — that compares with a last trade of $91.81. | (RTTNews) - Abbott Laboratories (ABT) announced Thursday that its Assert-IQ insertable cardiac monitor (ICM) has received U.S. Food and Drug Administration (FDA) clearance, giving physicians a new option for diagnostic evaluation and long-term monitoring of people experiencing irregular heartbeats. The Assert-IQ ICM also offers advanced diagnostic capabilities to provide physicians with more clinically relevant information about the cardiovascular health of the patient, allowing care providers to make clinical decisions faster. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2023-05-17,109.7699966430664,108.81999969482422,-0.23912639400639613,Guru Fundamental Report for ABT - Peter Lynch | Billionaire Paul Tudor Jones Pours Millions Into These 2 Stocks Amid Recession Fears,"Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Quantifying this stance, Furlong rates ABT shares an Overweight (i.e. Buy) while her $133 price target suggests share will appreciation of ~23% for the year ahead. Abbott Laboratories (ABT) During periods of economic downturn, healthcare stocks are often regarded as defensive investments due to their resilience and stability in the face of recessionary pressures. He opened a new position in ABT during the first quarter, with the purchase of 139,628 shares."
2023-05-16,109.54000091552734,109.38999938964844,-0.8654431787323861,Abbott Says FDA Approves Spinal Cord Stimulation Devices To Treat Chronic Back Pain | Which Healthcare Stock Is A Better Pick: Abbott Or This Robotic Products Company?,"(RTTNews) - Abbott Laboratories (ABT) announced Tuesday that the U.S. Food and Drug Administration (FDA) has approved its spinal cord stimulation (SCS) devices for the treatment of chronic back pain in people who have not had or are not eligible to receive back surgery, known as non-surgical back pain. This labeling expansion was supported by results from the DISTINCT study, which demonstrated that Abbott's proprietary BurstDR SCS technology improved pain levels, ability to perform daily activities and emotional well-being in people with chronic back pain. Abbott's DISTINCT study, which enrolled 270 participants who suffered for an average of 12.8 years with pain, is the largest randomized controlled trial for SCS in people with chronic back pain when surgery is not an option. | We believe that Intuitive Surgical stock (NASDAQ: ISRG) is a better pick than its sector peer, Abbott stock (NYSE: ABT). Looking at stock returns, ISRG has outperformed ABT and the broader indices. While ISRG is up 14% this year, ABT is up 0.4%, and the S&P500 index is up 8%."
2023-05-15,110.63999938964844,109.83999633789062,-0.13693767082819466,Abbott Labs is sued over PediaSure height claims | Abbott's (ABT) New Pact to Advance Clinical Trials Diversity,"By Jonathan Stempel NEW YORK, May 15 (Reuters) - A New York City woman sued Abbott Laboratories ABT.N on Monday, accusing the healthcare company of misleading consumers into believing its PediaSure nutrition drinks were ""clinically proven"" to increase children's height. In a proposed class action filed in Manhattan federal court, Joanne Noriega said she bought PediaSure Grow & Gain vanilla and strawberry drinks for her eight-year-old grandson, who was ""short for his age,"" believing they would help him get taller. For plaintiff: James Denlea, of Denlea & Carton; and Philip Smith, of Kravit Smith For Abbott: Not known (Reporting by Jonathan Stempel in New York; Editing by Bill Berkrot) ((jon.stempel@thomsonreuters.com; +1 646 223 6317; Reuters Messaging: jon.stempel.thomsonreuters.com@reuters.net)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report AmerisourceBergen Corporation (ABC) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories, Inc. ABT unveiled a number of new programmes within the framework of its multimillion-dollar drive to broaden participation in clinical trials and enhance care for underserved communities. In the same month, ABT announced new data from the meta-analysis of three randomized, controlled trials (CHAMPION, GUIDE-HF and LAPTOP-HF) presented at the Technology and Heart Failure Therapeutics Conference in Boston, MA."
2023-05-12,109.76000213623048,110.48999786376952,-0.7230685612536811,,
2023-05-11,110.05999755859376,110.0500030517578,0.6650835580642459,,
2023-05-10,110.9000015258789,110.69000244140624,-0.00908096225483291,"Noteworthy ETF Inflows: XLV, ABT, DHR, MDT | Guru Fundamental Report for ABT - Peter Lynch","Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.1%, Danaher Corp (Symbol: DHR) is up about 0.4%, and Medtronic PLC (Symbol: MDT) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $873.8 million dollar inflow -- that's a 2.2% increase week over week in outstanding units (from 297,620,000 to 304,220,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $118.75 per share, with $141.77 as the 52 week high point — that compares with a last trade of $132.51. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT)."
2023-05-09,110.12999725341795,110.25,-0.18935895544029044,Here's Why You Should Retain Abbott (ABT) Stock For Now,"Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT is well-poised for growth in the coming quarters, courtesy of continued growth in Medical Devices, EPD and Nutrition segments. Abbott projects 2023 organic sales growth, excluding COVID-19 testing-related sales, of at least high-single digits and COVID testing-related sales of around $1.5 billion."
2023-05-08,110.45999908447266,110.9000015258789,0.10896463232075591,"Abbott (ABT) EPD Business Grows Strong, Macro Issues Stay","Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories’ ABT branded generics and international diabetes businesses should drive growth in the coming quarters. Abbott Laboratories Price Abbott Laboratories price | Abbott Laboratories Quote Abbott’s first-quarter worldwide sales were down 18.1% year over year on a reported basis."
2023-05-05,111.37000274658205,111.26000213623048,0.39833645215745894,"Cigna (CI) Q1 Earnings Surpass Estimates, Ups '23 EPS View","Other Medical Sector Releases Of the Medical sector players that have reported first-quarter 2023 results so far, the bottom-line results of Elevance Health, Inc. ELV, HCA Healthcare, Inc. HCA and Abbott Laboratories ABT beat the respective Zacks Consensus Estimate. ABT reported an adjusted operating profit of $2.00 billion for the quarter under review, down 41.6% year over year. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Cigna Group (CI) : Free Stock Analysis Report HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here."
2023-05-04,111.4499969482422,110.86000061035156,-0.09877041181534714,"Becton Dickinson raises 2023 profit forecast as demand rebounds | The Zacks Analyst Blog Highlights Berkshire Hathaway, Tesla, JPMorgan Chase, Abbott Laboratories and Comcast","The medical device maker joins peers Stryker Corp SYK.N and Abbott Laboratories ABT.N, which have raised their full-year forecasts on the easing of staffing shortages and recovery in medical procedures volumes. May 4 (Reuters) - Becton Dickinson and Co BDX.N on Thursday raised its full-year profit forecast and beat estimates for the second-quarter results on strong demand for its drug delivery devices and surgical equipment. The company's largest unit that sells devices to administer drugs and automate pharmacy system has reported sales of $2.36 billion, beating analysts' average estimate of $2.23 billion. | Click to get this free report JPMorgan Chase & Co. (JPM) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Comcast Corporation (CMCSA) : Free Stock Analysis Report Berkshire Hathaway Inc. (BRK.B) : Free Stock Analysis Report Tesla, Inc. (TSLA) : Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include: Berkshire Hathaway Inc. (BRK.B), Tesla, Inc. TSLA, JPMorgan Chase & Co. JPM, Abbott Laboratories ABT and Comcast Corp. CMCSA. Here are highlights from Wednesday’s Analyst Blog: Top Research Reports for Berkshire Hathaway, Tesla and JPMorgan Chase The Zacks Research Daily presents the best research output of our analyst team."
2023-05-03,111.80999755859376,111.76000213623048,-0.5293821032266477,"Guru Fundamental Report for ABT - Peter Lynch | Top Research Reports for Berkshire Hathaway, Tesla & JPMorgan Chase","Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Click to get this free report JPMorgan Chase & Co. (JPM) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Comcast Corporation (CMCSA) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Berkshire Hathaway Inc. (BRK.B) : Free Stock Analysis Report Tesla, Inc. (TSLA) : Free Stock Analysis Report To read this article on Zacks.com click here. Other noteworthy reports we are featuring today include Eli Lilly and Company (LLY), Abbott Laboratories (ABT) and Comcast Corporation (CMCSA). Mounjaro's sales are already benefiting from strong demand trends EPD Sales Gain Aids Abbott (ABT) amid Inflationary Issues The Zacks analyst is upbeat about Abbott's Established Pharmaceuticals sales growth in key emerging markets on several therapeutic areas."
2023-05-02,111.05999755859376,111.5,-0.044714626111212706,Acadia Healthcare (ACHC) Q1 Earnings Beat on Higher Patient Volumes | Zimmer Biomet raises annual forecasts on knees and hips unit strength | Is Dexcom a Good Stock to Buy Now?,"Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report Acadia Healthcare Company, Inc. (ACHC) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Other Medical Sector Releases Of the Medical sector players that have reported first-quarter 2023 results so far, the bottom-line results of Elevance Health, Inc. ELV, HCA Healthcare, Inc. HCA and Abbott Laboratories ABT beat the respective Zacks Consensus Estimate. ABT reported an adjusted operating profit of $2.00 billion for the quarter under review, down 41.6% year over year. | Zimmer Biomet's upbeat outlook comes after several medical device makers, including Stryker Corp SYK.N and larger rival Abbott Laboratories ABT.N, raised their forecasts as easing staffing shortages at hospitals aid a recovery in medical procedures. Zimmer Biomet, which offers products such as knee replacements and surgical robots, now expects a profit of $7.40 to $7.50 per share for 2023, compared with $6.95 and $7.15 per share previously forecast. Excluding items, the company made a profit of $1.89 per share for the quarter ended March 31, compared with analysts' estimates of $1.64 per share. | The Food and Drug Administration granted clearance to FreeStyle Libre 3 from Abbott Laboratories (NYSE: ABT) last May so the giant healthcare conglomerate's new CGM has a long lead on Dexcom. Reasons to buy Dexcom stock now Dexcom's stock price didn't respond well to management's latestearnings call but the investment bankers who were listening in were more than satisfied. 10 stocks we like better than DexCom When our analyst team has a stock tip, it can pay to listen."
2023-05-01,110.45999908447266,111.11000061035156,0.39618445081821324,3 Stocks to Buy Before They Soar to New Heights in 2023,"RL Ralph Lauren $116.13 ABT Abbott Laboratories $110.40 JPM JPMorgan Chase $140.73 Ralph Lauren (RL) Source: Martin Good / Shutterstock.com Fashion designer and clothing retailer Ralph Lauren (NYSE:RL) has found its way onto my list of top stocks to buy. Abbott Laboratories (ABT) Source: testing / Shutterstock.com Abbot Laboratories (NYSE:ABT) finds itself on this list of stocks to buy due partly to the promising move ABT stock has made over the past six months. Incredibly, ABT stock recently jumped 8% in a single trading session after the company reported strong earnings, beating consensus estimates by four cents a share."
2023-04-28,109.44000244140624,110.47000122070312,0.5884496933426798,"Got $1,000? 2 Top Dividend Stocks to Buy Now","Abbott Laboratories First, let's talk about Abbott Laboratories' (NYSE: ABT) business and earnings. ABT Free Cash Flow data by YCharts. But you can boost your opportunities for gains if you invest in stocks that also pay you just for investing in them: dividend stocks."
2023-04-27,108.70999908447266,109.5,0.9411538343562691,"Why Abbott Laboratories Stock Looks Ridiculously Overpriced | Can Boston Scientific Set Another Net High? | The Zacks Analyst Blog Highlights BioRad Laboratories, Henry Schein, Insulet, Abbott and LabCorp","ABT Revenue (Quarterly YoY Growth) data by YCharts The stock is trading at a rich valuation This year, Abbott is projecting that its diluted earnings per share will fall within a range of $3.05 to $3.25. Abbott Laboratories (NYSE: ABT) has had a volatile couple of years. ABT PE Ratio data by YCharts Its valuation has been creeping down amid the current bear market, and investors should remember that this valuation was achieved while the business benefited from strong demand for COVID tests. | Among those are Abbott Laboratories (NYSE: ABT), which also provides diversification and Medtronic (NYSE: MDT). The market has been trending higher on a combination of factors that result in up trending sentiment and analyst price targets that have yet to end. The consensus price target is trending higher and supporting the price action, although it assumes the market is fairly valued at its current levels. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Laboratory Corporation of America Holdings (LH) : Free Stock Analysis Report Henry Schein, Inc. (HSIC) : Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include: BioRad Laboratories BIO, Henry Schein HSIC, Insulet PODD, Abbott ABT and LabCorp LH. Here are highlights from Wednesday’s Analyst Blog: 3 MedTech Stocks Likely to Beat Q1 Earnings Estimates So far, the first-quarter reporting cycle has displayed a year-over-year earnings deterioration for MedTech companies within the broader Medical sector."
2023-04-26,109.31999969482422,108.75,0.726704923356201,Guru Fundamental Report for ABT - Peter Lynch | 3 MedTech Stocks Likely to Beat Estimates in Q1 Earnings,"Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Laboratory Corporation of America Holdings (LH) : Free Stock Analysis Report Henry Schein, Inc. (HSIC) : Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT is one of the few companies whose base-business performance registered a strong recovery rate. Here we talk about three stocks, BioRad Laboratories BIO, Henry Schein HSIC and Insulet PODD that are expected to beat earnings estimates in the ongoing reporting cycle."
2023-04-25,110.38999938964844,109.97000122070312,-0.5214047716935784,"Centene (CNC) Q1 Earnings Miss Estimates, '23 EPS View Raised | NUVA vs. ABT: Which Stock Is the Better Value Option? | This Supercharged Dividend King Stock Might Soon Run Out of Steam | Abbott Announces Two New FDA Clearances For Life Support System | Pre-Market Most Active for Apr 25, 2023 : CSCO, FRC, TQQQ, SQQQ, INTC, INAB, BEKE, GOOGL, ABT, KO, MCD, GM | Is Abbott Laboratories Stock a Buy for Dividend Investors? | Unusual Call Option Trade in Abbott Laboratories (ABT) Worth $292.88K | The Fed Predicts a Recession: Should You Still Buy Stocks Now?","Other Medical Sector Releases Of the Medical sector players that have reported first-quarter 2023 results so far, the bottom-line results of Elevance Health, Inc. ELV, HCA Healthcare, Inc. HCA and Abbott Laboratories ABT beat the respective Zacks Consensus Estimate. ABT reported an adjusted operating profit of $2.00 billion in the quarter under review, down 41.6% year over year. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report Centene Corporation (CNC) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. | These are just a few of the metrics contributing to NUVA's Value grade of A and ABT's Value grade of C. NUVA is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. Click to get this free report NuVasive, Inc. (NUVA) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Investors looking for stocks in the Medical - Products sector might want to consider either NuVasive (NUVA) or Abbott (ABT). | AbbVie (NYSE: ABBV) has been a top growth and passive-income machine for investors since splitting off from parent company Abbott Laboratories (NYSE: ABT) in 2013. As a result of its rapid top-line growth and ever-rising dividend payout, AbbVie has been one of the best-performing Dividend King stocks over the past 10 years. AbbVie's success has centered around the anti-inflammatory biologic medicine Humira, which has topped $20 billion in annual sales each of the past three years. | (RTTNews) - Abbott Laboratories (ABT) announced Tuesday two new clearances from the U.S. Food and Drug Administration (FDA) for the company's industry-leading life support system. With the new indication, the CentriMag Blood Pump for use with the CentriMag System, is now cleared for longer-term use in adults when extracorporeal membrane oxygenation (ECMO) - a type of life support for people whose heart and lungs are not working - is critical to saving their life. Abbott also received FDA clearance for its new CentriMag Pre-connected Pack - a packaged system with several pre-connected components of the CentriMag system that can accelerate the deployment of the life support system. | Abbott Laboratories (ABT) is -0.53 at $109.87, with 1,151,994 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the ""buy range"". The total Pre-Market volume is currently 54,956,198 shares traded. | Abbott Laboratories (NYSE: ABT) has delivered 51 consecutive years of dividend growth to its shareholders. Dividend growth investing is among the most common investing strategies around, and for good reason: Buying quality businesses and dividend growth stocks often go hand in hand. This modest payout ratio gives Abbott flexibility to raise its dividend moderately ahead of its earnings growth in the near term as growth is uninspiring. | On April 25, 2023 at 11:49:44 ET an unusually large $292.88K block of Call contracts in Abbott Laboratories (ABT) was sold, with a strike price of $115.00 / share, expiring in 52 day(s) (on June 16, 2023). Fintel tracks all large options trades, and the premium spent on this trade was 1.40 sigmas above the mean, placing it in the 93.56th percentile of all recent large trades made in ABT options. Average portfolio weight of all funds dedicated to ABT is 0.49%, a decrease of 19.02%. | Let's look at a handful of top consumer goods and healthcare names: Amazon (NASDAQ: AMZN), Coca-Cola (NYSE: KO), Pfizer (NYSE: PFE), and Abbott Laboratories (NYSE: ABT). AMZN data by YCharts But if you held on for five years from the start of the recession, you would have seen gains in each stock. All of this means, even with a possible recession ahead, you still can buy stocks now and win over the long haul."
2023-04-24,111.75,110.4000015258789,-0.38046758879201226,"Validea's Top 5 Health Care Stocks Based On Peter Lynch - 4/24/2023 | XLV, ABT, DHR, ELV: ETF Inflow Alert | New Product Launches To Aid Boston Scientific's Q1","Detailed Analysis of THERMO FISHER SCIENTIFIC INC TMO Guru Analysis TMO Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis GOODRX HOLDINGS INC (GDRX) is a mid-cap growth stock in the Business Services industry. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. | Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.6%, Danaher Corp (Symbol: DHR) is up about 0.3%, and Elevance Health Inc (Symbol: ELV) is up by about 2.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $530.5 million dollar inflow -- that's a 1.3% increase week over week in outstanding units (from 295,670,000 to 299,620,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $118.75 per share, with $141.77 as the 52 week high point — that compares with a last trade of $134.87. | (1) Revenues expected to align with the consensus estimates Trefis estimates Boston Scientific’s Q1 2023 revenues to be around $3.2 billion, aligning with the consensus estimate and reflecting a mid-single-digit y-o-y growth. (2) EPS is likely to be in line with the consensus estimates Boston Scientific’s Q1 2023 adjusted earnings per share (EPS) is expected to be $0.44 per Trefis analysis, broadly in line with the consensus estimate of $0.43. Total [2] BSX Return 2% 10% 136% S&P 500 Return 1% 8% 85% Trefis Multi-Strategy Portfolio 2% 10% 246% [1] Month-to-date and year-to-date as of 4/24/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2023-04-21,110.87999725341795,111.66000366210938,-1.2080523258354305,"HCA Healthcare (HCA) Beats on Q1 Earnings, Ups '23 EPS View","Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. Other Medical Sector Releases Of the Medical sector players that have reported first-quarter results so far, the bottom-line results of UnitedHealth Group Incorporated UNH, Elevance Health, Inc. ELV  and Abbott Laboratories ABT beat the respective Zacks Consensus Estimate. ABT reported an adjusted operating profit of $2.00 billion in the quarter under review, down 41.6% year over year."
2023-04-20,112.25,110.3499984741211,0.7034690007330211,"Noteworthy Thursday Option Activity: MTZ, ABT, TPC | Barclays Maintains Abbott Laboratories (ABT) Overweight Recommendation | Raymond James Maintains Abbott Laboratories (ABT) Outperform Recommendation | UBS Maintains Abbott Laboratories (ABT) Buy Recommendation | Citigroup Maintains Abbott Laboratories (ABT) Buy Recommendation","Below is a chart showing MTZ's trailing twelve month trading history, with the $85 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) saw options trading volume of 26,957 contracts, representing approximately 2.7 million underlying shares or approximately 47% of ABT's average daily trading volume over the past month, of 5.7 million shares. Below is a chart showing ABT's trailing twelve month trading history, with the $110 strike highlighted in orange: And Tutor Perini Corp (Symbol: TPC) saw options trading volume of 1,760 contracts, representing approximately 176,000 underlying shares or approximately 46.8% of TPC's average daily trading volume over the past month, of 376,395 shares. Particularly high volume was seen for the $110 strike call option expiring May 19, 2023, with 2,466 contracts trading so far today, representing approximately 246,600 underlying shares of ABT. | Fintel reports that on April 20, 2023, Barclays maintained coverage of Abbott Laboratories (NYSE:ABT) with a Overweight recommendation. The firm decreased its portfolio allocation in ABT by 38.81% over the last quarter. The firm decreased its portfolio allocation in ABT by 99.89% over the last quarter. | The firm decreased its portfolio allocation in ABT by 99.89% over the last quarter. Fintel reports that on April 20, 2023, Raymond James maintained coverage of Abbott Laboratories (NYSE:ABT) with a Outperform recommendation. The firm increased its portfolio allocation in ABT by 6.25% over the last quarter. | Fintel reports that on April 20, 2023, UBS maintained coverage of Abbott Laboratories (NYSE:ABT) with a Buy recommendation. The firm decreased its portfolio allocation in ABT by 99.89% over the last quarter. The firm decreased its portfolio allocation in ABT by 99.90% over the last quarter. | The firm decreased its portfolio allocation in ABT by 99.89% over the last quarter. Fintel reports that on April 20, 2023, Citigroup maintained coverage of Abbott Laboratories (NYSE:ABT) with a Buy recommendation. The firm increased its portfolio allocation in ABT by 29.84% over the last quarter."
2023-04-19,108.5,112.29000091552734,-1.6926516934333242,"US STOCKS-S&P 500 little changed as investors digest mixed earnings | Diversified Abbott Laboratories Could Reverse And Move Higher | Guru Fundamental Report for ABT - Peter Lynch | Health Care Sector Update for 04/19/2023: ABT, BBIO, LEGN | US STOCKS-Dow dips, S&P 500 stable after medtech gains, Netflix drag | Wednesday Sector Leaders: Financial, Healthcare | Health Care Sector Update for 04/19/2023: AMGN, NVS, ABT, BBIO | S&P 500 ends little changed amid medtech gains, Netflix drag | Abbott Lab Climbs After Reporting Q1 Profit That Beats Estimates | Abbott (ABT) Beats Q1 Earnings and Revenue Estimates | Abbott (ABT) Reports Q1 Earnings: What Key Metrics Have to Say | US STOCKS-Futures retreat as Treasury yields rise, Tesla slides | Abbott's (ABT) Q1 Earnings Beat Estimates, Margins Down | Abbott beats profit estimates on strong medical device sales | Abbott Laboratories Q1 23 Earnings Conference Call At 9:00 AM ET | 2 Stocks That Could Help Make You a Millionaire by Retirement | Health Care Sector Update for 04/19/2023: LEGN, JNJ, GMDA, ABT, XLV, IBB | Abbott beats profit estimates on strong medical device sales","Elsewhere in healthcare, Abbott Laboratories ABT.N shares jumped 7.6% after the medical device maker said most delayed non-urgent medical procedures had resumed globally three years into the COVID-19 pandemic. By Lewis Krauskopf, Sruthi Shankar and Ankika Biswas April 19 (Reuters) - The S&P 500 was little changed on Wednesday as investors digested a mixed bag of corporate earnings, including upbeat reports from medical technology companies, while weakness in Netflix and Tesla shares weighed. The Dow edged lower, dragged down by declines in Walt Disney Co DIS.N and UnitedHealth Group Inc UNH.N shares following results from rivals in their respective industries. | It is no surprise that Abbott Laboratories (NYSE: ABT) produce a solid quarter. Med-tech companies like Intuitive Surgical (NASDAQ: ISRG), Boston Scientific (NYSE: BSX) and DexCom (NASDAQ: DXCM) have seen an increase in analyst interest driven by results and outlook. The revenue beat the consensus because of a 10% increase in organic sales driven by a 3.8% gain in Nutrition, a 3.7% gain in Established Pharmaceuticals and an 8.5% gain in Medical Devices. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | In company news, Abbott Laboratories (ABT) shares rose 8% after it posted forecast-beating Q1 results. Healthcare stocks were mixed Wednesday afternoon, with the NYSE Health Care Index falling 0.3% and the Health Care Select Sector SPDR Fund (XLV) up 0.1%. The company plans to sell 7.66 million ordinary shares to an undisclosed institutional investor in a private placement for $26.12 per share, equivalent to $52.24 per American Depositary Share. | Elsewhere in healthcare, Abbott Laboratories ABT.N shares jumped 7.8% after the medical device maker said most delayed non-urgent medical procedures had resumed globally three years into the COVID-19 pandemic. Netflix falls after downbeat forecast Abbott Labs, Intuitive Surgical jump after earnings Western Alliance surges as results allay deposit fears VIX falls to lowest since November 2021 Indexes: Dow down 0.23%, S&P down 0.01%, Nasdaq up 0.03% Updates with further market data By Lewis Krauskopf, Sruthi Shankar and Ankika Biswas April 19 (Reuters) - The S&P 500 ended virtually unchanged on Wednesday while the Dow dipped as investors digested a mixed bag of corporate earnings, including upbeat reports from medical technology companies, countered by weakness in Netflix shares. The Dow was weighed down by declines in Walt Disney Co DIS.N and UnitedHealth Group Inc UNH.N shares following results from rivals in their respective industries. | Among large Healthcare stocks, Intuitive Surgical Inc (Symbol: ISRG) and Abbott Laboratories (Symbol: ABT) are the most notable, showing a gain of 11.5% and 7.7%, respectively. Combined, ISRG and ABT make up approximately 5.8% of the underlying holdings of XLV. Among financial ETFs, one ETF following the sector is the Financial Select Sector SPDR ETF (Symbol: XLF), which is up 0.3% on the day, and down 2.02% year-to-date. | Abbott Laboratories (ABT) shares rose almost 8% after it posted forecast-beating Q1 results. In company news, Amgen (AMGN) has won an appeal to uphold patents covering psoriasis drug Otezla and banning the proposed generic versions by Zydus Pharmaceuticals and Novartis' (NVS) Sandoz, said the US Court of Appeals for the Federal Circuit in a Wednesday filing. BridgeBio Pharma (BBIO) shares were up past 10% after analysts at Evercore ISI initiated coverage of the company with an outperform rating and a $40 price target. | Elsewhere in healthcare, Abbott Laboratories ABT.N shares jumped after the medical device maker said most delayed non-urgent medical procedures had resumed globally three years into the COVID-19 pandemic. By Lewis Krauskopf, Sruthi Shankar and Ankika Biswas April 19 (Reuters) - The S&P 500 ended little changed on Wednesday as investors digested a mixed bag of corporate earnings, including upbeat reports from medical technology companies, countered by weakness in Netflix shares. Shares of Elevance Health Inc ELV.N fell after the insurer's strong quarterly profit failed to ease investor concerns over regulatory hits to the company's government-backed insurance business. | (RTTNews) - Abbott Laboratories (ABT) shares are gaining more than 5 percent on Wednesday morning trade after the company reported first-quarter profit that beat estimates. The company reaffirmed full-year earnings per share in a range of $4.30-$4.50. Excluding COVID-19 testing sales, the company now expects full-year organic sales growth of at least high single digits. | Abbott (ABT) came out with quarterly earnings of $1.03 per share, beating the Zacks Consensus Estimate of $0.98 per share. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Surmodics, Inc. (SRDX) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $9.75 billion for the quarter ended March 2023, surpassing the Zacks Consensus Estimate by 1.07%. | Abbott (ABT) reported $9.75 billion in revenue for the quarter ended March 2023, representing a year-over-year decline of 18.1%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Here is how Abbott performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net sales- Diagnostics- U.S. $1.34 billion versus $1.44 billion estimated by four analysts on average. | Wall Street bank Morgan Stanley MS.N, regional lender U.S. Bancorp USB.N, oilfield services firm Baker Hughes BKR.O and healthcare firm Abbott ABT.N are among the companies reporting results before the opening bell. Futures down: Dow 0.48%, S&P 0.61%, Nasdaq 0.92% April 19 (Reuters) - U.S. stock index futures fell on Wednesday as Treasury yields rose on expectations the Federal Reserve could keep interest rates higher for longer, while a slide in Tesla and Netflix shares was set to weigh on the tech-heavy Nasdaq. The 2-year Treasury yield US2YT=RR, most reflective of short-term rate expectations, hit a one-month high of 4.27% on Wednesday and the 10-year yield US10YT=RR hit a four-week high as traders scaled back expectations of rate cuts later this year. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report Henry Schein, Inc. (HSIC) : Free Stock Analysis Report AVANOS MEDICAL, INC. (AVNS) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT reported first-quarter 2023 adjusted earnings of $1.03 per share, which exceeded the Zacks Consensus Estimate by 5.1%. Abbott Laboratories Price, Consensus and EPS Surprise Abbott Laboratories price-consensus-eps-surprise-chart | Abbott Laboratories Quote The company reported an adjusted operating profit of $2.00 billion in the quarter under review, down 41.6% year over year. | April 19 (Reuters) - Abbott Laboratories ABT.N on Wednesday reported quarterly profit above expectations, driven by sales of its diabetes care devices and an improved demand for other devices due to a resumption in non-urgent medical procedures. Excluding one-off items, the company reported a profit of $1.03 per share for the first quarter ended March 31, higher than the average of analysts' estimates of 99 cents per share, according to Refinitiv IBES data. (Reporting by Leroy Leo and Khushi Mandowara in Bengaluru; Editing by Sherry Jacob-Phillips) ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on April 19, 2023, to discuss Q1 23 earnings results. To access the live webcast, log on to https://www.abbottinvestor.com/news-and-events?c=94004&p=irol-calall The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Let's look at two companies that can deliver on that front over the long run: Abbott Laboratories (NYSE: ABT) and Visa (NYSE: V). ABT Revenue (Quarterly) data by YCharts. Here's one more reason why Abbott Laboratories is an excellent stock to buy and hold: The company has raised its payouts for 51 consecutive years, which makes it a Dividend King. | Abbott Laboratories (ABT) was climbing past 3% after it reported Q1 adjusted earnings of $1.03 per diluted share, down from $1.73 a year earlier but still beating the $0.98 estimate from analysts polled by Capital IQ. The Health Care Select Sector SPDR Fund (XLV) was up 0.1% and the iShares Biotechnology ETF (IBB) was recently inactive. Johnson & Johnson (JNJ) and Legend Biotech's (LEGN) jointly developed CAR-T cancer therapy Carvykti has shown to significantly reduce the risk of relapse in multiple myeloma patients, Stat News reported, citing leaked results. | Adds details on medical device sales April 19 (Reuters) - Abbott Laboratories ABT.N reported quarterly profit above expectations on Wednesday, driven by sales of its diabetes care devices and an improved demand for other devices due to a resumption in non-urgent medical procedures. Sales of medical devices - Abbott's largest segment - grew 8.5% to $3.90 billion, of which glucose monitoring device Freestyle Libre reported a revenue of $1.2 billion. The sales of medical devices mirror a trend seen by rival Johnson & Johnson JNJ.N, which on Tuesday posted better-than-expected sales for the segment."
2023-04-18,105.44000244140624,104.1500015258789,3.4930884014076904,"Pre-Market Earnings Report for April 19, 2023 : ASML, ABT, MS, ELV, USB, TRV, BKR, NDAQ, CFG, SYF, ALLY, LAD","Zacks Investment Research reports that the 2023 Price to Earnings ratio for ABT is 23.97 vs. an industry ratio of 7.00, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories (ABT)is reporting for the quarter ending March 31, 2023. In the past year ABT has beat the expectations every quarter."
2023-04-17,104.0,104.5199966430664,-1.2234454530140895,Raymond James Maintains Abbott Laboratories (ABT) Outperform Recommendation | BTIG Maintains Abbott Laboratories (ABT) Buy Recommendation | Abbott (ABT) Gets FDA Clearance for FreeStyle Libre 3 Reader | 5 Dividend Aristocrats Where Analysts See Capital Gains,"Fintel reports that on April 17, 2023, Raymond James maintained coverage of Abbott Laboratories (NYSE:ABT) with a Outperform recommendation. The firm decreased its portfolio allocation in ABT by 99.89% over the last quarter. The firm increased its portfolio allocation in ABT by 5.71% over the last quarter. | Fintel reports that on April 17, 2023, BTIG maintained coverage of Abbott Laboratories (NYSE:ABT) with a Buy recommendation. The firm increased its portfolio allocation in ABT by 17.57% over the last quarter. The firm decreased its portfolio allocation in ABT by 0.39% over the last quarter. | Abbott Laboratories ABT recently announced the FDA clearance of a standalone reader for its FreeStyle Libre 3 integrated continuous glucose monitoring system (iCGM). Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH) : Free Stock Analysis Report AVANOS MEDICAL, INC. (AVNS) : Free Stock Analysis Report To read this article on Zacks.com click here. In the same month, ABT also announced new data from the meta-analysis of three randomized, controlled trials (CHAMPION, GUIDE-HF and LAPTOP-HF) presented at the Technology and Heart Failure Therapeutics Conference in Boston, MA. | Abbott Laboratories (Symbol: ABT) $103.96 $121.60 16.97% Brown & Brown Inc (Symbol: BRO) $58.77 $66.75 13.58% Lincoln Electric Holdings, Inc. (Symbol: LECO) $159.00 $177.67 11.74% Johnson & Johnson (Symbol: JNJ) $165.84 $183.69 10.76% Nucor Corp. (Symbol: NUE) $146.19 $161.67 10.59% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Abbott Laboratories (Symbol: ABT) 1.96% 16.97% 18.93% Brown & Brown Inc (Symbol: BRO) 0.78% 13.58% 14.36% Lincoln Electric Holdings, Inc. (Symbol: LECO) 1.61% 11.74% 13.35% Johnson & Johnson (Symbol: JNJ) 2.73% 10.76% 13.49% Nucor Corp. (Symbol: NUE) 1.40% 10.59% 11.99% Another consideration with dividend growth stocks is just how much the dividend is growing. Abbott Laboratories (Symbol: ABT) $1.84 $1.96 6.52% Brown & Brown Inc (Symbol: BRO) $0.392 $0.436 11.22% Lincoln Electric Holdings, Inc. (Symbol: LECO) $2.14 $2.4 12.15% Johnson & Johnson (Symbol: JNJ) $4.24 $4.52 6.60% Nucor Corp. (Symbol: NUE) $1.81 $2.02 11.60% These five stocks are part of our full Dividend Aristocrats List."
2023-04-14,103.61000061035156,103.95999908447266,0.4999967721792368,"Noteworthy ETF Outflows: XLV, ABT, ELV, MDT | Abbott: FDA Clears Reader For FreeStyle Libre 3 Integrated Continuous Glucose Monitoring System | Intuitive Surgical Stock To See Higher Levels Post Q1? | What To Expect From Abbott's Q1?","Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.4%, Elevance Health Inc (Symbol: ELV) is down about 2.2%, and Medtronic PLC (Symbol: MDT) is lower by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $101.7 million dollar outflow -- that's a 0.3% decrease week over week (from 297,070,000 to 296,320,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $118.75 per share, with $141.77 as the 52 week high point — that compares with a last trade of $134.57. | (RTTNews) - Abbott (ABT) said that the U.S. Food and Drug Administration has cleared a reader for its FreeStyle Libre 3 integrated continuous glucose monitoring (iCGM) system. The FreeStyle Libre 3 reader is a small handheld device that displays real-time glucose readings directly from a small sensor worn on the back of a person's upper arm, allowing them to manage their diabetes quickly and easily by viewing their glucose readings6 on a large, bright and easy-to-see screen. People who use the FreeStyle Libre 3 system will still have the option to use the current FreeStyle Libre 3 smartphone apps, the company said. | (1) A rise in procedure volume to drive revenue growth Trefis estimates Intuitive Surgical’s Q1 2023 revenues to be around $1.61 billion, marginally above the $1.59 billion consensus estimate. Note: P/E Multiples are based on Share Price at the end of the year and reported (or expected) Adjusted Earnings for the full year While ISRG stock looks appropriately priced, it is helpful to see how Intuitive Surgical’s Peers fare on metrics that matter. Total [2] ISRG Return 3% -1% 273% S&P 500 Return 0% 7% 84% Trefis Multi-Strategy Portfolio 1% 9% 242% [1] Month-to-date and year-to-date as of 4/12/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Total [2] ABT Return 2% -6% 169% S&P 500 Return 0% 7% 84% Trefis Multi-Strategy Portfolio 1% 9% 242% [1] Month-to-date and year-to-date as of 4/12/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott (NYSE: ABT) will report its Q1 2023 results on Wednesday, April 19. Although we expect Abbott to post an in-line Q1, our forecast indicates that ABT stock has some room for growth, as discussed below."
2023-04-13,102.75,103.61000061035156,0.3378037564514074,Abbott (ABT) Gains But Lags Market: What You Should Know,"Abbott (ABT) closed the most recent trading day at $103.61, moving +1.02% from the previous trading session. ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.36 per share and revenue of $39.74 billion. Also, we should mention that ABT has a PEG ratio of 4.62."
2023-04-12,103.38999938964844,102.55999755859376,0.836983562385949,"Notable Wednesday Option Activity: PTON, ABT, LULU | Guru Fundamental Report for ABT - Peter Lynch | What's in Store for Abbott Laboratories (ABT) in Q1 Earnings? | Earnings Preview: Abbott (ABT) Q1 Earnings Expected to Decline","Below is a chart showing PTON's trailing twelve month trading history, with the $11 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) saw options trading volume of 39,635 contracts, representing approximately 4.0 million underlying shares or approximately 69.5% of ABT's average daily trading volume over the past month, of 5.7 million shares. Below is a chart showing ABT's trailing twelve month trading history, with the $95 strike highlighted in orange: And lululemon athletica inc (Symbol: LULU) saw options trading volume of 16,968 contracts, representing approximately 1.7 million underlying shares or approximately 66.3% of LULU's average daily trading volume over the past month, of 2.6 million shares. Especially high volume was seen for the $95 strike put option expiring May 19, 2023, with 18,741 contracts trading so far today, representing approximately 1.9 million underlying shares of ABT. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA) : Free Stock Analysis Report Masimo Corporation (MASI) : Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT is slated to report first-quarter 2023 results on Apr 19 before market open. During the fourth quarter of 2022, ABT initiated the full launch of Libre 3 in the United States, which automatically delivers minute glucose readings with accuracy, courtesy of the world’s smallest and thinnest wearable sensor. | The market expects Abbott (ABT) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2023. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate."
2023-04-11,104.1999969482422,103.29000091552734,-0.8027873449603427,"Unusual Call Option Trade in Abbott Laboratories (ABT) Worth $316.32K | Ex-Dividend Reminder: AbbVie, Abbott Laboratories and Mid-America Apartment Communities | TG Therapeutics (TGTX) Surges 22.8%: Is This an Indication of Further Gains?","On April 11, 2023 at 10:35:12 ET an unusually large $316.32K block of Call contracts in Abbott Laboratories (ABT) was sold, with a strike price of $110.00 / share, expiring in 66 days (on June 16, 2023). Fintel tracks all large options trades, and the premium spent on this trade was 2.29 sigmas above the mean, placing it in the 98.05 percentile of all recent large trades made in ABT options. Average portfolio weight of all funds dedicated to ABT is 0.44%, a decrease of 28.50%. | Looking at the universe of stocks we cover at Dividend Channel, on 4/13/23, AbbVie Inc (Symbol: ABBV), Abbott Laboratories (Symbol: ABT), and Mid-America Apartment Communities Inc (Symbol: MAA) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc (Symbol: ABBV): Abbott Laboratories (Symbol: ABT): Mid-America Apartment Communities Inc (Symbol: MAA): In general, dividends are not always predictable, following the ups and downs of company profits over time. Similarly, investors should look for ABT to open 0.49% lower in price and for MAA to open 0.94% lower, all else being equal. | Click to get this free report TG Therapeutics, Inc. (TGTX) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. One other stock in the same industry, Abbott ABT, finished the last trading session 1.2% lower at $103.70. ABT has returned 8.2% over the past month."
2023-04-10,104.41999816894533,103.6999969482422,-0.8733167556299137,,
2023-04-06,104.48999786376952,104.93000030517578,-0.689524260992809,3 No-Brainer Medical Device Stocks to Buy Right Now | 3 Discounted Dividend Stocks With Combined 150+ Years Of Dividend Growth,"Edwards Lifesciences (NYSE: EW), Abbott Laboratories (NYSE: ABT), and DexCom (NASDAQ: DXCM) all stand out for their solid growth over time. ABT EPS Diluted (Annual) data by YCharts Abbott is keeping the FDA busy Abbott Laboratories has had several Food and Drug Administration (FDA) clearances for its devices this year that should help to drive future sales. Fourth-quarter sales were up 1% year over year to $1.35 billion while yearly revenue grew 3% to $5.38 billion. | All three of these dividend stocks are both S&P 500 stocks and they have grown their individual dividends for more than 25 consecutive years. Check out this video to learn more, consider subscribing to the channel, and check out the special offer in the link below. See the 10 stocks *Stock Advisor returns as of March 8, 2023 Mark Roussin, CPA has no position in any of the stocks mentioned."
2023-04-05,102.62999725341795,104.20999908447266,0.42109527265942176,Wells Fargo Maintains Abbott Laboratories (ABT) Overweight Recommendation | Guru Fundamental Report for ABT - Peter Lynch | Better Dividend Stock: AbbVie vs. Johnson & Johnson,"The firm decreased its portfolio allocation in ABT by 99.90% over the last quarter. The firm increased its portfolio allocation in ABT by 14.98% over the last quarter. The firm increased its portfolio allocation in ABT by 2.03% over the last quarter. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | The case for Johnson & Johnson: Its upcoming consumer health spinoff should boost revenue growth Johnson & Johnson has a diversified business. Johnson & Johnson has raised its dividend for 60 years straight, including by 71.2% in the past 10 years; its dividend yield is at 2.95%, also higher than that of the S&P 500. AbbVie's lower cash payout ratio shows that it can still afford to do so more than Johnson & Johnson, and what's more, AbbVie has a more attractive yield."
2023-04-04,101.9000015258789,102.8000030517578,1.5395126896021445,"Abbott (ABT) Gains As Market Dips: What You Should Know | Top Stock Reports for T-Mobile US, Abbott Laboratories & AMD","ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.38 per share and revenue of $39.74 billion. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott (ABT) closed at $102.80 in the latest trading session, marking a +1.19% move from the prior day. | Today's Must Read T-Mobile (TMUS) Poised to Gain from Nationwide 5G Footprint EPD Sales Gain Aids Abbott (ABT) amid Inflationary Issues AMD Rides on Strong Adoption of EPYC & Ryzen Processors Featured Reports Intuit (INTU) Rides on Product Refresh, Higher Subscriptions Per the Zacks analyst, Intuit is benefiting from frequent product refreshes, which help it to gain customers. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Advanced Micro Devices, Inc. (AMD) : Free Stock Analysis Report Cintas Corporation (CTAS) : Free Stock Analysis Report Intuit Inc. (INTU) : Free Stock Analysis Report T-Mobile US, Inc. (TMUS) : Free Stock Analysis Report S&P Global Inc. (SPGI) : Free Stock Analysis Report To read this article on Zacks.com click here. Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), Abbott Laboratories (ABT) and Advanced Micro Devices, Inc. (AMD)."
2023-04-03,100.8000030517578,101.58999633789062,0.8832203262041408,Invesco S&P 500 QVM Multi-factor ETF Experiences Big Outflow,"Among the largest underlying components of QVML, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.4%, Standard and Poors Global Inc (Symbol: SPGI) is up about 0.1%, and Caterpillar Inc. (Symbol: CAT) is higher by about 1.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Invesco S&P 500 QVM Multi-factor ETF (Symbol: QVML) where we have detected an approximate $141.8 million dollar outflow -- that's a 13.9% decrease week over week (from 42,050,000 to 36,200,000). For a complete list of holdings, visit the QVML Holdings page » The chart below shows the one year price performance of QVML, versus its 200 day moving average: Looking at the chart above, QVML's low point in its 52 week range is $21.3219 per share, with $26.8318 as the 52 week high point — that compares with a last trade of $24.33."
2023-03-31,99.91999816894533,101.26000213623048,0.7837234744201236,Abbott's (ABT) Epic Max Tissue Valve Receives FDA Approval | 3 Healthcare Stocks to Watch As the Industry Evolves,"Abbott Laboratories, Inc. ABT recently announced the receipt of the FDA approval for the company's Epic Max stented tissue valve to treat people with aortic regurgitation or stenosis. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report Henry Schein, Inc. (HSIC) : Free Stock Analysis Report AVANOS MEDICAL, INC. (AVNS) : Free Stock Analysis Report To read this article on Zacks.com click here. Benefits of Epic Max Tissue Valve The aortic valve is one of the heart valves most commonly impacted by cardiovascular disease, frequently requiring replacement. | Abbott Laboratories (ABT) Source: Sundry Photography/Shutterstock.com Abbott Laboratories (NYSE:ABT) is a top medical device sector player. CVS Health Corp (CVS) Source: Shutterstock As the largest pharmacy healthcare provider in the United States, CVS Health Corp (NYSE:CVS) has a strong balance sheet, impressive free cash flow, and an attractive valuation, according to some analysts. One such operation is its health insurance benefits management, bolstered by the acquisition of Aetna for approximately $78 billion in 2018, making CVS Health one of the largest health insurance benefits management providers in the United States."
2023-03-30,99.37999725341795,99.08000183105467,1.3410768533236657,,
2023-03-29,98.01000213623048,98.62000274658205,-0.3018670060920771,Guru Fundamental Report for ABT - Peter Lynch,"Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT)."
2023-03-28,98.0999984741211,97.11000061035156,0.6223860800489351,2 Dividend Stocks Down 11% to 22% to Buy and Hold Forever,"Let's look at two companies that fit the bill: Pfizer (NYSE: PFE) and Abbott Laboratories (NYSE: ABT). Having raised its dividend by 20.6% in the past five years, Pfizer is well-positioned to keep boosting its payouts for a long time thanks to the solid business backing these dividend payments. It has been one of the company's most important growth drivers in the past few years, and that probably won't change anytime soon given the large and growing number of people with diabetes worldwide, which currently stands at 422 million as of right now."
2023-03-27,99.0,98.45999908447266,-1.0091721500186301,Abbott (ABT) Outpaces Stock Market Gains: What You Should Know | Abbott's (ABT) CardioMEMS Favors Heart Failure Management,"Abbott (ABT) closed at $98.46 in the latest trading session, marking a +0.42% move from the prior day. Also, we should mention that ABT has a PEG ratio of 4.4. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | Image Source: Zacks Investment Research ABT’s advanced monitoring technology, CardioMEMS HF System, remotely monitors changes in pulmonary artery pressure, which is considered an early indicator of worsening heart failure. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report Catalyst Pharmaceuticals, Inc. (CPRX) : Free Stock Analysis Report AVANOS MEDICAL, INC. (AVNS) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT recently announced favorable findings on remote pressure monitoring."
2023-03-24,97.04000091552734,98.0500030517578,-0.5454554702296401,"Notable ETF Inflow Detected - SSO, TMO, ABT, DHR | Wall Street Analysts See Abbott (ABT) as a Buy: Should You Invest?","Among the largest underlying components of SSO, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is off about 0.7%, Abbott Laboratories (Symbol: ABT) is up about 0.5%, and Danaher Corp (Symbol: DHR) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the ProShares Ultra S&P500 (Symbol: SSO) where we have detected an approximate $417.4 million dollar inflow -- that's a 15.2% increase week over week in outstanding units (from 59,200,000 to 68,200,000). For a complete list of holdings, visit the SSO Holdings page » The chart below shows the one year price performance of SSO, versus its 200 day moving average: Looking at the chart above, SSO's low point in its 52 week range is $37.53 per share, with $68.66 as the 52 week high point — that compares with a last trade of $46.24. | Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Abbott (ABT). Brokerage Recommendation Trends for ABT Is ABT Worth Investing In?"
2023-03-23,96.9000015258789,97.04000091552734,1.0408101058342472,,
2023-03-22,98.61000061035156,96.86000061035156,0.1444782120163828,Here's Why You Should Retain Abbott (ABT) Stock for Now | Guru Fundamental Report for ABT - Peter Lynch,"Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report Henry Schein, Inc. (HSIC) : Free Stock Analysis Report AVANOS MEDICAL, INC. (AVNS) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT is well-poised for growth in the coming quarters, courtesy of its continued growth in the core Diagnostics arm. Image Source: Zacks Investment Research Progress With Diabetes Business: This business achieved organic sales growth of 17.3% in the fourth quarter of 2022 led by strong growth in FreeStyle Libre. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT)."
2023-03-21,98.16999816894533,98.33000183105467,-1.7746678725973908,S&P 500 Analyst Moves: ABT | Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?,"VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories is now the #59 analyst pick, moving up by 2 spots. This rank is formed by averaging the analyst opinions for each component from each broker, and then ranking the 500 components by those average opinion values. | Click to get this free report iShares U.S. Medical Devices ETF (IHI): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report SPDR S&P Health Care Equipment ETF (XHE): ETF Research Reports First Trust Indxx Medical Devices ETF (MDEV): ETF Research Reports To read this article on Zacks.com click here. Looking at individual holdings, Thermo Fisher Scientific Inc (TMO) accounts for about 17.47% of total assets, followed by Abbott Laboratories (ABT) and Medtronic Plc (MDT). First Trust Indxx Medical Devices ETF (MDEV) tracks INDXX GLOBAL MEDICAL EQUIPMENT INDEX and the SPDR S&P Health Care Equipment ETF (XHE) tracks S&P Health Care Equipment Select Industry Index."
2023-03-20,97.26000213623048,97.87000274658205,0.16298631465184385,Abbott (ABT) Stock Moves 0.89%: What You Should Know,"In the latest trading session, Abbott (ABT) closed at $97.87, marking a +0.89% move from the previous day. ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.38 per share and revenue of $39.74 billion. We can also see that ABT currently has a PEG ratio of 4.35."
2023-03-17,99.01000213623048,97.01000213623048,0.6271854790802336,"Abbott (ABT) Diabetes Arm Growth Robust Amid Macroeconomic Woes | SpaceX, Netflix, Boeing to join ""biggest-ever"" US business mission to Vietnam","Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report Akerna Corp. (KERN) : Free Stock Analysis Report TerrAscend Corp. (TRSSF) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT is gaining from new product launches and strategic acquisitions. COVID testing sales were $1.1 billion in the fourth quarter with rapid testing platforms, including BinaxNOW in the United States, Panbio internationally and ID NOW globally, comprising approximately 95% of the sales. | The mission will also include semiconductors companies, pharmaceutical giants Pfizer PFE.N and Johnson & Johnson PFE.N, medical device maker Abbott ABT.N, financial firms Visa V.N and Citibank C.N, internet and cloud companies Meta META.O and Amazon Web Services AMZN.O, the list showed. By Francesco Guarascio HANOI, March 17 (Reuters) - SpaceX, Netflix and Boeing are among the companies joining the ""biggest-ever"" U.S. business mission to Vietnam next week to discuss investment and sales opportunities in the booming Southeast Asian nation, the organiser said. Aerospace manufacturers Boeing BA.N, Lockheed Martin LMT.N and Bell TXT.N will hold meetings with state-owned Vietnamese defence procurement companies, Thanh told Reuters, adding that it was the first time in about a decade that security firms had decided to join the annual mission to Vietnam."
2023-03-16,97.05999755859376,99.02999877929688,-2.0199979364187337,"Notable ETF Inflow Detected - ITOT, TMO, COST, ABT","Among the largest underlying components of ITOT, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is up about 0.6%, Costco Wholesale Corp (Symbol: COST) is off about 0.2%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P Total U.S. Stock Market ETF (Symbol: ITOT) where we have detected an approximate $146.5 million dollar inflow -- that's a 0.4% increase week over week in outstanding units (from 452,050,000 to 453,750,000). For a complete list of holdings, visit the ITOT Holdings page » The chart below shows the one year price performance of ITOT, versus its 200 day moving average: Looking at the chart above, ITOT's low point in its 52 week range is $77.44 per share, with $103.48 as the 52 week high point — that compares with a last trade of $85.81."
2023-03-15,97.5,97.8000030517578,2.029673676340089,Guru Fundamental Report for ABT - Peter Lynch,"Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT)."
2023-03-14,99.27999877929688,98.5500030517578,0.30769543770030594,Abbott (ABT) Gains But Lags Market: What You Should Know | Healthcare Stocks With at Least 30 Years of Dividend Increases,"Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott (ABT) closed at $98.55 in the latest trading session, marking a +0.37% move from the prior day. ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.38 per share and revenue of $39.74 billion. | Indeed, big dogs like Johnson & Johnson (NYSE: JNJ), AbbVie, Inc. (NYSE: ABBV), and Abbott Laboratories (NYSE: ABT) have been increasing their dividends for more than 50 years; and ABBV is considered one of the best dividend stocks out there. Meanwhile, several lesser-known health sector stocks have paid increasing dividends for at least the last 30 years, dividend aristocrats and one qualifying as a dividend king. Roper Technologies, Inc: 31 years Medical and scientific imaging company Roper Technologies, Inc. (NYSE: ROP) is paying out an annual dividend of $2.73 at an impressive 3-year annualized growth of 10.20%."
2023-03-13,96.5999984741211,98.19000244140624,-0.7352898232421259,"Top Research Reports for AbbVie, NextEra Energy & ConocoPhillips | Abbott (ABT) to Pair CGM Sensors & AID System on FDA Clearance","If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read AbbVie's (ABBV) Skyrizi, Rinvoq Key to Long-Term Growth Steady Investment & Renewable Focus Aid NextEra Energy (NEE) ConocoPhillips (COP) Banks On Oil-Rich Bakken Shale Assets Featured Reports Abbott's (ABT) Core Diagnostics Grows amid Forex Woes The Zacks analyst is impressed with Abbott's worldwide Diagnostics sales growth in the fourth quarter led by rapid diagnostics. Click to get this free report NextEra Energy, Inc. (NEE) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Intercontinental Exchange Inc. (ICE) : Free Stock Analysis Report ConocoPhillips (COP) : Free Stock Analysis Report Canadian Pacific Railway Limited (CP) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. Other noteworthy reports we are featuring today include Abbott Laboratories (ABT), Canadian Pacific Railway Limited (CP) and Intercontinental Exchange, Inc. (ICE). | Abbott Laboratories ABT recently announced that its modified continuous glucose monitoring (CGM) system sensors, FreeStyle Libre 2 and FreeStyle Libre 3, have received FDA clearance for integration with automated insulin delivery (AID) systems. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report Akerna Corp. (KERN) : Free Stock Analysis Report TerrAscend Corp. (TRSSF) : Free Stock Analysis Report To read this article on Zacks.com click here. The five-year results show that MitraClip is safe and effective and can cut the rate of hospitalizations while improving survival for heart failure patients with severe secondary or functional MR. Price Performance In the past six months, ABT has mostly underperformed its industry."
2023-03-10,97.76000213623048,96.95999908447266,1.6459668658391338,Is Invesco Defensive Equity ETF (DEF) a Strong ETF Right Now?,"Click to get this free report Invesco Defensive Equity ETF (DEF): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Norfolk Southern Corporation (NSC) : Free Stock Analysis Report United Parcel Service, Inc. (UPS) : Free Stock Analysis Report Invesco QQQ (QQQ): ETF Research Reports Vanguard Growth ETF (VUG): ETF Research Reports To read this article on Zacks.com click here. Looking at individual holdings, United Parcel Service Inc (UPS) accounts for about 1.05% of total assets, followed by Abbott Laboratories (ABT) and Norfolk Southern Corp (NSC). The Invesco Defensive Equity ETF (DEF) made its debut on 12/15/2006, and is a smart beta exchange traded fund that provides broad exposure to the Style Box - Large Cap Growth category of the market."
2023-03-09,99.88999938964844,97.8499984741211,-0.8183337093661339,2 Top Dividend Stocks You Can Buy and Hold Forever,"Abbott Laboratories: A quality healthcare company Most people will probably recognize Abbott Laboratories (NYSE: ABT) for its BinaxNOW COVID-19 rapid tests and its consumer-facing brands like Similac infant formula. Most recently, the company just announced its 51st consecutive year of dividend growth with a 10% hike in the quarterly dividend, which will be paid in June of this year. This should allow for many more years of strong dividend growth since the company's dividend payout ratio will be around 67% in 2023."
2023-03-08,99.91999816894533,99.4000015258789,-2.0422474001323785,"Abbott (ABT) Stock Sinks As Market Gains: What You Should Know | Guru Fundamental Report for ABBOTT LABORATORIES - Peter Lynch | Abbott (ABT) Gets FDA Nod for Alinity I Laboratory Test | Notable ETF Outflow Detected - XLV, TMO, ABT, DHR | Abbott (ABT) Reveals Favorable Data on Tricuspid Regurgitation","Abbott (ABT) closed at $99.40 in the latest trading session, marking a -0.58% move from the prior day. ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.38 per share and revenue of $39.74 billion. It is also worth noting that ABT currently has a PEG ratio of 4.48. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report Akerna Corp. (KERN) : Free Stock Analysis Report TerrAscend Corp. (TRSSF) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories, Inc. ABT recently announced the receipt of the FDA approval for the Alinity i laboratory traumatic brain injury (TBI) blood test. About Alinity i Laboratory Test for TBI The Alinity i TBI test measures complementary biomarkers in blood plasma and serum - Ubiquitin C-terminal Hydrolase L1 (UCH-L1) and Glial Fibrillary Acidic Protein (GFAP), that, in elevated concentrations, are tightly correlated to brain injury. | Among the largest underlying components of XLV, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is up about 0.7%, Abbott Laboratories (Symbol: ABT) is off about 0.1%, and Danaher Corp (Symbol: DHR) is higher by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $539.9 million dollar outflow -- that's a 1.4% decrease week over week (from 306,470,000 to 302,220,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $118.75 per share, with $143.42 as the 52 week high point — that compares with a last trade of $126.41. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report Akerna Corp. (KERN) : Free Stock Analysis Report TerrAscend Corp. (TRSSF) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT recently announced late-breaking data on the company’s TriClip transcatheter edge-to-edge repair (TEER) system. About the Abbott Triluminate Pivotal Trial The Triluminate Pivotal trial is the first randomized, controlled clinical study to evaluate the safety and effectiveness of transcatheter repair with the TriClip system compared to medical therapy in people with severe TR."
2023-03-07,102.86000061035156,99.9800033569336,-0.5204129829818522,3 Value Stocks on Sale Now | Abbott (ABT) Makes Progress in the TAVI Space With Navitor | U.S. FDA clears Abbott's blood test for concussions | Abbott's (ABT) MitraClip Device Shows Favorable Outcome,"Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Procter & Gamble Company (The) (PG) : Free Stock Analysis Report To read this article on Zacks.com click here. Procter and Gamble PG, Johnson and Johnson JNJ, and Abbott Labs ABT, three of the most established corporations in the world, are on sale today. Over the last 25 years ABT stock has provided an average annual return of 10%. | Abbott ABT recently announced significant progress with Navitor, the company’s latest-generation transcatheter aortic valve implantation (TAVI) system. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report To read this article on Zacks.com click here. According to the company, the Amulet IDE trial’s findings demonstrated that the Amplatzer Amulet LAA Occluder with dual-seal technology (consisting of a lobe or piece to fill the cavity of the LAA and a disc to seal off the opening into the LAA) had fewer unresolved, severe peri-device leaks (PDLs), where blood leaks around the implant, compared to Boston Scientific's BSX Watchman‡ device that has a single component to close the LAA. | Adds details, background March 7 (Reuters) - The U.S. Food and Drug Administration has cleared Abbott Laboratories' ABT.N blood test that would help doctors assess traumatic brain injury (TBI), commonly known as concussions, the company said on Tuesday. The clearance marks the first commercially available laboratory blood test for TBI, according to the company, helping the doctors to rule out need for a CT scan in patients with mild TBI. (Reporting by Raghav Mahobe in Bengaluru; Editing by Shailesh Kuber) ((Raghav.Mahobe@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories, Inc. ABT recently presented late-breaking data from the Landmark COAPT trial for MitraClip, demonstrating the long-term benefits of the device in patients fighting heart failure. Study Details In the COAPT trial, symptomatic heart failure patients with severe secondary MR —  a condition in which a leaky valve caused by problems affecting other areas of the heart allows blood to flow back through the mitral valve — were evaluated with MitraClip plus guideline-directed medical therapy or guideline-directed medical therapy alone."
2023-03-06,104.51000213623048,102.75,-2.7999195375545556,"Abbott: FDA Clears FreeStyle Libre 2, 3 Sensors For Integration With AID Systems | Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar? | 7 Dividend Kings to Buy for an Uncertain Market Environment","(RTTNews) - Abbott (ABT) announced Monday that the U.S. Food and Drug Administration has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated continuous glucose monitoring or iCGM system sensors for integration with automated insulin delivery or AID systems in the U.S. Over time, the modified sensors will replace the current FreeStyle Libre 2 and FreeStyle Libre 3 sensors available at present in the country. Abbott said it is working with insulin pump manufacturers to integrate their systems with the FreeStyle Libre 2 and FreeStyle Libre 3 sensors as soon as possible. | Click to get this free report Invesco Defensive Equity ETF (DEF): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Norfolk Southern Corporation (NSC) : Free Stock Analysis Report United Parcel Service, Inc. (UPS) : Free Stock Analysis Report Invesco QQQ (QQQ): ETF Research Reports Vanguard Growth ETF (VUG): ETF Research Reports To read this article on Zacks.com click here. Looking at individual holdings, United Parcel Service Inc (UPS) accounts for about 1.05% of total assets, followed by Abbott Laboratories (ABT) and Norfolk Southern Corp (NSC). The Invesco Defensive Equity ETF (DEF) was launched on 12/15/2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Large Cap Growth segment of the US equity market. | Now, it’s worth pointing out for clarification that AbbVie spun off from Abbott Laboratories (NYSE:ABT) in 2012. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Though the term dividend aristocrats generate plenty of interest for the underlying elite status, another even more rarefied category exists called dividend kings to buy. Rather than 25 years of consecutive payout growth, the kings command at least 50 years."
2023-03-03,102.9000015258789,104.4499969482422,-1.6840513828870578,"Should You Invest in Abbott (ABT) Based on Bullish Wall Street Views? | 1 High-Flying Growth Stock With 19% Upside, According to Wall Street","Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Abbott (ABT). Brokerage Recommendation Trends for ABT Should You Invest in ABT? | In the past five years, DexCom's top line has increased by an average of 42.5% per year. Another problem for DexCom could be increased competition from Apple, which has been developing non-invasive ways to measure patients' blood glucose levels. The Motley Fool recommends DexCom and recommends the following options: long March 2023 $120 calls on Apple and short March 2023 $130 calls on Apple."
2023-03-02,100.2699966430664,102.62999725341795,1.5063123414759894,Abbott (ABT) Outpaces Stock Market Gains: What You Should Know | Validea Guru Fundamental Report for ABT - 3/2/2023 | Will Boston Scientific Stock See Higher Levels?,"Abbott (ABT) closed at $102.63 in the latest trading session, marking a +1.79% move from the prior day. We can also see that ABT currently has a PEG ratio of 4.52. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Boston Scientific stock (NYSE: BSX) has seen a fall of 3% in a month, compared with -5% returns for the broader S&P500 index. But, looking at valuation, at its current level of $47, BSX stock is already trading at 24x its forward expected earnings of $1.92 (which is at the higher end of the guided range), aligning with its last three-year average, implying that BSX stock is fully valued. Total [2] BSX Return 0% 1% 116% S&P 500 Return -1% 2% 75% Trefis Multi-Strategy Portfolio 0% 7% 237% [1] Month-to-date and year-to-date as of 3/2/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2023-03-01,100.6999969482422,100.83000183105467,2.3536458455788134,"Abbott (ABT) Dips More Than Broader Markets: What You Should Know | Get a Dividend Every Month With These 3 Healthcare Stocks | Lucira Stock Jumps over 250% on FDA Approval, Beware Chapter 11","Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott (ABT) closed the most recent trading day at $100.83, moving -0.87% from the previous trading session. It is also worth noting that ABT currently has a PEG ratio of 4.56. | Johnson & Johnson consistently delivers Johnson & Johnson raised its dividend by 6.6% last year to $1.13 a quarterly share, the 60th consecutive year it has increased its quarterly dividend. Johnson & Johnson's cash dividend payout ratio of 68% is a tad high, but the company expects revenue to rise by 5% this year to $97.4 billion, meaning another dividend increase seems likely. MDT Dividend data by YCharts AbbVie has planned for the future Pharmaceutical company AbbVie increased its quarterly dividend 4.9% this year to $1.48, the 51st consecutive year it has increased its dividend, counting its time as a division of Abbott Laboratories. | 2021, at $22.10 per share and currently has 40 million shares outstanding While it blames the FDA for its slow approval of its combo test, the company has still been selling its COVID-19 test, which competes with rapid tests from Abbott Laboratories Inc. (NYSE: ABT), Beckton, Dickinson & Co. Dickinson (NYSE: BDX) and QuidelOrtho Corp. (NASDAQ: QDEL). Lucira Health Inc. (NASDAQ: LHDX) shares spiked up 264% to close at $0.52 on a massive 278 million shares traded on the announcement of FDA approval for its combination at-home COVID-19 and a flu test. On Feb. 24, Lucira announced the long-awaited FDA approval for its combination COVID-19 and flu home test caused shares to surge over 700% off previous day lows to a high of $0.75 before closing at $0.52, up only 264% on a massive 278 million shares of the trading volume."
2023-02-28,99.83999633789062,101.72000122070312,0.12910117850280722,"Why Abbott Laboratories Stock Bumped Higher Today | Should Abbott and DexCom Investors Be Worried About Apple's Latest News? | XLV, TMO, ABT, DHR: ETF Outflow Alert","What happened On a piece of encouraging news from the laboratory, healthcare sector mainstay Abbott Laboratories (NYSE: ABT) saw its stock price rise by nearly 2% on Tuesday. Now what In the announcement, Abbott's Senior Vice President of the Structural Heart division Michael Dale said, ""These results for Navitor and Amulet demonstrate that the innovative designs of our minimally invasive devices are changing how doctors are approaching -- and patients are experiencing -- the treatment of structural heart conditions."" 10 stocks we like better than Abbott Laboratories When our award-winning analyst team has a stock tip, it can pay to listen. | Abbott Laboratories (NYSE: ABT) and DexCom (NASDAQ: DXCM) enjoy symbiotic relationships with Apple (NASDAQ: AAPL). The tech giant's goal is to launch its own CGM tied to its Apple Watch, according to Bloomberg's sources, who are familiar with Apple's efforts. A long way to go Should Abbott and DexCom investors really be worried about Apple's CGM efforts? | Among the largest underlying components of XLV, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is up about 0.3%, Abbott Laboratories (Symbol: ABT) is up about 0.6%, and Danaher Corp (Symbol: DHR) is lower by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $108.9 million dollar outflow -- that's a 0.3% decrease week over week (from 307,320,000 to 306,470,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $118.75 per share, with $143.42 as the 52 week high point — that compares with a last trade of $127.43."
2023-02-27,101.27999877929688,99.7699966430664,1.883017780219021,Better Dividend Stock: Abbott Laboratories or Medtronic? | Dividend Stocks To Buy Now? 3 For Your Watchlist,"The dividend powerhouses Abbott Laboratories (NYSE: ABT) and Medtronic (NYSE: MDT) apparently didn't get this memo, however. ABT data by YCharts. Abbott's stock has long held a premium valuation -- relative to Wall Street's fair value estimate -- due to its stable revenue stream, 51-year streak of raising its dividend, and highly diversified product portfolio. | (NYSE: MDT) Abbott Laboratories (NYSE: ABT) Exxon Mobil (XOM Stock) Exxon Mobil Corporation (XOM) is a multinational energy company. Source: TD Ameritrade TOS [Read More] 3 Copper Mining Stocks To Watch In February 2023 Abbott Laboratories (ABT Stock) Lastly, Abbott Laboratories (ABT) is a healthcare company. Currently, ABT has an annual dividend yield for shareholders of 2.02%."
2023-02-24,101.4499969482422,100.45999908447266,-1.4909183989239299,Why Is Abbott (ABT) Down 7.7% Since Last Earnings Report? | Better Buy: Abbott Laboratories or DexCom Stock?,"It has been about a month since the last earnings report for Abbott (ABT). Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Diabetes Care reported organic growth of 17.4% year over year, led by FreeStyle Libre, which contributed $1.1 billion of revenues in the reported quarter.Structural Heart sales rose 13% and Heart Failure sales improved 5.9% year over year organically. | Abbott Laboratories (NYSE: ABT) and DexCom (NASDAQ: DXCM) are both poised to benefit from increased spending on diabetes care devices as they manufacture continuous glucose monitoring devices used by diabetes patients. In the fourth quarter, the company reported revenue of $10.1 billion, down 12% year over year, thanks mostly to reduced COVID-19 testing sales. Within those sales, the company's Freestyle Libre continuous glucose monitors (CGMs) reported sales of $1.1 billion in Q4, up 40% year over year."
2023-02-23,103.23999786376952,102.5500030517578,-0.9758480961558066,Abbott (ABT) Stock Sinks As Market Gains: What You Should Know | Is Abbott Stock A Better Pick Over This Pharmaceuticals Bellwether?,"Abbott (ABT) closed the most recent trading day at $102.55, moving -0.14% from the previous trading session. ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.38 per share and revenue of $39.74 billion. It is also worth noting that ABT currently has a PEG ratio of 4.6. | We believe that Abbott stock (NYSE: ABT) is a better pick than its sector peer, Johnson & Johnson stock (NYSE: JNJ). Looking at stock returns, JNJ has outperformed ABT and the broader indices. While JNJ is down 2% in the last twelve months, ABT is down 12%, and the S&P500 index is down 6%."
2023-02-22,103.23999786376952,102.69000244140624,-0.6683405911362013,Will Medtronic Stock See Higher Levels After An Upbeat Q3? | ABT Crosses Above 2% Yield Territory | Abbott Laboratories is Oversold,"We forecast revenue of $30.6 billion, reflecting a 3.5% y-o-y decline on a reported basis, and adjusted earnings of $5.29 per share, in line with the company’s provided guidance. \n\nBased on article theme, variations to \""While may have moved\"" can be (a) While may be overvalued (or undervalued) (b) While can move (c) Although may not be attractive (d) While is worth considering""}"" data-sheets-userformat=""{""2"":1049345,""3"":{""1"":0},""11"":4,""12"":0,""23"":1}"" data-sheets-textstyleruns=""{""1"":0}{""1"":210,""2"":{""2"":{""1"":2,""2"":1136076},""5"":1,""9"":1}}{""1"":225}{""1"":229,""2"":{""4"":8}}{""1"":267,""2"":{""4"":8,""6"":1}}{""1"":299,""2"":{""4"":8}}"" data-sheets-hyperlinkruns=""{""1"":210,""2"":""https://dashboards.trefis.com/data/companies/PFE/no-login-required/HMIwIvym/Pfizer-vs-Merck-PFE-stock-s-similar-valuation-vs-MRK-stock-is-counter-intuitive""}{""1"":225}"">While MDT stock looks like it can gain more, the Covid-19 crisis and recent market volatility have created many pricing discontinuities, which can offer attractive trading opportunities. Total [2] MDT Return 2% 10% 20% S&P 500 Return -2% 4% 79% Trefis Multi-Strategy Portfolio -4% 7% 237% [1] Month-to-date and year-to-date as of 2/22/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Looking at the universe of stocks we cover at Dividend Channel, in trading on Wednesday, shares of Abbott Laboratories (Symbol: ABT) were yielding above the 2% mark based on its quarterly dividend (annualized to $2.04), with the stock changing hands as low as $100.50 on the day. Abbott Laboratories (Symbol: ABT) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index. In the case of Abbott Laboratories, looking at the history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2% annual yield. | Abbott Laboratories (Symbol: ABT) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most ""interesting"" ideas that merit further research by investors. But making Abbott Laboratories an even more interesting and timely stock to look at, is the fact that in trading on Wednesday, shares of ABT entered into oversold territory, changing hands as low as $100.50 per share. Indeed, ABT's recent annualized dividend of 2.04/share (currently paid in quarterly installments) works out to an annual yield of 1.97% based upon the recent $103.65 share price."
2023-02-21,105.8499984741211,103.6500015258789,-0.532734825400741,"Daily Dividend Report: ABT, NUE, WLK, TPR, PNR","Abbott (ABT) declared a quarterly common dividend of 51 cents per share. VIDEO: Daily Dividend Report: ABT, NUE, WLK, TPR, PNR The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The Board of Directors of Nucor Corporation (NUE) declared the regular quarterly cash dividend of $0.51 per share on Nucor's common stock."
2023-02-17,105.54000091552734,106.73999786376952,-2.078409995234962,"Interview With David Rolfe of Wedgewood Partners | How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula | Abbott gets FTC notice for information on infant formula products | Abbott gets FTC notice for information on infant formula products","The company probably ""under-earns"" as they commit between 15%-20% of revenues to R&D, a multiple of larger medtech conglomerates (e.g., Medtronic (NYSE: MDT), Abbott Laboratories (NYSE: ABT), and Stryker (NYSE: SYK). The powerful combination of a disciplined culture of investing for the true long term in best-of-breed businesses, combined with the synthesis of the time-tested, classic tenets of both growth company investing and intelligent value investing is a recipe for long-term wealth creation, as well as peer and index outperformance. It seemed that everything that could go wrong for the company in 2022 did go wrong: A post-pandemic growth hangover, the multibillion revenue hit from Apple's (NASDAQ: AAPL) infamous iOS 14.5 update that introduced the company's App Tracking Transparency (ATT), a cyclical slowdown in online advertising spending, poor capital allocation timing of stock buybacks, and Zuckerberg's unchecked spending of billions on both new hirings and massive billions to be spent on artificial intelligence and the metaverse. | New Life for Valproic Acid Could Mean Long-Term Growth for ABT Stock In October 2022, ABT plunged more than 10% in the third week, from around $104 to $95. The discovery has immense medical implications, of course, but it could lead to a windfall for investors, particularly those holding Abbott Laboratories (NYSE: ABT) and AbbVie, Inc (NYSE: ABBV) shares. Thus ABT and ABBV shareholders could benefit from the potential surge in sales if some formulations of these drugs can return to the market with a new purpose. | Feb 17 (Reuters) - Abbott Laboratories ABT.N said on Friday it received a civil investigative demand in January from the Federal Trade Commission related to a probe of the companies participating in bids for women, infants and children formula contracts. (Reporting by Granth Vanaik; Editing by Shailesh Kuber) ((Granth.Vanaik@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Adds background Feb 17 (Reuters) - Abbott Laboratories ABT.N said on Friday it received a civil investigative demand in January from the Federal Trade Commission related to a probe of the companies participating in bids for women, infants and children formula contracts. The FTC had launched an inquiry last year into the shortage for infant formula in the United States and had said it would examine the pattern of mergers and acquisitions in the formula market. In January, Abbott's Michigan plant, which was at the center of the U.S. baby formula shortage last year, faced a criminal investigation by the Justice Department, the Wall Street Journal had reported."
2023-02-16,105.7699966430664,106.08000183105467,1.1370067631538427,"Notable ETF Outflow Detected - ITOT, ABT, VZ, DHR | Labcorp beats quarterly profit estimates","Among the largest underlying components of ITOT, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.5%, Verizon Communications Inc (Symbol: VZ) is down about 1.3%, and Danaher Corp (Symbol: DHR) is up by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P Total U.S. Stock Market ETF (Symbol: ITOT) where we have detected an approximate $111.0 million dollar outflow -- that's a 0.3% decrease week over week (from 452,150,000 to 450,950,000). For a complete list of holdings, visit the ITOT Holdings page » The chart below shows the one year price performance of ITOT, versus its 200 day moving average: Looking at the chart above, ITOT's low point in its 52 week range is $77.44 per share, with $103.48 as the 52 week high point — that compares with a last trade of $91.73. | Test providers such as Quest Diagnostics DGX.N and Abbott Laboratories ABT.N have seen a rebound in demand for routine testing in the recent quarters, helping them cushion a decline in revenues from COVID-19 tests. Adds details about results, background Feb 16 (Reuters) - Laboratory Corp of America Holdings LH.N on Thursday beat quarterly profit estimates, helped by strength in its diagnostics business and demand for its drug development services. (Reporting by Raghav Mahobe and Mariam E Sunny in Bengaluru; Editing by Maju Samuel) ((Raghav.Mahobe@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2023-02-15,106.76000213623048,107.27999877929688,0.29309369180980205,,
2023-02-14,108.19000244140624,107.26000213623048,0.48707065629584134,Notable Two Hundred Day Moving Average Cross - ABT | Which Healthcare Stock Is a Better Pick in 2023? | Better Buy: Johnson & Johnson or AbbVie? | Candy? Flowers? These Top Stocks Offer You Something Even Sweeter,"In trading on Tuesday, shares of Abbott Laboratories (Symbol: ABT) crossed below their 200 day moving average of $107.31, changing hands as low as $106.36 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $93.25 per share, with $125.4199 as the 52 week high point — that compares with a last trade of $107.21. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other dividend stocks recently crossed below their 200 day moving average » Also see: • RDFN Videos • NRGY Insider Buying | Abbott Labs (ABT) Source: testing / Shutterstock.com 2022 was a tough year for Abbott (NYSE:ABT), not only due to macro pressures and currency headwinds but also due to the disruptions at its baby formula facility in Michigan. BTIG analyst Marie Thibault feels that this acquisition “is an inexpensive way for ABT to tap into large, high-growth, adjacent market opportunities with CSII’s R&D pipeline in mechanical thrombectomy, intravascular lithotripsy (IVL), drug-coated balloons (DCBs) and mechanical circulatory support (MCS).” Thibault reiterated a “buy” rating for Abbott with a price target of $125. At $123.90, the average ABT stock price target suggests 15% upside potential. | Johnson & Johnson is a little more diversified than AbbVie, even after the expected spinoff, because it is also a pharmaceutical company and a medtech company. While 2022 was a dreary year for some healthcare companies, Johnson & Johnson's shares are down around just 3% over the past year. The talcum powder lawsuits Johnson & Johnson is facing will now fall on Kenvue, though Johnson & Johnson will retain, for now, 80.1% ownership of the new company. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) gives investors two gifts every year: a dividend, and growth of that dividend. And the company's general growth in free cash flow means it has what it takes to keep boosting payouts: ABT Free Cash Flow data by YCharts. This might be a company with a solid plan for growth, one that's proven its commitment to dividend growth, or a company with a strong pipeline of potential products."
2023-02-13,108.31999969482422,108.5199966430664,-0.8595991165444554,The 7 Most Undervalued Dividend Aristocrats to Buy | Abbott (ABT) to Expand Vascular Device Line With New Buyout | Abbott (ABT) EPD Growth Continues Amid Macroeconomic Challenges,"To note, AbbVie spun off from Abbott Laboratories (NYSE:ABT) in 2013. AFL Aflac $71.01 DOV Dover $155.70 ABBV AbbVie $153.73 PNR Pentair $56.54 GD General Dynamics $232.88 EMR Emerson Electric $86.91 ADM Archer Daniels Midland $81.90 Aflac (AFL) Source: jittawit21/Shutterstock.com An American insurance company, Aflac (NYSE:AFL) specializes in supplemental insurance. Interestingly, GD represents a relatively new entry among the dividend aristocrats, featuring 26 years of consecutive dividend increases. | Abbott Laboratories, Inc. ABT recently entered into a definitive agreement to acquire Cardiovascular Systems CSII --  a medical device company with an innovative atherectomy system. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report AMN Healthcare Services Inc (AMN) : Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII) : Free Stock Analysis Report To read this article on Zacks.com click here. About Cardiovascular System Cardiovascular Systems is a medical device company that develops and commercializes innovative solutions for treating vascular and coronary disease. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report AMN Healthcare Services Inc (AMN) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT is gaining from new product launches and strategic acquisitions. COVID testing sales were $1.1 billion in the fourth quarter with rapid testing platforms, including BinaxNOW in the United States, Panbio internationally and ID NOW globally, comprising approximately 95% of the sales."
2023-02-10,108.26000213623048,108.16000366210938,0.18463529247198088,"The Zacks Analyst Blog Highlights Abbott Laboratories, Boeing, Diageo, Lam Research and Freeport-McMoRan","Click to get this free report The Boeing Company (BA) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Freeport-McMoRan Inc. (FCX) : Free Stock Analysis Report Lam Research Corporation (LRCX) : Free Stock Analysis Report Diageo plc (DEO) : Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include: Abbott Laboratories ABT, The Boeing Company BA, Diageo plc DEO, Lam Research Corp. LRCX and Freeport-McMoRan Inc. FCX. Here are highlights from Thursday’s Analyst Blog: Top Analyst Reports for Abbott Labs, Boeing and Diageo The Zacks Research Daily presents the best research output of our analyst team."
2023-02-09,110.69000244140624,108.06999969482422,-0.09236880856077713,"Why Cardiovascular Systems Stock Is Soaring Today | US STOCKS-Wall St dips as Alphabet extends fall; Disney hits 5-month high | US STOCKS-Wall St dips as Treasury yields rise; Disney hits 5-month high | Health Care Sector Update for 02/09/2023: AZN, BAX, CSII, ABT, XLV, IBB | US STOCKS-Wall St dips as Treasury yields rise after auction | US STOCKS-Wall St rises on robust earnings, Disney hits five-month high | US STOCKS-Wall St set to get a lift from robust earnings, rise in jobless claims | US STOCKS-Wall St dips as Treasury yields rise after auction","Cardiovascular Systems' stock is jumping in response to a buyout agreement with Abbott Laboratories (NYSE: ABT). 10 stocks we like better than Cardiovascular Systems When our award-winning analyst team has a stock tip, it can pay to listen. See the 10 stocks *Stock Advisor returns as of February 8, 2023 George Budwell has no position in any of the stocks mentioned. | Cardiovascular Systems IncCSII.O soared 48.5% after Abbott Laboratories ABT.N said it would buy the medical device maker for $837.6 million. For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Disney jumps on Q1 beat, layoff plans PepsiCo gains on quarterly profit, sales beat Salesforce rises on reports Third Point owns stake U.S. weekly jobless claims increase Indexes down: Dow 0.22%, S&P 0.24%, Nasdaq 0.25% Updates prices, details; adds comments By Johann M Cherian and Ankika Biswas Feb 9 (Reuters) - U.S. stock indexes turned lower by early afternoon on Thursday as Alphabet shares extended declines to another session, overshadowing gains in Disney after strong earnings. Wall Street's three main indexes opened higher after data showed initial claims for state unemployment benefits rose 13,000 to a seasonally adjusted 196,000 last week, above a forecast of 190,000 claims. | Cardiovascular Systems Inc CSII.O soared 48.38% after Abbott Laboratories ABT.N said it would buy the medical device maker for $837.6 million. For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Disney jumps on Q1 beat, layoff plans PepsiCo gains on quarterly profit, sales beat Salesforce rises on reports Third Point owns stake U.S. weekly jobless claims increase Dow down 0.52%, S&P 500 down 0.56%, Nasdaq down 0.65% Updates prices, details; adds comments By Carolina Mandl Feb 9 (Reuters) - U.S. stock indexes turned lower on Thursday afternoon as Treasury yields rose after an auction, overshadowing gains in Disney after strong earnings. ""The stock market started today's session with a distinct bullish bias, but then Treasury yields moved up and that took some of the steam out of the positive market today,"" said Jason Ware, chief investment officer at Albion Financial Group in Salt Lake City, Utah. | Cardiovascular Systems (CSII) was gaining over 48% in value after Abbott Laboratories (ABT) said it has agreed to acquire the company for $20 per share, representing approximately $890 million in equity value. The Health Care Select Sector SPDR Fund (XLV) was up 0.3% and the iShares Biotechnology ETF (IBB) was about 0.3% lower recently. Separately, Cardiovascular Systems posted a fiscal Q2 loss of $0.20 per diluted share, compared with a loss of $0.23 per share a year earlier. | Cardiovascular Systems Inc CSII.O soared after Abbott Laboratories ABT.N said it would buy the medical device maker for $837.6 million. By Carolina Mandl Feb 9 (Reuters) - U.S. stock indexes ended lower on Thursday, erasing earlier gains as Treasury yields rose after an auction of 30-year bonds went poorly and overshadowed strong earnings from corporate giants like Disney and PepsiCo. ""The stock market started today's session with a distinct bullish bias, but then Treasury yields moved up and that took some of the steam out of the positive market today,"" said Jason Ware, chief investment officer at Albion Financial Group in Salt Lake City, Utah. | Cardiovascular Systems Inc (CSI) CSII.O soared 48.1% after Abbott Laboratories ABT.N said it would buy the medical device maker for $837.6 million. Disney jumps on Q1 beat, layoff plans PepsiCo gains on quarterly profit, sales beat Salesforce rises on reports Third Point owns stake U.S. weekly jobless claims increase Indexes up: Dow 0.71%, S&P 0.73%, Nasdaq 1.11% Updates prices, details By Johann M Cherian and Ankika Biswas Feb 9 (Reuters) - U.S. main stock indexes rose on Thursday with Disney and Salesforce boosting the blue-chip Dow index, while data showing a rise in weekly jobless claims helped ease concerns about the Federal Reserve's rate-hike path. Fellow Dow component Salesforce IncCRM.N added 3% as a source familiar with the matter told Reuters that hedge fund Third Point LLC owns a stake in the company. | Cardiovascular Systems Inc (CSI) CSII.O jumped 48.3% after Abbott Laboratories ABT.N said it would buy the medical device maker for $837.6 million. By Sruthi Shankar and Johann M Cherian Feb 9 (Reuters) - U.S. main stock indexes were set for a higher open on Thursday as a slew of strong quarterly earnings and data showing a rise in weekly jobless claims outweighed concerns about the Federal Reserve's rate-hike path. ""This is a definite sign that weakness in the labor market is coming despite the huge job number last week,"" said Peter Cardillo, chief market economist at Spartan Capital Securities. | Cardiovascular Systems Inc CSII.O soared 48.38% after Abbott Laboratories ABT.N said it would buy the medical device maker for $837.6 million. For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Dow down 0.73%, S&P 500 down 0.88%, Nasdaq down 1.02% Weak demand for $21 bln sale of 30-year Treasury bonds PepsiCo gains on quarterly profit, sales beat Disney beats earnings estimates but ends down Salesforce rises on reports Third Point owns stake Updates prices, details; adds comments By Carolina Mandl Feb 9 (Reuters) - U.S. stock indexes ended lower on Thursday, erasing earlier gains as Treasury yields rose after an auction of 30-year bonds went poorly and overshadowed strong earnings from corporate giants like Disney and PepsiCo. ""The stock market started today's session with a distinct bullish bias, but then Treasury yields moved up and that took some of the steam out of the positive market today,"" said Jason Ware, chief investment officer at Albion Financial Group in Salt Lake City, Utah."
2023-02-08,111.4000015258789,110.1999969482422,-2.3669732485270436,"Abbott To Acquire Cardiovascular Systems In $890 Mln Deal | Abbott to acquire Cardiovascular Systems for $890 mln | Notable ETF Inflow Detected - VT, PFE, MRK, ABT | 3 MedTech Stocks Likely to Beat Estimates This Earnings Season","(RTTNews) - Abbott (ABT) said Wednesday that it agreed to acquire Cardiovascular Systems Inc, a medical device company with an atherectomy system used in treating peripheral and coronary artery disease, in a deal valued at about $890 million. The transaction, is subject to the approval of CSI stockholders and the satisfaction of customary closing conditions, including applicable regulatory approvals. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Feb 8 (Reuters) - Abbott Laboratories ABT.N said on Wednesday it has agreed to acquire medical device maker Cardiovascular Systems Inc in a deal valued at about $890 million. (Reporting by Khushi Mandowara in Bengaluru; Editing by Shailesh Kuber) ((Khushi.Mandowara@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VT, in trading today Pfizer Inc (Symbol: PFE) is up about 0.6%, Merck & Co Inc (Symbol: MRK) is up about 0.3%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Total World Stock ETF (Symbol: VT) where we have detected an approximate $472.5 million dollar inflow -- that's a 1.8% increase week over week in outstanding units (from 281,760,612 to 286,806,051). For a complete list of holdings, visit the VT Holdings page » The chart below shows the one year price performance of VT, versus its 200 day moving average: Looking at the chart above, VT's low point in its 52 week range is $76.80 per share, with $104.95 as the 52 week high point — that compares with a last trade of $93.31. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report Integra LifeSciences Holdings Corporation (IART) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT and Quest Diagnostics DGX are a few companies whose base-business performance registered a strong recovery rate. Exact Sciences Corporation Price and EPS Surprise Exact Sciences Corporation price-eps-surprise | Exact Sciences Corporation Quote Medtronic: Medtronic has been witnessing an adverse trend of procedure volume across its core business over the past few quarters, impacted by the choppy macroeconomic scenario globally in the form of supply chain disruption, a severe shortage of health professional labor and a record level of inflationary pressure."
2023-02-07,110.04000091552734,111.98999786376952,-1.077203376301513,Baby Formula Blues Hit Abbott Laboratories Stock Hard in 2022. Can It Rebound in 2023? | Is This Dividend King a Buy for Income Investors?,"Abbott Laboratories (NYSE: ABT) has generally been a good investment to hold over the years. Last year was the first time since 2016 that Abbott's stock didn't rise in value. But with a yield of 1.8%, which is only marginally higher than the 1.7% investors can get with the average S&P 500 stock, there isn't a huge incentive to buy Abbott's stock for its dividend right now -- certainly not given the challenges the business faces this year. | Abbott Laboratories' (NYSE: ABT) 50-year dividend growth streak makes it one of just 43 Dividend Kings. The valuation makes it a buy In a sense, Abbott has become a victim of the success of its own COVID rapid tests in recent years as retreating demand has weighed on its revenue. Its trailing-12-month (TTM) dividend yield of 1.8% is in line with the 10-year median yield, making the stock a buy for dividend growth investors at the current $112 price."
2023-02-06,111.56999969482422,110.75,1.7720800908926713,BlackRock Increases Position in Abbott Laboratories (ABT) | Ensign Group (ENSG) Shares Down 2% Since Q4 Earnings Release | Validea Daily Guru Fundamental Report for ABT - 2/6/2023,"Fintel reports that BlackRock has filed a 13G/A form with the SEC disclosing ownership of 139.53MM shares of Abbott Laboratories (ABT). Average portfolio weight of all funds dedicated to US:ABT is 0.6037%, a decrease of 3.0152%. The firm decreased its portfolio allocation in ABT by 7.58% over the last quarter. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Humana Inc. (HUM) : Free Stock Analysis Report Cigna Corporation (CI) : Free Stock Analysis Report The Ensign Group, Inc. (ENSG) : Free Stock Analysis Report To read this article on Zacks.com click here. Other Medical Sector Releases Of the Medical sector players that have reported fourth-quarter results so far, the bottom lines of Abbott Laboratories ABT, Cigna Corporation CI and Humana Inc. HUM beat the Zacks Consensus Estimate. ABT reported an adjusted operating profit of $1.80 billion for the quarter under review, down 37.8% year over year. | Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's daily guru fundamental report for ABBOTT LABORATORIES (ABT). Of the twelve guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch."
2023-02-03,111.80999755859376,111.79000091552734,-0.7349643246994281,,
2023-02-02,111.27999877929688,112.25,-0.01788448573745945,,
2023-02-01,110.77999877929688,111.81999969482422,0.8716761604454557,"2 Top Dividend Growth Stocks to Buy in February | Humana (HUM) Q4 Earnings Beat Mark, '23 EPS View Upbeat | ZBH vs. ABT: Which Stock Is the Better Value Option?","Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a diversified healthcare conglomerate that offers a 1.9% dividend yield. CVS Health CVS Health (NYSE: CVS) is a healthcare conglomerate that offers a 2.8% yield at recent prices. The company has raised its payout an impressive 169% over the past decade, but it doesn't show up on many dividend growth screens because it paused payout raises from 2017 through 2021. Dividend growth investors should know that CVS Health paused its payout to complete a $69 billion acquisition of Aetna, a major manager of health insurance benefits that collects monthly premiums from around 35 million people. | Other Medical Sector Release Of the Medical sector players that have reported fourth-quarter results so far, the bottom lines of UnitedHealth Group Incorporated UNH, Elevance Health Inc. ELV and Abbott Laboratories ABT beat the Zacks Consensus Estimate. ABT reported an adjusted operating profit of $1.80 billion for the quarter under review, down 37.8% year over year. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report Humana Inc. (HUM) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report To read this article on Zacks.com click here. | These are just a few of the metrics contributing to ZBH's Value grade of B and ABT's Value grade of C. ZBH stands above ABT thanks to its solid earnings outlook, and based on these valuation figures, we also feel that ZBH is the superior value option right now. Click to get this free report Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Investors looking for stocks in the Medical - Products sector might want to consider either Zimmer Biomet (ZBH) or Abbott (ABT)."
2023-01-31,109.79000091552734,110.5500030517578,0.9387984536805252,"Validea Daily Guru Fundamental Report for ABT - 1/31/2023 | 5 Top Stocks to Buy Now | U.S. food safety regulator announces shakeup after infant formula crisis | IWV, MRK, PFE, ABT: ETF Outflow Alert","Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's daily guru fundamental report for ABBOTT LABORATORIES (ABT). Of the twelve guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. | For different reasons, Delta Air Lines (NYSE: DAL), industrial technology company Trimble (NASDAQ: TRMB), infrastructure software company Bentley Systems (NASDAQ: BSY), oil equipment and services company Baker Hughes (NASDAQ: BKR), and industrial giant Siemens (OTC: SIEGY) are all attractive stocks to look at in 2023. Bentley Systems Sticking with the theme of infrastructure technology stocks, Bentley is a pure-play infrastructure software stock. Data by YCharts In the digital industries segment (3.9 billion euros in profit in 2022), it owns the world's leading automation and industrial software companies, competing with the likes of ABB, Emerson Electric, Rockwell, and PTC. | By Leah Douglas Jan 30 (Reuters) - The U.S. Food and Drug Administration (FDA) said on Tuesday it will restructure its food program that was slammed last year for responding too slowly to an outbreak of illness among infants who consumed formula from an Abbott Laboratories production plant. In response to recommendations made by an outside group following the crisis, the FDA will establish a Human Foods Program led by a deputy commissioner, uniting its Center for Food Safety and Applied Nutrition, food policy office, and certain functions of its regulatory affairs office, agency head Robert M. Califf announced. FDA oversees the vast majority of the U.S. food supply including produce, dairy, infant formula, and food additives. | Among the largest underlying components of IWV, in trading today Merck & Co Inc (Symbol: MRK) is up about 0.7%, Pfizer Inc (Symbol: PFE) is up about 0.2%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 3000 ETF (Symbol: IWV) where we have detected an approximate $313.3 million dollar outflow -- that's a 2.8% decrease week over week (from 48,300,000 to 46,950,000). For a complete list of holdings, visit the IWV Holdings page » The chart below shows the one year price performance of IWV, versus its 200 day moving average: Looking at the chart above, IWV's low point in its 52 week range is $201.8201 per share, with $268.70 as the 52 week high point — that compares with a last trade of $233.39."
2023-01-30,109.80999755859376,109.80999755859376,0.6922325620665599,,
2023-01-27,110.6500015258789,109.9499969482422,0.0,Interesting ABT Put And Call Options For June 2024,"Below is a chart showing ABT's trailing twelve month trading history, with the $115.00 strike highlighted in red: Considering the fact that the $115.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the June 2024 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new June 2024 contracts and identified one put and one call contract of particular interest."
2023-01-26,111.25,111.06999969482422,-0.6326295237085803,Abbott's Sales and Earnings Are Sinking: Should Investors Worry? | Two Dividend Kings: Johnson & Johnson or Abbott Laboratories? | Abbott (ABT) Reports Q4 Earnings: What Key Metrics Have to Say | Abbott Says FDA Oks Proclaim XR Spinal Cord Stimulation System To Treat DPN,"Abbott (NYSE: ABT) reported its full-year and fourth-quarter results for 2022 on Wednesday. A year ago, Abbott projected that it would generate adjusted earnings per share of at least $4.70 in full-year 2022. Abbott projects adjusted diluted earnings per share from continuing operations will be between $4.30 and $4.50 this year. | Johnson & Johnson (NYSE: JNJ) and Abbott Laboratories (NYSE: ABT) are 2 of the more attractive Dividend Kings for today’s market. Guidance is Mixed for JNJ and ABT The 2023 guidance from JNJ and ABT is a little mixed regarding each other. JNJ shares are trading about 16X their 2023 EPS with earnings growth on the table, while ABT shares are trading closer to 22X with earnings under pressure. | For the quarter ended December 2022, Abbott (ABT) reported revenue of $10.09 billion, down 12% over the same period last year. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. | (RTTNews) - Abbott Laboratories, Inc. (ABT) announced Thursday that the U.S. Food and Drug Administration (FDA) has approved its Proclaim XR spinal cord stimulation (SCS) system to treat painful diabetic peripheral neuropathy (DPN), a debilitating complication of diabetes. Currently, there are no disease modifying treatments for DPN, only symptom management and behavioral modifications to mitigate further nerve damage that can result from high blood sugar (glucose) levels Approved for the treatment of chronic pain in 2019, the Proclaim XR SCS system now offers DPN patients relief from chronic pain by delivering low amounts, or doses, of stimulation. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2023-01-25,110.0,111.0,-0.16179802712429775,"US STOCKS-Wall Street dips as weak corporate guidance fuels recession fears | US STOCKS-Wall St falls as Microsoft outlook dents tech stocks, earnings disappoint | Health Care Sector Update for 01/25/2023: ISRG,ABT,SNOA | Pre-Markets Edge Lower With Q4 Earnings Underway | S&P 500 closes slightly red as weak corporate guidance fuels recession fears | Health Care Sector Update for 01/25/2023: PGEN,ISRG,ABT,SNOA | Abbott Laboratories (ABT) Q4 2022 Earnings Call Transcript | Why Aurora Cannabis Stock Is Fading Today | US STOCKS-Wall St falls as Microsoft forecast hits tech stocks, earnings disappoint | Why Abbott Laboratories Stock Got Whacked on Wednesday | Abbott Issues FY23 Earnings, Sales Growth View - Update | Abbott Laboratories Q4 22 Earnings Conference Call At 9:00 AM ET | Abbott Laboratories Q4 Profit Decreases, but beats estimates | Pre-Markets Sink on Quarterly Earnings Ruminations | Abbott (ABT) Q4 Earnings and Revenues Top Estimates | US STOCKS-Wall St eyes lower open as weak earnings updates dent sentiment | Health Care Sector Update for 01/25/2023: AUPH, ISRG, ABT, XLV, IBB","Abbott Laboratories ABT.N dropped 2.0%, as weaker-than-expected medical device sales weighed on the stock. The tech-laden Nasdaq was down the most after Microsoft Corp MSFT.O, the first major technology firm to post quarterly results, offered dour guidance and raised red flags with respect to its megacap peers which have yet to report. Finally, in a post-script to Tuesday's technical glitch which halted the opening auctions for a spate of stocks and prompted a review by the U.S. Securities and Exchange Commission (SEC), the New York Stock Exchange (NYSE) said a manual error resulted in the snafu which caused widespread confusion at the opening bell. | Abbott Laboratories ABT.N fell 1.9%, weighed down by lower-than-expected medical device sales in the fourth quarter. By Shreyashi Sanyal and Johann M Cherian Jan 25 (Reuters) - Wall Street benchmarks dropped on Wednesday as a decline in technology stocks after Microsoft's downbeat forecast and a bleak quarterly report from Boeing fanned fears of a recession. Growth stocks, however, have enjoyed a bounce in January after a battering last year, with investors now focused on earnings reports to assess the impact of the Federal Reserve's rate hikes and to gauge whether the renewed enthusiasm for these stocks will be sustained. | Abbott Laboratories (ABT) fell 1.8% after the pharmaceutical and medical device company reported lower non-GAAP Q4 net income, falling to $1.03 per share during the three months ended Dec. 31 from $1.32 per share during the same quarter in 2021 but still beating the Capital IQ consensus expecting $0.93 per share. The iShares Biotechnology ETF (IBB) was dropping 0.4%. In company news, Intuitive Surgical (ISRG) retreated 5.4% after the surgical and diagnostic devices company reported a decline in its adjusted net income for its Q4 ended Dec. 31, falling to $1.23 per share compared with $1.29 per share during the year-ago period and lagging Wall Street expectations for a $1.25 per share non-GAAP profit. | Abbott Labs (ABT) put up prominent beats ahead of today’s opening bell, with earnings of $1.03 per share outpacing the 90 cents in the Zacks consensus on revenues of $10.09 billion, for a positive surprise of +6.47%. Click to get this free report The Boeing Company (BA) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Microsoft Corporation (MSFT) : Free Stock Analysis Report International Business Machines Corporation (IBM) : Free Stock Analysis Report Las Vegas Sands Corp. (LVS) : Free Stock Analysis Report Tesla, Inc. (TSLA) : Free Stock Analysis Report To read this article on Zacks.com click here. We also saw a -3600% negative earnings surprise from Boeing (BA) in its Q4 report this morning: the world’s biggest aircraft builder was expected to turn a profit of 5 cents per share in the quarter, but instead produced a -$1.75 per share loss. | Abbott Laboratories ABT.N dropped as weaker-than-expected medical device sales weighed on the stock. The tech-laden Nasdaq was weighed down after Microsoft Corp MSFT.O, the first major technology firm to post quarterly results, offered dour guidance and raised red flags with respect to its megacap peers which have yet to report. Among gainers, News Corp NWSA.O jumped after Rupert Murdoch withdrew a proposal to reunite News Corp and Fox Corp. AT&T Inc T.N also delivered disappointing guidance but its renewed focus on its telecoms business helped boost subscriber numbers, sending its shares higher. | Abbott Laboratories (ABT) fell 1.6% after the pharmaceutical and medical device company reported lower non-GAAP Q4 net income, falling to $1.03 per share during the three months ended Dec. 31 from $1.32 per share during the same quarter in 2021 but still beating the Capital IQ consensus expecting $0.93 per share. Intuitive Surgical (ISRG) retreated 5.5% after the surgical and diagnostic devices company reported a decline in its adjusted net income for its Q4 ended Dec. 31, falling to $1.23 per share compared with $1.29 per share during the year-ago period and lagging Wall Street expectations for a $1.25 per share non-GAAP profit. Among gainers, Sonoma Pharmaceuticals (SNOA) raced almost 38% higher after Wednesday, saying the Defense Logistics Agency has approved a distribution and pricing registration agreement for the company's Microcyn wound-care products, clearing the way for Sonoma and its privately held distribution partner, EMC Pharma, to sign supply contracts with agencies throughout the federal government as well as state and local prison systems. | Duration: 0 minutes Call participants: Scott Leinenweber -- Vice President of Investor Relations, Licensing, and Acquisition Robert Ford -- Chairman and Chief Executive Officer Bob Funck -- Executive Vice President, Finance, and Chief Financial Officer Robbie Marcus -- JPMorgan Chase and Company -- Analyst Larry Biegelsen -- Wells Fargo Securities -- Analyst Josh Jennings -- Cowen and Company -- Analyst Joanne Wuensch -- Citi -- Analyst Vijay Kumar -- Evercore ISI -- Analyst Travis Steed -- Bank of America Merrill Lynch -- Analyst Matt Miksic -- Barclays -- Analyst More ABT analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Abbott Laboratories (NYSE: ABT) Q4 2022 Earnings Call Jan 25, 2023, 9:00 a.m. Note that Abbott has not provided the GAAP financial measure for organic sales growth, excluding COVID testing sales, on a forward-looking basis because the company is unable to predict future changes in foreign exchange rates, which could impact reported sales growth. | Over the past year, for instance, Canadian cannabis companies have battled falling prices, declining profit margins, sizable goodwill impairment charges, a shift in consumer preferences toward higher-potency products, and legal red tape in various forms. Here's The Marijuana Stock You've Been Waiting For A little-known Canadian company just unlocked what some experts think could be the key to profiting off the coming marijuana boom. Cannabis legalization is sweeping over North America – 19 states plus Washington, D.C., have all legalized recreational marijuana over the last few years, and full legalization came to Canada in October 2018. | Abbott Laboratories ABT.N fell 0.7%, weighed down by lower-than-expected medical device sales in the fourth quarter. Microsoft falls on dismal Q3 cloud outlook Salesforce, Amazon, other cloud-based stocks drop Tech shares lead sectoral declines on S&P 500 Boeing slides after missing Q4 revenue estimates Indexes down: Nasdaq 2.0%, S&P 1.2%, Dow 0.7% Adds details; updates prices to open By Shreyashi Sanyal and Johann M Cherian Jan 25 (Reuters) - Wall Street's main indexes dropped on Wednesday, with the Nasdaq down 2% as Microsoft's outlook weighed down technology stocks, while a bleak quarterly report from Boeing added to fears of a recession. Growth stocks, however, have enjoyed a bounce in January after a battering last year, with investors now focused on earnings reports to assess the impact of the Federal Reserve's rate hikes and to gauge whether the renewed enthusiasm for these stocks will be sustained. | What happened Wednesday morning, Abbott Laboratories (NYSE: ABT) beat on both the top and bottom lines in its freshly reported fourth quarter of 2022. In fact, they were counting on Abbott to do worse; on average, those prognosticators estimated the company would book slightly more than $9.6 billion in sales and net a per-share, adjusted profit of only $0.92. 10 stocks we like better than Abbott Laboratories When our award-winning analyst team has a stock tip, it can pay to listen. | (RTTNews) - Abbott Laboratories (ABT), while announcing weak fourth-quarter results, issued fiscal 2023 earnings and sales forecast. For the year, the company projects earnings per share from continuing operations of $3.05 to $3.25 and adjusted earnings per share from continuing operations of $4.30 to $4.50. In fiscal 2022, the company's reported earnings were $3.91 and adjusted earnings per share were $5.34, on sales growth of 1.3 percent and organic sales growth of 6.4 percent. | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on Jan. 25, 2023, to discuss Q4 22 earnings results. To access the live webcast, log on to https://www.abbottinvestor.com/news-and-events?c=94004&p=irol-calall The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) revealed a profit for fourth quarter that decreased from the same period last year but beat the Street estimates. The company's revenue for the quarter fell 12.0% to $10.09 billion from $11.47 billion last year. -Analyst Estimates: $0.92 -Revenue (Q4): $10.09 Bln vs. $11.47 Bln last year. | Abbott Labs ABT put up prominent beats ahead of today’s opening bell, with earnings of $1.03 per share outpacing the 90 cents in the Zacks consensus on revenues of $10.09 billion, for a positive surprise of +6.47%. Click to get this free report The Boeing Company (BA) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Microsoft Corporation (MSFT) : Free Stock Analysis Report International Business Machines Corporation (IBM) : Free Stock Analysis Report Las Vegas Sands Corp. (LVS) : Free Stock Analysis Report Tesla, Inc. (TSLA) : Free Stock Analysis Report To read this article on Zacks.com click here. For more on ABT’s earnings, click here. | Abbott (ABT) came out with quarterly earnings of $1.03 per share, beating the Zacks Consensus Estimate of $0.90 per share. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Surmodics, Inc. (SRDX) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $10.09 billion for the quarter ended December 2022, surpassing the Zacks Consensus Estimate by 6.47%. | Abbott Laboratories ABT.Nslid over 1.5% weighed down by lower-than-expected medical device sales in the fourth quarter as COVID-19 lockdown restrictions in China and supply chain issues hit its international operations. Shares of the software giant MSFT.O fell 2.7% in premarket trading after it warned that growth in its lucrative cloud business could stall, while its PC unit continued to struggle. Growth stocks, however, have enjoyed a bounce in January after a battering last year, with investors now focused on earnings reports to assess the impact of the Federal Reserve's rate hikes and to gauge whether the renewed enthusiasm for such stocks will be sustained. | Abbott Laboratories (ABT) was more than 2% lower after it reported Q4 adjusted earnings of $1.03 per diluted share, down from $1.32 a year earlier. The Health Care Select Sector SPDR Fund (XLV) was slipping by 0.62% and the iShares Biotechnology ETF (IBB) was recently inactive. Intuitive Surgical (ISRG) fell by nearly 9% after it reported Q4 non-GAAP diluted earnings of $1.23 a share, down from $1.29 a year earlier."
2023-01-24,112.86000061035156,112.52999877929688,0.9090909090909091,"Pre-Market Earnings Report for January 25, 2023 : ASML, ABT, NEE, T, BA, ELV, ADP, PGR, USB, FCX, GD, NSC | Noteworthy Tuesday Option Activity: ACI, JOE, ABT | Will Abbott Stock Rise After Its Q4 Results?","Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABT is 21.88 vs. an industry ratio of 9.70, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories (ABT)is reporting for the quarter ending December 31, 2022. In the past year ABT has beat the expectations every quarter. | Below is a chart showing JOE's trailing twelve month trading history, with the $41 strike highlighted in orange: And Abbott Laboratories (Symbol: ABT) options are showing a volume of 19,547 contracts thus far today. That number of contracts represents approximately 2.0 million underlying shares, working out to a sizeable 42.7% of ABT's average daily trading volume over the past month, of 4.6 million shares. Especially high volume was seen for the $105 strike put option expiring February 17, 2023, with 2,908 contracts trading so far today, representing approximately 290,800 underlying shares of ABT. | At its current levels, ABT stock is trading at a forward P/E multiple of 25x based on our EPS estimate of $4.60 for 2023, compared to the last three-year average of 24x, implying that ABT stock is fully valued. Total [2] ABT Return 4% 4% 197% S&P 500 Return 5% 5% 80% Trefis Multi-Strategy Portfolio 10% 10% 245% [1] Month-to-date and year-to-date as of 1/24/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott (NYSE: ABT) is scheduled to report its Q4 2022 results on Wednesday, January 25."
2023-01-23,112.43000030517578,114.01000213623048,-0.29239928164985285,"Want Safe and Growing Passive Income? Buy These 2 Dividend Kings In 2023 | Noteworthy ETF Inflows: VONV, PFE, VZ, ABT | Abbott's (ABT) New FDA Approval to Improve Patient Outcome","Abbott Laboratories: An outstanding healthcare business Like J&J, Abbott Laboratories (NYSE: ABT) is a company that is well-known around the world, with market-leading positions in numerous areas of healthcare. Fifty-plus consecutive years means that Dividend Kings raised their dividends paid to shareholders through numerous recessions, stock market crashes, global pandemics, and military conflicts. Johnson & Johnson: The lengthiest dividend growth streak in all of healthcare Johnson & Johnson (NYSE: JNJ) is a company that needs no introduction, but here's one anyway: With corporate roots dating back to the late 19th century and over 140,000 employees throughout the world, J&J is a world-class business. | Among the largest underlying components of VONV, in trading today Pfizer Inc (Symbol: PFE) is up about 0.3%, Verizon Communications Inc (Symbol: VZ) is up about 0.2%, and Abbott Laboratories (Symbol: ABT) is up by about 0.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Russell 1000 Value ETF (Symbol: VONV) where we have detected an approximate $356.1 million dollar inflow -- that's a 5.4% increase week over week in outstanding units (from 97,102,615 to 102,302,615). For a complete list of holdings, visit the VONV Holdings page » The chart below shows the one year price performance of VONV, versus its 200 day moving average: Looking at the chart above, VONV's low point in its 52 week range is $58.8266 per share, with $74.4595 as the 52 week high point — that compares with a last trade of $68.90. | Abbott Laboratories ABT recently announced the receipt of the FDA’s approval for its latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor, to treat people with severe aortic stenosis who are at high or extreme risk for open-heart surgery. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report AMN Healthcare Services Inc (AMN) : Free Stock Analysis Report To read this article on Zacks.com click here. Image Source: Zacks Investment Research Zacks Rank & Key Picks Currently, Abbott carries a Zacks Rank #3 (Hold)."
2023-01-20,112.1999969482422,112.81999969482422,1.4053204898745921,Abbott faces U.S. criminal probe over baby formula -WSJ | Validea Daily Guru Fundamental Report for ABT - 1/20/2023 | Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings | Will Intuitive Surgical Stock Rise Post Q4? | Why Abbott (ABT) is Poised to Beat Earnings Estimates Again,"Adds Abbott's response Jan 20 (Reuters) - Abbott Laboratories' ABT.N Michigan plant, which was at the center of the U.S. baby formula shortage last year, is being investigated by the Justice Department, the Wall Street Journal reported on Friday. In February 2022, Abbott, the biggest U.S. supplier of baby formula, recalled Similac and other infant formula products produced at the Michigan facility after reports of bacterial infections in babies who had consumed products made there. (Reporting by Mrinalika Roy in Bengaluru; Editing by Himani Sarkar) ((mrinalika.roy@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's daily guru fundamental report for ABBOTT LABORATORIES (ABT). Of the twelve guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. | Abbott (ABT) holds a #3 (Hold) at the moment and its Most Accurate Estimate comes in at $0.92 a share five days away from its upcoming earnings release on January 25, 2023. Investors should also know that ABT is one of a large group of stocks with positive ESPs. ABT is just one of a large group of Medical stocks with a positive ESP figure. | (1) Revenues expected to align with the consensus estimates Trefis estimates Intuitive Surgical’s Q4 2022 revenues to be around $1.7 billion, aligning with the $1.7 billion consensus estimate. Note: P/E Multiples are based on Share Price at the end of the year and reported (or expected) Adjusted Earnings for the full year While ISRG stock looks appropriately priced, it is helpful to see how Intuitive Surgical’s Peers fare on metrics that matter. Total [2] ISRG Return -2% -2% 269% S&P 500 Return 4% 4% 79% Trefis Multi-Strategy Portfolio 8% 8% 241% [1] Month-to-date and year-to-date as of 1/17/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It is worth considering Abbott (ABT), which belongs to the Zacks Medical - Products industry. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the company is positive, which is a great sign of an earnings beat, especially when you combine this metric with its nice Zacks Rank."
2023-01-19,111.05999755859376,111.8000030517578,0.5525871331957558,3 Top Passive-Income Stocks to Own in 2023 | See Which Of The Latest 13F Filers Holds Abbott Laboratories | Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?,"Abbott Laboratories Abbott Laboratories (NYSE: ABT) also has increased its dividend for more than 50 years. ABT Free Cash Flow data by YCharts Like J&J, Abbott offers you another big reason to invest. Johnson & Johnson Johnson & Johnson (NYSE: JNJ) has lifted its dividend for more than 50 consecutive years. | Existing +81,424 +$9,514 J.P. Marvel Investment Advisors LLC Existing UNCH +$919 Mcdonald Partners LLC Existing +156 +$205 Aggregate Change: +23,754 +$7,064 In terms of shares owned, we count 4 of the above funds having increased existing ABT positions from 09/30/2022 to 12/31/2022, with 4 having decreased their positions and 1 new position. Ardevora Asset Management LLP 884,291 4-10 Find out the full Top 10 Hedge Funds Holding ABT » We'll keep following the latest 13F filings by hedge fund managers and bring you interesting stories derived from a look at the aggregate information across groups of managers between filing periods. At Holdings Channel, we have reviewed the latest batch of the 25 most recent 13F filings for the 12/31/2022 reporting period, and noticed that Abbott Laboratories (Symbol: ABT) was held by 15 of these funds. | Click to get this free report iShares U.S. Medical Devices ETF (IHI): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report SPDR S&P Health Care Equipment ETF (XHE): ETF Research Reports First Trust Indxx Medical Devices ETF (MDEV): ETF Research Reports To read this article on Zacks.com click here. Looking at individual holdings, Thermo Fisher Scientific Inc (TMO) accounts for about 17.47% of total assets, followed by Abbott Laboratories (ABT) and Medtronic Plc (MDT). First Trust Indxx Medical Devices ETF (MDEV) tracks INDXX GLOBAL MEDICAL EQUIPMENT INDEX and the SPDR S&P Health Care Equipment ETF (XHE) tracks S&P Health Care Equipment Select Industry Index."
2023-01-18,113.20999908447266,111.51000213623048,0.6663114617606731,"Top Analyst Reports for Pfizer, Abbott Laboratories & Union Pacific | Analysts Estimate Abbott (ABT) to Report a Decline in Earnings: What to Look Out for","If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Pfizer (PFE) Growth Drivers Beyond COVID Products a Concern Abbott (ABT) Rides on Diabetes Business amid Forex Woes Union Pacific's (UNP) Dividends Support, Fuel Costs Hurt Featured Reports Goldman (GS) Rides on Strong Consumer Banking Growth Per the Zacks analyst, Goldman benefits from robust consumer banking business, robust client engagement, and a decent investment banking backlog. Click to get this free report The Goldman Sachs Group, Inc. (GS) : Free Stock Analysis Report Citigroup Inc. (C) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Union Pacific Corporation (UNP) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report To read this article on Zacks.com click here. Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), Abbott Laboratories (ABT) and Union Pacific Corporation (UNP). | Wall Street expects a year-over-year decline in earnings on lower revenues when Abbott (ABT) reports results for the quarter ended December 2022. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate."
2023-01-17,113.5,113.38999938964844,-1.5016314477431496,What's in Store for Abbott Laboratories (ABT) in Q4 Earnings? | Abbott Says FDA Oks Navitor TAVI System To Treat Severe Aortic Stenosis,"Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Laboratory Corporation of America Holdings (LH) : Free Stock Analysis Report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT is slated to report fourth-quarter 2022 results on Jan 25, before market open. Abbott Laboratories Price and EPS Surprise Abbott Laboratories price-eps-surprise | Abbott Laboratories Quote In Diagnostics, we expect the company to report a year-over-year decline in COVID test sales due to lower demand for laboratory-based tests. | (RTTNews) - Abbott Laboratories (ABT) announced Tuesday that the U.S. Food and Drug Administration (FDA) has approved the company's latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor, to treat people with severe aortic stenosis who are at high or extreme risk for open-heart surgery. The Navitor TAVI system is the latest addition to the company's comprehensive transcatheter structural heart portfolio that offers less invasive treatment options to physicians and patients for some of the most common and serious heart diseases. The Navitor device is implanted using Abbott's FlexNav delivery system, which features a slim design to accommodate different patient anatomies and small vessels for stable, predictable and accurate valve delivery and placement."
2023-01-13,111.2699966430664,113.51000213623048,-0.09691683731415199,"Friday Sector Leaders: Healthcare, Services","Within the sector, Illumina Inc (Symbol: ILMN) and Abbott Laboratories (Symbol: ABT) are two large stocks leading the way, showing a gain of 2.8% and 1.7%, respectively. Combined, ILMN and ABT make up approximately 4.4% of the underlying holdings of XLV. Among healthcare ETFs, one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is up 0.2% on the day, and down 0.21% year-to-date."
2023-01-12,111.98999786376952,111.36000061035156,2.013126234154208,Abbott (ABT) Stock Sinks As Market Gains: What You Should Know | Should You Buy This Promising New Healthcare Stock?,"In the latest trading session, Abbott (ABT) closed at $111.36, marking a -1.58% move from the previous day. Investors should also note that ABT has a PEG ratio of 5.07 right now. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | As a leaner, isolated business, it's a lot easier for healthcare investors to buy shares of GE's healthcare business now without having to own a piece of the whole conglomerate. It's too early to invest in GE Healthcare With single-digit growth, a high debt load, and potentially no dividend for the foreseeable future, there's not much of a reason to buy shares of GE Healthcare today. There's no incentive just yet to buy shares of GE Healthcare instead of other healthcare stocks that may offer more growth potential."
2023-01-11,114.87000274658205,113.1500015258789,-0.5625477859052342,Validea Daily Guru Fundamental Report for ABT - 1/11/2023 | 3 Supercharged Dividend Stocks to Buy If There's a Stock Market Sell-Off,"Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's daily guru fundamental report for ABBOTT LABORATORIES (ABT). Of the twelve guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. | Many stocks with high yields also have high dividend payout ratios, meaning a company devotes much of its earnings to those dividends. So, in looking for three healthcare stocks with supercharged dividends to buy in a market sell-off, it makes sense to look for companies that are strong enough to handle a down market while protecting their dividends -- companies such as Bristol-Myers Squibb (NYSE: BMY), AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE). The company raised its quarterly dividend by 5.6% this year to $0.57, the 13th consecutive year it has boosted its dividend."
2023-01-10,112.5,113.8499984741211,-1.497345851464531,Abbott Laboratories To Present At J.P. Morgan Healthcare Conference; Webcast At 12:00 PM ET,"(RTTNews) - Abbott Laboratories (ABT) will present at the 41st Annual J.P. Morgan Healthcare Conference. The event is scheduled to begin at 12:00 PM ET on Jan. 10, 2023. To access the live webcast, log on to http://www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2023-01-09,113.5199966430664,112.1500015258789,1.1999986436631944,Abbott's (ABT) New Launch to Boost Blood Donation Experience | 3 Reliable Dividend Stocks You Can Buy With $600 | This Robotic Products Company Is A Better Pick Over Medtronic Stock,"Abbott Laboratories ABT recently unveiled an advanced new mixed reality experience for use during blood donation along with Blood Centers of America. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report AMN Healthcare Services Inc (AMN) : Free Stock Analysis Report To read this article on Zacks.com click here. More on Mixed Reality The mixed reality technology is an immersive digital experience intended to enhance the blood donation process, attract new donors and motivate a younger generation to give blood. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a healthcare conglomerate with a collection of businesses that include medical devices. To show just how accessible building wealth through dividend stock investing can be, I've pulled out three names that everyday investors can rely on to make regular dividend payments that rise year after year. CVS Health Shares of CVS Health (NYSE: CVS) pay a dividend that has grown 169% over the past decade. | Intuitive Surgical’s Revenue Growth Is Better Intuitive Surgical’s revenue growth of 11.3% over the last twelve months is much better than -1.7% for Medtronic. Even if we look at a longer time frame, Intuitive Surgical has fared better, with its sales rising at an average annual rate of 16.2% to $5.7 billion in 2021, compared to $3.7 billion in 2018, while Medtronic saw its revenue rise at an average annual rate of just 1.3% to $31.7 billion in fiscal 2022 (Medtronic’s fiscal ends in April), compared to $30.0 billion in 2018. The table below summarizes our revenue and return expectations for Medtronic and Intuitive Surgical over the next three years and points to an expected return of 15% for Medtronic over this period vs. a 46% expected return for Intuitive Surgical, based on Trefis Machine Learning analysis – Medtronic vs. Intuitive Surgical – which also provides more details on how we arrive at these numbers."
2023-01-06,112.0,112.33000183105467,-1.2068315342671188,Abbott (ABT) Gains But Lags Market: What You Should Know,"Abbott (ABT) closed at $112.33 in the latest trading session, marking a +1.38% move from the prior day. It is also worth noting that ABT currently has a PEG ratio of 4.95. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here."
2023-01-05,111.0999984741211,110.8000030517578,0.29464449201310117,"2 Best Healthcare Stocks to Buy Right Now | Noteworthy ETF Outflows: XLV, MRK, ABT, DHR","Abbott Laboratories: A healthcare giant Abbott Laboratories' (NYSE: ABT) $192 billion market capitalization makes it one of the biggest makers of medical devices and other healthcare products in the world. And with the dividend payout ratio standing at a very modest 12%, Humana should have no issues delivering 15%-plus annual dividend growth over the next five to 10 years. See the 10 stocks *Stock Advisor returns as of December 1, 2022 Kody Kester has positions in Abbott Laboratories. | Among the largest underlying components of XLV, in trading today Merck & Co Inc (Symbol: MRK) is up about 0.4%, Abbott Laboratories (Symbol: ABT) is trading flat, and Danaher Corp (Symbol: DHR) is lower by about 3.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $129.0 million dollar outflow -- that's a 0.3% decrease week over week (from 310,220,000 to 309,270,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $118.75 per share, with $143.42 as the 52 week high point — that compares with a last trade of $134.56."
2023-01-04,111.01000213623048,111.20999908447266,-0.27002288612377834,,
2023-01-03,110.51000213623048,109.58000183105467,0.18016119664310862,Beat the Dow Jones With This Unstoppable Dividend Stock,"This patent cliff won't sink AbbVie's prospects Since splitting off from Abbott Laboratories in 2013, AbbVie has comfortably beaten the Dow Jones. AbbVie's strong dividend record In the third quarter, AbbVie reported revenue growth of 3.3% year over year to $14.8 billion, while its adjusted earnings per share came in at $3.66, 29.3% higher than the year-ago period. Whatever happens to the pharma company in 2023, AbbVie has an excellent chance of outperforming the Dow Jones in the next five years and beyond."
2022-12-30,109.8000030517578,109.79000091552734,-0.8415530605359666,What Tech Investors Can Expect to See at CES 2023,"With chips and technologies seeping into more aspects of our daily lives, the kinds of companies participating in CES’s keynotes have expanded in the last few years to include technology companies such as IBM (IBM), AMD (AMD), Nvidia (NVDA) and Samsung (SSNLF) but also General Motors (GM), Verizon (VZ), Abbott Labs (ABT) and Unilever (UL). Calendar 2022 smartphone unit volume is expected to decline 10% year-over-year versus compared to Micron’s prior high single-digit percentage decline forecast and the company sees calendar year 2023 smartphone unit volume being flattish to up slightly on a year-over-year basis. While the company didn’t share any particular figure for 2024, it did say it is “now significantly reducing our fiscal 2024 capex from earlier plans to align with the supply-demand environment.” As companies close their books for the December quarter, assess the state of their end markets and take stock of upcoming economic data and what Fed monetary policy means for interest rates, there is a growing probability that earnings expectations for the coming year will be revised lower."
2022-12-29,108.75,110.30999755859376,-0.009109413435753465,,
2022-12-28,109.0199966430664,107.83000183105467,1.4344805136494383,iShares MSCI World ETF Experiences Big Inflow | Baby formula imports to face tariffs again in 2023 - WSJ | Baby formula imports to face tariffs again in 2023 - WSJ | Abbott (ABT) to Upgrade PHCs Across India With New Pact | Will Baxter Stock Rebound After A 9% Fall In A Month?,"Among the largest underlying components of URTH, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.6%, Danaher Corp (Symbol: DHR) is up about 1.1%, and NextEra Energy Inc (Symbol: NEE) is lower by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares MSCI World ETF (Symbol: URTH) where we have detected an approximate $174.7 million dollar inflow -- that's a 7.4% increase week over week in outstanding units (from 21,500,000 to 23,100,000). For a complete list of holdings, visit the URTH Holdings page » The chart below shows the one year price performance of URTH, versus its 200 day moving average: Looking at the chart above, URTH's low point in its 52 week range is $97.44 per share, with $136.69 as the 52 week high point — that compares with a last trade of $108.89. | The shortage that began due to pandemic-induced supply chain issues worsened in February when Abbott Laboratories ABT.N, the biggest U.S. supplier, recalled some products and closed a manufacturing plant after reports of bacterial infections. Adds details, background Dec 28 (Reuters) - Imported baby formula would be subject to tariffs again in the new year after the expiration of exemptions implemented amid a nationwide shortage, the Wall Street Journal reported on Wednesday. According to the WSJ report, a White House spokesman said the tariff waivers doubled the number of manufacturers selling baby formula in the United States. | The shortage that began due to pandemic-induced supply chain issues worsened in February when Abbott Laboratories ABT.N, the biggest U.S. supplier, recalled some products and closed a manufacturing plant after reports of bacterial infections. Dec 28 (Reuters) - Imported baby formula would be subject to tariffs again in the new year, after the expiration of exemptions implemented amid a nationwide shortage, the Wall Street Journal reported on Wednesday. According to the WSJ report, a White House spokesman said the tariff waivers doubled the number of manufacturers selling baby formula in the United States. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report ORTHOFIX MEDICAL INC. (OFIX) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report ShockWave Medical, Inc. (SWAV) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT recently partnered with Americares India Foundation to upgrade 75 Primary Health Centres (PHCs) to Health and Wellness Centres (HWCs) across nine States in India. Benefits of the HWC Program The HWC program is likely to expand ABT’s customer base across India. | This pattern suggests a higher chance of a rise in BAX stock over the next five, ten, and twenty-one days. Baxter (BAX) Stock Return (Recent) Comparison With Peers And S&P500 Five-Day Return: CAH highest at 2.5%; BAX lowest at -1.2% Ten-Day Return: EW highest at 2.7%; BAX lowest at -4.7% Twenty-One Days Return: BDX highest at 7.6%; BAX lowest at -9.4% While BAX stock looks like it can see higher levels, it is helpful to see how Baxter’s Peers fare on metrics that matter. Total [2] BAX Return -11% -42% 13% S&P 500 Return -6% -20% 71% Trefis Multi-Strategy Portfolio -6% -23% 212% [1] Month-to-date and year-to-date as of 12/23/2022 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2022-12-27,108.3499984741211,108.56999969482422,-1.091538111038289,Abbott (ABT) Gains As Market Dips: What You Should Know | Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know,"Abbott (ABT) closed at $108.57 in the latest trading session, marking a +0.36% move from the prior day. ABT's full-year Zacks Consensus Estimates are calling for earnings of $5.21 per share and revenue of $43.03 billion. Also, we should mention that ABT has a PEG ratio of 4.08. | Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions."
2022-12-23,107.66999816894533,108.18000030517578,0.20304681476822659,,
2022-12-22,107.70999908447266,108.02999877929688,0.473671537943382,FOCUS-U.S. baby formula shortage leads to boom in advertisements | Abbott's (ABT) FreeStyle Libre 3 Integrates With AID System | 2 Beaten-Down Growth Stocks Set to Rebound in 2023 | Is A Rise Imminent For Guardant Health Stock After A 38% Fall In A Month?,"The months-long closure of Abbott Laboratories' ABT.N formula plant in Michigan, after complaints of bacterial infections in infants, eroded the Similac maker's market share. Formula makers have stepped up marketing campaigns to grab a bigger piece of the lucrative, $5.6 billion formula market, after a severe shortage earlier this year shook consumer confidence, said Allen Sayler, an industry consultant. The last significant U.S. TV advertising campaign for formula was in 2017, when Enfamil ran commercials for its formula for toddlers over 1 year old, according to ISpotTV. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report ORTHOFIX MEDICAL INC. (OFIX) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report ShockWave Medical, Inc. (SWAV) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT recently announced that its FreeStyle Libre 3 sensor integrated with the mylife Loop solution — building a smart, automated process to deliver insulin based on real-time glucose data. Significance of the Integration By Integrating CamDiab's CamAPS FX mobile app and Ypsomed's mylife YpsoPump with accurate, real-time data from Abbott's FreeStyle Libre 3 sensor, the connected solution continuously tracks a person's glucose levels, adjusts and delivers the coorect amount of insulin at the right time, reduces diabetes complications and helps diabetes patients reach better treatment targets. | Take, for instance, medical device giants Intuitive Surgical (NASDAQ: ISRG) and Abbott Laboratories (NYSE: ABT). Intuitive Surgical Despite a terrible performance this year, Intuitive Surgical seems to be recovering -- that is, if its performance in the past three months is any indication. Intuitive Surgical's revenue increased by about 11% year over year in the third quarter to $1.56 billion, while its adjusted earnings per share (EPS) remained flat at $1.19. | Guardant Health stock (NASDAQ: GH), a healthcare company that offers non-invasive cancer diagnosis tests, has seen a fall of 38% in a month, while it’s down 70% this year. Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using the last seven years’ data After moving -34% or more over five days, the stock rose on 67% of the occasions in the next five days. Total [2] GH Return -42% -70% -20% S&P 500 Return -6% -20% 71% Trefis Multi-Strategy Portfolio -7% -23% 209% [1] Month-to-date and year-to-date as of 12/20/2022 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2022-12-21,107.08999633789062,108.13999938964844,0.2970937680291462,Abbott : FreeStyle Libre 3 Integrated With Automated Insulin Delivery System Mylife Loop In Germany,"(RTTNews) - Abbott (ABT) announced that its FreeStyle Libre 3 sensor is now compatible with the mylife Loop solution from partners, Ypsomed and CamDiab, creating a smart, automated process to deliver insulin based on real-time glucose data. Integrating CamDiab's CamAPS FX mobile app and Ypsomed's mylifeTM YpsoPump with accurate, real-time data from Abbott's FreeStyle Libre 3 sensor, the connected solution continuously monitors a person's glucose levels, and automatically adjusts and delivers the right amount of insulin at the right time, removing the guesswork of insulin dosing and helping people with diabetes reach better treatment targets. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2022-12-20,106.61000061035156,106.48999786376952,0.9804865885370285,What Stocks To Buy Today? 3 Dividend Aristocrats To Watch | 2 Exceptional Dividend Growth Stocks to Buy Now | Here's Why You Should Retain Abbott (ABT) Stock for Now | Abbott's (ABT) Eterna SCS System Receives FDA's Approval,"With that being said, let’s take a look at three dividend aristocrats to check out in thestock market today Dividend Aristocrats To Watch Right Now Abbott Laboratories (NYSE: ABT) Archer-Daniels-Midland Company (NYSE: ADM) Dover Corporation (NYSE: DOV) Abbott Laboratories (ABT Stock) Leading off, Abbott Laboratories (ABT) is a healthcare company that operates in a wide range of markets, including pharmaceuticals, medical devices, and consumer healthcare products. This month, the company announced that its Board of Directors has declared an increase in ABT’s quarterly dividend on common stock. In the last month of trading action, shares of ABT stock have started to recover by 2.40%, though shares are still down 23.50% year-to-date. | AbbVie looks like a great dividend growth stock to buy despite the impending loss of U.S. Humira sales. CVS Health At the current share price, CVS Health (NYSE: CVS) offers a 2.5% yield. And while CVS Health may be a bit infamous for the extraordinarily long receipts customers receive when shopping at its ubiquitous chain of retail pharmacies, it's the less-visible parts of the business that make it a great dividend growth stock to buy. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report ShockWave Medical, Inc. (SWAV) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT is well-poised for growth in the coming quarters, courtesy of its solid Diabetes business. This business achieved robust organic sales growth in the third quarter of 2022, led by strong growth in FreeStyle Libre. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report ORTHOFIX MEDICAL INC. (OFIX) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report ShockWave Medical, Inc. (SWAV) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT recently received FDA approval for its Eterna spinal cord stimulation (SCS) system for treating chronic pain. Some better-ranked stocks in the broader medical space that investors can consider are ShockWave Medical, Inc. SWAV, Orthofix Medical Inc. OFIX and Merit Medical System MMSI."
2022-12-19,106.73999786376952,106.58999633789062,-0.1125623730372566,Abbott (ABT) Stock Moves -0.3%: What You Should Know | Validea's Top Five Healthcare Stocks Based On Peter Lynch - 12/19/2022 | Validea's Top Five Healthcare Stocks Based On John Neff - 12/19/2022 | Abbott Says FDA Approves Eterna Spinal Cord Stimulation System To Treat Chronic Pain,"Abbott (ABT) closed the most recent trading day at $106.59, moving -0.3% from the previous trading session. We can also see that ABT currently has a PEG ratio of 4.03. ABT's industry had an average PEG ratio of 2.2 as of yesterday's close. | Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT> Full Factor Report for ABT> More details on Validea's Peter Lynch strategy Peter Lynch Stock Ideas About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Detailed Analysis of REGENERON PHARMACEUTICALS INC Full Guru Analysis for REGN> Full Factor Report for REGN> ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Its Established Pharmaceutical Products segment includes gastroenterology products, women's health products, cardiovascular and metabolic products, pain and central nervous system products and respiratory drugs and vaccines. | Detailed Analysis of ENSIGN GROUP INC Full Guru Analysis for ENSG> Full Factor Report for ENSG> ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT> Full Factor Report for ABT> AMERISOURCEBERGEN CORP. (ABC) is a large-cap growth stock in the Major Drugs industry. The U.S. Healthcare Solutions segment distributes an offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. | (RTTNews) - Abbott (ABT) announced Monday the U.S. Food and Drug Administration (FDA) approval of the company's Eterna spinal cord stimulation (SCS) system, which is the smallest implantable, rechargeable spinal cord stimulator currently available on the market for the treatment of chronic pain. Eterna SCS utilizes Abbott's proprietary low-dose BurstDR stimulation, the only SCS waveform technology with the highest level of clinical evidence (1A evidence), proven to reduce pain 23% more than traditional waveform technology approaches. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2022-12-16,107.6999969482422,106.91000366210938,-0.14052981907526033,"XLV, ABBV, ABT, DHR: Large Inflows Detected at ETF | Want $250 in Passive Income? Buy These 2 Dividend Kings and Wait | 2 Top Dividend Stocks to Buy Hand Over Fist Before 2023","Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.6%, Abbott Laboratories (Symbol: ABT) is off about 2.2%, and Danaher Corp (Symbol: DHR) is lower by about 2.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $302.6 million dollar inflow -- that's a 0.7% increase week over week in outstanding units (from 306,620,000 to 308,820,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $118.75 per share, with $143.42 as the 52 week high point — that compares with a last trade of $135.37. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a leading option for passive income investors, thanks to its perpetually rising dividend and its relatively low level of risk. Its forward dividend yield of around 1.8% isn't going to make you rich anytime soon, but the low yield is mitigated by the company's long-standing commitment to dividend growth spanning more than 50 years. That means if you were to invest around $8,064 today, it would yield you $150 in dividends per year, and if we (quite reasonably) assume that your payout will grow by at least the same CAGR moving forward, you'd only need to hold your shares for about five years before you'd be making just over $251 annually. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) recently raised its quarterly dividend by 8.5%. But Target is actually a terrific dividend stock. Like Target, Abbott is a Dividend King."
2022-12-15,109.8499984741211,108.5199966430664,-0.7335128212793514,Pick Either Intuitive Surgical Or Its Industry Peer – Both May Offer Similar Returns | What's Next For Boston Scientific Stock After An 11% Rise In A Month? | ABT Makes Notable Cross Below Critical Moving Average,"We believe that Intuitive Surgical stock (NASDAQ: ISRG) and Edwards Lifesciences stock (NYSE: EW), in the medical devices industry, will likely give similar returns over the next three years. We compare a slew of factors, such as historical revenue growth, returns, and valuation, in an interactive dashboard analysis of Intuitive Surgical vs. Edwards Lifesciences: Which Stock Is A Better Bet? The table below summarizes our revenue and return expectations for Intuitive Surgical and Edwards Lifesciences over the next three years and points to an expected return of 44% for ISRG over this period vs. a 41% expected return for EW stock, implying that both stocks offer good buying opportunity at current levels, based on Trefis Machine Learning analysis – Intuitive Surgical vs. Edwards Lifesciences – which also provides more details on how we arrive at these numbers. | Of 247 instances in the last ten years that BSX stock saw a twenty-one-day rise of 11% or more, 145 resulted in BSX stock rising over the subsequent one-month period (twenty-one trading days). Boston Scientific (BSX) Stock Return (Recent) Comparison With Peers Five-Day Return: SYK highest at 7.8%; ILMN lowest at 2.3% Ten-Day Return: SYK highest at 11.8%; ILMN lowest at 1.1% Twenty-One Day Return: SYK highest at 13.2%; ILMN lowest at -13.2% may have moved, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. Total [2] BSX Return 4% 11% 118% S&P 500 Return -1% -16% 80% Trefis Multi-Strategy Portfolio 0% -18% 231% [1] Month-to-date and year-to-date as of 12/14/2022 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Thursday, shares of Abbott Laboratories (Symbol: ABT) crossed below their 200 day moving average of $109.08, changing hands as low as $109.04 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $93.25 per share, with $142.60 as the 52 week high point — that compares with a last trade of $109.45. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other dividend stocks recently crossed below their 200 day moving average » Also see: • TRST Dividend Growth Rate • M Average Annual Return • TLT Videos The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2022-12-14,111.37000274658205,111.26000213623048,-1.2107436044871813,,
2022-12-13,112.31999969482422,111.52999877929688,-0.09877041181534714,"Why Abbott Laboratories Topped the Market on Tuesday | Abbott (ABT) Outpaces Stock Market Gains: What You Should Know | Noteworthy Tuesday Option Activity: XRX, PAR, ABT","What happened Abbott Laboratories (NYSE: ABT) concocted a stock market win on Tuesday, with its shares rising nearly 2% on the day against the S&P 500's 0.7% gain. ""We view $4.41 as a beatable number, and we expect ABT to be rewarded as it enters a post-pandemic era of solid growth with far less exposure to COVID test sales,"" the analyst concluded. 10 stocks we like better than Abbott Laboratories When our award-winning analyst team has a stock tip, it can pay to listen. | In the latest trading session, Abbott (ABT) closed at $111.53, marking a +1.86% move from the previous day. Investors should also note that ABT has a PEG ratio of 4.13 right now. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | That number of contracts represents approximately 2.1 million underlying shares, working out to a sizeable 44.3% of ABT's average daily trading volume over the past month, of 4.8 million shares. Below is a chart showing PAR's trailing twelve month trading history, with the $25 strike highlighted in orange: And Abbott Laboratories (Symbol: ABT) options are showing a volume of 21,321 contracts thus far today. Particularly high volume was seen for the $110 strike put option expiring June 16, 2023, with 2,706 contracts trading so far today, representing approximately 270,600 underlying shares of ABT."
2022-12-12,107.7300033569336,109.48999786376952,-0.703348395364844,Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock,"Abbott (ABT) has recently been on Zacks.com's list of the most searched stocks. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions."
2022-12-09,106.7300033569336,107.51000213623048,1.6337087644977304,"Have $1,000? 2 Top Dividend Stocks to Buy Right Now | 2 Supercharged Dividend Stocks to Buy in a Bear Market","If you're looking to add more dividend stocks to your portfolio this month, it's important to focus on companies that not only regularly increase their payout to investors but have a long track record of maintaining their dividends even in difficult environments. In the first nine months of 2022, AbbVie's net revenue grew 4% year over year to $43 billion, while its net earnings for the same period jumped 25% year over year to $9.4 billion. Kimberly-Clark's resilient business can drive growth even in a changing macro environment, which makes the consumer staples stock a worthwhile addition to the long-term income investor's portfolio. | Abbott Laboratories With a company history spanning 130 years and counting, Abbott Laboratories (NYSE: ABT) is also one of a handful of stocks on the list of Dividend Kings. Its leading market share across a wide range of food categories, combined with a robust track record of returns and dividend growth, create a compelling buying proposition for this stock. See the 10 stocks *Stock Advisor returns as of December 1, 2022 Rachel Warren has no position in any of the stocks mentioned."
2022-12-08,104.66000366210938,106.91999816894533,0.7308149112376258,"Noteworthy ETF Outflows: XLV, ABT, DHR, BMY","Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is up about 1%, Danaher Corp (Symbol: DHR) is up about 1.4%, and Bristol Myers Squibb Co. (Symbol: BMY) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $401.7 million dollar outflow -- that's a 0.9% decrease week over week (from 309,520,000 to 306,620,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $118.75 per share, with $143.42 as the 52 week high point — that compares with a last trade of $139.61."
2022-12-07,104.0199966430664,104.80999755859376,2.159367884346969,Abbott (ABT) Gains As Market Dips: What You Should Know | 2 Dividend Aristocrats to Buy for 2023,"Abbott (ABT) closed the most recent trading day at $104.81, moving +0.91% from the previous trading session. ABT's full-year Zacks Consensus Estimates are calling for earnings of $5.21 per share and revenue of $43.03 billion. It is also worth noting that ABT currently has a PEG ratio of 3.92. | Heading into next year, a couple of Aristocrats that look to be good investments are Abbott Laboratories (NYSE: ABT) and ExxonMobil (NYSE: XOM). Buying shares of a Dividend Aristocrat can be a good move whether you want some recurring dividend income or just a safe stock to buy and hold. For investors looking for a safe stock to buy and hold next year, Abbott Labs makes for an appealing buy."
2022-12-06,104.98999786376952,103.86000061035156,0.7594702374757446,Got $500? Where to Invest It Before 2023 | Is AbbVie Stock a Buy Now?,"Abbott Laboratories Abbott Laboratories (NYSE: ABT) has four businesses: medical devices, diagnostics, nutrition, and established pharmaceuticals. Disney Disney (NYSE: DIS) is heading for a 35% decline this year. The Motley Fool has positions in and recommends Target and Walt Disney. | Together the two did $2.32 billion in sales in their first year -- already more than Humira did in its third year: Data sources: Abbott Laboratories and AbbVie. AbbVie CEO Rick Gonzalez, in the company's third-quarter earnings call, said he expected Skyrizi and Rinvoq to together bring in $7.5 billion in sales this year, ahead of earlier company estimates. ^SPX data by YCharts Abbvie stock is waiting for the bounce AbbVie's Gonzalez has said he expects the company, after the Humira patent cliff hits, to see erosion of as much as 45% of Humira's revenue (the drug brought in more than $20 billion last year and is on track to do so again this year)."
2022-12-05,106.88999938964844,105.41000366210938,-1.0762903861415354,,
2022-12-02,106.75,108.08999633789062,-1.3845970025165795,EXCLUSIVE -Reckitt expects U.S. infant formula shortage until spring,"Panicked parents had earlier this year emptied the baby formula aisles at supermarkets after former top U.S. manufacturer Abbott Laboratories ABT.N in February recalled dozens of types of its Similac, Alimentum and EleCare formulas. By Richa Naidu LONDON, Dec 2 (Reuters) - The near year-long infant formula shortage in the United States that prompted the intervention of the White House is likely to ""persist"" until spring, according to Reckitt Benckiser, the maker of what is now the biggest brand in the market, Enfamil. ""We are in close touch with top retailers who continue to have supplies of formula on hand, but may still lack all the sizes and varieties they once carried,"" the official said, adding that industry data shows U.S. formula production so far this year has outpaced 2021 levels."
2022-12-01,108.23999786376952,107.93000030517578,1.2552658902956675,Abbott (ABT) Gains As Market Dips: What You Should Know | EXCLUSIVE -Reckitt expects U.S. infant formula shortage until spring | EXCLUSIVE-Enfamil maker Reckitt sees formula shortage continuing until Spring,"Abbott (ABT) closed at $107.93 in the latest trading session, marking a +0.33% move from the prior day. We can also see that ABT currently has a PEG ratio of 4.06. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | Panicked parents had earlier this year emptied the baby formula aisles at supermarkets after former top U.S. manufacturer Abbott Laboratories ABT.N in February recalled dozens of types of its Similac, Alimentum and EleCare formulas. By Richa Naidu LONDON, Dec 1 (Reuters) - The near year-long infant formula shortage in the United States that prompted the intervention of the White House is likely to ""persist"" until spring, according to Reckitt Benckiser, the maker of what is now the biggest brand in the market, Enfamil. Its top position has been further boosted by the United States saying it will temporarily cover the cost of baby formula for low-income families dependent on government discounts in states contracted with the company. | Earlier this year, baby formula aisles at supermarkets were emptied by panicked parents after former top U.S. manufacturer Abbott Laboratories ABT.N in February recalled dozens of types of its Similac, Alimentum and EleCare formulas. By Richa Naidu LONDON, Dec 1 (Reuters) - A shortage of infant formula that has hit the United States for most of this year - prompting White House intervention - is likely to ""persist to some degree"" until spring, according to the maker of Enfamil, now the biggest brand in the market. Reckitt, whose share of the U.S. infant formula market has skyrocketed since the recall to make it the no.1 supplier in the market, said it has yet to see its newfound popularity recede."
2022-11-30,105.12999725341795,107.58000183105467,-0.2863983413819886,3 Top Dividend Kings to Buy for the Long Haul,"It has also earned the title of Dividend King due to its consistent dividend increases over the last 66 years, proving to investors how stable its business is despite market highs and lows. Despite market headwinds, P&G expects to generate 90% free cash flow productivity this fiscal year, allowing it to pay close to $9 billion in dividends and repurchase $6 billion to $8 billion of common stock. JNJ Dividend Yield data by YCharts Why these are safe stocks All three stocks pay out significantly more than the S&P 500's current average dividend yield of 1.6%."
2022-11-29,105.0,105.0,2.3304524318886206,"Notable ETF Outflow Detected - SPY, ABT, DHR, AMGN","Among the largest underlying components of SPY, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.5%, Danaher Corp (Symbol: DHR) is down about 0.5%, and Amgen Inc (Symbol: AMGN) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P 500 ETF Trust (Symbol: SPY) where we have detected an approximate $673.2 million dollar outflow -- that's a 0.2% decrease week over week (from 952,180,000 to 950,480,000). For a complete list of holdings, visit the SPY Holdings page » The chart below shows the one year price performance of SPY, versus its 200 day moving average: Looking at the chart above, SPY's low point in its 52 week range is $348.11 per share, with $479.98 as the 52 week high point — that compares with a last trade of $397.02."
2022-11-28,106.72000122070312,105.38999938964844,0.0,Is Trending Stock Abbott Laboratories (ABT) a Buy Now?,"Abbott (ABT) has recently been on Zacks.com's list of the most searched stocks. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions."
2022-11-25,106.66999816894533,106.95999908447266,-1.2462535755637474,,
2022-11-23,104.97000122070312,106.0199966430664,0.27186736711856163,"Want $10,000 in Annual Dividend Income by Retirement? Here's How Much You Should Invest in AbbVie Today. | Could an Investment in AbbVie Give You $10,000 in Annual Dividend Income by Retirement? | AbbVie Boosts Its Dividend: Is the Dividend King a Buy?","The drugmaker behind the popular arthritis medication Humira has an excellent track record for paying and increasing dividends, and below I'll show you how much you would need to invest in the stock today to get your annual dividend income up to $10,000 by retirement. Here's how dividend income from AbbVie's stock could grow to $10,000 If you were to hang on to AbbVie's stock and the company were to continue to raise its dividend payments by 5%, it could take 14 or more years for the payout to double. But if the company were to increase the dividend by 5% per year (on average), this is how much you would need to invest today to get to $10,000 in annual dividend income by retirement: Chart by author. | The drugmaker behind the popular arthritis medication Humira has an excellent track record for paying and increasing dividends, and below I'll show you how much you would likely need to invest in the stock today to get your annual dividend income up to $10,000 by retirement. Here's how dividend income from AbbVie's stock could grow to $10,000 If you were to hang on to AbbVie's stock and the company were to continue to raise its dividend payments by 5%, it could take 14 or more years for the payout to double. But if the company were to increase the dividend by 5% per year (on average), this is how much you would need to invest today to get to $10,000 in annual dividend income by retirement: Chart by author. | Hot off the 5% hike in its quarterly dividend per share to $1.48, this raises the following question: Is AbbVie still a buy for dividend growth investors after its sizable rally? In addition to double-digit growth in net revenue from the antipsychotic drug Vraylar and the aesthetics drug franchise Botox Cosmetic, this is how AbbVie reported $14.8 billion in net revenue during the quarter. Along with a 0.1% reduction in the company's weighted-average diluted share count to 1.8 billion, that's why the company's adjusted diluted EPS growth far exceeded its net revenue growth during the quarter."
2022-11-22,103.9800033569336,104.87000274658205,1.0002814234093689,2 Reasons to Buy AbbVie Stock and 1 Reason to Sell | Good Stocks To Invest In Now? 3 Dividend Aristocrats Stocks For Your List | Want Passive Income in 2023? Buy These Dividend Kings,"1 to sell: Humira sales will soon crater The biggest reason to sell AbbVie right now is that its star moneymaker, the immunosuppressive drug Humira, is going to become a lot less lucrative starting next year. 1 to buy: AbbVie's valuation The silver lining of Humira's looming demise is that it's keeping the stock priced at a cheaper valuation than it might be trading at otherwise. Next, examine this chart tracking the price-to-earnings ratios of AbbVie and some of its major competitors, such as Johnson & Johnson, Bristol Myers Squibb, and Gilead Sciences: ABBV PE Ratio data by YCharts At the moment, the stock isn't exactly a bargain buy, but it does compare favorably to its peers. | Dividend Aristocrats Stocks To Watch Now 3M Company (NYSE: MMM) Cardinal Health Inc. (NYSE: CAH) Abbott Laboratories (NYSE: ABT) 1. Abbott Laboratories (ABT Stock) Topping off this list we have Abbott Laboratories (ABT). Additionally, ABT said it expects FY 2022 earnings of $5.17 to $5.23 per share. | AbbVie AbbVie (NYSE: ABBV) launched back in 2013 as a spinoff of Abbott Laboratories (NYSE: ABT). Abbott Abbott and AbbVie share a common history -- and that includes prioritizing dividends. The company's history of dividend growth and earnings track record are reason to be optimistic about Abbott's dividend over the long term."
2022-11-21,103.7300033569336,103.87999725341795,0.8559332188068302,,
2022-11-18,103.5199966430664,103.87000274658205,0.1446003004243948,Abbott (ABT) Up 7.7% Since Last Earnings Report: Can It Continue?,"It has been about a month since the last earnings report for Abbott (ABT). Abbott Laboratories (ABT): Free Stock Analysis Report Abbott's Q3 Earnings and Revenues Beat Estimates Abbott reported third-quarter 2022 adjusted earnings of $1.15 per share, which exceeded the Zacks Consensus Estimate by 26.4%."
2022-11-17,102.66999816894533,102.55999755859376,0.33810482502472344,3 Reasons to Retain Abbott (ABT) Stock in Your Portfolio | 2 Reasons to Buy Abbott Labs and 1 Reason to Sell | 2 Stocks Down 75% and 26% to Buy Right Now,"Abbott Laboratories ABT is well poised for growth in the coming quarters, courtesy of its solid Diabetes business. Abbott Laboratories (ABT): Free Stock Analysis Report This business achieved robust organic sales growth in the third quarter of 2022, led by strong growth in FreeStyle Libre. | Abbott Laboratories (NYSE: ABT) is a huge healthcare company with more than 130,000 employees that operates in more than 160 countries. Medical Devices and Diagnostics brought in $3.6 billion and $3.7 billion in revenue, respectively, in the third quarter, while Nutrition and Established Pharmaceuticals brought in $1.8 billion and $1.3 billion, respectively. The bottom is falling out of the company's COVID-19 testing sales Last year, Abbott said its COVID-19 testing sales were approximately $7.7 billion. | And Abbott Laboratories (NYSE: ABT) is a diversified healthcare company that's awarded investors with dividend growth year after year. A diamond in the rough Keith Speights (Teladoc Health): I have bad news, good news, and great news about Teladoc Health. So right now is the perfect time to check out Teladoc, Abbott, and other beaten-down stocks that may boost your portfolio over time."
2022-11-16,104.23999786376952,103.61000061035156,-0.10713997498135192,"Shortages a Boon for These 2 Medical Device Stocks | VTV, CVX, ABT, NEE: Large Inflows Detected at ETF","Abbott Labs (ABT) One of the most popular products of medical device maker Abbott Labs is its Libre blood-sugar monitoring device. However, this may present upside potential for industry players like Baxter International (NYSE:BAX) and Abbott Labs (NYSE:ABT). BAX and ABT are making maximum use of the surging demand and increased prices. | Among the largest underlying components of VTV, in trading today Chevron Corporation (Symbol: CVX) is off about 0.5%, Abbott Laboratories (Symbol: ABT) is up about 0.9%, and NextEra Energy Inc (Symbol: NEE) is higher by about 1.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Value ETF (Symbol: VTV) where we have detected an approximate $1.2 billion dollar inflow -- that's a 1.1% increase week over week in outstanding units (from 731,450,766 to 739,581,733). For a complete list of holdings, visit the VTV Holdings page » The chart below shows the one year price performance of VTV, versus its 200 day moving average: Looking at the chart above, VTV's low point in its 52 week range is $122.54 per share, with $151.89 as the 52 week high point — that compares with a last trade of $141.79."
2022-11-15,103.4499969482422,103.13999938964844,-0.604371897859489,FDA to review baby formula production rules to prevent bacterial illness | Is Most-Watched Stock Abbott Laboratories (ABT) Worth Betting on Now?,"Nov 15 (Reuters) - The U.S. health regulator said on Tuesday it would review guidance and rules about manufacturing infant formula as part of its strategy to prevent bacterial illness similar to Abbott Laboratories' ABT.N products this year. The FDA's statement follows a major shortage of baby formula earlier this year due to a shutdown at Abbott's plant in Michigan after complaints of infection by a bacteria called cronobacter sakazakii. The plant shutdown and the recall of Abbott infant formula products deepened a supply shortage and sent parents in the United States scrambling. | Abbott (ABT) is one of the stocks most watched by Zacks.com visitors lately. Abbott Laboratories (ABT): Free Stock Analysis Report Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions."
2022-11-14,103.66999816894533,102.01000213623048,-0.2996593211586669,,
2022-11-11,104.63999938964844,104.08999633789062,-1.6012308884289155,,
2022-11-10,103.02999877929688,104.2300033569336,-0.5256145402961669,Becton Dickinson expects fiscal 2023 COVID test sales to drag | Better Buy: Johnson & Johnson vs. Abbott Laboratories | 3 Top Healthcare Stocks Defying the Bear Market,"A fall in COVID cases has also led rivals such as Abbott Laboratories ABT.N and Thermo Fisher Scientific TMO.N to forecast lower sales of coronavirus test kits. By Leroy Leo Nov 10 (Reuters) - Becton Dickinson and Co BDX.N on Thursday forecast a sharp decline in COVID-19 test sales for fiscal year 2023 as it expects the testing market to shrink next year with infections dropping. The medical equipment maker forecast COVID testing sales to be in the range of $125 million to $175 million for its current fiscal year, compared with $511 million it generated a year earlier. | If you're a risk-averse investor looking for stocks to buy, it's hard to go wrong with stalwarts in the healthcare industry such as Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ). The case for Johnson & Johnson One of the most attractive reasons to buy Johnson & Johnson right now is the company's pivot more toward growth. While Johnson & Johnson's stock is outperforming Abbott this year, over the past five years, Abbott's shareholders have been the big winners, earning returns of 80% -- dwarfing the 24% gains for Johnson & Johnson's stock during that time. | Through the first nine months, the company has earned revenue of $192.5 billion, up 14% year over year, while earnings per share (EPS) was $16.15, compared to $13.82 in the same period last year. In the third quarter, the company reported revenue of $14.8 billion, up 3.3% year over year, and EPS of $2.21, up 24.2% over the same period last year. In the third quarter, the company reported revenue of $2.3 billion, up 18% year over year, led by increased sales for its lead CF therapy Trikafta, which had $2 billion in sales in the quarter, up 29% over the same period last year."
2022-11-09,99.91000366210938,99.45999908447266,1.1647137647815355,,
2022-11-08,99.9000015258789,99.63999938964844,-0.45040993007928587,"Noteworthy ETF Outflows: UPRO, ACN, WFC, ABT | Investing $1,000 in the Current Market? Don't Overlook These 2 Winning Dividend Stocks","Among the largest underlying components of UPRO, in trading today Accenture plc (Symbol: ACN) is up about 1.5%, Wells Fargo & Co (Symbol: WFC) is trading flat, and Abbott Laboratories (Symbol: ABT) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $109.3 million dollar outflow -- that's a 5.0% decrease week over week (from 65,750,000 to 62,450,000). For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $25.94 per share, with $78.715 as the 52 week high point — that compares with a last trade of $33.63. | Whether providing additional capital that you can put back into your portfolio again and again, or increasing your total returns with time, the best dividend stocks are compelling investments that you can buy and hold for decades or even a lifetime. AbbVie AbbVie (NYSE: ABBV) is a member of the esteemed group of companies known as Dividend Kings, meaning it has increased its dividend annually for at least 50 consecutive years. In the most recent quarter, the company reported total revenue of $14.8 billion, a 3% increase year over year."
2022-11-07,98.77999877929688,99.5,-0.2602623946538336,"2 Reasons to Buy DexCom, and 1 Reason to Sell","Reason to buy #1: Massive whitespace ahead DexCom develops continuous glucose monitoring (CGM) devices that help diabetes patients with an essential function: tracking their blood sugar levels. CGM devices like DexCom's G6 compete with blood glucose meters (BGM) in helping people with diabetes with this critical task. In addition to an underpenetrated and rapidly growing industry, DexCom is developing newer devices to help diabetes patients achieve even better health outcomes."
2022-11-04,97.83000183105467,98.06999969482422,0.7288937331451241,Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know,"Abbott (ABT) is one of the stocks most watched by Zacks.com visitors lately. Abbott Laboratories (ABT): Free Stock Analysis Report Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions."
2022-11-03,96.80999755859376,96.4499969482422,0.24532133218601423,"The Zacks Analyst Blog Highlights Abbott Laboratories, ServiceNow, Schlumberger, Shopify and Workday","Stocks recently featured in the blog include: Abbott Laboratories ABT, ServiceNow, Inc. NOW, Schlumberger Ltd. SLB, Shopify Inc. SHOP and Workday, Inc. WDAY. Abbott Laboratories (ABT): Free Stock Analysis Report Here are highlights from Wednesday’s Analyst Blog: Top Research Reports for Abbott Labs, ServiceNow and Schlumberger The Zacks Research Daily presents the best research output of our analyst team."
2022-11-02,98.7300033569336,98.04000091552734,-0.37186305074914805,"NZ's a2 Milk gets temporary approval to export infant milk formula to U.S. | Got $5,000? Buy These 3 Dividend Kings And Hold Them Forever | Is DexCom a Good Healthcare Stock to Buy Now? | 3 Dividend-Paying Stocks to Buy in November and Hold Forever","The move will help plug a gap in baby food supply in the United States after Abbott Laboratories ABT.N, the biggest U.S. supplier of powder infant formula, in February recalled dozens of products after reports of serious bacterial infections in four infants. Adds details, background Nov 3 (Reuters) - New Zealand's a2 Milk Co Ltd ATM.NZ has received U.S. approval to export its infant milk formula to the Unites States as the country faces a shortage of baby food. Under the approval from the U.S. Food and Drug Administration (FDA), the dairy major will be able to sell and distribute its a2 Platinum infant milk formula product through to Jan. 6, 2023, the company said on Thursday. | Abbott Laboratories Much like Becton, Dickinson, Abbott Laboratories (NYSE: ABT) wears many hats. Whether you're looking to make some extra dough from dividend income or build defensive investments into your portfolio, Dividend Kings are stocks you should know about these days. Becton, Dickinson Becton, Dickinson (NYSE: BDX) is an ""everything company"" in the healthcare sector, selling everything from syringes to diagnostic tests, medical devices, and scientific instruments for use in biomedical research. | Its biggest rival, Abbott Laboratories (NYSE: ABT), received FDA clearance for its next-generation CGM, FreeStyle Libre 3, in May. Why DexCom soared in October On Oct. 28, DexCom stock jumped in response to a third-quarter earnings report that beat expectations on the top and bottom lines. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) is an ultra-reliable healthcare conglomerate that hasn't missed a quarterly dividend payment since 1924. CVS Health You're most likely familiar with CVS Health's (NYSE: CVS) chain of retail pharmacies and walk-in medical clinics. Moreover, the company hasn't gone over a year without raising its payout at least once for 50 consecutive years."
2022-11-01,99.62000274658205,99.30999755859376,-0.6988781707134345,"Baby formula maker Perrigo buying Nestle's Good Start brand, Wisconsin plant | This Groundbreaking Device Just Keeps Winning for Abbott Labs | Eli Lilly cuts annual profit forecast on stronger dollar","U.S. retailers have been rationing formula and putting it behind lock-and-key due to a severe shortage stemming from the closure of a Sturgis, Michigan, Abbott Laboratories ABT.N plant earlier this year. By Jessica DiNapoli NEW YORK, Nov 1 (Reuters) - Infant formula manufacturer Perrigo Company Plc PRGO.N said on Tuesday it is buying the Good Start brand and a Wisconsin plant that makes the product from Nestle SA NESN.S, as U.S. retailers recover from shortages of the good. Good Start is a relatively ""small player"" in the U.S. infant formula market, which is dominated by Abbott's Similac and Reckitt Benckiser Group Plc's RKT.L Enfamil, said Tarun Malkani, the CEO of Nestle's Gerber Product's Company, in an interview. | In late September, Abbott Laboratories (NYSE: ABT) shared encouraging results from a study that tracked the efficacy of its FreeStyle Libre continuous glucose monitor (CGM) device for type 2 diabetes. A device with life-changing results for patients Abbott retrospectively observed 5,933 patients diagnosed with type 2 diabetes via the French national health claims database between Aug. 1, 2017, and Dec. 31, 2018. Abbott's study followed a select group of patients 12 months before FreeStyle Libre initiation and up to 24 months after FreeStyle Libre initiation to assess the frequency of acute diabetes-related events (ADEs), which are emergencies warranting hospitalization. | Multinational companies such as Abbott Laboratories ABT. Adds details on earnings, background Nov 1 (Reuters) - Eli Lilly and Co LLY.N on Tuesday cut its annual profit forecast for the third time, as a stronger dollar piled more pressure on the drugmaker struggling with lower insulin prices and generic competition for its cancer drug. The company now expects adjusted full-year earnings of $7.70 to $7.85 per share, compared to its prior forecast of $7.90 to $8.05."
2022-10-31,99.12999725341795,98.94000244140624,-0.31118769267341495,,
2022-10-28,97.31999969482422,99.48999786376952,-0.19166227910408604,Is This Dividend King a Buy Near Its 52-Week Low?,"Down 30% so far in 2022, diversified healthcare company Abbott Laboratories (NYSE: ABT) is one such example. The medical devices business logged 6.4% organic sales growth year over year in the third quarter, while sales for its established pharmaceuticals segment surged 12%. Given Abbott's reputation and the fact that its earnings growth prospects are in line with the medical devices industry average of 12.2% a year, this is a rational price for long-term investors to pay."
2022-10-27,98.66999816894533,96.93000030517578,2.229755626541279,,
2022-10-26,98.08999633789062,98.41999816894533,-1.7634518050666994,,
2022-10-25,98.06999969482422,97.9499969482422,0.33642761074018634,Is Weakness In Abbott Laboratories (NYSE:ABT) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? | Are Options Traders Betting on a Big Move in Abbott (ABT) Stock?,"Abbott Laboratories (NYSE:ABT) has had a rough three months with its share price down 9.9%. NYSE:ABT Past Earnings Growth October 25th 2022 The basis for attaching value to a company is, to a great extent, tied to its earnings growth. Has the market priced in the future outlook for ABT? | Investors in Abbott ABT need to pay close attention to the stock based on moves in the options market lately. Abbott Laboratories (ABT): Free Stock Analysis Report Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other."
2022-10-24,96.0500030517578,98.29000091552734,-0.12236437947939582,Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It,"Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. Abbott Laboratories (ABT): Free Stock Analysis Report With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions."
2022-10-21,94.3499984741211,95.05999755859376,2.3321163900041664,"SPLG, PFE, TMO, ABT: ETF Inflow Alert | Want Passive Income? 3 Dividend Kings to Buy Right Now","Among the largest underlying components of SPLG, in trading today Pfizer Inc (Symbol: PFE) is up about 4.6%, Thermo Fisher Scientific Inc (Symbol: TMO) is off about 0.5%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Portfolio S&P 500 ETF (Symbol: SPLG) where we have detected an approximate $133.2 million dollar inflow -- that's a 1.0% increase week over week in outstanding units (from 308,850,000 to 311,950,000). For a complete list of holdings, visit the SPLG Holdings page » The chart below shows the one year price performance of SPLG, versus its 200 day moving average: Looking at the chart above, SPLG's low point in its 52 week range is $40.92 per share, with $56.44 as the 52 week high point — that compares with a last trade of $43.20. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) has increased its dividend for the past 50 years and is on the prestigious list of Dividend Kings. But there's another element that's part of a good investment story: stocks that will pay you a dividend year after year. Target Target (NYSE: TGT) has increased its dividend for the past 51 years."
2022-10-20,96.5199966430664,95.20999908447266,0.7525162649233254,"See Which Of The Latest 13F Filers Holds Abbott Laboratories | Want $1 Million in Retirement? Invest $250,000 in These 3 Stocks and Wait a Decade | Thursday's ETF with Unusual Volume: FTHI | Abbott's (ABT) Q3 Earnings Top Estimates, 2022 EPS View Up (Revised) | US STOCKS-Nasdaq futures fall as Tesla warns on 2022 deliveries","Existing +365 -$38 Hanson & Doremus Investment Management Existing -46 -$150 Aggregate Change: +2,079 -$2,723 In terms of shares owned, we count 5 of the above funds having increased existing ABT positions from 06/30/2022 to 09/30/2022, with 3 having decreased their positions. Nordea Investment Management AB 887,043 4-10 Find out the full Top 10 Hedge Funds Holding ABT » We'll keep following the latest 13F filings by hedge fund managers and bring you interesting stories derived from a look at the aggregate information across groups of managers between filing periods. At Holdings Channel, we have reviewed the latest batch of the 22 most recent 13F filings for the 09/30/2022 reporting period, and noticed that Abbott Laboratories (Symbol: ABT) was held by 15 of these funds. | Let's look at three stocks that stand an excellent chance of generating these kinds of returns: Intuitive Surgical (NASDAQ: ISRG), Abbott Laboratories (NYSE: ABT), and Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL). Intuitive Surgical Intuitive Surgical is a medical device company best-known for its da Vinci surgical system, which allows physicians to perform various minimally invasive procedures. The Motley Fool has positions in and recommends Alphabet (A shares), Alphabet (C shares), and Intuitive Surgical. | Netflix (NFLX) is the component faring the best Thursday, up by about 13.1% on the day, while Abbott Laboratories (ABT) is lagging other components of the First Trust BuyWrite Income ETF, trading lower by about 6.5%. The First Trust BuyWrite Income ETF (FTHI) is seeing unusually high volume in afternoon trading Thursday, with over 1.2 million shares traded versus three month average volume of about 77,000. Components of that ETF with the highest volume on Thursday were Advanced Micro Devices (AMD), trading off about 1.2% with over 72.8 million shares changing hands so far this session, and Apple (AAPL), up about 0.1% on volume of over 58.0 million shares. | Abbott Laboratories ABT reported third-quarter 2022 adjusted earnings of $1.15 per share, which exceeded the Zacks Consensus Estimate by 26.4%. Abbott Laboratories (ABT): Free Stock Analysis Report On an organic basis (excluding the impact of foreign exchange), sales improved 1.3% year over year in the reported quarter. | The main U.S. indexes fell after two days of gains on Wednesday as weakness in shares of Abbott Laboratories ABT.N and a rise in Treasury yields sapped momentum from the current earnings season and outweighed a surge in Netflix's shares. Futures down: Dow 0.13%, S&P 0.49%, Nasdaq 0.82% Oct 20 (Reuters) - U.S. stock index futures slipped on Thursday, with those of the Nasdaq taking the biggest hit, after Tesla failed to meet estimates for quarterly revenue and warned of missing its vehicle delivery target. ET, Dow e-minis 1YMcv1 were down 39 points, or 0.13%, S&P 500 e-minis EScv1 were down 18.25 points, or 0.49%, and Nasdaq 100 e-minis NQcv1 were down 91.75 points, or 0.82%."
2022-10-19,101.0,98.11000061035156,-1.3572291796052967,"US STOCKS-Equities close lower as rise in yields overshadows earnings | US STOCKS-Equities close lower as rise in yields overshadows earnings | Why Abbott Laboratories Stock Is Slumping Today | Notable Wednesday Option Activity: MTB, EA, ABT | US STOCKS-Wall St struggles as losses in Abbott counter Netflix's gains | Pre-Markets Give Some Back; Housing Starts Lower; PG, ABT Beat | Abbott Laboratories (ABT) Q3 2022 Earnings Call Transcript | U.S. Housing Starts Declined in September | Health Care Sector Update for 10/19/2022: ABT, JAZZ, ZYME, ISRG, XLV, IBB | Abbott's (ABT) Q2 Earnings Top Estimates, 2022 EPS View Up | Abbott (ABT) Q3 Earnings and Revenues Surpass Estimates | Abbott (ABT) Q3 Earnings and Revenues Surpass Estimates | Abbott Laboratories Boosts FY22 Outlook - Update | Abbott raises 2022 profit forecast for second time | Abbott Laboratories Q3 Profit Decreases, but beats estimates | Abbott raises 2022 profit forecast for second time | Abbott Laboratories Q3 22 Earnings Conference Call At 9:00 AM ET","U.S. 10-year Treasury yield hits highest since July 2008 Netflix jumps after reversing customer losses Procter & Gamble, Travelers post upbeat earnings PHLX Housing Index falls on weak U.S. housing data Dow down 0.33%, S&P 500 down 0.67%, Nasdaq down 0.85% Adds Tesla results, market trading volume By Chuck Mikolajczak NEW YORK, Oct 19 (Reuters) - U.S. stocks snapped a two-day streak of gains on Wednesday as weakness in shares of Abbott Laboratories ABT.N and a rise in Treasury yields sapped momentum from the current earnings season and outweighed a surge in Netflix Inc NFLX.O shares. The yield on the 10-year U.S. Treasury US10YT=RR note touched its highest level in more than 14 years as soft housing data did little to alter expectations the Federal Reserve will remain aggressive in hiking interest rates as it attempts to wrestle down stubbornly high inflation. ""Ultimately earnings drives stocks but when they are being overshadowed it is tough to have that optimism, but ultimately good earnings will lead to stocks going higher, it is a matter of how much the macroeconomic picture is going to continue to hurt those earnings."" | By Chuck Mikolajczak NEW YORK, Oct 19 (Reuters) - U.S. stocks snapped a two-day streak of gains on Wednesday as weakness in shares of Abbott Laboratories ABT.N and a rise in Treasury yields sapped momentum from the current earnings season and outweighed a surge in Netflix Inc NFLX.O shares. The yield on the 10-year U.S. Treasury US10YT=RR note touched its highest level in more than 14 years as soft housing data did little to alter expectations the Federal Reserve will remain aggressive in hiking interest rates as it attempts to wrestle down stubbornly high inflation. ""Ultimately earnings drives stocks but when they are being overshadowed it is tough to have that optimism, but ultimately good earnings will lead to stocks going higher, it is a matter of how much the macroeconomic picture is going to continue to hurt those earnings."" | What happened Shares of the diversified healthcare company Abbott Laboratories (NYSE: ABT) are having a rough session today. 10 stocks we like better than Abbott Laboratories When our award-winning analyst team has a stock tip, it can pay to listen. * They just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! | Below is a chart showing EA's trailing twelve month trading history, with the $115 strike highlighted in orange: And Abbott Laboratories (Symbol: ABT) saw options trading volume of 31,212 contracts, representing approximately 3.1 million underlying shares or approximately 51.7% of ABT's average daily trading volume over the past month, of 6.0 million shares. Especially high volume was seen for the $100 strike call option expiring November 18, 2022, with 2,904 contracts trading so far today, representing approximately 290,400 underlying shares of ABT. Below is a chart showing ABT's trailing twelve month trading history, with the $100 strike highlighted in orange: For the various different available expirations for MTB options, EA options, or ABT options, visit StockOptionsChannel.com. | Abbott Laboratories ABT.N tumbled 8.08% after reporting lower-than-expected growth in international medical device sales, hit by a strong dollar and supply challenges in China. U.S. 10-year Treasury yield at highest since July 2008 Netflix jumps after reversing customer losses Tesla third quarter earnings awaited Procter & Gamble, Travelers post upbeat earnings PHLX Housing Index falls 3% on weak U.S. housing data Indexes down: Dow 0.16%, S&P 0.55%, Nasdaq 0.64% Updates prices through out, adds comments By Ankika Biswas and Shreyashi Sanyal Oct 19 (Reuters) - Wall Street's main indexes struggled to gain on Wednesday as weakness in shares of Abbott countered gains in Netflix, leaving investors muddled about the ongoing earnings momentum. The PHLX Housing Index .HGX fell 3.70%, adding more pain to stock markets attempting to break out of months of declines, with the three main indexes remaining deep in bear market territory. | Abbott Labs ABT also posted a positive surprise in its Q3 report this morning: earnings of $1.15 per share easily surpassed the 91 cents expected (though still down from the $1.40 per share in the year-ago quarter), for a +26.37% beat. For more on ABT’s earnings, click here. Abbott Laboratories (ABT): Free Stock Analysis Report | Operator [Operator signoff] Duration: 0 minutes Call participants: Scott Leinenweber -- Vice President of Investor Relations, Licensing, and Acquisition Robert Ford -- Chairman and Chief Executive Officer Bob Funck -- Executive Vice President, Finance, and Chief Financial Officer Robbie Marcus -- JPMorgan Chase and Company -- Analyst Larry Biegelsen -- Wells Fargo Securities -- Analyst Joanne Wuensch -- Citi -- Analyst Josh Jennings -- Cowen and Company -- Analyst Vijay Kumar -- Evercore ISI -- Analyst Travis Steed -- Bank of America Merrill Lynch -- Analyst More ABT analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Abbott Laboratories (NYSE: ABT) Q3 2022 Earnings Call Oct 19, 2022, 9:00 a.m. Robert Ford -- Chairman and Chief Executive Officer Yes, I think that's -- looking at the market between government contracts and nongovernment contracts is something that we spent a lot of time this year doing because obviously, those government contracts, they're high-volume and they ultimately skew a little bit of kind of the run rate as we're trying to kind of run rate this. | Abbott Labs (ABT) also posted a positive surprise in its Q3 report this morning: earnings of $1.15 per share easily surpassed the 91 cents expected (though still down from the $1.40 per share in the year-ago quarter), for a +26.37% beat. Abbott Laboratories (ABT): Free Stock Analysis Report Housing Starts for the month of September came in lower than expectations, with 1.439 million seasonally adjusted, annualized starts beneath the 1.47 million expected. | Abbott Laboratories (ABT) was declining by 3.8% after it reported Q3 adjusted earnings of $1.15 per diluted share, down from $1.40 a year earlier. Jazz Pharmaceuticals (JAZZ) and Zymeworks' (ZYME) subsidiary Zymeworks BC Inc. have entered into an exclusive licensing deal in which Jazz will be allowed to develop and commercialize Zymeworks' zanidatamab, a HER2-targeted bispecific antibody that the companies said has shown anti-tumor activity in several HER2-expressing cancers. Intuitive (ISRG) reported Q3 non-GAAP earnings of $1.19 per diluted share, flat from a year earlier. | Abbott Laboratories ABT reported third-quarter 2022 adjusted earnings of $1.15 per share, which exceeded the Zacks Consensus Estimate by 26.4%. Abbott Laboratories (ABT): Free Stock Analysis Report Abbott Laboratories Price, Consensus and EPS Surprise Abbott Laboratories price-consensus-eps-surprise-chart | Abbott Laboratories Quote Medical Devices business sales dropped 0.5% on a reported basis (up 6.4% on an organic basis) to $3.62 billion. | Abbott (ABT) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $0.91 per share. Abbott Laboratories (ABT): Free Stock Analysis Report Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $10.41 billion for the quarter ended September 2022, surpassing the Zacks Consensus Estimate by 8.67%. | Abbott (ABT) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $0.91 per share. Abbott Laboratories (ABT): Free Stock Analysis Report Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $10.41 billion for the quarter ended September 2022, surpassing the Zacks Consensus Estimate by 8.67%. | (RTTNews) - While reporting financial results for the third quarter on Wednesday, Abbott Laboratories (ABT) raised its earnings and adjusted earnings guidance for the full-year 2022. For fiscal 2022, the company now projects earnings in a range of $3.75 to $3.81 per share and adjusted earnings in a range of $5.17 to $5.23 per share. Previously, the company expected earnings of at least $3.50 per share and adjusted earnings of at least $4.90 per share. | Adds third-quarter results Oct 19 (Reuters) - Abbott Laboratories ABT.Non Wednesday raised its annual earnings forecast for the second time, citing strong demand for medical devices and pharmaceutical products. The company's medical devices sales grew 11% in the United States in the third quarter, driven by strong performance of its Freestyle Libre continuous glucose monitoring system, which clocked around $1 billion in sales. The company now expects $5.17-$5.23 per share in adjusted earnings this year, compared to at least $4.90 per share it forecast earlier. | (RTTNews) - Abbott Laboratories (ABT) revealed a profit for third quarter that decreased from the same period last year but beat the Street estimates. This compares with $2.10 billion, or $1.17 per share, in last year's third quarter. The company's revenue for the quarter fell 4.8% to $10.41 billion from $10.93 billion last year. | Oct 19 (Reuters) - Abbott Laboratories ABT.Non Wednesday raised its annual earnings forecast for the second time, citing strong demand for medical devices and pharmaceutical products. The company now expects $5.17-$5.23 per share in adjusted earnings this year, compared to at least $4.90 per share it forecast earlier. (Reporting by Leroy Leo and Bhanvi Satija in Bengaluru; Editing by Maju Samuel) ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on Oct. 19, 2022, to discuss Q3 22 earnings results. To access the live webcast, log on to https://www.abbottinvestor.com/news-and-events?c=94004&p=irol-calall The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2022-10-18,105.80999755859376,104.9800033569336,-2.861385534305384,"Abbott Laboratories Shares Approach 52-Week Low - Market Mover | Pre-Market Earnings Report for October 19, 2022 : PG, ABT, ELV, PLD, TRV, MTB, NDAQ, BKR, NTRS, CFG, CMA, ALLY | Pre-Market Earnings Report for October 19, 2022 : PG, ABT, ELV, PLD, TRV, MTB, NDAQ, BKR, NTRS, CFG, CMA, ALLY | The Zacks Analyst Blog Highlights Apple, Abbott Laboratories, International Business Machines, Estee Lauder and Progressive","Abbott Laboratories (ABT) shares closed today at 2.0% above its 52 week low of $96.22, giving the company a market cap of $183B. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 228.9% The company's stock price performance over the past 12 months lags the peer average by 709.5% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 287.4% higher than the average peer. This story was produced by the Kwhen Automated News Generator. | Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABT is 20.70 vs. an industry ratio of 1.30, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories (ABT)is reporting for the quarter ending September 30, 2022. In the past year ABT has beat the expectations every quarter. | Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABT is 20.70 vs. an industry ratio of 1.30, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories (ABT)is reporting for the quarter ending September 30, 2022. In the past year ABT has beat the expectations every quarter. | Stocks recently featured in the blog include: Apple Inc. AAPL, Abbott Laboratories ABT, International Business Machines Corp. IBM, The Estée Lauder Companies Inc. EL, and The Progressive Corporation PGR. Abbott Laboratories (ABT): Free Stock Analysis Report Here are highlights from Monday’s Analyst Blog: Q3 Earnings Scorecard and Analyst Reports for Apple, Abbott, IBM and Others The Zacks Research Daily presents the best research output of our analyst team."
2022-10-17,102.12000274658205,103.5199966430664,-0.784419450723973,"Q3 Earnings Scorecard and Analyst Reports for Apple, Abbott, IBM & Others | 3 Dividend Stocks to Buy Now for a Lifetime of Passive Income","Today's Research Daily features a real-time update on the ongoing Q3 earnings season and new research reports on 16 major stocks, including Apple Inc. (AAPL), Abbott Laboratories (ABT) and International Business Machines Corporation (IBM). If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Robust Portfolio, Services Strength to Benefit Apple (AAPL) Abbott (ABT) Thrives on Procedure Volume Gain, iCGM Launch IBM Rides on Solid Business Mix, Healthy Productivity Gains Featured Reports The Estee Lauder Companies (EL) Benefits From Online Business Per the Zacks analyst, The Estee Lauder Companies is gaining on solid online sales. Abbott Laboratories (ABT): Free Stock Analysis Report | Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a healthcare conglomerate that offers a 1.9% yield at the moment. CVS Health Most of us are familiar with CVS Health's (NYSE: CVS) enormous chain of retail pharmacies and medical clinics. CVS Health is a great dividend stock to buy because it usually manages the healthcare benefits folks receive at its physical locations."
2022-10-14,103.18000030517578,100.91000366210938,1.3709301398654914,Abbott (ABT) Stock Moves -1.52%: What You Should Know | Abbott recalls some ready-to-feed baby formula over bottle defect | Here's How Investors Can Find Strong Medical Stocks with the Zacks ESP Screener,"In the latest trading session, Abbott (ABT) closed at $100.91, marking a -1.52% move from the previous day. Meanwhile, ABT's PEG ratio is currently 3.88. To follow ABT in the coming trading sessions, be sure to utilize Zacks.com. | Adds background Oct 14 (Reuters) - Abbott Laboratories ABT.N said on Friday it was recalling some ready-to-feed baby formula products including Similac-branded items due to inadequate sealing of some bottle caps. The recall is one more setback for Abbott, which has been at the center of a baby formula shortage in the United States that sent parent scrambling for supplies earlier this year. A recall and temporary halt of production at its Michigan plant in February exacerbated a supply shortage of baby formula in the United States. | Abbott (ABT) holds a #3 (Hold) at the moment and its Most Accurate Estimate comes in at $0.91 a share five days away from its upcoming earnings release on October 19, 2022. Investors should also know that ABT is one of a large group of stocks with positive ESPs. ABT is one of just a large database of Medical stocks with positive ESPs."
2022-10-13,97.93000030517578,102.47000122070312,-2.200035507222747,"What To Expect From Intuitive Surgical's Q3? | What's in Store for Abbott Laboratories (ABT) in Q3 Earnings? | SPYG, ADBE, ORCL, ABT: Large Inflows Detected at ETF | Why the Bear Market May Not Be Over Anytime Soon","(1) Revenues expected to be marginally above the consensus estimates Trefis estimates Intuitive Surgical’s Q3 2022 revenues to be around $1.6 billion, slightly above the $1.5 billion consensus estimate. Note: P/E Multiples are based on Share Price at the end of the year and reported (or expected) Adjusted Earnings for the full year While ISRG stock looks undervalued, it is helpful to see how Intuitive Surgical’s Peers fare on metrics that matter. Total [2] ISRG Return -1% -48% 164% S&P 500 Return 0% -25% 60% Trefis Multi-Strategy Portfolio 0% -26% 192% [1] Month-to-date and year-to-date as of 10/12/2022 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT is slated to report third-quarter 2022 results on Oct 19, before market open. Abbott Laboratories (ABT): Free Stock Analysis Report Abbott Laboratories Price and EPS Surprise Abbott Laboratories price-eps-surprise | Abbott Laboratories Quote Worldwide Diagnostic sales are expected to have demonstrated growth in Q3 on the continuous rollout of Alinity, Abbott’s suite of diagnostic instruments as well as expanding menus across the company’s testing platforms. | Among the largest underlying components of SPYG, in trading today Adobe Inc (Symbol: ADBE) is down about 0.4%, Oracle Corp (Symbol: ORCL) is off about 2%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Portfolio S&P 500 Growth ETF (Symbol: SPYG) where we have detected an approximate $98.8 million dollar inflow -- that's a 0.8% increase week over week in outstanding units (from 239,600,000 to 241,600,000). For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $47.91 per share, with $73.64 as the 52 week high point — that compares with a last trade of $48.46. | Then there's Abbott Laboratories (NYSE: ABT), which voluntarily issued recalls on its baby formula products earlier this year. Many households are still holding lots of money in equities Another factor that looks to be still positively impacting the stock market is that more people are invested in stocks than is normally the case. The investment bank projects that next year, under challenging economic conditions and potentially higher unemployment, there could be many people pulling money out of the stock market; the bank expects households will sell up to $100 billion in stocks."
2022-10-12,101.25,100.08000183105467,4.635965384845808,What's Happening With Hologic Stock? | Will Abbott Stock Rise After Its Q3 Results? | Analysts Estimate Abbott (ABT) to Report a Decline in Earnings: What to Look Out for,"Hologic’s revenue rising a significant 69% to $5.2 billion over the last twelve months, compared to $3.1 billion in 2017, 2. a 10% fall in its total shares outstanding to 251 million, driven by $1.9 billion spent on share repurchases over this period, partly offset by 3. a 23% fall in the company’s P/S ratio to 3.0x trailing revenues currently, compared to 3.9x in 2017. The increase in revenue and a fall in shares outstanding have meant that Hologic’s revenue per share rose 88% to $20.82 over the last twelve months, vs. $11.08 in 2017. Total [2] HOLX Return -4% -19% 54% S&P 500 Return 1% -24% 61% Trefis Multi-Strategy Portfolio 1% -26% 195% [1] Month-to-date and year-to-date as of 10/11/2022 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Total [2] ABT Return 5% -28% 163% S&P 500 Return 1% -24% 61% Trefis Multi-Strategy Portfolio 1% -26% 195% [1] Month-to-date and year-to-date as of 10/11/2022 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott (NYSE: ABT) is scheduled to report its Q3 2022 results on Wednesday, October 19. Although we expect Abbott to post downbeat results in Q3, our forecast indicates that ABT stock has some room for growth from its current levels, as discussed below. | Wall Street expects a year-over-year decline in earnings on lower revenues when Abbott (ABT) reports results for the quarter ended September 2022. Abbott Laboratories (ABT): Free Stock Analysis Report The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate."
2022-10-11,100.8499984741211,101.75,-1.1555537471064956,"Ex-Dividend Reminder: AbbVie, Abbott Laboratories and American Express | Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know","Looking at the universe of stocks we cover at Dividend Channel, on 10/13/22, AbbVie Inc (Symbol: ABBV), Abbott Laboratories (Symbol: ABT), and American Express Co. (Symbol: AXP) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc (Symbol: ABBV): Abbott Laboratories (Symbol: ABT): American Express Co. (Symbol: AXP): In general, dividends are not always predictable, following the ups and downs of company profits over time. Similarly, investors should look for ABT to open 0.47% lower in price and for AXP to open 0.38% lower, all else being equal. | Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. Abbott Laboratories (ABT): Free Stock Analysis Report With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions."
2022-10-10,102.12000274658205,101.12999725341795,0.8924160034666275,What's Next For Eli Lilly Stock After Nearly A 3x Rise Since 2018? | After A 40% Fall This Year Illumina Stock Is A Better Pick Over Its Peer,"This 188% rise for LLY stock since late 2018 can primarily be attributed to 1. an 86% rise in the company’s P/S ratio to 10.3x trailing revenues currently, compared to 5.5x in 2018, 2. a 35% rise in Eli Lilly’s revenue to $29.1 billion over the last twelve months, compared to $21.5 billion in 2018, and 3. a 12% fall in its total shares outstanding to 900 million, driven by $7.7 billion the company spent on share repurchases over this period. The increase in revenue and a fall in shares outstanding have meant that Eli Lilly’s revenue per share rose 54% to $32.29 over the last twelve months, vs. $20.91 in 2018. Total [2] LLY Return 3% 21% 353% S&P 500 Return 4% -21% 67% Trefis Multi-Strategy Portfolio 7% -22% 211% [1] Month-to-date and year-to-date as of 10/7/2022 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Thermo Fisher Scientific’s Revenue Growth Has Been Better In Recent Years Illumina’s revenue growth of 49.2% over the last twelve months is much better than 11.9% for Thermo Fisher Scientific. Its 2% debt as a percentage of equity is lower than 14% for Thermo Fisher Scientific, while its 50% cash as a percentage of assets is higher than just 2% for the latter, implying that Illumina, with its better debt position and more cash cushion, offers lower financial risk compared to Thermo Fisher Scientific. The table below summarizes our revenue and return expectations for Illumina and Thermo Fisher Scientific over the next three years and points to an expected return of 30% for Illumina over this period vs. a 22% expected return for Thermo Fisher Scientific, implying that both are good investment opportunities currently."
2022-10-07,102.5,101.79000091552734,-0.9694530616306963,"Why DexCom Stock Popped on Friday, Even as the Market Crumbled | Abbott (ABT) Stock Moves -0.64%: What You Should Know","He views the news as ""an unequivocally positive development"" for DexCom and Abbott Laboratories (NYSE: ABT), its rival in the space. Investors shouldn't buy the stock solely based on this development, but there are plenty of other reasons to believe DexCom is a buy. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. | In the latest trading session, Abbott (ABT) closed at $101.79, marking a -0.64% move from the previous day. We can also see that ABT currently has a PEG ratio of 3.89. To follow ABT in the coming trading sessions, be sure to utilize Zacks.com."
2022-10-06,102.86000061035156,102.4499969482422,-0.6926820336318598,,
2022-10-05,102.16999816894533,103.37999725341795,-0.39860359680777513,Abbott (ABT) Gains As Market Dips: What You Should Know | 3 Dividend Stocks to Buy In October and Hold Forever,"In the latest trading session, Abbott (ABT) closed at $103.38, marking a +0.29% move from the previous day. Also, we should mention that ABT has a PEG ratio of 3.91. Abbott Laboratories (ABT): Free Stock Analysis Report | Abbott Laboratories Abbott Laboratories (NYSE: ABT) has been advancing various healthcare businesses for over 130 years. It's been 60 years since Abbott went more than a year without raising its dividend payout at least once. Abbott Laboratories has been able to raise its dividend payout 77% higher over the past five years."
2022-10-04,100.73999786376952,103.08000183105467,1.1842998004872318,"Noteworthy ETF Inflows: ITOT, DIS, MCD, ABT","Among the largest underlying components of ITOT, in trading today Walt Disney Co. (Symbol: DIS) is up about 2.9%, McDonald's Corp (Symbol: MCD) is up about 2%, and Abbott Laboratories (Symbol: ABT) is higher by about 2.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P Total U.S. Stock Market ETF (Symbol: ITOT) where we have detected an approximate $297.6 million dollar inflow -- that's a 0.8% increase week over week in outstanding units (from 484,650,000 to 488,300,000). For a complete list of holdings, visit the ITOT Holdings page » The chart below shows the one year price performance of ITOT, versus its 200 day moving average: Looking at the chart above, ITOT's low point in its 52 week range is $79.43 per share, with $108.15 as the 52 week high point — that compares with a last trade of $83.76."
2022-10-03,97.8000030517578,99.5199966430664,2.3228151845402447,Best Stocks To Buy During A Recession? 3 Defensive Stocks To Know,"In short, the company founded in 2013 as a spin-off from Abbott Laboratories (NYSE: ABT). With that being said, here are three defensive stocks for your list of stocks to watch during a recession in the stock market today. Defensive Stocks To Watch In October 2022 FedEx Corporation (NYSE: FDX) General Motors Company (NYSE: GM) AbbVie Inc. (NYSE: ABBV) 1."
2022-09-30,98.70999908447266,96.76000213623048,1.7586845988116704,This CGM Device Maker Is Likely To Outperform Abbott Stock,"The table below summarizes our revenue and return expectations for both companies over the next three years and points to an expected return of 21% for Abbott over this period and a 101% expected return for DexCom stock, implying that investors will likely be better off buying DXCM over ABT, based on Trefis Machine Learning analysis – Abbott vs. DexCom – which also provides more details on how we arrive at these numbers. We believe DexCom stock  (NASDAQ: DXCM) is currently a better pick than Abbott stock (NYSE: ABT), given its better prospects. If we look at stock returns, ABT, with a 30% fall this year, has fared better than a 39% decline for DXCM stock, but both have underperformed the broader S&P 500 index, down 23%."
2022-09-29,98.8499984741211,98.29000091552734,-1.9754806669316574,5 Dividend Growth Stocks With Upside To Analyst Targets,"NU Skin Enterprises, Inc. (Symbol: NUS) $35.36 $47.00 32.92% Abbott Laboratories (Symbol: ABT) $98.72 $127.15 28.80% Ecolab Inc (Symbol: ECL) $148.73 $188.56 26.78% Polaris Inc (Symbol: PII) $104.16 $125.56 20.54% NextEra Energy Inc (Symbol: NEE) $82.37 $97.89 18.84% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. NU Skin Enterprises, Inc. (Symbol: NUS) 4.36% 32.92% 37.28% Abbott Laboratories (Symbol: ABT) 1.90% 28.80% 30.7% Ecolab Inc (Symbol: ECL) 1.37% 26.78% 28.15% Polaris Inc (Symbol: PII) 2.46% 20.54% 23% NextEra Energy Inc (Symbol: NEE) 2.06% 18.84% 20.9% Another consideration with dividend growth stocks is just how much the dividend is growing. NU Skin Enterprises, Inc. (Symbol: NUS) $1.515 $1.535 1.32% Abbott Laboratories (Symbol: ABT) $1.71 $1.86 8.77% Ecolab Inc (Symbol: ECL) $1.92 $2.04 6.25% Polaris Inc (Symbol: PII) $2.51 $2.55 1.59% NextEra Energy Inc (Symbol: NEE) $1.505 $1.66 10.30% These five stocks are part of our full Dividend Aristocrats List."
2022-09-28,98.06999969482422,98.72000122070312,-0.5665124605341872,Medtronic Stock Is A Better Pick Over This Pharmaceuticals Bellwether | Want to Get Richer? 3 Top Stocks to Buy Now and Hold Forever,"We compare a slew of factors such as historical revenue growth, returns, and valuation multiple in an interactive dashboard analysis Medtronic vs. Johnson & Johnson: Which Stock Is A Better Bet? It rose at an average annual growth rate of 4.9% to $93.8 billion in 2021, compared to $81.6 billion in 2018, while Medtronic saw its revenue rise at an average annual rate of just 1.3% to $31.7 billion in fiscal 2022 (Medtronic’s fiscal ends in April), compared to $30.0 billion in 2018. The table below summarizes our revenue and return expectations for Medtronic and J&J over the next three years and points to an expected return of 14% for Medtronic over this period vs. an 8% expected return for J&J, based on Trefis Machine Learning analysis – Medtronic vs. Johnson & Johnson – which also provides more details on how we arrive at these numbers. | Abbott Laboratories You'll want to pick up Abbott Laboratories (NYSE: ABT) for two big reasons: Its diversified product profile and its dividend payments. Vertex Pharmaceuticals Vertex Pharmaceuticals (NASDAQ: VRTX) has been generating returns for investors for quite a while. And Intuitive's revenue and profit should continue to climb over time."
2022-09-27,100.25,98.33000183105467,0.6627934413190489,Abbott Laboratories Shares Near 52-Week Low - Market Mover | Abbott Laboratories Enters Oversold Territory,"Abbott Laboratories (ABT) shares closed today at 1.2% above its 52 week low of $97.57, giving the company a market cap of $172B. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 227.2% The company's stock price performance over the past 12 months lags the peer average by 249.3% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 250.6% higher than the average peer. This story was produced by the Kwhen Automated News Generator. | Among the fundamental datapoints dividend investors should investigate to decide if they are bullish on ABT is its dividend history. Abbott Laboratories (Symbol: ABT) presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most ""interesting"" ideas that merit further research by investors. But making Abbott Laboratories an even more interesting and timely stock to look at, is the fact that in trading on Tuesday, shares of ABT entered into oversold territory, changing hands as low as $97.91 per share."
2022-09-26,100.18000030517578,99.83999633789062,-1.9152101435863607,Abbott (ABT) Stock Moves -0.83%: What You Should Know | Good Stocks To Buy Right Now? 4 Healthcare Stocks To Know | 2 Growth Stocks Down 14% to 28% to Buy and Hold Forever,"Abbott (ABT) closed the most recent trading day at $99.84, moving -0.83% from the previous trading session. It is also worth noting that ABT currently has a PEG ratio of 3.73. To follow ABT in the coming trading sessions, be sure to utilize Zacks.com. | AbbVie (ABBV Stock) Following that, AbbVie Inc. (ABBV) is a global, research-based biopharmaceutical company formed in 2013 as a spin-off from Abbott Laboratories (NYSE: ABT). Healthcare Stocks To Buy [Or Sell] Right Now UnitedHealth Group Inc. (NYSE: UNH) Merck & Company Inc. (NYSE: MRK) AbbVie Inc. (NYSE: ABBV) CVS Health Corporation (NYSE: CVS) 1. CVS Health (CVS Stock) Rounding off the list, CVS Health Corporation (CVS) is an American healthcare company. | Let's examine two stocks worth keeping in this challenging market and beyond: Abbott Laboratories (NYSE: ABT) and Apple (NASDAQ: AAPL). ABT data by YCharts. Abbott Laboratories Abbott Laboratories focuses on medical devices, although it has a diversified business with multiple segments that allow it to navigate difficult times."
2022-09-23,100.38999938964844,100.68000030517578,-0.33939305874367226,Medical device makers see little impact from Fiona on Puerto Rico operations,"Integra Lifesciences IART.O and Abbott Laboratories ABT.N also upgraded back-up generators and communication capabilities and shored up infrastructure at plants such as improvements to roofs and pipes, their spokespeople said. By Leroy Leo and Khushi Mandowara Sept 23 (Reuters) - Medical device companies and some drugmakers with manufacturing operations in Puerto Rico said they do not expect meaningful disruption from Hurricane Fiona, which knocked out power for over 3 million people and caused flooding and landslides on the island. The U.S. Food and Drug Administration, which worked with companies to prevent shortages of drugs and medical devices after Hurricane Maria battered the medical manufacturing hub in 2017, said it is in discussion with companies it regulates there regarding any impact on supplies."
2022-09-22,100.0500030517578,101.06999969482422,0.2888743074912766,Abbott Laboratories Shares Approach 52-Week Low - Market Mover | Abbott (ABT) Reports Favorable Findings From RELIEF Study | December 16th Options Now Available For Abbott Laboratories (ABT),"Abbott Laboratories (ABT) shares closed today at 1.9% above its 52 week low of $98.81, giving the company a market cap of $176B. The stock closed at 1.1% lower than its 5-day moving average, 3.1% lower than its 20-day moving average, and 7.3% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 213.6% The company's stock price performance over the past 12 months lags the peer average by 180.7% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 281.2% higher than the average peer. | Abbott Laboratories ABT recently presented new data from the Real World Evidence of FreeStyle Libre (RELIEF) study at the 58th Annual European Association for the Study of Diabetes (EASD) meeting. Abbott Laboratories (ABT): Free Stock Analysis Report According to the latest findings, Type 2 diabetes patients receiving once-daily (basal) insulin therapy experienced a significantly lower rate of hospitalizations from acute diabetes events (ADEs) when using the FreeStyle Libre, a continuous glucose monitoring system (CGM). | Below is a chart showing ABT's trailing twelve month trading history, with the $105.00 strike highlighted in red: Considering the fact that the $105.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the December 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new December 16th contracts and identified one put and one call contract of particular interest."
2022-09-21,102.87000274658205,100.6500015258789,1.0194868685198906,Should You Buy Intuitive Surgical Stock Over This Healthcare Company?,"We believe Intuitive Surgical stock (NASDAQ: ISRG) is currently a better pick than Becton Dickinson stock (NYSE: BDX), despite ISRG being the more expensive of the two, with its P/S ratio of 12.4x, compared to just 3.5x for BDX stock. We compare a slew of factors such as historical revenue growth, returns, and valuation multiple in an interactive dashboard analysis Intuitive Surgical vs. Becton Dickinson: Which Stock Is A Better Bet? The table below summarizes our revenue and return expectations for Intuitive Surgical and Stryker over the next three years and points to an expected return of 63% for ISRG over this period vs. a 29% expected return for BDX stock, implying that both stocks offer good buying opportunity at current levels but if investors have to pick one, they will likely be better off buying ISRG over BDX, despite its high valuation, based on Trefis Machine Learning analysis – Intuitive Surgical vs. Becton Dickinson – which also provides more details on how we arrive at these numbers."
2022-09-20,102.79000091552734,102.30999755859376,-2.1580647044134555,,
2022-09-19,103.25,104.08999633789062,-0.4669747569396808,Abbott (ABT) Gains But Lags Market: What You Should Know,"In the latest trading session, Abbott (ABT) closed at $104.09, marking a +0.09% move from the previous day. Investors should also note that ABT has a PEG ratio of 3.85 right now. Abbott Laboratories (ABT): Free Stock Analysis Report"
2022-09-16,104.79000091552734,104.0,0.8135557751967313,"Daily Dividend Report: CIO,TXN,KR,ABT,INTC | Top Stock Reports for Alphabet, JPMorgan & Coca-Cola","VIDEO: Daily Dividend Report: CIO,TXN,KR,ABT,INTC The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. City Office REIT announced today that its Board of Directors has authorized a quarterly dividend amount of $0.20 per share of common stock and common unit of partnership interest for the third quarter of 2022. Abbott has increased its dividend payout for 50 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years. | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Alphabet (GOOGL) Benefits From Cloud & Search Initiatives Higher Rates, Buyouts Aid JPMorgan (JPM), Fee Income a Woe Coca-Cola's (KO) Digital Investments to Aid the Top Line Featured Reports Robust Diagnostics Sales Aids Abbott (ABT) Amid Forex Woes The Zacks analyst is encouraged by Abbott's growing Diagnostics revenue performance worldwide. (You can read the full research report on Coca-Cola here >>>) Other noteworthy reports we are featuring today include Abbott Laboratories (ABT), Salesforce, Inc. (CRM), and Linde plc (LIN). Abbott Laboratories (ABT): Free Stock Analysis Report"
2022-09-15,106.05999755859376,105.05999755859376,-0.7538895969322248,Should You Buy Baxter Stock Under $60? | This Healthcare Company Is Likely To Offer Better Returns Over Eli Lilly Stock | 7 Top-Rated Biotech Stocks to Buy for Q4 | Do Options Traders Know Something About Abbott (ABT) Stock We Don't?,"This 10% fall for Baxter stock since late 2017 can primarily be attributed to 1. a 33% decline in the company’s P/S ratio to 2.1x trailing revenues currently, compared to 3.1x in 2017, 2. an 11% rise in its total shares outstanding to 504 million, partly offset by 3. Baxter’s revenue rising 34% to $14.2 billion over the last twelve months, compared to $10.6 billion in 2017,  The rise in revenue and shares outstanding has meant that Baxter’s revenue per share rose only 20% to $28.16 over the last twelve months, vs. $23.38 in 2017. Total [2] BAX Return 1% -32% 31% S&P 500 Return -1% -17% 76% Trefis Multi-Strategy Portfolio 1% -15% 236% [1] Month-to-date and year-to-date as of 9/14/2022 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Although BDX stock is trading at a comparatively lower valuation of 3.6x trailing revenues, compared to 10.0x for LLY, this gap in valuation, to a large extent, makes sense, given Eli Lilly’s superior revenue growth, profitability, and lower financial risk, as discussed below. We compare a slew of factors such as historical revenue growth, returns, and valuation multiple in an interactive dashboard analysis of Eli Lilly vs. Becton Dickinson: Which Stock Is A Better Bet? The table below summarizes our revenue and return expectations for Eli Lilly and Becton Dickinson over the next three years and points to an expected return of -7% for Eli Lilly over this period vs. a 28% expected return for Becton Dickinson, implying that investors are better off buying BDX over LLY, based on Trefis Machine Learning analysis –Eli Lilly vs. Becton Dickinson – which also provides more details on how we arrive at these numbers. | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:ABBV) is one of the best-known biotech stocks in the U.S., after having spun off from Abbott Laboratories (NYSE:ABT). One way is to run biotech stocks through the Portfolio Grader, which is my tool to evaluate stocks on an “A” through  “F” scale, based on the stock’s earnings, momentum and performance, among other factors. Earnings per share also were better than expected – the company reported a loss of 7 cents per share, but the Street was expecting a loss of 8 cents per share. | Investors in Abbott Laboratories ABT need to pay close attention to the stock based on moves in the options market lately. Abbott Laboratories (ABT): Free Stock Analysis Report Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other."
2022-09-14,105.93000030517578,105.77999877929688,-0.9428625523468839,"Where to Invest $5,000 Right Now | Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?","Abbott Laboratories (NYSE: ABT) is one of my favorites for a few reasons. Given the extreme volatility the market has seen this year, you might be wondering whether it's still the right time to invest in the stock market. On that note, if you have $5,000 to invest in the stock market right now, here are two fantastic stocks to consider. | Looking at individual holdings, Thermo Fisher Scientific Inc (TMO) accounts for about 17.42% of total assets, followed by Abbott Laboratories (ABT) and Medtronic Plc (MDT). Abbott Laboratories (ABT): Free Stock Analysis Report First Trust Indxx Medical Devices ETF (MDEV) tracks INDXX GLOBAL MEDICAL EQUIPMENT INDEX and the SPDR S&P Health Care Equipment ETF (XHE) tracks S&P Health Care Equipment Select Industry Index."
2022-09-13,107.22000122070312,105.83999633789062,-0.14160438539296136,What's Happening With Cardinal Health Stock?,"Cardinal Health’s revenue rising 33% to $181 billion over the last twelve months, compared to $137 billion in 2017, 2. a 6% fall in its total shares outstanding to 294 million, partly offset by 3. a 7% decline in the company’s P/S ratio to 0.1x trailing revenues currently. While CAH stock looks fully priced, it is helpful to see how Cardinal Health’s Peers fare on metrics that matter. Total [2] CAH Return -1% 36% -3% S&P 500 Return 3% -15% 82% Trefis Multi-Strategy Portfolio 5% -12% 250% [1] Month-to-date and year-to-date as of 9/12/2022 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2022-09-12,108.77999877929688,109.29000091552734,-1.2870778465781576,"2 Dividend Aristocrats to Buy for Passive Income That Could Outperform the Market | A Look At The Intrinsic Value Of Abbott Laboratories (NYSE:ABT) | Abbott (ABT) Gains But Lags Market: What You Should Know | SPYG, DHR, NFLX, ABT: ETF Outflow Alert | Nestle's Gerber CEO sees formula shortage improving by October","Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a diversified healthcare conglomerate with a hand in diagnostics, medical devices, and nutrition. AbbVie AbbVie (NYSE: ABBV) was spun off from Abbott Laboratories in 2013 to shield Abbott's shareholders from the impending end of market exclusivity for the world's top-selling anti-inflammatory drug, Humira. Sales of Humira plus a growing roster of younger drugs have helped the company raise its payout a stunning 120% over the past five years. | NYSE:ABT Discounted Cash Flow September 12th 2022 The Assumptions Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. Today we will run through one way of estimating the intrinsic value of Abbott Laboratories (NYSE:ABT) by estimating the company's future cash flows and discounting them to their present value. Future Earnings: How does ABT's growth rate compare to its peers and the wider market? | Abbott (ABT) closed the most recent trading day at $109.29, moving +0.75% from the previous trading session. Meanwhile, ABT's PEG ratio is currently 4.02. Abbott Laboratories (ABT): Free Stock Analysis Report | Among the largest underlying components of SPYG, in trading today Danaher Corp (Symbol: DHR) is up about 1%, Netflix Inc (Symbol: NFLX) is up about 0.9%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Portfolio S&P 500 Growth ETF (Symbol: SPYG) where we have detected an approximate $166.8 million dollar outflow -- that's a 1.1% decrease week over week (from 261,450,000 to 258,550,000). For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $50.01 per share, with $73.64 as the 52 week high point — that compares with a last trade of $58.22. | Gerber added market share as it pumped out formula to meet the heightened demand during the shortage, caused by supply chain crunches and the closure of an Abbott Laboratories ABT.N plant in Michigan, Malkani said last Thursday during a media event at Nestle's U.S. headquarters in Arlington, Virginia. By Jessica DiNapoli NEW YORK, Sept 12 (Reuters) - Nestle SA's NESN.S Gerber Products Company is still in ""critical task force mode"" due to the U.S. infant formula shortage, its CEO Tarun Malkani said last week, adding that he expects the crunch to improve by October. Nestle also flew in infant formula supplies from Europe to the United States Major U.S. retailers including Walmart Inc WMT.N and Target Corp TGT.N both said last month they have seen formula supplies improve."
2022-09-09,107.12999725341795,108.4800033569336,0.4688381521912031,"Notable Friday Option Activity: WYNN, CL, ABT","That number of contracts represents approximately 1.9 million underlying shares, working out to a sizeable 41.7% of ABT's average daily trading volume over the past month, of 4.5 million shares. Below is a chart showing CL's trailing twelve month trading history, with the $80 strike highlighted in orange: And Abbott Laboratories (Symbol: ABT) options are showing a volume of 18,847 contracts thus far today. Especially high volume was seen for the $115 strike call option expiring January 20, 2023, with 4,739 contracts trading so far today, representing approximately 473,900 underlying shares of ABT."
2022-09-08,103.62999725341795,106.98999786376952,1.260156947752155,Why Abbot Stock Was a Winner Today | FDA warns of potential clip lock issue with Abbott's heart valve repair device | Abbott (ABT) Debuts Amplatzer Talisman System in Europe,"What happened Abbott Laboratories (NYSE: ABT) ended up outpacing the broader stock market on Thursday, with its share price rising by more than 2% against the 0.7% bump of the S&P 500 index. So what Abbott reported some highly encouraging data about its Amplatzer Piccolo Occluder, a device that treats a common congenital heart defect in infants called patent ductus arteriosus (PDA). Abbott's Amplatzer Piccolo Occluder is a wire mesh device inserted through an incision in the leg, then guided through blood vessels until it reaches the PDA site in the heart. | Sept 8 (Reuters) - The U.S. Food and Drug Administration on Thursday alerted healthcare providers about a potential clip lock issue with Abbott Laboratories' ABT.N MitraClip device used to stop heart valve leakage. The medical device treats mitral regurgitation, a condition in which the mitral valve of the heart does not close properly, causing blood leakage that can lead to stroke, heart attack or even death. The company said it has identified the cause of the clip lock malfunction and was working on producing new lots of the device with updated manufacturing processes and raw materials to mitigate the issue. | Abbott Laboratories ABT recently launched its Amplatzer Talisman PFO Occlusion System in Europe. Abbott Laboratories (ABT): Free Stock Analysis Report More About the Amplatzer Talisman System The Amplatzer Talisman system builds upon the company's industry-leading Amplatzer PFO Occluder."
2022-09-07,102.87999725341795,104.6999969482422,3.2423050269266915,,
2022-09-06,102.5,102.70999908447266,1.7690510725239952,Abbott (ABT) Gains As Market Dips: What You Should Know | FDA warns against use of Mother's Touch baby formula,"Abbott (ABT) closed the most recent trading day at $102.71, moving +0.2% from the previous trading session. Meanwhile, ABT's PEG ratio is currently 3.8. Abbott Laboratories (ABT): Free Stock Analysis Report | The directive comes as the United States recovers from a severe infant formula crunch that began with pandemic-led supply issues and worsened after Abbott ABT.N closed its Michigan plant in February due to reports of bacterial contamination. Sept 6 (Reuters) - The U.S. Food and Drug Administration (FDA) on Tuesday advised parents and caregivers against feeding Mother's Touch Formula to infants as the product has not undergone proper testing. The product has also not been tested to determine if it meets nutrient requirements, and contains label claims for seven nutrients that do not meet the requisite for infant formula."
2022-09-02,105.4499969482422,102.5,0.20487715558307928,,
2022-09-01,102.36000061035156,104.83999633789062,-2.7975315634102316,Abbott Laboratories Shares Approach 52-Week Low - Market Mover | 3 Dividend Stocks to Buy in September for Passive Income Generation,"Abbott Laboratories (ABT) shares closed today at 1.7% above its 52 week low of $100.79, giving the company a market cap of $183B. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 416.0% The company's stock price performance over the past 12 months lags the peer average by 231.3% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 379.3% higher than the average peer. This story was produced by the Kwhen Automated News Generator. | Shares of Abbott Laboratories (NYSE: ABT) have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. These three businesses are more than just reliable dividend payers; they're known for raising their dividend payouts year after year. CVS Health Shares of CVS Health (NYSE: CVS) surged late last year when the company announced that it would begin raising its dividend payout again."
2022-08-31,102.97000122070312,102.6500015258789,2.422817226212739,Foreign business travel missing ingredient for Irish hotel recovery - Dalata,"Ireland is the European base for technology companies like Google GOOGL.O, which, alongside pharmaceutical groups such as Pfizer PFE.N and Abbott ABT.N, are among the country's largest employers with the sector accounting for about one-in-nine workers in Ireland. By Padraic Halpin DUBLIN, Aug 31 (Reuters) - Executives at Ireland's large hub of multinational companies are still only going on a small fraction of the foreign business trips they made before the COVID-19 pandemic, the head of the country's largest hotel operator said. Dalata Hotel Group DHG.I, which has the Maldron and Clayton brands, said on Wednesday a strong rebound in leisure travel following the lifting of COVID-19 restrictions pushed first half revenue, average room rate and profit above 2019 levels."
2022-08-30,102.43000030517578,102.1999969482422,-0.3107698271638747,,
2022-08-29,101.5,101.83999633789062,-0.2245468673711968,Abbott Laboratories Shares Near 52-Week Low - Market Mover | Abbott: Study Shows HeartMate 3 Pump Extends Life Expectancy Of Advanced Heart Failure Patients | 5 Dividend Growth Stocks With Upside To Analyst Targets | Should You Buy Medtronic Stock Around $90?,"Abbott Laboratories (ABT) shares closed today at 1.4% above its 52 week low of $100.79, giving the company a market cap of $178B. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 378.6% The company's stock price performance over the past 12 months lags the peer average by 206.1% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 455.1% higher than the average peer. This story was produced by the Kwhen Automated News Generator. | (RTTNews) - Abbott (ABT) said the data from the MOMENTUM 3 trial showed its HeartMate 3 heart pump extended survival of advanced heart failure patients by at least five years. The company also noted that the latest MOMENTUM 3 data showed that the five-year survival for HeartMate 3 patients is approaching the five-year survival rates of heart transplant recipients who have a similar risk profile. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (Symbol: ABT) $101.90 $127.15 24.78% Ecolab Inc (Symbol: ECL) $165.26 $188.60 14.12% 3M Co (Symbol: MMM) $129.14 $146.00 13.06% NU Skin Enterprises, Inc. (Symbol: NUS) $42.28 $47.00 11.16% Polaris Inc (Symbol: PII) $116.97 $125.56 7.34% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Abbott Laboratories (Symbol: ABT) 1.84% 24.78% 26.62% Ecolab Inc (Symbol: ECL) 1.23% 14.12% 15.35% 3M Co (Symbol: MMM) 4.62% 13.06% 17.68% NU Skin Enterprises, Inc. (Symbol: NUS) 3.64% 11.16% 14.8% Polaris Inc (Symbol: PII) 2.19% 7.34% 9.53% Another consideration with dividend growth stocks is just how much the dividend is growing. Abbott Laboratories (Symbol: ABT) $1.71 $1.86 8.77% Ecolab Inc (Symbol: ECL) $1.91 $2.01 5.24% 3M Co (Symbol: MMM) $5.91 $5.95 0.68% NU Skin Enterprises, Inc. (Symbol: NUS) $1.515 $1.535 1.32% Polaris Inc (Symbol: PII) $2.5 $2.54 1.60% These five stocks are part of our full Dividend Aristocrats List. | At its current levels, MDT stock is trading under 16x its expected forward earnings, compared to the last three-year average of 20x, implying that MDT stock is attractive from a valuation point of view. After moving -5% or more over ten days, the stock rose in the next ten days on 59% of the occasions After moving -3% or more over a twenty-one-day period, the stock rose on 55% of the occasions in the next twenty-one days. Medtronic (MDT) Return (Recent) Comparison With Peers Five-Day Return: JNJ highest at -1.2%; MDT lowest at -5.9% Ten-Day Return: BSX highest at -1.7%; ISRG lowest at -7.3% Twenty-One Day Return: BSX highest at 8.4%; BAX lowest at -12.0% may have moved, 2020 has created many pricing discontinuities which can offer attractive trading opportunities."
2022-08-26,105.94000244140624,101.9000015258789,0.33497176146859603,,
2022-08-25,105.23999786376952,105.88999938964844,-3.8134801042333284,"Abbott (ABT) Gains But Lags Market: What You Should Know | Noteworthy Thursday Option Activity: NEM, WYNN, ABT | XLV, ABT, BMY, CVS: ETF Inflow Alert | Here's Why Intuitive Surgical Stock Is A Better Pick Over This Medical Devices Company","Abbott (ABT) closed at $105.89 in the latest trading session, marking a +0.43% move from the prior day. It is also worth noting that ABT currently has a PEG ratio of 3.91. Abbott Laboratories (ABT): Free Stock Analysis Report | Below is a chart showing WYNN's trailing twelve month trading history, with the $65 strike highlighted in orange: And Abbott Laboratories (Symbol: ABT) saw options trading volume of 17,556 contracts, representing approximately 1.8 million underlying shares or approximately 48.4% of ABT's average daily trading volume over the past month, of 3.6 million shares. Particularly high volume was seen for the $75 strike put option expiring January 20, 2023, with 11,748 contracts trading so far today, representing approximately 1.2 million underlying shares of ABT. Below is a chart showing ABT's trailing twelve month trading history, with the $75 strike highlighted in orange: For the various different available expirations for NEM options, WYNN options, or ABT options, visit StockOptionsChannel.com. | Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.1%, Bristol Myers Squibb Co. (Symbol: BMY) is down about 0.9%, and CVS Health Corporation (Symbol: CVS) is higher by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $349.7 million dollar inflow -- that's a 0.9% increase week over week in outstanding units (from 300,270,000 to 302,970,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $118.75 per share, with $143.42 as the 52 week high point — that compares with a last trade of $129.95. | We think Intuitive Surgical stock (NASDAQ: ISRG) is currently a better pick than Stryker stock (NYSE: SYK), despite ISRG being the more expensive of the two, with its P/S ratio of 13.7x, compared to just 4.7x for SYK stock. We compare a slew of factors such as historical revenue growth, returns, and valuation multiple in an interactive dashboard analysis Intuitive Surgical vs. Stryker: Which Stock Is A Better Bet? The table below summarizes our revenue and return expectations for Intuitive Surgical and Stryker over the next three years and points to an expected return of 60% for ISRG over this period vs. a 30% expected return for SYK stock, implying that both stocks offer good buying opportunity at current levels but if investors have to pick one, they will likely be better off buying ISRG over SYK, despite its high valuation, based on Trefis Machine Learning analysis – Intuitive Surgical vs. Stryker – which also provides more details on how we arrive at these numbers."
2022-08-24,105.9000015258789,105.44000244140624,0.6176373423347374,"Abbott (ABT) to Offer New Treatment Option for Chronic Pain | The Best Stocks to Invest $5,000 in Right Now","Abbott Laboratories ABT recently received FDA approval for its novel Proclaim Plus spinal cord stimulation (SCS) system featuring FlexBurst360 therapy. Abbott Laboratories (ABT): Free Stock Analysis Report An Overview of the BurstDR Therapy The BurstDR therapy from Abbott is an exclusive stimulation technology that delivers pulses or bursts of mild electrical energy to modify pain signals as they pass from the spinal cord to the brain. | No list of great companies to invest in will satisfy everyone, but Abbott Laboratories (NYSE: ABT) and Microsoft (NASDAQ: MSFT) are stocks worth watching. ABT data by YCharts 1. Abbott Laboratories Abbott Laboratories is one of the most notable medical device companies around."
2022-08-23,106.81999969482422,106.01000213623048,-0.4343711783235999,U.S. to extend baby formula waivers for low-income families - Politico,"The move was made after closure of Abbott Laboratories ABT.N Michigan plant due to complaints of bacterial contamination exacerbated a national shortage of the vital product. Abbott Laboratories ABT.N, the biggest participant in the WIC program, said on Tuesday it is extending rebates on competitive products to help low-income families through Oct. 31. Adds Abbott response Aug 23 (Reuters) - The Joe Biden administration will likely extend federal flexibilities for low-income families which are dependent on government discounts to access baby formula in coming days, Politico reported on Tuesday."
2022-08-22,108.97000122070312,107.4499969482422,-0.7582826819957226,What To Expect From Medtronic's Q1? | The Return Trends At Abbott Laboratories (NYSE:ABT) Look Promising,"(1) Revenues are expected to be higher than the consensus estimate Trefis estimates Medtronic’s Q1 fiscal 2023 total revenues to be around $7.3 billion, slightly higher than the $7.2 billion consensus estimate. (2) EPS likely to be above the consensus estimates Medtronic’s Q1 fiscal 2023 earnings per share (EPS) is expected to be $1.15 per Trefis analysis, above the consensus estimate of $1.12. Total [2] MDT Return 3% -8% 34% S&P 500 Return 4% -10% 91% Trefis Multi-Strategy Portfolio 5% -9% 258% [1] Month-to-date and year-to-date as of 8/19/2022 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | NYSE:ABT Return on Capital Employed August 22nd 2022 Above you can see how the current ROCE for Abbott Laboratories compares to its prior returns on capital, but there's only so much you can tell from the past. So on that note, Abbott Laboratories (NYSE:ABT) looks quite promising in regards to its trends of return on capital. Firstly, we'd want to identify a growing return on capital employed (ROCE) and then alongside that, an ever-increasing base of capital employed."
2022-08-19,110.4800033569336,110.05999755859376,-1.394883229727026,"Abbott (ABT) Down 0.7% Since Last Earnings Report: Can It Rebound? | The Zacks Analyst Blog Highlights JPMorgan Chase, AbbVie, Abbott Laboratories, Intuit and Caterpillar","It has been about a month since the last earnings report for Abbott (ABT). Abbott Laboratories (ABT): Free Stock Analysis Report Diabetes Care reported organic growth of 19.4% year over year, led by FreeStyle Libre, which contributed 25.6% to organic sales growth in the reported quarter. | Stocks recently featured in the blog include: JPMorgan Chase & Co. JPM, AbbVie Inc. ABBV, Abbott Laboratories ABT, Intuit Inc. INTU, and Caterpillar Inc. CAT. Abbott Laboratories (ABT): Free Stock Analysis Report Here are highlights from Thursday’s Analyst Blog: Top Analyst Reports for JPMorgan, AbbVie and Abbott The Zacks Research Daily presents the best research output of our analyst team."
2022-08-18,110.93000030517578,109.95999908447266,-0.38016454161654445,"Top Analyst Reports for JPMorgan Chase, AbbVie & Abbott | 3 Top Dividend Kings to Buy for the Long Haul","If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Higher Rates to Aid JPMorgan (JPM) Margins, Fee Income A Woe AbbVie's (ABBV) Skyrizi, Rinvoq Key to Long-Term Growth High Medical Device Sales Aid Abbott (ABT), Forex Woes Stay Featured Reports Linde (LIN) Benefits from Advanced Gas Processing Solutions The Zacks Analyst believes Linde's state-of-the-art solutions related to gas processing is likely to support customer expansion and help reduce emissions. Today's Research Daily features new research reports on 12 major stocks, including JPMorgan Chase & Co. (JPM), AbbVie Inc. (ABBV) and Abbott Laboratories (ABT). Abbott Laboratories (ABT): Free Stock Analysis Report | Abbott Laboratories Much like BD, Abbott Laboratories (NYSE: ABT) produces diagnostic tests and surgical goods, but it also makes medical devices like pacemakers and medical nutrition products like baby formula. If you're hunting for stocks that you can expect to keep hiking their dividends year after year, look no further than the Dividend Kings. Every member of this elite group has a history of raising dividend payments year after year without interruption for at least 50 years, and many of the businesses are eager to do the same for the next 50 years."
2022-08-17,111.62999725341795,110.5500030517578,-0.8744264112815175,,
2022-08-16,111.45999908447266,112.02999877929688,-0.9674766892705342,"Noteworthy ETF Outflows: VIG, KO, ABT, CMCSA","Among the largest underlying components of VIG, in trading today Coca-Cola Co (Symbol: KO) is up about 0.6%, Abbott Laboratories (Symbol: ABT) is off about 0.3%, and Comcast Corp (Symbol: CMCSA) is lower by about 1.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $240.1 million dollar outflow -- that's a 0.4% decrease week over week (from 418,096,347 to 416,583,787). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $137.50 per share, with $172.87 as the 52 week high point — that compares with a last trade of $158.99."
2022-08-15,111.30999755859376,111.9000015258789,0.5113939525445633,,
2022-08-12,110.86000061035156,111.4800033569336,0.5300547841397292,"October 21st Options Now Available For Abbott Laboratories (ABT) | Abbott to add 1,000 jobs in $450 million Irish investment","Below is a chart showing ABT's trailing twelve month trading history, with the $115.00 strike highlighted in red: Considering the fact that the $115.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the October 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new October 21st contracts and identified one put and one call contract of particular interest. | DUBLIN, Aug 12 (Reuters) - U.S. healthcare company Abbott Laboratories ABT.N plans to hire 1,000 more people in Ireland in one of the biggest job announcements this year in the country's booming multinational sector, state investment agency IDA Ireland said on Friday. Confirming the $450 million investment, Abbott's senior vice-president for diabetes care, Jared Watkin, told the Irish Times that choosing Ireland for its increased production of devices that monitor glucose levels made strategic sense. ($1 = 0.9728 euros) (Reporting by Padraic Halpin; editing by Jason Neely) ((padraic.halpin@thomsonreuters.com; +353 1 500 1504; Reuters Messaging: padraic.halpin.thomsonreuters.com@reuters.net)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2022-08-11,110.83999633789062,110.48999786376952,0.5592664109404113,"Abbott: Research Shows TBI Blood Test Helpful In Predicting Recovery From Traumatic Brain Injury | Down 15% In A Month, Will QuidelOrtho Stock Rebound? | 2 Healthcare Stocks That Could Help Set You Up for Life | 2 Dividend Kings That Have Hiked Their Payouts by More Than 50% in 5 Years","(RTTNews) - Abbott (ABT) said a new study concluded that elevated levels of two proteins help predict how a person will recover from a traumatic brain injury. The research showed that when a clinician conducts a blood test for these brain proteins soon after a possible injury, they quickly get a more accurate picture of how severe the injury is, the expected course of recovery and the longer-term implications. The researchers used Abbott's i-STAT TBI Plasma test and core laboratory ARCHITECT instrument to measure two biomarkers in blood plasma associated with brain injury. | This pattern suggests a higher chance of a decline in QDEL stock over the next five and ten days but a higher chance of a rise over the next twenty-one days. QuidelOrtho (QDEL) Return (Recent) Comparison With Peers Five-Day Return: OPGN highest at 10.8%; QDEL lowest at -11.4% Ten-Day Return: OPGN highest at 6.2%; QDEL lowest at -11.8% Twenty-One Day Return: TRIB highest at 3.7%; QDEL lowest at -15.2% While QDEL stock looks like it can gain over the next month, it is helpful to see how QuidelOrtho’s Peers fare on metrics that matter. Total [2] QDEL Return -12% -33% 322% S&P 500 Return 0% -13% 85% Trefis Multi-Strategy Portfolio 5% -9% 259% [1] Month-to-date and year-to-date as of 8/9/2022 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories Few healthcare companies are as diversified as Abbott Laboratories (NYSE: ABT) in terms of industries and geography. Investors can also be confident that Humana's future revenue growth will push the company's profits upward as well. This led the insurer's adjusted diluted earnings per share (EPS) to surge 14.7% higher year over year to $16.70 for the first half of the year. | However, both Abbott Laboratories (NYSE: ABT) and American States Water (NYSE: AWR) are exceptions. After all, to keep a dividend streak going, a company can just raise its dividend by a penny each year. Although these can be reliable dividend stocks to own for the long term, they aren't usually good dividend growth stocks to own."
2022-08-10,109.76000213623048,110.2699966430664,-0.31576911375398614,,
2022-08-09,108.08999633789062,107.91000366210938,0.4646451320244464,,
2022-08-08,109.79000091552734,109.0,-0.16652112302658492,,
2022-08-05,108.75,109.25,-0.7195563429634837,Should You Really Care About This Company's Short-Term Success?,"Medical-device company Abbott Laboratories (NYSE: ABT) reported impressive second-quarter earnings and raised guidance for the full year. Strong COVID-19 and medical device sales Abbott is one of the largest manufacturers of rapid COVID-19 antigen tests, offering personal and point-of-care testing to provide a real-time diagnosis of infection in less than 15 minutes. Despite Abbott's expectation that COVID-19 sales would sharply dwindle as the year progressed second-quarter sales remained robust."
2022-08-04,110.41000366210938,109.72000122070312,0.45977011494252873,,
2022-08-03,109.11000061035156,109.61000061035156,-0.6249455832986679,"Famed ""Big Short"" Investor Loves This Multibillion-Dollar Company -- Should You?","The phase 2 investigational drug milvexian is being evaluated to take over both the anti-platelet market -- think Plavix and its $7 billion in revenue for 2011 -- as well as the oral anti-coagulant market dominated by Eliquis, namely atrial fibrillation, and blood clots. Even over the last five years, Bristol still lags the market by 53% versus 81%. Blockbuster Revlimid, which generated $12.8 billion in fiscal year 2021, is beginning to see sales erode, with revenue expected to contract to the $9 billion to $9.5 billion range this year."
2022-08-02,109.62000274658205,108.63999938964844,0.4582531364705754,MonkeyPox Stocks To Buy Right Now? 3 To Know | Analysts Anticipate 15% Gains Ahead For MGV,"Check Out These Three MonkeyPox Stocks Making Headlines In The Stock Market Today Unless you’ve been living under a rock, it’s likely you’ve seen all the monkeypox headlines in the stock market today. Monkeypox Stocks To Watch Right Now Bavarian Nordic A/S (OTCMKTS: BVNRY) SIGA Technologies (NASDAQ: SIGA) Emergent BioSolutions Inc. (NYSE: EBS) Bavarian Nordic A/S First, on the list, we have Bavarian Nordic A/S (BVNRY). We believe these new orders and the ongoing inquiries highlight the overall importance of health security preparedness, and that by increasing both the scale and scope of TPOXX stockpiling, countries can be better prepared for the outbreak risks of smallpox, monkeypox, and other viruses in the orthopoxvirus family of viruses and make sure that patients are able to access treatment.” Considering all of this, are you keeping SIGA stock on watch right now? | Similarly, ABBV has 17.81% upside from the recent share price of $140.22 if the average analyst target price of $165.20/share is reached, and analysts on average are expecting ABT to reach a target price of $127.15/share, which is 16.10% above the recent price of $109.52. Three of MGV's underlying holdings with notable upside to their analyst target prices are Wells Fargo & Co (Symbol: WFC), AbbVie Inc (Symbol: ABBV), and Abbott Laboratories (Symbol: ABT). Below is a twelve month price history chart comparing the stock performance of WFC, ABBV, and ABT: Below is a summary table of the current analyst target prices discussed above:"
2022-08-01,108.37999725341795,109.5199966430664,-0.8940004856587768,,
2022-07-29,109.83000183105467,108.83999633789062,1.0518540492143256,,
2022-07-28,110.0999984741211,110.36000061035156,-0.9013980484921762,5 Dividend Aristocrats Where Analysts See Capital Gains,"Ecolab Inc (Symbol: ECL) $160.64 $195.23 21.53% Abbott Laboratories (Symbol: ABT) $109.99 $127.08 15.54% NU Skin Enterprises, Inc. (Symbol: NUS) $43.36 $48.75 12.43% NextEra Energy Inc (Symbol: NEE) $80.38 $89.38 11.19% Expeditors International of Washington, Inc. (Symbol: EXPD) $100.57 $111.28 10.65% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Ecolab Inc (Symbol: ECL) 1.27% 21.53% 22.8% Abbott Laboratories (Symbol: ABT) 1.71% 15.54% 17.25% NU Skin Enterprises, Inc. (Symbol: NUS) 3.55% 12.43% 15.98% NextEra Energy Inc (Symbol: NEE) 2.11% 11.19% 13.3% Expeditors International of Washington, Inc. (Symbol: EXPD) 1.33% 10.65% 11.98% Another consideration with dividend growth stocks is just how much the dividend is growing. Ecolab Inc (Symbol: ECL) $1.91 $2.01 5.24% Abbott Laboratories (Symbol: ABT) $1.71 $1.86 8.77% NU Skin Enterprises, Inc. (Symbol: NUS) $1.51 $1.53 1.32% NextEra Energy Inc (Symbol: NEE) $1.47 $1.62 10.20% Expeditors International of Washington, Inc. (Symbol: EXPD) $1.1 $1.25 13.64% These five stocks are part of our full Dividend Aristocrats List."
2022-07-27,109.37999725341795,109.98999786376952,0.23615089903164893,"3 MedTech Stocks That are Likely to Beat This Earnings Season | Merck avoided billions in U.S. tax by offshoring Keytruda profits - senator | iShares Russell 1000 Value ETF Experiences Big Outflow | 7 Large-Cap Stocks to Buy on the Dip | Why a Product Recall Won't Change This Company's Prospects | Reckitt raises sales forecast after quarterly beat | Wall Street Finds this Healthcare Stock more Enticing, Post Q2 Results | Reckitt posts 11.9% rise in quarterly like-for-like sales, beating expectations","Abbott ABT and Quest Diagnostics DGX are a few companies whose base-business performance registered a strong recovery rate. Abbott Laboratories (ABT): Free Stock Analysis Report Here we talk about three stocks, STERIS STE, Thermo Fisher TMO and IDEXX Laboratories IDXX that are expected to beat earnings estimates in the ongoing reporting cycle. | By Michael Erman July 27 (Reuters) - Drugmaker Merck & Co MRK.N avoided billions of dollars of U.S. taxes in recent years on its top-selling cancer drug Keytruda by booking all the profits from the treatment outside of the United States, according to an ongoing investigation by Democrats on the Senate Finance Committee. Democrats on the committee have been investigating how the tax law passed by Republicans in 2017 has benefited large U.S. pharmaceutical companies such as Merck and AbbVie and whether those companies have been exploiting foreign subsidiaries to avoid taxes. Wyden said in the letter that Merck was able to avoid U.S. taxes on Keytruda - even on sales in the United States - by holding patents in the Netherlands and manufacturing the drug in Ireland. | Among the largest underlying components of IWD, in trading today Bank of America Corp (Symbol: BAC) is up about 0.3%, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 0.4%, and Abbott Laboratories (Symbol: ABT) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $462.4 million dollar outflow -- that's a 0.9% decrease week over week (from 350,450,000 to 347,350,000). For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $139.96 per share, with $171.42 as the 52 week high point — that compares with a last trade of $149.73. | Ticker Company/Fund Recent Price ABT Abbott Laboratories $108.88 AVIV Avantis International Large Cap Value ETF $42.25 COST Costco Wholesale $510.85 DHR Danaher $274.04 ILCV iShares Morningstar Value ETF $62.12 LIN Linde $285.65 NVDA Nvidia $166.11 Abbott Laboratories (ABT) Healthcare giant Abbott Laboratories (NYSE:ABT), our first large-cap stock  It manufactures medical devices, nutritional products, diagnostic equipment, testing kits, as well as branded generic drugs. Long-term ABT investors will look at how it can contribute to Abbott’s bottom line. ABT stock has been hovering near its 52-week low. | Healthcare giant Abbott Laboratories (NYSE: ABT) has underperformed the market this year. ABT data by YCharts The benefits of diversification Abbott Laboratories restarted partial production in the facility that manufactured the infant formula in question only last month. Excluding sales of the products associated with the recall, Abbott Laboratories' nutrition revenue increased by 0.5%. | Quarterly sales also received a roughly 3.3% boost from sales of its Enfamil baby formula amid a shortage of supplies in the United States, after market leader Abbott Laboratories ABT.L recalled dozens of brands in February. Adds details, background LONDON, July 27 (Reuters) - Britain's Reckitt Benckiser RKT.L, maker of Dettol and Lysol cleaning products, on Wednesday raised its full-year revenue forecast after steep price hikes helped it beat second-quarter sales expectations. ""We now expect like-for-like net revenue growth of 5% - 8% for 2022, and growth in adjusted operating margins,"" Reckitt said in a statement. | Abbott Laboratories (NYSE: ABT) Abbott handily exceeded analysts’ revenue and EPS expectations for the second quarter, thanks to $2.3 billion in COVID-19 testing-related sales. We used the TipRanks Stock Comparison Tool to pit Johnson & Johnson, Abbott, and UnitedHealth against each other to pick the healthcare stock that Wall Street analysts are more bullish about. Johnson & Johnson (NYSE: JNJ) JNJ topped analysts’ second-quarter expectations, with sales rising 3% to $24 billion and adjusted earnings per share (EPS) up 4.4% to $2.59. | LONDON, July 27 (Reuters) - Britain's Reckitt Benckiser RKT.L, maker of Dettol and Lysol cleaning products, on Wednesday beat second-quarter sales expectations after raising prices to make up for soaring input costs. The company said quarterly like-for-like revenue rose 11.9%, on a constant currency basis, ahead of the 6.8% growth analysts had expected in a company-supplied poll. (Reporting by Richa Naidu Editing by Mark Potter) ((richa.naidu@tr.com; Follow me on Twitter https://twitter.com/Richa_Writes; +44 755 755 9587;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2022-07-26,108.70999908447266,109.08999633789062,0.5576893633835787,2 Surefire Dividend Stocks That Are Laughing Off Inflation | Abbott Unveils NeuroSphere Virtual Clinic In Canada,"Abbott Laboratories Abbott Laboratories (NYSE: ABT) isn't struggling with inflation, because its biggest customers are healthcare systems rather than consumers. When companies face rising prices and diminished consumer demand, it compresses their margins -- and with thinning margins, it's hard to justify paying a dividend or raising the payout that investors expect. Abbott Labs' burgeoning product portfolio is part of the reason it can keep hiking its dividend year after year, which should also give investors confidence in its ability to keep performing strongly during periods of inflation. | (RTTNews) - Abbott Laboratories (ABT) announced Tuesday that remote Neuromodulation Patient-Care Technology, NeuroSphere Virtual Clinic, has received the Health Canada licencing. This enables clinicians to prescribe new treatment settings remotely to the patient's neurostimulation device using the clinician programmer app and a new, simple, and secure remote care connection. NeuroSphere Virtual Clinic is compatible with Canadian-licensed Abbott neuromodulation devices, such as Proclaim spinal cord stimulation, Proclaim dorsal root ganglion therapy, and Infinity deep brain stimulation therapy."
2022-07-25,109.08999633789062,108.5,0.349551335312489,"The Zacks Analyst Blog Highlights Visa, Abbott Laboratories, Salesforce, Wells Fargo and Centene","Stocks recently featured in the blog include: Visa Inc. V, Abbott Laboratories ABT, Salesforce, Inc. CRM, Wells Fargo & Co. WFC and Centene Corp. CNC. Abbott Laboratories (ABT): Free Stock Analysis Report Here are highlights from Friday’s Analyst Blog: Top Research Reports for Visa, Abbott and Salesforce The Zacks Research Daily presents the best research output of our analyst team."
2022-07-22,112.0,109.1999969482422,-0.5408345015093738,"Top Research Reports for Visa, Abbott & Salesforce | What To Expect From Boston Scientific Stock Following Q2 Earnings?","If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Visa (V) Banks on Renewed Agreements, Rising Costs Hurt Organic Sales Gain, Rise in Fiscal View Aid Abbott (ABT) Digital Transformation and Acquisitions Aid Salesforce (CRM) Featured Reports Cost Control Aids Wells Fargo (WFC) Amid Declining Revenues Per the Zacks analyst, Wells Fargo's cost-saving measures like branch closures and headcount reduction will help offset falling revenue trends due to business divestures and volatile fee income. Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), Abbott Laboratories (ABT) and Salesforce, Inc. (CRM). Abbott Laboratories (ABT): Free Stock Analysis Report | (1) Revenues expected to align with the consensus estimates Trefis estimates Boston Scientific’s Q2 2022 revenues to be around $3.2 billion, in-line with the consensus estimates. (2) EPS is likely to be in line with the consensus estimates Boston Scientific’s Q2 2022 adjusted earnings per share (EPS) is expected to be $0.43 per Trefis analysis, aligning with the consensus estimate. Total [2] BSX Return 0% -12% 72% S&P 500 Return 1% -20% 71% Trefis Multi-Strategy Portfolio 3% -21% 214% [1] Month-to-date and year-to-date as of 7/19/2022 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2022-07-21,108.62000274658205,110.69000244140624,-2.5000027247837484,,
2022-07-20,106.98999786376952,108.2300033569336,1.9057260564185792,"Abbott's (ABT) Q2 Earnings Top Estimates, '22 EPS View Up | Abbott Laboratories (ABT) Q2 2022 Earnings Call Transcript | Stock Market Today: Dow Jones & S&P 500 Move Green; NFLX Stock Rallies On Earnings | Pre-Market Gives Back Some Gains; Abbott Beats, Raises | Earnings Season Gathers Pace, Home Sales Numbers Awaited | Health Care Sector Update for 07/20/2022: ADIL, ABT, IONS, NVS, XLV, IBB | Abbott (ABT) Q2 Earnings and Revenues Top Estimates | Abbott Q2 Profit Tops Estimates; Raises 2022 Earnings Guidance | Abbott raises 2022 forecast on strong diabetes, COVID test sales | Abbott Laboratories Q2 Profit Increases, beats estimates | Abbott Laboratories Q2 22 Earnings Conference Call At 9:00 AM ET","Abbott Laboratories ABT reported second-quarter 2022 adjusted earnings of $1.43 per share, which exceeded the Zacks Consensus Estimate by 31.2%. Abbott Laboratories (ABT): Free Stock Analysis Report Diabetes Care reported organic growth of 19.4% year over year, led by FreeStyle Libre, which contributed 25.6% to organic sales growth in the reported quarter. | Operator [Operator signoff] Duration: 0 minutes Call participants: Scott Leinenweber -- Vice President of Investor Relations, Licensing, and Acquisition Robert Ford -- Chairman and Chief Executive Officer Bob Funck -- Executive Vice President, Finance, and Chief Financial Officer Robbie Marcus -- J.P. Morgan -- Analyst Joshua Jennings -- Cowen and Company -- Analyst Larry Biegelsen -- Wells Fargo Securities -- Analyst Joanne Wuensch -- Citi -- Analyst Vijay Kumar -- Evercore ISI -- Analyst Travis Steed -- Bank of America Merrill Lynch -- Analyst Jayson Bedford -- Raymond James -- Analyst More ABT analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Abbott Laboratories (NYSE: ABT) Q2 2022 Earnings Call Jul 20, 2022, 9:00 a.m. EPD continues to execute and perform at a very high level in a dynamic environment, achieving double-digit organic sales growth over the past year and a half, including more than 11% organic growth for the first half of this year. | Earnings this morning from top companies such as Biogen (NASDAQ: BIIB), Abbott Laboratries (NYSE: ABT) and ASML Holding N.V. (NASDAQ: ASML) reported early morning Wednesday, while investors anxiously await Tesla, Inc. (NASDAQ: TSLA) will report after the market closes today. This beat the Street’s consensus estimate of $4.06 per share, following the company reporting better-than-expected quarterly revenue and earnings. 3 Consumer Discretionary Stocks In Focus Netflix Shares Jump After Reporting Better-Than-Expected Earnings Late Tuesday, the streaming giant Netflix reported better-than-expected second quarter fiscal earnings. | Ahead of today’s open, Abbott Labs ABT reported Q2 earnings which easily outperformed expectations on both top and bottom lines: earnings of $1.43 per share well surpassed the $1.10 Zacks consensus estimate, whereas $11.3 billion in sales crushed expectations by nearly a billion dollars, and well ahead of the $10.2 billion reported in the year-ago quarter. Abbott Laboratories (ABT): Free Stock Analysis Report Big-name companies like Tesla TSLA, United Airlines UAL and rail giant CSX CSX all report after the close, while Existing Home Sales for June come out after the regular trading session commences. | Ahead of today’s open, Abbott Labs ABT reported Q2 earnings which easily outperformed expectations on both top and bottom lines: earnings of $1.43 per share well surpassed the $1.10 Zacks consensus estimate, whereas $11.3 billion in sales crushed expectations by nearly a billion dollars, and well ahead of the $10.2 billion reported in the year-ago quarter. Abbott Laboratories (ABT): Free Stock Analysis Report Big-name companies like Tesla TSLA, United Airlines UAL and rail giant CSX CSX all report after the close, while Existing Home Sales for June come out after the regular trading session commences. | Abbott Laboratories (ABT) shares were down more than 3% even after it reported adjusted Q2 earnings of $1.43 per diluted share, up from $1.17 a year ago. Adial Pharmaceuticals (ADIL) said its phase 3 trial for potential treatment AD04 showed positive results in patients with alcohol use disorder. Ionis Pharmaceuticals (IONS) said Novartis (NVS) has completed enrolling patients for the phase 3 clinical study of pelacarsen with 8,325 participants. | Abbott (ABT) came out with quarterly earnings of $1.43 per share, beating the Zacks Consensus Estimate of $1.09 per share. Abbott Laboratories (ABT): Free Stock Analysis Report Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $11.26 billion for the quarter ended June 2022, surpassing the Zacks Consensus Estimate by 8.67%. | (RTTNews) - Abbott (ABT) said it recorded another quarter of strong growth with an increase in adjusted earnings per share of 22.2 percent year-over-year. The company noted that its 2022 guidance includes projected COVID-19 testing-related sales of $6.1 billion, which includes sales of $5.6 billion through June 2022 and projected sales of $500 million over the next few months. Worldwide sales, excluding COVID-19 testing-related sales, decreased 0.3 percent on a reported basis and increased 4.1 percent on an organic basis. | Compares with analysts' estimates, adds details on shutdown, analysts comment July 20 (Reuters) - Abbott Laboratories ABT.N raised its annual earnings forecast as the impact from a shutdown of its Michigan plant that triggered a nationwide baby formula shortage was more than offset by demand for its diabetes products and COVID-19 tests. Before the recall, Abbott controlled 40% of the infant formula market, including Similac, but the market share of other companies such as Reckitt Benckiser Group PLC RKT.L has grown since then. Sales at Abbott's nutrition unit fell 7.4%, hit by the recall and the plant shutdown. | (RTTNews) - Abbott Laboratories (ABT) revealed earnings for its second quarter that increased from the same period last year and beat the Street estimates. The company's revenue for the quarter rose 10.2% to $11.26 billion from $10.22 billion last year. -Analyst Estimate: $1.12 -Revenue (Q2): $11.26 Bln vs. $10.22 Bln last year. | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on July 20, 2022, to discuss Q2 22 earnings results. To access the live webcast, log on to https://www.abbottinvestor.com/news-and-events?c=94004&p=irol-calall The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2022-07-19,108.43000030517578,109.93000030517578,1.1589919786174565,"Pre-Market Earnings Report for July 20, 2022 : ASML, ABT, ELV, BIIB, MTB, BKR, NDAQ, NTRS, MKTX, CMA, LAD, BMI | Pre-Market Earnings Report for July 20, 2022 : ASML, ABT, ELV, BIIB, MTB, BKR, NDAQ, NTRS, MKTX, CMA, LAD, BMI | Notable ETF Inflow Detected - SPTM, BAC, ABT, DHR | 3 Healthcare Stocks That Could Help Set You Up for Life | 3 Dividend Growth Stocks You Can Buy Now and Hold Forever","Abbott Laboratories (ABT)is reporting for the quarter ending June 30, 2022. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABT is 22.53 vs. an industry ratio of 14.60, implying that they will have a higher earnings growth than their competitors in the same industry. | Abbott Laboratories (ABT)is reporting for the quarter ending June 30, 2022. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABT is 22.53 vs. an industry ratio of 14.60, implying that they will have a higher earnings growth than their competitors in the same industry. | Among the largest underlying components of SPTM, in trading today Bank of America Corp (Symbol: BAC) is up about 2.9%, Abbott Laboratories (Symbol: ABT) is up about 1.6%, and Danaher Corp (Symbol: DHR) is up by about 2.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Portfolio S&P 1500 Composite Stock Market ETF (Symbol: SPTM) where we have detected an approximate $65.9 million dollar inflow -- that's a 1.3% increase week over week in outstanding units (from 110,350,000 to 111,750,000). For a complete list of holdings, visit the SPTM Holdings page » The chart below shows the one year price performance of SPTM, versus its 200 day moving average: Looking at the chart above, SPTM's low point in its 52 week range is $44.87 per share, with $59.08 as the 52 week high point — that compares with a last trade of $47.85. | Abbott Laboratories A recall of Abbott Laboratories' (NYSE: ABT) baby formula earlier in the year weighed on first-quarter earnings. All of this means Abbott is a great company to buy and hold onto for a very long time. Moderna stock has lost more than 35% this year. | Abbott Laboratories Shares of Abbott Laboratories (NYSE: ABT) have fallen more than 20% from the peak they reached in January. These three leading healthcare businesses have long histories of making dividend payments and raising their payouts at least once every year. Abbott Laboratories has made consistent dividend payments since 1924, and it's been 50 years since it went more than a year without raising its payout at least once."
2022-07-18,108.55999755859376,107.0199966430664,1.3833809792292322,,
2022-07-15,107.41000366210938,108.81999969482422,-1.4185712510689432,Is DexCom Stock Too Pricey to Buy?,"There's no doubt that it's an expensive stock If you're just learning about DexCom for the first time, it develops and sells continuous glucose monitors (CGMs), which people with type 2 diabetes use to control their blood sugar levels more effectively and comfortably than with traditional finger-stick tests that need to be done several times per day. Over the last three years, DexCom's selling, general, and administrative (SG&A) expenses shot up significantly as a share of its quarterly revenue as did its total quarterly expenses as a share of revenue. * They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them!"
2022-07-14,104.62999725341795,105.70999908447266,1.3127231958304482,What's in Store for Abbott Laboratories (ABT) in Q2 Earnings? | 2 Top Healthcare Stocks to Buy and Hold for the Long Haul,"Abbott Laboratories ABT is slated to report second-quarter 2022 results on Jul 20, before market open. Abbott Laboratories (ABT): Free Stock Analysis Report Abbott Laboratories Price and EPS Surprise Abbott Laboratories price-eps-surprise | Abbott Laboratories Quote Within Nutrition, from the beginning of the pandemic till the last reported quarter, Abbott gained consistently in terms of adult nutrition products sales. | Let's look at two healthcare stocks worth buying today and holding on to for a long while: Intuitive Surgical (NASDAQ: ISRG) and Abbott Laboratories (NYSE: ABT). Intuitive Surgical Medical devices giant Intuitive Surgical has some critical attributes that companies need to succeed in the long run. Abbott Laboratories Abbott is another medical devices specialist, but its business is more diversified than Intuitive Surgical's."
2022-07-13,106.83999633789062,106.20999908447266,1.0322105126686516,Should You Buy Boston Scientific Stock At $38? | Enfamil maker Reckitt flies baby formula to U.S. from Singapore | Should You Invest in the iShares U.S. Medical Devices ETF (IHI)? | Abbott (ABT) Dips More Than Broader Markets: What You Should Know | Enfamil maker Reckitt flies baby formula to U.S. from Singapore,"This 16% fall for BSX stock since late 2019 was driven by: 1. the company’s P/E ratio, which fell 19% to 23x trailing adjusted earnings currently, compared to 28x in 2019, partly offset by 2. a 4% rise in the company’s earnings to $1.65 for the last twelve months, vs. $1.58 in 2019, on a per share and adjusted basis. We estimate Boston Scientific’s valuation to be $47 per share, reflecting a 25% upside from its current market price of $37, implying that investors are likely to be better off buying BSX stock in the recent dip for solid gains in the long-term. Total [2] BSX Return 1% -12% 73% S&P 500 Return 2% -19% 72% Trefis Multi-Strategy Portfolio 3% -20% 213% [1] Month-to-date and year-to-date as of 7/12/2022 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Similac maker Abbott Laboratories ABT.N in February recalled dozens of types of baby formula, taking the country's biggest industry player off the market and creating one of the biggest U.S. food shortages in recent American history. By Richa Naidu LONDON, July 13(Reuters) - Enfamil maker Reckitt on Wednesday afternoon flew 65 tonnes of baby formula to Chicago from its plant in Singapore, shoring up supplies amid a months-long shortage in the United States, the company said. (Reporting by Richa Naidu; editing by David Evans) ((richa.naidu@tr.com; Follow me on Twitter https://twitter.com/Richa_Writes; +44 755 755 9587;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Looking at individual holdings, Thermo Fisher Scientific Inc (TMO) accounts for about 15.42% of total assets, followed by Abbott Laboratories (ABT) and Medtronic Plc (MDT). Abbott Laboratories (ABT): Free Stock Analysis Report Alternatives IShares U.S. Medical Devices ETF carries a Zacks ETF Rank of 3 (Hold), which is based on expected asset class return, expense ratio, and momentum, among other factors. | In the latest trading session, Abbott (ABT) closed at $106.21, marking a -1.93% move from the previous day. ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.81 per share and revenue of $41.65 billion. We can also see that ABT currently has a PEG ratio of 3.93. | Similac maker Abbott Laboratories ABT.N in February recalled dozens of types of baby formula, taking the country's biggest industry player off the market and creating one of the biggest U.S. food shortages in recent American history. By Richa Naidu LONDON, July 13 (Reuters) - Enfamil maker Reckitt on Wednesday afternoon flew 65 tonnes of baby formula to Chicago from its plant in Singapore, shoring up supplies amid a months-long shortage in the United States, the company said. In July, Reckitt will bring into the country about 192 metric tons of baby formula, equal to more than 5.9 million 8-oz servings, the company said."
2022-07-12,108.5,108.3000030517578,-0.5896642409323458,"Ex-Dividend Reminder: Abbott Laboratories, Life Storage and Bank OZK | Target to add Bobbie brand infant formula to stores as shortage persists | Target to add Bobbie brand infant formula to stores as shortage persists | Abbott: FDA Grants Breakthrough Device Designation To Investigate DBS System In TRD | When the Market Recovers, You'll Want to Own These 2 Healthcare ETFs","Looking at the universe of stocks we cover at Dividend Channel, on 7/14/22, Abbott Laboratories (Symbol: ABT), Life Storage Inc (Symbol: LSI), and Bank OZK (Symbol: OZK) will all trade ex-dividend for their respective upcoming dividends. Abbott Laboratories (Symbol: ABT): Life Storage Inc (Symbol: LSI): Bank OZK (Symbol: OZK): In general, dividends are not always predictable, following the ups and downs of company profits over time. As a percentage of ABT's recent stock price of $109.60, this dividend works out to approximately 0.43%, so look for shares of Abbott Laboratories to trade 0.43% lower — all else being equal — when ABT shares open for trading on 7/14/22. | The U.S. infant formula shortage stems in part from the closure of an Abbott Laboratories ABT.N plant that manufactured specialty formulas, which re-opened this month. By Jessica DiNapoli NEW YORK, July 12 (Reuters) - Target Corp TGT.N has begun carrying Bobbie brand infant formula in some stores this week and the vast majority of its locations will be selling the product by September, as the national shortage persists. Bobbie formula will be available on Target's website this month. | The U.S. infant formula shortage stems in part from the closure of an Abbott Laboratories ABT.N plant that manufactured specialty formulas, which re-opened this month. By Jessica DiNapoli NEW YORK, July 12 (Reuters) - Target Corp TGT.N will start carrying the Bobbie brand infant formula in stores starting by September, and on its website this month, as the national shortage persists. The in-stock nationwide availability of powder baby formula has dipped a bit in recent weeks, to 69.6% for the week of July 3, from 70.7% in the week ending June 26, according to data service IRI. | (RTTNews) - Abbott (ABT) announced the FDA has granted Breakthrough Device Designation to investigate the use of its deep brain stimulation system in treatment-resistant depression. Abbott's DBS system is an adjustable therapy that involves implanting thin wires - or leads - into targeted areas of the brain. Abbott noted that, with the Breakthrough Device Designation, the DBS system could become available as a new treatment option sooner for people affected by TRD. | iShares U.S. Medical Devices ETF (NYSEMKT:IHI) and Vanguard Healthcare Index Fund ETF (NYSEMKT:VHT) are two exchange-traded funds (ETFs) that provide a broad swath of portfolio coverage across medical devices and large-cap pharmaceutical companies. 1. iShares U.S. Medical Devices ETF In 2022, Blackrock's medical device ETF is down nearly 22%. Not every company in healthcare will succeed, but investors can benefit by holding shares of an ETF that has a strong position -- 41% of all holdings -- in the top companies in the industry while also having a position in the lesser-known names that may one day be at the top."
2022-07-11,108.5999984741211,108.88999938964844,-0.18432898455502464,"IWD, BAC, ABT, BMY: ETF Outflow Alert | 2 Dividend Stocks You Can Confidently Buy in a Bear Market | US To Import 4.9 Mln Cans Of Baby Formula From Australia","Among the largest underlying components of IWD, in trading today Bank of America Corp (Symbol: BAC) is down about 0.8%, Abbott Laboratories (Symbol: ABT) is down about 0.7%, and Bristol Myers Squibb Co. (Symbol: BMY) is up by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $117.8 million dollar outflow -- that's a 0.2% decrease week over week (from 351,850,000 to 351,050,000). For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $139.96 per share, with $171.42 as the 52 week high point — that compares with a last trade of $145.99. | Abbott Laboratories You've more than likely seen some of Abbott Laboratories' (NYSE: ABT) COVID-19 diagnostic products. Johnson & Johnson If you're willing to trade slower growth in the future for a higher yield in the present, consider Johnson & Johnson (NYSE: JNJ). For example, Tremfya is a recently launched psoriasis treatment with sales that rose 41% year over year in the first quarter and it's already on pace to generate $2.4 billion in revenue this year, Johnson & Johnson's quarterly payouts have risen about 35% over the past five years. | Under the FDA's enforcement discretion to source more infant formula to the U.S., Australia's Care A2+ will send about 8.6 million pounds or about 121 million full-size, 8-ounce bottles of 0-12 months general infant formula. Media reported, citing Abbott spokesperson, that the formula plant in Sturgis, Michigan, resumed EleCare formula production on July 1 after a three-week shutdown caused by flooding. The initial plant closure by Abbott Nutrition, the largest U.S. infant formula manufacturer, and the resultant major recall of its most popular powder formulas, had triggered the ongoing severe shortage for infant formula supplies in the country."
2022-07-08,108.7300033569336,109.26000213623048,0.26703583757089067,3 Stalwart Stocks That Could Be Safer Than Amazon,"Abbott Laboratories You may have heard of Abbott Laboratories (NYSE: ABT) thanks to its recent troubles with safely manufacturing enough baby formula to meet demand, but its product offerings are far more diverse than nutrition solutions alone. Steris Steris (NYSE: STE) makes and distributes the disinfection equipment and sterilization goods that hospitals worldwide use to protect patients from contagion, and it's a safer stock than Amazon as a result. Costco Wholesale Costco Wholesale (NASDAQ: COST) and Amazon both target some of the same segments, like consumer goods."
2022-07-07,108.4800033569336,109.48999786376952,0.4874448293329256,Abbott (ABT) Gains But Lags Market: What You Should Know,"Abbott (ABT) closed at $109.49 in the latest trading session, marking a +0.74% move from the prior day. ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.81 per share and revenue of $41.69 billion. Also, we should mention that ABT has a PEG ratio of 3.94."
2022-07-06,108.83000183105467,108.69000244140624,0.9310421050714032,U.S. FDA working to allow overseas infant formula beyond shortage,"Abbott Laboratories' ABT.N recall in February of infant formula made in its plant in Michigan worsened an ongoing shortage of baby formula in the nation. Adds details from FDA statement, background July 6 (Reuters) - The U.S. Food and Drug Administration is looking at ways to allow overseas manufacturers of baby formula to keep selling in the country beyond the current shortage, the health regulator said on Wednesday. To ease the nationwide infant formula shortage, the FDA in May said it would allow baby formula imports until Nov. 14, leading to several companies such as Nestle SA NESN.S and Reckitt Benckiser RKT.L flying in products from overseas."
2022-07-05,108.73999786376952,109.3000030517578,-0.12864043672972597,"What's Happening With Boston Scientific Stock? | The Zacks Analyst Blog Highlights Abbott, T-Mobile US, Intuit, Analog Devices and The Progressive","Boston Scientific (BSX) Stock Return (Recent) Comparison With Peers Five-Day Return: ABT highest at 2.3%; ILMN lowest at -4.7% Ten-Day Return: ABT highest at 3.7%; ILMN lowest at -4.8% Twenty-One Day Return: ABT highest at -7.5%; ILMN lowest at -23.0% may have moved, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. Of 102 instances in the last ten years that BSX stock saw a twenty-one-day fall of 9% or more, 74 resulted in BSX stock rising over the subsequent one-month period (twenty-one trading days). This pattern suggests a higher chance of a rise in BSX stock over the next five days, ten days, and the next month. | Stocks recently featured in the blog includes Abbott Laboratories ABT, T-Mobile US, Inc. TMUS, Intuit Inc. INTU, Analog Devices, Inc. ADI and The Progressive Corp. PGR Here are highlights from Friday’s Analyst Blog: Top Stock Reports for Abbott Laboratories, T-Mobile and Intuit The Zacks Research Daily presents the best research output of our analyst team. Abbott Laboratories (ABT): Free Stock Analysis Report Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories, T-Mobile US, Inc. and Intuit Inc.."
2022-07-01,108.20999908447266,110.22000122070312,0.5149946652471531,"Abbott (ABT) Outpaces Stock Market Gains: What You Should Know | Top Stock Reports for Abbott Laboratories, T-Mobile & Intuit | iShares Russell 1000 ETF Experiences Big Inflow | US To Import 17 Mln Bottles Of Infant Formula From New Zealand, Ireland","Abbott (ABT) closed the most recent trading day at $110.22, moving +1.45% from the previous trading session. Also, we should mention that ABT has a PEG ratio of 3.93. ABT's industry had an average PEG ratio of 1.45 as of yesterday's close. | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Abbott's (ABT) Diabetes Arm Grows Amid Baby Formula Crisis T-Mobile (TMUS) Poised to Benefit From Extensive 5G Coverage Intuit (INTU) Rides on Product Refresh, Higher Subscriptions Featured Reports Rising Iron Prices to Aid BHP Group (BHP) Amid High Costs The Zacks analyst believes improving iron prices, focus on lowering debt, investment in major projects and efforts to make operations more efficient will drive BHP's results amid inflated costs. Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories (ABT), T-Mobile US, Inc. (TMUS) and Intuit Inc. (INTU). Abbott Laboratories (ABT): Free Stock Analysis Report | Among the largest underlying components of IWB, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.6%, Bristol Myers Squibb Co. (Symbol: BMY) is down about 1.4%, and Danaher Corp (Symbol: DHR) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $207.8 million dollar inflow -- that's a 0.8% increase week over week in outstanding units (from 124,150,000 to 125,150,000). For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $199.58 per share, with $267.13 as the 52 week high point — that compares with a last trade of $206.57. | Earlier this week, the FDA announced the availability of around 696,000 cans or about 21 million full-size, 8-ounce bottles of general formula milk from Australian organic infant formula and baby food producer, Bellamy's Organic. Earlier, UK-based Global Kosher also agreed to send more than 4.8 million cans of general infant formula, which are equal to more than 128 million full-size, 8-ounce bottles. In its latest update, the FDA noted that its increased flexibilities have resulted in total estimated quantity of 18.3 million cans, or about 400 million full-size, 8-ounce bottles of infant formula products from various countries."
2022-06-30,108.08000183105467,108.6500015258789,1.857501296771464,Analysts Predict 25% Upside For The Holdings of VOOV | 2 of the Safest Stocks to Buy in a Recession,"Similarly, ABT has 27.57% upside from the recent share price of $109.10 if the average analyst target price of $139.18/share is reached, and analysts on average are expecting TFC to reach a target price of $60.29/share, which is 27.20% above the recent price of $47.40. Three of VOOV's underlying holdings with notable upside to their analyst target prices are Under Armour Inc (Symbol: UA), Abbott Laboratories (Symbol: ABT), and Truist Financial Corp (Symbol: TFC). Below is a twelve month price history chart comparing the stock performance of UA, ABT, and TFC: Below is a summary table of the current analyst target prices discussed above: | Abbott Laboratories AbbVie spun off from Abbott Laboratories (NYSE: ABT) in 2013 as a way to shield the parent company from the incoming competition for Humira. Abbott Laboratories recently declared its 394th consecutive quarterly dividend, and it's been 50 years since the company went more than a year without raising the payout at least once. Abbott's stock price has fallen around 24% this year, and at the moment, you can scoop up shares for just 22.8 times the company's earnings expectation for 2022."
2022-06-29,107.45999908447266,109.0999984741211,0.5273868293555624,"Abbott (ABT) Gains As Market Dips: What You Should Know | ESLOY or ABT: Which Is the Better Value Stock Right Now? | The Best Stocks to Invest $5,000 in Right Now","ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.83 per share and revenue of $41.69 billion. Abbott (ABT) closed at $109.10 in the latest trading session, marking a +1.99% move from the prior day. Investors should also note that ABT has a PEG ratio of 3.87 right now. | Investors with an interest in Medical - Products stocks have likely encountered both EssilorLuxottica Unsponsored ADR (ESLOY) and Abbott (ABT). These are just a few of the metrics contributing to ESLOY's Value grade of B and ABT's Value grade of C. ESLOY stands above ABT thanks to its solid earnings outlook, and based on these valuation figures, we also feel that ESLOY is the superior value option right now. Investors should feel comfortable knowing that ESLOY likely has seen a stronger improvement to its earnings outlook than ABT has recently. | Let's look at two stocks worth investing $5,000 in right now for investors who want to score market-beating returns in the long run: AbbVie (NYSE: ABBV) and Intuitive Surgical (NASDAQ: ISRG). AbbVie Shares of AbbVie have easily outperformed the market this year, but the company remains reasonably valued. Intuitive Surgical Intuitive Surgical hasn't performed nearly as well as AbbVie this year."
2022-06-28,109.25,106.97000122070312,1.5261487098648299,,
2022-06-27,109.9000015258789,109.08000183105467,-2.0869554043907326,Strength Seen in Abbott (ABT): Can Its 3.1% Jump Turn into More Strength? | 5 Dividend Aristocrats Where Analysts See Capital Gains,"Abbott ABT shares ended the last trading session 3.1% higher at $109.45. So, make sure to keep an eye on ABT going forward to see if this recent jump can turn into more strength down the road. Abbott Laboratories (ABT): Free Stock Analysis Report | Abbott Laboratories (Symbol: ABT) $109.45 $139.73 27.66% Ecolab Inc (Symbol: ECL) $159.65 $202.50 26.84% Cullen/Frost Bankers, Inc. (Symbol: CFR) $118.44 $143.36 21.04% Illinois Tool Works, Inc. (Symbol: ITW) $187.92 $220.75 17.47% Expeditors International of Washington, Inc. (Symbol: EXPD) $100.49 $116.71 16.14% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Abbott Laboratories (Symbol: ABT) 1.72% 27.66% 29.38% Ecolab Inc (Symbol: ECL) 1.28% 26.84% 28.12% Cullen/Frost Bankers, Inc. (Symbol: CFR) 2.53% 21.04% 23.57% Illinois Tool Works, Inc. (Symbol: ITW) 2.60% 17.47% 20.07% Expeditors International of Washington, Inc. (Symbol: EXPD) 1.33% 16.14% 17.47% Another consideration with dividend growth stocks is just how much the dividend is growing. Abbott Laboratories (Symbol: ABT) $1.62 $1.84 13.58% Ecolab Inc (Symbol: ECL) $1.91 $2.01 5.24% Cullen/Frost Bankers, Inc. (Symbol: CFR) $2.87 $3 4.53% Illinois Tool Works, Inc. (Symbol: ITW) $4.49 $4.8 6.90% Expeditors International of Washington, Inc. (Symbol: EXPD) $1.1 $1.25 13.64% These five stocks are part of our full Dividend Aristocrats List."
2022-06-24,107.0,109.4499969482422,-0.7461325599992299,,
2022-06-23,105.9499969482422,106.20999908447266,2.2897167740581326,5 Dividend Kings to Buy Now | FDA probes one more infant death potentially related to Abbott baby formula | Why Investors Should Focus on Abbott's Medical Devices | Abbott (ABT) Gains But Lags Market: What You Should Know | FDA Probes Death Of Infant Who Consumed Abbott Infant Formula,"Abbott Laboratories With a market capitalization of $179.5 billion, Abbott Laboratories (NYSE: ABT) is one of the largest healthcare companies in the world. With a dividend payout ratio set to be 38.6% in 2022, Abbott Laboratories should have no problem extending its 50-year dividend growth streak in the years to come. 3M's diversification and influence over the lives of millions around the world hasn't just figuratively paid dividends -- it has allowed the stock to pay growing dividends to its shareholders for 64 consecutive years. | Adds Abbott response, changes dateline June 23 (Reuters) - The U.S. Food and Drug Administration (FDA) said on Wednesday it was notified of one more infant death in January potentially related to Abbott Laboratories' ABT.N baby formula and the agency has started an investigation. Abbott initiated a recall of its baby formula products and closed its Michigan plant in February after reports of serious bacterial infections in four infants, worsening a shortage among multiple manufacturers that began with pandemic supply chain issues. Abbott said on Thursday there was currently no evidence to suggest a connection between the death and its baby formula, adding that there was limited clinical and product information provided when the FDA notified the company last week. | Diversified healthcare company Abbott Laboratories (NYSE: ABT) has been front and center in the news this year. Abbott Labs's diabetes products The American Diabetes Association claims that diabetes is the most common chronic disease in the U.S., with 1.4 million Americans newly diagnosed each year. Abbott Labs's cardiovascular products Cardiovascular disease is Abbott's second primary focus in the medical device segment. | Abbott (ABT) closed at $106.21 in the latest trading session, marking a +0.73% move from the prior day. ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.83 per share and revenue of $41.62 billion. It is also worth noting that ABT currently has a PEG ratio of 3.82. | Abbott Nutrition, the largest U.S. infant formula manufacturer, had closed its baby formula plant in Sturgis, Michigan after reporting bacterial infections and related deaths in babies. Abbott had called back millions of powder formulas, including Similac, Alimentum, and EleCare, produced at the facility after four infants were diagnosed with Cronobacter sakazakii or Salmonella Newport, a rare bacterial infection, including two deaths reported to the FDA between September 2021 and February. But, following the worst shortage of the baby formula products, Abbott Nutrition reopened its Sturgis plant in early June, as agreed by the FDA, and restarted the production of specialty infant formula, EleCare."
2022-06-22,103.5500030517578,105.44000244140624,0.24540079633741618,"U.S. FDA gets complaint of one more infant death related to baby formula | SPLG, BRK.B, BAC, ABT: ETF Outflow Alert","June 22 (Reuters) - The U.S. Food and Drug Administration said on Wednesday it was notified of one more infant death in January potentially related to Abbott Laboratories' ABT.N baby formula and the agency has started a probe. Abbott initiated a recall of its infant formula products and closed its Michigan plant in February after reports of serious bacterial infections in four infants, worsening a shortage among multiple manufacturers that began with pandemic supply chain issues. (Reporting by Amruta Khandekar; Editing by Shounak Dasgupta) ((Amruta.Khandekar@thomsonreuters.com)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of SPLG, in trading today Berkshire Hathaway Inc New (Symbol: BRK.B) is off about 0.1%, Bank of America Corp (Symbol: BAC) is up about 0.1%, and Abbott Laboratories (Symbol: ABT) is up by about 0.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Portfolio S&P 500 ETF (Symbol: SPLG) where we have detected an approximate $302.1 million dollar outflow -- that's a 2.4% decrease week over week (from 288,750,000 to 281,900,000). For a complete list of holdings, visit the SPLG Holdings page » The chart below shows the one year price performance of SPLG, versus its 200 day moving average: Looking at the chart above, SPLG's low point in its 52 week range is $42.78 per share, with $56.44 as the 52 week high point — that compares with a last trade of $44.30."
2022-06-21,104.86000061035156,104.41000366210938,1.825204571653901,Abbott (ABT) Gains But Lags Market: What You Should Know,"Abbott (ABT) closed the most recent trading day at $104.41, moving +1.83% from the previous trading session. Investors should also note that ABT has a PEG ratio of 3.71 right now. Abbott Laboratories (ABT): Free Stock Analysis Report"
2022-06-17,101.23999786376952,102.52999877929688,-0.42914070725054404,,
2022-06-16,102.4000015258789,102.06999969482422,1.2742008521801906,Interesting ABT Put And Call Options For February 2023,"Below is a chart showing ABT's trailing twelve month trading history, with the $105.00 strike highlighted in red: Considering the fact that the $105.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the February 2023 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new February 2023 contracts and identified one put and one call contract of particular interest."
2022-06-15,104.31999969482422,104.8000030517578,-0.3222674083371847,FOCUS-Baby formula makers raced for FDA approval. They may be waiting a while | Abbott pauses baby formula production in Michigan after heavy rains | Bubs Australia shares surge on infant formula supply deal with Walmart | FOCUS-Baby formula makers raced for FDA approval. They may be waiting a while | Abbott (ABT) Outpaces Stock Market Gains: What You Should Know,"A shortage of formula due to pandemic supply chain issues escalated into a crisis after Abbott Laboratories ABT.N, the maker of Similac and specialty hypoallergenic formulas, shut its Michigan plant in February after reports of bacterial infection in children who consumed its products. By Jessica DiNapoli NEW YORK, June 15 (Reuters) - To ease the U.S. shortage of baby formula, Nature's One and Holle are poised to ship hundreds of thousands of pounds, if not millions of pounds, of additional formula into stores, company executives told Reuters. Despite the Biden administration's pledge to end formula shortages, slow responses and requests for more information from the U.S. Food and Drug Administration (FDA) have led to weeks-long delays for baby formula makers seeking U.S. approval, the two companies told Reuters. | Changes dateline, adds FDA Commissioner's tweet June 16 (Reuters) - Abbott Laboratories ABT.N said late Wednesday it has stopped production of its EleCare specialty formula after severe storms and heavy rains in southwestern Michigan flooded areas of its plant in Sturgis. The plant shutdown and Abbott's recall of infant formula products in February deepened the supply shortage in the United States, with global companies like Neocate maker Danone SA DANO.PA bringing baby formula products into the U.S. But Abbott, the biggest U.S. supplier of powder infant formula, including Similac, said it has enough existing supply of the baby formula until new products are available. | The crisis was triggered when Abbott Laboratories ABT.N recalled dozens of its brands in February after consumers complained of infants contracting bacterial infections. June 16 (Reuters) - Shares of Bubs Australia BUB.AX jumped on Thursday after the company signed a deal to supply its infant formula products to U.S. retail giant Walmart amid a baby food shortage in the world's largest economy. Walmart plans to buy a shipment of six Bubs Infant Formula and two Aussie Bubs Toddler Formula products, which would be delivered to about 800 Walmart stores across the United States, Bubs Australia said, adding that the new supply built on its existing online product sales on Walmart.com channel. | A shortage of formula due to pandemic supply chain issues escalated into a crisis after Abbott Laboratories ABT.N, the maker of Similac and specialty hypoallergenic formulas, shut its Michigan plant in February after reports of bacterial infection in children who consumed its products. By Jessica DiNapoli NEW YORK, June 15 (Reuters) - To ease the U.S. shortage of baby formula, Nature's One and Holle are poised to ship hundreds of thousands of pounds, if not millions of pounds, of additional formula into stores, company executives told Reuters. Despite the Biden administration's pledge to end formula shortages, slow responses and requests for more information from the U.S. Food and Drug Administration (FDA) have led to weeks-long delays for baby formula makers seeking U.S. approval, the two companies told Reuters. | Abbott (ABT) closed at $104.80 in the latest trading session, marking a +1.81% move from the prior day. Investors should also note that ABT has a PEG ratio of 3.72 right now. ABT's industry had an average PEG ratio of 1.48 as of yesterday's close."
2022-06-14,105.0999984741211,102.94000244140624,0.4601259186520058,"ACWI, BAC, ABT, WMT: Large Inflows Detected at ETF","Among the largest underlying components of ACWI, in trading today Bank of America Corp (Symbol: BAC) is up about 0.2%, Abbott Laboratories (Symbol: ABT) is off about 2.2%, and Walmart Inc (Symbol: WMT) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares MSCI ACWI ETF (Symbol: ACWI) where we have detected an approximate $233.6 million dollar inflow -- that's a 1.4% increase week over week in outstanding units (from 196,600,000 to 199,400,000). For a complete list of holdings, visit the ACWI Holdings page » The chart below shows the one year price performance of ACWI, versus its 200 day moving average: Looking at the chart above, ACWI's low point in its 52 week range is $83.12 per share, with $107.46 as the 52 week high point — that compares with a last trade of $83.23."
2022-06-13,107.68000030517578,105.91000366210938,-2.0551817926493277,ESLOY vs. ABT: Which Stock Is the Better Value Option?,"Investors looking for stocks in the Medical - Products sector might want to consider either EssilorLuxottica Unsponsored ADR (ESLOY) or Abbott (ABT). These are just a few of the metrics contributing to ESLOY's Value grade of B and ABT's Value grade of C. ESLOY stands above ABT thanks to its solid earnings outlook, and based on these valuation figures, we also feel that ESLOY is the superior value option right now. ESLOY currently has a forward P/E ratio of 22.04, while ABT has a forward P/E of 22.71."
2022-06-10,110.80999755859376,109.62999725341795,-1.6437561646081542,"White House says Delta to ship UK baby formula starting June 20 | Daily Dividend Report: AMAT,CARR,ABT,CL,UTZ | Is Abbott Laboratories Stock a Buy Now? | Abbott (ABT) Medical Devices Arm Gains Traction, FX Woe Stays | The Zacks Analyst Blog Highlights Novo Nordisk, Toyota Motor, Salesforce, Abbott Laboratories, Raytheon Technologies, and Equinor","Separately, the U.S. Food and Drug Administration said Abbott Laboratories ABT.N would have 16.5 million bottles of its Similac infant formula ready to be shipped from Spain this month. Adds details from FDA statement WASHINGTON, June 10 (Reuters) - Delta Air Lines Inc DAL.N will start transporting 3.2 million bottles of Kendamil baby formula on June 20, the White House said on Friday in announcing the sixth shipment of overseas formula to help quell a U.S. shortage. The shipments are the latest in a string of Operation Fly Formula flights aimed at restocking U.S. shelves after Abbott, a major U.S. infant formula supplier, saw a key factory in Michigan shut down earlier this year and recalled its product. | VIDEO: Daily Dividend Report: AMAT,CARR,ABT,CL,UTZ The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Applied Materials today announced that its Board of Directors has approved a quarterly cash dividend of $0.26 per share payable on the company's common stock. The Board of Directors of Colgate-Palmolive today declared a quarterly cash dividend of $0.47 per common share, payable on August 15, 2022, to shareholders of record on July 21, 2022. | Abbott Laboratories (NYSE: ABT) is a top healthcare stock that's been in the news recently for its role in the U.S. baby formula shortage. Pediatric nutrition sales fell more than 20% When Abbott reported its results for the first three months of the year, it noted that it initiated a voluntary recall of infant formula products in February. The company's diabetes care segment contributed $1.1 billion in revenue last quarter, with sales rising by 15% year over year. | Abbott Laboratories ABT is well poised for growth in the coming quarters, backed by its progress in the diabetes business. Abbott Laboratories (ABT): Free Stock Analysis Report Abbott Laboratories Price Abbott Laboratories price | Abbott Laboratories Quote Within cardiovascular devices, despite the adverse procedure volume-related scenario in Q1 on elevated COVID case rates early in the year, Abbott saw a steady improvement in procedure trends as the case rates came down in the second half of the quarter and the trend continued into April. | Stocks recently featured in the blog include: Novo Nordisk A/S NVO, Toyota Motor Corp. TM, Salesforce, Inc. CRM, Abbott Laboratories ABT,Raytheon Technologies Corporation RTX, and Equinor ASA EQNR. Abbott Laboratories (ABT): Free Stock Analysis Report Here are highlights from Thursday’s Analyst Blog: Top Research Reports for Novo Nordisk, Toyota and salesforce.com The Zacks Research Daily presents the best research output of our analyst team."
2022-06-09,114.63999938964844,112.70999908447266,-1.064886139494636,"Abbott (ABT) Stock Moves -1.73%: What You Should Know | Top Research Reports for Novo Nordisk, Toyota & Salesforce | 7 Monkeypox Stocks That May Take Off in Q2","In the latest trading session, Abbott (ABT) closed at $112.71, marking a -1.73% move from the previous day. ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.83 per share and revenue of $41.62 billion. It is also worth noting that ABT currently has a PEG ratio of 4.13. | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Novo Nordisk's (NVO) Diabetes Drugs Aid Growth Amid Rivalry Supply Chain Troubles & Escalating R&D Costs Ail Toyota (TM) Digital Transformation and Acquisitions Aid Salesforce (CRM) Featured Reports Abbott's (ABT) Diabetes Care Business Grows amid Forex Woes The Zacks analyst is impressed with Abbott's diabetes business arm performance in the first quarter 2022 led by strong growth in FreeStyle Libre. (You can read the full research report on Salesforce here >>>) Other noteworthy reports we are featuring today include Abbott Laboratories (ABT), Raytheon Technologies Corporation (RTX), and Equinor ASA (EQNR). Abbott Laboratories (ABT): Free Stock Analysis Report | SIGA SIGA Technologies, Inc. $10.90 EBS Emergent BioSolutions Inc. $31.78 CMRX Chimerix, Inc. $1.79 BVNRY Bavarian Nordic A/S $9.80 ABT Abott Laboratories $114.50 INO Inovio Pharmaceuticals, Inc. $1.79 TNXP Tonix Pharmaceuticals Holding Corp. $2.22 Monkeypox Stocks to Watch: SIGA Technologies Inc. (SIGA) Source: Shutterstock SIGA Technologies (NASDAQ:SIGA) produces the Tecovirimat SIGA, or TPOXX smallpox vaccine as it’s known in the U.S., SIGA’s vaccine was approved in the United States for the treatment of smallpox in July 2018, and it received European approvals for the treatment of Smallpox, Monkeypox and Cowpox in January 2022. Monkeypox Stocks to Watch: Abbott Laboratories (ABT) Source: testing / Shutterstock.com After reporting a strong 18% organic sales growth during the first quarter, and a 31% adjusted earnings growth, medical devices manufacturer Abbott Laboratories (NYSE:ABT) could see its business sustain double-digit growth rates into the future, and the latest Monkeypox outbreak could offer a new target market. Claims that INO’s smallpox vaccine study offered 100% protection against smallpox in non-human primates could have made investors hopeful that perhaps the vaccine candidate could be worth something as Monkeypox becomes a topical threat to global health."
2022-06-08,115.73999786376952,114.69000244140624,-1.6835313289002451,,
2022-06-07,116.0999984741211,116.87999725341795,-0.9072018677580821,,
2022-06-06,117.37999725341795,116.41999816894533,0.6718335827288783,U.S. organizes flight from Germany to Texas with Nestle baby formula | U.S. organizes Germany-to-Texas flight with Nestle baby formula | The Health Care Select Sector SPDR Fund Experiences Big Inflow | U.S. organizes Germany-to-Texas flight with Nestle baby formula | Abbott Restarts Baby Formula Production At Michigan Plant,"WASHINGTON, June 6 (Reuters) - The United States has organized a flight to deliver 110,000 pounds of Nestlé infant formula from Germany to Texas on June 9, the White House said on Monday. The formula, an equivalent of roughly 1.6 million 8-ounce bottles, will be made available nationwide and further announcements of deliveries of Nestle formula would be made in the coming days, it said. (Reporting by Jeff Mason) ((jeff.mason@thomsonreuters.com; +1 202 898 8300; On Twitter: @jeffmason1; Reuters Messaging: jeff.mason.thomsonreuters.com@thomsonreuters.net)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | By Jeff Mason WASHINGTON, June 6 (Reuters) - The United States has organized a flight to deliver 110,000 pounds of Nestlé infant formula from Germany to Texas on June 9, the White House said on Monday. The formula, an equivalent of roughly 1.6 million 8-ounce bottles, will be made available nationwide and further announcements of deliveries of Nestle formula would be made in the coming days, it said. Biden's Operation Fly Formula has delivered 1.5 million ""bottle equivalents"" of Nestle formula and has arranged to get 8.3 million from Bubs Australia and Kendamil, the White House said. | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is trading flat, Abbott Laboratories (Symbol: ABT) is up about 0.9%, and Danaher Corp (Symbol: DHR) is higher by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $908.7 million dollar inflow -- that's a 2.4% increase week over week in outstanding units (from 292,170,000 to 299,170,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $121.21 per share, with $143.42 as the 52 week high point — that compares with a last trade of $130.78. | By Jeff Mason WASHINGTON, June 6 (Reuters) - The United States has organized a flight to deliver 110,000 pounds of Nestlé infant formula from Germany to Texas on June 9, the White House said on Monday. The formula, an equivalent of roughly 1.6 million 8-ounce bottles, will be made available nationwide and further announcements of deliveries of Nestle formula would be made in the coming days, it said. Biden's Operation Fly Formula has delivered 1.5 million ""bottle equivalents"" of Nestle formula and has arranged to get 8.3 million from Bubs Australia and Kendamil, the White House said. | Abbott then had confirmed that EleCare would be the first formula produced at the Sturgis facility when it restarts production, and other specialty metabolic formulas will closely follow. The FDA also approved then the release of Abbott's about 300,000 cans of EleCare amino acid-based infant formula previously produced at Abbott Nutrition's Sturgis, Michigan, facility to individuals needing urgent, life-sustaining supplies of this specialty formula on a case-by-case basis. The FDA, which urged infant formula manufacturers worldwide to import products to the U.S., recently announced the intended availability of around 39.5 million additional bottles of infant formula from Swiss food major Nestle SA starting June through October."
2022-06-03,116.77999877929688,116.56999969482422,-0.8178557735011992,Abbott (ABT) Stock Moves -0.8%: What You Should Know | Cardiovascular Systems (CSII) Up 0.9% Since Last Earnings Report: Can It Continue? | 2 Dividend Kings to Buy and Hold Forever,"ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.82 per share and revenue of $41.62 billion. In the latest trading session, Abbott (ABT) closed at $116.57, marking a -0.8% move from the previous day. It is also worth noting that ABT currently has a PEG ratio of 3.11. | Another stock from the same industry, Abbott (ABT), has gained 4% over the past month. Abbott Laboratories (ABT): Free Stock Analysis Report Cardiovascular Systems Q3 Earnings Top Estimates Cardiovascular Systems reported a loss of 25 cents per share for third-quarter fiscal 2022, compared to the loss of 15 cents in the prior-year period. | Let's look at two Dividend Kings worth buying now and holding onto forever: Johnson & Johnson (NYSE: JNJ) and Abbott Laboratories (NYSE: ABT). Johnson & Johnson Johnson & Johnson has been a leader in the pharmaceutical industry for several decades. For the period, Johnson & Johnson's total sales grew by 5% year over year to $23.4 billion."
2022-06-02,115.29000091552734,117.51000213623048,-0.17982453045708163,Federal investigators to review FDA response to baby formula recall | Federal agency to review FDA response to baby formula recall,"Adds data on baby formula shortage, background, related links June 2 (Reuters) - Federal investigators have launched a review into whether the U.S. Food and Drug Administration properly inspected Abbott Laboratories' ABT.N Michigan plant and how the agency oversaw the baby formula recall that led to severe U.S. shortages. Abbott subsequently closed the plant and recalled baby formula made there, deepening a nationwide shortage that has left parents scrambling to feed their babies. TIMELINE-Baby formula crunch in U.S. forces scramble to boost supplies FACTBOX-Global baby formula makers send products to restock U.S. shelves (Reporting by Manas Mishra in Bengaluru; Editing by Shounak Dasgupta and Maju Samuel) ((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manaswrites15)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | June 2 (Reuters) - A federal agency will start a review if the U.S. Food and Drug Administration (FDA) properly conducted its inspection of Abbott Laboratories' ABT.N Michigan plant and oversaw baby formula recalls that led to severe shortages in the United States. The FDA started its inspection of the plant in late January following reports of bacterial infections in babies potentially linked to Abbott's formula. Abbott subsequently closed the plant and recalled baby formula made there, deepening a nationwide shortage that has left parents scrambling to feed their babies."
2022-06-01,117.8499984741211,115.08000183105467,1.9255800182790594,"Abbott (ABT) Receives FDA Nod for FreeStyle Libre 3 System | Biden, baby formula cos to meet on efforts to ease shortage | Biden to get supply update from infant formula producers | Australia in talks with U.S. to supply infant formula","Abbott Laboratories’ ABT next-generation FreeStyle Libre 3 system was recently approved by the FDA for diabetes patients aged four years and older. Abbott Laboratories (ABT): Free Stock Analysis Report Few Words on the FreeStyle Libre 3 Abbott’s FreeStyle Libre 3 system has demonstrated the greatest accuracy, with an overall mean absolute relative difference (MARD) of 7.9%. | U.S. parents have struggled to find baby formula in recent months as supplies suffered after a February recall of some formulas by one of the nation's main manufacturers, Abbott Laboratories ABT.N, coupled with other pandemic-related supply chain issues. By Jarrett Renshaw June 1 (Reuters) - U.S. President Joe Biden will meet with major infant formula manufacturers on Wednesday as his administration presses ahead with efforts to boost imported supplies to help ease a nationwide shortage. FACTBOX-Global baby formula makers send products to restock U.S. shelves (Reporting by Jarrett Renshaw; Additional writing by Susan Heavey; Editing by Leslie Adler and Chizu Nomiyama) ((jarrett.renshaw@thomsonreuters.com; (646) 223-6193;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The U.S. has been dealing with a baby formula shortage due to a February recall at Abbott Laboratories ABT.N and pandemic-related supply-chain issues, prompting Biden to invoke the Defense Production Act to ensure manufacturers have the necessary supplies for baby formula production. By Jarrett Renshaw June 1 (Reuters) - U.S. President Joe Biden on Wednesday will convene a virtual roundtable with producers of infant formula to get updates on the industry's efforts to ramp up supplies to address a national shortage. Global companies that make baby formula have delivered products to the U.S. after health regulators relaxed import policies to address the shortage. | Adds background, New Zealand government spokesperson's quote June 1 (Reuters) - Australia is in talks with the United States to supply baby food, an Australian government spokesperson said on Wednesday, after the apex U.S. health regulator relaxed its import policy to address a nationwide shortage. Two million cans of formula from the UK are headed to American shores, while Bubs Australia BUB.AX struck a deal with the U.S. Food and Drug Administration (FDA) last week to supply 1.25 million cans. ""Australian Government agencies have been actively engaging with the Australian infant formula industry to help secure supply of infant formula to the U.S."" The agency didn't provide additional details on the extent of talks with the U.S. government."
2022-05-31,115.55999755859376,117.45999908447266,-2.3504426634970974,Here's A Better Pick Over Abbott Stock | Abbott Says FDA Oks FreeStyle Libre 3 System As Glucose Monitor For Diabetic Patients | What Makes DexCom Stock A Better Pick Over This Insulin Pump Maker?,"We think that Teva stock (NYSE: TEVA) currently is a better pick compared to its industry peer, Abbott stock (NYSE: ABT), given its comparatively lower valuation and better prospects. The table below summarizes our revenue and return expectations for Abbott and Teva over the next three years and points to an expected return of 20% for Teva over this period vs. a 12% expected return for ABT stock, implying that investors are better off buying TEVA over ABT, based on Trefis Machine Learning analysis – Abbott vs. Teva – which also provides more details on how we arrive at these numbers. Even if we were to look at the P/EBIT ratio, ABT stock appears to be more expensive, with a 20.7x P/EBIT ratio, compared to 16.6x for TEVA stock. | (RTTNews) - Abbott Laboratories (ABT) announced Tuesday that the U.S. Food and Drug Administration (FDA) cleared its next-generation FreeStyle Libre 3 system for use by people four years and older living with diabetes. Designed for access and affordability, the FreeStyle Libre 3 system will be available at the same price as previous versions, which is one-third the cost of other competing continuous glucose monitoring systems available today. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We think that DexCom stock (NASDAQ: DXCM) is currently a better pick than Insulet stock (NASDAQ: PODD), given DexCom’s better prospects and comparatively lower valuation. We compare a slew of factors such as historical revenue growth, returns, and valuation multiple in an interactive dashboard analysis of DexCom vs. Insulet: Which Stock Is A Better Bet? The table below summarizes our revenue and return expectations for DexCom and Insulet over the next three years and points to an expected return of 98% for DexCom over this period vs. a 79% expected return for Insulet, based on Trefis Machine Learning analysis – DexCom vs. Insulet – which also provides more details on how we arrive at these numbers."
2022-05-27,116.08000183105467,116.69000244140624,1.6441688871752629,"Bubs Australia to ship at least 1.25 mln baby formula cans to United States | Bubs Australia plans to ship at least 1.25 mln baby formula cans to U.S., says FDA | ESLOY vs. ABT: Which Stock Should Value Investors Buy Now? | ANALYSIS-As shortage persists, Reckitt tightens grip on U.S. baby formula market","The shortage is partly due to Abbott Laboratories' ABT.N manufacturing plant in Michigan recalling some products including Similac in February. Adds details from HHS statement on Cargill Inc May 27 (Reuters) - Bubs Australia Ltd BUB.AX plans to ship at least 1.25 million cans of its baby formula to the United States to help ease a nationwide shortage, the U.S. Food and Drug Administration (FDA) said on Friday. Cargill supplies dozens of products to infant formula makers and the move will allow the manufacturers to produce at full capacity to address the ""urgent marketplace shortages"", the department said in a statement. | The shortage is partly due to Abbott Laboratories' ABT.N manufacturing plant in Michigan recalling some products including Similac in February. May 27 (Reuters) - Bubs Australia Ltd BUB.AX plans to ship at least 1.25 million cans of its baby formula to the United States to help ease a nationwide shortage, the U.S. Food and Drug Administration (FDA) said on Friday. Bubs' supply is another import allowed by the FDA as part of its regulatory flexibility started earlier this month in an attempt to mitigate one of the biggest baby formula shortages in recent history. | Investors interested in Medical - Products stocks are likely familiar with EssilorLuxottica Unsponsored ADR (ESLOY) and Abbott (ABT). These metrics, and several others, help ESLOY earn a Value grade of B, while ABT has been given a Value grade of C. ESLOY is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. Investors should feel comfortable knowing that ESLOY likely has seen a stronger improvement to its earnings outlook than ABT has recently. | Reckitt RKT.L has ramped up production of its Enfamil formula since U.S. rival Abbott Laboratories ABT.N in February recalled dozens of products in the United States after customers complained of infants contracting bacterial infections. The British consumer goods company, which boosted formula production by 30%, told Reuters last week it now accounted for more than 50% of total baby formula supply in United States, up from around a third before the crisis. But margins have been further boosted by the United States saying it will temporarily cover the cost of baby formula for low-income families dependent on government discounts in states contracted with Nestle and Reckitt."
2022-05-26,113.77999877929688,114.87000274658205,0.5255001729233003,"Abbott developing test for monkeypox | U.S. FDA expands collaboration with Danone to boost baby formula supply | Quant Ratings Updated on 75 Stocks | Abbott (ABT) to Commence Limited Release of EleCare Soon | 5 Dividend Aristocrats Where Analysts See Capital Gains | SPY, ABBV, ABT, ACN: ETF Inflow Alert","By Leroy Leo May 26 (Reuters) - Abbott Laboratories ABT.N said on Thursday it is actively developing a test for monkeypox, as the disease spreads in various countries. The company will provide the test kits to partners of its Pandemic Defense Coalition, a network of scientific and public health partnerships aimed at identifying future pandemic threats, an Abbott spokesperson told Reuters. Abbott's announcement comes on a day when the Centers for Diseases Control and Prevention (CDC) confirmed it has identified nine monkeypox cases in seven U.S. states. | Meanwhile, lawmakers grilled the agency officials on Wednesday over what they saw as a lack of urgency in their response to complaints about possible baby formula contamination at a now shuttered Abbott Laboratories ABT.N plant that led to severe nationwide shortages. May 26 (Reuters) - The U.S. Food and Drug Administration said on Thursday it has expanded its collaboration with Danone's Nutricia business to boost supplies of specialized medical baby formula bottles to address its shortage among infants with certain allergies or critical health conditions. Abbott controlled 40% of the market before the plant closed, Christopher Calamari, president of Abbott U.S. nutrition, told lawmakers, and the plant accounted for 40% of Abbott's product. | A Agilent Technologies, Inc. B ABT Abbott Laboratories B AMGN Amgen Inc. B APO Apollo Global Management Inc. B CE Celanese Corporation B CNA CNA Financial Corporation B CTLT Catalent Inc. B DAL Delta Air Lines Inc. B DHR Danaher Corporation B FCX Freeport-McMoRan, Inc. B The reality is money flow is ultimately what determines if a stock will go up or down — and this is exactly what my system tracks. InvestorPlace - Stock Market News, Stock Advice & Trading Tips First, I want to thank those who joined me for my special event on Tuesday, The Great American Wealth Shift. This is a perfect example of what I like to call “money flow.” Money flowing into a stock drives it higher, while money that flows out of a stock triggers a selloff. | Abbott Laboratories ABT recently announced that following the U.S. District Court for the Western District of Michigan’s amendment of a recent consent decree, the company would release limited quantities of its EleCare specialty amino acid-based formulas. Abbott Laboratories (ABT): Free Stock Analysis Report Abbott’s plans to restart production on Jun 4 at the Sturgis facility, where it will prioritize EleCare production, is expected to provide a significant boost to the company’s Nutritional Products segment on a global scale. | Ecolab Inc (Symbol: ECL) $157.82 $207.50 31.48% Abbott Laboratories (Symbol: ABT) $113.19 $139.85 23.55% Illinois Tool Works, Inc. (Symbol: ITW) $201.93 $222.78 10.32% Expeditors International of Washington, Inc. (Symbol: EXPD) $106.13 $116.71 9.97% Prosperity Bancshares Inc. (Symbol: PB) $70.80 $76.56 8.13% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Ecolab Inc (Symbol: ECL) 1.29% 31.48% 32.77% Abbott Laboratories (Symbol: ABT) 1.66% 23.55% 25.21% Illinois Tool Works, Inc. (Symbol: ITW) 2.42% 10.32% 12.74% Expeditors International of Washington, Inc. (Symbol: EXPD) 1.26% 9.97% 11.23% Prosperity Bancshares Inc. (Symbol: PB) 2.94% 8.13% 11.07% Another consideration with dividend growth stocks is just how much the dividend is growing. Ecolab Inc (Symbol: ECL) $1.9 $1.98 4.21% Abbott Laboratories (Symbol: ABT) $1.62 $1.84 13.58% Illinois Tool Works, Inc. (Symbol: ITW) $4.49 $4.8 6.90% Expeditors International of Washington, Inc. (Symbol: EXPD) $1.04 $1.16 11.54% Prosperity Bancshares Inc. (Symbol: PB) $1.9 $2.02 6.32% These five stocks are part of our full Dividend Aristocrats List. | Among the largest underlying components of SPY, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.3%, Abbott Laboratories (Symbol: ABT) is up about 0.9%, and Accenture plc (Symbol: ACN) is up by about 2.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P 500 ETF Trust (Symbol: SPY) where we have detected an approximate $1 inflow -- that's a 0.3% increase week over week in outstanding units (from 90,0,8,80,,000 to 90,3,9,80,,000). For a complete list of holdings, visit the SPY Holdings page » The chart below shows the one year price performance of SPY, versus its 200 day moving average: Looking at the chart above, SPY's low point in its 52 week range is $380.54 per share, with $479.98 as the 52 week high point — that compares with a last trade of $403.46."
2022-05-25,113.1999969482422,113.19000244140624,0.9579925988569309,"U.S. baby formula shortage: FDA defends response, cites safety problems at Abbott plant | U.S. FDA defends baby formula shortage response in Congress | 2 Dividend Kings That Are Soundly Beating the Market in 2022 | US To Get About 2 Mln Infant Formula Cans From UK's Kendal Nutricare: FDA | Danone doubles supply of some baby formula to U.S. | Will Medtronic Stock See Higher Levels Following Its Q4 Results?","By Ahmed Aboulenein and Manas Mishra WASHINGTON, May 25 (Reuters) - The U.S. Food and Drug Administration on Wednesday in testimony to lawmakers defended steps it took to address complaints about possible baby formula contamination at a now shuttered Abbott Laboratories ABT.N plant that led to severe nationwide shortages. The plant is one of three run by Abbott, which has the largest U.S. market share for infant formula, and the company did not have a contingency plan to produce its specialty formulas that serve as the only source of nutrition for thousands of babies with metabolic disorders, the FDA said. The FDA conducted an inspection of the plant following reports of bacterial infections in babies potentially linked to baby formula, and a whistleblower complaint from a former employee at the plant in late October. | By Ahmed Aboulenein WASHINGTON, May 25 (Reuters) - The U.S. Food and Drug Administration on Wednesday in testimony to lawmakers defended the steps it took to address complaints about possible baby formula contamination at an Abbott Laboratories ABT.N plant that has been closed since February. It was critical to get the Sturgis plant online as soon as possible because it is one of three run by Abbott, which has the largest U.S. market share for infant formula, and because Abbott did not have a contingency plan to produce its lines of specialty formulas that serve as the only source of nutrition for thousands of babies with metabolic disorders, they said. After the FDA inspection of the Sturgis facility, the consent decree was the only way for the FDA to have confidence in Abbott ""where we literally have oversight of every single step"" FDA Commissioner Dr. Robert Califf said in testimony before the U.S. House of Representatives Commerce and Energy Subcommittee on Oversight and Investigations. | It would take a $26,800 investment in the stock to generate $1,000 in annual dividend income from AbbVie at its current rate. Both stocks could make for attractive investment options right now, especially if you're worried about the state of the stock market. See the 10 stocks *Stock Advisor returns as of April 27, 2022 David Jagielski has no position in any of the stocks mentioned. | Under the agency's recent increased flexibilities, British nutrition products maker Kendal Nutricare will send about 2 million cans of infant formula under the Kendamil brand initially to U.S. beginning in June. Regarding Abbott, the FDA said it approved the release of about 300,000 cans of EleCare amino acid-based infant formula previously produced at Abbott Nutrition's Sturgis, Michigan, facility to individuals needing urgent, life-sustaining supplies of this specialty formula on a case-by-case basis. Abbott has confirmed to the agency that EleCare will be the first formula produced at the Sturgis facility when it restarts production, and other specialty metabolic formulas will closely follow. | The world's second-biggest baby formula maker told Reuters that it is in talks with U.S. authorities over what more it can do to ease the formula shortage following a recall by Abbott Laboratories ABT.N. By Richa Naidu LONDON, May 25 (Reuters) - Danone SA DANO.PA on Wednesday said it has been doubling shipments to the United States of Neocate formula for infants allergic to cow's milk. (Reporting by Richa Naidu Editing by Matt Scuffham and David Goodman ) ((richa.naidu@tr.com; Follow me on Twitter https://twitter.com/Richa_Writes; +44 755 755 9587;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (1) Revenues expected to be above the consensus estimate Trefis estimates Medtronic’s Q4 fiscal 2022 total revenues to be around $8.5 billion, compared to the $8.4 billion consensus estimate. (2) EPS likely to be just above the consensus estimates Medtronic’s Q4 fiscal 2022 earnings per share (EPS) is expected to be $1.57 per Trefis analysis, just a cent above the consensus estimate of $1.56. Total [2] MDT Return 0% 1% 46% S&P 500 Return -4% -17% 78% Trefis Multi-Strategy Portfolio -5% -21% 210% [1] Month-to-date and year-to-date as of 5/24/2022 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2022-05-24,115.16000366210938,113.7699966430664,-0.008829069881102252,"U.S. FDA allows importing of 2 mln baby formula cans from UK | U.S. FTC launches inquiry into infant formula shortage | U.S. FTC launches inquiry into infant formula crisis | U.S. states, manufacturers to decide if gov't benefits apply to imported baby formula | Abbott (ABT) Transcatheter Valve Devices' Study Data Favorable","The United States is experiencing one of the biggest infant formula shortages in recent history after Abbott Laboratories ABT.N in February recalled some products including Similac and closed its manufacturing plant in Sturgis, Michigan. By Ahmed Aboulenein and Ananya Mariam Rajesh WASHINGTON, May 24 (Reuters) - The U.S. Food and Drug Administration is easing regulations to allow infant formula imports from Britain, a move it said on Tuesday would bring around 2 million cans onto empty shelves by June to ease a nationwide shortage. ""Under the agency's recent increased flexibilities regarding importation of certain infant formula products, the company initially estimates that about 2 million cans of infant formula are expected to land on U.S. store shelves beginning in June,"" it said in a statement. | The inquiry comes after a Feb. 17 recall by top baby formula maker Abbott Laboratories ABT.N and the closing of its manufacturing plant in Sturgis, Michigan created one of the biggest baby formula shortages in recent history for U.S. families. Adds details on inquiry, quote from FTC chair WASHINGTON, May 24 (Reuters) - The Federal Trade Commission said on Tuesday it had launched an inquiry into the ongoing shortage for infant formula in the United States and would examine the pattern of mergers and acquisitions in the formula market. The FTC will also seek public comment on whether the FTC itself or state or federal agencies may have taken steps that contributed to fragile supply chains for infant formula, it added. | The inquiry comes in the wake of a product recall by top baby formula maker Abbott Laboratories ABT.N and the closing of its manufacturing plant in Sturgis, Michigan during a probe by the U.S. Food and Drug Administration that has created one of the biggest infant formula shortages in recent history for U.S. families. May 24 (Reuters) - The Federal Trade Commission said on Tuesday it has launched an inquiry into the ongoing shortage for infant formula. (Reporting by Ananya Mariam Rajesh in Bengaluru; Editing by Arun Koyyur) ((AnanyaMariam.Rajesh@thomsonreuters.com ; Twitter: https://twitter.com/AnanyaMariam;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT.N, the top formula maker whose Michigan plant closure due to possible bacterial contamination greatly exacerbated the current national shortage, holds about 55% of WIC contracts. Infants enrolled in the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) program for low-income families consumed about 56% of all infant formula in the United States in 2018, according to available USDA data. The first shipment from Europe on Sunday in Operation Fly Formula - the Biden administration's effort to offset the shortage with imports - was of specialty formulas that will be available to eligible WIC infants, a USDA official said. | Abbott Laboratories ABT presented two late-breaking study data evaluating the company’s TriClip — a first-of-its-kind minimally invasive tricuspid heart valve repair device, and Navitor — the company's newest-generation transcatheter aortic valve implantation (TAVI) system. Abbott Laboratories (ABT): Free Stock Analysis Report Study Outcome Details The first 30-day results from the TriClip bRIGHT study, highlighted in a late-breaking data presentation, demonstrated that the TriClip and TriClip G4 transcatheter edge-to-edge repair systems considerably minimize tricuspid regurgitation and substantially enhance the quality of life across a wide range of anatomically diverse patients."
2022-05-23,113.8499984741211,115.02999877929688,-1.2070223817649262,U.S. agency issues order to speed baby formula ingredient deliveries,"The order comes in the wake of a product recall by top baby formula maker Abbott Laboratories ABT.N, and the closing of its manufacturing plant in Sturgis, Michigan during an investigation by the U.S. Food and Drug Administration that has created one of the biggest infant formula shortages in recent history for U.S. families. By David Shepardson WASHINGTON, May 23 (Reuters) - The U.S. Federal Motor Carrier Safety Administration (FMCSA) said late Monday it was issuing a national emergency declaration to waive hours-of-service requirements for commercial vehicle drivers transporting baby formula ingredients and packaging. As a result, the agency moved to issue the declaration ""that both finished formula and the products involved in the production of formula are included"" in waivers."
2022-05-20,113.4000015258789,113.23999786376952,1.0364517531759156,Abbott (ABT) Down 8.9% Since Last Earnings Report: Can It Rebound? | Abbott completes India recall of baby formula products imported from U.S. | EXCLUSIVE-Danone ramps up U.S. baby formula shipments to address shortage | EXCLUSIVE-French baby formula maker Danone sharply ramps up U.S. shipments,"A month has gone by since the last earnings report for Abbott (ABT). Abbott Laboratories (ABT): Free Stock Analysis Report Abbott's Q1 Earnings and Revenues Beat Estimates Abbott reported first-quarter 2022 adjusted earnings of $1.73 per share, which exceeded the Zacks Consensus Estimate by 17.7%. | By Leroy Leo May 20 (Reuters) - Abbott Laboratories' ABT.N India unit has completed a recall of baby formula products that were manufactured at the company's troubled Michigan facility in the United States, a spokesperson for the company said on Friday. No other Abbott nutrition products, or Similac products, distributed in India were affected by the recall,"" the spokesperson told Reuters. The recall in February by Abbott in the United States created one of the most urgent food shortages in recent history for U.S. families, with other baby formula makers stepping up shipments to the country. | This followed a Feb. 17 recall by top manufacturer Abbott Laboratories ABT.N which recalled dozens of types of its Similac, Alimentum and EleCare formulas, creating one of the most urgent food shortages in recent history for U.S. families. By Richa Naidu and Lisa Baertlein LONDON/LOS ANGELES, May 20 (Reuters) - Aptamil maker Danone SA DANO.PA has stepped up shipments of infant formula from Europe to address a shortage in the United States, analysis of ocean cargo data by U.S. customs data and shipping consultancy Ocean Audit for Reuters shows. Danone, the world's second biggest baby milk formula maker but a relatively small player in the United States, shipped much of the product from Britain and the Netherlands by ocean freight through its Nutricia North America arm. | Danone, the world's second biggest baby formula maker but a relatively small player in the U.S. market, shipped much of the product from the United Kingdom and the Netherlands by ocean freight through its Nutricia North America arm after a Feb. 17 recall by top manufacturer Abbott Laboratories ABT.N touched off the U.S. shortage. By Richa Naidu and Lisa Baertlein LONDON/LOS ANGELES, May 20 (Reuters) - Aptamil maker Danone SA DANO.PA has stepped up shipments of infant formula from Europe to the United States, according to U.S. customs data and shipping consultancy Ocean Audit, which analyzed ocean cargo data exclusively for Reuters. Separate U.S. customs data analyzed by Reuters shows that on Feb. 22, five days after the Abbott recall, nearly 38,000 kilograms (83,775.66 pounds) of Danone Nutricia cargo arrived in the United States from the United Kingdom and the Netherlands."
2022-05-19,112.02999877929688,112.44000244140624,-0.1410967019016088,"Abbott baby formula plant in Michigan on track to reopen in 1-2 weeks | Abbott Presents Data Reinforcing Impact Of Its Minimally Invasive Heart Devices | The Zacks Analyst Blog Highlights Alibaba, McDonald, Advanced Micro Devices, Abbott Laboratories, and Vertex Pharmaceuticals | These 3 Stocks Have Doubled Over the Past 3 Years. Can They Do It Again?","By Ahmed Aboulenein and Susan Heavey WASHINGTON, May 19 (Reuters) - Abbott Laboratories ABT.N and the U.S. Food and Drug Administration are on track to reopen the company's Sturgis, Michigan, baby formula manufacturing plant within one or two weeks, FDA Commissioner Robert Califf said on Thursday. The company had initiated a recall of its infant formula products and closed the plant in February after reports of serious bacterial infections in four infants, worsening a shortage among multiple manufacturers that began with pandemic supply chain issues. Abbott, FDA reach agreement to reopen baby formula facility in Michigan (Reporting by Ahmed Aboulenein and Susan Heavey; Editing by Franklin Paul and Chizu Nomiyama) ((ahmed.aboulenein@tr.com; +1 202-519-3051;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott (ABT) said data highlighting both TriClip, a minimally invasive tricuspid heart valve repair device, and Navitor, the company's latest-generation transcatheter aortic valve implantation system reinforced the impact of the company's minimally invasive heart devices on patient outcomes and quality of life. The 30-day results from the TriClip bRIGHT study showed that the TriClip and TriClip G4 transcatheter edge-to-edge repair systems significantly reduce tricuspid regurgitation and substantially improve quality of life across a wide range of anatomically diverse patients. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include:Alibaba Group Holding Ltd. BABA, McDonald's Corp. MCD, Advanced Micro Devices, Inc. AMDAbbott Laboratories ABT, and Vertex Pharmaceuticals Inc. VRTX. Abbott Laboratories (ABT): Free Stock Analysis Report Here are highlights from Wednesday’s Analyst Blog: Top Stock Reports for Alibaba, McDonald's and AMD The Zacks Research Daily presents the best research output of our analyst team. | Carlisle Companies (NYSE: CSL), Innovative Industrial Properties (NYSE: IIPR) and AbbVie (NYSE: ABBV) have all seen shares double over the past three years. Carlisle has increased its dividend every year for 45 years, including a 3% raise last year to $0.54 per share, which works out to a yield of 0.87%. Because of its higher price, Carlisle Companies would have the most difficult time doubling its share price in three years, but the company is probably the safest bet of the three companies to continue rising."
2022-05-18,113.41999816894533,112.73999786376952,0.36597667283482055,"Biden invokes Defense Production Act to increase infant formula supply | Top Stock Reports for Alibaba, McDonald's & Advanced Micro Devices","Baby formula aisles at U.S. supermarkets have been decimated since top U.S. manufacturer Abbott Laboratories ABT.N in February recalled formulas after complaints of bacterial infections. Adds details WASHINGTON, May 18 (Reuters) - President Joe Biden took steps on Wednesday to address the shortage of infant formula in the United States, invoking the Defense Production Act to help manufacturers obtain the ingredients needed to ramp up supply, the White House said. The White House said Biden was invoking the Defense Production Act to ensure manufacturers have the ingredients to make safe formula. | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Retail & Cloud Businesses Momentum Benefits Alibaba (BABA) Loyalty Program Aid McDonald's (MCD), China Comps Woes Stay Robust Product Portfolio & Partnerships Aid AMD's Prospects Featured Reports Abbott's (ABT) Diagnostics Arm Grows Amid Forex Headwinds The Zacks analyst is upbeat about the strong revenue growth within Abbott's (ABT) Diagnostics segment. (You can read the full research report on Advanced Micro Devices here >>>) Other noteworthy reports we are featuring today include Abbott Laboratories (ABT), Medtronic plc (MDT), and Vertex Pharmaceuticals Incorporated (VRTX). Abbott Laboratories (ABT): Free Stock Analysis Report"
2022-05-17,111.58999633789062,114.54000091552734,-0.5995418058135672,"Is It Too Late to Buy AbbVie Stock? | 2 No-Brainer Stocks to Buy Right Now for Less than $55 | VHT, TMO, ABT, DHR: Large Inflows Detected at ETF | U.S. Democrats unveil bill to address baby formula shortage | Morning Brief: Top Financial Stories Dominating on Tuesday, May 17 | How the Infant Formula Recall Will Impact Abbott's Revenue | EXCLUSIVE-Nestle flies baby formula supplies to U.S. from Europe | Baby formula makers ramp up U.S. supplies to tackle shortage","In the first quarter, sales of Skyrizi increased by 63.7% year over year to $940 million while Rinvoq's sales grew by 53.6% year over year to $465 million. Sales of AbbVie's aesthetics unit -- spearheaded by Botox Cosmetics -- grew by 20.5% year over year to $1.4 billion. First, as we have already seen, the company's lineup is strong enough to handle the inevitable sales drop that Humira will experience once it starts facing generic competition in the U.S. With the potential for label expansions and brand new drugs, AbbVie's pipeline will also be instrumental in helping the company keep its revenue afloat. | When the pandemic began, Fulgent was able to pivot to providing COVID-19 tests, which resulted in incredible revenue growth that has allowed the company to pour resources back into the business as well as make some key acquisitions. Put simply, Fulgent's business is built around its Net Generation Sequencing (NGS) genetic testing, and once revenue related to COVID-19 fades away, this core business will be what investors should keep an eye on. See the 10 stocks *Stock Advisor returns as of April 7, 2022 Jeff Santoro has positions in Fulgent Genetics, Inc. and Outset Medical, Inc. | Among the largest underlying components of VHT, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is up about 2.2%, Abbott Laboratories (Symbol: ABT) is up about 4.7%, and Danaher Corp (Symbol: DHR) is up by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Health Care ETF (Symbol: VHT) where we have detected an approximate $615.8 million dollar inflow -- that's a 3.9% increase week over week in outstanding units (from 66,888,677 to 69,491,925). For a complete list of holdings, visit the VHT Holdings page » The chart below shows the one year price performance of VHT, versus its 200 day moving average: Looking at the chart above, VHT's low point in its 52 week range is $228 per share, with $268.72 as the 52 week high point — that compares with a last trade of $238.69. | Adds detail of bill, background WASHINGTON, May 17 (Reuters) - U.S. House Democrats on Tuesday unveiled a bill to provide $28 million to the Food and Drug Administration to help respond to a nationwide shortage of infant formula. The supplementary funds for ""salaries and expenses"" would be available until the end of September 2023 ""to address the current shortage of FDA-regulated infant formula and certain medical foods in the United States and to prevent future shortages,"" according to the legislation. The FDA said on Monday the United States would allow baby formula imports from foreign makers that do not usually sell their products here, in a bid to ease the shortage that has left parents scrambling to feed their babies. | US Baby Formula Crisis Could See Some Relief As FDA, Abbott Agree On Deal The baby formula shortage that has morphed into a crisis in the U.S. could soon see some relief following an agreement between market leader Abbott Laboratories (NYSE: ABT) and the Food and Drug Administration. Analyst Says Bots Issue An Excuse To Lower Price Or Walk Away Tesla Inc (NASDAQ: TSLA) CEO Elon Musk is likely using the bots issue as a scapegoat to walk away from his $44 billion deal to buy Twitter Inc (NYSE: TWTR) or negotiate a lower price, according to Wedbush Securities analyst Dan Ives. “The elephant in the room for the Twitter board is Musk can walk away for a $1 billion as a small breakup fee ... and likely cite the bot/fake account issue as the reason, even though this likely would be contested by Twitter in the courts.” Coming Soon: Order A Tesla Or Polestar For Your Uber Ride Across The World In These Cities Uber Technologies Inc (NYSE: UBER) will soon let users in select cities across the world book a Tesla Inc (NASDAQ: TSLA) or a Polestar electric vehicle for their rides, as it seeks to accelerate its 2030 electrification ambitions. | Supply chain issues have created problems since the start of the pandemic, but healthcare equipment provider Abbott Laboratories' (NYSE: ABT) division Abbott Nutrition in particular has drawn the heat for the current severe shortage. Shortages triggered by recall and plant shutdown In mid-February, Abbott voluntarily recalled all powdered infant formula produced by its Sturgis, Michigan plant after four infants who consumed formula from the plant were hospitalized with infections caused by the common environmental bacteria Cronobacter sakazakii. Abbott may post declining sales in other nutritional segments in future quarters, however, because it's borrowing plant capacity from other products to meet demands for infant formula. | By Richa Naidu LONDON, May 17 (Reuters) - Nestle SA NESN.S is flying baby formula supplies to the United States from the Netherlands and Switzerland to alleviate tha shortage in U.S. supermarkets, the company said in an emailed statement to Reuters on Tuesday. ""Both products were already being imported but we moved shipments up and rushed via air to help fill immediate needs,"" Nestle said. (Editing by Matt Scuffham and Jason Neely) ((matthew.scuffham@thomsonreuters.com; Reuters Messaging: matthew.scuffham.reuters.com@reuters.net)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Baby formula aisles at U.S. supermarkets have been decimated since top U.S. manufacturer Abbott Laboratories ABT.N in February recalled formulas after complaints of bacterial infections. By Richa Naidu LONDON, May 17 (Reuters) - Top baby formula makers Reckitt Benckiser RKT.L and Nestle NESN.N have ramped up supplies to the United States to resolve a shortage that has emptied shelves and caused panic among parents. In the meantime, other baby formula makers have stepped up production and shipped extra supplies to the United States."
2022-05-16,109.4000015258789,109.70999908447266,2.643610246839876,"Abbott Reaches Agreement With FDA To Restart Baby Formula Production Amid U.S. Shortage | Abbott, FDA enter agreement over reopening of baby formula facility in Michigan | Here's Why Investors Should Retain Abbott (ABT) Stock Now | FDA to address baby formula imports as soon as Monday -chief | Enfamil maker Reckitt cranks up operations to put baby formula on U.S shelves | Abbott, FDA enter deal over reopening of baby formula facility in Michigan","(RTTNews) - Abbott has reached an agreement with the U.S. Food and Drug Administration to restart production of baby formula at the company's plant in Sturgis, Michigan amid a nationwide formula shortage. The baby formula maker closed the plant in February after bacterial infections were reported in four babies who consumed formula made at the plant; two of the babies died. Abbott in February had recalled various lots of its most popular powder formulas, including Similac, Alimentum, and EleCare, produced in its manufacturing facility in Sturgis, Michigan after four infants were diagnosed with Cronobacter sakazakii or Salmonella Newport, a rare bacterial infection. | May 16 (Reuters) - Abbott Laboratories ABT.N said on Monday it has entered into an agreement with the U.S. Food and Drug Administration on the steps necessary to resume production and maintain its baby formula facility at Sturgis, Michigan. (Reporting by Mrinalika Roy in Bengaluru; Editing by Amy Caren Daniel) ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 806749 8325;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT is gaining from strength in the Established Pharmaceuticals Division (EPD) business. Abbott Laboratories (ABT): Free Stock Analysis Report Within Nutrition, while the pediatric nutrition business witnessed a drag, the adult nutrition business continues to perform well with global organic sales growth of 11.5%, led by the company’s Ensure and Glucerna brands. | FDA Commissioner Robert Califf added he does not expect the shortage of the critical baby product to last until the end of year, adding it was ""quite likely"" there could be movement to reopen Abbott Laboratories' ABT.N Sturgis, Michigan, manufacturing facility in about two weeks. Adds Califf comments WASHINGTON, May 16 (Reuters) - The U.S. Food and Drug Administration will make an announcement regarding imported infant formula as soon as later on Monday, the agency's chief told NBC News in an interview as regulators and lawmakers seek to address ongoing supply shortages. ""I expect by the end of the day today that we're likely to have an announcement about that path forward,"" he told NBC's ""Today"" program regarding efforts to import formula from other countries for U.S. consumers. | Baby formula aisles at supermarkets have been emptied by panicked parents since top U.S. manufacturer Abbott Laboratories ABT.N in February recalled dozens of types of its Similac, Alimentum and EleCare formulas. By Richa Naidu LONDON, May 17 (Reuters) - Reckitt Benckiser RKT.L is boosting baby formula production by about 30% and making more frequent deliveries to stores as it looks to counter a nationwide shortage in U.S. supermarkets, an executive told Reuters. Reckitt, which makes its U.S. formula in three facilities in Michigan, Indiana and Minnesota, has also granted plants ""unlimited overtime"" to put in extra shifts, Robert Cleveland, senior vice president, North America and Europe Nutrition at Reckitt, told Reuters in an interview. | Adds details on agreement, background on formula recall May 16 (Reuters) - Abbott Laboratories ABT.N said on Monday it had struck a deal with the U.S. health regulator under which it would resume production of baby formula at its troubled Michigan plant in two weeks, following certain clearances. Abbott, the biggest U.S. supplier of milk formula, in February recalled Similac and other baby formula made at the Michigan facility. The company, which shutdown production at the plant in February, said last week it could restart production of infant formula at its Michigan facility within two weeks, subject to approval from the FDA."
2022-05-13,108.36000061035156,109.87999725341795,0.28336156697440185,"EXCLUSIVE-Maker of Walmart, Amazon store-brand infant formulas expects shortages through rest of 2022 | EXCLUSIVE-Maker of Walmart, Amazon store-brand infant formulas expects shortages through rest of 2022 | Abbott says shipped millions of cans of infant formula from Ireland | Here's Why This Dividend King Is a Buy for Income Investors | U.S. House panel to investigate infant milk formula shortage -ABC","The closure of Abbott Laboratories' ABT.Ninfant-formula plant in Sturgis, Michigan, exacerbated national pandemic-related shortages, leading to empty shelves in big box stores and supermarkets and panicked parents. By Jessica DiNapoli NEW YORK, May 13 (Reuters) - Perrigo Company PLC PRGO.N, which makes store-brand baby formulas for retailers including Walmart Inc WMT.N and Amazon.com Inc AMZN.O expects shortages and heightened demand to last for the ""balance of the year,"" said CEO Murray Kessler in an interview with Reuters. Bobbie, a European-style infant formula new to the market, saw its customer count double the first week after the recall of Abbott formulas, and it has continued to climb, CEO Laura Modi told Reuters. | The closure of an Abbott Laboratories ABT.N infant-formula plant in Michigan exacerbated pandemic-related shortages, leading to empty shelves in big box stores and supermarkets. By Jessica DiNapoli NEW YORK, May 13 (Reuters) - Perrigo Company PLC PRGO.N, which makes store-brand baby formulas for retailers including Walmart Inc WMT.N and Amazon.com Inc AMZN.O expects shortages and heightened demand to last for the ""balance of the year,"" said CEO Murray Kessler in an interview with Reuters. At the request of the U.S. Food and Drug Administration, the company is making only four items, the store-brand versions of Similac Pro Sensitive and Pro Advance and Enfamil Gentle Ease and Infant, Kessler said. | Rewrites throughout, adds background May 13 (Reuters) - Abbott Laboratories ABT.N said on Friday it has air shipped millions of cans of infant formula powder into the United States from its facility in Ireland to address shortages here as it tries to reopen its Michigan manufacturing plant. The company said in a blog it was shipping infant formula produced at its Cootehill, Ireland facility to be used by consumers eligible for the U.S. government's Women, Infants and Children (WIC) nutrition assistance program for low-income families. Abbott in February recalled some baby formulas, including certain Similac products, made at the Sturgis plant after complaints about bacterial infections in infants who had consumed the products. | With its stock falling 23% so far this year, Abbott Laboratories (NYSE: ABT) is a fitting recent example. Another quarter, another revenue and earnings beat Abbott Laboratories was able to easily surpass analysts' expectations for both revenue and non-GAAP earnings per share (EPS) when it reported first-quarter results on April 20. 10 stocks we like better than Abbott Laboratories When our award-winning analyst team has a stock tip, it can pay to listen. | Adds quotes from letter to companies, background WASHINGTON, May 13 (Reuters) - The U.S. House Oversight Committee plans to investigate a nationwide baby formula shortage and will seek records from the four largest manufacturers, ABC News reported on Friday, citing letters from the committee chairwoman. ""The national formula shortage poses a threat to the health and economic security of infants and families in communities across the country - particularly those with less income who have historically experienced health inequities, including food insecurity,"" U.S. Representative Carolyn Maloney, who leads the committee, wrote in letters to Abbott Nutrition, Mead Johnson Nutrition, Nestle USA and Perrigo, ABC reported. Formula shortages because of a factory being taken offline have been compounded by supply chain snags and historic inflation, leaving about 40% of baby formula products out of stock nationwide, according to data firm Datasembly."
2022-05-12,105.5,107.97000122070312,1.4027285294433522,"Biden to get update on U.S. infant formula supplies on Thursday | Biden presses companies on infant formula, FDA to announce import steps | Should You Invest in the iShares U.S. Medical Devices ETF (IHI)? | How Will Baby Formula Shortage Affect Abbott?","Shortages developed after Abbott Laboratories ABT.N in February recalled Similac and other baby formula made at its Michigan plant following complaints of bacterial infections in infants who consumed the products. Adds quote, background WASHINGTON, May 12 (Reuters) - U.S. President Joe Biden will speak with infant formula retailers and manufacturers about supply issues on Thursday before the White House announces additional actions to address shortages, a White House official said. Abbott, the biggest supplier of milk formula in the United States, said on Wednesdasy it could restart production within two weeks of infant formula at the Michigan plant that has been tied to the shortages. | WASHINGTON, May 12 (Reuters) - U.S. President Joe Biden met with executives from infant formula manufactures and retailers including Target, Walmart and Nestle's Gerber on Thursday to discuss doing everything they could to get families access to formula, an administration official said. The U.S. Food & Drug Administration will announce new steps in the coming days regarding importing certain infant formula products from abroad, the White House said, and Biden has asked the Federal Trade Commission to use all its tools to probe reports of predatory conduct such as price gouging related to infant formula. (Reporting by Jeff Mason and Christopher Gallagher) ((jeff.mason@thomsonreuters.com; +1 202 898 8300; On Twitter: @jeffmason1; Reuters Messaging: jeff.mason.thomsonreuters.com@thomsonreuters.net)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Looking at individual holdings, Thermo Fisher Scientific Inc (TMO) accounts for about 15.42% of total assets, followed by Abbott Laboratories (ABT) and Medtronic Plc (MDT). Abbott Laboratories (ABT): Free Stock Analysis Report Alternatives IShares U.S. Medical Devices ETF holds a Zacks ETF Rank of 2 (Buy), which is based on expected asset class return, expense ratio, and momentum, among other factors. | Citing the voluntary recall of its certain infant formula products, medical devices and healthcare company, Abbott Laboratories (NYSE: ABT) lowered its full-year organic sales growth guidance during the Q1 conference call. BTIG analyst Marie Thibault stated, “We think it could take some time to restart production, work through quality checks, and get product back on the shelf.” She added that “despite the shortage of baby formula, we think ABT may also need to make added investments to win back brand loyalty from parents.” The analyst projects “a gradual recovery beginning in Q3.” Thibault has a Buy recommendation on ABT stock with a price target of $140. Wall Street analysts are bullish about ABT stock."
2022-05-11,106.66000366210938,105.83999633789062,2.341233384552725,Abbott could restart infant formula production at Michigan plant in two weeks | Abbott could restart infant formula production at Michigan plant | U.S. lawmakers to examine infant formula shortage,"Adds details on production restart, background on formula shortage May 11 (Reuters) - Abbott Laboratories ABT.N said on Wednesday it could restart production of infant formula at its troubled Michigan facility within two weeks. The company in February recalled some baby formulas, including certain Similac products, made at the plant in Sturgis after complaints about bacterial infections in infants who had consumed the products. Abbott will restart production of EleCare, Alimentum and metabolic formulas first, followed by Similac and other brands, after receiving the go-ahead from the U.S. Food & Drug Administration (FDA). | May 11 (Reuters) - Abbott Laboratories ABT.N said on Wednesday it could restart production of infant formula at its troubled Michigan facility within two weeks. The company in February recalled some baby formulas, including certain Similac products, made at the plant in Sturgis after complaints about bacterial infections in infants who had consumed the products. It said the resumption was subject to FDA's approval. | Current constraints come after top supplier Abbott Laboratories ABT.N recalled Similac and other baby formula in February made at its plant in Michigan following complaints of bacterial infections in infants who consumed the products. Adds details from statement, White House comment WASHINGTON, May 11 (Reuters) - U.S. lawmakers plan to hold a hearing this month on shortages of infant formula, the House Energy and Commerce Committee said on Wednesday, calling the situation ""increasingly alarming."" The hearing will focus on the shortage's causes, efforts to increase production, and what action is needed ""to ensure access to safe formula across the nation,"" the committee chair, Representative Frank Pallone, a Democrat, said in a statement."
2022-05-10,108.91000366210938,106.75,-0.7688048903659048,Major U.S. retailers limit infant formula purchases on shortage | Major U.S. retailers limit baby formula purchases on shortage,"The limits come after top supplier Abbott Laboratories ABT.N in February recalled some baby formula including Similac made at its plant in Michigan over complaints of bacterial infections in infants who consumed the products. Repeats to change keyword used by media clients to SUPPLY-CHAIN/BABY FORUMLA from CVS HEALTH-INFANT FORMULA/; no change to text or headline May 10 (Reuters) - U.S. retailers including Target Corp TGT.N, CVS Health Corp CVS.N and Walgreens Boots Alliance WBA.O said on Tuesday they have limited purchases of infant formula due to a supply shortage. Abbott said on Tuesday it was ""doing everything"" it can to address the shortage, including prioritizing production of the products and air shipping them from its U.S. drug regulator-approved facility in Ireland. | The limits come after major supplier Abbott Laboratories ABT.N recalled some baby formula including Similac in February following complaints of bacterial infections in infants who consumed the products. Adds details from Kroger, Target and Walgreens statements May 10 (Reuters) - U.S. retailers including Target Corp TGT.N, CVS Health Corp CVS.N and Walgreens Boots Alliance WBA.O said on Tuesday they have limited purchases of baby formula due to a supply shortfall. (Reporting by Deborah Sophia and Manas Mishra in Bengaluru; Editing by Aditya Soni) ((DeborahMary.Sophia@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2022-05-09,110.69000244140624,107.38999938964844,-1.983292250003713,3 Medical Product Stocks Set to Beat on Earnings This Season,"In fact, Abbott ABT and Intuitive Surgical ISRG are a few companies that have registered strong recovery rate in base-business performance. Abbott Laboratories (ABT): Free Stock Analysis Report Here we talk about three stocks, Canopy Growth Corporation CGC, Haemonetics Corporation HAE and Alcon Inc. ALC that are expected to beat earnings estimates in the ongoing reporting cycle."
2022-05-06,112.5500030517578,112.2699966430664,-2.981301814953573,,
2022-05-05,114.86000061035156,113.01000213623048,-0.2487840080845017,Here's How Abbott Laboratories Increased Its Profits by 37% in Q1 | Better Dividend King: Johnson & Johnson vs. Abbott Laboratories,"Healthcare giant Abbott Laboratories (NYSE: ABT) reported quarterly earnings numbers last month, and the results were impressive with net earnings rising by 37% year over year. Sales grew nearly 4% when factoring out COVID-19 testing During the first three months of 2022, Abbott reported $11.9 billion in sales (up 13.8% year over year) with $3.3 billion of that coming from COVID-19 testing. See the 10 stocks *Stock Advisor returns as of April 7, 2022 David Jagielski has no position in any of the stocks mentioned. | A couple of Dividend Kings you won't have to worry about paying low payouts today are Johnson & Johnson (NYSE: JNJ) and Abbott Laboratories (NYSE: ABT). Johnson & Johnson has typically paid a higher yield If you were to buy based on yield alone, you might be tempted to go with Johnson & Johnson as the healthcare giant has for the past five years generally provided investors with the higher payout: Free cash flow versus dividends paid Although there are generally fluctuations in the timing of when cash comes in and flows out, Johnson & Johnson's free cash usually has been much higher than the dividends it has paid out every quarter."
2022-05-04,112.5,115.6999969482422,-1.610655114304737,,
2022-05-03,113.0500030517578,112.43000030517578,2.844441731770846,,
2022-05-02,113.5,112.83000183105467,-0.5484323129988422,,
2022-04-29,117.05999755859376,113.5,-0.5903067567800235,"Abbott to release some nutrition products halted after baby formula recall | Abbott to release limited quantities of some nutrition formulas | The Zacks Analyst Blog Highlights Visa, Walt Disney, Abbott Laboratories, Nike and United Parcel Service","Adds background, details on products, FDA comment April 29 (Reuters) - Abbott Laboratories ABT.N said on Friday it would release limited quantities of nutrition products that had been put on hold following a recall of some powdered infant formulas from its Michigan facility. The company had in February recalled some baby formulas, including certain Similac products, made at its plant in Sturgis after complaints about bacterial infections in infants who consumed the products. The FDA said on Friday the company had conducted standard product testing and committed to completing further testing of the product batches prior to release. | April 29 (Reuters) - Abbott Laboratories ABT.N said on Friday it would release limited quantities of some nutrition products that had been on hold after the company recalled certain powder infant formulas produced at its Michigan facility. Abbott had recalled some baby formulas earlier in the year following complaints about bacterial infections in infants who consumed the products. (Reporting by Amruta Khandekar; Editing by Aditya Soni) ((Amruta.Khandekar@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include: Visa Inc. V, The Walt Disney Co. DIS, Abbott Laboratories ABT, Nike, Inc. NKE and United Parcel Service, Inc. UPS. Abbott Laboratories (ABT): Free Stock Analysis Report Here are highlights from Thursday’s Analyst Blog: Top Analyst Reports for Visa, Walt Disney and Abbott The Zacks Research Daily presents the best research output of our analyst team."
2022-04-28,117.5500030517578,118.01000213623048,-3.041173443397542,"Top Analyst Reports for Visa, Walt Disney & Abbott","If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Visa (V) Rides on Improving Top Line & Solid Balance Sheet Disney (DIS) Banks on Disney+ Growth & Reopening of Parks Abbott's (ABT) Diabetes Business Grows Amid Forex Headwinds Featured Reports Improved Traffic & Digital Trends Aid NIKE (NKE) Direct Per the Zacks analyst, the NIKE Direct business benefits from the steady normalization of the owned retail business on improved traffic. Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), The Walt Disney Co. (DIS), and Abbott Laboratories (ABT). Abbott Laboratories (ABT): Free Stock Analysis Report"
2022-04-27,117.29000091552734,116.72000122070312,0.3913220523440948,"Noteworthy ETF Inflows: XLV, UNH, TMO, ABT | We Did The Math XRLV Can Go To $55","Among the largest underlying components of XLV, in trading today UnitedHealth Group Inc (Symbol: UNH) is down about 0.1%, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 0.7%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $674.2 million dollar inflow -- that's a 1.8% increase week over week in outstanding units (from 276,670,000 to 281,770,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $120.61 per share, with $143.42 as the 52 week high point — that compares with a last trade of $131.61. | Three of XRLV's underlying holdings with notable upside to their analyst target prices are Abbott Laboratories (Symbol: ABT), Linde plc (Symbol: LIN), and CSX Corp (Symbol: CSX). Although ABT has traded at a recent price of $116.97/share, the average analyst target is 19.56% higher at $139.85/share. Below is a twelve month price history chart comparing the stock performance of ABT, LIN, and CSX: Below is a summary table of the current analyst target prices discussed above:"
2022-04-26,118.61000061035156,116.97000122070312,-0.4859746699420136,"Here's the Worst News for Abbott Right Now (and Why Investors Shouldn't Worry) | The Zacks Analyst Blog Highlights Alcon, Zimmer Biomet, Cardiovascular Systems, Abbott and Intuitive Surgical","Abbott Laboratories (NYSE: ABT) investors have plenty to be happy about when they look at the company's recent earnings report. In fact, Abbott said that if we remove the positive impact of its coronavirus test sales and the negative impact of the product recall, the company is seeing 11% growth. And as I mentioned earlier -- excluding the nutrition business due to the recall -- all of Abbott's other businesses posted strong revenue growth in the first quarter. | Stocks recently featured in the blog include: Alcon ALC, Zimmer Biomet ZBH, Cardiovascular Systems CSII, Abbott ABT and Intuitive Surgical, Inc. ISRG. Abbott Laboratories (ABT): Free Stock Analysis Report Here are highlights from Monday’s Analyst Blog: 3 Medical Product Stocks Poised to Beat This Earnings Season So far, this reporting cycle has displayed a year-over-year improvement for the medical product companies within the broader Medical sector."
2022-04-25,119.16000366210938,120.01000213623048,-1.3826822200566689,3 Medical Product Stocks Poised to Beat This Earnings Season | 5 Dividend Growth Stocks With Upside To Analyst Targets,"Abbott ABT and Intuitive Surgical, Inc. ISRG are a few companies whose base-business performance registered a strong recovery rate. Abbott Laboratories (ABT): Free Stock Analysis Report Here we talk about three stocks, Alcon ALC, Zimmer Biomet ZBH and Cardiovascular Systems CSII that are expected to beat earnings estimates in the ongoing reporting cycle. | Expeditors International of Washington, Inc. (Symbol: EXPD) $96.69 $116.75 20.75% Prosperity Bancshares Inc. (Symbol: PB) $66.74 $79.72 19.45% Abbott Laboratories (Symbol: ABT) $117.69 $140.46 19.35% Illinois Tool Works, Inc. (Symbol: ITW) $196.27 $232.10 18.26% Ecolab Inc (Symbol: ECL) $176.60 $205.42 16.32% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Expeditors International of Washington, Inc. (Symbol: EXPD) 1.17% 20.75% 21.92% Prosperity Bancshares Inc. (Symbol: PB) 3.15% 19.45% 22.6% Abbott Laboratories (Symbol: ABT) 1.57% 19.35% 20.92% Illinois Tool Works, Inc. (Symbol: ITW) 2.40% 18.26% 20.66% Ecolab Inc (Symbol: ECL) 1.16% 16.32% 17.48% Another consideration with dividend growth stocks is just how much the dividend is growing. Expeditors International of Washington, Inc. (Symbol: EXPD) $1.04 $1.16 11.54% Prosperity Bancshares Inc. (Symbol: PB) $1.9 $2.02 6.32% Abbott Laboratories (Symbol: ABT) $1.62 $1.84 13.58% Illinois Tool Works, Inc. (Symbol: ITW) $4.49 $4.8 6.90% Ecolab Inc (Symbol: ECL) $1.9 $1.98 4.21% These five stocks are part of our full Dividend Aristocrats List."
2022-04-22,123.0199966430664,119.63999938964844,0.713325317219163,7 Stocks to Buy If You Think Inflation Is Topping Out,"InvestorPlace - Stock Market News, Stock Advice & Trading Tips UnitedHealth Group (NYSE:UNH) – This managed care leader offers double-digit earnings and dividend growth Abbott Laboratories (NYSE:ABT) – A dividend king with a forecast for continued revenue and earnings growth Deere & Co. (NYSE:DE) – Well positioned for strong demand in the second quarter Nucor (NYSE:NUE) – A savvy investment in clean energy adds another vertical Lam Research Corp (NASDAQ:LRCX) – An undervalued semiconductor stock with strong free cash flow Qualcomm (NASDAQ:QCOM) – A major move into the connected car sector supports an attractive valuation Nike (NYSE:NKE) – Further proof that premium brands can support a premium valuation Source: Sauko Andrei / Shutterstock Inflation remains a top-of-mind concern for investors as they look for the best stocks to buy, and April’s Consumer Price Index (CPI) and Producer Price Index (PPI) readings did nothing to change that. UNH UnitedHealth Group $537.44 ABT Abbott Laboratories $123.37 DE Deere & Co $424.36 NUE Nucor $175.59 LRCX Lam Research Corp $469.51 QCOM Qualcomm $136.11 NKE Nike $135.46 Inflation Stocks to Buy: UnitedHealth Group (UNH) Source: Ken Wolter / Shutterstock.com UnitedHealth Group is becoming a giant in the managed health care sector. Abbott Laboratories (ABT) Source: testing / Shutterstock.com Whatever UNH Group can do, Abbott Laboratories can do better."
2022-04-21,123.18000030517578,123.37000274658205,-2.747518570679843,"Got $5,000? This Dividend King Is Down More Than 15% This Year | Pre-Market Most Active for Apr 21, 2022 : AAL, CRXT, RDBX, TQQQ, SQQQ, AAPL, T, ABT, CCL, NIO, RELX, ELAN | Abbott Q1 EPS, Sales Rise, ANTM Hits All-time High, Healthcare Services' Q1 Results Trump Estimates","Healthcare company Abbott Laboratories (NYSE: ABT) is one of those casualties, declining by a surprising 12%. As the following chart illustrates, a decline in share price means you're collecting the same dividend for less of an investment, and thus, you are earning a higher yield: ABT data by YCharts At just under 1.6%, Abbott is now paying investors more than the S&P 500 average of around 1.4%. The company said that during the last three months of 2021, revenue related to its COVID-19 tests totaled $2.3 billion and $7.7 billion for the full year -- that's 18% of the $43.1 billion in total revenue that Abbott reported last year. | Abbott Laboratories (ABT) is +1.06 at $123.70, with 963,164 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the ""buy range"". The total Pre-Market volume is currently 37,109,415 shares traded. | Abbott (ABT) has reported strong earnings and sales for the first quarter ended March 31, 2022. ABT closed Wednesday's trading at $122.64, up 2.22%. For the first quarter of 2022, adjusted net earnings increased to $3.08 billion or $1.73 per share on net sales of $11.9 billion."
2022-04-20,119.4800033569336,122.63999938964844,0.15424780072701516,"Abbott Laboratories (ABT) Q1 2022 Earnings Call Transcript | Abbott's (ABT) Q1 Earnings and Revenues Exceed Estimates | Health Care Sector Update for 04/20/2022: ALVR, ANTM, ABT, XLV, IBB | Abbott (ABT) Surpasses Q1 Earnings and Revenue Estimates | Abbott: FY22 Adj. EPS Guidance Remains Unchanged | Abbott reports 36% rise in quarterly profit on Omicron-driven testing demand | Abbott Laboratories Q1 Profit Increases, beats estimates | Abbott Laboratories Q1 22 Earnings Conference Call At 9:00 AM ET","Operator [Operator signoff] Duration: 62 minutes Call participants: Scott Leinenweber -- Vice President of Investor Relations, Licensing, and Acquisition Robert Ford -- Chairman and Chief Executive Officer Bob Funck -- Executive Vice President, Finance, and Chief Financial Officer Robbie Marcus -- J.P. Morgan -- Analyst Vijay Kumar -- Evercore ISI -- Analyst Josh Jennings -- Cowen and Company -- Analyst Larry Biegelsen -- Wells Fargo Securities -- Analyst Joanne Wuensch -- Citi -- Analyst Travis Steed -- Bank of America Merrill Lynch -- Analyst Matt Miksic -- Credit Suisse -- Analyst More ABT analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Abbott Laboratories (NYSE: ABT) Q1 2022 Earnings Call Apr 20, 2022, 9:00 a.m. In addition to these strong results during the quarter, we continue to strengthen our strategic position and long-term growth opportunities with regulatory approvals of new products and expanded indications of use along with continued market uptake of several recently launched products in attractive growth areas. | Abbott Laboratories ABT reported first-quarter 2022 adjusted earnings of $1.73 per share, which exceeded the Zacks Consensus Estimate by 17.7%. Abbott Laboratories (ABT): Free Stock Analysis Report Abbott Laboratories Price, Consensus and EPS Surprise Abbott Laboratories price-consensus-eps-surprise-chart | Abbott Laboratories Quote Diabetes Care reported organic growth of 20.4% year over year led by FreeStyle Libre, which represented 26.2% of organic sales growth in the reported quarter. | Abbott Laboratories (ABT) reported Q1 adjusted earnings of $1.73 per diluted share, up from $1.32 a year earlier. The Health Care SPDR (XLV) was 0.27% higher and the iShares NASDAQ Biotechnology Index (IBB) was recently inactive. Anthem (ANTM) was climbing past 2% after it reported Q1 adjusted earnings of $8.25 per diluted share, up from $7.01 a year earlier. | Abbott (ABT) came out with quarterly earnings of $1.73 per share, beating the Zacks Consensus Estimate of $1.47 per share. Abbott Laboratories (ABT): Free Stock Analysis Report Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $11.9 billion for the quarter ended March 2022, surpassing the Zacks Consensus Estimate by 7.17%. | (RTTNews) - While reporting first-quarter results on Wednesday, Abbott (ABT) said it continues to expect fiscal 2022 adjusted earnings per share of at least $4.70. The company noted that its 2022 guidance includes projected COVID-19 testing-related sales of approximately $4.5 billion, which Abbott expects to largely occur in the first half of the year and will update on a quarterly basis. First quarter earnings came in at $2.45 billion, or $1.37 per share compared with $1.79 billion, or $1.00 per share, a year ago. | April 20 (Reuters) - Abbott Laboratories ABT.N reported a 36% rise in quarterly profit on Wednesday, boosted by an Omicron-led demand for its COVID-19 test kits and a recovery in elective procedures, which boosted demand for its medical devices. The company's net earnings rose to $2.45 billion, or $1.37 per share, in the first quarter ended March 31, from $1.8 billion, or $1 per share, a year earlier. (Reporting by Mrinalika Roy and Bhanvi Satija in Bengaluru; Editing by Amy Caren Daniel) ((mrinalika.roy@thomsonreuters.com)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) revealed earnings for its first quarter that increased from last year and beat the Street estimates. The company's revenue for the quarter rose 13.8% to $11.90 billion from $10.46 billion last year. -Analyst Estimate: $1.46 -Revenue (Q1): $11.90 Bln vs. $10.46 Bln last year. | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on April 20, 2022, to discuss Q1 22 earnings results. To access the live webcast, log on to https://www.abbottinvestor.com/news-and-events?c=94004&p=irol-calall The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2022-04-19,116.68000030517578,119.9800033569336,2.6447907130322865,"Pre-Market Earnings Report for April 20, 2022 : PG, ASML, ABT, ANTM, BKR, NDAQ, RCI, MTB, CMA, MKTX, LAD, GATX | Why Abbott (ABT) Could Beat Earnings Estimates Again | 3 Things About Abbott Laboratories That Smart Investors Know","Abbott Laboratories (ABT)is reporting for the quarter ending March 31, 2022. ABT missed the consensus earnings per share in the 1st calendar quarter of 2021 by -0.75%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABT is 24.33 vs. an industry ratio of -19.40, implying that they will have a higher earnings growth than their competitors in the same industry. | Abbott (ABT), which belongs to the Zacks Medical - Products industry, could be a great candidate to consider. Abbott Laboratories (ABT): Free Stock Analysis Report For the last reported quarter, Abbott came out with earnings of $1.32 per share versus the Zacks Consensus Estimate of $1.18 per share, representing a surprise of 11.86%. | Grace Groner spent 43 years as a secretary at healthcare conglomerate Abbott Laboratories (NYSE: ABT) before retiring and later passing away in 2010 at the age of 100. ABT Total Long Term Debt (Quarterly) data by YCharts But today, total debt has fallen to $18 billion, and its debt-to-EBITDA ratio has fallen by more than half to 1.6. Abbott is dividend royalty Abbott's identity as a company has evolved over the years; it had an enormous pharmaceutical business until it spun off most of it as AbbVie in 2013."
2022-04-18,117.0199966430664,116.29000091552734,2.828250808301916,What's in Store for Abbott Laboratories (ABT) in Q1 Earnings?,"Abbott Laboratories ABT is slated to report first-quarter 2022 results on Apr 20, before market open. Abbott Laboratories (ABT): Free Stock Analysis Report Abbott Laboratories Price and Consensus Abbott Laboratories price-consensus-chart | Abbott Laboratories Quote Within Nutrition, from the beginning of the pandemic till the last reported quarter, Abbott gained consistently in terms of adult nutrition products sales."
2022-04-14,120.0500030517578,117.69000244140624,-0.623821354025236,,
2022-04-13,117.55999755859376,119.4800033569336,-1.9658480219563865,"Abbott (ABT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release | OEF, PFE, DIS, ABT: ETF Inflow Alert","Wall Street expects a year-over-year increase in earnings on higher revenues when Abbott (ABT) reports results for the quarter ended March 2022. Abbott Laboratories (ABT): Free Stock Analysis Report Price, Consensus and EPS Surprise Earnings Whisper Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. | Among the largest underlying components of OEF, in trading today Pfizer Inc (Symbol: PFE) is down about 0.4%, Walt Disney Co. (Symbol: DIS) is up about 1%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 100 ETF (Symbol: OEF) where we have detected an approximate $150.7 million dollar inflow -- that's a 1.8% increase week over week in outstanding units (from 42,150,000 to 42,900,000). For a complete list of holdings, visit the OEF Holdings page » The chart below shows the one year price performance of OEF, versus its 200 day moving average: Looking at the chart above, OEF's low point in its 52 week range is $183.77 per share, with $222.35 as the 52 week high point — that compares with a last trade of $201.24."
2022-04-12,119.79000091552734,118.38999938964844,1.6332135405011967,Retailers Ration Baby Formula Sales Amid Widespread Shortage | This Medical Devices Company Is Likely To Offer Better Returns Over Medtronic Stock,"(RTTNews) - Retailers in the U.S are rationing the sales of baby formula products as severe shortage continues to grapple the supply of one of the important food for majority of babies, according to reports. Real-time product data provider Datasembly stated, after tracking baby formula stock at more than 11,000 stores, that 29% of the top-selling baby formula products were out of stock as of the week of March 13 at retailers across the country. Along with the ongoing supply-chain issues related to COVID-19 including shortage of key ingredients, packaging hangups and labor shortages, a recent recall of drug major Abbott's baby formula have contributed to the severe shortage of formula products around the country. | We think that Stryker Corp. stock (NYSE: SYK) currently is a better pick compared to its industry peer, Medtronic stock (NYSE: MDT), despite it being the more expensive of the two, trading at 5.7x trailing revenues compared to 4.7x for Medtronic. We compare a slew of factors such as historical revenue growth, returns, and valuation multiple in an interactive dashboard analysis of Stryker vs. Medtronic: Which Stock Is A Better Bet? The table below summarizes our revenue and return expectations for Stryker and Medtronic over the next three years and points to an expected return of 18% for Stryker over this period vs. a 3% expected return for MDT stock, implying that investors are better off buying SYK over MDT, based on Trefis Machine Learning analysis – Stryker vs. Medtronic – which also provides more details on how we arrive at these numbers."
2022-04-11,123.4800033569336,120.04000091552734,-1.1687131773762565,See Which Of The Latest 13F Filers Holds Abbott Laboratories,"Existing -30 -$141 Trust Co Existing -147 -$53 Clarius Group LLC Existing UNCH $UNCH Lowe Wealth Advisors LLC Existing UNCH -$5 Israel Discount Bank of New York Existing +119 -$232 Nexus Investment Management ULC Existing UNCH -$63 Acropolis Investment Management LLC Existing UNCH -$92 Northwest Quadrant Wealth Management LLC Existing +6 -$56 Deltec Asset Management LLC Existing UNCH -$44 Aggregate Change: +4,364 -$4,081 In terms of shares owned, we count 5 of the above funds having increased existing ABT positions from 12/31/2021 to 03/31/2022, with 5 having decreased their positions. We then compared that number to the sum total of ABT shares those same funds held back at the 12/31/2021 period, to see how the aggregate share count held by hedge funds has moved for ABT. Vigilant Capital Management LLC 324,484 4-10 Find out the full Top 10 Hedge Funds Holding ABT » We'll keep following the latest 13F filings by hedge fund managers and bring you interesting stories derived from a look at the aggregate information across groups of managers between filing periods."
2022-04-08,123.41999816894533,123.25,-2.7858781566943396,"Best Stocks for 2022: Up 20% This Year, AbbVie Is Doing Great","It has now increased its dividend for 50 consecutive years, going back to its days as a subsidiary of Abbott Laboratories (NYSE:ABT). Finally, AbbVie stock also provided a high dividend yield, with regular dividend increases — AbbVie is one of just 66 Dividend Aristocrats, and one of just 40 Dividend Kings. Lastly, AbbVie’s global aesthetics portfolio grew revenue by 23% for the fourth quarter, due to 27% growth in global Botox revenue."
2022-04-07,119.5999984741211,123.37000274658205,-0.13773956527905806,,
2022-04-06,119.0,119.94000244140624,3.152177525551307,,
2022-04-05,118.26000213623048,119.4800033569336,0.7899180179884333,Abbott (ABT) Aveir VR Leadless Pacemaker Receives FDA Nod | Should You Pick Intuitive Surgical Stock For Better Gains?,"Abbott Laboratories ABT recently announced the receipt of FDA approval for Aveir single-chamber (VR) leadless pacemaker to treat patients with slow heart rhythms in the United States. Abbott Laboratories (ABT): Free Stock Analysis Report About Aveir VR Abbott's Aveir single chamber (VR) pacing system is the world's only leadless pacemaker with a unique mapping capability designed to enable physicians to measure electrical signals within the heart and determine the correct placement of the device before final implantation. | We compare a slew of factors such as historical revenue growth, returns, and valuation multiple in an interactive dashboard analysis Ralph Lauren vs. Intuitive Surgical: Which Stock Is A Better Bet? Looking at a longer time frame, Ralph Lauren’s sales declined to $6.0 billion over the last twelve months, compared to $6.3 billion in fiscal 2019, while Intuitive Surgical’s revenues grew at a CAGR of 6% to $5.7 billion currently, compared to $3.7 billion in 2018. The table below summarizes our revenue and return expectations for Ralph Lauren and Intuitive Surgical over the next three years and points to an expected return of 35% for ISRG over this period vs. a 7% expected return for RL stock, implying that investors are better off buying ISRG over RL, despite its high valuation, based on Trefis Machine Learning analysis – Ralph Lauren vs. Intuitive Surgical – which also provides more details on how we arrive at these numbers."
2022-04-04,117.87000274658205,118.87999725341795,1.0316262461231156,Abbott: FDA Approves Aveir Pacemaker For Treatment Of Patients With Slow Heart Rhythms | What Makes Insulet Stock A Good Bet?,"(RTTNews) - Abbott (ABT) announced the FDA has approved the Aveir single-chamber leadless pacemaker for the treatment of patients in the U.S. with slow heart rhythms. ""The Aveir VR leadless pacemaker was designed to make the implantation and retrieval processes as seamless as possible for physicians and provide improvements over existing options,"" said Randel Woodgrift, senior vice president, Cardiac Rhythm Management, Abbott. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We think that Insulet stock (NASDAQ: PODD), a company best known for selling the Omnipod continuous insulin delivery system that caters to people with diabetes, currently is a better pick compared to ConMed (NASDAQ: CNMD), a medical devices company that specializes in products for orthopedic and general surgery, despite PODD being the more expensive of the two with its P/S ratio of 16x, compared to just 4x for CNMD. The table below summarizes our revenue and return expectation for ConMed and Insulet over the next three years and points to an expected return of 80% for PODD over this period vs. a 6% expected return for CNMD stock, implying that investors are better off buying PODD over CNMD, despite its high valuation, based on Trefis Machine Learning analysis – ConMed vs. Insulet – which also provides more details on how we arrive at these numbers. Total [2] CNMD Return 2% 5% 238% PODD Return 0% -1% 600% S&P 500 Return 5% -3% 106% Trefis MS Portfolio Return 3% -7% 266% [1] Month-to-date and year-to-date as of 3/30/2022 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2022-04-01,118.83999633789062,118.58000183105467,0.8568715392391867,,
2022-03-31,120.20999908447266,118.36000061035156,-0.2187769394545629,3 Top Healthcare ETFs to Buy Now and Hold for the Long Haul,"Three healthcare ETFs that provide long-term investors with diversification, along with growth opportunities to outpace the S&P 500, include Vanguard Health Care ETF (NYSEMKT: VHT), Blackrock iShares U.S. Healthcare Providers ETF (NYSEMKT: IHF), and Blackrock iShares U.S. Medical Devices ETF (NYSEMKT: IHI). Blackrock's U.S. Medical Devices ETF is well worth a high expense ratio A third healthcare ETF for a solid portfolio could be the Blackrock U.S. Medical Devices ETF. But like Blackrock's healthcare provider ETF, this medical devices-focused ETF has a heavy 72% of its total assets in the top 10 holdings, making it riskier than an ETF that is more broadly spread out."
2022-03-30,119.87000274658205,120.37999725341795,-1.5389722054827426,,
2022-03-29,121.83000183105467,120.19000244140624,0.42545632364261454,iShares Core S&P Total U.S. Stock Market ETF Experiences Big Inflow | Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?,"Among the largest underlying components of ITOT, in trading today Eli Lilly (Symbol: LLY) is off about 0.8%, Salesforce Inc (Symbol: CRM) is up about 1.3%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P Total U.S. Stock Market ETF (Symbol: ITOT) where we have detected an approximate $147.6 million dollar inflow -- that's a 0.3% increase week over week in outstanding units (from 440,950,000 to 442,400,000). For a complete list of holdings, visit the ITOT Holdings page » The chart below shows the one year price performance of ITOT, versus its 200 day moving average: Looking at the chart above, ITOT's low point in its 52 week range is $90.54 per share, with $108.15 as the 52 week high point — that compares with a last trade of $102.61. | Taking into account individual holdings, Merck & Co Inc (MRK) accounts for about 6.99% of the fund's total assets, followed by Abbott Laboratories (ABT) and Eli Lilly & Co (LLY). Abbott Laboratories (ABT): Free Stock Analysis Report Launched on 06/23/2005, the Invesco Dynamic Pharmaceuticals ETF (PJP) is a smart beta exchange traded fund offering broad exposure to the Health Care ETFs category of the market."
2022-03-28,119.37999725341795,119.98999786376952,-1.3461375400147115,"The Zacks Analyst Blog Highlights Alphabet, Abbott Laboratories, The Charles Schwab, Canadian National Railway Company and Air Products and Chemicals | Abbott (ABT) Outpaces Stock Market Gains: What You Should Know | Abbott's (ABT) CGM Device Gets MHLW Nod for Expanded Coverage","Stocks recently featured in the blog include: Alphabet Inc. GOOGL, Abbott Laboratories ABT, The Charles Schwab Corp. SCHW, Canadian National Railway Company CNI and Air Products and Chemicals, Inc. APD. Abbott Laboratories (ABT): Free Stock Analysis Report Here are highlights from Friday’s Analyst Blog: Top Research Reports for Alphabet, Abbott and Charles Schwab The Zacks Research Daily presents the best research output of our analyst team. | Abbott (ABT) closed the most recent trading day at $119.99, moving +0.87% from the previous trading session. Meanwhile, ABT's PEG ratio is currently 3.18. Abbott Laboratories (ABT): Free Stock Analysis Report | Abbott Laboratories ABT has gained approval from the Japanese Ministry of Health, Labour and Welfare (“MHLW”) to expand the reimbursement coverage for its FreeStyle Libre system to include all people with diabetes who require insulin at least once a day. Abbott Laboratories (ABT): Free Stock Analysis Report The expanded reimbursement coverage was granted based on the overall value proposition of FreeStyle Libre, which considered ease-of-use and scientific evidence demonstrating the clinical benefits of utilizing the FreeStyle Libre system among patients taking self-injections of insulin."
2022-03-25,118.6500015258789,118.9499969482422,0.5109738853961129,"Top Research Reports for Alphabet, Abbott, & Charles Schwab","Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Abbott Laboratories (ABT) and The Charles Schwab Corporation (SCHW). Abbott Laboratories (ABT): Free Stock Analysis Report You can see all of today’s research reports here >>> Shares of Alphabet have outperformed the Zacks Internet - Services industry over the past year (+39.8% vs. +17.8%) on the back of solid momentum across search, advertising, cloud and YouTube businesses."
2022-03-24,117.37999725341795,117.81999969482422,0.2528406392796068,,
2022-03-23,121.11000061035156,116.91999816894533,0.37485300025720686,Is DexCom a Buy? | FDA probe of Abbott facility finds quality control issues,"Though it has the benefit of focusing entirely on CGMs rather than other medical devices like some of its adversaries, DexCom still faces a fight for market share once the market is saturated. And even for those who prefer to chase growth stocks, multiples that high are a major red flag as they leave the stock vulnerable to a collapse in the event of a flight to value. 10 stocks we like better than DexCom When our award-winning analyst team has a stock tip, it can pay to listen. | Changes dateline, adds Abbott's response March 23 (Reuters) - An inspection at the Abbott Laboratories ABT.N facility in Sturgis, Michigan found a harmful bacteria called Cronobacter sakazakii on the surface of some areas producing its powdered baby formula, the U.S. health regulator said on Tuesday. Complaints that the facility's products had caused bacterial infections forced Abbott to recall certain Alimentum, Similac and EleCare baby formulas last month, prompting a probe from the U.S. Food and Drug Administration (FDA). No Cronobacter sakazakii was found during the company's testing of products that were distributed to consumers, Abbott added."
2022-03-22,121.88999938964844,121.88999938964844,-3.4596667659896836,FDA probe of Abbott facility finds quality control issues | Want to Beat the Market? 2 Stocks to Buy and Hold Forever | Is There A Better Pick Over Owens & Minor Stock?,"March 22 (Reuters) - An inspection at the Abbott Laboratories ABT.N facility in Sturgis, Michigan found a harmful bacteria on surfaces in some areas of its powdered baby formula production, the U.S. health regulator said on Tuesday. Complaints that the facility's products had caused bacterial infections forced Abbott to recall certain Alimentum, Similac and EleCare baby formulas last month, prompting a probe from the U.S. Food and Drug Administration (FDA). The inspection from Jan. 31 to March 18 showed that Abbott did not have a control system covering all stages of processing to prevent microbe contamination of infant formula. | On that note, let's look at two excellent stocks that are worth holding onto for a long time: Abbott Laboratories (NYSE: ABT) and Airbnb (NASDAQ: ABNB). Last year, sales by Abbott's structural heart division increased 29.1% year over year to $1.6 billion. Last year, sales of Abbott's diabetes care segment grew by 32.5% year over year to $4.3 billion. | We think that Intuit stock (NASDAQ: INTU), a company that specializes in financial and tax preparation software, currently is a better pick compared to medical devices maker Owens & Minor stock (NYSE: OMI), a global healthcare logistics company, despite INTU being more expensive of the two with its P/S ratio of 11.0x, compared to just 0.3x for OMI. We compare a slew of factors such as historical revenue growth, returns, and valuation multiple in an interactive dashboard analysis Owens & Minor vs. Intuit: Which Stock Is A Better Bet? The table below summarizes our revenue and return expectation for Owens & Minor and Intuit over the next three years and points to an expected return of 33% for INTU over this period vs. -25% expected return for OMI stock, implying that investors are better off buying INTU over OMI, based on Trefis Machine Learning analysis – Owens & Minor vs. Intuit – which also provides more details on how we arrive at these numbers."
2022-03-21,121.93000030517578,121.76000213623048,0.0,Abbott (ABT) Dips More Than Broader Markets: What You Should Know | Here's Why You Should Retain Abbott (ABT) Stock for Now,"Abbott (ABT) closed at $121.76 in the latest trading session, marking a -0.56% move from the prior day. We can also see that ABT currently has a PEG ratio of 3.28. Abbott Laboratories (ABT): Free Stock Analysis Report | Abbott Laboratories ABT is well poised for growth in the coming quarters, backed by its progress in the diabetes business. Abbott Laboratories (ABT): Free Stock Analysis Report Let’s delve deeper Key Growth Catalysts Progress With Diabetes Business: This business achieved organic sales growth of 28.3% in fourth-quarter 2021 led by strong growth in FreeStyle Libre, contributing 36% to organic sales growth in the quarter."
2022-03-18,121.73999786376952,122.4499969482422,-0.13942275774609514,,
2022-03-17,119.0,121.1999969482422,0.583209378126648,"Want $1 Million in Retirement? Invest $150,000 in These 3 Stocks and Wait a Decade | This Software Company Is Likely To Offer Better Returns Over Boston Scientific Stock","Today, Abbott Labs (NYSE: ABT) is positioned primarily in consumer products, medical devices, analytics, testing, and making generic drugs for emerging markets. Pharmaceutical companies live and die by their product pipelines, and Pfizer's nearly $30 billion in 2021 free cash flow gives the company a war chest of money for research and development that should buoy Pfizer's growth efforts, even after its revenues from COVID-19 treatments fade. Analysts expect the company to grow its earnings-per-share (EPS) by more than 12% annually over the next three to five years, and Pfizer's large balance sheet should help the company fund its growth beyond that. | We think that Intuit stock (NASDAQ: INTU), a company that specializes in financial and tax preparation software, currently is a better pick compared to medical devices maker Boston Scientific stock (NYSE: BSX), despite INTU being more expensive of the two with its P/S ratio of 11.2x, compared to 5.0x for BSX. We compare a slew of factors such as historical revenue growth, returns, and valuation multiple in an interactive dashboard analysis Intuit vs. Boston Scientific: Which Stock Is A Better Bet? The table below summarizes our revenue and return expectation for Boston Scientific and Intuit over the next three years and points to an expected return of 43% for INTU over this period vs. 9% expected return for BSX stock, implying that investors are better off buying INTU over BSX, based on Trefis Machine Learning analysis – Intuit vs. Boston Scientific – which also provides more details on how we arrive at these numbers."
2022-03-16,118.20999908447266,119.4800033569336,1.8487369312959678,"VTI, ABT, CRM, WFC: Large Inflows Detected at ETF","Among the largest underlying components of VTI, in trading today Abbott Laboratories (Symbol: ABT) is up about 1.3%, Salesforce.com Inc (Symbol: CRM) is up about 4.7%, and Wells Fargo & Co (Symbol: WFC) is higher by about 3.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Total Stock Market ETF (Symbol: VTI) where we have detected an approximate $1.3 billion dollar inflow -- that's a 0.5% increase week over week in outstanding units (from 1,255,178,019 to 1,261,233,950). For a complete list of holdings, visit the VTI Holdings page » The chart below shows the one year price performance of VTI, versus its 200 day moving average: Looking at the chart above, VTI's low point in its 52 week range is $199.50 per share, with $244.06 as the 52 week high point — that compares with a last trade of $218.62."
2022-03-15,117.5,117.4800033569336,1.0743628138880152,Abbott (ABT) Gains But Lags Market: What You Should Know,"Abbott (ABT) closed at $117.48 in the latest trading session, marking a +1.7% move from the prior day. Investors should also note that ABT has a PEG ratio of 2.32 right now. Abbott Laboratories (ABT): Free Stock Analysis Report"
2022-03-14,114.9000015258789,115.5199966430664,-0.017018419630984043,Is There A Better Pick Over West Pharmaceutical Services Stock?,"We compare a slew of factors such as historical revenue growth, returns, and valuation multiple in an interactive dashboard analysis – Catalent vs. West Pharmaceutical Services: Which Stock Is A Better Bet? Our Catalent Revenue and West Pharmaceuticals Services Revenue dashboards provide more details on the companies’ revenues. The table below summarizes our revenue and return expectation for CTLT and WST over the next three years and points to an expected return of 29% for CTLT over this period vs. just a 5% expected return for WST stock, implying that investors are better off buying CTLT over WST, based on Trefis Machine Learning analysis – Catalent vs. West Pharmaceutical Services – which also provides more details on how we arrive at these numbers."
2022-03-11,117.44000244140624,114.0199966430664,0.5395953950860989,Want to Get Richer? 3 Top Stocks to Buy Now and Hold Forever | 3 Supercharged Dividend Stocks to Buy if There's a Stock Market Sell-Off,"Abbott Laboratories Much like BD, Abbott Laboratories (NYSE: ABT) is a healthcare supplier and medical device maker with a long history of steady growth. STAAR Surgical STAAR Surgical (NASDAQ: STAA) is worth holding forever because it's creating a solution to a problem that will only become more prevalent with time: myopia. Becton, Dickinson Whereas STAAR Surgical is a tightly focused growth stock bent on advancing with its lone class of products, Becton, Dickinson (NYSE: BDX) is a mature healthcare supply company that's broadly diversified. | If you guessed that they're just a few of the products made by Abbott Laboratories (NYSE: ABT), you'd be correct. All three of these stocks have dividend yields that are a bit on the low side compared to the market's average of 1.2%, and that's one of the many reasons why they're ripe for purchase if there's a sell-off, correction, or crash in the market. Costco Wholesale If you're not familiar, Costco Wholesale (NASDAQ: COST) is a massive discount retailer and it's also a great dividend stock."
2022-03-10,117.18000030517578,117.0,-2.9121302173389823,,
2022-03-09,117.9000015258789,118.38999938964844,-0.1536100910624684,2 Cheap Dividend Stocks Near Their 52-Week Lows | Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?,"At a forward price-to-earnings (P/E) ratio of 19, Medtronic is cheap compared to many other healthcare stocks; shares of Abbott Laboratories and Eli Lilly are trading at 24 and 30 times their future earnings, respectively. 10 stocks we like better than Medtronic When our award-winning analyst team has a stock tip, it can pay to listen. See the 10 stocks *Stock Advisor returns as of March 3, 2022 David Jagielski has no position in any of the stocks mentioned. | Looking at individual holdings, Thermo Fisher Scientific Inc (TMO) accounts for about 14.07% of total assets, followed by Abbott Laboratories (ABT) and Danaher Corp (DHR). Abbott Laboratories (ABT): Free Stock Analysis Report Alternatives IShares U.S. Medical Devices ETF holds a Zacks ETF Rank of 2 (Buy), which is based on expected asset class return, expense ratio, and momentum, among other factors."
2022-03-08,117.91000366210938,116.11000061035156,0.41560462886166916,iShares Core S&P Total U.S. Stock Market ETF Experiences Big Outflow | Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?,"Among the largest underlying components of ITOT, in trading today Comcast Corp (Symbol: CMCSA) is up about 0.5%, Abbott Laboratories (Symbol: ABT) is off about 2.4%, and Wells Fargo & Co (Symbol: WFC) is higher by about 2.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P Total U.S. Stock Market ETF (Symbol: ITOT) where we have detected an approximate $271.7 million dollar outflow -- that's a 0.7% decrease week over week (from 442,700,000 to 439,800,000). For a complete list of holdings, visit the ITOT Holdings page » The chart below shows the one year price performance of ITOT, versus its 200 day moving average: Looking at the chart above, ITOT's low point in its 52 week range is $88.45 per share, with $108.15 as the 52 week high point — that compares with a last trade of $93.05. | Looking at individual holdings, Merck & Co Inc (MRK) accounts for about 6.99% of total assets, followed by Abbott Laboratories (ABT) and Eli Lilly & Co (LLY). Abbott Laboratories (ABT): Free Stock Analysis Report Alternatives Invesco Dynamic Pharmaceuticals ETF carries a Zacks ETF Rank of 3 (Hold), which is based on expected asset class return, expense ratio, and momentum, among other factors."
2022-03-07,120.54000091552734,118.86000061035156,-1.5265906164467766,This Healthcare Company Is A Better Pick Over Abbott Stock,"The table below summarizes our revenue and return expectation for Abbott and Thermo Fisher Scientific over the next three years and points to an expected return of 9% for ABT stock over this period vs. 26% expected returns for TMO stock, implying that investors are better off buying TMO over ABT, based on our dashboard – Abbott vs. Thermo Fisher Scientific – which also provides more details on how we arrive at these numbers. We think that Thermo Fisher Scientific stock (NYSE: TMO) currently is a better pick compared to Abbott Labs stock (NYSE: ABT), with a similar market capitalization in the healthcare sector, despite its comparatively expensive valuation. ABT stock trades at 4.9x trailing revenues, compared to 5.6x for Thermo Fisher Scientific."
2022-03-04,119.93000030517578,121.41000366210938,-1.3937284655847155,1 Stock Warren Buffett Is Selling That Income Investors Should Consider Buying,"* They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! See the 10 stocks *Stock Advisor returns as of January 20, 2022 Keith Speights owns AbbVie and Berkshire Hathaway (B shares). The Motley Fool recommends the following options: long January 2023 $200 calls on Berkshire Hathaway (B shares), short January 2023 $200 puts on Berkshire Hathaway (B shares), and short January 2023 $265 calls on Berkshire Hathaway (B shares)."
2022-03-03,120.8000030517578,120.97000122070312,1.234055993635916,,
2022-03-02,118.62000274658205,120.36000061035156,0.14072695749228545,"Consumer Spending, E-Commerce, and the Business of Lodging | 2 Fantastic Dividend Stocks for Retirees","In this week's episode of Motley Fool Money, Motley Fool analyst Olivia Zitkus and Motley Fool contributor Keith Speights, along with host Chris Hill, discuss a new wave of biosimilar drugs and the challenges (and opportunities for investors) that they present. Chris Hill: Last thing and then we'll move on, because I think that there are always going to be people who will lump JD.com, and Shopify in the same big bucket of, ""Well, these are e-commerce companies."" The Motley Fool recommends Hyatt Hotels, Marriott International, and Viatris Inc. and recommends the following options: long January 2023 $1,140 calls on Shopify, long January 2023 $115 calls on Marriott International, long January 2024 $145 calls on Walt Disney, short January 2023 $1,160 calls on Shopify, and short January 2024 $155 calls on Walt Disney. | AbbVie and Kimberly Clark have been increasing dividends for 50 consecutive years, earning them the status of Dividend Kings. Though price appreciation trails AbbVie, Kimberly-Clark pays an annual dividend of $4.64 at a yield of 3.52%, compared to a 2.25% average for consumer goods stocks in the S&P. If I had to choose between one or the other right now, I'd go with AbbVie, based on its growth trajectory, stock price history, and higher annual dividend payout -- considering the per-share stock price of AbbVie is only 10% higher than Kimberly-Clark."
2022-03-01,120.30999755859376,118.16999816894533,1.4668671585574162,"Abbott Recalls Another Lot Of Simila After A Second Infant-fatality | Up 9% In A Month, Will Intuitive Surgical Stock Continue To See Higher Levels?","The recent case of the death of the infant shows that the patient had consumed Similac PM 60/40 and when the company was informed about the development, it issued a voluntary recall of the product with the lot code 27032K80 (can) and 27032K800 (case). ""The most recent patient was reported to have consumed Abbott Nutrition's Similac PM 60/40 product with the lot code 27032K800 prior to Cronobacter sakazakii infection,"" said the FDA. The FDA has issued a method of identification for the products in question, The first two digits of the code are 22 through 37 The code has K8, SH, or Z2 The expiration date is 4-1-2022 or later The lot number can also be searched on the company website. | Out of 350 instances in the last ten years that ISRG stock saw a twenty-one-day increase of 9% or more, 211 of them resulted in ISRG stock rising over the subsequent one-month period (twenty-one trading days). Intuitive Surgical (ISRG) Stock Return (Recent) Comparison With Peers Five-Day Return: MDT highest at 0.2%; BDX lowest at -1.8% Ten-Day Return: SYK highest at 1.0%; BDX lowest at -3.9% Twenty-One Days Return: ISRG highest at 9.2%; MDT lowest at -0.8% may have moved, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. Total [2] ISRG Return 1% -20% 309% S&P 500 Return -5% -10% 92% Trefis MS Portfolio Return -3% -12% 246% [1] Month-to-date and year-to-date as of 2/24/2022 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2022-02-28,121.0500030517578,120.62000274658205,-1.7787377882758315,Abbott recalls more Similac-branded baby formula,"Feb 28 (Reuters) - Abbott Laboratories ABT.N recalled some Similac PM 60/40 cans and cases produced at a Michigan facility, after an infant who was exposed to the powdered baby formula died, the U.S. Food and Drug Administration (FDA) said on Monday. A few days earlier, Abbott recalled certain Alimentum, Similac and EleCare baby formulas made at the facility in Sturgis city following complaints about bacterial infections in infants who consumed the products. The investigation included four reports of Cronobacter sakazakii infections in infants and one complaint of a Salmonella Newport infection in an infant, the federal agency said on Monday, adding that Cronobacter might have contributed to death in two patients."
2022-02-25,118.72000122070312,122.41000366210938,-0.3552253567411279,What To Expect From Medtronic's Q3? | Should You Buy Abbott Stock After Its Recent Fall? | Abbott (ABT) Down 1.4% Since Last Earnings Report: Can It Rebound?,"(1) Revenues expected to be above the consensus estimate Trefis estimates Medtronic’s Q3 fiscal 2022 total revenues to be around $8.0 billion, slightly above the $7.9 billion consensus estimate. Medtronic (MDT) Stock Return (Recent) Comparison With Peers Five-Day Return: MDT highest at 2.0%; ISRG lowest at -6.4% Ten-Day Return: BAX highest at 4.8%; ISRG lowest at -1.8% Twenty-One Days Return: BAX highest at 10.9%; MDT lowest at -3.8% [Updated: Nov 26, 2021] Medtronic Earnings Update Medtronic (NYSE:MDT) recently reported its Q2 FY22 results, which were mixed with revenue slightly below, and earnings above our estimates. Given these changes to our forecasts, we have revised our Medtronic Valuation to $144 per share, based on $5.71 expected adjusted EPS and a 25x P/E multiple for fiscal 2022, reflecting a 26% upside from its current levels of $114, implying that MDT stock is currently undervalued and it will likely see higher levels in the near term, in our view. | Out of 167 instances in the last ten years that ABT stock saw a twenty-one-day fall of 7% or more, 105 of them resulted in ABT stock rising over the subsequent one-month period (twenty-one trading days). Abbott (ABT) Stock Return (Recent) Comparison With Peers Five-Day Return: MDT highest at 1.4%; ABT lowest at -4.3% Ten-Day Return: MDT highest at 1.7%; ABT lowest at -8.2% Twenty-One Day Return: BSX highest at 0.0%; DXCM lowest at -7.4% Looking at the long term view, we estimate Abbott’s Valuation to be $152 per share, reflecting a 29% upside from its current levels of $118. Total [2] ABT Return -8% -17% 206% S&P 500 Return -5% -10% 92% Trefis MS Portfolio Return -3% -12% 246% [1] Month-to-date and year-to-date as of 2/23/2022 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A month has gone by since the last earnings report for Abbott (ABT). Abbott Laboratories (ABT): Free Stock Analysis Report Abbott's Q4 Earnings and Revenues Beat Estimates Abbott reported fourth-quarter 2021 adjusted earnings from continuing operations of $1.32 per share, which exceeded the Zacks Consensus Estimate by 11.9%."
2022-02-24,115.0,118.72000122070312,3.1081556632959035,"Got $5,000? These 2 Dividend Kings Are On Sale","And two of them, Abbott Laboratories (NYSE: ABT) and Stanley Black & Decker (NYSE: SWK), are currently on sale and yielding more than the S&P 500 average of 1.3%. ABT PE Ratio data by YCharts 2. Stanley Black & Decker Stanley Black & Decker, which owns popular brands such as DeWalt and Craftsman (and, of course, Stanley and Black+Decker), boasts the longest dividend streak of any industrial company on the NYSE -- 506 quarters of uninterrupted dividend payments."
2022-02-23,118.0,117.25,3.2347836701766304,"Abbott (ABT) Stock Moves -0.22%: What You Should Know | Abbott (ABT) COVID Testing Sales Surge, FX Headwind Stays","Abbott (ABT) closed the most recent trading day at $117.25, moving -0.22% from the previous trading session. ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.82 per share and revenue of $40.56 billion. Investors should also note that ABT has a PEG ratio of 2.32 right now. | Abbott Laboratories ABT has been delivering consistent organic growth in the Established Pharmaceuticals Division (EPD) and Diabetes segments. Abbott Laboratories (ABT): Free Stock Analysis Report Even though COVID-19 case rates surged in the United States and other geographies during the fourth quarter, the company registered strong growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care."
2022-02-22,116.54000091552734,117.51000213623048,-0.6355932203389831,Want to Get Richer? 5 Best Stocks to Buy Now and Hold Forever,"Abbott Laboratories (NYSE: ABT) is a healthcare conglomerate that sells consumer products, medical devices, and generic pharmaceutical drugs. Berkshire Hathaway Investing in holding company Berkshire Hathaway (NYSE: BRK.B) means trusting your money with investing legends like Charlie Munger and Warren Buffett, who still run the ship there to this day. The company's revenue has been flat over the past decade, but has grown 11% annually on average over the past five years, so it looks like Abbott's moves to generate growth are working."
2022-02-18,120.0,116.79000091552734,0.8323332873544708,"Noteworthy Friday Option Activity: ABT, GS, NFLX | Relative Strength Alert For Abbott Laboratories | Notable ETF Inflow Detected - VHT, ABT, DHR, MDT | Here's Why Intuitive Surgical Stock Is A Better Pick Over This Software Company","Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Abbott Laboratories (Symbol: ABT), where a total of 45,722 contracts have traded so far, representing approximately 4.6 million underlying shares. Below is a chart showing ABT's trailing twelve month trading history, with the $114 strike highlighted in orange: Goldman Sachs Group Inc (Symbol: GS) saw options trading volume of 20,557 contracts, representing approximately 2.1 million underlying shares or approximately 63.7% of GS's average daily trading volume over the past month, of 3.2 million shares. That amounts to about 67.3% of ABT's average daily trading volume over the past month of 6.8 million shares. | Abbott Laboratories (Symbol: ABT) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most ""interesting"" ideas that merit further research by investors. But making Abbott Laboratories an even more interesting and timely stock to look at, is the fact that in trading on Friday, shares of ABT entered into oversold territory, changing hands as low as $116.22 per share. Indeed, ABT's recent annualized dividend of 1.88/share (currently paid in quarterly installments) works out to an annual yield of 1.56% based upon the recent $120.58 share price. | Among the largest underlying components of VHT, in trading today Abbott Laboratories (Symbol: ABT) is off about 2.4%, Danaher Corp (Symbol: DHR) is off about 0.2%, and Medtronic PLC (Symbol: MDT) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Health Care ETF (Symbol: VHT) where we have detected an approximate $259.5 million dollar inflow -- that's a 1.6% increase week over week in outstanding units (from 66,278,321 to 67,359,926). For a complete list of holdings, visit the VHT Holdings page » The chart below shows the one year price performance of VHT, versus its 200 day moving average: Looking at the chart above, VHT's low point in its 52 week range is $216.25 per share, with $268.72 as the 52 week high point — that compares with a last trade of $240.32. | We think Intuitive Surgical stock (NASDAQ: ISRG) is currently a better pick than Roper Technologies stock (NYSE: ROP), a software, engineered products, and solutions provider, with a similar revenue base as Intuitive Surgical, despite Intuitive Surgical’s comparatively higher valuation. Intuitive Surgical’s Revenue Growth Has Been Stronger Both companies managed to see sales growth over the recent years, but Intuitive Surgical has witnessed a comparatively faster revenue growth. The table below summarizes our revenue and return expectation for ISRG and ROP over the next three years and points to an expected return of 41% for ISRG over this period vs. 7% expected return for ROP stock, implying that investors are better off buying ISRG over ROP, based on Trefis Machine Learning analysis – Intuitive Surgical vs. Roper Technologies – which also provides more details on how we arrive at these numbers."
2022-02-17,122.98999786376952,120.58000183105467,-2.674999237060547,Abbott recalls certain Similac baby formula made at Michigan facility | 2 Green Flags for Abbott Laboratories' Future | AbbVie Is a Better Stock Than You Might Think -- Here's Why | Is Boston Scientific Stock A Good Buy At $43?,"Feb 17 (Reuters) - Abbott Laboratories ABT.N said on Thursday it was recalling powdered baby formulas, including Similac, made at a Michigan facility after four consumers complained about bacterial infections in infants who consumed the products. The complaints were related to Cronobacter sakazakii bacteria or Salmonella Newport and Abbott will also recall its Alimentum and EleCare baby formulas manufactured at the plant in Sturgis. (Reporting by Dania Nadeem in Bengaluru; Editing by Aditya Soni) ((Dania.Nadeem@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The past year hasn't been the best for Abbott Laboratories (NYSE: ABT) and its shareholders, as the medical devices giant has lagged the broader market. ABT data by YCharts. Nutrition $8.29 billion 7.7% 19.3% Diagnostics $15.64 billion 42.7% 36.3% Established pharmaceuticals $4.72 billion 10.4% 11% Medical devices $14.37 billion 19.4% 33.4% Data source: Abbott. | AbbVie CEO Rick Gonzalez said in the company's recent fourth-quarter conference call, ""We expect combined peak sales for Skyrizi and Rinvoq to exceed the peak revenues achieved by Humira."" Don't underestimate the power of a juicy dividend AbbVie's dividend has been a big plus for the stock throughout the years. Room to run Perhaps the most important thing for investors to understand is that the anticipated sales declines for Humira are fully priced into AbbVie's share price. | We expect the company to report revenues in-line but earnings marginally below the consensus estimates, as the rise of Covid-19 cases with the spread of Omicron, likely weighed on the overall procedures volume, while the rise of material cost and wages may adversely impact the company’s operating margin growth. (1) Revenues expected to be in-line with the consensus estimates Trefis estimates Boston Scientific’s Q4 2021 revenues to be around $3.1 billion, in-line with the consensus estimate. (2) EPS likely to be marginally below the consensus estimates Boston Scientific’s Q4 2021 adjusted earnings per share (EPS) is expected to be $0.43 per Trefis analysis, just a cent below the consensus estimate of $0.44."
2022-02-16,123.4499969482422,123.68000030517578,-1.9595057115004488,,
2022-02-15,124.19000244140624,123.9800033569336,0.18631297093511556,,
2022-02-14,125.0,122.77999877929688,-0.16909499987466475,Abbott Laboratories Breaks Below 200-Day Moving Average - Notable for ABT,"In trading on Monday, shares of Abbott Laboratories (Symbol: ABT) crossed below their 200 day moving average of $123.54, changing hands as low as $121.98 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $105.36 per share, with $142.60 as the 52 week high point — that compares with a last trade of $122.86. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other dividend stocks recently crossed below their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2022-02-11,127.77999877929688,125.48999786376952,-1.7760009765625,Why This Healthcare Giant Expects Decreased Covid Profits in 2022,"Abbott (NYSE: ABT) is projecting $2.5 billion in COVID-19 testing revenue for all of 2022, a low estimate considering the company made nearly that much in the fourth quarter alone. You are right though Brian, COVID testing revenue fell from $2.4 billion in the fourth quarter of 2020, to $2.3 billion in the latest quarter. In the latest quarter, the fourth quarter of 2021, rapid tests accounted for 90 percent of total COVID-19 testing revenue."
2022-02-10,128.57000732421875,127.76000213623048,-1.7921434789514084,"SPLG, WFC, ABT, ACN: ETF Inflow Alert | Here's Why You Should Retain Abbott (ABT) Stock For Now","Among the largest underlying components of SPLG, in trading today Wells Fargo & Co (Symbol: WFC) is up about 1.6%, Abbott Laboratories (Symbol: ABT) is down about 0.7%, and Accenture plc (Symbol: ACN) is lower by about 1.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR— Portfolio S&P 500— ETF (Symbol: SPLG) where we have detected an approximate $755.9 million dollar inflow -- that's a 5.6% increase week over week in outstanding units (from 251,700,000 to 265,750,000). For a complete list of holdings, visit the SPLG Holdings page » The chart below shows the one year price performance of SPLG, versus its 200 day moving average: Looking at the chart above, SPLG's low point in its 52 week range is $43.735 per share, with $56.44 as the 52 week high point — that compares with a last trade of $53.64. | Abbott Laboratories ABT is well poised for growth in the coming quarters, backed by its solid diagnostics business. Abbott Laboratories (ABT): Free Stock Analysis Report COVID testing sales in the fourth quarter with rapid testing platforms, including BinaxNOW in the United States, Panbio internationally, and ID NOW globally, comprised approximately 90% of those sales."
2022-02-09,129.52000427246094,130.49000549316406,-0.6300109993349018,What's The Outlook For Covid-19 Testing Stocks As Omicron Wave Fades,"Abbott Laboratories (ABT) has a diverse range of solutions including a test called BinaxNOW that provides test results in 5 minutes and works without relying on lab equipment. [12/20/2021] Omicron Brings Covid Testing Stocks Back In Focus Our indicative theme on Covid-19 Testing Stocks – which includes companies that produce or carry out tests for Covid-19 infections –  is up by 24% year-to-date, roughly in line with the S&P 500. Within our theme, Laboratory Corp. of America (LH)has been the strongest performer gaining about 53% year-to-date, driven by strong demand for Covid-19 tests and a recovery in demand for testing and diagnostics outside of Covid."
2022-02-08,127.52999877929688,128.64999389648438,0.7489200036332693,Qiagen sales rise on COVID-19 testing demand | 3 Top Healthcare Stocks to Buy for February,"Rival Abbott Labs ABT.N and clinical laboratory Quest Diagnostics DGX.N also said earlier this year that the Omicron variant had pushed up demand for their tests. Adds background, 2022 forecast Feb 8 (Reuters) - Qiagen QIA.DE reported a small rise in quarterly sales on Tuesday as the rapid spread of the Omicron coronavirus variant lifted demand for its COVID-19 tests. Qiagen posted fourth-quarter net sales of $582 million, compared with $571 million a year earlier. | Dividend growth stock: Johnson & Johnson Johnson & Johnson (NYSE: JNJ) is a healthcare conglomerate that offers investors a ""little bit of everything"" in the industry. Johnson & Johnson is a Dividend King, a stock that's paid and increased its dividend for 59 consecutive years. High dividend yield stock: AbbVie AbbVie (NYSE: ABBV) is a pharmaceutical company that makes prescription products, including Botox and Humira (the world's top-selling drug)."
2022-02-07,129.8699951171875,128.0500030517578,0.8782209110859955,AbbVie Wins Yet Another Approval for This Drug,"On Jan. 14, AbbVie's (NYSE: ABBV) Rinvoq received approval from the U.S. Food and Drug Administration (FDA) to treat adults and children at least 12 years old with moderate-to-severe atopic dermatitis (eczema) whose condition didn't respond to other medicines. This news is huge for AbbVie's immunology segment Rinvoq could be a powerful treatment for many patients with eczema. Second, although 55% of moderate-to-severe eczema patients aren't satisfied with their treatment plan, I'll assume that approximately 20% of the patient pool could start Cibinqo."
2022-02-04,129.55999755859375,129.7100067138672,-1.4013953444653842,Should Investors Sell the Rumor With ShockWave Medical? | 6 Stocks That Could Soar If New Coronavirus Variants Emerge,"Mabel asks, she says, ""They're more rumors about ShockWave Medical [ticker there is SWAV] being acquired by Medtronic (NYSE: MDT), Abbott (NYSE: ABT), etc. In this Motley Fool Live video, recorded on Jan. 26, Fool contributors Keith Speights and Brian Orelli discuss whether or not investors should sell the rumor with ShockWave. * They just revealed what they believe are the ten best stocks for investors to buy right now... and ShockWave Medical wasn't one of them! | I think Abbott (NYSE: ABT) is big in the at-home market. In this Motley Fool Live video, recorded on Jan. 26, though, Fool contributors Keith Speights and Brian Orelli discuss six stocks that could soar if new coronavirus variants emerge. See the 10 stocks *Stock Advisor returns as of January 10, 2022 Keith Speights: Moving to the next topic... World Health Organization head and I'm going to butcher his name here, I apologize, Tedros Adhanom Ghebreyesus, recently warned that current conditions across the world could mean that more coronavirus variants will emerge."
2022-02-03,128.6300048828125,130.11000061035156,0.1157835428374376,March 25th Options Now Available For Abbott Laboratories (ABT),"Below is a chart showing ABT's trailing twelve month trading history, with the $132.00 strike highlighted in red: Considering the fact that the $132.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the March 25th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new March 25th contracts and identified one put and one call contract of particular interest."
2022-02-02,128.25,130.0399932861328,1.150583589643336,"Abbott's (ABT) Diabetes Arm Booms, Neuromodulation Sales Soft | Notable ETF Inflow Detected - IOO, ABT, RTX, CAT | What To Expect From Boston Scientific Stock Following Q4 Earnings?","Abbott Laboratories ABT has been delivering consistent organic growth in the Established Pharmaceuticals Division (EPD) and Diabetes segments. Abbott Laboratories (ABT): Free Stock Analysis Report Abbott Laboratories Price Abbott Laboratories price | Abbott Laboratories Quote In the fourth quarter, within Nutrition, strong growth was led by U.S. pediatric and international adult nutrition. | Among the largest underlying components of IOO, in trading today Abbott Laboratories (Symbol: ABT) is up about 1.3%, Raytheon Technologies Corp (Symbol: RTX) is up about 0.1%, and Caterpillar Inc. (Symbol: CAT) is lower by about 1.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Global 100 ETF (Symbol: IOO) where we have detected an approximate $164.4 million dollar inflow -- that's a 4.3% increase week over week in outstanding units (from 50,350,000 to 52,500,000). For a complete list of holdings, visit the IOO Holdings page » The chart below shows the one year price performance of IOO, versus its 200 day moving average: Looking at the chart above, IOO's low point in its 52 week range is $63.11 per share, with $79.0761 as the 52 week high point — that compares with a last trade of $77.05. | We expect the company to report revenues in-line but earnings marginally below the consensus estimates, as the rise of Covid-19 cases with the spread of Omicron, likely weighed on the overall procedures volume, while the rise of material cost and wages may adversely impact the company’s operating margin growth. (1) Revenues expected to be in-line with the consensus estimates Trefis estimates Boston Scientific’s Q4 2021 revenues to be around $3.1 billion, in-line with the consensus estimate. (2) EPS likely to be marginally below the consensus estimates Boston Scientific’s Q4 2021 adjusted earnings per share (EPS) is expected to be $0.43 per Trefis analysis, just a cent below the consensus estimate of $0.44."
2022-02-01,127.37000274658205,127.1999969482422,1.395706265990497,"Medical Device Stocks Earnings on Feb 2: IDXX, ABC & ALGN","More specifically, in the fourth quarter, Abbott Laboratories’ ABT underlying legacy diagnostics business continued to improve. This was driven by strength in ABT’s COVID-19 testing-related sales on the back of strong demand for BinaxNOW, Panbio and ID NOW rapid testing platforms. Abbott Laboratories (ABT): Free Stock Analysis Report"
2022-01-31,125.5199966430664,127.45999908447266,-0.13347396928151972,"Top Analyst Reports for Apple, Tesla & Johnson & Johnson | EXCLUSIVE-U.S. diabetes deaths top 100,000 for second straight year, federal panel urges new strategy | Intuitive Surgical Stock Looks Attractive After Its Recent Fall","If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Robust Portfolio, Services Strength to Benefit Apple (AAPL) Tesla (TSLA) Rides on High Deliveries Amid Escalating Costs J&J's (JNJ) Three Segments Register Mixed Performance Featured Reports Organic Sales Gain, High COVID Tests Demand Aid Abbott (ABT) The Zacks analyst is impressed with Abbott's strong recovery in the organic base business. (You can read the full research report on Johnson & Johnson here >>>) Other noteworthy reports we are featuring today include Abbott Laboratories (ABT), Intel Corporation (INTC) and PetroChina Company Limited (PTR). Abbott Laboratories (ABT): Free Stock Analysis Report | ""Diabetes in the U.S. cannot simply be viewed as a medical or health care problem, but also must be addressed as a societal problem that cuts across many sectors, including food, housing, commerce, transportation and the environment,"" the commission wrote in its Jan. 5 report to Congress and the U.S. Department of Health and Human Services (HHS). To further ease financial barriers, the panel recommended that patients’ out-of-pocket costs be waived for other ""high-value"" treatments, including certain diabetes drugs, continuous glucose monitors, basic supplies and diabetes education. The commission said the United States should better promote the purchase of fruits and vegetables in food assistance programs and ensure mothers have paid family leave to aid breastfeeding, which can help reduce the risk of diabetes in mothers and is associated with a reduced risk of obesity and diabetes in children. | [Updated: Jan 27, 2022] Intuitive Surgical Q4 Earnings Update Intuitive Surgical (NASDAQ:ISRG) reported its Q4 results last week, with revenue above, but earnings falling short of our estimates. [Updated: Jan 19, 2022] Intuitive Surgical Q4 Earnings Preview Intuitive Surgical (NASDAQ:ISRG), a fast growing robotic surgical platform company, is scheduled to report its Q4 2021 results on Thursday, January 20. (1) Revenues expected to be above the consensus estimate Trefis estimates Intuitive Surgical’s Q4 2021 revenues to be around $1.53 billion, slightly above the $1.52 billion consensus estimate."
2022-01-28,120.7699966430664,125.3499984741211,1.5455724133923594,Will Abbott Stock Rise After Its Q4 Results?,"While we estimate Abbott’s Q4 results to be slightly below the street estimates, our forecast indicates that Abbott’s valuation is $141 per share, which is 12% higher than the current market price of around $126, implying that there is some room for growth in ABT stock. Total [2] ABT Return -12% -12% 224% S&P 500 Return -8% -8% 96% Trefis MS Portfolio Return -11% -11% 248% [1] Month-to-date and year-to-date as of 1/24/2022 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott (NYSE:ABT) is scheduled to report its Q4 2021 results on Wednesday, January 26, and we expect it to be below the consensus estimates."
2022-01-27,120.9800033569336,120.44000244140624,3.792334154476134,5 Top Health Care Stocks To Watch Before February 2022 | March 11th Options Now Available For Abbott Laboratories (ABT),"Best Health Care Stocks To Watch Before February 2022 Anthem Inc (NYSE: ANTM) Abbott Laboratories (NYSE: ABT) Align Technology, Inc (NASDAQ: ALGN) Thermo Fisher Scientific Inc (NYSE: TMO) Davita Inc (NYSE: DVA) Anthem Anthem is a leading health care company dedicated to improving lives and making healthcare simpler. With that in mind, should ABT stock warrant more attention in the stock market right now? 5 Health Care Stocks For Your February 2022 Watchlist Without question, the global pandemic brought health care stocks to the minds of many investors in the stock market. | Below is a chart showing ABT's trailing twelve month trading history, with the $124.00 strike highlighted in red: Considering the fact that the $124.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the March 11th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new March 11th contracts and identified one put and one call contract of particular interest."
2022-01-26,119.19000244140624,120.06999969482422,-0.4463555137572324,"Abbott Laboratories (ABT) Q4 2021 Earnings Call Transcript | Abbott's (ABT) Q4 Earnings and Revenues Beat Estimates | Health Care Sector Update for 01/26/2022: IMCR, ABT, ANTM, XLV, IBB | Abbott (ABT) Q4 Earnings and Revenues Surpass Estimates | Abbott Q4 Profit Tops Estimates; Net Sales Up 7.7% On Organic Basis | Abbott sales rise 7.2% as COVID test demand surges | Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now? | Abbott Laboratories Q4 21 Earnings Conference Call At 9:00 AM ET","Operator [Operator signoff] Duration: 58 minutes Call participants: Scott Leinenweber -- Vice President of Investor Relations, Licensing, and Acquisition Robert Ford -- Chairman and Chief Executive Officer Bob Funck -- Executive Vice President, Finance, and Chief Financial Officer Larry Biegelsen -- Wells Fargo -- Analyst Robbie Marcus -- J.P. Morgan -- Analyst Vijay Kumar -- Evercore ISI -- Analyst Josh Jennings -- Cowen and Company -- Analyst Joanne Wuensch -- Citi -- Analyst Matt Taylor -- UBS -- Analyst More ABT analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Abbott Laboratories (NYSE: ABT) Q4 2021 Earnings Call Jan 26, 2022, 9:00 a.m. We're going to see that a greater impact in the first quarter, around 3% in kind of -- and in the second quarter, and you don't get the impact would be a little bit less severe as we kind of go through the course of the year into the back half of the year. | Abbott Laboratories ABT reported fourth-quarter 2021 adjusted earnings from continuing operations of $1.32 per share, which exceeded the Zacks Consensus Estimate by 11.9%. Abbott Laboratories (ABT): Free Stock Analysis Report The top line exceeded the Zacks Consensus Estimate by 8.5%.On an organic basis (adjusting for the impact of foreign exchange), sales improved 7.7% year over year in the reported quarter. | Abbott Laboratories (ABT) was down more than 3% as it reported Q4 adjusted diluted earnings of $1.32 per share, compared with $1.45 a year earlier. The Health Care SPDR (XLV) was up 0.27% and the iShares Biotechnology ETF (IBB) was recently advancing by more than 1%. Anthem (ANTM) reported a Q4 adjusted income of $5.14 per share, up from $2.54 a year earlier. | Abbott (ABT) came out with quarterly earnings of $1.32 per share, beating the Zacks Consensus Estimate of $1.18 per share. Abbott Laboratories (ABT): Free Stock Analysis Report Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $11.47 billion for the quarter ended December 2021, surpassing the Zacks Consensus Estimate by 8.52%. | (RTTNews) - Abbott (ABT) reported fourth quarter earnings per share from continuing operations, excluding items, of $1.32 compared to $1.45, prior year. Net profit from continuing operations was $1.99 billion or $1.11 per share compared to $2.16 billion or $1.20 per share. Excluding items, projected adjusted earnings per share from continuing operations would be at least $4.70. | Adds details on results Jan 26 (Reuters) - Abbott Laboratories ABT.N on Wednesday reported a 7.2% rise in quarterly sales on strong demand for diagnostics products, including its COVID-19 tests, led by a sharp surge in cases due to the Omicron variant. The company's net earnings fell to $1.99 billion, or $1.11 per share, in the fourth quarter ended Dec. 31 from $2.16 billion, $1.20 per share, a year earlier. (Reporting by Leroy Leo; Editing by Maju Samuel) ((Leroy.Dsouza@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Looking at individual holdings, Merck & Co Inc (MRK) accounts for about 6.99% of total assets, followed by Abbott Laboratories (ABT) and Eli Lilly & Co (LLY). Abbott Laboratories (ABT): Free Stock Analysis Report Launched on 06/23/2005, the Invesco Dynamic Pharmaceuticals ETF (PJP) is a smart beta exchange traded fund offering broad exposure to the Health Care ETFs category of the market. | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on Jan. 26, 2022, to discuss Q4 21 earnings results. To access the live webcast, log on to https://www.abbottinvestor.com/news-and-events?c=94004&p=irol-calall The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2022-01-25,123.08000183105467,123.2699966430664,0.7383146534044156,"After Hours Most Active for Jan 25, 2022 : MSFT, AAPL, QQQ, TQQQ, ZNGA, BAC, BMY, ACWI, PFE, ABT, STT, T | Pre-Market Earnings Report for January 26, 2022 : ABT, T, BA, ANTM, ADP, NSC, PGR, FCX, GD, TEL, KMB, APH | Notable Tuesday Option Activity: ATVI, ABT, BW | S&P 500 Corrects Ahead Of Fed Meeting: Let's Check The Technicals | PREVIEW-Abbott's COVID test sales in spotlight as Omicron fuels demand | Where to Invest $5,000 for the Next 5 Years","Abbott Laboratories (ABT) is +0.42 at $123.69, with 2,537,296 shares traded.ABT is scheduled to provide an earnings report on 1/26/2022, for the fiscal quarter ending Dec2021. The consensus earnings per share forecast is 1.89 per share, which represents a 168 percent increase over the EPS one Year Ago The consensus earnings per share forecast is 1.18 per share, which represents a 145 percent increase over the EPS one Year Ago | Abbott Laboratories (ABT)is reporting for the quarter ending December 31, 2021. ABT missed the consensus earnings per share in the 1st calendar quarter of 2021 by -0.75%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for ABT is 24.42 vs. an industry ratio of 9.50, implying that they will have a higher earnings growth than their competitors in the same industry. | Below is a chart showing ATVI's trailing twelve month trading history, with the $79 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) saw options trading volume of 28,449 contracts, representing approximately 2.8 million underlying shares or approximately 46.3% of ABT's average daily trading volume over the past month, of 6.2 million shares. Below is a chart showing ABT's trailing twelve month trading history, with the $110 strike highlighted in orange: And Babcock & Wilcox Enterprises Inc (Symbol: BW) saw options trading volume of 2,354 contracts, representing approximately 235,400 underlying shares or approximately 46.2% of BW's average daily trading volume over the past month, of 509,995 shares. Particularly high volume was seen for the $110 strike put option expiring June 17, 2022, with 2,078 contracts trading so far today, representing approximately 207,800 underlying shares of ABT. | Abbott ABT, Intel INTC, AT&T T, and Boeing BA release their Q4 results on Wednesday (1/26). Abbott Laboratories (ABT): Free Stock Analysis Report Fundamentals are taking back the stock market after months of euphoria-driven neglect, and this week's big-tech results could provide an excellent value-powered springboard for recently compressed growth equities. | By Amruta Khandekar and Leroy Leo Jan 25 (Reuters) - Abbott Laboratories ABT.N is likely to report a surge in fourth-quarter sales of COVID-19 test kits as makers of rapid tests benefited from supercharged demand due to the fast-spreading Omicron variant, even as they wrestled supply snarls. Despite the early gains, Abbott, which has been scaling up production capacity for rapid tests such as its BinaxNOW, may hold back on providing COVID-19 test sales estimates beyond the first quarter or the first half of 2022, analysts said. COVID-19 test makers have seen strong sales over the past several quartershttps://tmsnrt.rs/3HaAukQ COVID-19 test makers have seen strong sales over the past several quartershttps://tmsnrt.rs/3fUW5lC Abbott's rapid COVID-19 tests boost its diagnostics sales https://tmsnrt.rs/3rNdmCE Americans grapple with prolonged testing woes amid Omicron surgehttps://www.reuters.com/world/us/americans-grapple-with-prolonged-testing-woes-amid-omicron-surge-2022-01-12/ Walmart, U.S. pharmacy chains cap COVID-19 test sales amid Omicron surge https://www.reuters.com/business/healthcare-pharmaceuticals/walgreens-limits-sales-at-home-covid-19-tests-four-per-customer-cnbc-2021-12-21/ US starts shipping free COVID tests amid Omicron -White Househttps://www.reuters.com/world/us/us-omicron-driven-covid-cases-dip-some-areas-may-still-see-rise-cdc-2022-01-21/ Abbott's rapid COVID-19 tests boost its diagnostics saleshttps://tmsnrt.rs/3tZG4mI (Reporting by Amruta Khandekar and Leroy Leo; Editing by Sriraj Kalluvila) ((Leroy.Dsouza@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Two strong companies here are Intuitive Surgical (NASDAQ: ISRG) and Abbott Laboratories (NYSE: ABT). The start of the year is the time for good resolutions -- and an investment plan. Dividend Kings If you prefer to avoid high-risk investments and want some security, opt for dividend stocks."
2022-01-24,124.01000213623048,123.81999969482422,0.1543669232898848,Abbott Laboratories is Oversold | ABT Makes Notable Cross Below Critical Moving Average | Is a Surprise Coming for Abbott (ABT) This Earnings Season? | 3 No-Brainer Healthcare Stocks to Buy Right Now for Less than $150,"Abbott Laboratories (Symbol: ABT) presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most ""interesting"" ideas that merit further research by investors. But making Abbott Laboratories an even more interesting and timely stock to look at, is the fact that in trading on Monday, shares of ABT entered into oversold territory, changing hands as low as $121.29 per share. Indeed, ABT's recent annualized dividend of 1.88/share (currently paid in quarterly installments) works out to an annual yield of 1.49% based upon the recent $125.83 share price. | In trading on Monday, shares of Abbott Laboratories (Symbol: ABT) crossed below their 200 day moving average of $123.23, changing hands as low as $121.69 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $105.36 per share, with $142.60 as the 52 week high point — that compares with a last trade of $121.88. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other dividend stocks recently crossed below their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | This suggests that analysts have very recently bumped up their estimates for ABT, giving the stock a Zacks Earnings ESP of +2.82% heading into earnings season. Given that ABT has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Investors are always looking for stocks that are poised to beat at earnings season and Abbott Laboratories ABT may be one such company. | Through the first nine months, the company reported revenue of $41.3 billion, up 29.3% year over year, and diluted earnings per share of $4.19, up 51.3% over the same period last year. In the third quarter, Merck reported year-to-date revenue of $35.2 billion, up 13% year over year, while non-GAAP EPS was $4.22, up 18% over the same period last year. Also, the company's healthcare benefits segment (insured and self-insured medical, pharmacy, dental, and behavioral health products and services) reported nine-month revenue of $61.4 billion, up 9% year over year, which the company attributed to a rise in business from government services."
2022-01-21,126.80999755859376,125.83000183105467,-0.15321541660610416,"Rise in COVID-19 Test Demand to Boost Abbott (ABT) Q4 Earnings | 3 Reasons to Buy Intuitive Surgical, and 1 Reason to Sell | Will Quest Diagnostics Stock Rebound After A Large 19% Fall In A Month?","Abbott Laboratories ABT is slated to report fourth-quarter and full-year 2021 results on Jan 26, before market open. Abbott Laboratories (ABT): Free Stock Analysis Report Abbott Laboratories Price and EPS Surprise Abbott Laboratories price-eps-surprise | Abbott Laboratories Quote Within pediatric nutrition, the company is expected to have registered strong growth in the United States from continued share gains in its infant formula and toddler portfolio. | For comparison, peers like Medtronic (NYSE: MDT), Abbot Laboratories (NYSE: ABT), and Stryker (NYSE: SYK) have forward EV-to-EBITDA ratios ranging from 16 to 20. Intuitive Surgical's (NASDAQ: ISRG) da Vinci surgical system is the dominant market leader, with thousands of systems installed worldwide. Three reasons to buy Anyone who has had surgery recently may have experienced the advantages of Intuitive's da Vinci surgical system firsthand. | Check out Quest Diagnostics Stock Comparison With Peers to see how DGX stock compares against peers on metrics that matter. Quest Diagnostics (DGX) Stock Return (Recent) Comparison With Peers Five-Day Return: NEO highest at 20.7%; DGX lowest at -13.0% Ten-Day Return: HCA highest at -2.1%; DGX lowest at -15.5% Twenty-One Day Return: DVA highest at 6.1%; DGX lowest at -19.2% We estimate Quest Diagnostics Valuation to be around $140 per share which is in-line with the current market price. Total [2] DGX Return -20% -20% 51% S&P 500 Return -4% -4% 105% Trefis MS Portfolio Return -9% -9% 257% [1] Month-to-date and year-to-date as of 1/19/2022 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2022-01-20,126.23999786376952,124.70999908447266,-0.7728063610176118,Abbott (ABT) Stock Moves -1.06%: What You Should Know | See Which Of The Latest 13F Filers Holds Abbott Laboratories | 3 Dividend Aristocrats Yielding Over 4%,"In the latest trading session, Abbott (ABT) closed at $124.71, marking a -1.06% move from the previous day. Investors should also note that ABT has a PEG ratio of 2.44 right now. To follow ABT in the coming trading sessions, be sure to utilize Zacks.com. | Existing +967 +$338 Transcend Wealth Collective LLC Existing +2,702 +$446 Fortem Financial Group LLC Existing +239 +$275 Retirement Systems of Alabama Existing +152,720 +$49,051 Sound View Wealth Advisors Group LLC Existing +512 +$509 CRA Financial Services LLC Existing +1 +$63 Aggregate Change: +160,153 +$55,689 In terms of shares owned, we count 9 of the above funds having increased existing ABT positions from 09/30/2021 to 12/31/2021, with 1 new position. Royal London Asset Management Ltd. 588,454 4-10 Find out the full Top 10 Hedge Funds Holding ABT » We'll keep following the latest 13F filings by hedge fund managers and bring you interesting stories derived from a look at the aggregate information across groups of managers between filing periods. At Holdings Channel, we have reviewed the latest batch of the 20 most recent 13F filings for the 12/31/2021 reporting period, and noticed that Abbott Laboratories (Symbol: ABT) was held by 12 of these funds. | AbbVie was formed in 2012 but prior to that, was part of Abbott Laboratories (NYSE:ABT). InvestorPlace - Stock Market News, Stock Advice & Trading Tips When it comes to income investing, we prefer dividend stocks that have demonstrated long histories of being able to raise their dividends throughout all kinds of economic conditions. 7 Best Mutual Funds to Buy for the Coming Rate Hikes Not all Dividend Aristocrats are created equal, as some are more geared towards earnings growth, dividend growth, or current yield."
2022-01-19,126.75,126.0500030517578,-1.2119762398506548,Why Covid-19 Testing Stocks Are Selling Off Despite Surging Demand | Abbott (ABT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? | March 18th Options Now Available For Abbott Laboratories (ABT) | Analysts Forecast 10% Gains Ahead For The Holdings of VTV | 3 Dividend Stocks to Buy and Hold Forever,"For example, Quest Diagnostics (DGX) recently raised its full-year guidance for 2021, signaling higher demand for testing through the end of December, while Abbott Laboratories (ABT) also sees testing demand holding strong in the near term. Abbott Laboratories (ABT) has a diverse range of solutions including a test called BinaxNOW that provides test results in 5 minutes and works without relying on lab equipment. Total [2] ABT Return -9% -9% 234% S&P 500 Return -2% -2% 108% Trefis MS Portfolio Return -7% -7% 264% [1] Month-to-date and year-to-date as of 1/16/2022 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2021. Abbott Laboratories (ABT): Free Stock Analysis Report Price, Consensus and EPS Surprise Earnings Whisper Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. | Below is a chart showing ABT's trailing twelve month trading history, with the $130.00 strike highlighted in red: Considering the fact that the $130.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the March 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new March 18th contracts and identified one put and one call contract of particular interest. | Three of VTV's underlying holdings with notable upside to their analyst target prices are Abbott Laboratories (Symbol: ABT), Crown Holdings Inc (Symbol: CCK), and Simon Property Group, Inc. (Symbol: SPG). Although ABT has traded at a recent price of $126.57/share, the average analyst target is 10.87% higher at $140.33/share. Below is a twelve month price history chart comparing the stock performance of ABT, CCK, and SPG: Below is a summary table of the current analyst target prices discussed above: | AbbVie (NYSE:ABBV) Kroger (NYSE:KR) Chevron (NYSE:CVX) Dividend Stocks to Buy: AbbVie (ABBV) ABBV) website and logo on mobile phone"" width=""300"" height=""169""> Source: Piotr Swat / Shutterstock.com Pharmaceutical manufacturer AbbVie has been a winner since it was spun off from Abbott Laboratories (NYSE:ABT) in 2013. Dividend Stocks to Buy: Chevron (CVX) Source: LesPalenik / Shutterstock.com Energy stocks are hot right now, and shares of Chevron have been marching higher as a result. While the gain in the stock’s price has been great, Chevron has the added bonus of providing shareholders with a hefty dividend yield of 4.1%, which equates to a quarterly dividend payout of $1.34 per share and an annual total of $5.36 per share."
2022-01-18,127.4000015258789,126.56999969482422,-0.5522658368774767,Abbott's (ABT) Organic Base Sales Grow Amid COVID Case Surge | Will Abbott Laboratories Be a Trillion-Dollar Stock by 2035?,"Abbott Laboratories ABT has been delivering consistent organic growth in the Established Pharmaceuticals Division (EPD) and Diabetes segments. Abbott Laboratories (ABT): Free Stock Analysis Report Even though COVID-19 case rates surged in the United States and other geographies during the third quarter, the company registered strong growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care. | In the unlikely event that someone's never heard of it, Abbott Laboratories (NYSE: ABT) is one of the world's largest and longest-operating healthcare companies, weighing in at a market cap of $237.6 billion. Therefore, if we multiply the P/E multiple by the net income, we can calculate that Abbott Labs will have a market cap of $420.6 billion in 2035, which is nowhere close to our target of $1 trillion. Coronavirus testing revenue won't be around forever The trouble with banking on Abbott's valuation to rise through the next decade and beyond is that its latest and greatest driver of new earnings, rapid coronavirus diagnostic tests, won't be as relevant moving forward as it has been since 2020."
2022-01-14,130.49000549316406,128.16000366210938,-0.6514927952226816,iShares Russell 1000 Value ETF Experiences Big Outflow | 5 Dividend Aristocrats Where Analysts See Capital Gains | Abbott (ABT) Gets FDA Nod for New Cardiac Mapping System,"Among the largest underlying components of IWD, in trading today AT&T Inc (Symbol: T) is off about 0.3%, Abbott Laboratories (Symbol: ABT) is down about 1.1%, and Boeing Co. (Symbol: BA) is lower by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $628.4 million dollar outflow -- that's a 1.0% decrease week over week (from 354,900,000 to 351,200,000). For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $134.90 per share, with $171.42 as the 52 week high point — that compares with a last trade of $168.88. | Abbott Laboratories (Symbol: ABT) $129.65 $140.33 8.24% Sherwin-Williams Co (Symbol: SHW) $317.39 $342.06 7.77% RenaissanceRe Holdings Ltd. (Symbol: RNR) $169.68 $180.00 6.08% AbbVie Inc (Symbol: ABBV) $133.52 $141.42 5.91% McDonald's Corp (Symbol: MCD) $261.41 $275.29 5.31% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Abbott Laboratories (Symbol: ABT) 1.45% 8.24% 9.69% Sherwin-Williams Co (Symbol: SHW) 0.69% 7.77% 8.46% RenaissanceRe Holdings Ltd. (Symbol: RNR) 0.85% 6.08% 6.93% AbbVie Inc (Symbol: ABBV) 4.22% 5.91% 10.13% McDonald's Corp (Symbol: MCD) 2.11% 5.31% 7.42% Another consideration with dividend growth stocks is just how much the dividend is growing. Abbott Laboratories (Symbol: ABT) $1.44 $2.27 57.64% Sherwin-Williams Co (Symbol: SHW) $1.78666666666667 $2.2 23.13% RenaissanceRe Holdings Ltd. (Symbol: RNR) $1.4 $1.44 2.86% AbbVie Inc (Symbol: ABBV) $4.72 $6.61 40.04% McDonald's Corp (Symbol: MCD) $5.04 $5.25 4.17% These five stocks are part of our full Dividend Aristocrats List. | Abbott Laboratories ABT recently announced the receipt of the FDA clearance for the EnSite X EP System with EnSite Omnipolar Technology (OT). Abbott Laboratories (ABT): Free Stock Analysis Report More on EnSite X EP System The EnSite X EP system creates highly detailed three-dimensional maps of the heart to aid physicians in identifying and treating areas of the heart where abnormal rhythms originate."
2022-01-13,132.38999938964844,129.64999389648438,-1.7855787669322678,3 Reasons to Buy This Newly Minted Dividend King | Should You Buy Boston Scientific Stock Over Its Industry Peer?,"Last month, the diversified healthcare company Abbott Laboratories (NYSE: ABT) raised its quarterly dividend 4.4% from $0.45 to $0.47 per share. This marked the 50th consecutive year that the stock has increased its payout, which means that the stock will become a Dividend King in the likely event that it sticks with this dividend throughout the year. This makes Abbott a great stock for dividend growth investors to consider buying in 2022. | We think that Boston Scientific stock (NYSE: BSX) currently is a better pick compared to its industry peer, Medtronic stock (NYSE: MDT), despite it being the more expensive of the two, trading at 5.3x trailing revenues compared to 4.4x for Medtronic. Boston Scientific’s Revenue Growth Is Stronger Boston Scientific’s sales have jumped from $8.4 billion in 2016 to $11.5 billion over the last twelve months, while Medtronic’s revenues have risen from $29.7 billion in fiscal 2017 to $31.8 billion over the last twelve months. The table below summarizes our revenue and return expectation for BSX and MDT over the next three years, and points to an expected return of 18% for BSX over this period vs. just 7% for MDT, implying that investors are better off buying BSX over MDT, based on our dashboard – Boston Scientific vs Medtronic – which also provides more details on how we arrive at these numbers."
2022-01-12,134.88999938964844,133.72000122070312,-2.0696468810304287,"Does Johnson & Johnson's Split Make Sense? | 2 No-Brainer Stocks to Invest $1,000 in Right Now | Abbott Receives FDA Clearance For Cardiac Mapping System","Many were blindsided when the company announced late last year that it would be splitting its medical device and pharmaceutical businesses from its consumer health business. But last month, the 135-year-old pharmaceutical giant Johnson & Johnson, announced that it would be splitting its business in two. The consumer health business, I find it interesting that this is the business that's not going to retain the name of Johnson & Johnson because I think that this is the one that most people think of when they think of Johnson & Johnson. | Let's look at two companies that closely fit this description: Abbott Laboratories (NYSE: ABT) and Adyen N.V. (OTC: ADYE.Y). Abbott Laboratories Abbott Laboratories is best known as a medical devices specialist -- and it is one of the most established leaders in this field. In the third quarter, Abbott Laboratories' diagnostics segment's sales soared by 48.2% year over year to $3.9 billion, largely thanks to its coronavirus-related products. | (RTTNews) - Abbott (ABT) said that it has received clearance from the U.S. Food and Drug Administration for the EnSite X EP System with EnSite Omnipolar Technology, a new cardiac mapping platform available in the U.S. and across Europe that is designed to help physicians better treat abnormal heart rhythms, also known as cardiac arrhythmias. The company noted that the system creates three-dimensional maps of the heart to help physicians identify and then treat areas of the heart where abnormal rhythms originate. EnSite X EP System with EnSite Omnipolar Technology provides a 360-degree view of the heart, regardless of catheter orientation, for cardiac mapping without compromise."
2022-01-11,135.22999572753906,135.6999969482422,-0.8673720618573143,"5 Best Stocks to Buy in January and Hold Forever | Ex-Dividend Reminder: DTE Energy, AbbVie and Abbott Laboratories | Abbott Laboratories To Present At J.P. Morgan Healthcare Conference; Webcast At 9:00 AM ET","Abbott Labs Healthcare conglomerate Abbott Laboratories (NYSE: ABT) concentrates on consumer health products like baby formula and nutrition shakes, medical devices, established pharmaceuticals, and diagnostics systems, including a COVID-19 testing device. The company has grown earnings per share at an average rate of 5% over the past decade, driven by a steady drug pipeline that produces enough profits to buy back stock and pay investors a dividend (currently yielding 2.9%). Beckton, Dickinson Medical technology company Beckton, Dickinson & Company (NYSE: BDX) creates and sells various medical products, including supplies, devices, diagnostic and analyzer equipment, and much more. | Looking at the universe of stocks we cover at Dividend Channel, on 1/13/22, DTE Energy Co (Symbol: DTP), AbbVie Inc (Symbol: ABBV), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. DTE Energy Co (Symbol: DTP): AbbVie Inc (Symbol: ABBV): Abbott Laboratories (Symbol: ABT): In general, dividends are not always predictable, following the ups and downs of company profits over time. Similarly, investors should look for ABBV to open 1.04% lower in price and for ABT to open 0.35% lower, all else being equal. | (RTTNews) - Abbott Laboratories (ABT) will present virtually at the 40th Annual J.P. Morgan Healthcare Conference. The event is scheduled to begin at 9:00 AM ET on Jan. 11, 2021. To access the live webcast, log on to www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2022-01-10,134.7899932861328,135.25999450683594,0.34755692934434596,"3 Top Stock Trades for the Week of Jan. 10, 2022 | What's Happening With Medtronic Stock?","Top Stock Trades for the Week: Abbot Laboratories (ABT) Source: The thinkorswim® platform from TD Ameritrade We’re returning to the healthcare sector for the final top stock trades idea. Comcast (NASDAQ:CMCSA) Bristol-Myers Squibb (NYSE:BMY) Abbot Laboratories (NYSE:ABT) Let’s take a closer look at each and map out a trade to profit. The correlation between ABT and its sector has been high during the pullback, and now both are offering clean buy-the-dip patterns. | Going by our Medtronic Valuation of $144 per share, based on $5.71 expected adjusted EPS and a 25x P/E multiple for fiscal 2022, there is around 36% upside from its current levels of $106, implying that MDT stock is currently undervalued and it will likely see higher levels going forward, in our view. Medtronic (MDT) Stock Return (Recent) Comparison With Peers Five-Day Return: MDT highest at 2.0%; ISRG lowest at -6.4% Ten-Day Return: BAX highest at 4.8%; ISRG lowest at -1.8% Twenty-One Days Return: BAX highest at 10.9%; MDT lowest at -3.8% Below you’ll find our previous coverage of MDT stock where you can track our view over time. Given these changes to our forecasts, we have revised our Medtronic Valuation to $144 per share, based on $5.71 expected adjusted EPS and a 25x P/E multiple for fiscal 2022, reflecting a 26% upside from its current levels of $114, implying that MDT stock is currently undervalued and it will likely see higher levels in the near term, in our view."
2022-01-07,134.8800048828125,135.55999755859375,0.34869147868076844,,
2022-01-06,135.0,135.13999938964844,0.5041463902466837,2 Safe Growth Stocks to Buy for 2022,"However, there are two growth stocks that look to be fairly safe bets to do well this year: Abbott Laboratories (NYSE: ABT) and Meta Platforms (NASDAQ: FB). 10 stocks we like better than Abbott Laboratories When our award-winning analyst team has a stock tip, it can pay to listen. See the 10 stocks *Stock Advisor returns as of December 16, 2021 Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors."
2022-01-05,135.14999389648438,135.16000366210938,0.10370325159143519,,
2022-01-04,139.5,135.77000427246094,0.007406412191677045,,
2022-01-03,139.42999267578125,139.0399932861328,-2.673832062752016,3 COVID Stocks That Could Double in 2022 | My Top 5 Dividend Stocks to Buy for 2022,"Read more to see why three Fool.com contributors think COVID stocks Fulgent Genetics (NASDAQ: FLGT), NRx Pharmaceuticals (NASDAQ: NRXP), and Adaptive Biotechnologies (NASDAQ: ADPT) could double your money this year. Although the drugmaker's shares initially popped during the first few months of 2021, Wall Street's enthusiasm for this speculative coronavirus stock steadily waned as the year progressed thanks to the U.S. Food and Drug Administration (FDA) declining to grant Emergency Use Authorization (EUA) for the company's severe COVID-19 treatment, Zyesami (aviptadil). Later this decade, Adaptive says it could have a universal blood test on the market: A doctor will take a blood sample and be able to ""hack"" your immune system and see what diseases it is fighting. | PM Cash Dividend Payout Ratio data by YCharts Philip Morris International is the highest-yielding dividend stock on this list, offering up a 5.3% dividend yield. HD Cash Dividend Payout Ratio data by YCharts Home Depot's dividend yields 1.6%, and the payout has grown at an average of 19.7% annually over the past five years. O Cash Dividend Payout Ratio data by YCharts REITs are excellent dividend stocks because their business structure requires paying at least 90% of their taxable income out as dividends to investors."
2021-12-31,141.0,140.74000549316406,-0.2797098258158194,Abbott Laboratories Shares Close in on 52-Week High - Market Mover,"Abbott Laboratories (ABT) shares closed today at 1.1% below its 52 week high of $142.60, giving the company a market cap of $249B. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 73.0% The company's stock price performance over the past 12 months beats the peer average by 72.1% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 9.7% higher than the average peer. This story was produced by the Kwhen Automated News Generator."
2021-12-30,141.41000366210938,141.0,-0.18439326725953015,5 Dividend Stocks To Watch In 2022 | Best Stocks for 2022: Why AbbVie Looks Like High Dividend Growth Stock | Abbott Laboratories (NYSE:ABT) Is Increasing Its Dividend To US$0.47,"Top Dividend Stocks To Watch In 2022 Pfizer Inc. (NYSE: PFE) Brookfield Renewable Partners LP (NYSE: BEP) Caterpillar Inc. (NYSE: CAT) Abbott Laboratories (NYSE: ABT) Abbvie Inc. (NYSE: ABBV) Pfizer Pfizer has been stealing the show since its Comirnaty coronavirus vaccine was approved in most major countries. All things considered, would you add ABT stock to your portfolio? Having read all of this, would you consider CAT stock a top dividend stock to buy now? | Business Overview AbbVie is a pharmaceutical company that was spun off from Abbott Laboratories (NYSE:ABT) in 2013. There are growth stocks that could generate superior share price gains, but growth stocks typically have elevated valuations and low dividend yields. Final Thoughts on ABBV Stock Putting it all together, AbbVie is a rare example of a growth company with a reasonable valuation and a high dividend yield. | NYSE:ABT Historic Dividend December 30th 2021 Dividend Volatility The company has a long dividend track record, but it doesn't look great with cuts in the past. The board of Abbott Laboratories (NYSE:ABT) has announced that it will be increasing its dividend on the 15th of February to US$0.47. Abbott Laboratories' Dividend Is Well Covered By Earnings We like to see a healthy dividend yield, but that is only helpful to us if the payment can continue."
2021-12-29,140.47000122070312,141.19000244140625,-0.28993964464427413,,
2021-12-28,141.5800018310547,140.47000122070312,0.51256582504892,Abbott Laboratories Shares Close in on 52-Week High - Market Mover | 3 Healthcare Stocks to Buy and Hold for the Next 10 Years,"Abbott Laboratories (ABT) shares closed today at 1.5% below its 52 week high of $142.60, giving the company a market cap of $250B. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 71.4% The company's stock price performance over the past 12 months beats the peer average by 58.9% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 10.3% higher than the average peer. This story was produced by the Kwhen Automated News Generator. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) is another slow-burning healthcare stock that's a worthy contributor to most portfolios, but it's also the company on this list that's grown the most in the last decade. Viatris As a generic drugmaker, Viatris (NASDAQ: VTRS) is a stock that you shouldn't even consider holding unless you're willing to do so for the long term. See the 10 stocks *Stock Advisor returns as of December 16, 2021 Alex Carchidi owns Abbott Laboratories."
2021-12-27,139.82000732421875,141.4600067138672,-0.7840094617855068,,
2021-12-23,139.64999389648438,139.16000366210938,1.1729361348448213,"Notable Thursday Option Activity: H, ABT, JPM","Especially high volume was seen for the $95 strike call option expiring March 18, 2022, with 2,403 contracts trading so far today, representing approximately 240,300 underlying shares of H. Below is a chart showing H's trailing twelve month trading history, with the $95 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) saw options trading volume of 26,620 contracts, representing approximately 2.7 million underlying shares or approximately 44.4% of ABT's average daily trading volume over the past month, of 6.0 million shares. Below is a chart showing ABT's trailing twelve month trading history, with the $146 strike highlighted in orange: And JPMorgan Chase & Co (Symbol: JPM) saw options trading volume of 58,280 contracts, representing approximately 5.8 million underlying shares or approximately 43.7% of JPM's average daily trading volume over the past month, of 13.3 million shares. Particularly high volume was seen for the $146 strike call option expiring January 21, 2022, with 3,672 contracts trading so far today, representing approximately 367,200 underlying shares of ABT."
2021-12-22,135.8800048828125,138.99000549316406,-0.3508702153887708,Abbott Laboratories Shares Close in on 52-Week High - Market Mover,"Abbott Laboratories (ABT) shares closed today at 0.2% below its 52 week high of $139.27, giving the company a market cap of $239B. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 59.6% The company's stock price performance over the past 12 months beats the peer average by 56.2% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 8.1% higher than the average peer. This story was produced by the Kwhen Automated News Generator."
2021-12-21,136.02000427246094,135.27000427246094,2.2887845883091718,"Best Long Term Stocks To Buy? 4 Health Care Stocks For Your Watchlist | SPHQ, ABT, UPS, SPGI: ETF Inflow Alert | 3 Great Stocks to Buy With the Omicron Variant Spreading Like Wildfire","Best Health Care Stocks To Buy [Or Sell] This Week Cerner Corporation (NASDAQ: CERN) Veracyte Inc (NASDAQ: VCYT) Novavax, Inc. (NASDAQ: NVAX) Abbott Laboratories (NYSE: ABT) Cerner First, we have Cerner, a health care company that is a supplier of health information technology services, devices, and hardware. ABT stock has risen by over 20% this year. All things considered, would you add ABT stock to your portfolio? | Among the largest underlying components of SPHQ, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.7%, United Parcel Service Inc (Symbol: UPS) is up about 1.5%, and Standard and Poors Global Inc (Symbol: SPGI) is up by about 1.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Invesco S&P 500— Quality ETF (Symbol: SPHQ) where we have detected an approximate $584.4 million dollar inflow -- that's a 17.3% increase week over week in outstanding units (from 66,260,000 to 77,690,000). For a complete list of holdings, visit the SPHQ Holdings page » The chart below shows the one year price performance of SPHQ, versus its 200 day moving average: Looking at the chart above, SPHQ's low point in its 52 week range is $41.18 per share, with $53.25 as the 52 week high point — that compares with a last trade of $51.29. | Abbott Abbott (NYSE: ABT) made $1.9 billion in the third quarter from sales of its COVID-19 testing products. Here are three great stocks to buy with the omicron variant spreading like wildfire. 10 stocks we like better than Abbott Laboratories When our award-winning analyst team has a stock tip, it can pay to listen."
2021-12-20,136.1999969482422,134.97999572753906,-0.5513894842244521,,
2021-12-17,137.5399932861328,137.11000061035156,-0.8957424728627137,,
2021-12-16,135.44000244140625,136.08999633789062,-0.3126310140838164,Here's Why Investors Should Consider DexCom Stock | Unstoppable Dividend King for 2022: AbbVie or Johnson & Johnson? | Interesting ABT Put And Call Options For August 2022 | 3 Stocks That Just Declared Dividend Raises | Abbott Laboratories (NYSE:ABT) Is Increasing Its Dividend To US$0.47,"See the 10 stocks *Stock Advisor returns as of November 10, 2021 Rachel Warren: This is another company I talk about fairly frequently and it's a healthcare stock I really like. Just a quick highlight of the third-quarter performance revenue was up 30% year over year for a total of $650 million, U.S. revenue growth was up 23% year over year while its international revenue in the third quarter were up 57% year over year. There was a study done in 2020 by a company called Bigfoot Biomedical and it reported that only one in four potential CGM users actually use this device, which means that DexCom has a lot of runway left to tap into users it hasn't yet reached, potential customers within the CGM industry. | The case for Johnson & Johnson Johnson & Johnson had revenue of $82.5 billion last year, more than the gross domestic product of many countries. The case for AbbVie Since splitting off from Abbott Laboratories in 2013, AbbVie has seen revenue increase steadily -- up 115% over the past five years -- and it has been up every year. It has seen greater growth in its share price, revenue, and dividends over the past five years than has Johnson & Johnson -- and I expect that to continue. | Below is a chart showing ABT's trailing twelve month trading history, with the $145.00 strike highlighted in red: Considering the fact that the $145.00 strike represents an approximate 7% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the August 2022 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new August 2022 contracts and identified one put and one call contract of particular interest. | In the very recent past, three prominent names in the healthcare industry have declared dividend raises: Pfizer (NYSE: PFE), Abbott Laboratories (NYSE: ABT), and CVS Health (NYSE: CVS). And then there's the company's ever-growing dividend, yielding 1.4% at the current stock price. The sprawling pharmacy chain declared its own dividend increase in mid-December, hiking its quarterly payout 10% to $0.55 per share. | NYSE:ABT Historic Dividend December 16th 2021 Dividend Volatility Although the company has a long dividend history, it has been cut at least once in the last 10 years. Abbott Laboratories (NYSE:ABT) will increase its dividend on the 15th of February to US$0.47. Abbott Laboratories' Dividend Is Well Covered By Earnings We like to see a healthy dividend yield, but that is only helpful to us if the payment can continue."
2021-12-15,133.5399932861328,135.55999755859375,0.4799127914705804,Intuitive Surgical Stock Appears To Have A Limited Upside,"Out of 248 instances in the last ten years that ISRG stock saw a twenty-one day fall of 7% or more, 161 of them resulted in ISRG stock rising over the subsequent one-month period (twenty-one trading days). [Updated: Dec 9, 2021] ISRG Stock Update The stock price of Intuitive Surgical (NASDAQ: ISRG) has seen a rise of over 6% over the last five trading days."
2021-12-14,135.92999267578125,132.94000244140625,1.512658659591756,Is It Too Late to Buy AbbVie Stock?,"The bears will point to declining sales of AbbVie's rheumatoid arthritis drug Humira in Europe as evidence that its growth days are well behind it. Meanwhile, sales within AbbVie's oncology segment rose 8.4% year over year to $1.9 billion. Products such as immunosuppressants Skyrizi and Rinvoq, cancer drug Venclexta, and skin treatment Botox (added to the lineup through AbbVie's $63 billion acquisition of Allergan) are all performing well."
2021-12-13,134.5,135.9600067138672,-2.199654524742521,"BKLN, MDEV: Big ETF Outflows | Noteworthy ETF Inflows: URTH, ABT, UPS, PM | 3 Investors Pick Their Top Wealth-Building Stocks | Abbott Rewards Shareholders; Shares Record New All-Time High","Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel, the biggest outflow was seen in the Invesco Senior Loan ETF, where 21,300,000 units were destroyed, or a 7.0% decrease week over week. And on a percentage change basis, the ETF with the biggest outflow was the First Trust Indxx Medical Devices ETF, which lost 50,000 of its units, representing a 33.3% decline in outstanding units compared to the week prior. VIDEO: BKLN, MDEV: Big ETF Outflows The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of URTH, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.5%, United Parcel Service Inc (Symbol: UPS) is down about 0.8%, and Philip Morris International Inc (Symbol: PM) is up by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares MSCI World ETF (Symbol: URTH) where we have detected an approximate $121.1 million dollar inflow -- that's a 6.7% increase week over week in outstanding units (from 13,400,000 to 14,300,000). For a complete list of holdings, visit the URTH Holdings page » The chart below shows the one year price performance of URTH, versus its 200 day moving average: Looking at the chart above, URTH's low point in its 52 week range is $109.152 per share, with $136.75 as the 52 week high point — that compares with a last trade of $132.71. | He started it off here with some stocks, Berkshire Hathaway, Verizon Communications -- ABT, is that Abbott Labs? I'm not sure, ABT. Toby Bordelon owns shares of Alphabet (A shares), Apple, Berkshire Hathaway (B shares), Mastercard, and Microsoft. | Management Comments President, and CEO of Abbott, Robert B. Ford, said, “Fifty years of dividend growth reflects the consistently strong performance of our diversified business model… It exemplifies our longstanding commitment to delivering sustainable growth that fuels innovation as well as shareholder returns.” See Analysts’ Top Stocks on TipRanks >> Wall Street View With 11 Buys and 2 Holds, the ABT stock commands a Strong Buy consensus rating. Multinational medical devices and healthcare company, Abbott Laboratories (ABT) announced an increase in its quarterly cash common dividend for the 50th consecutive year. Rewarding Shareholders Abbott, which is a part of The Dividend Aristocrat Index, increased its quarterly common dividend by 4.4% to $0.47 per share, following a 25% increase in its common dividend in 2021."
2021-12-10,133.4199981689453,134.3699951171875,1.0855068504588754,3 Healthcare Stocks for Long-Term Dividend Growth | My Take: 4 Strong Growth Stocks To Buy This Week,"The companies are: Johnson & Johnson (NYSE:JNJ) Medtronic (NYSE:MDT) Abbott Labs (NYSE:ABT) Johnson & Johnson (JNJ) Source: Sundry Photography / Shutterstock.com First on our list of healthcare stocks is Johnson & Johnson, a highly diversified company that develops, manufactures and distributes a huge range of products in various markets in healthcare globally. Abbott Labs (ABT) ABT) sign with lighting behind letters"" width=""300"" height=""169""> Source: testing / Shutterstock.com Our finalist among healthcare stocks is Abbott, a fully integrated pharmaceutical, medical device, and nutrition company that operates globally. In addition, we see 6% earnings growth on an annualized basis in the coming years for Johnson & Johnson, meaning that over time, the pool from which it can pay rising dividends should rise as well, making it that much easier for the company to fund years of additional dividend increases. | Palantir Technologies It's not a household name, but Palantir Technologies (NYSE: PLTR) plays a crucial role in helping organizations handle the deluge of digital data they've been collecting for years now. DexCom Finally, investors on the hunt for growth stocks may want to consider DexCom (NASDAQ: DXCM), a maker of continuous glucose monitoring systems (GMS) used by diabetics. Analysts expect DexCom's revenue will grow 27% this year and 22% next year."
2021-12-09,132.5,132.52999877929688,0.7120348982760725,,
2021-12-08,132.8000030517578,132.3699951171875,0.022640588148584904,These 4 Measures Indicate That Abbott Laboratories (NYSE:ABT) Is Using Debt Safely,"NYSE:ABT Debt to Equity History December 8th 2021 A Look At Abbott Laboratories' Liabilities Zooming in on the latest balance sheet data, we can see that Abbott Laboratories had liabilities of US$12.9b due within 12 months and liabilities of US$26.3b due beyond that. As with many other companies Abbott Laboratories (NYSE:ABT) makes use of debt. The first thing to do when considering how much debt a business uses is to look at its cash and debt together."
2021-12-07,134.0,132.4199981689453,-0.32380114810895005,,
2021-12-06,130.75999450683594,132.47000122070312,-1.1791058440706623,,
2021-12-03,128.8800048828125,130.27000427246094,1.3077445592717512,Even Good Penny Stocks Like Senseonics Aren’t Always Profitable | iShares S&P 500 Growth ETF Experiences Big Inflow,"There’s also Abbott Laboratories (NYSE:ABT), which offers a system called MyFreeStyle with a sensor that lasts 14 days. InvestorPlace - Stock Market News, Stock Advice & Trading Tips To call Senseonics Holdings (NYSEAMERICAN:SENS) a penny stock isn’t to say it sells for a penny. The Bottom Line on SENS Stock Senseonics is what I call a “good” penny stock. | Among the largest underlying components of IVW, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.6%, Standard and Poors Global Inc (Symbol: SPGI) is off about 0.6%, and United Parcel Service Inc (Symbol: UPS) is up by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 500 Growth ETF (Symbol: IVW) where we have detected an approximate $93.3 million dollar inflow -- that's a 0.2% increase week over week in outstanding units (from 480,650,000 to 481,800,000). For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year price performance of IVW, versus its 200 day moving average: Looking at the chart above, IVW's low point in its 52 week range is $60.70 per share, with $84.88 as the 52 week high point — that compares with a last trade of $80.60."
2021-12-02,126.29000091552734,128.3800048828125,1.078522142292228,,
2021-12-01,126.4800033569336,126.73999786376952,1.654924342492574,Will Intuitive Surgical Stock Rebound After Its Recent Fall?,"Out of 248 instances in the last ten years that ISRG stock saw a twenty-one day fall of 7% or more, 161 of them resulted in ISRG stock rising over the subsequent one-month period (twenty-one trading days). Intuitive Surgical (ISRG) Stock Return (Recent) Comparison With Peers Five-Day Return: BDX highest at -1.4%; EW lowest at -6.4% Ten-Day Return: BDX highest at 0.4%; BSX lowest at -8.3% Twenty-One Days Return: BDX highest at 2.7%; BSX lowest at -10.7% may have moved, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. Total [2] ISRG Return -6% 21% 367% S&P 500 Return 1% 22% 105% Trefis MS Portfolio Return -3% 46% 297% [1] Month-to-date and year-to-date as of 11/29/2021 [2] Cumulative total returns since 2017 Invest with Trefis Market Beating PortfoliosSee all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2021-11-30,128.1999969482422,125.7699966430664,0.2055617488419923,What's Next For Medtronic Stock After A Mixed Q2? | Intuitive Surgical Stock Appears To Be A Better Bet Over This Medical Technology Company,"[Updated: Nov 26, 2021] Medtronic Earnings Update Medtronic (NYSE:MDT) recently reported its Q2 FY22 results, which were mixed with revenue slightly below, and earnings above our estimates. (1) Revenues expected to be in-line with the consensus estimate Trefis estimates Medtronic’s Q2 fiscal 2022 total revenues to be around $8.0 billion, in-line with the consensus estimates. (3) Stock price estimate 27% above the current market price Going by our Medtronic Valuation, with an EPS estimate of around $5.75 and P/E multiple of 26x in fiscal 2022, this translates into a price of $149, which is 27% above the current market price of around $118. | Intuitive Surgical Revenue Growth Has Been Stronger Now, Intuitive Surgical’s revenue growth over the last twelve month period was better than Edwards Lifesciences (27% vs. 17%), given a sharp rebound in total procedure volume, resulting in more da Vinci system placements. Intuitive Surgical Is More Profitable Similar to the pattern seen in revenue growth, Intuitive Surgical’s last three year average operating margin of 29% is higher than 22% for Edwards Lifesciences. While Edwards Lifesciences current valuation is surely more attractive than that of Intuitive Surgical, with EW stock trading at about 14x trailing revenues, versus 22x for Intuitive Surgical, the latter has demonstrated better revenue growth and better profitability  over the last few years."
2021-11-29,126.3499984741211,128.02999877929688,-1.8954761022005626,Thermo Fisher says its COVID-19 tests accurately detects Omicron variant,"Other COVID-19 tests, including from Roche Holding AG ROG.S and Abbott Laboratories ABT.N, can also be used to diagnose positive cases of COVID-19 caused by the variant, though only Thermo Fisher has so far confirmed that its test can be used to help identify the variant. By Radhika Anilkumar and Carl O'Donnell Nov 29 (Reuters) - Thermo Fisher Scientific Inc TMO.N said on Monday its COVID-19 diagnostic tests can accurately detect the new coronavirus variant Omicron that has prompted several countries to shut their borders. Test samples must still be sent to a lab for sequencing to confirm that the case was caused by Omicron and not another variant with similar features, such as the Alpha variant, Stevenson said."
2021-11-26,127.80999755859376,125.87999725341795,1.3296401467862917,,
2021-11-24,124.06999969482422,125.06999969482422,-1.5100542540038873,"Pre-Market Most Active for Nov 24, 2021 : SQQQ, WISH, GPS, JWN, PROG, ABT, OIS, MNOV, FUTU, VNE, CAH, LCID | What To Expect From Medtronic's Q2?","Abbott Laboratories (ABT) is -0.48 at $124.00, with 712,331 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the ""buy range"". The total Pre-Market volume is currently 20,007,072 shares traded. | (1) Revenues expected to be in-line with the consensus estimate Trefis estimates Medtronic’s Q2 fiscal 2022 total revenues to be around $8.0 billion, in-line with the consensus estimates. 2) EPS likely to be in-line with the consensus estimates Medtronic’s Q2 fiscal 2022 earnings per share (EPS) is expected to be $1.30 per Trefis analysis, in-line with the consensus estimate of $1.29. (3) Stock price estimate 27% above the current market price Going by our Medtronic Valuation, with an EPS estimate of around $5.75 and P/E multiple of 26x in fiscal 2022, this translates into a price of $149, which is 27% above the current market price of around $118."
2021-11-23,124.51000213623048,124.4800033569336,0.805996616796733,"3 December Dividend Growers to Buy for 5.4% Yields, 40% Payout Growth","Abbott Dividends--and Shares--Set for a Second Big Pop Medical device maker Abbott Laboratories (ABT) sent a message last December when it delivered the biggest payout hike in its history--a 25% boost that instantly bounced its stock to all-time highs last year: December 10 Payout Raise Could Top Last Year's 25% Hike Step 1: Buy Just as a Dividend Hike Is Announced We'll start by ""timing"" our buys just as dividend hikes are announced. These 23 Stocks Are Primed for Big Dividend Hikes (Starting Soon) I'll give you my latest buy/sell/hold advice on Progressive and the other 22 dividend growers in my Hidden Yields portfolio when you take advantage of my special invitation to road test the service with no risk and no obligation!"
2021-11-22,126.77999877929688,125.26000213623048,-0.024093469425907295,,
2021-11-19,128.41000366210938,126.83999633789062,-1.198924639297762,,
2021-11-18,129.30999755859375,127.63999938964844,-1.2226518802615847,3 Reasons This Stock Could 10X in 10 Years | Should You Be Adding Abbott Laboratories (NYSE:ABT) To Your Watchlist Today?,"A solid market share Naturally, DexCom isn't the only company looking to cash in on the CGM space. DexCom is unquestionably one of the leaders with an estimated 41% share of the total CGM market. Some analysts may feel that DexCom's shares have outpaced its intrinsic value in the past year -- with its stock having soared by more than 90% in the past 12 months -- and that it is likely to be volatile in the period ahead. | If, on the other hand, you like companies that have revenue, and even earn profits, then you may well be interested in Abbott Laboratories (NYSE:ABT). NYSE:ABT Earnings and Revenue History November 18th 2021 While we live in the present moment at all times, there's no doubt in my mind that the future matters more than the past. Over the last three years, Abbott Laboratories has grown earnings per share (EPS) like young bamboo after rain; fast, and from a low base."
2021-11-17,130.61000061035156,128.6199951171875,-1.291468718950824,This Pharma Stock Appears To Be A Better Pick Over Abbott Labs | 1 Dividend Stock to Help You Fight Inflation | Will Investors Win With Johnson & Johnson's Planned Spinoff? Here's What History Shows,"We think that Eli Lilly stock (NYSE: LLY) currently is a better pick compared to Abbott Labs stock (NYSE: ABT) with similar market capitalization in the healthcare sector, despite Eli Lilly being the more expensive of the two. Abbott’s current valuation is seemingly more attractive than that of Eli Lilly, with ABT stock trading at about 5.5x trailing revenues, versus 9.5x for LLY stock, and Abbott has also seen better revenue growth. LLY stock trades at about 9.5x trailing revenues, compared to 5.5x for ABT stock. | Looking at AbbVie's dividend record AbbVie made its debut on the stock market in January 2013 when it split from its former parent company, Abbott Laboratories. In the third quarter, sales of Botox Cosmetics grew by 38.5% year over year to $545 million, while sales of Botox Therapeutics jumped by 23.4% year over year to $645 million. AbbVie is here to stay An excellent dividend track record, coupled with a deep lineup and solid pipeline, makes the company an outstanding dividend-paying stock to help you smooth out the harmful effects of inflation. | In 2013, Abbott (NYSE: ABT) created AbbVie (NYSE: ABBV). ABT data by YCharts Going into the spinoff of AbbVie, Abbott was already a member of the Dividend Aristocrats -- an exclusive group of S&P 500 members with consecutive dividend increases for at least 25 years. Johnson & Johnson (NYSE: JNJ) announced last week that it plans to spin off its consumer healthcare business into a separate publicly traded entity."
2021-11-16,129.63999938964844,130.88999938964844,-1.5236241358736686,"Notable ETF Inflow Detected - VTI, XOM, PFE, ABT","Among the largest underlying components of VTI, in trading today Exxon Mobil Corp (Symbol: XOM) is up about 0.6%, Pfizer Inc (Symbol: PFE) is off about 0.4%, and Abbott Laboratories (Symbol: ABT) is higher by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Total Stock Market ETF (Symbol: VTI) where we have detected an approximate $2.6 billion dollar inflow -- that's a 0.9% increase week over week in outstanding units (from 1,183,922,203 to 1,194,563,534). For a complete list of holdings, visit the VTI Holdings page » The chart below shows the one year price performance of VTI, versus its 200 day moving average: Looking at the chart above, VTI's low point in its 52 week range is $182.21 per share, with $243.56 as the 52 week high point — that compares with a last trade of $241.97."
2021-11-15,128.77000427246094,129.44000244140625,0.9642085821390484,,
2021-11-12,127.94000244140624,128.4499969482422,0.5203060858239017,Abbott's New Leadless Pacemaker System Meets Main Goal In Pivotal Trial,"(RTTNews) - Abbott Laboratories (ABT) said that its new leadless pacemaker system met primary endpoints in pivotal trial. The company noted that the new, late-breaking data from the Leadless II IDE study confirmed the company's investigational Aveir leadless pacemaker achieved the pre-specified primary endpoints in treating patients with certain types of abnormal heart rhythms. Abbott noted that its Aveir system is the world's only leadless pacemaker specifically designed to be retrieved when the device needs to be replaced or if a patient's therapy needs to be changed."
2021-11-11,127.97000122070312,127.25,0.3986200540128317,2 Dividend Aristocrats That Could Announce Generous Rate Hikes in December,"Both Abbott Laboratories (NYSE: ABT) and Enbridge (NYSE: ENB) raised their payouts last year and have done so for decades. One more increase to the dividend would make the company a Dividend King, solidifying its presence as one of the top dividend stocks in the world. Enbridge Pipeline company Enbridge doesn't have nearly as long of a streak going as Abbott Labs has."
2021-11-10,126.19000244140624,127.81999969482422,-0.5626328153747352,,
2021-11-09,126.6999969482422,126.43000030517578,1.2917007860229175,,
2021-11-08,124.0,126.8000030517578,-0.21309917093109,"IWB, ACN, PEP, ABT: ETF Outflow Alert","Among the largest underlying components of IWB, in trading today Accenture plc (Symbol: ACN) is up about 0.1%, PepsiCo Inc (Symbol: PEP) is off about 1.8%, and Abbott Laboratories (Symbol: ABT) is higher by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $856.3 million dollar outflow -- that's a 2.6% decrease week over week (from 123,450,000 to 120,200,000). For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $196 per share, with $264.87 as the 52 week high point — that compares with a last trade of $264.14."
2021-11-05,127.08000183105467,124.37000274658205,2.258066977224031,10 S&P 500 Stocks to Buy After Winning in Q3,"Abbott Laboratories (NYSE:ABT) Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL) Chevron (NYSE:CVX) Delta Air Lines (NYSE:DAL) Ford (NYSE:F) Intel (NASDAQ:INTC) MGM Resorts (NYSE:MGM) Pfizer (NYSE:PFE) SVB Financial (NASDAQ:SIVB) Thomson Reuters (NYSE:TRI) S&P 500 Stocks to Buy: Abbott Laboratories (ABT) ABT) sign with lighting behind letters"" width=""300"" height=""169""> Source: testing / Shutterstock.com First up on this list of S&P 500 stocks is Abbott Laboratories. Based on past valuations, this is a pretty reasonable figure for ABT stock. Moving forward, I expect the 34% earnings beat ($2.96 vs. $2.21 estimate) and 10% sales beat ($44.71 billion vs. $40.52 billion estimate) ought to help even the score for this pick of the S&P 500 stocks in Q4 and beyond."
2021-11-04,128.9499969482422,129.08999633789062,-2.132514200051249,December 23rd Options Now Available For Abbott Laboratories (ABT),"Below is a chart showing ABT's trailing twelve month trading history, with the $130.00 strike highlighted in red: Considering the fact that the $130.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the December 23rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new December 23rd contracts and identified one put and one call contract of particular interest."
2021-11-03,127.37999725341795,128.6999969482422,0.10856874211841222,What's Happening With Dexcom Stock?,"Predict average return on DexCom (DXCM) Stock Return: AI Predicts DXCM Average and Excess Return After a Fall or Rise DexCom (DXCM) Stock Return (Recent) Comparison With Peers Five-Day Return: IDXX highest at 2.9%; ABT lowest at -1.7% Ten-Day Return: DXCM highest at 3.6%; RMD lowest at -4.3% Twenty-One Day Return: DXCM highest at 11%; PODD lowest at -3.1% [Updated: 6/22/2021] DXCM Stock Rise Last month, we discussed why the sell-off in Dexcom Stock (NASDAQ: DXCM) was unwarranted, and we expected it to see higher levels. Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using last 10 year data 3.4% or higher return during five-day period in 794 times out of 2517; Stock rose in the next 5 days in 448 of these 794 instances 9.3% or higher return during ten-day period in 463 times out of 2517; Stock rose in the next 10 days in 260 of these 463 instances 23% or higher return during twenty-one day period in 184 times out of 2516; Stock rose in the next 21 days in 99 of these 184 instances Predict average return on DexCom (DXCM) Stock Return: AI Predicts DXCM Average and Excess Return After a Fall or Rise DexCom (DXCM) Stock Return (Recent) Comparison With Peers Five-Day Return: DXCM highest at 3.4%; SPY lowest at -1% Ten-Day Return: DXCM highest at 9.3%; SPY lowest at -0.3% Twenty-One Days Return: DXCM highest at 23%; ABT lowest at -5.4% [Updated: 5/6/2021] DXCM Stock Decline The stock price of Dexcom (NASDAQ: DXCM), best known for its continuous glucose monitoring (CGM) systems, has seen an 11% drop over the last five trading days, and we believe the stock is likely to rebound in the near term. Out of 184 instances in the last ten years that Dexcom stock saw a twenty-one day rise of 23% or more, 99 of them resulted in DXCM stock rising over the subsequent one month period (twenty-one trading days)."
2021-11-02,129.3300018310547,127.70999908447266,1.036269212816939,This Stock Is Likely To Outperform Medtronic,"Intuitive Surgical Revenue Growth Has Been Stronger Now, Intuitive Surgical’s revenue growth over the last twelve month period was better than Medtronic (27% vs. 13%), given a sharp rebound in total procedure volume, resulting in more da Vinci system placements. Intuitive Surgical Has Better Profitability Unlike the pattern seen in revenue growth, Intuitive Surgical’s operating margin change of -8% over the last three years is worse than -6% for Medtronic. While Medtronic’s current valuation is surely more attractive than that of Intuitive Surgical, with MDT stock trading at about 5x trailing revenues, versus 23x for Intuitive Surgical, the latter has demonstrated better revenue growth and better profitability  over the last few years."
2021-11-01,128.63999938964844,128.94000244140625,-1.2526117093064453,,
2021-10-29,127.26000213623048,128.88999938964844,0.2332113286545565,"IWB, ACN, ABT, CVX: ETF Inflow Alert | Insiders at Abbott Laboratories (NYSE:ABT) sold US$2.8m worth of stock, possibly indicating weakness in the future","Among the largest underlying components of IWB, in trading today Accenture plc (Symbol: ACN) is up about 0.5%, Abbott Laboratories (Symbol: ABT) is down about 0.2%, and Chevron Corporation (Symbol: CVX) is up by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $180.5 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 122,550,000 to 123,250,000). For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $180.78 per share, with $258.58 as the 52 week high point — that compares with a last trade of $257.23. | In the last year, many Abbott Laboratories (NYSE:ABT) insiders sold a substantial stake in the company which may have sparked shareholders' attention. NYSE:ABT Insider Trading Volume October 29th 2021 If you are like me, then you will not want to miss this free list of growing companies that insiders are buying. The Last 12 Months Of Insider Transactions At Abbott Laboratories Over the last year, we can see that the biggest insider sale was by the insider, Roger Bird, for US$1.2m worth of shares, at about US$122 per share."
2021-10-28,128.02999877929688,127.70999908447266,1.2808401902060789,Why Investors Need to Pay Attention to the At-Home Diagnostics Market | December 10th Options Now Available For Abbott Laboratories (ABT),"Products like Abbot Labs (ABT) FreeStyle Libre 2 continuous glucose monitoring (iCGM) system is being used to not only help those with diabetes manage it better but is also being used to help others understand their body’s reactions to various foods and activities to prevent Type 2 diabetes. Comparing life expectancies around the world, we get an idea of just how poor of a return the U.S. is getting on its healthcare dollars: The nation with the highest life expectancy was Hong Kong at 82.2 years for men and 88.1 for women, but data is not available on per capita healthcare spending. Singapore had the world’s fourth-highest life expectancy for men at 81.4 years and the sixth highest for women at 85.7 years and spent just 27% ($2,824) of what the U.S. spent. | Below is a chart showing ABT's trailing twelve month trading history, with the $130.00 strike highlighted in red: Considering the fact that the $130.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the December 10th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new December 10th contracts and identified one put and one call contract of particular interest."
2021-10-27,129.0,127.70999908447266,-0.24994118400004575,,
2021-10-26,127.0,128.1300048828125,-1.0000007097111192,"PREVIEW-Thermo Fisher set to benefit from demand for testing kits, vaccines | Got $5,000? These 2 Unstoppable Stocks Are No-Brainer Buys | What's Next For Intuitive Surgical Stock? | What To Expect From Boston Scientific Stock In Q3?","** Last week, rival Abbott Laboratories ABT.N raised its 2021 profit forecast due to the recent uptick in testing demand. By Amruta Khandekar and Mrinalika Roy Oct 26 (Reuters) - Thermo Fisher Scientific Inc's TMO.N third-quarter profit is likely to get a boost from a rebound in COVID-19 testing due to the highly contagious Delta variant and sustained demand for vaccines against the coronavirus, Wall Street analysts said. ** Thermo Fisher's COVID-19 response revenue, which consists of supply for vaccines and therapies as well as testing kits, helped cushion the hit to its mainstay business from COVID-19 curbs and beat profit expectations for the past few quarters. | Abbott Laboratories (NYSE: ABT) and Palantir Technologies (NYSE: PLTR) are two suitable options for long-term investors. Given that its net earnings through the first three quarters of this year are more than double what they were a year ago, it wouldn't be surprising to see another solid rate hike before the end of the year. Palantir Technologies Tech company Palantir doesn't pay a dividend, but investors likely won't mind given its attractive growth prospects. | (1) Revenues expected to fall short of the consensus estimate Trefis estimates Intuitive Surgical’s Q3 2021 revenues to be around $1.34 billion, slightly below the $1.39 billion consensus estimate. 2) EPS likely to be ahead of consensus estimates Intuitive Surgical’s Q3 2021 adjusted earnings per share (EPS) is expected to be $1.22 per Trefis analysis, slightly above the consensus estimate of $1.17. (3) Stock price estimate above the current market price Going by our Intuitive Surgical’s Valuation, with an EPS estimate of around $4.96 and a P/E multiple of around 70x in 2021, this translates into a price of $345, which is 6% above the current market price of around $326. | (1) Revenues expected to be in-line with the consensus estimates Trefis estimates Boston Scientific’s Q3 2021 revenues to be around $2.94 billion, in-line with the consensus estimate. 2) EPS also likely to be in-line with the consensus estimates Boston Scientific’s Q3 2021 adjusted earnings per share (EPS) is expected to be $0.37 per Trefis analysis, in-line with the consensus estimate. (3) Stock price estimate 11% higher than the current market price Going by our Boston Scientific’s Valuation, with an EPS estimate of around $1.62 and a P/E multiple of around 31x in 2021, this translates into a price of $50, which is 11% above the current market price of under $45."
2021-10-25,126.48999786376952,126.58000183105467,0.889767624261811,What Could These Clinical Results Mean for AbbVie's Shareholders?,"Earlier this month, AbbVie (NYSE: ABBV) announced promising top-line results from a phase 3 study examining the efficacy and safety of Rinvoq in treating patients diagnosed with active ankylosing spondylitis. AbbVie enrolled 420 adult patients with ankylosing spondylitis who previously failed at least one biologic disease-modifying antirheumatic drug (bDMARD) into its phase 3 clinical trial to test the efficacy and safety of Rinvoq. Factoring in 7,300 patients taking Rinvoq for ankylosing spondylitis in the U.S. at a net annual price of $40,000, the indication in the U.S. could realistically haul in nearly $300 million in annual revenue for AbbVie."
2021-10-22,125.51000213623048,126.72000122070312,0.0711550073564639,Why Senseonics Holdings Stock Popped This Week,"While the medical device company has so far maintained radio silence this week, investors are apparently piling into this stock in anticipation of a long-awaited approval for the 180-day version of the company's implantable Eversense device. * They just revealed what they believe are the ten best stocks for investors to buy right now... and Senseonics Holdings, Inc. wasn't one of them! See the 10 stocks *Stock Advisor returns as of October 20, 2021 George Budwell has no position in any of the stocks mentioned."
2021-10-21,123.51000213623048,125.0500030517578,0.9640658623838524,Quest Diagnostics raises full-year forecast on strong COVID-19 test demand | 3 Things Investors Should Love About Abbott's Q3 Results,"Diagnostic companies like Abbott Laboratories ABT.N have said demand for COVID-19 tests rebounded during the quarter. Adds details on earnings, background, share movement Oct 21 (Reuters) - U.S. laboratory Quest Diagnostics Inc DGX.N on Thursday raised its full-year forecast for profit and revenue and beat third-quarter estimates, on strong demand for its COVID-19 tests due to the spread of the virulent Delta variant in the United States. The company raised its full-year revenue forecast to between $10.45 billion and $10.60 billion, from $9.84 billion to $10.09 billion, and full-year profit outlook to $13.50 to $13.90, from $11.65 to $12.35. | Abbott Laboratories (NYSE: ABT) has given investors plenty to like through the years. Big revenue and earnings beats Abbott's shares rose more than 2% on Wednesday after its Q3 earnings update. Abbott's molecular-diagnostics revenue rose 14.9% year over year, excluding all COVID-19 testing."
2021-10-20,123.52999877929688,123.30999755859376,1.2468633219103238,"US STOCKS-Futures flat on worries over supply chain disruptions; Netflix falls | US STOCKS-Wall Street closes higher as earnings reports soothe investor fears | Why Abbott Laboratories Shot Higher Today | US STOCKS-Wall Street closes higher as earnings reports soothe investor fears | Health Care Sector Update for 10/20/2021: ABT,LMDX,ANTM,MITO | US STOCKS-S&P 500, Dow near records as earnings reports soothe investor fears | US STOCKS-S&P 500, Dow near record highs on solid forecasts from healthcare firms | S&P 500 Movers: OMC, ANTM | Best Health Care Stocks To Buy In Q4? 4 For Your Watchlist | Health Care Sector Update for 10/20/2021: LMDX, ABT, TMO, XLV, IBB | Abbott raises annual profit forecast after upbeat quarterly results | Abbott quarterly profit surges more than 70% | Abbott Laboratories Q3 adjusted earnings Beat Estimates | US STOCKS-Futures flat on worries over supply chain disruptions; Netflix falls | Abbott Laboratories Q3 21 Earnings Conference Call At 9:00 AM ET | Will Abbott Stock Rise After Its Q3 Results? | US STOCKS-Wall St grinds higher on solid healthcare earnings; supply woes linger","Abbott Laboratories ABT.N rose 3.2% after raising its full-year profit forecast on a rebound in COVID-19 test sales. By Devik Jain Oct 20 (Reuters) - U.S. stock index futures struggled for direction on Wednesday as investors weighed the impact of supply chain constraints and inflation on corporate earnings, while Netflix shares remained sluggish after its quarterly report. Analysts expect S&P 500 earnings to rise 33% from a year earlier, according to Refinitiv data, while keeping a close eye on growth outlook from companies that are faced with rising costs, labor shortages and supply chain disruptions. | The S&P's healthcare index rallied for a second day in a row with help from Anthem ANTM.K and Abbott ABT.N, which both gained ground on impressive financial forecasts. Abbott Laboratories ABT.N had finished the regular trading session up 3.3% after raising its full-year profit forecast on a rebound in COVID-19 test sales. By Devik Jain, Shreyashi Sanyal and Sinéad Carew Oct 20 (Reuters) - The S&P 500 and the Dow climbed on Wednesday with the Dow hitting an intraday record high as investors eyed better than expected third-quarter earnings from U.S. companies. | What happened Abbott Laboratories (NYSE: ABT) easily surmounted Hump Day, rising by 3.4% and trouncing the S&P 500 index's gain as it did so. Collectively, prognosticators tracking the healthcare company estimated that it would earn a bit more than $9.4 billion on the top line and post an adjusted net profit of $0.93. 10 stocks we like better than Abbott Laboratories When our award-winning analyst team has a stock tip, it can pay to listen. | The S&P's healthcare index rallied for a second day in a row with help from Anthem ANTM.K and Abbott ABT.N, which gained on impressive financial forecasts. Abbott Laboratories ABT.Nadvanced after raising its full-year profit forecast on a rebound in COVID-19 test sales. While the Nasdaq lagged as technology stocks took a breather, the Dow Jones Industrials Average .DJI briefly surpassed its previous record reached in mid-August during, while the benchmark S&P 500 index .SPX came within five points of its early September record during the session. | In company news, Abbott Laboratories (ABT) climbed 3.3% after reporting improved Q3 net income and revenue and raised its FY21 earnings forecast, with its top-line results benefitting by ongoing sales of its COVID-19 testing products. Health care stocks eased only slightly from their market-leading gains, with the NYSE Health Care Index rising 1.5% in late trade while the SPDR Health Care Select Sector ETF (XLV) was up 1.4%. Excluding one-time items, the health care products company earned $1.40 per share, up from $0.98 per share during the same quarter last year, while net sales increased 23.5% to $10.93 billion. | While the Nasdaq lagged as technology stocks took a breather, the S&P's utility sector was gaining sharply and the healthcare index rallied for a second day in a row after strong forecasts from Anthem ANTM.K and Abbott ABT.N. Abbott Laboratories ABT.N rose 3.6% after raising its full-year profit forecast on a rebound in COVID-19 test sales. By Devik Jain, Shreyashi Sanyal and Sinéad Carew Oct 20 (Reuters) - The Dow briefly touched a record high and the S&P 500 traded close to its peak on Wednesday as investors eyed better than expected third-quarter earnings from U.S. companies. | Abbott Laboratories ABT.N rose 2.9% after raising its full-year profit forecast on a rebound in COVID-19 test sales. By Devik Jain and Shreyashi Sanyal Oct 20 (Reuters) - The S&P 500 and the Dow inched closer to record highs on Wednesday after strong forecasts from healthcare companies Anthem and Abbott, while the Nasdaq lagged as technology stocks took a breather. Analysts expect S&P 500 earnings to rise 33% from a year earlier, according to Refinitiv data, as they kept a close eye on growth outlook from companies faced with rising costs, labor shortages and supply chain disruptions. | In early trading on Wednesday, shares of Anthem topped the list of the day's best performing components of the S&P 500 index, trading up 5.9%. And the worst performing S&P 500 component thus far on the day is Omnicom Group, trading down 5.8%. Two other components making moves today are Baker Hughes, trading down 4.1%, and Abbott Laboratories, trading up 4.1% on the day. | Top Health Care Stocks To Buy [Or Sell] This Week Pfizer Inc. (NYSE: PFE) Abbott Laboratories (NYSE: ABT) LumiraDx (NASDAQ: LMDX) Johnson & Johnson Inc. (NYSE: JNJ) Pfizer Inc. First on this list, we have Pfizer, a multinational pharmaceutical and biotechnology company with headquarters in New York City. More importantly, ABT stock is now making waves in the stock market thanks to the company’s latest quarterly earnings report. With that in mind, would you be watching ABT stock? | Abbott Laboratories (ABT) was climbing past 4% as it reported adjusted Q3 earnings from continuing operations of $1.40 per diluted share, up from $0.98 a year earlier. The Health Care SPDR (XLV) was 0.40% higher while the iShares NASDAQ Biotechnology Index (IBB) was flat in recent activity. LumiraDx Limited (LMDX) was gaining over 22% in value as the company has received approval from India's Central Drugs Standard Control Organization for emergency use of its SARS-CoV-2 Antigen test in India. | Adds details on forecast, background Oct 20 (Reuters) - Abbott Laboratories ABT.N raised its full-year adjusted earnings forecast after reporting a rise in quarterly profit, driven by strength in its mainstay businesses and a rebound in COVID-19 test sales due to the spread of the Delta variant. The U.S. government has also announced policies aimed at pushing large employers to have their workers inoculated or tested weekly and has so far invested around $3 billion to procure rapid COVID-19 tests from Abbott and other manufacturers. Third-quarter sales at Abbott's diagnostics business grew 48.2% to $3.91 billion, with coronavirus test-related sales at $1.9 billion, up from $1.3 billion in the second quarter. | Oct 20 (Reuters) - Abbott Laboratories ABT.N reported a 70.5% rise in quarterly profit on Wednesday, helped by strength in its medical device and diagnostics businesses and a rebound in COVID-19 test sales due to the spread of the Delta variant of the coronavirus. The company's net earnings rose to $2.1 billion, or $1.17 per share, in the third quarter ended Sept. 30, from $1.23 billion, or 69 cents per share, a year earlier. (Reporting by Mrinalika Roy in Bengaluru; Editing by Sriraj Kalluvila) ((mrinalika.roy@thomsonreuters.com)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) released earnings for its third quarter that advanced from last year. Excluding items, Abbott Laboratories reported adjusted earnings of $2.52 billion or $1.40 per share for the period. The company's revenue for the quarter rose 23.5% to $10.93 billion from $8.85 billion last year. | Verizon Communication VZ.N, Abbott Laboratories ABT.N, Tesla Inc TSLA.O, Kinder Morgan KMI.N and IBM IBM.N are set to report their earnings later in the day. By Devik Jain Oct 20 (Reuters) - U.S. stock index futures were flat on Wednesday as investors weighed the impact of supply chain constraints and inflation on corporate earnings, while Netflix shares remained sluggish after its quarterly report. Analysts expect S&P 500 earnings to rise 32.4% from a year earlier, according to Refinitiv data, while also keeping a close eye on growth outlook from companies that are faced with rising costs, labor shortages and supply chain disruptions. | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on Oct. 20 , 2021, to discuss Q3 21 earnings results. To access the live webcast, log on to https://www.abbottinvestor.com/news-and-events?c=94004&p=irol-calall The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (NYSE:ABT) is scheduled to report its Q3 2021 results on Wednesday, October 20, and we expect it to be slightly above the consensus estimates, driven by a rise in demand for medical devices as well as its established pharmaceuticals business. We expect the company to navigate well based on these trends over the latest quarter, and ABT stock to rise in the near term. The 29x P/E multiple compares with levels of 30x seen as recently as late 2020, implying there is some more room for growth for ABT stock. | Abbott Laboratories ABT.N rose 4.2% after raising its full-year profit forecast on a rebound in COVID-19 test sales. By Devik Jain and Shreyashi Sanyal Oct 20 (Reuters) - U.S. stock indexes edged higher on Wednesday, helped by strong quarterly updates from healthcare companies including Anthem and Abbott, while worries remained about the impact of supply chain constraints and inflation on corporate earnings. Analysts expect S&P 500 earnings to rise 33% from a year earlier, according to Refinitiv data, while keeping a close eye on growth outlook from companies that are faced with rising costs, labor shortages and supply chain disruptions."
2021-10-19,117.05999755859376,119.33999633789062,-0.1780953799701503,"Abbott Laboratories Breaks Above 200-Day Moving Average - Bullish for ABT | Pre-Market Earnings Report for October 20, 2021 : ASML, VZ, ABT, NEE, ANTM, CP, BIIB, NDAQ, NTRS, BKR, CFG, MTB | What's Next For Sarepta Stock After A 12% Fall? | What To Expect From Intuitive Surgical's Q3?","In trading on Tuesday, shares of Abbott Laboratories (Symbol: ABT) crossed above their 200 day moving average of $119.19, changing hands as high as $120.18 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $103.13 per share, with $129.6992 as the 52 week high point — that compares with a last trade of $119.41. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com Free Report: Top 7%+ Dividends (paid monthly) Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (ABT)is reporting for the quarter ending September 30, 2021. ABT missed the consensus earnings per share in the 1st calendar quarter of 2021 by -0.75%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for ABT is 26.43 vs. an industry ratio of -16.40, implying that they will have a higher earnings growth than their competitors in the same industry. | The stock price of Sarepta Therapeutics (NASDAQ:SRPT), a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, plunged 12% yesterday, while it is down 14% in the last five trading days. Sarepta saw its stock fall after releasing preliminary Q3 results with revenues expected to be $167 million and a cash balance of $1.6 billion. 5D: SRPT -14%, vs. S&P500 -0.03%; Underperformed market (5% likelihood event; 56% probability of rise over next 5 days) Sarepta Therapeutics stock declined 14% over the last five trading days (one week), compared to broader market (S&P500) decline of 0.03% A change of -14% or more over five trading days (one week) is a 5% likelihood event, which has occurred 134 times out of 2516 in the last 10 years Of these 134 instances, the stock has seen a positive movement over the next five trading days on 75 occasions This points to a 56% probability for the stock rising over the next five trading days 21D: SRPT 3.7%, vs. S&P500 -2%; Outperformed market (48% likelihood event; 58% probability of rise over next 21 days) Sarepta Therapeutics stock rose 3.7% the last twenty-one trading days (one month), compared to broader market (S&P500) decline of 2.0% A change of 3.7% or more over twenty-one trading days is a 48% likelihood event, which has occurred 1211 times out of 2516 in the last 10 years Of these 1211 instances, the stock has seen a positive movement over the next twenty-one trading days on 699 occasions This points to a 58% probability for the stock rising over the next twenty-one trading days While SRPT stock may see higher levels, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. | (1) Revenues expected to fall short of the consensus estimate Trefis estimates Intuitive Surgical’s Q3 2021 revenues to be around $1.34 billion, slightly below the $1.39 billion consensus estimate. 2) EPS likely to be ahead of consensus estimates Intuitive Surgical’s Q3 2021 adjusted earnings per share (EPS) is expected to be $1.22 per Trefis analysis, slightly above the consensus estimate of $1.17. (3) Stock price estimate above the current market price Going by our Intuitive Surgical’s Valuation, with an EPS estimate of around $4.96 and a P/E multiple of around 70x in 2021, this translates into a price of $345, which is 6% above the current market price of around $326."
2021-10-18,117.29000091552734,116.81999969482422,1.9477181162212305,,
2021-10-15,118.08000183105467,117.48999786376952,-0.4007172112153205,,
2021-10-14,116.66000366210938,117.56999969482422,-0.49966459869243246,ABT December 17th Options Begin Trading,"Below is a chart showing ABT's trailing twelve month trading history, with the $125.00 strike highlighted in red: Considering the fact that the $125.00 strike represents an approximate 6% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the December 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new December 17th contracts and identified one put and one call contract of particular interest."
2021-10-13,117.5,117.0,0.7800411487646869,"Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for October 14, 2021","Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the abt Dividend History page. The following ETF(s) have ABT as a top-10 holding: iShares Evolved U.S. Healthcare Staples ETF (IEHS) Invesco Dynamic Pharmaceuticals ETF (PJP) Pacer BioThreat Strategy ETF (VIRS) IQ Healthy Hearts ETF (HART) iShares U.S. Medical Devices ETF (IHI)."
2021-10-12,117.9000015258789,117.31999969482422,-0.425531914893617,"Notable ETF Outflow Detected - SPYG, AMD, ABT, LLY | Ex-Dividend Reminder: Buckle, DTE Energy and Abbott Laboratories","Among the largest underlying components of SPYG, in trading today Advanced Micro Devices Inc (Symbol: AMD) is up about 0.9%, Abbott Laboratories (Symbol: ABT) is up about 0.1%, and Eli Lilly (Symbol: LLY) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR— Portfolio S&P 500— Growth ETF (Symbol: SPYG) where we have detected an approximate $335.9 million dollar outflow -- that's a 2.5% decrease week over week (from 210,350,000 to 205,150,000). For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $48.07 per share, with $68.59 as the 52 week high point — that compares with a last trade of $64.56. | Looking at the universe of stocks we cover at Dividend Channel, on 10/14/21, Buckle, Inc. (Symbol: BKE), DTE Energy Co (Symbol: DTP), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Buckle, Inc. (Symbol: BKE): DTE Energy Co (Symbol: DTP): Abbott Laboratories (Symbol: ABT): In general, dividends are not always predictable, following the ups and downs of company profits over time. Similarly, investors should look for DTP to open 1.55% lower in price and for ABT to open 0.38% lower, all else being equal."
2021-10-11,118.1500015258789,116.87999725341795,-0.49194387069399464,,
2021-10-08,118.08999633789062,118.38999938964844,-1.0749083843073648,"After Hours Most Active for Oct 8, 2021 : JWSM, VZ, CPUH, T, ABT, KKR^C | Noteworthy Friday Option Activity: PETS, ABT, EXAS","Abbott Laboratories (ABT) is unchanged at $118.39, with 1,175,012 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the ""buy range"". The total After hours volume is currently 62,252,456 shares traded. | Below is a chart showing EXAS's trailing twelve month trading history, with the $93 strike highlighted in orange: For the various different available expirations for PETS options, ABT options, or EXAS options, visit StockOptionsChannel.com. Below is a chart showing PETS's trailing twelve month trading history, with the $20 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) options are showing a volume of 23,348 contracts thus far today. That number of contracts represents approximately 2.3 million underlying shares, working out to a sizeable 44% of ABT's average daily trading volume over the past month, of 5.3 million shares."
2021-10-07,117.5500030517578,117.91000366210938,0.25404611826679585,,
2021-10-06,115.75,116.48999786376952,0.3062531697196697,U.S. to invest another $1 bln in rapid COVID-19 tests,"The U.S. government agreed in September to purchase $2 billion worth of rapid COVID-19 tests from Abbott Laboratories ABT.N and Celltrion Inc 068270.KS to ship to nursing homes and other high risk populations as part of President Joe Biden's plans to increase vaccinations and tests. By Carl O'Donnell and Alexandra Alper Oct 6 (Reuters) - The U.S. government is committing to purchase an additional 180 million rapid COVID-19 tests for $1 billion, adding to the $2 billion test buying plan it announced in September, a top U.S. health official said on Wednesday. ""We'll continue to pull every lever to expand manufacturing production of tests which will have the impact of driving down the cost per test and making sure that tests are widely available and convenient,"" Zients said."
2021-10-05,116.11000061035156,115.87999725341795,0.6393070097360838,"FOCUS-Rapid COVID-19 tests increasingly scarce, pricey as demand from employers jumps","Testmakers including Abbott Laboratories ABT.N, Quidel Corp QDEL.O and LumiraDX Ltd LMDX.O are scaling up production to meet rising demand. By Carl O'Donnell Oct 5 (Reuters) - Surging demand for COVID-19 tests from U.S. employers has exacerbated a nationwide shortage of rapid tests in recent weeks and is driving up costs for state and local testing programs, according to industry executives and state officials. ""We are exploring other rapid antigen tests and finding most are at least three times higher than Abbott’s rapid antigen test,"" the spokesperson said, adding that Missouri has not yet had to purchase the pricier tests."
2021-10-04,116.61000061035156,115.52999877929688,-0.19809091010641375,,
2021-10-01,118.1999969482422,117.20999908447266,-0.9261657022569425,,
2021-09-30,119.86000061035156,118.12999725341795,-0.8375616660997454,2 Unstoppable Stocks to Buy and Hold Forever,"With that in mind, let's look into two stocks that can help investors beat the market for many years to come: Abbott Laboratories (NYSE: ABT) and Visa (NYSE: V). ABT data by YCharts 1. Visa Visa is one of those companies whose services people use daily."
2021-09-29,118.91999816894533,119.45999908447266,-1.443353369033938,LGLV's Underlying Holdings Could Mean 10% Gain Potential | Here's Why AbbVie Is a Great Healthcare Stock for Long-Term Investors,"Similarly, DUK has 10.77% upside from the recent share price of $97.05 if the average analyst target price of $107.50/share is reached, and analysts on average are expecting ABT to reach a target price of $131.38/share, which is 10.65% above the recent price of $118.74. Three of LGLV's underlying holdings with notable upside to their analyst target prices are Roper Technologies Inc (Symbol: ROP), Duke Energy Corp (Symbol: DUK), and Abbott Laboratories (Symbol: ABT). Below is a twelve month price history chart comparing the stock performance of ROP, DUK, and ABT: Below is a summary table of the current analyst target prices discussed above: | See the 10 stocks *Stock Advisor returns as of September 17, 2021 Brian Withers: The next company is AbbVie, I was just going to jump on to the next company, the next company is AbbVie. For those who don't know, AbbVie started out, it was a split off from Abbott, and Abbott has been just over a century-old company that is focused on healthcare research and producing products that makes people's lives better. But I would say that AbbVie's product portfolio, like you were mentioning has grown so much in recent years, and with its acquisition of Allergan has really changed direction and spanning so many different healthcare areas that are really raking in more and more profits for the company."
2021-09-28,119.5999984741211,118.73999786376952,0.45408755788927097,RSI Alert: Abbott Laboratories Now Oversold | ABT Makes Notable Cross Below Critical Moving Average | Will Dexcom Stock Continue To Make Fresh Highs?,"Among the fundamental datapoints dividend investors should investigate to decide if they are bullish on ABT is its dividend history. Abbott Laboratories (Symbol: ABT) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most ""interesting"" ideas that merit further research by investors. But making Abbott Laboratories an even more interesting and timely stock to look at, is the fact that in trading on Tuesday, shares of ABT entered into oversold territory, changing hands as low as $118.06 per share. | In trading on Tuesday, shares of Abbott Laboratories (Symbol: ABT) crossed below their 200 day moving average of $118.48, changing hands as low as $118.06 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $103.13 per share, with $129.6992 as the 52 week high point — that compares with a last trade of $118.55. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other dividend stocks recently crossed below their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Predict average return on DexCom (DXCM) Stock Return: AI Predicts DXCM Average and Excess Return After a Fall or Rise DexCom (DXCM) Stock Return (Recent) Comparison With Peers Five-Day Return: IDXX highest at 2.9%; ABT lowest at -1.7% Ten-Day Return: DXCM highest at 3.6%; RMD lowest at -4.3% Twenty-One Day Return: DXCM highest at 11%; PODD lowest at -3.1% [Updated: 6/22/2021] DXCM Stock Rise Last month, we discussed why the sell-off in Dexcom Stock (NASDAQ: DXCM) was unwarranted, and we expected it to see higher levels. Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using last 10 year data 3.4% or higher return during five-day period in 794 times out of 2517; Stock rose in the next 5 days in 448 of these 794 instances 9.3% or higher return during ten-day period in 463 times out of 2517; Stock rose in the next 10 days in 260 of these 463 instances 23% or higher return during twenty-one day period in 184 times out of 2516; Stock rose in the next 21 days in 99 of these 184 instances Predict average return on DexCom (DXCM) Stock Return: AI Predicts DXCM Average and Excess Return After a Fall or Rise DexCom (DXCM) Stock Return (Recent) Comparison With Peers Five-Day Return: DXCM highest at 3.4%; SPY lowest at -1% Ten-Day Return: DXCM highest at 9.3%; SPY lowest at -0.3% Twenty-One Days Return: DXCM highest at 23%; ABT lowest at -5.4% [Updated: 5/6/2021] DXCM Stock Decline The stock price of Dexcom (NASDAQ: DXCM), best known for its continuous glucose monitoring (CGM) systems, has seen an 11% drop over the last five trading days, and we believe the stock is likely to rebound in the near term. Twenty-One Days: DXCM 5.4%, vs. S&P500 4.3%; Outperformed market (44% likelihood event) Dexcom stock rose 5.4% the last twenty-one trading days (1 month), compared to the broader market (S&P500) rise of 4.3% A change of 5.4% or more over twenty-one trading days is a 44% likelihood event, which has occurred 1107 times out of 2500 in the last ten years."
2021-09-27,123.33000183105467,120.58000183105467,-0.7190640646518592,Is Abbott Laboratories' (NYSE:ABT) Stock's Recent Performance A Reflection Of Its Financial Health?,Most readers would already know that Abbott Laboratories' (NYSE:ABT) stock increased by 7.5% over the past three months. NYSE:ABT Past Earnings Growth September 27th 2021 Earnings growth is a huge factor in stock valuation. Is ABT fairly valued?
2021-09-24,124.80999755859376,124.37000274658205,-2.2297899612189465,"Should You Take the ""Basket Approach"" to Investing in Tech Stocks?","I like what he's saying and I think it applies pretty broadly, he says, ""Gotta love medical devices, basket approach, Intuitive Surgical, ShockWave Medical, DexCom"" -- the huge winner in diabetes testing -- ""InMode, Inari Medical"" -- getting into some that are a little more up-and-comers -- ""Stryker, Medtronic, Abbott Laboratories, riding the wave."" Clay Bruning owns shares of Abbott Laboratories and CrowdStrike Holdings, Inc. Jason Hall owns shares of Intuitive Surgical and Zscaler. The Motley Fool recommends DexCom and recommends the following options: long January 2022 $580 calls on Intuitive Surgical and short January 2022 $600 calls on Intuitive Surgical."
2021-09-23,125.41999816894533,125.3000030517578,-0.35253170468588235,Top Stocks To Buy Today? 4 Health Care Stocks For Your Watchlist,"We saw the U.S. government agreeing to purchase point-of-care COVID-19 tests from Abbott Laboratories (NYSE: ABT) and Celltrion earlier today. Top Health Care Stocks To Watch Right Now In a world where a global pandemic has been overshadowing our daily lives, health care stocks would often be top picks in the stock market. With that in mind, here is a list of the top four health care stocks to watch in thestock market today Best Health Care Stocks To Watch Before October 2021 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Inotiv Inc (NASDAQ: NOTV) Bausch Health Companies Inc (NYSE: BHC) Inmode Ltd (NASDAQ: INMD) Regeneron Pharmaceuticals Regeneron is a biotechnology company that specializes in medicines for the treatment of serious diseases."
2021-09-22,125.5,124.6500015258789,-0.09567462840008226,7 Healthcare Stocks to Buy Now as the Pandemic Forces a Rethink,"Pfizer (NYSE:PFE) CVS Health (NYSE:CVS) Abbott Laboratories (NYSE:ABT) Talkspace (NASDAQ:TALK) American Well (NYSE:AMWL) Ginkgo Bioworks (NYSE:DNA) Welltower (NYSE:WELL) While there’s a temptation to think that the coronavirus impact is a one-off deal, this time really might be different. Healthcare Stocks to Buy: Abbott Laboratories (ABT) Source: Sundry Photography/Shutterstock.com One of the quiet beneficiaries out of the healthcare stocks that received a Covid-boost, Abbott Laboratories is currently stuck in an extremely awkward situation, to put it mildly. ABT’s generally steady rise higher provides confidence for prospective buyers to hold true to shares."
2021-09-21,125.56999969482422,125.12999725341795,-0.6772896208136205,"U.S. government to buy rapid COVID-19 tests from Abbott, Celltrion -official","By Jeff Mason Sept 21 (Reuters) - The U.S. government has agreed to purchase rapid COVID-19 tests from Abbott Laboratories ABT.N and Celltrion Inc 068270.KS to ship to nursing homes and other high risk populations as part of President Joe Biden's vaccinate or test plans, a senior administration official said on Tuesday. The federal government will purchase tests as needed and has agreed to spend up to $626 million in its agreement with Celltrion and $554.4 million in its deal with Abbott, the official said. Demand for tests has been spurred in recent months by the emergence of the contagious Delta variant of COVID-19, reopenings of K-12 schools, and an earlier mandate by the White House that will require most U.S. federal employees to either get vaccinated or receive weekly tests."
2021-09-20,125.5999984741211,124.87000274658205,-0.3504041112332665,Abbott Reports FDA Approval For Portico With FlexNav TAVR System - Quick Facts | Intuitive Surgical Stock To Bounce Back After A 3% Fall In A Week? | Is A Fall Imminent For Quidel Stock After A 22% Rise In A Month?,"(RTTNews) - Abbott (ABT) announced FDA approval for Portico with FlexNav transcatheter aortic valve replacement system to treat people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery. ""With the approval of our TAVR therapy in the U.S., physicians now have access to an even more robust set of solutions to treat structural heart disease,"" said Michael Dale, senior vice president of Abbott's structural heart business. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | According to the Trefis Machine Learning Engine, which identifies trends in the company’s stock price using ten years of historical data, returns for ISRG stock average around 4.2% in the next one-month (twenty-one trading days) period after experiencing a 3.4% drop over the previous week (five trading days), implying that the stock will likely rebound in the near term. Answer: Consider two situations, Case 1: Intuitive Surgical stock drops by -5% or more in a week Case 2: Intuitive Surgical stock rises by 5% or more in a week Is the average return for Intuitive Surgical stock higher over the subsequent month after Case 1 or Case 2? Predict average return on Intuitive Surgical (ISRG) Stock Return: AI Predicts ISRG Average and Excess Return After a Fall or Rise Intuitive Surgical (ISRG) Stock Return (Recent) Comparison With Peers Five-Day Return: ISRG highest at 3.9%; BDX lowest at -5.8% Ten-Day Return: ISRG highest at 5.5%; BDX lowest at -4% Twenty-One Days Return: ISRG highest at 8.2%; BDX lowest at -4% While the historical performance suggests even higher levels are likely for ISRG stock, we continue to believe that it is richly valued. | [Updated: Sep 16, 2021] Quidel Stock Update A few months back we discussed that Quidel (NASDAQ:QDEL) stock looks undervalued at levels of around $108, based on the testing demand and the company’s future growth prospects. Out of 152 instances in the last ten years that QDEL stock saw a twenty-one day rise of 22% or more, 91 of them resulted in QDEL stock falling over the subsequent one-month period (twenty-one trading days). Predict average return on Quidel (QDEL) Stock Return: AI Predicts QDEL Average and Excess Return After a Fall or Rise Quidel (QDEL) Stock Return (Recent) Comparison With Peers Five-Day Return: VIVO highest at 11%; OPGN lowest at -36% Ten-Day Return: QDEL highest at 14%; OPGN lowest at -29% Twenty-One Day Return: QDEL highest at 22%; OPGN lowest at -13% [Updated: Jun 4, 2021] QDEL Stock Rise We believe that the stock price of Quidel (NASDAQ:QDEL), a clinical genetic testing company, looks undervalued at current levels near $108."
2021-09-17,126.77999877929688,126.79000091552734,-0.5812067965028345,"Notable ETF Inflow Detected - VTI, KO, VZ, ABT","Among the largest underlying components of VTI, in trading today Coca-Cola Co (Symbol: KO) is off about 0.6%, Verizon Communications Inc (Symbol: VZ) is trading flat, and Abbott Laboratories (Symbol: ABT) is lower by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Total Stock Market ETF (Symbol: VTI) where we have detected an approximate $4.4 billion dollar inflow -- that's a 1.6% increase week over week in outstanding units (from 1,148,426,434 to 1,167,308,153). For a complete list of holdings, visit the VTI Holdings page » The chart below shows the one year price performance of VTI, versus its 200 day moving average: Looking at the chart above, VTI's low point in its 52 week range is $162.85 per share, with $234.65 as the 52 week high point — that compares with a last trade of $229.64."
2021-09-16,127.87000274658205,127.44000244140624,0.007889364510785982,3 Top Growth Stocks You Can Buy and Hold Forever,"Three stocks to put on your list if you're a buy-and-hold investor are Abbott Laboratories (NYSE: ABT), Palantir Technologies (NYSE: PLTR), and Walmart (NYSE: WMT). When Abbott last reported earnings on July 22, its sales for the period ending June 30 topped $10.2 billion, up by nearly 40% year over year. And while the surge in e-commerce sales may be slowing down from a year ago when consumers were stuck at home, the retailer still reported that U.S. e-commerce sales grew 6% year over year in its latest quarter, for the period ending July 31."
2021-09-15,126.87999725341795,127.48999786376952,-0.3362792648311752,2 Sizzling Hot Stocks to Buy Right Now,"Nvidia Semiconductor stock Nvidia (NASDAQ: NVDA) is known for its computer-graphics processors used by companies of all sizes across a broad spectrum of industries. The stock is trading about 66% higher than it was just six months ago -- and over the trailing five years, the stock has appreciated by a whopping 1,300%. See the 10 stocks *Stock Advisor returns as of August 9, 2021 Teresa Kersten, an employee of LinkedIn, a Microsoft subsidiary, is a member of The Motley Fool's board of directors."
2021-09-14,127.3499984741211,127.0500030517578,0.4807697222228069,,
2021-09-13,129.6699981689453,126.62000274658205,-0.23556766859660216,"January 2024 Options Now Available For Abbott Laboratories (ABT) | Got $3,000? Keep It Safe With These 3 Healthcare Stocks","Below is a chart showing ABT's trailing twelve month trading history, with the $130.00 strike highlighted in red: Considering the fact that the $130.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the January 2024 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new January 2024 contracts and identified one put and one call contract of particular interest. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) is one of the largest healthcare companies on the planet, and it makes a massive variety of products. For nearly the last 50 years, Abbott Labs has increased its dividend on an annual basis, making it a Dividend Aristocrat, one of the most reliable dividend-paying stocks. Alexandria Real Estate Equities Unlike AstraZeneca and Abbott Laboratories, Alexandria Real Estate Equities (NYSE: ARE) is a real estate investment trust (REIT)."
2021-09-10,128.0,128.8000030517578,-2.352121127039324,"3M, Qiagen to comply with Biden's COVID-19 vaccination, test mandate","Abbott Laboratories ABT.N, one of the largest U.S. manufacturers of rapid COVID-19 tests, said it was quickly working to scale up manufacturing of its two tests - BinaxNOW and ID NOW test kits - including hiring additional employees. Adds 3M's statement Sept. 10 (Reuters) - 3M Co MMM.N, the biggest U.S. producer of N95 masks, and German genetic testing specialist Qiagen QIA.DE said separately on Friday that they will comply with the Biden administration's new COVID-19 vaccination and testing mandate for workplaces. U.S. President Joe Biden on Thursday announced policies requiring most federal employees to get COVID-19 vaccinations and pushing large and small private employers to have their workers inoculated or tested weekly."
2021-09-09,129.14999389648438,127.9800033569336,0.625002384185791,"Noteworthy ETF Inflows: SPLG, BRK.B, ABT, VZ | Biden to lay out 'path ahead' in COVID-19 fight | What's Next For Baxter Stock After An 11% Rise In A Month?","Among the largest underlying components of SPLG, in trading today Berkshire Hathaway Inc New (Symbol: BRK.B) is trading flat, Abbott Laboratories (Symbol: ABT) is off about 0.5%, and Verizon Communications Inc (Symbol: VZ) is lower by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR— Portfolio S&P 500— ETF (Symbol: SPLG) where we have detected an approximate $135.2 million dollar inflow -- that's a 1.1% increase week over week in outstanding units (from 232,800,000 to 235,350,000). For a complete list of holdings, visit the SPLG Holdings page » The chart below shows the one year price performance of SPLG, versus its 200 day moving average: Looking at the chart above, SPLG's low point in its 52 week range is $37.575 per share, with $53.385 as the 52 week high point — that compares with a last trade of $53.17. | Abbott Laboratories ABT.N and other test manufacturers are trying to boost production as cases soar, after having scaled back in recent months. Adds White House comment, quotes WASHINGTON, Sept 9 (Reuters) - President Joe Biden on Thursday will press for new approaches to control the COVID-19 pandemic in the United States, which rages on despite the wide availability of vaccines, with surging cases in some U.S. statesoverwhelming local hospitals. In a speech, Biden will focus on new plans to get more people vaccinated, enhancing protection for those who already have had shots and keeping schools open, White House spokeswoman Jen Psaki said. | Baxter International (BAX) Stock Return (Recent) Comparison With Peers Five-Day Return: BAX highest at 12%; BSX lowest at 0.3% Ten-Day Return: BAX highest at 10%; BSX lowest at 1.1% Twenty-One Day Return: BAX highest at 11%; BSX lowest at 0.6% [Updated: Aug 3, 2021] Baxter Stock Decline The stock price of medical supplies company Baxter (NYSE: BAX) has seen a fall of 4% over the last five trading days, while it is also down over 7% in the last year. According to the Trefis Machine Learning Engine, which identifies trends in the company’s stock price using ten years of historical data, returns for BAX stock average 2.6% in the next one-month (twenty-one trading days) period after experiencing an 4.4% drop over the previous week (five trading days), implying that BAX stock may rebound in the near term. Answer: Consider two situations, Case 1: Baxter International stock drops by -5% or more in a week Case 2: Baxter International stock rises by 5% or more in a week Is the average return for Baxter International stock higher over the subsequent month after Case 1 or Case 2?"
2021-09-08,128.55999755859375,129.05999755859375,-0.9059160625966006,Validea Martin Zweig Strategy Daily Upgrade Report - 9/8/2021 | How Does Sarepta's Stock Performance In The Current Crisis Compare With That In 2008? | What's Happening With Abbott Stock?,"ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT Full Factor Report for ABT JPMORGAN CHASE & CO. (JPM) is a large-cap value stock in the Investment Services industry. Detailed Analysis of HOULIHAN LOKEY INC Full Guru Analysis for HLI Full Factor Report for HLI ALLEGIANCE BANCSHARES INC (ABTX) is a small-cap value stock in the Regional Banks industry. | We believe that Sarepta Therapeutics stock (NASDAQ: SRPT), a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases,  is a good buying opportunity at the present time. In contrast, here is how SRPT stock and the broader market fared during the 2007-08 crisis Timeline of 2007-08 Crisis 10/1/2007: Approximate pre-crisis peak in S&P 500 index 9/1/2008 – 10/1/2008: Accelerated market decline corresponding to Lehman bankruptcy filing (9/15/08) 3/1/2009: Approximate bottoming out of S&P 500 index 12/31/2009: Initial recovery to levels before accelerated decline (around 9/1/2008) SRPT and S&P 500 Performance Over 2007-08 Financial Crisis SRPT stock plummeted from from levels of about $15 in October 2007 (pre-crisis peak for the broader markets) to levels of under $7 in September 2008 before plunging to around $4 in March 2009 (as the markets bottomed out), implying SRPT stock lost 73% from its peak. Conclusion Phases of Covid-19 Crisis: Early- to mid-March 2020: Fear of the coronavirus outbreak spreading rapidly translates into reality, with the number of cases accelerating globally Late-March 2020 onward: Social distancing measures + lockdowns April 2020: Fed stimulus suppresses near-term survival anxiety May-June 2020: Recovery of demand, with gradual lifting of lockdowns – no panic anymore despite a steady increase in the number of cases Since late 2020: Weak quarterly results, but continued improvement in demand and progress with vaccine development buoy market sentiment. | [Updated: Sep 3, 2021] Abbott Stock Update The stock price of Abbott (NYSE:ABT) has seen a rise of around 20% since early June this year. Although there are multiple positive triggers for ABT stock, going by our Abbott Valuation of $130 per share based on $4.42 EPS and 29x P/E multiple, it appears that ABT stock is fully valued at its current levels. [Updated: Jul 20, 2021] Abbott Q2 Earnings Preview Abbott (NYSE:ABT) is scheduled to report its Q2 2021 results on Thursday, July 22."
2021-09-07,128.1199951171875,128.38999938964844,0.3889234672489124,Calculating The Fair Value Of Abbott Laboratories (NYSE:ABT),Does the September share price for Abbott Laboratories (NYSE:ABT) reflect what it's really worth? NYSE:ABT Discounted Cash Flow September 7th 2021 Important assumptions The calculation above is very dependent on two assumptions. Future Earnings: How does ABT's growth rate compare to its peers and the wider market?
2021-09-03,129.0,128.94000244140625,0.21074327407987545,,
2021-09-02,127.5,128.49000549316406,-0.04650973534399225,Why Shares of Quidel Surged 10% This Week | Abbott Announces Acquisition Of Walk Vascular - Quick Facts | This May Be Abbott's Billion-Dollar Opportunity,"Other test makers Abbott Labs (NYSE: ABT) and Becton Dickinson (NYSE: BDX) had also curbed production this summer. So what Early last month, Quidel said sales in its fiscal second quarter declined 12% from the year earlier due in part to a drop-off in its COVID testing business. 10 stocks we like better than Quidel When our award-winning analyst team has a stock tip, it can pay to listen. | (RTTNews) - Abbott (ABT) has acquired Walk Vascular, a commercial-stage medical device company. Financial terms of the deal were not disclosed. Walk Vascular's JETi Peripheral Thrombectomy System and next-generation JETi AIO Peripheral Thrombectomy System are aspiration systems for the removal of intravascular clots. | You might not immediately think of Abbott Laboratories (NYSE: ABT) as a coronavirus stock. States closed some free testing sites, and Abbott cut production of its tests. It's important to keep in mind that the BinaxNOW laboratory test earned authorization in August 2020 -- and the at-home version of the test won authorization at the end of the year."
2021-09-01,125.72000122070312,127.4000015258789,0.7764748965992647,"Notable ETF Inflow Detected - SPLG, BRK.B, VZ, ABT | Here's Why United Therapeutics Stock May Continue To Trend Higher","Among the largest underlying components of SPLG, in trading today Berkshire Hathaway Inc New (Symbol: BRK.B) is down about 0.2%, Verizon Communications Inc (Symbol: VZ) is trading flat, and Abbott Laboratories (Symbol: ABT) is higher by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR— Portfolio S&P 500— ETF (Symbol: SPLG) where we have detected an approximate $135.4 million dollar inflow -- that's a 1.1% increase week over week in outstanding units (from 230,250,000 to 232,800,000). For a complete list of holdings, visit the SPLG Holdings page » The chart below shows the one year price performance of SPLG, versus its 200 day moving average: Looking at the chart above, SPLG's low point in its 52 week range is $37.575 per share, with $53.27 as the 52 week high point — that compares with a last trade of $53.18. | Out of 213 instances in the last ten years that UTHR stock saw a twenty-one day rise of 10% or more, 116 of them resulted in UTHR stock rising over the subsequent one-month period (twenty-one trading days). After moving 4.2% or more over a ten-day period, the stock rose in the next ten days on 59% of the occasions After moving 15% or more over a twenty-one-day period, the stock rose in the next twenty-one days on 54% of the occasions. Predict average return on United Therapeutics (UTHR) Stock Return: AI Predicts UTHR Average and Excess Return After a Fall or Rise United Therapeutics (UTHR) Stock Return (Recent) Comparison With Peers Five-Day Return: UTHR highest at 3.4%; LLY lowest at -4.1% Ten-Day Return: UTHR highest at 4.2%; AMGN lowest at -3% Twenty-One Days Return: UTHR highest at 15%; AMGN lowest at -8.1% may have moved, 2020 has created many pricing discontinuities which can offer attractive trading opportunities."
2021-08-31,126.4000015258789,126.37000274658205,1.33630312509027,"COVID 19 Stocks -- Vaccines, Diagnostics, or Treatments?","For perspective, the company ran about 36,000 tests in the most recent quarter, so while the mobile phlebotomy segment represents a small portion of total tests run, it's not the test volume I'm impressed with -- it is management's ability to find innovative ways to meet patient and clinician needs. With COVID-19 testing slowing faster than some companies were expecting, and cancer diagnostic growth companies like Guardant Health growing revenue at a lesser clip than CareDx (39% year over year in the most recent quarter) and being somewhat reliant on an in-person sales force, this transplant diagnostics company seems to be immune from the adverse effects of the coronavirus. See the 10 stocks *Stock Advisor returns as of August 9, 2021 Patrick Bafuma has no position in any of the stocks mentioned."
2021-08-30,124.52999877929688,125.94000244140624,-0.02373321118253222,2 Little-Followed Stocks That Are Soaring Monday,"Investors continued to have confidence in the stock market on Monday morning, and that translated into more record highs for some of the most popular stock indexes in the U.S. market. 10 stocks we like better than Hill-Rom Holdings When our award-winning analyst team has a stock tip, it can pay to listen. The Motley Fool recommends Hill-Rom Holdings and recommends the following options: long March 2023 $120 calls on Apple and short March 2023 $130 calls on Apple."
2021-08-27,125.68000030517578,124.58999633789062,1.132260239244276,"3 Reasons to Buy This Undervalued Dividend Stock | FOCUS-U.S. COVID-19 tests again in short supply as infections soar, schools reopen | Is There More Room For Growth In Medtronic Stock?","The stock offers investors a compelling mix of exposure to growth industries (automation, industrial software, smart infrastructure, electrification) balanced by earnings from its majority holding in a world-class healthcare company, Siemens Healthineers. Digital Industries 11.972 billion euros 2.506 billion euros 2.694 billion euros Smart Infrastructure 10.809 billion euros 1.238 billion euros 1.197 billion euros Mobility 6.722 billion euros 630 billion euros (347 million euros) Siemens Healthineers* 12.833 billion euros 2.161 billion euros 2.488 billion euros Total Industrial 42.336 billion euros 6.535 billion euros 6.032 billion euros Total Company** 44.820 billion euros 5.656 billion euros 4.517 billion euros Data source: Siemens presentations. Siemens Healthineers Siemens' stake in the publicly listed medical technology company, Siemens Healthineers (OTC: SMMNY), provides it with valuable earnings and free cash flow even during economic downturns. | Test manufacturers including Abbott Laboratories ABT.N, Becton Dickinson and Co BDX.N, and Quidel Corp QDEL.O in recent months scaled back production of rapid COVID-19 tests, which can produce results on-site in minutes, as well as test kits that are sent to laboratories for analysis. By Carl O'Donnell Aug 27 (Reuters) - U.S. companies are scrambling to boost production of coronavirus tests increasingly in short supply as COVID-19 cases soar and schools and employers revive surveillance programs that will require tens of millions of tests, according to industry executives and state health officials. Delaware, which was among the first to roll out a comprehensive surveillance testing program in July, has already begun to see some test shortages, said Dr. Rick Pescatore, an associate medical director in the state’s public health agency. | (1) Revenues expected to be in-line with the consensus estimate Trefis estimates Medtronic’s Q1 fiscal 2022 total revenues to be around $7.9 billion, in-line with the consensus estimates. 2) EPS likely to be slightly above the consensus estimates Medtronic’s Q1 fiscal 2022 earnings per share (EPS) is expected to be $1.35 per Trefis analysis, slightly above the consensus estimate of $1.32. (3) Stock price estimate 15% above the current market price Going by our Medtronic Valuation, with an EPS estimate of around $5.71 and P/E multiple of 26x in fiscal 2022, this translates into a price of $148, which is 15% above the current market price of around $129."
2021-08-26,124.69000244140624,125.47000122070312,-0.8672851405461585,,
2021-08-25,125.83999633789062,124.73999786376952,0.6255503761525891,"Senseonics Can Move Higher, but Competitive Concerns Abound","With DexCom (NASDAQ:DXCM) and Abbott Laboratories (NYSE:ABT) in the mix, Senseonics will be plying its trade in contested territory. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Generally speaking, I’m not the biggest fan of discussing publicly traded companies with a strong social media following. According to a research paper from BMJ Journals, an analysis on diabetes patients with visual impairments revealed the following statistics: Of the patients assessed at the time of the diabetes diagnosis the prevalence of moderate to severe visual impairment and blindness was 5.4% (95% CI 4.1 to 6.7) and 0.9% (95% CI 0.4 to 1.4), respectively."
2021-08-24,125.5999984741211,125.5,-0.8741246870093056,"Will Illumina Stock Rebound After A 6% Fall Last Week? | SPLG, ABT, TMO, COST: ETF Inflow Alert | What To Expect From Medtronic's Q1?","According to the Trefis Machine Learning Engine, which identifies trends in the company’s stock price using ten years of historical data, returns for ILMN stock average around 3% in the next one-month (twenty-one trading days) period after experiencing a 6% drop over the previous week (five trading days). Answer: Consider two situations, Case 1: Illumina stock drops by -5% or more in a week Case 2: Illumina stock rises by 5% or more in a week Is the average return for Illumina stock higher over the subsequent month after Case 1 or Case 2? ILMN stock fares better after Case 2, with an average return of 2.9% over the next month (21 trading days) under Case 1 (where the stock has just suffered a 5% loss over the previous week), versus, an average return of 4.6% for Case 2. | Among the largest underlying components of SPLG, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.1%, Thermo Fisher Scientific Inc (Symbol: TMO) is down about 0.1%, and Costco Wholesale Corp (Symbol: COST) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR— Portfolio S&P 500— ETF (Symbol: SPLG) where we have detected an approximate $262.9 million dollar inflow -- that's a 2.2% increase week over week in outstanding units (from 225,250,000 to 230,250,000). For a complete list of holdings, visit the SPLG Holdings page » The chart below shows the one year price performance of SPLG, versus its 200 day moving average: Looking at the chart above, SPLG's low point in its 52 week range is $37.575 per share, with $52.715 as the 52 week high point — that compares with a last trade of $52.72. | (1) Revenues expected to be in-line with the consensus estimate Trefis estimates Medtronic’s Q1 fiscal 2022 total revenues to be around $7.9 billion, in-line with the consensus estimates. 2) EPS likely to be slightly above the consensus estimates Medtronic’s Q1 fiscal 2022 earnings per share (EPS) is expected to be $1.35 per Trefis analysis, slightly above the consensus estimate of $1.32. (3) Stock price estimate 15% above the current market price Going by our Medtronic Valuation, with an EPS estimate of around $5.71 and P/E multiple of 26x in fiscal 2022, this translates into a price of $148, which is 15% above the current market price of around $129."
2021-08-23,126.66999816894533,125.83999633789062,-0.07961662049040363,,
2021-08-20,125.91000366210938,126.31999969482422,-0.655247369584463,,
2021-08-19,123.72000122070312,125.72000122070312,0.32562625747760626,,
2021-08-18,125.80999755859376,123.93000030517578,1.6165534919711293,Abbott Laboratories' (NYSE:ABT) investors will be pleased with their splendid 214% return over the last five years,"Long term Abbott Laboratories (NYSE:ABT) shareholders would be well aware of this, since the stock is up 186% in five years. NYSE:ABT Earnings Per Share Growth August 18th 2021 We like that insiders have been buying shares in the last twelve months. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS)."
2021-08-17,124.63999938964844,125.69000244140624,-1.494314672840215,Could AbbVie Stock Help You Retire a Millionaire?,"Owning this stock will probably make you richer There are a few ways that buying and holding AbbVie's stock will bolster your portfolio's value in the long term. It isn't about to make you millions on its own As beneficial as buying AbbVie stock could be, don't expect it to make you rich. See the 10 stocks *Stock Advisor returns as of June 7, 2021 Alex Carchidi owns shares of AbbVie and Abbott Laboratories."
2021-08-16,123.69000244140624,124.66000366210938,0.842428640002868,FDA OKs Abbott's Amplatzer Amulet Device To Treat Atrial Fibrillation - Quick Facts,"(RTTNews) - Abbott Laboratories (ABT) announced Monday that the U.S. Food and Drug Administration (FDA) approved the company's Amplatzer Amulet Left Atrial Appendage Occluder to treat people with atrial fibrillation (AFib) who are at risk of ischemic stroke. The device offers immediate closure of the left atrial appendage (LAA), an area where blood clots can form in people suffering from AFib, reducing their risk of stroke and immediately eliminating the need for blood-thinning medication. For patients with AFib who are unable to take blood-thinning medication long term, physicians may opt for occlusion (or closure) of the LAA through a minimally invasive procedure using devices like Abbott's Amulet to seal off the LAA entirely and reduce the risk of stroke."
2021-08-13,122.72000122070312,123.05999755859376,0.7842195824700084,,
2021-08-12,121.18000030517578,122.80999755859376,0.27705046814592205,,
2021-08-11,122.83999633789062,121.45999908447266,1.3451041832918393,"Forget Robinhood, These 3 Healthcare Stocks Are Better Buys","A dominant industry leader changing healthcare as we know it Steve Ditto (Illumina): If you're looking for industries and companies that could outperform over the next 10 years, there are few better to consider than DNA sequencing company Illumina. With an installed base of more than 17,000 sequencing systems, Illumina holds more than 90% of theglobal market This level of industry dominance has led to outstanding stock market performance. See the 10 stocks *Stock Advisor returns as of August 9, 2021 Jason Hawthorne owns shares of Illumina and Inari Medical, Inc. Rachel Warren has no position in any of the stocks mentioned."
2021-08-10,123.3499984741211,122.6999969482422,-1.1234103667848299,"Will Intuitive Surgical Stock Continue To Make Fresh Highs? | 2 Stocks That Could Turn $200,000 Into $1,000,000 in 10 Years","Out of 468 instances in the last ten years that ISRG stock saw a twenty-one day rise of 8% or more, 291 of them resulted in ISRG stock rising over the subsequent one-month period (twenty-one trading days). After moving 5.5% or more over a ten-day period, the stock rose in the next ten days on 51% of the occasions After moving 8.2% or more over a twenty-one-day period, the stock rose in the next twenty-one days on 62% of the occasions. Predict average return on Intuitive Surgical (ISRG) Stock Return: AI Predicts ISRG Average and Excess Return After a Fall or Rise Intuitive Surgical (ISRG) Stock Return (Recent) Comparison With Peers Five-Day Return: ISRG highest at 3.9%; BDX lowest at -5.8% Ten-Day Return: ISRG highest at 5.5%; BDX lowest at -4% Twenty-One Days Return: ISRG highest at 8.2%; BDX lowest at -4% While the historical performance suggests even higher levels are likely for ISRG stock, we continue to believe that it is richly valued. | If you're looking for excellent stocks to buy and hold through the next decade, here are two that could turn $200,000 into $1,000,000 (that's a compound annual growth rate of about 17.5%) in the next 10 years: Abbott Laboratories (NYSE: ABT) and Match Group (NASDAQ: MTCH). With the online dating market set to continue growing, so will Match Group's network of users, including paying users. This will help drive Match Group's stock in the right direction, and while this tech giant has comfortably beaten the market over the past five years, don't bet against it to continue doing just that for the next decade."
2021-08-09,122.38999938964844,123.16000366210938,-0.5269570603320783,,
2021-08-06,122.0,122.16999816894533,0.6291398613456185,1 Healthcare Dividend Giant to Bank On Right Now,"Abbott Laboratories (NYSE: ABT) is a distinguished member of this group, having raised its annual dividend for 49 consecutive years. By comparison, this number is slightly lower than the average for companies in the healthcare sector, which have an average 2.28% dividend yield, while the average of healthcare companies belonging to the S&P 500 -- including Abbott -- is 1.75%. Even the lowered price targets are above the current stock price; the average target is $128, providing investors today with a current discount of approximately 6% based on the current $121 share price."
2021-08-05,122.36000061035156,122.20999908447266,0.13934276143059565,iShares Core S&P 500 ETF Experiences Big Outflow | What's Next For Baxter Stock After A 4% Fall Last Week?,"Among the largest underlying components of IVV, in trading today Nike (Symbol: NKE) is up about 0.1%, Abbott Laboratories (Symbol: ABT) is off about 0.1%, and Chevron Corporation (Symbol: CVX) is up by about 1.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P 500 ETF (Symbol: IVV) where we have detected an approximate $683.4 million dollar outflow -- that's a 0.2% decrease week over week (from 671,300,000 to 669,750,000). For a complete list of holdings, visit the IVV Holdings page » The chart below shows the one year price performance of IVV, versus its 200 day moving average: Looking at the chart above, IVV's low point in its 52 week range is $320.92 per share, with $443.7161 as the 52 week high point — that compares with a last trade of $442.37. | According to the Trefis Machine Learning Engine, which identifies trends in the company’s stock price using ten years of historical data, returns for BAX stock average 2.6% in the next one-month (twenty-one trading days) period after experiencing an 4.4% drop over the previous week (five trading days), implying that BAX stock may rebound in the near term. Answer: Consider two situations, Case 1: Baxter International stock drops by -5% or more in a week Case 2: Baxter International stock rises by 5% or more in a week Is the average return for Baxter International stock higher over the subsequent month after Case 1 or Case 2? BAX stock fares better after Case 1, with an average return of 2.9% over the next month (21 trading days) under Case 1 (where the stock has just suffered a 5% loss over the previous week), versus, an average return of 0.4% for Case 2."
2021-08-04,121.37999725341795,121.56999969482422,-0.12259032782827253,"Got $5,000? Buy and Hold These 3 Market-Beating Stocks","Three stocks that fall into that bucket and that have outperformed the market over the past five years are Abbott Laboratories (NYSE: ABT), Adobe (NASDAQ: ADBE), and Visa (NYSE: V). Even though diagnostics revenue of $3.2 billion for the period ending June 30 grew 63% year over year, it still wasn't the company's top segment. Although Adobe's stock isn't cheap, trading at more than 50 times its earnings (the average tech stock in the Technology Select Sector SPDR Fund trades at a multiple of 34), if it continues generating these types of numbers, that multiple won't matter much; the ratio will likely come down in the future."
2021-08-03,121.37999725341795,122.12000274658205,0.15653521643238785,5 Dividend Growth Stocks With Upside To Analyst Targets | Senseonics Financials Don’t Support Its Billion-Dollar-Plus Market Cap,"McDonald's Corp (Symbol: MCD) $240.10 $259.12 7.92% Brown-Forman Corp (Symbol: BF.B) $70.79 $75.40 6.51% Lancaster Colony Corp. (Symbol: LANC) $197.32 $210.00 6.43% Abbott Laboratories (Symbol: ABT) $120.92 $128.64 6.39% General Dynamics Corp (Symbol: GD) $195.83 $207.18 5.80% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. McDonald's Corp (Symbol: MCD) 2.15% 7.92% 10.07% Brown-Forman Corp (Symbol: BF.B) 1.01% 6.51% 7.52% Lancaster Colony Corp. (Symbol: LANC) 1.52% 6.43% 7.95% Abbott Laboratories (Symbol: ABT) 1.49% 6.39% 7.88% General Dynamics Corp (Symbol: GD) 2.43% 5.80% 8.23% Another consideration with dividend growth stocks is just how much the dividend is growing. McDonald's Corp (Symbol: MCD) $4.91 $5.12 4.28% Brown-Forman Corp (Symbol: BF.B) $0.688 $0.714 3.78% Lancaster Colony Corp. (Symbol: LANC) $2.75 $2.95 7.27% Abbott Laboratories (Symbol: ABT) $1.4 $1.71 22.14% General Dynamics Corp (Symbol: GD) $4.24 $4.58 8.02% These five stocks are part of our full Dividend Aristocrats List. | There are three other key CGM medical device plays in the US market: Abbott Laboratories’ (NYSE:ABT) FreeStyle Libre DexCom’s (NASDAQ:DXCM) G6 Medtronic’s (NYSE:MDT) Guardian Connect and Guardian Sensor 3 However, Senseonics’ Eversense is the FDA’s first long-term implantable continuous glucose monitor. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Senseonics Holdings (NYSE:SENS) is a medical technology company. Source: Minerva Studio / Shutterstock.com The company’s key product line is the Eversense system which, according to the company, “…in addition to featuring the first long-term and first implantable CGM sensor, the system is also the first to feature a smart transmitter that provides wearers with discreet on-body vibratory alerts for high and low glucose and can be removed, recharged and re-attached to the skin without discarding the sensor.”"
2021-08-02,121.5,120.91999816894533,0.6096601663444617,"China quietly sets new 'buy Chinese' targets for state companies - U.S. sources | Abbott Labs to pay $160 mln over kickbacks, false diabetes claims to Medicare | U.S. says Abbott units to pay $160 mln to resolve alleged false Medicare claims | FDA Clears Abbott's FreeStyle Libre 2 IOS App For Diabetes Management","By Andrea Shalal WASHINGTON, Aug 2 (Reuters) - China's government quietly issued new procurement guidelines in May that require up to 100% local content on hundreds of items including X-ray machines and magnetic resonance imaging equipment, erecting fresh barriers for foreign suppliers, three U.S.-based sources told Reuters. U.S. trade experts said China's local content rules differed from planned increases in U.S. ""Buy American"" thresholds because they were not publicly released, and affect far greater volumes of medical equipment and other goods since China's state-owned enterprises include hospitals and other entities. The U.S. Trade Representative's office, which is reviewing U.S.-China trade policies, declined to comment on the Chinese document or whether it violates the U.S.-China trade deal. | By Jonathan Stempel Aug 2 (Reuters) - Abbott Laboratories ABT.N will pay $160 million to resolve claims that two of its units submitted false claims to Medicare by providing kickbacks to diabetes patients, including ""free"" or ""no cost"" glucose monitors, the U.S. Department of Justice said. Monday's settlement resolves claims that Arriva Medical LLC - once the largest Medicare mail-order diabetes testing supplier - and its parent Alere Inc violated the federal False Claims Act from 2009 to 2016 by diverting Medicare funding from where it was needed. Arriva was also accused of systematically charging Medicare, a U.S. government health plan, for glucometers given to ineligible patients, and submitting claims for 211 patients who had been dead at least two weeks. | Aug 2 (Reuters) - Two units of Abbott Laboratories ABT.N will pay $160 million to resolve claims they violated the federal False Claims Act by submitting false claims to Medicare, the U.S. Department of Justice said on Monday. The Justice Department settled with Arriva Medical LLC, once the largest Medicare mail-order diabetic testing supplier, and its parent Alere Inc. Abbott bought both companies in 2017 after the alleged wrongful conduct took place, the department said. (Reporting by Jonathan Stempel in New York Editing by Paul Simao) ((jon.stempel@thomsonreuters.com; +1 646 223 6317; Reuters Messaging: jon.stempel.thomsonreuters.com@reuters.net)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott said that the U.S. Food and Drug Administration has cleared the FreeStyle Libre 2 iOS application for use with compatible iPhones, providing a comprehensive digital offering for its FreeStyle Libre 2 integrated continuous glucose monitoring (iCGM) system. FreeStyle Libre 2 iOS app is the sensor-based glucose monitoring app that allows users to check their glucose with a compatible iPhone every minute with optional real-time glucose alarms. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2021-07-30,121.0,120.9800033569336,-0.4773677621849163,,
2021-07-29,121.08000183105467,121.08999633789062,-0.01652615129455062,"3 Dividend Stocks Safe Enough to Bet the Farm On | Watch These Companies Closely This Earnings Season | Returns Are Gaining Momentum At Abbott Laboratories (NYSE:ABT) | ANALYSIS-Biden's COVID-19 strategy thwarted by anti-vaxxers, Delta variant","Abbott Laboratories Like BD, Abbott Laboratories (NYSE: ABT) sells a huge number of different products that the healthcare system needs to keep working. Johnson & Johnson Johnson & Johnson (NYSE: JNJ) makes everything from pharmaceuticals to medical devices and even consumer health products like shampoo. And the business is just as devoted to raising its dividend every year as Abbott has been, so holding on to the stock for decades is a smart move. | I would throw Abbott Labs (NYSE: ABT) in there, I would throw Pfizer (NYSE: PFE) in the mix, those are great examples. In this Motley Fool Live video recorded on July 19, 2021, healthcare and cannabis bureau chief Corinne Cardina and Motley Fool contributor Keith Speights talk about several reports that investors should pay particular attention to this earnings season. See the 10 stocks *Stock Advisor returns as of June 7, 2021 Corinne Cardina: Earning season is back. | NYSE:ABT Return on Capital Employed July 29th 2021 Above you can see how the current ROCE for Abbott Laboratories compares to its prior returns on capital, but there's only so much you can tell from the past. So on that note, Abbott Laboratories (NYSE:ABT) looks quite promising in regards to its trends of return on capital. Ideally, a business will show two trends; firstly a growing return on capital employed (ROCE) and secondly, an increasing amount of capital employed. | ""Vaccination remains the most important thing we can do to prevent the spread of the virus, and so we need to be pulling all levers to support vaccination,"" said Carole Johnson, the White House's coordinator on COVID-19 testing. While vaccines largely protect people from contracting and transmitting the Delta variant, there are rare cases where fully vaccinated people get the virus and may be able to pass it on. Some Republican lawmakers have refused to say whether they have taken a vaccine and opposed Biden's efforts to get more people vaccinated."
2021-07-28,119.80999755859376,120.5199966430664,0.008254465382233182,"SPYG, TMO, INTU, ABT: ETF Inflow Alert | Under 35? Here's Where to Put $10,000 Right Now for That Beach House in Retirement | Anxious About a Market Crash? Start Doing These 3 Things Right Now","Among the largest underlying components of SPYG, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is off about 0.4%, Intuit Inc (Symbol: INTU) is up about 0.7%, and Abbott Laboratories (Symbol: ABT) is up by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR— Portfolio S&P 500— Growth ETF (Symbol: SPYG) where we have detected an approximate $104.9 million dollar inflow -- that's a 0.8% increase week over week in outstanding units (from 204,000,000 to 205,600,000). For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $46.6596 per share, with $66.22 as the 52 week high point — that compares with a last trade of $65.87. | A share split On June 29, the ETF announced a 6-for-1 share split, meaning that for every one share previously held by investors, they will now hold six shares at a per-share price equal to one-sixth the previous share price. For those who may not be familiar with share splits, the value of your portfolio holdings doesn't change and neither does the total value of the ETF's shares -- but the price of each individual share does change. See the 10 stocks *Stock Advisor returns as of June 7, 2021 Jeff Little owns shares of iShares Dow Jones US Medical Dev. | The timeless stocks include companies like Abbott Laboratories (NYSE: ABT), which pay a dividend and are rarely available at a big discount. Make a watchlist that's a wish list Now that you're ready to recognize a plummeting market as a chance to buy the stocks you want on the cheap, you'll need to make a shopping list for the day of the sale, should it come. I divide my ""buy after a crash"" watch list into two categories: Timeless stocks, and growth stocks."
2021-07-27,119.5999984741211,119.80999755859376,0.5926042057762441,"Dow Jones Falls Below 35,000 on Boeing and Tech Stock Sell-Offs, Delta Variant Worries | Worries About the Delta Variant Could Be Overdone Based on Clues From These Healthcare Giants","However, executives of pharma and medical device companies Abbott Laboratories (NYSE: ABT) and Intuitive Surgical (NASDAQ: ISRG), and healthcare (and Dow Jones component) Johnson & Johnson (NYSE: JNJ) all had generally positive things to say about the limited risk the variant is likely to have for their prospects. Shares of beleaguered semiconductor maker Intel (NASDAQ: INTC) were down almost 4%, with fellow tech giants Salesforce.com (NYSE: CRM) down almost 2%, and Apple (NASDAQ: AAPL) and Microsoft (NASDAQ: MSFT) off 1.5% or more ahead of earnings reports after market close this afternoon. Shares of aerospace giant Boeing (NYSE: BA) were also off more than 2% today, joining broader stock market declines as investors once again weigh the implications of the delta coronavirus variant taking a bite out of what has been a very strong global economic resurgence. | Abbott (NYSE: ABT) CEO Robert Ford was asked about the potential impact of coronavirus variants in his company's Q2 call as well. Johnson & Johnson (NYSE: JNJ) CFO Joe Wolk said in his company's second-quarter conference call that J&J's base business is expected to ""remain strong"" throughout this year and is poised for growth in 2022 and beyond. If there were serious reasons to worry about how the delta variant might impact the economy, we probably would have heard more negativity from Abbott, Intuitive Surgical, and J&J."
2021-07-26,120.23999786376952,119.5199966430664,0.17558452102999803,Monday's ETF with Unusual Volume: IHI | The Smartest Dividend Aristocrats to Buy With $500 Right Now,"The iShares U.S. Medical Devices ETF is seeing unusually high volume in afternoon trading Monday, with over 338,000 shares traded versus three month average volume of about 78,000. Components of that ETF with the highest volume on Monday were Abbott Laboratories, trading off about 1.3% with over 1.9 million shares changing hands so far this session, and Boston Scientific, down about 0.5% on volume of over 1.8 million shares. Intersect is the component faring the best Monday, higher by about 5.8% on the day, while Inari Medical is lagging other components of the iShares U.S. Medical Devices ETF, trading lower by about 3.6%. | You'd think that stocks that are Dividend Aristocrats -- members of the S&P 500 with at least 25 consecutive years of dividend increases -- would by default have really attractive dividends. The drugmaker is only one dividend hike away from becoming a Dividend King -- the highest level of dividend royalty reserved for S&P 500 members with 50 or more consecutive years of dividend increases. Lowe's Lowe's (NYSE: LOW) is one of those Dividend Aristocrats I mentioned earlier that doesn't provide a dividend that's going to fire up many investors."
2021-07-23,119.62999725341795,120.8000030517578,-0.5988034210703028,"4 Medical Diagnostic Stocks To Watch Next Week | Validea Martin Zweig Strategy Daily Upgrade Report - 7/23/2021 | Abbott’s Q2 Earnings Rise 105%, Beat Estimates","We can see companies such as Abbott Laboratories (NYSE: ABT) and Quidel Corporation (NASDAQ: QDEL) playing an important role in combating the global pandemic. Medical diagnostic stocks are a branch of health care stocks in the stock market. Top Medical Diagnostic Stocks To Watch Laboratory Corp. of America Holdings (NYSE: LH) Co-Diagnostics Inc (NASDAQ: CODX) Thermo Fisher Scientific Inc (NYSE: TMO) Quest Diagnostics Inc (NYSE: DGX) Laboratory Corp. of America Holdings Firstly, we have the healthcare diagnostic company, Laboratory Corp. | Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT Full Factor Report for ABT More details on Validea's Martin Zweig strategy About Martin Zweig: During the 15 years that it was monitored, Zweig's stock recommendation newsletter returned an average of 15.9 percent per year, during which time it was ranked number one based on risk-adjusted returns by Hulbert Financial Digest. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. | Multinational medical devices and healthcare firm Abbott Labs (ABT) has reported solid second-quarter 2021 financial results. Nutrition sales increased nearly 12% to $2.1 billion; Diagnostics sales rose 62.8% to $3.2 billion; Established Pharmaceuticals sales climbed 16.4% to $1.2 billion; and Medical Devices sales surged 51.3% to $3.7 billion. (See Abbott stock chart on TipRanks) On July 12, Wells Fargo analyst Larry Biegelsen reiterated a Buy rating on the stock and raised the price target from $125 to $135 (14.2% upside potential)."
2021-07-22,118.0,118.25,0.9780204172882864,"The Next Nano-X, but With Less Risk? | US STOCKS-Wall Street set for muted open as jobless claims rise | Abbott profit more than doubles as medical device sales rebound | U.S. stock futures edge higher ahead of jobless claims data, earnings reports | Quest Diagnostics beats profit estimates on rebound in non-COVID testing | Will Abbott Stock Rise Post Q2? | Will Boston Scientific Stock Rise After A 5% Fall In A Week?","What this machine does is it can be wheeled around a healthcare facility, and if somebody needs an MRI, the MRI machine can come to them and a little latch opens up, the patient can be slid into the MRI machine and then you get the MRI reading right from the machine itself, that is then uploaded to the Cloud. For me, as a potential investor in this company, I'm basically going to assume that that business goes to zero and doesn't happen at all and I'm just going to focus on the MRI business that exists today. On the other side, the other two businesses are still years away from FDA approval and it's really hard to know what the chances of this happening is definitely be unprofitable for many, many years, that's not all that common, and we don't know things like insider ownership, and I wouldn't invest in a company unless I knew that kind of thing. | [nL4N2OY1QT] Healthcare companies including, drugmaker Biogen Inc BIIB.O rose 0.9% on raising its full-year revenue expectations, while medical device maker Abbott Laboratories ABT.N added 0.2% after its quarterly profit more than doubled. By Devik Jain and Shreyashi Sanyal July 22 (Reuters) - U.S. stock indexes were set for a subdued open on Thursday after data showed an unexpected rise in weekly jobless claims, while a steady flow of positive earnings reports offered markets some support. AT&T Inc T.N added 0.9% in premarket trading as the telecom operator beat estimates for monthly phone bill paying subscriber additions in the second quarter, while chemicals maker Dow Inc DOW.N rose 1.3%after it forecast better-than-expected sales for the current quarter. | Adds background, segment sales, forecast July 22 (Reuters) - Abbott Laboratories' ABT.N quarterly profit more than doubled on Thursday, due to strength in its diagnostics business and a rebound in medical device sales. Second-quarter sales in Abbott's diagnostics business grew nearly 63% to $3.25 billion, with COVID-19 testing-related sales at $1.3 billion, down from the previous quarter. The company's net earnings rose to $1.19 billion, or 66 cents per share, in the quarter ended June 30, from $537 million, or 30 cents per share, a year earlier. | Abbott Laboratories ABT.N, Domino's Pizza Inc DPZ.N, Biogen Inc BIIB.O, Snap Inc SNAP.N and Intel Corp INTC.O are among the major companies reporting results later in the day. By Devik Jain July 22 (Reuters) - U.S. stock index futures edged higher on Thursday, with energy and mega-cap technology stocks gaining ahead of a new batch of earnings reports and data that allow investors to gauge the pace of the labor market recovery. Second-quarter earnings are expected to grow 75% for S&P 500 companies, according to Refinitiv IBES estimates, with 88% of the 73 reported companies in the benchmark index .SPX beating consensus expectations. | Quest and its rivals Abbott Laboratories ABT.N and Becton Dickinson BDX.N have recorded improvements in their non-COVID-19 businesses as vaccinations speed up and the economy reopens. Adds estimates, revenue details, background July 22 (Reuters) - Quest Diagnostics Inc DGX.N topped second-quarter profit estimates on Thursday, driven by a rebound in its non-COVID-19-related businesses as more Americans get vaccinated and pandemic-related restrictions lift. Net income attributable to the company rose to $631 million, or $4.96 per share, in the second quarter ended June 30, from $185 million, or $1.36 per share, a year earlier. | Abbott (NYSE:ABT) is scheduled to report its Q2 2021 results on Thursday, July 22. We expect the company to navigate well based on these trends over the latest quarter, and ABT stock to rise in the near term. This factor was also responsible for a 10% drop in ABT stock a couple of months back. | According to the Trefis Machine Learning Engine, which identifies trends in the company’s stock price using ten years of historical data, returns for BSX stock average 3.2% in the next one-month (twenty-one trading days) period after experiencing a 5% drop over the previous week (five trading days). Answer: Consider two situations, Case 1: Boston Scientific stock drops by -5% or more in a week Case 2: Boston Scientific stock rises by 5% or more in a week Is the average return for Boston Scientific stock higher over the subsequent month after Case 1 or Case 2? BSX stock fares better after Case 1, with an average return of 3.2% over the next month (21 trading days) under Case 1 (where the stock has just suffered a 5% loss over the previous week), versus, an average return of 1.4% for Case 2."
2021-07-21,119.22000122070312,118.9800033569336,0.211864406779661,"Pre-Market Earnings Report for July 22, 2021 : ABT, DHR, T, UNP, MMC, BIIB, NEM, FCX, DOW, AEP, DHI, LUV","Abbott Laboratories (ABT)is reporting for the quarter ending June 30, 2021. ABT missed the consensus earnings per share in the 1st calendar quarter of 2021 by -0.75%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for ABT is 27.29 vs. an industry ratio of 12.00, implying that they will have a higher earnings growth than their competitors in the same industry."
2021-07-20,118.54000091552734,118.7300033569336,-0.20130671138414188,S&P 500 Analyst Moves: ABT | iShares Core S&P 500 ETF Experiences Big Inflow,"VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories is now the #60 analyst pick, moving up by 1 spot. This rank is formed by averaging the analyst opinions for each component from each broker, and then ranking the 500 components by those average opinion values. | Among the largest underlying components of IVV, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.2%, Nike (Symbol: NKE) is up about 0.3%, and Thermo Fisher Scientific Inc (Symbol: TMO) is higher by about 0.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P 500 ETF (Symbol: IVV) where we have detected an approximate $576.5 million dollar inflow -- that's a 0.2% increase week over week in outstanding units (from 667,250,000 to 668,600,000). For a complete list of holdings, visit the IVV Holdings page » The chart below shows the one year price performance of IVV, versus its 200 day moving average: Looking at the chart above, IVV's low point in its 52 week range is $320.55 per share, with $439.81 as the 52 week high point — that compares with a last trade of $430.93."
2021-07-19,116.9800033569336,118.79000091552734,0.1602855069502213,3 High-Yield Dividend Aristocrats To Buy Now,"AbbVie Inc. (ABBV) ABBV) website and logo on mobile phone"" width=""300"" height=""169""> Source: Piotr Swat / Shutterstock.com AbbVie is a pharmaceutical giant that spun off from its former parent company Abbott Laboratories (NYSE:ABT) in 2013. We consider these to be some of the best dividend stocks in the entire market — and high-yield Dividend Aristocrats can bring an even stronger income. 7 A-Rated Retirement Stocks to Buy to for Your Golden Years These three dividend stocks from the list have yields above 4% and can raise their dividends each year due to their strong business models: Chevron Corporation (NYSE:CVX) AbbVie Inc. (NYSE:ABBV) Realty Income (NYSE:O) Dividend Stocks: Chevron Corporation (CVX) CVX) logo on gas station sign with ""diesel"" and ""food mart"" written underneath"" width=""300"" height=""169"" /> Source: Sundry Photography / Shutterstock.com Chevron is an integrated oil and gas company with a large upstream exploration and production business."
2021-07-16,117.04000091552734,117.51000213623048,1.547270906695925,,
2021-07-15,116.6999969482422,116.66000366210938,0.40157315193662607,,
2021-07-14,118.12000274658205,117.16999816894533,-0.03427016896201308,5 Stocks to Own for the Surge in Coronavirus Variants,"That's why Fulgent Genetics (NASDAQ: FLGT), Lucira Health (NASDAQ: LHDX), Abbott Labs (NYSE: ABT), Roche Holdings (OTC: RHHBY), and BioNTech (NASDAQ: BNTX) are on my watch list as cases start climbing. Lucira Health Lucira Health has only been a public company since February after launching an at-home COVID test in November 2020. Abbott Laboratories Similar to Lucira, Abbott's BinaxNOW COVID test will provide results in about half an hour."
2021-07-13,118.56999969482422,118.6500015258789,-0.8042707039847308,"Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for July 14, 2021 | 5 “Strong Buy” Dividend Stocks for July 2021","Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. The following ETF(s) have ABT as a top-10 holding: iShares U.S. ETF Trust (ABT) Invesco Dynamic Pharmaceuticals ETF (ABT) SPDR Select Sector Fund - Health Care (ABT) iShares U.S. Healthcare ETF (ABT) iShares U.S. Medical Devices ETF (ABT). | Abbott Labs (ABT) Dividend yield: 1.43% Ex-dividend date: July 14, 2021 Payout ratio: 50.66% Payout date: Aug. 16, 2021 Medical devices and healthcare leader Abbott Labs has paid dividends since 1924. Top Dividend Stocks Using the TipRanks Dividend Calendar, this article zeroes in on five Strong Buy stocks with an ex-dividend date in July 2021. Lowe’s Companies (LOW) Dividend yield: 1.33% Ex-dividend date: July 20, 2021 Payout ratio: 25.57% Payout date: Aug. 4, 2021 Home improvement company Lowe’s Companies has paid a regular dividend since 1961 and raised it for 25 consecutive years."
2021-07-12,118.80999755859376,118.80999755859376,0.06747223687323642,"IVW, V, TMO, ABT: Large Inflows Detected at ETF | Ex-Dividend Reminder: Abbott Laboratories, AbbVie and BankUnited | Will Intuitive Surgical Stock Continue Its Rally After A 15% Rise In A Month?","Among the largest underlying components of IVW, in trading today Visa Inc (Symbol: V) is down about 0.1%, Thermo Fisher Scientific Inc (Symbol: TMO) is trading flat, and Abbott Laboratories (Symbol: ABT) is lower by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 500 Growth ETF (Symbol: IVW) where we have detected an approximate $89.5 million dollar inflow -- that's a 0.3% increase week over week in outstanding units (from 470,650,000 to 471,850,000). For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year price performance of IVW, versus its 200 day moving average: Looking at the chart above, IVW's low point in its 52 week range is $52.585 per share, with $74.9138 as the 52 week high point — that compares with a last trade of $74.77. | Looking at the universe of stocks we cover at Dividend Channel, on 7/14/21, Abbott Laboratories (Symbol: ABT), AbbVie Inc (Symbol: ABBV), and BankUnited Inc. (Symbol: BKU) will all trade ex-dividend for their respective upcoming dividends. Abbott Laboratories (Symbol: ABT): AbbVie Inc (Symbol: ABBV): BankUnited Inc. (Symbol: BKU): In general, dividends are not always predictable, following the ups and downs of company profits over time. As a percentage of ABT's recent stock price of $119.38, this dividend works out to approximately 0.38%, so look for shares of Abbott Laboratories to trade 0.38% lower — all else being equal — when ABT shares open for trading on 7/14/21. | [Updated: 7/8/2021] ISRG Stock Rise The stock price of  Intuitive Surgical (NASDAQ: ISRG) has seen a 15% rise over the last twenty-one trading days, while it is up a solid 64% over the last year. Out of 43 instances in the last two years that ISRG stock saw a twenty-one day rise of 15% or more, 24 of them resulted in ISRG stock rising over the subsequent one month period (twenty-one trading days). Predict average return on Intuitive Surgical (ISRG) Stock Return: AI Predicts ISRG Average and Excess Return After a Fall or Rise Intuitive Surgical (ISRG) Stock Return (Recent) Comparison With Peers Five-Day Return: EW highest at 4%; BSX lowest at 1.3% Ten-Day Return: ISRG highest at 5.6%; BSX lowest at -0.09% Twenty-One Days Return: ISRG highest at 15%; MDT lowest at 2.7% Although with momentum on its side and going by historical performance, it appears that ISRG stock may see even higher levels, we continue to believe that it is richly valued at the current levels, and investors may be better off to wait for any dip to buy the stock."
2021-07-09,119.6500015258789,119.73999786376952,0.0,Why Lucira Health Is Rocketing Higher Today | 7 Super-Safe Dividend Stock Performers to Buy,"What happened Shares of Lucira Health (NASDAQ: LHDX) -- a maker of consumer-friendly at-home COVID-19 tests -- climbed as much as 40% higher Friday afternoon. 10 stocks we like better than Lucira Health, Inc. See the 10 stocks *Stock Advisor returns as of June 7, 2021 Jason Hawthorne has no position in any of the stocks mentioned. | Costco (NASDAQ:COST) Apple (NASDAQ:AAPL) Abbott Laboratories (NYSE:ABT) Procter & Gamble (NYSE:PG) Coca-Cola (NYSE:KO) AbbVie (NYSE:ABBV) Prudential Financial (NYSE:PRU) Before we move forward, I want to make clear one thing: this isn’t about pivoting all your investments toward dividend stocks. Safe Dividend Stocks: Abbott Laboratories (ABT) Source: Sundry Photography/Shutterstock.com Traditionally, analysts regard Abbott Laboratories as one of the safer dividend stocks to buy. Of course, that all changed during the coronavirus onslaught when investors couldn’t get enough of ABT stock."
2021-07-08,118.86000061035156,119.26000213623048,0.07521632824312638,Abbott's St. Jude Medical To Pay $27 Mln To Settle Allegations Over Heart Devices | St. Jude Medical to pay $27 mln to settle allegations over heart devices | St. Jude Medical to pay $27 mln to settle allegations over heart devices -DOJ | Here's What Abbott Laboratories' (NYSE:ABT) Shareholder Ownership Structure Looks Like,"(RTTNews) - St. Jude Medical Inc. agreed to pay $27 million to settle allegations that, between November 2014 and October 2016, it knowingly sold defective heart devices to health care facilities that, in turn, implanted the devices into patients insured by federal health care programs, the U.S. Department of Justice said in a statement. The U.S. alleged that St. Jude failed to disclose serious adverse health events in connection with the premature depletion of the battery in certain models of its Fortify, Fortify Assura, Quadra and Unify devices, which are implantable defibrillators used in patients at risk of cardiac arrest due to an irregular heartbeat. The U.S. alleged that, by 2013, St. Jude knew that lithium clusters formed on the batteries of the devices, causing some of the batteries to short and, in turn, suffer a premature power drain. | Adds background WASHINGTON, July 8 (Reuters) - St. Jude Medical, which was acquired by Abbott Laboratories ABT.N in 2017, has agreed to pay $27 million to settle allegations it knowingly sold defective heart devices, the U.S. Justice Department said on Thursday. It said St. Jude allegedly failed to disclose serious adverse health events in connection with premature battery depletion in certain models of its implantable defibrillators that were sold between November 2014 and October 2016. (Reporting by Eric Beech in Washington Editing by Mohammad Zargham and Matthew Lewis) ((eric.beech@thomsonreuters.com; 202-898-8322; Reuters Messaging: eric.beech.reuters.com@reuters.net)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | WASHINGTON, July 8 (Reuters) - St. Jude Medical, which was acquired by Abbott Laboratories ABT.N in 2017, has agreed to pay $27 million to settle allegations it knowingly sold defective heart devices, the U.S. Justice Department said on Thursday. (Reporting by Eric Beech; Editing by Mohammad Zargham) ((eric.beech@thomsonreuters.com; 202-898-8322; Reuters Messaging: eric.beech.reuters.com@reuters.net)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | NYSE:ABT Ownership Breakdown July 8th 2021 What Does The Institutional Ownership Tell Us About Abbott Laboratories? Every investor in Abbott Laboratories (NYSE:ABT) should be aware of the most powerful shareholder groups. NYSE:ABT Earnings and Revenue Growth July 8th 2021 Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences."
2021-07-07,119.08000183105467,119.87000274658205,0.3365316538994567,,
2021-07-06,118.0,118.81999969482422,0.6634203085151021,Wait For a Pullback Before Taking a Position In Senseonics,"Competition and Financial Positioning Few CGM devices are currently prevalent in the U.S. market from Abbott (NYSE:ABT), Medtronic, and DexCom (NASDAQ:DXCM). InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of medical device maker Senseonics (NYSE:SENS) have been rallying in the past month. Additionally, with stronger product and expansion marketing efforts in the European market and the growing U.S. market, Senseonics could witness double-digit growth in the long run."
2021-07-02,116.91999816894533,118.04000091552734,0.6949149956137447,The 7 Best Dividend Stocks to Buy for Income Investors In July 2021  | Got $400? 3 Fantastic Dividend Stocks to Buy Right Now,"Abbott Laboratories (NYSE:ABT) Becton Dickinson (NYSE:BDX) Clorox (NYSE:CLX) Ecolab  (NYSE:ECL) Iron Mountain (NYSE:IRM) Invesco Dow Jones Industrial Average Dividend ETF (NYSEARCA:DJD) iShares International Select Dividend ETF (BATS:IDV) Investors tend to prefer stocks that provide higher dividend yields. Best Dividend Stocks to Buy: Abbott Laboratories (ABT) Source: testing / Shutterstock.com 52-week range: $86.16 – $128.54 Dividend yield: 1.65% Abbott Park, Illinois-based Abbott manufactures diversified line of health care products that include medical devices, diagnostic equipment, nutritional products, testing kits, and branded generic drugs. ABT stock currently hovers around $113 per share, up 3% year-to-date (YTD). | Innovative Industrial Properties Innovative Industrial Properties (NYSE: IIPR) ranks as the most expensive of the three dividend stocks on the list, with its share price a little over $190. Easterly Government Properties Innovative Industrial Properties offers tremendous growth with its dividend. See the 10 stocks *Stock Advisor returns as of June 7, 2021 Keith Speights owns shares of AbbVie and Innovative Industrial Properties."
2021-07-01,115.61000061035156,117.16000366210938,0.9579223093757255,"August 13th Options Now Available For Abbott Laboratories (ABT) | IVV, ABT, T, TMO: ETF Inflow Alert","Below is a chart showing ABT's trailing twelve month trading history, with the $118.00 strike highlighted in red: Considering the fact that the $118.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the August 13th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new August 13th contracts and identified one put and one call contract of particular interest. | Among the largest underlying components of IVV, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.6%, AT&T Inc (Symbol: T) is up about 0.8%, and Thermo Fisher Scientific Inc (Symbol: TMO) is higher by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P 500 ETF (Symbol: IVV) where we have detected an approximate $129.0 million dollar inflow -- that's a 0.05% increase week over week in outstanding units (from 666,350,000 to 666,650,000). For a complete list of holdings, visit the IVV Holdings page » The chart below shows the one year price performance of IVV, versus its 200 day moving average: Looking at the chart above, IVV's low point in its 52 week range is $311.89 per share, with $431.51 as the 52 week high point — that compares with a last trade of $431.18."
2021-06-30,117.0,115.93000030517578,1.3407171036888892,"5 Dividend Aristocrats Where Analysts See Capital Gains | SPY, HIPR: Big ETF Inflows | Forget AMC: Here Are 2 Better Post-Pandemic Stocks | Intuitive Surgical Stock Is Richly Valued At $900 Levels","New Jersey Resources Corp (Symbol: NJR) $39.56 $42.60 7.68% General Dynamics Corp (Symbol: GD) $186.70 $198.42 6.28% Abbott Laboratories (Symbol: ABT) $117.21 $124.50 6.22% National Retail Properties Inc (Symbol: NNN) $47.20 $49.68 5.26% Emerson Electric Co. (Symbol: EMR) $94.69 $99.45 5.03% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. New Jersey Resources Corp (Symbol: NJR) 3.36% 7.68% 11.04% General Dynamics Corp (Symbol: GD) 2.55% 6.28% 8.83% Abbott Laboratories (Symbol: ABT) 1.54% 6.22% 7.76% National Retail Properties Inc (Symbol: NNN) 4.41% 5.26% 9.67% Emerson Electric Co. (Symbol: EMR) 2.13% 5.03% 7.16% Another consideration with dividend growth stocks is just how much the dividend is growing. New Jersey Resources Corp (Symbol: NJR) $1.252 $1.332 6.39% General Dynamics Corp (Symbol: GD) $4.16 $4.49 7.93% Abbott Laboratories (Symbol: ABT) $1.36 $1.62 19.12% National Retail Properties Inc (Symbol: NNN) $2.06 $2.08 0.97% Emerson Electric Co. (Symbol: EMR) $1.99 $2.015 1.26% These five stocks are part of our full Dividend Aristocrats List. | Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel, the biggest inflow was seen in the SPDR S&P 500 ETF Trust, which added 12,300,000 units, or a 1.4% increase week over week. Among the largest underlying components of SPY, in morning trading today Apple is up about 0.3%, and Microsoft is lower by about 0.3%. And on a percentage change basis, the ETF with the biggest increase in inflows was the Direxion High Growth ETF, which added 50,000 units, for a 40.0% increase in outstanding units. | Abbott Laboratories Abbott Laboratories' (NYSE: ABT) strength in coronavirus testing made it a stock to watch -- and buy -- during the worst of the pandemic. ABT PE Ratio data by YCharts. Nike Nike (NYSE: NKE) shares soared 14% in one trading session last week after reporting double-digit quarterly and fiscal year revenue gains and predicting ""significant"" opportunity ahead. | At the current levels of over $900, ISRG stock is trading at 67x its forward estimated adjusted EPS of $13.50 in 2021, compared to levels of around 60x seen in 2019 and 2020, and levels of under 40x seen prior to 2019. This means that the P/E multiple for ISRG stock is much higher than its historical levels, and the stock is vulnerable to some downside risk, in our view. Although ISRG is a high-quality stock to invest in, given the company’s business model, which ensures recurring revenues from consumables on each installed device, and that the robotic-assisted surgery market will be large enough over the coming years for multiple players to thrive, based on the current valuation, we believe that it will be prudent for investors to wait for a better entry point in ISRG stock to buy for higher gains."
2021-06-29,115.73999786376952,117.20999908447266,-0.9145296536959134,Edwards Lifesciences May Continue To Rise After Positive Clinical Trial Data,"After moving 7.9% or more over a ten-day period, the stock rose in the next 10 days on 54% of the occasions After moving 9.8% or more over a twenty-one-day period, the stock rose in the next 21 days on 59% of the occasions Predict average return on Edwards Lifesciences (EW) Stock Return: AI Predicts EW Average and Excess Return After a Fall or Rise Edwards Lifesciences (EW) Stock Return (Recent) Comparison With Peers Five-Day Return: EW highest at 4.6%; BAX lowest at -1% Ten-Day Return: EW highest at 7.9%; BAX lowest at 1.7% Twenty-One Day Return: EW highest at 9.8%; ABT lowest at -5.5% While EW stock may see higher levels, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. The stock price of Edward Lifesciences (NYSE:EW), a company specializing in artificial heart valves and hemodynamic monitoring, has seen a rise of 10% in the last twenty-one trading days. Out of 387 instances in the last ten years that Edwards Lifesciences stock saw a twenty-one day rise of 10% or more, 228 of them resulted in EW stock rising over the subsequent one month period (twenty-one trading days)."
2021-06-28,112.98999786376952,115.6999969482422,1.2700892067005114,ABT Makes Bullish Cross Above Critical Moving Average | These 3 High-Dividend Stocks Have Cathie Wood's Seal of Approval,"In trading on Monday, shares of Abbott Laboratories (Symbol: ABT) crossed above their 200 day moving average of $113.78, changing hands as high as $116.36 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $88.09 per share, with $128.54 as the 52 week high point — that compares with a last trade of $115.69. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The pharmaceutical company qualifies as a Dividend Aristocrat, as it has consistently boosted its annual payouts to shareholders since its spinoff from Abbott Laboratories (NYSE: ABT) in the early 2010s. AbbVie AbbVie (NYSE: ABBV) is perhaps the best-known dividend stock among the holdings of Cathie Wood's ETFs. AbbVie isn't a huge holding for Wood, but her ARK Genomic Revolution ETF (NYSEMKT: ARKG) has about $60 million invested in the pharma company."
2021-06-25,111.87999725341795,112.72000122070312,2.39844157510304,What's Next For Masimo Stock After A 14% Rise In 10 Days?,"The stock price of Masimo Corporation (NASDAQ:MASI), a medical devices company best known for its remote patient monitoring systems, has seen a rise of 9.4% in last twenty-one trading days, while it is up 14% over the last ten days. Out of 432 instances in the last ten years that Masimo stock saw a twenty-one day rise of 9.4% or more, 293 of them resulted in MASI stock rising over the subsequent one month period (twenty-one trading days). After moving 14% or more over a ten-day period, the stock rose in the next 10 days on 69% of the occasions After moving 9.4% or more over a twenty-one-day period, the stock rose in the next 21 days on 68% of the occasions Predict average return on Masimo (MASI) Stock Return: AI Predicts MASI Average and Excess Return After a Fall or Rise Masimo (MASI) Stock Return (Recent) Comparison With Peers Five-Day Return: MASI highest at 6.2%; SPY lowest at -0.3% Ten-Day Return: MASI highest at 14%; SPY lowest at 0.2% Twenty-One Day Return: DXCM highest at 25%; MDT lowest at -0.4% While MASI stock may see higher levels, 2020 has created many pricing discontinuities which can offer attractive trading opportunities."
2021-06-24,111.5,111.6999969482422,0.7508079977714767,Interesting ABT Put And Call Options For August 6th | Despite A 23% Rise In A Month Dexcom Stock Will Likely See Higher Levels,"Below is a chart showing ABT's trailing twelve month trading history, with the $115.00 strike highlighted in red: Considering the fact that the $115.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the August 6th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new August 6th contracts and identified one put and one call contract of particular interest. | Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using last 10 year data 3.4% or higher return during five-day period in 794 times out of 2517; Stock rose in the next 5 days in 448 of these 794 instances 9.3% or higher return during ten-day period in 463 times out of 2517; Stock rose in the next 10 days in 260 of these 463 instances 23% or higher return during twenty-one day period in 184 times out of 2516; Stock rose in the next 21 days in 99 of these 184 instances Predict average return on DexCom (DXCM) Stock Return: AI Predicts DXCM Average and Excess Return After a Fall or Rise DexCom (DXCM) Stock Return (Recent) Comparison With Peers Five-Day Return: DXCM highest at 3.4%; SPY lowest at -1% Ten-Day Return: DXCM highest at 9.3%; SPY lowest at -0.3% Twenty-One Days Return: DXCM highest at 23%; ABT lowest at -5.4% [Updated: 5/6/2021] DXCM Stock Decline The stock price of Dexcom (NASDAQ: DXCM), best known for its continuous glucose monitoring (CGM) systems, has seen an 11% drop over the last five trading days, and we believe the stock is likely to rebound in the near term. Ten Days: DXCM -8.5%, vs. S&P500 0.4%; Underperformed market (11% likelihood event) Dexcom stock declined 8.5% over the last ten trading days (two weeks), compared to the broader market (S&P500) rise of 0.4% A change of -8.5% or more over ten trading days is a 11% likelihood event, which has occurred 268 times out of 2511 in the last ten years. Twenty-One Days: DXCM 5.4%, vs. S&P500 4.3%; Outperformed market (44% likelihood event) Dexcom stock rose 5.4% the last twenty-one trading days (1 month), compared to the broader market (S&P500) rise of 4.3% A change of 5.4% or more over twenty-one trading days is a 44% likelihood event, which has occurred 1107 times out of 2500 in the last ten years."
2021-06-23,110.5999984741211,110.83999633789062,0.17936946030690737,,
2021-06-22,111.66000366210938,110.95999908447266,0.21699626318321105,"IVE, MDT, MDLZ, ABT: ETF Outflow Alert","Among the largest underlying components of IVE, in trading today Medtronic PLC (Symbol: MDT) is up about 0.6%, Mondelez International Inc (Symbol: MDLZ) is up about 0.3%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 500 Value ETF (Symbol: IVE) where we have detected an approximate $248.9 million dollar outflow -- that's a 1.1% decrease week over week (from 154,250,000 to 152,550,000). For a complete list of holdings, visit the IVE Holdings page » The chart below shows the one year price performance of IVE, versus its 200 day moving average: Looking at the chart above, IVE's low point in its 52 week range is $104.70 per share, with $152.22 as the 52 week high point — that compares with a last trade of $146.21."
2021-06-21,110.25,111.44000244140624,-0.6269071777527245,These Stocks Are Better Priced Compared To Abbott,"We believe that there are other stocks in the healthcare sector that are currently better valued than Aboott Laboratories (NYSE: ABT). This disconnect between valuation and performance could mean that you are better off buying PKI and QDEL vs. ABT. As such, we believe that PKI and QDEL are currently better buying opportunities compared to ABT stock."
2021-06-18,110.0,110.33000183105467,1.079367293792504,This Safe 5-Stock Healthcare Portfolio Yields 5.5% | Next Market Crash 101: 2 Top Growth Stocks to Buy Right Now,"Here, we'll examine five healthcare names that should keep your income portfolio in peak condition for years to come: AbbVie (ABBV) Dividend Yield: 4.5% AbbVie (ABBV) was famously spun off from Abbott Laboratories (ABT) at the start of 2013. And keeping in line with the pharmaceutical industry, ABBV has offered the superior dividend ever since parting with ABT. Sabra Health Care REIT (SBRA) Dividend Yield: 6.7% Sabra Health Care REIT (SBRA) is a similar play that took its dividend lumps last year. | Facebook Facebook (NASDAQ: FB) is hardly a new choice for long-term investors, but it's the type of stock you can add more of to your portfolio time and time again. In addition, Facebook reported that its ""daily active users"" (what it calls daily Facebook users) and ""daily active people"" (what it calls daily users of any of Facebook's suite of products) surged by respective rates of 8% and 15% in the month of March alone. AbbVie Healthcare stock AbbVie (NYSE: ABBV) is another golden egg to have in your basket before the next market crash rolls around."
2021-06-17,109.75,111.62999725341795,0.30000166459515754,February 2022 Options Now Available For Abbott Laboratories (ABT),"Below is a chart showing ABT's trailing twelve month trading history, with the $120.00 strike highlighted in red: Considering the fact that the $120.00 strike represents an approximate 8% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the February 2022 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new February 2022 contracts and identified one put and one call contract of particular interest."
2021-06-16,110.19000244140624,110.05999755859376,1.7129815520892524,,
2021-06-15,110.94000244140624,110.41000366210938,-0.11798246658684117,What Abbott Laboratories' (NYSE:ABT) P/E Is Not Telling You | This Underappreciated Healthcare Stock Is on Sale: Should You Buy?,"When close to half the companies in the United States have price-to-earnings ratios (or ""P/E's"") below 19x, you may consider Abbott Laboratories (NYSE:ABT) as a stock to avoid entirely with its 34.4x P/E ratio. NYSE:ABT Price Based on Past Earnings June 15th 2021 If you'd like to see what analysts are forecasting going forward, you should check out our free report on Abbott Laboratories. Abbott Laboratories certainly has been doing a good job lately as it's been growing earnings more than most other companies. | Medical devices giant Abbott Laboratories (NYSE: ABT) was on fire last year for one simple reason: Even though many of its business segments suffered due to the pandemic, the company established itself as one of the leaders in the COVID-19 testing market. ABT data by YCharts A closer look at Abbott Laboratories' new guidance The worldwide efforts to vaccinate as many people as possible against COVID-19 continue. In the fiscal year 2020, ending Dec. 31, Abbott Laboratories recorded sales of $34.6 billion -- an 8.5% year over year increase."
2021-06-14,110.08000183105467,110.4800033569336,-0.477734602157399,Invesco Dynamic Large Cap Growth ETF Experiences Big Outflow,"Among the largest underlying components of PWB, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is trading flat, Danaher Corp (Symbol: DHR) is off about 1.1%, and Abbott Laboratories (Symbol: ABT) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Invesco Dynamic Large Cap Growth ETF (Symbol: PWB) where we have detected an approximate $228.8 million dollar outflow -- that's a 23.4% decrease week over week (from 13,660,000 to 10,460,000). For a complete list of holdings, visit the PWB Holdings page » The chart below shows the one year price performance of PWB, versus its 200 day moving average: Looking at the chart above, PWB's low point in its 52 week range is $51.32 per share, with $73.48 as the 52 week high point — that compares with a last trade of $71.61."
2021-06-11,110.33000183105467,109.91000366210938,0.363373473133497,"Daily Dividend Report: ABT,AMAT,PM,CL,ODC","VIDEO: Daily Dividend Report: ABT,AMAT,PM,CL,ODC The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott has increased its dividend payout for 49 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years. The Board of Directors of Colgate-Palmolive today declared a quarterly cash dividend of $0.45 per common share, payable on August 16, 2021 to shareholders of record as of July 21, 2021."
2021-06-10,109.0500030517578,110.1500015258789,-0.38067448742403726,,
2021-06-09,107.80999755859376,109.0500030517578,1.0087101727076724,2 High-Yield Dividend Stocks for 2021 | Is Abbott Laboratories a Buy on the Dip?,"High-yielding dividend stocks may not always be a safe investment, as an unusually high yield might signal a company in trouble or an impending dividend cut. Humira will lose patent protection here in the U.S in 2023, and given the drug's superstar status, investors might be concerned about whether AbbVie can sustain revenues and if the dividend is safe. Skyrizi and Rinvoq combined to bring in about $2.3 billion in sales for 2020, only 14% of the $16 billion Humira notched for the year. | Shares of top healthcare stock Abbott Laboratories (NYSE: ABT) are down 8% over the past month while the S&P 500 has been relatively steady, up by less than 1% during that period. And with the stock trading at such a high multiple of earnings, I wouldn't be surprised to see Abbott's stock fall further down as the year goes on and investors shift to stocks that will benefit as a result of the economy opening back up. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen."
2021-06-08,110.5,107.9000015258789,1.1501767194550787,Here's Why We Believe Quidel Stock Is Undervalued,"We believe that the stock price of Quidel (NASDAQ:QDEL), a clinical genetic testing company, looks undervalued at current levels near $108. Because Covid-19 testing led the company’s sales higher and now with several countries working fast on vaccination, the demand for testing is bound to decline. Lastly, the average analyst price estimate for QDEL stock is around $173, reflecting a large 60% premium to the current market price of $108, and we also believe that Quidel is significantly undervalued at the current levels."
2021-06-07,109.9800033569336,110.0,-2.3529397955847005,How The Parts Add Up: XLG Targets $351,"Similarly, NFLX has 21.81% upside from the recent share price of $494.74 if the average analyst target price of $602.63/share is reached, and analysts on average are expecting ABT to reach a target price of $124.50/share, which is 13.92% above the recent price of $109.29. Three of XLG's underlying holdings with notable upside to their analyst target prices are Amazon.com Inc (Symbol: AMZN), Netflix Inc (Symbol: NFLX), and Abbott Laboratories (Symbol: ABT). Below is a twelve month price history chart comparing the stock performance of AMZN, NFLX, and ABT: Combined, AMZN, NFLX, and ABT represent 9.79% of the Invesco S&P 500— Top 50 ETF."
2021-06-04,109.3000030517578,109.29000091552734,0.018182071700351136,,
2021-06-03,107.0,109.1999969482422,-0.0091510850422558,Interesting ABT Put And Call Options For July 23rd | Medtronic stops sale of heart device HVAD System over safety concerns | This Big Player in the COVID-19 Market Just Lowered Its Forecast. Should You Be Worried?,"Below is a chart showing ABT's trailing twelve month trading history, with the $110.00 strike highlighted in red: Considering the fact that the $110.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the July 23rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new July 23rd contracts and identified one put and one call contract of particular interest. | Rival medical device maker Abbott ABT.N said in a statement on Thursday it had the capacity and supply to support the growing demand for heart pumps. Adds details on device, Abbott statement June 3 (Reuters) - Medtronic Plc MDT.N said on Thursday it was stopping the distribution and sale of its heart device HVAD System due to safety concerns. Pump restart failure can potentially worsen a patient's heart condition, lead to a heart attack, require hospitalization and result in death, it said. | My favorite is Abbott Laboratories (NYSE: ABT). ABT PE Ratio data by YCharts. The pandemic's impact The pandemic hurt Abbott's ability to grow sales in these core businesses."
2021-06-02,105.79000091552734,106.9000015258789,2.0560719142450483,After A Large Decline Is Quidel A Better Bet Compared To Abbott Stock?,"We think that Quidel (NASDAQ:QDEL) currently is a better pick compared to Abbott (NYSE:ABT). Our dashboard Abbott vs. Quidel: ABT stock looks overvalued compared to QDEL stock has more details on this. Revenue Growth Between 2017 and 2020, Abbott’s revenues grew by about 26%, from around $27.4 billion to $34.6 billion, primarily led by a strong growth in diagnostics business, which saw its revenue nearly double to $10.8 billion in 2020, compared to $5.6 billion in 2017."
2021-06-01,110.1500015258789,105.79000091552734,1.049249079067398,"US STOCKS-Dow, S&P 500 rise on optimism about economic recovery | Notable Tuesday Option Activity: BIIB, ABT, OXY | Tuesday Sector Laggards: Healthcare, Utilities | US STOCKS-Dow, S&P 500 rise on optimism about economic recovery | Health Care Sector Update for 06/01/2021: ABT,CGC,WEED.TO,VCYT | Health Care Sector Update for 06/01/2021: NUWE,ABT,CGC,WEED.TO,VCYT | US STOCKS-Wall St ends little changed; energy gains, health sags | S&P 500 Movers: ABT, DVN | Abbott Laboratories Slashes FY21 Outlook - Quick Facts | Why Abbott Stock Is Tumbling Today | Tuesday's ETF Movers: XOP, IHI | This Significant New Partnership Makes Senseonics Stock Worth Another Look | S&P 500 dips, as healthcare weighs; Dow ends higher | Abbott cuts 2021 profit forecast on lower COVID-19 testing demand | Abbott Laboratories Enters Oversold Territory","Abbott Laboratories ABT.N fell 7.8%, weighing the most on the S&P 500, after cutting its full-year 2021 profit forecast due to a projected drop in COVID-19 diagnostic testing demand. By Shashank Nayar and Medha Singh June 1 (Reuters) - The S&P 500 and the Dow rose on Tuesday, with the benchmark S&P 500 within 0.5% of its record high as investors cheered signs of an improving economy ahead of a week packed with major data that is expected to shed more light on the path of inflation. ""For now, (investors) are embracing the economic data that shows improvements in the economy and are ignoring data that suggests that it's going to lead to much higher prices and shortages that affect specific companies,"" said Rick Meckler, partner, Cherry Lane Investments in New Vernon, New Jersey. | Below is a chart showing ABT's trailing twelve month trading history, with the $107 strike highlighted in orange: And Occidental Petroleum Corp (Symbol: OXY) saw options trading volume of 127,821 contracts, representing approximately 12.8 million underlying shares or approximately 75.4% of OXY's average daily trading volume over the past month, of 17.0 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $300 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) options are showing a volume of 38,236 contracts thus far today. That number of contracts represents approximately 3.8 million underlying shares, working out to a sizeable 79% of ABT's average daily trading volume over the past month, of 4.8 million shares. | Within that group, Abbott Laboratories (Symbol: ABT) and Thermo Fisher Scientific Inc (Symbol: TMO) are two of the day's laggards, showing a loss of 8.2% and 4.7%, respectively. Combined, ABT and TMO make up approximately 8.1% of the underlying holdings of XLV. Among healthcare ETFs, one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is down 1.4% on the day, and up 7.75% year-to-date. | Abbott Laboratories ABT.N fell 6.2% after cutting its full-year 2021 profit forecast due to a projected drop in COVID-19 diagnostic testing demand. By Shashank Nayar and Medha Singh June 1 (Reuters) - The S&P 500 and the Dow rose on Tuesday, with the benchmark S&P 500 within 0.5% of its record highas investors cheered signs of an improving economy ahead of a week packed with major data that is expected to shed more light on the path of inflation. ""For now, they (investors) are embracing the economic data that shows improvements in the economy and are ignoring data that suggests that it's going to lead to much higher prices and shortages that affect specific companies,"" said Rick Meckler, partner, Cherry Lane Investments in New Vernon, New Jersey. | In company news, Abbott (ABT) dropped 8.5% after cutting its non-GAAP FY21 profit outlook to $4.30 to $4.50 per share, down from its prior forecast expecting around $5.00 per share and trailing the Capital IQ consensus expecting the health care products company to earn $5.04 per share this year, excluding one-time items. Health care stocks were sinking this afternoon, with the NYSE Health Care Index falling 1.5% while the SPDR Health Care Select Sector ETF also was down 1.6%. Veracyte (VCYT) slid 7.3% after the genomic diagnostics company announced its purchase of privately held cancer diagnostics company HalioDx for 260 million euros ($317.9 million), consisting of 147 million euros in cash and the rest in Veracyte stock, subject to customary adjustments. | To the downside, Abbott (ABT) dropped 9.2% after cutting its non-GAAP FY21 profit outlook to a range of $4.30 to $4.50 per share, from $5 per share previously and trailing analyst consensus expecting the health care products company to earn $5.04 per share this year, excluding one-time items, based on a Capital IQ survey. Health care stocks extended Tuesday's retreat in late going, with the NYSE Health Care Index falling 1.5% while the SPDR Health Care Select Sector ETF (XLV) was down 1.6% shortly before the closing bell. Canopy Growth (CGC) fell 7.3% after the Canadian cannabis company reported a fiscal Q4 net loss of 1.85 Canadian dollars ($1.54) per share, paring its CA$3.72 per share loss during the same quarter last year and missing the analyst consensus for a CA$0.26 per share loss in a Capital IQ poll. | The healthcare sector .SPXHC was dragged down by a weak profit forecast from Abbott Laboratories ABT.N. By Lewis Krauskopf, Shashank Nayar and Medha Singh June 1 (Reuters) - Wall Street's main indexes ended little changed on Tuesday, with gains in energy and financial shares countering declines in healthcare, as investors weighed the latest U.S. economic data for signs of a rebound and rising inflation. The S&P 500 financial sector .SPSY hit a record high, while expected growth in fuel demand boosted oil prices and helped lift the energy sector .SPNY. | VIDEO: S&P 500 Movers: ABT, DVN The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Tuesday, shares of Devon Energy topped the list of the day's best performing components of the S&P 500 index, trading up 10.8%. And the worst performing S&P 500 component thus far on the day is Abbott Laboratories, trading down 5.6%. | (RTTNews) - Providing an update to its financial outlook on Tuesday, Abbott Laboratories (ABT) lowered its earnings and adjusted earnings guidance for the full-year 2021, due to significantly lower recent and projected COVID-19 diagnostic testing demand. For fiscal 2021, the company now projects earnings from continuing operations in a range of $2.75 to $2.95 per share and adjusted earnings from continuing operations in a range of $4.30 to $4.50 per share, reflecting a double-digit growth from last year. Previously, the company expected earnings from continuing operations of at least $3.74 per share and adjusted earnings from continuing operations of at least $5.00 per share, reflecting a growth of more than 35 percent from last year. | What happened Shares of Abbott Laboratories (NYSE: ABT) were tumbling 7.5% as of 11:32 a.m. EDT on Tuesday. Abbott now expects diluted earnings per share (EPS) of between $2.75 and $2.95 based on generally accepted accounting principles (GAAP), compared to its previous outlook of GAAP EPS of at least $3.74. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | In trading on Tuesday, the SPDR— S&P— Oil & Gas Exploration & Production ETF is outperforming other ETFs, up about 5.2% on the day. Components of that ETF showing particular strength include shares of SM Energy, up about 12.8% and shares of Devon Energy, up about 11.6% on the day. Among components of that ETF with the weakest showing on Tuesday were shares of Abbott Laboratories, lower by about 7.5%, and shares of Inari Medical, lower by about 6.6% on the day. | Other well-funded competitors like Abbott (NYSE:ABT) and Dexcom (NASDAQ:DXCM) are active in continuous glucose monitoring as well. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Senseonics (NYSEAMERICAN:SENS) stock has surged over the past six months. 7 Cheap Stocks to Put on Your Buy List for June Before we take a look at whether Senseonics worth getting involved in at all let’s back up and take a look at how Senseonics hopes to start making money. | The heavyweight tech sector .SPLRCT fell while the healthcare sector .SPXHC was dragged down by a weak profit forecast from Abbott Laboratories ABT.N. US manufacturing gains steam; shortages mount Abbott Labs shares tumble after co cuts forecast Meme stocks extend gains; AMC Entertainment shares jump Data analytics firm Cloudera soars on plans to go private Dow up 0.13%, S&P down 0.05%, Nasdaq down 0.09% Updates with additional market data By Lewis Krauskopf, Shashank Nayar and Medha Singh June 1 (Reuters) - The S&P 500 .SPX dipped on Tuesday, with declines in healthcare and tech shares countered by energy and financial gains, as investors weighed the latest U.S. economic data for signs of a rebound and rising inflation. The S&P 500 financial sector .SPSY hit a record high, while expected growth in fuel demand boosted oil prices and helped lift the energy sector .SPNY3.9%, its biggest one-day gain in nearly four months. | Adds details from release, share movement June 1 (Reuters) - Abbott Laboratories ABT.N on Tuesday cut its full-year 2021 profit forecast due to a projected drop in COVID-19 diagnostic testing demand, sending its shares down 4.1% before the bell. Abbott sees second-quarter adjusted profit from continuing operations of at least $1 per share, compared with analysts' estimates of $1.23 per share. (Reporting by Dania Nadeem in Bengaluru; Editing by Shounak Dasgupta and Shailesh Kuber) ((Dania.Nadeem@thomsonreuters.com)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the fundamental datapoints dividend investors should investigate to decide if they are bullish on ABT is its dividend history. Abbott Laboratories (Symbol: ABT) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most ""interesting"" ideas that merit further research by investors. But making Abbott Laboratories an even more interesting and timely stock to look at, is the fact that in trading on Tuesday, shares of ABT entered into oversold territory, changing hands as low as $108.362 per share."
2021-05-28,116.47000122070312,116.6500015258789,-3.9582392645970264,,
2021-05-27,117.0,115.69000244140624,0.1545464954831522,2 Great Income Stocks to Buy Right Now | Despite A 7x Rally Owens & Minor Stock Will Likely Continue Higher | 5 Dividend Growth Stocks With Upside To Analyst Targets,"And while its payouts haven't risen nearly as impressively as Amgen's have, with quarterly payments of $0.37, its shareholders are earning 76% more than they were in 2016 when Cisco was paying just $0.21 each quarter. Like Amgen, Cisco offers investors some promising growth opportunities, a decent valuation, and an above-average yield, making it a solid income stock to add to your portfolio today. 10 stocks we like better than Amgen When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | [Updated: 9/29/2020] OMI Stock Performance 2020 vs. 2008 Crisis We believe Owens & Minor stock (NYSE:OMI), a global healthcare logistics company, could continue to rally in the near term. Timeline of 2007-08 Crisis 10/1/2007: Approximate pre-crisis peak in S&P 500 index 9/1/2008 – 10/1/2008: Accelerated market decline corresponding to Lehman bankruptcy filing (9/15/08) 3/1/2009: Approximate bottoming out of S&P 500 index 1/1/2010: Initial recovery to levels before accelerated decline (around 9/1/2008) Owens & Minor vs S&P 500 Performance Over 2007-08 Financial Crisis OMI stock declined from levels of around $19 in September 2007 (pre-crisis peak for the markets) to levels of around $17 in March 2009 (as the markets bottomed out), implying OMI stock lost a mere 12% from its approximate pre-crisis peak. Phases of Covid-19 crisis: Early- to mid-March 2020: Fear of the coronavirus outbreak spreading rapidly translates into reality, with the number of cases accelerating globally Late-March 2020 onward: Social distancing measures + lockdowns April 2020: Fed stimulus suppresses near-term survival anxiety May-June 2020: Recovery of demand, with gradual lifting of lockdowns – no panic anymore despite a steady increase in the number of cases July-September 2020: Poor Q2 results for many companies, but continued improvement in demand and a decline in the number of new cases and progress with vaccine development buoy expectations Going by the current trends and continued growth in demand for PPE, we believe that OMI stock has more room for growth in the near future. | Telephone & Data Systems Inc (Symbol: TDS) $25.31 $31.38 23.96% ABM Industries, Inc. (Symbol: ABM) $49.74 $58.33 17.28% Black Hills Corporation (Symbol: BKH) $65.65 $75.20 14.55% Abbott Laboratories (Symbol: ABT) $116.75 $132.50 13.49% SEI Investments Co (Symbol: SEIC) $62.92 $71.00 12.84% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Telephone & Data Systems Inc (Symbol: TDS) 2.77% 23.96% 26.73% ABM Industries, Inc. (Symbol: ABM) 1.53% 17.28% 18.81% Black Hills Corporation (Symbol: BKH) 3.44% 14.55% 17.99% Abbott Laboratories (Symbol: ABT) 1.54% 13.49% 15.03% SEI Investments Co (Symbol: SEIC) 1.18% 12.84% 14.02% Another consideration with dividend growth stocks is just how much the dividend is growing. Telephone & Data Systems Inc (Symbol: TDS) $0.665 $0.685 3.01% ABM Industries, Inc. (Symbol: ABM) $0.73 $0.75 2.74% Black Hills Corporation (Symbol: BKH) $2.11 $2.23 5.69% Abbott Laboratories (Symbol: ABT) $1.36 $1.62 19.12% SEI Investments Co (Symbol: SEIC) $0.68 $0.72 5.88% These five stocks are part of our full Dividend Aristocrats List."
2021-05-26,117.5199966430664,116.75,-1.1196560329861234,What To Expect From Medtronic's Q4?,"(1) Revenues expected to be slightly below the consensus estimate Trefis estimates Medtronic’s Q4 fiscal 2021 total revenues to be around $8.10 billion, just a tad below $8.14 billion consensus estimates. 2) EPS likely to be below the consensus estimates Medtronic’s Q4 2021 earnings per share (EPS) is expected to be $1.37 per Trefis analysis, 3.5% below the consensus estimate of $1.42. (3) Stock price estimate slightly above the current market price Going by our Medtronic Valuation, with an EPS estimate of around $4.30 and P/E multiple of 31x in fiscal 2021, this translates into a price of $133, which is 5% above the current market price of around $127."
2021-05-25,118.0,118.4000015258789,-0.6552047864714056,2 High-Yield Dividend Stocks for 2021 | Is Lucira Health a Good Stock to Buy Right Now?,"Still, there are a few attractive high-yield dividend stocks in today's market, two of them being AbbVie (NYSE: ABBV) and Bristol Myers Squibb (NYSE: BMY). The company recently grew its dividend to $2.29 this past year, a 9.3% increase from 2019.I believe this will be the beginning of a set of high dividend increases for shareholders , given that management promised in the recent Q1 earnings report to accelerate debt repayments and continue growing its payout. See the 10 stocks *Stock Advisor returns as of May 11, 2021 Anirudh Shankar owns shares of AbbVie and Bristol Myers Squibb. | Abbott Laboratories' (NYSE: ABT) already-popular antigen-based test reached thousands of CVS pharmacies across the country, but Lucira's test didn't make the cut. Lucira Health's over-the-counter COVID-19 tests racked up millions of dollars in sales during the first three months of 2021, leading some investors to wonder if this beaten-down stock can bounce back. Reasons to buy Lucira Health now During the first three months of 2021, sales of over-the-counter test kits reached $5 million."
2021-05-24,118.04000091552734,117.29000091552734,0.3389843439651748,Is Abbott Laboratories (NYSE:ABT) Using Too Much Debt?,"NYSE:ABT Debt to Equity History May 24th 2021 A Look At Abbott Laboratories' Liabilities According to the last reported balance sheet, Abbott Laboratories had liabilities of US$12.5b due within 12 months, and liabilities of US$26.5b due beyond 12 months. As with many other companies Abbott Laboratories (NYSE:ABT) makes use of debt. The first step when considering a company's debt levels is to consider its cash and debt together."
2021-05-21,118.2300033569336,117.12999725341795,-0.6353778330929704,2 Stocks to Buy if a Market Crash Comes,"Abbott Laboratories The case for buying Abbott Laboratories (NYSE: ABT) after a correction or crash is a bit different than the case for Moderna. Similarly, dividend stocks are no-brainer buys after a crash, as investors get a higher yield for their dollar. Moderna Moderna (NASDAQ: MRNA) is a household name thanks to its blockbuster coronavirus vaccine, and it's also one of the hottest stocks of this year."
2021-05-20,116.5500030517578,117.8000030517578,-0.9303950539481477,,
2021-05-19,116.16000366210938,116.37999725341795,1.0725010444185894,Tech Stock Correction: Buy These 2 Healthcare Stocks on the Dip,"Abbott Abbott Laboratories' (NYSE: ABT) diversification makes it a great healthcare stock to own in good times and bad. Intuitive Surgical Intuitive Surgical (NASDAQ: ISRG) is the global leader in robotic surgery. With postponed surgeries being rescheduled and hospitals returning to normal business, revenue and profit should benefit in Intuitive's upcoming earnings reports."
2021-05-18,116.72000122070312,116.9800033569336,0.1893884162990432,Guardant Health Stock Looks Attractive After The Recent 16% Fall | Here's Why Sarepta Stock Looks Attractive At $75 Levels,"Lastly, GH stock has already seen a large correction in a matter of days, and using the recent trend (16% fall in a week) and ten years of historical stock data, the Trefis AI engine finds that GH stock will likely move higher over the next one month (twenty-one trading days). According to the Trefis Machine Learning Engine, which identifies trends in a company’s stock price using historical stock data, returns for GH stock average around 2.5% in the next one-month (twenty-one trading days) period after experiencing a 5% fall in a week (five trading days), slightly higher than the 1.9% expected return for the S&P500 over the next month (twenty-one trading days). Answer: Consider two situations, Case 1: Guardant Health stock drops by -5% or more in a week Case 2: Guardant Health stock rises by 5% or more in a week Is the average return for Guardant Health stock higher over the subsequent month after Case 1 or Case 2? | [Updated: 5/17/2021] SRPT Stock Update Last month we discussed why the stock price of Sarepta Therapeutics (NASDAQ:SRPT), a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, looked undervalued at $71, given the company’s solid pipeline. We believe that the stock price of Sarepta Therapeutics (NASDAQ:SRPT), a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, is undervalued at current levels of $71. At the current price of $71, SRPT stock is trading at just 9x its 2021 and 6x its 2022 RPS, compared to levels of 24x seen over the recent years, implying that SRPT stock is undervalued currently."
2021-05-17,118.0,116.73999786376952,0.22275713974577227,"Noteworthy ETF Inflows: SPYG, NFLX, ABT, DHR","Among the largest underlying components of SPYG, in trading today Netflix Inc (Symbol: NFLX) is off about 1.2%, Abbott Laboratories (Symbol: ABT) is off about 0.7%, and Danaher Corp (Symbol: DHR) is lower by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR— Portfolio S&P 500— Growth ETF (Symbol: SPYG) where we have detected an approximate $129.3 million dollar inflow -- that's a 1.3% increase week over week in outstanding units (from 175,550,000 to 177,750,000). For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $41.83 per share, with $61.09 as the 52 week high point — that compares with a last trade of $58.41."
2021-05-14,117.98999786376952,118.30999755859376,-1.0677984205343076,3 Dividend Stocks That Pay You Better Than Coca-Cola Does,"Chevron is poised to bounce back Last year was horrible for oil companies, but despite its lagging revenue, Chevron last month announced that it was raising its quarterly dividend by 4% to $1.34 per share, making this the 34th consecutive year that the company has hiked its payout. The company raised its quarterly payout by 6.5% to $1.14 per share this year, making 2021 its 49th consecutive year of dividend hikes. Over the past three years, Kimberly Clark has raised its dividend by a solid 14%, and with a cash dividend payout ratio of 66.56% (TTM), it has plenty of room to keep boosting it."
2021-05-13,117.0,117.4499969482422,0.2712091707923554,,
2021-05-12,117.16999816894533,116.3499984741211,0.3846127762753861,7 Great Growth Stocks to Consider for Your Short List,"Abbot Laboratories (NYSE:ABT) Apple (NASDAQ:AAPL) Broadcom (NASDAQ:AVGO) Nvidia (NASDAQ:NVDA) Paypal (NASDAQ:PYPL) Qualcomm (NASDAQ:QCOM) United Parcel Service (NYSE:UPS) The list is a little heavy on the tech side. Growth Stocks: Abbot Laboratories (ABT) Source: Sundry Photography/Shutterstock.com Abbot Laboratories produces a wide range of high-tech medical devices. Over the past five years, ABT stock has delivered a return of 216%."
2021-05-11,118.86000061035156,118.38999938964844,-0.6998375929321856,,
2021-05-10,119.1999969482422,118.94000244140624,-0.39542421192129157,Can Dexcom Stock Rebound After The Recent 11% Drop? | What's Next For Illumina Stock After The Recent 7% Drop?,"Five Days: DXCM -11%, vs. S&P500 -0.7%; Underperformed market (3% likelihood event) Dexcom stock declined 11% over a five-day trading period ending 5/5/2021, compared to the broader market (S&P500) decline of 0.7% A change of -11% or more over five trading days is a 3% likelihood event, which has occurred 76 times out of 2516 in the last ten years. Ten Days: DXCM -8.5%, vs. S&P500 0.4%; Underperformed market (11% likelihood event) Dexcom stock declined 8.5% over the last ten trading days (two weeks), compared to the broader market (S&P500) rise of 0.4% A change of -8.5% or more over ten trading days is a 11% likelihood event, which has occurred 268 times out of 2511 in the last ten years. Twenty-One Days: DXCM 5.4%, vs. S&P500 4.3%; Outperformed market (44% likelihood event) Dexcom stock rose 5.4% the last twenty-one trading days (1 month), compared to the broader market (S&P500) rise of 4.3% A change of 5.4% or more over twenty-one trading days is a 44% likelihood event, which has occurred 1107 times out of 2500 in the last ten years. | According to the Trefis Machine Learning Engine, which identifies trends in a company’s stock price using historical stock data, returns for ILMN stock average around 2.2% in the next one-month (twenty-one trading days) period after experiencing a 5% fall in a week (five trading days). Answer: Consider two situations, Case 1: Illumina stock drops by -5% or more in a week Case 2: Illumina stock rises by 5% or more in a week Is the average return for Illumina stock higher over the subsequent month after Case 1 or Case 2? Illumina’s revenue growth, operating income growth, and operating margins, all compare favorably with Boston Scientific over the recent years, and this has been rewarded by the investors in the form of a high multiple that ILMN stock trades at."
2021-05-07,119.7699966430664,118.9499969482422,-0.2181162025942484,,
2021-05-06,118.0500030517578,118.79000091552734,-0.6846453350649526,ABT June 25th Options Begin Trading,"Below is a chart showing ABT's trailing twelve month trading history, with the $120.00 strike highlighted in red: Considering the fact that the $120.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the June 25th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new June 25th contracts and identified one put and one call contract of particular interest."
2021-05-05,117.8000030517578,118.51000213623048,0.6268512025748115,Sum Up The Pieces: SPMO Could Be Worth $61,"Similarly, TYL has 13.09% upside from the recent share price of $415.03 if the average analyst target price of $469.38/share is reached, and analysts on average are expecting ABT to reach a target price of $132.50/share, which is 12.73% above the recent price of $117.54. Three of SPMO's underlying holdings with notable upside to their analyst target prices are General Motors Co (Symbol: GM), Tyler Technologies, Inc. (Symbol: TYL), and Abbott Laboratories (Symbol: ABT). Below is a twelve month price history chart comparing the stock performance of GM, TYL, and ABT: Below is a summary table of the current analyst target prices discussed above:"
2021-05-04,119.1999969482422,117.54000091552734,0.6027156757888472,Why Abbott Labs' Sizzling Growth Could Taper Off | 2 Top Stocks to Buy and Hold for 10 Years,"Abbott Laboratories (NYSE: ABT) reported its first-quarter results on April 20, 2021. In this Motley Fool Live video recorded on April 21, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss why Abbott's sizzling growth could taper off in the near future. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | Abbott Laboratories (NYSE: ABT) and Bristol Myers Squibb (NYSE: BMY) are two excellent candidates. In the first quarter ending March 31, the healthcare giant recorded revenue of $10.5 billion, which grew by 35.3% year over year and included $2.2 billion in coronavirus testing-related sales. While the company's revenue continues to face headwinds due to the impact of the COVID-19 pandemic, Bristol Myers Squibb boasts a rich lineup of products, including more than half a dozen blockbuster medicines."
2021-05-03,120.5500030517578,119.52999877929688,-1.3926141570587829,This Is Why Humira Isn't AbbVie's Biggest Problem Right Now,"The beginning of Imbruvica's end In 2015, AbbVie acquired Pharmacyclics for about $21 billion to gain rights to the portion of sales for Imbruvica, a new cancer drug that Johnson & Johnson (NYSE: JNJ) already owned part of. That's because it's a first-generation Bruton's tyrosine kinase (BTK) inhibitor that isn't nearly as targeted as next-generation BTK inhibitors from AstraZeneca (NASDAQ: AZN) and BeiGene (NASDAQ: BGNE). Don't panic Right now, you can find better pharma stocks to buy than AbbVie, but you shouldn't dump the stock if you're already holding it."
2021-04-30,120.5,120.08000183105467,-0.8461254638234952,Is it Time to Rotate to Health Care?,"XLV consists of many appealing stocks based on our fundamental analysis, Abbott Laboratories (ABT), Johnson & Johnson (JNJ), Medtronic (MDT), Pfizer (PFE), and United Health Group (UNH). The ETF is market-cap weighted with 51% of assets invested in the top-10 securities such as Abbot Laboratories (ABT), Johnson & Johnson (JNJ), and United Health Group (UNH). Beyond, ABT, JNJ, and UNH, the top positions include Strong Buy recommended on Eli Lilly (LLY), Medtronic (MDT), and Thermo Fisher Scientific (TMO)."
2021-04-29,121.5,121.01000213623048,-0.34854619829487693,Thermo Fisher profit beats estimates on vaccine-making demand surge,"As vaccinations gain steam across the globe, diagnostic companies like Abbott Laboratories ABT.N have seen demand easing for some of its COVID-19 tests, stoking fears of slowing growth for the business. Recasts lead, adds specialty diagnostics unit sales, share movement April 29 (Reuters) - Thermo Fisher Scientific Inc TMO.N beat first-quarter profit estimates on Thursday boosted by revenue at its life sciences unit, which makes raw materials used in COVID-19 vaccines, offsetting slowing demand for tests that detect the coronavirus. Sales at Thermo Fisher's specialty diagnostics unit, which makes tests for COVID-19, rose 68.6% to $1.62 billion, but missed analyst estimates of $1.83 billion."
2021-04-28,121.5199966430664,121.4499969482422,-0.40329042285556954,3 Top Healthcare Stocks to Buy and Hold for the Next 10 Years,"Three healthcare stocks you should be able to comfortably hold for at least the next decade are Abbott Laboratories (NYSE: ABT), Johnson & Johnson (NYSE: JNJ), and Intuitive Surgical (NASDAQ: ISRG). Johnson & Johnson A dividend payer with an even more storied history, Johnson & Johnson raised its payout in April for the 59th year in a row. Like Abbott, Johnson & Johnson is well-diversified and generates revenue from multiple areas -- this company will likely do well even if its vaccine struggles to generate the sales the company is hoping for."
2021-04-27,122.0,121.6999969482422,-0.05760343709505733,Can This Popular Reddit Stock Make You Rich?,"Its peers, such as Abbott Laboratories (NYSE: ABT), Dexcom, and Medtronic (NYSE: MDT), are all better capitalized and farther ahead in their technology. There were few better zero-to-hero penny stocks in 2020 than that of continuous glucose monitor (CGM) manufacturer Senseonic Holdings (NYSEMKT: SENS). The bull case for Senseonic Back in September, Senseonic received a life-saving $35 million cash infusion from Ascensia to resume the commercialization of its GCM device, Eversense."
2021-04-26,123.38999938964844,122.58000183105467,-0.24590414078508055,5 Dividend Growth Stocks With Upside To Analyst Targets,"Telephone & Data Systems Inc (Symbol: TDS) $23.78 $30.12 26.68% SEI Investments Co (Symbol: SEIC) $57.85 $71.00 22.73% ABM Industries, Inc. (Symbol: ABM) $53.52 $58.33 8.99% Abbott Laboratories (Symbol: ABT) $123.31 $132.50 7.45% Black Hills Corporation (Symbol: BKH) $69.56 $74.50 7.10% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Telephone & Data Systems Inc (Symbol: TDS) 2.94% 26.68% 29.62% SEI Investments Co (Symbol: SEIC) 1.28% 22.73% 24.01% ABM Industries, Inc. (Symbol: ABM) 1.42% 8.99% 10.41% Abbott Laboratories (Symbol: ABT) 1.46% 7.45% 8.91% Black Hills Corporation (Symbol: BKH) 3.25% 7.10% 10.35% Another consideration with dividend growth stocks is just how much the dividend is growing. Telephone & Data Systems Inc (Symbol: TDS) $0.665 $0.685 3.01% SEI Investments Co (Symbol: SEIC) $0.68 $0.72 5.88% ABM Industries, Inc. (Symbol: ABM) $0.73 $0.75 2.74% Abbott Laboratories (Symbol: ABT) $1.36 $1.62 19.12% Black Hills Corporation (Symbol: BKH) $2.08 $2.2 5.77% These five stocks are part of our full Dividend Aristocrats List."
2021-04-23,123.62000274658205,123.30999755859376,-0.65645316686963,Should You Buy Sarepta Stock At $71?,"We believe that the stock price of Sarepta Therapeutics (NASDAQ:SRPT), a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, is undervalued at current levels of $71. However, now that the stock has corrected (down 40% in the last one year) despite revenue growing 42% y-o-y over the last four quarters, we believe SRPT stock is likely to see higher levels. At the current price of $71, SRPT stock is trading at just 9x its 2021 and 6x its 2022 RPS, compared to levels of 24x seen over the recent years, implying that SRPT stock is undervalued currently."
2021-04-22,122.80999755859376,123.5,-0.2507726752148552,"Notable ETF Outflow Detected - IVV, T, ABT, CVX | Quest Diagnostics beats profit estimates as non-COVID-19 businesses recover | Which Stocks Are the Biggest Losers From Sinking COVID Testing Rates? | 3 Things to Cheer About in Abbott's Earnings Report","Among the largest underlying components of IVV, in trading today AT&T Inc (Symbol: T) is up about 5.1%, Abbott Laboratories (Symbol: ABT) is up about 0.9%, and Chevron Corporation (Symbol: CVX) is lower by about 1.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P 500 ETF (Symbol: IVV) where we have detected an approximate $1.2 billion dollar outflow -- that's a 0.4% decrease week over week (from 662,700,000 to 659,800,000). For a complete list of holdings, visit the IVV Holdings page » The chart below shows the one year price performance of IVV, versus its 200 day moving average: Looking at the chart above, IVV's low point in its 52 week range is $275 per share, with $419.48 as the 52 week high point — that compares with a last trade of $416.90. | Bigger rival Abbott Laboratories ABT.N also saw a drop in demand for its COVID-19 tests and fell short of its first-quarter revenue estimates on Tuesday. Compares with estimates, adds background April 22 (Reuters) - Medical device maker Quest Diagnostics Inc DGX.N beat first-quarter profit estimates on Thursday boosted by a recovery of its non-COVID-19-related businesses, which helped offset a fall in demand for its coronavirus testing services. Quest also raised its profit forecast for the first half of 2021 to between $6.30 and $6.80 per share, from earlier expectations $5.90 to $6.90 per share. | Obviously, there's plenty of other test makers, Abbott (NYSE: ABT) comes to mind, Becton, Dickenson (NYSE: BDX). Abbott and Becton and Dickinson, ABT and BDX there. In this Motley Fool Live video recorded on April 14, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss which stocks could be the biggest losers from this trend. | Abbott Laboratories (NYSE: ABT) disappointed some investors after first-quarter revenue lagged behind analysts' estimates. ABT Revenue (Quarterly) data by YCharts Another big positive is the fact that Abbott is on track to meet its goal of 35% earnings-per-share growth for the full year 2021. Investors probably were hoping that Abbott's coronavirus diagnostics along with the strength of its star product -- the FreeStyle Libre continuous glucose monitoring system -- would offer revenue a bigger push."
2021-04-21,120.43000030517578,122.5999984741211,0.5618454972096464,Validea Peter Lynch Strategy Daily Upgrade Report - 4/21/2021,"Detailed Analysis of FARMERS & MERCHANTS BANCORP INC Full Guru Analysis for FMAO Full Factor Report for FMAO ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES Full Guru Analysis for ABT Full Factor Report for ABT KEYCORP (KEY) is a large-cap value stock in the Regional Banks industry. The Company provides a wide range of specialty construction services, fabrication, maintenance, replacement, procurement and engineering services through its three segments: Utilities Segment, Energy Segment and Pipeline Services Segment."
2021-04-20,120.5,120.0,1.8018750838216606,"Abbott Laboratories Shares Sink on Mixed Q1; New Dividend Declared | Abbott Laboratories (ABT) Q1 2021 Earnings Call Transcript | Abbott's Sales Soared in Q1, but Not Enough to Satisfy Wall Street | Health Care Sector Update for 04/20/2021: ABT, JNJ, CRSP, VRTX, XLV, IBB | US STOCKS-Wall St headed for lower open as focus turns to tech earnings | Abbott first-quarter profit surges on COVID-19 test demand | Abbott Laboratories Backs FY21 Outlook - Quick Facts | Abbott Laboratories Q1 21 Earnings Conference Call At 9:30 AM ET | What To Expect From Intuitive Surgical's Q1?","That seemed to be the dynamic behind Abbott Laboratories (NYSE: ABT) on Tuesday, following the release of its Q1 of fiscal 2021 results. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! | Operator [Operator Closing Remarks] Duration: 57 minutes Call participants: Scott Michael Leinenweber -- Vice President of Investor Relations, Licensing and Acquisitions Robert B. Ford -- President and Chief Executive Officer Robert E. Funck -- Executive Vice President, Finance and Chief Finance Officer Bob Hopkins -- Bank of America -- Analyst Robbie Marcus -- JP Morgan -- Analyst Larry Biegelsen -- Wells Fargo -- Analyst Vijay Kumar -- Evercore ISI -- Analyst Matt Miksic -- Credit Suisse -- Analyst Matt Taylor -- UBS -- Analyst Joanne Wuensch -- Citibank -- Analyst Josh Jennings -- Cowen -- Analyst More ABT analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Abbott Laboratories (NYSE: ABT) Q1 2021 Earnings Call Apr 20, 2021, 9:30 a.m. Strong sales growth across all four of our major business areas, which resulted in base business organic sales growth excluding COVID testing related sales of nearly 6%. | Abbott Laboratories (NYSE: ABT) entered 2020 as a strong and growing business. Abbott's medical device segment generated sales of $3.3 billion, up 13.1% year over year. With its solid growth prospects and strong dividend, Abbott still appears to be a stock that can make investors richer in the coming months. | Abbott Laboratories (ABT) was shedding more than 3%. The Health Care SPDR (XLV) was down 0.30% and the iShares NASDAQ Biotechnology Index (IBB) was unchanged recently. Johnson & Johnson (JNJ) was slightly declining after it reported Q1 adjusted earnings of $2.59 per share, up from $2.30 per share a year earlier. | Abbott Laboratories ABT.N fell 3%, despite posting a three-fold jump in quarterly profit. By Shivani Kumaresan April 20 (Reuters) - Futures pointed to a lower open for Wall Street's main indexes on Tuesday as investors banked on results from Netflix and other major technology-related companies this week to sustain the positive start to the earnings season. After blockbuster earnings from major U.S. banks last week, analysts expect first-quarter profit for overall S&P 500 firms to jump 30.9% from a year earlier, according to Refinitiv IBES data. | Adds background, forecast, segment growth April 20 (Reuters) - Abbott Laboratories ABT.N reported a more than threefold jump in quarterly profit on Tuesday, buoyed by robust demand for its COVID-19 test kits and a recovery in its medical devices business. In the latest quarter, Abbott's COVID-19 test kits generated sales of $2.2 billion and accounted for more than half of its diagnostic unit's revenue. Worldwide nutrition sales increased 6.9% in the quarter, while medical device sales increased 13.1%, led by Abbott's blood sugar monitoring device, FreeStyle Libre. | (RTTNews) - While reporting its financial results for the first quarter on Tuesday, Abbott Laboratories (ABT) maintained its earnings and adjusted earnings guidance for the full-year 2021. For fiscal 2021, the company continues to project earnings from continuing operations in a range of at least $3.74 per share and adjusted earnings from continuing operations of at least $5.00 per share, reflects a growth of more than 35 percent from last year. On average, analysts polled by Thomson Reuters expect the company to report earnings of $5.04 per share for the year. | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:30 AM ET on April 20, 2021, to discuss Q1 21 earnings results. To access the live webcast, log on to http://www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (1) Revenues expected to beat the consensus estimates Trefis estimates Intuitive Surgical’s Q1 2021 revenues to be around $1.2 Bil, slightly ahead of the $1.1 Bil consensus estimate. 2) EPS also likely to be ahead of consensus estimates Intuitive Surgical’s Q1 2021 adjusted earnings per share (EPS) is expected to be $2.72 per Trefis analysis, over 3% above the consensus estimate of $2.63. (3) Stock price estimate higher than the current market price Going by our Intuitive Surgical’s Valuation, with an EPS estimate of around $12.90 and a P/E multiple of around 67x in 2021, this translates into a price of $870, which is 8% above the current market price of around $805."
2021-04-19,123.5999984741211,124.52999877929688,-0.4149377593360996,"CVS Announces the Availability of Over-the-Counter COVID-19 Tests | Pre-Market Earnings Report for April 20, 2021 : JNJ, PG, ABT, PM, LMT, TRV, FITB, NTRS, DOV, KEY, OMC, CMA | Noteworthy Monday Option Activity: ABT, LNTH, AMAT | PREVIEW-Abbott's results a litmus test for COVID-19 testing demand | CVS to offer three over-the-counter COVID-19 tests for use at home | CVS to offer three over-the-counter COVID-19 tests for use at home | Abbott Begins Shipping BinaxNOW COVID-19 Ag Self Test To Retailers Today - Quick Facts | Here's Why We Think Abbott Stock Will Rise Post Q1","The products -- the Ellume COVID-19 Home Test, Abbott Laboratories' BinaxNOW Antigen Self Test, and the Pixel by Labcorp PCR Test Home Collection Kit -- are now available in a number of CVS locations. ""CVS Health has been a leader in providing accessible testing in communities nationwide, and we continue to bring new solutions to market to ensure that consumers have a variety of COVID-19 testing options available to them,"" said George Coleman, senior vice president and chief merchant of the CVS Pharmacy unit. 10 stocks we like better than CVS Health When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | Zacks Investment Research reports that the 2021 Price to Earnings ratio for ABT is 24.53 vs. an industry ratio of 10.60, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories (ABT) is reporting for the quarter ending March 31, 2021. In the past year ABT has beat the expectations every quarter. | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Abbott Laboratories (Symbol: ABT), where a total volume of 23,450 contracts has been traded thus far today, a contract volume which is representative of approximately 2.3 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 45.3% of ABT's average daily trading volume over the past month, of 5.2 million shares. Especially high volume was seen for the $124 strike put option expiring April 23, 2021, with 1,620 contracts trading so far today, representing approximately 162,000 underlying shares of ABT. | By Manojna Maddipatla April 19 (Reuters) - Investors will be squarely focused on Abbott Laboratories ABT.N results on Tuesday to assess the impact of swift vaccination rollout on demand for the company's COVID-19 tests. Diagnostic test makers such as Abbott, Becton Dickinson BDX.N and Quest Diagnostics Inc DGX.N have relied on brisk sales of COVID-19 molecular and antigen tests to offset soft demand for routine testing and medical devices due to pandemic-induced restrictions on movement. 31 2020 0.58 0.65 Beat UPDATE 3-Abbott's profit forecast gets a lift from COVID-19 test demand UPDATE 3-Quest expects demand for COVID-19 tests to wane as vaccine rollout gathers steam UPDATE 3-Becton Dickinson lifts 2021 profit forecast on robust COVID-19 test demand UPDATE 1-Roche test boss says COVID rapid test effectiveness to wane as shots increase COVID-19 testing engines Abbott's diagnostics sales growth COVID-19 testing engines Abbott's diagnostics sales growthhttps://tmsnrt.rs/3v1jgzZ COVID-19 testing engines Abbott's diagnostics sales growth COVID-19 testing engines Abbott's diagnostics sales growthhttps://tmsnrt.rs/3v2UPCe Abbott, Quest Diagnostics share performance in the past 12 months Abbott, Quest Diagnostics share performance in the past 12 monthshttps://tmsnrt.rs/3tzf3TR (Reporting by Manojna Maddipatla in Bengaluru; Editing by Anil D'Silva) ((manojna.kalyani@thomsonreuters.com; +91 8061822700;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | CVS said it was offering tests from Australian diagnostic test maker Ellume, Abbott Laboratories ABT.N and LabCorp LH.N that do not require a prescription and can be used by individuals with or without symptoms. Adds Walgreens, Walmart update on Abbott test April 19 (Reuters) - CVS Health Corp CVS.N said on Monday it would offer three over-the-counter COVID-19 tests at its drugstores as well as online, expanding access to home testing in the United States. Walmart will sell the test online and in stores for $19.88 per kit, while Walgreens said the test can initially be purchased online and in-store later this week. | The company said the tests include a home test by Australian diagnostic test maker Ellume, Abbott Laboratories' ABT.N BinaxNOW antigen self-test and LabCorp's LH.N home collection kits, all of which do not require a prescription, and can be used by individuals with or without symptoms. April 19 (Reuters) - CVS Health Corp CVS.N said on Monday it would offer three over-the-counter COVID-19 tests at its drugstores as well as online, expanding access to home testing as the United States speeds up its vaccine rollout. CVS is the first drug retailer to offer Ellume's test, the company said, adding that the test will be available in select pharmacy locations in Rhode-Island and Massachusetts from this week, and at CVS.com and most pharmacy stores by the end of May. | (RTTNews) - Abbott Laboratories (ABT) announced Monday that it began shipping its BinaxNOW COVID-19 Ag Self Test to retailers across the country. BinaxNOW is the most studied and widely available rapid antigen test in the U.S. and initially will be available at CVS Pharmacy, Walgreens and Walmart without a prescription. The BinaxNOW Self Test, which can be purchased over the counter without a prescription, will be sold in 2-count packs for an MSRP of $23.99, making it the most affordable over-the-counter (OTC) COVID-19 rapid test available in the U.S. Abbott said it will manufacture tens of millions of BinaxNOW Self Tests per month and can scale capacity upward based on demand. | Abbott stock (NYSE: ABT) is scheduled to report its Q1 2021 results on Tuesday, April 20. At current levels of $122, Abbott is trading at 23x its expected EPS of $5.25 in 2021, and the 23x figure compares with levels of 30x seen as recent as late 2020, and 27x seen in late 2019, implying there is more room for growth for ABT stock. \n\nBased on article theme, variations to \""While may have moved\"" can be (a) While may be overvalued (or undervalued) (b) While can move (c) Although may not be attractive (d) While is worth considering""}"" data-sheets-userformat=""{""2"":1049345,""3"":{""1"":0},""11"":4,""12"":0,""23"":1}"" data-sheets-textstyleruns=""{""1"":0}{""1"":210,""2"":{""2"":{""1"":2,""2"":1136076},""5"":1,""9"":1}}{""1"":225}{""1"":229,""2"":{""4"":8}}{""1"":267,""2"":{""4"":8,""6"":1}}{""1"":299,""2"":{""4"":8}}"" data-sheets-hyperlinkruns=""{""1"":210,""2"":""https://dashboards.trefis.com/data/companies/PFE/no-login-required/HMIwIvym/Pfizer-vs-Merck-PFE-stock-s-similar-valuation-vs-MRK-stock-is-counter-intuitive""}{""1"":225}"">While ABT stock may be undervalued, 2020 has created many pricing discontinuities which can offer attractive trading opportunities."
2021-04-16,124.38999938964844,124.3499984741211,0.7524274406609327,,
2021-04-15,122.4000015258789,123.94000244140624,-0.03215766196930504,Medtronic Is Healing Hearts and Padding Portfolios,"Major players such as Abbott Laboratories (NYSE: ABT), EBR Systems, and Boston Scientific (NYSE: BSX) are working on continued advancements in pacemakers, including leadless devices. Technological evolution As one of the big names in the MedTech space -- and commonly synonymous with pacemakers -- Medtronic is actively developing new devices to provide more treatment options to more patients. Micra continues to perform extremely well, with 64% growth globally, including 76% growth in the U.S. Medtronic is looking forward to sales growth from Micra AV, noting the potential for a Micra target population from approximately 15% to 55% of pacemaker patients, driving market expansion and share gains."
2021-04-14,122.5500030517578,121.5,1.2581706669355954,"XLV, ABT, PFE, MDT: ETF Outflow Alert | Follow Warren Buffett Into These 3 Pharma Companies","Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.4%, Pfizer Inc (Symbol: PFE) is up about 0.2%, and Medtronic PLC (Symbol: MDT) is higher by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR— Fund (Symbol: XLV) where we have detected an approximate $94.8 million dollar outflow -- that's a 0.4% decrease week over week (from 210,920,000 to 210,120,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $95.285 per share, with $118.9856 as the 52 week high point — that compares with a last trade of $118.98. | Three undervalued plays with little downside When Warren Buffett invests in stocks, he looks at something called a margin of safety -- the difference between a company's current price and its average market valuation. Declining or stagnating stock prices can suggest to investors that something is wrong with a business, but it's also possible that the market has simply mispriced a stock, making for a great opportunity to pick up shares on the cheap. See the 10 stocks *Stock Advisor returns as of February 24, 2021 Anirudh Shankar owns shares in AbbVie, Bristol-Myers Squibb, Merck, and Johnson & Johnson."
2021-04-13,121.0500030517578,123.01000213623048,-0.8567956145332283,"Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for April 14, 2021","Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. The following ETF(s) have ABT as a top-10 holding: iShares U.S. ETF Trust (IEHS) Invesco Dynamic Pharmaceuticals ETF (PJP) SPDR Select Sector Fund - Health Care (XLV) iShares U.S. Healthcare ETF (IYH) iShares U.S. Medical Devices ETF (IHI)."
2021-04-12,120.55999755859376,121.04000091552734,1.619164836893594,,
2021-04-09,119.6500015258789,120.9000015258789,0.3981447964946179,Abbott Laboratories (NYSE:ABT) Goes Ex-Dividend Soon,"It looks like Abbott Laboratories (NYSE:ABT) is about to go ex-dividend in the next 4 days. NYSE:ABT Historic Dividend April 9th 2021 Have Earnings And Dividends Been Growing? So we need to investigate whether Abbott Laboratories can afford its dividend, and if the dividend could grow."
2021-04-08,121.01000213623048,119.77999877929688,1.0447137351098483,Abbott Gets CE Mark Approval For Next-Generation TriClip Device - Quick Facts,"(RTTNews) - Abbott (ABT) has received CE Mark for its next-generation TriClip Transcatheter Tricuspid Valve Repair System, the minimally invasive tricuspid heart valve repair device available in Europe to treat tricuspid regurgitation. The company noted that TriClip and TriClip G4 Transcatheter Tricuspid Valve Repair Systems are approved for investigational use only in the U.S. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2021-04-07,119.81999969482422,120.11000061035156,-1.0164476780596172,,
2021-04-06,120.01000213623048,119.97000122070312,0.24203047593553845,Abbott: XIENCE Stent Gets CE Mark In Europe For Shorter Duration Of Dual Anti-platelet Therapy | Despite A 2X Rise Over The Last Year Abbott Stock Still Looks Attractive At $120,"(RTTNews) - Abbott (ABT) said its XIENCE stent has received CE Mark in Europe for shorter duration of dual anti-platelet therapy - as short as 28 days for patients with high bleeding risk. ""In patients with high bleeding risk, the XIENCE stent has proven that it can ensure patient safety without compromising efficacy when duration of blood-thinning medications is shortened,"" said Nick West, chief medical officer and divisional vice president of global medical affairs at Abbott's vascular business. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs (NYSE: ABT) looks attractive at current levels of $120, despite the stock rising 2x from levels of $62 it was at on March 23, 2020, when broader markets made a bottom due to the spread of Covid-19. Now, given the strong earnings growth expected over the coming years from Abbott, we believe the company’s P/E multiple will also expand, resulting in appreciation of ABT stock. Looking at a longer time period, ABT stock is up 66% from levels seen toward the end of 2018."
2021-04-05,119.6500015258789,119.86000061035156,-0.03333131806959769,"Noteworthy ETF Outflows: XLV, ABT, MDT, LLY","Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.6%, Medtronic PLC (Symbol: MDT) is up about 0.5%, and Lilly (Eli) & Co (Symbol: LLY) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR— Fund (Symbol: XLV) where we have detected an approximate $454.0 million dollar outflow -- that's a 1.8% decrease week over week (from 214,720,000 to 210,820,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $89.14 per share, with $118.9856 as the 52 week high point — that compares with a last trade of $117.11."
2021-04-01,120.27999877929688,118.94000244140624,0.1755111423272618,Abbott’s BinaxNOW COVID-19 Ag Self Test Cleared For Emergency Use In US,"Abbott (ABT) expects the shipping of the tests to major food, drug and mass merchandiser retailers to begin in the coming weeks and the test to be accessible through some of their online store websites at a reasonable price. According to Bedford, “ABT has paused on concerns around 1) the slowdown in CV-testing and 2) their perceived ability to drive double-digit EPS growth in 2022.” “We are comfortable with these concerns, and believe this dynamic is more than accounted for in the valuation, which, on a relative basis, is as attractive as it has been in three years,” the analyst added. The BinaxNOW professional test was launched nationwide in Aug. 2020 and Abbott increased the production at its new US manufacturing facilities to produce 50 million tests per month."
2021-03-31,120.0,119.83999633789062,-1.1140641432408174,Abbott's BinaxNOW COVID-19 Ag Self Test Receives FDA EUA To Detect COVID-19 Infection | U.S. okays Abbott's rapid COVID-19 test for at-home screenings in those without symptoms,"(RTTNews) - Abbott (ABT) said Wednesday that it has received U.S. Food and Drug Administration Emergency Use Authorization for over-the-counter, non-prescription, asymptomatic use of its BinaxNOW COVID-19 Ag Self Test for detection of COVID-19 infection. The BinaxNOW Self Test is the same technology as the existing BinaxNOW test that has been available since August 2020 but is indicated by the FDA for serial asymptomatic testing, meaning that people should test themselves frequently. BinaxNOW demonstrates overall performance of 84.6% positive agreement (sensitivity) and 98.5% negative agreement (specificity) in people seven days or less post-symptom onset at all Ct counts. | By Carl O'Donnell March 31 (Reuters) - Abbott Laboratories ABT.N said on Wednesday that U.S. regulators have cleared its rapid COVID-19 antigen test for over-the-counter, at-home use in people without symptoms, making the cheap and abundant tests more easily available for regular screening at schools and workplaces. ""We've now accomplished what we set out to do when we launched BinaxNOW, which is to bring an accurate, affordable and readily available test to the American people that they can have on hand,"" Chief Executive Officer Robert Ford said in a statement. Demand for COVID-19 tests is increasing as more schools and employers resume in-person operations, Quidel Corp Chief Executive Douglas Bryant said, adding that the White House's recent $10 billion funding package to help schools afford tests has also boosted demand."
2021-03-30,121.5,119.75,-0.13333638509114584,These 3 Stocks Will Make You Rethink Your Portfolio,"You can do well by going against the conventional wisdom when considering these companies: Quidel (NASDAQ: QDEL) is not just a COVID stock; Abbott Laboratories (NYSE: ABT) is not just a solid pharmaceutical company with a nice dividend; and CVS Health (NYSE: CVS) is diversified enough to thrive even amid rising competition from e-pharmacies. COVID-19 had a big impact on the company's pharmaceutical and retail sales in 2020, yet CVS came through the year with revenue growth of 4.6% to $268.7 billion, and net income of $7.2 billion compared to $6.6 billion in 2019. Growth in the company's top-performing segment, health care benefits, seems to be accelerating: Last year, its revenue rose 8.4% to $75.4 billion, and fourth-quarter revenue of $19.1 billion was up 11.4% year over year."
2021-03-29,121.0,122.2300033569336,-1.440329218106996,"Intercontinental Exchange Achieves #21 Analyst Rank, Surpassing Abbott Laboratories","In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Intercontinental Exchange Inc (Symbol: ICE) has taken over the #21 spot from Abbott Laboratories (Symbol: ABT), according to ETF Channel. Below is a chart of Intercontinental Exchange Inc versus Abbott Laboratories plotting their respective rank within the S&P 500 over time (ICE plotted in blue; ABT plotted in green): Below is a three month price history chart comparing the stock performance of ICE vs. ABT: ICE is currently trading off about 0.6%, while ABT is up about 0.1% midday Monday. Favorites » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2021-03-26,119.27999877929688,122.06999969482422,1.0165316999451188,"Covid Fatigue Threatens to Derail Once Relevant Quidel | Noteworthy ETF Outflows: IXJ, JNJ, ABT, GILD | Got $1,400? 3 COVID Stocks to Buy and Hold for the Long Term | Here's Why We Believe Boston Scientific Is A Better Pick Over Illumina Stock","That’s a huge blow for multiple transportation, lodgings and service-related businesses but it also negatively impacts QDEL stock and related investments like Abbott Laboratories (NYSE:ABT). InvestorPlace - Stock Market News, Stock Advice & Trading Tips As one of the more intriguing narratives during this novel coronavirus pandemic, Quidel (NASDAQ:QDEL), a medical diagnostics firm, is relevant so long as this health crisis stays front and center. Why You Don’t Want to Rush into QDEL Stock Recently, I had an interesting discussion with a cineplex manager who reported a significant uptick in business near the Seattle, Washington area. | Among the largest underlying components of IXJ, in trading today Johnson & Johnson (Symbol: JNJ) is down about 0.1%, Abbott Laboratories (Symbol: ABT) is up about 0.1%, and Gilead Sciences Inc (Symbol: GILD) is higher by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Global Healthcare ETF (Symbol: IXJ) where we have detected an approximate $34.3 million dollar outflow -- that's a 1.3% decrease week over week (from 35,550,000 to 35,100,000). For a complete list of holdings, visit the IXJ Holdings page » The chart below shows the one year price performance of IXJ, versus its 200 day moving average: Looking at the chart above, IXJ's low point in its 52 week range is $57.90 per share, with $79.80 as the 52 week high point — that compares with a last trade of $76.35. | Abbott Labs Abbott Labs (NYSE: ABT) achieved remarkable success in developing and marketing diagnostic tests for COVID-19. Look for that dividend to continue to increase: Abbott ranks as a Dividend Aristocrat, with 49 consecutive years of dividend hikes. Johnson & Johnson Johnson & Johnson (NYSE: JNJ) boasts an even more impressive dividend track record than Abbott. | Our dashboard Boston Scientific vs. Illumina: BSX stock looks undervalued compared to ILMN stock has more details on this. Operating Income Boston Scientific’s operating income declined from $1.4 billion in 2017 to $-0.5 billion in 2020, due to a sharp decline in operating margins from 15% in 2017 to -5% in 2020, due to increased operating costs during the pandemic and increased R&D investments. Illumina’s revenue growth, operating income growth, and operating margins, all compare favorably with Boston Scientific over the recent years, and this has been rewarded by the investors in the form of a high multiple that ILMN stock trades at."
2021-03-25,118.7300033569336,119.0500030517578,2.3390349967136292,Should You Buy Medtronic At $117?,"Medtronic (NYSE: MDT) looks attractive at current levels of $117, as it is up 60% from the levels it was at on March 23, 2020, when broader markets made a bottom due to the spread of Covid-19. For Medtronic, its Diabetes Group segment has been the key growth driver, with sales growth of 11% between 2018 and 2020. Looking at valuation, at the current price of $117, Medtronic is trading at 20x its estimated adjusted EPS of around $5.72 in fiscal 2022, compared to levels of 22x seen as recent as late 2020, implying there is more room for growth for MDT stock."
2021-03-24,120.0,118.0199966430664,0.2695188122434406,Should You Buy Sarepta Therapeutics Stock For 50% Gains?,"Finally, after the January developments, many analysts cut their price targets for SRPT stock, but still the average price estimate stands at $130, implying a potential premium of over 50% to the current stock price of $83. In contrast, here is how SRPT stock and the broader market fared during the 2007-08 crisis Timeline of 2007-08 Crisis 10/1/2007: Approximate pre-crisis peak in S&P 500 index 9/1/2008 – 10/1/2008: Accelerated market decline corresponding to Lehman bankruptcy filing (9/15/08) 3/1/2009: Approximate bottoming out of S&P 500 index 12/31/2009: Initial recovery to levels before accelerated decline (around 9/1/2008) SRPT and S&P 500 Performance Over 2007-08 Financial Crisis SRPT stock plummeted from from levels of about $15 in October 2007 (pre-crisis peak for the broader markets) to levels of under $7 in September 2008 before plunging to under $4 in March 2009 (as the markets bottomed out), implying SRPT stock lost 77% from its peak. Conclusion Phases of Covid-19 Crisis: Early- to mid-March 2020: Fear of the coronavirus outbreak spreading rapidly translates into reality, with the number of cases accelerating globally Late-March 2020 onward: Social distancing measures + lockdowns April 2020: Fed stimulus suppresses near-term survival anxiety May-June 2020: Recovery of demand, with gradual lifting of lockdowns – no panic anymore despite a steady increase in the number of cases July-October 2020: After poor Q2 results, Q3 expectations were lukewarm, but continued improvement in demand, and progress with vaccine development aided stock indices growth."
2021-03-23,121.7699966430664,120.48999786376952,-1.6500027974446614,Roche test boss says COVID rapid test effectiveness to wane as shots increase,"Roche has rapid antigen tests, via its South Korean partner SD Biosensor Inc, as well as its own PCR tests that compete with diagnostics from rivals including Abbott Laboratories ABT.N. Rapid antigen tests are reasonably accurate in detecting COVID-19 infections, especially compared to the flu, since viral loads in respiratory passageways are higher, Schinecker said on an investor call. Schinecker expected the global PCR testing market for COVID-19 to be ""a bit bigger"" than existing annual flu testing, now in the low single-digit billions of dollars every year."
2021-03-22,120.26000213623048,121.47000122070312,-1.0511610532837872,,
2021-03-19,118.37999725341795,120.25,1.0061525552793151,This Is Why Abbott Labs Is a Great Stock to Buy Right Now | Here's Why Medtronic Is A Better Pick Over Intuitive Surgical Stock,"But Abbott Laboratories (NYSE: ABT) managed to flourish despite of this drag on its medical-device business. ABT Net Income (Annual) data by YCharts. Quick, cheap, and portable One of Abbott's newer tests also is a reason to expect revenue growth. | We understand that the market for robotic assisted surgeries is huge, but for a company like Medtronic, it shouldn’t be tough to gain some of the market share from Intuitive Surgical, given Medtronic’s size and its strong global reach. Looking at Intuitive Surgical, the operating income declined from $1.1 billion in 2018 to $1.0 billion in 2020, as revenue growth was more than offset by margin contraction. Intuitive Surgical’s revenue growth, operating income, and operating margins, all compare favorably with Medtronic over the recent years, and this has been rewarded by the investors in the form of a high multiple that ISRG stock trades at."
2021-03-18,117.5,118.11000061035156,1.5796610829267892,"November 19th Options Now Available For Abbott Laboratories (ABT) | UPRO, JNJ, ABT, CVX: ETF Outflow Alert","Below is a chart showing ABT's trailing twelve month trading history, with the $120.00 strike highlighted in red: Considering the fact that the $120.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the November 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new November 19th contracts and identified one put and one call contract of particular interest. | Among the largest underlying components of UPRO, in trading today Johnson & Johnson (Symbol: JNJ) is down about 0.3%, Abbott Laboratories (Symbol: ABT) is off about 0.1%, and Chevron Corporation (Symbol: CVX) is lower by about 1.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the ProShares ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $94.9 million dollar outflow -- that's a 4.5% decrease week over week (from 23,200,000 to 22,150,000). For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $17.51 per share, with $90.95 as the 52 week high point — that compares with a last trade of $88.83."
2021-03-17,117.66999816894533,117.62000274658205,0.519149455618351,2 Hot Growth Stocks That Could Be Millionaire-Makers,"Let's take a look at two companies that have what it takes to shatter the broader market for many years to come: Tandem Diabetes Care (NASDAQ: TNDM) and Pinterest (NYSE: PINS). For the full fiscal year 2020, Tandem's sales jumped by 38% year over year to $498.8 million. During the fourth quarter of its fiscal 2020, which ended Dec. 31, the company's revenue jumped by about 76% year over year to $705.6 million."
2021-03-16,118.4499969482422,118.22000122070312,-0.042487824544281926,"Fonterra to sell China JV farms, Beingmate stake as profit jumps 43% | These 3 Zero-Effort Stocks Could Make You Rich","Fonterra owns a farming hub in China's Shandong province along with its joint venture partner, Abbott Laboratories ABT.N. Company warns of margin pressure in second half Reaffirms full-year earnings forecast New throughout, adds details on China reorganisation, analyst comment March 17 (Reuters) - New Zealand's Fonterra FCG.NZ said on Wednesday it will sell its joint venture farms in China and its remaining stake in infant formula maker Beingmate 002570.SZ as it looks to move its focus from Beijing and prioritise domestic operations. Fonterra also posted half-year results, with a 43% surge in adjusted profit due to robust demand from China and firmer global dairy prices. | Abbott Abbott Laboratories (NYSE: ABT) became a leader in COVID-19 testing as the U.S. Food and Drug Administration authorized several of its diagnostics last year. The company aims to double revenue of the men's line, double digital revenue, and quadruple international revenue -- all by 2023. Find out why Amazon is one of the 10 best stocks to buy now Motley Fool co-founders Tom and David Gardner have spent more than a decade beating the market."
2021-03-15,117.19000244140624,118.0999984741211,-0.19417115531001275,EXCLUSIVE-Colombian softgel maker Procaps in talks to go public on Nasdaq -sources,"Procaps' investors include the World Bank's International Finance Corporation (IFC) and Alejandro Weinstein, who was previously CEO of generic drugmaker CFR Pharmaceuticals SA which was acquired by Abbott Laboratories ABT.N in 2014. is in talks to go public on Nasdaq through a merger with U.S. blank-check company Union Acquisition Corp II LATN.O in a deal which would value it at more than $1 billion, people familiar with the matter said on Monday. Union Acquisition Corp II is in the process of engaging with potential investors to raise a $100 million private investment in public equity, or PIPE, which would provide additional funding to Procaps, the sources said."
2021-03-12,117.08999633789062,116.70999908447266,0.7765133661208399,,
2021-03-11,116.69000244140624,117.5199966430664,-0.3245343456339324,Interesting ABT Put And Call Options For April 30th | Abbott Pandemic Defense Coalition Formed For Early Detection Of Future Pandemic Threats,"Below is a chart showing ABT's trailing twelve month trading history, with the $117.00 strike highlighted in red: Considering the fact that the $117.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the April 30th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new April 30th contracts and identified one put and one call contract of particular interest. | (RTTNews) - Abbott (ABT) said that it has formed Abbott Pandemic Defense Coalition, which is a first-of-its-kind global scientific network dedicated to the early detection of, and rapid response to, future pandemic threats. Abbott noted that the coalition builds on its decades of leadership in virus surveillance and helps to analyze virus samples for unknown diseases and detect mutations and variants including for COVID-19. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2021-03-10,117.23999786376952,115.87999725341795,0.7112813302724343,,
2021-03-09,116.73999786376952,116.6999969482422,-1.1600141889561064,"IHI, ABT, TMO, DHR: Large Outflows Detected at ETF | How The Parts Add Up: SPHQ Targets $47 | Warren Buffett Just Bought These 3 High-Yield Dividend Stocks. Should You?","Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is up about 3%, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 4.3%, and Danaher Corp (Symbol: DHR) is higher by about 2.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $301.9 million dollar outflow -- that's a 3.6% decrease week over week (from 26,350,000 to 25,400,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $183.25 per share, with $351.615 as the 52 week high point — that compares with a last trade of $326.52. | Similarly, XLNX has 14.79% upside from the recent share price of $112.09 if the average analyst target price of $128.67/share is reached, and analysts on average are expecting ABT to reach a target price of $128.92/share, which is 11.50% above the recent price of $115.63. Three of SPHQ's underlying holdings with notable upside to their analyst target prices are Teradyne, Inc. (Symbol: TER), Xilinx, Inc. (Symbol: XLNX), and Abbott Laboratories (Symbol: ABT). Below is a twelve month price history chart comparing the stock performance of TER, XLNX, and ABT: Below is a summary table of the current analyst target prices discussed above: | Although Verizon isn't a Dividend Aristocrat, it has increased its dividend payout for 14 years running. See the 10 stocks *Stock Advisor returns as of February 24, 2021 Keith Speights owns shares of AbbVie, Berkshire Hathaway (B shares), and Chevron. The Motley Fool recommends Verizon Communications and recommends the following options: short January 2023 $200 puts on Berkshire Hathaway (B shares), short March 2021 $225 calls on Berkshire Hathaway (B shares), and long January 2023 $200 calls on Berkshire Hathaway (B shares)."
2021-03-08,117.0,115.62999725341795,-0.034264961674913386,Abbott Announces U.S. Launch Of NeuroSphere Virtual Clinic | These Stocks Can Offer Higher Returns Compared To Abbott Labs,"(RTTNews) - Abbott (ABT) Monday announced the launch of NeuroSphere Virtual Clinic, a technology that allows patients to communicate with physicians and receive treatment remotely. ""With NeuroSphere Virtual Clinic, physicians can communicate and digitally prescribe new stimulation settings remotely, allowing them to extend care beyond their clinic walls and optimize therapy management,"" said Timothy Deer, M.D., DABPM, president and chief executive officer of The Spine and Nerve Center of the Virginias in Charleston, W.Va. ""This is a significant advancement for chronic pain patients."" ""We are continuing to make these kinds of investments and working with regulatory authorities to make these telehealth changes permanent, as we believe that patients should be able to receive the care they need, regardless of whether they can make it physically to the doctor's office,"" said Keith Boettiger, vice president, Neuromodulation, Abbott. | We believe that there are several stocks in the healthcare sector that are better than Abbott Labs (NYSE:ABT). Our dashboard Better Bet Than ABT Stock: Pay Less To Get More From EBS, VRTX, CORT has more details – parts of which are summarized below. Revenue Growth Abbott’s revenues grew at an average of 8.5% over the last three years, which compares with a 40% growth for Emergent, 36% growth for Vertex, and a large 59% figure for Corcept."
2021-03-05,117.0,117.25,-1.1709425184461928,Abbott's test to distinguish coronavirus and flu viruses gets U.S. authorization | Abbott Gets EUA For Laboratory PCR Assay That Detects Four Viruses In One Test,"adds details about test March 5 (Reuters) - Abbott Laboratories ABT.N said on Friday the U.S. health regulator has granted emergency use authorization for its molecular test to detect and distinguish the coronavirus and two types of flu viruses with a single test. The test, Alinity m Resp-4-Plex, can be conducted with one nasal swab sample and can differentiate the coronavirus, flu A, flu B and another respiratory virus called respiratory syncytial virus (RSV), the company said. Abbott has a range of COVID-19 tests, including antigen, molecular and serology tests which have been authorized for emergency use by the U.S. Food and Drug Administration. | (RTTNews) - Abbott (ABT) said that it has received emergency use authorization from the U.S. Food and Drug Administration for the company's Alinity m Resp-4-Plex molecular assay to detect and differentiate SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus or RSV in one test. The Alinity m Resp-4-Plex assay will allow healthcare workers to test for four viruses in one test, a critically important tool as flu presents with similar symptoms. Abbott also announced that the EUA for the company's Alinity m SARS-CoV-2 test has been updated to include an asymptomatic claim - detecting COVID-19 in individuals who do not have symptoms."
2021-03-04,119.0,116.01000213623048,0.2136752136752137,Should You Buy Invitae Stock?,"The company's biggest move last year was its purchase in October of ArcherDX, another genetic testing company that specialized in oncology, including personalized cancer monitoring and liquid and tissue biopsy analysis, for $1.4 billion in cash and stock. While some of Invitae's tests are covered by insurance carriers, the company said that for those whose insurance doesn't cover the costs, the tests can be as low as $99 for noninvasive prenatal screening and $250 for diagnostic, carrier, or proactive testing. Cautious investors may want to wait until they see Invitae's path toward profitability, but at its current price, this is an opportunity to buy on the dip before the company's shares rise again, especially as more people return to their regular doctors and create the opportunity and need for more genetic tests."
2021-03-03,121.69000244140624,119.18000030517578,-2.5126032468651407,What Should You Do With Owens & Minor Stock After A Large 35% Move In 5 Days?,"The stock price of Owens & Minor stock (NYSE:OMI), a global healthcare logistics company, has seen a large 35% rise over the last five trading days, while it’s up 25% over the last ten trading days, but we believe the stock, after the recent rally, may trend lower in the near term. Furthermore, the stock has already seen a sharp rally, implying some of the positives are now already priced in, and based on our machine learning analysis of trends in the stock price over the last few years, we believe that there is a strong chance of a drop in OMI stock over the next month (twenty-one trading days). Five Days: OMI 35%, vs. S&P500 1%; Outperformed market (2% likelihood event) Owens & Minor stock rose 35% over a five-day trading period ending 3/1/2021, compared to broader market (S&P500) rise of 1.0% A change of 35% or more over five trading days is a 2% likelihood event, which has occurred 25 times out of 1256 in the last five years Ten Days: OMI 25%, vs. S&P500 -0.5%; Outperformed market (10% likelihood event) Owens & Minor stock rose 25% over the last 10 trading days (2 weeks), compared to broader market (S&P500) decline of 0.5% A change of 25% or more over 10 trading days is a 10% likelihood event, which has occurred 131 times out of 1240 in the last five years While OMI stock may see a decline, 2020 has created many pricing discontinuities which can offer attractive trading opportunities."
2021-03-02,122.20999908447266,122.52999877929688,-2.0626198421181074,,
2021-03-01,120.98999786376952,122.20999908447266,0.2618441185021465,iShares S&P 500 Growth ETF Experiences Big Outflow,"Among the largest underlying components of IVW, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is up about 1.4%, AbbVie Inc (Symbol: ABBV) is up about 0.7%, and Abbott Laboratories (Symbol: ABT) is up by about 1.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 500 Growth ETF (Symbol: IVW) where we have detected an approximate $295.0 million dollar outflow -- that's a 0.9% decrease week over week (from 491,200,000 to 486,550,000). For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year price performance of IVW, versus its 200 day moving average: Looking at the chart above, IVW's low point in its 52 week range is $35.21 per share, with $67.5226 as the 52 week high point — that compares with a last trade of $64.61."
2021-02-26,122.19000244140624,119.77999877929688,1.0083488240712408,,
2021-02-25,121.66000366210938,121.58000183105467,-1.9723411195322873,,
2021-02-24,120.8000030517578,122.37999725341795,-0.0657585308618711,,
2021-02-23,122.25,120.8000030517578,1.3079421868749408,What To Expect From Medtronic Stock In Q3?,"(1) Revenues expected to be above the consensus estimate Trefis estimates Medtronic’s Q3 fiscal 2021 total revenues to be around $7.8 Bil, in-line with the consensus estimates. 2) EPS likely to be above the consensus estimates Medtronic’s Q3 2021 earnings per share (EPS) is expected to be $1.20 per Trefis analysis, 4% above the consensus estimate of $1.15. (3) Stock price estimate higher than the current market price Going by our Medtronic Valuation, with an EPS estimate of around $4.30 and P/E multiple of 30x in fiscal 2021, this translates into a price of $128, which is 8% above the current market price of around $115."
2021-02-22,122.9499969482422,122.5500030517578,-1.186091573204255,"Daily Dividend Report: ALL,ABT,WLK,CHE,LDOS","VIDEO: Daily Dividend Report: ALL,ABT,WLK,CHE,LDOS The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The Allstate board of directors has approved a quarterly dividend of $0.81 cents on each outstanding share of the corporation's common stock, payable in cash on April 1, 2021, to stockholders of record at the close of business on March 4, 2021. Abbott has increased its dividend payout for 49 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years."
2021-02-19,125.25,123.04000091552734,-0.32533054608597295,"Noteworthy ETF Inflows: ESGU, ABT, TMO, ABBV","Among the largest underlying components of ESGU, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.9%, Thermo Fisher Scientific Inc (Symbol: TMO) is down about 1.4%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares ESG Aware MSCI USA ETF (Symbol: ESGU) where we have detected an approximate $221.5 million dollar inflow -- that's a 1.6% increase week over week in outstanding units (from 155,900,000 to 158,350,000). For a complete list of holdings, visit the ESGU Holdings page » The chart below shows the one year price performance of ESGU, versus its 200 day moving average: Looking at the chart above, ESGU's low point in its 52 week range is $49.12 per share, with $91.34 as the 52 week high point — that compares with a last trade of $90.66."
2021-02-18,125.47000122070312,125.41000366210938,-1.7644703269242765,Interesting ABT Put And Call Options For April 16th,"Below is a chart showing ABT's trailing twelve month trading history, with the $130.00 strike highlighted in red: Considering the fact that the $130.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the April 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new April 16th contracts and identified one put and one call contract of particular interest."
2021-02-17,127.37000274658205,127.23999786376952,-0.04781824978881895,,
2021-02-16,128.49000549316406,128.02000427246094,-0.1020686818003677,,
2021-02-12,126.41000366210938,128.22999572753906,-0.36578815519478675,3 Top Healthcare Stocks to Buy in February,"Abbott Laboratories (NYSE: ABT), Teladoc Health (NYSE: TDOC), and CRISPR Therapeutics (NASDAQ: CRSP) are three stocks that neatly fit the bill. Abbott Laboratories Abbott Laboratories is a healthcare company with a presence across 160 countries and a business diversified across diagnostics, nutrition, medical devices, and pharmaceuticals segments. With the acquisitions of InTouch Health and Livongo Health, Teladoc Health's virtual care platform now caters to all aspects of healthcare, from acute care, to mental health, chronic care, complex care, primary care, specialty care, as well as wellness and prevention."
2021-02-11,125.69000244140624,126.83999633789062,1.4397531941336532,Forget Moderna! This Is a More Lucrative Coronavirus Stock | 4 Top COVID Stocks to Buy in February,"One such company is Abbott Laboratories (NYSE: ABT). The market research and consulting company, Grand View Research, estimates that this segment will expand at a compound annual growth rate of 3.1% between 2021 and 2027, and Abbott Laboratories is well-positioned to profit. A juicy dividend too There's another major reason why Abbott Laboratories is a more lucrative stock than Moderna: The medical-devices company is a Dividend Aristocrat, having increased its dividend for 49 years in a row; it currently offers a yield of 1.23%. | Abbott Abbott Laboratories (NYSE: ABT) has become a leader in coronavirus diagnostics. Here, I'll talk about two stocks cautious investors may consider buying this month -- and two stocks aggressive investors may consider. So far, for the full year 2021, Moderna has signed advanced purchase agreements totaling $11.7 billion in coronavirus vaccine sales."
2021-02-10,125.79000091552734,125.29000091552734,0.9149446050973622,Looking For The Best Health Care Stocks To Buy This Month? 4 To Consider,"For instance, medical technology companies like TransMedics (NASDAQ: TMDX) and Abbott Laboratories (NYSE: ABT) have skyrocketed in value over the past year. 4 Top Health Care Stocks To Watch This Month Health care stocks have been among the top performers on the stock market this year. Picking Out The Best Health Care Stocks From biotech companies to telehealth and commercial health care companies, there are plenty of options to choose from."
2021-02-09,124.83000183105467,125.1500015258789,-0.39748787372675876,This Stock Could Be a Surprise Growth Pick | Here's Why Investors Should Remember These 2 Healthcare Lessons in 2021 | Can DexCom Stock Gain More After A 10% Rise In Last 5 Days?,"I'm talking about healthcare giant Abbott Laboratories (NYSE: ABT). A surge in testing This surge in testing helped sales of Abbott's diagnostics business soar 111% in the fourth quarter and 40% for the year. And while Abbott's coronavirus testing had to compensate for flagging medical device sales this year, it probably won't have to do that again. | What do investors considering healthcare stocks like Intuitive Surgical (NASDAQ: ISRG), Abbott Labs (NYSE: ABT), and Johnson & Johnson (NYSE: JNJ) need to remember in 2021? See the 10 stocks *Stock Advisor returns as of November 20, 2020 Corinne Cardina: What are three takeaways for investors who are thinking about buying healthcare stocks? If you're an investor that gets nervous about day-to-day stock market fluctuations, you know this past week was a little bit nerve-racking, holding a strongly profitable company like Intuitive Surgical or Abbott Labs, or Johnson & Johnson, makes it a lot easier to take short-term market fluctuations in stride, and the best way to make money in stocks is to hold those stocks for a long time. | There is a 61% chance of a rise in DXCM stock over the next month (twenty one trading days) based on our machine learning analysis of trends in the stock price over the last five years. Check out the DXCM Stock AI Dashboard: Chances Of Rise And Fall for a variety of scenarios on how DXCM stock could move. 5D: DXCM 9.9%, vs. S&P500 2.4%; Outperformed market (7% likelihood event) DexCom stock rose 9.9% over a five-day trading period ending 2/4/2021, compared to the broader market (S&P500) rise of 2.4% A change of 9.9% or more over five trading days is a 7% likelihood event, which has occurred 94 times out of 1256 in the last five years 10D: DXCM 9.7%, vs. S&P500 0.7%; Outperformed market (30% likelihood event) DexCom stock rose 9.7% over the last ten trading days (two weeks), compared to broader market (S&P500) rise of 0.7% A change of 9.7% or more over ten trading days is a 30% likelihood event, which has occurred 380 times out of 1240 in the last five years While DXCM stock could gain more, 2020 has also created many pricing discontinuities which can offer attractive trading opportunities."
2021-02-08,125.0,124.5,0.2563483859091195,,
2021-02-05,120.43000030517578,124.02999877929688,-0.4,Here's the Best Dividend Aristocrat on the Market Right Now,"A healthcare giant After examining all of the current Dividend Aristocrats, I selected Abbott Laboratories (NYSE: ABT) as the best in the group. The company has increased its dividend for 49 years in a row and will probably move into the even more prestigious group of dividend stocks known as Dividend Kings -- S&P 500 members with at least 50 years of consecutive dividend increases -- later this year. What really sets Abbott apart Of course, other Dividend Aristocrats have great dividend track records (some even better than Abbott's)."
2021-02-04,119.83000183105467,119.73999786376952,2.9892871086926127,"Where to Invest $10,000 Right Now | 3 Dividend Stocks That Just Hiked Their Payouts by 20%","Abbott You might not think ""coronavirus stock"" when you first see Abbott Laboratories (NYSE: ABT). In the most recent quarter (ending Dec. 31, 2020), Abbott's sales rose more than 28% to $10.7 billion year over year. In the quarter ended Nov. 1, 2020, lululemon's revenue climbed 22% to $1.1 billion year over year. | And three stocks that recently hiked their payouts by at least 20% include Abbott Laboratories (NYSE: ABT), Nexstar Media (NASDAQ: NXST), and Reliant Bancorp (NASDAQ: RBNC). With a payout ratio -- the ratio of total dividends paid to net income -- of around 40%, Abbott has room to continue hiking its payouts but investors shouldn't get too accustomed to 25% increases: last year, the company raised its dividend by a more modest 12.5% which is still on the high side but a lot more reasonable. These types of increases aren't uncommon for Nexstar as last year it raised its payouts by 24% and in 2019 its dividend payments were 20% higher than the previous year."
2021-02-03,119.73999786376952,120.22000122070312,-0.07510971034787314,"Noteworthy ETF Inflows: ITOT, ABT, TMO, ABBV | AbbVie profit beats expectations on Humira demand | AbbVie revenue beats expectations on Humira demand","Among the largest underlying components of ITOT, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.4%, Thermo Fisher Scientific Inc (Symbol: TMO) is down about 1.5%, and AbbVie Inc (Symbol: ABBV) is up by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P Total U.S. Stock Market ETF (Symbol: ITOT) where we have detected an approximate $283.8 million dollar inflow -- that's a 0.9% increase week over week in outstanding units (from 375,000,000 to 378,200,000). For a complete list of holdings, visit the ITOT Holdings page » The chart below shows the one year price performance of ITOT, versus its 200 day moving average: Looking at the chart above, ITOT's low point in its 52 week range is $48.52 per share, with $89.64 as the 52 week high point — that compares with a last trade of $88.55. | Adds details on botox sales, profit estimates, share movement Feb 3 (Reuters) - AbbVie Inc ABBV.N forecast annual profit above expectations and beat quarterly estimates on Wednesday on higher demand for its blockbuster drug Humira as well as newer treatments for psoriasis and rheumatoid arthritis, sending its shares up 1.7%. Overall quarterly sales of Humira rose 4.8% to $5.2 billion in the fourth quarter, just above estimates of $5.1 billion. In the reported quarter, psoriasis drug Skyrizi brought in sales of $525 million, topping estimates of $472 million. | Overall quarterly sales of Humira rose 4.8% to $5.2 billion in the fourth quarter, just above estimates of $5.1 billion. In the fourth quarter, psoriasis drug Skyrizi brought in sales of $525 million, topping estimates of $472 million, according to Refinitiv data. Overall sales rose 59.2% to $13.9 billion in the quarter, topping estimates of $13.7 billion."
2021-02-02,123.4000015258789,120.23999786376952,0.4008713591925373,,
2021-02-01,123.23999786376952,122.54000091552734,-2.5607808938695085,3 Mega-Trends Healthcare Investors Should Watch Right Now,"Teladoc Health (NYSE: TDOC) established its foothold in telemedicine, Abbott Labs (NYSE: ABT) received Emergency Use Authorization for its at-home coronavirus diagnostic tests, and the Pfizer (NYSE: PFE)-BioNTech (NASDAQ: BNTX) team brought the first ever mRNA vaccine to market. See the 10 stocks *Stock Advisor returns as of November 20, 2020 Olivia Zitkus: Are you expecting more digital health IPOs in 2021? I think we've all started to see behavioral and mental health be one of the really hot topics after that year that was 2020, and also fintech, and beyond fintech as well, any digital health technology that is actually starting to address health inequities or health disparities."
2021-01-29,120.25,123.58999633789062,-0.5679949370138383,ABT Crosses Above Average Analyst Target,"And so with ABT crossing above that average target price of $117.92/share, investors in ABT have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $117.92 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? In recent trading, shares of Abbott Laboratories (Symbol: ABT) have crossed above the average analyst 12-month target price of $117.92, changing hands for $120.39/share. But the whole reason to look at the average ABT price target in the first place is to tap into a ""wisdom of crowds"" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes."
2021-01-28,117.91000366210938,120.38999938964844,2.777543732133576,"Noteworthy Thursday Option Activity: NFLX, NVDA, ABT | See Which Of The Latest 13F Filers Holds Abbott Laboratories | Interesting ABT Put And Call Options For March 12th | Why Abbott Labs Stock Is Jumping Today | Better Buy: Abbott Laboratories vs. Intuitive Surgical","Below is a chart showing NVDA's trailing twelve month trading history, with the $530 strike highlighted in orange: And Abbott Laboratories (Symbol: ABT) options are showing a volume of 39,883 contracts thus far today. That number of contracts represents approximately 4.0 million underlying shares, working out to a sizeable 84.1% of ABT's average daily trading volume over the past month, of 4.7 million shares. Especially high volume was seen for the $120 strike call option expiring January 29, 2021, with 2,910 contracts trading so far today, representing approximately 291,000 underlying shares of ABT. | Existing UNCH $UNCH CHICAGO TRUST Co NA Existing -1,072 -$93 HHM Wealth Advisors LLC Existing UNCH +$1 Asset Dedication LLC Existing -277 -$24 Scott Investment Partners LLP NEW +48,300 +$5,288 Venturi Wealth Management LLC Existing +161 +$28 Cedar Mountain Advisors LLC Existing +1 $UNCH Dupont Capital Management Corp Existing -22,696 -$2,361 Aggregate Change: -224,708 -$23,156 In terms of shares owned, we count 5 of the above funds having increased existing ABT positions from 09/30/2020 to 12/31/2020, with 7 having decreased their positions and 1 new position. We then compared that number to the sum total of ABT shares those same funds held back at the 09/30/2020 period, to see how the aggregate share count held by hedge funds has moved for ABT. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA 1,828,239 4-10 Find out the full Top 10 Hedge Funds Holding ABT » We'll keep following the latest 13F filings by hedge fund managers and bring you interesting stories derived from a look at the aggregate information across groups of managers between filing periods. | Below is a chart showing ABT's trailing twelve month trading history, with the $123.00 strike highlighted in red: Considering the fact that the $123.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the March 12th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new March 12th contracts and identified one put and one call contract of particular interest. | What happened Shares of Abbott Laboratories (NYSE: ABT) were jumping 7.6% higher as of 10:53 a.m. EST on Thursday. The big gain came after Raymond James analysts upped the price target for the stock to $126, reflecting a premium of more than 10% to Abbott's closing price on Wednesday. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | Abbott Laboratories (NYSE: ABT) and Intuitive Surgical (NASDAQ: ISRG) are a pair of stocks that I stand behind, and both companies are working to increase their revenue to build on their long-term successes. ABT data by YCharts Where should you invest? The case for Intuitive Surgical Intuitive Surgical's future is bright, perhaps even more so than Abbott Laboratories'."
2021-01-27,115.1999969482422,114.29000091552734,2.1032954376338586,"Health Care Sector Update for 01/27/2021: ABT, SRNE, ANTM, XLV, IBB | Abbott profit more than doubles on strong demand for COVID-19 tests | Abbott Laboratories (ABT) Q4 2020 Earnings Call Transcript | Abbott Projects 2021 EPS Growth Of More Than 35% - Quick Facts | Here's How Abbott Labs Hit a Home Run With Its Q4 Results | Abbott Laboratories Q4 20 Earnings Conference Call At 9:00 AM ET | Abbott Laboratories Q4 adjusted earnings Beat Estimates","Abbott Laboratories (ABT) was gaining over 1% in value after posting Q4 adjusted EPS of $1.45, up from $0.95 a year earlier. The Health Care SPDR (XLV) and the iShares NASDAQ Biotechnology Index (IBB) were declining by more than 1% recently. Anthem (ANTM) was declining by over 2% as it reported Q4 adjusted earnings of $2.54 per share, down from $3.88 a year ago.The average estimate of analysts surveyed by Capital IQ was for EPS of $2.53. | Adds details on sales of diagnostics kits, shares Jan 27 (Reuters) - Abbott Laboratories' ABT.N quarterly profit more than doubled on Wednesday, driven by strong sales of its COVID-19 test kits and strength in its nutrition and diabetes businesses. The company's net earnings rose to $2.16 billion, or $1.20 per share, in the fourth quarter ended Dec. 31 from $1.05 billion, or 59 cents per share, a year earlier. (Reporting by Mrinalika Roy and Amruta Khandekar in Bengaluru; Editing by Anil D'Silva) ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 806749 8325;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Duration: 62 minutes Call participants: Scott Leinenweber -- Vice President, Investor Relations, Licensing and Acquisitions Robert B. Ford -- President and Chief Executive Officer Robert E. Funck -- Executive Vice President, Finance and Chief Financial Officer Bob Hopkins -- Bank of America Merrill Lynch -- Analyst Matthew Taylor -- UBS -- Analyst Robert Marcus -- J.P. Morgan -- Analyst David Lewis -- Morgan Stanley -- Analyst Lawrence Biegelsen -- Wells Fargo -- Analyst Joanne Wuensch -- Citi -- Analyst Vijay Kumar -- Evercore ISI -- Analyst More ABT analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Abbott Laboratories (NYSE: ABT) Q4 2020 Earnings Call Jan 27, 2021, 9:00 a.m. During the past year, we continue to expand our nutrition portfolio with several new product and line extension including; the continued rollout of infant formula products across our Similac brand family that contain human oligosaccharides or HMO which supports a healthy immune system, global expansion of our PediaSure, Glucerna and Ensure brands including the continued rollout of Ensure high protein products and the launch of four new Pedialyte rehydration products; Pedialyte Zero Sugar, Sport, Organic and Immune Support. | (RTTNews) - Abbott (ABT) said the company projects full-year 2021 earnings per share from continuing operations under GAAP of at least $3.74. Excluding items, projected adjusted earnings per share from continuing operations would be at least $5.00 for full-year 2021. Sales were $10.7 billion increased 28.7 percent on a reported basis and 28.4 percent on an organic basis, which excludes the impact of foreign exchange. | Abbott Laboratories (NYSE: ABT) made its shareholders quite happy last year with a market-beating stock price gain of 26%. Abbott's overall diagnostics segment revenue skyrocketed 111% year over year to $4.3 billion, fueled largely by demand for its COVID-19 tests. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on Jan. 27, 2021, to discuss Q4 20 earnings results. To access the live webcast, log on to http://www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) revealed a profit for its fourth quarter that increased from the same period last year. Excluding items, Abbott Laboratories reported adjusted earnings of $2.61 billion or $1.45 per share for the period. The company's revenue for the quarter rose 28.8% to $10.70 billion from $8.31 billion last year."
2021-01-26,114.25,114.7300033569336,-0.7899271326575702,"Can Abbott Stock Trade Higher Post Q4 Results? | Pre-Market Earnings Report for January 27, 2021 : T, ABT, BA, ANTM, ADP, NSC, PGR, GD, BX, TEL, APH, VFC | Abbott Receives CE Mark For Two New Uses Of Panbio COVID-19 Ag Rapid Test Device | 2 Stocks I'll Hold Forever | 3 Stocks to Bankroll Your Retirement","Abbott stock (NYSE: ABT) is scheduled to report its Q4 2020 results on Wednesday, January 27. Going by the 2021 earnings estimate of $4.40, ABT stock is currently trading at 26x, which is closer to the range seen over the recent years. \n\nBased on article theme, variations to \""While may have moved\"" can be (a) While may be overvalued (or undervalued) (b) While can move (c) Although may not be attractive (d) While is worth considering""}"" data-sheets-userformat=""{""2"":1049345,""3"":{""1"":0},""11"":4,""12"":0,""23"":1}"" data-sheets-textstyleruns=""{""1"":0}{""1"":210,""2"":{""2"":{""1"":2,""2"":1136076},""5"":1,""9"":1}}{""1"":225}{""1"":229,""2"":{""4"":8}}{""1"":267,""2"":{""4"":8,""6"":1}}{""1"":299,""2"":{""4"":8}}"" data-sheets-hyperlinkruns=""{""1"":210,""2"":""https://dashboards.trefis.com/data/companies/PFE/no-login-required/HMIwIvym/Pfizer-vs-Merck-PFE-stock-s-similar-valuation-vs-MRK-stock-is-counter-intuitive""}{""1"":225}"">While ABT stock may be undervalued, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. | Abbott Laboratories (ABT) is reporting for the quarter ending December 31, 2020. In the past year ABT has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2020 Price to Earnings ratio for ABT is 32.13 vs. an industry ratio of 60.70. | (RTTNews) - Abbott (ABT) said it has received CE Mark for two new uses of its Panbio COVID-19 Ag Rapid Test Device for the detection of the SARS-CoV-2 virus: asymptomatic testing and self-swabbing. Panbio COVID-19 Ag's label has been updated with clinical data on asymptomatic individuals, which enables mass testing (mass screening) of people who do not currently present symptoms of the disease. Panbio COVID-19 Ag is not available in the U.S., where Abbott manufactures and sells the BinaxNOW COVID-19 Ag Card, which has received emergency use authorization or EUA by the U.S. Food and Drug Administration. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) is another healthcare stock that I'll hold forever. Many of these goods don't require any additional investment to keep selling year after year, which means that Abbott can invest its funds to make new products to add to its repertoire. 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | PETS Payout Ratio data by YCharts AbbVie is also a predictable growth stock with increased revenue every year. The company is headed for its fifth consecutive year of annual revenue growth, with a compound annual revenue growth of 32.87% in that period. Of the three, AbbVie is the easiest choice because it has the highest dividend yield, strongest dividend growth history, and greatest track record of revenue growth."
2021-01-25,113.05999755859376,114.72000122070312,0.4201342292635394,"Notable ETF Outflow Detected - IVV, INTC, TMO, ABT | 3 Reasons To Invest in Pfizer Stock Despite Its Dismal Performance","Among the largest underlying components of IVV, in trading today Intel Corp (Symbol: INTC) is off about 2.6%, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 1.2%, and Abbott Laboratories (Symbol: ABT) is higher by about 1.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P 500 ETF (Symbol: IVV) where we have detected an approximate $2.3 billion dollar outflow -- that's a 0.9% decrease week over week (from 635,650,000 to 629,700,000). For a complete list of holdings, visit the IVV Holdings page » The chart below shows the one year price performance of IVV, versus its 200 day moving average: Looking at the chart above, IVV's low point in its 52 week range is $220.2756 per share, with $386.3781 as the 52 week high point — that compares with a last trade of $385.96. | However, the Abbott Laboratories (NYSE:ABT) spin-off is not a frontrunner in the vaccine game, a major reason for investing in Pfizer stock. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pfizer (NYSE:PFE) stock is down nearly 1% so far this year. Pfizer Stock Is a Value Play in the Pharma Sector Vaccine stocks are slowly losing steam after a bumper 2020."
2021-01-22,113.0,112.83999633789062,1.4682502193130313,,
2021-01-21,112.25,112.9499969482422,-0.14159616115873894,3 COVID Stocks to Buy if You're Not a Big Risk-Taker,"Abbott Labs Abbott Labs (NYSE: ABT) moved quickly last year to develop COVID-19 tests. The stocks of several small companies developing COVID-19 diagnostics, therapies, and vaccines skyrocketed last year. If you're looking for a COVID-19 vaccine stock that will allow you to follow Buffett's rules, you'll probably go with Johnson & Johnson (NYSE: JNJ)."
2021-01-20,112.6500015258789,112.88999938964844,0.6236052991021842,,
2021-01-19,111.73999786376952,112.56999969482422,0.21304736841427996,"Abbott's COVID-19 antigen test may help with faster detection, isolation - CDC | Abbott's COVID-19 antigen test may help with faster detection, isolation - CDC | Abbott vs Dexcom: Which “Strong Buy” Stock Could Deliver Higher Returns in 2021?","By Vishwadha Chander Jan 19 (Reuters) - Abbott Laboratories' ABT.N rapid COVID-19 antigen test is highly likely to correctly detect if people have ever contracted the virus and could help with earlier isolation, according to the U.S. Centers for Disease Control and Prevention. Several rapid antigen tests have been approved by the U.S. Food and Drug Administration for emergency use, but data lacks on test performance in asymptomatic people, according to a team of scientists from CDC's COVID-19 Response Team and the Arizona Department of Health Services. Compared with RT-PCR, Abbott's BinaxNOW antigen test had a sensitivity of 64.2% for specimens from symptomatic people and only 35.8% for specimens from asymptomatic people. | By Vishwadha Chander Jan 19 (Reuters) - Abbott Laboratories' ABT.N rapid COVID-19 antigen test is highly likely to correctly detect if people have ever contracted the virus and could help with earlier isolation, according to the U.S. Centers for Disease Control and Prevention. Several rapid antigen tests have been approved by the U.S. Food and Drug Administration for emergency use, but data lacks on test performance in asymptomatic people, according to a team of scientists from CDC's COVID-19 Response Team and the Arizona Department of Health Services. Compared with RT-PCR, Abbott's BinaxNOW antigen test had a sensitivity of 64.2% for specimens from symptomatic people and only 35.8% for specimens from asymptomatic people. | (See ABT stock analysis on TipRanks) Last month, Raymond James analyst Jayson Bedford reiterated a Buy rating for Abbott following a call with the company’s management. Abbott Laboratories (ABT) Abbott has a diversified business that includes four segments: Medical Devices, Diagnostics, Nutrition and Established Pharmaceutical Products (which generates revenue from the sale of branded generic pharmaceutical products outside of the US). To back his bullish stance on Abbott, the analyst concluded, “The 'third wave' of CV-19 has raised the near-term uncertainty level (for the group), but ABT remains well positioned given its diversified portfolio, and the CV-19 testing tailwind, which lessens the near-term risk profile."
2021-01-15,110.0,111.3000030517578,0.742797428783396,"IVV, ABT, QCOM, WFC: Large Outflows Detected at ETF | Baxter Is A Better Choice Than Boston Scientific Stock","Among the largest underlying components of IVV, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.5%, Qualcomm Inc (Symbol: QCOM) is off about 1.8%, and Wells Fargo & Co (Symbol: WFC) is lower by about 7.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P 500 ETF (Symbol: IVV) where we have detected an approximate $361.0 million dollar outflow -- that's a 0.1% decrease week over week (from 636,700,000 to 635,750,000). For a complete list of holdings, visit the IVV Holdings page » The chart below shows the one year price performance of IVV, versus its 200 day moving average: Looking at the chart above, IVV's low point in its 52 week range is $220.2756 per share, with $382.86 as the 52 week high point — that compares with a last trade of $375.76. | Operating Income Baxter’s operating income grew from $0.7 billion in 2016 to $1.7 billion in 2019, reflecting a 2.4x growth, led by both an increase in revenues and expansion of operating margins, which grew from 6.7% to 15.0% over the same period. The Net of It All Although Boston Scientific’s Revenue growth compares favorably with Baxter over the recent years, Baxter’s growth has been better over the last twelve months. Now Boston Scientific’s revenue is expected to grow 15% from an estimated $10.0 billion in 2020 to $11.6 billion in 2021, while Baxter’s revenue is expected to grow 5% to $12.1 billion in 2021 compared to an estimated figure of $11.5 billion in 2020."
2021-01-14,111.20999908447266,110.04000091552734,1.181820956143453,Qiagen warns against using standard tests to track coronavirus variants | My Best Growth Stock for 2021 | 2 Healthcare Stocks to Buy in 2021 and Hold for the Next Decade | My Top 3 Large-Cap Stocks to Own in 2021,"Qiagen, which competes in the diagnostics market with Roche ROG.S, Abbott ABT.N, Danaher DHR.N and Thermo Fisher TMO.N, supplies PCR tests and makes genetic sequencing tools that run on Illumina ILMN.O analytical machines. By Ludwig Burger and Nikolaj Skydsgaard FRANKFURT/COPENHAGEN, Jan 14 (Reuters) - Germany's Qiagen QIA.DE, a leading genetic testing supplier, on Thursday warned against re-engineering standard tests to monitor for new variants of the coronavirus, saying the more onerous decoding of the entire viral genome was the best method. Standard COVID-19 diagnostic kits, called polymerase chain reaction (PCR) tests, scan for a few characteristic genes in the viral genome, while whole genome sequencing, the established procedure to identify new variants, means reading out and analysing the entire genetic code. | That's why diagnostics and testing company Quidel (NASDAQ: QDEL) looks to be the best growth stock to buy this year. Quidel's stock is also incredibly cheap Given its sales numbers and the growth that it's generating, Quidel's stock gives you a lot of bang for your buck. Quidel isn't a stock you can just buy and forget about because a lot will depend on the future of COVID-19 and how long people will need to be tested for it, as well as how the company's business will adapt once the pandemic is really over and testing isn't needed (assuming that point is ever reached). | Abbott Everyone has been talking about Abbott Laboratories (NYSE: ABT) for its role in coronavirus testing. ABT Revenue (Annual) data by YCharts. CF drugs may bring the company as much as $6.2 billion in full-year 2020 product revenue, according to Vertex's guidance. | ABT Gross Profit Margin (Annual) data by YCharts Two key elements are likely to push revenue higher in 2021: the company's coronavirus tests and the next generation of its FreeStyle Libre glucose monitoring system for diabetes. Abbott Abbott Laboratories (NYSE: ABT) is a Dividend Aristocrat. Both have climbed annually for the past six years and two years, respectively."
2021-01-13,109.08999633789062,112.1500015258789,-1.0520620255167952,"Noteworthy Wednesday Option Activity: ABT, AAXN, HLT | Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for January 14, 2021 | 3 Dividend Aristocrats to Buy Right Now","Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Abbott Laboratories (Symbol: ABT), where a total volume of 36,405 contracts has been traded thus far today, a contract volume which is representative of approximately 3.6 million underlying shares (given that every 1 contract represents 100 underlying shares). Especially high volume was seen for the $110 strike call option expiring January 15, 2021, with 2,847 contracts trading so far today, representing approximately 284,700 underlying shares of ABT. That number works out to 82.5% of ABT's average daily trading volume over the past month, of 4.4 million shares. | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. The following ETF(s) have ABT as a top-10 holding: iShares U.S. ETF Trust (IEHS) DecideAct (ACT) Invesco Dynamic Pharmaceuticals ETF (PJP) iShares U.S. Medical Devices ETF (IHI) VictoryShares US 500 Volatility Wtd ETF (CFA). | Abbott Labs Abbott Labs (NYSE: ABT) increased its dividend in December 2020 by 25%. Unlike many Dividend Aristocrats, Abbott's dividend isn't the main reason to like the stock. Because it was part of Abbott until 2013 and has continued to increase its dividend every year, AbbVie's track record of dividend increases mirrors its parent company."
2021-01-12,110.5199966430664,108.83999633789062,2.805028225054068,"Ex-Dividend Reminder: Abbott Laboratories, Mid-America Apartment Communities and American Financial Group | How to Play Stock Spinoffs for 176%+ Payout Growth, 200%+ Upside | 5 Dividend Growth Stocks With Upside To Analyst Targets","Looking at the universe of stocks we cover at Dividend Channel, on 1/14/21, Abbott Laboratories (Symbol: ABT), Mid-America Apartment Communities Inc (Symbol: MAA), and American Financial Group Inc (Symbol: AFG) will all trade ex-dividend for their respective upcoming dividends. Abbott Laboratories (Symbol: ABT): Mid-America Apartment Communities Inc (Symbol: MAA): American Financial Group Inc (Symbol: AFG): In general, dividends are not always predictable, following the ups and downs of company profits over time. As a percentage of ABT's recent stock price of $110.62, this dividend works out to approximately 0.41%, so look for shares of Abbott Laboratories to trade 0.41% lower — all else being equal — when ABT shares open for trading on 1/14/21. | How Spinoffs Can Deliver Triple-Digit Gains, Accelerating Payouts Medical-equipment maker Abbott Labs (ABT) and its spinoff, pharmaceutical firm AbbVie (ABBV), are classic examples of the gains (and fast-growing dividends) a spinoff can hand us. Prior to their breakup eight years ago, the dividend of the old parent company, Abbott, was already growing at a healthy clip, more than doubling in the preceding 10 years and reaching $0.51 a share right before the spinoff took effect: Abbott's Dividend Soared Pre-Split ... Abbott, for its part, had reduced its payout to $0.14 a share to account for AbbVie's dividend, so investors now had two dividend streams that paid them $0.54 a share in all--more than the $0.51 they were getting from the ""old"" Abbott. | Consolidated Edison Inc (Symbol: ED) $68.73 $77.50 12.76% Lowe's Companies Inc (Symbol: LOW) $166.32 $181.50 9.13% Church & Dwight Co Inc (Symbol: CHD) $84.92 $92.25 8.63% Cintas Corporation (Symbol: CTAS) $339.50 $365.00 7.51% Abbott Laboratories (Symbol: ABT) $110.84 $117.92 6.38% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Consolidated Edison Inc (Symbol: ED) 4.45% 12.76% 17.21% Lowe's Companies Inc (Symbol: LOW) 1.44% 9.13% 10.57% Church & Dwight Co Inc (Symbol: CHD) 1.13% 8.63% 9.76% Cintas Corporation (Symbol: CTAS) 0.83% 7.51% 8.34% Abbott Laboratories (Symbol: ABT) 1.62% 6.38% 8% Another consideration with dividend growth stocks is just how much the dividend is growing. Consolidated Edison Inc (Symbol: ED) $2.96 $3.06 3.38% Lowe's Companies Inc (Symbol: LOW) $2.06 $2.25 9.22% Church & Dwight Co Inc (Symbol: CHD) $0.912 $0.96 5.26% Cintas Corporation (Symbol: CTAS) $2.55 $3.51 37.65% Abbott Laboratories (Symbol: ABT) $1.28 $1.44 12.50% These five stocks are part of our full Dividend Aristocrats List."
2021-01-11,111.20999908447266,110.83999633789062,-1.520087184404722,Abbott Gets FDA Clearance For Rapid Handheld Blood Test For Mild Traumatic Brain Injury,"(RTTNews) - Abbott (ABT) said it has received 510(k) clearance from the U.S. FDA for the first rapid handheld traumatic brain injury blood test. According to the company, the test measures specific proteins present in the blood after a traumatic brain injury. For those who test positive, this test result complements CT scans to help clinicians evaluate whether someone has a traumatic brain injury."
2021-01-08,111.66999816894533,111.61000061035156,-0.33270636599950454,,
2021-01-07,110.27999877929688,111.3000030517578,-0.05372755402305462,"Notable ETF Outflow Detected - IVW, TMO, ABBV, ABT | Where to Invest $100,000 Right Now","Among the largest underlying components of IVW, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is up about 3.2%, AbbVie Inc (Symbol: ABBV) is up about 1.2%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 500 Growth ETF (Symbol: IVW) where we have detected an approximate $191.2 million dollar outflow -- that's a 0.6% decrease week over week (from 506,500,000 to 503,450,000). For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year price performance of IVW, versus its 200 day moving average: Looking at the chart above, IVW's low point in its 52 week range is $35.21 per share, with $64.185 as the 52 week high point — that compares with a last trade of $63.89. | Considering this, I would invest $10,000 each in Abbott Laboratories (NYSE: ABT), Teladoc Health (NYSE: TDOC), Vertex Pharmaceuticals (NASDAQ: VRTX), Amazon (NASDAQ: AMZN), and Target (NYSE: TGT). Regeneron may gain as its cocktail adds to revenue in the near term, and in the long term, its seven commercialized products may boost revenue and, eventually, the share price. The Motley Fool recommends Vertex Pharmaceuticals and recommends the following options: long January 2022 $1920 calls on Amazon and short January 2022 $1940 calls on Amazon."
2021-01-06,108.9499969482422,110.2300033569336,0.9249222739857439,2 Coronavirus Stocks That Will Keep Winning in 2021 | 3 Top Coronavirus Stocks to Buy Right Now,"Shares of Moderna (NASDAQ: MRNA) and Abbott Laboratories (NYSE: ABT) both climbed last year due to the companies' potential to combat the coronavirus. ABT Annual EPS Estimates data by YCharts Last year, investors imagined the roles Moderna and Abbott might play in the fight against coronavirus. Revenue from Abbott's COVID-19 tests has climbed from quarter to quarter -- to $881 million in the third quarter, from $615 million in the second. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) isn't working on a vaccine, but its diagnostic tests make it a lucrative coronavirus stock. Johnson & Johnson While Johnson & Johnson (NYSE: JNJ) is still working on its coronavirus vaccine candidate, it has one big advantage that the vaccines by Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) don't: It only takes one dose to generate immunity. Expect Abbott to continue developing and releasing more sophisticated coronavirus diagnostic tests and emphasizing digital solutions like NAVICA that add perks like traceability and third-party verification of diagnostic results."
2021-01-05,108.8499984741211,110.45999908447266,1.174856764153442,,
2021-01-04,109.52999877929688,109.11000061035156,1.4791002599180905,Is It Too Late to Invest in Coronavirus Test Stocks?,"Another EUA for testing last week went to Abbott Labs (NYSE: ABT). There's a couple 100 authorized tests, so adding one or two extra tests is not going to probably do that much, especially as they're going to take a while to ramp up production of their tests, but definitely at-home testing are easier and if they're available, would be helpful for patients. Orelli: I think the ones where the tests have to be run on a machine and the amount of machines that people have been buying, either small machines that go into doctor's offices or large machines that go into laboratories."
2020-12-31,108.16999816894533,109.48999786376952,-0.38345491977189694,,
2020-12-30,108.69000244140624,108.44000244140624,1.2203011159920225,The 3 Safest Stocks to Buy With Your Stimulus Money,"Abbott Labs When it comes to evergreen healthcare stocks, Abbott Laboratories (NYSE: ABT) is one of the leaders. Because the company charges a membership fee each year, it also has significant and strong recurring revenue; more than 90% of its members renew their subscription each year. The pandemic hasn't harmed Costco's margins, and its sales grew by 17% year over year in the most recent quarter."
2020-12-29,108.5,108.33000183105467,-0.23001195545539954,,
2020-12-28,108.95999908447266,107.79000091552734,-0.15668034004177575,,
2020-12-24,107.44000244140624,108.3499984741211,-1.0737868747945345,The 3 Best Stocks for 2021,"Abbott President-elect Joe Biden plans to expand coronavirus testing in the U.S. And that's good news for testing leader Abbott Laboratories (NYSE: ABT). Disney expected between 60 million and 90 million Disney+ subscribers, between 40 million and 60 million Hulu subscribers, and between 8 million and 12 million ESPN+ subscribers by FY 2024. Beyond coronavirus testing, the company generates revenue from other diagnostic tests, medical devices, nutrition products, and pharmaceuticals."
2020-12-23,108.87000274658205,107.4499969482422,0.8469806515605172,,
2020-12-22,107.83000183105467,108.27999877929688,-1.3043131831687444,"iShares Core S&P U.S. Growth ETF Experiences Big Inflow | Got $1,000? 3 Smart Stocks to Buy Right Now","Among the largest underlying components of IUSG, in trading today Merck & Co Inc (Symbol: MRK) is off about 0.6%, Abbott Laboratories (Symbol: ABT) is off about 0.2%, and ServiceNow Inc (Symbol: NOW) is higher by about 1.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P U.S. Growth ETF (Symbol: IUSG) where we have detected an approximate $1.1 billion dollar inflow -- that's a 10.7% increase week over week in outstanding units (from 116,850,000 to 129,350,000). For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average: Looking at the chart above, IUSG's low point in its 52 week range is $48.5501 per share, with $88.03 as the 52 week high point — that compares with a last trade of $87.64. | Abbott Laboratories (NYSE: ABT) quickly stepped up to the plate, and has since developed eight different tests to detect coronavirus infection. Given the company's impressive growth figures prior to the pandemic, its stellar financial results throughout this year, and the ever-increasing popularity of remote solutions across the broader workforce, Fiverr is both a top growth stock of the pandemic era and a valuable play for long-term investors. Abbott's robust third-quarter performance quelled any investor fears, as it reported nearly 10% total sales growth year over year."
2020-12-21,107.55999755859376,108.08999633789062,0.41732072762759065,Quidel Rapid Antigen Test for COVID-19 Wins Authorization,"Shares of Quidel have pulled back 34% from their high this summer as vaccines have come to the forefront and investors have become worried about competition from industry giant Abbott Laboratories (NYSE: ABT). Diagnostic healthcare specialist Quidel (NASDAQ: QDEL) today announced it has received Emergency Use Authorization from the Food and Drug Administration for a rapid COVID-19 antigen test that returns results without the use of a test instrument. Quidel expects the test will help meet urgent testing needs in school systems and rural locations, saying that it plans to reach a production run rate of 600 million tests by the end of next year."
2020-12-18,108.8499984741211,108.97000122070312,0.4927471098241163,3 Stocks to Buy With Dividends Yielding More Than 3%,"Siemens retains a 35.1% stake in Siemens Energy If this isn't complicated enough, Siemens also retains a 79% stake in a publicly listed subsidiary, Siemens Healthineers. Digital Industries 3.25 billion euros Factory and process automation, industrial software, motion control ABB, Emerson Electric, Schneider Electric, Rockwell Automation, Dassault Systemes Smart Infrastructure 1.3 billion euros Electrical and building products, digital grid solutions, distribution systems ABB, Honeywell, Johnson Controls, Schneider Electric Mobility 822 million euros Rail infrastructure, rolling stock, traffic systems. Alstom, Bombardier Siemens Healthineers* 2.18 billion euros Imaging, diagnostics, advanced therapies General Electric, Philips, Roche, Abbott Labs Total Industrial 7.65 billion euros n/a n/a Siemens Financial Services 345 million euros n/a n/a Portfolio Companies (504 million euros) Energy businesses, logistics, commercial vehicles, mechanical systems Assorted Data source: Siemens presentations."
2020-12-17,107.83000183105467,108.77999877929688,0.11024597911277113,"August 2021 Options Now Available For Abbott Laboratories (ABT) | Daily Markets: Equities Rise as a Stimulus Deals Inches Closer | Up 60% In 2020, Here's Why DexCom Is Just Getting Started | Abbott Wins FDA Approval For At-Home Covid-19 Test; Street Says Buy | FDA Nod For Abbott's At-home Covid-19 Test","Below is a chart showing ABT's trailing twelve month trading history, with the $110.00 strike highlighted in red: Considering the fact that the $110.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the August 2021 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new August 2021 contracts and identified one put and one call contract of particular interest. | The FDA authorized Abbott Lab’s (ABT) BinaxNOW Covid-19 test for home use yesterday. After making new record highs for four consecutive months, the National Association of Home Builders Index fell more than expected yesterday, dropping to 86 from 90 in November, from which it was expected to decline to just 88. Later today, we will get the usual weekly jobless claims, Philly and Kansas Fed Manufacturing Indices, Building Permits are expected to drop from 1.54 million to 1.52 million and, Housing Starts are expected to remain flat at 1.53 million (SAAR). | Abbott Laboratories (NYSE: ABT), Medtronic (NYSE: MDT), and Roche (OTC: RHHBY) all have competing products in their diabetes management businesses. DexCom's continuous glucose monitoring (CGM) system allows diabetes patients to track their glucose levels via a wearable device that transmits biometrics to a smart device every five minutes. The company has been disrupting the diabetes market for years and G7 should have a significantly positive impact as the company reduces manufacturing costs and drives penetration into the type 2 diabetes market. | Abbott (ABT) said that the $25 test is the cheapest available at-home antigen test. “The 'third wave' of COVID-19 has raised the near-term uncertainty level (for the group), but ABT remains well positioned given its diversified portfolio, and the COVID-19 testing tailwind, which lessens the near-term risk profile,” Bedford wrote in a note to investors. Once a BinaxNOW at-home test kit is available at home, the user logs into the eMed portal for a guided testing procedure and can expect results in about 20 minutes. | Jeff Shuren, director of FDA's Center for Devices and Radiological Health, now said, ""With today's authorization of the BinaxNOW COVID-19 Ag Card Home Test, there are now three tests that can be used completely at home. It is the first antigen test where results can be read directly from the testing card, a similar design to some pregnancy tests. Since the start of the pandemic, the FDA has authorized more than 225 Covid-19 diagnostic tests including more than 25 tests in which swab samples can be collected at home and then send to a lab for testing."
2020-12-16,107.4499969482422,107.33999633789062,0.8810135696099058,,
2020-12-15,106.94000244140624,107.4499969482422,-0.10237376777643198,This Dividend Aristocrat Just Gave Investors a Great Early Christmas Gift | United Therapeutics Stock Looks Fully Valued At $137 | Abbott Obtains CE Mark For COVID-19 IgG Quantitative Antibody Blood Test,"Abbott Laboratories (NYSE: ABT) announced a dividend increase on Dec. 11. It's the largest dividend increase for the company since 2013, when Abbott raised its dividend by the same percentage. Abbott is only a year away from reaching the next level of dividend greatness by becoming a Dividend King -- members of the S&P 500 with 50 or more years of consecutive dividend increases. | After a 63% rise since the March 23 levels of this year, at the current price of around $137 per share we believe United Therapeutics stock (NASDAQ: UTHR), a biotechnology company, has reached its near-term potential. Now that the company’s P/S has expanded to 4.1x, there is a potential downside risk when the current P/S is compared to levels seen in the past years, P/S of around 2.9x at the end of 2018 and 2.7x as recently as late 2019. Comprised of companies with strong revenue growth, healthy profits, lots of cash, and low risk, it has outperformed the broader market year after year, consistently. | (RTTNews) - Abbott Laboratories (ABT) said it has received CE Mark for its COVID-19 IgG quantitative antibody blood test. According to the company, SARS-CoV-2 IgG II Quant antibody test measures levels of IgG antibodies to help measure and understand a person's immune response. The test specifically identifies levels of IgG antibodies that attach to the virus' spike protein which can be helpful to evaluate a person's immune response to the vaccines."
2020-12-14,107.5,106.79000091552734,0.47689778865995286,3 COVID Stocks That Are Screaming Buys,"Abbott Labs Abbott Labs (NYSE: ABT) quickly emerged as a leader in COVID-19 diagnostic tests. This maxim isn't necessarily true for every category of stocks, but it does apply to coronavirus stocks. Novavax I think that the biggest winner in the COVID vaccine market next year just might be Novavax (NASDAQ: NVAX)."
2020-12-11,106.0999984741211,107.0199966430664,-0.6604642646257267,"Dividend Aristocrat Abbott Laboratories Hikes Dividend by 25% | Daily Dividend Report: ABT,PFE,NLY,AWK,CAG | 5 Dividend Growth Stocks With Upside To Analyst Targets | Quidel, Abbott, Quest: Why Covid-19 Testing Stocks Are Still Worth A Look","On Friday, Abbott Laboratories (NYSE: ABT) undertook its long-standing annual ritual and raised its quarterly dividend. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! | VIDEO: Daily Dividend Report: ABT,PFE,NLY,AWK,CAG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott has increased its dividend payout for 49 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years. The board of directors of Pfizer declared a 39-cent first-quarter 2021 dividend on the company's common stock, payable March 5, 2021, to holders of the Common Stock of record at the close of business on January 29, 2021. | Lowe's Companies Inc (Symbol: LOW) $160.22 $177.00 10.47% Abbott Laboratories (Symbol: ABT) $106.52 $116.92 9.76% Church & Dwight Co Inc (Symbol: CHD) $85.33 $93.42 9.48% Consolidated Edison Inc (Symbol: ED) $73.35 $78.94 7.63% Leggett & Platt, Inc. (Symbol: LEG) $42.55 $45.67 7.32% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Lowe's Companies Inc (Symbol: LOW) 1.50% 10.47% 11.97% Abbott Laboratories (Symbol: ABT) 1.35% 9.76% 11.11% Church & Dwight Co Inc (Symbol: CHD) 1.12% 9.48% 10.6% Consolidated Edison Inc (Symbol: ED) 4.17% 7.63% 11.8% Leggett & Platt, Inc. (Symbol: LEG) 3.76% 7.32% 11.08% Another consideration with dividend growth stocks is just how much the dividend is growing. Lowe's Companies Inc (Symbol: LOW) $2.06 $2.25 9.22% Abbott Laboratories (Symbol: ABT) $1.28 $1.44 12.50% Church & Dwight Co Inc (Symbol: CHD) $0.912 $0.96 5.26% Consolidated Edison Inc (Symbol: ED) $2.96 $3.06 3.38% Leggett & Platt, Inc. (Symbol: LEG) $1.56 $1.6 2.56% These five stocks are part of our full Dividend Aristocrats List. | While companies such as Abbott Laboratories (NYSE:ABT) and Quidel (NASDAQ:QDEL) are well-diversified, offering a range of medical devices or diagnostic products which will continue to drive growth, the likes of Quest Diagnostics (NYSE:DGX) and Laboratory of America (NYSE:LH) should see their core testing and diagnostic operations, which were impacted through Covid, pick up. Abbott Laboratories (ABT) has a diverse range of solutions including a test called BinaxNOW that provides test results in fifteen minutes and works without relying on lab equipment. [Updated 11/3/2020] Quidel, Abbott, Quest: Testing Stocks To Watch As Covid-19 Cases Surge Our indicative theme of Covid-19 Testing Stocks, which includes medical device and diagnostic companies that are involved in Covid-19 testing – is up by about 66% year-to-date, significantly outperforming the S&P 500 which has gained about 3% over the same period."
2020-12-10,106.76000213623048,106.5199966430664,0.8671047899870703,3 Warren Buffett Dividend Stocks You Can Buy Right Now,"Bank of America cut its dividend during the Great Recession period and didn't provide any dividend hikes for a few years afterward. See the 10 stocks *Stock Advisor returns as of November 20, 2020 Keith Speights owns shares of AbbVie, Bank of America, Berkshire Hathaway (B shares), and Pfizer. The Motley Fool recommends Viatris Inc and recommends the following options: long January 2021 $200 calls on Berkshire Hathaway (B shares), short January 2021 $200 puts on Berkshire Hathaway (B shares), and short December 2020 $210 calls on Berkshire Hathaway (B shares)."
2020-12-09,107.0999984741211,106.31999969482422,-0.22480843795583583,DexCom Has a Lot to Prove in 2021,"However , investors are concerned about the success Abbott Laboratories (NYSE: ABT) is having with its second-generation CGM, FreeStyle Libre 2, which was approved in Europe in October 2018 and launched in the U.S. last quarter. No one really knows at this point, but they're partly why DexCom stock gets a premium valuation, and could partly account for why the company has maintained its growth in the face of competition. There are enough questions about the impact of growing competition for DexCom that investors were probably justified in driving the share price down 26% from their all-time high earlier this year."
2020-12-08,106.8000030517578,106.8000030517578,-0.7282901871239041,,
2020-12-07,107.72000122070312,107.18000030517578,0.0,9 Stocks to Buy Despite the Rocky Transition,"Costco (NASDAQ:COST) Procter & Gamble (NYSE:PG) Abbott Laboratories (NYSE:ABT) Novavax (NASDAQ:NVAX) International Paper (NYSE:IP) Olin Corporation (NYSE:OLN) Vista Outdoor (NYSE:VSTO) Ammo Inc (NASDAQ:POWW) Wheaton Precious Metals (NYSE:WPM) 7 Auto Stocks to Watch Going Into 2021 Also remember that while our world is focused on present events, people have a long memory. Abbott Laboratories (ABT) Source: testing / Shutterstock.com Besides the apparent electoral victory of former Vice President Joe Biden, the most significant event over the past several weeks has been the announcement of encouraging results from Covid-19 vaccine developers Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA). However, the presence of potentially greenlit vaccines won’t end the importance of ABT stock."
2020-12-04,107.08000183105467,107.9000015258789,-0.5013005100333762,,
2020-12-03,108.1500015258789,107.52999877929688,0.7657822943615432,,
2020-12-02,108.30999755859376,108.1500015258789,-0.5732803863471722,Are These The Best Biotech Stocks To Watch Right Now? 3 To Consider As Pfizer’s Vaccine Rollout Begins | Abbott: Health Canada Approves FreeStyle Libre 2 For Adults And Children With Diabetes | Should You Follow Robinhood Investors Into These 2 Risky Coronavirus Stocks? | Further Upside For Medtronic Stock,"Top Biotech Stocks To Watch Now: AbbVie Inc Next up, AbbVie (ABBV Stock Report) is a biopharmaceutical company that has been around since 2013 and is a spin-off of Abbott Laboratories (ABT Stock Report). 3 Tech Stocks To Watch Before Friday Top Biotech Stocks To Watch Now: Moderna Inc Starting us off is Moderna (MRNA Stock Report). 3 Tech Stocks To Watch Before Friday Top Biotech Stocks To Watch Now: Alnylam Pharmaceuticals Inc. Our last entry on this list is Alnylam (ALNY Stock Report). | (RTTNews) - Abbott Laboratories (ABT) said Wednesday that Health Canada has approved the company's next-generation, sensor-based glucose monitoring technology, FreeStyle Libre 2, for adults and children aged 4 years and older, with diabetes. The company noted that FreeStyle Libre 2 features optional, real-time alarms that measure glucose levels every minute, giving users the option to be alerted in real-time of critical events such as hypoglycemia (low glucose levels) or hyperglycemia (high glucose levels). The FreeStyle Libre 2 sensor is worn on the back of the upper arm for up to 14 days and measures glucose every minute to help users and their healthcare providers make informed treatment decisions. | These days, Robinhood investors are piling into shares of coronavirus stocks, including Inovio Pharmaceuticals (NASDAQ: INO) and Sorrento Therapeutics (NASDAQ: SRNE). Inovio and Sorrento shares gained earlier this year among optimism about their coronavirus programs, then slipped. See the 10 stocks *Stock Advisor returns as of November 20, 2020 Adria Cimino has no position in any of the stocks mentioned. | In contrast, here is how MDT stock and the broader market fared during the 2007-08 crisis Timeline of 2007-08 Crisis 10/1/2007: Approximate pre-crisis peak in S&P 500 index 9/1/2008 – 10/1/2008: Accelerated market decline corresponding to Lehman bankruptcy filing (9/15/08) 3/1/2009: Approximate bottoming out of S&P 500 index 12/31/2009: Initial recovery to levels before accelerated decline (around 9/1/2008) MDT and S&P 500 Performance Over 2007-08 Financial Crisis MDT stock declined from levels of about $58 in September 2007 (pre-crisis peak) to levels of $30 in March 2009 (as the markets bottomed out), implying MDT stock lost 49%. Medtronic Fundamentals Over Recent Years Have Been Robust Medtronic’s revenues increased from $28.8 billion in fiscal 2016 (fiscal ends in April) to $30.6 billion in 2019, but declined to $28.9 billion in 2020, owing to the impact of the pandemic. Conclusion Phases of Covid-19 Crisis: Early- to mid-March 2020: Fear of the coronavirus outbreak spreading rapidly translates into reality, with the number of cases accelerating globally Late-March 2020 onward: Social distancing measures + lockdowns April 2020: Fed stimulus suppresses near-term survival anxiety May-June 2020: Recovery of demand, with gradual lifting of lockdowns – no panic anymore despite a steady increase in the number of cases July-October 2020: After poor Q2 results, Q3 expectations were lukewarm, but continued improvement in demand, and progress with vaccine development buoyed market sentiment As the global economy opens up and lockdowns are lifted in phases, consumer demand is expected to pick up."
2020-12-01,109.23999786376952,108.48999786376952,-0.14772046562765637,,
2020-11-30,107.7699966430664,108.22000122070312,-0.6865617124373312,,
2020-11-27,106.66999816894533,107.62000274658205,0.41756016670124924,,
2020-11-25,107.0500030517578,106.41000366210938,0.890601475526501,,
2020-11-24,109.30999755859376,107.61000061035156,-0.5978508840760974,Earnings Beat On The Cards For Medtronic Stock?,"(1) Revenues expected to be ahead of consensus estimates Trefis estimates Medtronic’s fiscal Q2 2021 revenues to be around $7.5 Bil, roughly 6% ahead of the $7.1 Bil consensus estimate. 2) EPS also likely to be ahead of consensus estimates Medtronic’s Q2 2021 adjusted earnings per share (EPS) is expected to be 90 cents per Trefis analysis, almost 13% above the consensus estimate of 80 cents. (3) Stock price estimate higher than the current market price Going by our Medtronic Valuation, with a revenue estimate of around $30.0 Bil and P/E multiple of 26x in fiscal 2021, this translates into a price of $116, which is 5% above the current market price of around $110."
2020-11-23,111.43000030517578,109.2699966430664,-1.5552071962410823,Should Investors Consider These Coronavirus Stocks After AstraZeneca’s Vaccine News? 3 Names To Watch | Illumina Looks Like Great Value Compared To Intuitive Surgical Stock,"[Read More] Top 5 Things To Know In The Stock Market This Week Top Coronavirus Stocks To Watch Right Now: Abbott Labs Abbott Labs (ABT Stock Report) has been building a leading position in COVID-19 testing since the early days of the pandemic. With that in mind, could ABT stock continue to rally amid the surging coronavirus infections? 1 Up Over 1200% Year-To-Date Top Coronavirus Stocks To Watch Right Now: Moderna Moderna (MRNA Stock Report) has been one of the best coronavirus stocks to watch this year. | Illumina (NASDAQ: ILMN), best known for its genetic variation and biological function systems, trades at about 12x trailing Revenues, compared to over 19x for Intuitive Surgical (NASDAQ: ISRG), which manufactures robotic surgical platforms. Returns (Profits) While Illumina’s Free cash flows as a % of Revenues stood at about 30% in 2019,  dropping slightly from around 32% in 2016, Intuitive Surgical’s Free cash flows as a % of Revenues stood at about 36%, down from around 40% in 2016. The Net Of It All Although Intuitive Surgical’s Revenue Growth, Returns, and Risk metrics compare quite favorably with Illumina, we don’t think this really justifies the difference in P/S multiple of 12x versus 19x for Intuitive Surgical."
2020-11-20,110.73999786376952,110.88999938964844,-1.938439967866576,,
2020-11-19,110.0,111.0,0.1354537915590804,Could DexCom Be a Millionaire-Maker Stock?,"First, it probably can't continue to expand its revenue as rapidly as it has in the past, now that large and powerful competitors like Abbott Laboratories (NYSE: ABT) are staking their claims in the CGM market. DexCom's product is a great fit for its market DexCom's wearable continuous glucose monitoring (CGM) products help people with diabetes to manage their conditions without the pain of repeatedly pricking their fingers to take glucose measurements from droplets of blood. Why you won't make millions with this stock Despite its positive qualities, I don't think that the stock is about to make anyone into a millionaire."
2020-11-18,113.66999816894533,109.7699966430664,0.9090909090909091,These 3 Medical Device Stocks Leave Biotech in the Dust,"While it expects to eventually face competition from larger players like Abbott Laboratories (NYSE: ABT), Abiomed is the dominant actor in the market for the time being. Strong sales of the latest monitor, the G6, have driven yearly total revenue to grow at least 34% year over year since the start of 2018. Given that only around 20% of the people with type 2 diabetes in the U.S. have a continuous monitoring device, it's clear that revenue will grow for years to come as DexCom expands its reach into its massive target market."
2020-11-17,113.22000122070312,113.05999755859376,-3.430985826253318,Better Buy: Abbott Laboratories vs. DexCom,"Medical device makers Abbott Laboratories (NYSE: ABT) and DexCom (NASDAQ: DXCM) are hoping small products can have a big effect for patients and investors alike; both companies have new, sleeker continuous glucose monitoring devices (CGMs) in the works. This is despite some very good third-quarter figures that included revenue of $500.9 million, a rise of 26% year over year; net income of $72.2 million, up 58.6%; and $138.4 million in net income so far this year. That $8.9 billion was a 9.6% better than the year before; Abbott's net earnings of $2.3 billion, meanwhile, were down 11.7% year over year."
2020-11-16,112.0500030517578,113.66999816894533,-0.1413210213604051,U.S. government to send over eight million Abbott BinaxNOW tests to stockpile this week,"Nov 16 (Reuters) - The U.S. government will send over eight million of Abbott Laboratories' ABT.N BinaxNOW rapid antigen tests for COVID-19 to the national stockpile this week, a top administration official said at a press briefing on Monday. The U.S. Department of Health and Human Services will push the U.S. Food and Drug Administration to review COVID-19 tests developed by universities, said Admiral Brett Giroir, assistant secretary for health at the U.S. Department of Health and Human Services. (Reporting by Manojna Maddipatla in Bengaluru and Rebecca Spalding, Editing by Franklin Paul) ((manojna.kalyani@thomsonreuters.com; +91 8061822700;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2020-11-13,113.0,112.5999984741211,1.4457787354447684,,
2020-11-12,112.41000366210938,111.9499969482422,-0.35398365122027103,,
2020-11-11,111.94000244140624,112.6500015258789,-0.4092222212267663,9 Outbreak-Fueled Stocks to Buy This Week,"Pfizer (NYSE:PFE) Abbott Laboratories (NYSE:ABT) Johnson & Johnson (NYSE:JNJ) Archer Daniels Midland (NYSE:ADM) NextEra Energy (NYSE:NEE) Wheaton Precious Metals (NYSE:WPM) Axon Enterprise (NASDAQ:AAXN) Blink Charging (NASDAQ:BLNK) Sturm Ruger (NYSE:RGR) For maximum utility, I’ve separated these companies into three categories (with three stocks each): higher-probability names with limited upside, a balanced approach between upside potential and risk, and finally, the downright speculative trades. Abbott Laboratories (ABT) Source: testing / Shutterstock.com With significant developments in the vaccine front, you’d naturally assume that Abbott Laboratories would be incredibly volatile. However, ABT stock has performed resiliently despite the encouraging vaccine news."
2020-11-10,109.25,110.80999755859376,0.6342675263423473,5 Dividend Aristocrats Where Analysts See Capital Gains,"Lowe's Companies Inc (Symbol: LOW) $153.45 $174.00 13.39% Church & Dwight Co Inc (Symbol: CHD) $84.83 $93.36 10.06% Leggett & Platt, Inc. (Symbol: LEG) $41.80 $45.67 9.25% Target Corp (Symbol: TGT) $154.91 $166.13 7.24% Abbott Laboratories (Symbol: ABT) $109.39 $116.58 6.58% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Lowe's Companies Inc (Symbol: LOW) 1.56% 13.39% 14.95% Church & Dwight Co Inc (Symbol: CHD) 1.13% 10.06% 11.19% Leggett & Platt, Inc. (Symbol: LEG) 3.83% 9.25% 13.08% Target Corp (Symbol: TGT) 1.76% 7.24% 9% Abbott Laboratories (Symbol: ABT) 1.32% 6.58% 7.9% Another consideration with dividend growth stocks is just how much the dividend is growing. Lowe's Companies Inc (Symbol: LOW) $2.06 $2.25 9.22% Church & Dwight Co Inc (Symbol: CHD) $0.902 $0.948 5.10% Leggett & Platt, Inc. (Symbol: LEG) $1.56 $1.6 2.56% Target Corp (Symbol: TGT) $2.58 $2.66 3.10% Abbott Laboratories (Symbol: ABT) $1.28 $1.44 12.50% These five stocks are part of our full Dividend Aristocrats List."
2020-11-09,111.8000030517578,109.38999938964844,1.4279153854405164,,
2020-11-06,113.87999725341795,114.41999816894533,-2.1556382793600193,"3 Stocks to Buy and Hold for Decades | Quidel, Abbott, Quest: Testing Stocks To Watch As Covid-19 Cases Surge","Abbott Laboratories Abbott Laboratories (NYSE: ABT) isn't the kind of stock you can buy and hold for only decades -- you can hold this one for centuries. See the 10 stocks *Stock Advisor returns as of October 20, 2020 Keith Speights owns shares of Intuitive Surgical and PayPal Holdings. The Motley Fool owns shares of and recommends Intuitive Surgical and PayPal Holdings and recommends the following options: long January 2022 $75 calls on PayPal Holdings, long January 2022 $580 calls on Intuitive Surgical, and short January 2022 $600 calls on Intuitive Surgical. | Abbott Laboratories (ABT) has a diverse range of solutions including a test called BinaxNOW that provides test results in fifteen minutes and works without relying on lab equipment. Our indicative theme of Covid-19 Testing Stocks, which includes medical device and diagnostic companies that are involved in Covid-19 testing – is up by about 66% year-to-date, significantly outperforming the S&P 500 which has gained about 3% over the same period. Covid-19 testing stocks could be a relatively safe way for investors to play the containment of the pandemic in the near-term, considering that companies are already generating revenue from tests, unlike vaccine stocks – which are still in the trial phases and Covid therapeutics which have shown relatively mixed efficacy thus far."
2020-11-05,113.51000213623048,113.52999877929688,0.4741841662725934,Becton Dickinson beats profit estimates on strong demand for COVID-19 tests | Becton Dickinson posts 16% fall in quarterly profit,"Demand for point-of-care tests like the ones made by Becton and rival Abbott Laboratories ABT.N has shot up in recent weeks as countries strain to contain a second wave of coronavirus infections. Compares with estimates, adds details on earnings Nov 5 (Reuters) - Medical technology company Becton Dickinson and Co BDX.N beat fourth-quarter profit estimates on Thursday, fueled by strong demand for its COVID-19 diagnostic tests. Net profit attributable to shareholders was $105 million, or 36 cents per share, in the quarter ended Sept. 30, compared to net earnings of $125 million, or 45 cents per share, last year. | Nov 5 (Reuters) - Becton Dickinson and Co BDX.N on Thursday posted a 16% fall in fourth-quarter profit, as the medical technology company was hurt by patients deferring discretionary procedures due to the COVID-19 pandemic. Net profit attributable to shareholders was $105 million, or 36 cents per share, in the quarter ended Sept. 30, compared to net earnings of $125 million, or 45 cents per share, last year. (Reporting by Vishwadha Chander and Trisha Roy in Bengaluru; Editing by Amy Caren Daniel) ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6749 6132;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2020-11-04,110.16999816894533,111.52999877929688,0.017616635265668316,,
2020-11-03,108.73999786376952,109.55999755859376,1.2344564154988837,Your First Instinct About Sorrento Therapeutics Is Probably Right,"Larry Ramer wrote that the current “gold standard” test from Abbott (NYSE:ABT) has to be administered by a health professional or other trained individual. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sorrento Therapeutics (NASDAQ:SRNE) has given investors a wild ride this year. In particular, the company announced in August that its CEO Henry Ji would receive 25 million shares of stock if the company reaches a market capitalization of $5 billion."
2020-11-02,107.08999633789062,107.4800033569336,0.7540920644964059,3 Top Stocks With High Dividend Yields | 3 Dividend Stocks to Supplement Your Social Security,"VZ Return on Equity data by YCharts AbbVie remains a great dividend AbbVie's share price is down 3.7% this year, which offers another opportunity and drives up the yield on the company's dividend to 5.85%. With Friday's announcement, the company will have raised its dividend for eight consecutive years and in the past three years, its dividends have seen a compound annual growth rate (CAGR) of 23.36%. In the company's third-quarter report released Friday, it reported revenues of $12.9 billion, up 52.1% year over year and earnings per share of $2.83, up 21.5% year over year. | In addition to drawing down on your savings accounts, one way to meet your need for a steady flow of income after you stop working full time is to invest in dividend stocks. 10 stocks we like better than Waste Management When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. See the 10 stocks *Stock Advisor returns as of October 20, 2020 Barbara Eisner Bayer owns shares of AbbVie and Waste Management."
2020-10-30,104.76000213623048,105.11000061035156,0.364186228760731,2 No-Brainer Stocks to Buy In The Next Market Crash | Hologic Stock Is Up 145% Off The Recent Bottom But The Rally May Continue,"Of course, there's no guarantee that another market crash will happen soon, but two stocks you should consider buying on the dip if it does -- or even if it doesn't -- are Abbott Laboratories (NYSE: ABT) and Netflix (NASDAQ: NFLX). ABT data by YCharts 1. Abbott Laboratories is well-positioned to keep profiting from the growing CGM market, and thanks to its COVID-19 (and other) efforts, the healthcare stock will probably keep outperforming the market. | Despite almost a 145% rise in the stock price of  Hologic (NASDAQ:HOLX), since the March lows of this year, at the current price of around $70 per share, we believe HOLX stock has more room for growth. The coronavirus testing is expected to remain high across the globe in the coming months, which will bolster Hologic’s revenue growth, especially now that the US FDA has approved Hologic’s Covid-19 test for asymptomatic individuals. That said, now that the company’s installed base is growing at a faster pace and it will likely result in increased recurring revenues over the coming years, investors may assign a higher valuation multiple for Hologic going forward, resulting in an upside to the stock."
2020-10-29,106.37999725341795,105.0,0.3340955202214864,9 Companies to Invest In Before We Hit 2021 | 2 Healthcare Dividend Stocks to Buy No Matter Who Wins the Election,"Kroger (NYSE:KR) Procter & Gamble (NYSE:PG) Anheuser Busch (NYSE:BUD) Abbott Laboratories (NYSE:ABT) Novavax (NASDAQ:NVAX) NextEra Energy (NYSE:NEE) H&R Block (NYSE:HRB) Sturm Ruger (NYSE:RGR) Vista Outdoor (NYSE:VSTO) Finally, because the election will likely be contentious (to say the least), the American economy will likely suffer. Abbott Laboratories (ABT) Source: testing / Shutterstock.com According to the Centers for Disease Control and Prevention, we saw nearly 84,000 new Covid-19 infections on Oct. 24. But because the coronavirus could ebb and flow, it might be better to get in on ABT stock before year’s end. | ABT Cash Dividend Payout Ratio (Annual) data by YCharts Having a diverse product offering in a demographically advantaged industry -- 10,000 baby boomers turn 65 every day -- puts Abbott Labs in an enviable position. Abbott Labs Abbott Labs is a diversified healthcare company comprised of four business units: medical devices, diagnostics, established pharmaceuticals, and nutrition. With strong prospects and a dividend that management can easily pay from cash flow, Abbott Labs deserves a place in the portfolio of healthcare investors looking for yield."
2020-10-28,106.80999755859376,106.41999816894533,-1.2972337742503708,Boston Scientific reports loss as COVID-19 slams demand for medical devices,"Rival Abbott Laboratories ABT.N, however, raised its 2020 profit forecast last week on strong COVID-19 testing revenue and a recovery in its medical device business. Adds segment figures, background Oct 28 (Reuters) - Boston Scientific Corp BSX.N swung to a loss in the third quarter from profit a year ago, as demand for its medical devices was hurt by the ongoing COVID-19 pandemic. Net loss attributable to Boston Scientific was $169 million, or 12 cents per share, in the quarter ended Sept 30, compared with net earnings of $126 million, or 9 cents per share, last year."
2020-10-27,108.88999938964844,108.58000183105467,-0.36513378762553744,CANADA STOCKS-TSX futures inch lower as bullion eases on buoyant dollar,"Bird Construction Inc BDT.TO: CIBC initiates coverage with ""outperform"" rating Canadian Tire Corp Ltd CTCa.TO: RBC raises target price to C$173 from C$168 Absolute Software Corp ABT.TO: National Bank of Canada raises target to C$18 from C$17 COMMODITIES AT 7:00 a.m. Oct 27 (Reuters) - Canada's main stock index futures inched lower on Tuesday, as weakness in bullion weighed by a buoyant dollar and lack of progress on a U.S. stimulus package offset firmer oil prices. ET, while S&P 500 e-mini futures ESc1 were up 0.48% and Nasdaq 100 e-mini futures NQc1 were up 0.51%."
2020-10-26,107.56999969482422,109.0,-0.2846887320519481,"BUZZ-U.S. STOCKS ON THE MOVE-Moderna, Royal Caribbean, oil and tech stocks | BUZZ-U.S. STOCKS ON THE MOVE-Kroger, Carnival, Silvergate","Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks decline picked pace on Monday afternoon, setting the Dow for its worst day in more than seven weeks, as soaring coronavirus cases and a political deadlock over the fiscal relief bill raised doubts about the fate of the economy recovery. The top three S&P 500 .PG.INX percentage gainers: ** American Electric Power Company Inc , up 1.8% ** Consolidated Edison Inc , up 1.3% ** Abbott Labs , up 1.1% The top three S&P 500 .PL.INX percentage losers: ** Royal Caribbean Cruises Ltd , down 13.2% ** Norwegian Cruise Line Holdings Ltd , down 10.7% ** Hasbro Inc , down 10.5% The top NYSE .PG.N percentage gainer: ** Document Security Systems Inc , up 41.3% The top three NYSE .PL.N percentage losers: ** SAP SE , down 23.3% ** 3D Systems Corp , down 15.9% ** Royal Caribbean Cruises Ltd , down 13.2% The top three Nasdaq .PG.O percentage gainers: ** Lianluo Smart Ltd , up 28.1% ** Mid-Con Energy Partners LP , up 22.1% ** SLM Corp , up 20.2% The top three Nasdaq .PL.O percentage losers: ** BioSig Technologies Inc , down 41.4% ** Nano Dimension Ltd , down 23.4% ** BiondVax Pharmaceuticals Ltd , down 22.8% ** Exxon Mobil Corp XOM.N down 2.9% ** Chevron Corp CVX.N down 2.9% ** Schlumberger NV SLB.N down 1.9% ** Halliburton Co HAL.N down 3.2% ** Pioneer Natural Resources PXD.N down 4.1% ** Occidental Petroleum OXY.N down 6.1% ** Marathon Oil MRO.N down 6.8% ** Callon Petroleum CPE.N down 6.6% BUZZ-Energy firms fall as crude prices drop on COVID-19 demand concerns ** Titan Pharma TTNP.O : up 10.1% BUZZ-Titan Pharma: Surges after settling debt of $5.2 mln ** Microsoft MSFT.O: down 3.1% ** Amazon.com AMZN.O: down 0.9% ** Alphabet Inc GOOGL.O : down 3.4% ** International Business Machines IBM.N:down 2.9% ** Oracle Corp ORCL.N: down 4.0% **Salesforce.com CRM.N: down 4.7% BUZZ-Tech cos fall after SAP scraps medium-term margin goals ** Raytheon Co RTX.N: down 3.5% BUZZ-U.S. weapons makers dip after China to impose sanctions over Taiwan arms sales ** Advanced Micro Devices Inc AMD.O: down 1.0% BUZZ-Advanced Micro Devices: Susquehanna raises PT on strong Q3 hopes ** Apple Inc AAPL.O: down 1.0% BUZZ-Apple Inc: Citi Research sees upside from strength in Macs, iPads ** Mid-Con Energy Partners LP MCEP.O: up 22.1% BUZZ-Mid-Con Energy Partners: Surges on merger deal with Contango Oil & Gas ** Esports Entertainment Group Inc GMBL.O down 0.6% BUZZ-Rises on deal to buy assets worth $43 mln ** Zoom Video Communications Inc ZM.O up 1.0% BUZZ-Rises on launch of end-to-end encryption for all users ** Turning Point Therapeutics Inc down 8.4% BUZZ-Slips on $400 mln equity raise plans ** New Residential Investment Corp NRZ.N down 8.3% BUZZ-Slides after Q3 profit miss ** Amgen AMGN.O down 1.8% BUZZ-Dips on competitive lung cancer data from Mirati ** Silvergate Capital Corp SI.N up 8.3% BUZZ-Scales all-time high on upbeat Q3 ** BioXcel BTAI.O down 2.0% BUZZ- Gains after FDA nod for mid-stage study of delirium associated agitation drug ** HCA Healthcare HCA.N down 1.7% BUZZ-Falls as Q3 results signal slower recovery from COVID-19 hit ** Galera Therapeutics GRTX.O up 2.1% BUZZ-Up on promising interim data from pancreatic cancer drug study ** Moderna Inc MRNA.O down 1.6% BUZZ-Up on Qatar deal for COVID-19 vaccine ** Spirit AeroSystems SPR.N down 7.7% BUZZ-Spirit AeroSystems: says deal price for Bombardier unit cut to $275 mln ** Beyond Meat BYND.O down 4.5% BUZZ-Falls as Impossible Foods set to make Canada retail debut ** Hasbro HAS.O down 10.5% BUZZ-Down as results fail to live up to heightened expectations ** Boot Barn Holdings BOOT.N down 5.8% BUZZ-Down after brokerage downgrades to 'hold' The 11 major S&P 500 sectors: Communication Services down 2.65% Consumer Discretionary | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's indexes fell sharply on Monday as soaring coronavirus cases and a deadlock in Washington over the next fiscal aid bill darkened the economic outlook in the run up to the Nov. 3 presidential election.N At 11:07 a.m. ET, the Dow Jones Industrial Average .DJI was down 2.33% at 27,674.18. The top three S&P 500 .PG.INX percentage gainers: ** Abbott Laboratories , up 0.9 % ** American Electric Power Company Inc. , up 0.8 % ** Kroger Co , up 0.6 % The top three S&P 500 .PL.INX percentage losers: ** Royal Caribbean Cruises Ltd., down 9.8 % ** Hasbro Inc , down 9.7 % ** Carnival Corp , down 9.5 % The top three NYSE .PG.N percentage gainers: ** Document Security Systems Inc, up 36.5 % ** Silvergate Capital Corp., up 10.1 % ** ProShares Ultra VIX Short-Term Futures ETF, up 9.8 % The top three NYSE .PL.N percentage losers: ** Sap Ae Drc , down 22.7 % ** Cenovus Enrg , down 14.3 % ** 3D Systems Corp , down 13.6 % The top three Nasdaq .PG.O percentage gainers: ** Muscle Maker Inc , up 41.8 % ** Lianluo Smart Ltd,, up 31.8 % ** Galera Therapeutics Inc , up 18.2 % The top three Nasdaq .PL.O percentage losers: ** BioSig Technologies Inc , down 38.8 % ** BiondVax Pharmaceuticals Ltd , down 24.9 % ** Revolution Medicines Inc , down 19 % ** Exxon Mobil Corp XOM.N down 3.2% ** Chevron Corp CVX.N down 2.4% ** Schlumberger NV SLB.N down 2.9% ** Halliburton Co HAL.N down 3.9% ** Pioneer Natural Resources PXD.N down 2.7% ** Occidental Petroleum OXY.N down 4.9% ** Marathon Oil MRO.N down 6.1% ** Callon Petroleum CPE.N down 7.7% BUZZ-Energy firms fall as crude prices drop on COVID-19 demand concerns ** Titan Pharma TTNP.O : up 16.1% BUZZ-Titan Pharma: Surges after settling debt of $5.2 mln ** Microsoft MSFT.O: down 1.9% ** Amazon.com AMZN.O: up 0.3% ** Alphabet Inc GOOGL.O : down 2.0% ** International Business Machines IBM.N:down 2.6% ** Oracle Corp ORCL.N: down 5.4% **Salesforce.com CRM.N: down 3.7% BUZZ-Tech cos fall after SAP scraps medium-term margin goals ** Raytheon Co RTX.N: down 4.1% BUZZ-U.S. weapons makers dip after China to impose sanctions over Taiwan arms sales ** Advanced Micro Devices Inc AMD.O: up 0.6% BUZZ-Advanced Micro Devices: Susquehanna raises PT on strong Q3 hopes ** Apple Inc AAPL.O: down 0.2% BUZZ-Apple Inc: Citi Research sees upside from strength in Macs, iPads ** Mid-Con Energy Partners LP MCEP.O: up 15.9% BUZZ-Mid-Con Energy Partners: Surges on merger deal with Contango Oil & Gas The 11 major S&P 500 sectors: Communication Services"
2020-10-23,109.63999938964844,107.79000091552734,1.3293672113346546,,
2020-10-22,106.41999816894533,109.4800033569336,-1.6873390043960177,"European cities plead for more flu shots as winter looms, pandemic rages | 2 Stocks to Buy as the Third Coronavirus Wave Hits","Top manufacturers such as GlaxoSmithKline GSK.L, Sanofi SASY.PA, Abbott ABT.N and Seqirus have boosted supplies to the region by an average of 30% in anticipation of higher demand. Seasonal flu viruses cause between 4 million and 50 million infections each year and up to 70,000 Europeans die each year of causes linked to flu, particularly among older adults and at-risk groups. Given the long lead times needed for flu vaccines to be produced, manufacturers made all possible efforts to increase production in the exceptional circumstances, Vaccines Europe said. | Abbott Labs Like many companies, Abbott Laboratories (NYSE: ABT) has experienced challenges as a result of the COVID-19 pandemic. Teladoc Health Teladoc Health (NYSE: TDOC) stands out as one of the biggest winners from the COVID-19 pandemic. See the 10 stocks *Stock Advisor returns as of September 24, 2020 Keith Speights owns shares of Livongo Health and Teladoc Health."
2020-10-21,108.01000213623048,105.93000030517578,2.875404285508825,"Abbott Laboratories Q3 adjusted earnings Beat Estimates | BUZZ-U.S. STOCKS ON THE MOVE-Snap Inc, Facebook, Astrotech Corp | Here's What to Really Like About Abbott Labs' Q3 Results | Abbott raises annual profit view as COVID-19 tests power growth | US STOCKS-Futures tick higher on stimulus optimism","(RTTNews) - Abbott Laboratories (ABT) reported a profit for its third quarter that advanced from last year. Excluding items, Abbott Laboratories reported adjusted earnings of $1.76 billion or $0.98 per share for the period. The company's revenue for the quarter rose 9.5% to $8.85 billion from $8.08 billion last year. | The top three NYSE percentage gainers premarket .PRPG.NQ: ** Snap Inc , up 21.3% ** VOC Energy Trust , up 20.5% ** Calix Inc , up 14.6% The top three NYSE percentage losers premarket .PRPL.NQ: ** GSX Techedu Inc , down 22.3% ** Armstrong Flooring Inc , down 17.6% ** Hertz Global Holdings Inc , down 8.7% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Marin Software Inc , up 143.0% ** Astrotech Corp , up 145.0% ** China Xiangtai Food Co Ltd , up 94.2% The top three Nasdaq percentage losers premarket .PRPL.O: ** Iterum Therapeutics Plc , down 16.5% ** Code Chain New Continent Ltd , down 14.4% ** CRISPR Therapeutics , down 13.6% ** Astrotech Corp ASTC.O: up 145.0% premarket BUZZ-Astrotech: Surges on deal to develop rapid COVID-19 breath test ** Container Store Group Inc TCS.N: up 8.9% premarket BUZZ-The Container Store: Rises on strong Q2 results, Marie Kondo tie-up ** Facebook Inc FB.O: up 3.1% premarket ** Twitter Inc TWTR.N: up 5.2% premarket ** Snap Inc SNAP.N: up 21.3% premarket ** Pinterest Inc PINS.N: up 8.8% premarket BUZZ-Social media cos up on Snap's strong Q3 revenue, user growth ** Thermo Fisher Scientific Inc TMO.N: up 2.1% premarket BUZZ-Thermo Fisher rises as Q3 profit, revenue top estimates ** Mosaic Co MOS.N: down 2.3% premarket BUZZ-Mosaic: Slips as Citi cuts PT on limited upside to phosphate import duties ** Sunrun Inc RUN.O: down 4.5% premarket BUZZ-Sunrun down after Morgan Stanley prices big block of shares ** CRISPR Therapeutics CRSP.O: down 13.6% premarket BUZZ-CRISPR Therapeutics: Falls as co reports patient death in CAR-T cancer therapy trial ** Abbott Laboratories ABT.N: up 0.8% premarket BUZZ-Abbott: Rises as COVID-19 tests drive Q3 profit beat, outlook raise (Compiled by Tiyashi Datta) ((tiyashi.datta@thomsonreuters.com)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock index futures edged higher on Wednesday on signs that Washington could be close to agreeing on the next coronavirus aid package to support a fragile economic recovery. S&P 500 e-minis ESc1 were down 0.07% at 3,429.75, while Nasdaq 100 e-minis NQc1 were down 0.17% at 11,641.25. | It's been a banner year so far for Abbott Laboratories (NYSE: ABT). Abbott's nutrition sales increased by 2.6% in the third quarter to $1.9 billion. The worst performance in Q3 came from Abbott's established pharmaceuticals segment, with sales falling 9.3% year over year on a reported basis to nearly $1.1 billion. | Adds details on full-year forecast Oct 21 (Reuters) - Abbott Laboratories ABT.N raised its annual profit forecast on Wednesday on demand for its COVID-19 tests and on signs of recovery in sales of its medical devices as patients catch up on the optional surgeries they had put off due to the pandemic. Companies like Roche Holding AG ROG.S, Becton Dickinson BDX.N and Abbott have been betting on their COVID-19 tests to make up for weakness in sales of medical devices and diagnostics due to COVID-19 induced movement restrictions. Its net earnings rose to $1.23 billion, or 69 cents per share in the quarter ended Sept. 30, from $960 million or 53 cents per share, a year earlier. | Abbott Laboratories ABT.N rose 0.8% after it raised its annual profit forecast. By Medha Singh Oct 21 (Reuters) - U.S. stock index futures edged higher on Wednesday on signs that Washington could be close to agreeing on the next coronavirus aid package to support a fragile economic recovery. White House Chief of Staff Mark Meadows said the Trump administration and House Democrats shared a goal of reaching an agreement in the next 48 hours."
2020-10-20,108.3499984741211,108.36000061035156,-1.9257492731379118,"5 Top Stock Trades for Wednesday: LOGI, PM, VZ, IRBT, ABT | Pre-Market Earnings Report for October 21, 2020 : VZ, ABT, TMO, NEE, BIIB, APH, ERIC, NDAQ, NTRS, KEY, TDY, AVY","More From InvestorPlace Forget The Election… Pick These Stocks for the Win in 2021 Why Everyone Is Investing in 5G All WRONG America’s #1 Stock Picker Reveals His Next 1,000% Winner Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company The post 5 Top Stock Trades for Wednesday: LOGI, PM, VZ, IRBT, ABT appeared first on InvestorPlace. 5: Abbott Labs (ABT) Click to EnlargeSource: Chart courtesy of StockCharts.com Abbott Labs (NYSE:ABT) continues to trade higher in a slowly but surely manner. | Abbott Laboratories (ABT) is reporting for the quarter ending September 30, 2020. In the past year ABT has met analyst expectations twice and beat the expectations the other two quarters. Zacks Investment Research reports that the 2020 Price to Earnings ratio for ABT is 32.74 vs. an industry ratio of 30.20, implying that they will have a higher earnings growth than their competitors in the same industry."
2020-10-19,109.9000015258789,108.04000091552734,0.009231321062600398,"BUZZ-U.S. STOCKS ON THE MOVE-American Airlines, Centogene, L Brands, AMC, JinkoSolar | BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Abbott, Concho, Biogen | BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Abbott, Microsoft, American Airlines","The top three S&P 500 .PG.INX percentage gainers: ** L Brands Inc , up 4.7 % ** United Airlines Holdings Inc , up 3.8 % ** Freeport-McMoRan Inc , up 3.4 % The top three S&P 500 .PL.INX percentage losers: ** EOG Resources Inc , down 2.5 % ** Vornado Realty Trust , down 2.3 % ** Diamondback Energy Inc , down 2 % The top three NYSE .PG.N percentage gainers: ** Front Yard Residential Corp , up 35.6 % ** AMC Entertainment Holdings Inc , up 23 % ** Natuzzi S.p.A. , up 21.1 % The top three NYSE .PL.N percentage losers: ** American Equity Investment Life Holding Co , down 15 % ** Ihuman Inc , down 10.4 % ** Hyliion Holdings Corp , down 6.5 % The top three Nasdaq .PG.O percentage gainers: ** Kaixin Auto Holdings , up 183.6 % ** Code Chain New Continent Ltd , up 122.7 % ** BOQI International Medical Inc , up 60.8 % The top three Nasdaq .PL.O percentage losers: ** Abraxas Petroleum Corp , down 25.5 % ** CHF Solutions, Inc , down 18.2 % ** The9 Ltd , down 15.2 % ** Tesla TSLA.O: up 0.8% BUZZ-Tesla: Wedbush bets on strong Q3 performance, hikes PT to $500 ** Abbott ABT.N: up 1.0% BUZZ-Abbott's heart device could receive national coverage under Medicare- Cowen ** American Airlines AAL.O: up 1.3% BUZZ-American Airlines: Gains after co hints 737 MAX could return by 2020-end ** Concho Resources CXO.N: up 0.2% BUZZ-Concho Resources rises on ConocoPhillips' $9.7 bln buyout deal ** Biogen Inc BIIB.O: down 1.0% BUZZ-FDA panel meet on Alzheimer's drug remains focus - analysts ** Centogene CNTG.O: up 14.3% BUZZ-Centogene: Up as U.S. FDA grants emergency use for COVID-19 test ** L Brands LB.N: up 4.7% BUZZ-L Brands: J.P.Morgan raises PT on strong Bath & Body Works margins expectations ** Fluidigm FLDM.O: up 4.7% BUZZ-Fluidigm leaps after Trump administration provides COVID-19 test in Texas ** Cisco CSCO.O: down 0.9% BUZZ-Cisco: Credit Suisse cuts PT ahead of Q1 results ** AMC AMC.N: up 23.0% BUZZ-AMC shares rise as New York state prepares to reopen theaters ** D.R. .N At 10:28 ET, the Dow Jones Industrial Average .DJI was up 0.11% at 28,636.93. Horton: Rises on buying smaller rival in Texas for $23 mln ** Front Yard Residential RESI.N: up 35.6% BUZZ-Front Yard Residential: Jumps on $767 mln go-private deal ** GoodRx Holdings GDRX.O: down 3.7% BUZZ-Street View: Wall Street expects GoodRx to benefit from strong consumer brand ** JinkoSolar JKS.N: up 6.1% BUZZ-JinkoSolar: Up on supply deal for Kozani project ** BioSpecifics BSTC.O: up 44.4% BUZZ-BioSpecifics: Hits record high on takeover deal from Endo ** Kamada KMDA.O: up 8.8% BUZZ-Kamada: Rises on supply deal with Israel for experimental COVID-19 treatment ** ARC Document Solutions ARC.N: up 18.4% BUZZ-ARC Document Solutions: Up on stronger Q3 result expectations ** Aerie Pharma AERI.O: down 13.9% BUZZ-Aerie Pharma: BOFA says post COVID-19 pathway looks challenging, downgrades ** Warner Music WMG.O: up 2.4% BUZZ-Warner Music rises on upbeat FY20 revenue forecast ** Microchip Technology MCHP.O: up 2.4% BUZZ-Microchip Technology: MS sees upside in second half, upgrades ** Tivity Health Inc TVTY.O: up 3.6% BUZZ-Tivity Health Inc: Rises after divesting nutrition business ** OraSure Tech OSUR.O: up 18.0% BUZZ-OraSure Tech: Surges as COVID-19 saliva testing device gets emergency use tag ** Bentley Systems BSY.O: down 8.1% BUZZ-Bentley Systems: IPO banks' initiations skew 'neutral' after research quiet period ends ** MEDNAX Inc MD.N: down 6.0% BUZZ-MEDNAX Inc: At 5-month low after Deutsche Bank downgrade ** BOQI International Medical Inc BIMI.N: up 57.0% BUZZ-BOQI International Medical surges as Guanzan acquisition powers Q2 revenue jump The 11 major S&P 500 sectors: Communication Services | The top three NYSE percentage gainers premarket .PRPG.NQ: ** Front Yard Residential Corp , up 34.8% ** ARC Document Solutions Inc , up 22.3% ** SEACOR Marine Holdings Inc , up 18.0% The top three NYSE percentage losers premarket .PRPL.NQ: ** American Equity Investment Life Holding , down 8.7% ** Hudbay Minerals Inc , down 8.1% ** Navios Maritime Partners , down 7.5% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Code Chain New Continent Ltd , up 164.5% ** Kaixin Auto Holdings , up 71.0% ** Boqi International Medical Inc , up 58.8% The top three Nasdaq percentage losers premarket .PRPL.O: ** Paya Holdings Equity Warrants , down 35.1% ** Ameri Holdings Equity Warrants , down 32.3% ** CHF Solutions Inc , down 18.9% ** Tesla TSLA.O: up 1.5% premarket BUZZ-Tesla: Wedbush bets on strong Q3 performance, hikes PT to $500 ** Abbott ABT.N: up 0.8% premarket BUZZ-Abbott's heart device could receive national coverage under Medicare- Cowen ** Microsoft Corp MSFT.O: up 0.5% premarket BUZZ-Microsoft: Jefferies raises PT on hopes of strong Q1 results ** American Airlines AAL.O: up 1.0% premarket BUZZ-American Airlines: Gains after co hints 737 MAX could return by 2020-end ** OraSure Tech OSUR.O: up 19.5% premarket BUZZ-OraSure Tech: Surges as COVID-19 saliva testing device gets emergency use tag ** Biogen Inc BIIB.O: down 0.2% premarket BUZZ-FDA panel meet on Alzheimer's drug remains focus - analysts ** Centogene CNTG.O: up 7.7% premarket BUZZ-Centogene: Up as U.S. FDA grants emergency use for COVID-19 test ** Schlumberger NV SLB.N: up 0.9% premarket BUZZ-Street View: Schlumberger's 2021 margins likely to grow above 2019 levels ** L Brands LB.N: up 3.2% premarket BUZZ-L Brands: J.P.Morgan raises PT on strong Bath & Body Works margins expectations ** Concho Resources CXO.N: up 2.9% premarket BUZZ-Concho Resources rises on ConocoPhillips' $9.7 bln buyout deal ** Beyond Air Inc XAIR.O: up 3.6% premarket BUZZ-Beyond Air Inc: Jumps on upcoming data presentation on Nitric Oxide on coronavirus ** AMC AMC.N: up 8.2% premarket BUZZ-AMC shares rise as New York state prepares to reopen theaters ** D.R. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes were set to inch higher at the open on Monday on hopes of a coronavirus vaccine by the year-end, while investors were also encouraged by signs an agreement in Washington on a fiscal package could be reached soon. S&P 500 e-minis ESc1 were up 0.75% at 3,488.25, while Nasdaq 100 e-minis NQc1 were up 0.95% at 11,910.25. | The top three NYSE percentage gainers premarket .PRPG.NQ: ** Mistras Group Inc MG.N, up 14.7% ** MGM Growth Properties LLC MGP.N, up 11.8% ** Concho Resources Inc CXO.N, up 11.1% The top three NYSE percentage losers premarket .PRPL.NQ: ** American Equity Investment Life Holding Co AEL.N, down 9.9% ** J.Jill Inc JILL.N, down 7.9% ** Plains GP Holdings LP PAGP.N, down 6.9% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Kaixin Auto Holdings KXIN.O, up 63.3% ** Midatech Pharma Plc MTP.O, up 39.0% ** Senmiao Technology Ltd AIHS.O, up 23.3% The top three Nasdaq percentage losers premarket .PRPL.O: ** Paya Holdings Equity Warrant PAYAW.O, down 35.1% ** The9 Ltd NCTY.O, down 16.3% ** CHF Solutions Inc CHFS.O, down 11.3% ** Tesla TSLA.O: up 1.4% premarket BUZZ-Tesla: Wedbush bets on strong Q3 performance, hikes PT to $500 ** Abbott ABT.N: up 0.6% premarket BUZZ-Abbott's heart device could receive national coverage under Medicare- Cowen ** Microsoft Corp MSFT.O: up 0.7% premarket BUZZ-Microsoft: Jefferies raises PT on hopes of strong Q1 results ** American Airlines AAL.O: up 1.0% premarket BUZZ-American Airlines: Gains after co hints 737 MAX could return by 2020-end ** Concho Resources CXO.N: up 1.6% premarket BUZZ-Concho Resources: Jumps on takeover by ConocoPhillips (Compiled by Tiyashi Datta in Bengaluru) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock index futures climbed on Monday on hopes of a coronavirus vaccine by the year end, while remarks from House Speaker Nancy Pelosi revived bets that an agreement in Washington on a fiscal package could be reached soon .N At 07:14 ET, Dow e-minis 1YMc1 were up 0.79% at 28,633. S&P 500 e-minis ESc1 were up 0.82% at 3,490.75, while Nasdaq 100 e-minis NQc1 were up 1.02% at 11,917.75."
2020-10-16,107.6999969482422,109.66999816894533,-1.6924482115803934,,
2020-10-15,106.8499984741211,107.31999969482422,1.8291562456123893,"Covid Testing Stocks To Watch As The Holidays Near | Hologic Stock Is Up 15% In A Month, What Are The Chances It'll Fall From Here?","Abbott Laboratories (ABT) has a diverse range of solutions including a test called BinaxNOW that provides test results in 5 minutes and works without relying on lab equipment. Our indicative theme of Covid-19 Testing Stocks, which includes medical devices and diagnostic companies that are involved in Covid-19 testing – is up by about 69% year-to-date, significantly outperforming the S&P 500 which is up by about 8% over the same period. Quidel (QDEL) is a company that sells diagnostic healthcare products including rapid diagnostic testing solutions, cellular-based virology assays, and molecular diagnostic systems. | According to the Trefis Machine Learning Engine, which identifies trends in a company’s stock price, returns for Hologic stock average around 0.4% in the next one-month (21 trading days) period after experiencing 15% gains over the previous month (21 trading days). 1 day -0.3% 0.5% 5 days -0.1% 1.1% 10 days 0.2% 0.9% 21 days 3.8% 3.1% 63 days 12.8% 5.2% 126 days 21.5% 7.4% 252 days 17.8% 15.6% You can try the engine to see what this table looks like for Hologic after a larger loss over the last week, month, or quarter. 1 day 0.2% -0.3% 5 days 1% -0.3% 10 days 4.5% 0.1% 21 days 7.1% 0.5% 63 days 15.4% 3.0% 126 days 19.3% 6.6% 252 days 13.5% 11.7% It’s pretty powerful to test the trend for yourself for Hologic stock by changing the inputs in the charts above."
2020-10-14,108.61000061035156,107.75,0.4398701239260744,"Healthineers launches rapid coronavirus antigen test, sees tight supply | Better Buy: AbbVie vs. Johnson & Johnson | Healthineers launches rapid COVID-19 antigen test kit in Europe | Countries turn to rapid antigen tests to contain second wave of COVID-19","The German group, whose rivals in diagnostics include Roche ROG.S, Abbott ABT.Nand Becton Dickinson BDX.N, said its test cassette did not require lab processing and would deliver results in 15 minutes, but that the required nasal swabs would have to be taken by healthcare professionals. PCR (polymerase chain reaction) tests, which scan genetic code for the markers of a virus, are the gold standard for finding infections but are two to three times more expensive than antigen tests and require processing in a lab. The regional state of Bavaria followed up this week with an order for 10 million antigen tests, saying it had options to purchase from Healthineers, Roche and Abbott. | AbbVie was spun out of Abbott Labs (NYSE: ABT) in 2013 in order separate its pharmaceutical business from its legacy medical products business. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) are two pharmaceutical companies that fit the widow-and-orphan description. So similar, yet so different Pharmaceutical companies like AbbVie and Johnson & Johnson all develop, manufacture, and market drugs, but are wildly different businesses when you dig into the details. | The German group, whose main rivals in diagnostics are Roche ROG.S and Abbott ABT.N, said on Wednesday its test cassette does not require specialized laboratory instruments or personnel and it delivers results in 15 minutes. FRANKFURT, Oct 14 (Reuters) - Siemens Healthineers SHLG.DE is launching a rapid antigen test kit to detect infections with the coronavirus in Europe, as public health systems scramble to provide quick diagnostics tools to fight the pandemic. Healthcare professionals would still have to perform a nasal swab, it added. | Rivals including Siemens Healthineers SHLG.DE, Abbott Laboratories ABT.N and Becton Dickinson BDX.N also offer numerous COVID-19 diagnostic tests. Germany's Robert Koch Institute (RKI) now recommends antigen tests to complement existing molecular PCR tests, which have become the standard for assessing active infections but which have also suffered shortages as the pandemic overwhelmed laboratories and outstripped manufacturers' production capacity. PCR tests detect genetic material in the virus while antigen tests detect proteins on the virus's surface, though both are meant to pick up active infections."
2020-10-13,110.5,108.37000274658205,-0.7918245147948156,"Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for October 14, 2020","Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. The following ETF(s) have ABT as a top-10 holding: iShares U.S. ETF Trust (IEHS) AdvisorShares Vice ETF (ACT) Invesco Dynamic Pharmaceuticals ETF (PJP) SPDR Select Sector Fund - Health Care (XLV) iShares U.S. Medical Devices ETF (IHI)."
2020-10-12,110.25,111.0500030517578,-1.9275993243601397,"BUZZ-U.S. STOCKS ON THE MOVE-Facebook, Apple, Goldman Sachs, Amazon | Abbott Gets Emergency Use Authorization For COVID-19 IgM Antibody Test - Quick Facts | Market Crash 2.0: Where to Invest $1,000 | 2 Top Healthcare Stocks to Watch in October | BUZZ-U.S. STOCKS ON THE MOVE-Twitter, Apple, Dillard's, Fat Brands | Abbott wins U.S. emergency use authorization for new COVID-19 antibody test","The top three S&P 500 .PG.INX percentage gainers: ** Ford Motor Co , up 6.6% ** Apple Inc , up 5.7% ** Westrock Company , up 5.7% The top three S&P 500 .PL.INX percentage losers: ** Apache Corp , down 4.4% ** CF Industries Holdings Inc , down 3.7% ** LyondellBasell Industries N.V. , down 2.7% The top three NYSE .PG.N percentage gainers: ** Ihuman Inc , up 45.9% ** Dillard's Inc , up 39.5% ** Acorn International Inc , up 37.3% The top three NYSE .PL.N percentage losers: ** Renesola Ltd , down 18% ** Adams Resources & Energy Inc , down 15.6% ** AgeX Therapeutics Inc , down 15.3% The top three Nasdaq .PG.O percentage gainers: ** Wah Fu Education Group Limited , up 30.1% ** Lizhi Inc , up 29.8% ** Apex Global Brands Inc , up 25% The top three Nasdaq .PL.O percentage losers: ** Avenue Therapeutics Inc , down 58.1% ** Zynex Inc , down 27.9% ** Marine Petroleum Trust , down 27.2% ** Alibaba Group Holding Limited BABA.N: up 2.7% BUZZ- Set for record high, Jefferies raises PT on earnings expectations ** PG&E Corp PCG.N: down 2.2% BUZZ- Falls on plans to cut power in N. California to avert fire risk ** GameStop Corp GME.N: down 1.2% BUZZ- Down after Jefferies downgrades to 'hold' ** Draftkings Inc DKNG.O: up 4.6% BUZZ- Rises as Credit Suisse starts coverage with 'outperform' ** General Motors Co GM.N: up 1.1% BUZZ- Up on first China quarterly sales growth in two years ** Walmart Inc WMT.N: up 1.5% BUZZ- Cowen raises PT on increasing ad business ** Avenue Therapeutics ATXI.O: down 58.1% ** Fortress Biotech Inc FBIO.O: down 21.6% BUZZ- Plunges after FDA declines to approve non-opioid ** Alkermes Plc ALKS.O: up 4.7% BUZZ- Rises as FDA supports drug to treat schizophrenia, bipolar disorder ** Altimmune Inc ALT.O: up 6% BUZZ- Rises after positive pre-clinical data on COVID-19 vaccine candidate ** RedBall Acquisition Corp RBAC.N: up 3.2% BUZZ- Rises on report of deal talks with Red Sox owner ** Ford Motor Co F.N: up 6.6% BUZZ- Rises after Benchmark upgrades on leadership, new product strengths ** Twitter Inc TWTR.N: up 5.5% BUZZ- Up as DB says co well positioned for cyclical recovery, upgrades ** Twilio Inc TWLO.N: up 6.4% BUZZ-Twilio to buy customer data startup Segment in $3.2 bln deal, shares rise ** American Well Corp AMWL.N: up 5.6% BUZZ- Well-positioned to ride next wave of growth in telehealth ** DouYu International Holdings DOYU.O: up 11.3% BUZZ- Jumps on merger agreement with Huya ** Applied DNA Sciences APDN.O: up 6.1% BUZZ- Gains after bagging COVID-19 surveillance testing contracts ** Apple Inc AAPL.O: up 5.7% BUZZ- Rises ahead of expected iPhone launch; RBC raises PT ** LMP Automotive Holdings LMPX.O: up 15% BUZZ- Rises on $608 mln acquisition deal ** Eyenovia Inc EYEN.O: up 5.9% BUZZ- Rises on license agreement for pediatric myopia treatment ** Fat Brands Inc FAT.O: up 8.5% BUZZ- Rises after Noble Capital upgrades to 'outperform' ** Acorn International ATV.N: up 37.3% BUZZ- Surges on take-private agreement ** JFrog Ltd FROG.O: up 2.8% BUZZ- Gains after multiple brokerages initiate with bullish ratings ** Century Casinos CNTY.O: up 1.7% BUZZ- Surges on internet sports betting partnership with Tipico ** Dillard's Inc DDS.N: up 39.5% BUZZ-Dillard's rises after Berkshire Hathaway's Weschler grabs a stake ** Abbott ABT.N: up 1.5% BUZZ- Up as COVID-19 antibody test gets emergency use authorization ** Honeywell International Inc HON.N: up 0.7% BUZZ- Up on 5-year contract with U.S. army ** Helios Technologies HLIO.O: up 5.8% BUZZ- Climbs on deal to acquire Balboa Water ** Carnival Corp CCL.N: down 2.4% BUZZ- Falls on scrapping all November cruises ** Globus Maritime GLBS.O: up 14.3% BUZZ- Rises on new vessel acquisition ** Consol Energy CEIX.N: up 2.6% BUZZ- Up on executing sale of various assets ** Cloudflare Inc NET.N: up 16.6% BUZZ- Jumps on launching cloud-based digital platform ** Lazydays Holdings LAZY.O: up 7.9% BUZZ- Jumps on upbeat prelim results ** JPMorgan Chase & Co JPM.N: up 0.4% ** Citigroup C.N: up 0.8% ** Goldman Sachs GS.N: up 2.5% ** Wells Fargo WFC.N: up 0.5% ** Bank of America BAC.N: up 0.5% ** Morgan Stanley MS.N: up 2% BUZZ-U.S. big banks track broader market rise on hopes of fiscal support ** Ligand Pharm LGND.O: up 1% BUZZ- Rises on sale of Vernalis research operations ** Greenlane Holdings Inc GNLN.O: up 13.7% BUZZ-Greenlane to distribute Marley Natural accessories globally, shares jump ** Sonoco SON.N: up 2.2% BUZZ-Sonoco to divest European unit for $120 mln, shares rise ** Facebook Inc FB.O: up 4.9% ** Apple Inc AAPL.O: up 5.7% ** Amazon.com Inc AMZN.O: up 5.3% ** Netflix Inc NFLX.O: up 1.6% ** Alphabet Inc GOOGL.O: up 3.8% BUZZ-FAANG stocks rise on wider market gains The 11 major S&P 500 sectors: Communication Services up 2.82% Consumer Discretionary up 2.53% Consumer Staples | (RTTNews) - Abbott (ABT) announced the FDA has issued Emergency Use Authorization for the company's AdviseDx SARS-CoV-2 IgM (Immunoglobulin M) lab-based serology test for use on the ARCHITECT and Alinity platforms. Abbott earlier developed an IgG blood test, which often is the antibody that is longer-lasting in the body after infection. The IgM antibody is useful for determining a recent infection as these antibodies become undetectable weeks to months following infection. | No matter when or why it happens, here are two stocks that will survive the next market crash and continue climbing long after: Guardant Health (NASDAQ: GH) and Abbott Laboratories (NYSE: ABT). GH data by YCharts Guardant Health: The future of cancer diagnostics Guardant Health develops liquid biopsies -- tests that allow physicians to look for cancer cells from tumors in blood samples. Abbott Laboratories: a leader in medical devices Abbott Laboratories is a medical device specialist with a long track record of success. | However, Abbott Labs (NYSE: ABT) is making progress. In the U.S., an at-home coronavirus test would go a long way in closing the gaps in daily testing, but no developer has yet filed for U.S. Food and Drug Administration (FDA) authorization of such a test. Moderna Because investors' eyes are peeled on Moderna (NASDAQ: MRNA), the biotech company that is attempting to deliver a coronavirus vaccine, it's easy to miss the fact that the company has never had a treatment approved using its messenger RNA (mRNA)-based approach. | Eikon search string for individual stock moves: STXBZ | Oct 12 (Reuters) - Abbott Laboratories ABT.N said on Monday the U.S. Food and Drug Administration has issued an emergency use authorization for its lab-based COVID-19 antibody blood test. The test, AdviseDx, can be used to identify a type of antibody called Immunoglobulin M (IgM) in blood samples to determine if someone has been exposure to the novel coronavirus, potentially indicating a recent or prior infection. Abbott has already received emergency use authorization for seven tests, including molecular tests, a rapid antigen test and another test which can detect a type of antibody called IgG."
2020-10-09,109.33999633789062,109.6500015258789,0.7256263508007241,Nevada's ban on Quidel and Becton Dickinson COVID-19 tests violates law -HHS official,"He said Nevada's directive does not apply to BinaxNOW rapid antigen tests produced by Abbott Laboratories ABT.N. By Manojna Maddipatla and Carl O'Donnell Oct 9 (Reuters) - Nevada's recent ban on the use of Quidel Corp's QDEL.O Sofia and Becton Dickinson and Co's BDX.N Veritor point-of-care antigen tests for COVID-19 in long-term care facilities violates federal law, a U.S. government official said on Friday. An official of the U.S. Department of Health and Human Services (HHS) on Friday said the directive was a violation of federal law and put lives at risk, adding that any accuracy problems with the tests are offset by the public health benefits of the rapid results they provide."
2020-10-08,108.13999938964844,108.54000091552734,0.2835240519217506,Why Co-Diagnostics Stock Soared 25% in September | 3 Safe Stocks to Buy in a Not-So-Safe Market,"So what Co-Diagnostics stock, which is very volatile, started September off on a down note, falling 21.9% in the first three days of the month. Since no financial details of the deal were disclosed, my colleague Keith Speights wrote at the time that a good portion of the pop in Co-Diagnostics stock was probably due to short-sellers (those who bet on the stock falling) covering their positions. See the 10 stocks *Stock Advisor returns as of September 24, 2020 Beth McKenna has no position in any of the stocks mentioned. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) practically oozes security and stability. * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Amazon wasn't one of them! See the 10 stocks *Stock Advisor returns as of September 24, 2020 John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors."
2020-10-07,107.37000274658205,107.73999786376952,0.36989229529919515,"Abbott says ID NOW COVID-19 rapid test shows high sensitivity in study | Abbott Laboratories Says Its Rapid Coronavirus Test Correctly Identifies Positive Cases 95% of the Time | BUZZ-U.S. STOCKS ON THE MOVE-Workday, Stable Road Acquisition, RedHill Biopharma, Fox Corp, Disney | Abbott says fast COVID-19 test correctly identifies positive cases 95% of the time | Abbott: ID NOW COVID-19 Interim Results Confirm Previous Data Submitted To FDA | Medtronic Stock Appears Attractive Around $100 Levels | BUZZ-U.S. STOCKS ON THE MOVE-Rave Restaurant, Vedanta, Hill International, Workday, Bristol-Myers","Oct 7 (Reuters) - Abbott Laboratories ABT.N said on Wednesday its ID NOW COVID-19 rapid test showed 96.2% sensitivity and 99.5% specificity compared to lab-based molecular PCR tests, according to interim data from a study. The results confirm the data submitted to the U.S. Food and Drug Administration in March for emergency use authorization, the medical device maker said. (https://refini.tv/2GLCVA4) (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shounak Dasgupta) ((manojna.kalyani@thomsonreuters.com; +91 8061822700)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | On Wednesday, Abbott Laboratories (NYSE: ABT) announced that interim clinical data indicates that its ID NOW COVID-19 test correctly identified positive cases in 95% of instances. ""The facts we're seeing from one of the largest clinical studies of any COVID-19 test, conducted at some of the nation's leading academic centers, show that ID NOW delivers effective, consistent and reliable performance,"" according to John Hackett, vice president of the Applied Research and Technology Division for Abbott's diagnostics unit. Since rolling out ID NOW, it has brought to market the low-cost BinaxNOW antigen test, another point-of-care test that delivers results quickly, and on Tuesday, it signed a deal to supply up to around 21 million Panbio COVID-19 tests to the government of Canada. | The top three S&P 500 .PG.INX percentage gainers: ** Alexion Pharmaceuticals Inc ALXN.O, up 8.4% ** Freeport-McMoRan Inc FCX.N, up 6.4% ** Gap Inc GPS.N, up 6.3% The top three S&P 500 .PL.INX percentage losers: ** Everest Re Group Ltd RE.N, down 2.3% ** Hess Corp HES.N, down 2.3% ** Cincinnati Financial Corp CINF.O, down 1.7% The top three NYSE .PG.N percentage gainers: ** ReneSola Ltd SOL.N, up 28.8% ** Planet Green Holdings Corp PLAG.N, up 28.3% ** Natuzzi S.p.A. NTZ.N, up 15.1% The top three NYSE .PL.N percentage losers: ** China Green Agriculture Inc CGA.N, down 19.3% ** Hyliion Holdings Corp HYLN.N, down 9.7% ** Liberty Oilfield Services Inc LBRT.N, down 8.7% The top three Nasdaq .PG.O percentage gainers: ** American Resources Corp AREC.O, up 127% ** Peck Company Holdings Inc PECK.O, up 60.7% ** CVD Equipment Corp CVV.O, up 58% The top two Nasdaq .PL.O percentage losers: ** Electro-Sensors Inc ELSE.O, down 35.8% ** Forum Merger II Corp FMCIU.O, down 17.9% ** Levi Strauss & Co LEVI.N: up 6.1% BUZZ-Levi Strauss: Gains on upbeat results, retail push ** American Airlines Group Inc AAL.O: up 4.2% ** United Airlines Holdings Inc UAL.O: up 4.2% ** Delta Air Lines Inc DAL.N: up 3.1% ** JetBlue Airways Corp JBLU.O: up 5.7% BUZZ-U.S. airlines rebound as Trump pushes for $25 bln bailout plan ** CleanSpark Inc CLSK.O: down 10.8% BUZZ-Drops after discounted stock offering ** Sirius XM Holdings Inc SIRI.O: up 4.6% BUZZ-Gains after raising qtrly dividend ** Pluristem Therapeutics Inc PSTI.O: up 6.1% BUZZ-Shares up on nod for COVID-19 therapy trial in Israel ** Coty Inc COTY.N: up 7.1% BUZZ-Jefferies sees turnaround under new CEO, upgrades to 'buy' ** Datadog Inc DDOG.O: up 3.1% BUZZ-Berenberg starts coverage with 'hold' ** Perion Network Ltd PERI.O: up 12.6% BUZZ-Jumps after lifting H2 forecast ** Workday Inc WDAY.O: up 5.7% BUZZ-Rises as brokerage upgrades rating to ""buy"", hikes PT ** Netflix Inc NFLX.O: up 5.6% BUZZ-Pivotal raises PT to Street high on streaming domination ** DraftKings Inc DKNG.O: down 4.1% BUZZ-Slides on report of discounted equity offering ** Stable Road Acquisition Corp SRAC.O: up 1.8% BUZZ-Rises on merger with Momentus ** Bristol-Myers Squibb Co BMY.N: up 4.2% BUZZ-Rises after Opdivo combo meets main goal in late-stage study ** Sorrento Therapeutics Inc SRNE.O: up 5.8% BUZZ-Rises as unit posts strong Q3 sales ** Abbott Laboratories ABT.N: up 1.4% BUZZ-Wells Fargo hikes PT, Q3 estimates on demand recovery ** Aytu BioScience Inc AYTU.O: down 13.9% BUZZ-Drops after fourth-quarter loss ** TransEnterix Inc TRXC.A: up 14.7% BUZZ-Rises as Japan's hospital to use co's surgical system ** RAVE Restaurant Group Inc RAVE.O: up 105.3% BUZZ-Quadruples on new hiring to lead expansion ** Citius Pharmaceuticals Inc CTXR.O: up 5.9% BUZZ-Citius Pharma rises on licensing agreement for stem cell therapy ** AzurRx BioPharma Inc AZRX.O: flat BUZZ-Rises as CEO reassures on cash position ** Eli Lilly and Co LLY.N: up 2.7% BUZZ-Gains after applying for FDA emergency use for COVID-19 treatment ** Peck Company Holdings Inc PECK.O: up 60.7% BUZZ-Surges on contract for solar project in Rhode Island ** ARCA Biopharma Inc ABIO.O: down 6.7% BUZZ-Surges on FDA nod to begin potential COVID-19 drug trial ** Vaxart Inc VXRT.O: up 2.2% BUZZ-Up on expanding manufacturing deal for COVID-19 vaccine candidate ** Sunworks Inc SUNW.O: up 42.9% BUZZ-Surges on $10 mln commercial, agriculture projects ** Phunware Inc PHUN.O: up 16.6% BUZZ-Rises on Honeywell contracts ** Paychex Inc PAYX.O: up 1.8% BUZZ-Rises as Q1 results beat ** RPM International Inc RPM.N: up 2.2% BUZZ-Climbs on Q1 beat, bullish outlook ** Achieve Life Sciences Inc ACHV.O: up 7.2% BUZZ-Up on launch of late-stage trial of smoking cessation drug ** Ocular Therapeutix Inc OCUL.O: up 24.1% BUZZ-Rises on higher product sales in Q3 ** Element Solutions Inc ESI.N: up 3.6% BUZZ-Rises after announcing share buyback ** Silicon Motion Technology Corp SIMO.O: up 6.8% BUZZ-Up on upbeat preliminary Q3 results ** Gap Inc GPS.N: up 6.3% BUZZ-Gains as Barclays upgrades to 'overweight' ** RedHill Biopharma Ltd RDHL.O: up 1.7% BUZZ-Gains as COVID-19 drug study passes second safety review ** Eton Pharmaceuticals Inc ETON.O: up 4.7% BUZZ-Jumps on new drug application to treat seizures, migraine ** Landec Corp LNDC.O: down 4.8% BUZZ-Falls as first-quarter loss widens ** Alkermes Plc ALKS.O: up 4.8% BUZZ-Rises as FDA posts briefing documents ahead of expert panel meeting ** Crocs Inc CROX.O: flat BUZZ-Rises on tie-up with Justin Bieber ** Elanco Animal Health Inc ELAN.N: up 12.2% BUZZ-Rises as Sachem Head builds $1.2 bln stake in co ** Quanterix Corp QTRX.O: up 11.1% BUZZ-Jumps on contract to advance COVID-19 antigen test ** Clorox Co CLX.N: up 2.2% BUZZ-Rises on unveiling symptom-detecting device amid pandemic ** Vishay Intertechnology Inc VSH.N: up 6.2% BUZZ-Eyes best day in 5 months as Stifel raises to 'buy' ** JPMorgan Chase & Co JPM.N: up 0.9% ** Citigroup Inc C.N: up 0.7% ** Goldman Sachs Group Inc GS.N: up 0.4% ** Wells Fargo & Co WFC.N: up 1.9% ** Morgan Stanley MS.N: up 1.3% ** Bank of America Corp BAC.N: up 1.4% BUZZ-U.S. big banks follow gains on yields as risk sentiment rebounds ** Celanese Corp CE.N: up 3.9% BUZZ-Up after increasing acetate tow prices by 5% ** OrthoPediatrics Corp KIDS.O: up 6.8% BUZZ-Jumps after BTIG raises price target ** Taiwan Liposome Co Ltd TLC.O: up 27.7% BUZZ-Gains on Australia, Taiwan nod for COVID-19 therapy human trials ** Lightspeed POS Inc LSPD.N: up 6.8% BUZZ-Gains on deal with U.S. golf course operator ** American Resources Corp AREC.O: up 127.0% BUZZ-Considers strategic options for unit, shares surge ** Advanced Micro Devices Inc AMD.O: up 2.4% BUZZ-Gains after Jefferies hikes PT ** Lamb Weston Holdings Inc LW.N: up 2.5% BUZZ-French fry seller's stock heats up after upbeat report ** Pfizer Inc PFE.N: down 0.2% ** BioNTech SE BNTX.O: down 1.3% BUZZ-U.S. authorization for Pfizer, BioNTech COVID-19 vaccine unlikely before election ** Kontoor Brands KTB.N: up 8.1% BUZZ-Kontoor Brands: Gains as Barclays hikes PT, upgrades to 'overweight' ** PTC Therapeutics Inc PTCT.O: up 7.1% BUZZ-PTC Therapeutics: Rises after JP Morgan raises rating to overweight ** Haverty Furniture HVT.N: up 5.7% BUZZ-Haverty Furniture: Hits 17-month high on strong sales ** Castor Maritime Inc CTRM.O: up 6.4% BUZZ-Castor Maritime rises on securing charter agreement for new vessel ** Walt Disney Co DIS.N: up 1.7% BUZZ-Third Point's Loeb calls for redirecting dividend to fund content, shares rise ** HC2 Holdings Inc HCHC.N: down 7.1% BUZZ-Falls after commencing rights offering ** Steris Plc STE.N: up 1.7% BUZZ-Steris gains after brokerage raises price target ** Masimo Corp MASI.O: up 3.1% BUZZ-Rises on upbeat forecast; Needham points to elective procedure recovery ** Fox Corp FOXA.O: up 3.5% BUZZ-Rises as BofA hikes PT to Street high ** Tesla Inc TSLA.O: up 3.7% BUZZ-Musk moots idea of making half a million cars in 2020, shares rise The 11 major S&P 500 sectors: Communication Services .N At 13:37 ET, the Dow Jones Industrial Average .DJI was up 1.54% at 28,199.7. up 0.63% Consumer Discretionary | Adds details about study, background Oct 7 (Reuters) - Abbott Laboratories ABT.N said on Wednesday its rapid coronavirus test, which can deliver results within minutes, correctly identified positive COVID-19 cases 95% of the time, based on interim data from a study. According to the new 1,003-participant study being conducted after the Food and Drug Administration's emergency use authorization, the Abbott ID Now test was able to detect those without antibodies to the coronavirus 97.9% of the time within seven days from the onset of symptoms. The results appear to contradict a study conducted by Cleveland Clinic in April that showed the test, which is used in the White House and elsewhere to spot COVID-19, detected the virus in around 85% of cases, lower than some other COVID-19 tests. | (RTTNews) - Abbott (ABT) presented new interim clinical data results on its ID NOW COVID-19 rapid test. The company said the results confirmed the data submitted to the FDA in March for Emergency Use Authorization and the interim results. The company said data showed ID NOW performance of 95.0% positive agreement (sensitivity) and 97.9% negative agreement (specificity) in subjects within seven days post symptom onset. | Timeline of 2007-08 Crisis 10/1/2007: Approximate pre-crisis peak in S&P 500 index 9/1/2008 – 10/1/2008: Accelerated market decline corresponding to Lehman bankruptcy filing (9/15/08) 3/1/2009: Approximate bottoming out of S&P 500 index 1/1/2010: Initial recovery to levels before accelerated decline (around 9/1/2008) Medtronic vs S&P 500 Performance Over 2007-08 Financial Crisis MDT stock declined from levels of around $44 in September 2007 (pre-crisis peak) to levels of around $23 in March 2009 (as the markets bottomed out), implying MDT stock lost 48% from its approximate pre-crisis peak. Medtronic’s Fundamentals in Recent Years Look Strong Though Medtronic’s Revenue grew steadily from $28.8 billion in fiscal 2016 to $30.6 billion in fiscal 2019 (fiscal ends in April), it declined to $28.9 billion in 2020, primarily due to the impact of Covid-19. Phases of Covid-19 crisis: Early- to mid-March 2020: Fear of the coronavirus outbreak spreading rapidly translates into reality, with the number of cases accelerating globally Late-March 2020 onward: Social distancing measures + lockdowns April 2020: Fed stimulus suppresses near-term survival anxiety May-June 2020: Recovery of demand, with gradual lifting of lockdowns – no panic anymore despite a steady increase in the number of cases July-September 2020: Poor Q2 results for many companies, but continued improvement in demand and a decline in the number of new cases and progress with vaccine development buoy expectations Going by the historical performance and in view of the growth in elective surgeries, we believe that MDT stock has roughly 15% room for growth in the near future. | The top three NYSE percentage gainers premarket .PRPG.NQ: ** Hill International Inc HIL.N, up 19.1% ** Renesola Ltd SOL.N, up 15.9% ** YPF SA YPF.N, up 14.8% The top three NYSE percentage losers premarket .PRPL.NQ: ** Ashford Hospitality Trust Inc AHT.N, down 14.4% ** Natuzzi S.p.A NTZ.N, down 11.1% ** Vedanta Ltd VEDL.N, down 7.5% The top Nasdaq percentage gainers premarket .PRPG.O: ** Rave Restaurant Group Inc RAVE.O, up 306.6% ** Sunworks Inc SUNW.O, up 72.9% The top three Nasdaq percentage losers premarket .PRPL.O: ** Electro-Sensors Inc ELSE.O, down 23.9% ** CleanSpark Inc CLSK.O, down 21% ** Asia Pacific Wire & Cable Corp Ltd APWC.O, down 20.9% ** Levi Strauss & Co LEVI.N: up 12.7% premarket BUZZ-Levi Strauss: Gains on upbeat results, retail push ** American Airlines Group Inc AAL.O: up 4.2% premarket ** United Airlines Holdings Inc UAL.O: up 4.4% premarket ** Delta Air Lines Inc DAL.N: up 3.5% premarket ** JetBlue Airways Corp JBLU.O: up 6.3% premarket BUZZ-U.S. airlines rebound as Trump pushes for $25 bln bailout plan ** CleanSpark Inc CLSK.O: down 21.0% premarket BUZZ-Drops after discounted stock offering ** Sirius XM Holdings Inc SIRI.O: up 3.2% premarket BUZZ-Gains after raising qtrly dividend ** Pluristem Therapeutics Inc PSTI.O: up 6.3% premarket BUZZ-Shares up on nod for COVID-19 therapy trial in Israel ** Coty Inc COTY.N: up 4.3% premarket BUZZ-Jefferies sees turnaround under new CEO, upgrades to 'buy' ** Datadog Inc DDOG.O: up 1.7% premarket BUZZ-Berenberg starts coverage with 'hold' ** Workday Inc WDAY.O: up 3.6% premarket BUZZ-Rises as brokerage upgrades rating to ""buy"", hikes PT ** Netflix Inc NFLX.O: up 1.7% premarket BUZZ-Pivotal raises PT to Street high on streaming domination ** DraftKings Inc DKNG.O: down 8.3% premarket BUZZ-Slides on report of discounted equity offering ** Stable Road Acquisition Corp SRAC.O: up 0.5% premarket BUZZ-Rises on merger with Momentus ** Bristol-Myers Squibb Co BMY.N: up 1.3% premarket BUZZ-Rises after Opdivo combo meets main goal in late-stage study ** Sorrento Therapeutics Inc SRNE.O: up 2.5% premarket BUZZ-Rises as unit posts strong Q3 sales ** Abbott Laboratories ABT.N: up 0.7% premarket BUZZ-Wells Fargo hikes PT, Q3 estimates on demand recovery ** AnPac Bio-Medical Science Co Ltd ANPC.O: up 7.2% premarket BUZZ-Jumps on securing $8 mln funding in China ** Aytu BioScience Inc AYTU.O: down 9.8% premarket BUZZ-Drops after fourth-quarter loss ** TransEnterix Inc TRXC.A: up 18.6% premarket BUZZ-Rises as Japan's hospital to use co's surgical system (Compiled by C Nivedita in Bengaluru) ((c.nivedita@thomsonreuters.com)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock indexes were set to open higher on Wednesday after President Donald Trump's abrupt call to end stimulus talks sent Wall Street tumbling in the previous session, while shares of Levi Strauss surged following a surprise quarterly profit. S&P 500 e-minis ESc1 were up 0.79% at 3,379.75, while Nasdaq 100 e-minis NQc1 were up 0.84% at 11,369."
2020-10-06,108.55999755859376,106.25,0.3445982189837,Abbott Labs to Sell 20.5 Million COVID-19 Antigen Tests to Canadian Government | Canada signs deal with Abbott for Panbio COVID-19 antigen tests | 3 Stocks You Can Keep Forever,"Abbott Laboratories (NYSE: ABT) has signed a deal with the government of Canada to potentially supply around 21 million of its Panbio COVID-19 tests, the latter announced on Tuesday. ""To be clear, the strategy in terms of our procurements is not to replace the standardized testing model but to enhance the capacity of provinces and territories to keep up with the increasing demand for tests,"" Public Services and Procurement Minister Anita Anand was quoted as saying by the Canadian Broadcasting Company. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | Adds background OTTAWA, Oct 6 (Reuters) - Canada said on Tuesday that it had signed a deal with Abbott ABT.N to purchase up to 20.5 million Panbio COVID-19 antigen tests as Health Canada approved the device, the first of its kind in Canada. The disposable swab test may help ease pressure on testing sites and labs in Ontario and Quebec, where cases are surging and some patients must wait a week or longer for results. ""These antigens tests will have a role to play in avoiding large cluster outbreaks, when results are needed quickly to avoid further spread of the virus,"" said Patty Hajdu, Canada's Health Minister, in the statement. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a titan in the healthcare sector, producing a tremendous number of items ranging from pharmaceutical drugs to diagnostic tests and laboratory reagents. While Abbott's trailing dividend yield of 1.3% isn't lucrative, behind the S&P 500's average of 2%, the company's stock has grown steadily over its time on the market, expanding by more than 325% in the past 10 years alone. Even if Abbott isn't among the most rapidly growing companies in the healthcare sector, it's certainly one of the anchors you can count on to appreciate in value over time. Thermo Fisher Scientific Thermo Fisher Scientific (NYSE: TMO) isn't exactly a household name for members of the general public, but it's well known in the pharmaceutical and biotech industries."
2020-10-05,107.18000030517578,108.55999755859376,-2.1278533626964897,Why OPKO Health Jumped 13.9% in September | 2 Top Coronavirus Stocks to Buy Right Now,"So what OPKO's stock plunged over 35% in August after Abbott Labs (NYSE: ABT) announced it would begin offering a cheap, quick COVID-19 test at the end of the month. What happened Shares of OPKO Health (NASDAQ: OPK) jumped 13.9% in September, according to data from S&P Global Market Intelligence, after it began its coronavirus vaccine testing program in New York City schools and again following phase 2 testing starting on a COVID-19 treatment. 10 stocks we like better than Opko Health When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | SPY data by YCharts Abbott Laboratories Abbott Laboratories (NYSE: ABT), meanwhile, is a top coronavirus stock thanks to its efforts in the diagnostic testing market. And, with the U.S. Food and Drug Administration (FDA) announcing Oct. 2 that its regulatory inquiry into these side effects would need to expand rather than conclude, it looks like AstraZeneca's trial will remain on hold for even longer. How could this seemingly expanding obstacle possibly make AstraZeneca a coronavirus stock that's worth buying now? Abbott has products in every segment of the testing market, including rapid tests, multiplexable diagnostic tests, and antibody tests."
2020-10-02,107.68000030517578,106.5,1.2875510818144138,Why DexCom Stock Is Slipping Today,"Abbott Labs (NYSE: ABT) recently won approval of its Freestyle Libre 3 CGM in Europe. The decline came after Wells Fargo analyst Larry Biegelsen downgraded the stock to underweight from equal weight and cut his price target to $350 from $420. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen."
2020-10-01,109.18000030517578,108.63999938964844,-1.09583980482127,"BUZZ-U.S. STOCKS ON THE MOVE-XPO Logistics, VerifyMe, Workday, LogicBio Therapeutics | BUZZ-U.S. STOCKS ON THE MOVE-Walt Disney, Amazon.com, Ford Motor, Skyworks | Canadian aviation sector to be permanently hurt without aid, unions say | BUZZ-U.S. STOCKS ON THE MOVE-VAALCO Energy, Pfizer, Genworth Financial, Lonestar Resources | Owens & Minor Stock Up 4x This Year But The Rally Is Not Over Yet | Canadian aviation sector to be permanently hurt without aid, unions say","The top three S&P 500 .PG.INX percentage gainers: ** ETSY Inc ETSY.O, up 7.2% ** L Brands Inc LB.N, up 4.5% ** Gap Inc GPS.N, up 4.3% The top three S&P 500 .PL.INX percentage losers: ** Valero Energy Corp VLO.N, down 7.8% ** Halliburton Co HAL.N, down 6.5% ** Abiomed Inc ABMD.O, down 6.1% The top three NYSE .PG.N percentage gainers: ** Amer Eq Inv Life AEL.N, up 39% ** Container Store Group Inc TCS.N, up 16.3% ** SailPoint Technologies Holdings Inc SAIL.N, up 13.5% The top three NYSE .PL.N percentage losers: ** Bluegreen Vacations Holding Corp BVH.N, down 22.3% ** Ambow Education Holding Ltd AMBO.N, down 21.2% ** Boqii Holding Ltd BQ.N, down 14.9% The top three Nasdaq .PG.O percentage gainers: ** Solid Biosciences Inc SLDB.O, up 111.3% ** Pulmonx Corp LUNG.O, up 107.2% ** Thryv Holdings Inc THRY.O, up 81.4% The top three Nasdaq .PL.O percentage losers: ** LogicBio Therapeutics Inc LOGC.O, down 32% ** Benitec Biopharma Inc BNTC.O, down 25.9% ** Kismet Acquisition One Corp KSMTU.O, down 21.5% ** LogicBio Therapeutics Inc LOGC.O: down 32.0% BUZZ-Slumps on deep-discounted stock offering ** XPO Logistics Inc XPO.N: up 1.4% BUZZ-Up after co's app downloads doubles ** VerifyMe Inc VRME.O: up 2.6% BUZZ-Jumps on reviewing potential acquisition opportunities ** Workday Inc WDAY.O: up 1.5% BUZZ-Rises as Citigroup upgrades on growth opportunities ** Triton International Ltd TRTN.N: down 6.6% BUZZ-Drops on secondary stock offering by selling shareholders ** PAR Technology Corp PAR.N: down 11.1% BUZZ-Slides on equity offering ** Genfit SA GNFT.O: down 15.9% BUZZ-Drops on workforce reduction, bigger loss ** Draftkings Inc DKNG.O: up 5.1% BUZZ-Hits record high on sport betting deal with Philadelphia Eagles ** Wells Fargo & Co WFC.N: down 0.7% ** Citigroup Inc C.N: down 0.5% ** Goldman Sachs Group Inc GS.N: down 0.1% ** Morgan Stanley MS.N: down 0.5% ** Bank of America Corp BAC.N: down 0.1% BUZZ-U.S. big banks fall as U.S. Fed to extend curbs on capital distribution ** Lixiang Education Holding Co Ltd LXEH.O: down 17.3% BUZZ-Shares plunge nearly 25% in Nasdaq debut ** Exxon Mobil Corp XOM.N: down 3.4% ** Chevron Corp CVX.N: down 1.6% ** TechnipFMC PLC FTI.N: down 1.9% ** Halliburton Co HAL.N: down 6.5% ** Marathon Petroleum Corp MPC.N: down 5.4% ** Phillips 66 PSX.N: down 3.4% ** Diamondback Energy Inc FANG.O: down 4.5% ** Marathon Oil Corp MRO.N: down 3.7% ** ConocoPhillips COP.N: down 2.2% ** Apache Corp APA.O: down 4.1% ** Devon Energy Corp DVN.N: down 2.4% ** Occidental Petroleum Corp OXY.N: down 3.8% ** Patterson-UTI Energy Inc PTEN.O: down 6.7% BUZZ-U.S. energy shares slide on 5% drop in U.S. crude ** Textron Inc TXT.N: down 2.3% BUZZ-Falls as Cowen downgrades on bleak recovery prospects ** Datadog Inc DDOG.O: up 1.0% BUZZ-Rises as brokerage hikes PT to Street high on Microsoft partnership ** AMAG Pharmaceuticals Inc AMAG.O: up 44.6% BUZZ-Surges as Apollo-backed Covis to buy co for $647 mln ** CareDx Inc CDNA.O: up 6.6% BUZZ-Reaches record high on Medicare coverage decision for AlloSure heart ** Amazon.com Inc AMZN.O: up 1.3% BUZZ-Pivotal says ad business underappreciated, boosts PT to Street high ** Houghton Mifflin Harcourt Co HMHC.O: up 10.7% BUZZ-Soars on restructuring plan; to slash 22% jobs ** Cyclerion Therapeutics Inc CYCN.O: up 4.4% BUZZ-Up on sickle cell, nervous system disease study updates ** Skyworks Solutions Inc SWKS.O: up 1.8% BUZZ-Cowen hikes PT as OEMs seek to fill Huawei void ** VAALCO Energy Inc EGY.N: up 11.4% BUZZ-Jumps on Q3 production outlook ** Bed Bath & Beyond Inc BBBY.O: up 33.4% BUZZ-Surges as co swings to quarterly profit ** Abbott Laboratories ABT.N: up 0.6% BUZZ-Up after Air Canada says finalizing order for 25,000 COVID-19 tests ** Pennsylvania Real Estate Investment Trust: PEI.N: up 1.0% BUZZ-Up on securing one-month extension to liquidity facility ** Advanced Emissions Solutions Inc ADES.O: up 25.4% BUZZ-Surges on 15-year carbon supply contract ** Enlivex Therapeutics Ltd ENLV.O: up 45.8% BUZZ-Surges on positive data from potential COVID-19 treatment ** Gridsum Holding Inc GSUM.O: up 35.5% BUZZ-Soars on take-private offer ** American Equity Investment Life Holding Co AEL.N: up 38.9% BUZZ-Jumps on report of Athene, MassMutual $3-bln-plus takeover bid ** Papa John's International Inc PZZA.O: up 2.4% BUZZ-KeyBanc starts with 'overweight' rating ** Genworth Financial Inc GNW.N: down 3.4% BUZZ-Drops on extension of merger agreement with Oceanwide ** Zillow Group Inc ZG.O: up 4.0% BUZZ-Brokerages hike PTs on growth prospects ** Callon Petroleum Co CPE.N: up 2.7% BUZZ-Jumps after signing asset monetization deals ** Solid Biosciences Inc SLDB.O: up 111.3% BUZZ-Surges after FDA allows gene therapy trial to resumeUSN ** American Airlines Group Inc AAL.O: up 1.5% ** United Airlines Holdings Inc UAL.O: up 0.2% ** Delta Air Line Inc DAL.N: up 0.7% ** Southwest Airlines Co LUV.N: up 0.1% ** JetBlue Airways Corp JBLU.N: up 0.5% BUZZ-U.S. airlines: Up on talks of federal aid extension ** Boeing Co BA.N: up 1.4% BUZZ-Up after FAA conducts 737 MAX test flight ** ProPhase Labs Inc PRPH.O: up 9.8% BUZZ-Up on plans to acquire CLIA certified labs for COVID-19 testing ** Lonestar Resources LONE.O: down 12.3% BUZZ-Slumps after bankruptcy filing ** Tesla Inc TSLA.O: up 2.9% BUZZ-Set to open at 1-1/2 week high, cuts China Model 3 price ** AMAG Pharmaceuticals Inc AMAG.O: up 44.6% BUZZ-Surges on report of potential takeover deal ** PepsiCo Inc PEP.O: up 0.9% BUZZ-Gains on Q3 results, upbeat outlook as at-home snacking jumps ** Alibaba Group Holding Ltd BABA.N: down 1.4% BUZZ-Up as Needham hikes PT on growth prospects ** LogicBio Therapeutics Inc LOGC.O: down 32.0% BUZZ-Slumps on proposed stock offering ** Mastercard Inc MA.N: up 1.5% BUZZ-JPMorgan hikes PT and estimates on positive growth trends ** Selecta Biosciences Inc SELB.O: down 32.9% BUZZ-Plunges as drug fails to meet trial main goal The 11 major S&P 500 sectors: Communication Services up 1.18% Consumer Discretionary up 1.25% Consumer Staples | The top three S&P 500 .PG.INX percentage gainers: ** ETSY Inc , up 4.9% ** Autodesk Inc , up 3.1% ** Gap Inc , up 3.1% The top three S&P 500 .PL.INX percentage losers: ** Valero Energy , down 6.3% ** Halliburton Co , down 5.9% ** Hess Corp , down 4.6% The top three NYSE .PG.N percentage gainers: ** American Equity Investment Life Holding Co , up 36.3% ** SailPoint Technologies Holdings Inc , up 14.3% ** Leaf Group Ltd , up 11% The top three NYSE .PL.N percentage losers: ** Mizuho Financial Group Inc , down 90% ** Ambow Education Holding Ltd , down 17.2% ** BBX Capital Corp , down 16% The top three Nasdaq .PG.O percentage gainers: ** Solid Biosciencs Inc , up 127.6% ** Enlivex Therapeutics Ltd , up 52.5% ** AMAG Pharmaceuticals Inc , up 43.1% The top three Nasdaq .PL.O percentage losers: ** LogicBio Therapeutics Inc , down 33% ** Lixiang Education Holding Co Ltd , down 22.6% ** Kismet Acquisition Once Corp , down 21.1% ** Amazon.com Inc AMZN.O: up 1.2% BUZZ-Amazon.com: Pivotal says ad business underappreciated, boosts PT to Street high ** Snowflake Inc SNOW.N: down 3.3% BUZZ-Jefferies starts coverage on the sidelines, cites valuation ** Houghton Mifflin Harcourt Co HMHC.O: up 16.8% BUZZ-Soars on restructuring plan; to slash 22% jobs ** Cyclerion Therapeutics Inc CYCN.O: up 2.0% BUZZ-Up on sickle cell, nervous system disease study updates ** Skyworks SWKS.O: up 1.5% BUZZ-Cowen hikes PT as OEMs seek to fill Huawei void ** VAALCO Energy Inc EGY.N: up 6.5% BUZZ-Jumps on Q3 production outlook ** Bed Bath & Beyond Inc BBBY.O: up 30.0% BUZZ-Surges as co swings to quarterly profit ** Abbott Laboratories ABT.N: up 0.8% BUZZ-Up after Air Canada says finalizing order for 25,000 COVID-19 tests ** Pfizer Inc PFE.N: down 0.6% BUZZ-Obtains FDA 'Fast Track' designation for muscle degeneration therapy ** Pennsylvania Real Estate Investment Trust: PEI.N: up 3.2% BUZZ-Up on securing one-month extension to liquidity facility ** Advanced Emissions Solutions Inc ADES.O: up 36.9% BUZZ-Surges on 15-year carbon supply contract ** Enlivex Therapeutics Ltd ENLV.O: up 52.5% BUZZ-Surges on positive data from potential COVID-19 treatment ** Gridsum Holding Inc GSUM.O: up 39.5% BUZZ-Soars on take-private offer ** American Equity Investment Life Holding Co AEL.N: up 36.4% BUZZ-Jumps on report of Athene, MassMutual $3-bln-plus takeover bid ** Papa John's International Inc PZZA.O: up 3.2% BUZZ-KeyBanc starts with 'overweight' rating ** Genworth Financial Inc GNW.N: down 4.6% BUZZ-Drops on extension of merger agreement with Oceanwide ** Zillow Group Inc ZG.O: up 3.7% BUZZ-Brokerages hike PTs on growth prospects ** Callon Petroleum Co CPE.N: up 5.0% BUZZ-Jumps after signing asset monetization deals ** Solid Biosciences Inc SLDB.O: up 127.6% BUZZ-Surges after FDA allows gene therapy trial to resumeUSN ** American Airlines Group Inc AAL.O: up 1.2% ** United Airlines Holdings Inc UAL.O: up 0.5% ** Delta Air Line Inc DAL.N: up 0.9% ** Southwest Airlines Co LUV.N: up 1.3% ** JetBlue Airways Corp JBLU.O: up 0.9% BUZZ-U.S. airlines: Up on talks of federal aid extension ** Boeing Co BA.N: up 2.0% BUZZ-Up after FAA conducts 737 MAX test flight ** ProPhase Labs Inc PRPH.O: up 12.7% BUZZ-Up on plans to acquire CLIA certified labs for COVID-19 testing ** Lonestar Resources LONE.O: down 12.4% BUZZ-Slumps after bankruptcy filing ** Tesla Inc TSLA.O: up 1.5% BUZZ-Set to open at 1-1/2 week high, cuts China Model 3 price ** AMAG Pharmaceuticals Inc AMAG.O: up 43.1% BUZZ-Surges on report of potential takeover deal ** PepsiCo Inc PEP.O: up 0.2% BUZZ-Gains on Q3 results, upbeat outlook as at-home snacking jumps ** Alibaba Group Holding Ltd BABA.N: down 0.8% BUZZ-Up as Needham hikes PT on growth prospects ** LogicBio Therapeutics Inc LOGC.O: down 33.0% BUZZ-Slumps on proposed stock offering ** Mastercard Inc MA.N: up 1.3% BUZZ-JPMorgan hikes PT and estimates on positive growth trends ** Selecta Biosciences Inc SELB.O: down 31.7% BUZZ-Plunges as drug fails to meet trial main goal The 11 major S&P 500 sectors: Communication Services ET, the Dow Jones Industrial Average .DJI was up 0.33% at 27,872.05. up 0.87% Consumer Discretionary | On Thursday, Air Canada said it was finalizing an initial order for 25,000 rapid testing kits from Abbott Laboratories ABT.N. By David Ljunggren OTTAWA, Oct 1 (Reuters) - Major Canadian labor unions said on Thursday the aviation sector would suffer permanent damage unless Ottawa provided a C$7 billion ($5.3 billion) 10-year low-interest loan to offset the effects of the coronavirus outbreak, which has slashed travel. ""We need urgent funds for the aviation sector or there won't be Canadian airlines, and that will cost us all much more,"" said Jerry Dias, national president of Unifor, Canada's largest private sector union. | The top three NYSE percentage gainers premarket .PRPG.NQ: ** American Equity Investment Life Holding Co , up 53.0% ** HC2 Holdings Inc , up 18.0% ** Callon Petroleum Co , up 14.9% The top three NYSE percentage losers premarket .PRPL.NQ: ** Mizuho Financial Group Inc , down 89.9% ** Biglari Holdings Inc , down 15.7% ** Borr Drillng Ltd , down 9.9% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Solid Biosciences Inc , up 140.9% ** Enlivex Therapeutics Ltd , up 70.4% ** Gridsum Holding Inc , up 45.5% The top three Nasdaq percentage losers premarket .PRPL.O: ** South Mountain Merger Corp , down 99.1% ** Zosano Pharma Corp ZSAN.O, down 53.2% ** Selecta Biosciences Inc SELB.O down 37.9% ** VAALCO Energy Inc EGY.N: up 7.0% premarket BUZZ-Jumps on Q3 production outlook ** Bed Bath & Beyond Inc BBBY.O: up 24.0% premarket BUZZ-Surges as co swings to quarterly profit ** Abbott Laboratories ABT.N: up 0.9% premarket BUZZ-Up after Air Canada says finalizing order for 25,000 COVID-19 tests ** Pfizer Inc PFE.N: up 0.5% premarket BUZZ-Obtains FDA 'Fast Track' designation for muscle degeneration therapy ** Pennsylvania Real Estate Investment Trust: PEI.N: up 4.7% premarket BUZZ-Up on securing one-month extension to liquidity facility ** Advanced Emissions Solutions Inc ADES.O: up 43.6% premarket BUZZ-Surges on 15-year carbon supply contract ** Enlivex Therapeutics Ltd ENLV.O: up 70.4% premarket BUZZ-Surges on positive data from potential COVID-19 treatment ** Gridsum Holding Inc GSUM.O: up 45.5% premarket BUZZ-Soars on take-private offer ** American Equity Investment Life Holding Co AEL.N: up 53.0% premarket BUZZ-Jumps on report of Athene, MassMutual $3-bln-plus takeover bid ** Papa John's International Inc PZZA.O: up 1.2% premarket BUZZ-KeyBanc starts with 'overweight' rating ** Genworth Financial Inc GNW.N: down 9.9% premarket BUZZ-Drops on extension of merger agreement with Oceanwide ** Zillow Group Inc ZG.O: up 2.7% premarket BUZZ-Brokerages hike PTs on growth prospects ** Callon Petroleum Co CPE.N: up 14.9% premarket BUZZ-Jumps after signing asset monetization deals ** Solid Biosciences Inc SLDB.O: up 140.9% premarket BUZZ-Surges after FDA allows gene therapy trial to resumeUSN ** American Airlines Group Inc AAL.O: up 1.2% premarket ** United Airlines Holdings Inc UAL.O: up 1.5% premarket ** Delta Air Line Inc DAL.N: up 0.9% premarket ** Southwest Airlines Co LUV.N: up 0.7% premarket BUZZ-U.S. airlines: Up on talks of federal aid extension ** Boeing Co BA.N: up 2.5% premarket BUZZ-Up after FAA conducts 737 MAX test flight ** ProPhase Labs Inc PRPH.O: up 15.6% premarket BUZZ-Up on plans to acquire CLIA certified labs for COVID-19 testing ** Lonestar Resources LONE.O: down 16.9% premarket BUZZ-Slumps after bankruptcy filing ** Tesla Inc TSLA.O: up 2.1% premarket BUZZ-Set to open at 1-1/2 week high, cuts China Model 3 price ** AMAG Pharmaceuticals Inc AMAG.O: up 40.6% premarket BUZZ-Surges on report of potential takeover deal ** PepsiCo Inc PEP.O: up 0.7% premarket BUZZ-Gains on Q3 results, upbeat outlook as at-home snacking jumps ** Alibaba Group Holding Ltd BABA.N: up 0.6% premarket BUZZ-Up as Needham hikes PT on growth prospects ** LogicBio Therapeutics Inc LOGC.O: down 30.6% premarket BUZZ-Slumps on proposed stock offering ** Mastercard Inc MA.N: up 0.6% premarket BUZZ-JPMorgan hikes PT and estimates on positive growth trends ** Selecta Biosciences Inc SELB.O: down 37.9% premarket BUZZ-Plunges as drug fails to meet trial main goal (Compiled by Niket Nishant in Bengaluru) ((Niket.Nishant@thomsonreuters.com)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes were set to jump on the first day of the fourth quarter on Thursday as investors remained hopeful of a new coronavirus fiscal aid package, while data showed weekly jobless claims hovered at recession levels..N At 9:09 ET, Dow e-minis 1YMc1 were up 0.61% at 27,832. S&P 500 e-minis ESc1 were up 0.73% at 3,376.5, while Nasdaq 100 e-minis NQc1 were up 1.30% at 11,556. | Timeline of 2007-08 Crisis 10/1/2007: Approximate pre-crisis peak in S&P 500 index 9/1/2008 – 10/1/2008: Accelerated market decline corresponding to Lehman bankruptcy filing (9/15/08) 3/1/2009: Approximate bottoming out of S&P 500 index 1/1/2010: Initial recovery to levels before accelerated decline (around 9/1/2008) Owens & Minor vs S&P 500 Performance Over 2007-08 Financial Crisis OMI stock declined from levels of around $19 in September 2007 (pre-crisis peak for the markets) to levels of around $17 in March 2009 (as the markets bottomed out), implying OMI stock lost a mere 12% from its approximate pre-crisis peak. While Owens & Minor total revenue could see a high-single-digit decline for the full year, at the mid-point of its guidance, the EPS of $1.75 on an adjusted basis would imply a 3x growth from the $0.60 figure in 2019. Phases of Covid-19 crisis: Early- to mid-March 2020: Fear of the coronavirus outbreak spreading rapidly translates into reality, with the number of cases accelerating globally Late-March 2020 onward: Social distancing measures + lockdowns April 2020: Fed stimulus suppresses near-term survival anxiety May-June 2020: Recovery of demand, with gradual lifting of lockdowns – no panic anymore despite a steady increase in the number of cases July-September 2020: Poor Q2 results for many companies, but continued improvement in demand and a decline in the number of new cases and progress with vaccine development buoy expectations Going by the current trends and continued growth in demand for PPE, we believe that OMI stock has more room for growth in the near future. | Separately on Thursday, Air Canada said it was finalizing an initial order for 25,000 rapid testing kits from Abbott Laboratories ABT.N. By David Ljunggren OTTAWA, Oct 1 (Reuters) - Major Canadian labor unions on Thursday said the aviation sector would suffer permanent damage unless Ottawa provided a C$7 billion ($5.3 billion) 10-year low-interest loan to offset the effects of the coronavirus outbreak, which has slashed travel. ""We need urgent funds for the aviation sector or there won't be Canadian airlines, and that will cost us all much more,"" said Jerry Dias of Unifor, Canada's largest private sector union."
2020-09-30,105.98999786376952,108.83000183105467,-0.494596917034213,Abbott Labs Stock is Not Cheap But Should Do Well as Virus Test Debuts,"InvestorPlace - Stock Market News, Stock Advice & Trading Tips At current levels, Abbott Laboratories (NYSE:ABT) is not that cheap but ABT stock should do reasonably well over the next year. Impact of Covid-19 Tests Maybe ABT stock is worth more according to some analysts since it is responsible for producing fast-response Covid-19 tests for hospitals. But according to its own history ABT stock is still very cheap."
2020-09-29,106.01000213623048,105.19000244140624,2.6795018629356466,"Canada expects to approve new COVID-19 tests soon, govt official says | BUZZ-U.S. STOCKS ON THE MOVE-Scorpio Bulkers, LifeSci Acquisition, Shutterstock, Intellia Therapeutics | BUZZ-U.S. STOCKS ON THE MOVE-Infinity Pharmaceuticals, BioCardia, Caesars Entertainment, TransMedics Group | 120 Million Coronavirus Tests to Be Sold to Low- and Middle-Income Countries at Steep Discount | Why I Bought Shares in This International Stock | Here's When Bill Gates Thinks the Coronavirus Pandemic Will End | BUZZ-U.S. STOCKS ON THE MOVE-Caravana, Vroom, Peabody Energy, Canadian Solar | Canada expects to approve new COVID-19 tests soon, govt official says","The regulator is currently reviewing antigen tests from Abbott ABT.N, Quidel QDEL.O and Sona Nanotech SONA.CD, according to public data. TORONTO, Sept 29 (Reuters) - Health Canada expects to authorize new antigen tests for COVID-19 soon, a senior government official said on Tuesday, in an effort to provide additional testing as a second wave of novel coronavirus infections overwhelms laboratories. Antigen tests can provide rapid results outside of a lab, but may be less accurate than some lab-based diagnostic tests. | The top three S&P 500 .PG.INX percentage gainers: ** Paycom Software Inc , up 2.7% ** Albemarle Corp , up 2.5% ** Qorvo Inc , up 2.5% The top three S&P 500 .PL.INX percentage losers: ** Devon Energy Corp , down 8% ** National Oilwell Varco Inc , down 7% ** Apache Corp , down 6.7% The top three NYSE .PG.N percentage gainers: ** Houston American Energy Corp , up 202.8% ** Mexco Energy Corp, up 37.8% ** Container Store Group Inc , up 11.2% The top three NYSE .PL.N percentage losers: ** Just Energy Group Inc , down 37.4% ** Myovant Sciences Ltd , down 22.4% ** Peabody Energy Corp , down 17.5% The top three Nasdaq .PG.O percentage gainers: ** Aptorum Group Ltd , up 708.2% ** U.S. Energy Corp , up 174.5% ** Novus Capital Corp , up 117.2% The top three Nasdaq .PL.O percentage losers: ** Oxbridge Re Holdings Ltd , down 26.4% ** Piedmont Lithium Ltd , down 23.1% ** SPI Energy Co Ltd , down 18.9% ** Scorpio Bulkers Inc SALT.N: up 3.9% BUZZ-Up on sale of a Kamsarmax vessel ** LifeSci Acquisition Corp LSAC.O: up 12.9% BUZZ-Jumps on cancer drug developer Vincera SPAC deal ** Shutterstock Inc SSTK.N: up 2.5% BUZZ-Rises as BofA starts coverage with 'buy' ** Orphazyme A/S ORPH.O: down 6.3% BUZZ-Shares of drugmaker fall in Nasdaq debut ** Adial Pharmaceuticals Inc ADIL.O: up 29.8% BUZZ-Surges as FDA grants emergency use for COVID-19 antibody test ** Arcutis Biotherapeutics Inc ARQT.O: up 13.4% BUZZ-Rises on positive data from skin disease treatment study ** Radware Ltd RDWR.O: up 0.2% BUZZ-Gains on cloud security service deal with India's Airtel ** Vistra Corp VST.N: up 3.5% BUZZ-Soars on lifting outlook, pivot to clean energy ** China Ceramics Co Ltd CCCL.O: down 4.2% BUZZ-Drops as H1 revenue plummets on pandemic hit ** ONEOK Inc OKE.N: up 1.3% BUZZ-Gains as UBS sees improving volume, upgrades to 'buy' ** NanoVibronix Inc NAOV.O: up 0.2% BUZZ-Rises on filing U.S. patent for pain management device ** Beyond Meat Inc BYND.O: up 10.4% BUZZ-Jumps as burger patty distribution at Walmart stores triples ** TTM Technologies Inc TTMI.O: up 0.9% BUZZ-Rises as Craig-Hallum starts coverage with 'buy' ** Caesars Entertainment Inc CZR.O: down 7.7% BUZZ-Falls after co prices upsized $1.7 bln equity offering ** JP Morgan Chase & Co JPM.N: down 1.7% BUZZ-U.S. big banks fall as broader market remains muted ahead of presidential debate ** UTStarcom Holdings Corp UTSI.O: up 0.9% BUZZ-Jumps on new product launch ** BioCardia Inc BCDA.O: up 1.8% BUZZ-Rises on U.S. patent for catheter system ** Novus Capital Corp NOVS.O: up 22.5% BUZZ-Soars on plan to take indoor farm operator AppHarvest public ** BridgeBio Pharma Inc BBIO.O: up 1.9% BUZZ- FDA accepts application for rare metabolic disorder treatment ** Ardmore Shipping Corp ASC.N: up 6.6% BUZZ-Rises on share buyback plan ** Artelo Biosciences Inc ARTL.O: up 18.9% BUZZ-Soars as UK ethics panel approves cancer treatment study ** Molina Healthcare Inc MOH.N: up 3.0% BUZZ-Affinity Health deal will boost New York presence - SVB Leerink ** Caesars Entertainment Inc CZR.O: down 7.7% BUZZ-Falls after co prices $1.7 bln equity offering ** TransMedics Group Inc TMDX.O: down 9.2% BUZZ-Down after FDA postpones review meeting for donor heart system ** Molson Coors Beverage Co TAP.N: up 1.0% BUZZ-Gains on deal with Coca-Cola to launch alcoholic beverage ** Myovant Sciences Ltd MYOV.N: down 22.4% BUZZ-Drops as cancer drug misses secondary goal in late-stage trial ** Ironwood Pharmaceuticals Inc IRWD.O: down 6.6% BUZZ-Scraps development of digestive disorder drug, shares tumble ** Nikola Corp NKLA.O: down 7.0% BUZZ-EV makers Tesla, Nikola on track to trade lower ** Big Lots Inc BIG.N: up 2.3% BUZZ-Climbs on lifting Q3 outlook ** U.S. Energy Corp USEG.O: up 174.5% BUZZ-Surges on buying FieldPoint Petroleum's upstream assets ** Sogou Inc SOGO.N: up 2.5% BUZZ-Set to open at 2-year peak on Tencent's $3.5 bln take-private deal ** Fitbit Inc FIT.N: up 6.2% BUZZ-Rises as Reuters reports Google set to win EU nod for $2.1 bln deal ** Fuelcell Energy Inc FCEL.O: up 3.5% BUZZ-Rises on multiple project wins in Connecticut ** Aerie Pharmaceuticals Inc AERI.O: up 1.2% BUZZ-Up as FDA approves clinical study for dry eye treatment ** Moleculin Biotech Inc MBRX.O: up 3.2% BUZZ-New molecule in portfolio shows potential to fight COVID-19 ** Abbott Laboratories ABT.N: up 0.9% BUZZ-Rises as its COVID-19 test gets deployed ** Hershey Co HSY.N: up 0.1% BUZZ-BMO upgrades, says Halloween concerns overblown ** United Natural Foods Inc UNFI.N: down 11.7% BUZZ-CEO to retire, shares slip ** Tonix Pharmaceuticals Holding Corp TNXP.O: up 6.9% BUZZ-Rises as co buys new facility to develop COVID-19 vaccines ** Sorrento Therapeutics Inc SRNE.O: up 17.6% BUZZ-Up as COVID-19 antibody candidates show promise in study ** Fluidigm Corp FLDM.O: up 3.7% BUZZ-Jumps on increased NIH funding to scale up COVID-19 testing ** Aptorum Group Ltd APM.O: up 708.2% BUZZ-Surges after launching diagnostics subsidiary ** Party City Holdco Inc PRTY.N: down 8.6% BUZZ-Loses sheen on plans of 13 mln share offering The 11 major S&P 500 sectors: Communication Services ET, the Dow Jones Industrial Average .DJI was down 0.80% at 27,363.24. down 0.09% Consumer Discretionary | The top three S&P 500 .PG.INX percentage gainers: ** Molson Coors Beverage Co , up 4% ** Paycom Software Inc , up 3.5% ** Western Digital Corp , up 3% The top three S&P 500 .PL.INX percentage losers: ** Devon Energy Corp , down 5% ** McCormick & Company Inc , down 3.8% ** Apache Corp , down 3.8% The top three NYSE .PG.N percentage gainers: ** Houston American Energy Corp , up 184.3% ** Mexco Energy Corp , up 53.7% ** Sos Ltd , up 12.9% The top three NYSE .PL.N percentage losers: ** Just Energy Group Inc , down 27.4% ** Myovant Sciences Ltd , down 23.5% ** Ambow Education Holding Ltd , down 18% The top three Nasdaq .PG.O percentage gainers: ** Aptorum Group Ltd , up 711.4% ** U.S. Energy Corp , up 177.8% ** Adial Pharmaceuticals Inc , up 45.8% The top three Nasdaq .PL.O percentage losers: ** Piedmont Lithium Ltd , down 17.8% ** CIM Commercial Trust Corp , down 17.2% ** Peck Company Holdings Inc , down 15.9% ** UTStarcom Holdings Corp UTSI.O: up 2.8% BUZZ-Jumps on new product launch ** BioCardia Inc BCDA.O: up 4.7% BUZZ-Rises on U.S. patent for catheter system ** Novus Capital Corp NOVS.O: up 22.0% BUZZ-Soars on plan to take indoor farm operator AppHarvest public ** BridgeBio Pharma Inc BBIO.O: up 0.5% BUZZ- FDA accepts application for rare metabolic disorder treatment ** Ardmore Shipping Corp ASC.N: up 12.0% BUZZ-Rises on share buyback plan ** Artelo Biosciences Inc ARTL.O: up 25.0% BUZZ-Soars as UK ethics panel approves cancer treatment study ** Molina Healthcare Inc MOH.N: up 3.0% BUZZ-Affinity Health deal will boost New York presence - SVB Leerink ** Caesars Entertainment Inc CZR.O: down 1.9% BUZZ-Falls after co prices $1.7 bln equity offering ** TransMedics Group Inc TMDX.O: down 10.5% BUZZ-Down after FDA postpones review meeting for donor heart system ** Sino-Global Shipping America Ltd SINO.O: up 8.3% BUZZ-Jumps on joint-venture deal with Tianjin Anboweiye ** Molson Coors Beverage Co TAP.N: up 4.1% BUZZ-Gains on deal with Coca-Cola to launch alcoholic beverage ** Myovant Sciences Ltd MYOV.N: down 23.5% BUZZ-Drops as cancer drug misses secondary goal in late-stage trial ** Ironwood Pharmaceuticals Inc IRWD.O: down 5.5% BUZZ-Scraps development of digestive disorder drug, shares tumble ** Tesla Inc TSLA.O: down 1.8% BUZZ-EV makers on track to trade lower ** Nikola Corp NKLA.O: down 4.5% BUZZ-EV makers on track to trade lower ** Big Lots Inc BIG.N: up 6.2% BUZZ-Climbs on lifting Q3 outlook ** U.S. Energy Corp USEG.O: up 177.8% BUZZ-Surges on buying FieldPoint Petroleum's upstream assets ** Sogou Inc SOGO.N: up 2.5% BUZZ-Set to open at 2-year peak on Tencent's $3.5 bln take-private deal ** Fitbit Inc FIT.N: up 6.2% BUZZ-Rises as Reuters reports Google set to win EU nod for $2.1 bln deal ** Fuelcell Energy Inc FCEL.O: up 2.5% BUZZ-Rises on multiple project wins in Connecticut ** Aerie Pharmaceuticals Inc AERI.O: up 1.1% BUZZ-Up as FDA approves clinical study for dry eye treatment ** Moleculin Biotech Inc MBRX.O: up 2.5% BUZZ-New molecule in portfolio shows potential to fight COVID-19 ** Abbott Laboratories ABT.N: up 1.5% BUZZ-Rises as its COVID-19 test gets deployed ** Hershey Co HSY.N: up 1.0% BUZZ-BMO upgrades, says Halloween concerns overblown ** United Natural Foods Inc UNFI.N: down 10.5% BUZZ-CEO to retire, shares slip ** Tonix Pharmaceuticals Holding Corp TNXP.O: up 4.3% BUZZ-Rises as co buys new facility to develop COVID-19 vaccines ** Polaris Inc PII.N: up 2.2% BUZZ-Up on partnership to make electric vehicles ** Sorrento Therapeutics Inc SRNE.O: up 9.7% BUZZ-Up as COVID-19 antibody candidates show promise in study ** Fluidigm Corp FLDM.O: up 3.6% BUZZ-Jumps on increased NIH funding to scale up COVID-19 testing ** Aptorum Group Ltd APM.O: up 711.4% BUZZ-Surges after launching diagnostics subsidiary ** Party City Holdco Inc PRTY.N: down 3.7% BUZZ-Loses sheen on plans of 13 mln share offering ** Providence Service Corp PRSC.O: up 2.2% BUZZ-To acquire Simplura Health to expand into home care The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes were muted at the open on Tuesday as investors stayed away from making big bets ahead of the first presidential debate, while awaiting a reading on consumer confidence..N At 9:59 ET, the Dow Jones Industrial Average .DJI was down 0.23% at 27,520.95. down 0.20% Information Technology | The tests will be supplied by U.S.-based Abbott (NYSE: ABT) and South Korea's SD Biosensor, over a period of six months, and will cost the purchasing nations $5 or less apiece. A global partnership will be making 120 million rapid coronavirus tests available to 133 economically less-advantaged nations at heavily discounted prices, the World Health Organization (WHO) announced on Monday. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | However, the overarching case for buying the stock remains in place: The fact that Siemens issued debt with negative yields is not only beneficial to Siemens financially, it's also an indication of the quality of the company's earnings and the bond market's confidence in it. Moreover, analysts are expecting 4.3 billion euros and 5.4 billion euros in FCF in 2020 and 2021, putting the company on 21 times FCF in 2020 and 16.7 times FCF in 2021 -- contrast this with the FCF difficulties at its fierce rival General Electric (NYSE: GE) Data by YCharts Siemens has good growth prospects Not only does the company have a very solid financial history, its future looks bright too. Meanwhile, Siemens is set to combine a 67% share in Siemens Gamesa with its gas and power business and then spin it off into a new company, Siemens Energy, at the end of September. | Abbott Laboratories (NYSE: ABT) stands out as a great example. Bill Gates' prediction In an interview with Fox News Sunday, Gates told host Chris Wallace that he's ""optimistic this [the pandemic] won't last indefinitely."" Stocks to buy in the meantime With another year or more of disruptions to normal life expected for Americans, which stocks should investors buy in the meantime? | The top three S&P 500 .PG.INX percentage gainers: ** Paycom Software Inc PAYC.N, up 3.2% ** Advanced Micro Devices Inc AMD.O, up 3.1% ** Albemarle Corp ALB.N, up 2.7% The top three S&P 500 .PL.INX percentage losers: ** Apache Corp APA.O, down 7.3% ** National Oilwell Varco Inc NOV.N, down 6.8% ** Tapestry Inc TPR.N, down 6% The top three NYSE .PG.N percentage gainers: ** Houston American Energy Corp HUSA.N, up 253.7% ** Mexco Energy Corp MXC.N, up 37.8% ** Medley LLC MDLQ.N, up 12.1% The top three NYSE .PL.N percentage losers: ** Just Energy Group Inc JE.N, down 39.2% ** Myovant Sciences Ltd MYOV.N, down 23.4% ** Peabody Energy Corp BTU.N, down 17.5% The top three Nasdaq .PG.O percentage gainers: ** Aptorum Group Ltd APM.O, up 594.3% ** U.S. Energy Corp USEG.O, up 168.5% ** Innodata Inc INOD.O, up 33.5% The top three Nasdaq .PL.O percentage losers: ** Oxbridge Re Holdings Ltd OXBR.O, down 25.6% ** Piedmont Lithium Ltd PLL.O, down 24.6% ** SPI Energy Co Ltd SPI.O, down 22% ** Carvana Co CVNA.N: up 4.1% BUZZ-Rises as Piper sees long-term share gains ** Vroom Inc VRM.O: up 1.8% BUZZ-Rises as Piper sees long-term share gains ** Peabody Energy Corp BTU.N: down 17.8% BUZZ-Falls after U.S. District Court backs lawsuit to block JV ** Canadian Solar Inc CSIQ.O: down 0.4% BUZZ-Down as Maxeon Solar files patent infringement lawsuit ** Piedmont Lithium Ltd PLL.O: down 24.6% BUZZ-U.S. shares drop to narrow premium over surging Aussie stock ** Digimarc Corp DMRC.O: up 28.4% BUZZ-Jumps on $53.5 mln investment by TCM Strategic Partners ** Danaher Corp DHR.N: up 0.4% BUZZ-Evercore ISI says COVID-19 combination test will be positive for revenue ** Beam Therapeutics Inc BEAM.O: down 7.1% BUZZ-Falls on planned equity raise ** LifeSci Acquisition Corp LSAC.O: up 14.3% BUZZ-Jumps on cancer drug developer Vincera SPAC deal ** Shutterstock Inc SSTK.N: up 3.3% BUZZ-Rises as BofA starts coverage with 'buy' ** Scorpio Bulkers Inc SALT.N: up 3.1% BUZZ-Up on sale of a Kamsarmax vessel ** Intellia Therapeutics Inc NTLA.O: up 0.1% BUZZ-Up after gene therapy shows promise in mice study ** Orphazyme A/S ORPH.O: down 7.9% BUZZ-Shares of drugmaker fall in Nasdaq debut ** Adial Pharmaceuticals Inc ADIL.O: up 34.0% BUZZ-Surges as FDA grants emergency use for COVID-19 antibody test ** Arcutis Biotherapeutics Inc ARQT.O: up 16.2% BUZZ-Rises on positive data from skin disease treatment study ** Radware Ltd RDWR.O: up 0.5% BUZZ-Gains on cloud security service deal with India's Airtel ** China Ceramics Co Ltd CCCL.O: down 7.2% BUZZ-Drops as H1 revenue plummets on pandemic hit ** ONEOK Inc OKE.N: up 1.7% BUZZ-Gains as UBS sees improving volume, upgrades to 'buy' ** NanoVibronix Inc NAOV.O: up 2.6% BUZZ-Rises on filing U.S. patent for pain management device ** Beyond Meat Inc BYND.O: up 9.4% BUZZ-Jumps as burger patty distribution at Walmart stores triples ** TTM Technologies Inc TTMI.O: up 0.8% BUZZ-Rises as Craig-Hallum starts coverage with 'buy' ** Infinity Pharmaceuticals Inc INFI.O: up 0.9% BUZZ-Jumps on fast track tag for breast cancer treatment ** Novus Capital Corp NOVS.O: up 18.6% BUZZ-Soars on plan to take indoor farm operator AppHarvest public ** BridgeBio Pharma Inc BBIO.O: up 1.5% BUZZ-FDA accepts application for rare metabolic disorder treatment ** Ardmore Shipping Corp ASC.N: up 5.0% BUZZ-Rises on share buyback plan ** Artelo Biosciences Inc ARTL.O: up 19.8% BUZZ-Soars as UK ethics panel approves cancer treatment study ** Molina Healthcare Inc MOH.N: up 3.9% BUZZ-Affinity Health deal will boost New York presence - SVB Leerink ** Caesars Entertainment Inc CZR.O: down 5.3% BUZZ-Falls after co prices $1.7 bln equity offering ** TransMedics Group Inc TMDX.O: down 4.1% BUZZ-Down after FDA postpones review meeting for donor heart system ** Molson Coors Beverage Co TAP.N: up 0.2% BUZZ-Gains on deal with Coca-Cola to launch alcoholic beverage ** Myovant Sciences Ltd MYOV.N: down 23.4% BUZZ-Drops as cancer drug misses secondary goal in late-stage trial ** Ironwood Pharmaceuticals Inc IRWD.O: down 2.0% BUZZ-Scraps development of digestive disorder drug, shares tumble ** Nikola Corp NKLA.O: down 6.1% BUZZ-EV maker on track to trade lower ** McCormick & Company Inc MKC.N: down 3.1% BUZZ-Rises on Q2 results beat, 2-for-1 stock split ** Big Lots Inc BIG.N: up 1.3% BUZZ-Climbs on lifting Q3 outlook ** U.S. Energy Corp USEG.O: up 168.5% BUZZ-Surges on buying FieldPoint Petroleum's upstream assets ** Sogou Inc SOGO.N: up 2.4% BUZZ-Set to open at 2-year peak on Tencent's $3.5 bln take-private deal ** Fitbit Inc FIT.N: up 6.3% BUZZ-Rises as Reuters reports Google set to win EU nod for $2.1 bln deal ** Fuelcell Energy Inc FCEL.O: up 4.1% BUZZ-Rises on multiple project wins in Connecticut ** Aerie Pharmaceuticals Inc AERI.O: up 1.5% BUZZ-Up as FDA approves clinical study for dry eye treatment ** Moleculin Biotech Inc MBRX.O: up 2.3% BUZZ-New molecule in portfolio shows potential to fight COVID-19 ** Abbott Laboratories ABT.N: up 0.7% BUZZ-Rises as its COVID-19 test gets deployed ** Hershey Co HSY.N: up 0.1% BUZZ-BMO upgrades, says Halloween concerns overblown ** United Natural Foods Inc UNFI.N: down 12.6% BUZZ-CEO to retire, shares slip ** Tonix Pharmaceuticals Holding Corp TNXP.O: up 5.6% BUZZ-Rises as co buys new facility to develop COVID-19 vaccines ** Sorrento Therapeutics Inc SRNE.O: up 18.0% BUZZ-Up as COVID-19 antibody candidates show promise in study ** Fluidigm Corp FLDM.O: up 3.9% BUZZ-Jumps on increased NIH funding to scale up COVID-19 testing ** Aptorum Group Ltd APM.O: up 594.3% BUZZ-Surges after launching diagnostics subsidiary ** Party City Holdco Inc PRTY.N: down 7.4% BUZZ-Loses sheen on plans of 13 mln share offering ** Providence Service Corp PRSC.O: down 1.1% BUZZ-To acquire Simplura Health to expand into home care The 11 major S&P 500 sectors: Communication Services .N At 13:23 ET, the Dow Jones Industrial Average .DJI was down 0.67% at 27,400.45. down 0.23% Consumer Discretionary | Separately on Tuesday, the federal government said it had signed an agreement up to buy 7.9 million Abbott ABT.N ID NOW rapid point of care tests, pending Health Canada approval of that test. The regulator is currently reviewing antigen tests from Abbott ABT.N, Quidel QDEL.O and Sona Nanotech SONA.CD, according to public data. Adds Abbott procurement deal TORONTO, Sept 29 (Reuters) - Health Canada expects to authorize new antigen tests for COVID-19 soon, a senior government official said on Tuesday, in an effort to provide additional testing as a second wave of novel coronavirus infections overwhelms laboratories."
2020-09-28,104.23999786376952,104.44000244140624,-0.7735116293748288,"Abbott wins EU approval for smallest version of glucose monitoring device | Under pressure over virus, Trump to announce more tests for states | Trump, pressured over pandemic, says states to receive 150 mln tests | Poorer countries to get 120 million $5 coronavirus tests, WHO says | BUZZ-U.S. STOCKS ON THE MOVE-Boeing, Bank of America, Eiger BioPharmaceuticals, Pangaea Logistics","Sept 28 (Reuters) - Abbott Laboratories' ABT.N said on Monday it had received clearance to market the smallest version of its fastest-growing low-cost diabetes monitoring product in the European Union. FreeStyle Libre 3, which received the European CE Mark, is a more discreet sensor and will be priced the same as previous versions of the device, the company said. FreeStyle Libre 3 is a continuous glucose monitoring device that allows diabetics to track their blood sugar levels without multiple daily finger sticks. | The U.S. government will send an ""overwhelming majority"" of the 150 million rapid COVID-19 tests it purchased from Abbott Laboratories ABT.N in August to governors of states and territories to support school reopenings and other critical tasks, an administration official said at a press briefing earlier this month. WASHINGTON, Sept 28 (Reuters) - Under pressure over his handling of the coronavirus outbreak, U.S. President Donald Trump planned to announce on Monday that the government would distribute millions of rapid tests to states this week with an eye towards using them to reopen schools. Abbott has said it would scale its production capacity to 50 million tests per month by October and that it could currently produce ""tens of millions"" of the tests, indicating it will take at least a few months for the tests to be fully distributed to states and territories. | The rapid tests announced by Trump were purchased from Abbott Laboratories ABT.N in August for sending to governors of states and territories to support school reopenings and other critical tasks. New throughout, adds Trump comments WASHINGTON, Sept 28 (Reuters) - President Donald Trump, under pressure over his handling of the coronavirus outbreak, announced on Monday the federal government would ship 150 million rapid tests to U.S. states for opening schools and ensuring safety at centers for senior citizens. Abbott has said it would scale production capacity to 50 million tests per month by October and that it could currently produce ""tens of millions"" of the tests, indicating it will take at least a few months for the tests to be fully distributed to states and territories. | WHO Director General Tedros Adhanom Ghebreyesus said the manufacturers Abbott ABT.N and SD Biosensor had agreed with the Bill & Melinda Gates Foundation to ""make 120 million of these new, highly portable and easy-to-use rapid COVID-19 diagnostic tests available over a period of six months"". By Emma Farge and Kate Kelland GENEVA/LONDON, Sept 28 (Reuters) - Some 120 million rapid diagnostic tests for coronavirus will be made available to low- and middle-income countries at a maximum of $5 each, the World Health Organization (WHO) said on Monday. ""This will enable the expansion of testing, particularly in hard-to-reach areas that do not have laboratory facilities or enough trained health workers to carry out tests,"" Tedros said. | The top three S&P 500 .PG.INX percentage gainers: ** Devon Energy Corp , up 12.4% ** Apache Corp , up 7.5% ** Boeing Co , up 6.7% The top three S&P 500 .PL.INX percentage losers: ** DexCom Inc , down 2.6% ** Westrock Co , down 2.5% ** Regeneron Pharmaceuticals Inc , down 2% The top three NYSE .PG.N percentage gainers: ** Ambow Education Holding Ltd , up 115.5% ** Ashford Hospitality Trust Inc , up 58.7% ** Amer Shared Hospital Services , up 30.4% The top three NYSE .PL.N percentage losers: ** Annovis Bio Inc ANVS.N, down 10% ** Great Ajax Corp AJX.N down 9.33% ** PG&E Corp PCG.N, down 7.5% The top three Nasdaq .PG.O percentage gainers: ** Piedmont Lithium Ltd , up 316.1% ** Oxbridge Re Holdings Ltd , up 245.8% ** Perceptron Inc , up 66.1% The top three Nasdaq .PL.O percentage losers: ** Aquestive Thrapeutics Inc , down 34.5% ** Inovio Pharmaceuticals Inc , down 26% ** Sky Solar Holdings Ltd , down 18.8% ** Boeing Co BA.N: up 6.7% BUZZ-Rises as Alembic Global upgrades on hopes of 737 MAX return ** Bank of America Corp BAC.N: up 3.2% BUZZ-Bank stocks lift Wall Street amid global recovery hopes ** Piedmont Lithium Ltd PLL.O: up 316.1% BUZZ-U.S.-listed shares hit record high on Tesla supply deal ** Masimo Corp MASI.O: up 2.1% BUZZ-Gains after FDA clears its pulse oximeter ** Eiger BioPharmaceuticals Inc EIGR.O: down 13.0% BUZZ-Slips after Lambda fails as possible COVID-19 treatment ** Sorrento Therapeutics Inc SRNE.O: up 4.8% BUZZ-Rises on positive early data from knee pain therapy study ** Plug Power Inc PLUG.O: up 11.9% BUZZ-Gains as Morgan Stanley raises FY24 revenue estimate, upgrades rating ** Pangaea Logistics Solutions Ltd PANL.O: up 4.7% BUZZ-Gains after raising stake in Nordic Bulk Holding ** Exxon Mobil Corp XOM.N: up 3.2% BUZZ-Oil stocks gain tracking crude prices ** Chevron Corp CVX.N: up 3% BUZZ-Oil stocks gain tracking crude prices ** Tessco Technologies Inc TESS.O: up 4% BUZZ-Up after founder urges to remove directors ** Natera Inc NTRA.O: up 2.2% BUZZ-Gains after Morgan Stanley starts coverage with 'overweight' ** Virgin Galactic Holdings Inc SPCE.N: up 19.8% BUZZ-Soars as two more bulls board ** Abbott Laboratories ABT.N: up 1% BUZZ-Up on EU approval for smallest version of glucose monitoring device ** Chesapeake Utilities Corp CPK.N: up 12% BUZZ-Rises as set join S&P SmallCap 600 ** OpGen Inc OPGN.O: up 6% BUZZ-Rises on potential use of tool to detect COVID-19 co-infections ** Perceptron Inc PRCP.O: up 66.1% BUZZ-Gains on takeover offer from Sweden's Atlas Copco ** United Parcel Service Inc UPS.N: up 2.6% BUZZ-Eyes record high open after KeyBanc upgrade ** Hologic Inc HOLX.O: up 1.5% BUZZ-Rises as FDA allows emergency use of asymptomatic COVID-19 test ** AbbVie Inc ABBV.N: up 1.5% BUZZ-Gains on orphan drug, fast track tag for spinal cord injury treatment ** Staffing 360 Solutions Inc STAF.O: up 13.7% BUZZ-Gains on sale of recruitment business unit ** Heron Therapeutics Inc HRTX.O: up 5.4% BUZZ-Rises on European marketing approval for non-opioid painkiller ** Virgin Galactic Holdings Inc SPCE.N: up 19.0% BUZZ-Soars after BofA says 'buy' ** American Airlines Group Inc AAL.O: up 4.8% BUZZ-Rises after securing $5.5 bln Treasury loan ** CBL & Associates Properties Inc CBL.N: down 1.7% BUZZ-Falls after restructuring petition extention ** Tesla Inc TSLA.O: up 2.7% BUZZ-Set to rise for third straight session ** Pinterest Inc PINS.N: up 2.2% BUZZ-Up as Guggenheim starts coverage with ""buy"" rating ** Quotient Ltd QTNT.O: up 3.3% BUZZ-Rises as FDA approves emergency use of its COVID-19 antibody test ** WPX Energy Inc WPX.N: up 16.4% BUZZ-Jumps after shale producers agree to merger deal ** Devon Energy Corp DVN.N: up 12.3% BUZZ-Jumps after shale producers agree to merger deal ** Mallinckrodt PLC MNK.N: down 23.3% BUZZ-Falls after report says drugmaker weeks away from filing for bankruptcy ** MobileIron Inc MOBL.O: up 5.6% BUZZ-Rises on $872 mln deal to go private ** Snap Inc SNAP.N: up 3.6% BUZZ-U.S. tech stocks: Guggenheim hikes PTs on 'sustainable' strength ** Ford Motor Co F.N: up 2.9% BUZZ-Taps into German coronavirus relief aid - Handelsblatt ** Xpeng Inc XPEV.N: up 5.3% BUZZ-Surges on plans to open new car factory in China ** Aquestive Therapeutics Inc AQST.O: down 34.5% BUZZ-Slumps after FDA declines co's treatment for seizures ** Uber Technologies Inc UBER.N: up 3.4% BUZZ-Uber jumps as co wins legal bid to restart London operations ** Sina Corp SINA.O: up 6.1% BUZZ-Rises on $2.6 bln deal to go private ** Expedia Group Inc EXPE.O: down 0.9% BUZZ-RBC downgrades as survey suggests slow travel recovery ** Weibo Corp WB.O: up 6.7% BUZZ-Rises on Q2 revenue beat ** Square Inc SQ.N: up 1.3% BUZZ-Gains after Credit Suisse raises price target ** Cleveland-Cliffs Inc CLF.N: up 10.5% BUZZ-Rises on purchase of ArcelorMittal's U.S. assets The 11 major S&P 500 sectors: Communication Services up 0.73% Consumer Discretionary up 1.39% Consumer Staples"
2020-09-25,100.55999755859376,103.4499969482422,0.19186932246305613,3 Dividend Aristocrats to Buy and Hold Forever | Boston Scientific Stock Can See Over 10% Gains,"Abbott Laboratories Abbott Laboratories (NYSE: ABT) has increased its dividend for 48 years in a row. Johnson & Johnson If you like Abbott's dividend track record, you'll probably love Johnson & Johnson (NYSE: JNJ). That's a streak that qualifies J&J as not only a Dividend Aristocrat but also a Dividend King -- stocks that have increased their dividends at least 50 years in a row. | Timeline of 2007-08 Crisis 10/1/2007: Approximate pre-crisis peak in S&P 500 index 9/1/2008 – 10/1/2008: Accelerated market decline corresponding to Lehman bankruptcy filing (9/15/08) 3/1/2009: Approximate bottoming out of S&P 500 index 1/1/2010: Initial recovery to levels before accelerated decline (around 9/1/2008) Boston Scientific vs S&P 500 Performance Over 2007-08 Financial Crisis BSX stock declined from levels of around $14 in September 2007 (pre-crisis peak) to levels of around $7 in March 2009 (as the markets bottomed out), implying BSX stock lost 50% from its approximate pre-crisis peak. In comparison, the S&P 500 Index saw a decline of 51%, followed by a recovery of 48%. Boston Scientific’s Fundamentals in Recent Years Look Strong Boston Scientific’s Revenues grew a strong 43% from $7.5 billion in 2015 to $10.7 billion in 2019, primarily led by its MedSurg and Cardiovascular segments, which added around $1.3 billion each in sales during the same period. Phases of Covid-19 crisis: Early- to mid-March 2020: Fear of the coronavirus outbreak spreading rapidly translates into reality, with the number of cases accelerating globally Late-March 2020 onward: Social distancing measures + lockdowns April 2020: Fed stimulus suppresses near-term survival anxiety May-June 2020: Recovery of demand, with gradual lifting of lockdowns – no panic anymore despite a steady increase in the number of cases July-September 2020: Poor Q2 results for many companies, but continued improvement in demand and a decline in the number of new cases and progress with vaccine development buoy expectations Going by the historical performance, we believe that BSX stock has more room for growth in the near future."
2020-09-24,102.75,100.91999816894533,2.8739055885164557,Everything Investors Need to Know About Coronavirus Tests,"Antibody tests aren't all they're hyped to be, but Abbott's new product might be At present, the U.S. Food and Drug Administration (FDA) has issued emergency use authorization to a handful of different antibody tests, including those produced by companies such as Abbott Laboratories (NYSE: ABT) and Bio-Rad Laboratories (NYSE: BIO). Diagnostic tests are the bedrock of the public health response There are two classes of test: diagnostic tests and antibody tests. Once the patient's sample is in hand, there are two types of diagnostic tests that can be run: molecular tests and antigen tests."
2020-09-23,104.98999786376952,102.7300033569336,-1.7810236798585628,ANALYSIS-Canada's COVID-19 testing system overwhelmed after slow move to new tests | 3 Safe Coronavirus Stocks to Buy Ahead of a Market Crash,"In the United States, part of the next wave of testing expansion will come in the form of inexpensive disposable tests like Abbott's ABT.N BinaxNOW, a $5 credit card-sized device. Right now, that group must rely on the same testing sites as those who need proof of a negative test to visit care homes, and anyone else who wants a test. Other cheap, rapid tests may not be as acurate as lab tests, detecting the virus 80% to 90% of the time versus more than 95% for lab-based tests and the BinaxNOW - but could help ease the current backlog through speed and scale. | Abbott Laboratories In a matter of months, Abbott Laboratories (NYSE: ABT) has become a coronavirus testing giant. We should expect coronavirus testing sales growth in the coming months as more and more Americans want or require testing. So, in coming quarters, a return to normal for the rest of Abbott's business plus growth in coronavirus tests and diabetes care should be a winning combination."
2020-09-22,105.45999908447266,104.8000030517578,-2.152580772283084,Abbott Wins European Approval for Latest MitraClip Heart Valve Device,"Abbott Laboratories (NYSE: ABT) has scored a fresh victory across the Atlantic Ocean. ""This CE Mark, along with other recent approvals and advancements for our MitraClip device, underscores the need for MitraClip's innovative therapy -- which has become a preferred choice for the treatment of mitral regurgitation around the world,"" Abbott quoted Michael Dale, senior vice president of its structural heart business, as saying. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen."
2020-09-21,105.8000030517578,105.9499969482422,-0.6258259420106823,Is The Rally Over For Abbott Stock?,"That said, going by historical performance, and in view of the strong rally in ABT stock since late March, we believe that the stock has little room for growth in the near future. Timeline of 2007-08 Crisis 10/1/2007: Approximate pre-crisis peak in S&P 500 index 9/1/2008 – 10/1/2008: Accelerated market decline corresponding to Lehman bankruptcy filing (9/15/08) 3/1/2009: Approximate bottoming out of S&P 500 index 1/1/2010: Initial recovery to levels before accelerated decline (around 9/1/2008) Abbott Stock Performance Over 2007-08 Financial Crisis We see ABT stock declined from levels of around $19 in September 2007 (pre-crisis peak for markets) to levels of around $17 in March 2009 (as the markets bottomed out), implying ABT stock lost 11% from its approximate pre-crisis peak. Abbott Labs’ stock (NYSE:ABT) trades at $107 currently and it has gained 24% in value so far this year."
2020-09-18,106.55999755859376,106.86000061035156,0.14177116461048284,Is Sorrento Stock Really Worth the Speculation? | Is Co-Diagnostics Stock a Buy? | 3 Dividend Stocks Perfect for Retirees | 20/20 GeneSystems Stock: Leveraging AI for More Accurate Cancer Screening,"While there are various other diagnostic tests – such as from Abbott (NYSE:ABT) – Sorrento’s does have some advantages. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Until this year, Sorrento Therapetics (NASDAQ:SRNE) was an obscure biotech operator. Further, when it comes to biotech companies, it can take a considerable amount of time for FDA approval, which many biotech stocks rely on for performance. | Abbott Laboratories (NYSE: ABT), for example, has a $5 antigen-based test that gives results in 15 minutes. Co-Diagnostics manufactures polymerase chain reaction (PCR) test kits to detect various infectious diseases, but its COVID-19 tests have been the primary driver for the company's revenues this year. While an effective vaccine for COVID-19 would obviously put a dent in the demand for a coronavirus test kit, the tests will still be needed as schools and companies ramp up the return of students and workers. | Abbott Laboratories Abbott Laboratories (NYSE: ABT) definitely checks off the box for stability. That's great news for Brookfield Renewable (NYSE: BEP) (NYSE: BEPC), one of the world's top renewable energy companies. The company's yield now stands at 3.8% for limited partnership Brookfield Renewable Partners and 3.4% for Brookfield Renewable Corporation. | He has also been able to strike sales and marketing agreements with Fortune 500 companies like Johnson & Johnson (NYSE:JNJ), Abbott Laboratories (NYSE:ABT) and Ping An (the largest health insurance company in China). InvestorPlace - Stock Market News, Stock Advice & Trading Tips 20/20 GeneSystems is the developer of diagnostic testing tools for cancer and other diseases. Key Global Partnerships According to the investment materials from 20/20 GeneSystems, the company believes it is the only one to launch a multi-cancer screening test that is based on AI."
2020-09-17,104.95999908447266,106.66000366210938,0.28153440186861556,"Abbott Launches World's First Glucose Monitor for Athletes | FOCUS-U.S. plans for hundreds of millions of cheap, fast COVID-19 tests | Is The Rally Over For DexCom Near $400?","Abbott Laboratories (NYSE: ABT) has decided to adapt the technology used in its FreeStyle Libre diabetes system to help athletes monitor their glucose levels with a new device called the Libre Sense Glucose Sport Biosensor. Considering how many more diabetics there are relative to the number of professional athletes, the Libre Sense Glucose Sport Biosensor probably isn't going to move the revenue needle that much for the Libre line of products. See the 10 stocks *Stock Advisor returns as of August 1, 2020 Brian Orelli, PhD and The Motley Fool have no position in any of the stocks mentioned. | When planned production of the newly authorized tests are combined with previously approved diagnostics, overall monthly U.S. testing capacity will exceed 200 million per month by year end, these sources said. “If we could get testing to a scale where everyone you want to test can be tested quickly and cheaply with a quick turnaround time (for results), then you could screen people"" before they spread the virus, said Dwayne Breining, director of labs at Northwell Health, New York state's largest hospital system. The National Institutes of Health is working with companies on new tests that will likely add as many as another 30 million tests per month to overall capacity this year, a U.S. official told Reuters. | DexCom Performance During 2020 Coronavirus DXCM stock declined from levels of around $292 in mid February (pre-crisis peak) to levels of around $210 as of March 23 (as the markets bottomed out), implying DXCM stock lost 28% from its approximate pre-crisis peak. 2007-08 Financial Crisis Timeline of 2007-08 Crisis 10/1/2007: Approximate pre-crisis peak in S&P 500 index 9/1/2008 – 10/1/2008: Accelerated market decline corresponding to Lehman bankruptcy filing (9/15/08) 3/1/2009: Approximate bottoming out of S&P 500 index 1/1/2010: Initial recovery to levels before accelerated decline (around 9/1/2008) DexCom Stock Performance Over 2007-08 Financial Crisis We see DXCM stock declined from levels of around $10 in September 2007 (pre-crisis peak) to levels of around $4 in March 2009 (as the markets bottomed out), implying DXCM stock lost 61% from its approximate pre-crisis peak. Phases of COVID-19 crisis: Early- to mid-March 2020: Fear of the coronavirus outbreak spreading rapidly translates into reality, with the number of cases accelerating globally Late-March 2020 onward: Social distancing measures + lockdowns April 2020: Fed stimulus suppresses near-term survival anxiety May-June 2020: Recovery of demand, with gradual lifting of lockdowns – no panic anymore despite a steady increase in the number of cases July-September 2020: Poor Q2 results for many companies, but continued improvement in demand and a decline in the number of new cases and progress with vaccine development buoy expectations Going by the historical performance and in view of the strong rally in DexCom stock since late March, we believe that the stock has little room for growth in the near future."
2020-09-16,106.9499969482422,105.6999969482422,1.6196690095895878,,
2020-09-15,107.0,106.58000183105467,-1.1687704868331412,The Key Question Surrounding XpresSpa Group Right Now | How Does Illumina Stock Performance In 2020 Compare With That During 2008 Crisis?,"And it has agreed to install rapid testing equipment from Abbott Laboratories (NYSE:ABT). InvestorPlace - Stock Market News, Stock Advice & Trading Tips In late March, XpresSpa Group (NASDAQ:XSPA) announced that it was pivoting its business to providing coronavirus testing in airports. The Thin Case for XSPA Stock To own XSPA stock even after the big pullback, investors need to believe that the company can make at least $100 million off its testing efforts — or that it can find a viable business after that. | We largely think that they are, and we believe that the stock is likely to continue to see higher levels in the coming quarters, as demand for Covid testing remains high, and its consumables segment sales will likely trend higher. We see ILMN stock gained from levels of around $26 in October 2007 (the pre-crisis peak for the markets) to roughly $43 in September 2008 (the pre-crisis peak for the stock), and it then declined to $31 levels (as the markets bottomed out) – implying that the stock lost as much as 28% of its value from its approximate pre-crisis peak. Thus far in 2020, Illumina has seen an 11% decline in revenues, primarily due to a 30% decline in instruments revenue, while the consumables segment fared better with only 6% decline in sales."
2020-09-14,105.58999633789062,105.69000244140624,-0.39252165321993154,"Thermo Fisher Is a Buy Despite Recent Setbacks | Intuitive Surgical Stock Headed To $1,000 Levels?","TMO stock sold off two weeks ago on news that Abbott (NYSE:ABT) got its rapid Covid-19 test approved, and the federal government will buy those instead. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Thermo Fisher (NYSE:TMO) stock is one of those champion holdings that many investors don’t know about. Given that Thermo Fisher is one of the top testing companies worldwide, it’s only natural that the company got into the testing market for this ailment as well. | For more details on Intuitive Surgical’s historical performance, see our interactive dashboard What Factors Drove Intuitive Surgical stock up 97% Since The End Of 2017 Intuitive Surgical’s Revenues could grow 50% from the estimated $4.3 billion in 2020 to around $6.7 billion by 2023, representing a growth rate of roughly 16% per year (for context annual growth was about 18% between 2016 and 2019). While Intuitive Surgical will likely post a decline in earnings this year, the company could see strong earnings growth over 2020-2023, as the company’s past investments in R&D and product development start paying off, along with continued expansion of its installed base. For context, Intuitive Surgical has seen a steady growth in P/E multiple from 40x in 2017 to 46x in 2019, given the increased adoption of robotic surgery, a trend which is likely to continue over the coming years."
2020-09-11,105.27999877929688,104.6999969482422,0.0947117217388556,Dividend Aristocrat AbbVie Declares Its Latest Payout; Yield Is 5.3% | 2 Top Dividend Stocks to Buy in a Stock Market Crash | Quidel Stock Looks Attractive After A Healthy Correction,"AbbVie has been a steady dividend payer and lifter since it was spun off from Abbott Laboratories (NYSE: ABT) in 2013. It also compares favorably to the yields of many blue chip stocks favored by dividend stock investors. 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | In that spirit, here are two top dividend stocks in the pharma sector you can buy on the dip and hold with confidence when another downturn comes: AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN). During the second quarter, revenue from Botox Cosmetic was $226 million, a 43.1% decrease, while revenue from Botox Therapeutics rang in at $297 million, dropping by 22.3% year over year. Amgen has raised its dividends by 240.4% since 2013, and currently offers a dividend yield of 2.59%, along with a cash payout ratio of 35.41%, giving the company plenty of room for more dividend increases. | We largely think that they are, and we believe that the stock is likely to see significant upside from the current levels, as demand for coronavirus testing remains high, and the stock has seen a healthy correction over the recent weeks owing to increased competition. While the S&P fell by about 34% and rebounded by about 54% in the current crisis, QDEL stock has only moved higher gaining 7% of its value between the market peak on February 19 to the low on March 23, and it continued to rally with gains of over 240% to around $300 levels in early August. Secondly, other than its existing tests, Quidel is currently working on multiple new tests, including Influenza A+B and SARS Antigen rapid point-of-care combination test, and Influenza A+B, SARS Antigen, and Respiratory Syncytial Virus (RSV), which are expected to drive future sales growth."
2020-09-10,105.5999984741211,104.0,-0.5509135997147538,,
2020-09-09,104.26000213623048,105.80999755859376,-1.5151500920837588,Why Shares of These 3 Coronavirus-Test Makers Saw Big Moves in August,"But the very next day, it all came crashing down, as heavyweight Abbott Laboratories (NYSE: ABT) announced that its own coronavirus test had been granted EUA by the FDA. Unlike B-D's and Fluidigm's tests, it is self-contained, so it doesn't require a Veritor, Biomark, or any other testing system to be used. B-D hasn't tried to put a positive spin on the news, but it says it should be able to produce 2 million of its own 15-minute tests per week by the end of September, and it's unlikely that Abbott will be able to meet demand for rapid-response testing by itself, meaning B-D is sure to remain a part of the testing landscape."
2020-09-08,103.16999816894533,102.83999633789062,1.4866635244626145,Why Expedia Shares Gained 21% Last Month | Why These 3 Coronavirus-Related Stocks Plummeted More Than 35% in August | Why Co-Diagnostics Stock Is Skyrocketing Today,"Though revenue plunged 82% during the lockdown-impacted quarter, and the company posted an adjusted net loss of $577 million, investors were willing to look past those figures as Expedia was one of several travel stocks, including Booking Holdings and TripAdvisor, that rose by double-digits during August. 10 stocks we like better than Expedia When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. See the 10 stocks *Stock Advisor returns as of August 1, 2020 Jeremy Bowman has no position in any of the stocks mentioned. | For companies that had been making coronavirus diagnostic test kits, a similar situation occurred when heavy hitter Abbott Laboratories (NYSE: ABT) announced on Aug. 26 that it had received emergency use authorization (EUA) from the FDA for a rapid COVID-19 antibody test. What happened Shares of COVID-19 vaccine developer Vaxart (NASDAQ: VXRT) and coronavirus diagnostic test manufacturers Opko Health (NASDAQ: OPK) and Quidel (NASDAQ: QDEL) plunged more than 35% in August, according to data provided by S&P Global Market Intelligence. You see, Quidel's test requires its Sofia diagnostic testing machine, which many testing locations don't own. | The big gain came after the company announced that it had entered into an agreement with Arches Research, a subsidiary of Polarity TE (NASDAQ: PTE), to expand Arches' use of Co-Diagnostics' Logix Smart COVID-19 test. 10 stocks we like better than Co-Diagnostics, Inc. See the 10 stocks *Stock Advisor returns as of August 1, 2020 Keith Speights has no position in any of the stocks mentioned."
2020-09-04,105.4499969482422,104.16000366210938,-0.3198622050126525,"Why Darden Restaurants Stock Was Up 14% in August | IVW, ABT, AMD, ACN: Large Outflows Detected at ETF | Next Coronavirus Market Crash: Where to Invest $1,000 | Like Dividends? I Bet You'll Love These 2 Stocks","Although Darden stock is rising, a recent filing with the Securities and Exchange Commission (SEC) is a reminder for investors that the company isn't back to normal yet. 10 stocks we like better than Darden Restaurants When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. See the 10 stocks *Stock Advisor returns as of August 1, 2020 Jon Quast has no position in any of the stocks mentioned. | Among the largest underlying components of IVW, in trading today Abbott Laboratories (Symbol: ABT) is off about 1.8%, Advanced Micro Devices Inc (Symbol: AMD) is down about 5.8%, and Accenture plc (Symbol: ACN) is lower by about 1.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 500 Growth ETF (Symbol: IVW) where we have detected an approximate $47.7 million dollar outflow -- that's a 0.2% decrease week over week (from 131,450,000 to 131,250,000). For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year price performance of IVW, versus its 200 day moving average: Looking at the chart above, IVW's low point in its 52 week range is $140.84 per share, with $250.42 as the 52 week high point — that compares with a last trade of $232.16. | TNDM data by YCharts Abbott Laboratories In business since 1888, Abbott Laboratories (NYSE: ABT) boasts an extremely diverse portfolio including cardiovascular solutions, medicines, and nutritional products. During the first quarter of 2020 (which ended March 31), the company reported a 48% year-over-year increase in global sales, with global pump shipments rising by 18% and domestic pump shipments up 36%. During the second quarter, which ran through June, Tandem's worldwide sales saw a 17% increase year over year to $109.2 million. | To be listed on the S&P 500's Dividend Aristocrat index, a stock must boost its dividend every year for at least 25 years in a row; AbbVie's history as part of Abbott Laboratories (NYSE: ABT), from which it spun off in 2013, is included there. Dividend stocks are a tried-and-true way of adding value to your portfolio -- when a company pays a generous dividend, this can be a sign of its potential as a reliable long-term investment. The company is contributing its pandemic adjuvant system to multiple vaccine collaborations with different companies."
2020-09-03,108.6999969482422,105.52999877929688,-1.2233222602803786,,
2020-09-02,106.4499969482422,109.44000244140624,-2.9162817460378863,"Abbot Labs: New COVID-19 Antibody Test Is a Game Changer, Says Analyst | Why Co-Diagnostics Shares Sank Today While the Stock Market Jumped | Why DexCom Stock Jumped Today | Why Shake Stock Surged 41% Last Month","However, Miksic expects the “debate over the sustainability of Covid testing sales to continue.” The 5-star analyst said, “While there is little debate among investors over the magnitude of near-term sales these new COVID-19 tests will generate, the question as to how long these sales will continue, or how much share ABT will ultimately capture remains actively contested. While serology (i.e. antibody) tests have seen only limited utility and demand to date, we expect demand for immunity testing to increase as vaccines are approved, distributed and administered.” Accordingly, Miksic raised his price target for ABT shares from $109 to $136. Last week, Abbott Laboratories (ABT) announced it had been granted emergency use authorization (EUA) by the FDA for its rapid COVID-19 antibody test, BinaxNOW. | The most likely culprit behind the decline is a continued sell-off resulting from Abbott Labs (NYSE: ABT) winning FDA emergency use authorization (EUA) last week for its inexpensive rapid COVID-19 antibody test. The company provided an unscheduled operational update on Tuesday playing up the importance of RT-PCR (or reverse-transcriptase polymerase chain reaction) tests like its Logix Smart COVID-19 test, stating that these tests remain the ""gold standard"" for novel coronavirus testing. While Co-Diagnostics is correct that RT-PCR tests are the best option, Abbott will likely make major inroads with its BinaxNOW test. | Instead, DexCom's gains appear to be the result of investors' general optimism about the economy as the overall stock market rose on Wednesday. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. See the 10 stocks *Stock Advisor returns as of August 1, 2020 Keith Speights has no position in any of the stocks mentioned. | SHAK data by YCharts So what There was little news out on Shake Shack in the first half of the month, but the stock seemed to gain as coronavirus cases nationwide pulled back from a peak in July, boosting hopes for a continued economic reopening that would help Shake Shack, which has been battered by a loss of office workers and tourists. Setyan noted that Shake Shack had been one of the best growth stocks in the restaurant industry before the pandemic, and said that the earlier sell-off this year added to the stock's growth potential. See the 10 stocks *Stock Advisor returns as of August 1, 2020 Jeremy Bowman has no position in any of the stocks mentioned."
2020-09-01,108.93000030517578,106.5500030517578,2.808835677672988,"Trump administration sending rapid COVID tests to states, CDC bars evictions | In Canada, airlines face uphill climb to replace quarantines with COVID-19 testing | Why Abbott Stock Is Up | Abbott Announces Availability Of FreeStyle Libre 2 ICGM System For Medicare Patients | Forget Johnson & Johnson, AbbVie Is a Better Dividend Stock | Medtronic Stock Looks Attractive At $107 | Carnival Stock Could Rebound Significantly Once a Vaccine Arrives","In announcing that the ""overwhelming majority"" of 150 rapid antigen tests purchased from Abbot Laboratories ABT.N would be sent to state governors, U.S. Health and Human Services Assistant Secretary Admiral Brett Giror said top priorities included day care centers and first responders L1N2FY1SE The portable tests can deliver results within 15 minutes and will sell for $5. By Dan Whitcomb Sept 1 (Reuters) - The Trump administration will send most of its newly purchased 150 million rapid COVID-19 tests to U.S. states for schools and critical services, a White House official said on Tuesday, as New York City pushed back reopening classrooms in a deal with union leaders. In New York City, Mayor Bill de Blasio said an agreement had been reached with reluctant teachers union leaders to reopen school buildings to students on September 21 as part of his plan for a mix of in-class and remote learning. | Last week U.S. regulators approved a rapid test from Abbott Laboratories ABT.N but it is currently approved only for people who have symptoms. By Allison Lampert and Allison Martell MONTREAL/TORONTO, Sept 1 (Reuters) - Transport Canada is holding early talks with airlines to introduce COVID-19 testing at airports, but the day when such tests could become an alternative to the quarantines decimating travel could still be far off, sources familiar with the discussions said. The use of airport testing to reduce or eliminate Canada's strict two-week self quarantine rule would be logistically challenging as it would require cooperation from airports, airlines, federal and provincial health authorities, the sources said. | Hill: Obviously, we're all hoping for a vaccine, but you're absolutely right that rapid testing is the first and most important step to, I don't want to say ""getting back to normal,"" because I don't think we're ever going to get back [laughs] to normal, but getting closer, getting a lot closer. Am I wrong to be surprised by the drop in Fulgent Genetics' stock price, I guess I never -- in the same way that people much smarter than me have talked about the vaccine and have said things like, look, we're going to need a bunch of different companies producing the vaccine, so don't look for one -- you know, because everyone, from an investing standpoint, it's a natural ask, well, who's going to produce the vaccine, I want to invest in them. Because in the past when you and I have talked about Scotiabank [Bank of Nova Scotia] and others, you've laid out a pretty good case for them, I think, particularly relative to the big banks in America, which have the whole investment side -- it just seems like the Canadian big banks are a little bit clearer in terms of being able to understand them. | (RTTNews) - Abbott (ABT) announced the company's next-generation FreeStyle Libre 2 integrated continuous glucose monitoring system is now available to Medicare patients. The FreeStyle Libre 2 Flash Glucose Monitoring System is a continuous glucose monitoring device with real time alarms capability indicated for the management of diabetes in persons age 4 and older. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here's why: AbbVie's dividend yield is much higher -- and likely to stay that way Today, J&J pays its shareholders a quarterly dividend of $1.01 for an annual yield of 2.6%, which is well above the S&P 500 average of 2%. Unless there's a significant change in dividend policies from either of these two companies, it is unlikely that J&J's dividend and yield will best AbbVie's anytime soon. AbbVie's dividend is at less risk in the long-term Another reason income investors should opt for AbbVie's dividend? | Medtronic’s revenues declined 3.5% from $30.0 billion to $28.9 billion between fiscal 2018 and fiscal 2020 (fiscal ends in April), and this translated into a similar decline in Non-GAAP EPS, as a low single-digit decline in net income margin was offset by a similar decline in total shares outstanding. While Medtronic stock appears expensive when compared to its historical P/E multiple of 21x in 2019, it is trading at 19x its estimated earnings for fiscal 2022, when the company expects the business to return to normalcy. Overall, we believe that Medtronic will likely see steady revenue and earnings growth over the coming years, and the stock trading at just 18x its fiscal 2022 expected earnings appears to be an attractive level for investors wiling to invest for the long-term. | Moreover, this past week the news that a cheap and quick, no-lab-required Covid-19 test would be available from Abbott Laboratories (NYSE:ABT) has also lifted cruise stocks. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Carnival Corp (NYSE:CCL) is on the rise again. CCL) ship on the water"" width=""300"" height=""169""> Source: Ruth Peterkin / Shutterstock.com If that occurs, the U.S. Center for Disease Control (CDC) could end up lifting its “no sail” order for cruise companies."
2020-08-31,110.6999969482422,109.47000122070312,-2.1848868509595496,"Sorrento’s Covid-19 Test, Acquisitions Should Help SRNE Stock Surge","According to the columnist, labs usually charge at least $80 per test that they evaluate, while Sorrento has said that its test “might cost only $10.” A recent test made by Abbott (NYSE:ABT) and approved by the FDA reportedly yields results in 15 minutes, costs only $5, and does not require lab equipment. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sorrento (NASDAQ:SRNE) should continue to climb in the very likely case the company’s superior coronavirus test is approved and then becomes widely used in the U.S. and potentially around the world. Sorrento reported that it was able to use SmartPharm’s system, in conjunction with Sorrento’s STI-1499 antibody, to develop “an antibody encoded DNA plasmid candidate” which “has the potential to generate long-lasting anti-viral protection with a single intra-muscular administration.” Sorrento has said that STI-1499 “demonstrated (a) 100% neutralizing effect” of Covid-19 in lab tests and stopped the virus from entering healthy cells in tests in animals."
2020-08-28,113.54000091552734,110.79000091552734,-1.1111072822469557,"Coronavirus Testing Hopes Lift Shares of BJ's, Dave & Buster's, and Bloomin' Brands | Abbott Laboratories Reaches Analyst Target Price | Why Royal Caribbean, Carnival Corporation, and Norwegian Cruise Line Stocks All Just Popped 5% (and More) | XpresSpa Group’s Stock Drop Ignores the Potential of Pivot to Virus Testing | GLOBAL MARKETS-Japan markets roiled by Abe resignation news, stocks choppy after Fed shift","And investors believe that's good news for beaten-down restaurant stocks like BJ's Restaurants (NASDAQ: BJRI), Dave & Buster's Entertainment (NASDAQ: PLAY) and Bloomin' Brands (NASDAQ: BLMN). Today, BJ's Restaurants stock was up 14%, Dave & Buster's shares were up 16%, and Bloomin' Brands was up 9%. But even if I'm wrong, investors need to keep in mind that the new coronavirus tests aren't immediate fixes for the problems at BJ's Restaurants, Dave & Buster's, and Bloomin' Brands. | And so with ABT crossing above that average target price of $108.18/share, investors in ABT have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $108.18 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? In recent trading, shares of Abbott Laboratories (Symbol: ABT) have crossed above the average analyst 12-month target price of $108.18, changing hands for $111.29/share. But the whole reason to look at the average ABT price target in the first place is to tap into a ""wisdom of crowds"" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. | Yesterday as you may recall, Big Pharma company Abbott Laboratories (NYSE: ABT) announced the release of a ""fast, $5, 15-minute, easy-to-use COVID-19 test"" that promises to quickly permit patients to discover if they have antibodies indicating prior infection with the novel coronavirus (such that they can be confident they're now immune, noninfective, and thus ""safe"" to travel on cruise ships). The more progress they make -- or even just promise (VBI's vaccines, after all, haven't even begun Phase 1/2 trials yet) -- the more enthusiasm you can expect to see about cruise line stocks among investors hoping for a recovery in the business. 10 stocks we like better than Carnival When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | However, on Aug. 24, XpresSpa announced that it had signed a contract with Abbott Labs (NYSE:ABT) to secure 100 ID NOW testing instruments. InvestorPlace - Stock Market News, Stock Advice & Trading Tips XpresSpa Group (NASDAQ:XSPA) announced a $35.3 million direct offering Aug. 25 that gave investors one share of XSPA stock and short-term warrants to purchase another at $3.05. Source: Maridav / Shutterstock The news sent the share price for the provider of Covid-19 screening and testing services at JFK International Airport and Newark Liberty International Airport down 20% at the Aug. 26 market open. | Stocks also rose on news that Abbott Laboratories ABT.N won U.S. marketing authorization for a COVID-19 portable antigen test that can deliver results in 15 minutes and will sell for $5. The Fed's move pushed up longer dated U.S. paper and largely supported stocks, while the Japanese share market sold off sharply and the yen rose in the wake of the Abe news. Shares in China .CSI300 rose 1.04%, while Tokyo stocks .N225 erased losses and fell 1.14% Eurostoxx 50 futures STXEc1 rose 0.54%, German stock futures FDXc1 gained 0.6% and FTSE futures FFIc1 rose 0.49%."
2020-08-27,111.01000213623048,111.29000091552734,-2.4220538821784694,"S&P 500 Airline Stocks, Cruise Stocks Surge on Abbott Labs FDA Approval, Federal Reserve Policy Change | GLOBAL MARKETS-Treasury yields, dollar gain after Fed's historic policy shift | GLOBAL MARKETS-Asian stocks may be choppy despite U.S. Fed inflation shift, COVID outlook | Why a New COVID-19 Test Is Giving Shake Shack and Other Restaurants a Big Boost | Why Fluidigm Stock Plunged Today | 4 Top Stock Trades for Friday: WMT, ULTA, ABT, QDEL | Noteworthy Thursday Option Activity: ABT, BYND, GS | S&P, Dow close higher on new Fed inflation stance, COVID test hopes | Here's Why Quidel, Hologic, and Quest Diagnostics Shares Fell Today | Trump administration to purchase 150 mln Abbott COVID-19 tests for $750 mln | S&P, Dow head higher on new Fed stance, COVID progress | Abbott to Receive Order for 150 Million Rapid COVID-19 Tests | Pacific Ethanol Stock Jumped 24% Today: What Investors Need To Know | Why Overstock.com Sank 12% Today | Nasdaq Falls 40; Fulgent, Fluidigm Collapse on COVID-19 Competition | Futures fall as jobless claims hover at 1 mln mark; focus shifts to Powell | BUZZ-U.S. STOCKS ON THE MOVE-Cassiopea, Box Inc, Abbott Laboratories, Tencent Music | Wall Street rises as Fed targets 2% average inflation | Why Fulgent Genetics Is Crashing Today | BUZZ-U.S. STOCKS ON THE MOVE-Microsoft Corp, Beyond Meat Inc, Peloton Interactive Inc, Electronic Arts Inc | Fed Lifts Stock Markets; Abbott's $5 Quick Test Gives Travel Stocks Big Gains | iShares S&P 500 Growth ETF Experiences Big Outflow | Fed's inflation push lifts S&P 500, Nasdaq to new highs | BUZZ-U.S. STOCKS ON THE MOVE-Coty Inc, Sandridge Permian, ReneSola Ltd, Moxian Inc | Pre-Market Most Active for Aug 27, 2020 : NIO, CLVS, FLDM, ABT, AAL, COTY, QQQ, SQQQ, LI, CCL, NCLH, ANF | Trump administration to purchase 150 million Abbott COVID-19 tests for $750 mln | US STOCKS-Futures down ahead of Powell's speech on monetary policy | Pre-market Movers In Healthcare Sector: EYPT, CLVS, ABT, VBIV, LPCN... | FDA Approves Abbott's $5 COVID-19 Antigen Portable Rapid Test | Why Co-Diagnostics, GenMark, Luminex, and Opko Stocks Are Sinking Today","Additionally, news that broke yesterday is having a positive lift for the market: Abbott Laboratories (NYSE: ABT) was expected to receive emergency use authorization from the U.S. Food and Drug Administration for its 15-minute coronavirus test. Fifty-million tests per month may sound like a lot, but there are tens of millions of essential workers in the U.S. who would likely get priority and will be tested regularly, not to mention the tens of millions of students, teachers, and other staff who would get priority for test access before any airline's orders were filled. Walmart and Microsoft up on TikTok deal prospects Microsoft shares moved higher while its fellow mega-cap tech giant's shares fell, after CNBC broke the news that it, along with Walmart (NYSE: WMT) were now the leading bidders to acquire TikTok's North American and some other geographical operations. | Stocks also rose on news that Abbott Laboratories ABT.N won U.S. marketing authorization for a COVID-19 portable antigen test that can deliver results in 15 minutes and will sell for $5. By Stanley White and Katanga Johnson TOKYO/WASHINGTON, Aug 28 (Reuters) - Longer-dated Treasury yields and the dollar rose in Asia on Friday after the U.S. Federal Reserve shifted its policy framework to place more emphasis on boosting economic growth and less on worries about letting inflation run too high. Markets swirled after Fed Chairman Jerome Powell laid out a policy that aims for 2% inflation on average so that too low a pace would be followed by an effort to lift inflation ""moderately above 2% for some time."" | Stocks also rose on news that Abbott Laboratories ABT.N won U.S. marketing authorization for a COVID-19 portable antigen test that can deliver results in 15 minutes and will sell for $5. Japan's Nikkei 225 futures NKc1 added 0.09%, while the Nikkei 225 index .N225 closed the overnight session down 0.35% Hong Kong's Hang Seng index futures .HSI, HSIc1 rose 0.05%. Global assetshttp://tmsnrt.rs/2jvdmXl Global currencies vs. dollar http://tmsnrt.rs/2egbfVh Emerging marketshttp://tmsnrt.rs/2ihRugV MSCI All Country Wolrd Index Market Caphttp://tmsnrt.rs/2EmTD6j (Reporting by Katanga Johnson; Editing by Richard Chang) ((Katanga.Johnson@thomsonreuters.com; 202-898-8403; Reuters Messaging: Katanga.Johnson.thomsonreuters.com@reuters.net)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | With Abbott Laboratories (NYSE: ABT) developing a $5 COVID-19 test that takes 15 minutes to produce results with no additional equipment required, dozens of restaurant stocks climbed today, including Shake Shack (NYSE: SHAK), up 6%, The Cheesecake Factory (NASDAQ: CAKE), with 4.91% gains, Bloomin' Brands, Inc. (NASDAQ: BLMN), up 3%, and Darden Restaurants (NYSE: DRI), up 3.66%, among others. Even if this scenario doesn't fully play out and the coronavirus continues to spread at a reduced level, a cheap, fast test could theoretically facilitate testing of restaurant personnel on arrival if enough tests are made available, allowing ongoing assurance of service staff health. See the 10 stocks *Stock Advisor returns as of August 1, 2020 Rhian Hunt has no position in any of the stocks mentioned. | Today, however, they're decidedly less so, following news that healthcare giant Abbott Laboratories (NYSE: ABT) had also been granted an emergency use authorization by the FDA. For these reasons -- and although it's not a saliva-based test, like that of Fluidigm -- Abbott's test is considered to be a major breakthrough in the battle against COVID-19. 10 stocks we like better than Fluidigm When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | The post 4 Top Stock Trades for Friday: WMT, ULTA, ABT, QDEL appeared first on InvestorPlace. 3: Abbott Labs (ABT) Click to Enlarge Source: Chart courtesy of StockCharts.com Abbott Labs (NYSE:ABT) caught a nice boost on Thursday, rising almost 8% on news of its new rapid test for the novel coronavirus. | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Abbott Laboratories (Symbol: ABT), where a total of 209,008 contracts have traded so far, representing approximately 20.9 million underlying shares. That amounts to about 610.2% of ABT's average daily trading volume over the past month of 3.4 million shares. Particularly high volume was seen for the $120 strike call option expiring September 04, 2020, with 28,186 contracts trading so far today, representing approximately 2.8 million underlying shares of ABT. | Shares of Abbott Laboratories ABT.Njumped 7.8% after the company won U.S. approval to market a cheap, portable, rapid COVID-19 antigen test, which could be a step toward containing the pandemic that sent the U.S. economy spiraling into recession. By Stephen Culp NEW YORK, Aug 27 (Reuters) - The S&P 500 and the Dow advanced but the Nasdaq closed lower on Thursday as investors digested the U.S. Federal Reserve's new strategy to adopt an average inflation target and restore the United States to full employment, as well as a promising development in the fight to contain the coronavirus pandemic. ""The steepening of the yield curve is a welcome addition, particularly on a day where the market is rising,"" said Matthew Keator, managing partner in the Keator Group, a wealth management firm in Lenox, Massachusetts. | What happened Shares of Quidel (NASDAQ: QDEL) were down a whopping 27% at 2:27 p.m. EDT on Thursday after rival Abbott Laboratories (NYSE: ABT) gained emergency use authorization from the Food and Drug Administration for its 15-minute, $5 test for the novel coronavirus. Quidel's test can also generate results in 15 minutes, rivaling Abbott's test, but it requires the testing location to own one of Quidel's Sofia instruments, which can run tests for a wide range of diseases from strep throat to the flu. The FDA has authorized 181 molecular tests, but Abbott's test was only the fourth antigen test to be given an emergency use authorization. | Adds details on test, background, share price Aug 27 (Reuters) - The Trump administration will purchase 150 million rapid coronavirus tests from Abbott Laboratories ABT.N for about $750 million, a White House spokeswoman said on Thursday. Antigen tests are cheaper and faster than molecular diagnostic tests, but somewhat more likely to fail to identify positive cases of the virus than lab-based diagnostic tests. So why is it falling so short?https://reut.rs/3b2c1yZ REFILE-UPDATE 1-Abbott wins U.S. authorization for $5 rapid COVID-19 antigen test (Reporting by Jeff Mason in Washngton; Additional reporting by Ankur Banerjee in Bengaluru; Editing by Dan Grebler and Shounak Dasgupta) ((jeff.mason@thomsonreuters.com ; On Twitter: https://twitter.com/jeffmason1)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares of Abbott Laboratories ABT.N jumped 7.9% after the company won U.S. approval to market a cheap, portable, rapid COVID-19 antigen test, which could be a step toward containing the pandemic that sent the U.S. economy spiraling into recession. By Stephen Culp NEW YORK, Aug 27 (Reuters) - The S&P 500 and the Dow advanced on Thursday as investors digested the U.S. Federal Reserve's new strategy to adopt an average inflation target and restore the United States to full employment, as well as a promising development in the fight against COVID-19. The Dow Jones Industrial Average .DJI rose 211.78 points, or 0.75%, to 28,543.7, the S&P 500 .SPX gained 10.01 points, or 0.29%, to 3,488.74 and the Nasdaq Composite .IXIC dropped 21.48 points, or 0.18%, to 11,643.58. | According to Politico, the Trump administration struck a $750 million deal with Abbott (NYSE: ABT) to acquire 150 million rapid tests. The company will begin shipping the test cards in September and expects to deliver at a rate of 50 million tests per month by October. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | Additionally, the news that Abbott Labs (NYSE: ABT) has been given emergency use authorization for a COVID-19 test that costs $5 and delivers a result in 15 minutes is likely having some impact, too. 10 stocks we like better than Pacific Ethanol When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Pacific Ethanol wasn't one of them! | But today's news that Abbott Laboratories (NYSE: ABT) received emergency use authorization for its rapid COVID-19 test has investors taking profits and buying the ""reopen"" stocks like airlines and cruise operators instead. See the 10 stocks *Stock Advisor returns as of August 1, 2020 Howard Smith owns shares of Home Depot. The Motley Fool recommends Lowe's and recommends the following options: long January 2021 $120 calls on Home Depot and short January 2021 $210 calls on Home Depot. | The source of the bad news for both companies was Abbott Laboratories (NYSE: ABT). That upped the ante for the standard of care for testing, and it'll require both Fluidigm and Fulgent to show that their own test products can make the grade. A quick reversal for Fluidigm The decline in Fluidigm shares comes just a day after the stock soared on its own news. | Abbott Laboratories ABT.N surged 9% after the medical device maker won U.S. marketing authorization for a $5 rapid COVID-19 portable antigen test. By Medha Singh and Devik Jain Aug 27 (Reuters) - U.S. stock index futures fell on Thursday as weekly jobless claims hovered near the 1 million mark, while investors waited to hear from Jerome Powell on the Federal Reserve's approach to lifting the economy out of a pandemic-led recession. Initial claims for state unemployment benefits totaled a seasonally adjusted 1.006 million for the week ended Aug. 22, compared with 1.104 million in the prior week, the Labor Department said on Thursday. | The top three NYSE percentage gainers premarket .PRPG.NQ: ** Sandridge Permian Trust , up 51.1% ** Renesola Ltd , up 22.2% ** Box Inc , up 8.4% The top three NYSE percentage losers premarket .PRPL.NQ: ** Quest Diagnostics Inc , down 5.4% ** Clear Channel Outdoor Holdings Inc , down 5.2% ** The Howard Hughes Corp , down 4.7% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Moxian Inc , up 61.4% ** Mediaco Holding Inc , up 22.2% ** Clovis Oncology Inc , up 21.0% The top three Nasdaq percentage losers premarket .PRPL.O: ** Kaixin Auto Holdings , down 36.4% ** Lonestar Resources Us Inc , down 24.9% ** Cocrystal Pharma Inc , down 24.3% ** Cassiopea SpA SKIN.S: up 17.3% premarket BUZZ-Rallies on FDA approval for acne treatment ** Box Inc BOX.N: up 8.4% premarket BUZZ-Rises after co raises annual revenue forecast ** Abbott Laboratories ABT.N: up 8.1% premarket BUZZ-Set to touch record high on U.S. authorization for COVID-19 test ** Williams-Sonoma Inc WSM.N: down 4.4% premarket BUZZ-JP Morgan lifts PT on near-term outlook ** Tencent Music Entertainment TME.N: down 2.0% premarket BUZZ-Falls on $800 mln notes offering (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock index futures dipped on Thursday as tensions between Washington and Beijing dampened the mood ahead of an address by Federal Reserve Chair Jerome Powell, in which he is expected to take a softer stance on inflation to support a fragile economy. S&P 500 e-minis ESc1 were down 0.20% at 3,473.25, while Nasdaq 100 e-minis NQc1 were down 0.19% at 11,969. | Abbott Laboratories ABT.N surged 7.8% after the medical device maker won U.S. marketing authorization for a $5 rapid COVID-19 portable antigen test. By Medha Singh and Devik Jain Aug 27 (Reuters) - Wall Street's main indexes rose on Thursday as Federal Reserve Chair Jerome Powell rolled out the U.S. central bank's aggressive new strategy to restore the United States to full employment and lift inflation back to healthier levels. ""This market these days is all driven by expectations for more or less Fed liquidity,"" said Ernesto Ramos, managing director of active equities at BMO Global Asset Management in Chicago. | What happened After competitor Abbott Labs (NYSE: ABT) unveiled a $5, 15-minute COVID-19 test, shares of Fulgent Genetics (NASDAQ: FLGT) are tumbling 28.7% at 11:15 a.m. EDT on Thursday. So what Fulgent Genetics' bread-and-butter business is providing genetic testing for cancer patients and would-be parents. However, Fulgent Genetics' main business of genetic testing for cancer patients and parents-to-be has been negatively impacted by COVID-19 lockdowns, so demand for those services should benefit if widespread testing results in more people visiting doctors. | The top three S&P 500 .PG.INX percentage gainers: ** Live Nation Entertainment Inc , up 9.5% ** Abbott Laboratories , up 6.9% ** Norwegian Cruise Line Holdings Ltd , up 6.6% The top three S&P 500 .PL.INX percentage losers: ** Quest Diagnostics Inc , down 6.7% ** Hologic Inc , down 6.1% ** Coty Inc , down 5.7% The top three NYSE .PG.N percentage gainers: ** Amc Entertainment Holdings Inc , up 18.9% ** Abercrombie & Fitch Co , up 17.2% ** Veoneer Inc , up 16.4% The top three NYSE .PL.N percentage losers: ** Laix Inc , down 16.2% ** Lannett Company Inc , down 15.5% ** Garret Motion Inc , down 13% The top three Nasdaq .PG.O percentage gainers: ** Vbi Vaccines Inc , up 44.2% ** Sunpower Corp , up 26.9% ** Rekor Systems Inc , up 21.2% The top three Nasdaq .PL.O percentage losers: ** Maxeon Solar Technologies Ltd , down 59.8% ** Quidel Corp , down 35.4% ** Fluidigm Corp , down 33.3% ** Cassiopea SpA SKIN.S: up 15.2% BUZZ-Rallies on FDA approval for acne treatment ** Box Inc BOX.N: up 7.1% BUZZ-Rises after co raises annual revenue forecast ** Abbott Laboratories ABT.N: up 6.8% BUZZ-Abbott shares hit record high on U.S. authorization for COVID-19 test ** Tencent Music Entertainment TME.N: down 0.2% BUZZ-Falls on $800 mln notes offering ** Coty Inc COTY.N: down 5.6% BUZZ-Falls after Q4 results disappoint ** Sandridge Permian Trust PER.N: up 54.7% BUZZ-Surges as PEDEVCO shows takeover interest ** Pluristem Therapeutics Inc PSTI.O: up 4.8% BUZZ-Rises as FDA clears expanded access program for its COVID-19 therapy ** RedHill Biopharma Ltd RDHL.O: up 3.5% BUZZ-Rises after safety panel allows COVID-19 treatment study to continue ** Tiffany & Co TIF.N: up 2.2% BUZZ-Shares rise on profit beat, upbeat demand outlook ** ReneSola Ltd SOL.N: up 4.9% BUZZ-Surges after Q2 revenue nearly doubles ** Moxian Inc MOXC.O: up 8.6% BUZZ-Jumps after Btab acquisition ** Boeing Co BA.N: up 2.3% BUZZ-Rises as Europe regulator to start 737 MAX tests in September ** ViacomCBS VIAC.O: up 0.8% BUZZ-Wells Fargo upgrades to 'Equal Weight' on DTC potential ** Abercrombie & Fitch ANF.N: up 17.2% BUZZ-Jumps as online boost, cost cuts drive surprise profit ** VBI Vaccines VBIV.O: up 44.2% BUZZ-Up as Raymond James says co might have ""best COVID-19 vaccine"" ** Veoneer Inc VNE.N: up 16.3% BUZZ-Surges on autonomous driving tie-up with Qualcomm ** Laboratory Corporation of America Holdings LH.N: down 2.1% ** Quidel Corp QDEL.O: down 35.4% BUZZ-Labs pressured as Abbott to market $5 rapid COVID-19 test ** Sanderson Farms Inc SAFM.O: up 6.4% BUZZ-Rises as retail demand spurs solid Q3 beat ** 1-800-Flowers.Com FLWS.O: up 3.5% BUZZ-Rises on Q4 earnings beat ** Microsoft Corp MSFT.O: up 3.5% BUZZ-Rises as report suggests TikTok deal imminent ** Beyond Meat Inc BYND.O: up 10.0% BUZZ-Sizzles after starting direct online sales of products ** Peloton Interactive Inc PTON.O: up 4.2% BUZZ-Rises as Goldman Sachs hikes PT to Street high ** Electronic Arts Inc EA.O: down 1.1% BUZZ-EA down as rival Epic Games launches latest version of ""Fortnite"" The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 and the Nasdaq rose to record highs on Thursday as the Federal Reserve sought to achieve inflation averaging 2% over time in an attempt to lift the U.S. economy out of a deep pandemic-driven recession. down 0.57% Consumer Discretionary | Meanwhile, news of a $5 COVID-19 test from Abbott Laboratories (NYSE: ABT) helped boost not only the healthcare company's stock but also shares of travel companies that are relying on a permanent coronavirus solution sooner rather than later. Airlines ascend, cruise stocks set sail The travel industry in particular stands to benefit from quick testing, as it would help companies evaluate passenger health in ways that would be practical even under normal operating conditions. See the 10 stocks *Stock Advisor returns as of August 1, 2020 Dan Caplinger has no position in any of the stocks mentioned. | Among the largest underlying components of IVW, in trading today Facebook Inc (Symbol: FB) is off about 1.4%, Abbott Laboratories (Symbol: ABT) is up about 7.6%, and Advanced Micro Devices Inc (Symbol: AMD) is lower by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 500 Growth ETF (Symbol: IVW) where we have detected an approximate $60.5 million dollar outflow -- that's a 0.2% decrease week over week (from 131,700,000 to 131,450,000). For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year price performance of IVW, versus its 200 day moving average: Looking at the chart above, IVW's low point in its 52 week range is $140.84 per share, with $242.89 as the 52 week high point — that compares with a last trade of $242.46. | Abbott Laboratories ABT.N surged 6.6% after the medical device maker won U.S. marketing authorization for a $5 rapid COVID-19 portable antigen test. By Medha Singh and Devik Jain Aug 27 (Reuters) - The S&P 500 and the Nasdaq rose to record highs on Thursday as the Federal Reserve sought to achieve inflation averaging 2% over time in an attempt to lift the U.S. economy out of a deep pandemic-driven recession. Setting out the central bank's aggressive new strategy at a virtual Jackson Hole symposium, Fed chief Jerome Powell said it would offset below-2% periods with higher inflation ""for some time,"" and ensure employment doesn't fall short of its maximum level. | The top three NYSE percentage gainers premarket .PRPG.NQ: ** SandRidge Permian Trust , up 51.1% ** Veoneer Inc , up 17.7% ** Renesola Ltd , up 15.6% The top three NYSE percentage losers premarket .PRPL.NQ: ** Ryerson Holding Corp , down 32.2% ** Shft4 Payments Inc , down 7.5% ** Williams-Sonoma Inc , down 7.4% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Moxian Inc , up 65.2% ** Greenvision Acquisition Corp , up 62.9% ** Vbi Vaccines Inc , up 34.9% The top three Nasdaq percentage losers premarket .PRPL.O: ** Kaixin Auto Holdings , down 38.7% ** SpringWorks Therapeutics Inc , down 23.8% ** Cocrystal Pharma Inc , down 23.5% ** Cassiopea SpA SKIN.S: up 17.8% premarket BUZZ-Rallies on FDA approval for acne treatment ** Box Inc BOX.N: up 10.2% premarket BUZZ-Rises after co raises annual revenue forecast ** Abbott Laboratories ABT.N: up 7.9% premarket BUZZ-Set to touch record high on U.S. authorization for COVID-19 test ** Tencent Music Entertainment TME.N: down 0.6% premarket BUZZ-Falls on $800 mln notes offering ** Coty Inc COTY.N: down 4.4% premarket BUZZ-Falls after Q4 results disappoint ** Sandridge Permian Trust PER.N: up 51.1% premarket BUZZ-Surges as PEDEVCO shows takeover interest ** Pluristem Therapeutics Inc PSTI.O: up 9.1% premarket BUZZ-Rises as FDA clears expanded access program for its COVID-19 therapy ** RedHill Biopharma Ltd RDHL.O: up 3.5% premarket BUZZ-Rises after safety panel allows COVID-19 treatment study to continue ** Tiffany & Co TIF.N: up 1.6% premarket BUZZ-Shares rise on profit beat, upbeat demand outlook ** ReneSola Ltd SOL.N: up 15.6% premarket BUZZ-Surges after Q2 revenue nearly doubles ** Moxian Inc MOXC.O: up 65.2% premarket BUZZ-Jumps after Btab acquisition ** Boeing Co BA.N: up 0.7% premarket BUZZ-Rises as Europe regulator to start 737 MAX tests in September ** Dollar General Corp DG.N: up 1.1% premarket BUZZ-Up as same-store sales beat expectations ** ViacomCBS VIAC.O: up 0.6% premarket BUZZ-Wells Fargo upgrades to 'Equal Weight' on DTC potential ** Abercrombie & Fitch ANF.N: up 8.7% premarket BUZZ-Jumps as online boost, cost cuts drive surprise profit ** VBI Vaccines VBIV.O: up 34.9% premarket BUZZ-Up as Raymond James says co might have ""best COVID-19 vaccine"" (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock index futures fell on Thursday as weekly jobless claims hovered near the 1 million mark, while investors waited to hear from Jerome Powell on the Federal Reserve's approach to lifting the economy out of a pandemic-led recession. S&P 500 e-minis ESc1 were down 0.19% at 3,473.75, while Nasdaq 100 e-minis NQc1 were down 0.24% at 11,962.25. | Abbott Laboratories (ABT) is +8.16 at $111.35, with 945,262 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the ""buy range"". NIO Inc. (NIO) is -0.61 at $19.83, with 4,871,952 shares traded., following a 52-week high recorded in prior regular session. | WASHINGTON, Aug 27 (Reuters) - The Trump administration will purchase 150 million rapid coronavirus tests from Abbott Laboratories ABT.N for about $750 million, a White House spokeswoman said on Thursday. The portable antigen tests, which can deliver results within 15 minutes and will sell for $5, received emergency use authorization from the U.S. Food and Drug Administration on Wednesday. So why is it falling so short?https://reut.rs/3b2c1yZ (Reporting by Jeff Mason; Editing by Dan Grebler) ((jeff.mason@thomsonreuters.com ; On Twitter: https://twitter.com/jeffmason1)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT.N gained 9.2% after the medical device maker won U.S. marketing authorization for a $5 rapid COVID-19 portable antigen test. By Medha Singh Aug 27 (Reuters) - U.S. stock index futures dipped on Thursday as tensions between Washington and Beijing dampened the mood ahead of an address by Federal Reserve Chair Jerome Powell, in which he is expected to take a softer stance on inflation to support a fragile economy. ET, Dow e-minis 1YMcv1 were down 84 points, or 0.3%, S&P 500 e-minis EScv1 were down 7.75 points, or 0.22% and Nasdaq 100 e-minis NQcv1 were down 27.25 points, or 0.23%. | Abbott Laboratories (ABT) is up over 9% at $112.80 in pre-market hours. The company is hoping to ship tens of millions of tests in September, ramping to 50 million tests a month at the beginning of October. On August 21, the company closed an underwritten public offering of units for gross proceeds of about $14.37 million, including the full exercise of the over-allotment option. | Abbott also said it will offer a mobile app at no charge that will allow people to display their results obtained through a healthcare provider when entering facilities requiring proof of testing. If test results are negative, the app will display a digital health pass via a QR code, similar to an airline boarding pass. The company noted that the digital health pass is stored in the app temporarily and expires after the time period specified by organizations that accept the app. | What happened Several stocks of companies that make COVID-19 diagnostic tests were sinking on Thursday following big news from Abbott Laboratories (NYSE: ABT) on Wednesday evening. 10 stocks we like better than GenMark Diagnostics When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. See the 10 stocks *Stock Advisor returns as of August 1, 2020 Keith Speights has no position in any of the stocks mentioned."
2020-08-26,101.98999786376952,103.19000244140624,0.2522284243840017,Abbott wins U.S. authorization for $5 rapid COVID-19 antigen | Abbott wins U.S. approval for rapid COVID-19 test,"By Carl O'Donnell and Mrinalika Roy Aug 26 (Reuters) - Abbott Laboratories ABT.N said on Wednesday it won U.S. marketing authorization for a COVID-19 portable antigen test that can deliver results within 15 minutes and will sell for $5. The portable test is about the size of a credit card, requires no additional equipment to operate, and can be conducted using a less invasive nasal swab than traditional lab tests, Abbott executives said on a call with reporters. Antigen tests are cheaper and faster than molecular diagnostic tests but somewhat more likely to fail to identify positive cases of the virus than lab-based diagnostic tests. | Aug 26 (Reuters) - Abbott Laboratories ABT.N said on Wednesday it won U.S. marketing approval for a COVID-19 portable test that can deliver results within 15 minutes. (https://reut.rs/2QsSyOC) The portable test, BinaxNOW COVID-19 Ag Card, is for use by healthcare professionals at hospitals and labs, and Abbott plans to sell the tests for $5 each. Abbott expects to ship tens of millions of tests in September, ramping to 50 million tests a month from the beginning of October."
2020-08-25,101.9800033569336,102.47000122070312,1.1765904527614497,"Medtronic signals recovery in procedure volumes, profit plunges","Several medical device makers, including Abbott Laboratories ABT.N, have said demand for less urgent medical procedures has recovered from the lows experienced in April as coronavirus-induced restrictions eased across the United States. Adds details on the quarter, share movement Aug 25 (Reuters) - Medtronic MDT.N said on Tuesday demand for medical devices was improving as elective surgeries picked up pace following the easing of COVID-19 restrictions, while posting a 44% decline in first-quarter profit due to the pandemic. The company's chief executive officer, Geoff Martha, said the medical device maker's results reflect a ""faster than expected recovery"" from the depths of the pandemic seen back in April."
2020-08-24,102.6999969482422,101.38999938964844,0.4804842593057401,The 4 Best Dividend Aristocrats to Buy Now,"At 26x forward earnings, ABT trades at a notable premium to Medtronic (NYSE:MDT), another health care dividend aristocrat I’ve recommended this year. They are: Abbott Laboratories (NYSE:ABT) Ross Stores (NASDAQ:ROST) PepsiCo (NASDAQ:PEP) V.F. Corporation (NYSE:VFC) Best Dividend Aristocrats: Abbott Labs (ABT) Source: Sundry Photography/Shutterstock.com Simply put, Abbott Laboratories is one of the world’s great health care companies."
2020-08-21,101.62999725341795,102.4000015258789,-1.2755575438370896,,
2020-08-20,99.98999786376952,101.62999725341795,0.7576545245208647,"Let High Flyer Fulgent Genetics Take a Breather Before Dipping In | Noteworthy Thursday Option Activity: KEYS, ABT, FMC","For example, Abbott Laboratories (NYSE:ABT) is well known among the medical and investing communities for providing testing instruments for Covid-19. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Genetic testing services specialist Fulgent Genetics (NASDAQ:FLGT) is known for providing molecular and antibody testing for Covid-19. Fulgent Genetics Chief Commercial Officer Brandon Perthuis explained how the company’s at-home test was an ideal complement to Fulgent’s highly successful RT-PCR Covid-19 test: “Since launching our RT-PCR Test (non at-home test) several months ago, we have won several strategic accounts and are processing thousands of tests daily with an average turnaround time of 24 hours from receipt of sample. | Below is a chart showing KEYS's trailing twelve month trading history, with the $100 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) saw options trading volume of 16,061 contracts, representing approximately 1.6 million underlying shares or approximately 42.4% of ABT's average daily trading volume over the past month, of 3.8 million shares. Below is a chart showing ABT's trailing twelve month trading history, with the $100 strike highlighted in orange: And FMC Corp. (Symbol: FMC) saw options trading volume of 2,572 contracts, representing approximately 257,200 underlying shares or approximately 41.3% of FMC's average daily trading volume over the past month, of 622,645 shares. Particularly high volume was seen for the $100 strike call option expiring August 21, 2020, with 2,331 contracts trading so far today, representing approximately 233,100 underlying shares of ABT."
2020-08-19,101.08000183105467,100.4800033569336,1.640163441030212,"SPYG, ABT, AMD, PEP: ETF Outflow Alert","Among the largest underlying components of SPYG, in trading today Abbott Laboratories (Symbol: ABT) is trading flat, Advanced Micro Devices Inc (Symbol: AMD) is down about 0.4%, and PepsiCo Inc (Symbol: PEP) is higher by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR— Portfolio S&P 500— Growth ETF (Symbol: SPYG) where we have detected an approximate $233.3 million dollar outflow -- that's a 2.6% decrease week over week (from 181,000,000 to 176,350,000). For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $30.39 per share, with $50.32 as the 52 week high point — that compares with a last trade of $50.24."
2020-08-18,101.08999633789062,100.95999908447266,-0.5935877159202254,Abbott Laboratories Is a Surefire Covid-19 Diagnostics Investment | FDA Gives EUA to a Unique COVID-19 Saliva Test,"Abbott Laboratories (NYSE:ABT), for example, is contributing to the battle against the novel coronavirus and ABT stock holders are earning strong returns, yet the company’s focus isn’t on a vaccine. Yet, an argument could be made that there’s much more room for ABT to run. A Closer Look at ABT Stock On Aug. 14, I recall watching Abbott stock closely to see if it would close the day at exactly $100. | Becton, Dickinson (NYSE: BDC), for one, has a blood testing kit for coronavirus antibodies that it says can deliver results in 15 minutes, while Abbott's (NYSE: ABT) five-minute ID NOW COVID-19 test received its EUA relatively early in the pandemic. Research indicates that SalivaDirect tests are similar in accuracy and sensitivity to those that use fairly uncomfortable nasopharyngeal swabbing to harvest test samples from within the nose. See the 10 stocks Stock Advisor returns as of 2/1/20 Eric Volkman has no position in any of the stocks mentioned."
2020-08-17,100.3000030517578,100.70999908447266,-0.12859556645294198,,
2020-08-14,100.93000030517578,99.98999786376952,0.40876971110687577,,
2020-08-13,100.33999633789062,101.0999984741211,-0.9313409675656763,2 Top Stocks for Retirees,"SPY data by YCharts Abbott Laboratories Abbott Laboratories (NYSE: ABT) is similar to Johnson & Johnson in that it's a deeply established healthcare company with a plethora of critical products and therapies. Johnson & Johnson Johnson & Johnson (NYSE: JNJ) is one of the largest companies in the world. What's more, Johnson & Johnson hasn't diluted equity value for its shareholders by issuing new common stock in more than 10 years, so retirees can have some confidence that their holdings won't weaken over time."
2020-08-12,99.5500030517578,100.6500015258789,0.7574269124658867,,
2020-08-11,100.43000030517578,99.05999755859376,1.1049708090407586,"SPYG, FB, ABT, AMD: Large Inflows Detected at ETF | TSX futures rise on firmer oil prices","Among the largest underlying components of SPYG, in trading today Facebook Inc (Symbol: FB) is off about 0.3%, Abbott Laboratories (Symbol: ABT) is down about 0.2%, and Advanced Micro Devices Inc (Symbol: AMD) is lower by about 3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR— Portfolio S&P 500— Growth ETF (Symbol: SPYG) where we have detected an approximate $113.1 million dollar inflow -- that's a 1.3% increase week over week in outstanding units (from 178,700,000 to 181,000,000). For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $30.39 per share, with $49.625 as the 52 week high point — that compares with a last trade of $49.10. | Absolute Software Corp ABT.TO: BMO raises target price to C$18 from C$12.50 Equinox Gold Corp EQX.TO: TD Securities Raises Target Price to C$25 from C$21 Teranga Gold Corp TGZ.TO: RBC rsises target price to C$20 from C$13 COMMODITIES AT 7:00 a.m. Aug 11 (Reuters) - Canada's main stock index futures rose on Tuesday, helped by gains in oil prices and hopes of a U.S. stimulus package to revive the economy. 0600 NFIB Business Optimism Index for Jul: Prior 100.60 0830 PPI final demand yy for Jul: Expected -0.7%; Prior -0.8% 0830 PPI final demand mm for Jul: Expected 0.3%; Prior -0.2% 0830 PPI exfood/energy yy for Jul: Expected 0.0%; Prior 0.1% 0830 PPI exfood/energy mm for Jul: Expected 0.1%; Prior -0.3% 0830 PPI ex food/energy/transport yy for Jul: Prior -0.1% 0830 PPI ex food/energy/transport mm for Jul: Prior 0.3%"
2020-08-10,100.94000244140624,100.04000091552734,-1.3641369535188703,,
2020-08-07,101.6999969482422,101.2300033569336,-0.8916202735395473,2 Coronavirus Stocks Robinhood Investors Love. Should You? | The Next Bull Run Will Be Harder For Sorrento Therapeutics,"Notable companies that have already developed successful tests for COVID-19 include Abbott Laboratories (NYSE: ABT) and Roche Holdings (OTC: RHHBY). A peek at the stocks in the most recent ranking (as of this writing) reveals that Robinhood investors have been busy buying shares of companies that are involved in the development of vaccines or treatments for the coronavirus. In particular, Gilead Sciences (NASDAQ: GILD) and Sorrento Therapeutics (NASDAQ: SRNE) both feature on the list. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips CNBC’s Jim Cramer recently discussed some of the “clueless buying” that’s been taking place in the markets. In particular, the Mad Money host is confounded about the Aug. 4 buying in Sorrento Therapeutics (NASDAQ:SRNE) stock. Interestingly, while Cramer’s bullish about the company’s prospects due to its 30-minute spit test for the novel coronavirus, he has a hard time understanding why Sorrento’s stock was up 30% a week after Sorrento’s announcement."
2020-08-06,101.5199966430664,101.75,-0.46213727179146336,,
2020-08-05,99.97000122070312,102.13999938964844,0.22655965774138204,,
2020-08-04,100.16000366210938,99.93000030517578,2.170649337249303,Abbott Begins Study To Evaluate New Device To Treat Recurrent Atrial Fibrillation | 3 Key Questions to Answer Before Buying Sorrento Therapeutics Stock,"(RTTNews) - Abbott (ABT) announced first enrollments in the TactiFlex PAF IDE study to evaluate a new device to treat people suffering from paroxysmal atrial fibrillation or PAF, a type of irregular heartbeat. The study will evaluate the performance of the investigational TactiFlex Ablation Catheter, Sensor Enabled (SE) for people whose atrial fibrillation (AFib) symptoms are unable to be managed by medication. The TactiFlex Ablation Catheter, SE is being clinically evaluated as part of the TactiFlex PAF IDE - a global study - and is not yet commercially available. | What’s more, competitor Abbott Laboratories (NYSE:ABT) has suffered setbacks regarding its testing accuracy. InvestorPlace - Stock Market News, Stock Advice & Trading Tips From relative obscurity to becoming one of the hottest names on Wall Street, Sorrento Therapeutics (NASDAQ:SRNE) stock has enjoyed quite a ride. If Sorrento’s claims are proven valid through additional testing and peer review, it could change the game for SRNE stock."
2020-08-03,101.08000183105467,100.68000030517578,-0.22963593103441973,"IHI, ABT, BDX, BSX: Large Inflows Detected at ETF","Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.4%, Becton, Dickinson & Co (Symbol: BDX) is up about 0.1%, and Boston Scientific Corp. (Symbol: BSX) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $219.8 million dollar inflow -- that's a 2.9% increase week over week in outstanding units (from 25,700,000 to 26,450,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $183.25 per share, with $296.755 as the 52 week high point — that compares with a last trade of $295.15."
2020-07-31,101.20999908447266,100.63999938964844,-0.39572765990591835,,
2020-07-30,100.9800033569336,101.52999877929688,-0.5631851595497805,,
2020-07-29,100.18000030517578,102.5199966430664,0.5446577580505862,Boston Scientific posts surprise profit as demand for elective surgery picks up,"Elective procedures rebounded in May and approached pre-crisis levels by June-end, as restrictions eased in some states, according to health insurer UnitedHealth Group Inc UNH.N and medical device maker Abbott Laboratories ABT.N. Adds background, shares, estimates July 29 (Reuters) - Boston Scientific Corp BSX.N reported a surprise second-quarter profit on Wednesday, as elective procedures slowly started picking pace following the easing of coronavirus-induced restrictions in several U.S. states. Boston Scientific's medical devices unit, its biggest, brought in revenue of $1.94 billion in the quarter, 26.5% lower than last year."
2020-07-28,100.13999938964844,99.86000061035156,2.335791905332755,"3 Rock-Solid Healthcare Stocks to Buy in a Market Crash | If You Had Invested $1,000 in Abbott Labs During the Last Recession, This Is How Much You Would Have Today","Abbott Labs Abbott Laboratories' (NYSE: ABT) annual revenue has been climbing for the past three years, and earnings have been rising for the past two. Bristol Myers Squibb With the acquisition of Celgene last fall, Bristol Myers Squibb (NYSE: BMY) obtained multiple myeloma blockbusters Revlimid and Pomalyst. And not counting the Celgene drugs, four of Bristol Myers Squibb's drugs posted revenue growth as high as 37% in the first quarter. | Abbott Laboratories (NYSE: ABT) is a blue-chip stock that has been at the forefront of coronavirus testing since the early days of the pandemic. If you had invested $1,000 in Abbott Labs in the last recession, this is how much your investment would be worth today. While Abbott Labs has been no exception, its coronavirus tests have helped to counteract the negative effects the pandemic has had on its medical devices segment, which was booming before the coronavirus."
2020-07-27,98.5500030517578,99.98999786376952,-0.2796073307404261,INSIGHT-The U.S. has more COVID-19 testing than most. So why is it falling so short?,"A few companies – Cepheid DHR.N, Hologic Inc HOLX.O, Roche ROG.S and Abbott Laboratories ABT.N – dominate this market. The U.S. Department of Health and Human Services told Reuters the government had used the DPA to buy some testing supplies, but reagents used to run the CDC test are already available, so buying more would not help. For states seeking to boost testing capacity, the most sought-after machine has been Hologic's Panther, which can process up to 1,000 tests in 24 hours, state filings show."
2020-07-24,100.20999908447266,98.9499969482422,1.461181905043111,"Noteworthy ETF Inflows: IHI, ABT, EW, BAX","Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is down about 1.7%, Edwards Lifesciences Corp (Symbol: EW) is off about 0.1%, and Baxter International Inc (Symbol: BAX) is lower by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $116.6 million dollar inflow -- that's a 1.6% increase week over week in outstanding units (from 25,150,000 to 25,550,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $183.25 per share, with $295.5268 as the 52 week high point — that compares with a last trade of $288.30."
2020-07-23,100.27999877929688,100.81999969482422,-1.2573616881967316,YieldBoost Abbott Laboratories To 28.8% Using Options | 5 Dividend Aristocrats Where Analysts See Capital Gains,"Shareholders of Abbott Laboratories (Symbol: ABT) looking to boost their income beyond the stock's 1.4% annualized dividend yield can sell the September covered call at the $101 strike and collect the premium based on the $3.25 bid, which annualizes to an additional 27.4% rate of return against the current stock price (at Stock Options Channel we call this the YieldBoost), for a total of 28.8% annualized rate in the scenario where the stock is not called away. Any upside above $101 would be lost if the stock rises there and is called away, but ABT shares would have to advance 0.4% from current levels for that to occur, meaning that in the scenario where the stock is called, the shareholder has earned a 3.6% return from this trading level, in addition to any dividends collected before the stock was called. In the case of Abbott Laboratories, looking at the dividend history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 1.4% annualized dividend yield. | South Jersey Industries Inc (Symbol: SJI) $24.13 $28.00 16.04% Johnson & Johnson (Symbol: JNJ) $150.01 $165.77 10.51% Abbott Laboratories (Symbol: ABT) $100.19 $108.18 7.98% PPG Industries Inc (Symbol: PPG) $111.68 $120.38 7.79% MSA Safety Inc (Symbol: MSA) $113.65 $122.33 7.64% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. South Jersey Industries Inc (Symbol: SJI) 4.89% 16.04% 20.93% Johnson & Johnson (Symbol: JNJ) 2.69% 10.51% 13.2% Abbott Laboratories (Symbol: ABT) 1.44% 7.98% 9.42% PPG Industries Inc (Symbol: PPG) 1.93% 7.79% 9.72% MSA Safety Inc (Symbol: MSA) 1.51% 7.64% 9.15% Another consideration with dividend growth stocks is just how much the dividend is growing. South Jersey Industries Inc (Symbol: SJI) $1.144 $1.173 2.53% Johnson & Johnson (Symbol: JNJ) $3.65 $3.86 5.75% Abbott Laboratories (Symbol: ABT) $1.24 $1.4 12.90% PPG Industries Inc (Symbol: PPG) $1.92 $2.04 6.25% MSA Safety Inc (Symbol: MSA) $1.56 $1.69 8.33% These five stocks are part of our full Dividend Aristocrats List."
2020-07-22,98.11000061035156,100.19000244140624,0.5384931413050921,HCA Healthcare quarterly profit jumps nearly 38% on government stimulus | Is AbbVie a Great Dividend Stock?,"July 22 (Reuters) - HCA Healthcare Inc HCA.N reported a nearly 38% rise in second-quarter profit on Wednesday, as the hospital operator received $822 million in government stimulus income related to the Coronavirus Aid, Relief, and Economic Security (CARES) Act. Net income attributable to HCA rose to $1.079 billion, or $3.16 per share, in the quarter, from $783 million, or $2.25 per share, a year earlier. (Reporting by Manojna Maddipatla and Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | When we include the time AbbVie spent as a division of Abbott, the company has raised its dividends for 47 consecutive years, making the drugmaker a Dividend Aristocrat. AbbVie can still deliver strong financial results Even though AbbVie boasts a stellar dividend history, a high dividend yield, and a reasonable payout ratio, it is critical to ensure that the company can continue growing its revenue and earnings at a good clip before adding it to your dividend portfolio. Overall, AbbVie fits all the criteria of a great dividend stock: A high yield, a low payout ratio, and the ability to raise its dividend payouts along with its revenue and profits."
2020-07-21,98.87999725341795,98.19000244140624,2.1200711630973252,"Have $2,000? Consider Buying These 2 Top Coronavirus Stocks","In case you do, and if you still have $2,000 lying around, here are two stocks that could be great long-term picks: Abbott Laboratories (NYSE: ABT) and Pfizer (NYSE: PFE). ABT data by YCharts 1. During the second quarter, the company's diagnostics segments reported sales of about $2 billion -- a 7.1% year-over-year organic increase -- which the company largely attributed to its newly developed coronavirus tests."
2020-07-20,100.0,99.08000183105467,-0.6978103066117024,,
2020-07-17,97.87000274658205,99.25,-0.9199981689453266,S&P 500 rises as traders weigh stimulus and virus worries,"Abbott Laboratories <ABT.N> rose 3.2%, lifting the S&P 500 more than any other stock. By Noel Randewich July 17 (Reuters) - The S&P 500 rose in choppy trading on Friday as investors weighed the prospect of more fiscal stimulus against fears of further business disruptions due to a record rise in COVID-19 cases. The S&P 500 and the Dow are set to close the week higher after optimism over an eventual coronavirus vaccine and hopes of a post-pandemic economic recovery helped investors look past a continuous surge in COVID-19 cases."
2020-07-16,97.8499984741211,96.4000015258789,1.410030872269643,"Abbott Laboratories Beats on Q2 Estimates, But Stock Slides | Health Care Sector Update for 07/16/2020: TCDA, TLSA, ABT, XLV, IBB | Abbott quarterly profit beats as COVID-19 tests cushion virus impact | Abbott Laboratories Sees FY20 Adj. Earnings Above Estimates - Quick Facts | Abbott quarterly profit plunges as COVID-19 batters medical device unit | Abbott Laboratories Q2 adjusted earnings Beat Estimates | U.S. stock futures fall as China data weighs ahead of bank earnings, economic data | Abbott Laboratories Q2 20 Earnings Conference Call At 9:30 AM ET | Abbott Labs' Earnings Sink in Q2 but Still Trounce Wall Street Estimates | ITOT, ABT, CL, MS: Large Outflows Detected at ETF","Although it's popular as a coronavirus stock these days, Abbot Laboratories (NYSE: ABT) nevertheless is struggling with other areas of its business. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! | Meanwhile, Abbott (ABT) gained 1% after reporting on Thursday Q2 adjusted EPS of $0.57, down from $0.82 a year earlier, but higher than the $0.42 average estimate of analysts surveyed by Capital IQ. Health care firms were slipping premarket Thursday as the Health Care SPDR (XLV) was down 0.2% and the iShares NASDAQ Biotechnology Index (IBB) was 0.8% lower recently. Tricida (TCDA) declined by more than 33% after saying the US Food and Drug Administration has found deficiencies in its new drug application for veverimer to treat metabolic acidosis in patients with chronic kidney disease. | Adds details on the quarter, estimates July 16 (Reuters) - Abbott Laboratories ABT.N on Thursday reported a better-than-anticipated quarterly profit as a surge in sales of its coronavirus tests helped it cushion a fall in demand for its devices due to virus-induced lockdowns and deferred elective care. It has since March won U.S. authorization for five coronavirus tests, including two antibody tests, an automated test used in labs and a test that can deliver results within minutes and is used at the White House. Net sales fell to $7.33 billion from $7.98 billion, but came above estimates of $6.81 billion, helped by $615 million in sales from COVID-19 tests. | (RTTNews) - While reporting its second-quarter financial results on Thursday, medical devices and healthcare company Abbott Laboratories (ABT) forecast fiscal 2020 earnings per share from continuing operations of at least $2.00, and adjusted earnings per share from continuing operations of at least $3.25. On average, analysts polled by Thomson Reuters expect the company to report earnings of $2.84 per share for the year. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | July 16 (Reuters) - Abbott Laboratories ABT.N on Thursday reported a 46.6% fall in second-quarter profit as the COVID-19 pandemic continued to batter its medical device unit. The company's net earnings fell to $$537 million, or 30 cents per share, in the quarter ended June 30, from $1 billion, or 56 cents per share, a year earlier. (Reporting by Trisha Roy and Manojna Maddipatla in Bengaluru; Editing by Maju Samuel) ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 3635;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) reported earnings for second quarter that declined from the same period last year. Excluding items, Abbott Laboratories reported adjusted earnings of $1.02 billion or $0.57 per share for the period. -Analysts Estimate: $0.41 -Revenue (Q2): $7.33 Bln vs. $7.98 Bln last year. | Diversified manufacturer Honeywell HON.N and medical device maker Abbott Laboratories ABT.N are also slated to report their quarterly results on Thursday. By Medha Singh and Devik Jain July 16 (Reuters) - U.S. stock index futures fell on Thursday after a surprise drop in China's retail sales signaled a bumpy economic recovery, with investors now turning to the next set of quarterly bank earnings and economic data to gauge the pace of a domestic rebound. Stock markets in Asia and Europe fell earlier in the day after data showed China's retail sales fell 1.8% in June. | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:30 AM ET on July 16, 2020, to discuss Q2 20 earnings results. To access the live webcast, log on to http://www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs (NYSE: ABT) suspended its full-year 2020 guidance in April because of uncertainty about the COVID-19 pandemic. While Abbott's revenue slid 8.2% year over year on a reported basis, the decrease was 5.4% on an organic constant-currency basis. Abbott's established pharmaceuticals sales also fell 8.6% year over year primarily due to lower demand in Brazil, Colombia, and Russia due to the COVID-19 pandemic. | Among the largest underlying components of ITOT, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.4%, Colgate-Palmolive Co. (Symbol: CL) is up about 0.1%, and Morgan Stanley (Symbol: MS) is higher by about 2.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P Total U.S. Stock Market ETF (Symbol: ITOT) where we have detected an approximate $58.0 million dollar outflow -- that's a 0.2% decrease week over week (from 359,400,000 to 358,600,000). For a complete list of holdings, visit the ITOT Holdings page » The chart below shows the one year price performance of ITOT, versus its 200 day moving average: Looking at the chart above, ITOT's low point in its 52 week range is $48.52 per share, with $76.57 as the 52 week high point — that compares with a last trade of $72.04."
2020-07-15,95.9000015258789,96.7300033569336,-1.481856894076167,,
2020-07-14,92.63999938964844,94.81999969482422,0.8654867756500598,Why Big Pharma's $1 Billion Bet to Prevent a Bacterial Pandemic Matters for You,"Another stock that I like is Abbott Labs (NYSE: ABT). Key investors in the AMR Action Fund include Pfizer (NYSE: PFE), Roche (OTC: RHHBY), Eli Lilly (NYSE: LLY), Merck (NYSE: MRK), and Johnson & Johnson (NYSE: JNJ). Behind the big bet There's one simple goal for big pharma's partnership with the AMR Action Fund: Develop between two and four new antibiotics by the end of the decade."
2020-07-13,93.13999938964844,93.08999633789062,2.353195509001022,Abbott Laboratories and Edwards Lifesciences Settle Patent Fight,"Abbott Laboratories (NYSE: ABT) and Edwards Lifesciences (NYSE: EW) are burying the hatchet. It puts to rest a dispute that grew increasingly hostile,after Abbott sued Edwards for patent infringement in January 2019 over the former company's MitraClip, which it describes as ""the world's first transcatheter mitral valve repair therapy."" 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen."
2020-07-10,93.47000122070312,93.04000091552734,-0.05368590518089463,"Are We in a Stock Market Bubble? These 3 Stocks Say Yes | Ex-Dividend Reminder: Campbell Soup, DTE Energy and Abbott Laboratories","XpresSpa was losing money before the pandemic, and coronavirus testing isn't as lucrative for testing sites as investors seem to think it is -- most of the money goes to the companies that make the diagnostic tests like Labcorp, Quest, and Abbott Labs. In a few weeks, some of the air could begin to escape from stocks like Nikola, Genius Brands, and XpresSpa. See the 10 stocks *Stock Advisor returns as of June 2, 2020 Jeremy Bowman owns shares of Netflix and Rite Aid. | Looking at the universe of stocks we cover at Dividend Channel, on 7/14/20, Campbell Soup Co (Symbol: CPB), DTE Energy Co (Symbol: DTP), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Campbell Soup Co (Symbol: CPB): DTE Energy Co (Symbol: DTP): Abbott Laboratories (Symbol: ABT): In general, dividends are not always predictable, following the ups and downs of company profits over time. Similarly, investors should look for DTP to open 1.84% lower in price and for ABT to open 0.39% lower, all else being equal."
2020-07-09,92.73999786376952,93.66999816894533,-0.46004097524344356,,
2020-07-08,92.83999633789062,92.58000183105467,1.0028038889346689,Here’s How The Coronavirus Pandemic Became an Investing Opportunity For Me | UK tech firm Smiths to aid COVID-19 antibody test production,"I also was drawn to Abbott Labs (NYSE: ABT) which was the first to produce a fast-results COVID-19 test. I also invested in a healthcare ETF, the IShares Dow Jones US Healthcare ETF (NYSEMKT: IYH). Within the 3 sectors I identified for my ETF investing, I also found some companies performing well during the pandemic that were worth a direct investment. | Other firms making antibody tests for the respiratory illness include Roche ROG.S and Abbott ABT.N. Adds antibody test details, company background July 8 (Reuters) - Technology firm Smiths Group SMIN.L said on Wednesday it would help produce a blood-based COVID-19 antibody test approved by the British healthcare regulator, another move by the company to develop products to combat the pandemic. London-listed Smiths said it had agreed with biopharmaceutical firm Attomarker, for an undisclosed amount, to make its portable, triple antibody test device at unit Smiths Detection's site in Hemel Hempstead, England."
2020-07-07,92.45999908447266,92.45999908447266,-0.2800457960917008,3 Best-Performing Dividend Aristocrats in the First Half of 2020: Are They Buys Now?,"Including its time as part of parent Abbott Labs (NYSE: ABT), AbbVie has increased its dividend for 47 years. Lowe's Lowe's (NYSE: LOW) ranks in the upper echelon of Dividend Aristocrats with a remarkable 57 consecutive years of dividend hikes. The home improvement retailer's stock performance was also among the best among the group during the first six months of the year, with Lowes' shares jumping nearly 13%."
2020-07-06,92.76000213623048,92.97000122070312,0.0,"Implied RNLC Analyst Target Price: $25 | FDA Approves Abbott's NexGen Gallant ICD, CRT-D Devices - Quick Facts","Similarly, ABT has 11.77% upside from the recent share price of $92.23 if the average analyst target price of $103.08/share is reached, and analysts on average are expecting KKR to reach a target price of $34.30/share, which is 9.94% above the recent price of $31.20. Three of RNLC's underlying holdings with notable upside to their analyst target prices are AES Corp. (Symbol: AES), Abbott Laboratories (Symbol: ABT), and KKR & Co Inc (Symbol: KKR). Below is a twelve month price history chart comparing the stock performance of AES, ABT, and KKR: Below is a summary table of the current analyst target prices discussed above: | (RTTNews) - Abbott (ABT) announced that the U.S. FDA has approved the company's next-generation Gallant implantable cardioverter defibrillator or ICD and cardiac resynchronization therapy defibrillator or CRT-D devices. The company noted that the devices bring new benefits to patients with heart rhythm disorders, including a patient-preferred design without compromising battery longevity and MRI compatibility. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2020-07-02,92.5,92.2300033569336,0.2263896934416089,,
2020-07-01,91.9800033569336,91.63999938964844,-0.2918882627744932,,
2020-06-30,88.75,91.43000030517578,-0.36964987483828593,,
2020-06-29,89.58000183105469,89.01000213623047,3.0197186537191905,"Abbott, Tandem Diabetes Care Partner To Develop Integrated Diabetes Solutions | U.S. FDA allows emergency use of Danaher's COVID-19 antibody test","(RTTNews) - Abbott (ABT) and Tandem Diabetes Care (TNDM) have finalized an agreement to develop and commercialize integrated diabetes solutions that combine Abbott's continuous glucose monitoring technology with Tandem's insulin delivery systems. Jared Watkin, senior vice president, Diabetes Care, Abbott, said: ""By combining our glucose sensing technology with Tandem's insulin delivery systems, we will be able to create a cohesive ecosystem for people with diabetes that can fit easily into their daily lives."" The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories' ABT.N antibody test has a specificity rate of 99.9%, while the rate stands at 99.8% for Roche Holding AG's ROG.S test. The company's unit Beckman Coulter said it had shipped the antibody tests to nearly 400 U.S. hospitals and laboratories, and has ramped up production to deliver more than 30 million tests a month. High demand for the test has led to the entry of several fraudulent kits, prompting the FDA to tighten its rules over the tests."
2020-06-26,89.81999969482422,88.70999908447266,-0.636302392468379,,
2020-06-25,87.23999786376953,89.62000274658203,-1.2358056269460498,"CRBN, CMCSA, SLB, ABT: ETF Outflow Alert | Many studies of COVID-19 antibody test accuracy fall short - review","Among the largest underlying components of CRBN, in trading today Comcast Corp (Symbol: CMCSA) is off about 0.8%, Schlumberger Ltd (Symbol: SLB) is up about 4%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares MSCI ACWI Low Carbon Target ETF (Symbol: CRBN) where we have detected an approximate $83.7 million dollar outflow -- that's a 17.1% decrease week over week (from 4,100,000 to 3,400,000). For a complete list of holdings, visit the CRBN Holdings page » The chart below shows the one year price performance of CRBN, versus its 200 day moving average: Looking at the chart above, CRBN's low point in its 52 week range is $87.45 per share, with $133.84 as the 52 week high point — that compares with a last trade of $119.30. | Their review did not include tests offered by Roche ROG.S or Abbott Laboratories ABT.N, which were approved by regulators after the cut-off deadline of April 27. By John Miller ZURICH, June 25 (Reuters) - Many studies assessing the accuracy of COVID-19 antibody tests had major shortcomings, a review released on Thursday concluded, offering further evidence the blood tests are of little use for people seeking to know with certainty if they have been infected. While the studies reviewed by Cochrane showed the antibody tests were better at detecting COVID-19 antibodies in people two or more weeks after their symptoms started, they did not provide clues as to how well they work in patients further from infection."
2020-06-24,90.62999725341795,87.30000305175781,2.728112037014283,,
2020-06-23,91.11000061035156,91.3000030517578,-3.6742737532572933,,
2020-06-22,90.33000183105467,90.33999633789062,0.20854180675381143,,
2020-06-19,91.66999816894533,90.68000030517578,0.011064437765256068,,
2020-06-18,90.5,90.27999877929688,-1.0799584199238295,Better Coronavirus Stock: Abbott Labs or Hologic? | 5 Dividend Growth Stocks With Upside To Analyst Targets,"In light of that, this is an opportune moment to take a look at two companies making COVID-19 diagnostic tests, Abbott Laboratories (NYSE: ABT) and Hologic (NASDAQ: HOLX), and consider which is the better coronavirus stock to buy now. The problem with COVID-19 testing The main problem with disease testing is that a test's accuracy can vary significantly based on the overall prevalence of the condition in the population being tested. Abbott's COVID-19 tests Abbott's ID Now test for COVID-19 suffers from the problem described above. | New Jersey Resources Corp (Symbol: NJR) $31.58 $40.67 28.77% UGI Corp. (Symbol: UGI) $32.21 $41.25 28.07% AFLAC Inc (Symbol: AFL) $36.79 $45.80 24.49% National Fuel Gas Co. (Symbol: NFG) $41.33 $47.67 15.33% Abbott Laboratories (Symbol: ABT) $90.90 $103.75 14.14% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. New Jersey Resources Corp (Symbol: NJR) 3.96% 28.77% 32.73% UGI Corp. (Symbol: UGI) 4.10% 28.07% 32.17% AFLAC Inc (Symbol: AFL) 3.04% 24.49% 27.53% National Fuel Gas Co. (Symbol: NFG) 4.31% 15.33% 19.64% Abbott Laboratories (Symbol: ABT) 1.58% 14.14% 15.72% Another consideration with dividend growth stocks is just how much the dividend is growing. New Jersey Resources Corp (Symbol: NJR) $1.172 $1.252 6.83% UGI Corp. (Symbol: UGI) $1.08 $1.305 20.83% AFLAC Inc (Symbol: AFL) $1.06 $1.1 3.77% National Fuel Gas Co. (Symbol: NFG) $1.7 $1.74 2.35% Abbott Laboratories (Symbol: ABT) $1.2 $1.36 13.33% These five stocks are part of our full Dividend Aristocrats List."
2020-06-17,90.41999816894533,90.9000015258789,-0.24309527149516574,"Notable ETF Inflow Detected - VHT, ABT, DHR, CI","Among the largest underlying components of VHT, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.5%, Danaher Corp (Symbol: DHR) is up about 0.9%, and Cigna Corp (Symbol: CI) is lower by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Health Care ETF (Symbol: VHT) where we have detected an approximate $307.5 million dollar inflow -- that's a 2.9% increase week over week in outstanding units (from 54,580,656 to 56,182,689). For a complete list of holdings, visit the VHT Holdings page » The chart below shows the one year price performance of VHT, versus its 200 day moving average: Looking at the chart above, VHT's low point in its 52 week range is $138.11 per share, with $198.675 as the 52 week high point — that compares with a last trade of $191.60."
2020-06-16,90.62000274658205,89.73999786376953,0.5308597286594906,Abbott's FreeStyle Libre System Reduces Diabetic Ketoacidosis-Related Hospitalization Rates | FOCUS-U.S. health insurers may balk at paying for coronavirus antibody testing,"(RTTNews) - Abbott (ABT) announced results from multiple new real-world studies that demonstrate how use of the FreeStyle Libre system, the world-leading5 continuous glucose monitoring technology, can lead to significant clinical benefits among people living with type 1 and type 2 diabetes. In the study, researchers assessed nationwide reimbursement claims data in France of 74,158 people living with diabetes, including 33,203 people with type 1 diabetes and 40,955 people with type 2 diabetes. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AdvaMedDX, a trade group that represents test makers including Roche Holding AG ROG.S and Abbott Laboratories ABT.N, expects about 94 million laboratory-based tests to be shipped by the end of June. By Caroline Humer NEW YORK, June 16 (Reuters) - U.S. health insurers may balk at covering tests that look for coronavirus antibodies in some cases, arguing that employers or the government should foot a bill expected to run into billions of dollars. The biggest national insurers including UnitedHealth Group Inc UNH.N, CVS Health Corp's CVS.N Aetna unit and Cigna Corp CI.N have policies to cover the tests, which cost around $50, and related appointment fees, when doctors say they are medically necessary."
2020-06-15,87.5199966430664,89.55000305175781,-0.9710934188265689,Is Thermo Fisher Scientific a Buy? | U.S. FDA clears version 2.0 of Abbott's low-cost glucose monitor | U.S. FDA clears version 2.0 of Abbott's low-cost glucose monitor,"Abbott Laboratories (NYSE: ABT) and Roche Holding (OTC: RHHBY) are some of the bigger names involved in COVID-19 testing that have received EUA for their tests. If it's no better off as a result of the added testing from the coronavirus, then Thermo Fisher is essentially the stock it was before COVID-19: one of low growth. 10 stocks we like better than Thermo Fisher Scientific When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | By Manas Mishra and Mrinalika Roy June 15 (Reuters) - The U.S. Food and Drug Administration on Monday cleared a new version of Abbott Laboratories' ABT.N continuous glucose monitoring device, FreeStyle Libre, helping the company build upon the success of its fastest-growing diabetes product. FreeStyle Libre 2, which was approved in Europe in 2018, will be priced the same as its precursor and is offered at a discount compared to rival devices, Abbott said. It was launched in Europe in 2014 and three years later in the U.S. Each sensor of the device, worn at the back of the upper arm for 14 days, is available at a list price of $54, while the handheld reader, used to scan the sensor, will be available for a one-time cost of $70. | June 15 (Reuters) - The U.S. Food and Drug Administration on Monday cleared a new version of Abbott Laboratories' ABT.N continuous glucose monitoring device. FreeStyle Libre 2, which was approved in Europe in 2018, will be priced the same as its precursor and is offered at a discount compared to rival devices, Abbott said. (Reporting by Manas Mishra in Bengaluru; Editing by Shounak Dasgupta) ((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manasmishra24; within U.S. +1 646 223 8780, outside U.S. +91 806749 2709)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2020-06-12,89.25,89.0199966430664,2.3194772469775105,"Daily Dividend Report: ABT,BMY,CL,AMAT,PKI","VIDEO: Daily Dividend Report: ABT,BMY,CL,AMAT,PKI The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott has increased its dividend payout for 48 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years. The Board of Directors of Colgate-Palmolive today declared a quarterly cash dividend of $0.44 per common share, payable on August 14, 2020, to shareholders of record on July 20, 2020."
2020-06-11,92.16999816894533,87.77999877929688,-0.25770684250262604,Why Sorrento Therapeutics Stock Is Up Today,"Other companies such as Abbott Laboratories (NYSE: ABT) and Roche Holding (OTC: RHHBY) have been providing the public with COVID-19 test kits for several weeks, and some of these tests (like Abbott's ID Now COVID-19 antibody test) can return positive results in as little as five minutes. 10 stocks we like better than Sorrento Therapeutics When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. See the 10 stocks *Stock Advisor returns as of June 2, 2020 Prosper Junior Bakiny has no position in any of the stocks mentioned."
2020-06-10,90.8499984741211,92.16000366210938,-4.762937481675644,,
2020-06-09,92.31999969482422,90.2699966430664,1.441942993935702,,
2020-06-08,88.9800033569336,92.55999755859376,-2.2205405746689393,Why Co-Diagnostics Stock Soared 59% in May,"A study conducted at New York University's Langone Tisch Hospital found that Abbott Labs' (NYSE: ABT) ID NOW test missed up to 48% of positive results, according to MassDevice. So what We can attribute Co-Diagnostics stock's powerful May performance largely to a continuation of the momentum it's had since mid-April, when the company announced that its Logix Smart COVID-19 testing technology had been validated by OralDNA Labs for use on saliva samples. We can probably attribute this at least in part to investors being satisfied with Abbott's May 14 response to the Langone study (that it was ""not consistent with other studies""), or at least to many investors believing that sales of Co-Diagnostics' COVID-19 test wouldn't get that significant of a boost from the Abbott news."
2020-06-05,88.47000122070312,89.86000061035156,4.023369371317523,FDA Evaluates 5 More COVID-19 Antibody Tests,"That's comparable to Abbott Labs' (NYSE: ABT) Architect SARS-CoV-2 IgG, which registered a sensitivity of 100% and a specificity of 99.6% in the previous round of testing. One of the tests in the recent batch that still has an emergency use authorization, Healgen's COVID-19 IgG/IgM Rapid Test Cassette, scored quite high with a sensitivity -- the ability to detect a true positive case -- of 100% and a specificity -- the ability to detect a true negative -- of 97.5%. While the results aren't competitive with the best tests, PerkinElmer's test can certainly find a place on the market, where demand outstrips supply."
2020-06-04,91.0500030517578,88.25,1.5711533519490444,3 Dividend Stocks to Bankroll Your Retirement,"Abbott Laboratories Healthcare giant Abbott Laboratories (NYSE: ABT) made news recently when it rolled out a five-minute COVID-19 test. Wall Street is looking for 10% compounded annual earnings growth for the next five years, and though Abbott's stock traded for 46 times trailing earnings by Wednesday's closing prices, it went for a somewhat more reasonable 30 times next year's estimates. Abbott's dividend of $1.44 per share yields a modest 1.6%, but the company has made the payout every single quarter for the past 96 years, which means it's handled its share of market ups and downs."
2020-06-03,92.55999755859376,91.4000015258789,-3.075236636912712,Make This Biotech Play if You Like Co-Diagnostics’ Chances,"Abbott Labs (NYSE:ABT) and Thermo Fisher Scientific (NYSE:TMO) are two companies providing Covid-19 tests. InvestorPlace - Stock Market News, Stock Advice & Trading Tips InvestorPlace contributor and longtime stock jockey, Louis Navellier, recently selected Co-Diagnostics (NASDAQ:CODX) and CODX stock as one of seven biotech stocks to buy that are trying to beat back the novel coronavirus, and at the same time, possibly come up with a vaccine. “The 5% false-positive rate of Co-Diagnostics’ test seems too high and too differentiated from most of the tests evaluated by FIND to be due to chance or an evaluation error.” Ramer goes on to suggest that if you were in charge of picking a test for your state, you would surely pick one that is 100% accurate for both positive and negative Covid-19 results."
2020-06-02,92.91999816894533,92.62000274658205,-1.2532368877608704,Should You Sell Abbott Laboratories Stock? | 3 Stocks With Dividends Yielding More Than 3% | We Did The Math IHI Can Go To $294,"Shares of Abbott Laboratories (NYSE: ABT) are up by 6.3% year to date, a better-than-average performance relative to the broader market that it owes in part to its involvement in the fight against COVID-19. Why Abbott Laboratories is worth buying First, it is worth noting that Abbott's ID Now COVID-19 test is one of the fastest on the market, capable of giving a positive result in as little as five minutes. * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! | Dividend yield is an important factor investors consider when choosing a dividend stock to invest in. Currently, the company pays a quarterly dividend of $2 per share, which pays 4% per year. Currently, the stock pays investors a quarterly dividend of $1.47, which yields 3.7%. | Similarly, CSII has 20.78% upside from the recent share price of $38.50 if the average analyst target price of $46.50/share is reached, and analysts on average are expecting ABT to reach a target price of $103.75/share, which is 11.55% above the recent price of $93.01. Three of IHI's underlying holdings with notable upside to their analyst target prices are CryoLife, Inc. (Symbol: CRY), Cardiovascular Systems, Inc (Symbol: CSII), and Abbott Laboratories (Symbol: ABT). Below is a twelve month price history chart comparing the stock performance of CRY, CSII, and ABT: Combined, CRY, CSII, and ABT represent 14.08% of the iShares U.S. Medical Devices ETF."
2020-06-01,92.9499969482422,93.01000213623048,-0.3228534527280505,"Quidel Stock Is Up 130% This Year: Is This Coronavirus Stock Still a Hot Buy? | Notable ETF Inflow Detected - IHI, ABT, ISRG, SYK","In addition to Quidel's test, the FDA's already approved four tests from Abbott Labs (NYSE: ABT), including one that can produce results within five minutes, the ID NOW COVID-19 test. Among those stocks is the diagnostics and testing company, Quidel (NASDAQ: QDEL). Emergency use authorization of its test turned the stock's fortunes On March 17, the U.S. Food and Drug Administration (FDA) gave Quidel emergency use authorization (EUA) for its Lyra SARS-CoV-2 Assay rapid point-of-care test. | Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is down about 2.7%, Intuitive Surgical Inc (Symbol: ISRG) is down about 1.3%, and Stryker Corp (Symbol: SYK) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $94.0 million dollar inflow -- that's a 1.4% increase week over week in outstanding units (from 24,900,000 to 25,250,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $183.25 per share, with $278.19 as the 52 week high point — that compares with a last trade of $265.91."
2020-05-29,92.9000015258789,94.91999816894533,0.06455641738395562,,
2020-05-28,91.9499969482422,92.0999984741211,2.1743774056922005,Coronavirus 2020: Where to Invest $500 Right Now,Abbott Labs Abbott Labs (NYSE: ABT) ranks as one of the biggest companies making COVID-19 diagnostic tests. Gilead Sciences Gilead Sciences' (NASDAQ: GILD) remdesivir has been near the top of the list for treating COVID-19 for several months even though there was uncertainty about the drug's efficacy. The biotech stock has soared in 2020 thanks in large part to the success of its flu vaccine candidate NanoFlu in late-stage clinical testing.
2020-05-27,89.27999877929688,90.76000213623048,0.16313380191119148,,
2020-05-26,92.9499969482422,89.4800033569336,1.6577098758616984,,
2020-05-22,90.41999816894533,91.47000122070312,-3.7331831148319687,"Wall St Week Ahead-Investors look beyond drug makers as hunt for Covid-19 treatment heats up | BUZZ-U.S. STOCKS ON THE MOVE-LiveRamp, T2 Biosystems, Foot locker | BUZZ-U.S. STOCKS ON THE MOVE-Abbott, Tetraphase Pharma, HPE | Notable ETF Inflow Detected - ACWI, JNJ, JPM, ABT | UK Stocks-Factors to watch on May 22","He is betting on companies such as Roche Holding ROG.S and Abbott Laboratories ABT.N, which have large diagnostics businesses that will likely be a part of any future COVID-19 treatment. By David Randall NEW YORK, May 22 (Reuters) - Investors are diversifying bets in the healthcare sector, as the rush to develop treatments for Covid-19 has driven up prices for some pharmaceutical stocks. Hopes for a treatment have also sparked outsize rallies in the shares of companies such as Moderna and Inovio Pharmaceutcials, up 253% and 327% since the start of the year, respectively, as of Friday's close. | Beauty Inc ELF.N: up 15.1% BUZZ-Surges on fourth-quarter beat ** Abbott Laboratories ABT.N: up 0.3% BUZZ-CS says COVID-19 test interim data a positive, should ease accuracy concerns ** Coty Inc COTY.N: up 11.3% BUZZ-Kylie Skin enters Europe, Coty surges The 11 major S&P 500 sectors: Communication Services The top three S&P 500 .PG.INX percentage gainers: ** Coty Inc , up 11.4% ** Harley-Davidson Inc , up 5.7% ** American Tower Corp , up 5.2% The top three S&P 500 .PL.INX percentage losers: ** Hewlett Packard Enterprise Co , down 10.8% ** Wynn Resorts Ltd , down 6.3% ** Alaska Air Group Inc , down 4.1% The top three NYSE .PG.N percentage gainers: ** Navidea Biopharmaceuticals Inc , up 113.3% ** Renren Inc , up 26.2% ** LiveRamp Holdings Inc , up 23.3% The top three NYSE .PL.N percentage losers: ** Nabors Industries Ltd , down 14% ** Foot Locker Inc , down 13.3% ** AeroCentury Corp , down 12.5% The top three Nasdaq .PG.O percentage gainers: ** Inari Medical Inc , up 121.2 % ** Celsion Corp , up 30.2% ** Village Farms International Inc , up 18.4% The top three Nasdaq .PL.O percentage losers: ** Recon Technlogy Ltd , down 44.7% ** Syndax Pharmaceuticals Inc , down 20.2% ** Gulf Resources Inc , down 17.2% ** T2 Biosystems Inc TTOO.O: up 15.6% BUZZ-Jumps as it gets ready to ship COVID-19 tests by end-June ** Buckle Inc BKE.N: down 6.6% BUZZ-Down after co swings to Q1 loss ** Intercept Pharmaceuticals Inc ICPT.O: down 14.5% BUZZ-Drops after FDA delays panel meeting for NASH drug ** Whiting Petroleum Corp WLL.N: down 4.7% ** Exxon Mobil Corp XOM.N: down 1.5% ** Chevron Corp CVX.N: down 2.2% ** Devon Energy Corp DVN.N: down 3.0% ** ConocoPhillips COP.N: down 2.1% ** Occidental Petroleum Corp OXY.N: down 2.8% ** Apache Corp APA.N: down 0.5% ** Hess Corp HES.N: down 1.5% ** Pioneer Natural Resources Co PXD.N: down 0.9% ** TechnipFMC Plc FTI.N: down 1.9% ** Schlumberger NV SLB.N: down 2.7% ** Halliburton Co HAL.N: down 4.1% ** Baker Hughes Co BKR.N: down 1.7% ** Marathon Petroleum Corp MPC.N: down 1.0% ** HollyFrontier Corp HFC.N: down 1.6% ** Phillips 66 PSX.N: down 1.2% ** Valero Energy Corp VLO.N: down 1.1% ** Plains All American Pipline LP PAA.N: down 1.3% ** ONEOK Inc OKE.N: down 1.8% ** Kinder Morgan Inc KMI.N: down 1.2% BUZZ-Oil stocks slip on U.S.-China tensions, demand concerns ** Splunk Inc SPLK.O: up 11.7% BUZZ-Street view: Brokerages bet on Splunk's positive cloud growth prospects ** Nvidia Corp NVDA.O: up 3.2% BUZZ-Rises as co forecasts Q2 sales above estimates ** LiveRamp Holdings Inc RAMP.N: up 23.2% BUZZ- Eyes best day on better-than-expected Q4 rev ** Joyy Inc YY.O: down 8.4% BUZZ-Falls as Q2 revenue forecast misses expectations ** Deckers Outdoor Corp DECK.N: up 6.8% BUZZ-Rises on strong high-margin online UGG, HOKA sales ** Aurora Cannabis Inc ACB.N: down 4.1% BUZZ-Jefferies sees recent re-rating as excessive, downgrades ** Hewlett Packard Enterprise Co HPE.N: down 10.9% BUZZ-Falls on disappointing Q2 results ** Tetraphase Pharmacauticals Inc TTPH.O: up 14.8% BUZZ-Surges on Melinta's ""superior"" buyout offer ** Palo Alto Networks Inc PANW.N: up 3.0% BUZZ-Q3 beats as remote work boosts cybersecurity demand; shares rise ** ONEOK Inc OKE.N: down 1.8% BUZZ-JPMorgan downgrades to 'neutral' on challenging Bakken outlook ** Amarin Corporation Plc AMRN.O: down 1.2% BUZZ-Slips after FDA approval of heart drug's generic version ** Foot locker Inc FL.N: down 13.4% BUZZ-Slips on Q1 loss, drop in sales ** Pinduoduo Inc PDD.O: up 11.1% BUZZ-Gains as online marketing services fuels rev beat ** Medtronic Plc MDT.N: down 1.6% BUZZ-Street View: Medtronic's product pipeline, balance sheet to help weather COVID-19 storm ** Moderna Inc MRNA.O: up 2.2% BUZZ-Fauci calls COVID-19 vaccine trial results 'good sign' ** Ross Stores Inc ROST.O: down 3.8% BUZZ-Falls on weak Q1, lack of forecast ** Agilent Technologies Inc A.N: up 5.0% BUZZ-Up as brokerages raise PT after ""downright impressive"" Q2 ** e.l.f. up 0.19% Consumer Discretionary | Beauty Inc ELF.N: up 10.6% BUZZ-Surges on fourth-quarter beat ** Abbott Laboratories ABT.N: up 0.7% BUZZ-CS says COVID-19 test interim data a positive, should ease accuracy concerns ** Coty Inc COTY.N: up 6.2% BUZZ-Kylie Skin enters Europe, Coty surges The 11 major S&P 500 sectors: Communication Services The top three S&P 500 .PG.INX percentage gainers: ** Coty Inc , up 6.3% ** Agilent Technologies Inc , up 5.9% ** American Tower Corp , up 4.9% The top three S&P 500 .PL.INX percentage losers: ** Hewlett Packard Enterprise Co , down 12.1% ** Wynn Resorts Ltd , down 6% ** State Street Corp , down 5.5% The top three NYSE .PG.N percentage gainers: ** Navidea Biopharmaceuticals Inc , up 85.1% ** Liveramp Holdings Inc , up 22.5% ** Renren Inc , up 12.8% The top three NYSE .PL.N percentage losers: ** Aerocentury Corp , down 12.5% ** Hewlett Packard Enterprise Co , down 12.1% ** Nabors Industries Ltd , down 11.8% The top three Nasdaq .PG.O percentage gainers: ** Evolus Inc , up 34.9% ** Tetraphase Pharmaceuticals Inc , up 31.7% ** Celsion Corp , up 27.9% The top three Nasdaq .PL.O percentage losers: ** Recon Technology Ltd , down 44.2% ** Syndax Pharmaceuticals Inc , down 22.9% ** Gulf Resources Inc , down 19.6% ** Bed Bath & Beyond Inc BBBY.O: up 0.6% BUZZ-Up on plans to reopen 600 stores, bring back furloughed staff ** T2 Biosystems Inc TTOO.O: up 12.8% BUZZ-Jumps as it gets ready to ship COVID-19 tests by end-June ** Buckle Inc BKE.N: down 6.9% BUZZ-Down after co swings to Q1 loss ** Intercept Pharmaceuticals Inc ICPT.O: down 15.3% BUZZ-Drops after FDA delays panel meeting for NASH drug ** Whiting Petroleum Corp WLL.N: down 5.7% ** Exxon Mobil Corp XOM.N: down 1.6% ** Chevron Corp CVX.N: down 1.7% ** Devon Energy Corp DVN.N: down 2.4% ** ConocoPhillips COP.N: down 1.6% ** Occidental Petroleum Corp OXY.N: down 2.2% ** Apache Corp APA.N: down 1.1% ** Hess Corp HES.N: down 0.8% ** Pioneer Natural Resources Co PXD.N: down 1.3% ** TechnipFMC Plc FTI.N: down 3.6% ** Schlumberger NV SLB.N: down 2.7% ** Halliburton Co HAL.N: down 3.8% ** Baker Hughes Co BKR.N: down 2.2% ** Marathon Petroleum Corp MPC.N: down 1.3% ** HollyFrontier Corp HFC.N: down 1.9% ** Phillips 66 PSX.N: down 1.5% ** Valero Energy Corp VLO.N: down 1.6% ** Plains All American Pipline LP PAA.N: down 1.4% ** ONEOK Inc OKE.N: down 1.9% ** Kinder Morgan Inc KMI.N: down 1.7% BUZZ-Oil stocks slip on U.S.-China tensions, demand concerns ** Aurora Cannabis Inc ACB.N: down 8.9% BUZZ-Jefferies sees recent re-rating as excessive, downgrades ** Hewlett Packard Enterprise Co HPE.N: down 12.1% BUZZ-Falls on disappointing Q2 results ** Tetraphase Pharmacauticals Inc TTPH.O: up 31.7% BUZZ-Surges on Melinta's ""superior"" buyout offer ** Palo Alto Networks Inc PANW.N: up 2.7% BUZZ-Q3 beats as remote work boosts cybersecurity demand; shares rise ** ONEOK Inc OKE.N: down 1.9% BUZZ-JPMorgan downgrades to 'neutral' on challenging Bakken outlook ** Amarin Corporation Plc AMRN.O: down 1.3% BUZZ-Slips after FDA approval of heart drug's generic version ** Foot locker Inc FL.N: down 11.6% BUZZ-Slips on Q1 loss, drop in sales ** Pinduoduo Inc PDD.O: up 9.4% BUZZ-Gains as online marketing services fuels rev beat ** Medtronic Plc MDT.N: down 2.4% BUZZ-Street View: Medtronic's product pipeline, balance sheet to help weather COVID-19 storm ** Moderna Inc MRNA.O: up 1.5% BUZZ-Fauci calls COVID-19 vaccine trial results 'good sign' ** Ross Stores Inc ROST.O: down 4.5% BUZZ-Falls on weak Q1, lack of forecast ** Agilent Technologies Inc A.N: up 6.0% BUZZ-Up as brokerages raise PT after ""downright impressive"" Q2 ** e.l.f. down 0.54% Consumer Discretionary | Among the largest underlying components of ACWI, in trading today Johnson & Johnson (Symbol: JNJ) is up about 0.3%, JPMorgan Chase & Co (Symbol: JPM) is down about 1.2%, and Abbott Laboratories (Symbol: ABT) is up by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares MSCI ACWI ETF (Symbol: ACWI) where we have detected an approximate $419.2 million dollar inflow -- that's a 4.1% increase week over week in outstanding units (from 147,200,000 to 153,200,000). For a complete list of holdings, visit the ACWI Holdings page » The chart below shows the one year price performance of ACWI, versus its 200 day moving average: Looking at the chart above, ACWI's low point in its 52 week range is $53.31 per share, with $81.75 as the 52 week high point — that compares with a last trade of $69.54. | * Britain said on Thursday it had agreed to acquire over 10 million coronavirus antibody tests from Roche ROG.S and Abbott ABT.N which would be rolled out to health and care workers from next week. * British Prime Minister Boris Johnson has instructed civil servants to make plans to end UK's reliance on China for vital medical supplies and other strategic imports in light of the coronavirus outbreak, The Times newspaper reported on Friday. * OIL: Oil prices slumped on Friday after China's decision to omit an economic growth target for 2020 renewed concerns that the fallout from the coronavirus pandemic will continue to depress fuel demand in the world's second-largest oil user."
2020-05-21,89.63999938964844,90.38999938964844,1.1612509102200148,Abbott says new data on rapid coronavirus test used in White House shows high accuracy | Britain signs deals for 10 million antibody tests from Roche and Abbott | Abbott: Health Canada Approves New COVID-19 Antibody Test - Quick Facts,"By Carl O'Donnell May 21 (Reuters) - Abbott Laboratories ABT.N on Thursday said an analysis of data from an ongoing study of its ID NOW rapid test, which is used in the White House and elsewhere to spot COVID-19, shows it is highly accurate when compared with industry-standard tests. Abbott's data has so far shown that the test, which can be used at the point of care and produces results in minutes, finds positive cases of COVID-19 nearly 95% of the time when compared with two other tests performed in laboratories. The FDA said last week it was reviewing data on the test’s accuracy and Abbott agreed to conduct multiple studies of the test that will each include at least 150 COVID-19-positive patients in a variety of healthcare settings. | LONDON, May 21 (Reuters) - Britain will buy 10 million coronavirus antibody tests from Roche ROG.S and Abbott ABT.N and will roll them out to health workers from next week, health minister Matt Hancock said on Thursday. The antibody tests - also known as serology tests - show who has been infected, although it is not yet clear whether the presence of antibodies to the new coronavirus, SARS-CoV-2, confers permanent immunity. (Reporting by Alistair Smout and Estelle Shirbon; editing by Stephen Addison) ((alistair.smout@thomsonreuters.com; +44 207 542 7064; Reuters Messaging: alistair.smout.thomsonreuters.com@reuters.net)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott (ABT) has received Health Canada authorization for the ARCHITECT SARS-CoV-2 IgG test, a laboratory-based serology blood test for the detection of the antibody, IgG, that identifies if a person has had COVID-19. Abbott expects to begin shipping antibody tests to Canada in the current week and intends to distribute 30 million tests globally by the end of June. Abbott noted that its new antibody test adds to the company's existing COVID-19 tests in Canada that are already being used on its m2000 molecular laboratory system."
2020-05-20,89.58000183105469,90.08999633789062,0.8366800592444108,,
2020-05-19,90.33000183105467,88.22000122070312,0.5693173659426493,5 Dividend Growth Stocks With Upside To Analyst Targets | Is Abbott Labs Stock a Buy After Its COVID-19 Test Controversy? | Co-Diagnostics Stock Positioned for Continued Growth in 2020,"Automatic Data Processing Inc. (Symbol: ADP) $136.40 $159.46 16.91% Abbott Laboratories (Symbol: ABT) $90.27 $103.75 14.93% Procter & Gamble Company (Symbol: PG) $116.21 $131.27 12.96% McDonald's Corp (Symbol: MCD) $179.83 $202.95 12.86% National Fuel Gas Co. (Symbol: NFG) $41.57 $46.80 12.58% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Automatic Data Processing Inc. (Symbol: ADP) 2.67% 16.91% 19.58% Abbott Laboratories (Symbol: ABT) 1.60% 14.93% 16.53% Procter & Gamble Company (Symbol: PG) 2.72% 12.96% 15.68% McDonald's Corp (Symbol: MCD) 2.78% 12.86% 15.64% National Fuel Gas Co. (Symbol: NFG) 4.19% 12.58% 16.77% Another consideration with dividend growth stocks is just how much the dividend is growing. Automatic Data Processing Inc. (Symbol: ADP) $2.96 $3.4 14.86% Abbott Laboratories (Symbol: ABT) $1.2 $1.36 13.33% Procter & Gamble Company (Symbol: PG) $2.897 $3.029 4.56% McDonald's Corp (Symbol: MCD) $4.34 $4.82 11.06% National Fuel Gas Co. (Symbol: NFG) $1.7 $1.74 2.35% These five stocks are part of our full Dividend Aristocrats List. | Did the White House and others celebrate Abbott Labs' (NYSE: ABT) super-fast COVID-19 diagnostic test too soon? A study conducted by researchers at New York University found that Abbott's COVID-19 test that runs on its popular ID NOW platform missed one-third of the samples detected as positive by Danaher's Cepheid Xpert Xpress system when using nasopharyngeal swabs and over 48% of positive results when using dry nasal swabs. Abbott's response It's important to note that Abbott disputes the NYU findings. | Abbot Laboratories (NYSE:ABT) is one of them. InvestorPlace - Stock Market News, Stock Advice & Trading Tips How many stocks can you name that have seen over 1,800% growth in 2020? Ongoing Testing Is Key for CODX Stock The rapid growth of CODX stock could be written off as investor excitement over a stock that finds itself in the spotlight."
2020-05-18,91.9000015258789,90.2699966430664,-2.335880181091891,"BUZZ-U.S. STOCKS ON THE MOVE-Centric Brands, Fulgent Genetics, Moderna","The top three S&P 500 .PG.INX percentage gainers: ** Royal Caribbean Cruises Ltd , up 17.6% ** Host Hotels and Resorts Inc , up 16.4% ** L Brands Inc , up 16.3% The top three S&P 500 .PL.INX percentage losers: ** Kroger Co , down 2.5% ** Citrix Systems Inc , down 2.3% ** Campbell Soup Company , down 2.3% The top three NYSE .PG.N percentage gainers: ** Aurora Cannabis Inc , up 73% ** Credit Suisse Velocityshares 3x ETN , up 27.4% ** MicroSectors U.S. Big Oil Index 3x ETN , up 25.1 % The top three NYSE .PL.N percentage losers: ** Velocityshares 3X Inverse Natural Gas ETN , down 27.9% ** Direxion Daily S&P 500 High Beta Bear 3X Shares , down 23% ** ProShares UltraShort Bloomberg Natural Gas , down 19.5% The top three Nasdaq .PG.O percentage gainers: ** Oasis Midstream Partners LP , up 37.2% ** Vir Biotechnology Inc , up 32.2% ** Novavax Inc , up 31.2% The top three Nasdaq .PL.O percentage losers: ** ForeScout Technologies Inc , down 22.9% ** Medigus Ltd , down 10.3% ** VelocityShares Daily Short-Term ETN , down 10.2% ** Ford Motor Co F.N: up 6.7% ** General Motors Co GM.N: up 8.6% ** Fiat Chrysler Automobiles N.V. FCAU.N: up 7.2% BUZZ-Ford, GM rise as U.S. auto industry shifts into gear after lockdown ** Apple Inc AAPL.O: up 1.9% BUZZ-Gains on plans to reopen 25 more U.S. stores ** ForeScout Technologies Inc FSCT.O: down 22.9% BUZZ-Falls after Advent cancels deal ** Diffusion Pharmaceuticals Inc DFFN.O: down 22.6% BUZZ-Falls on direct stock offering ** Hertz Global Holdings Inc HTZ.N: up 14.3% BUZZ-Rises after appointing new CEO ** NantKwest Inc NK.O: up 6.5% BUZZ-Jumps as FDA clears IND application for COVID-19 treatment ** BioSig Technologies Inc BSGM.O: up 5.7% BUZZ-Jumps as unit gets FDA nod for human trial of COVID-19 therapy ** Abbott Laboratories ABT.N: up 1.7% ** Baxter International Inc BAX.N: up 0.4% ** Johnson & Johnson JNJ.N: up 0.5% ** Edwards Lifesciences Corp EW.N: up 2.7% ** Stryker Corp SYK.N: up 5.7% ** Boston Scientific Corp BSX.N: up 4.9% ** Zimmer Biomet Holdings ZBH.N: up 8.5% ** Medtronic Plc MDT.N: up 6.3% BUZZ-Rising elective surgeries in U.S positive for medtech sector - Credit Suisse ** Twin River Worldwide Holdings Inc TRWH.N: up 9.5% BUZZ-Stifel says valuation grossly dislocated ** DraftKings Inc DKNG.O: up 0.3% BUZZ-Surges as brokerages hike PTs after strong Q1 report ** JPMorgan Chase & Co JPM.N: up 3.9% ** Citigroup Inc C.N: up 5.2% ** Wells Fargo & Co WFC.N: up 5.4% ** Bank of America Corp BAC.N: up 4.3% ** Morgan Stanley MS.N: up 5.0% ** Goldman Sachs Group Inc GS.N: up 2.5% BUZZ-U.S. big banks: Shares rise as easing lockdowns soothe markets ** Chevron Corp CVX.N: up 5.7% ** Exxon Mobil Corp XOM.N: up 6.3% ** Apache Corp APA.N: up 11.6% ** Devon Energy Corp DVN.N: up 8.8% ** Hess Corp HES.N: up 11.6% ** Occidental Petroleum Corp OXY.N: up 8.4% ** Cimarex Energy Co XEC.N: up 9.2% ** EOG Resources EOG.N: up 7.4% ** TechnipFMC Plc FTI.N: up 9.8% ** Helmerich and Payne Inc HP.N: up 6.5% ** ONEOK Inc OKE.N: up 8.1% ** Kinder Morgan Inc KMI.N: up 4.0% ** HollyFrontier Corp HFC.N: up 13.7% ** Marathon Petroleum Corp MPC.N: up 13.1% ** Phillips 66 PSX.N: up 8.5% ** Valero Energy Corp VLO.N: up 9.2% ** Schlumberger NV SLB.N: up 8.5% BUZZ-Oil stocks climb over easing restrictions, output curbs ** Under Armour Inc UAA.N: up 8.6% BUZZ-Appoints El-Erian as lead independent director, shares rise ** Deciphera Pharmaceuticals Inc DCPH.O: up 7.7% BUZZ-Rises on U.S. FDA nod for stomach cancer drug ** Chembio Diagnostics Inc CEMI.O: up 1.6% BUZZ-Rises after COVID-19 test distribution deal with Thermo Fisher ** Nutrien Ltd NTR.N: up 3.6% BUZZ-Berenberg says Nutrien's earnings momentum may slow during H2 2020, cuts PT ** VistaGen Therapeutics Inc VTGN.O: up 25.0% BUZZ-Up on submitting trial design to FDA for COVID-19 related anti-anxiety drug ** Centric Brands Inc CTRC.O: down 57.7% BUZZ-Plunges as apparel maker files for bankruptcy ** Fulgent Genetics Inc FLGT.O: up 13.2% BUZZ-Surges on U.S. FDA nod for emergency use of COVID-19 test kit ** Best Buy Co Inc BBY.N: up 9.1% BUZZ-TAG says Best Buy to emerge a retail winner, upgrades ** PG&E Corp PCG.N: up 7.5% BUZZ-Rises after wildfire victims support reorganization plan ** Teva Pharmaceutical TEVA.N: up 2.9% BUZZ-Rises on China approval for Huntington's treatment ** Camping World Holdings Inc CWH.N: up 9.4% BUZZ-Jumps on qtrly, special dividend ** Moderna Inc MRNA.O: up 22.7% BUZZ-Moderna: Surges after co's experimental COVID-19 vaccine shows promise ** Microsoft Corp MSFT.O: up 1.1% BUZZ-RBC says Microsoft's broad product portfolio to benefit from cloud business, hikes PT ** Lululemon Athletica Inc LULU.O: up 3.8% BUZZ-Best positioned to benefit from work-from-home trend - Brokerage ** Workday Inc WDAY.O: down 0.1% BUZZ-RBC sees dampening subscription growth for Workday, cuts PT The 11 major S&P 500 sectors: Communication Services up 2.02% Consumer Discretionary up 3.19% Consumer Staples"
2020-05-15,89.95999908447266,89.88999938964844,-1.7736723131103465,"U.S. health secretary expresses confidence in Abbott's fast COVID-19 test | Wall Street falls as trade war fears add to virus woes | Abbott Stands By Quick Covid-19 Test After FDA Warning | Wall Street retreats as trade war fears compound virus woes | U.S. health secretary expresses confidence in Abbott's fast COVID-19 test | U.S. employers wary of coronavirus 'immunity' tests as they move to reopen | Health Care Sector Update for 05/15/2020: ABT, MYO, OCUL, REGN, XLV, IBB | FDA Warns Public About Inaccuracy Issues With Abbott's Coronavirus Test | Wall Street eyes weak open as trade war fears add to virus woes | U.S. stocks futures fall as China trade war fears add to coronavirus woes | U.S. employers wary of coronavirus 'immunity' tests as they move to reopen | U.S. stocks futures edge higher on China industrial data | FDA : Abbott's Rapid Coronavirus Test May Deliver Inaccurate Results","Adds detail about research into tests' effectiveness and quote from Abbott executive WASHINGTON, May 15 (Reuters) - A top Trump administration official said on Friday the government still has confidence in Abbott Laboratories’ ABT.N speedy coronavirus test used at the White House, which regulators have warned could deliver inaccurate results. Abbott said in a statement on Thursday that the number of patients studied by NYU was small and that some studies of its test had used it in ways it was not intended to be. A study done in a testing clinic in Detroit said the ID NOW test was accurate 98% of the time. | Abbott Laboratories ABT.N slipped 2.6% after the U.S. Food and Drug Administration said the company's speedy coronavirus test could potentially be inaccurate, but can still be used to test patients. By Ambar Warrick and Medha Singh May 15 (Reuters) - A slump in technology stocks knocked Wall Street's main indexes lower on Friday, as signs of deteriorating trade relations between the United States and China added to economic worries due to the novel coronavirus pandemic. China's countermeasures include launching investigations and imposing restrictions on U.S. companies such as Apple Inc AAPL.O, Cisco Systems Inc CSCO.O, Qualcomm Inc QCOM.O, as well as suspending purchase of Boeing Co BA.N airplanes, the report said, citing a source. | Shares of Abbott (ticker: ABT) were down 2.9% Friday morning. The medical device maker Abbott Laboratories is issuing new advice to doctors for use of its rapid test for Covid-19 after the Food and Drug Administration warned of new data suggesting the test could return false negatives. In its own statement, Abbott stood by the test, and was critical of a paper by doctors at NYU Langone posted online early this week that claimed the Abbott system had reported as negatives “a third of the samples detected positive” by a widely used, slower system. | Abbott Laboratories ABT.N slipped 1.4% after the U.S. Food and Drug Administration said the company's speedy coronavirus test could potentially be inaccurate, but can still be used to test patients. By Ambar Warrick and Medha Singh May 15 (Reuters) - U.S. stocks dropped on Friday as signs of deteriorating trade relations between the United States and China added to economic worries due to the novel coronavirus pandemic. After a strong rally from their 2020 lows, the three major stock indexes are on course for their worst week since mid-March, as sobering comments on the pandemic from major U.S. officials pointed to a longer period of economic weakness. | WASHINGTON, May 15 (Reuters) - A top Trump administration official said on Friday the government still has confidence in Abbott Laboratories’ ABT.N speedy coronavirus test, which is used at the White House but which regulators have warned could deliver inaccurate results. The Food and Drug Administration said on Thursday early data about the Abbott ID Now test suggested it could produce potentially inaccurate results, particularly by failing to detect people who have the illness. (Reporting by Tim Ahmann, Editing by Franklin Paul) ((tim.ahmann@thomsonreuters.com; +1 202 898-8370; Reuters Messaging: tim.ahmann.reuters.com@reuters.net)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It has also authorized two highly-accurate tests from Roche and Abbott Laboratories ABT.N, which are able to supply millions of tests per week. Collective Health, a healthcare technology company that has built back-to-work strategies for large companies, is advising employers to use diagnostic tests, not antibody tests. ""There has been a proliferation of low-quality antibody tests and the antibody tests themselves don't necessarily answer any questions about immunity,"" said Rajaie Batniji, Collective Health’s chief health officer. | The Health Care SPDR (XLV) was inactive while the iShares NASDAQ Biotechnology Index (IBB) was 0.74% lower recently Abbott Laboratories (ABT) was down more than 2% after saying the results of a New York University study showing its ID NOW COVID-19 testing technology misses sensitivity marks were not consistent with the results of other studies. Myomo (MYO) was declining more than 6% after it posted a Q1 net loss of $2.51 per share, compared with a loss of $6.82 per share a year earlier. Ocular Therapeutix (OCUL) was 8% higher as it amended its collaboration and licensing deal with Regeneron Pharmaceuticals (REGN) to develop treatments for eye conditions based on Ocular's hydrogel technology and Regeneron's vascular endothelial growth factor-targeting compounds, shifting the collaboration's focus to the research and development of an extended delivery formulation of aflibercept via the suprachoroidal space. | The U.S. Food and Drug Administration alerted the public on Thursday evening that Abbott's (NYSE: ABT) ID NOW coronavirus test could have some serious issues. Researchers from NYU Langone Health ran samples from over 100 patients through Abbott's ID NOW COVID-19 test and then ran the same samples through another rapid point-of-care diagnostic, the Cepheid Xpert Xpress SARS-CoV-2 test using a variety of sample collection techniques. Depending on the technique used, Abbott's test missed between one-third and 48% of the samples that tested positive with Cepheid's test. | Abbott Laboratories ABT.N slipped 2.7% after U.S. Food and Drug Administration (FDA) said the company's speedy coronavirus test could potentially be inaccurate, but can still be used to test patients. By Ambar Warrick and Medha Singh May 15 (Reuters) - Wall Street's main indexes were set to open lower on Friday after the Trump administration's move to block semiconductor shipments to China's Huawei Technologies ratcheted up fears of trade hostilities between Washington and Beijing. In response, the Global Times editor-in-chief said China would activate the ""unreliable entity list"", restrict or investigate U.S. companies such as Qualcomm Inc QCOM.O, Cisco Systems Inc CSCO.O, Apple Inc AAPL.O and suspend the purchase of Boeing Co BA.N airplanes. | Abbott Laboratories ABT.N slipped 3% after U.S. Food and Drug Administration said the company's speedy coronavirus test could potentially be inaccurate, but can still be used to test patients. By Ambar Warrick and Medha Singh May 15 (Reuters) - U.S. stock index futures slipped on Friday after the Trump administration moved to block shipments of semiconductors to China's Huawei Technologies from global chipmakers, a move that could ramp up trade tensions between Washington and Beijing. Still, all three major U.S. stock indexes are set for their worst week since mid-March, as sobering comments on the outbreak from major U.S. officials pointed to a longer period of economic weakness. | It has also authorized two highly-accurate tests from Roche and Abbott Laboratories ABT.N, which are able to supply millions of tests per week. Collective Health, a healthcare technology company that has built back-to-work strategies for large companies, is advising employers to use diagnostic tests, not antibody tests. ""There has been a proliferation of low-quality antibody tests and the antibody tests themselves don't necessarily answer any questions about immunity,"" said Rajaie Batniji, Collective Health’s chief health officer. | Abbott Laboratories ABT.N slipped 3% after U.S. Food and Drug Administration said the company's speedy coronavirus test could potentially be inaccurate, but can still be used to test patients. However, all three major U.S. stock indexes were set for their worst week since mid-March, as sobering comments on the outbreak from major U.S. officials pointed to a longer period of economic weakness, while worries of a renewed Sino-U.S. trade war added to the gloom. S&P 500 e-minis EScv1 were up 4.75 points, or 0.17% and Nasdaq 100 e-minis NQcv1 were up 37 points, or 0.41%. | The Abbott ID NOW point-of-care test may return false negative results, the FDA said. The FDA alert comes a day after New York University researchers reportedly alleged that the Abbott ID NOW test missed a third of samples collected with nasal swabs that tested positive with a test from rival Cepheid. ""While we understand no test is perfect, test outcomes depend on a number of factors including patient selection, specimen type, collection, handling, storage, transport and conformity to the way the test was designed to be run."
2020-05-14,90.5,91.77999877929688,-0.07781202260627956,"U.S. regulator is reviewing Abbott's fast COVID test after studies raise accuracy concerns | Why Co-Diagnostics Stock Is Jumping Today | ITOT, ABT, LLY, AMT: ETF Outflow Alert | CVS Health to launch COVID-19 drive-thru test sites in 5 U.S. states","By Carl O'Donnell May 14 (Reuters) - The U.S. Food and Drug Administration said on Thursday that Abbott Laboratories’ ABT.N speedy coronavirus test, which can deliver results within minutes and is used at the White House, could potentially be inaccurate but can still be used to test patients. Abbott has also criticized the studies, saying in a statement on Thursday that the number of patients studied by NYU was small and that some studies had used the test in ways it was not intended to be. It also said there were other studies that showed a much higher rate of accuracy for its tests, including a study done in a testing clinic in Detroit that said the ID NOW test was accurate 98% of the time. | The big gain appears to be related in part to a New York University Langone Health study that identified possible inaccuracies with Abbott Labs' (NYSE: ABT) ID NOW diagnostics test for novel coronavirus disease COVID-19. The NYU study found that Abbott's ID NOW COVID-19 test missed one-third of samples that were identified as positive for COVID-19 by Danaher's Cepheid Xpert Xpress test. Abbott quickly responded to the NYU study, stating that the results from the study ""are not consistent with other studies."" | Among the largest underlying components of ITOT, in trading today Abbott Laboratories (Symbol: ABT) is off about 2.5%, Lilly (Eli) & Co (Symbol: LLY) is down about 0.6%, and American Tower Corp (Symbol: AMT) is lower by about 2.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P Total U.S. Stock Market ETF (Symbol: ITOT) where we have detected an approximate $150.6 million dollar outflow -- that's a 0.7% decrease week over week (from 363,700,000 to 361,300,000). For a complete list of holdings, visit the ITOT Holdings page » The chart below shows the one year price performance of ITOT, versus its 200 day moving average: Looking at the chart above, ITOT's low point in its 52 week range is $48.52 per share, with $76.57 as the 52 week high point — that compares with a last trade of $61.64. | Last month, the company announced two drive-through testing sites in Georgia and Rhode Island that use Abbott Laboratories' ABT.N diagnostic kit, which can work in 15 minutes. May 14 (Reuters) - CVS Health Corp CVS.N said on Thursday it would roll out more than 50 COVID-19 testing sites at select pharmacy drive-thru locations in five U.S. states, and expects to have up to 1,000 such locations across the country by the end of the month. The new sites will use self-swab tests that will be sent to an independent, third-party lab for processing and the results will be available in about three days, CVS said, adding that it currently operates large-scale rapid testing sites in coordination with five states, which can process a total of nearly 30,000 tests every week."
2020-05-13,93.2699966430664,92.16000366210938,1.4143632920407458,"Abbott's fast COVID test could be missing cases, study says | Thermo Fisher to Turn Coronavirus Antibody Testing on Its Head | Notable Wednesday Option Activity: FLT, ZBRA, ABT","By Michael Erman NEW YORK, May 13 (Reuters) - Abbott Laboratories' ABT.N speedy coronavirus test, which can deliver results within minutes, could be missing a third to nearly half of positive cases, according to a study from New York University researchers published on Wednesday. The study said the Abbott ID NOW COVID-19 test missed around 48% of samples detected positive by Cepheid's Xpert Xpress test from dry nasal swabs and a third of those kept in a substance designed for viral transport. It says another study conducted by the city of Detroit found that the rapid test had 98% accuracy when compared to a molecular lab test. | The Mayo Clinic and WuXi Diagnostics will collaborate with it on the development of the Thermo Fisher Scientific OmniPath COVID-19 Total Antibody ELISA test. The clinical experience of its physicians and the laboratory experience of its scientists could help Thermo Fisher's new antibody test quickly become one of the more popular COVID-19 diagnostics. 10 stocks we like better than Thermo Fisher Scientific When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | Especially high volume was seen for the $115 strike call option expiring June 19, 2020, with 4,273 contracts trading so far today, representing approximately 427,300 underlying shares of ABT. Below is a chart showing ZBRA's trailing twelve month trading history, with the $260 strike highlighted in orange: And Abbott Laboratories (Symbol: ABT) options are showing a volume of 39,041 contracts thus far today. That number of contracts represents approximately 3.9 million underlying shares, working out to a sizeable 40.4% of ABT's average daily trading volume over the past month, of 9.7 million shares."
2020-05-12,96.45999908447266,93.8000030517578,-1.1900857949044936,Abbott: FDA Issues Emergency Use Authorization For Its Fifth COVID-19 Test,"(RTTNews) - Abbott (ABT) reported that the FDA has issued Emergency Use Authorization for the company's molecular test for COVID-19 for use on its new Alinity m molecular laboratory instrument. The Alinity m system is an automated platform, which is able to run up to 1,080 tests in 24 hours. The company's m2000 RealTime system can run up to 480 tests in 24 hours."
2020-05-11,93.22000122070312,96.06999969482422,-2.7576156520439388,Coronavirus Antibody Test From Abbott Receives Emergency Use Authorization | U.S. FDA authorizes use of Abbott's COVID-19 antibody test on second system | Don’t Buy Into the Bitcoin Halvening Hype | FDA Approves Abbott's Covid-19 Antibody Blood Test On Alinity I System,"Wide deployment of Abbott's (NYSE: ABT) freshly authorized SARS-CoV-2 antibody test could help people safely return to some semblance of normal life sooner rather than later. To know if enough people are being tested to spot new outbreaks and hotspots before they spread out of control, public health officials need to see the percentage of positive tests fall to the low single-digit percentage range. See the 10 stocks *Stock Advisor returns as of April 16, 2020 Cory Renauer has no position in any of the stocks mentioned. | May 11 (Reuters) - The U.S. Food and Drug Administration on Monday authorized the emergency use of Abbott Laboratories' ABT.N coronavirus test for detecting antibodies using another of its diagnostic platforms, which will allow the company to ship nearly 30 million tests this month. Abbott also said it could have capacity for shipping 60 million antibody tests across the world in June, which included tests on its Architect system, for which it gained authorization last month. Abbott has previously won U.S. authorization for two other coronavirus testing kits: an automated test that can be used in labs and a test that can deliver results within minutes and be used in physicians' offices, clinics and hospitals. | That sounds enormous, but it’s about the same as Abbott Laboratories (NYSE:ABT). InvestorPlace - Stock Market News, Stock Advice & Trading Tips There is some logic to the idea that bitcoin (CCC:BTC), as an asset class, should do well. On his website Wright not only claims to be the “original” Nakamoto, but says another coin, called bitcoin SV (CCC:BSV), is the “original bitcoin.” Try to run a world economy on that. | (RTTNews) - Abbott has received Emergency Use Authorization from the U.S. Food and Drug Administration for Covid-19 antibody blood test on Alinity i System. The company plans to ship about 30 million antibody tests globally in May across its ARCHITECT and Alinity i platforms and will have capacity for 60 million tests in June. Last month, Abbott received FDA EUA and CE Mark for its SARS-CoV-2 IgG antibody blood test on the ARCHITECT system."
2020-05-08,94.83999633789062,93.6999969482422,3.0572821677759654,Abbott's Coronavirus Antibody Test Proves Highly Accurate | COVID SCIENCE-Abbott coronavirus test is accurate; infected mother's breast milk may protect infants | Study suggests Abbott COVID-19 antibody test highly likely to give correct results,"Researchers from the University of Washington School of Medicine found that the blood test for SARS-CoV-2 antibodies recently launched by Abbott Laboratories (NYSE: ABT) is highly accurate in detecting antibodies in patients tested at least 17 days after the onset of symptoms. The Crush the Curve Idaho initiative -- which only tests people who think they may have had COVID-19 and recovered -- has tested over 10,000 individuals in the Boise area, with 0.71% of them returning positive results. See the 10 stocks *Stock Advisor returns as of April 16, 2020 Jim Crumly has no position in any of the stocks mentioned. | Researchers at the University of Washington School of Medicine found the test, manufactured by Abbott Laboratories ABT.N, had a specificity rate of 99.9% and a sensitivity rate of 100%, suggesting little chance of incorrectly diagnosing a healthy person as having been infected and virtually no chance of a false negative readout. New coronavirus antibody test highly accurate A new antibody test is highly accurate at determining whether people have been infected with the novel coronavirus, according to a study published on Friday in The Journal of Clinical Microbiology. (https://bit.ly/2WHvJcA) Hydroxychloroquine fails to show benefit in hospitalized coronavirus patients In a large observational study of hospitalized coronavirus patients, hydroxychloroquine - an old malaria drug championed by U.S. President Donald Trump as a ""game changer"" in the fight against the virus - neither lessened patients' need for breathing assistance nor their risk of death, according to a report published on Thursday in The New England Journal of Medicine. | May 8 (Reuters) - Abbott Laboratories' ABT.N antibody test for the new coronavirus is highly likely to correctly determine whether people have ever been infected with the fast-spreading virus, the company said, citing a U.S. study. Abbott's test was launched last month under the U.S. Food and Drug Administration's relaxed rules for some coronavirus tests, allowing their distribution before regulatory clearance. Roche Holding AG ROG.S has said its antibody test has a specificity rate of more than 99.8% and sensitivity rate of 100%, and expects to ramp-up production to make more than 100 million tests a month by the end of the year."
2020-05-07,92.13999938964844,93.98999786376952,-1.2020238651073936,,
2020-05-06,93.1500015258789,91.08000183105467,2.007812553045143,3 Dividend Stocks Perfect for Retirees | 3 Best-Performing Dividend Aristocrats of 2020 So Far,"This top healthcare stock won't disappoint you AbbVie (NYSE: ABBV) is a great choice for retirees for two big reasons: Its incredible dividend track record and clout in healthcare, another defensive sector. These dividends should help you during tough times Johnson & Johnson (NYSE: JNJ) increased its dividend by 6% in April, marking its 58th consecutive year of annual dividend increases. See the 10 stocks *Stock Advisor returns as of April 16, 2020 Neha Chamaria has no position in any of the stocks mentioned. | Abbott Labs Abbott Labs (NYSE: ABT) isn't too far behind S&P Global. This is true even for the elite group of stocks known as Dividend Aristocrats, members of the S&P 500 index that have increased their dividends for at least 25 consecutive years. S&P Global S&P Global (NYSE: SPGI) is a true outlier among stocks in the financial sector, with its shares rising close to 8% year to date."
2020-05-05,90.9499969482422,93.02999877929688,-2.222221858202704,"5 Top Stock Trades for Wednesday: ATVI, SHOP, CHGG, ABT, ABBV | 3 Healthcare Stocks Popping Off Support","The post 5 Top Stock Trades for Wednesday: ATVI, SHOP, CHGG, ABT, ABBV appeared first on InvestorPlace. 4: Abbott Labs (ABT) Abbott Labs (NYSE:ABT) made a powerful rally off the March $62.50 low up to the April high near $100. | Here are my three favorite healthcare stocks right now: Eli Lilly (NYSE:LLY) Johnson & Johnson (NYSE:JNJ) Abbott Laboratories (NYSE:ABT) 10 Overleveraged Stocks to Sell For Peace of Mind The lot of them all have low-risk entry points and are popping off support today to confirm the start of the next upswing. Abbott Laboratories (ABT) Source: The thinkorswim® platform from TD Ameritrade Abbott Labs soared to a record high after last month’s earnings report gave investors something to cheer about. ABT stock isn’t wasting time this morning with a 3.10% gain that is powering it back above the 20-day moving average."
2020-05-04,89.79000091552734,89.83000183105469,2.286972953103407,Why Abbott Shares Rose 16.7% in April,"What happened Shares of Abbott Laboratories (NYSE: ABT) rose 16.7% in April, according to data provided by S&P Global Market Intelligence, as the company launched a third coronavirus test and announced work on a fourth. The company launched its first two coronavirus tests in late March and followed up with another test last month. Abbott said during its latestearnings callthat it now is working on a lateral flow serology test that would make mass testing across the entire population possible."
2020-05-01,91.0,89.8499984741211,0.04454940986689133,How The Pieces Add Up: RYH Targets $236,"Similarly, ABT has 12.66% upside from the recent share price of $92.09 if the average analyst target price of $103.75/share is reached, and analysts on average are expecting CERN to reach a target price of $78.16/share, which is 12.63% above the recent price of $69.39. Three of RYH's underlying holdings with notable upside to their analyst target prices are DENTSPLY SIRONA Inc (Symbol: XRAY), Abbott Laboratories (Symbol: ABT), and Cerner Corp. (Symbol: CERN). Below is a twelve month price history chart comparing the stock performance of XRAY, ABT, and CERN: Below is a summary table of the current analyst target prices discussed above:"
2020-04-30,91.8499984741211,92.08999633789062,-1.2637379405262705,"Have $3,000 to Invest? Here Are 3 Top Coronavirus Stocks to Buy Right Now.","Abbott Labs Abbott Labs (NYSE: ABT) introduced its first diagnostic test for COVID-19 on March 18 for its m2000 system after obtaining FDA emergency use authorization (EUA). Gilead Sciences While Abbott Labs has made waves with its COVID-19 diagnostics capabilities, Gilead Sciences (NASDAQ: GILD) has been at the center of attention with its antiviral drug remdesivir. 10 stocks we like better than Gilead Sciences When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen."
2020-04-29,92.08999633789062,92.27999877929688,0.26129326919602625,How Diversification Helps Businesses | Labs see bottlenecks in France's plan to scale-up COVID-19 testing | Something Worse Than the Coronavirus Could Be on the Way -- Here's How You Can Invest Accordingly,"In this episode of Market Foolery, Chris Hill and Motley Fool analyst Ron Gross bring you the latest headlines from the markets. Stock is kind of right in line with the market, year to date down about 11% or so, a little bit weak today on the news about how the rest of the year will shape up. Hill: As always, people on the program may have interests in the stocks they talk about, and The Motley Fool may have formal recommendations for or against, so don't buy or sell stocks based solely on what you hear. | France has authorised about 40 reagents for use in COVID-19 testing, manufactured by large pharmaceutical groups like Switzerland's Roche ROG.S and the United States' Abbott Laboratories ABT.N, as well as small and mid-sized companies. By Matthias Blamont PARIS, April 29 (Reuters) - The leaders of two federations representing thousands of private laboratories across France cast doubt on the country's ability to more than double coronavirus testing before the country begins unwinding its lockdown on May 11. The industry officials cited two looming bottlenecks: a potential shortage of workers able to conduct tests and the availability of government-approved reagents, with countries around the world racing to get hold of testing kits. | Abbott Labs (NYSE: ABT) stands out, in my view, as a company that would be a top contender to quickly develop diagnostics for detecting superbug infections. Redfield expressed optimism that preventing infections, improving antibiotic use, detecting threats, and quickly implementing interventions could save lives and help protect the U.S. and the world from antimicrobial resistance. The Motley Fool owns shares of and recommends Amazon and Emergent BioSolutions and recommends the following options: short January 2022 $1940 calls on Amazon and long January 2022 $1920 calls on Amazon."
2020-04-28,94.87999725341795,91.45999908447266,0.2063225637550309,3 Dividend Stocks Yielding More Than 5% That Are Safe Buys Right Now,"Like AbbVie, AT&T (NYSE: T) is a member of the Dividend Aristocrats club, an elite group of S&P 500 stocks that have raised their dividends for at least 25 years. Brookfield Infrastructure Partners/Brookfield Infrastructure Corporation I've included both Brookfield Infrastructure Partners (NYSE: BIP) and Brookfield Infrastructure Corporation (NYSE: BIPC) on the list of safe high-yield dividend stock to buy. See the 10 stocks *Stock Advisor returns as of April 16, 2020 Keith Speights owns shares of AbbVie, Brookfield Infrastructure, and Brookfield Infrastructure Partners."
2020-04-27,95.4800033569336,94.9499969482422,-3.6045512942108524,"ANALYSIS-Investors bet on testing, treatments for restart of U.S. economy","Test developers include Abbott Laboratories ABT.N and Roche Holding ROG.S. By Sinéad Carew April 26 (Reuters) - Investors are pinning their hopes for the reopening of the U.S. economy on the potential for wider availability of testing for COVID-19 cases and on drug trials for treatments of the deadly disease but said, until there is concrete progress in these areas, further stock market gains may be limited. While there are more than 70 vaccines in development for coronavirus, Manulife Investment Management's Steven Slaughter, who manages a roughly $3.5 billion dedicated healthcare fund said he expects development of a successful vaccine to take at least 12-18 months compared to the average vaccine development time of 5-7 years."
2020-04-24,94.5,94.05999755859376,-0.5550967637800192,"Abbott's COVID-19 Test Is Fast, but Lab Personnel Are Worried About Their Safety | TSX futures rise as oil prices hold on to gains","Abbott Labs (NYSE: ABT) introduced its quick five-minute ID NOW COVID-19 test to diagnose COVID-19, the disease caused by the novel coronavirus, after the Food and Drug Administration gave the test an emergency use authorization last month. When the Department of Health and Human Services announced earlier this month that it was procuring both the ID NOW COVID-19 tests and the ID NOW devices that run the test for public health labs, Indian Health Services, and the Strategic National Stockpile, the agency noted that the test will save on personal protective equipment because ""only gloves and a facemask are necessary to administer this rapid point-of-care test."" See the 10 stocks *Stock Advisor returns as of April 16, 2020 Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. | Absolute Software ABT.TO: National Bank of Canada cuts target price to C$8.5 from C$9.5 Franco-Nevada Corp FNV.TO: CIBC raises target price to C$195 from C$162 Turquoise Hill Resources Ltd TRQ.TO: CIBC raises target price to C$0.8 from C$0.7 COMMODITIES AT 7:00 a.m. April 24 (Reuters) - Canada's main stock index futures pointed to a higher opening on Friday, as oil prices broadly retained their recovery from a price collapse this week, helped by producers such as Kuwait saying they would move to cut output. ET, while S&P 500 e-mini futures ESc1 were up 0.89% and Nasdaq 100 e-mini futures NQc1 were up 0.7%."
2020-04-23,95.87000274658205,93.94000244140624,-0.4656110491071278,Siemens Healthineers joins race to supply coronavirus antibody tests | 3 Dividend Stocks Weathering the Coronavirus Storm | Thinking About Buying Coronavirus Stocks? Answer This Question First | Better Buy: AbbVie vs. Gilead Sciences,"By Ludwig Burger FRANKFURT, April 23 (Reuters) - German diagnostics and medical imaging firm Siemens Healthineers SHLG.DE will launch an antibody test to identify past coronavirus infections, competing with rivals Roche ROG.S and Abbott ABT.N. The test will ""identify individuals infected with the virus who have developed an immune response to the virus, even if they were asymptomatic or never diagnosed with the disease"", Healthineers said. Abbott Laboratories laid out plans last week to produce 20 million antibody tests per month by June, followed by an announcement from Switzerland's Roche that it would also launch such a test next month. | Over the years since AbbVie broke away from Abbott Laboratories (NYSE: ABT) in 2013, the company's dividend payout has risen by a mind-blowing 195%. While there are valid arguments for both the pros and cons of dividend investing in the COVID-19 market, there are still strong dividend stocks to be found for investors with a long-term buying philosophy in mind. Amgen entered the coronavirus bear market from a position of relative strength in fiscal 2020, amassing sales of $6.2 billion in Q4 and total yearly revenue of $23.4 billion. | A coronavirus stock that is worth serious consideration One coronavirus stock I think may be worth buying is Abbott Laboratories (NYSE: ABT). Abbott also boasts a strong balance sheet, and unlike companies such as Moderna, Inovio Pharmaceuticals, and Novavax, Abbott is profitable. See the 10 stocks *Stock Advisor returns as of April 16, 2020 Prosper Junior Bakiny has no position in any of the stocks mentioned. | The acquisition of Allergan offers an exciting boost in growth for a company where revenue has already seen steady gains since the spinoff from Abbott Laboratories (NYSE: ABT) in 2013. The case for AbbVie Blockbuster anti-inflammatory drug Humira, with $19 billion in annual sales, accounts for 60% of AbbVie's annual revenue. Sales of Gilead's blockbuster HIV drug, Biktarvy, quadrupled to $4.7 billion last year from the prior year's level, and EvaluatePharma predicts that number may reach almost $7 billion in 2024."
2020-04-22,94.27999877929688,95.4800033569336,-2.013143058186277,"3 Stocks Hitting All-Time Highs | How Banks Have Prepared for a Slowdown | Abbot Laboratories: COVID-19 Tests Will Drive Further Growth, 5-Star Analyst Raises Price Target","Abbott Laboratories (NYSE: ABT), Dexcom (NASDAQ: DXCM), and MarketAxess Holdings (NASDAQ: MKTX) have never been more highly valued than they are today. That marketwide weakness has knocked down the share price of almost every stock, but a few dozen companies have managed to sidestep the sell-off and are currently trading at all-time highs. This amazing growth propelled Dexcom's stock to new heights all along the way, which made the company one of the best-performing healthcare stocks you could have owned over the past decade. | In this episode of Motley Fool Money, Chris Hill and Motley Fool analysts Jason Moser and Ron Gross discuss the rising stock market and the upcoming earnings season. So there's nothing going on in those first couple of years other than building the software, trying to put the first team together, spending a lot of time with potential customers, or not even customers, because you don't have any customers, but just talking to people about what kinds of problems you would help them solve. I think we were largely talking about if that will happen among public companies and that BlueJeans is, obviously, private, but it's interesting to see Verizon putting some money to work here during a time when maybe BlueJeans valuation was down because the competition was heating up, hard to say, but I think we're going to continue to see lots of these little tuck-in acquisitions. | “Perhaps the most significant takeaways from Q1 results and management commentary related to the substantial increase in volumes and growth in new COVID-19 tests,” the 5-star analyst said, adding, “We view this wave of new tests as a significant new growth driver for ABT over the next 2-3 years, and expect consensus estimates and growth expectations to rise accordingly in the coming months.” Over the past several weeks, Abbot has launched three approved COVID-19 tests; two molecular tests on the company’s ID NOW point-of-care platform and m2000 lab-based platform and a lab-based serology blood test. Unlike other smaller healthcare companies, powerhouse Abbott Laboratories (ABT) hardly needed a global pandemic to raise awareness. “We estimate this wave of COVID-19 tests could reach annual volumes in 2021 of ~50 mil for molecular and ~550 mil serological, driving significant incremental Diagnostics sales of $2.7 bil and 85c to sales and EPS for 2021, respectively, and continued growth in 2022,” Miksic noted."
2020-04-21,96.0999984741211,94.0500030517578,1.2728092842320125,Better Coronavirus Stock: Abbott Labs vs. Moderna | 3 Dividend Stocks I'd Buy Right Now,"Abbott Laboraties (NYSE: ABT) is a key leader on the diagnostics front. The case for Moderna Moderna was among the first drugmakers to launch a program to develop a novel coronavirus vaccine. Better coronavirus stock Moderna has definitely benefited the most so far from its coronavirus programs. | Stable dividend stocks are in short supply lately, but the three stocks listed below offer investors a good mix of value and dividends, and they all look like solid long-term buys. So you may be wondering why, then, Wells Fargo would be on a list of dividend stocks to buy today. With a high dividend and the stock coming off a disappointing quarter, it could be an opportune time to buy the stock at a low."
2020-04-20,94.81999969482422,98.0,-2.1331898594309986,"Monday Sector Leaders: Healthcare, Technology & Communications | Medtronic Shares Ventilator Specs Online | BUZZ-U.S. STOCKS ON THE MOVE-Co-Diagnostics, Xeris Pharma, Cyclacel Pharma | BUZZ-U.S. STOCKS ON THE MOVE-DuPont, Occidental Petroleum, Safe-T Group","Within the sector, Alexion Pharmaceuticals Inc. (Symbol: ALXN) and Abbott Laboratories (Symbol: ABT) are two of the day's stand-outs, showing a gain of 4.6% and 3.8%, respectively. Combined, ALXN and ABT make up approximately 4.7% of the underlying holdings of XLV. Among healthcare ETFs, one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is up 0.2% on the day, and down 0.50% year-to-date. | Abbott Labs (NYSE: ABT) posts strong results across segments. And the airlines have to abide by certain things, such as no furloughing employees through Sept. 30 and limits on dividends and share repurchases and executive comp limitations, all very important things, things that I think the airline should be certainly willing to do for the, you know, $4 billion to $10 billion that each of the majors will receive. Hill: As always, people on the program may have interests in the stocks they talk about, and The Motley Fool may have formal recommendations for or against, so don't buy or sell stocks based solely on what you hear. | The top three S&P 500 .PG.INX percentage gainers: ** FLIR Systems Inc , up 14.7% ** Carrier Global Corp , up 6.6% ** Howmet Aerospace Inc , up 6.4% The top three S&P 500 .PL.INX percentage losers: ** L Brands Inc , down 7.5% ** Vornado Realty Trust , down 6.3% ** Occidental Petroleum Corp , down 6% The top three NYSE .PG.N percentage gainers: ** Regional Health Properties Inc , up 36.5% ** Pacer Developed Markets International Cash CWS , up 23.2% ** Montage Resources Corp , up 23% The top three NYSE .PL.N percentage losers: ** Invesco Mortgage Capital Inc , down 22.5% ** Direxion Daily S&P Biotech Bear 3X Shares , down 16.5% ** Independence Contract Drilling Inc , down 11.9% The top three Nasdaq .PG.O percentage gainers: ** Benitec Biopharma Limited , up 107.4% ** Cyclacel Pharmaceuticals Inc , up 103.8% ** Novavax Inc , up 32.9% The top three Nasdaq .PL.O percentage losers: ** Vericity Inc , down 19.5% ** Akazoo SA , down 19% ** Liberty TripAdvisor Holdings Inc , down 17.9% ** Aytu BioScience Inc AYTU.O: up 3.6% BUZZ-Aytu: Rises on gaining exclusive license to potential COVID-19 treatment ** Redhill Biopharma RDHL.O: up 12.5% BUZZ-Redhill Biopharma: Rises on agreement with NIAID to test cancer drug for COVID-19 ** Atossa Therapeutics Inc ATOS.O: up 5.6% BUZZ-Atossa Therapeutics up as co seeks FDA nod to begin COVID-19 study ** Gilead Sciences Inc GILD.O: down 1.3% BUZZ-Gilead: Brokerages downgrade on uncertainty over commercial value of COVID-19 drug ** Seattle Genetics Inc SGEN.O: up 5.1% BUZZ-Street View: Seattle Genetics' breast cancer therapy approval brings some cheer ** Campbell Soup Co CPB.N: up 3.4% BUZZ-Campbell Soup: Rises on strong retail demand ** Incyte Corp INCY.O: up 1.4% BUZZ-Incyte: Touches fresh 2-yr high after FDA approval of cancer therapy ** ViaSat Inc VSAT.O: up 2.5% BUZZ-ViaSat Inc: Rises as brokerage upgrades on higher residential internet demand ** 2U Inc TWOU.O: down 7.4% BUZZ-2U drops ahead of $300 mln convertible debt deal ** Masimo Corp MASI.O: down 0.4% BUZZ-Masimo Corp: Needham downgrades on likely slow 2H20 growth ** Avalon GloboCare Corp AVCO.O: up 7.9% BUZZ-Avalon GloboCare: Rises as therapy shows promise in combating cytokine storm - Reuters News ** Shake Shack Inc SHAK.N: up 5.9% BUZZ-Shake Shack beefs up capital, gives back government loan; shares dip ** Exelixis Inc EXEL.O: up 23.5% BUZZ-Exelixis jumps as cancer drug combo shows promise in study ** AGNC Investment Corp AGNC.O: down 0.5% ** Annaly Capital Management Inc NLY.N: down 1.8% ** Apollo CRE Finance ARI.N: down 4.9% ** Blackstone Mortgage Trust Inc BXMT.N: down 3.1% ** Ladder Capital Corp LADR.N: down 3.4% ** Starwood Property Trust Inc STWD.N: down 3.9% ** TPG RE Finance Trust Inc TRTX.N: down 3.8% BUZZ-U.S. mortgage REITs: DB cuts PT citing ""stressed scenarios"" ** INmune Bio Inc INMB.O: up 9.3% BUZZ-INmune Bio Inc: Rises on plans to begin COVID-19 trial ** Mustang Bio Inc MBIO.O: up 1.4% BUZZ-Mustang Bio: Rises after EMA's favorable classification of ""bubble boy"" therapy ** Meredith Corp MDP.N: down 6.5% BUZZ-Meredith Corp: Falls on withdrawing 2020 outlook as ad sales get hit ** Lennox International LII.N: up 2.0% BUZZ-Lennox International: Falls on weak Q1, warns of 20% hit from coronavirus ** Ducommun Inc DCO.N: up 3.6% BUZZ-Ducommun: Jumps as Q1 revenue forecast higher than Wall Street estimates ** Alexion Pharmaceuticals Inc ALXN.O: up 4.9% BUZZ-Alexion rises on study to test blood disorder drug for COVID-19 ** Clorox Co CLX.N: up 1.8% BUZZ-Clorox: Up as Deutsche Bank expects strong Q3 helped by coronavirus ** Peloton Interative Inc PTON.O: down 3.2% BUZZ-Peloton skids as BMO slaps with first ""sell"" rating since IPO ** Terex Corp TEX.N: down 4.2% ** Manitowoc Company Inc MTW.N: down 3.4% BUZZ-GS removes Terex and Manitowoc from ""buy list"", downgrades to ""neutral"" ** Anixa Biosciences Inc ANIX.O: up 10.6% BUZZ-Anixa Biosciences: Rises on partnership for potential treatment of COVID-19 ** Cyclacel Pharmaceutical Inc CYCC.O: up 103.8% BUZZ-Cyclacel: Jumps on deal to study drugs to treat COVID-19 patients ** Boeing Co BA.N: down 4.9% BUZZ-Benchmark sees Boeing cut 787 production by 30%; lowers PT ** Eros International EROS.N: down 0.2% BUZZ-Eros International: Soars after deal to merge with STX Entertainment ** Medpace Holdings Inc MEDP.O: down 0.8% ** ICON Plc ICLR.O: down 0.4% BUZZ-Baird downgrades two contract research organizations on COVID-19 impact ** Xeris Pharmaceutical Inc XERS.O: up 15.1% BUZZ-Xeris Pharma: Rises on positive results from seizure medication study ** United Airlines Holdings Inc UAL.O: down 3.4% BUZZ-United Airlines drops on estimated quarterly loss, dour outlook ** Walt Disney Co DIS.N: down 2.3% BUZZ-Disney: Falls as brokerages move to sidelines citing hit to theme parks ** Cheesecake Factory Inc CAKE.O: up 5.9% BUZZ-Cheesecake Factory: Rises on $200 mln investment from Roark Capital ** Exxon Mobil Corp XOM.N: down 3.0% ** Chevron Corp CVX.N: down 1.8% ** Devon Energy Corp DVN.N: down 0.4% ** Callon Petroleum Co CPE.N: down 3.4% ** Chesapeake Energy Corp CHK.N: down 1.5% ** Occidental Petroleum Corp OXY.N: down 6.1% ** Schlumberger NV SLB.N: flat ** Halliburton Co HAL.N: up 0.1% ** TechnipFMC Plc FTI.N: down 1.4% BUZZ-Oil stocks drop as concerns over rising crude storage weigh on prices BUZZ-Street View: Schlumberger's dividend cut the first step on road to recovery BUZZ-Halliburton: Falls on $1.1 bln impairment charges ** Safe-T Group SFET.O: up 18.2% BUZZ-Safe-T Group: Jumps on upbeat Q1 revenue forecast ** AbbVie Inc ABBV.N: up 1.8% BUZZ-AbbVie Inc: RBC expects rebound in 2021, upgrades to ""outperform"" ** Facebook Inc FB.O: flat BUZZ-Facebook: Credit Suisse cuts PT as coronavirus impacts ad revenue ** Biogen Inc BIIB.O: up 1.3% BUZZ-Biogen Inc: Alzheimer's drug in focus ahead of Q1, not earnings ** Abbott Laboratories ABT.N: up 3.9% BUZZ-Abbott, Roche to benefit from surging demand for COVID-19 antibody tests - analyst ** DuPont de Nemours Inc DD.N: up 5.5% BUZZ-DuPont: Rises on expectations of stronger Q1 from coronavirus-driven demand ** Co-Diagnostics Inc CODX.O: up 17.4% BUZZ-Co-Diagnostics: Rises on increased U.S. sales of COVID-19 testing kits ** Acadia Healthcare Co Inc ACHC.O: down 0.1% ** Brookdale Senior Living Inc BKD.N: down 3.2% ** Ensign Group Inc ENSG.O: down 0.4% ** Select Medical Holdings Corp SEM.N: down 4.1% BUZZ-Strong headwinds imminent for facility-based health care providers - Analyst ** General Motors Co GM.N: flat ** Ford Motor Co F.N: down 1.7% BUZZ-CS cuts PT on Ford, GM on heavy cash burn in H1 2020 ** Royal Caribbean Cruises Ltd RCL.N: down 3.4% ** Norwegian Cruise Line Holdings Ltd NCLH.N: down 4.9% ** Carnival Corp CCL.N: down 1.4% BUZZ-J.P. Morgan slashes cruise operators' PT on virus impact The 11 major S&P 500 sectors: Communication Services down 1.01% Information Technology down 0.52% Real Estate | The top three S&P 500 .PG.INX percentage gainers: ** FLIR Systems Inc , up 14.1% ** Carrier Global Corp , up 6.6% ** DuPont de Nemours Inc, up 5% The top three S&P 500 .PL.INX percentage losers: ** Vornado Realty Trust , down 4.9% ** Lennar Corporation , down 4.7% ** Occidental Petroleum Corp , down 4.7% The top three NYSE .PG.N percentage gainers: ** Regional Health Properties Inc , up 41.6% ** Montage Resources Corp , up 26.8% ** Build-A-Bear Workshop Inc , up 26.2% The top three NYSE .PL.N percentage losers: ** Invesco Mortgage Capital Inc , down 19.5% ** Direxion Daily S&P Biotech Bear 3X Shares , down 13% ** Manning & Napier Inc , down 12.7% The top three Nasdaq .PG.O percentage gainers: ** Cyclacel Pharmaceuticals Inc , up 89.5% ** American Virtual Cloud Technologies Inc , up 43.8% ** Benitec Biopharma Limited , up 42.9% The top three Nasdaq .PL.O percentage losers: ** Liberty TripAdvisor Holdings Inc , down 18.4% ** BiondVax Pharmaceuticals Equity Warrants , down 15% ** Green Plains Partners LP , down 14% ** Avalon GloboCare Corp AVCO.O: up 12.9% BUZZ-Avalon GloboCare: Rises as therapy shows promise in combating cytokine storm ** Shake Shack Inc SHAK.N: up 6.3% BUZZ-Shake Shack beefs up capital, gives back government loan ** Exelixis Inc EXEL.O: up 25.5% BUZZ-Exelixis jumps as cancer drug combo shows promise in study ** AGNC Investment Corp AGNC.O: up 0.1% ** Annaly Capital Management Inc NLY.N: up 0.2% ** Apollo CRE Finance ARI.N: down 3.7% ** Blackstone Mortgage Trust Inc BXMT.N: down 3.0% ** Ladder Capital Corp LADR.N: flat ** Starwood Property Trust Inc STWD.N: down 2.1% ** TPG RE Finance Trust Inc TRTX.N: down 3.0% BUZZ-U.S. mortgage REITs: DB cuts PT citing ""stressed scenarios"" ** INmune Bio Inc INMB.O: up 7.1% BUZZ-INmune Bio Inc: Rises on plans to begin COVID-19 trial ** Mustang Bio Inc MBIO.O: up 2.4% BUZZ-Mustang Bio: Rises after EMA's favorable classification of ""bubble boy"" therapy ** Meredith Corp MDP.N: down 9.7% BUZZ-Meredith Corp: Falls on withdrawing 2020 outlook as ad sales get hit ** Ducommun Inc DCO.N: up 4.6% BUZZ-Ducommun: Jumps as Q1 revenue forecast higher than Wall Street estimates ** Alexion Pharmaceuticals Inc ALXN.O: up 4.4% BUZZ-Alexion rises on study to test blood disorder drug for COVID-19 ** Clorox Co CLX.N: up 1.9% BUZZ-Clorox: Up as Deutsche Bank expects strong Q3 helped by coronavirus ** Peloton Interative Inc PTON.O: down 4.5% BUZZ-Peloton skids as BMO slaps first ""sell"" rating since IPO ** Terex Corp TEX.N: down 4.7% ** Manitowoc Company Inc MTW.N: down 2.5% BUZZ-GS removes Terex and Manitowoc from ""buy list"", downgrades to ""neutral"" ** Anixa Biosciences Inc ANIX.O: up 11.6% BUZZ-Anixa Biosciences: Rises on partnership for potential treatment of COVID-19 ** Cyclacel Pharmaceutical Inc CYCC.O: up 89.5% BUZZ-Cyclacel: Jumps on deal to study drugs to treat COVID-19 patients ** Boeing Co BA.N: down 3.1% BUZZ-Benchmark sees Boeing cut 787 production by 30%; lowers PT ** Eros International EROS.N: up 9.0% BUZZ-Eros International: Soars after deal to merge with STX Entertainment ** Medpace Holdings Inc MEDP.O: down 1.9% ** ICON Plc ICLR.O: up 0.1% BUZZ-Baird downgrades two contract research organizations on COVID-19 impact ** Xeris Pharmaceutical Inc XERS.O: up 10.2% BUZZ-Xeris Pharma: Rises on positive results from seizure medication study ** United Airlines Holdings Inc UAL.O: down 3.2% BUZZ-United Airlines drops on estimated quarterly loss, dour outlook ** Walt Disney Co DIS.N: down 2.8% BUZZ-Disney: Falls as brokerages move to sidelines citing hit to theme parks ** Cheesecake Factory Inc CAKE.O: up 7.6% BUZZ-Cheesecake Factory: Rises on $200 mln investment from Roark Capital ** Exxon Mobil Corp XOM.N: down 2.2% ** Chevron Corp CVX.N: down 1.0% ** Devon Energy Corp DVN.N: up 1.1% ** Callon Petroleum Co CPE.N: down 2.5% ** Chesapeake Energy Corp CHK.N: down 1.0% ** Occidental Petroleum Corp OXY.N: down 4.8% ** Schlumberger NV SLB.N: up 0.4% ** Halliburton Co HAL.N: up 3.5% ** TechnipFMC Plc FTI.N: down 0.5% BUZZ-Oil stocks drop as concerns over rising crude storage weigh on prices BUZZ-Street View: Schlumberger's dividend cut the first step on road to recovery BUZZ-Halliburton: Falls on $1.1 bln impairment charges ** Safe-T Group SFET.O: up 17.6% BUZZ-Safe-T Group: Jumps on upbeat Q1 revenue forecast ** AbbVie Inc ABBV.N: up 0.3% BUZZ-AbbVie Inc: RBC expects rebound in 2021, upgrades to ""outperform"" ** Facebook Inc FB.O: up 0.3% BUZZ-Facebook: Credit Suisse cuts PT as coronavirus impacts ad revenue ** Biogen Inc BIIB.O: up 1.5% BUZZ-Biogen Inc: Alzheimer's drug in focus ahead of Q1, not earnings ** Abbott Laboratories ABT.N: up 1.0% BUZZ-Abbott, Roche to benefit from surging demand for COVID-19 antibody tests - analyst ** DuPont de Nemours Inc DD.N: up 5.0% BUZZ-DuPont: Rises on expectations of stronger Q1 from coronavirus-driven demand ** Co-Diagnostics Inc CODX.O: up 13.8% BUZZ-Co-Diagnostics: Rises on increased U.S. sales of COVID-19 testing kits ** Acadia Healthcare Co Inc ACHC.O: up 0.4% ** Brookdale Senior Living Inc BKD.N: down 1.8% ** Ensign Group Inc ENSG.O: down 1.2% ** Select Medical Holdings Corp SEM.N: down 3.6% BUZZ-Strong headwinds imminent for facility-based health care providers - Analyst ** General Motors Co GM.N: down 0.3% ** Ford Motor Co F.N: down 1.2% BUZZ-CS cuts PT on Ford, GM on heavy cash burn in H1 2020 ** Royal Caribbean Cruises Ltd RCL.N: down 1.6% ** Norwegian Cruise Line Holdings Ltd NCLH.N: down 2.7% ** Carnival Corp CCL.N: down 1.4% BUZZ-J.P. Morgan slashes cruise operators' PT on virus impact The 11 major S&P 500 sectors: Communication Services down 0.15% Consumer Discretionary up 0.32% Consumer Staples"
2020-04-17,97.4499969482422,96.01000213623048,3.353723175923362,"BUZZ-U.S. STOCKS ON THE MOVE-Schlumberger, Banks, Spirit AeroSystems, State Street | BUZZ-U.S. STOCKS ON THE MOVE-Netflix, Cutera, Moderna | BUZZ-U.S. STOCKS ON THE MOVE-Schlumberger, Biohaven Pharmaceutical, Spirit AeroSystems | ITOT, ABT, COST, AMGN: ETF Outflow Alert | BUZZ-U.S. STOCKS ON THE MOVE-Pulmatrix, Cutera, Moderna, Spirit AeroSystems | Switzerland's Roche joins global race to make coronavirus antibody tests | Switzerland's Roche joins race to make coronavirus antibody tests | Abbott Laboratories Reaches Analyst Target Price","The top three NYSE percentage gainers premarket .PRPG.NQ: ** AMC Entertainment Holdings Inc AMC.N, up 58.6% ** Silvergate Capital Corp SI.N, up 34.6% ** Regis Corp RGS.N, up 20.3% The top three NYSE percentage losers premarket .PRPL.NQ: ** Velocity Financial Inc VEL.N, down 15.6% ** Medley Capital Corp MCC.N, down 9.1% ** Mueller Industries Inc MLI.N, down 7.6% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Allegro Merger Corp ALGRR.O, up 1,022.4% ** Allegro Merger Equity Warrants ALGRW.O, up 733.3% ** Inspired Entertainment Inc INSE.O, up 43.7% The top three Nasdaq percentage losers premarket .PRPL.O: ** Liberty TripAdvisor Holdings LTRPB.O, down 33.9% ** Keros Therapeutics Inc KROS.O, down 37.3% ** Coffee Holding Co Inc JVA.O, down 34.5% ** State Street STT.N: up 7.8% premarket BUZZ-Eyes one-month high on Q1 beat ** Biohaven Pharma BHVN.N: up 5.5% premarket BUZZ-Rises as Cowen starts with ""outperform"" on migraine drug's potential ** Schlumberger SLB.N: up 3.9% premarket BUZZ-Rises as Q1 profit scrapes past expectations ** Regeneron Pharma REGN.O: up 2.4% premarket BUZZ-BMO hikes PT as eye drug appears safer than rival ** Caesars Entertainment Corp CZR.O: up 4.5% premarket BUZZ-SunTrust upgrades casino operators Twin River and Caesars to ""buy"" ** The Stars Group TSG.O: up 13.3% premarket BUZZ-The Stars Group jumps on upbeat Q1 revenue forecast ** Goldman Sachs GS.N: up 3.8% premarket ** JPMorgan JPM.N: up 5.4% premarket ** Citi C.N: up 6.4% premarket ** Wells Fargo WFC.N: up 5.8% premarket ** Bank of America BAC.N: up 5.2% premarket ** Morgan Stanley MS.N: up 5.2% premarket BUZZ-U.S. big banks rise amid broad-market gains, higher Treasury yields BUZZ-Street View: Morgan Stanley's online platforms stable, but near-term outlook muted ** Spirit AeroSystems SPR.N: up 10.5% premarket BUZZ-Lifts off on Boeing's plan to restart production ** Kohl's Corp KSS.N: up 10.4% premarket BUZZ-Shares rise; lands new $1.5 bln credit line ** EPR Properties EPR.N: up 11.1% premarket BUZZ-Brokerages cut PT on concerns of rent deferment ** Pulmatrix Inc PULM.O: down 27.1% premarket BUZZ-Tumbles on direct stock-and-warrants offering ** Las Vegas Sands Corp LVS.N: up 4.6% premarket BUZZ-Says Asia expansion on track, shares rise ** Cutera CUTR.O: down 16.6% premarket BUZZ-Drops on deep-discounted stock deal ** Edwards Lifesciences EW.N: up 2.5% premarket BUZZ-SVB upgrades on likely sharper post-COVID recovery ** Gilead Sciences GILD.O: up 9.7% premarket BUZZ-Street View: Report on Gilead's coronavirus drug adds confusion, not confidence ** Moderna MRNA.O: up 18.6% premarket BUZZ-Jumps on $483 mln award to accelerate COVID-19 vaccine development ** Abbott Laboratories ABT.N: up 1.5% premarket BUZZ-Street View: Abbott shows strength across businesses amid coronavirus storm ** BlackRock BLK.N: up 2.8% premarket BUZZ-Street View: BlackRock will brace the turmoil like a rock (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ET, Dow e-minis 1YMc1 were up 2.94% at 24,094. S&P 500 e-minis ESc1 were up 2.52% at 2,857.75, while Nasdaq 100 e-minis NQc1 were up 1.63% at 8,876.75. | The top three S&P 500 .PG.INX percentage gainers: ** TransDigm Group Corp , up 13.7% ** HollyFrontier Corp , up 13.5% ** Citizens Financial Group Inc , up 13.3% The top three S&P 500 .PL.INX percentage losers: ** Netflix Inc , down 4.1% ** Electronic Arts Inc , down 3.7% ** Activision Blizzard Inc , down 3% The top three NYSE .PG.N percentage gainers: ** Wideopenwest Inc , up 34.2% ** Silvergate Capital Corp, up 34% ** AMC Entertainment Holdings , up 28.5% The top three NYSE .PL.N percentage losers: ** VelocityShares 3x Inverse Natural Gas , down 15.3% ** Direxion Daily S&P Oil & Gas , down 15.1% ** Casper Sleep Inc , down 14.1% The top three Nasdaq .PG.O percentage gainers: ** Golden Bull Ltd , up 49.2% ** Genetic Technologies Ltd , up 41.4% ** Surgery Partners Inc , up 33.2% The top three Nasdaq .PL.O percentage losers: ** Cutera Inc , down 20.1%- ** Liberty TripAdvisor Holdings , down 18.6% ** RedHill Biopharma Ltd , down 14.6% ** Netflix Inc NFLX.O: down 4.1% BUZZ-Netflix loses ground, analyst starts with sell rating ** MGM Resorts International MGM.N: up 2.6% ** Wynn Resorts Ltd WYNN.O: up 6.6% ** Las Vegas Sands Corp LVS.N: up 4.7% ** Melco Resorts & Entertainment Ltd MLCO.O: up 4.3% ** Carnival Corp CCL.N: up 5.8% ** Royal Caribbean Cruises Ltd RCL.N: up 8.8% ** Norwegian Cruise Line Holdings NCLH.N: up 8.5% ** American Airlines Group Inc AAL.O: up 5.4% ** Delta Air Lines Inc DAL.N: up 6.0% ** United Airlines Holdings Inc UAL.O: up 4.1% ** Hilton Worldwide Holdings Inc HLT.N: up 6.7% ** Marriott International Inc MAR.O: up 4.7% ** Hyatt Hotels Corp H.N: up 4.5% BUZZ-U.S. casino, travel stocks jump on hopes of COVID-19 treatment BUZZ-Las Vegas Sands Corp says Asia expansion on track, shares rise ** Moderna Inc MRNA.O: up 17.6% BUZZ-Street View: U.S. BARDA award puts spotlight on Moderna's coronavirus vaccine BUZZ-Moderna: Jumps on $483 mln award to accelerate COVID-19 vaccine development ** Planet Fitness Inc PLNT.N: up 11.0% BUZZ-Planet Fitness jumps on Trump's plan to end shutdown; Peloton backpedals ** AMC Entertainment Holdings AMC.N: up 28.5% ** IMAX Corp IMAX.N: up 6.4% ** Cinemark Holdings Inc CNK.N: up 15.5% BUZZ-Cinemas: Set for blockbuster day on Trump's plan to end shutdown ** Cree Inc CREE.O: down 0.3% BUZZ-Cree flat after $500 mln liquidity boost, JP Morgan PT hike ** Kansas City Southern KSU.N: up 2.8% BUZZ-Kansas City Southern rises as higher Mexico shipments drive Q1 beat ** Corteva Inc CTVA.N: up 0.6% BUZZ-Corteva: BofA cuts to ""neutral"" on long-term concerns ** Prudential Financial Inc PRU.N: up 6.2% ** MetLife Inc MET.N: up 5.7% ** American International Group AIG.N: up 4.0% ** Travelers Companies Inc TRV.N: up 3.5% BUZZ-U.S. insurers rise as broader market gains ** Biohaven Pharmaceutical Holding Co BHVN.N: up 10.0% BUZZ-Biohaven Pharma: Rises as Cowen starts with ""outperform"" on migraine drug's potential ** Schlumberger NV SLB.N: up 6.5% BUZZ-Schlumberger: Rises as Q1 profit scrapes past expectations ** Regeneron Pharmaceuticals Inc REGN.O: up 4.5% BUZZ-Regeneron Pharma: BMO hikes PT as eye drug appears safer than rival ** Twin River Worldwide Holdings TRWH.N: up 1.1% Caesars Entertainment Corp CZR.O: up 3.8% BUZZ-SunTrust upgrades casino operators Twin River and Caesars to ""buy"" ** The Stars Group TSG.O: up 17.4% BUZZ-The Stars Group jumps on upbeat Q1 revenue forecast ** Goldman Sachs Group Inc GS.N: up 1.1% ** JPMorgan Chase & Co JPM.N: up 6.6% ** Citigroup Inc C.N: up 8.7% ** Wells Fargo & Co WFC.N: up 4.7% ** Bank of America Corp BAC.N: up 6.6% ** Morgan Stanley MS.N: up 0.2% BUZZ-U.S. big banks rise amid broad-market gains, higher Treasury yields BUZZ-Street View: Morgan Stanley's online platforms stable, but near-term outlook muted ** Spirit AeroSystems SPR.N: up 14.5% BUZZ-Spirit AeroSystems: Lifts off on Boeing's plan to restart production ** Kohls Corp KSS.N: up 6.4% BUZZ-Kohls Corp: Shares rise; lands new $1.5 bln credit line ** EPR Properties EPR.N: up 12.3% BUZZ-EPR Properties: Brokerages cut PT on concerns of rent deferment ** Pulmatrix Inc PULM.O: down 27.4% BUZZ-Pulmatrix Inc: Tumbles on direct stock-and-warrants offering ** Cutera Inc CUTR.O: down 20.1% BUZZ-Cutera drops on deep-discounted stock deal ** Edwards Lifesciences EW.N: up 4.6% BUZZ-Edwards Lifesciences: SVB upgrades on likely sharper post-COVID recovery ** Gilead Sciences GILD.O: up 9.0% BUZZ-Street View: Report on Gilead's coronavirus drug adds confusion, not confidence ** Apple Inc AAPL.O: down 2.1% BUZZ-Apple Inc: Goldman Sachs downgrades to ""sell"" on coronavirus fears ** Abbott Laboratories ABT.N: flat BUZZ-Street View: Abbott shows strength across businesses amid coronavirus storm ** Procter & Gamble PG.N: up 1.3% BUZZ-Procter & Gamble: Rises on profit beat as consumers stock up essentials ** BlackRock Inc BLK.N: up 4.1% BUZZ-Street View: BlackRock will brace the turmoil like a rock The 11 major S&P 500 sectors: Communication Services up 0.60% Energy up 3.24% Real Estate | The top three S&P 500 .PG.INX percentage gainers: ** Citizens Financial Group Inc , up 14% - ** Boeing Co , up 12.4%- ** HollyFrontier Corp , up 11.5% The top three S&P 500 .PL.INX percentage losers: ** Netflix Inc , down 4.8% - ** Activision Blizzard Inc , down 4.2% ** Electronic Arts Inc , down 4.2% The top three NYSE .PG.N percentage gainers: ** AMC Entertainment Holdings , up 30.7% - ** Silvergate Capital Corp , up 30% ** Triumph Group Inc , up 23.5% - The top three NYSE .PL.N percentage losers: ** VelocityShares 3x Inverse Natural Gas , down 15.3% ** Casper Sleep Inc , down 13.6% - ** ProShares UltraShort Oil & Gas , down 11.4% The top three Nasdaq .PG.O percentage gainers: ** Genetic Technolgies Ltd , up 43.2% ** Surgery Partners Inc , up 42.1% ** Golden Bull Ltd , up 30.6% The top three Nasdaq .PL.O percentage losers: ** Liberty TripAdvisor Holdings , down 22% ** Cutera Inc , down 18.7% - ** RedHill Biopharma Ltd , down 15.8% ** AMC Entertainment Holdings AMC.N: up 31.1% ** IMAX Corp IMAX.N: up 4.2% ** Cinemark Holdings Inc CNK.N: up 12.0% BUZZ-Cinemas: Set for blockbuster day on Trump's plan to end shutdown ** Cree Inc CREE.O: down 0.4% BUZZ-Cree flat after $500 mln liquidity boost, JP Morgan PT hike ** Kansas City Southern KSU.N: up 2.2% BUZZ-Kansas City Southern rises as higher Mexico shipments drive Q1 beat ** Corteva Inc CTVA.N: up 0.8% BUZZ-Corteva: BofA cuts to ""neutral"" on long-term concerns ** Prudential Financial Inc PRU.N: up 6.0% ** MetLife Inc MET.N: up 5.75% ** American International Group AIG.N: up 3.45% ** Travelers Companies Inc TRV.N: up 2.43% BUZZ-U.S. insurers rise as broader market gains ** State Street Corp STT.N: up 0.2% BUZZ-State Street: Eyes one-month high on Q1 beat ** Biohaven Pharmaceutical Holding Co BHVN.N: up 8.5% BUZZ-Biohaven Pharma: Rises as Cowen starts with ""outperform"" on migraine drug's potential ** Schlumberger NV SLB.N: up 6.8% BUZZ-Schlumberger: Rises as Q1 profit scrapes past expectations ** Regeneron Pharmaceuticals Inc REGN.O: up 3.5% BUZZ-Regeneron Pharma: BMO hikes PT as eye drug appears safer than rival ** Twin River Worldwide Holdings TRWH.N: up 0.7% Caesars Entertainment Corp CZR.O: up 3.2% BUZZ-SunTrust upgrades casino operators Twin River and Caesars to ""buy"" ** The Stars Group TSG.O: up 16.7% BUZZ-The Stars Group jumps on upbeat Q1 revenue forecast ** Goldman Sachs Group Inc GS.N: up 1.1% ** JPMorgan Chase & Co JPM.N: up 6.5% ** Citigroup Inc C.N: up 8.7% ** Wells Fargo & Co WFC.N: up 4.9% ** Bank of America Corp BAC.N: up 6.5% ** Morgan Stanley MS.N: up 0.8% BUZZ-U.S. big banks rise amid broad-market gains, higher Treasury yields BUZZ-Street View: Morgan Stanley's online platforms stable, but near-term outlook muted ** Spirit AeroSystems SPR.N: up 18.2% BUZZ-Spirit AeroSystems: Lifts off on Boeing's plan to restart production ** Kohls Corp KSS.N: up 5.5% BUZZ-Kohls Corp: Shares rise; lands new $1.5 bln credit line ** Pulmatrix Inc PULM.O: down 27.0% BUZZ-Pulmatrix Inc: Tumbles on direct stock-and-warrants offering ** Las Vegas Sands Corp LVS.N: up 3.3% BUZZ-Las Vegas Sands Corp says Asia expansion on track, shares rise ** Cutera Inc CUTR.O: down 18.7% BUZZ-Cutera drops on deep-discounted stock deal ** Edwards Lifesciences EW.N: up 4.1% BUZZ-Edwards Lifesciences: SVB upgrades on likely sharper post-COVID recovery ** Gilead Sciences GILD.O: up 8.2% BUZZ-Street View: Report on Gilead's coronavirus drug adds confusion, not confidence ** Moderna Inc MRNA.O: up 14.2% BUZZ-Moderna: Jumps on $483 mln award to accelerate COVID-19 vaccine development ** Apple Inc AAPL.O: down 2.1% BUZZ-Apple Inc: Goldman Sachs downgrades to ""sell"" on coronavirus fears ** Abbott Laboratories ABT.N: down 0.3% BUZZ-Street View: Abbott shows strength across businesses amid coronavirus storm ** BlackRock Inc BLK.N: up 4.0% BUZZ-Street View: BlackRock will brace the turmoil like a rock The 11 major S&P 500 sectors: Communication Services up 0.66% Consumer Discretionary up 0.78% Consumer Staples | Among the largest underlying components of ITOT, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.6%, Costco Wholesale Corp (Symbol: COST) is down about 1%, and Amgen Inc (Symbol: AMGN) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P Total U.S. Stock Market ETF (Symbol: ITOT) where we have detected an approximate $543.0 million dollar outflow -- that's a 2.3% decrease week over week (from 375,800,000 to 367,000,000). For a complete list of holdings, visit the ITOT Holdings page » The chart below shows the one year price performance of ITOT, versus its 200 day moving average: Looking at the chart above, ITOT's low point in its 52 week range is $48.52 per share, with $76.57 as the 52 week high point — that compares with a last trade of $62.87. | The top three NYSE percentage gainers premarket .PRPG.NQ: ** Mohawk Industries Inc , up 3.4% ** AMC Entertainment Holdings , up 55.7% ** Ashford Hospitality Trust , up 29% The top three NYSE percentage losers premarket .PRPL.NQ: ** Velocity Financial Inc , down 15.6% ** Castlight Health Inc , down 7.7% ** Nautilus Inc , down 4.7% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Allegro Merger Corp , up 185.7% ** Allegro Merger Equity Warrants , up 316.7% ** IZEA Worldwide Inc , up 72% The top three Nasdaq percentage losers premarket .PRPL.O: ** Coffee Holding Co , down 34.5% ** Stein Mart Inc , down 23.8% ** Pegasystems Inc , down 29.5% ** Goldman Sachs GS.N: up 4.5% premarket JPMorgan JPM.N: up 5.2% premarket Citi C.N: up 5.9% premarket Wells Fargo WFC.N: up 6.1% premarket Bank of America BAC.N: up 5.7% premarket Morgan Stanley MS.N: up 4.9% premarket BUZZ-U.S. big banks rise amid broad-market gains, higher Treasury yields ** Spirit AeroSystems SPR.N: up 10.0% premarket BUZZ-Spirit AeroSystems: Lifts off on Boeing's plan to restart production ** Kohls Corp KSS.N: up 10.4% premarket BUZZ-Kohls Corp: Shares rise; lands new $1.5 bln credit line ** EPR Properties EPR.N: up 10.6% premarket BUZZ-EPR Properties: Brokerages cut PT on concerns of rent deferment ** Pulmatrix Inc PULM.O: down 27.1% premarket BUZZ-Pulmatrix Inc: Tumbles on direct stock-and-warrants offering ** Las Vegas Sands Corp LVS.N: up 4.9% premarket BUZZ-Las Vegas Sands Corp says Asia expansion on track, shares rise ** Cutera CUTR.O: down 13.6% premarket BUZZ-Cutera drops on deep-discounted stock deal ** Edwards Lifesciences EW.N: up 3.0% premarket BUZZ-Edwards Lifesciences: SVB upgrades on likely sharper post-COVID recovery ** Gilead Sciences GILD.O: up 12.2% premarket BUZZ-Street View: Report on Gilead's coronavirus drug adds confusion, not confidence ** Moderna MRNA.O: up 18.2% premarket BUZZ-Moderna: Jumps on $483 mln award to accelerate COVID-19 vaccine development ** Abbott Laboratories ABT.N: up 1.0% premarket BUZZ-Street View: Abbott shows strength across businesses amid coronavirus storm ** BlackRock BLK.N: up 3.5% premarket BUZZ-Street View: BlackRock will brace the turmoil like a rock ** Morgan Stanley MS.N: up 4.9% premarket BUZZ-Street View: Morgan Stanley's online platforms stable, but near-term outlook muted (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. .N At 8:13 ET, Dow e-minis 1YMc1 were up 3.14% at 24,142. S&P 500 e-minis ESc1 were up 2.79% at 2,865.25, while Nasdaq 100 e-minis NQc1 were up 1.87% at 8,898. | Roche's announcement on Friday follows others including U.S.-based Abbott Laboratories ABT.N, Becton Dickinson and Co BDX.N, Italy's DiaSorin DIAS.MI that aim to develop and sell tests to identify antibodies. By John Miller ZURICH, April 17 (Reuters) - Swiss drugmaker Roche ROG.S aims next month to be able to offer blood tests to identify those who have been infected with the coronavirus, joining a huge global push to inform locked-down nations about who might have some immunity and return to work. Amazon.com AMZN.O has voiced interest in testing, but in Spain, the purchase by Siemens wind turbine maker Siemens Gamesa Renewable Energy SA SGREN.MC of 2,000 assays to test employees, prompted the Spanish government to requisition the tests, union leaders said. | Roche joins a global race in which U.S.-based Abbott Laboratories ABT.N and Becton Dickinson and Co BDX.N, Italy's DiaSorin DIAS.MI and others hope to sell tests that demonstrate people's immune systems have developed antibodies in response to the new coronavirus. By John Miller ZURICH, April 17 (Reuters) - Swiss drugmaker Roche ROG.S aims by next month to offer blood tests to identify those who had been infected with the coronavirus, potentially helping inform locked-down nations of who might have some immunity and be able to resume work or contact with the public. Roche's test, which differs from the PCR assays it also makes that use a nose swab to identify active infections, will run on more than 40,000 of its cobas e testing machines installed worldwide. | And so with ABT crossing above that average target price of $92.00/share, investors in ABT have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $92.00 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? In recent trading, shares of Abbott Laboratories (Symbol: ABT) have crossed above the average analyst 12-month target price of $92.00, changing hands for $96.00/share. But the whole reason to look at the average ABT price target in the first place is to tap into a ""wisdom of crowds"" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes."
2020-04-16,92.5999984741211,96.0,-1.477675584511851,"Abbott beats quarterly profit, but pulls forecast on coronavirus concerns | Thursday Sector Leaders: Healthcare, Technology & Communications | Good News for COVID-19 Testing Companies: Medicare Nearly Doubles Reimbursement | Abbott Labs Soars After Pandemic Buying Boosts Results | BUZZ-U.S. STOCKS ON THE MOVE-Roku, Rite Aid, Jack in the Box, ThermoGenesis | Abbott Laboratories (ABT) Q1 2020 Earnings Call Transcript | Here's Why Investors Liked Abbott Labs' Q1 Earnings Results | Triage Your Portfolio With Abbott Laboratories | S&P 500 Movers: UAL, ABT | BUZZ-U.S. STOCKS ON THE MOVE-Edison Nation, Soligenix, Arcus Biosciences, Bed Bath & Beyond | 5 Dividend Aristocrats Where Analysts See Capital Gains | US STOCKS-Lockdown easing hopes lift futures ahead of jobless claims | 3 Great Stocks That Are Still Ridiculously Cheap Right Now | Abbott posts 16% fall in profit, suspends 2020 forecast on coronavirus concerns | Abbott Laboratories Q1 adjusted earnings Beat Estimates | How Safe Are AbbVie Stock and Its Dividend? | U.S. stock index futures gain ahead of earnings reports, jobless claims | Abbott Laboratories Q1 20 Earnings Conference Call At 9:00 AM ET | Wall St set for higher open on lockdown easing hopes, jobless claims","Compares with estimates April 16 (Reuters) - Abbott Laboratories ABT.N beat quarterly profit estimates on Thursday as stay-at-home orders prompted customers to stockpile its nutrition products but the company suspended its full-year forecast due to the coronavirus-fueled uncertainty. However, sales in its diagnostics unit fell nearly 1% to $1.83 billion, as increased use of its tests for the fast-spreading virus could not offset the decline in demand for its other diagnostic tests. Sales at the company's nutrition products division rose 6.3% to $1.90 billion, benefiting from increased demand for children's products in late March as U.S. states began to impose shelter-in-place restrictions to curb the spread of the virus. | Within that group, Abbott Laboratories (Symbol: ABT) and Cigna Corp (Symbol: CI) are two large stocks leading the way, showing a gain of 6.0% and 5.0%, respectively. Combined, ABT and CI make up approximately 6.1% of the underlying holdings of XLV. Among healthcare ETFs, one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is up 1.8% on the day, and down 3.03% year-to-date. | Image source: Abbott Labs via PRNewswire It's less clear how much of the increased reimbursement will trickle through to the companies that developed those tests for COVID-19, such as Roche Holding (OTC: RHHBY), Thermo Fisher Scientific (NYSE: TMO), and Abbott Labs (NYSE: ABT). As of Tuesday, the Centers for Medicare and Medicaid Services (CMS) began paying laboratories $100 for each COVID-19 diagnostic test they conduct using high-throughput technologies to rapidly process large numbers of samples, nearly twice the approximately $51 per test the agency pays them for other types of COVID-19 tests. The increased reimbursement will benefit diagnostic companies, such as Laboratory Corporation of America (NYSE: LH) and Quest Diagnostics (NYSE: DGX), which both have large networks of labs that have been running COVID-19 tests for over a month. | Stay-at-home orders prompted consumers to stock up on nutrition products and customers in emerging markets were strong buyers of pharmaceuticals, helping Abbott Laboratories (NYSE: ABT) beat expectations for first-quarter results. Abbott had originally guided to EPS between $0.69 and $0.71 for the quarter, but analysts lowered estimates in the last month to $0.58 on expectations of significantly lower sales of medical devices and diagnostics as hospitals canceled routine procedures. Medical device sales still managed 2.9% organic growth year over year, and the diagnostics segment eked out a sales gain of 0.7%. | The top three S&P 500 .PG.INX percentage gainers: ** Akamai Technologies AKAM.OQ, up 5.1% ** Anthem Inc ANTM.N, up 5% ** AutoZone Inc AZO.N, up 4.9% The top three S&P 500 .PL.INX percentage losers: ** United Airlines Holdings UAL.OQ, down 11.8% ** American Airlines GroupAAL.OQ, down 10% ** Simon Property Group SPG.N, down 10% The top three NYSE .PG.N percentage gainers: ** VanEck Vectors Energy Income ETF EINC.N, up 197.2% ** VanEck Vectors Rare Earth ETF REMX.N, up 185.7% ** Arcus Biosciences Inc RCUS.N, up 80.5% The top NYSE .PL.N percentage losers: ** Rite Aid Corp RAD.N, down 22.6% ** Plantronics PLT.N, down 20.8% The top three Nasdaq .PG.O percentage gainers: ** OpGen Equity Warrants OPGNW.O, up 109.7% ** MoSys Inc MOSY.O, up 96.4% ** Edison Nation EDNT.O, up 73.1% The top three Nasdaq .PL.O percentage losers: ** Athersys Inc ATHX.O, down 25.5% ** Global Eagle Entertainment ENT.O, down 24.9% ** Calithera Biosciences Inc CALA.O, down 19.7% ** Netflix NFLX.O: up 3.6% BUZZ-Netflix hits record high as lockdowns, ""Tiger King"" spur more PT raises ** Outfront Media OUT.N: up 1.5% BUZZ-Outfront Media jumps on Providence, Ares liquidity infusion ** Sonoco Products SON.N: down 7.1% BUZZ-Sonoco Products expects hit to Q2 profit due to coronavirus ** BioSig Technologies BSGM.O: down 1.0% BUZZ-BioSig Technologies rises on plan to test antiviral drug as COVID-19 therapy ** Everi Holdings Inc EVRI.N: down 6.7% International Game Technology Plc IGT.N: down 0.9% PlayAGS Inc AGS.N: down 11.9% Scientific Games Corp SGMS.O: down 2.5% BUZZ-Gaming equipment makers: Jefferies sees 2020 EBITDA down 26% to 35% ** Roku ROKU.O: up 11.8% BUZZ-Roku rises after Berenberg says buy ** Cree CREE.O: down 6.8% BUZZ-Cree drops on $500 mln convertible debt deal ** Hilton Worldwide Holdings HLT.N: down 1.1% BUZZ-Hilton dips as COVID-19 likely to weigh on brand, Q1 results ** EBay EBAY.O: up 1.8% BUZZ-EBay: Rises as Starboard withdraws board nominations ** PDS Biotechnology PDSB.O: up 45.3% BUZZ-PDS jumps on plan to start COVID-19 vaccine development program ** Inovio INO.O: up 6.9% BUZZ-Inovio rises as coronavirus vaccine study in S.Korea gets $6.9 mln funding ** Rite Aid RAD.N: down 22.6% BUZZ-Rite Aid: Falls on wider Q4 loss, maintains 2021 outlook ** ConocoPhillips COP.N: down 4.3% BUZZ-ConocoPhillips: Falls on output cut, share buyback suspension ** Jack in the Box JACK.O: up 16.5% BUZZ-Jack in the Box jumps after Q2 projections impress Wall Street ** Eagle Pharma EGRX.O: up 5.5% BUZZ-Eagle Pharma: Rise as hyperthermia drug inhibits virus causing COVID-19 ** Atossa Therapeutics ATOS.O: up 45.1% BUZZ-Atossa leaps on plans to develop potential COVID-19 therapy ** ThermoGenesis THMO.O: up 39.5% BUZZ-ThermoGenesis: Gains after FDA allows COVID-19 diagnostic kit distribution ** Co-Diagnostics CODX.O: up 22.1% BUZZ-Co-Diagnostics: Jumps as COVID-19 test on saliva samples uses co's tech ** Calithera Biosciences CALA.O: down 19.7% Calithera slides on equity raise ** Athersys ATHX.O: down 25.5% BUZZ-Athersys drops on $50 mln equity raise to fund COVID-19 trial ** Bed Bath & Beyond BBBY.O: up 17.1% BUZZ-Bed Bath & Beyond: Rises after escaping Q4 with a profit beat amid pandemic ** Arcus Biosciences RCUS.N: up 80.8% BUZZ-Arcus: Surges on report of Gilead in talks for picking stake ** Soligenix Inc SNGX.O: up 11.4% BUZZ-Soligenix: Rises on scoring license for potential COVID-19 vaccine ** Dynavax Tech DVAX.O: up 3.9% BUZZ-Dynavax jumps on entering coronavirus vaccine tie-up ** Twitter TWTR.N: down 4.1% BUZZ-Twitter: Drops as JP Morgan downgrades to 'neutral' ** GoPro GPRO.O: down 3.4% BUZZ-GoPro: Falls after co scraps 2020 forecast on coronavirus fears ** Chegg Inc CHGG.N: down 7.2% BUZZ-Chegg Inc: New grading policy at universities to hurt online learning co ** Bloomin' Brands BLMN.O: up 3.3% BUZZ-Bloomin' Brands: Take-out, delivery sales nearly triple since March ** Bank of New York Mellon BK.N: up 3.7% BUZZ-Bank of New York Mellon rises on Q1 results beat ** Edison Nation EDNT.O: up 73.1% BUZZ-Edison Nation: Surges after securing orders for personal protective equipment ** Abbott Labs ABT.N: up 4.3% BUZZ-Abbott: Rises on quarterly results beat ** Diamond Offshore Drilling DO.N: down 39.0% BUZZ-Diamond Offshore Drilling: Slips after skipping interest payment ** Ra Medical Systems RMED.N: down 13.7% BUZZ-Ra Medical Systems: Falls after filing for stock offering ** Goodyear Tire GT.O: down 6.2% BUZZ-Goodyear Tire: Burns rubber after estimating quarterly loss ** UroGen Pharma URGN.O: up 1.0% BUZZ-UroGen Pharma: Jumps after cancer drug gets FDA nod ** Taiwan Semiconductor Manufacturing Co TSM.N: up 5.8% BUZZ-Taiwan Semiconductor rises as profit nearly doubles ** Pulmatrix PULM.O: up 5.4% BUZZ-Pulmatrix: Jumps after granting license for respiratory disease products ** Marathon Petroleum MPC.N: down 8.2% BUZZ-Marathon Petroleum: Costs, midstream structure keeps Cowen on sidelines ** Square Inc SQ.N: down 6.6% BUZZ-Square Inc: Drops after Raymond James downgrades on COVID-19 risks The 11 major S&P 500 sectors: Communication Services down 0.42% Consumer Discretionary up 1.31% Consumer Staples | Operator [Operator Closing Remarks] Duration: 60 minutes Call participants: Scott Leinenweber -- Vice President of Investor Relations, Licensing and Acquisitions Robert B. Ford -- President and Chief Executive Officer Robert E. Funck Jr. -- Executive Vice President, Finance and Chief Financial Officer Robert Marcus -- J.P. Morgan -- Analyst David Lewis -- Morgan Stanley -- Analyst Bob Hopkins -- Bank of America Merrill Lynch -- Analyst Vijay Kumar -- Evercore ISI -- Analyst Matt Taylor -- UBS -- Analyst Larry Biegelsen -- Wells Fargo -- Analyst More ABT analysis All earnings call transcripts {%sfr%} 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Abbott Laboratories (NYSE: ABT) Q1 2020 Earnings Call Apr 16, 2020, 9:00 a.m. I mean, there was obviously some collaboration between them, but we wanted them stand-alone going after four different types of tests, say, a molecular lab test, a molecular point-of-care test, a lab-based serology test and a lateral raw serology test. | The stock of Abbott Laboratories (NYSE: ABT) was hammered like many stocks were when the COVID-19 crisis hit. By the numbers Abbott announced Q1 revenue of $7.7 billion, a 2.5% increase from the $7.5 billion reported in the same quarter of the previous year. The company announced nutrition revenue of $1.9 billion, up 6.3% year over year on a reported basis and a 7.3% year-over-year organic increase. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips The novel coronavirus has made Abbott Laboratories (NYSE:ABT) stock a star. All About ABT Stock As the pandemic worsened in March, ABT stock fell along with the market. The question is whether, with a price-earnings ratio of 42 and a dividend yielding just 1.6%, is it too late for you to get in to ABT stock? | VIDEO: S&P 500 Movers: UAL, ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Thursday, shares of Abbott Laboratories topped the list of the day's best performing components of the S&P 500 index, trading up 5.5%. And the worst performing S&P 500 component thus far on the day is United Airlines Holdings, trading down 10.4%. | The top three S&P 500 .PG.INX percentage gainers: ** Nvidia Corp NVDA.OQ, up 5.6% ** Akamai Technologies AKAM.OQ, up 5.5% ** AutoZone Inc AZO.N, up 4.9% The top three S&P 500 .PL.INX percentage losers: ** United Airlines Holdings UAL.OQ, down 9.5% ** American Airlines Group AAL.OQ, down 7% ** Alaska Air Group ALK.N, down 6.5% The top three NYSE .PG.N percentage gainers: ** VanEck Vectors Energy Income ETF EINC.N, up 197.2% ** VanEck Vectors Rare Earth ETF REMX.N, up 185.7% ** Arcus Biosciences Inc RCUS.N, up 83.7% The top three NYSE .PL.N percentage losers: ** Rite Aid Corp RAD.N, down 24.5% ** Hertz Global Holdings HTZ.N, down 17.1% ** Apergy Corp APY.N, down 14.1% The top three Nasdaq .PG.O percentage gainers: ** Liberty TripAdvisor Holdings LTRPB.O, up 119% ** MoSys Inc MOSY.O, up 95.6% ** Edison Nation EDNT.O, up 91.6% The top three Nasdaq .PL.O percentage losers: ** Global Eagle Entertainment ENT.O, down 26.5% ** Athersys Inc ATHX.O, down 23.6% ** Calithera Biosciences Inc CALA.O, down 15.7% ** Cree CREE.O: down 4.7% BUZZ-Cree drops on $500 mln convertible debt deal ** EBay EBAY.O: up 1.9% BUZZ-EBay: Rises as Starboard withdraws board nominations ** PDS Biotechnology PDSB.O: up 63.9% BUZZ-PDS Biotechnology: Jumps on plan to start COVID-19 vaccine development program ** Inovio INO.O: up 8.1% BUZZ-Inovio rises as coronavirus vaccine study in S.Korea gets $6.9 mln funding ** Rite Aid RAD.N: down 24.5% BUZZ-Rite Aid: Falls on wider Q4 loss, maintains 2021 outlook ** ConocoPhillips COP.N: down 2.7% BUZZ-ConocoPhillips: Falls on output cut, share buyback suspension ** Jack in the Box JACK.O: up 17.9% BUZZ-Jack in the Box: Surges after BTIG ups rating to ""buy"" ** Eagle Pharma EGRX.O: up 6.6% BUZZ-Eagle Pharma: Rises as hyperthermia drug inhibits virus causing COVID-19 ** Atossa Therapeutics ATOS.O: up 37.9% BUZZ-Atossa Therapeutics leaps on plans to develop potential COVID-19 therapy ** ThermoGenesis THMO.O: up 50.1% BUZZ-ThermoGenesis: Gains after FDA allows COVID-19 diagnostic kit distribution ** Co-Diagnostics CODX.O: up 16.6% BUZZ-Co-Diagnostics: Jumps as COVID-19 test on saliva samples uses co's tech - Reuters News ** Calithera Biosciences CALA.O: down 15.7% Calithera Biosciences slides on equity raise ** Athersys ATHX.O: down 23.6% BUZZ-Athersys drops on $50 mln equity raise to fund COVID-19 trial ** Bed Bath & Beyond BBBY.O: up 18.2% BUZZ-Bed Bath & Beyond: Rises after escaping Q4 with a profit beat amid pandemic ** Arcus Biosciences RCUS.N: up 83.3% BUZZ-Arcus Biosciences: Surges on report of Gilead in talks for picking stake ** Soligenix Inc SNGX.O: up 14.3% BUZZ-Soligenix Inc: Rises on scoring license for potential COVID-19 vaccine ** Dynavax Tech DVAX.O: up 2.3% BUZZ-Dynavax Tech jumps on entering coronavirus vaccine tie-up ** Twitter TWTR.N: down 2.0% BUZZ-Twitter: Drops as JP Morgan downgrades to 'neutral' ** GoPro GPRO.O: down 1.9% BUZZ-GoPro: Falls after co scraps 2020 forecast on coronavirus fears ** Chegg Inc CHGG.N: down 3.6% BUZZ-Chegg Inc: New grading policy at universities to hurt online learning co ** Bloomin' Brands BLMN.O: up 4.3% BUZZ-Bloomin' Brands: Take-out, delivery sales nearly triple since March, shares rise ** Bank of New York Mellon BK.N: up 4.5% BUZZ-Bank of New York Mellon rises on Q1 results beat ** Edison Nation EDNT.O: up 91.6% BUZZ-Edison Nation: Surges after securing orders for personal protective equipment ** Abbott ABT.N: up 4.5% BUZZ-Abbott: Rises on quarterly results beat ** Diamond Offshore Drilling DO.N: down 40.5% BUZZ-Diamond Offshore Drilling: Slips after skipping interest payment ** Ra Medical Systems RMED.N: down 4.6% BUZZ-Ra Medical Systems: Falls after filing for stock offering ** Goodyear Tire GT.O: down 3.2% BUZZ-Goodyear Tire: Burns rubber after estimating quarterly loss ** UroGen Pharma URGN.O: down 3.0% BUZZ-UroGen Pharma: Jumps after cancer drug gets FDA nod ** Netflix NFLX.O: up 4.6% BUZZ-Netflix: Evercore ISI raises PT on favorable trends amid virus outbreak ** Taiwan Semiconductor Manufacturing Co TSM.N: up 6.8% BUZZ-Taiwan Semiconductor Manufacturing rises as profit nearly doubles ** Pulmatrix PULM.O: up 10.6% BUZZ-Pulmatrix: Jumps after granting license for respiratory disease products ** Marathon Petroleum MPC.N: down 6.2% BUZZ-Marathon Petroleum: Costs, midstream structure keeps Cowen on sidelines ** Square Inc SQ.N: down 5.4% BUZZ-Square Inc: Drops after Raymond James downgrades on COVID-19 risks The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 and Dow Jones slipped on Thursday, giving up early gains as concerns about dismal first-quarter earnings and lasting economic damage from the coronavirus pandemic offset better-than-expected weekly jobless claims numbers..N At 11:15 ET, the Dow Jones Industrial Average .DJI was down 0.13% at 23,474.8. up 0.32% Consumer Discretionary | UGI Corp. (Symbol: UGI) $44.23 $53.67 21.33% New Jersey Resources Corp (Symbol: NJR) $44.04 $52.00 18.07% Smith (A O) Corp (Symbol: AOS) $46.61 $52.43 12.48% International Business Machines Corp (Symbol: IBM) $136.62 $153.54 12.38% Abbott Laboratories (Symbol: ABT) $87.38 $95.50 9.29% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. UGI Corp. (Symbol: UGI) 4.76% 21.33% 26.09% New Jersey Resources Corp (Symbol: NJR) 3.84% 18.07% 21.91% Smith (A O) Corp (Symbol: AOS) 2.40% 12.48% 14.88% International Business Machines Corp (Symbol: IBM) 5.46% 12.38% 17.84% Abbott Laboratories (Symbol: ABT) 1.58% 9.29% 10.87% Another consideration with dividend growth stocks is just how much the dividend is growing. UGI Corp. (Symbol: UGI) $1.04 $1.275 22.60% New Jersey Resources Corp (Symbol: NJR) $1.152 $1.232 6.94% Smith (A O) Corp (Symbol: AOS) $0.8 $0.92 15.00% International Business Machines Corp (Symbol: IBM) $6.28 $6.48 3.18% Abbott Laboratories (Symbol: ABT) $1.2 $1.36 13.33% These five stocks are part of our full Dividend Aristocrats List. | Medical equipment maker Abbott Laboratories Inc ABT.N posted a 16% drop in quarterly profit and suspended its full-year forecast due to uncertainty caused by the virus outbreak. By Medha Singh April 16 (Reuters) - U.S. stock index futures edged higher on Thursday, as hopes President Donald Trump would ease strict stay-at-home restrictions lifted the mood even as investors braced for another staggering jobless claims figure. ""Expectations for economic data and the current earnings season are already extremely low (but) these figures could act as a reminder that the global economy is facing a deep recession and that recovery might take longer than initially expected,"" said Milan Cutkovic, market analyst at AxiCorp. | Berkshire CEO Warren Buffett might not be a big fan of any of these valuation metrics, but he undoubtedly likes the stock's current valuation considering that the company was buying back shares last year when the stock was priced well above current levels. See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie, Berkshire Hathaway (B shares), and Bristol Myers Squibb. The Motley Fool owns shares of and recommends Berkshire Hathaway (B shares) and Bristol Myers Squibb and recommends the following options: long January 2021 $200 calls on Berkshire Hathaway (B shares), short January 2021 $200 puts on Berkshire Hathaway (B shares), and short June 2020 $205 calls on Berkshire Hathaway (B shares). | April 16 (Reuters) - Abbott Laboratories Inc ABT.N posted a 16% drop in quarterly profit on Thursday partly due to a tax expense and suspended its full-year forecast citing the uncertainty caused by the coronavirus outbreak. The company's net earnings fell to $564 million, or 31 cents per share, in the first quarter ended March 31, from $672 million, or 38 cents per share, a year earlier. (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Sriraj Kalluvila) ((saumya.joseph@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 2676; Twitter: @SaumyaSibi;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) announced a profit for first quarter that dropped from last year. Excluding items, Abbott Laboratories reported adjusted earnings of $1.16 billion or $0.65 per share for the period. The company's revenue for the quarter rose 2.5% to $7.73 billion from $7.54 billion last year. | When Humira and Botox got married Spun off from Abbott Laboratories (NYSE: ABT) in 2013, AbbVie has grown annual revenue from $18.8 billion that year to $33.3 billion in 2019. AbbVie's management expects several financial benefits from the merger, including an immediate 10% increase to earnings per share over the first full year of the combination, cost reductions of at least $2 billion by year three, and operating cash flow estimated at $19 billion. Regarding dividend safety, AbbVie said in a company announcement regarding the Allergan acquisition: ""The combined company will produce robust cash flow which will support continued growth of our dividend, further investment in our pipeline, and reduction of debt. | Medical equipment maker Abbott Laboratories Inc ABT.N and Morgan Stanley MS.N are scheduled to report quarterly results later in the day. By Medha Singh April 16 (Reuters) - U.S. stock index futures edged higher on Thursday, with investors weighing the prospects of the economy re-opening against worsening macroeconomic data and dour first-quarter earnings reports. S&P 500 e-minis EScv1 were up 9.25 points, or 0.33% and Nasdaq 100 e-minis NQcv1 were up 55 points, or 0.64%. | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on April 16, 2020, to discuss Q1 20 earnings results. To access the live webcast, log on to www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Medical equipment maker Abbott Laboratories Inc ABT.N beat quarterly profit estimates, but suspended its full-year forecast due to uncertainty caused by the virus outbreak. By Medha Singh and Akanksha Rana April 16 (Reuters) - Wall Street was set to open higher on Thursday as weekly jobless claims fell slightly from the previous week and on hopes President Donald Trump would push to ease strict stay-at-home restrictions. Latest data showed jobless claims fell slightly to 5.2 million last week from an upwardly revised 6.62 million the week before, but the total figure for the past month still topped 20 million as the outbreak crushed business activity."
2020-04-15,90.01000213623047,90.94000244140624,3.671707971819356,"Notable Wednesday Option Activity: T, ABT, BBBY | Abbott Rolling Out a Coronavirus Antibody Test | BUZZ-U.S. STOCKS ON THE MOVE-U.S. oil stocks, retailers, restaurants, BofA, J.C. Penny, IBM, Gilead, LyondellBasell | BUZZ-U.S. STOCKS ON THE MOVE-Netflix, Wells Fargo, Tesla, BofA, J.C. Penny, Noble Energy | Abbott launches COVID-19 antibody test, plans 20 mln tests per month by June | Abbott Launches Antibody Blood Test For COVID-19 - Quick Facts | Abbott launches antibody test for coronavirus, plans to deliver 20 mln tests by June","Especially high volume was seen for the $31 strike call option expiring April 17, 2020, with 109,180 contracts trading so far today, representing approximately 10.9 million underlying shares of T. Below is a chart showing T's trailing twelve month trading history, with the $31 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) saw options trading volume of 80,505 contracts, representing approximately 8.1 million underlying shares or approximately 58.5% of ABT's average daily trading volume over the past month, of 13.7 million shares. Especially high volume was seen for the $95 strike call option expiring April 17, 2020, with 6,318 contracts trading so far today, representing approximately 631,800 underlying shares of ABT. Below is a chart showing ABT's trailing twelve month trading history, with the $95 strike highlighted in orange: And Bed, Bath & Beyond, Inc. (Symbol: BBBY) options are showing a volume of 68,127 contracts thus far today. | Abbott (NYSE: ABT) announced Wednesday it is launching a third test for SARS-CoV-2 -- and its first antibody test for the coronavirus. In addition to determining whether a person has been exposed to or infected by the coronavirus, the new test's results will aid researchers in determining how long it remains in the body, and whether those who have fought it off once develop an immunity from further infection. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | The top three S&P 500 .PG.INX percentage gainers: ** Netflix Inc , up 4.4% ** UnitedHealth Group , up 4% ** Activision Blizzard Inc , up 3% The top three S&P 500 .PL.INX percentage losers: ** Noble Energy Inc , down 13.6% ** Helmerich & Payne Inc , down 13% ** PVH Corp , down 11.9% The top NYSE .PG.N percentage gainers: ** Manning & Napier Inc , up 21.8% The top NYSE .PL.N percentage losers: ** Chesapeake Energy , down 35.6% ** Pfenex Inc , down 30.1% The top three Nasdaq .PG.O percentage gainers: ** Liberty TripAdvisor Holdings Inc , up 1,435.1% ** Comstock Holding Companies Inc , up 111.9% ** ShiftPixy Inc , up 59.2% The top three Nasdaq .PL.O percentage losers: ** Medallion Bank , down 21.3% ** Lizhi Inc , down 18.2% ** 9F Inc , down 17.8% ** Wells Fargo & Co WFC.N : down 5.3% BUZZ-Street View: Wells Fargo's losses manageable at this stage ** UnitedHealth Group UNH.N: up 4.0% BUZZ-Rises on Q1 profit beat ** Goldman Sachs GS.N: down 0.5% BUZZ-Goldman slips as profit halves on hit from loan loss provisions ** Aphria APHA.N: up 4.1% BUZZ-Gains as co swings to quarterly profit ** Tesla TSLA.O: up 1.8% BUZZ-Rises as China car registrations surge in March ** Bank of America Corp BAC.N: down 6.3% BUZZ-BofA slips as profit nearly halves, loan loss provisions soar ** ToughBuilt Industries TBLT.O: down 5.0% BUZZ-Plunges on reverse stock split ** J.C. Penny JCP.N: down 25.8% BUZZ-Falls on report of co considering bankruptcy ** JB Hunt Transport JBHT.O: up 2.8% BUZZ-Rises after revenue beats amid coronavirus-led disruption ** Chesapeake Energy CHK.N: down 35.6% BUZZ-Credit Suisse cuts PT on reverse stock split, lowers outlook ** Applied DNA APDN.O: up 34.1% BUZZ-Surges after co says mice will be tested with COVID-19 vaccines ** Noble Energy NBL.O: down 13.6% BUZZ-Drops as liquidity needs prompt dividend cut ** Oragenics OGEN.A: down 46.1% BUZZ-Plunges after drug for cancer therapy side-effect fails study ** Carnival Corp CCL.N: down 3.2% BUZZ-Falls as virus-stricken cruise line drops anchor till July ** Lifeway Foods LWAY.O: up 21.3% BUZZ-Gains on expectations for increased sales ** Citigroup C.N: down 3.9% BUZZ-Falls as quarterly profit nearly halves ** Frontier Communications FTR.O: down 31.4% BUZZ-Slumps after filing for bankruptcy protection ** Netflix InNFLX.O: up 4.4% BUZZ-Hits record high as analysts see strong Q1 amid coronavirus outbreak ** Dick's Sporting Goods Inc DKS.N: down 1.7% BUZZ-Drops after $500 mln liquidity boost ** Top Ships Inc TOPS.O: down 24.4% BUZZ-Sinks on $6 mln direct offering ** Apple Inc AAPL.O: down 1.1% BUZZ-Launches new budget iPhone ** Exxon Mobil Corp XOM.N: down 5.7% ** Chevron Corp CVX.N: down 4.9% ** Apache Corp APA.N: down 8.8% ** Whiting Petroleum CorpWLL.N: down 6.4% ** Marathon Oil Corp MRO.N: down 4.5% ** Hess Corp HES.N: down 10.6% ** Occidental Petroleum Corp OXY.N: down 11.3% ** Devon Energy DVN.N: down 9.4% ** Helmerich & Payne HP.N: down 13.0% ** Halliburton HAL.N: down 7.5% ** Schlumberger NV SLB.N: down 6.6% ** Cheaspeake Energy CHK.N: down 35.6% BUZZ-Energy stocks lose ground as oil slides towards $28 a barrel ** International Business Corp IBM.N: down 4.8% BUZZ-Brokerages cut PT on virus impact ** LyondellBasell Industries NV LYB.N: down 9.9% BUZZ-LyondellBasell: Falls as Q1 expectations disappoint ** Howmet Aerospace Inc HWM.N: down 11.1% BUZZ-Drops on scrapping outlook, dividend ** Chembio Diagnostics Inc CEMI.O: up 3.5% BUZZ-Up after FDA approves emergency use of COVID-19 test ** Gilead Sciences Inc GILD.O: down 3.8% BUZZ-Down on suspension of China remdesivir trial in COVID-19 patients ** Abbott Laboratories ABT.N: up 1.8% BUZZ-Wells Fargo says 3rd COVID-19 test gives additional boost to diagnostics unit ** Nike Inc NKE.N: down 2.6% ** Under Armour Inc UAA.N: down 3.9% ** Gap Inc GPS.N: down 10.4% ** Guess Inc GES.N: down 6.9% ** Abercrombie & Fitch ANF.N: down 9.3% ** American Eagle AEO.N: down 10.9% ** Tapestry TPR.N: down 7.2% ** Capri Holdings CPRI.N: down 7.1% ** Ralph Lauren RL.N: down 8.8% ** Macy's M.N: down 7.3% ** Kohl's KSS.N: down 7.4% ** Nordstrom JWN.N: down 11.3% ** J.C. Penney JCP.N: down 25.8% ** Chipotle CMG.N: down 2.0% ** Starbucks SBUX.O: down 2.4% ** McDonald's MCD.N: down 3.1% ** Shake Shack SHAK.N: down 5.6% BUZZ-Shares of U.S. retailers, restaurants dive on gloomy March sales data The 11 major S&P 500 sectors: Communication Services down 1.13% Consumer Discretionary down 1.65% Consumer Staples | The top three S&P 500 .PG.INX percentage gainers: ** Netflix Inc , up 3.6% ** Abbott Labs , up 2.6% ** Nortonlifelock Inc , up 2% The top three S&P 500 .PL.INX percentage losers: ** Noble Energy Inc , down 16% ** PVH Corp , down 14.1% ** Helmerich Payne , down 13.5% The top three NYSE .PL.N percentage losers: ** Chesapeake Energy , down 39.7% ** Independence Contract Drilling , down 29.1% ** Pfenex Inc , down 24% The top three Nasdaq .PG.O percentage gainers: ** Liberty TripAdvisor Holdings Inc , up 205.3% ** Comstock Holding Companies Inc , up 168.1% ** Shiftpixy Inc , up 67.9% The top three Nasdaq .PL.O percentage losers: ** Summit Wireless Technologies Inc , down 21.3% ** Penn Virgin Corp , down 19.4% ** 9F Inc , down 18.5% ** Wells Fargo & Co WFC.N : down 6.1% BUZZ-Street View: Wells Fargo's losses manageable at this stage ** UnitedHealth Group UNH.N: up 1.6% BUZZ-Rises on Q1 profit beat ** Goldman Sachs GS.N: down 0.8% BUZZ-Goldman slips as profit halves on hit from loan loss provisions ** Aphria APHA.N: up 5.2% BUZZ-Gains as co swings to quarterly profit ** Tesla TSLA.O: up 3.7% BUZZ-Rises as China car registrations surge in March ** Bank of America Corp BAC.N: down 6.4% BUZZ-BofA slips as profit nearly halves, loan loss provisions soar ** ToughBuilt Industries TBLT.O: down 9.1% BUZZ-Plunges on reverse stock split ** J.C. Penny JCP.N: down 27.8% BUZZ-Falls on report of co considering bankruptcy ** JB Hunt Transport JBHT.O: up 1.8% BUZZ-Rises after revenue beats amid coronavirus-led disruption ** Chesapeake Energy CHK.N: down 39.7% BUZZ-Credit Suisse cuts PT on reverse stock split, lowers outlook ** Applied DNA APDN.O: up 40.5% BUZZ-Surges after co says mice will be tested with COVID-19 vaccines ** Noble Energy NBL.O: down 15.9% BUZZ-Drops as liquidity needs prompt dividend cut ** Oragenics OGEN.A: down 45.0% BUZZ-Plunges after drug for cancer therapy side-effect fails study ** Carnival Corp CCL.N : down 6.6% BUZZ-Falls as virus-stricken cruise line drops anchor till July ** Lifeway Foods LWAY.O: up 22.4% BUZZ-Gains on expectations for increased sales ** Citigroup C.N: down 3.5% BUZZ-Citigroup: Falls as quarterly profit nearly halves ** Frontier Communications FTR.O: down 31.4% BUZZ-Frontier Communications: Slumps after filing for bankruptcy protection ** Netflix InNFLX.O: up 3.6% BUZZ-Hits record high as analysts see strong Q1 amid coronavirus outbreak The 11 major S&P 500 sectors: Communication Services down 1.56% Consumer Discretionary down 2.22% Consumer Staples | Adds details on launch, background April 15 (Reuters) - Abbott Laboratories Inc ABT.N said on Wednesday it launched a coronavirus blood test that could show whether a person has been infected and plans to ramp up manufacturing to produce 20 million tests per month by June. The test helps identify disease-fighting antibodies in people who have been infected but may have had mild symptoms or none at all, making it different from the current diagnostic tests that require nasal swabs to confirm active infection. Abbott has previously won U.S. authorization for two coronavirus testing kits: an automated test that can be used in labs and a test that can deliver results within minutes and be used in physicians' offices, clinics and hospitals. | (RTTNews) - Abbott (ABT) launched its third COVID-19 test, a lab-based serology blood test for the detection of the antibody, IgG. The antibody test adds to the company's existing COVID-19 tests, m2000 molecular laboratory system and ID NOW molecular point-of-care device. Abbott said the company is significantly scaling up its manufacturing for antibody testing and is expecting to immediately ship close to 1 million tests in the current week to U.S. customers. | April 15 (Reuters) - Abbott Laboratories Inc ABT.N on Wednesday launched a coronavirus blood test that could show whether a person has been infected and plans to ramp up manufacturing to produce 20 million tests in June. The test helps identify disease-fighting antibodies in people who have been infected but may have had mild symptoms or none at all, making it different from the current diagnostic tests that require nasal swabs to confirm active infection. Abbott has previously won U.S. authorization for two coronavirus testing kits: an automated test that can be used in labs and a test that can deliver results within minutes and be used in physicians' offices, clinics and hospitals."
2020-04-14,87.0,89.13999938964844,1.0332188457991682,,
2020-04-13,86.31999969482422,85.8499984741211,2.4597694133890085,"Ex-Dividend Reminder: AbbVie, Allergan and Abbott Laboratories","Looking at the universe of stocks we cover at Dividend Channel, on 4/14/20, AbbVie Inc (Symbol: ABBV), Allergan PLC (Symbol: AGN), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc (Symbol: ABBV): Allergan PLC (Symbol: AGN): Abbott Laboratories (Symbol: ABT): In general, dividends are not always predictable, following the ups and downs of company profits over time. Similarly, investors should look for AGN to open 0.40% lower in price and for ABT to open 0.42% lower, all else being equal."
2020-04-09,85.0,86.04000091552734,-0.5444870509323072,iShares S&P 100 ETF Experiences Big Inflow | Abbott's TriClip Transcatheter Tricuspid Valve Repair System Gets CE Mark,"Among the largest underlying components of OEF, in trading today Adobe Inc (Symbol: ADBE) is down about 1%, Abbott Laboratories (Symbol: ABT) is down about 0.5%, and Costco Wholesale Corp (Symbol: COST) is lower by about 2.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 100 ETF (Symbol: OEF) where we have detected an approximate $144.6 million dollar inflow -- that's a 2.8% increase week over week in outstanding units (from 40,500,000 to 41,650,000). For a complete list of holdings, visit the OEF Holdings page » The chart below shows the one year price performance of OEF, versus its 200 day moving average: Looking at the chart above, OEF's low point in its 52 week range is $101.8696 per share, with $152.576 as the 52 week high point — that compares with a last trade of $127.12. | (RTTNews) - Abbott (ABT) said that its TriClip Transcatheter Tricuspid Valve Repair System has received CE Mark and is now approved for use in Europe and other countries that recognize CE Mark as a non-surgical treatment for people with a leaky tricuspid valve, a condition known as tricuspid regurgitation. The tricuspid valve, often referred to as the ""forgotten heart valve,"" has three leaflets that control the flow of blood between the two chambers on the right side of the heart. The device is delivered to the heart through the femoral vein in the leg and works by clipping together a portion of the leaflets of the tricuspid valve to reduce the backflow of blood."
2020-04-08,82.5,84.94999694824219,1.2235304888556986,Abbott's CGM Available For Hospitalized Patients With Diabetes During COVID-19,"(RTTNews) - Abbott (ABT) said that its continuous glucose monitoring technology, FreeStyle Libre 14 day system, is now available in U.S. for hospitalized patients with diabetes during the COVID-19 pandemic. Abbott said it will donate 25,000 FreeStyle Libre 14 day sensors to U.S. hospitals and medical centers in outbreak hotspots to help accelerate access to technology. With a one-second scan using a reader or smartphone over the FreeStyle Libre 14 day sensor worn on the back of the upper arm, users get real-time glucose readings every minute, historical trends and patterns."
2020-04-07,83.44999694824219,81.93000030517578,2.969693270596591,"Walgreens to Expand Drive-Thru COVID-19 Testing | Walgreens to expand drive-through coronavirus testing sites | Walgreens to expand drive-through COVID-19 testing sites | Here Are All the Companies Working on COVID-19 Vaccines, Treatments, and Testing","The company's pharmacists will run patient samples through Abbott's (NYSE: ABT) ID NOW machines, which can provide results in less than 15 minutes. On Tuesday, Walgreens Boots Alliance (NASDAQ: WBA) announced plans to expand a drive-thru coronavirus testing service that can provide rapid results while customers wait. On Monday, CVS Health (NYSE: CVS) began providing Abbott's ID NOW COVID-19 test in two parking lots outside of retail medical clinics it operates in Rhode Island and Georgia. | Like CVS Health Corp CVS.N, which said on Monday it was launching two offsite testing locations, Walgreens will also use Abbott Laboratories's ABT.N faster test kits, allowing the drugstore chain to do 3,000 tests per day across the sites. Adds details, background April 7 (Reuters) - Walgreens Boots Alliance WBA.O is launching 15 ""drive-thru"" testing sites for coronavirus infections, the company said on Tuesday, as it follows up on a pledge it made to work with the Trump Administration on expanding diagnostic centers. Testing for COVID-19, the serious respiratory illness caused by the new coronavirus, has been slow in the United States due to a lack of test kits and other equipment. | (https://reut.rs/2RiC1NT) The new sites will use Abbot Laboratories's ABT.N COVID-19 diagnostic tests, which deliver positive results in as little as five minutes and negative results within 13 minutes. April 7 (Reuters) - Walgreens Boots Alliance WBA.O is working to expand its drive-through testing for COVID-19 to 15 new sites in seven states, the drugstore chain said on Tuesday. (Reporting by Trisha Roy in Bengaluru; Editing by Amy Caren Daniel) ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 3635;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs (NYSE: ABT) $142 billion Bayer  $60.2 billion Becton Dickinson (NYSE: BDX) $63.2 billion bioMerieux (OTC: BMXMF) $13.2 billion Co-Diagnostics (NASDAQ: CODX) $273 million Danaher (NYSE: DHR) $98.5 billion Eli Lilly $135.8 billion Grifols $19.5 billion LabCorp (NYSE: LH) $11.9 billion OPKO Health (NASDAQ: OPK) $817.2 million Quest Diagnostics (NYSE: DGX) $10.4 billion Roche Holdings $286.7 billion Thermo Fisher Scientific (NYSE: TMO) $117.7 billion Data sources: Biotechnology Innovation Organization, EvaluateMedTech, company press releases, Yahoo! Arcturus Therapeutics (NASDAQ:ARCT) $249.1 million BioNTech (NASDAQ: BNTX) $12.2 billion CSL Behring (OTC: CSLLY) $89.8 billion Dynavax (NASDAQ: DVAX) $293.9 million GlaxoSmithKline (NYSE: GSK) $93.7 billion Inovio Pharmaceuticals (NASDAQ: INO) $1.2 billion Johnson & Johnson (NYSE: JNJ) $357.9 billion Moderna (NASDAQ: MRNA) $11.4 billion Novavax (NASDAQ: NVAX) $821.8 million Pfizer (NYSE: PFE) $190.2 billion Sanofi (NASDAQ: SNY) $112.9 billion TranslateBio (NASDAQ: TBIO) $614.1 million Data sources: Biotechnology Innovation Organization, company press releases, Yahoo! AbbVie (NYSE: ABBV) $113.7 billion Adaptive Biotechnologies (NASDAQ: ADPT)  $3.4 billion Alnylam Pharmaceuticals (NASDAQ: ALNY) $12.6 billion Amgen (NASDAQ: AMGN) $122.9 billion Bayer (OTC: BAYRY) $60.2 billion Biogen (NASDAQ: BIIB) $54.1 billion CSL Behring  $89.8 billion CytoDyn (NASDAQOTH:CYDY) $1.3 billion Gilead Sciences (NASDAQ: GILD) $96.6 billion Grifols (NASDAQ: GRFS) $19.5 billion Incyte (NASDAQ: INCY) $18 billion Eli Lilly (NYSE: LLY) $135.8 billion Novartis (NYSE: NVS) $193.1 billion Regeneron Pharmaceuticals (NASDAQ: REGN) $55.5 billion Roche Holding (OTC: RHHBY) $286.7 billion Sanofi $112.9 billion Takeda Pharmaceutical (NYSE: TAK) $47.6 billion Vanda Pharmaceuticals (NASDAQ: VNDA) $568.7 million Vir Biotechnology (NASDAQ: VIR) $3.9 billion Data sources: Biotechnology Innovation Organization, company press releases, Yahoo!"
2020-04-06,81.08000183105469,82.7300033569336,-1.821446013963484,CVS Health to Open Rapid Drive-Through COVID-19 Testing Sites | CVS ramps up drive-through coronavirus testing sites with faster kits | CVS to launch two new drive-through COVID-19 testing sites,"The technology making this new rapid drive-up service possible is Abbott's (NYSE: ABT) ID NOW system. Some CVS Health (NYSE: CVS) customers are getting a fast new option for COVID-19 testing. Healthcare providers that normally work at the company's retail medical clinics in Georgia and Rhode Island will begin providing drive-up testing in two parking lot pop-ups with results provided while customers wait. | By Michael Erman April 6 (Reuters) - CVS Health Corp CVS.N, called on by the Trump administration last month to help test Americans for infections from the new coronavirus, said it was launching two offsite testing locations with Abbott Laboratories' ABT.N faster diagnostic kit and would be able to handle 1,000 tests per day. CVS' two new drive-through COVID-19 testing sites in Georgia and Rhode Island will use the new Abbott tests, which can work in 15 minutes, and that up to four more locations to follow. Brennan said the company expects to announce a third testing site in a different state on Tuesday and could launch up to three more sites afterward. | The company said both drive-through testing sites will use testing equipment made by Abbott Laboratories ABT.N that can deliver results within minutes. By Michael Erman April 6 (Reuters) - CVS Health Corp CVS.N said that it will launch two new drive-through COVID-19 testing sites in Georgia and Rhode Island on Monday using new, faster tests than had previously been available, with up to four more locations to follow. Brennan said the company expects to announce a third testing site in a different state on Tuesday and could launch up to three more sites afterward."
2020-04-03,78.79000091552734,79.44999694824219,2.0350289696798383,Why Abbott Labs Shares Rose 2.44% in March,"What happened Though many stocks entered a bear market in March, shares of Abbott Laboratories (NYSE: ABT) gained 2.44% in the month, according to data provided by S&P Global Market Intelligence. The stock climbed as Abbott announced the clearance of its coronavirus test. See the 10 stocks *Stock Advisor returns as of March 18, 2020 Adria Cimino has no position in any of the stocks mentioned."
2020-04-02,76.12000274658203,79.44000244140625,0.8376647100466992,ABT May 22nd Options Begin Trading | Better Coronavirus Stock: Abbott Labs vs. Gilead Sciences,"Below is a chart showing ABT's trailing twelve month trading history, with the $78.50 strike highlighted in red: Considering the fact that the $78.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the May 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new May 22nd contracts and identified one put and one call contract of particular interest. | I'll admit that labeling Abbott Laboratories (NYSE: ABT) and Gilead Sciences (NASDAQ: GILD) as ""coronavirus stocks"" is kind of like calling Michael Jordan a once-aspiring minor league baseball player. However, it's fair to say that the coronavirus programs of Abbott Labs and Gilead Sciences have put both stocks on the forefront of investors' minds in recent weeks. 10 stocks we like better than Gilead Sciences When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen."
2020-04-01,77.0,76.56999969482422,4.361533861049807,"There's a New 15-Minute Coronavirus Test | OEF, COST, ABT, BMY: ETF Inflow Alert | Got $5,000 to Invest? 3 Great Medical Device Stocks to Buy Right Now","Unlike a recently approved point-of-care test from Abbott (NYSE: ABT) that looks for genetic material specific to SARS-CoV-2, Becton Dickinson's new test looks for some of the proteins produced from that genetic material. A new coronavirus test from Becton Dickinson (NYSE: BDX) can deliver results about 15 minutes after a healthcare provider drops a person's blood sample in the test kit. Becton Dickinson's new antibody test hasn't been reviewed by the FDA, but the company will be allowed to distribute it immediately to U.S. healthcare providers thanks to emergency guidance issued by the regulator in March. | Among the largest underlying components of OEF, in trading today Costco Wholesale Corp (Symbol: COST) is down about 0.3%, Abbott Laboratories (Symbol: ABT) is down about 3.5%, and Bristol-Myers Squibb Co. (Symbol: BMY) is lower by about 2.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 100 ETF (Symbol: OEF) where we have detected an approximate $154.2 million dollar inflow -- that's a 3.3% increase week over week in outstanding units (from 39,200,000 to 40,500,000). For a complete list of holdings, visit the OEF Holdings page » The chart below shows the one year price performance of OEF, versus its 200 day moving average: Looking at the chart above, OEF's low point in its 52 week range is $101.8696 per share, with $152.576 as the 52 week high point — that compares with a last trade of $115.16. | Abbott Labs Abbott Labs (NYSE: ABT) stock has rebounded stronger than most stocks have in recent days. I think medical device stocks will continue to beat the overall market throughout this decade. ShockWave Medical ShockWave Medical (NASDAQ: SWAV) stock took a bigger beating during the coronavirus market sell-off than either Abbott or DexCom."
2020-03-31,81.43000030517578,78.91000366210938,-0.5584419547737419,"How The Parts Add Up: PWB Targets $53 | 3 Big Stock Charts for Tuesday: Abbott Laboratories, Johnson & Johnson, and Regeneron Pharmaceuticals | Is Abbott Labs Stock a Screaming Buy Because of Its Game-Changing COVID-19 Test?","Three of PWB's underlying holdings with notable upside to their analyst target prices are Abbott Laboratories (Symbol: ABT), Visa Inc (Symbol: V), and Mastercard Inc (Symbol: MA). Although ABT has traded at a recent price of $79.34/share, the average analyst target is 23.86% higher at $98.27/share. Below is a twelve month price history chart comparing the stock performance of ABT, V, and MA: Combined, ABT, V, and MA represent 10.44% of the Invesco Dynamic Large Cap Growth ETF. | Abbott Laboratories (ABT) Source: Source: Provided by Finviz The first of Tuesday’s big stock charts, Abbott Laboratories (NYSE:ABT) stock, soared on Monday as investors cheered the news that the company had received regulatory approval for its five-minute COVID-19 test. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Big daily moves are still the trend in big stock charts, it seems. Johnson & Johnson (JNJ) Source: Source: Provided by Finviz Traders cheered Johnson & Johnson (NYSE:JNJ) and bid up its stock price heartily on Monday. | That's about to change -- thanks to Abbott Laboratories (NYSE: ABT). The company's ID NOW platform on which the test runs is already the most widely available molecular point-of-care testing platform in the country. And there's more While Abbott's tremendous progress in COVID-19 testing is gaining a lot of attention right now, there's actually a lot more to like about the healthcare stock."
2020-03-30,82.83000183105469,79.33999633789062,-3.0946784153533065,"5 Top Stock Trades for Tuesday: ZM, WORK, TWTR, ABT, DDD | FDA Approves Abbott's 5-minute Coronavirus Test | Stock Market News: These 2 Coronavirus-Fighting Stocks Are Taking Off | New Shutdown Repeal Dates and a Testing Breakthrough Could Be Game-Changers for the Market | Why Abbott Laboratories Stock Is on Fire Today","The post 5 Top Stock Trades for Tuesday: ZM, WORK, TWTR, ABT, DDD appeared first on InvestorPlace. 4: Abbott Labs (ABT) Click to Enlarge Source: Chart courtesy of StockCharts.com Despite good news about its new coronavirus testing kit, Abbott Labs (NYSE:ABT) was unable to push through resistance on Monday. | Abbott received emergency use authorization from the FDA for its test for the detection of COVID-19, which delivers fast positive results in as little as five minutes and negative results in 13 minutes. The new Abbott ID NOW COVID-19 test runs on Abbott's ID NOWTM platform—a lightweight box. ""With rapid testing on ID NOW, healthcare providers can perform molecular point-of-care testing outside the traditional four walls of a hospital in outbreak hotspots."" | Both Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ) had good news on the coronavirus front, and while it could take a while for the global community to see the positive impacts, their actions are adding to the overall success of efforts around the world. Abbott worked hard to get a COVID-19 point-of-care test out to healthcare professionals, and it got the go-ahead to make those tests available to those who need them within the next week. Running on Abbott's ID NOW platform, the tests will allow healthcare workers to administer the tests and get results in hospitals, urgent care clinics, and doctors' offices. | The Food and Drug Administration just gave an emergency use authorization for a new test from Abbott Laboratories (NYSE: ABT) that can test a person for COVID-19 in just five minutes. Two weeks ago, Gates had said that it would take roughly six to 10 weeks of social distancing in order to break the chain of transmission and get cases down to a level where we could once again begin relaxing social distance restrictions. Abbott's new test That being said, in order to really get things back to quasi-normal, Gates says we also need a national database as well as widespread testing, as happened in South Korea. | What happened Shares of Abbott Laboratories (NYSE: ABT), a large-cap medical device and molecular diagnostic company, are gearing up for a potentially historic day Monday. The company's other COVID-19 test, Abbott m2000 RealTime SARS-CoV-2 EUA test, can process a far higher volume of samples per day, but it requires a centralized location to do so. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen."
2020-03-27,77.5,74.55999755859375,-4.213455772079419,,
2020-03-26,71.08000183105469,75.80999755859375,-3.793551537298387,"Health Care Sector Update for 03/26/2020: JNJ, PFE, ABT, MRK, AMGN, HTGM, RKDA, BIOC","Among health care stocks moving on news: (+) HTG Molecular Diagnostics (HTGM), which rose more than 11% after the company reported a net loss of $0.51 per share for the year ended Dec. 31, 2019, compared with a loss of $0.60 per share a year earlier. (-) Arcadia Biosciences (RKDA), which was down more than 15% after posting Q4 net loss of $0.72 per share, or $6.2 million, compared with a loss of $646,000 in the year-ago quarter. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2020-03-25,68.94999694824219,70.75,6.654467650101465,ABT a Top 25 Dividend Giant With $10.86B Held By ETFs,"Abbott Laboratories (Symbol: ABT) has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a whopping $10.86B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 2.07% yield, according to the most recent Dividend Channel ''DividendRank'' report. Below is a long-term dividend history chart for ABT, which the report stressed as being of key importance. The report noted a strong quarterly dividend history at Abbott Laboratories, and favorable long-term multi-year growth rates in key fundamental data points."
2020-03-24,64.91000366210938,69.69000244140625,2.6105919237516395,Better Buy: AbbVie vs. Biogen,"It also pays a dividend that has increased for more than 40 consecutive years (counting the time it spent as part of Abbott Laboratories (NYSE: ABT)), making it a Dividend Aristocrat. Drug manufacturers AbbVie (NYSE: ABBV) and Biogen (NASDAQ: BIIB) are two of the bigger names in the industry, and their stocks offer investors two enticing approaches: one that's focused on growth, and another that's centered around stability and recurring income. Last month, Biogen's stock price got another boost when investors learned that Mylan (NASDAQ: MYL) had been unsuccessful in its patent challenge against Biogen's multiple sclerosis drug, Tecfidera."
2020-03-23,67.06999969482422,62.81999969482422,7.364040224337802,S&P 500 Analyst Moves: ABT | These 3 Dividend Stocks Are Now Yielding Up to 20%,"VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories is now the #60 analyst pick, moving up by 1 spot. This rank is formed by averaging the analyst opinions for each component from each broker, and then ranking the 500 components by those average opinion values. | It's a Dividend Aristocrat, as its payouts have increased for more than 25 years including AbbVie's time as part of Abbott Laboratories (NYSE: ABT). The energy stock is down 30% this year as concerns in the Canadian oil and gas industry continue to rise, and both the coronavirus and low oil prices threaten the survival of many Alberta-based companies like Enbridge. Cash from the company's operating activities of CA$9.4 billion during the year was insufficient to cover dividend payments of CA$6 billion after factoring in CA$5.5 billion in capital spending."
2020-03-20,74.05000305175781,68.0,-6.3366632165468335,"FDA Warns About Unauthorized Fraudulent COVID-19 Tests | Notable ETF Inflow Detected - OEF, ABT, CVX, MCD | 3 Dividend Stocks Ideal for Retirees With Money To Invest In The Bear Market","The FDA has authorized tests from Abbott Labs (NYSE: ABT), Thermo Fisher Scientific (NYSE: TMO), and Roche (OTC: RHHBY) under its Emergency Use Authorization program. The FDA hasn't approved any test kits for use in homes, although it's working with test-makers on taking in-home samples that can be shipped to labs to be tested. The lack of available tests is likely making some people desperate to get tested any way they can -- thus the FDA's warning on Friday to be on the lookout for unauthorized fraudulent test kits. | Among the largest underlying components of OEF, in trading today Abbott Laboratories (Symbol: ABT) is down about 2.2%, Chevron Corporation (Symbol: CVX) is up about 3.7%, and McDonald's Corp (Symbol: MCD) is up by about 6.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 100 ETF (Symbol: OEF) where we have detected an approximate $134.3 million dollar inflow -- that's a 3.1% increase week over week in outstanding units (from 38,300,000 to 39,500,000). For a complete list of holdings, visit the OEF Holdings page » The chart below shows the one year price performance of OEF, versus its 200 day moving average: Looking at the chart above, OEF's low point in its 52 week range is $106.01 per share, with $152.576 as the 52 week high point — that compares with a last trade of $112.72. | Profit increases appear set to continue, and the payout ratio indicates that AbbVie pays out around 48.8% of profits in the form of dividends meaning the annual payout hikes should continue for the foreseeable future. Innovative Industrial Properties The massive decline in marijuana stocks may make Innovative Industrial Properties (NYSE: IIPR) seem like a strange choice. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Will Healy owns shares of AbbVie."
2020-03-19,81.36000061035156,74.5,-8.17015908497548,,
2020-03-18,74.9800033569336,79.26000213623047,-8.43166243717893,Coronavirus Test-makers Ramp Up Production,"On Wednesday, Abbott Labs (NYSE: ABT) was granted an Emergency Use Authorization (EUA) from the Food and Drug Administration for its RealTime SARS-CoV-2, which tests for the coronavirus that causes COVID-19. The company has 150,000 tests ready to distribute and is ramping up production with a goal of up to 1 million tests per week. Last week, the FDA granted an EUA to Roche's (OTC: RHHBY) cobas SARS-CoV-2 test, which runs on two different machines sold by Roche and has a higher throughput of 1,440 or 4,128 tests per hour depending on the machine."
2020-03-17,75.5199966430664,79.48999786376953,5.708186966760242,"Health Care Sector Update for 03/17/2020: JNJ, PFE, ABT, MRK, AMGN, DBVT, AVRO, MRNA","Top health care stocks rose during pre-market trading hours on Tuesday. (+) Biotechnology company Moderna (MRNA), which rose more than 9% after the company said the first participant in its phase 1 study for mRNA-1273 was dosed, a total of 63 days from sequence selection to first human dosing. (+) Gene therapy company AVROBIO (AVRO), which was up more than 4% after reporting Q4 loss of $0.72 per share, compared with a loss of $0.67 a year ago and missing the consensus estimate of $0.61 loss compiled by Capital IQ."
2020-03-16,70.6500015258789,73.66000366210938,5.256887443290976,,
2020-03-13,77.91000366210938,81.6500015258789,4.260441714396727,,
2020-03-12,73.27999877929688,74.73999786376953,4.8004077627690265,Validea Peter Lynch Strategy Daily Upgrade Report - 3/12/2020 | iShares MSCI World ETF Experiences Big Inflow | ABT May 1st Options Begin Trading,"ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products. The Company operates through three business segments: Real estate lending (the Lending Segment), which engages primarily in originating, acquiring, financing and managing commercial first mortgages, subordinated mortgages, mezzanine loans, preferred equity, commercial mortgage-backed securities (CMBS), residential mortgage-backed securities, and other real estate and real estate-related debt investments; Real estate investing and servicing (the Investing and Servicing Segment), which includes a servicing business in the United States that manages and works out problem assets; an investment business that selectively acquires and manages unrated, investment grade and non-investment grade rated CMBS, and a mortgage loan business, and Real estate property (the Property Segment), which engages primarily in acquiring and managing equity interests in stabilized commercial real estate properties. | Among the largest underlying components of URTH, in trading today Visa Inc (Symbol: V) is down about 7.4%, Mastercard Inc (Symbol: MA) is down about 9.2%, and Abbott Laboratories (Symbol: ABT) is lower by about 3.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares MSCI World ETF (Symbol: URTH) where we have detected an approximate $106.9 million dollar inflow -- that's a 12.1% increase week over week in outstanding units (from 10,700,000 to 12,000,000). For a complete list of holdings, visit the URTH Holdings page » The chart below shows the one year price performance of URTH, versus its 200 day moving average: Looking at the chart above, URTH's low point in its 52 week range is $74.10 per share, with $102.2778 as the 52 week high point — that compares with a last trade of $76.11. | Below is a chart showing ABT's trailing twelve month trading history, with the $79.50 strike highlighted in red: Considering the fact that the $79.50 strike represents an approximate 5% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the May 1st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new May 1st contracts and identified one put and one call contract of particular interest."
2020-03-11,78.52999877929688,78.08999633789062,1.9923568624364336,"Health Care Sector Update for 03/11/2020: JNJ, PFE, ABT, MRK, AMGN, SPHS, CDMO, KALA","Health care stocks moving on news include: (-) Sophiris Bio (SPHS), which dropped more than 38% after the biopharmaceutical company announced that its shares will be delisted from Nasdaq on March 12. (-) Avid Bioservices (CDMO), which was also down more than 21% after reporting fiscal Q3 net loss of $0.06 per share, compared with a loss of $0.05 per share from a year earlier and missing the consensus estimate of a loss of $0.05 per share from analysts polled by Capital IQ. (+) Meanwhile, Kala Pharmaceuticals (KALA) rose more than 7% after pricing its offering of 16 million common shares at $7.89 per share for gross proceeds of about $126.2 million."
2020-03-10,79.2300033569336,80.87999725341797,-0.5602985460917252,,
2020-03-09,76.61000061035156,77.0199966430664,2.0825366989461074,,
2020-03-06,78.5999984741211,81.73999786376953,0.5351729923618418,,
2020-03-05,80.29000091552734,80.5199966430664,3.994910242501183,Why Abbott Labs Shares Fell 11.6% in February | Abbott Receives EU Approval For FlexNav Delivery System,"What happened Shares of Abbott Laboratories (NYSE: ABT) slipped 11.6% in February, according to data provided by S&P Global Market Intelligence, amid concern that a deepening of the coronavirus outbreak may hurt sales of companies with business in the country. Reuters reported that the company is developing a test and said Abbott was one of several diagnostics companies to meet with President Trump this week to discuss making tests more accessible. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | (RTTNews) - Abbott (ABT) said Thursday that it has received CE Mark for the new FlexNav delivery system for the company's Portico transcatheter aortic valve implantation system, enabling marketing authorization in Europe. Transcatheter aortic valve replacement is a minimally invasive alternative to surgical aortic valve replacement for patients at high or extreme risk for open heart surgery who are diagnosed with severe aortic stenosis, a condition which restricts blood flow through the valve. While valve technology improvements have helped reduce adverse events and improve patient outcomes, improvements to delivery systems are critical to improving the placement and positioning of the valve."
2020-03-04,80.66000366210938,82.08999633789062,0.2864562522312582,"Health Care Sector Update for 03/04/2020: JNJ, PFE, ABT, MRK, AMGN, MRNA, REPH, CNC, DRRX | Health Care Sector Update for 03/04/2020: JNJ, PFE, ABT, MRK, AMGN, DRRX, VVUS, VYGR","Health care stocks were stronger, including a 4% gain for the NYSE Health Care Index in recent trade. Health care stocks moving on news include: (+) Moderna (MRNA) gained almost 1% after the US Food and Drug Administration allowed its SARS-CoV-2 vaccine candidate, mRNA-1273, to advance into the clinic following a review of its new drug application. (+) VIVUS (VVUS) was up more than 4% after reporting Q4 net loss of $0.61 per share, compared with a loss of $1.04 per share sequentially and beating the consensus estimate of a loss of $0.68 per share in a Capital IQ poll. | Top health care stocks were up before markets open on Wednesday. (+) VIVUS (VVUS), which was up more than 6% after reporting Q4 net loss of $0.61 per share, compared with a loss of $1.04 per share sequentially and beating the consensus estimate of a loss of $0.68 per share from analysts polled by Capital IQ. (+) Voyager Therapeutics (VYGR), which added more than 2% after reporting Q4 net loss of $0.34 per share, narrower than the year-ago loss of $0.77 per share and beating the consensus estimate of a loss of $0.81 per share compiled by Capital IQ."
2020-03-03,81.58000183105469,77.98999786376953,1.7728646303707019,"Health Care Sector Update for 03/03/2020: JNJ, PFE, ABT, MRK, AMGN, KMPH, OMER, GNMK","Stocks moving on news include: (+) KemPharm (KMPH), which jumped more than 41% after submitting to the US Food and Drug Administration a new drug application for KP415, which is intended for the treatment of attention deficit hyperactivity disorder. (+) GenMark Diagnostics (GNMK), which gained more than 26% after the company narrowed its net loss to $0.17 per share in Q4 from $0.21 per share a year ago, but missed the analysts' estimates of $0.16 loss per share in a Capital IQ poll. (+) Omer (OMER), which rose almost 13% after reporting Q4 GAAP net loss of $0.58 per share, wider than both the $0.48 loss per share reported a year ago and the $0.35 loss per share average estimate of analysts surveyed by Capital IQ."
2020-03-02,77.87999725341797,81.61000061035156,-4.400593143794912,"Notable ETF Outflow Detected - IWB, CVX, MCD, ABT","Among the largest underlying components of IWB, in trading today Chevron Corporation (Symbol: CVX) is up about 0.1%, McDonald's Corp (Symbol: MCD) is up about 0.2%, and Abbott Laboratories (Symbol: ABT) is higher by about 1.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $115.0 million dollar outflow -- that's a 0.6% decrease week over week (from 124,700,000 to 124,000,000). For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $151.66 per share, with $188.47 as the 52 week high point — that compares with a last trade of $164.44."
2020-02-28,77.12000274658203,77.02999877929688,4.789424099228371,Validea Peter Lynch Strategy Daily Upgrade Report - 2/28/2020,"For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The Company's assets consist of systems, such as Clifton Ridge Crude System, Eagle Ford Gathering System, Ponca Crude System, Billings Crude System, Borger Crude System, Sweeny to Pasadena Products System, Hartford Connector Products System, Gold Line Products System, Cross-Channel Connector Products System, Ponca Products System, Billings Products System, Bayway Products System, Standish Pipeline, Borger Products System, River Parish NGL System, Medford Spheres, Bayway Rail Rack, Ferndale Rail Rack, Sand Hills/Southern Hills Joint Ventures, Explorer Pipeline Joint Venture, Bakken Joint Ventures, Bayou Bridge Pipeline Joint Venture, STACK Pipeline Joint Venture, and Sweeny Fractionator and Clemens Caverns. The Company is a holding company for IBERIABANK, a Louisiana state chartered banking corporation; Lenders Title Company, an Arkansas-chartered title insurance and closing services agency (Lenders Title); IBERIA Capital Partners LLC (ICP), a corporate finance services firm; 1887 Leasing, LLC, a holding company for its aircraft; IBERIA Asset Management, Inc. (IAM), which provides wealth management and trust advisory services to high net worth individuals, pension funds, corporations and trusts; 840 Denning, LLC, which invests in a commercial rental property, and IBERIA CDE, LLC (CDE), which invests in purchased tax credits."
2020-02-27,80.4000015258789,79.19000244140625,-0.1167063849581427,"Mylan Q4 Beats on Sales, Misses on EPS","On average, prognosticators tracking the stock expected $3.23 billion in revenue and an adjusted per-share net profit of $1.30. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) should come in at $3.2 billion to $3.9 billion against the latest result of $3.54 billion. 10 stocks we like better than Mylan When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen."
2020-02-26,82.12999725341797,81.36000061035156,-1.504973957100219,"Abbott's EPS Growth Is 2x Compared To Medtronic's | Diabetes Stock Insulet Drops 8.5% on Earnings Miss and Softer-Than-Expected Outlook | Better Buy: Exact Sciences vs. Bio-Rad Laboratories | If You Invested $5,000 in AbbVie IPO, This Is How Much Money You'd Have Now | What's The Upside For Intuitive Surgical's Stock? | What Happens With AbbVie If Its Allergan Buyout Is Blocked?","Abbott’s (NYSE:ABT) adjusted earnings per share (EPS) grew at a CAGR of 11% from $2.16 in 2015 to $3.26 in 2019. #2.1 Revenue Growth: Both Medtronic And Abbott’s Revenues Grew At A CAGR of Around 12% Between 2015 And 2019 Both Abbott and Boston Scientific saw similar growth in revenues in the recent years. #6 EPS Growth: Abbott’s EPS Grew 2x Faster Than Medtronic’s Medtronic’s adjusted EPS grew at a CAGR of 5.1% from $4.28 in fiscal 2015 to $5.22 in fiscal 2019. | Revenue $209.4 million $164.9 million 27% Operating income $18.2 million $16.2 million 12% Net income $5.0 million $9.9 million (49%) Earnings per share (EPS) $0.08 $0.16  (50%) Data source: Insulet. In the fourth quarter, global Omnipod revenue surged 30% year over year to $192.5 million. Management issued first quarter and full year revenue guidance: Q1: Revenue growth 17% to 20% year over year. | The case for Exact Sciences In contrast to Bio-Rad, Exact Sciences has performed relatively poorly over the past 12 months, having lost 6% of its value over that period compared to the S&P 500's 12% gain. Exact focuses on providing cancer diagnostic tests and products in the colorectal market, with its most iconic product being Cologuard, a noninvasive colon cancer diagnostic test. Bio-Rad $12.3 billion $624.4 million 2.3% $553.5 million 5.3x Exact Sciences $15.1 billion $295.6 million 106.7% $77.9 million 15.5x Data Source: YCharts, Bio-Rad, Exact Sciences. | AbbVie (NYSE: ABBV) was officially launched on Jan. 2, 2013 as a spinoff from Abbott Laboratories (NYSE: ABT). Cancer drug Imbruvica, which was the 14th best-seller in 2018, saw sales increase 28.9% in the fourth quarter, year over year, to $1.3 billion. Over the ensuing seven-plus years, the stock has returned about 20.1% per year with a total return of about 168%. | We estimate Intuitive Surgical’s fair price estimate to be around $652, based on expected EPS of $14.59 on an adjusted basis for full year 2020 and price to earnings multiple of 44.7x. In this dashboard on Intuitive Surgical’s valuation, we focus on four factors: revenue, net income margin, number of shares, and price to earnings multiple to arrive at our price estimate. Estimating Intuitive Surgical’s Stock Price: Our price estimate of $652 for Intuitive Surgical’s stock is based on our Detailed Valuation Model, and implies 44.7x P/E Multiple on expected 2020 Adjusted EPS of $14.59. | And for AbbVie's (NYSE: ABBV) pending acquisition of Allergan (NYSE: AGN), the ink hasn't dried yet. These groups pointed out in the letter to the FTC that AstraZeneca wasn't able to bring brazikumab to the market in the past and doesn't have the immunology infrastructure in place to be successful against AbbVie. AbbVie's plan B What would AbbVie's backup plan be if the FTC blocks its acquisition of Allergan?"
2020-02-25,84.93000030517578,81.12999725341797,-0.9375339934452045,3 Value Stocks to Buy if the Stock Market Implodes,"The pharmaceutical companies AbbVie (NYSE: ABBV), Bausch Health Companies Inc. (NYSE: BHC), and Bristol-Myers Squibb (NYSE: BMY) are all trading at less than 10 times next year's projected earnings right now. See the 10 stocks *Stock Advisor returns as of December 1, 2019 George Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bausch Health Companies, Berkshire Hathaway (B shares), and Bristol-Myers Squibb and recommends the following options: long January 2021 $200 calls on Berkshire Hathaway (B shares), short January 2021 $200 puts on Berkshire Hathaway (B shares), and short March 2020 $225 calls on Berkshire Hathaway (B shares)."
2020-02-24,85.44999694824219,84.62999725341797,-4.474276507833986,Interesting ABT Put And Call Options For April 17th,"Below is a chart showing ABT's trailing twelve month trading history, with the $87.50 strike highlighted in red: Considering the fact that the $87.50 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the April 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new April 17th contracts and identified one put and one call contract of particular interest."
2020-02-21,88.04000091552734,87.44999694824219,-0.9596251891277419,"IWB, ABT, AMGN, LIN: Large Outflows Detected at ETF","Among the largest underlying components of IWB, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.7%, Amgen Inc (Symbol: AMGN) is up about 0.2%, and Linde plc (Symbol: LIN) is lower by about 1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $75.0 million dollar outflow -- that's a 0.3% decrease week over week (from 125,100,000 to 124,700,000). For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $151.66 per share, with $188.47 as the 52 week high point — that compares with a last trade of $185.83."
2020-02-20,89.0999984741211,88.45999908447266,-0.6701544311105284,"Abbott Presents Data Showing its Glucose Monitor Helps People With Diabetes | Abbott Labs Recalls Some Catheters Due to Possible Defects | Health Care Sector Update for 02/20/2020: TOCA, FMS, TEVA, JNJ, ABT, MRK, PFE, AMGN | The Growth Opportunity That Will Move Medtronic Ahead of Its Rivals | Abbott's FreeStyle Libre Shows Positive Outcomes For Type 1, Type 2 Diabetes","At the 13th Advanced Technologies & Treatments for Diabetes meeting, Abbott Laboratories (NYSE: ABT) is presenting a series of studies showing that its glucose monitor FreeStyle Libre system helped people with diabetes across the globe improved their glucose levels. An analysis by Abbott of patients in Sweden's National Diabetes Register showed patients using the system for three months to nine months had a 0.44% reduction in HbA1c for people with Type 1 diabetes and 0.67% for people with Type 2 diabetes. Finally, a study from the U.S. of more than 12,000 people with diabetes who switched from using test strips to using a continuous glucose monitor, including the FreeStyle Libre, showed that switching reduced acute diabetes complications by 44% in patients with Type 1 diabetes and by 51% in patients with Type 2 diabetes. | The U.S. Food and Drug Administration stated on Wednesday that some lots of two catheters models sold by Abbott Laboratories (NYSE: ABT) needed to be recalled due to potentially severe safety issues. ""Use of these devices may cause serious adverse health consequences, such as prolonged cardiac ischemia (reduced blow flow to the heart), air embolism, thrombosis (clot in the artery), myocardial infarction (heart attack), and additional surgery that could lead to post-operative complications, including death,"" warned the agency in an official statement. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Mark Prvulovic has no position in any of the stocks mentioned. | ABT: Flat MRK: Flat Moving stocks include: (+) Tocagen (TOCA), which was surging 70% after saying it entered into an agreement to merge with privately held Forte Biosciences in an all-stock transaction. (-) Teva Pharmaceutical (TEVA) was declining more than 2% after saying its two clinical trials evaluating deutetrabenazine as treatment for pediatric patients with moderate to severe Tourette syndrome failed to meet the primary endpoint. | The stand-alone CGM market continues to show progress as well, with 50% growth in the third quarter; here, Medtronic competes with market leader DexCom (NASDAQ: DXCM) as well as emerging rival Abbott Laboratories (NYSE: ABT). Cardiac and Vascular Group Heart failure, coronary heart disease, surgical tools 36.9% 37.7% 37.9% 35.3% 9.6% Minimally Invasive Therapies Group Surgical tools; therapies for lungs, stomach, kidneys 28% 27.7% 29.1% 33.4% (14.5%) Restorative Therapies Group Therapies for spine, neurological disorders, and pain 27.2% 26.8% 25.9% 24.8% 11.1% Diabetes Group Insulin pumps, blood sugar monitors (continuous glucose monitoring), therapy management software 7.9% 7.8% 7.1% 6.5% 24.1% Source: Medtronic. Dominance in the insulin pump space Medtronic's MiniMed pumps have been a major sales driver in the past, and the international markets provide growth opportunities that should offset a U.S. revenue decline brought on by increased competition. | (RTTNews) - Abbott (ABT) said four real-world data showed that users of the FreeStyle Libre system have improved glucose control, increased time in target glucose range, and decreased time in hyperglycemiaiv or high glucose levels and hypoglycemia or low glucose levels, as well as reduced HbA1Ci (average glucose levels over a three month period). Abbott's FreeStyle Libre system is now being used by more than 2 million people living with diabetes across 46 countries.Abbott has secured partial or full reimbursement for the FreeStyle Libre system in 36 countries, including France, Ireland, Japan, the United Kingdom, and the U.S. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2020-02-19,88.83000183105469,89.36000061035156,-0.7182933789099042,"Insulet Announces Agreements With Abbott and DexCom | Health Care Sector Update for 02/19/2020: JNJ, PFE, ABT, MRK, AMGN, MREO, AMED, CTSO | Is DexCom's Stock a Buy?","On Wednesday, insulin pump maker Insulet (NASDAQ: PODD) announced agreements with Abbott (NYSE: ABT) and DexCom (NASDAQ: DXCM), two leading sellers of continuous glucose monitors (CGMs), to sell automated insulin delivery systems. The increasing cooperation between Insulet and DexCom on an integrated system should come as little surprise, as the companies had already announced their partnership as part of Insulet's development program for Horizon, which is in a pivotal trial with up to 240 participants. The Horizon system was designed to work with multiple sensors, and although Abbott was the logical choice as a second partner, Insulet hadn't previously confirmed the companies were working on an integrated product. | Among stocks moving on news: (+) Cytosorbents (CTSO), which gained nearly 14% after announcing that it has signed a deal with pharmaceutical company China Medical System to bring CytoSorb to mainland China to treat critically ill patients infected by the novel coronavirus. Revenue grew to $500.68 million from $434.38 million a year ago, lagging the $511.58 million estimate. (+) Mereo BioPharma (MREO), which gained almost 5% after announcing that a US-based institutional health care investor agreed to invest $3 million to purchase 12.3 million of the company's common shares. | Another initiative the company is focusing on is a new G7 product, with DexCom looking to offer patients a slimmer, less expensive product. Tandem Diabetes is another diabetes company that had revenue of $94.7 million in its third-quarter, which is more than double the sales the company recorded in the prior-year quarter. While there are many CGM products available on the market, and many are cheaper than DexCom's, the company's impressive sales numbers suggest that's not a concern, at least not yet."
2020-02-18,89.41999816894531,88.87999725341797,0.596643890996284,Want to Know What Your Heart Defibrillator Is Doing? Abbott Has an App for That,"Abbott (NYSE: ABT) has received European approval for its new Gallant implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices for patients with abnormal heart rhythms and heart failure. In addition to all the normal functions of a defibrillator, which shocks a patient's heart back into normal rhythms if it starts beating erratically, the new devices can connect to Abbott's myMerlinPulse mobile app via Bluetooth to give doctors and patients more information on what's happening with the device. In addition their remote-monitoring capabilities, the Gallant devices have all the bells and whistles of its earlier model defibrillators, including the ability to program the ICD to a patient's specific needs and Abbott's MultiPoint Pacing and SyncAV features in the CRT-D, which increase the likelihood that patients will respond to CRT therapy."
2020-02-14,88.87000274658203,89.66000366210938,-0.6038927830294687,3 Reasons AbbVie Is a Better Bargain Than You Might Think,"For investors who have fretted about the impact that loss of exclusivity for Humira would have on AbbVie, the fact that the company's protection plan for the drug appears to be working well overall is very good news. AbbVie has an ace in the hole While AbbVie's shares trade at only nine times expected earnings, some investors won't consider the stock a bargain because of its longer-term prospects are clouded by the future for Humira. The combination of a strong lineup of other drugs with fast-growing sales, the likely addition of more drugs on the way with the close of the Allergan deal, and its mouth-watering dividend should provide solid total returns for AbbVie over the long run."
2020-02-13,88.5,88.68000030517578,0.888939902230089,"Notable ETF Inflow Detected - IHI, ABT, DHR, SYK | Better Buy: Abbott Laboratories vs. Novo Nordisk","Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.9%, Danaher Corp (Symbol: DHR) is off about 0.8%, and Stryker Corp (Symbol: SYK) is up by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $68.0 million dollar inflow -- that's a 1.4% increase week over week in outstanding units (from 18,300,000 to 18,550,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $211.47 per share, with $278.19 as the 52 week high point — that compares with a last trade of $270.69. | Both Novo Nordisk (NYSE: NVO) and Abbott Laboratories (NYSE: ABT) are great examples, with market caps of around $150 billion each. Both of these stocks look to be attractive long-term buys, and in three years both have outperformed the Health Care Select Sector SPDR ETF: ABT data by YCharts. Abbott's strength is its diversification For investors who are in search of consistency, Abbott Laboratories offers a strong mix of dividends and growth that other stocks simply can't beat."
2020-02-12,89.55999755859375,88.79000091552734,0.2033901753398658,AbbVie Is a Dividend Growth Stock at a Bargain Price,"With the stock still trading at a discount to the market multiple and a dividend yield of 4.6%, AbbVie still has plenty of appeal for the long-term investor. Sales of AbbVie's hematological oncology drugs grew 39% to over $1.5 billion, driven by Imbruvica and Venclexta which combined for $5.5 billion in sales in 2019. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Greg Jones owns shares of AbbVie."
2020-02-11,88.63999938964844,89.16999816894531,-0.8597550960881207,,
2020-02-10,87.20999908447266,88.30000305175781,0.5979228146957426,,
2020-02-07,89.2300033569336,87.87000274658203,1.249861230051574,"Health Care Sector Update for 02/07/2020: JNJ, PFE, ABT, MRK, AMGN, ASRT, ZGNX, MYGN","ABT: flat AMGN: flat Top health care stocks were mixed during pre-market trading hours on Friday. Health care stocks moving on news include: (+) Assertio Therapeutics (ASRT), which jumped more than 65% after the pharmaceutical company agreed to sell the Nucynta franchise products to Collegium Pharmaceutical for $375 million in cash."
2020-02-06,90.0,89.47000122070312,-1.5241516969481141,"Health Care Sector Update for 02/06/2020: BDX, CAH, CI, JNJ, ABT, MRK, PFE, AMGN","Stocks moving on news include: (-) Becton Dickinson (BDX), which was slipping more than 9% as it booked fiscal Q1 adjusted earnings of $2.65 per share, down from $2.70 a year ago and beating the $2.64 average estimate from analysts polled by Capital IQ. (+) Cardinal Health (CAH) was rallying more than 6% after it posted fiscal Q2 non-GAAP EPS of $1.52, up from $1.29 in the year-ago quarter and above the Capital IQ estimate of $1.22 a share. (+) Cigna (CI) was up more than 2% after it reported a Q4 net income of $4.31 per share in adjusted terms, up from $2.46 per share in the year-ago period and well above the consensus of $4.20 per share from analysts polled by Capital IQ."
2020-02-05,88.87000274658203,89.55999755859375,-0.5888875325520834,"Noteworthy ETF Outflows: IWB, WMT, ABT, BMY | Health Care Sector Update for 02/05/2020: AIMT, NVO, JNJ, PFE, ABT, MRK, AMGN | Health Care Sector Update for 02/05/2020: AIMT, NVO, JNJ, PFE, ABT, MRK, AMGN","Among the largest underlying components of IWB, in trading today Walmart Inc (Symbol: WMT) is up about 0.2%, Abbott Laboratories (Symbol: ABT) is up about 0.6%, and Bristol-Myers Squibb Co. (Symbol: BMY) is higher by about 1.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $91.5 million dollar outflow -- that's a 0.4% decrease week over week (from 125,200,000 to 124,700,000). For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $149.19 per share, with $184.79 as the 52 week high point — that compares with a last trade of $183.87. | Stocks moving on news include: (+) Aimmune Therapeutics (AIMT), which was almost 7% higher after the biopharmaceutical company said Nestle Health Science would make an additional equity investment of $200 million, bringing its total investment to $473 million. (+) Novo Nordisk (NVO) was climbing more than 3% as it booked Q4 earnings of DKK3.70 ($0.55) per share, up from DKK3.53 per share in the year-ago quarter, which was behind consensus compiled by Capital IQ for DKK3.76 a share. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks moving on news include: (+) Aimmune Therapeutics (AIMT), which was almost 7% higher after the biopharmaceutical company said Nestle Health Science would make an additional equity investment of $200 million, bringing its total investment to $473 million. (+) Novo Nordisk (NVO) was climbing more than 3% as it booked Q4 earnings of DKK3.70 ($0.55) per share, up from DKK3.53 per share in the year-ago quarter, which was behind consensus compiled by Capital IQ for DKK3.76 a share. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2020-02-04,88.1500015258789,88.2300033569336,0.7764091264622541,,
2020-02-03,87.77999877929688,87.05999755859375,0.09075647154833084,Abbott Laboratories Reports Rise In Q2 Earnings | Abbott's Trial To Assess New Therapy Option For People At Risk Of Stroke | Why Abbott Laboratories Just Became an Even Better Buy,"(RTTNews) - Abbott Laboratories (ABT) reported earnings for its second quarter that rose from last year. The company's revenue for the quarter rose 5.7% to $25.8 million from $24.4 million last year. -Revenue (Q2): $25.8 Mln vs. $24.4 Mln last year. | (RTTNews) - Abbott (ABT) said that the U.S. Food and Drug Administration has approved a new trial designed to assess its Amplatzer Amulet Left Atrial Appendage Occluder for people with atrial fibrillation or AF - a condition in which the normal rhythm of the heart's upper chambers is disrupted and becomes erratic - who are at risk of stroke. The CATALYST trial is the first-ever clinical trial comparing the effectiveness of a left atrial appendage (LAA) closure device to a newer class of blood thinners, known as non-vitamin K antagonist oral anticoagulant (NOAC) drugs, which are currently the standard treatment option for AF. Blood thinners, first warfarin and now NOACs, are commonly the first-line therapy to reduce the risk of ischemic stroke - the most common type of all stroke - in patients with AF who are at an increased risk. | Abbott Laboratories (NYSE: ABT) has been a great buy for many years. The company showed strong sales growth in 2019 Abbott released its fourth-quarter earnings on Jan. 22, and the numbers were very strong. It was the same story when looking at the company's full-year results, as Abbott's revenue growth of 4.3% was well above the 1.7% increase that its operating expenses rose by, leaving more of the top line to trickle through to the bottom."
2020-01-31,89.12999725341797,87.13999938964844,-0.8202338012255008,,
2020-01-30,88.29000091552734,89.16000366210938,-2.2326914900619705,,
2020-01-29,89.61000061035156,89.13999938964844,0.9853921594297164,MIT Researchers Create First Bionic Heart to Test Cardiac Devices,"While still at an experimental stage, this device could be useful for major medical device manufacturers, such as Abbott Laboratories (NYSE: ABT) and Medtronic (NYSE: MDT), in helping test the next generation of cardiac devices. While it's an impressive technical achievement to produce a heart which so accurately mimics the human heart, this device is expected to be very useful for medical device makers, that can better test new cardiac devices for potential complications without using live patients. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Mark Prvulovic has no position in any of the stocks mentioned."
2020-01-28,89.69999694824219,89.54000091552734,-0.5244963927037753,"Health Care Sector Update for 01/28/2020: XLRN, PHG, JNJ, ABT, MRK, PFE, AMGN | 3 Dividend Stocks Perfect for Retirees","Top Health Care Stocks: JNJ: Flat Leading health care stocks were mixed pre-market Tuesday. (-) Royal Philips (PHG) was down more than 3% after posting a Q4 adjusted EPS of EUR0.83 ($0.91), up from EUR0.76 a year ago and in line with the average estimate of EUR0.83 from analysts surveyed by Capital IQ. | Retirees have to strike a balance among stocks that offer big enough yields to create a meaningful stream of income, trade at valuations that protect the principal of the investment, and have business strengths that will allow them to navigate some twists and turns and keep the dividends flowing. The company's mobile wireless business is sturdy and poised to benefit from 5G tailwinds, its Time Warner has a runway for growth amid growing global demand for entertainment content, and its DirecTV satellite television subsidiary is still generating substantial free cash flow (even though it's losing subscribers due to cord-cutting). The biopharmaceutical company's shares now trade at roughly 8.5 times this year's expected earnings and look attractively valued for retirees seeking high yield stocks."
2020-01-27,89.11000061035156,89.58999633789062,-0.17836793551638924,,
2020-01-24,90.8499984741211,90.4000015258789,0.5386552847619477,Abbot's Brain Stimulation System Approved to Treat Parkinson's,"Abbott Laboratories (NYSE: ABT) announced on Friday that it's Infinity Deep Brain Stimulation (DPS) system had received approval from the Food and Drug Administration (FDA) to target specific areas of the brain associated with motor functions. More specifically, the expanded indication permits Abbott's DPS system to target the internal globus pallidus (GPi), a specific part of the brain that regulates voluntary movement. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Mark Prvulovic has no position in any of the stocks mentioned."
2020-01-23,91.80999755859376,90.7300033569336,-0.4953186084756738,Abbott's Proclaim XR Neurostimulation Implant Device Said to Reduce Pain | Abbott Announces Positive Results In Chronic Pain Study,"At the 2020 North American Neuromodulation Society annual meeting, Abbott (NYSE: ABT) reported data from a clinical trial testing its Proclaim XR neurostimulation implant in patients with chronic pain. Using another measure for pain, the Oswestry Disability Index (ODI), 78% of patients had a score of ""severe,"" ""crippling,"" or ""bed bound,"" at the start of the study, which was reduced to just 29% of patients after six months of having the implant -- with none of the patients reported as ""bed bound."" See the 10 stocks *Stock Advisor returns as of December 1, 2019 Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. | (RTTNews) - Abbott (ABT) announced positive results from a study, providing the scientific basis for the company's Proclaim XR recharge-free neurostimulation system for people living with chronic pain. The company noted that its proclaim XR system allows physicians to identify the lowest effective dose of BurstDR stimulation customized to each patient, optimizing system longevity while maintaining effective pain and symptom relief, and eliminating the need for recharging (for up to 10 years at low-dose settings). About 30% of those living with chronic pain develop depression or psychological effects when patients develop a preoccupation with pain that makes it difficult to live a normal life."
2020-01-22,90.77999877929688,91.86000061035156,-1.1763361620513177,"Health Care Sector Update for 01/22/2020: AKCA, IONS, JNJ, PFE, ABT, MRK, AMGN | Abbott Laboratories (ABT) Q4 2019 Earnings Call Transcript | Wednesday Sector Leaders: Healthcare, Technology & Communications | Abbott Laboratories Beats Revenue Expectations With Balanced Growth | Abbott Laboratories Guides FY20 Adj. EPS In Line - Quick Facts | Here's Why Investors Really Liked Abbott Labs' Q4 Earnings Results | Abbott Laboratories Q4 adjusted earnings Inline With Estimates | Abbott Laboratories Q4 19 Earnings Conference Call At 9:30 AM ET | Abbott Laboratories Q4 19 Earnings Conference Call At 9:30 AM ET","(+) Abbott Laboratories (ABT) was over 1% higher as it posted Q4 adjusted earnings of $0.95 per diluted share, up from $0.81 per share a year ago but in line with the $0.95 average analyst estimate compiled by Capital IQ. Early movers include: (+) Akcea Therapeutics (AKCA), which was climbing by more than 13% after the company and Ionis Pharmaceuticals (IONS) reported positive topline results from a phase 2 study of the drug AKCEA-APOCIII-LRx to treat patients with hypertriglyceridemia who are at risk for or have established cardiovascular disease (CVD). In other sector news: (-) Johnson & Johnson (JNJ) was slipping by more than 1% after booking Q4 adjusted earnings of $1.88 per share, down from $1.97 a year ago but narrowly topping the $1.87 average estimate from analysts polled by Capital IQ. | Operator [Operator Closing Remarks] Duration: 62 minutes Call participants: Scott Leinenweber -- Vice President of Investor Relations, Licensing and Acquisitions Miles D. White -- Chairman and Chief Executive Officer Brian B. Yoor -- Executive Vice President of Finance and Chief Financial Officer Robert B. Ford -- President and Chief Operating Officer Bob Hopkins -- Bank of America Merrill Lynch -- Analyst Robert Marcus -- J.P. Morgan -- Analyst David Lewis -- Morgan Stanley -- Analyst Vijay Kumar -- Evercore ISI -- Analyst Larry Biegelsen -- Wells Fargo -- Analyst Rick Wise -- Stifel Nicolaus -- Analyst Kristen Stewart -- Barclays -- Analyst More ABT analysis All earnings call transcripts 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Abbott Laboratories (NYSE: ABT) Q4 2019 Earnings Call Jan 22, 2020, 9:30 a.m. In Diagnostics, we forecast mid to high single-digit growth for both the first quarter and full year, and in Medical Devices, we forecast double-digit growth similar to last year for both the first quarter and full year. | Within that group, Abbott Laboratories (Symbol: ABT) and Align Technology Inc (Symbol: ALGN) are two large stocks leading the way, showing a gain of 2.7% and 2.4%, respectively. Combined, ABT and ALGN make up approximately 4.6% of the underlying holdings of XLV. Among healthcare ETFs, one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is up 0.4% on the day, and up 3.14% year-to-date. | Abbott Laboratories (NYSE: ABT) released its fourth-quarter  report Wednesday morning, beating expectations for revenue and meeting its guidance for earnings per share. For the quarter, revenue rose by 7.1% year over year to $8.31 billion  compared to analysts' consensus estimate of $8.26 billion, and was up 8.5% after excluding foreign currency effects and a discontinued business. Adjusted earnings per share were up 17.3% to $0.95, precisely hitting the midpoint of the guidance range management provided three months ago. | (RTTNews) - While reporting its financial results for the fourth quarter on Wednesday, Abbott Laboratories (ABT) initiated earnings and organic sales growth guidance for the full-year 2020. For fiscal 2020, the company now expects earnings from continuing operations in a range of $2.35 to $2.45 per share and adjusted earnings from continuing operations in a range of $3.55 to $3.65 per share on organic sales growth of 7.0 to 8.0 percent, which excludes the impact of foreign exchange. On average, analysts polled by Thomson Reuters expect the company to report earnings of $3.60 per share for the year. | It's fair to say that Abbott Laboratories' (NYSE: ABT) stock performance in 2019 was good but not great. The company's medical devices unit was the biggest winner, with revenue jumping 9.7% year over year to $3.2 billion thanks to double-digit organic sales growth in its diabetes care, electrophysiology, heart failure, and structural heart businesses. Abbott remains one of the top blue chip stocks on the market with solid growth and an attractive dividend. | (RTTNews) - Abbott Laboratories (ABT) reported a profit for its fourth quarter that climbed from the same period last year. This compares with $0.65 billion, or $0.37 per share, in last year's fourth quarter. The company's revenue for the quarter rose 6.9% to $8.31 billion from $7.77 billion last year. | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:30 AM ET on January 22, 2020, to discuss Q4 19 earnings results. To access the live webcast, log on to www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:30 AM ET on January 22, 2020, to discuss Q4 19 earnings results. To access the live webcast, log on to www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2020-01-21,88.86000061035156,89.7300033569336,1.1896913919115306,"VIG, CMCSA, ABT, COST: ETF Inflow Alert","Among the largest underlying components of VIG, in trading today Comcast Corp (Symbol: CMCSA) is down about 0.8%, Abbott Laboratories (Symbol: ABT) is off about 0.1%, and Costco Wholesale Corp (Symbol: COST) is up by about 2.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $535.3 million dollar inflow -- that's a 1.2% increase week over week in outstanding units (from 333,554,755 to 337,717,239). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $101.11 per share, with $128.64 as the 52 week high point — that compares with a last trade of $128.38."
2020-01-17,88.44999694824219,89.0,0.9790712813484745,,
2020-01-16,87.94000244140625,88.27999877929688,0.6218237091400408,,
2020-01-15,86.11000061035156,87.37999725341797,0.3866230707887027,,
2020-01-14,84.12999725341797,85.73999786376953,1.4748538312212436,,
2020-01-13,85.5,85.12000274658203,1.9137057683502452,"Notable ETF Inflow Detected - IHI, ABT, DHR, SYK | Health Care Sector Update for 01/13/2020: JNJ, PFE, ABT, MRK, AMGN, IOVA, OCX, NVTA | 5 Dividend Aristocrats Where Analysts See Capital Gains","Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.2%, Danaher Corp (Symbol: DHR) is up about 0.3%, and Stryker Corp (Symbol: SYK) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $80.7 million dollar inflow -- that's a 1.6% increase week over week in outstanding units (from 18,400,000 to 18,700,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $200.84 per share, with $270.7396 as the 52 week high point — that compares with a last trade of $268.73. | ABT: flat MRK: flat AMGN: flat The majority of the biggest stocks in the health care sector were flat during pre-market trading hours on Monday. The company said it has recently agreed to acquire privately-held Insight Genetics for $12 million, consisting of $7 million cash and the rest in shares. The company recently agreed to an exclusive worldwide license agreement with Cellectis (CLLS) to develop tumor-infiltrating lymphocytes to create more potent cancer therapeutics. | UGI Corp. (Symbol: UGI) $44.10 $53.67 21.69% New Jersey Resources Corp (Symbol: NJR) $42.82 $52.00 21.44% International Business Machines Corp (Symbol: IBM) $136.69 $154.25 12.85% Abbott Laboratories (Symbol: ABT) $85.36 $95.50 11.88% Smith (A O) Corp (Symbol: AOS) $47.62 $52.43 10.10% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. UGI Corp. (Symbol: UGI) 2.95% 21.69% 24.64% New Jersey Resources Corp (Symbol: NJR) 2.92% 21.44% 24.36% International Business Machines Corp (Symbol: IBM) 4.74% 12.85% 17.59% Abbott Laboratories (Symbol: ABT) 1.69% 11.88% 13.57% Smith (A O) Corp (Symbol: AOS) 2.02% 10.10% 12.12% Another consideration with dividend growth stocks is just how much the dividend is growing. UGI Corp. (Symbol: UGI) $1.03 $1.21 17.48% New Jersey Resources Corp (Symbol: NJR) $1.132 $1.212 7.07% International Business Machines Corp (Symbol: IBM) $6.21 $6.43 3.54% Abbott Laboratories (Symbol: ABT) $0.84 $1.28 52.38% Smith (A O) Corp (Symbol: AOS) $0.76 $0.9 18.42% These five stocks are part of our full Dividend Aristocrats List."
2020-01-10,86.79000091552734,85.36000061035156,-0.44444123206779973,"Health Care Sector Update for 01/10/2020: JNJ, PFE, ABT, MRK, AMGN, ACRS, MRNA, PTLA","ABT: flat AMGN: flat Most of the leading health care stocks were trading higher before markets open on Friday. Among health care stocks moving on news: (-) Portola Pharmaceuticals (PTLA), which dipped more than 40%."
2020-01-09,86.30000305175781,86.44000244140625,-1.6476555940673394,,
2020-01-08,86.23999786376953,86.20999908447266,0.16222408423841406,,
2020-01-07,85.7699966430664,85.86000061035156,-0.034785227319071924,Abbott : FDA Okays Less Invasive Surgical Approach To Avoid Open Heart Surgery | The 10 Best Healthcare Stocks of the Decade | 3 Top Medical Device Stocks to Buy in January,"(RTTNews) - Abbott Laboratories (ABT) said that the U.S. Food and Drug Administration has approved a new alternative surgical technique for the company's HeartMate 3 heart pump that will allow more advanced heart failure patients to avoid open heart surgery. The company noted that Heart pumps are small, implantable mechanical devices that pump blood through the body in people whose heart is too weak to do so on its own. But, Abbott's HeartMate 3 heart pump can now be implanted via lateral thoracotomy - a surgical approach where an incision is made between a patient's ribs to access the heart. | The company provides simulation software and services to drug companies to help with drug discovery and development. Instead of taking the risks of drug discovery and drug failure, you can invest in Repligen, a company that provides equipment to a multitude of companies so that biologic drugs can be manufactured. Neurocrine Biosciences $2.77 $109.78 3,863% ACADIA Pharmaceuticals $1.32 $40.35 2,956% Exact Sciences $3.50 $94.94 2,612% DexCom $8.21 $218.70 2,563% Repligen $4.17 $92.74 2,123% Simulations Plus $1.37 $28.79 2,001% Accelerate Diagnostics $0.89 $17.03 1,813% NeoGenomics $1.55 $29.31 1,790% Abiomed $8.86 $166.82 1,782% Jazz Pharmaceuticals $8.06 $145.10 1,700% It's been a pretty amazing decade for healthcare stocks. | Abbott Labs Abbott Laboratories (NYSE: ABT) ranks as one of the most attractive blue chip stocks on the market right now, in my view. Intuitive Surgical Intuitive Surgical (NASDAQ: ISRG) is another big medical device stock that underperformed a bit last year. Although increased competition usually isn't great news for a stock, my view is that the moves by Medtronic and others to launch new products will expand the robotic surgery market and benefit Intuitive Surgical over the long run."
2020-01-06,85.62000274658203,86.33999633789062,0.1049364239335459,"Health Care Sector Update for 01/06/2020: JNJ, PFE, ABT, MRK, AMGN, LIFE, LPTX, NOVN","ABT: flat Most top health care stocks were trading lower during pre-market hours on Monday. Among stocks moving on news: (+) aTyr Pharma (LIFE), which is up more than 67%, after the company signed a deal with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATYR1923, a drug candidate for interstitial lung disease, in Japan."
2020-01-03,85.75,85.88999938964844,0.8409175055035092,,
2020-01-02,86.05999755859375,86.94999694824219,0.16326459434220117,"SPDR Portfolio S&P 500 Growth ETF Experiences Big Outflow | Health Care Sector Update for 01/02/2020: JNJ, PFE, ABT, MRK, AMGN, IPHA, ONTX, AERI | Does Medtronic's Current P/E Ratio Offer Any Opportunity To Investors? | How Does Abbott's Revenue And Other Key Metrics Compare With That of Boston Scientific?","Among the largest underlying components of SPYG, in trading today Salesforce.com Inc (Symbol: CRM) is up about 1.3%, Broadcom Inc (Symbol: AVGO) is up about 1.1%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR— Portfolio S&P 500— Growth ETF (Symbol: SPYG) where we have detected an approximate $1.0 billion dollar outflow -- that's a 15.8% decrease week over week (from 152,050,000 to 128,000,000). For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $31.55 per share, with $42.30 as the 52 week high point — that compares with a last trade of $42.18. | AMGN: Flat Most of the biggest stocks in the health care sector were gaining during pre-market trading hours on Thursday. Among health care stocks moving on news: (+) Innate Pharma (IPHA), which rose more than 23%, after announcing that the European Medicines Agency has accepted its marketing authorization application for Lumoxiti for the treatment of adult patients with relapsed or refractory hairy cell leukemia. (+) Onconova Therapeutics (ONTX), which was up more than 6%, after announcing plans for a $10 million private placement, selling nearly 27.7 million common shares to two healthcare-focused institutional investors at 36.15 cents apiece. | Medtronic vs. S&P 500: Higher 2020 Revenue Growth For Medtronic Could Present Opportunity Medtronic’s P/E has been consistently lower than the S&P 500, explained by Medtronic’s smaller revenue growth for the most part. Medtronic vs. Boston Scientific: Compared to Boston Scientific, Medtronic’s P/E Ratio is much lower This is expected given that Medtronic’s Revenue Growth has been consistently lower than Boston Scientific’s, even though margins are comparable. Medtronic vs. Abbott: Compared to Abbott as well, Medtronic’s P/E Ratio is much lower Medtronic’s Revenue Growth has largely been lower than Abbott’s, even though Medtronic’s margins are slightly higher. | Abbott (NYSE:ABT) and Boston Scientific (NYSE:BSX) are both engaged in the medical devices business. Abbott’s Revenues of $31 Billion Are Much Higher Than $10 Billion For Boston Scientific Abbott and Boston Scientific are both engaged primarily in the Medical Devices business. Abbott’s Revenues Grew At A Higher Pace On Average When Compared To Boston Scientific Both Abbott and Boston Scientific saw growth in revenues in the recent years."
2019-12-31,86.5,86.86000061035156,1.0341615325313989,"Health Care Sector Update for 12/31/2019: NVCN, SVRA, JNJ, PFE, ABT, MRK, AMGN | How Much Revenue Does Abbott Generate From The United States?","ABT: Flat AMGN: Flat Health care giants were flat to lower pre-bell Tuesday. Stocks moving on news include: (+) Neovasc (NVCN), which was surging more than 107% after saying it has submitted a pre-market approval application to the US Food and Drug Administration for its Neovasc Reducer medical device for the treatment of refractory angina. | Abbott (NYSE:ABT) generates its revenue from sales of medical devices across the globe. Abbott’s Revenue Contribution As of 2018: United States ~ 35% China ~ 8% Germany ~ 5% India ~ 4% Japan ~ 4% Switzerland ~ 3% The Netherlands ~ 3% Others ~ 38% Abbott’s Sales In the United States Are Higher Than That of Boston Scientific, But Lower Than Medtronic Abbott’s sales in the United States grew from $6.1 billion in 2014 to $10.8 billion in 2018. The Contribution of the United States To Abbott’s Total Sales Has Increased In The Recent Years Abbott’s total sales grew from $20.2 billion in 2014 to $30.6 billion in 2018."
2019-12-30,87.5199966430664,86.80000305175781,0.4161856767070087,7 High-Yield Dividend Stocks for Growth and Income in the 2020s,"Those who bought the stock as late as 2003 and reinvested the dividend in more MO stock now earn their initial investment back in payouts alone. Since dividend aristocrats such as T stock tend to suffer for years when they cut payouts, investors can likely expect continued increases in future years. Throughout Mr. Dudley’s tenure, BP became a dividend stocks that did not see significant stock price gains."
2019-12-27,87.48999786376953,87.4000015258789,-0.8226618132138991,,
2019-12-26,87.20999908447266,87.27999877929688,-0.10286471606818198,,
2019-12-24,87.37000274658203,87.27999877929688,0.08026567544900007,,
2019-12-23,86.30999755859375,87.3499984741211,-0.10301472411099043,,
2019-12-20,88.98999786376953,86.66000366210938,1.204959964019594,"Noteworthy Friday Option Activity: ABT, WNC, MS","Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Abbott Laboratories (Symbol: ABT), where a total volume of 23,433 contracts has been traded thus far today, a contract volume which is representative of approximately 2.3 million underlying shares (given that every 1 contract represents 100 underlying shares). Especially high volume was seen for the $50 strike call option expiring January 17, 2020, with 5,861 contracts trading so far today, representing approximately 586,100 underlying shares of MS. Below is a chart showing MS's trailing twelve month trading history, with the $50 strike highlighted in orange: For the various different available expirations for ABT options, WNC options, or MS options, visit StockOptionsChannel.com. That number works out to 54.7% of ABT's average daily trading volume over the past month, of 4.3 million shares."
2019-12-19,86.73999786376953,87.3499984741211,-2.618265263054654,This Dividend Aristocrat Just Gave Shareholders a Great Gift,Abbott Laboratories (NYSE: ABT) has a gift on the way for all of its shareholders. Abbott's dividend increase brings the healthcare giant's dividend yield to nearly 1.7%. That track record lands Abbott a spot among the elite group of stocks known as Dividend Aristocrats -- S&P 500 members that have raised their dividends for at least 25 years in a row.
2019-12-18,87.08000183105469,86.93000030517578,0.7032518162031843,,
2019-12-17,86.58000183105469,87.05999755859375,-0.17225714598620084,,
2019-12-16,86.94999694824219,86.4000015258789,0.554395607978489,2 Stocks You Can Keep Forever | Is AbbVie’s Dividend Capable Of Long-Term Growth?,"Abbott Laboratories Abbott Laboratories (NYSE: ABT) is another Dividend Aristocrat that investors can add to their list for long-term dividend income. The medical device maker's dividend yield of 1.5% is a more modest payout than what Coca-Cola offers, but the company's streak of increasing dividends for more than 40 straight years makes it a formidable income stock for investors. The healthcare stock's impressive track record for dividends and impressive mix of products makes it a good stock to buy and hold forever. | Nearly 20 years ago on Dec. 15, 2000, medical device and pharmaceutical maker Abbott Laboratories (NYSE: ABT) announced its $6.9 billion acquisition of Knoll Pharmaceuticals, a subsidiary of chemical giant BASF. Another $6.3 billion of Humira sales (19% of total sales) was generated outside the U.S. Late last year, biosimilars of Humira (generic biologics) were approved in Europe. So in other words, AbbVie is viewing Allergan as a similar-sized asset that will replace the lost sales from Humira; and Humira will pay for it."
2019-12-13,85.77999877929688,86.3499984741211,-0.6325421985818714,"Daily Dividend Report: T, ABT, AMT, EIX, ORCL","Abbott (ABT) increased the company's quarterly common dividend to 36 cents per share - a 12.5% increase. VIDEO: Daily Dividend Report: T, ABT, AMT, EIX, ORCL The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. AT&T's quarterly dividend will increase from $0.51 per share to $0.52 per share."
2019-12-12,84.77999877929688,85.97000122070312,0.6644902109299039,5 Dividend Aristocrats Where Analysts See Capital Gains,"Get the latest Zacks research report on ROP — FREE Get the latest Zacks research report on ABT — FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect."
2019-12-11,84.62000274658203,84.91000366210938,1.4036358322015527,"Best ETFs for 2020: The AdvisorShares Vice ETF Is a Long-Term Winner | Health Care Sector Update for 12/11/2019: JNJ, PFE, ABT, MRK, AMGN, AQST, RCKT, MRNS | How Does Boston Scientific’s Revenue And Other Key Metrics Compare With That of Medtronic?","Furthermore, the success of ACT’s management team is reflected in the fact that despite the general pain in many marijuana and tobacco stocks this year, the ETF is up almost 16% year to date. For investors interested in an ETF that is solely focused on marijuana stocks there are other options like the AdvisorShares Pure Cannabis ETF (NYSEARCA:). As such, the ACT ETF is one of the best ETFs to consider now regardless of whether it ends up winning InvestorPlace.com’s ETF contest. | ABT: flat AMGN: flat The top health care stocks were mostly gaining during pre-market trading Wednesday. Stocks moving on news include: (-) Aquestive Therapeutics (AQST), which fell more than 10% after announcing that it is planning to offer $35 million of common shares. | You can look at our interactive dashboard analysis ~ Boston Scientific vs. Medtronic: How Have Revenues & Other Key Metrics Changed Over Recent Years? Medtronic’s Revenues of $30 Billion Are Much Higher Than $10 Billion For Boston Scientific. Boston Scientific’s revenue grew at a CAGR of 7.5% between 2014 and 2018, while the figure was 12.0% for Medtronic between fiscal 2015 and fiscal 2019."
2019-12-10,83.87999725341797,84.55999755859375,0.34270965033625866,"Health Care Sector Update for 12/10/2019: EQ, SUPN, SNY, JNJ, ABT, PFE, MRK, AMGN | Analysts See 11% Gains Ahead For FTXH","ABT: Flat AMGN: Flat Health care majors were flat to lower pre-market Tuesday. Stocks moving on news include: (+) Equillium (EQ), which was up more than 18% after its investigational drug itolizumab for the treatment of lupus nephritis was given a Fast Track Designation by the US Food and Drug Administration. | Similarly, ALKS has 14.08% upside from the recent share price of $21.74 if the average analyst target price of $24.80/share is reached, and analysts on average are expecting ABT to reach a target price of $93.80/share, which is 11.84% above the recent price of $83.87. Three of FTXH's underlying holdings with notable upside to their analyst target prices are Pacira BioSciences Inc (Symbol: PCRX), Alkermes plc (Symbol: ALKS), and Abbott Laboratories (Symbol: ABT). Below is a twelve month price history chart comparing the stock performance of PCRX, ALKS, and ABT: Combined, PCRX, ALKS, and ABT represent 9.28% of the First Trust Nasdaq Pharmaceuticals ETF."
2019-12-09,85.12000274658203,83.87000274658203,0.810682316931135,"Health Care Sector Update for 12/09/2019: JNJ, PFE, ABT, MRK, AMGN, ARQL, THOR, MBIO, XBIT","Health care stocks were weaker broadly in midday trade, with the NYSE Health Care Index declining over 0.3% while the shares of health care companies in the S&P 500 also were down over 0.4% as a group. Among health care stocks moving on news: (+) ArQule (ARQL) more than doubled after the biopharmaceutical company agreed to be acquired by Merck (MRK) for $20 per share in cash, implying a total equity value of about $2.7 billion. (+) Synthorx (THOR) was surging 170% after French drug giant Sanofi (SNY) said it has agreed to acquire all of the outstanding Synthorx shares for $68 per share in cash or approximately $2.5 billion."
2019-12-06,85.66999816894531,85.4800033569336,-1.4685149902091532,"Health Care Sector Update for 12/06/2019: JNJ, PFE, ABT, MRK, AMGN, CYAD, SAVA, CRIS | Health Care Sector Update for 12/06/2019: JNJ, PFE, ABT, MRK, AMGN, CYAD, ONCY, RCKT, SAVA","Health care stocks pared early gains but remained in positive territory in late Friday trade, with the NYSE Health Care Index advancing over 0.4% while the shares of health care companies in the S&P 500 also were up almost 0.7% as a group. Among health care stocks moving on news: (+) Celyad (CYAD) was rising over 3% after the CAR-T cell therapies company secured EUR2.5 million ($2.8 million) in non-dilutive funding, taking the total from two donors to EUR11 million for this year. (+) Amgen (AMGN) was up 0.2% after receiving US Food and Drug Administration's approval for Avsola, a treatment for autoimmune diseases such as Crohn's disease and psoriatic arthritis to help stop inflammation. | Health care stocks were gaining broadly, with the NYSE Health Care Index advancing over 0.7% while the shares of health care companies in the S&P 500 also were up almost 1% as a group. Among health care stocks moving on news: (+) Celyad (CYAD) was rising 5% after the CAR-T cell therapies company secured EUR2.5 million ($2.8 million) in non-dilutive funding, taking the total from two donors to EUR11 million for this year. (+) Rocket Pharmaceuticals (RCKT) was surging more than 13% after saying it has treated the first patient in the phase 2 trial of RP-L102, a gene therapy for the treatment of Fanconi Anemia, a rare genetic disorder that affects the bone marrow The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2019-12-05,85.12000274658203,85.23999786376953,-0.2217752026059811,"Strong Q3 Results Drive Guardant's Stock 15% Higher In 20 Days | Noteworthy ETF Outflows: IUSG, BA, ABT, MDT | Strong Q3 Results Drive Guardant's Stock 15% Higher In 20 Days","Total Revenues for Guardant Health substantially increased from $49.8 Mil in 2017 to $90.6 Mil in 2018; an increase of 81.9%. A closer look At Guardant Health’s Total Expenses over the last few years and the outlook Total Expense for Guardant Health substantially increased from $133 Mil in 2017 to $175 Mil in 2018; an increase of 31.4%. For more information on how Guardant Health’s revenue growth compares with Alnylam Pharmaceuticals, Alkermes and Agios Pharmaceuticals, view our interactive dashboard analysis. | Among the largest underlying components of IUSG, in trading today Boeing Co. (Symbol: BA) is off about 0.3%, Abbott Laboratories (Symbol: ABT) is off about 0.4%, and Medtronic PLC (Symbol: MDT) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P U.S. Growth ETF (Symbol: IUSG) where we have detected an approximate $23.0 million dollar outflow -- that's a 0.3% decrease week over week (from 111,900,000 to 111,550,000). For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average: Looking at the chart above, IUSG's low point in its 52 week range is $49.14 per share, with $66.45 as the 52 week high point — that compares with a last trade of $65.50. | Total Revenues for Guardant Health substantially increased from $49.8 Mil in 2017 to $90.6 Mil in 2018; an increase of 81.9%. A closer look At Guardant Health’s Total Expenses over the last few years and the outlook Total Expense for Guardant Health substantially increased from $133 Mil in 2017 to $175 Mil in 2018; an increase of 31.4%. For more information on how Guardant Health’s revenue growth compares with Alnylam Pharmaceuticals, Alkermes and Agios Pharmaceuticals, view our interactive dashboard analysis."
2019-12-04,84.5,85.18000030517578,0.1409717026733982,,
2019-12-03,83.58999633789062,84.36000061035156,0.8047340889654216,"Medtronic Spending Less On Building, And More On Selling? | Despite the Naysayers, AbbVie Keeps Marching On","Medtronic’s Total Expenses As Percentage of Revenue Has Declined In Recent Years Breaking Down Medtronic’s Total Expenses Other Operating Expenses Other Operating Expenses accounted for 9% of the company’s total expenses in fiscal 2016. Interest & Other Expenses Interest & Other Expense, which includes interest expense and investment income, among others, accounted for 4% of the company’s total expenses in fiscal 2019. | AbbVie's third-quarter results AbbVie released its third-quarter earnings report on Nov. 1, and the company's results were solid. In addition to its strong position in the immunology department thanks to Humira and newcomers Skyrizi and Rinvoq -- which have already racked up more than $100 million in sales after hitting the market earlier this year -- the company will inherit Allergan's products, including offerings in medical aesthetics, eye care, central nervous system (CNS), and gastroenterology. Better days ahead With the continued dominance of Humira in the U.S. and AbbVie's acquisition of Allergan -- which will give it access to a much wider portfolio of products -- the company will likely see much better days ahead."
2019-12-02,85.56999969482422,84.51000213623047,0.9211679700862736,,
2019-11-29,85.30000305175781,85.44999694824219,-1.2387490503378662,"Health Care Sector Update for 11/29/2019: JNJ, PFE, ABT, MRK, AMGN, CANF, REGN, AZN","ABT: Flat Health care stocks moving on news include: (+) Can-Fite Biopharma Ltd (CANF), which rose more than 47% after reporting a net loss of $0.11 per share in the first nine months of 2019 compared with a loss of $0.08 per share a year ago. Revenue declined to $1.84 million from $3.53 million in the 2018 period."
2019-11-27,85.97000122070312,85.41999816894531,0.17584277973983498,"Exclusive Interview: Livongo Health CEO on Chronic Illness, the U.S. Healthcare System, and Its Opportunity | Health Care Sector Update for 11/27/2019: JNJ, PFE, ABT, MRK, AMGN, ARAV, TNXP, VRCA","Livongo calls these interactions ""health nudges,"" and it has the data to prove that they lead patients to make smarter health choices that drive behavior changes, improve clinical outcomes, and lower healthcare costs. When that member has decided to prick their finger, or step on a weight scale, or put the blood pressure cuff on, at the moment of that health signal when the member is actually taking their health into their own hands, there's a real live human on the other end. Because it's a person with diabetes, a person with hypertension, a person who has weight management challenges, or behavioral health challenges. | ABT: flat AMGN: flat Most of the biggest stocks in the health care sector were trading higher during pre-market hours on Wednesday. Among health care stocks moving on news: (-) Aravive (ARAV) retreated more than 19% after the biopharmaceutical company priced an underwritten public offering of its common shares at a discount."
2019-11-26,84.6500015258789,85.41999816894531,-0.6397615958453213,"Health Care Sector Update for 11/26/2019: JNJ, PFE, ABT, MRK, AMGN, CCXI, XFOR, SNOA","ABT: flat AMGN: flat Leading health care stocks were mixed during pre-bell trading on Tuesday. The company, along with Vifor Fresenius Medical Care Renal Pharma, reported positive topline data from its phase III advocate trial of avacopan for the treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (ANCA vasculitis)."
2019-11-25,83.91000366210938,84.48999786376953,0.9096238974443557,"Health Care Sector Update for 11/25/2019: JNJ, PFE, ABT, MRK, AMGN, SRNE, MDCO, NVS, ZIOP | What’s Boston Scientific’s Fair Stock Price Estimate Based On Expected 2020 Earnings?","The majority of the biggest stocks in the health care sector were trading higher during pre-market hours on Monday. Among health care stocks moving on news: (+) Medicines Company (MDCO), was up more than 22%, after it signed an agreement under which Swiss drug giant Novartis (NVS) will acquire the firm in a $9.7 billion deal. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Boston Scientific’s (NYSE:BSX) fair price estimate based on expected fiscal 2020 earnings is $44, according to Trefis estimates. Our Price Estimate of $44 For Boston Scientific’s Stock Based On Our Detailed Valuation Model Implies A 23x Earnings Multiple On Expected 2020 Adjusted Earnings of $1.88 Per Share. 4.1 Comparing Boston Scientific’s Historical P/E With That of Its Peers P/E Multiples shown are based on the stock prices at the end of September of each year, and adjusted earnings for that full year (fiscal)."
2019-11-22,83.94999694824219,83.73999786376953,0.6912098395272267,"Health Care Sector Update for 11/22/2019: JNJ, PFE, ABT, MRK, AMGN, SENS, ORGO, HSDT","Top Health Care Stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Leading health care stocks were flat during pre-market trading Friday. (+) Senseonics Holdings (SENS), which gained more than 12%, after releasing positive data showing that the performance of its Eversense sensor over four sensor cycles is stable and does not decrease over time and there was no degradation of patient glucose outcomes over the four sensor cycles. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2019-11-21,83.72000122070312,83.68000030517578,-0.2501478166844095,January 2020 Options Now Available For Abbott Laboratories (ABT),"Below is a chart showing ABT's trailing twelve month trading history, with the $83.50 strike highlighted in red: Considering the fact that the $83.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the January 2020 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new January 2020 contracts and identified one put and one call contract of particular interest."
2019-11-20,84.33999633789062,83.88999938964844,-0.04777940150991293,"Why Is Insulet Stock Up More Than 15% Over The Last Month? | Health Care Sector Update for 11/20/2019: JNJ, PFE, ABT, MRK, AMGN, ALC, BCRX, CRSP","The context for the last few years: A closer look At Insulet’s Total Revenues over the last few years and the outlook Total Revenues for Insulet significantly increased from $464 Mil in 2017 to $564 Mil in 2018; an increase of 21.6%. This compares with Total Revenues growth of: 14.1% in 2015 39.1% in 2016 26.4% in 2017 We expect Total Revenues growth to be 29.5% in 2019. A closer look At Insulet’s Total Expenses over the last few years and the outlook Total Expense for Insulet increased from $490 Mil in 2017 to $559 Mil in 2018; an increase of 13.9%. | Among health care stocks moving on news: (-) CRISPR Therapeutics AG (CRSP) was down by more than 3% after it announced that it is commencing a public offering of 4.25 million common shares. The company earlier reported revenue of $1.84 billion in the three months ended Sept. 30, up 4% year over year. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2019-11-19,84.62000274658203,84.29000091552734,-0.5335510644787895,"VTI, ABT, MDT, COST: ETF Inflow Alert","Among the largest underlying components of VTI, in trading today Abbott Laboratories (Symbol: ABT) is trading flat, Medtronic PLC (Symbol: MDT) is trading flat, and Costco Wholesale Corp (Symbol: COST) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Total Stock Market ETF (Symbol: VTI) where we have detected an approximate $2.7 billion dollar inflow -- that's a 2.1% increase week over week in outstanding units (from 809,865,889 to 827,190,339). For a complete list of holdings, visit the VTI Holdings page » The chart below shows the one year price performance of VTI, versus its 200 day moving average: Looking at the chart above, VTI's low point in its 52 week range is $119.35 per share, with $159.15 as the 52 week high point — that compares with a last trade of $158.62."
2019-11-18,85.70999908447266,84.26000213623047,-0.38998087963075245,,
2019-11-15,84.66999816894531,85.70999908447266,-1.691747711737954,,
2019-11-14,84.08999633789062,84.12000274658203,1.2282992063519238,,
2019-11-13,83.95999908447266,84.22000122070312,0.03568368414577452,Abbott CEO Miles White To Step Down After Two Decades | Why Does AbbVie Pay a Much Higher Dividend Than Its Peers?,"(RTTNews) - Abbott Laboratories' (ABT) chief executive officer Miles White will step down on March 31, 2020, after 21 years at the helm of the diversified healthcare company. The company said it appointed Robert Ford, who currently serves as president and chief operating officer of the company, to succeed White as chief executive officer. The company stated that Mr. Ford will become the 13th CEO of Abbott in its 131-year history, all having been appointed from within the Company. | While high dividend yields are great for investors who need income with minimal volatility, suspiciously high yields indicate that the market expects the dividend to fall or the stock to depreciate in the future. AbbVie will have to figure out how to replace Humira AbbVie holds patents in several countries for numerous applications for Humira, some of which have already begun to expire outside of the U.S. and will begin to expire domestically in 2023. AbbVie could be a very interesting story for investors who are seeking a high dividend yield to offset anticipated market weakness in the next two to three years."
2019-11-12,83.66000366210938,84.33999633789062,0.30967381975418923,,
2019-11-11,83.30999755859375,83.76000213623047,0.8128049796981146,3 Top Healthcare Stocks to Buy Right Now | 5 Dividend Aristocrats Where Analysts See Capital Gains,"AbbVie Abbvie was spun-off from Abbott Labs (NYSE: ABT) in 2013 and it has heavily relied on its legacy Humira drug, which treats arthritis, Crohn's disease, and psoriasis. The subscription services showed an increase of 28% year over year, hitting $217.3 million up from $169.6 million a year ago. The company thinks Skyrizi could reach annual sales of $5 billion and Rinvoq could achieve yearly sales of $6.5 billion. | Get the latest Zacks research report on ROP — FREE Get the latest Zacks research report on ABT — FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect."
2019-11-08,83.33000183105469,83.73999786376953,0.5401567528797737,"IWV, WMT, ABT, COST: ETF Outflow Alert","Among the largest underlying components of IWV, in trading today Walmart Inc (Symbol: WMT) is off about 0.4%, Abbott Laboratories (Symbol: ABT) is up about 0.3%, and Costco Wholesale Corp (Symbol: COST) is lower by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 3000 ETF (Symbol: IWV) where we have detected an approximate $126.3 million dollar outflow -- that's a 1.3% decrease week over week (from 55,500,000 to 54,800,000). For a complete list of holdings, visit the IWV Holdings page » The chart below shows the one year price performance of IWV, versus its 200 day moving average: Looking at the chart above, IWV's low point in its 52 week range is $137.4493 per share, with $181.11 as the 52 week high point — that compares with a last trade of $180.26."
2019-11-07,83.12999725341797,83.38999938964844,0.49201490904329975,,
2019-11-06,82.5,83.12000274658203,0.31276572214704185,Abbott Identifies New Subtype Of HIV,"(RTTNews) - Abbott (ABT) said that its scientists identified a new subtype of the human immunodeficiency virus or HIV, called HIV-1 Group M, subtype L. The discovery marked the first time a new subtype of HIV-1 has been identified since 2000. Abbott stated that the new findings show the role next-generation genome sequencing is playing in helping researchers stay one step ahead of mutating viruses and avoiding new pandemics. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2019-11-05,82.87000274658203,82.33999633789062,0.7515184807054924,,
2019-11-04,83.04000091552734,82.22000122070312,-0.6395636432065478,,
2019-11-01,84.08999633789062,82.66000366210938,-0.9874755368299737,,
2019-10-31,83.7699966430664,83.61000061035156,-1.7005502890441928,"IVW, ABT, MDT, PYPL: ETF Outflow Alert","Among the largest underlying components of IVW, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.3%, Medtronic PLC (Symbol: MDT) is up about 0.2%, and PayPal Holdings Inc (Symbol: PYPL) is lower by about 1.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 500 Growth ETF (Symbol: IVW) where we have detected an approximate $55.1 million dollar outflow -- that's a 0.2% decrease week over week (from 129,250,000 to 128,950,000). For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year price performance of IVW, versus its 200 day moving average: Looking at the chart above, IVW's low point in its 52 week range is $140.49 per share, with $185.23 as the 52 week high point — that compares with a last trade of $182.94."
2019-10-30,83.31999969482422,84.01000213623047,-0.1909944361064822,,
2019-10-29,82.44999694824219,83.44999694824219,0.8281354343897249,,
2019-10-28,81.80000305175781,82.66000366210938,1.212856321423211,We Did The Math VOOG Can Go To $181,"Similarly, ABT has 13.68% upside from the recent share price of $81.65 if the average analyst target price of $92.82/share is reached, and analysts on average are expecting AXP to reach a target price of $133.27/share, which is 12.69% above the recent price of $118.26. Below is a twelve month price history chart comparing the stock performance of UHS, ABT, and AXP: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of VOOG's underlying holdings with notable upside to their analyst target prices are Universal Health Services, Inc. (Symbol: UHS), Abbott Laboratories (Symbol: ABT), and American Express Co. (Symbol: AXP)."
2019-10-25,81.44999694824219,81.6500015258789,1.051345450204212,,
2019-10-24,81.58999633789062,81.36000061035156,0.24555504620069252,,
2019-10-23,80.69000244140625,81.2699966430664,-0.2818920674865282,,
2019-10-22,81.80999755859375,80.54000091552734,0.7187931393127966,,
2019-10-21,83.13999938964844,81.6500015258789,-1.552373402965588,,
2019-10-18,82.41000366210938,82.79000091552734,-1.7921552498291784,"Health Care Sector Update for 10/18/2019: RDHL, TRXC, ISRG, JNJ, ABT, PFE, MRK, AMGN","PFE: Flat ABT: Flat AMGN: Flat Leading health care stocks were mostly flat pre-market Friday. (+) TransEnterix (TRXC) was advancing by more than 5% after saying it is restructuring the company to cut costs and is also considering strategic alternatives, including a sale, for the company, as it expects revenue of $1.9 million to $2.1 million in Q3, sharply lower than market expectations."
2019-10-17,81.5199966430664,82.37999725341797,0.46110573538620603,,
2019-10-16,81.36000061035156,81.77999877929688,1.0549566312141265,"Health Care Sector Update for 10/16/2019: TXG,CRMD,ABT,NTRA | 5 Top Stock Trades for Thursday: ADBE, NFLX, ABT | Abbott Laboratories (ABT) Q3 2019 Earnings Call Transcript | Health Care Sector Update for 10/16/2019: CRMD,ABT,NTRA | Health Care Sector Update for 10/16/2019: TEVA, JNJ, PFE, ABT, MRK, AMGN, JNJ, MNK, ENDP, RYTM | Abbott Laboratories Q3 19 Earnings Conference Call At 9:00 AM ET | Abbott Sees Q4 Profit In Line With View; Narrows FY Profit View | Abbott Laboratories Q3 adjusted earnings Inline With Estimates","(-) Abbott Laboratories (ABT) was ending fractionally lower after the medical device company reported a 5.5% increase in Q3 revenue compared with the same quarter last year, rising to $8.08 billion but narrowly lagging the $8.10 billion analyst mean. Health care stocks were closing little changed on Wednesday, with the NYSE Health Care Index falling slightly more than 0.1% while the shares of health care companies in the S&P 500 were down almost 0.1% as a group. Among health care stocks moving on news: (+) 10x Genomics (TXG) climbed almost 5% after a new regulatory filing late Tuesday showed CEO Serge Saxonov Monday exercised options to buy 22,829 shares of the biological diagnostics company's stock priced between $1.07 to $11.48 apiece. | On the upside, see if ABT stock can break out over downtrend resistance and the 50-day moving average. 3: Abbott Labs (ABT) Abbott Labs (NYSE:) was mixed on Wednesday after it reported earnings. On the upside, see that NFLX reclaims and holds the 50-day moving average and 38.2% retracement. | Operator [Operator Closing Remarks] Duration: 50 minutes Call participants: Scott Leinenweber -- Vice President-Investor Relations, Licensing, and Acquisitions Miles D. White -- Chairman and Chief Executive Officer Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer Robert B. Ford -- President and Chief Operating Officer David Lewis -- Morgan Stanley -- Analyst Larry Biegelsen -- Wells Fargo -- Analyst Bob Hopkins -- Bank of America -- Analyst Vijay Kumar -- Evercore ISI -- Analyst Robbie Marcus -- JP Morgan -- Analyst Rick Wise -- Stifel -- Analyst Matt Taylor -- UBS -- Analyst More ABT analysis All earnings call transcripts 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Abbott Laboratories (NYSE: ABT) Q3 2019 Earnings Call Oct 16, 2019, 9:00 a.m. With me today are Miles White, Chairman of the Board and Chief Executive Officer; Robert Ford, President and Chief Operating Officer; and Brian Yoor, Executive Vice President, Finance and Chief Financial Officer. | In other sector news: (-) Abbott Laboratories (ABT) was fractionally lower after the medical device company reported a 5.5% increase in Q3 revenue compared with the same quarter last year, rising to $8.08 billion but narrowly lagging the $8.10 billion analyst mean. Health care stocks were little changed in recent trade, with the NYSE Health Care Index falling less than 0.1% while the shares of health care companies in the S&P 500 were down almost 0.1% as a group. Among health care stocks moving on news: (+) CorMedix (CRMD) raced 13% higher on Wednesday after the specialty drugmaker said it has successfully completed talks with the US Food and Drug Administration over the chemistry, manufacturing and controls for its Neutrolin drug candidate ahead of the company submitting the new drug application for the prospective medication to prevent infections in adult patients during hemodialysis. | MRK: Flat AMGN: Flat Leading health care stocks were mixed pre-market Tuesday. Stocks moving on news include: (+) Opioid-associated players were advancing pre-bell, with Teva Pharmaceutical Industries (TEVA) up 3%, Endo International (ENDP) gaining 2%, Mallinckrodt (MNK) surging 8%, Johnson & Johnson (JNJ) up more than 1%, as media reports said late Tuesday that drug distributors are engaging in discussions to reach an opioid settlement for $18 billion. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on Oct. 16, 2019, to discuss Q3 19 earnings results. To access the live webcast, log on to www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) said it expects earnings per share from continuing operations to be in the range of $0.59 to $0.61, and adjusted earnings per share from continuing operations of $0.94 to $0.96 for the fourth quarter. Excluding specified items, adjusted earnings per share from continuing operations would be $3.23 to $3.25 for the full year 2019. The company said in July that it expected earnings per share from continuing operations to be in the range of $2.06 to $2.12, adjusted earnings per share from continuing operations of $3.21 to $3.27. | (RTTNews) - Abbott Laboratories (ABT) revealed earnings for its third quarter that advanced from last year. -Analysts Estimate: $0.84 -Revenue (Q3): $8.08 Bln vs. $7.66 Bln last year. -Guidance: Next quarter EPS guidance: $0.94 to $0.96 Full year EPS guidance: $3.23 to $3.25 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2019-10-15,80.69999694824219,81.9800033569336,0.5162219343590756,"Noteworthy Tuesday Option Activity: WFC, HSIC, ABT","That number of contracts represents approximately 1.8 million underlying shares, working out to a sizeable 45.4% of ABT's average daily trading volume over the past month, of 4.0 million shares. Below is a chart showing HSIC's trailing twelve month trading history, with the $60 strike highlighted in orange: And Abbott Laboratories (Symbol: ABT) options are showing a volume of 18,202 contracts thus far today. Especially high volume was seen for the $81 strike put option expiring October 18, 2019, with 1,647 contracts trading so far today, representing approximately 164,700 underlying shares of ABT."
2019-10-14,79.69000244140625,79.81999969482422,1.5861294387809608,Abbott: Omada To Provide FreeStyle Libre As Exclusive CGM - Quick Facts,"(RTTNews) - Abbott (ABT) and Omada Health have partnered to integrate Abbott's FreeStyle Libre system, a continuous glucose monitoring or CGM technology, with Omada Health's digital care program. Through the collaboration, the companies are creating a personalized care program that combines Abbott's CGM technology with Omada Health's professional coaching and digital platform to provide on-the-go care to people with Type 2 diabetes. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2019-10-11,80.7300033569336,79.62999725341797,0.1631286854502884,,
2019-10-10,79.08999633789062,80.13999938964844,-1.3625740837048408,,
2019-10-09,79.30999755859375,79.5,1.3276053867444353,"Health Care Sector Update for 10/09/2019: OCGN, EYEG, JNJ, PFE, ABT, MRK, AMGN","ABT: Flat AMGN: Flat Health care heavyweights were mixed pre-bell Wednesday. Stocks moving on news include: (+) Ocugen (OCGN), which was surging by around 25% after the biopharmaceutical firm said its board has authorized the repurchase of up to $2 million in common stock."
2019-10-08,80.55999755859375,78.51000213623047,0.23956934466663843,What Led To 60% Growth In Intuitive Surgical's Stock Over The Last Two Years? | What's Driving Medtronic's Revenue Growth? | How Much Can Boston Scientific Revenues Grow Over The Next Three Years?,"Intuitive Surgical’s total revenues grew from $3.1 billion in 2017 to $3.7 billion in 2018, and they will likely grow to $4.3 billion in 2019. Intuitive Surgical’s adjusted net income grew from $1.1 billion in 2017 to $1.3 billion in 2018, and an estimated $1.4 billion in 2019. Intuitive Surgical’s total expenses grew from $2.1 billion in 2017 to $2.4 billion in 2018, and an estimated $2.9 billion in 2019, while total expenses as % of revenue could increase slightly from 66.3% in 2017 to 66.9% in 2019. | Cardiac & vascular group revenue grew from $10.2 billion in fiscal 2016 to $11.5 billion in fiscal 2019, and it could grow to $12.2 billion in fiscal 2021, primarily led by higher Evolut PRO valve sales. Minimally invasive therapies group revenue declined from $9.6 billion in fiscal 2016 to $8.5 billion in fiscal 2019, but it could grow to $9.4 billion in fiscal 2021, The decline earlier was due to the divestiture of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses. Restorative therapies group revenue increased from $7.2 billion in fiscal 2016 to $8.2 billion in fiscal 2019, and it could grow to $9.1 billion in fiscal 2021, primarily led by higher demand for its brain and pain therapies, which have seen strong growth in the recent quarters, led by its Intellis spinal cord stimulation platform, and StealthStation surgical navigation systems. | Boston Scientific (NYSE:BSX) generates its revenue primarily from sales of medical devices, and it reports revenues under three segments – Cardiovascular, Rhythm & Neuro, and MedSurg. The company reports its revenues under three segments, Cardiovascular, which includes devices for Interventional Cardiology and Peripheral Interventions, Rhythm & Neuro, which includes devices for Cardiac Rhythm Management, Electrophysiology and Neuromodulation, and MedSurg, which includes devices for Endoscopy and Urology & Pelvic Health. All Segments Will Likely See Steady Revenue Growth In Coming Years Cardio & Neuro revenues grew from $2.9 billion in 2014 to $3.8 billion in 2018, and it is estimated to be $4.4 billion in 2021."
2019-10-07,81.4000015258789,81.04000091552734,-2.5446815845199806,"Health Care Sector Update for 10/07/2019: JNJ, ABT, PFE, MRK, AMGN, MREO, XENT, CAPR","Stocks moving on news include: (+) Mereo BioPharma Group (MREO), which was trading 10% higher after the company said the US Food and Drug Administration granted fast-track designation to navicixizumab to treat ovarian, peritoneal or fallopian-tube cancer in patients who have received at least three prior therapies including bevacizumab. (-) Intersect ENT (XENT), which was down more than 13% pre-bell after the company posted unuccessful results on a study of it drug-coated sinus balloon dilating the frontal sinus ostium to lower post-balloon dilation edema through the localized delivery of steroid directly to dilated tissue. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2019-10-04,81.30000305175781,81.98999786376953,-0.4422611837877057,,
2019-10-03,79.25,81.06999969482422,0.8487020739377453,"Noteworthy ETF Inflows: SPLG, PEP, WMT, ABT","Among the largest underlying components of SPLG, in trading today PepsiCo Inc (Symbol: PEP) is up about 3.5%, Walmart Inc (Symbol: WMT) is down about 0.4%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Portfolio Large Cap ETF (Symbol: SPLG) where we have detected an approximate $86.2 million dollar inflow -- that's a 3.1% increase week over week in outstanding units (from 82,900,000 to 85,450,000). For a complete list of holdings, visit the SPLG Holdings page » The chart below shows the one year price performance of SPLG, versus its 200 day moving average: Looking at the chart above, SPLG's low point in its 52 week range is $27.30 per share, with $35.59 as the 52 week high point — that compares with a last trade of $33.70."
2019-10-02,81.4000015258789,79.52999877929688,2.2965295833744084,What's Fueling Abbott's Stock Price Growth?,"Abbott Labs’ (NYSE:ABT) share price has more than doubled over the last three years. Established Pharmaceutical Products revenue grew from $3.9 billion in 2016 to $4.4 billion in 2018, and it could grow to $4.6 billion in 2019, led by continued expansion in key emerging markets. Abbott’s adjusted net income grew from $3.3 billion in 2016 to $5.1 billion in 2018, and an estimated $5.7 billion in 2019."
2019-10-01,84.02999877929688,81.83999633789062,-2.2973006284127835,4 Healthcare Stocks to Buy Now,"Abbott Laboratories (ABT) Abbott Laboratories (NYSE:) shares look ready for another attempt at the $90 level in a continuation of the smooth, steady uptrend the stock has enjoyed since late 2016. Healthcare Stocks to Buy: Merck (MRK) Merck (NYSE:) shares are pushing back up and getting close to the company’s 50-day moving average. Analysts are looking for earnings of 84 cents per share on revenues of $8.1 billion."
2019-09-30,82.19000244140625,83.66999816894531,-2.6062150103777197,"Monday's ETF Movers: IHI, GDXJ","Components of that ETF showing particular strength include shares of Abbott Laboratories (ABT), up about 2.7% and shares of Angiodynamics (ANGO), up about 2.5% on the day. In trading on Monday, the iShares U.S. Medical Devices ETF (IHI) is outperforming other ETFs, up about 1.8% on the day. And underperforming other ETFs today is the Junior Gold Miners ETF (GDXJ), off about 3.8% in Monday afternoon trading."
2019-09-27,83.04000091552734,81.83999633789062,1.8007004301942446,"Health Care Sector Update for 09/27/2019: HSGX, PRPO, ABBV, JNJ, ABT, PFE, MRK, AMGN","ABT: Flat Top health care stocks were flat to higher pre-market Friday. Stocks moving on news include: (-) Histogenics (HSGX), which was down more than 9% as its stockholders approved all proposals related to its proposed combination with Ocugen."
2019-09-26,83.27999877929688,82.66000366210938,-1.4450922018382761,"Health Care Sector Update for 09/26/2019: BTAI, TAK, JNJ, PFE, ABT, MRK, AMGN | FDA Approves Abbott's Spinal Cord Stimulation System For Chronic Pain","ABT: Flat MRK: Flat AMGN: Flat Leading health care stocks were flat to higher pre-bell Thursday. In other sector news: (=) Abbott Laboratories (ABT) was flat after saying the Food and Drug Administration has approved the company's Proclaim XR recharge-free neurostimulation system for people living with chronic pain. (=) Takeda Pharmaceutical (TAK) was unchanged after additional results from its VARSITY study showed that ulcerative colitis patients using Entyvio (vedolizumab) have better chances of achieving clinical remission, the primary endpoint of the study, than with Humira (adalimumab). | (RTTNews) - Abbott Laboratories (ABT) said Thursday that the U.S. Food and Drug Administration has approved the company's Proclaim XR, recharge-free neurostimulation system for people living with chronic pain. The delivery of lower doses of spinal cord stimulation helps extend the system's battery life, allowing people to experience pain relief, without the hassle of recharging, for up to 10 years. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2019-09-25,82.4000015258789,82.86000061035156,-0.7444706127224736,,
2019-09-24,83.66000366210938,82.44000244140625,0.558251305769924,"IHI, ABT, MDT, TMO: Large Outflows Detected at ETF | Better Buy: AbbVie vs. Eli Lilly | Healthy Dividend Aristocrats: 6 Great Health-Care Dividend Stocks","Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.6%, Medtronic PLC (Symbol: MDT) is up about 0.9%, and Thermo Fisher Scientific Inc (Symbol: TMO) is up by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $137.5 million dollar outflow -- that's a 3.1% decrease week over week (from 17,650,000 to 17,100,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $183.57 per share, with $252.63 as the 52 week high point — that compares with a last trade of $251.17. | AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) have been outstanding dividend and growth stocks for the better part of the last decade. Lilly's stock has slipped by nearly 1.5% in 2019 due to a variety of headwinds, including the ongoing cliff dives of former star products like Humalog and Cialis, the withdrawal of the soft tissue cancer medicine Lartruvo from the market, a safety ding for the breast cancer treatment Verzenio, and, most importantly, an increasingly competitive landscape for the company's best-selling type 2 diabetes medication, Trulicity. See the 10 stocks *Stock Advisor returns as of June 1, 2019 George Budwell has no position in any of the stocks mentioned. | SEE ALSO: The Berkshire Hathaway Portfolio: All 47 Buffett Stocks Explained Abbott Laboratories Market value: $147.0 billion Dividend yield: 1.5% Consecutive annual dividend increases: 47 Analysts' opinion: 11 strong buy, 7 buy, 3 hold, 1 sell, 0 strong sell Abbott Laboratories (ABT, $83.16) actually split into a pair of Dividend Aristocrats when it spun off AbbVie in 2013. ABT has raised its dividend for 47 straight years, including a hefty 14.3% hike that went into effect in February 2019. SEE ALSO: 101 Best Dividend Stocks to Buy for 2019 and Beyond Becton Dickinson Market value: $68.4 billion Dividend yield: 1.2% Consecutive annual dividend increases: 47 Analysts' opinion: 10 strong buy, 3 buy, 7 hold, 0 sell, 0 strong sell Medical devices maker Becton Dickinson (BDX, $253.43) has been leaning on mergers & acquisitions (M&A) to make hay over the past few years."
2019-09-23,83.43000030517578,83.16000366210938,-1.458284923857442,"3 Big Stock Charts for Monday: MSCI, Macerich and Abbott Laboratories","• The white 200-day moving average line is also in play here, so if the short-term, yellow floor that’s guided Abbott to higher lows since the end of last year doesn’t hold up, ABT stock doesn’t necessarily have to fall all the way back to the mid-$70’s. Abbott Laboratories (ABT) The past couple of months haven’t been especially good ones for Abbott Laboratories shareholders. ABT stock is somewhat in limbo right now, trapped between various floors and ceilings."
2019-09-20,83.51000213623047,83.58000183105469,-0.32362057063261973,"Noteworthy Friday Option Activity: MRK, ABT, ARNA","That number of contracts represents approximately 1.7 million underlying shares, working out to a sizeable 42.2% of ABT's average daily trading volume over the past month, of 4.1 million shares. Below is a chart showing MRK's trailing twelve month trading history, with the $85 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) options are showing a volume of 17,108 contracts thus far today. Particularly high volume was seen for the $87.50 strike call option expiring October 18, 2019, with 4,102 contracts trading so far today, representing approximately 410,200 underlying shares of ABT."
2019-09-19,83.83000183105469,83.2300033569336,0.08382192915050792,,
2019-09-18,83.58000183105469,83.63999938964844,-0.715732388185187,,
2019-09-17,83.4000015258789,83.58000183105469,0.07178458635957762,"Health Care Sector Update for 09/17/2019: IMMP,ABT,ACRS,ADPT,AMGN | Health Care Sector Update for 09/17/2019: ABT,ACRS,ADPT,AMGN","(+) Abbott Laboratories (ABT) was edging higher in recent trade after the medical device company earlier said European regulators have cleared its Amplatzer Piccolo occluder and the Masters HP rotatable mechanical heart valve for public sales, making the two devices used to treat certain congenital heart defects in infants and children available in Europe and other countries that recognize the CE Mark. Health care stocks were hanging on to small gains, with the NYSE Health Care Index climbing over 0.2% in late trade while the shares of health care companies in the S&P 500 also were up slightly more than 0.1% as a group. Among health care stocks moving on news: (+) Immutep (IMMP) rose almost 3% on Tuesday after the immunotherapeutic company said it has received a patent from Japanese regulators for its LAG525 antibody for the treatment of cancer and infectious disease. | Among health care stocks moving on news: (+) Abbott Laboratories (ABT) still was edging higher in recent trade after the medical device company earlier said European regulators have cleared its Amplatzer Piccolo occluder and the Masters HP rotatable mechanical heart valve for public sales, making the two devices used to treat certain congenital heart defects in infants and children available in Europe and other countries that recognize the CE Mark. Health care stocks were rising, with the NYSE Health Care Index climbing almost 0.3% in recent trade while the shares of health care companies in the S&P 500 were up fractionally. (-) Adaptive Biotechnologies (ADPT) was 3% lower after Tuesday announcing a four-year global agreement with larger biotechnology rival Amgen (AMGN) for the use of its next generation sequencing-based clonoSEQ assay in Amgen's hematology drug development program."
2019-09-16,83.91000366210938,83.36000061035156,0.21582770009893515,"Interesting ABT Put And Call Options For January 2022 | Sanofi, Abbott To Integrate Glucose Sensing And Insulin Delivery Technologies","Below is a chart showing ABT's trailing twelve month trading history, with the $85.00 strike highlighted in red: Considering the fact that the $85.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the January 2022 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new January 2022 contracts and identified one put and one call contract of particular interest. | (RTTNews) - Sanofi (SNYNF, SNY) and Abbott have partnered to integrate glucose sensing and insulin delivery technologies that would initially enable data sharing, at the consent of the user, between Abbott's FreeStyle Libre mobile app and cloud software and Sanofi's connected insulin pens, apps and cloud software that are currently in development. Sanofi said it is currently working to provide connected pens, apps and cloud software that will be compatible with the FreeStyle Libre system and its compatible digital health tools. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2019-09-13,85.30000305175781,84.2699966430664,-0.6554677961552435,"Daily Dividend Report: INTC, ABT, AVGO, TJX, EOG","Abbott (ABT) declared a quarterly common dividend of 32 cents per share. VIDEO: Daily Dividend Report: INTC, ABT, AVGO, TJX, EOG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Intel has declared a quarterly dividend of $0.315 per share ($1.26 per share on an annual basis) on the company's common stock."
2019-09-12,85.02999877929688,85.20999908447266,-1.2075104007515982,,
2019-09-11,82.44999694824219,84.5199966430664,0.21169035371032813,,
2019-09-10,83.44000244140625,83.20999908447266,2.5106122152116717,"Notable Tuesday Option Activity: INTU, ABT, EW | Abbott Develops Algorithm For Diagnosing Heart Attacks - Quick Facts","Below is a chart showing ABT's trailing twelve month trading history, with the $77.50 strike highlighted in orange: And Edwards Lifesciences Corp (Symbol: EW) saw options trading volume of 4,408 contracts, representing approximately 440,800 underlying shares or approximately 45.2% of EW's average daily trading volume over the past month, of 975,610 shares. Below is a chart showing INTU's trailing twelve month trading history, with the $280 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) options are showing a volume of 20,154 contracts thus far today. That number of contracts represents approximately 2.0 million underlying shares, working out to a sizeable 47.4% of ABT's average daily trading volume over the past month, of 4.3 million shares. | (RTTNews) - Abbott (ABT) said a new research showed that Abbott's technology developed using artificial intelligence could help doctors in diagnosing heart attacks. Agim Beshiri, senior medical director, global medical and scientific affairs, Diagnostics, Abbott, said: ""In the future, you could imagine using this technology to develop algorithms that help doctors not only better determine if their patient is having a heart attack or not, but potentially before a heart attack occurs."" The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2019-09-09,86.33999633789062,84.22000122070312,-0.2756511867255854,,
2019-09-06,86.2300033569336,86.04000091552734,-2.4554032975527615,,
2019-09-05,85.0,85.9000015258789,-0.22034377132025504,Abbott Begins Trial To Evaluate Transcatheter Tricuspid Valve Repair,"(RTTNews) - Abbott (ABT) has launched TRILUMINATE pivotal trial to evaluate TriClip transcatheter tricuspid valve repair system for the treatment of severe tricuspid regurgitation. Abbott's TriClip tricuspid valve repair system is built on the company's MitraClip technology. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2019-09-04,84.5,84.22000122070312,1.0588253245634192,,
2019-09-03,84.43000030517578,84.05999755859375,-0.3313595021264793,,
2019-08-30,85.47000122070312,85.31999969482422,-0.43823610712381944,,
2019-08-29,85.0,84.81999969482422,-0.17550195827371987,"Health Care Sector Update for 08/29/2019: LCI, JNJ, PFE, ABT, MRK, AMGN, SOLY, ESPR, CANF","Health care stocks closed mixed Thursday, including a 0.8% gain for the NYSE Health Care Index. Among health care stocks moving on news: (+) Lannett (LCI) jumped almost 10% higher Thursday after the drugmaker announced an exclusive distribution agreement with China's Sinotherapeutics for its posaconazole anti-fungal medication. It also reported non-GAAP Q4 net income of $0.37 per share, trailing its $0.64 per share net loss during the year-ago period but still beating the Capital IQ consensus expecting an adjusted $0.21 per share quarterly profit."
2019-08-28,83.19999694824219,84.22000122070312,-0.21176506491268382,,
2019-08-27,83.81999969482422,83.6500015258789,1.2259667185991256,"Should You Buy AbbVie for the Dividend? | Notable ETF Outflow Detected - XLV, MRK, PFE, ABT | Health Care Sector Update for 08/27/2019: NVTR, CTLT, JNJ, PFE, ABT, MRK, AMGN","This prolonged slump is unprecedented for AbbVie, at least since the firm spun off from Abbott Laboratories (NYSE: ABT). US sales of Humira increased by about 8% during AbbVie's second quarter, but its international sales decreased by 35%, resulting in a net decrease of 6% year over year. AbbVie merges with Allergan Perhaps the biggest move AbbVie made recently was its blockbuster merger with Allergan (NYSE: AGN) in a cash-and-stock deal valued at $63 billion. | Among the largest underlying components of XLV, in trading today Merck & Co Inc (Symbol: MRK) is up about 0.7%, Pfizer Inc (Symbol: PFE) is off about 0.3%, and Abbott Laboratories (Symbol: ABT) is up by about 1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $421.5 million dollar outflow -- that's a 2.4% decrease week over week (from 194,370,000 to 189,670,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $80.61 per share, with $96.06 as the 52 week high point — that compares with a last trade of $90.38. | ABT: Flat MRK: Flat AMGN: Flat Top heath care stocks were flat to higher pre-market Tuesday. Stocks moving on news include: (+) Nuvectra (NVTR), which was surging by more than 16% after saying its board will explore strategic options, including sale or merger of the company, to boost the value of the company's shares. (+) Johnson & Johnson (JNJ) was ordered to pay over $572 million for playing a part in the Oklahoma opioid crisis, according to media reports, citing a ruling by Cleveland County District Judge Thad Balkman."
2019-08-26,82.61000061035156,83.12000274658203,-0.2028133733765805,,
2019-08-23,83.83999633789062,81.93000030517578,0.617361254645194,,
2019-08-22,84.91999816894531,84.37000274658203,-2.27814422249878,,
2019-08-21,85.05000305175781,84.9000015258789,-0.6476630172189652,3 Top Diabetes Stocks to Watch in August,"They picked Eli Lilly (NYSE: LLY), Abbott Laboratories (NYSE: ABT), and Tandem Diabetes Care (NASDAQ: TNDM). Waiting on a big decision Keith Speights (Abbott Laboratories): While Abbott Labs isn't only focused on diabetes, there's no question that diabetes care is an important growth driver for the company. Abbott has filed with the U.S. Food and Drug Administration (FDA) for approval of the next-generation version of the device as an integrated continuous glucose monitoring (iCGM) system to be used as part of an integrated system with other medical devices such as automated insulin dosing systems and insulin pumps."
2019-08-20,85.94999694824219,84.54000091552734,-0.17636863080136717,,
2019-08-19,85.79000091552734,85.55999755859375,-1.6404840986369347,"Notable ETF Inflow Detected - XLV, ABT, MDT, TMO","Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is up about 1.1%, Medtronic PLC (Symbol: MDT) is up about 0.8%, and Thermo Fisher Scientific Inc (Symbol: TMO) is higher by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $167.5 million dollar inflow -- that's a 1.0% increase week over week in outstanding units (from 192,520,000 to 194,370,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $80.61 per share, with $96.06 as the 52 week high point — that compares with a last trade of $91.25."
2019-08-16,84.73999786376953,84.77999877929688,-0.2681004248502868,"Health Care Sector Update for 08/16/2019: ARAY, TTOO, JNJ, PFE, ABT, MRK, AMGN","Stocks moving on news include: (-) Accuray (ARAY), which was down 3% in pre-market trading after it reported late Thursday that its net loss widened to $0.02 per share in Q4 from a $0.01 loss per share a year earlier. In other sector news: (+) T2 Biosystems (TTOO), a manufacturer of diagnostic products, was up 0.2% after saying it entered into an exclusive distribution agreement to introduce its rapid diagnostic technologies to new markets in Australia, Fiji, and New Zealand. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2019-08-15,84.16000366210938,83.94000244140625,0.047204291403984196,S&P 500 Analyst Moves: ABT,"The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories (ABT) is now the #56 analyst pick, moving up by 2 spots. VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Looking at the stock price movement year to date, Abbott Laboratories (ABT) is showing a gain of 16.3%."
2019-08-14,85.87999725341797,83.94000244140625,-0.2614082831868676,,
2019-08-13,85.31999969482422,86.88999938964844,-2.258960030339903,,
2019-08-12,86.38999938964844,84.66000366210938,1.8401309194091098,"Health Care Sector Update for 08/12/2019: NVAX, SXTC, JNJ, PFE, ABT, MRK, AMGN","Leading health care stocks were mixed in pre-bell trading Monday. Early movers include: (+) China SXT Pharmaceuticals (SXTC), which were up nearly 21% Monday pre-bell after the company said it has received a new certificate of Good Manufacturing Practice for Pharmaceutical Products by the Food and Drug Administration of Jiangsu Province, China. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2019-08-09,85.62999725341797,86.62000274658203,-2.002541659638392,The Health Care Select Sector SPDR Fund Experiences Big Inflow,"Among the largest underlying components of XLV, in trading today Merck & Co Inc (Symbol: MRK) is up about 0.6%, Abbott Laboratories (Symbol: ABT) is up about 0.6%, and Medtronic PLC (Symbol: MDT) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $232.8 million dollar inflow -- that's a 1.4% increase week over week in outstanding units (from 188,020,000 to 190,570,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $80.61 per share, with $96.06 as the 52 week high point — that compares with a last trade of $91.03."
2019-08-08,85.11000061035156,85.55999755859375,1.1561433200029045,,
2019-08-07,83.80000305175781,84.5999984741211,0.5287239396253234,,
2019-08-06,83.80999755859375,84.86000061035156,0.9546484406082612,Why Insulet's Shares Are Rocketing 20.8% Higher Today,"Increasingly, these patients are shifting to continuous glucose monitors, such as those made by DexCom (NASDAQ: DXCM) or Abbott Labs (NYSE: ABT), and insulin pumps, such as those made by Insulet and Tandem Diabetes (NASDAQ: TNDM). In the second quarter, increasing adoption of Omnipod translated into Insulet revenue of $177.1 million, up 43% from the same quarter last year. The dip in margin was more than made up for by sales growth and controlled operating expenses, so Insulet's net income in the period improved to $1.4 million from a loss of $1.7 million one year ago."
2019-08-05,84.7300033569336,83.16000366210938,1.252837468493813,,
2019-08-02,85.94999694824219,85.81999969482422,-1.852944214117918,,
2019-08-01,87.18000030517578,86.08000183105469,-0.15124753697926385,"Notable ETF Outflow Detected - IHI, ABT, TMO, EW","Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.8%, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 1.6%, and Edwards Lifesciences Corp (Symbol: EW) is higher by about 2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $49.3 million dollar outflow -- that's a 1.2% decrease week over week (from 16,000,000 to 15,800,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $183.57 per share, with $250.14 as the 52 week high point — that compares with a last trade of $248.45."
2019-07-31,88.18000030517578,87.0999984741211,-1.2617555291013094,,
2019-07-30,88.18000030517578,88.30999755859375,-1.2247695932376812,,
2019-07-29,88.05999755859375,88.55000305175781,0.14742260486286082,,
2019-07-26,88.3499984741211,87.75,0.5564450451387084,,
2019-07-25,88.2699966430664,88.0,-0.6791154323526575,A Conversation on ESG and Sustainability With As You Sow CEO Andrew Behar,"One involved genetically modified organisms (GMOs) that was filed with Abbott Laboratories (NYSE: ABT). Behar: Shareholders have legal standing with corporations in which they own shares and may bring a proposal to their company management about how to reduce risk and be a better company. Behar: Similar to Fossil Free Funds but focused on companies that produce palm oil, the banks that fund them, and the companies with palm oil in their snack food products."
2019-07-24,88.44999694824219,88.58999633789062,-0.3058758959266534,"Noteworthy ETF Outflows: XLV, ABT, MDT, TMO","Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.6%, Medtronic PLC (Symbol: MDT) is up about 0.1%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 3.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $350.1 million dollar outflow -- that's a 2.0% decrease week over week (from 194,770,000 to 190,970,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $80.61 per share, with $96.06 as the 52 week high point — that compares with a last trade of $91.83."
2019-07-23,88.0999984741211,88.73999786376953,0.15828083038867735,"Health Care Sector Update for 07/23/2019: JNJ, PFE, ABT, MRK, AMGN","Stocks moving on news include (-) Viveve Medical (VIVE), was down 63% after reporting aftermarket Monday disappointing results for its Liberate-International trial for stress urinary incontinence (SUI) in women, unveiled plans to transition to a new US business model, and said it is considering a review of financial and strategic alternatives. (-) Marinus Pharmaceuticals (MRNS) plunged 66% after saying Tuesday that results from part two of a phase 2 Magnolia clinical trial showed ganaxolone was ""well-tolerated"" but at 28 days, did not show much difference from the placebo. (-) ACADIA Pharmaceuticals (ACAD) dropped 13% on Tuesday after reporting on Monday top-line results from its phase 3 ENHANCE study evaluating pimavanserin as an adjunctive treatment in adult schizophrenia patients did not achieve statistical significance on the primary endpoint, but showed a consistent trend in improvement of psychotic symptoms."
2019-07-22,87.36000061035156,88.06999969482422,0.7264465388571306,How to Invest in Medical Device Stocks,"Know what to look for in medical device stocks While medical devices can be complicated, the key things to look for in buying medical device stocks are straightforward. There are currently two ETFs that focus on medical device stocks: iShares U.S. Medical Devices ETF (NYSEMKT: IHI) SPDR S&P Health Care Equipment ETF (NYSEMKT: XHE) The primary advantage of buying a medical device ETF is that it provides diversification across a large number of medical device stocks. Invest in one or more medical device stocks After evaluating the top medical device stocks and/or ETFs, you should be ready to actually invest."
2019-07-19,88.29000091552734,87.48999786376953,0.8127278840569584,ABT Crosses Above Average Analyst Target | Investing in Chicago Stocks,"And so with ABT crossing above that average target price of $86.58/share, investors in ABT have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $86.58 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? In recent trading, shares of Abbott Laboratories (Symbol: ABT) have crossed above the average analyst 12-month target price of $86.58, changing hands for $87.76/share. But the whole reason to look at the average ABT price target in the first place is to tap into a ""wisdom of crowds"" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. | If you're considering investing in Chicago stocks -- the publicly traded stocks of the businesses that have their headquarters in the Chicago metro area -- it's important to remember that. You should be able to assess the financial position of a company and see what investors think about the stock and its potential by looking at a company's balance sheet and some common metrics like: Trailing price-to-earnings ratio (P/E): This metric analyzes a company's earnings in relation to its share price. Boeing stock is down over serious issues with its 737 MAX plane; Kraft Heinz stock is down on issues including a writedown, an SEC probe and a slashed dividend; McDonald's stock is up in recent years because of some smart changes in strategy; AbbVie stock is down because it just offered to buy Allergan in a $63 billion deal and take on a lot of additional debt to do it; and United Airlines stock has suffered of late over economic issues with China."
2019-07-18,86.23999786376953,87.76000213623047,-0.9061083287599309,,
2019-07-17,85.88999938964844,85.76000213623047,1.762528188906078,"Wednesday Sector Leaders: Utilities, Healthcare | Abbott Laboratories (ABT) Q2 2019 Earnings Call Transcript | Abbott Laboratories Earnings: ABT Stock Surges on Guidance, Q2 Beat | 5 Top Stock Trades for Thursday: TSLA, GLD, ABT | Noteworthy Wednesday Option Activity: MAR, ABT, NSC","Among large Healthcare stocks, Abbott Laboratories (Symbol: ABT) and ABIOMED, Inc. (Symbol: ABMD) are the most notable, showing a gain of 3.3% and 2.7%, respectively. Combined, ABT and ABMD make up approximately 4.7% of the underlying holdings of XLV. Among utilities ETFs, one ETF following the sector is the Utilities Select Sector SPDR ETF (Symbol: XLU), which is up 0.6% on the day, and up 16.72% year-to-date. | Operator [Operator Closing Remarks] Duration: 55 minutes Call participants: Scott Leinenweber -- Vice President, Investor Relations, Licensing, and Acquisitions Miles D. White -- Chairman of the Board and Chief Executive Officer Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer Robert B. Ford -- President and Chief Operating Officer David Lewis -- Morgan Stanley -- Analyst Robbie Marcus -- JPMorgan -- Analyst Bob Hopkins -- Bank of America -- Analyst Kristen Stewart -- Barclays -- Analyst Joanne Wuensch -- BMO Capital Markets -- Analyst Matthew Taylor -- UBS -- Analyst More ABT analysis All earnings call transcripts 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Abbott Laboratories (NYSE: ABT) Q2 2019 Earnings Call Jul 17, 2019, 9:00 a.m. Quite certainly there's been an awful lot of people that has been part of my management team for a long time and a lot of our managers are long term Abbott groomed and grown management team, but we've also been thinking about making sure that with all the growth we've got, the new products, the new organization and the new structure to that organization that we're always looking at the talent and the experience of our management team as we look forward now toward, let's just call it a decade for what I think it's going to be pretty robust growth. | Abbott Laboratories earnings for the company’s second quarter of 2019 has ABT stock heading higher on Wednesday. That’s good news for ABT stock as Wall Street is looking for earnings per share of $3.22 for the year. That has it missing Wall Street’s revenue estimates of $8.00 billion for the period, but it wasn’t keeping ABT stock down today. | I want to see ABT stock hold $85 on the downside and see if it can push up to channel resistance on the upside. Top Stock Trades for Tomorrow #1: Tesla Tesla (NASDAQ:) stock has been moving favorably, working on its seventh straight week of gains. Top Stock Trades for Tomorrow #3: Gold The move has been years in the making, but the SPDR Gold ETF (NYSEARCA:) is starting to make some waves. | That number of contracts represents approximately 3.5 million underlying shares, working out to a sizeable 65.9% of ABT's average daily trading volume over the past month, of 5.3 million shares. Below is a chart showing MAR's trailing twelve month trading history, with the $120 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) options are showing a volume of 34,763 contracts thus far today. Especially high volume was seen for the $85 strike call option expiring August 16, 2019, with 4,201 contracts trading so far today, representing approximately 420,100 underlying shares of ABT."
2019-07-16,84.11000061035156,83.16000366210938,-0.15135318936052544,"XLV, ABT, MDT, TMO: ETF Outflow Alert | Health Care Sector Update for 07/16/2019: IMRN, MLNT, JNJ, PFE, ABT, MRK, AMGN","Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.3%, Medtronic PLC (Symbol: MDT) is off about 0.1%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $162.1 million dollar outflow -- that's a 0.9% decrease week over week (from 196,520,000 to 194,770,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $80.61 per share, with $96.06 as the 52 week high point — that compares with a last trade of $92.36. | ABT: Flat Stocks moving on news include: (+) Immuron (IMRN), which was surging more than 125% as its FY19 revenue jumped 52% in North America to AUD1.16 million ($820,000), driven by the sales of Travelan, which exceeded AUD1 million in the US for the first time. In other sector news: (-) Johnson & Johnson (JNJ) was recently lower even after the health care company posted Q2 adjusted earnings of $2.58 per share, up from $2.10 in the same period a year ago and exceeding the estimate of $2.44 from analysts polled by Capital IQ."
2019-07-15,83.80999755859375,83.80999755859375,-1.1294696722725617,,
2019-07-12,85.27999877929688,83.91999816894531,0.0,Strange: Bullish ABT Analysts Actually See -2.96% Downside,"The average 12-month price target for ABT — averaging the work of 13 analysts — reveals an average price target of $83.23/share. The average rating of 1.44 for ABT leans strongly towards the bullish end of the spectrum, yet the ABT price target paints a different picture. And so with ABT trading so far above that average target price of $83.23/share, the -2.96% downside to that average target does seem to be a paradox against the bullish analyst ratings."
2019-07-11,85.6500015258789,85.7699966430664,-1.5947474552283003,,
2019-07-10,85.68000030517578,85.37999725341797,0.14009937542294593,"The 10 Biggest Healthcare Stocks | Ex-Dividend Reminder: Becton, Dickinson, Abbott Laboratories and AbbVie | Insiders Bullish on Certain Holdings of DLN","Merck's current product lineup also includes five other blockbuster products: diabetes drug Januvia, vaccines Gardasil and ProQuad/M-M-R II/Varivax, cardiovascular drug Zetia, and HIV drug Isentress. This segment claims 15 drugs that were blockbusters in 2018, including multiple sclerosis drug Gilenya, immunology drug Cosentyx, and age-related macular degeneration (AMD) drug Lucentis. The company's current product lineup includes seven blockbuster drugs, but sales for several of its top-selling drugs are declining. | Looking at the universe of stocks we cover at Dividend Channel, on 7/12/19, Becton, Dickinson & Co (Symbol: BDXA), Abbott Laboratories (Symbol: ABT), and AbbVie Inc (Symbol: ABBV) will all trade ex-dividend for their respective upcoming dividends. Becton, Dickinson & Co (Symbol: BDXA): Abbott Laboratories (Symbol: ABT): AbbVie Inc (Symbol: ABBV): In general, dividends are not always predictable, following the ups and downs of company profits over time. Similarly, investors should look for ABT to open 0.37% lower in price and for ABBV to open 1.49% lower, all else being equal. | The table below details the recent insider buying activity observed at ABT: ABT — last trade: $85.27 — Recent Insider Buys: And Keurig Dr Pepper Inc (Symbol: KDP), the #139 largest holding among components of the WisdomTree U.S. LargeCap Dividend Fund (DLN), shows 5 directors and officers as recently filing Form 4's indicating purchases. Abbott Laboratories (Symbol: ABT), which makes up 0.48% of the WisdomTree U.S. LargeCap Dividend Fund (DLN), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $10,280,625 worth of ABT, making it the #52 largest holding."
2019-07-09,84.95999908447266,85.2699966430664,-0.3501436165841025,How Much Can Intuitive Surgical's System Revenue Grow Over The Next Three Years?,"da Vinci Systems’ Sales Have Grown In High Teens On Average In The Recent Years Intuitive Surgical’s da Vinci systems revenue grew from $800 million in 2016 to $1.13 billion in 2018, reflecting average annual growth of around 19%. Higher System Sales Has Resulted In Continued Growth In The Company’s Installed Base, Which Further Aids The Revenue Growth For Other Segments The company’s installed base has grown from less than 4,000 units in 2016 to a little under 5,000 units in 2018, and it can grow to north of 6,000 units by 2021. da Vinci Systems Account For Close To 30% of Intuitive Surgical’s Total Sales Intuitive Surgical generates its revenue from three sources ~ sales of da Vinci systems, sales of instruments & accessories, and the service business."
2019-07-08,85.27999877929688,85.08999633789062,0.36487471979081665,,
2019-07-05,85.16000366210938,85.41999816894531,-0.22279836318709728,,
2019-07-03,85.05000305175781,85.63999938964844,0.3053011926438162,,
2019-07-02,84.75,84.94999694824219,0.6937052518758622,,
2019-07-01,84.73999786376953,84.48999786376953,0.23598459969579647,,
2019-06-28,83.81999969482422,84.0999984741211,-0.29502006880140264,,
2019-06-27,83.38999938964844,83.69000244140625,0.33404769782427546,,
2019-06-26,84.05000305175781,82.95999908447266,0.35975902860487746,"IOO, MCD, ABT, AMT: ETF Outflow Alert","Among the largest underlying components of IOO, in trading today McDonald's Corp (Symbol: MCD) is down about 0.5%, Abbott Laboratories (Symbol: ABT) is down about 1.7%, and American Tower Corp (Symbol: AMT) is lower by about 1.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Global 100 ETF (Symbol: IOO) where we have detected an approximate $94.8 million dollar outflow -- that's a 4.6% decrease week over week (from 42,650,000 to 40,700,000). For a complete list of holdings, visit the IOO Holdings page » The chart below shows the one year price performance of IOO, versus its 200 day moving average: Looking at the chart above, IOO's low point in its 52 week range is $40.25 per share, with $49.73 as the 52 week high point — that compares with a last trade of $48.77."
2019-06-25,84.94000244140625,84.23999786376953,-1.2968517878743373,3 Biopharma Stocks to Buy for Income,"Despite competitive pressures from other big pharma and biotech companies, GSK, ABBV, and JNJ stocks have strong balance sheets, proactive management and several important drugs in the pipeline that are likely to keep them ahead of the competition. Due to its rock-solid dividend, which stands at over 5.1%, and its robust growth potential, GSK stock belongs in any balanced portfolio of healthcare stocks. Investors who pay attention to short-term should note that Johnson & Johnson stock has also become “overbought.” Therefore, JNJ stock might drop towards the $135 level, where the stock is likely to find major support in the coming weeks."
2019-06-24,84.77999877929688,84.70999908447266,-0.8241165028451694,,
2019-06-21,85.36000061035156,85.0,-0.08256628430302897,,
2019-06-20,84.83999633789062,84.94000244140625,-0.4217439172650444,,
2019-06-19,83.4000015258789,84.33000183105469,0.11787612898677248,Is Abbott Laboratories a Buy?,"Diversified healthcare company Abbott Laboratories (NYSE: ABT) has been rewarding its shareholders with solid growth without the ups and downs that pharmaceutical stocks often deliver. The post-spinoff Abbott is a balanced company with four businesses that are all contributing well to the company's growth. Four segments with steady underlying growth The company's largest segment at 37% of 2018 revenue is medical devices, bolstered by the 2017 acquisition of St. Jude Medical and proving to be the company's strongest source of growth."
2019-06-18,82.44999694824219,83.41999816894531,1.1151082591853472,"Noteworthy ETF Inflows: SPYG, MCD, NFLX, ABT | Abbott Labs Stock Just Hit an All-Time High: Buy, Sell, or Hold?","Among the largest underlying components of SPYG, in trading today McDonald's Corp (Symbol: MCD) is up about 0.1%, Netflix Inc (Symbol: NFLX) is up about 2.8%, and Abbott Laboratories (Symbol: ABT) is up by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Portfolio S&P 500 Growth ETF (Symbol: SPYG) where we have detected an approximate $78.6 million dollar inflow -- that's a 1.5% increase week over week in outstanding units (from 134,550,000 to 136,600,000). For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $30.31 per share, with $38.8166 as the 52 week high point — that compares with a last trade of $38.76. | Abbott Laboratories (NYSE: ABT) is on a roll no matter how you look at it. Why still buy Abbott That leaves us with the final option: buy Abbott stock. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen."
2019-06-17,82.38999938964844,82.05000305175781,1.1764721123180164,Why AbbVie Is a Retiree's Dream Stock,"Including the time that it was still part of its parent company, Abbott Labs (NYSE: ABT), AbbVie has increased its dividend for 47 consecutive years. A fantastic -- and growing -- dividend Let's start with AbbVie's dividend. Based on AbbVie's current dividend level and its history of dividend growth, I fully expect that the dividend will double within the next seven years."
2019-06-14,82.16999816894531,82.22000122070312,-0.4126669989189762,,
2019-06-13,81.9800033569336,82.29000091552734,0.06085317375205962,3 Top Diabetes Stocks to Watch in June,"They suggested Eli Lilly (NYSE: LLY), Abbott Laboratories (NYSE: ABT), and Provention Bio (NASDAQ: PRVB). Since 2014, the company has brought to market the oral type 2 diabetes medication known as Jardiance; the once-weekly injected type 2 diabetes therapy Trulicity; and Basaglar, an alternative to Sanofi's long-acting insulin Lantus. A Freestyle sequel could boost this stock Keith Speights (Abbott Laboratories): Abbott Laboratories isn't just a diabetes stock."
2019-06-12,81.29000091552734,81.94999694824219,0.37813801646731876,,
2019-06-11,81.79000091552734,81.12000274658203,0.8119030942079578,ABT Crosses Above Average Analyst Target,"And so with ABT crossing above that average target price of $80.86/share, investors in ABT have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $80.86 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? In recent trading, shares of Abbott Laboratories (Symbol: ABT) have crossed above the average analyst 12-month target price of $80.86, changing hands for $81.27/share. But the whole reason to look at the average ABT price target in the first place is to tap into a ""wisdom of crowds"" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes."
2019-06-10,81.0,81.2699966430664,-0.8191687999090331,,
2019-06-07,80.48999786376953,80.73999786376953,0.3333291889708719,"SPY, BRK.B, NFLX, ABT: Large Outflows Detected at ETF","Among the largest underlying components of SPY, in trading today Berkshire Hathaway Inc New (Symbol: BRK.B) is up about 0.5%, Netflix Inc (Symbol: NFLX) is up about 1.8%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P 500 ETF (Symbol: SPY) where we have detected an approximate $5.2 billion dollar outflow -- that's a 2.0% decrease week over week (from 919,130,000 to 900,980,000). For a complete list of holdings, visit the SPY Holdings page » The chart below shows the one year price performance of SPY, versus its 200 day moving average: Looking at the chart above, SPY's low point in its 52 week range is $233.76 per share, with $294.95 as the 52 week high point — that compares with a last trade of $287.42."
2019-06-06,78.8499984741211,80.08999633789062,0.3105975980060635,,
2019-06-05,77.83999633789062,78.69000244140625,1.5726035355301926,,
2019-06-04,76.25,77.45999908447266,1.091991448491195,Insiders Buy the Holdings of VTV ETF,"The table below details the recent insider buying activity observed at ABT: ABT — last trade: $75.71 — Recent Insider Buys: And Aramark (Symbol: ARMK), the #242 largest holding among components of the Vanguard Value ETF (VTV), shows 3 directors and officers as recently filing Form 4's indicating purchases. Abbott Laboratories (Symbol: ABT), which makes up 1.20% of the Vanguard Value ETF (VTV), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $865,989,174 worth of ABT, making it the #20 largest holding."
2019-06-03,76.25,75.70999908447266,1.5868840452100412,,
2019-05-31,75.97000122070312,76.12999725341797,-0.7081979220030737,"Health Care Sector Update for 05/31/2019: IOVA, MYOV, JNJ, PFE, ABT, MRK, AMGN","AMGN: Flat Most leading health care stocks were falling in Friday's pre-bell trading. (+) Myovant Sciences (MYOV) was climbing by more than 5%, recovering from the previous day's plunge after it priced an underwritten public offering of 15,151,516 common shares at $8.25 per share, to raise approximately $125.0 million in gross proceeds. In other sector news: (-) Merck & Co. (MRK) said new findings from the phase 3 Keynote-048 trial demonstrate superior overall survival outcomes from its drug Keytruda in combination with chemotherapy for patients with recurrent or metastatic head and neck squamous cell carcinoma."
2019-05-30,76.01000213623047,76.5199966430664,0.21060422554164984,,
2019-05-29,75.37000274658203,75.66999816894531,0.6709571010429516,,
2019-05-28,77.02999877929688,75.70999908447266,0.39803026592948587,,
2019-05-24,76.0199966430664,76.9800033569336,-1.7136177018595398,,
2019-05-23,76.13999938964844,75.62999725341797,1.2628344596944248,,
2019-05-22,76.13999938964844,76.26000213623047,-0.6698215659557856,3 Dividend Aristocrats to Buy and Hold Forever,"Three that look especially stable to our Motley Fool contributors are Walmart (NYSE: WMT), Target (NYSE: TGT), and Abbott Laboratories (NYSE: ABT). The dividend yield stands at a generous 3.6% today, and Target has plenty of headroom for future increases -- only 54% of the trailing free cash flows were allocated to cover dividend checks. For instance, medical device company Abbott Labs has not only been in business for over 130 years, it's also rewarded investors with dividend increases for 47 consecutive years, including a 14% increase in January."
2019-05-21,76.55999755859375,76.02999877929688,0.15760802146571354,,
2019-05-20,75.5999984741211,75.7699966430664,-0.692265930248039,,
2019-05-17,76.29000091552734,75.97000122070312,0.22486530737630261,,
2019-05-16,76.5199966430664,76.5999984741211,-0.4194516856521482,,
2019-05-15,75.5,76.51000213623047,0.10455022812907636,,
2019-05-14,75.63999938964844,76.02999877929688,1.3377511738151904,,
2019-05-13,75.16999816894531,75.5,0.5155994087723513,,
2019-05-10,76.20999908447266,76.44999694824219,0.4390073687550252,"Health Care Sector Update for 05/10/2019: JNJ, PFE, ABT, MRK, AMGN, GENE, PIRS, TGTX","Health care stocks were mixed just ahead of the close of Friday's session, including a 0.2% rise in the NYSE Health Care Index (^NYP). In other sector news: (+) Pieris Pharmaceuticals (PIRS) rose 4% after it reported a Q1 net loss of $0.20 per share, compared with a loss of $0.17 per share in the same quarter a year ago. Net loss narrowed to $0.43 per share in Q1 from $0.59 per share a year earlier, better than analysts' estimates of $0.44 loss per share in a Capital IQ survey."
2019-05-09,75.66000366210938,76.41999816894531,0.31491650262784143,,
2019-05-08,76.93000030517578,76.22000122070312,1.0044864790517367,The Health Care Select Sector SPDR Fund Experiences Big Outflow,"Among the largest underlying components of XLV, in trading today Johnson & Johnson (Symbol: JNJ) is up about 0.1%, Pfizer Inc (Symbol: PFE) is down about 0.6%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $546.6 million dollar outflow -- that's a 3.0% decrease week over week (from 204,820,000 to 198,670,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $80.61 per share, with $96.06 as the 52 week high point — that compares with a last trade of $88.89."
2019-05-07,78.5,76.91000366210938,-0.9229157437360469,,
2019-05-06,77.41999816894531,79.06999969482422,-2.025473041898885,,
2019-05-03,78.83000183105469,78.69000244140625,2.1312342610474957,,
2019-05-02,78.41999816894531,78.77999877929688,-0.17759658302238607,ABBOTT LABORATORIES (ABT) Q1 2019 Earnings Call Transcript | Abbott Gets WHO Prequalification Approval For HIV Point-of-Care Test,"Duration: 52 minutes Call participants: Scott Leinenweber -- Vice President-Investor Relations, Licensing, and Acquisitions Miles D. White -- Chairman and Chief Executive Officer Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer Matthew Taylor -- UBS -- Analyst Robert B. Ford -- President and Chief Operating Officer David Lewis -- Morgan Stanley -- Analyst Bob Hopkins -- Bank of America -- Analyst Larry Biegelsen -- Wells Fargo -- Analyst Vijay Kumar -- Evercore ISI -- Analyst Chris Pasquale -- Guggenheim -- Analyst More ABT analysis Transcript powered by AlphaStreet This article is a transcript of this conference call produced for The Motley Fool. So in summary, we're right on track with our high expectations to start the year, all of our long-term growth drivers are intact and achieving significant growth, including FreeStyle Libre, MitraClip and Alinity. I think in the fourth quarter, the messaging was core growth drivers very much intact, some one-off dynamics were suppressing growth and you expected that growth to improve in the first quarter. | (RTTNews) - Abbott Laboratories (ABT) said Thursday that m-PIMA HIV-1/2 VL, the company's point-of-care viral load diagnostic test, has received the World Health Organization's Prequalification approval or WHO PQ. Damian Halloran, vice president, Infectious Disease - Emerging Markets, Rapid Diagnostics, Abbott said, ""With WHO PQ, global funders and ministries of health can now confidently expand access to viral load testing, reaching more people who need the test, with the most compact and efficient point-of-care HIV diagnostic platform available anywhere in the world today."" The WHO recommends that everyone receiving antiretroviral therapy or ART should undergo a viral load test at 6 months and 12 months, and annually thereafter, if the individual is stable on ART."
2019-05-01,79.3499984741211,78.73999786376953,0.4590673536818883,,
2019-04-30,78.2699966430664,79.55999755859375,-0.7687468457236402,"SPYG, FB, GOOG, ABT: ETF Inflow Alert","Among the largest underlying components of SPYG, in trading today Facebook Inc (Symbol: FB) is up about 0.1%, Alphabet Inc (Symbol: GOOG) is off about 8.2%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Portfolio S&P 500 Growth ETF (Symbol: SPYG) where we have detected an approximate $42.5 million dollar inflow -- that's a 0.9% increase week over week in outstanding units (from 124,800,000 to 125,900,000). For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $30.31 per share, with $38.74 as the 52 week high point — that compares with a last trade of $38.52."
2019-04-29,78.55999755859375,78.2699966430664,1.6481422906022563,20 High-Growth Stocks For The Next 20 Years,"Its sales increased 44% year over year to $1.032 billion in 2018 and while it faces stiff competition from Abbott Labs (NYSE: ABT), DexCom is still guiding for 14% growth this year. In 2018, 2U Inc. revenue increased 44% to $412 million and revenue is expected to grow to $547 million in 2019. Because Zscaler (NASDAQ: ZS) addresses challenges associated with securing data in an increasingly complex work environment, its revenue has grown from $54 million in fiscal 2015 to $190 million in fiscal 2018."
2019-04-26,78.45999908447266,78.55999755859375,-0.3691457797093838,Insiders Bullish on Certain Holdings of DGRO,"The table below details the recent insider buying activity observed at ABT: ABT — last trade: $78.11 — Recent Insider Buys: And Aqua America Inc (Symbol: WTR), the #240 largest holding among components of the iShares Core Dividend Growth ETF (DGRO), shows 5 directors and officers as recently filing Form 4's indicating purchases. Abbott Laboratories (Symbol: ABT), which makes up 0.67% of the iShares Core Dividend Growth ETF (DGRO), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $46,838,588 worth of ABT, making it the #36 largest holding."
2019-04-25,76.62000274658203,78.11000061035156,0.12745153618142674,"Thursday 4/25 Insider Buying Report: TPTX, ABT","And at Abbott Laboratories (ABT), there was insider buying on Monday, by Senior Vice President Randel William Woodgrift who bought 2,000 shares at a cost of $73.40 each, for a trade totaling $146,798. VIDEO: Thursday 4/25 Insider Buying Report: TPTX, ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money."
2019-04-24,76.05000305175781,76.75,1.9446591103600543,"Health Care Sector Update for 04/24/2019: ANTM, RAD, JNJ, PFE, ABT, MRK, AMGN",ABT: Flat MRK: Flat Top Health Care Stocks: JNJ: Flat Leading health care stocks were mostly flat pre-market Wednesday.
2019-04-23,74.62999725341797,76.0999984741211,0.9204430245266215,,
2019-04-22,73.12999725341797,74.51000213623047,1.9697189800389556,,
2019-04-18,73.63999938964844,73.91999816894531,1.8870572058554274,,
2019-04-17,76.18000030517578,72.87999725341797,0.3802264823704417,"Health Care Sector Update for 04/17/2019: ONCS, TXMD, ABT, JNJ, PFE, MRK, AMGN | U.S. STOCKS ON THE MOVE-Qualcomm, BNY Mellon, Domino's, PepsiCo, Sprint | Notable Wednesday Option Activity: ALXN, SWKS, ABT | Abbott Laboratories Earnings: ABT Stock Down After Q1 Beat | U.S. STOCKS ON THE MOVE-Qualcomm, BNY Mellon, PepsiCo, Sprint, Domino's Pizza | Abbott Labs Starts 2019 Off by Beating Expectations | Notable Wednesday Option Activity: ALXN, SWKS, ABT | Earnings Reaction History: Abbott Laboratories, 50.0% Follow-Through Indicator, 1.7% Sensitive | Abbott Laboratories Q1 adjusted earnings Beat Estimates | Abbott Q1 19 Earnings Conference Call At 9:00 AM ET | Abbott Lab's first-quarter sales beat expectations | Abbott Labs beats first-quarter expectations on higher diabetes devices sales","In other sector news: (+) Abbott Laboratories (ABT) was up slightly after saying its Q1 adjusted diluted EPS rose to $0.63 from $0.59 a year ago, narrowly beating the $0.62 average estimate from analysts polled by Capital IQ. Stocks moving on news include: (+) OncoSec Medical (ONCS), which was climbing nearly 20% after announcing a collaborative research agreement with Duke University School of Medicine to evaluate the use of OncoSec's TAVOPLUS (enhanced IL-12 DNA-plasmid) in combination or sequence with a HER2-plasmid vaccine administered with OncoSec's novel intratumoral delivery system. (+) TherapeuticsMD (TXMD) was more than 5% higher as it signed a binding commitment letter with TPG Sixth Street Partners for a $300 million non-dilutive secured term loan financing facility, to be available in three tranches. | ET, the Dow Jones Industrial Average was down 0.09 percent at 26,429.31. The S&P 500 was down 0.07 percent at 2,905.17 and the Nasdaq Composite was up 0.07 percent at 8,005.579. The top three S&P 500 percentage gainers: ** Qualcomm Inc up 13.5 pct ** Textron Inc up 8 pct ** CSX Corp up 5.9 pct The top three S&P 500 percentage losers: ** Bank of New York Mellon Corp down 8 pct ** Anthem Inc down 4.5 pct ** Pentair Plc down 4.4 pct The top NYSE percentage gainers: ** Smart & Final Stores Inc up 20.2 pct ** Puxin Ltd up 17.2 pct The top NYSE percentage losers: ** Tenet Healthcare Corp down 11.3 pct ** Rexahn Pharmaceuticals Inc down 8.9 pct The top three Nasdaq percentage gainers: ** Uxin Ltd up 48.7 pct ** Helius Medical Technologies Inc up 17 pct ** Greenpro Capital Corp up 14.6 pct The top three Nasdaq percentage losers: ** CEVA Inc down 17.6 pct ** eHealth Inc down 13.8 pct ** Ionis Pharmaceuticals Inc down 11.2 pct ** PepsiCo Inc : up 3.3 pct Shares tick higher on demand for snacks, low-sugar soda Street View: Happy hours for PepsiCo investors after solid Q1 beat ** T-Mobile : down 3.3 pct ** Sprint Corp : down 5.2 pct Sprint, T-Mobile drop on DOJ concerns about merger ** CSX Corp : up 5.9 pct ** Union Pacific Corp : up 1.2 pct ** Kansas City Southern : up 3.1 pct Shares rise on Q1 profit beat Railroad rivals chug along as CSX tops profit view ** Arconic Inc : down 3.4 pct Slides on block trade ** OncoSec Medical Inc : up 2.5 pct Surges on research collaboration with Duke University ** Textron Inc : up 8.0 pct Set to open at more than 1-month high after profit beat ** Future FinTech Group Inc : down 13.5 pct Drops on delaying filing of FY18 results ** Smart & Final Stores Inc : up 20.2 pct Smart & Final Stores set for best day in 5 months on Apollo deal ** United Continental Holdings Inc : up 3.5 pct United Airlines first-quarter profit rises, holds 2019 target United Airlines: Shares rise on Q1 profit beat, 2019 forecast unchanged ** Qualcomm Inc : up 13.6 pct Gains set to add over $25 bln in market cap since settlement with Apple Street View: Qualcomm moves past litigations to focus on 5G dominance ** Aurora Cannabis Inc : up 1.1 pct ** Canopy Growth Corp : up 1.4 pct Aurora Cannabis, Canopy Growth: BofA starts coverage with ""buy"" ** Morgan Stanley : up 2.4 pct Morgan Stanley profit beats estimates on wealth management, lower costs Gains after better-than-expected results ** Hollysys Automation Technologies Ltd : up 6.3 pct Rises after pulling stock offering ** Domino's Pizza : up 4.3 pct ** Chipotle Mexican Grill : down 1.6 pct Pizza over burritos: MS upgrades Domino's, sidelines Chipotle Chipotle Mexican Grill: Morgan Stanley downgrades to 'equal-weight' ** Moleculin Biotech Inc : up 11.0 pct Jumps on new data from cancer drug testing ** DPW Holdings Inc : up 19.8 pct Soars on bright outlook ** Bank of New York Mellon Corp : down 8.0 pct BNY Mellon profit misses estimates on lower fee revenue Slides on first profit miss in 2 years ** International Business Machines Corp : down 2.9 pct Street View: IBM's story in progress, with all eyes on RHT ** Pinduoduo Inc : up 3.4 pct Keybanc calls Pinduoduo new online disruptor, starts with 'overweight' ** Pentair Plc : down 4.4 pct Slips after biggest quarterly results miss in at least 2 years ** GasLog Partners LP : down 8.4 pct GasLog Partners: Distribution growth running out of steam-MS ** Abbott Laboratories : down 3.3 pct Falls on unchanged 2019 forecast ** Hooker Furniture Corp : down 9.3 pct Slides on Q1 sales warning ** Boston Scientific Corp : down 1.3 pct Dips as co sees $25 mln hit to 2019 rev The 11 major S&P 500 sectors: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is a chart showing ABT's trailing twelve month trading history, with the $80 strike highlighted in orange: For the various different available expirations for ALXN options, SWKS options, or ABT options, visit StockOptionsChannel.com. Below is a chart showing SWKS's trailing twelve month trading history, with the $77.50 strike highlighted in orange: And Abbott Laboratories (Symbol: ABT) options are showing a volume of 26,045 contracts thus far today. That number of contracts represents approximately 2.6 million underlying shares, working out to a sizeable 51.9% of ABT's average daily trading volume over the past month, of 5.0 million shares. | Abbott Laboratories earnings for the first quarter of 2019 have ABT stock down on Wednesday. It also beats out Wall Street’s earnings per share estimate of 61 cents for the quarter, but that couldn’t keep ABT stock from falling today. It also beats out analysts’ revenue estimate of $7.47 billion for the period, but was unable to stop ABT stock from dropping. | The Day Ahead newsletter: The Morning News Call newsletter: At 11:26 ET, the Dow Jones Industrial Average was down 0.03 percent at 26,444.88. The S&P 500 was down 0.11 percent at 2,903.98 and the Nasdaq Composite was down 0.01 percent at 7,999.569. The top three S&P 500 percentage gainers: ** Qualcomm Inc up 9.5 pct ** Textron Inc up 6.2 pct ** CSX Corp up 4.9 pct The top three S&P 500 percentage losers: ** Bank of New York Mellon Corp down 8.4 pct ** DaVita Inc down 5.8 pct ** Alexion Pharmaceuticals Inc down 5.7 pct The top NYSE percentage gainers: ** Smart & Final Stores Inc up 20.3 pct ** Puxin Ltd up 10.8 pct The top NYSE percentage losers: ** Tenet Healthcare Corp down 10.1 pct ** GasLog Partners LP down 9.4 pct The top three Nasdaq percentage gainers: ** Uxin Ltd up 41 pct ** Palomar Holdings Inc up 22.1 pct ** Greenpro Capital Corp up 16.8 pct The top three Nasdaq percentage losers: ** eHealth Inc down 21.4 pct ** UP Fintech Holding Ltd down 18.6 pct ** CEVA Inc down 16 pct ** PepsiCo Inc : up 3.3 pct PepsiCo results beat as new CEO's ad push lifts sales Shares tick higher on demand for snacks, low-sugar soda Street View: Happy hours for PepsiCo investors after solid Q1 beat ** T-Mobile : down 2.9 pct ** Sprint Corp : down 5.2 pct Sprint, T-Mobile drop on DOJ concerns about merger ** CSX Corp : up 4.9 pct ** Union Pacific Corp : up 0.9 pct ** Kansas City Southern : up 3.7 pct Shares rise on Q1 profit beat Railroad rivals chug along as CSX tops profit view ** Arconic Inc : down 3.5 pct Slides on block trade ** OncoSec Medical Inc : up 4.8 pct Surges on research collaboration with Duke University ** Textron Inc : up 6.2 pct Set to open at more than 1-month high after profit beat ** Future FinTech Group Inc : down 12.6 pct Drops on delaying filing of FY18 results ** Smart & Final Stores Inc : up 20.3 pct Smart & Final Stores set for best day in 5 months on Apollo deal ** United Continental Holdings Inc : up 4.0 pct United Airlines first-quarter profit rises, holds 2019 target ** Qualcomm Inc : up 9.5 pct Gains set to add over $25 bln in market cap since settlement with Apple Street View: Qualcomm moves past litigations to focus on 5G dominance ** Aurora Cannabis Inc : up 1.1 pct ** Canopy Growth Corp : up 2.7 pct Aurora Cannabis, Canopy Growth: Bofa starts coverage with ""buy"" ** Morgan Stanley : up 2.1 pct Morgan Stanley profit beats estimates on wealth management, lower costs Gains after better-than-expected results ** Hollysys Automation Technologies Ltd : up 6.5 pct Rises after pulling stock offering ** Domino's Pizza : up 3.8 pct ** Chipotle Mexican Grill : down 2.5 pct Pizza over burritos: MS upgrades Domino's, sidelines Chipotle Chipotle Mexican Grill: Morgan Stanley downgrades to 'equal-weight' ** Moleculin Biotech Inc : up 5.7 pct Jumps on new data from cancer drug testing ** DPW Holdings Inc : up 10.8 pct Soars on bright outlook ** Bank of New York Mellon Corp : down 8.4 pct BNY Mellon profit misses estimates on lower fee revenue Set for worst day in over 7 yrs on profit miss ** International Business Machines Corp : down 3.2 pct Street View: IBM's story in progress, with all eyes on RHT ** Pinduoduo Inc : up 3.2 pct Keybanc calls Pinduoduo new online disruptor, starts with 'overweight' ** Pentair Plc : down 2.6 pct Pentair slips after biggest quarterly results miss in at least 2 years ** GasLog Partners LP : down 9.4 pct Distribution growth running out of steam-MS ** Abbott Laboratories : down 2.7 pct Falls on unchanged 2019 forecast Abbott likely lost market share to Medtronic, Boston Scientific - analyst ** Hooker Furniture Corp : down 8.6 pct Slides on Q1 sales warning ** Boston Scientific Corp : down 1.7 pct Dips as co sees $25 mln hit to 2019 rev ** Quotient Technology Inc : up 2.6 pct Rises on Craig-Hallum's 'buy' call ** PolyOne Corp : down 7.7 pct Set for worst day in more than six months ** Marker Therapeutics Inc : down 6.3 pct Falls after cancer therapy data presentation gets delayed ** Signature Bank : down 3.3 pct Falls after quarterly report disappoints The 11 major S&P 500 sectors: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | So far in 2019, Abbott Laboratories (NYSE: ABT) has had a reasonably good year, with its stock up 5.6% to date earlier this week. By the numbers Abbott Labs announced Q1 revenue of $7.5 billion, a 2% increase from the $7.4 billion reported in the same quarter of the previous year. This was an improvement over Abbott Labs' result in the prior-year period, when the company announced adjusted net earnings of $0.59 per share. | Below is a chart showing ABT's trailing twelve month trading history, with the $80 strike highlighted in orange: For the various different available expirations for ALXN options , SWKS options , or ABT options , visit StockOptionsChannel.com. Below is a chart showing SWKS's trailing twelve month trading history, with the $77.50 strike highlighted in orange: And Abbott Laboratories (Symbol: ABT) options are showing a volume of 26,045 contracts thus far today. That number of contracts represents approximately 2.6 million underlying shares, working out to a sizeable 51.9% of ABT's average daily trading volume over the past month, of 5.0 million shares. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 57.1% Average next regular session additional gain: 1.2% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 57.1% of the time (4 events) the stock posted additional gains in the following regular session by an average of 1.2%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 40% Average next regular session additional loss: 0.5% Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 40.0% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 0.5% by the following regular session close. Extended-Hours Dollar Volume: $3,898,722 Abbott Laboratories (ABT) is due to issue its quarterly earnings report in the upcoming extended-hours session. | (RTTNews) - Abbott Laboratories (ABT) announced a profit for its first quarter that advanced from last year. The company's revenue for the quarter rose 2.0% to $7.54 billion from $7.39 billion last year. -Analysts Estimate: $0.61 -Revenue (Q1): $7.54 Bln vs. $7.39 Bln last year. | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on April 17, 2019, to discuss Q1 19 earnings results. To access the live webcast, log on to www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ""The decisions we made three, five, seven years ago - and the ones we're making today - are driving positive long-term outlooks for all of our businesses,"" said Chief Executive Officer Miles White. The company, whose products range from medical devices to infant nutritional formula, posted net earnings of $672 million, or 38 cents per share, in the first quarter ended March 31, from $418 million, or 23 cents per share. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | By Manas Mishra April 17 () - Abbott Laboratories Inc reported higher-than-expected quarterly profit and sales on surging demand for its glucose monitoring device, but an unchanged forecast along with regulatory uncertainty kept investors on the edge. I kind of feel like if I raised in the first quarter, why didn't I put it in the original plan 3 months ago or 6 months ago,"" Chief Executive Officer Miles White said on a conference call. While total medical device sales rose 5.5 percent to $2.90 billion and came in-line with expectations, sales in its generic drugs unit fell 4.9 percent to $992 million and missed expectations of $1 billion."
2019-04-16,77.94000244140625,76.37999725341797,-4.331849617403592,"Close Update: Nasdaq Closes Above 8,000 as Stocks Post Modest Advance in Tuesday Trading | Pre-Market Earnings Report for April 17, 2019 : PEP, ABT, ASML, USB, MS, BK, ERIC, TXT, KSU, SBNY, PNR, POL | Is AbbVie Stock An Undiscovered Cannabis Play Waiting For Some Attention?","Looking ahead to Wednesday's earnings, Abbott Laboratories ( ABT ), PepsiCo ( PEP ) and US Bancorp ( USB ) are among a host of companies set to report. Dow Jones Industrial Average was up 67.89 points (+0.26%) to 26,452.66 S&P 500 was up 1.48 points (+0.05%) to 2,907.06 Nasdaq Composite Index was up 24.21 points (+0.30%) to 8,000.23 FTSE 100 was up 33.05 points (+0.44%) to 7,469.92 Hang Seng Index was up 319.15 points (+1.07%) to 30,129.87 Shanghai China Composite Index was up 75.81 points (+2.39%) to 3,253.60 | Abbott Laboratories ( ABT ) is reporting for the quarter ending March 31, 2019. In the past year ABT has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2019 Price to Earnings ratio for ABT is 24.22 vs. an industry ratio of 9.00, implying that they will have a higher earnings growth than their competitors in the same industry. | Nowadays there are more publicly traded companies to play this , including names like Canopy Growth (NYSE:), Aurora Cannabis (NYSE:), Cronos Group (NASDAQ:), and Tilray (NASDAQ:). More importantly, as for AbbVie stock, the drug is an indication of the company’s ability to push innovation with alternative treatments. Bottom Line on AbbVie Stock Granted, it would not be a good idea to invest in AbbVie stock just because it has a cannabis drug."
2019-04-15,78.11000061035156,77.5,-2.0015462395719865,Interesting ABT Put Options For May 31st | The Future Keeps Looking Better and Better for BAX Stock,"At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new May 31st contracts and identified the following put contract of particular interest. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the May 31st expiration. To an investor already interested in purchasing shares of ABT, that could represent an attractive alternative to paying $77.88/share today. | Baxter Improves Floseal Baxter just received approval from the FDA for its next generation of its Floseal Hemostatic Matrix. The Bulls and BAX stock Interestingly, despite the compelling benefits Floseal appears to offer, it may not affect BAX significantly. The Bottom Line on BAX Stock Although a better Floseal should bring improved revenues to Baxter, demographics will continue to serve as the driving force behind BAX."
2019-04-12,78.37000274658203,78.01000213623047,-0.7809507176866184,,
2019-04-11,79.19000244140625,78.51000213623047,-0.45936021147742434,"Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for April 12, 2019","Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. The following ETF(s) have ABT as a top-10 holding: First Trust Nasdaq Pharmaceuticals ETF ( FTXH ) Invesco Dynamic Pharmaceuticals ETF ( PJP ) AdvisorShares Vice ETF ( ACT ) SPDR Select Sector Fund - Health Care ( XLV ) iShares U.S. Medical Devices ETF ( IHI )."
2019-04-10,78.72000122070312,78.97000122070312,-0.8586946384790461,"ProShares UltraPro S&P500 Experiences Big Outflow | Ex-Dividend Reminder: Becton, Dickinson, AbbVie and Abbott Laboratories","Among the largest underlying components of UPRO, in trading today Walt Disney Co. (Symbol: DIS) is up about 0.1%, Abbott Laboratories (Symbol: ABT) is up about 0.6%, and Amgen Inc (Symbol: AMGN) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $54.2 million dollar outflow -- that's a 3.8% decrease week over week (from 27,600,000 to 26,550,000). For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $28.65 per share, with $58.95 as the 52 week high point — that compares with a last trade of $51.72. | Looking at the universe of stocks we cover at Dividend Channel, on 4/12/19, Becton, Dickinson & Co (Symbol: BDXA), AbbVie Inc (Symbol: ABBV), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Becton, Dickinson & Co (Symbol: BDXA): AbbVie Inc (Symbol: ABBV): Abbott Laboratories (Symbol: ABT): In general, dividends are not always predictable, following the ups and downs of company profits over time. Similarly, investors should look for ABBV to open 1.29% lower in price and for ABT to open 0.41% lower, all else being equal."
2019-04-09,78.23999786376953,78.66999816894531,0.3175812958883069,Abbott (ABT) Gains As Market Dips: What You Should Know,"Abbott (ABT) closed the most recent trading day at $78.67, moving +0.19% from the previous trading session. Wall Street will be looking for positivity from ABT as it approaches its nex t earnings report date. In tha t report , analysts expect ABT to post earnings of $0.61 per share."
2019-04-08,78.91000366210938,78.5199966430664,0.5495914071016363,,
2019-04-05,78.9000015258789,79.0,-0.494242809457935,,
2019-04-04,79.47000122070312,78.62000274658203,0.12674077590264002,Here's Why DexCom Shares Slumped 14.5% in March,"In a report released last month, Spruce Point said the launch of Abbott Labs ' (NYSE: ABT) next-generation Freestyle Libre CGM and a maturing market among type 1 patients could cause DexCom to lose significant value. Currently, DexCom competes against Medtronic 's Guardian brand of CGMs and the first-generation Freestyle Libre, a CGM that, unlike DexCom's G6, still requires patients to prick their fingers during the first 11 hours of wear to confirm readings -- and doesn't include blood glucose high and low alarms. Abbott's already next-generation finger-stick-less Freestyle Libre has launched overseas, and while there's no timeline for a potential launch in the U.S., an eventual release could challenge DexCom because G6 sensors are approved for only 10 days of wear, while Freestyle Libre's sensors can be worn for 14 days."
2019-04-03,79.97000122070312,79.5,-1.0695840707998585,Abbott (ABT) Stock Sinks As Market Gains: What You Should Know,"ABT's full-year Zacks Consensus Estimates are calling for earnings of $3.20 per share and revenue of $31.80 billion. ABT currently has a Zacks Rank of #3 (Hold). Abbott (ABT) closed the most recent trading day at $79.50, moving -0.15% from the previous trading session."
2019-04-02,79.83000183105469,79.62000274658203,-0.5877219126282172,"IHI, ABT, MDT, TMO: ETF Inflow Alert | IHI, ABT, MDT, TMO: ETF Inflow Alert","Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.3%, Medtronic PLC (Symbol: MDT) is down about 0.2%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $138.7 million dollar inflow -- that's a 3.9% increase week over week in outstanding units (from 15,200,000 to 15,800,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $179.371 per share, with $233.99 as the 52 week high point — that compares with a last trade of $230.35. | Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.3%, Medtronic PLC (Symbol: MDT) is down about 0.2%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $138.7 million dollar inflow -- that's a 3.9% increase week over week in outstanding units (from 15,200,000 to 15,800,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $179.371 per share, with $233.99 as the 52 week high point - that compares with a last trade of $230.35."
2019-04-01,80.66999816894531,79.66000366210938,-0.2630578474958326,,
2019-03-29,79.86000061035156,79.94000244140625,-1.2520075985631354,,
2019-03-28,79.16000366210938,79.44000244140625,0.10017759885205604,How Much Can Intuitive Surgical's Share Price Grow If da Vinci Systems Garner 25% Share In Global Surgical Robots Market? | How Much Can Intuitive Surgical's Share Price Grow If da Vinci Systems Garner 25% Share In Global Surgical Robots Market?,"Intuitive Surgical (NASDAQ:ISRG) could see an upside of over 30% to its stock price, if da Vinci systems garners 25% share in the global surgical robots market. We have created an interactive dashboard analysis ~ What’s The Upside For Intuitive Surgical If da Vinci Systems Garners 25% Share of The Global Surgical Robots Market By 2025? da Vinci Systems’ Current Market Share ~ 17% The da Vinci systems current market share of 17% is derived from its reported sales of $1.1 billion, and an estimated global surgical robots market size of a little over $6.8 billion in 2018. | Intuitive Surgical ( ISRG ) could see an upside of over 30% to its stock price, if da Vinci systems garners 25% share in the global surgical robots market. We have created an interactive dashboard analysis ~ What's The Upside For Intuitive Surgical If da Vinci Systems Garners 25% Share of The Global Surgical Robots Market By 2025? da Vinci Systems' Current Market Share ~ 17% The da Vinci systems current market share of 17% is derived from its reported sales of $1.1 billion, and an estimated global surgical robots market size of a little over $6.8 billion in 2018."
2019-03-27,79.0,78.7300033569336,0.3537124385340306,,
2019-03-26,78.88999938964844,79.0,-0.3417679026157041,What Are Abbott Laboratories' Key Sources of Revenue?,"Abbott Labs (NYSE:ABT) generates its revenues from Medical Devices, Nutritionals, Diagnostics, and Generic Pharmaceuticals business. We forecast mid-single-digit revenue growth for Abbott in 2019, led by steady growth across its businesses. Expect Revenues To Grow In Mid-Single-Digits Abbott’s Medical Devices business includes minimally invasive medical devices for heart diseases, stroke, carotid artery disease, and other vascular conditions."
2019-03-25,77.80999755859375,78.2300033569336,0.13943543060287594,"Abbott's New CE Mark to Boost Core Laboratory Diagnostics Arm | Quest Diagnostics Grows on New Pacts Amid Reimbursement Issue | 6 Excellent Dividend Growth Stocks to Buy Now | Abbott (ABT) Gains As Market Dips: What You Should Know | Thermo Fisher to Buy Brammer Bio, Tightens Gene Therapy Grip","Expanding offerings within the Core Laboratory Diagnostics business, AbbottABT recently announced the receipt of CE Mark for the Alinity m diagnostics system and assays. Click to get this free report Veeva Systems Inc. (VEEV): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Integer Holdings Corporation (ITGR): Free Stock Analysis Report Hologic, Inc. (HOLX): Free Stock Analysis Report To read this article on Zacks.com click here. Alinity - a Strong Growth Driver Abbott's Core Laboratory Diagnostics offers a suite of products in the areas of immunoassay, clinical chemistry, hematology and transfusion, including the Alinity family of instruments, ARCHITECT, ABBOTT PRISM and Cell-Dyn. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks to Consider A few better-ranked stocks in the broader medical space are Abbott Laboratories ABT , Penumbra, Inc., PEN and Masimo, Inc. MASI . Quest Diagnostics is currently focusing on diagnostic information services and disciplined capital deployment. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report LPL Financial Holdings Inc. (LPLA): Free Stock Analysis Report SS&C Technologies Holdings, Inc. (SSNC): Free Stock Analysis Report Caseys General Stores, Inc. (CASY): Free Stock Analysis Report Columbia Sportswear Company (COLM): Free Stock Analysis Report Robert Half International Inc. (RHI): Free Stock Analysis Report To read this article on Zacks.com click here. It has a Zacks Rank #2 and a Growth Score of A. Illinois-based Abbott Laboratories ABT discovers, develops, manufactures and sells health care products worldwide. Dividend Growth: A Winning Strategy Stocks that have a strong history of dividend growth belong to mature companies, which are less susceptible to large swings in the market, and thus act as a hedge against economic or political uncertainty as well as stock market volatility. | Abbott (ABT) closed the most recent trading day at $78.23, moving +0.33% from the previous trading session. Wall Street will be looking for positivity from ABT as it approaches its nex t earnings report date. Any recent changes to analyst estimates for ABT should also be noted by investors. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space are Abbott Laboratories ABT , Penumbra, Inc., PEN and Masimo, Inc. MASI , each stock currently carrying a Zacks Rank #2 (Buy). Thermo Fisher Scientific Inc. Price Thermo Fisher Scientific Inc. Price | Thermo Fisher Scientific Inc. Quote This clearly indicates that the latest move by Thermo Fisher is strategically aligned and well timed."
2019-03-22,79.80999755859375,77.97000122070312,0.539783847215217,"Baxter (BAX) Soars to 52-Week High, Time to Cash Out? | Varian (VAR) Scales New 52-Week High on Solid Prospects","Click to get this free report Baxter International Inc. (BAX): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report ICU Medical, Inc. (ICUI): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report To read this article on Zacks.com click here. Some of its industry peers are also impressive, including Abbott Laboratories (ABT), Stryker (SYK), and ICU Medical (ICUI), all of which currently have a Zacks Rank of at least #2 and a VGM Score of at least B, making them well-rounded choices. Zacks Rank We also need to look at the Zacks Rank for the stock, as this supersedes any trend on the style score front. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report To read this article on Zacks.com click here. Other Key Picks Some other top-ranked stocks in the broader medical space are Abbott Laboratories ABT , Penumbra, Inc., PEN and Masimo, Inc. MASI . Growth Drivers Increasing net sales from Oncology Systems and Proton Solutions have been a major growth driver for Varian."
2019-03-21,79.44999694824219,80.05999755859375,-2.305470986313166,"Notable ETF Outflow Detected - IWD, INTC, T, ABT | Abbott's (ABT) HeartMate 3 Pump Study Shows Favorable Results | Edwards Lifesciences Presents Positive Partner 3 Trial Data","Among the largest underlying components of IWD, in trading today Intel Corp (Symbol: INTC) is up about 1.1%, AT&T Inc (Symbol: T) is up about 1.1%, and Abbott Laboratories (Symbol: ABT) is up by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $43.1 million dollar outflow -- that's a 0.1% decrease week over week (from 307,000,000 to 306,650,000). For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $104.0697 per share, with $129.82 as the 52 week high point - that compares with a last trade of $123.47. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT recently announced late-breaking results from the MOMENTUM 3 randomized control clinical trial. Market Prospects Per Allied market research, the global ventricular assist devices market is projected toreach a worth of $1.78 billion by 2023, at a CAGR of 11.8% during the 2017-2023 period. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. However, Edwards Lifesciences faces competition from a few imminent players like Medtronic plc MDT , Boston Scientific Corporation BSX and Abbott Laboratories ABT in the niche space. PARTNER 3 Trial in Detail Independently assessed, the PARTNER 3 trial compared outcomes between transcatheter aortic valve replacement (""TAVR"") and open-heart surgery in patients with severe symptomatic AS at a low risk of death from surgery."
2019-03-20,79.87000274658203,79.94000244140625,0.7677792747417577,Abbott (ABT) Gains Ground on Solid EPD and Diabetes Arms | Medtronic (MDT) Releases Encouraging Evalut TAVR Result | Abbott's (ABT) MitraClip COAPT Trial Shows Favorable Results (Revised) | Is Abbott Laboratories (ABT) Outperforming Other Medical Stocks This Year?,"Click to get this free report Veeva Systems Inc. (VEEV): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Integer Holdings Corporation (ITGR): Free Stock Analysis Report Hologic, Inc. (HOLX): Free Stock Analysis Report To read this article on Zacks.com click here. On Mar 19, we issued an updated research report on Abbott LaboratoriesABT . The company recently noted that the Branded Generic operating model has positioned EPD for sustained above-market growth in many of these growing pharmaceutical markets. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Other major peers of Medtronic in this field are Boston Scientific Corporation BSX and Abbott Laboratories ABT who are also presenting their study results at the latest session of the Americal College of Cardiology. Data at a Glance In the second year, the findings of this randomized Evolut Low Risk study claim to meet its primary non-inferiority endpoint of all-cause mortality or disabling stroke as compared to surgery. | Abbott LaboratoriesABT recently announced favorable results from two distinctly-conducted analyses of the two-year long COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) clinical trial. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report To read this article on Zacks.com click here. Other Researches by Abbott New late-breaking Momentum 3 data has highlighted the efficiency of Abbott's recently-approved HeartMate 3 left ventricular assist device in treating advanced heart failure. | Investors focused on the Medical space have likely heard of Abbott Laboratories (ABT), but is the stock performing well in comparison to the rest of its sector peers? Looking more specifically, ABT belongs to the Medical - Products industry, which includes 77 individual stocks and currently sits at #74 in the Zacks Industry Rank. ABT is currently sporting a Zacks Rank of #2 (Buy)."
2019-03-19,79.18000030517578,79.95999908447266,0.08764203382629072,What Makes Abbott (ABT) a New Buy Stock | Abbott's (ABT) MitraClip COAPT Trial Shows Favorable Results | Why You Should Buy ABBV Stock for Income and Value | 3 Blue Chip Stocks That Just Hit 52-Week Highs: Are They Buys?,"Abbott (ABT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Most Powerful Force Impacting Stock Prices The change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. | Abbott LifesciencesABT recently announced favorable results from two distinctly-conducted analyses of the two-year long COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) clinical trial. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report To read this article on Zacks.com click here. Market Prospects Per Allied market research, the global market for transcatheter heart valve replacement and repair is projected to reach a worth of $8.13 billion, at a CAGR of 13.8% during the 2017-2025 period.Abbott expects MitraClip to reach a market worth $4 billion in the United States, where about 6.5 million people suffer from heart failures. | A Hiccup in the Robust Fundamental Story In 2013, Abbott Laboratories (NYSE: ABT ) spun off its research-based pharmaceuticals business, creating AbbVie, an independent biopharmaceutical company. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, I'd like to discuss the outlook for AbbVie (NYSE: ABBV ), the $116-billion-market-cap biopharmaceutical stock, whose shares have been in a downtrend for almost a year and have especially been hammered following its earning report of Jan. 25. The Bottom Line on AbbVie Stock Like most biopharma stocks, AbbVie is a high-momentum stock. | Here's why Abbott Labs (NYSE: ABT) , Novartis (NYSE: NVS) , and Stryker (NYSE: SYK) are performing so well -- and whether any of these stocks are buys right now. Abbott Labs Abbott Labs is the best performer of the three blue chip stocks on this list, with its shares up 24% over the last 12 months. Stryker CEO Kevin Lobo stated on the company's conference call that the company ""had an excellent finish to 2018 with the best organic sales growth in a decade, and strong adjusted earnings performance."""
2019-03-18,79.94999694824219,78.83000183105469,0.9850957013015933,Abbott (ABT) Stock Sinks As Market Gains: What You Should Know,"Abbott (ABT) closed at $78.83 in the latest trading session, marking a -1.29% move from the prior day. Investors will be hoping for strength from ABT as it approaches its nex t earnings release. In tha t report , analysts expect ABT to post earnings of $0.61 per share."
2019-03-15,79.02999877929688,79.86000061035156,-1.4008694933566532,Abbott (ABT) Gets FDA Approval for Expanded Use of MitraClip,"Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT recently announced that its flagship platform - MitraClip transcatheter clip-based device - has received FDA approval for the treatment of secondary or functional mitral regurgitation (""MR""). Structural Heart Unit Strengthens Abbott's structural heart business is a leader in occlusion devices that treat or close openings in the heart caused by congenital defects."
2019-03-14,78.5,78.9800033569336,1.050236421453823,"Health Care Sector Update for 03/14/2019: AXGT, JNJ, BDX, PFE, ABT, MRK, AMGN","ABT: Flat AMGN: Flat Leading health care stocks were mixed in pre-market trading Thursday. Stocks moving on news include: (-) Axovant Sciences ( AXGT ), which was down more than 18% after the company priced a public offering of 26.7 million shares at $1.50 per share, a 14.3% discount from the stock's previous close, for total expected gross proceeds of $40 million."
2019-03-13,78.66999816894531,78.62000274658203,0.6114692445013934,,
2019-03-12,77.98999786376953,78.23999786376953,-0.06355081165238512,Abbott (ABT) Outpaces Stock Market Gains: What You Should Know,"In the latest trading session, Abbott (ABT) closed at $78.24, marking a +0.55% move from the previous day. Investors will be hoping for strength from ABT as it approaches its nex t earnings release. It is also important to note the recent changes to analyst estimates for ABT."
2019-03-11,76.91999816894531,77.80999755859375,0.32055392594918664,,
2019-03-08,76.3499984741211,76.62999725341797,1.157045515905582,Is DexCom a Buy?,"Another heavy hitter in the CGM space is Abbott Labs (NYSE: ABT) , which won FDA approval for a CGM device called the Freestyle Libre in 2017. The business DexCom, a medical device company focused on diabetes, sells a popular continuous glucose monitor (CGM) system called the DexCom G6. While DexCom isn't an appropriate stock for risk-averse investors, I still think there is a lot like about the company."
2019-03-07,77.69000244140625,76.80000305175781,0.36673056305532326,S&P 500 Analyst Moves: ABT,"The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories ( ABT ) is now the #66 analyst pick, moving up by 1 spot. VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Looking at the stock price movement year to date, Abbott Laboratories ( ABT ) is showing a gain of 6.9%."
2019-03-06,78.11000061035156,77.69999694824219,-1.145577759917918,"The Zacks Analyst Blog Highlights: Boeing, Abbott, PayPal, Caterpillar and Anthem","Click to get this free report PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report The Boeing Company (BA): Free Stock Analysis Report Caterpillar Inc. (CAT): Free Stock Analysis Report Anthem, Inc. (ANTM): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include: BoeingBA , AbbottABT , PayPalPYPL , CaterpillarCAT and AnthemANTM . Here are highlights from Tuesday's Analyst Blog: Top Analyst Reports for Boeing, Abbott and PayPal The Zacks Research Daily presents the best research output of our analyst team."
2019-03-05,78.55999755859375,78.22000122070312,-0.5249054652485038,,
2019-03-04,78.83999633789062,78.62000274658203,-0.432785575937728,Here's Why You Should Snap Up Abbott (ABT) Stock Right Now | Abbott Laboratories Reaches Analyst Target Price,"Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT has been gaining investor confidence on continued positive results. Alere Integration Synergies Impressive The integration of Alere has added Rapid Diagnostics to Abbott's existing leadership position in the $50-billion global diagnostics market. | And so with ABT crossing above that average target price of $78.19/share, investors in ABT have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $78.19 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? In recent trading, shares of Abbott Laboratories (Symbol: ABT) have crossed above the average analyst 12-month target price of $78.19, changing hands for $78.59/share. But the whole reason to look at the average ABT price target in the first place is to tap into a ""wisdom of crowds"" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes."
2019-03-01,77.98999786376953,78.58999633789062,-0.2790380536875602,Here's Why You Should Buy Varian Medical (VAR) Stock Now,"Varian Medical Systems, Inc. Price and Consensus Varian Medical Systems, Inc. Price and Consensus | Varian Medical Systems, Inc. Quote Other Key Picks Other top-ranked stocks in the broader medical space are Abbott Laboratories ABT , Merit Medical Systems, Inc. MMSI and Surmodics, Inc. SRDX . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI): Free Stock Analysis Report To read this article on Zacks.com click here. Fiscal Q1 Results Varian Medical's first-quarter fiscal 2019 adjusted earnings of $1.06 per share were on par with the Zacks Consensus Estimate."
2019-02-28,77.01000213623047,77.62000274658203,0.7693274657721522,"IYH, ABT, MDT, ABBV: Large Outflows Detected at ETF | Merit Medical (MMSI) Q4 Earnings & Revenues Surpass Estimates | Orthofix (OFIX) Earnings Beat Estimates in Q4, Margins Fall","Among the largest underlying components of IYH, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.7%, Medtronic PLC (Symbol: MDT) is up about 0.2%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $58.2 million dollar outflow -- that's a 2.4% decrease week over week (from 12,450,000 to 12,150,000). For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $166.89 per share, with $204.83 as the 52 week high point - that compares with a last trade of $194.16. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI): Free Stock Analysis Report To read this article on Zacks.com click here. Key Picks Other top-ranked stocks in the MedTech space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Segmental Analysis Cardiovascular The Cardiovascular unit recorded fourth-quarter revenues of $225.1 million, up 22.7% year over year. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report ORTHOFIX MEDICAL INC. (OFIX): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. A few other top-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . For the quarter under review, revenues from Bone Growth Therapies totaled $52.8 million, up 6.1 % year over year both on a reported basis and at CER."
2019-02-27,76.44999694824219,77.2300033569336,0.7921056920274762,Veeva Systems (VEEV) Beats on Q4 Earnings and Revenues | Wright Medical (WMGI) Q4 Earnings & Revenues Beat Estimates,"Click to get this free report Veeva Systems Inc. (VEEV): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report To read this article on Zacks.com click here. Key Picks Some better-ranked stocks in the MedTech space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Veeva Systems Inc. VEEV reported fourth-quarter fiscal 2019 adjusted earnings of 45 cents per share, which surpassed the Zacks Consensus Estimate of 31 cents. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Wright Medical Group N.V. (WMGI): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report To read this article on Zacks.com click here. Other Key Picks Some other top-ranked stocks in the MedTech space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . While international revenues at the segment rose 8.6% to $7.4 million, U.S. revenues summed $24 million, up 10.1% year over year."
2019-02-26,76.58000183105469,76.75,1.0202831129208316,"Teleflex (TFX) Q4 Earnings Miss Estimates, Margins Rise | Bruker Rides on Robust NANO & CALID Groups, Recent Buyouts | Here's Why Investors Should Buy DexCom (DXCM) Stock Now","Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Teleflex Incorporated (TFX): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Revenues in Detail In the fourth quarter, Teleflex's Vascular North America segment recognized net revenues of $85.7 million, up 6.3% year over year at CER. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Bruker Corporation (BRKR): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report To read this article on Zacks.com click here. Other Key Picks Some other top-ranked stocks in the broader medical space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . In 2018, the Bruker Nano Surfaces group, which includes Bruker's atomic force microscopy product, reported high single-digit revenue growth. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report To read this article on Zacks.com click here. Key Picks Other top-ranked stocks in the MedTech space are Surmodics, Inc. SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . DexCom exited the fourth quarter on a strong note, wherein earnings and revenues outpaced the Zacks Consensus Estimate."
2019-02-25,76.38999938964844,76.86000061035156,0.22198767939487687,"CVS Health Rides on Aetna Synergy, PBM Selling Season Modest | Chemed (CHE) Q4 Earnings Beat Estimates, Gross Margin Falls","Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report CVS Health Corporation (CVS): Free Stock Analysis Report To read this article on Zacks.com click here. Key Picks A few better-ranked stocks in the MedTech space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . With regard to its 2019 PBM selling season, CVS Health notes that the net benefits from this selling season are expected to be modest on Anthem-related headwinds. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report Chemed Corporation (CHE): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Chemed Corporation Price, Consensus and EPS Surprise Chemed Corporation Price, Consensus and EPS Surprise | Chemed Corporation Quote In the fourth quarter, net revenues at VITAS totaled $306.9 million, reflecting an increase of 4.9% year over year."
2019-02-22,75.3499984741211,76.12999725341797,0.6152653808854652,"Quest Diagnostics Grows on Innovation Amid Reimbursement Woe | Daily Dividend Report: PLD, SRE, DLR, ABT, CCI | NuVasive (NUVA) Q4 Earnings Beat Estimates, Margins Fall | Why Is Abbott (ABT) Up 6% Since Last Earnings Report?","Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report To read this article on Zacks.com click here. PEN , Amedisys, Inc. AMED and Abbott Laboratories ABT . Quest Diagnostics Incorporated Price Quest Diagnostics Incorporated Price | Quest Diagnostics Incorporated Quote This expanded agreement will provide in-network access to Quest Diagnostics' complete portfolio of laboratory services to more than 48 million eligible members. | Abbott ( ABT ) declared a quarterly common dividend of 32 cents per share. VIDEO: Daily Dividend Report: PLD, SRE, DLR, ABT, CCI The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The board declared a regular cash dividend of $0.53 per share of the company's common stock, which will be payable on March 29, 2019, to common stockholders of record at the close of business on March 15, 2019. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report NuVasive, Inc. (NUVA): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. A few top-ranked medical stocks that have reported quarterly results in the recently are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . NuVasive, Inc. Price, Consensus and EPS Surprise NuVasive, Inc. Price, Consensus and EPS Surprise | NuVasive, Inc. Quote Within the Biologics segment, there was a sequential revenue increment of 4% over the third quarter, even though the business line faced a 6.5% year-over-year decline. | It has been about a month since the las t earnings report for Abbott (ABT). Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Posts In Line Q4 Earnings, Provides '19 View Abbot t report ed fourth-quarter 2018 adjusted earnings from continuing operations of 81 cents per share, in line with the Zacks Consensus Estimate."
2019-02-21,75.11000061035156,75.13999938964844,1.0351676112704435,"Medidata's (MDSO) Margins Under Pressure, Competition Rife | Abbott (ABT) Dips More Than Broader Markets: What You Should Know","Stocks to Consider A few better-ranked stocks in the broader medical space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Medidata Solutions, Inc. (MDSO): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report To read this article on Zacks.com click here. Price Performance Shares of Medidata have gained 11.1% compared with the industry 's growth of 2.3% in a year's time. | Abbott (ABT) closed the most recent trading day at $75.14, moving -0.53% from the previous trading session. Wall Street will be looking for positivity from ABT as it approaches its nex t earnings report date. On that day, ABT is projected to report earnings of $0.61 per share, which would represent year-over-year growth of 3.39%."
2019-02-20,74.83000183105469,75.54000091552734,0.039939793706699304,"CVS Health's (CVS) Q4 Earnings Top Estimates, Margins Up | Notable ETF Outflow Detected - IYH, ABT, MDT, ABBV | Intuitive Surgical Gets FDA Nod for Ion Endoluminal System","Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report CVS Health Corporation (CVS): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . CVS Health Corporation 's CVS fourth-quarter 2018 adjusted earnings per share (EPS) of $2.14 surged 11.5% year over year and exceeded the Zacks Consensus Estimate by 3.4%. | Among the largest underlying components of IYH, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.4%, Medtronic PLC (Symbol: MDT) is up about 0.1%, and AbbVie Inc (Symbol: ABBV) is lower by about 1.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $68.2 million dollar outflow -- that's a 2.7% decrease week over week (from 12,800,000 to 12,450,000). For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $166.89 per share, with $204.83 as the 52 week high point - that compares with a last trade of $194.19. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report QIAGEN N.V. (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Apart from Intuitive Surgical, Abbot Laboratories ABT and Medtronic MDT are the other key players in this space. Apart from lung nodule biopsy, Ion integrates existing imaging technology including fluoroscopy, radial-endobronchial ultrasound, and cone-beam CT. Market Prospects The Ion platform represents Intuitive Surgical's solid focus on minimally invasive care."
2019-02-19,75.16000366210938,75.0,0.9488160725635643,"Medtronic (MDT) Beats on Q3 Earnings, Gross Margin Down | Here's Why Investors Should Buy Surmodics (SRDX) Stock Now | Align Technology Unveils iTero Element 5D Imaging System","Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Medtronic PLC Price, Consensus and EPS Surprise Medtronic PLC Price, Consensus and EPS Surprise | Medtronic PLC Quote In the quarter under review, U.S. sales (53% of total revenues) increased 2.3% year over year on a reported basis to $4 billion. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Wright Medical Group N.V. (WMGI): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report To read this article on Zacks.com click here. Other Key Picks Some other top-ranked stocks in the broader medical space are Wright Medical Group N.V. WMGI , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . The company's impressive performance in first-quarter fiscal 2019 and consistent focus on Research and Development (R&D) are working in favor of the stock. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. PEN , Amedisys, Inc. AMED and Abbott Laboratories ABT . Expanding the iTero suite, Align Technology, Inc.ALGN recently announced the launch of its first intraoral scanner with near-infrared imaging (NIRI) technology - iTero Element 5D Imaging System."
2019-02-15,74.55999755859375,75.25,-0.2128840531044813,Here's Why You Must Buy Cardiovascular Systems' (CSII) Stock,"Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. PEN , Amedisys, Inc. AMED and Abbott Laboratories ABT . Market Dynamics Currently, Cardiovascular Systems firmly stands to gain from several favorable trends existing in the peripheral artery disease (PAD) as well coronary artery disease (CAD) market spaces."
2019-02-14,74.08000183105469,73.97000122070312,0.9254324892701403,"Baxter's Acute Therapies Profile Strong, Competition Rife | Bio-Techne (TECH) Q2 Earnings Beat, Gross Margin Declines | Johnson & Johnson (JNJ) to Acquire Auris Health for $3.4B","Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report To read this article on Zacks.com click here. Key Picks A few better-ranked stocks in the broader medical space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Solid Acute Therapies Profile Baxter's performance in Acute Therapies has been consistently driven by improving utilization for CRRT globally and increased demand for multi-organ support products. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report Bio-Techne Corp (TECH): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Bio-Techne Corp Price, Consensus and EPS Surprise Bio-Techne Corp Price, Consensus and EPS Surprise | Bio-Techne Corp Quote In the reported quarter, Protein Sciences saw 15.7% growth from the prior-year quarter (up 14% organically) to $135.5 million. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. In February 2017, J&J acquired Abbott's ABT vision care business, Abbott Medical Optics for $4.325 billion, which has strengthened the former's Medical Device segment. Johnson & Johnson 's JNJ robotic surgery and medical device division, Ethicon entered into a definitive agreement to acquire Auris Health, Inc., a developer of robotic technologies focused on lung cancer, for approximately $3.4 billion in cash."
2019-02-13,75.04000091552734,74.37999725341797,-0.14848894118878075,Boston Scientific Benefits From New Buyouts & Product Launch | Here's Why Investors Should Retain AmerisourceBergen Stock | Edwards Lifesciences to Buy CASMED to Boost Critical Care Arm,"Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Penumbra, Inc. (PEN): Get Free Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Amedisys, Inc. (AMED): Get Free Report To read this article on Zacks.com click here. PEN , Amedisys, Inc. AMED and Abbott Laboratories ABT . The company is leaving no stone unturned to strengthen its core businesses and invest in new technologies and global market s. We are also optimistic about the receipt of an FDA approval for its SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System with 4.50 mm and 5 mm diameter. | AmerisourceBergen Corporation Price and Consensus AmerisourceBergen Corporation Price and Consensus | AmerisourceBergen Corporation Quote Key Picks A few better-ranked stocks in the broader medical space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report AmerisourceBergen Corporation (ABC): Free Stock Analysis Report To read this article on Zacks.com click here. From an operating income standpoint, MWI's operating income of $99 million decreased about 1% year over year. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Penumbra, Inc. (PEN): Get Free Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Amedisys, Inc. (AMED): Get Free Report To read this article on Zacks.com click here. PEN , Amedisys, Inc. AMED and Abbott Laboratories ABT . Per Edwards Lifesciences, integration of CASMED's FORE-SIGHT technology with its hemodynamic monitoring platform, along with the company's predictive analytic capability, will strengthen Edwards Lifesciences' position in smart monitoring technologies."
2019-02-12,73.98999786376953,75.05999755859375,-0.8795357863232733,"Here's Why You Should Buy IDEXX Laboratories (IDXX) Stock | STERIS (STE) Q3 Earnings In Line, Revenues Beat Estimates | Here's Why Investors Should Retain Accuray (ARAY) Stock Now | Bruker (BRKR) Q4 Earnings In Line, Margin Growth Strong","Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Penumbra, Inc. (PEN): Get Free Report IDEXX Laboratories, Inc. (IDXX): Get Free Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. PEN , Amedisys, Inc. AMED and Abbott Laboratories ABT . In the fourth quarter, CAG revenues rose 13% organically year over year, supported by strong CAG Diagnostics recurring organic revenue growth, high premium CAG instrument placements and continued solid growth in software, services and diagnostic imaging system businesses. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report STERIS plc (STE): Get Free Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. Other top-ranked medical stocks that have recently reported quarterly results are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Quarter in Detail Organic revenue growth at constant currency was 7% year over year in the fiscal third quarter, mainly driven by growth across all segments. | Accuray Incorporated Price and Consensus Accuray Incorporated Price and Consensus | Accuray Incorporated Quote Key Picks A few better-ranked stocks in the broader medical space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Accuray Incorporated (ARAY): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Get Free Report Surmodics, Inc. (SRDX): Free Stock Analysis Report To read this article on Zacks.com click here. While, the CyberKnife System faces challenges from Varian's Trilogy system, TomoTherapy systems are challenged by Varian's RapidArc technology and the TrueBeam systems. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Bruker Corporation (BRKR): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked medical stocks that have reported quarterly results are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Revenues in Detail Bruker registered revenues of $553.6 million in the fourth quarter, up 4.4% year over year."
2019-02-11,73.4800033569336,73.54000091552734,1.446140999752836,"Here's Why Momentum Investors Will Love Abbott (ABT) | IRADIMED (IRMD) Q4 Earnings Surpass Estimates, Margins Up | Here's Why You Should Buy Wright Medical (WMGI) Stock Now | Top Ranked Momentum Stocks to Buy for February 11th","Below, we take a look at Abbott (ABT) , a company that currently holds a Momentum Style Score of B. In order to see if ABT is a promising momentum pick, let's examine some Momentum Style elements to see if this maker of infant formula, medical devices and drugs holds up. For ABT, shares are up 1.7% over the past week while the Zacks Medical - Products industry is up 0.91% over the same time period. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report iRadimed Corporation (IRMD): Get Free Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. Key Picks A few top-ranked medical stocks that have reported quarterly results in the recently are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Revenue details In the fourth quarter of 2018, revenues totaled $8.3 million, up 24.5% year over year. | Wright Medical Group N.V. Price and Consensus Wright Medical Group N.V. Price and Consensus | Wright Medical Group N.V. Quote Key Picks A few top-ranked stocks in the broader medical space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Wright Medical Group N.V. (WMGI): Get Free Report To read this article on Zacks.com click here. Strong Foothold in the Foot & Ankle Market Wright Medical's solid foot and ankle products portfolio, and extensive training provided to extremities-dedicated surgeons have enabled it to emerge as a leading player in the foot and ankle market. | The company possesses a Momentum Score of A. ABIOMED, Inc. Price ABIOMED, Inc. price | ABIOMED, Inc. Quote Abbott Laboratories (ABT): This developer and manufacturer of health care products has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.3% over the last 60 days. Click to get this free report Apartment Investment and Management Company (AIV): Get Free Report Abbott Laboratories (ABT): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Get Free Report To read this article on Zacks.com click here. Apartment Investment and Management Company Price and Consensus Apartment Investment and Management Company price-consensus-chart | Apartment Investment and Management Company Quote Apartment Investment's shares gained 8.9% over the last one month more than S&P 500's gain of 4.9%."
2019-02-08,72.16000366210938,73.33000183105469,0.0816515457985327,"Omnicell (OMCL) Q4 Earnings Beat Estimates, Revenues Miss | Here's Why You Should Invest in Stryker (SYK) Stock Right Now | Smith & Nephew in talks to buy NuVasive for over $3 bln - FT","Some better-ranked MedTech stocks that delivered solid results in the respective quarters are Abbott Laboraories ABT , AngioDynamics ANGO and CONMED Corp. CNMD . Click to get this free report Omnicell, Inc. (OMCL): Get Free Report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. Moreover, the figure exceeded the Zacks Consensus Estimate of $2.04 Revenues in Detail Adjusted revenues in the fourth quarter increased 7.7% year over year to $211.8 million. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report BioLife Solutions, Inc. (BLFS): Get Free Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Stryker Corporation (SYK): Get Free Report To read this article on Zacks.com click here. Other top-ranked stocks from the Medical Product space are Abbott Laboratories ABT , Surmodics, Inc. SRDX and BioLife Solutions, Inc. BLFS . The Michigan-based medical device company reported revenues of $3.80 billion, which were well ahead of the Zacks Consensus Estimate of $3.73 billion. | Feb 8 (Reuters) - Britain'sSmith & Nephew Plc has held talks to buy U.S. medical equipment maker NuVasive in a deal that would be worth more than $3 billion, the Financial Times reported on Friday, citing people familiar with the talks. Smith & Nephew has been under pressure to improve its margins and find new sources of growth to tighten its competition with bigger rivals such as Stryker Corp, Zimmer Biomet Holdings and Johnson & Johnson. Smith & Nephew is valued at 13.28 billion GBP ($17.19 billion)."
2019-02-07,72.98999786376953,72.73999786376953,1.621394276008981,,
2019-02-06,72.9000015258789,73.48999786376953,-0.34251268299336934,Here's Why You Should Invest in McKesson (MCK) Stock Now,"Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report McKesson Corporation (MCK): Get Free Report To read this article on Zacks.com click here. A few other top-ranked stocks in the MedTech space are Surmodics, Inc. SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . It is encouraging to note that, Rite Aid renewed its distribution and sourcing relationship with McKesson for another 10 years in the fiscal third quarter."
2019-02-05,72.9000015258789,73.11000061035156,0.8093228059551976,,
2019-02-04,72.38999938964844,72.5,0.28806458172447125,Here's Why You Should Hold Intuitive Surgical (ISRG) Stock,"Intuitive Surgical, Inc. Price and Consensus Intuitive Surgical, Inc. Price and Consensus | Intuitive Surgical, Inc. Quote Key Picks A few better-ranked stocks in the broader medical space are Surmodics, Inc. SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report To read this article on Zacks.com click here. The platform bolstered Intuitive Surgical's foothold in the Cardiac Surgery, Colorectal Surgery, General Surgery, Gynecologic Surgery, Head & Neck Surgery, Thoracic Surgery and Urologic Surgerymarkets."
2019-02-01,73.0199966430664,72.36000061035156,0.15195553429897152,,
2019-01-31,71.30999755859375,72.9800033569336,-0.9038565640327423,"Surmodics (SRDX) Q1 Earnings & Revenues Beat, Guidance Solid | iShares S&P 100 ETF Experiences Big Outflow","Surmodics, Inc. Price, Consensus and EPS Surprise Surmodics, Inc. Price, Consensus and EPS Surprise | Surmodics, Inc. Quote Segmental Analysis Medical Device In the reported quarter, sales at the segment rose 35.1% to $17.3 million, which includes $2.4 million from the SurVeil agreement with Abbott ABT . Click to get this free report Abbott Laboratories (ABT): Get Free Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report To read this article on Zacks.com click here. The Medical Device business unit also reported $0.4 million of operating income in the first quarter against an operating loss of $0.4 million a year ago. | Among the largest underlying components of OEF, in trading today PepsiCo Inc (Symbol: PEP) is up about 0.3%, Abbott Laboratories (Symbol: ABT) is up about 0.6%, and International Business Machines Corp (Symbol: IBM) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares S&P 100 ETF (Symbol: OEF) where we have detected an approximate $112.4 million dollar outflow -- that's a 2.5% decrease week over week (from 38,750,000 to 37,800,000). For a complete list of holdings, visit the OEF Holdings page » The chart below shows the one year price performance of OEF, versus its 200 day moving average: Looking at the chart above, OEF's low point in its 52 week range is $104.23 per share, with $131.30 as the 52 week high point - that compares with a last trade of $119.16."
2019-01-30,69.91000366210938,71.68000030517578,2.341895744657177,,
2019-01-29,69.08999633789062,69.69000244140625,2.531821699825957,Here's Why You Should Snap Up Abbott (ABT) Stock Right Now | Abbott (ABT) Gains As Market Dips: What You Should Know,"Click to get this free report Omnicell, Inc. (OMCL): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT has been gaining investor confidence on continued positive results. Progress With Diabetes Business This business achieved 35% growth in 2018, led by FreeStyle Libre, which achieved global sales of more than $1 billion during the year, reflecting a 100% increase from a year ago. | ABT's full-year Zacks Consensus Estimates are calling for earnings of $3.20 per share and revenue of $31.81 billion. Abbott (ABT) closed at $69.69 in the latest trading session, marking a +0.93% move from the prior day. Investors will be hoping for strength from ABT as it approaches its nex t earnings release, which is expected to be April 17, 2019."
2019-01-28,70.5199966430664,69.05000305175781,0.8684413595583983,,
2019-01-25,71.2699966430664,71.1500015258789,-2.084506042660348,,
2019-01-24,70.0,70.86000061035156,-0.1683669465966979,"Company News For Jan 24, 2019 | Abbott (ABT) Q4 Earnings Meet Estimates, Organic Growth Solid","Kimberly-Clark Corp. KMB shares declined 2.7% after reporting fourth-quarter 2018 adjusted earnings per share of $1.60, missing the Zacks Consensus Estimate of $1.68 Shares of Abbott Laboratories ABT fell 2.2% after posting fourth quarter 2018 revenues of $7.77 billion, lagging the Zacks Consensus Estimate of $7.79 billion Synchrony Financial SYF shares jumped 10.7% after the company extended its partnership with Walmart Inc.'s WMT Sam's club Shares of Restaurant Brands International Inc. QSR surged 9.8% after the company promoted Jose Cil, president of Burger King division, as it CEO Want the latest recommendations from Zacks Investment Research? Click to get this free report Kimberly-Clark Corporation (KMB): Get Free Report Abbott Laboratories (ABT): Free Stock Analysis Report Synchrony Financial (SYF): Free Stock Analysis Report Walmart Inc. (WMT): Get Free Report Restaurant Brands International Inc. (QSR): Get Free Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT reported fourth-quarter 2018 adjusted earnings from continuing operations of 81 cents per share, in line with the Zacks Consensus Estimate. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report BioTelemetry, Inc. (BEAT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories Price, Consensus and EPS Surprise Abbott Laboratories Price, Consensus and EPS Surprise | Abbott Laboratories Quote In the fourth quarter, EPD sales dropped 4.8% on a reported basis (improved 3.6% on an organic basis) to $1.09 billion."
2019-01-23,70.5,69.91000366210938,1.2285723005022322,"U.S. STOCKS ON THE MOVE-IBM, Synchrony Financial, Twitter | Health Care Sector Update for 01/23/2019: BLPH, ATHX, JNJ, PFE, MRK, ABT, AMGN | U.S. STOCKS ON THE MOVE-United Technologies, P&G, IBM, Synchrony | US STOCKS-Wall Street bounces back on strong corporate earnings | US STOCKS-Wall St set to open higher on strong earnings from Dow members | Noteworthy ETF Outflows: XLV, ABT, LLY, TMO | S&P, Nasdaq dip as healthcare, financials weigh; IBM keeps Dow higher | US STOCKS-S&P, Nasdaq dip as healthcare, financials weigh; IBM keeps Dow higher | Wall St set to open higher on strong earnings from Dow members | U.S. STOCKS ON THE MOVE-IBM, Synchrony Financial, Waters, Boxlight | Abbott Sees Q1 Profit Below View | Abbott misses revenue estimates, sees lackluster first-qtr profit | Abbott Laboratories (ABT) Q4 2018 Earnings Conference Call Transcript | Abbott Laboratories Q4 18 Earnings Conference Call At 9:00 AM ET | 5 Must-See Stock Charts for Thursday: ABT, IBM, SBUX, PZZA | Abbott Labs (ABT) Stock Slips Despite Solid Q4 Earnings | Abbott (ABT) Meets Q4 Earnings Estimates | Earnings Reaction History: Abbott Laboratories, 50.0% Follow-Through Indicator, 2.3% Sensitive | Abbott Lab's fourth-quarter revenue rises 2.3 pct | U.S. STOCKS ON THE MOVE-IBM, P&G, Synchrony Financial","At 10:17 ET, the Dow Jones Industrial Average was up 0.96 percent at 24,638.62. The S&P 500 was up 0.56 percent at 2,647.77 and the Nasdaq Composite was up 0.69 percent at 7,068.989. The top three S&P 500 percentage gainers: ** Waters Corp, up 11.3 pct ** Synchrony Financial, up 11.1 pct ** IBM Corp, up 8 pct The top three S&P 500 percentage losers: ** Rollins Inc, down 6.4 pct ** Capital One Financial Corp, down 5.6 pct ** Twitter Inc, down 3.5 pct The top three NYSE percentage gainers: ** Waters Corp, up 11.3 pct ** Synchrony Financial, up 11.1 pct ** Vipshop Hold Ltd, up 10.7 pct The top three NYSE percentage losers: ** Quotient Technology, down 17.8 pct ** Fb Financial Corp, down 9.4 pct ** Trinseo Sa, down 8.9 pct The top three Nasdaq percentage gainers: ** Boxlight Corp, up 65 pct ** Microbot Medical, up 20.6 pct ** Reto Eco Solutions, up 18.1 pct The top three Nasdaq percentage losers: ** Avalon Globocare, down 34.5 pct ** Bridgford Food, down 17.9 pct ** Datasea Inc, down 16 pct ** United Technologies Corp: up 6.1 pct United Technologies Corp: Shares rise on Q4 profit beat United Tech profit beats on higher aero parts sales ** Procter & Gamble Co: up 5.9 pct Procter & Gamble: Up as Q2 results beat P&G raises forecast on strength of skin care, detergent brands ** Comcast Corp: up 6.1 pct Comcast Corp: Set to jump as Q4 revenue beats analyst expectations Comcast results beat on lower-than-expected video losses ** Rollins Inc: down 6.4 pct Rollins Inc: Drops after Q4 EPS and revenue miss ** Waters Corp: up 11.7 pct Waters Corp: Eyes one-year high on sparkling FY profit forecast ** Accuray Inc: up 9.9 pct Accuray Inc: Jumps as strong China orders spur profitability target ** PTC Therapeutics: down 9.0 pct PTC Therapeutics: Slides on $200 mln stock offering plan ** Restaurant Brands: up 7.4 pct Restaurant Brands: Rises after naming Burger King chief Jose Cil as CEO Restaurant Brands names Burger King boss Jose Cil as CEO ** Bellerophon Therapeutics Inc: down 23.4 pct Small drugmakers Bellerophon and Rexahn slide on stock deal plans ** IBM Corp: up 8.6 pct IBM: Gains on strong 2019 profit forecast ** Merck & Co: down 0.5 pct Merck's Keytruda seems ahead of Bristol-Myers' Opdivo in Q4 ** Tesla Inc: down 2.6 pct Tesla: 'Dream deferred,' sell the 'Elon premium' - RBC ** Walmart Inc: up 1.5 pct MS cautious of hard goods retailers, ups Walmart to 'outperform' ** Teva Pharmaceuticals Industries Ltd: up 4.7 pct Teva: Rises after UBS says stock ""too cheap to ignore"", upgrades ** Synchrony Financial: up 10.8 pct Synchrony Financial: Rises after Walmart drops lawsuit, strong Q4 results ** Kimberly-Clark Corp: down 1.9 pct Kimberly-Clark: Drops on weak 2019 profit forecast Kimberly-Clark misses profit estimates, shares fall ** Abbott Laboratories: down 0.4 pct Abbott Labs: Falls on Q4 revenue miss; weak Q1 profit forecast ** Athersys Inc: up 13.7 pct Athersys: Surges on positive lung disease treatment results The 11 major S&P 500 sectors: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (-) Abbott Laboratories ( ABT ) was declining by over 2% as i t report ed Q4 adjusted earnings of $0.81 per diluted share, up from $0.74 per share a year ago in line with the $0.81 average estimate from analysts polled by Capital IQ. (+) Athersys ( ATHX ) was up by more than 20% after saying summary results from its study of the intravenous administration of MultiStem cell therapy to treat patients suffering from acute respiratory distress syndrome ( ARDS ) showed lower mortality and a greater number of ventilator-free and intensive care unit (ICU) free days in the first month following diagnosis relative to patients receiving placebo. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | At 9:14 ET, Dow e-minis were up 0.78 percent at 24,580. S&P 500 e-minis were up 0.50 percent at 2,645.25, while Nasdaq 100 e-minis were up 0.54 percent at 6,689.25. The top three NYSE percentage gainers premarket: ** Synchrony Financial, up 12.3 pct ** Portland General Electric Co, up 10.1 pct ** Restaurant Brands International Inc, up 8.8 pct The top three NYSE percentage losers premarket: ** Trinseo Sa, down 12.3 pct ** Bellatrix Exploration Ltd, down 8.8 pct ** Quotient Technology Inc, down 9.4 pct The top three Nasdaq percentage gainers premarket: ** Auris Medical Holding, up 31.9 pct ** Soligenix Inc, up 30.1 pct ** Athersys Inc, up 20.1 pct The top three Nasdaq percentage losers premarket: ** Bellerophon Therapeutics Inc, down 25.9 pct ** Selecta Biosciences Inc, down 23.7 pct ** Avalon Globocare Corp, down 23.5 pct ** United Technologies Corp: up 4.9 pct premarket United Technologies Corp: Shares rise on Q4 profit beat United Tech profit beats on higher aero parts sales ** Procter & Gamble Co: up 4.4 pct premarket Procter & Gamble: Up as Q2 results beat P&G raises forecast on strength of skin care, detergent brands ** Comcast Corp: up 2.9 pct premarket Comcast Corp: Set to jump as Q4 revenue beats analyst expectations Comcast results beat on lower-than-expected video losses ** Rollins Inc: down 4.9 pct premarket Rollins Inc: Drops after Q4 EPS and revenue miss ** PTC Therapeutics: down 8.9 pct premarket PTC Therapeutics: Slides on $200 mln stock offering plan ** Restaurant Brands: up 8.8 pct premarket Restaurant Brands: Rises after naming Burger King chief Jose Cil as CEO Restaurant Brands names Burger King boss Jose Cil as CEO ** Bellerophon Therapeutics Inc: down 25.9 pct premarket Small drugmakers Bellerophon and Rexahn slide on stock deal plans ** IBM Corp: up 7.2 pct premarket IBM: Gains on strong 2019 profit forecast ** Merck & Co: down 0.3 pct premarket Merck needs more aggressive business development - BMO Capital Markets ** Tesla Inc: down 2.2 pct premarket Tesla: 'Dream deferred,' sell the 'Elon premium' - RBC ** Walmart Inc: up 1.4 pct premarket MS cautious of hard goods retailers, ups Walmart to 'outperform' ** Teva Pharmaceuticals Industries Ltd: up 2.9 pct premarket Teva: Rises after UBS says stock ""too cheap to ignore"", upgrades ** Synchrony Financial: up 12.3 pct premarket Synchrony Financial: Rises after Walmart drops lawsuit, strong Q4 results ** Kimberly-Clark Corp: down 3.7 pct premarket Kimberly-Clark: Drops on weak 2019 profit forecast Kimberly-Clark misses profit estimates, shares fall ** Abbott Laboratories: down 2.4 pct premarket Abbott Labs: Falls on Q4 revenue miss; weak Q1 profit forecast ** Athersys Inc: up 20.1 pct premarket Athersys: Surges on positive lung disease treatment results The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | urn:newsml:reuters.com:*:nL1N1ZM1SD Abbott LaboratoriesABT.N dropped 1.36 percent after thehealthcare company missed quarterly revenue estimate due tolower sales of generic drugs in emerging markets and gave adownbeat forecast for the current quarter. * P&G, UTX, Comcast rise after results beat * IBM biggest gainer among Dow components * Abbott, Kimberly-Clark fall on disappointing results * Indexes up: Dow 1.16 pct, S&P 0.71 pct, Nasdaq 0.84 pct (Updates to open) By Shreyashi Sanyal Jan 23 (Reuters) - U.S. stocks rose on Wednesday, as strongearnings from IBM, United Technologies and Procter & Gamble leda rebound for Wall Street from its second biggest decline in2019. ET the Dow Jones Industrial Average .DJI wasup 283.95 points, or 1.16 percent, at 24,688.43, the S&P 500 .SPX was up 18.80 points, or 0.71 percent, at 2,651.70 and theNasdaq Composite .IXIC was up 58.66 points, or 0.84 percent,at 7,079.02. | urn:newsml:reuters.com:*:nL3N1ZN43P Abbott LaboratoriesABT.N dropped 2.4 percent after thehealthcare company missed quarterly revenue estimate due tolower sales of generic drugs in emerging markets and gave adownbeat forecast for the current quarter. * P&G, UTX rise premarket after results beat * IBM biggest premarket gainer on Dow * Futures up: Dow 0.65 pct, S&P 0.38 pct, Nasdaq 0.39 pct (Updates prices, adds comments, background) By Shreyashi Sanyal Jan 23 (Reuters) - U.S. stocks were set to open higher onWednesday, with strong earnings from Dow components IBM, UnitedTechnologies and Procter & Gamble looking to propel a reboundafter Wall Street suffered its second biggest decline in 2019. urn:newsml:reuters.com:*:nL3N1ZN44X Of the 61 S&P 500 companies that reported until Tuesday,78.7 percent have beat Wall Street's profit estimates and thatis above the historical average of 64 percent, according toRefinitiv data. | Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is off about 1.2%, Lilly (Eli) & Co (Symbol: LLY) is up about 0.8%, and Thermo Fisher Scientific Inc (Symbol: TMO) is higher by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $120.8 million dollar outflow -- that's a 0.6% decrease week over week (from 211,220,000 to 209,870,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $89.60. | The healthcare sector dropped 0.5 percent, with Abbott Laboratories falling 2.4 percent after projecting current-quarter earnings below analysts' estimates. ET the Dow Jones Industrial Average was up 50.43 points, or 0.21 percent, at 24,454.91, the S&P 500 was down 3.01 points, or 0.11 percent, at 2,629.89 and the Nasdaq Composite was down 12.09 points, or 0.17 percent, at 7,008.26. A 3.48 percent rise in United Technologies Corp, which reported a better-than-expected quarterly profit, helped the industrials sector eke out a 0.12 percent gain. | The healthcaresector .SPXHC dropped 0.5 percent, with Abbott LaboratoriesABT.N falling 2.4 percent after projecting current-quarterearnings below analysts' estimates. * Three of the 11 major S&P sectors higher * P&G, UTX, IBM rise after results beat * Indexes: Dow up 0.21 pct; S&P down 0.11 pct, Nasdaq off0.17 pct (Updates prices, adds comments, background) By Shreyashi Sanyal Jan 23 (Reuters) - The S&P 500 and the Nasdaq reversedcourse to dip slightly on Wednesday due to losses in healthcareand financial sectors, while the Dow stayed afloat on positiveearnings reports from IBM, United Technologies and Procter &Gamble. ET the Dow Jones Industrial Average .DJI wasup 50.43 points, or 0.21 percent, at 24,454.91, the S&P 500 .SPX was down 3.01 points, or 0.11 percent, at 2,629.89 andthe Nasdaq Composite .IXIC was down 12.09 points, or 0.17percent, at 7,008.26. | Futures pointed to a 0.7 percent gain on the Dow Jones Industrial Average at the open, with shares of International Business Machines Corp jumping 6.9 percent after projecting 2019 profit above expectations. S&P 500 e-minis were up 10 points, or 0.38 percent and Nasdaq 100 e-minis were up 25.75 points, or 0.39 percent. Of the 61 S&P 500 companies that reported until Tuesday, 78.7 percent have beat Wall Street's profit estimates and that is above the historical average of 64 percent, according to Refinitiv data. | The Day Ahead newsletter: The Morning News Call newsletter: The S&P 500 and the Nasdaq reversed course to dip slightly on Wednesday due to losses in healthcare and financial sectors, while the Dow stayed afloat on positive earnings reports from IBM, United Technologies and Procter & Gamble. The top three S&P 500 percentage gainers: ** Waters Corp, up 10.1 pct ** Synchrony Financial, up 8.7 pct ** IBM Corp, up 7.6 pct The top three S&P 500 percentage losers: ** Capital One Financial, down 6.5 pct ** Whirlpool Corp, down 5.3 pct ** Take Two, down 5.1 pct The top three NYSE percentage gainers: ** Daxor Corp, up 13.2 pct ** Vipshop Hold Ltd, up 10.7 pct ** Waters Corp, up 10.1 pct The top three NYSE percentage losers: ** Quotient Technlogy, down 14.5 pct ** Ion Geophysical, down 11.5 pct ** Trinseo Sa, down 11.1 pct The top three Nasdaq percentage gainers: ** Spi Energy Co, up 199.5 pct ** Boxlight Corp, up 40.8 pct ** Blink Charging Co, up 25 pct The top three Nasdaq percentage losers: ** Avalon Globocare, down 48.2 pct ** Borqs Technl Ord, down 15.6 pct ** Cocrystal Pharma Inc, down 15.4 pct ** United Technologies Corp: up 3.5 pct United Technologies Corp: Shares rise on Q4 profit beat United Tech profit beats on higher aero parts sales ** Procter & Gamble Co: up 3.8 pct Procter & Gamble: Up as Q2 results beat P&G raises forecast on strength of skin care, detergent brands ** Comcast Corp: up 4.1 pct Comcast Corp: Set to jump as Q4 revenue beats analyst expectations Comcast results beat on lower-than-expected video losses ** Rollins Inc: down 4.7 pct Rollins Inc: Drops after Q4 EPS and revenue miss ** Amdocs Ltd: down 12.4 pct Amdocs: Short-seller Spruce Point sets 'strong sell' rating ** Waters Corp: up 9.9 pct Waters Corp: Eyes one-year high on sparkling FY profit forecast ** Quotient Technology: down 15.0 pct Quotient Technology: Hits near 3-year low after slashing revenue forecast ** Dell: up 1.5 pct Dell: 'Buy' rating at Citi snaps lackluster Wall St run ** TE Connectivity Ltd: down 2.2 pct TE Connectivity Ltd: Cuts fiscal 2019 forecast on China weakness ** Accuray Inc: up 11.1 pct Accuray Inc: Jumps as strong China orders spur profitability target ** Bellerophon Therapeutics: down 23.8 pct Selecta Biosciences: down 20.0 pct PTC Therapeutics: down 10.4 pct Four healthcare companies slide on pricing of stock deals ** Restaurant Brands: up 7.3 pct Restaurant Brands: Rises after M&A chatter, CEO appointment Restaurant Brands names Burger King boss Jose Cil as CEO ** IBM Corp: up 7.8 pct IBM: Gains on strong 2019 profit forecast ** Merck & Co: down 1.1 pct Merck's Keytruda seems ahead of Bristol-Myers' Opdivo in Q4 ** Tesla Inc: down 2.6 pct Tesla: 'Dream deferred,' sell the 'Elon premium' - RBC ** Walmart Inc: up 0.6 pct MS cautious of hard goods retailers, ups Walmart to 'outperform' ** Teva Pharmaceuticals Industries Ltd: up 2.9 pct Teva: Rises after UBS says stock ""too cheap to ignore"", upgrades ** Synchrony Financial: up 9.6 pct Synchrony Financial: Rises after Walmart drops lawsuit, strong Q4 results ** Kimberly-Clark Corp: down 3.0 pct Kimberly-Clark: Drops on weak 2019 profit forecast Kimberly-Clark misses profit estimates, shares fall ** Abbott Laboratories: down 2.1 pct Abbott Labs: Falls on Q4 revenue miss; weak Q1 profit forecast ** Athersys Inc: up 12.9 pct Athersys: Surges on positive lung disease treatment results The 11 major S&P 500 sectors: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews.com) - Abbott Laboratories ( ABT ) said it expects first-quarter 2019 earnings per share from continuing operations under GAAP of $0.25 to $0.27. Abbott forecasts specified items for the first quarter 2019 of $0.35 per share primarily related to intangible amortization, acquisition-related expenses, cost reduction initiatives and other expenses. Excluding specified items, projected adjusted earnings per share from continuing operations would be $0.60 to $0.62 for the first quarter. | Abbott forecast full-year organic sales growth in the range of 6.5 percent to 7.5 percent, after posting a 7.3 percent organic sales growth in 2018. Fourth-quarter sales in the company's pharmaceuticals unit, which sells generic drugs in countries such as India and China, fell 4.8 percent to $1.09 billion, while analysts on average had expected $1.16 billion. A better-than-expected 6.7 percent rise in sales at the medical device segment, its largest, partly lifted the overall sales by 2.3 percent to $7.77 billion, but missed expectation of $7.82 billion. | Duration: 59 minutes Call participants: Scott Leinenweber -- Vice President, Investor Relations, Licensing, and Acquisitions Miles D. White -- Chairman and Chief Executive Officer Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer Matt Taylor -- UBS -- Executive Director Robert Marcus -- J.P. Morgan Chase -- Analyst David Lewis -- Morgan Stanley -- Managing Director Joanne Wuensch -- BMO Capital Markets -- Managing Director Bob Hopkins -- Bank of America Merrill Lynch -- Managing Director Glenn Novarro -- RBC Capital Markets -- Managing Director Rick Wise -- Stifel Financial Corporation -- Analyst More ABT analysis This article is a transcript of this conference call produced for The Motley Fool. Abbott Laboratories (NYSE: ABT) Q4 2018 Earnings Conference Call Jan. 23, 2019, 9:00 a.m. We base our growth rates and our growth projections on our products, on the market dynamics we see in each of our product areas and the segments we compete in, and we've got a rich portfolio of products right now, and a rich portfolio of products coming out of our organic R&D, and a lot of longevity on the driving of those products in the market for years to come. | (RTTNews.com) - Abbott Laboratories ( ABT ) will host a conference call at 9:00 AM ET on Jan. 23, 2019, to discuss Q4 18 earnings results. To access the live webcast, log on to www.abbottinvestor.com Read the original article on RTTNews (http://www.rttnews.com/2971476/abbott-laboratories-q4-18-earnings-conference-call-at-9-00-am-et.aspx) For comments and feedback: contact editorial@rttnews.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | More From InvestorPlace 2 Toxic Pot Stocks You Should Avoid 10 Consumer Stocks to Buy for Income 7 Dark Horse Stocks You Really Need to Look at for 2019 7 Retail Stocks to Buy for the Rise of Menswear Compare Brokers The post 5 Must-See Stock Charts for Thursday: ABT, IBM, SBUX, PZZA appeared first on InvestorPlace . Must-See Stock Charts #2: Abbott Labs Abbott Labs (NYSE: ABT ) shares are down 2% after the company reported in-line earnings results and missed on revenue expectations. Below these marks and ABT will likely pay a visit to the 200-day. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Abbott Labs (NYSE: ABT ) reported its latest quarterly earnings results early in the day Wednesday, which came were in line with Wall Street's expectations, but the company's stock declined during regular trading hours and after the bell. More From InvestorPlace 7 Stupidly Cheap Stocks to Buy Now 7 Dark Horse Stocks You Really Need to Look at for 2019 7 Retail Stocks to Buy for the Rise of Menswear Compare Brokers The post Abbott Labs (ABT) Stock Slips Despite Solid Q4 Earnings appeared first on InvestorPlace . ABT stock is down more than 2.2% on Wednesday following the company's results. | Abbott (ABT) came out with quarterly earnings of $0.81 per share, in line with the Zacks Consensus Estimate. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $7.77 billion for the quarter ended December 2018, missing the Zacks Consensus Estimate by 0.29%. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 57.1% Average next regular session additional gain: 1.2% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 57.1% of the time (4 events) the stock posted additional gains in the following regular session by an average of 1.2%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 40% Average next regular session additional loss: 2.7% Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 40.0% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close. Extended-Hours Dollar Volume: $3,591,905 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Jan 23 () - Abbott Laboratories posted a 2.3 percent rise in fourth-quarter revenue on Wednesday, helped by growing demand for its heart valves and glucose monitoring devices. The company posted net earnings of $654 million, or 37 cents per share, in the fourth quarter ended Dec. 31, from a loss of $828 million, or 48 cents per share, a year earlier, when it had taken a $1.4 billion charge related to changes to the U.S. tax law. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The Day Ahead newsletter: The Morning News Call newsletter: Strong earnings from Dow members IBM, United Technologies and Procter & Gamble lifted U.S. stock index futures on Wednesday, putting Wall Street on track to recover from its second biggest decline in 2019. S&P 500 e-minis were up 0.55 percent at 2,646.5, while Nasdaq 100 e-minis were up 0.60 percent at 6,693.25. The top three NYSE percentage gainers premarket: ** Amtrust Financal, up 21.8 pct ** Synchrony Financial, up 10.5 pct ** IBM Corp, up 7.2 pct The top three NYSE percentage losers premarket: ** Trinseo Sa.N, down 10.2 pct ** K12 Inc, down 9.1 pct ** Capital One Financial Corp, down 5.9 pct The top three Nasdaq percentage gainers premarket: ** Recon Technology Ltd, up 33.7 pct ** Soligenix Inc, up 28.2 pct ** Athersys"
2019-01-22,70.97000122070312,71.48999786376953,-0.8368742381427305,"All Signals Are Positive for Buying Abbott Laboratories | Health Care Sector Update for 01/22/2019: TGTX, SRNE, JNJ, ABT, MRK, AMGN, PFE | Medical Product Stocks' Earnings on Jan 23: ABT, NXGN & VAR | Pre-Market Earnings Report for January 23, 2019 : PG, CMCSA, ABT, UTX, ASML, KMB, PGR, TEL, APH, NTRS, SYF, WAT","InvestorPlace - Stock Market News, Stock Advice & Trading Tips Abbott Laboratories (NYSE: ABT ) stock rose steadily in the last year and is up around 20% in that time. Full-Year 2018 Forecast for ABT Stock Abbott forecast earnings of $2.87 to $2.89 (adjusted), reflecting growth of 15%. (Source: https://simplywall.st) Outlook for ABT Stock Synergies from the integration of Abbott's St Jude unit will save on costs. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Early movers include: (+) TG Therapeutics ( TGTX ), which was advancing by more than 9% after the biopharmaceutical company said the US Food and Drug Administration (FDA) has granted breakthrough therapy designation for umbralisib (TGR-1202) to treat adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20 regimen. | Abbott LaboratoriesABT is anticipated to gain from a strong fourth-quarter performance by the Established Pharmaceuticals Division business. Click to get this free report Abbott Laboratories (ABT): Get Free Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Quality Systems, Inc. (NXGN): Get Free Report To read this article on Zacks.com click here. Earnings Expectations From Medical Sector Medical - one of the 16 Zacks sectors - is expected to record earnings growth this season. | Zacks Investment Research reports that the 2018 Price to Earnings ratio for ABT is 24.71 vs. an industry ratio of -40.30, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories ( ABT ) is reporting for the quarter ending December 31, 2018. In the past year ABT has beat the expectations every quarter."
2019-01-18,70.98999786376953,71.41999816894531,0.732699216742742,Can Medical Devices Strength Drive Abbott (ABT) Q4 Earnings? | Is a Surprise Coming for Abbott (ABT) This Earnings Season?,"Click to get this free report Veeva Systems Inc. (VEEV): Free Stock Analysis Report Abbott Laboratories (ABT): Get Free Report Illumina, Inc. (ILMN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott 's ABT Medical Devices business has been going strong of late on solid sub-segmental performance. Medical Devices in Focus Abbott's Medical Devices segment presently comprises the new Cardiovascular and Neuromodulation, Heart Failure, Electrophysiology, Structural Heart, Rhythm Management, Vascular businesses along with the Diabetes Care business. | After all, analysts raising estimates right before earnings - with the most up-to-date information possible - is a pretty good indicator of some favorable trends underneath the surface for ABT in this report. This suggests that analysts have very recently bumped up their estimates for ABT, giving the stock a Zacks Earnings ESP of +0.25% heading into earnings season. Investors are always looking for stocks that are poised to beat a t earnings season and Abbott LaboratoriesABT may be one such company."
2019-01-17,69.87000274658203,70.5199966430664,0.6057195634812609,,
2019-01-16,70.5,69.81999969482422,0.9302903548492734,Abbott (ABT) Earnings Expected to Grow: Should You Buy? | 3 Healthcare Stocks That Will Keep Your Portfolio Healthy,"Wall Street expects a year-over-year increase in earnings on higher revenues when Abbott (ABT) reports results for the quarter ended December 2018. Price, Consensus and EPS Surprise Earnings Whisper Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is subject to change. | Abbott Laboratories (NYSE: ABT ) created AbbVie when it spun off its pharmaceutical division in 2013. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Healthcare stocks cover a wide range of equities. 7 Oversold Small-Cap Stocks With Massive Profit Growth While this can mean pain for the healthcare consumer, it can also bring benefit to those who invest in healthcare."
2019-01-15,68.41000366210938,70.47000122070312,-0.9645394399656471,SPDR Portfolio S&P 500 Growth ETF Experiences Big Inflow | 3 Top Diabetes Stocks to Watch in January,"Among the largest underlying components of SPYG, in trading today Mastercard Inc (Symbol: MA) is up about 0.1%, Abbott Laboratories (Symbol: ABT) is up about 2%, and PepsiCo Inc (Symbol: PEP) is up by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR Portfolio S&P 500 Growth ETF (Symbol: SPYG) where we have detected an approximate $190.2 million dollar inflow -- that's a 5.9% increase week over week in outstanding units (from 96,700,000 to 102,400,000). For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $30.31 per share, with $38.55 as the 52 week high point - that compares with a last trade of $33.73. | We asked three of our contributors to pick a company worth watching that is addressing some aspect of the illness, and they selected Abbott Laboratories (NYSE: ABT) , DexCom (NASDAQ: DXCM) , and Novo Nordisk (NYSE: NVO) . DexCom estimates its current addressable market of insulin-intensive type and type 2 diabetes patients is 3.2 million; however, advances that will make CGMs smarter, smaller, and cheaper could increase that market significantly. Addressing the gestational diabetes market could increase its target market by about 800,000 patients; monitoring patients in hospitals would add about 10 million patients; and serving the entire type 2 diabetes population expands the addressable population to roughly 27 million in the U.S alone."
2019-01-14,68.41000366210938,68.2699966430664,3.0112519343932327,Abbott: FDA Approves Amplatzer Piccolo Occluder Medical Device - Quick Facts | Abbott (ABT) Dips More Than Broader Markets: What You Should Know,"(RTTNews.com) - Abbott Laboratories ( ABT ) said Monday that the U.S. Food and Drug Administration or FDA approved the Amplatzer Piccolo Occluder, the world's first medical device that can be implanted in the tiniest babies - weighing as little as two pounds - using a minimally invasive procedure to treat patent ductus arteriosus, or PDA. One of the most common congenital heart defects occurring in premature babies, PDA is a potentially life-threatening opening between two blood vessels leading from the heart. About 60,000 premature babies in the U.S. are born each year with a very low birth weight, and nearly 12,000, or one out of five, of these have a hemodynamically significant PDA - a PDA that is large and causes symptoms - which will require urgent treatment for the baby to survive. | Abbott (ABT) closed at $68.27 in the latest trading session, marking a -1.53% move from the prior day. Wall Street will be looking for positivity from ABT as it approaches its nex t earnings report date. In tha t report , analysts expect ABT to post earnings of $0.81 per share."
2019-01-11,68.5999984741211,69.33000183105469,-0.20465869251300042,"Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for January 14, 2019","Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. The following ETF(s) have ABT as a top-10 holding: iShares U.S. Medical Devices ETF ( IHI ) First Trust Nasdaq Pharmaceuticals ETF ( FTXH ) Invesco Dynamic Pharmaceuticals ETF ( PJP ) AdvisorShares Vice ETF ( ACT ) SPDR Select Sector Fund - Health Care ( XLV )."
2019-01-10,68.68000030517578,69.08000183105469,1.0641448588500813,"Ex-Dividend Reminder: Becton, Dickinson, Abbott Laboratories and American Financial Group | Zacks Value Trader Highlights: PayPal, Abbott Labs, UnitedHealth, Lam Research and Visa","Looking at the universe of stocks we cover at Dividend Channel , on 1/14/19, Becton, Dickinson & Co (Symbol: BDXA), Abbott Laboratories (Symbol: ABT), and American Financial Group Inc (Symbol: AFG) will all trade ex-dividend for their respective upcoming dividends. Becton, Dickinson & Co (Symbol: BDXA) : Abbott Laboratories (Symbol: ABT) : American Financial Group Inc (Symbol: AFG) : In general, dividends are not always predictable, following the ups and downs of company profits over time. Similarly, investors should look for ABT to open 0.46% lower in price and for AFG to open 0.43% lower, all else being equal. | Click to get this free report PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Lam Research Corporation (LRCX): Free Stock Analysis Report Visa Inc. (V): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LabsABT has the best chart of the big drug stocks. To listen to the podcast, click here: https://www.zacks.com/stock/news/346585/these-5-companies-are-earnings-perfection These 5 Companies Are Earnings Perfection The ""official"" start to the fourth quarter 2018 earnings season is just a week away when JP Morgan and Bank of America will kick it off."
2019-01-09,68.93000030517578,69.44000244140625,0.5824134014291229,These 5 Companies are Earnings Perfection,"Click to get this free report PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Lam Research Corporation (LRCX): Free Stock Analysis Report Visa Inc. (V): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ABT has the best chart of the big drug stocks. What it Takes to Beat Every Quarter Despite what you may think, it's not easy to beat the earnings estimate quarter after quarter, year after year."
2019-01-08,69.55000305175781,68.30000305175781,0.7398841345894698,Abbott To Present At J.P. Morgan Conference; Webcast At 12:00 PM ET,"(RTTNews.com) - Abbott Laboratories ( ABT ) will present at the 37th Annual J.P. Morgan Healthcare Conference. The event is scheduled to begin at 12:00 PM ET on Jan. 8, 2019. To access the live webcast, log on to www.abbottinvestor.com Read the original article on RTTNews (http://www.rttnews.com/2967777/abbott-to-present-at-j-p-morgan-conference-webcast-at-12-00-pm-et.aspx) For comments and feedback: contact editorial@rttnews.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2019-01-07,68.19000244140625,69.12999725341797,-1.797268073546702,"Noteworthy ETF Outflows: XLV, MRK, ABT, AMGN | Abbott (ABT) Outpaces Stock Market Gains: What You Should Know","Among the largest underlying components of XLV, in trading today Merck & Co Inc (Symbol: MRK) is down about 0.9%, Abbott Laboratories (Symbol: ABT) is up about 1.5%, and Amgen Inc (Symbol: AMGN) is up by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $459.9 million dollar outflow -- that's a 2.5% decrease week over week (from 213,470,000 to 208,120,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $86.12. | Abbott (ABT) closed the most recent trading day at $69.13, moving +1.5% from the previous trading session. Wall Street will be looking for positivity from ABT as it approaches its nex t earnings report date. Any recent changes to analyst estimates for ABT should also be noted by investors."
2019-01-04,67.12000274658203,68.11000061035156,1.3784935890263823,"3 Big Stock Charts for Friday: Incyte, Schlumberger and Abbott Laboratories","The market environment makes trading tricky for the foreseeable future, but the stock charts of Schlumberger Limited (NYSE: SLB ), Abbott Laboratories (NYSE: ABT ) and Incyte Corporation (NASDAQ: INCY ) look positioned to do their own thing regardless of what the broad market does from here. Abbott Laboratories (ABT) With nothing more than a quick glance at Abbott Laboratories, the last few days just look like the same volatility other stocks have faced of last. Zooming out to a weekly chart of ABT, the recent wild swings are different, and telling."
2019-01-03,68.73999786376953,66.22000122070312,1.4749669595625057,,
2019-01-02,70.38999938964844,69.5,-3.6659830104455224,"U.S. STOCKS ON THE MOVE-General Electric, Netflix, Tesla, MyoKardia | U.S. STOCKS ON THE MOVE-Netflix, Tesla, Walgreens, Hologic","The Day Ahead newsletter: The Morning News Call newsletter: U.S. stocks were flat on Wednesday morning, clawing back from losses of more than 1 percent earlier, helped by energy stocks as oil prices reversed earlier losses and bank stocks as 10-year U.S. treasury yields moved off a near year-low. The top three S&P 500 percentage gainers: ** General Electric Co, up 5.5 pct [ ** Wynn Resorts Ltd, up 5.4 pct ** Perrigo Company PLC, up 4.7 pct The top three S&P 500 percentage losers: ** Hologic Inc, down 6 pct ** Abbott Labs, down 4 pct ** Akamai Technologies Inc, down 4 pct The top three NYSE percentage gainers: ** MedEquities Realty Trust Inc, up 44.4 pct ** PermRock Royalty Trust, up 22.3 pct ** Bright Scholar Education Holdings Ltd, up 21.2 pct The top NYSE percentage loser: ** Bitauto Holdings Ltd, down 18.1 pct The top three Nasdaq percentage gainers: ** Estre Ambiental Inc, up 43 pct ** Novus Therapeutics Inc, up 25.6 pct ** Windstream Holdings Inc, up 25.4 pct The top two Nasdaq percentage losers: ** Uxin Ltd, down 17.9 pct ** Pingtan Marine Enterprise Ltd, down 14.5 pct ** General Electric Co: up 6.1 pct Hits more than 1-month high ** The Estee Lauder Companies Inc: up 1.2 pct Citi upgrades rating to ""buy"", sees upside to 2019 EPS forecast ** JPMorgan Chase & Co.: up 1.2 pct ** The Goldman Sachs Group Inc.: up 2.3 pct Barclays positive on U.S. large-cap banks ** Wells Fargo & Co: up 1.5 pct Not ""out of the woods"" yet regarding regulatory issues, says RBC ** CVS Health Corp: down 0.7 pct Stock an execution story in 2019 ** Walgreens Boots Alliance Inc: down 0.5 pct Jefferies sees choppy year ahead ** Hologic Inc: down 6.0 pct MS downgrades to underweight, sees limited room for end-market growth ** Moderna Inc: down 3.7 pct Brokerages start with bullish ratings on Moderna's shares ** Netflix Inc: down 1.2 pct Suntrust Robinson cuts PT, says Q4 new subscribers could be less than co's guidance ** Tesla Inc: down 6.9 pct Set to erase 2018's gains on slide as Q4 deliveries miss estimates ** Akamai Technologies Inc: down 4.0 pct Cowen moves to sidelines expecting slowing revenue trends ** MyoKardia Inc: down 14.2 pct Drops on conclusion of collaboration with Sanofi ** Bausch Health Companies Inc: up 7.0 pct Climbs after Piper upgrade to ""overweight"" ** Schlumberger NV: up 3.4 pct Susquehanna cuts PT on lower crude prices ** Sirius XM Holdings Inc: up 2.8 pct JPM's double upgrade to 'outperform' lifts shares ** Wynn Resorts Ltd: up 5.4 pct ** Melco Resorts & Entertainment Ltd: up 3.9 pct ** Las Vegas Sands Corp: up 3.3 pct ** MGM Resorts International: up 2.9 pct ** Caesars Entertainment Corp: up 1.2 pct U.S. casinos: Higher after Macau Dec gambling revenue beats estimates The 11 major S&P 500 sectors: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The Day Ahead newsletter: The Morning News Call newsletter: U.S. stocks started the new year with a more than 1 percent decline on Wednesday, as weak data in Asia and Europe confirmed fears of a global economic slowdown while the U.S. government shutdown dragged on. The top three S&P 500 percentage gainers: ** General Electric Co, up 4.2 pct ** Wynn Resorts Ltd, up 3.8 pct ** Nektar Therapeutics, up 3.3 pct The top three S&P 500 percentage losers: ** Hologic Inc, down 6 pct ** Akamai Technologies Inc, down 4.4 pct ** Abbott Labs, down 3.4 pct The top two NYSE percentage gainers: ** MedEquities Realty Trust Inc, up 43.9 pct ** Bright Scholar Education Holdings Ltd, up 16 pct The top two NYSE percentage losers: ** Bitauto Holdings Ltd, down 16.6 pct ** James Hardie Industries Plc, down 10.4 pct The top three Nasdaq percentage gainers: ** China Ceramics Co. Ltd, up 44.4 pct ** Apyx Medical"
2018-12-31,71.56999969482422,72.33000183105469,-1.2643832893388558,"The Zacks Analyst Blog Highlights: Merck, Abbott, Lockheed Martin, United Parcel Service and Bank of New York Mellon","Click to get this free report The Bank of New York Mellon Corporation (BK): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Lockheed Martin Corporation (LMT): Free Stock Analysis Report United Parcel Service, Inc. (UPS): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include: Merck MRK , Abbott ABT , Lockheed Martin LMT , United Parcel Service UPS and Bank of New York Mellon BK . Here are highlights from Friday's Analyst Blog: Top Analyst Reports for Merck, Abbott and Lockheed Martin The Zacks Research Daily presents the best research output of our analyst team."
2018-12-28,71.05000305175781,71.08999633789062,1.0619004324034256,,
2018-12-27,68.41000366210938,70.62999725341797,0.05628892950740422,Abbott (ABT) Outpaces Stock Market Gains: What You Should Know,"In the latest trading session, Abbott (ABT) closed at $70.63, marking a +1.45% move from the previous day. Wall Street will be looking for positivity from ABT as it approaches its next earnings report date. Investors might also notice recent changes to analyst estimates for ABT."
2018-12-26,65.9000015258789,69.62000274658203,3.2451300576938777,,
2018-12-24,66.81999969482422,65.55999755859375,5.6449182618642,Why Abbott (ABT) Could Beat Earnings Estimates Again,"It is worth considering Abbott (ABT), which belongs to the Zacks Medical - Products industry. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. For the last reported quarter, Abbott came out with earnings of $0.75 per share versus the Zacks Consensus Estimate of $0.74 per share, representing a surprise of 1.35%."
2018-12-21,68.06999969482422,67.2699966430664,-1.8856661807618456,,
2018-12-20,68.33999633789062,68.37999725341797,-1.1752652495143785,"Notable ETF Inflow Detected - XLV, ABBV, ABT, CVS","Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.6%, Abbott Laboratories (Symbol: ABT) is off about 1.4%, and CVS Health Corporation (Symbol: CVS) is lower by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $520.3 million dollar inflow -- that's a 2.9% increase week over week in outstanding units (from 209,920,000 to 216,020,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $84.75."
2018-12-19,70.33999633789062,69.0,0.058532217838539055,,
2018-12-18,70.8499984741211,70.08000183105469,-1.9050275912067371,5 Dividend Aristocrats Where Analysts See Capital Gains,"But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential: Another consideration with dividend growth stocks is just how much the dividend is growing ."
2018-12-17,70.37999725341797,69.75,-1.0867983904723129,,
2018-12-14,71.31999969482422,70.76000213623047,-0.8951367973907861,"Daily Dividend Report: NLY, ABT, PFE, T, EQR | 5 Biggest Medtech Stocks -- Are They Buys? | Health Care Sector Update for 12/14/2018: JNJ, KANG, AXON, PFE, ABT, MRK, AMGN","VIDEO: Daily Dividend Report: NLY, ABT, PFE, T, EQR The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The board of directors of Abbott today increased the company's quarterly common dividend to 32 cents per share, marking a 14 percent increase. Abbott has increased its dividend payout for 47 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years. | Currently, the five largest companies in terms of global medtech sales are Medtronic (NYSE: MDT) , Johnson & Johnson (NYSE: JNJ) , Abbott Laboratories (NYSE: ABT) , Siemens Healthineers (NASDAQOTH: SMMNY) , and Koninklijke Philips (NYSE: PHG) . Abbott's medtech sales totaled $16 billion last year, giving the company a market share of around 4%. If you're looking to profit from growth in the medtech space, I think Abbott Labs is the best of the biggest medtech stocks. | Health care stocks were sinking in early Friday afternoon trading, including a 2.8% decline for the NYSE Health Care Index. Stocks moving on news include: (-) Johnson & Johnson ( JNJ ) was down 9% after Reuters reported that the company didn't disclose to regulators or the public that the its talc and finished powders tested positive for small amounts of asbestos from at least 1971 to the early 2000s. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2018-12-13,72.70999908447266,72.18000030517578,-0.7851900742988782,,
2018-12-12,72.80999755859375,72.52999877929688,-0.7289214495535005,"Notable ETF Outflow Detected - XLV, ABBV, ABT, CVS | Abbott (ABT) Outpaces Stock Market Gains: What You Should Know","Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 2%, Abbott Laboratories (Symbol: ABT) is up about 2.1%, and CVS Health Corporation (Symbol: CVS) is higher by about 1.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $122.7 million dollar outflow -- that's a 0.6% decrease week over week (from 211,265,324 to 209,920,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $92.82. | Abbott (ABT) closed at $72.53 in the latest trading session, marking a +0.96% move from the prior day. Wall Street will be looking for positivity from ABT as it approaches its next earnings report date. Investors should also note any recent changes to analyst estimates for ABT."
2018-12-11,71.66000366210938,71.83999633789062,-0.38456089642297586,,
2018-12-10,70.04000091552734,70.91999816894531,0.25117592322482973,,
2018-12-07,71.75,69.94999694824219,1.2564209621860243,,
2018-12-06,70.58999633789062,71.54000091552734,-2.5087150547147212,,
2018-12-04,74.23999786376953,71.5,1.3458062429828805,,
2018-12-03,74.29000091552734,74.2699966430664,-3.690729987354566,AbbVie Stock Could Become a New Happy Pill for Investors,"Competition Aggravates Patent Expirations Since its split from Abbott Laboratories (NYSE: ABT ) in 2013, AbbVie has built its fortunes on Humira, a treatment for a range of conditions, including rheumatoid arthritis, psoriatic arthritis and Crohn's disease. InvestorPlace - Stock Market News, Stock Advice & Trading Tips While AbbVie (NYSE: ABBV ) has shown strong profit growth over the last year, ABBV stock has sold off recently over worries about Humira patent expirations in some parts of the world. Bottom Line on AbbVie Stock As Humira begins a slow fade from driving AbbVie revenue, new drugs should keep ABBV stock on a growth trajectory."
2018-11-30,73.93000030517578,74.05000305175781,-0.026927274484332936,3 Beaten-Down Biotech Stocks to Buy Before the End of 2018,"Since its spin-off from Abbott Laboratories (NYSE: ABT ) - another dividend king - in 2013, ABV has increased dividends every year. The Bottom Line on These Three Biotechnology Stocks Source: Shutterstock All three biotech stocks, ABBV, CELG and MYL stock, have strong fundamental growth prospects in the long-run, despite having come off significantly from their recent highs. If I had to rank them, I would start the buying with ABBV stock, followed by MYL stock and finally CELG stock."
2018-11-29,72.43000030517578,73.26000213623047,0.16231941848596199,,
2018-11-28,70.0999984741211,72.83000183105469,1.1459365284517007,,
2018-11-27,68.70999908447266,69.70999908447266,3.894441392807494,,
2018-11-26,68.7300033569336,68.80999755859375,1.4553922475978955,"Notable ETF Inflow Detected - SPYG, ABT, BKNG, AMGN","Among the largest underlying components of SPYG, in trading today Abbott Laboratories (Symbol: ABT) is up about 1.2%, Booking Holdings Inc (Symbol: BKNG) is up about 1.8%, and Amgen Inc (Symbol: AMGN) is higher by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR Portfolio S&P 500 Growth ETF (Symbol: SPYG) where we have detected an approximate $112.8 million dollar inflow -- that's a 3.6% increase week over week in outstanding units (from 92,650,108 to 96,000,108). For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $31.69 per share, with $38.55 as the 52 week high point - that compares with a last trade of $34.14."
2018-11-23,67.94000244140625,68.11000061035156,0.11638905536600168,,
2018-11-21,69.3499984741211,68.52999877929688,0.25021807894682463,"ABT January 2019 Options Begin Trading | Health Care Sector Update for 11/21/2018: SYN, CYAD, JNJ, PFE, ABT, MRK, AMGN | Abbott (ABT) Stock Sinks As Market Gains: What You Should Know","Below is a chart showing ABT's trailing twelve month trading history, with the $69.00 strike highlighted in red: Considering the fact that the $69.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the January 2019 expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ABT options chain for the new January 2019 contracts and identified one put and one call contract of particular interest. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ABT: Flat In other sector news: (-) The US Court of Appeals for the Federal Circuit denied Johnson & Johnson's ( JNJ ) request to block low-cost versions of Zytinga from entering the US market while the pharmaceutical firm appeals a trial judge's ruling that invalidated a patent on the blockbuster colorectal cancer drug, Bloomberg News reported. | ABT's full-year Zacks Consensus Estimates are calling for earnings of $2.88 per share and revenue of $30.61 billion. Abbott (ABT) closed the most recent trading day at $68.53, moving -0.77% from the previous trading session. ABT will be looking to display strength as it nears its next earnings release, which is expected to be January 23, 2019."
2018-11-20,70.38999938964844,69.05999755859375,-1.1824076609463992,,
2018-11-19,72.0,70.54000091552734,-1.8894755541797572,"Health Care Sector Update for 11/19/2018: SNOA, GSK, PFE, MRK, ABT, AMGN, JNJ","Top Health Care Stocks: JNJ: Flat PFE: +o.23% ABT: Flat Early movers include: (-) Sonoma Pharmaceuticals ( SNOA ), which was tumbling more than 22% after it priced a best efforts public offering of units, consisting of one share of common stock and one half of one warrant, at $1 per unit, a 9% discount to the stock's closing price on Friday. In other sector news: (+) GlaxoSmithKline ( GSK ) was slightly up after it filed a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration seeking an additional indication for the use of Nucala as an add-on treatment for severe eosinophilic asthma in pediatric patients aged six to 11 years."
2018-11-16,70.4800033569336,72.04000091552734,-2.0277765062120223,Abbott (ABT) Up 3.8% Since Last Earnings Report: Can It Continue?,"It has been about a month since the last earnings report for Abbott (ABT). Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Beats on Q3 Earnings, Narrows '18 EPS View Abbott reported third-quarter 2018 adjusted earnings from continuing operations of 75 cents per share, a penny ahead of the Zacks Consensus Estimate."
2018-11-15,68.93000030517578,70.7300033569336,2.2133903012084386,5 Dividend Growth Stocks With Upside To Analyst Targets,"Get the latest Zacks research report on TROW - FREE Get the latest Zacks research report on ABT - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect."
2018-11-14,70.0999984741211,69.41000366210938,2.6113492583615363,Abbott (ABT) Stock Moves -0.12%: What You Should Know,"Abbott (ABT) closed at $69.41 in the latest trading session, marking a -0.12% move from the prior day. ABT will be looking to display strength as it nears its next earnings release, which is expected to be January 23, 2019. On that day, ABT is projected to report earnings of $0.81 per share, which would represent year-over-year growth of 9.46%."
2018-11-13,70.87000274658203,69.48999786376953,-0.984300751827327,,
2018-11-12,72.7300033569336,70.55999755859375,-1.9472341319742026,Surmodics' (SRDX) Q4 Earnings and Revenues Beat Estimates,"Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report To read this article on Zacks.com click here. Per management, this includes $2.2 million from Surmodics' SurVeil agreement with Abbott Laboratories ABT . Surmodics, Inc. Price, Consensus and EPS Surprise Surmodics, Inc. Price, Consensus and EPS Surprise | Surmodics, Inc. Quote Q4 Details Notably, Product sales in the quarter were $10.7 million, up 21.3% year over year."
2018-11-09,72.87999725341797,72.79000091552734,-2.9836459482755817,,
2018-11-08,72.0,72.95999908447266,-0.12348564939936835,Abbott (ABT) Gains As Market Dips: What You Should Know,"Abbott (ABT) closed the most recent trading day at $72.96, moving +0.63% from the previous trading session. Wall Street will be looking for positivity from ABT as it approaches its next earnings report date. Any recent changes to analyst estimates for ABT should also be noted by investors."
2018-11-07,71.69000244140625,72.5,1.3333320617675781,,
2018-11-06,70.33000183105469,70.95999908447266,1.1298612512334312,,
2018-11-05,70.4800033569336,70.38999938964844,0.8957731224454331,,
2018-11-02,70.75,70.19000244140625,-0.12770142309634547,Abbott (ABT) Q3 Earnings Top Estimates,"Abbott (ABT) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.74 per share. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $7.66 billion for the quarter ended December 2018, missing the Zacks Consensus Estimate by 0.12%."
2018-11-01,69.08999633789062,70.1500015258789,-0.791515983878092,,
2018-10-31,68.69999694824219,68.94000244140625,1.5342383039133969,"XLV, MDT, ABT, LLY: ETF Inflow Alert","Among the largest underlying components of XLV, in trading today Medtronic PLC (Symbol: MDT) is up about 1%, Abbott Laboratories (Symbol: ABT) is up about 2.1%, and Lilly (Eli) & Co (Symbol: LLY) is higher by about 1.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $146.2 million dollar inflow -- that's a 0.8% increase week over week in outstanding units (from 202,165,324 to 203,815,324). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $89.33."
2018-10-30,67.7699966430664,68.0,0.3493529895567244,,
2018-10-29,68.0,67.30999755859375,0.33938817814169914,,
2018-10-26,66.75,66.98999786376953,-1.01470947265625,"Health Care Sector Update for 10/26/2018: SGYP, RARE, JNJ, PFE, ABT, MRK, AMGN","The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ABT: Flat Stocks moving on news include: (-) Synergy Pharmaceuticals ( SGYP ), which was slumping more than 67% after the company said its strategic review process has resulted in offers significantly below the market value and it does not believe it will get any offers much higher than what it has already seen."
2018-10-25,67.19999694824219,67.66999816894531,0.3595473614524813,Abbott (ABT) Gains But Lags Market: What You Should Know,"Abbott (ABT) closed at $67.68 in the latest trading session, marking a +1.11% move from the prior day. Investors will be hoping for strength from ABT as it approaches its next earnings release, which is expected to be January 23, 2019. On that day, ABT is projected to report earnings of $0.81 per share, which would represent year-over-year growth of 9.46%."
2018-10-24,68.7300033569336,66.94000244140625,0.6994066101894656,,
2018-10-23,67.58000183105469,68.56999969482422,-2.604395210387787,,
2018-10-22,67.73999786376953,68.5199966430664,1.4649272520655698,"Noteworthy ETF Inflows: IHI, MDT, ABT, TMO","Among the largest underlying components of IHI, in trading today Medtronic PLC (Symbol: MDT) is off about 0.9%, Abbott Laboratories (Symbol: ABT) is down about 0.2%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 1.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $197.5 million dollar inflow -- that's a 7.8% increase week over week in outstanding units (from 12,250,000 to 13,200,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $170.272 per share, with $228.902 as the 52 week high point - that compares with a last trade of $206.05."
2018-10-19,68.12999725341797,67.58999633789062,1.1514597045980337,Analysts Expect IEHS Will Reach $32,"Similarly, PRAH has 11.05% upside from the recent share price of $102.26 if the average analyst target price of $113.56/share is reached, and analysts on average are expecting ABT to reach a target price of $75.56/share, which is 10.89% above the recent price of $68.14. Three of IEHS's underlying holdings with notable upside to their analyst target prices are Bruker Corp (Symbol: BRKR), PRA Health Sciences Inc (Symbol: PRAH), and Abbott Laboratories (Symbol: ABT). Below is a twelve month price history chart comparing the stock performance of BRKR, PRAH, and ABT: Combined, BRKR, PRAH, and ABT represent 5.27% of the iShares Evolved U.S. Healthcare Staples ETF."
2018-10-18,69.58000183105469,68.13999938964844,-0.7926037535547572,"DexCom Launches CLARITY Mobile App, Strengthens CGM Profile | Mid-Morning Market Update: Markets Open Lower; Philip Morris Profit Beats Estimates","Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Fitbit, Inc. (FIT): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. Also, MedTech behemoth Abbott ABT is dedicated to developing innovative products that make glucose testing easier and more accurate. Notably, Notably, this smart app is a cloud-based diabetes management software that simplifies CGM (Continuous Glucose Monitoring) data reporting and facilitates confidential sharing of data between physicians and their patients. | Top Headline Philip Morris International Inc. (NYSE: ABT ) reported upbeat earnings for its third quarter. Yulong Eco-Materials Limited (NASDAQ: YECO ) shares were also up, gaining 38 percent to $14.0500 after climbing 571.05 percent on Wednesday. The eurozone's STOXX 600 rose 0.12 percent, the Spanish Ibex Index fell 0.59 percent, while Italy's FTSE MIB Index slipped 0.63 percent."
2018-10-17,70.4000015258789,70.2300033569336,-2.069563672767185,"Mid-Day Market Update: Crude Oil Down 2.7%; vTv Therapeutics Shares Spike Higher | Earnings & Economic Data Deluge | Mid-Morning Market Update: Markets Open Lower; Abbott Laboratories Posts In-Line Q3 Earnings | Health Care Sector Update for 10/17/2018: VTVT, OGEN, FMS, JNJ, PFE, ABT, MRK, AMGN | Abbott (ABT) Q3 Earnings Top Estimates | Earnings Reaction History: Abbott Laboratories, 54.5% Follow-Through Indicator, 2.3% Sensitive | 5 Top Stock Trades for Thursday | Abbott (ABT) Q3 Earnings Top Estimates, Guidance Narrowed | Bank Stocks Earnings Scorecard, Fed Minutes, & Trade Talks on ""Hiatus"" | Abbott Laboratories (ABT) Q3 2018 Earnings Conference Call Transcript","Top Headline Abbott Laboratories (NYSE: ABT ) reported in-line earnings for its third quarter. Equities Trading DOWN Revolution Lighting Technologies, Inc. (NASDAQ: RVLT ) shares dropped 36 percent to $1.64 after the company cut FY18 and Q3 guidance estimates and said it does not believe it is in the best interest of shareholders to continue as a publicly traded company, proposed to take company private. The eurozone's STOXX 600 dropped 0.62 percent, the Spanish Ibex Index fell 0.98 percent, while Italy's FTSE MIB Index slipped 1.42 percent. | Abbott Labs ABT posted a slight beat on both top and bottom lines in its Q3 earnings report this morning, with 75 cents per share a penny above expectations, with a slight beat on revenues to $7.66 billion in the quarter, and well above last year's Q3 top line of $6.83 billion. Click to get this free report United Continental Holdings, Inc. (UAL): Free Stock Analysis Report U.S. Bancorp (USB): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. For more on ABT's earnings, click here. | Top Headline Abbott Laboratories (NYSE: ABT ) reported in-line earnings for its third quarter. Following the market opening Wednesday, the Dow traded down 0.87 percent to 25,574.66 while the NASDAQ declined 0.57 percent to 7,602.03. The eurozone's STOXX 600 dropped 0.24 percent, the Spanish Ibex Index fell 0.63 percent, while Italy's FTSE MIB Index slipped 0.65 percent. | (-) Abbott ( ABT ) was declining over 2% as it reported Q3 adjusted earnings of $0.75 per diluted share, up from $0.66 in the same period a year ago. Stocks moving on news include: (+) vTv Therapeutics ( VTVT ), up by 47% after it said it will detail the results from the phase 3 STEADFAST study of azeliragon in patients with mild Alzheimer's disease on Oct. 26 at the Alzheimer's Disease (CTAD) Conference in Barcelona, Spain. (-) Fresenius Medical Care ( FMS ) was down 18% as the dialysis equipment provider reported Q3 adjusted income of EUR310 million ($363.4 million), down from EUR314 million in the same period a year ago. | Abbott (ABT) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.74 per share. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $7.66 billion for the quarter ended September 2018, missing the Zacks Consensus Estimate by 0.12%. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 57.1% Average next regular session additional gain: 1.2% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 57.1% of the time (4 events) the stock posted additional gains in the following regular session by an average of 1.2%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 50% Average next regular session additional loss: 2.7% Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 50.0% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close. Extended-Hours Dollar Volume: $2,799,494 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Abbott Labs Abbott Labs (NYSE: ABT ) also beat on revenue expectations and reported in-line earnings results , but is down slightly on the day. On a break below, I'd love a shot at buying ABT at $63. 7 Stocks Warren Buffett Can't Stop Buying Over the 20-day and ABT can retest its highs. | Abbott LaboratoriesABT reported third-quarter 2018 adjusted earnings from continuing operations of 75 cents per share, a penny ahead of the Zacks Consensus Estimate. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories Price, Consensus and EPS Surprise Abbott Laboratories Price, Consensus and EPS Surprise | Abbott Laboratories Quote EPD sales dropped 0.9% on a reported basis (improved 5.9% on an organic basis) to $1.16 billion. | Click to get this free report United Continental Holdings, Inc. (UAL): Free Stock Analysis Report U.S. Bancorp (USB): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. These headwinds helped outweigh decent earnings results from the likes of United UAL , Abbot Labs ABT , and U.S Bancorp USB early this morning, although major indexes did muster a rally into the lunch hour. Bank stocks have had a rough year, and although this earnings season once again proved that the business is going its profits, investors are more concerned with stagnating revenue growth and less-frequent top-line outperformance. | Duration:52 minutes Call participants: Scott Leinenweber -- Vice President, Investor Relations, Licensing, and Acquisitions Miles D. White -- Chairman and Chief Executive Officer Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer David Lewis -- Morgan Stanley -- Analyst Robbie Marcus -- J.P. Morgan -- Analyst Bob Hopkins -- Bank of America Merrill Lynch -- Analyst Vijay Kumar -- EvercoreISI -- Analyst Raj Denhoy -- Jefferies -- Analyst Glenn Navarro -- RBC Capital Markets -- Analyst Larry Biegelsen -- Wells Fargo Securities -- Analyst Christopher Pasquale -- Guggenheim Securities -- Analyst More ABT analysis This article is a transcript of this conference call produced for The Motley Fool. Abbott Laboratories (NYSE: ABT) Q3 2018 Earnings Conference Call Oct. 17, 2018, 9:00 a.m. Unless otherwise noted, our commentary on sales growth refers to organic sales growth, which adjusts the 2017 basis of comparison to exclude the impact of exchange and historical results for Abbott's medical optics and St. Jude's vascular closure businesses, which were divested during the first quarter of 2017, as well as current and prior-year sales for Alere, which was acquired on October 3rd, 2017."
2018-10-16,69.55000305175781,70.94999694824219,-0.24147466656349645,"Can Abbott's (ABT) Steady Overall Growth Aid Q3 Earnings? | 5 Earnings Charts in the Spotlight | Pre-Market Earnings Report for October 17, 2018 : ABT, USB, ASML, MTB, NTRS, MTG, UNF, UBSH, BMI, WGO","Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report DaVita Inc. (DVA): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is slated to report third-quarter 2018 results before the market opens on Oct 17. Abbott Laboratories Price and EPS Surprise Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote In sync with the prior quarter, Abbott is anticipated to gain from a strong performance by the Established Pharmaceuticals Division (EPD) business, which has been recording operational sales growth over the last few quarters. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report United Rentals, Inc. (URI): Free Stock Analysis Report Winnebago Industries, Inc. (WGO): Free Stock Analysis Report Pool Corporation (POOL): Free Stock Analysis Report Snap-On Incorporated (SNA): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ABT hasn't missed in 5 years. Shares are trading at just 8x now, however, as investors are worried about rising commodity cost and the super tight Northern Indian labor market. | Zacks Investment Research reports that the 2018 Price to Earnings ratio for ABT is 23.85 vs. an industry ratio of -21.00, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories ( ABT ) is reporting for the quarter ending September 30, 2018. In the past year ABT has beat the expectations every quarter."
2018-10-15,69.33999633789062,68.69999694824219,2.012931466649291,"Health Care Sector Update for 10/15/2018: SNGX, TNDM, JNJ, PFE, ABT, MRK, AMGN | Why Abbott Laboratories (ABT) Might Surprise This Earnings Season","Top Health Care Stocks: JNJ: Flat AMGN: Flat Health care stocks were mixed in pre-market trading Monday. The company said it received a positive recommendation from the independent Data Monitoring Committee (DMC) to continue enrolling into the company's phase 3 ""Fluorescent Light Activated Synthetic Hypericin"" (FLASH) study for SGX301 (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL). | This suggests that analysts have very recently bumped up their estimates for ABT, giving the stock a Zacks Earnings ESP of +0.49% heading into earnings season. Given that ABT has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Investors are always looking for stocks that are poised to beat at earnings season and Abbott LaboratoriesABT may be one such company."
2018-10-12,69.37000274658203,69.33000183105469,-0.9229873427303772,Abbott (ABT) Gains But Lags Market: What You Should Know,"Abbott (ABT) closed the most recent trading day at $69.33, moving +1.39% from the previous trading session. Investors will be hoping for strength from ABT as it approaches its next earnings release, which is expected to be October 17, 2018. Investors should also note any recent changes to analyst estimates for ABT."
2018-10-11,68.91999816894531,68.37999725341797,-0.05766313095513703,"Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for October 12, 2018","Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. The following ETF(s) have ABT as a top-10 holding: iShares U.S. Healthcare ETF ( IYH ) Fidelity MSCI Health Care Index ETF ( FHLC ) iShares Global Healthcare ETF ( IXJ ) NuShares Enhanced Yield US Aggregate Bond ETF ( NULV ) First Trust BuyWrite Income ETF ( FTHI )."
2018-10-10,71.05000305175781,68.91999816894531,-0.7835184705078286,"Abbott (ABT) Q3 Earnings Preview: How Are Events Shaping Up? | Ex-Dividend Reminder: Publix Super Markets, Becton, Dickinson and Abbott Laboratories | Health Care Sector Update for 10/10/2018: IGC, AKRX, JNJ, PFE, ABT, MRK, AMGN","Wall Street expects a year-over-year increase in earnings on higher revenues when Abbott (ABT) reports results for the quarter ended September 2018. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Price, Consensus and EPS Surprise Earnings Whisper Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. | Looking at the universe of stocks we cover at Dividend Channel , on 10/12/18, Publix Super Markets Inc (Symbol: PUSH), Becton, Dickinson & Co (Symbol: BDXA), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Publix Super Markets Inc (Symbol: PUSH) : Becton, Dickinson & Co (Symbol: BDXA) : Abbott Laboratories (Symbol: ABT) : In general, dividends are not always predictable, following the ups and downs of company profits over time. Similarly, investors should look for BDXA to open 1.22% lower in price and for ABT to open 0.40% lower, all else being equal. | AMGN: Flat Health care stocks were mixed pre-bell Wednesday. Early movers include: (+) India Globalization Capital ( IGC ) was trading more than 17% higher after the company said it filed a provisional method and composition patent application in the US for a cannabidiol-infused drink for the treatment of fatigue and energy restoration. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2018-10-09,71.23999786376953,71.29000091552734,-2.9978955542913277,,
2018-10-08,71.58000183105469,71.44000244140625,0.07018957503821391,"Top Stock Reports for Apple, Microsoft & Pfizer","Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report ConocoPhillips (COP): Free Stock Analysis Report Caterpillar Inc. (CAT): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Apple Inc. (AAPL): Free Stock Analysis Report To read this article on Zacks.com click here. Other noteworthy reports we are featuring today include Abbott (ABT), Caterpillar (CAT) and ConocoPhillips (COP). EPD in Russia Worries Abbott (ABT), Soft Vascular Sales Ail The Zacks analyst worries about Abbott's dull Established Pharmaceuticals (EPD) sales in Russia due to a distribution channel dynamics disruption."
2018-10-05,71.81999969482422,71.58000183105469,-0.19558450135118513,"Health Care Sector Update for 10/05/2018: JNJ, PFE, ABT, MRK, AMGN, HSGX, KMPH","The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ABT: Flat MRK: Flat Among the stocks moving on recent news: (-) Histogenics ( HSGX ) was trading more than 40% lower after unveiling a plan to to sell shares and accompanying warrants through an underwritten public offering to raise funds to complete its NeoCart biologics license application and commercialization following approval by the US Food and Drug Administration."
2018-10-04,71.7699966430664,71.81999969482422,-0.33416578221849663,Will Walgreens (WBA) Q4 Earnings Gain From Overall Strength? | US Diabetes Market Gaining Momentum: 3 Stocks in Focus,"Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT has an Earnings ESP of +0.27% and is a Zacks #3 Ranked player. Walgreens Boots Alliance, Inc. Price and EPS Surprise Walgreens Boots Alliance, Inc. Price and EPS Surprise | Walgreens Boots Alliance, Inc. Quote However, the company has been taking steps like entering into tie-ups and controlling costs to boost segments. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Fitbit, Inc. (FIT): Free Stock Analysis Report Tandem Diabetes Care, Inc. (TNDM): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Becton, Dickinson and Company (BDX): Free Stock Analysis Report To read this article on Zacks.com click here. Our first pick is Abbott LaboratoriesABT . The company also offers a wide array of insulin syringes like BD 1-mL conventional insulin syringes, SafetyGlide 6mm insulin syringe, Safety-Lok insulin syringe."
2018-10-03,73.80999755859375,72.04000091552734,0.06967124717379128,"Notable ETF Inflow Detected - SPYG, ABT, INTC, PFE | Abbott's CE Mark for FreeStyle Libre 2 Boosts Diabetes Arm","Among the largest underlying components of SPYG, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.4%, Intel Corp (Symbol: INTC) is up about 1.9%, and Pfizer Inc (Symbol: PFE) is up by about 1.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR Portfolio S&P 500 Growth ETF (Symbol: SPYG) where we have detected an approximate $55.5 million dollar inflow -- that's a 1.5% increase week over week in outstanding units (from 96,750,108 to 98,200,108). For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $7.7753 per share, with $38.55 as the 52 week high point - that compares with a last trade of $38.48. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT recently announced the receipt of CE Mark for its next-generation FreeStyle Libre 2 - a continuous glucose monitoring system. Notably, these developments are expected to fortify the company's hold in the Diabetes Care segment, which saw significant sales growth in the last reported quarter on continued consumer acceptance of FreeStyle Libre internationally."
2018-10-02,74.0,73.80999755859375,-2.3980445760905247,3 Medical-Device Stocks at All-Time Highs -- Are They Buys?,"Three big medical-device stocks are now at all-time highs: Abbott Laboratories (NYSE: ABT) , Abiomed (NASDAQ: ABMD) , and Edwards Lifesciences (NYSE: EW) . Abiomed Abiomed stock has soared close to 140% year to date. But instead of heart pumps, Edwards makes products for structural heart disease -- especially transcatheter heart valve therapies (THVTs) -- and critical-care monitoring systems."
2018-10-01,73.80999755859375,74.12000274658203,-0.2567600559543919,,
2018-09-28,72.77999877929688,73.36000061035156,0.4200043330745066,,
2018-09-27,73.0199966430664,73.0199966430664,0.7969247606248598,"Abbott's Troponin-I Wins CE Mark, Vascular Arm Gets a Revamp","Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. As a major breakthrough for its vascular business, Abbott LaboratoriesABT recently received a CE Mark for its High Sensitive Troponin-I diagnostic test. it is important to note that the European guidelines traditionally recommend indirect heart health factors to determine risk for developing heart disease."
2018-09-26,72.05999755859375,72.83999633789062,0.0,,
2018-09-25,71.73999786376953,72.19999694824219,1.0824296499075494,iShares Edge MSCI USA Momentum Factor ETF Experiences Big Inflow,"Among the largest underlying components of MTUM, in trading today JPMorgan Chase & Co (Symbol: JPM) is up about 1%, Intel Corp (Symbol: INTC) is down about 1.8%, and Abbott Laboratories (Symbol: ABT) is up by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Edge MSCI USA Momentum Factor ETF (Symbol: MTUM) where we have detected an approximate $65.2 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 86,950,000 to 87,500,000). For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year price performance of MTUM, versus its 200 day moving average: Looking at the chart above, MTUM's low point in its 52 week range is $88.58 per share, with $119.0671 as the 52 week high point - that compares with a last trade of $118.80."
2018-09-24,70.79000091552734,71.44000244140625,0.6412030919573907,Why Abbott (ABT) is Poised to Beat Earnings Estimates Again,"It is worth considering Abbott (ABT), which belongs to the Zacks Medical - Products industry. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the stock is positive, which is a great indicator of an earnings beat, particularly when combined with its solid Zacks Rank."
2018-09-21,68.9000015258789,69.05000305175781,0.9182109301771919,,
2018-09-20,68.62999725341797,68.79000091552734,0.2177090312872715,"Abbott Banks on New Approvals and Buyouts, Competition Rife","Click to get this free report Veeva Systems Inc. (VEEV): Free Stock Analysis Report athenahealth, Inc. (ATHN): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. On Sep 19, we issued an updated research report on Abbott LaboratoriesABT . Abbott Laboratories Price Abbott Laboratories Price | Abbott Laboratories Quote We believe, the company's receipt of FDA approval for XIENCE Sierra coronary stent system as well as a reimbursement nod in Japan for the same device will help it revive the dull Vascular business."
2018-09-19,68.5199966430664,68.5,0.23313954322124988,,
2018-09-18,67.76000213623047,68.41000366210938,-0.02918366031243775,ABT or PETQ: Which Is the Better Value Stock Right Now? | Here's Why You Should Add Abbott (ABT) to Your Portfolio Now | Medical - Products Stock Outlook: Short-Term Pain Inevitable,"Based on these metrics and many more, ABT holds a Value grade of B, while PETQ has a Value grade of C. ABT is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report PetIQ, Inc. (PETQ): Free Stock Analysis Report To read this article on Zacks.com click here. Investors looking for stocks in the Medical - Products sector might want to consider either Abbott (ABT) or PetIQ (PETQ). | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT has been gaining investors' confidence on consistently positive results. Per our Zacks Style Score system, Abbott has a Growth Score of B which reflects the company's solid prospects. | Price and Consensus: ICUI Abbott Laboratories (ABT): Abbott Park, IL-based Abbott discovers, develops, manufactures and sells a diversified line of health care products. Price and Consensus: ABT New Report: An Investor's Guide to Cybersecurity Cyberattacks have become more frequent and destructive than ever. Click to get this free report Surmodics, Inc. (SRDX): Free Stock Analysis Report Quidel Corporation (QDEL): Free Stock Analysis Report ICU Medical, Inc. (ICUI): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here."
2018-09-17,68.41999816894531,67.66999816894531,0.9592702263675965,Cyber Attack Fears Grip MedTech: 3 Safe Stocks,"Click to get this free report HMS Holdings Corp (HMSY): Free Stock Analysis Report athenahealth, Inc. (ATHN): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report FULGENT GENETIC (FLGT): Free Stock Analysis Report To read this article on Zacks.com click here. For instance, in April, the FDA had to issue a Safety Communication to inform the patients about the availability of an additional firmware update to combat with the confirmed cybersecurity risks discovered in Abbott Laboratories' ABT implantable cardiac devices along with managing rapid battery depletion. Combating Cyber Risk: A Tough Challenge for MedTech Players There is a growing need for medical device manufacturers to prevent hacking in case of network-connected medical devices."
2018-09-14,68.51000213623047,68.41999816894531,-1.0961707396543199,,
2018-09-13,67.2300033569336,68.5,-0.13137347026524032,"Daily Dividend Report: ABT, BMY, ZBH, CW, NFG","VIDEO: Daily Dividend Report: ABT, BMY, ZBH, CW, NFG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott ( ABT ) declared a quarterly common dividend of 28 cents per share. The next quarterly dividend will be payable on November 1, 2018, to stockholders of record at the close of business on October 5, 2018. Zimmer Biomet Holdings ( ZBH ) has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2018."
2018-09-12,66.5999984741211,66.97000122070312,1.8890325444784146,,
2018-09-11,66.37999725341797,66.5999984741211,0.5555596922810802,,
2018-09-10,66.44999694824219,66.55000305175781,0.33142698072618093,"The Zacks Analyst Blog Highlights: Abbott, Gilead, FedEx, Archer Daniels and CBRE","Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report FedEx Corporation (FDX): Free Stock Analysis Report Archer Daniels Midland Company (ADM): Free Stock Analysis Report CBRE Group, Inc. (CBRE): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include: AbbottABT , GileadGILD , FedExFDX , Archer DanielsADM and CBRE GroupCBRE . Here are highlights from Friday's Analyst Blog: Top Research Reports for Abbott, Gilead and FedEx The Zacks Research Daily presents the best research output of our analyst team."
2018-09-07,65.79000091552734,66.20999908447266,0.15049828157783005,"Noteworthy ETF Inflows: XLV, MDT, ABT, BMY","Among the largest underlying components of XLV, in trading today Medtronic PLC (Symbol: MDT) is up about 0.1%, Abbott Laboratories (Symbol: ABT) is up about 0.5%, and Bristol-Myers Squibb Co. (Symbol: BMY) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $115.4 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 196,315,324 to 197,565,324). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $93.11 as the 52 week high point - that compares with a last trade of $92.43."
2018-09-06,66.01000213623047,65.83000183105469,0.6383921007761943,7 Lucrative Biotech Stocks With Up to 300% Upside,"However, one of the key advantages for Linzagolix is the potential to be administered in certain patients without needing add-back therapy (ABT). Biotech Stocks to Buy: Tocagen Inc (TOCA) This cutting-edge biotech stock is at the forefront of cancer therapy. 20 Consumer Discretionary Stocks to Bolster Your Portfolio In total, four analysts have published buy ratings on TOCA stock in the last three months."
2018-09-05,66.95999908447266,66.0,-0.27268641016599166,,
2018-09-04,66.73999786376953,67.11000061035156,-1.4336904085998865,,
2018-08-31,66.95999908447266,66.83999633789062,0.5543943039034631,,
2018-08-30,66.94000244140625,67.0199966430664,-0.17921557380943673,"SPYG, HD, BAC, ABT: Large Outflows Detected at ETF","Among the largest underlying components of SPYG, in trading today Home Depot Inc (Symbol: HD) is down about 1%, Bank of America Corp (Symbol: BAC) is down about 0.3%, and Abbott Laboratories (Symbol: ABT) is up by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR Portfolio S&P 500 Growth ETF (Symbol: SPYG) where we have detected an approximate $99.2 million dollar outflow -- that's a 2.7% decrease week over week (from 95,500,108 to 92,900,108). For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $7.6119 per share, with $38.20 as the 52 week high point - that compares with a last trade of $38.15."
2018-08-29,66.72000122070312,67.12999725341797,0.11950134260926651,,
2018-08-28,67.02999877929688,66.79000091552734,0.6145024358716926,,
2018-08-27,66.44999694824219,66.83999633789062,-0.35804545448337055,,
2018-08-24,65.9000015258789,66.0999984741211,0.5869065576514737,,
2018-08-23,65.66999816894531,65.83000183105469,0.3034854986515422,,
2018-08-22,64.51000213623047,65.66999816894531,0.24364803802452234,"IUSG, BAC, ABT, TXN: Large Inflows Detected at ETF | Wednesday Sector Leaders: Energy, Healthcare","Among the largest underlying components of IUSG, in trading today Bank of America Corp (Symbol: BAC) is down about 0.3%, Abbott Laboratories (Symbol: ABT) is trading flat, and Texas Instruments Inc. (Symbol: TXN) is lower by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core S&P U.S. Growth ETF (Symbol: IUSG) where we have detected an approximate $54.4 million dollar inflow -- that's a 1.1% increase week over week in outstanding units (from 82,900,000 to 83,800,000). For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average: Looking at the chart above, IUSG's low point in its 52 week range is $48.90 per share, with $60.65 as the 52 week high point - that compares with a last trade of $60.36. | Among large Healthcare stocks, Abbott Laboratories (Symbol: ABT) and Align Technology Inc (Symbol: ALGN) are the most notable, showing a gain of 1.5% and 1.5%, respectively. Combined, ABT and ALGN make up approximately 3.9% of the underlying holdings of XLV. Among energy ETFs , one ETF following the sector is the Energy Select Sector SPDR ETF (Symbol: XLE), which is up 1.3% on the day, and up 4.38% year-to-date."
2018-08-21,64.91000366210938,64.75,1.7981646168065468,,
2018-08-20,65.0,64.63999938964844,-0.2465007750458281,,
2018-08-17,64.23999786376953,64.72000122070312,-0.5538470928485577,S&P 500 Analyst Moves: ABT,"The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories ( ABT ) is now the #42 analyst pick, moving up by 1 spot. VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Looking at the stock price movement year to date, Abbott Laboratories ( ABT ) is showing a gain of 12.6%."
2018-08-16,63.790000915527344,64.16000366210938,0.7472032579320944,,
2018-08-15,63.45000076293945,63.470001220703125,0.580032514926595,,
2018-08-14,63.45000076293945,63.630001068115234,0.03152160366143597,IYH's Holdings Imply 10% Gain Potential,"Similarly, ABT has 10.26% upside from the recent share price of $63.43 if the average analyst target price of $69.94/share is reached, and analysts on average are expecting AVNS to reach a target price of $68.75/share, which is 9.88% above the recent price of $62.57. Below is a twelve month price history chart comparing the stock performance of ICPT, ABT, and AVNS: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of IYH's underlying holdings with notable upside to their analyst target prices are Intercept Pharmaceuticals Inc (Symbol: ICPT), Abbott Laboratories (Symbol: ABT), and Avanos Medical Inc (Symbol: AVNS)."
2018-08-13,64.0199966430664,63.43000030517578,0.28368842082176576,,
2018-08-10,64.44000244140625,64.02999877929688,-0.9215813321266765,,
2018-08-09,64.79000091552734,64.63999938964844,-0.6362564347854913,,
2018-08-08,64.73999786376953,64.83999633789062,-0.23151956128921342,,
2018-08-07,65.18000030517578,64.73999786376953,0.15446165804873457,,
2018-08-06,65.08999633789062,65.23999786376953,-0.6750574399296382,,
2018-08-03,64.7699966430664,65.2300033569336,0.23045250317764476,,
2018-08-02,64.5,64.58000183105469,0.7102157444938373,Why Dexcom Is Soaring Today | Health Care Select Sector SPDR Fund Experiences Big Inflow | What DexCom Just Said About Its Future,"Now what Dexcom's second-quarter results should go a long way to silence the doubters who believed that Abbott Laboratories ' (NYSE: ABT) FreeStyle Libre glucose monitoring system was going to put a stop to the company's huge growth. Instead, Dexcom just reported an acceleration in its revenue growth rate, which suggests that the total market is large enough for both companies' products to coexist. 10 stocks we like better than DexCom When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | Among the largest underlying components of XLV, in trading today Johnson & Johnson (Symbol: JNJ) is trading flat, Pfizer Inc (Symbol: PFE) is trading flat, and Abbott Laboratories (Symbol: ABT) is lower by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $142.3 million dollar inflow -- that's a 0.8% increase week over week in outstanding units (from 189,765,324 to 191,365,324). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $77.82 per share, with $91.79 as the 52 week high point - that compares with a last trade of $88.90. | A big advance in care Until competitor Abbott Labs (NYSE: ABT) won approval of its Freestyle Libre CGM last year, patients still had to use fingersticks to calibrate their CGMs. DexCom, Inc. 's (NASDAQ: DXCM) continuous glucose monitors (CGM) are increasingly being used by diabetics to track their blood glucose levels, and based on the company's second-quarter results, the company's sales momentum is accelerating following the approval of its newest device, the G6. In the past, patients with type 1 disease and many patients with type 2 diabetes have relied upon finger sticks to draw blood, blood glucose monitors to measure blood sugar levels, and insulin injections to bring blood glucose readings down to a normal range."
2018-08-01,65.3499984741211,64.77999877929688,0.12403384659641474,,
2018-07-31,65.37000274658203,65.54000091552734,-0.872226026217799,,
2018-07-30,64.97000122070312,65.16999816894531,0.2600553186517972,,
2018-07-27,65.51000213623047,65.26000213623047,0.3078296821371417,"Edwards Lifesciences (EW) Q2 Earnings Beat, Revenues Miss | Omnicell (OMCL) Earnings & Revenues Beat Estimates in Q2","Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the broader medical sector which reported solid results this season are Intuitive Surgical ISRG , Abbott ABT and Align Technology, Inc. ALGN . Sales Details Second-quarter sales improved 12.1% to $943.7 million but fell short of the Zacks Consensus Estimate of $964.7 million by 2.2%. | Click to get this free report Omnicell, Inc. (OMCL): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the broader medical sector which reported solid results this earnings season are Intuitive Surgical ISRG , Abbott ABT and Align Technology, Inc. ALGN . Revenues in Detail Adjusted revenues in the second quarter increased 4% year over year to $188.7 million, slightly above the Zacks Consensus Estimate of $188.5 million."
2018-07-26,65.36000061035156,65.66000366210938,-0.381621114101196,,
2018-07-25,64.16000366210938,65.2300033569336,0.45900099289518476,,
2018-07-24,63.54999923706055,64.4000015258789,1.667705164823927,,
2018-07-23,63.2599983215332,63.20000076293945,1.337533121987297,Agios (AGIO) Secures FDA Approval for Leukemia Drug Tibsovo,"Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Agios Pharmaceuticals, Inc. (AGIO): Free Stock Analysis Report Eagle Pharmaceuticals, Inc. (EGRX): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. The drug was approved simultaneously with Abbott's ABT RealTime IDH1 companion diagnostic test for detecting patients with R/R AML. Agios Pharmaceuticals, Inc AGIO announced that the FDA has approved its leukemia drug Tibsovo (ivosidenib) for treating adult patients suffering from relapsed/refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH-1) mutation."
2018-07-20,63.61000061035156,63.31999969482422,-0.0948428077547503,"Here's Why You Should Add Abbott (ABT) to Your Portfolio Now | The Zacks Analyst Blog Highlights: Wells Fargo, IBM, Abbott, Texas Instruments and Praxair","Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report Genomic Health, Inc. (GHDX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT has been gaining investors' confidence on consistently positive results. Per our Zacks Style Score system, Abbott has a Growth Score of A which reflects the company's solid prospects. | Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo (WFC), IBM (IBM) and Abbott (ABT). Click to get this free report International Business Machines Corporation (IBM): Free Stock Analysis Report Wells Fargo & Company (WFC): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Praxair, Inc. (PX): Free Stock Analysis Report Texas Instruments Incorporated (TXN): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include Wells FargoWFC , IBMIBM , AbbottABT , Texas InstrumentsTXN and PraxairPX ."
2018-07-19,64.68000030517578,63.77999877929688,-0.4559045947881197,Can Solid Global Prospects Drive Align's (ALGN) Q2 Earnings?,"Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report Genomic Health, Inc. (GHDX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Other top-ranked stocks in the broader medical space are Genomic Health GHDX , Abbott ABT and Baxter International Inc. BAX . Align Technology, Inc. Price and EPS Surprise Align Technology, Inc. Price and EPS Surprise | Align Technology, Inc. Quote In EMEA, first-quarter volumes were up 36.6% on solid Invisalign adoption in the markets of Iberia and France as well as rapid growth in smaller markets like Eastern Europe and Central Europe along with Benelux."
2018-07-18,64.30999755859375,64.75,-1.391468029734811,"Abbott Laboratories (ABT) Q2 2018 Earnings Conference Call Transcript | Abbott Laboratories Stock Gets a Boost From Q2 Earnings Beat | Housing Starts/Permits Disappoint; MS, USB and ABT Beat | Morning Movers: Clorox Slides, United Continental Flies, Morgan Stanley Jumps | Health Care Sector Update for 07/18/2018: ABT, MBRX, CLRB | 3 Big Stock Charts for Wednesday: United Technologies, Abbott Laboratories and Leggett & Platt | Earnings Reaction History: Abbott Laboratories, 54.5% Follow-Through Indicator, 2.3% Sensitive | Health Care Sector Update for 07/18/2018: CLRB,ABT,MBRX,CARA | Abbott (ABT) Q2 Earnings & Revenues Top Estimates, View Up | Noteworthy Wednesday Option Activity: ABT, TRV, AMRS | Health Care Sector Update for 07/18/2018: MBRX,ABT","Duration: 61 minutes Call participants: Scott Leinenweber -- Vice President, Investor Relations Miles D. White -- Chairman and Chief Executive Officer Brian B. Yoor -- Executive Vice President, Finance and Chief Financial Officer David Lewis -- Morgan Stanley -- Managing Director Larry Biegelsen -- Wells Fargo Securities -- Analyst Bob Hopkins -- Bank of America Merrill Lynch -- Managing Director Glenn Novarro -- RBC Capital Markets -- Managing Director Rick Wise -- Stifel Financial Corporation -- Analyst Joanne Wuensch -- BMO Capital Markets -- Managing Director Christopher Pasquale -- Guggenheim Securities -- Director More ABT analysis This article is a transcript of this conference call produced for The Motley Fool. Abbott Laboratories (NYSE: ABT) Q2 2018 Earnings Conference Call July 17, 2018, 9:00 a.m. The good news is even when it's down, the growth rate is still pretty high, so we go from a good growth rate to a great growth rate to a good growth rate, back and forth, because it's a bit volatile. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Abbott Laboratories (NYSE: ABT ) stock was up on Wednesday following the release of its earnings report for the second quarter of 2018. It also beat out Wall Street's earnings per share estimate of 71 cents for the quarter, making it a boon to ABT stock. It was also good news for ABT stock by coming in above analysts' revenue estimate of $7.71 billion. | Click to get this free report International Business Machines Corporation (IBM): Free Stock Analysis Report U.S. Bancorp (USB): Free Stock Analysis Report eBay Inc. (EBAY): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Morgan Stanley (MS): Free Stock Analysis Report American Express Company (AXP): Free Stock Analysis Report To read this article on Zacks.com click here. Many of these are from the Financial sector, like Morgan Stanley MS and U.S. Bancorp USB , but we also hear from other industries, like Abbott Labs ABT , as well. For more on ABT's earnings, click here. | Earnings & News Abbott Laboratories (ABT) is up 2.4% to $64.30 after reporting second-quarter earnings. In today's Morning Movers, we... Getty Images •...fret about the lack of stocks joining the Nasdaq's rally; •...review Morgan Stanley's (MS) stellar earnings; •...and highlight a Goldman Sachs downgrade of Clorox (CLX). Jason Goepfert of Sundial Capital Research notes that even with the Nasdaq Composite hitting new highs, as of last Friday just 57% of its constituents were trading above their 50-day moving averages, and 59% above their 200-day moving averages. | Expected movers: - Abbott Laboratories ( ABT ): Q2 adj. Health care shares were higher ahead of the bell on Wednesday. EPS, sales top estimates; Q3 and FY adj. | Among the best of those best are Leggett & Platt (NYSE: LEG ), Abbott Laboratories (NYSE: ABT ) and United Technologies (NYSE: UTX ). Abbott Laboratories (ABT) The one thing more affirming than an unfettered streak of bullish momentum is a quelled effort to kill a rally. One more solidly bullish day could get ABT shares over a major hump. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 57.1% Average next regular session additional gain: 1.8% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 57.1% of the time (4 events) the stock posted additional gains in the following regular session by an average of 1.8%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 50% Average next regular session additional loss: 2.7% Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 50.0% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close. Extended-Hours Dollar Volume: $2,472,801 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | In other sector news: + Abbott Laboratories ( ABT ) climbed almost 3% on Wednesday after reporting GAAP Q2 net income of $0.40 per share and adjusted per share earnings of $0.73 per share, matching the consensus view for GAAP profit and beating non-GAAP Street projections by $0.02 per share. Health care stocks were narrowly higher in late trading, including a nearly 0.3% gain for the NYSE Health Care Index. Among health care stocks moving on news: - Cellectar Biosciences ( CLRB ) tumbled Wednesday, at one point falling 14% lower, despite the early-stage oncology pharmaceuticals company saying it was expanding Phase II testing of its CLR131 drug candidate to include up to 30 more patients after reporting positive interim results for the medication in patients with large B-cell candidate lymphoma. | Abbott LaboratoriesABT reported second-quarter 2018 adjusted earnings from continuing operations of 73 cents per share, beating the Zacks Consensus Estimate by a couple of cents. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Integer Holdings Corporation (ITGR): Free Stock Analysis Report Genomic Health, Inc. (GHDX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories Price, Consensus and EPS Surprise Abbott Laboratories Price, Consensus and EPS Surprise | Abbott Laboratories Quote The Medical Devices business sales increased 11.3% on a reported basis to $2.89 billion. | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Abbott Laboratories (Symbol: ABT), where a total volume of 20,141 contracts has been traded thus far today, a contract volume which is representative of approximately 2.0 million underlying shares (given that every 1 contract represents 100 underlying shares). Especially high volume was seen for the $65 strike call option expiring August 17, 2018 , with 2,338 contracts trading so far today, representing approximately 233,800 underlying shares of ABT. That number works out to 42.8% of ABT's average daily trading volume over the past month, of 4.7 million shares. | In other sector news: + Abbott Laboratories ( ABT ) climbed almost 3% on Wednesday after reporting GAAP Q2 net income of $0.40 per share and adjusted per share earnings of $0.73 per share, matching the consensus view for GAAP profit while beating Street projections for normalized EPS by $0.02 per share. Health care stocks were narrowly mixed in recent trading, including a slightly more than 0.2% gain for the NYSE Health Care Index. Among health care stocks moving on news: + Moleculin Biotech ( MBRX ) was climbing over 2% higher in recent trading, trying to retrace a more than 3% gain soon after the opening bell."
2018-07-17,61.84000015258789,62.79999923706055,0.6841897964703816,These Companies are Earnings All-Stars,"Click to get this free report CSX Corporation (CSX): Free Stock Analysis Report eBay Inc. (EBAY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report United Rentals, Inc. (URI): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ABT has a perfect 5-year earnings surprise record. CSX CSX is the first of the railroads to report earnings this quarter."
2018-07-16,62.95000076293945,61.77999877929688,1.5523917886544216,,
2018-07-13,62.75,63.060001373291016,-1.8586210793684155,,
2018-07-12,62.5,62.7400016784668,0.4940260928940488,Can Established Pharmaceuticals Up Abbott (ABT) Q2 Earnings? | Can Medical Devices Strength Drive Abbott (ABT) Q2 Earnings?,"Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report ResMed Inc. (RMD): Free Stock Analysis Report McKesson Corporation (MCK): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ' ABT Established Pharmaceuticals Division (EPD) business has been recording operational sales growth in the last few quarters. Abbott Laboratories Price and EPS Surprise Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote Per the company, key emerging markets represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report Genomic Health, Inc. (GHDX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott'sABT Medical Devices business has been going strong of late on solid sub-segmental performance. Medical Devices in Focus Abbott's Medical Devices segment presently comprises the new Cardiovascular and Neuromodulation, Heart Failure, Electrophysiology, Structural Heart, Rhythm Management, Vascular businesses along with the Diabetes Care business."
2018-07-11,62.560001373291016,62.56999969482422,0.384002685546875,"Can Abbott (ABT) Rise on Robust Overall Growth in Q2 Earnings? | iShares U.S. Medical Devices ETF Experiences Big Inflow | Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for July 12, 2018 | 3 Top Growth Stocks to Buy in July","Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report ResMed Inc. (RMD): Free Stock Analysis Report McKesson Corporation (MCK): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT is slated to report second-quarter 2018 results before the market opens on Jul 18. Abbott Laboratories Price and EPS Surprise Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote We are also upbeat about the consistently sturdy Diagnostics business, courtesy of solid contributions from all sub-segments, namely Core Laboratories Diagnostics, Molecular Diagnostics and Point of Care. | Among the largest underlying components of IHI, in trading today Medtronic PLC (Symbol: MDT) is down about 0.1%, Abbott Laboratories (Symbol: ABT) is trading flat, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 1.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $72.1 million dollar inflow -- that's a 2.9% increase week over week in outstanding units (from 11,900,000 to 12,250,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $160.37 per share, with $206.90 as the 52 week high point - that compares with a last trade of $205.56. | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. The following ETF(s) have ABT as a top-10 holding: iShares U.S. Healthcare ETF ( IYH ) Vanguard Health Care ETF ( VHT ) Vanguard Div Appreciation ETF ( VIG ) iShares Global Healthcare ETF ( IXJ ) NuShares Enhanced Yield US Aggregate Bond ETF ( NULV ). | In 2017, DexCom's sales were held back by the launch of Abbott Labs ' (NYSE: ABT) Freestyle Libre, the first CGM to remove the need for diabetes patients to stick their fingers to confirm readings or to calibrate the system. A small-cap semiconductor company Tim Green(Kulicke & Soffa Industries): Kulicke & Soffa manufactures equipment used by the semiconductor industry to package semiconductor components. But even so, with plenty of long-term growth potential, Kulicke & Soffa is a solid growth stock pick."
2018-07-10,62.560001373291016,62.810001373291016,0.015981971409405604,,
2018-07-09,62.22999954223633,62.43999862670898,0.3996163595142334,,
2018-07-06,61.56999969482422,62.15999984741211,0.3374563490557636,,
2018-07-05,61.18999862670898,61.33000183105469,0.9582591448956724,Here's Why AbbVie Stock is Good for Your Portfolio's Health,"Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie came into existence on Jan 1, 2013, after Abbott Laboratories ABT divested its pharmaceutical division Here are six reasons to invest in the stock. Promising candidates include elagolix (endometriosis), risankizumab (inflammatory diseases), Depatux-M/ABT-414 (glioblastoma multiforme), ABBV-8E12 (early Alzheimer's disease and progressive supranuclear palsy (PSP)), and upadacitinib/ABT-494 (inflammatory diseases).The company expects to move 10 tumor candidates into clinical development in 2018."
2018-07-03,60.970001220703125,60.810001373291016,0.22880079667888711,,
2018-07-02,60.630001068115234,61.0,-0.26242388749990614,,
2018-06-29,61.4900016784668,60.9900016784668,0.6102571752705191,,
2018-06-28,60.459999084472656,61.27000045776367,-0.8131403258281178,,
2018-06-27,61.209999084472656,60.4900016784668,1.3397310379699299,"The Zacks Analyst Blog Highlights: Facebook, Amgen, Abbott, Coca-Cola and 3M","Click to get this free report Facebook, Inc. (FB): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Coca-Cola Company (The) (KO): Free Stock Analysis Report 3M Company (MMM): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include Facebook FB , Amgen AMGN , Abbott ABT , Coca-Cola KO and 3M MMM . Here are highlights from Tuesday's Analyst Blog: Top Stock Reports for Facebook, Amgen and Abbott The Zacks Research Daily presents the best research output of our analyst team."
2018-06-26,60.63999938964844,60.810001373291016,-1.1762741656183158,,
2018-06-25,61.70000076293945,60.77000045776367,0.28034628191569266,,
2018-06-22,62.22999954223633,61.93999862670898,-1.50729383091741,The Implied Analyst 12-Month Target For PBUS,"Similarly, ABT has 9.82% upside from the recent share price of $61.75 if the average analyst target price of $67.81/share is reached, and analysts on average are expecting NYCB to reach a target price of $12.61/share, which is 9.77% above the recent price of $11.49. Below is a twelve month price history chart comparing the stock performance of UHAL, ABT, and NYCB: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of PBUS's underlying holdings with notable upside to their analyst target prices are AMERCO (Symbol: UHAL), Abbott Laboratories (Symbol: ABT), and New York Community Bancorp Inc. (Symbol: NYCB)."
2018-06-21,61.970001220703125,61.75,-0.4660146515516578,Tap Cardiovascular Devices Market Boom With These 3 Stocks,"Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT : This Zacks Rank #3 company has Cardiovascular and Neuromodulation business under the broader Medical Devices segment. The company offers a wide range of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders."
2018-06-20,62.209999084472656,62.13999938964844,-0.35501245178227675,,
2018-06-19,62.2400016784668,62.34000015258789,-0.1125216136543721,"IUSG, ABT, ACN, TMO: ETF Inflow Alert","Among the largest underlying components of IUSG, in trading today Abbott Laboratories (Symbol: ABT) is down about 1.4%, Accenture plc (Symbol: ACN) is off about 0.7%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core S&P U.S. Growth ETF (Symbol: IUSG) where we have detected an approximate $67.8 million dollar inflow -- that's a 1.6% increase week over week in outstanding units (from 73,300,000 to 74,450,000). For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average: Looking at the chart above, IUSG's low point in its 52 week range is $48.59 per share, with $59.23 as the 52 week high point - that compares with a last trade of $58.15."
2018-06-18,62.59000015258789,62.81999969482422,0.16066592452501532,"Zacks Industry Outlook Highlights: Boston Scientific, Stryker, Medtronic, Abbott and Varian Medical","For Immediate Release Chicago, IL - June 18, 2018 - Today, Zacks Equity Research discusses the Industry: Medical Devices, Part 2, including Boston Scientific BSX , Stryker Corporation SYK , Medtronic MDT , Abbott ABT and Varian Medical VAR . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report To read this article on Zacks.com click here. Industry: Medical Devices, Part 2 Link: https://www.zacks.com/commentary/167761/medtech-overcomes-policy-hurdles-long-term-prospects-bright With the suspension of the controversial 2.3% medical device tax for another two years, the medical device industry is currently riding high on optimism."
2018-06-15,62.86000061035156,62.90999984741211,0.3674701097229801,3 High-Yield Stocks at Rock-Bottom Prices,"The big pharma company was part of Dividend AristocratAbbott Labs (NYSE: ABT) until it was spun off as a separate entity in 2013. Has yield, will travel Maxx Chatsko(Brookfield Infrastructure Partners): The relationship between Mr. Market and Brookfield Infrastructure Partners has frayed in 2018, with the stock sliding 16% year to date. A grocery-anchored REIT Brian Feroldi(Retail Opportunity Investment Corp): Between rising interest rate and the recent troubles of the retail industry, it's not hard to figure out why Retail Opportunity Investments Corp (ROIC) has underperformed the S&P 500 over the past year."
2018-06-14,62.86000061035156,62.959999084472656,0.07954062452285941,,
2018-06-13,63.060001373291016,62.630001068115234,0.15908124904571883,,
2018-06-12,63.27000045776367,62.91999816894531,-0.6818907323365637,Boston Scientific Up on Possible Takeover Bid by Stryker,"Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. It is important to note that post the colossal mergers of Medtronic MDT -Covidien and Abbott ABT -St. Jude Medical over the last couple of years, Boston Scientific also needed to make a mammoth move to maintain its foothold in the highly competitive medical-technology space. Shares of Boston Scientific Corporation BSX gained 7.4% to close at $34.32 on Jun 11, 2018, following a speculation that the company's rival Stryker Corporation SYK might consider a bid for acquiring the former."
2018-06-11,63.27999877929688,63.130001068115234,-0.5531883772499825,,
2018-06-08,63.0099983215332,63.27000045776367,-0.23703810694560573,"Bio-Rad Banks on Solid Global Scenario, Competition Rife | Daily Dividend Report: PM, GE, ABT, AMAT, CDK","Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. Again, some prominent competitors in the Clinical Diagnostics segment are Abbott Laboratories ABT and DiaSorin. Further, constant currency sales at the Life Science segment were particularly strong in North America, China and Europe, while currency-neutral sales at the company's Clinical Diagnostics segment saw strength in China, Asia Pacific and North America. | VIDEO: Daily Dividend Report: PM, GE, ABT, AMAT, CDK The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott ( ABT ) declared a quarterly common dividend of 28 cents per share. The new quarterly dividend of $1.14 per share, up from $1.07 per share, is payable on July 11, 2018, to shareholders of record as of June 22, 2018."
2018-06-07,63.560001373291016,63.18000030517578,0.412636316705971,"Noteworthy ETF Inflows: IUSG, MA, ABT, PG","Among the largest underlying components of IUSG, in trading today Mastercard Inc (Symbol: MA) is down about 1%, Abbott Laboratories (Symbol: ABT) is down about 0.3%, and Procter & Gamble Company (Symbol: PG) is up by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core S&P U.S. Growth ETF (Symbol: IUSG) where we have detected an approximate $132.2 million dollar inflow -- that's a 3.2% increase week over week in outstanding units (from 71,050,000 to 73,300,000). For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average: Looking at the chart above, IUSG's low point in its 52 week range is $48.59 per share, with $58.92 as the 52 week high point - that compares with a last trade of $58.58."
2018-06-06,63.11000061035156,63.540000915527344,-0.5978619570560885,,
2018-06-05,63.09000015258789,63.02999877929688,0.6813505007402121,,
2018-06-04,62.31999969482422,63.02000045776367,-0.09510441138990443,,
2018-06-01,61.959999084472656,62.40999984741211,1.1232361462889888,Abbott Launches Afinion 2 Analyzer Rapid Test in the U.S.,"Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT recently announced the launch of the latest generation of the Afinion test system - Afinion 2 analyzer - in the United States. A Glimpse at the Diagnostics Business Abbott's Diagnostics division manufacturesand markets diagnostic systems as well as tests in four business lines - Core Laboratory, Molecular, Point of Care and Rapid Diagnostics (reflects sales from Alere, which was acquired on Oct. 3, 2017)."
2018-05-31,61.900001525878906,61.52999877929688,0.7262762582128968,Thursday's ETF with Unusual Volume: XHE,"Components of that ETF with the highest volume on Thursday were Boston Scientific ( BSX ), trading up about 0.1% with over 3.9 million shares changing hands so far this session, and Abbott Laboratories ( ABT ), down about 0.5% on volume of over 2.0 million shares. The SPDR S&P Health Care Equipment ETF ( XHE ) is seeing unusually high volume in afternoon trading Thursday, with over 305,000 shares traded versus three month average volume of about 41,000. VIDEO: Thursday's ETF with Unusual Volume: XHE The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2018-05-30,61.77999877929688,62.06999969482422,-0.597742709953464,,
2018-05-29,61.58000183105469,61.29999923706055,0.4694090664574745,The 7 Best Long-Term Stocks for Risk-Off Investors,"Long-Term Stocks to Buy: Abbott Labs (ABT) Right there in the first sentence of its Q1 2018 press release are the words ""long-term sustainable and organic growth."" Companies like Abbott Laboratories (NYSE: ABT ) that are focused on the long-term don't care much about short-term gyrations in revenues and earnings. Yielding 1.8% and expected to generate adjusted earnings per share of $2.85 in fiscal 2018, ABT stock is currently trading at a reasonable valuation."
2018-05-25,62.4900016784668,62.369998931884766,-0.4546972810464189,Five Top MedTech Stocks in Diabetes | A Focus on Eye Care Is Setting Up Johnson & Johnson Stock for the Future | S&P 500 Analyst Moves: ABT | Abbott Presents Positive Study Results for Tendyne Device | How to Invest in Diabetes Stocks,"From medtech Goliaths Medtronic (NYSE: MDT) and Abbott Labs (NYSE: ABT) to small pure plays Dexcom (NASDAQ: DXCM) , Insulet Corp. (NASDAQ: PODD) , and Tandem Diabetes Care (NASDAQ: TNDM) , we've got you covered. Their ticker is ABT. On this episode of The Motley Fool's Industry Focus: Healthcare , host Kristine Harjes and Motley Fool contributor Todd Campbell explain how artificial pancreases, continuous glucose monitors, and insulin pumps are reshaping diabetes treatment and what could be at stake for investors. | Back in 2016 , it made a big $4.33-billion purchase of the Abbott Laboratories (NYSE: ABT ) Medical Optics unit. A Big Jump for Johnson & Johnson By all measures, Johnson & Johnson had a pretty good quarter . And given the growth potential and already-realized earnings jumps its seen, eye care becomes very exciting for Johnson & Johnson. | VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories is now the #38 analyst pick, moving up by 1 spot. This rank is formed by averaging the analyst opinions for each component from each broker, and then ranking the 500 components by those average opinion values. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT has been in the spotlight of late on favorable developments in its Medical Device business including its core Structural Heart division. Although this global study of Tendyne device expects to register up to 350 adult patients, the early results were based on successful implantation of Tendyne device in 97 of the first 100 patients. | Type 2 diabetes The most common form of diabetes is type 2 diabetes. Other types of diabetes Two other less common types of the disease are monogenic diabetes and cystic-fibrosis-related diabetes. Diabetes stocks Diabetes stocks fall into three broad categories: Drugmakers, medical-device makers, and companies that market medical supplies for diabetes."
2018-05-24,61.88999938964844,62.5099983215332,-0.19203511499245576,"Abbott Gets FDA Nod for XIENCE Sierra, To Boost Vascular Wing","Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT , providing an impetus to the Vascular business in the United States, recently announced the receipt of FDA approval for XIENCE Sierra. We encouragingly note, under Vascular business, Abbott has been on a slew of developments in regards with its XIENCE Sierra coronary stent system."
2018-05-23,61.220001220703125,61.84000015258789,1.0017756309567276,,
2018-05-22,62.09999847412109,61.38999938964844,1.0127391694253953,Cardiovascular Systems Rides on New Products Amid Tight Race,"Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. Larger players contesting in the stent and balloon angioplasty market segments include bigwigs like Abbott Laboratories ABT . For instance, the company's firm position in the coronary arterial disease (CAD) and peripheral arterial disease (PAD) market spaces, positive study results highlighting its effective technologies, an impressive portfolio expansion as well as a strong gross margin scenario."
2018-05-21,62.0,62.11000061035156,-1.143315784087381,,
2018-05-18,61.02000045776367,61.709999084472656,0.17742033927671372,Why Is Abbott (ABT) Up 2% Since Its Last Earnings Report?,"Abbott Laboratories Price and Consensus Abbott Laboratories Price and Consensus | Abbott Laboratories Quote VGM Scores At this time, ABT has a great Growth Score of A, though it is lagging a lot on the momentum front with a C. The stock was also allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy. It has been about a month since the last earnings report for Abbott LaboratoriesABT . Will the recent positive trend continue leading up to its next earnings release, or is ABT due for a pullback?"
2018-05-17,60.79999923706055,61.060001373291016,1.1307745354518344,,
2018-05-16,60.56999969482422,60.77000045776367,0.42763509785043685,,
2018-05-15,61.43999862670898,60.540000915527344,0.33019772816103127,3 Top Healthcare Stocks to Buy in May,"The company has increased its dividend payout by a whopping 140% since it was spun off from parent Abbott Labs (NYSE: ABT) in 2013. We asked these three Motley Fool investors to weigh in, and they picked AbbVie (NYSE: ABBV) , Cardinal Health (NYSE: CAH) , and Masimo (NASDAQ: MASI) . A big pharma stock that has it all Keith Speights (AbbVie): AbbVie was rocking along, with the stock soaring more than 50% in 2017 and up over 20% year to date in 2018."
2018-05-14,61.5,62.02000045776367,-1.4648400574514169,"Notable ETF Outflow Detected - VIG, ABT, UTX, LMT","Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is up about 1.4%, United Technologies Corp (Symbol: UTX) is up about 0.6%, and Lockheed Martin Corp (Symbol: LMT) is lower by about 1.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $43.3 million dollar outflow -- that's a 0.2% decrease week over week (from 270,530,982 to 270,105,982). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $89.90 per share, with $108.99 as the 52 week high point - that compares with a last trade of $102.05."
2018-05-11,60.220001220703125,61.2599983215332,0.8455291996157266,Merck vs. Pfizer: Which Stock Looks Better Post Q1 Earnings?,"Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report To read this article on Zacks.com click here. Other major earnings came from other pharma giants like Abbott ABT and Johnson & Johnson JNJ . Q1 Earnings Performance In the first quarter, Merck reported adjusted earnings per share of $1.05, surpassing the Zacks Consensus Estimate by six cents."
2018-05-10,59.630001068115234,60.560001373291016,1.726996147041817,,
2018-05-09,58.810001373291016,59.400001525878906,1.5596181259722663,,
2018-05-08,59.119998931884766,58.709999084472656,1.0032309791032303,,
2018-05-07,58.9900016784668,59.31999969482422,-0.6935044905607857,,
2018-05-04,57.63999938964844,58.7400016784668,0.5594134717203806,,
2018-05-03,57.790000915527344,57.93000030517578,1.9084009376584217,,
2018-05-02,58.4900016784668,57.84999847412109,0.24225538575968716,,
2018-05-01,57.70000076293945,58.81999969482422,-1.094209584509772,,
2018-04-30,59.7599983215332,58.130001068115234,1.9410726465780876,June 2019 Options Now Available For Abbott Laboratories (ABT),"Below is a chart showing ABT's trailing twelve month trading history, with the $60.00 strike highlighted in red: Considering the fact that the $60.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the June 2019 expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ABT options chain for the new June 2019 contracts and identified one put and one call contract of particular interest."
2018-04-27,59.4900016784668,59.560001373291016,-2.7275724551528895,9 Highest-Yielding Dividend Aristocrats to Buy Today,"The company was formed as a spin-off from Abbott Laboratories (ABT) in 2013 and produces drugs for treating chronic autoimmune diseases in different therapeutic areas such as rheumatology, oncology, and virology. Dividend Aristocrats to Buy Today: Procter & Gamble (PG) Source: Mike Mozart via Flickr (Modified) Ticker: PG Sector: Consumer Staples Dividend Yield: 3.9% Procter & Gamble (NYSE: PG ) is a leading consumer goods company selling products in more than 180 countries. Dividend Aristocrats to Buy Today: Coca-Cola (KO) Source: Coca-Cola Ticker: KO Sector: Consumer Staples Dividend Yield: 3.6% Coca-Cola ( KO ) is one of the largest holdings in Warren Buffett's dividend stock portfolio and also the largest beverage company in the world, with a portfolio of more than 500 non-alcoholic beverage brands."
2018-04-26,58.68999862670898,59.5,0.11766631845558694,Universal Health (UHS) Q1 Earnings & Revenues Lag Estimates,"Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Universal Health Services, Inc. (UHS): Free Stock Analysis Report To read this article on Zacks.com click here. Among other players in the Medical sector having reported first-quarter earnings so far, Novartis AG NVS , UnitedHealth Group Incorporated UNH and Abbott Laboratories ABT surpassed the respective Zacks Consensus Estimate. Universal Health Services, Inc. Price, Consensus and EPS Surprise Universal Health Services, Inc. Price, Consensus and EPS Surprise | Universal Health Services, Inc. Quote Financial Update As of Mar 31, 2018, the company had cash and cash equivalents of nearly $73 million, down 1.3% from year-end 2017."
2018-04-25,58.040000915527344,58.650001525878906,1.3801352738870276,"SPYG, ABT, CRM, CHTR: ETF Inflow Alert | Anthem (ANTM) Beats on Q1 Earnings, Raises '18 Guidance","Among the largest underlying components of SPYG, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.1%, Salesforce.com Inc (Symbol: CRM) is off about 1.6%, and Charter Communications Inc (Symbol: CHTR) is lower by about 1.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR Portfolio S&P 500 Growth ETF (Symbol: SPYG) where we have detected an approximate $96.3 million dollar inflow -- that's a 5.0% increase week over week in outstanding units (from 58,400,108 to 61,300,108). For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $7.2019 per share, with $35.959 as the 52 week high point - that compares with a last trade of $33.03. | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Anthem, Inc. (ANTM): Free Stock Analysis Report To read this article on Zacks.com click here. Among other players in the Medical sector having reported first-quarter earnings so far, Novartis AG NVS , UnitedHealth Group Incorporated UNH and Abbott Laboratories ABT surpassed the respective Zacks Consensus Estimate. Segment Update Commercial & Specialty Business Operating revenues were $9 billion in the first quarter, down 12% year over year."
2018-04-24,59.09000015258789,58.310001373291016,1.0510003458466004,"Centene (CNC) Q1 Earnings & Revenues Top, '18 View Lowered","Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Centene Corporation (CNC): Free Stock Analysis Report To read this article on Zacks.com click here. Among other players in the Medical sector having reported first-quarter earnings so far, Novartis AG NVS , UnitedHealth Group Incorporated UNH and Abbott Laboratories ABT surpassed the respective Zacks Consensus Estimate. This represents a deterioration of 100 basis points year over year, arising from growth in the Health Insurance Marketplace business, operating at a higher SG&A expense ratio."
2018-04-23,59.27999877929688,58.84000015258789,-1.3200182387589898,"The Zacks Analyst Blog Highlights: Goldman, Abbott, Altria, PayPal and Progressive","Click to get this free report PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report The Goldman Sachs Group, Inc. (GS): Free Stock Analysis Report The Progressive Corporation (PGR): Free Stock Analysis Report Altria Group, Inc. (MO): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include Goldman SachsGS , Abbott LabsABT , AltriaMO , PayPalPYPL and Progressive CorpPGR . Here are highlights from Friday's Analyst Blog: Top Analyst Reports for Goldman Sachs, Abbott Labs and Altria The Zacks Research Daily presents the best research output of our analyst team."
2018-04-20,59.84999847412109,59.18999862670898,-0.7422379145909461,5 Dividend Growth Stocks With Upside To Analyst Targets,"But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential: Another consideration with dividend growth stocks is just how much the dividend is growing ."
2018-04-19,59.52000045776367,59.880001068115234,-1.1027566653948886,,
2018-04-18,59.0,59.52000045776367,0.6048397304818984,"Earnings Reaction History: Abbott Laboratories, 63.6% Follow-Through Indicator, 2.4% Sensitive | Abbott (ABT) Q1 Earnings & Revenues Top, '18 View Retained | MS, USB, ABT & TXT Leads Q1 Earnings | Abbott (ABT) Beats on Earnings and Revenues in Q1 | Q1 Earnings Keep Markets in the Green: MS, USB, ABT & TXT | Health Care Sector Update for 04/18/2018: ABT, FCSC, ENDP, SLDB | Health Care Sector Update for 04/18/2018: SLDB,FCSC,ABT,ENDP,EGRX | Health Care Sector Update for 04/18/2018: FCSC,ABT,ENDP,EGRX | Morning Movers: Morgan Stanley Gains, Intuitive Surgical Climbs, First Solar Shines","Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 62.5% Average next regular session additional gain: 1.7% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 62.5% of the time (5 events) the stock posted additional gains in the following regular session by an average of 1.7%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 66.7% Average next regular session additional loss: 2.7% Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 66.7% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close. Extended-Hours Dollar Volume: $2,032,183 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Abbott ABT reported first-quarter 2018 adjusted earnings from continuing operations of 59 cents per share, beating the Zacks Consensus Estimate by a penny. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Abaxis,Inc. Abbott Laboratories Price, Consensus and EPS Surprise Abbott Laboratories Price, Consensus and EPS Surprise | Abbott Laboratories Quote Diabetes Care sales improved 44.2% (up 32.9%), buoyed by double-digit international sales growth, led by a consistent consumer uptake of FreeStyle Libre, the revolutionary continuous glucose monitoring system of Abbott. | Click to get this free report International Business Machines Corporation (IBM): Free Stock Analysis Report U.S. Bancorp (USB): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Textron Inc. (TXT): Free Stock Analysis Report Morgan Stanley (MS): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. Based on Chicago's North Shore, Abbott LabsABT also topped earnings consensus by a penny to 59 cents per share. For more on ABT's earnings, click here. | Abbott LaboratoriesABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories Price and EPS Surprise Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote The company rides on its strong EPD business and strategic buyouts. | Click to get this free report International Business Machines Corporation (IBM): Free Stock Analysis Report U.S. Bancorp (USB): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Textron Inc. (TXT): Free Stock Analysis Report Morgan Stanley (MS): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. Based on Chicago's North Shore, Abbott Labs ABT also topped earnings consensus by a penny to 59 cents per share. For more on ABT's earnings, click here. | Expected movers: - Abbott Laboratories ( ABT ): posts Q1 beat - Fibrocell ( FCSC ): launches review of strategic alternatives; shares halted - Endo ( ENDP ): gets notice that Eagle Pharmaceuticals ( EGRX ) seeks US regulatory nod for generic Vasostrict - Solid Biosciences ( SLDB ): plans response to US FDA letter relating to SGT-001 trial halt The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. AMGN: flat Health care shares were mixed ahead of the bell on Wednesday. All rights reserved. | - Abbott Laboratories ( ABT ) was less than 2% lower in late trade, recovering from a 4% decline earlier in the session, despite the medical device company reporting a Q1 beat amid rising demand. Health care stocks were little changed just before Wednesday close, including a 0.1% decline for the NYSE Health Care Index in late trade. Among health care stocks moving on news: + Solid Biosciences ( SLDB ) has returned to positive ground Wednesday afternoon, bouncing back from a nearly 2% decline, after saying the U.S. Food and Drug Administration has delivered a letter to the specialty drugmaker explaining the factors that led to the agency's March 14 clinical hold on Phase I/II testing of its SGT-001 investigational gene therapy for the treatment of Duchenne muscular dystrophy in response to a serious adverse event involving the first patient dosed in the trial. | In other sector news: - Abbott Laboratories ( ABT ) was less than 2% lower, recovering from a 4% decline earlier in the session, despite the medical device company reporting a Q1 beat amid rising demand. Health care stocks were mixed Wednesday, including a less than 0.1% decline for the NYSE Health Care Index in recent trading. Shares of health care companies in the S&P 500 were up almost 0.3% as a group while the Nasdaq Biotechnology index was posting a 0.6% gain. | - Ben Levisohn Earnings & News Abbot Laboratories (ABT) is down 1.4% to $58.96 after reporting first-quarter earnings. The health care firm earned 59 cents a share on revenue of $7.39 billion, while analysts were looking for earnings of 58 cents a share on revenue of $7.28 billion. The tech giant said that it earned $2.45 a share, on revenue of $19.1 billion, while analysts were looking for earnings of $2.42 a share on revenue of $18.81 billion."
2018-04-17,59.650001525878906,59.79999923706055,0.8813567080740201,"IWD, ABT, MDT, CVS: ETF Outflow Alert | Varian Medical (VAR) Q2 Earnings: Is a Surprise in Store? | Can Hospital-Products Unit Aid Baxter (BAX) in Q1 Earnings? | 5 Amazing Earnings Charts This Week | Pre-Market Earnings Report for April 18, 2018 : ABT, MS, ASML, USB, TXT, MTG, QCRH","Among the largest underlying components of IWD, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.2%, Medtronic PLC (Symbol: MDT) is off about 0.6%, and CVS Health Corporation (Symbol: CVS) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $66.9 million dollar outflow -- that's a 0.2% decrease week over week (from 303,150,000 to 302,600,000). For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $112.39 per share, with $131.56 as the 52 week high point - that compares with a last trade of $122.19. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Cardinal Health, Inc. (CAH): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT has an Earnings ESP of +0.75% and a Zacks Rank #3. Varian Medical Systems, Inc. Price and EPS Surprise Varian Medical Systems, Inc. Price and EPS Surprise | Varian Medical Systems, Inc. Quote Let's delve into factors which are likely to impact Varian Medical's upcoming quarterly results. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Cardinal Health, Inc. (CAH): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT has an Earnings ESP of +0.75% and a Zacks Rank #3. Last quarter, Baxter posted adjusted earnings per share of 64 cents, which beat the Zacks Consensus Estimate by 5 cents and improved from the year-ago quarter's figure of 57 cents. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report United Rentals, Inc. (URI): Free Stock Analysis Report PPG Industries, Inc. (PPG): Free Stock Analysis Report Pool Corporation (POOL): Free Stock Analysis Report Snap-On Incorporated (SNA): Free Stock Analysis Report To read this article on Zacks.com click here. 5 Amazing Earnings Charts This Week Abbott Labs ABT has a perfect record and the shares have finally broken out to new highs. PPG Industries PPG hasn't missed in 5 years but shares have been stuck in a narrow trading range the last 3 years. | Zacks Investment Research reports that the 2018 Price to Earnings ratio for ABT is 20.72 vs. an industry ratio of -21.00, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories ( ABT ) is reporting for the quarter ending March 31, 2018. In the past year ABT has beat the expectations every quarter."
2018-04-16,59.0,59.27000045776367,0.2514630466799984,Can Instruments Drive Intuitive Surgical (ISRG) Q1 Earnings? | 3 Stocks to Buy Ahead of Earnings,"Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Cardinal Health, Inc. (CAH): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT has an Earnings ESP of +0.75% and a Zacks Rank #3. Intuitive Surgical, Inc. Price and Consensus Intuitive Surgical, Inc. Price and Consensus | Intuitive Surgical, Inc. Quote In 2017, the company had introduced da Vinci X and Xi surgical systems in response to customer needs. | Click to get this free report The PNC Financial Services Group, Inc (PNC): Free Stock Analysis Report Citigroup Inc. (C): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Honeywell International Inc. (HON): Free Stock Analysis Report E*TRADE Financial Corporation (ETFC): Free Stock Analysis Report JMP Group LLC (JMP): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT Shares of Abbott popped on Monday morning just a couple of days before the diversified healthcare company is set to report its first quarter earnings results. With that said, investors still need to be selective during earnings season and hunt for stocks that look poised to top quarterly earnings estimates."
2018-04-13,59.18000030517578,58.4900016784668,0.4576278945146981,Can Solid Medical Devices Drive Abbott's (ABT) Q1 Earnings?,"Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott 's ABT Medical Devices business has been on a strong growth trajectory of late on solid contributions from all sub-segments. Medical Device in Focus Abbott's Medical Device segment presently comprises the new Cardiovascular and Neuromodulation, Heart Failure, Electrophysiology, Structural Heart, Rhythm Management, Vascular businesses along with the Diabetes Care business."
2018-04-12,58.5,58.83000183105469,-1.1659321107651943,Can Solid EPD Business Drive Abbott's (ABT) Q1 Earnings?,"Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott 's ABT Established Pharmaceuticals Division (""EPD"") business has been recording operational sales growth in the last few quarters. Abbott Laboratories Price and EPS Surprise Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote We encouragingly note that, management expects high single-digit growth in EPD sales in the first quarter of 2018."
2018-04-11,58.63999938964844,58.45000076293945,0.5641056941105769,"Can Steady Overall Growth Drive Abbott's (ABT) Q1 Earnings? | Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for April 12, 2018","Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT is slated to report first-quarter 2018 results, before the market opens on Apr 18. Abbott Laboratories Price and EPS Surprise Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote We are also upbeat about the Diagnostics business which has been going strong on solid contributions from all sub-segments - Core Laboratories Diagnostics, Molecular Diagnostics and Point of Care. | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. The following ETF(s) have ABT as a top-10 holding: iShares U.S. Healthcare ETF ( IYH ) Vanguard Health Care ETF ( VHT ) Vanguard Div Appreciation ETF ( VIG ) iShares Global Healthcare ETF ( IXJ ) NuShares Enhanced Yield US Aggregate Bond ETF ( NULV )."
2018-04-10,59.02000045776367,59.13999938964844,-0.32400857552281,Will Buyouts Help Quest Diagnostics (DGX) Beat Q1 Earnings?,"Abbott Laboratories ABT has an Earnings ESP of +0.89% and a Zacks Rank of 3. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Abaxis,Inc. Quest Diagnostics Incorporated Price and EPS Surprise Quest Diagnostics Incorporated Price and EPS Surprise | Quest Diagnostics Incorporated Quote We are also optimistic about the company's successful execution of its strategy to build esoteric testing business as well as boost profitable growth."
2018-04-09,57.86000061035156,58.220001220703125,0.20331909683843555,,
2018-04-06,59.43999862670898,57.56999969482422,0.6221925450293823,,
2018-04-05,59.900001525878906,59.86000061035156,-3.1460278854119736,,
2018-04-04,58.34000015258789,59.459999084472656,-0.06677948999727813,"Health Care Sector Update for 04/04/2018: SNN,AMRN,GSK,LLY","Nawana previously was chief executive of Alere, a medical diagnostics firm acquired by Abbott Laboratories ( ABT ) last year in a $5.3 billion deal. Health care stocks were mostly higher, including a 1.0% gain for the NYSE Health Care Index in recent trade. Among health care stocks moving on news: -Smith & Nephew ( SNN ) still was on negative turf late in Wednesday trading, paring most of a 2% decline earlier in the session after the medical device company today named Namal Nawana to be its new chief executive officer, replacing Olivier Bohuon who had announced his retirement plans six months ago."
2018-04-03,58.400001525878906,59.0,1.9197787606366399,,
2018-04-02,59.81999969482422,58.209999084472656,1.0273946206237945,Abbott Starts GUIDE-HF Clinical Trial for CardioMEMS Device,"In a bid to fortify its Heart Failure business, AbbottABT recently announced the start of the - GUIDE-HF clinical trial - largest heart failure medical device study in the United States. Click to get this free report athenahealth, Inc. (ATHN): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. GUIDE-HF Cinical Trial in Detail The GUIDE-HF clinical trial will enroll 3,600 patients at 140 hospitals with stage C, NYHA Class II-IV heart failure along with either elevated brain-type natriuretic peptide (BNP) levels or prior heart failure hospitalizations in the past year across North America."
2018-03-29,59.56999969482422,59.91999816894531,-2.691408590045285,Sum Up The Pieces: SPLV Could Be Worth $51,"Below is a twelve month price history chart comparing the stock performance of ABT, CTSH, and APH: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of SPLV's underlying holdings with notable upside to their analyst target prices are Abbott Laboratories (Symbol: ABT), Cognizant Technology Solutions Corp. (Symbol: CTSH), and Amphenol Corp. (Symbol: APH). Although ABT has traded at a recent price of $59.23/share, the average analyst target is 13.33% higher at $67.12/share."
2018-03-28,60.52999877929688,59.22999954223633,0.5875415073260503,Trade War Fears Grip MedTech: 3 Stocks on the Line of Fire,"Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH): Free Stock Analysis Report Becton, Dickinson and Company (BDX): Free Stock Analysis Report To read this article on Zacks.com click here. Medtronic PLC Price Medtronic PLC Price | Medtronic PLC Quote Over the last few years, Abbott ABT has been leading the emerging market investment trend, with about 50% of total sales coming from this region. Going by a Market Realist report, companies like Medtronic plc MDT , Becton, Dickinson and Company BDX , Abbott and others saw considerable weakness on Mar 23 as talks of a U.S.-China trade war started doing the rounds."
2018-03-27,61.27000045776367,60.27999877929688,-2.147694140554309,"Notable ETF Inflow Detected - IWD, ABT, MDT, PNC","Among the largest underlying components of IWD, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.2%, Medtronic PLC (Symbol: MDT) is up about 0.3%, and PNC Financial Services Group (Symbol: PNC) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $59.9 million dollar inflow -- that's a 0.2% increase week over week in outstanding units (from 301,350,000 to 301,850,000). For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $112.39 per share, with $131.56 as the 52 week high point - that compares with a last trade of $119.78."
2018-03-26,60.27999877929688,61.06999969482422,-1.61580165018808,Is Pfizer's Best Option Now a Consumer Healthcare Spinoff?,"One other possibility is Abbott Labs (NYSE: ABT) . However, the front-runner for buying Pfizer's consumer healthcare business, GlaxoSmithKline (NYSE: GSK) , dropped out of the bidding on March 23. Dropping like flies In 2006, Pfizer sold its consumer healthcare business to Johnson & Johnson (NYSE: JNJ) for $16.6 billion."
2018-03-23,61.02999877929688,59.5,1.3105523084361141,,
2018-03-22,61.81999969482422,60.93000030517578,-2.5069618382753456,Baxter (BAX) Closes Acquisition of RECOTHROM & PREVELEAK | Can Boston Scientific's Pain be a Boon for Edwards & Others?,"Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. Considering the bullish market sentiments, we think this latest development is timely.A leading player in this niche space is Abbott ABT . Baxter International Inc.BAX has completed the acquisition of two hemostat and sealant products from Mallinckrodt plc to widen its existing surgical portfolio of hemostats and sealants, especially for intraoperative bleeding. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. Furthermore, post the acquisition of St. Jude Medical in 2017, Abbott Laboratories ABT integrated the popular CE Marked Portico TAVR of the former into its Structural Heart portfolio and is expected to gain momentum in this space. We note that some market speculators believe Edwards Lifesciences' solid global presence, particularly in high-potential regions like Europe and Japan, along with delay in the comeback of some key competitive products like Boston Scientific's Lotus Valve, will help the company further cement its hold in the highly potential TAVR space."
2018-03-21,62.75,62.41999816894531,-1.4396625591102215,,
2018-03-20,62.47999954223633,62.650001525878906,-0.5258993323580677,Abbott's MitraClip Therapy Wins Reimbursement Nod From MHLW | Goldman Sachs Backs Emerging Markets: MedTech Stocks in Focus,"Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. The Ministry of Health Labour and Welfare (""MHLW"") in Japan granted national reimbursement to Abbott 's ABT MitraClip therapy. The MitraClip system is approved in Japan for the treatment of both severe degenerative mitral regurgitation (""DMR"") and functional mitral regurgitation (""FMR"") heart diseases. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT continues to lead the emerging market investment trend with about 50% of sales from this region. Emerging Market Healthcare Scenario Way Better Than the United States While Patel particularly talked about the growing prospects of the Indian healthcare market, data shows that the prospects of the broader emerging market are equally encouraging."
2018-03-19,63.130001068115234,62.2599983215332,0.27209024469927723,5 Dividend Growth Stocks With Upside To Analyst Targets,"But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential: Another consideration with dividend growth stocks is just how much the dividend is growing ."
2018-03-16,62.77999877929688,63.18000030517578,-1.3781129920199533,,
2018-03-15,63.04999923706055,62.59000015258789,0.6371480306731204,"Noteworthy ETF Inflows: IHI, ABT, BDX, SYK","Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.1%, Becton, Dickinson & Co (Symbol: BDX) is up about 0.5%, and Stryker Corp (Symbol: SYK) is up by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $85.7 million dollar inflow -- that's a 5.0% increase week over week in outstanding units (from 9,050,000 to 9,500,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $149.14 per share, with $194.27 as the 52 week high point - that compares with a last trade of $190.81."
2018-03-14,63.41999816894531,62.86000061035156,-0.7295782554145862,,
2018-03-13,63.88999938964844,63.20000076293945,-0.8829983834152212,10 Dividend Aristocrats You Never Have to Worry About,"Source: Flickr Dividend Aristocrats to Buy: Abbott Laboratories (ABT) It's one of those companies that's easy to forget. Abbott Laboratories (NYSE: ABT ) makes a little of everything, and the diagnostics and diabetes care landscape would look much different without Abbott. Source: Dawn Via Flickr Dividend Aristocrats to Buy: Johnson & Johnson (JNJ) Like Texas Instruments, Johnson & Johnson (NYSE: JNJ ) may be one of the most boring health product companies an investor could think of."
2018-03-12,63.59000015258789,63.619998931884766,-1.0799790785735695,,
2018-03-09,62.04999923706055,63.59999847412109,0.047175309364508866,Is Big Pharma Using Corporate Tax Savings to Lower Drug Costs?,"Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. The Senator has sent letters to CEOs of Pfizer Inc. PFE , Merck & Co., Inc. MRK , Johnson & Johnson JNJ , AbbVie Inc. ABBV and Abbott Laboratories ABT to provide the details of how they intend to utilize major savings from the tax overhaul. Last week, Senator Tina Smith in letters to five big pharma companies, expressed concern about how big pharma companies plan to used billions of dollars they will save from the tax cut offered under the tax bill passed in December 2017."
2018-03-08,61.34000015258789,61.869998931884766,2.497984296726265,,
2018-03-07,60.27000045776367,61.290000915527344,0.8640345255599331,"Abbott Gets FDA Nod for Masters HP 15mm, Boosts Portfolio","Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report PerkinElmer, Inc. (PKI): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT has been in the limelight since the receipt of FDA approval for the world's smallest rotatable, bileaflet mechanical heart valve - Masters HP 15mm. A Glimpse of the Structural Heart Business Abbott's Medical Device segment presently comprises the new Cardiovascular and Neuromodulation, Heart Failure, Electrophysiology, Structural Heart, Rhythm Management, Vascular businesses along with the Diabetes Care business."
2018-03-06,60.59000015258789,60.880001068115234,1.6923850174490593,iShares Russell 1000 Value ETF Experiences Big Inflow,"Among the largest underlying components of IWD, in trading today General Electric Co (Symbol: GE) is up about 1.3%, Abbott Laboratories (Symbol: ABT) is up about 0.3%, and Medtronic PLC (Symbol: MDT) is higher by about 1.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $123.5 million dollar inflow -- that's a 0.3% increase week over week in outstanding units (from 298,800,000 to 299,800,000). For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $112.39 per share, with $131.56 as the 52 week high point - that compares with a last trade of $123.57."
2018-03-05,58.90999984741211,60.369998931884766,0.4786283459267451,Here's My Top Stock to Buy in March,"However, March is a great month to buy stocks, because for long-term investors, the sooner you buy a great stock, the more time you have to accumulate gains. Here's why AbbVie (NYSE: ABBV) is my top stock to buy in March. Dividend AbbVie stock is up more than 80% over the past 12 months and more than 15% so far this year."
2018-03-02,58.47999954223633,59.459999084472656,2.478355267788705,,
2018-03-01,60.15999984741211,58.790000915527344,1.675785824055176,"Zacks Industry Outlook Highlights: Abbott, Becton and Dickinson, Stryker, Varian Medical and Boston Scientific","Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report Becton, Dickinson and Company (BDX): Free Stock Analysis Report To read this article on Zacks.com click here. For Immediate Release Chicago, IL - March 1, 2018 - Today, Zacks Equity Research discusses the Industry: Medical Devices, Part 2, including Abbott ABT , Becton, Dickinson and Co.BDX , StrykerSYK , Varian MedicalVAR and Boston ScientificBSX. Industry: Medical Devices, Part 2 Link: https://www.zacks.com/commentary/151130/medtechs-long-term-prospects-outweigh-near-term-risks In the past few years, the U.S. medical device market has undergone substantial transformation."
2018-02-28,60.66999816894531,60.33000183105469,-2.2772588686163346,"Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Covidien and Smith & Nephew, Abbott Labs and Boston Scientific","Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic plc (MDT): Free Stock Analysis Report Smith & Nephew SNATS, Inc. (SNN): Free Stock Analysis Report To read this article on Zacks.com click here. For Immediate Release Chicago, IL - Feb 28, 2018 - Today, Zacks Equity Research discusses the Industry: Medical Devices, Part 1, including Johnson & JohnsonJNJ , MedtronicMDT , Covidien and Smith & NephewSNN , Abbott LabsABT and Boston ScientificBSX. Zacks Industry Rank Within the Zacks Industry classification, Medical Device is broadly grouped into the Medical sector (one of the 16 Zacks sectors) and further sub-divided into four industries at the expanded level: Medical - Instruments, Medical - Products, Medical - Dental Supplies and Medical Info Systems."
2018-02-27,60.75,60.54999923706055,-0.5604027495498696,Mid-Day Update: Stocks Turn Negative as Powell Spooks Wall Street With Hint of Four Rate Hikes,"(+) MNK (+21.87%) Fiscal Q4 results top expectations (+) LXU (+16.25%) Q4 loss narrowed, but revenue rose less-than-expected (+) DDS (+12.69%) Reported better-than-expected Q4 results (+) SRDX (+11.03%) Reported an agreement with Abbott Labs ( ABT ) for next-generation drug-coated balloon NYSE Composite Index was down 66.70 points (-0.62%) to 12,919.13 Dow Jones Industrial Index was down 38.29 points (-0.15%) to 25,670.98 S&P 500 was down 12.57 points (-0.45%) to 2,767.02 Nasdaq Composite Index was down 66.25 points (-0.90%) to 7,354.75 FTSE 100 was up 12.76 points (+0.18%) to 7,302.34 DAX was down 17.78 points (-0.14%) to 12,509.26 CAC 40 was up 6.27 points (+0.12%) to 5,350.53 Nikkei 225 was up 236.23 points (+1.07%) to 22,389.86 Hang Seng Index was down 229.94 points (-0.73%) to 31,268.66 Shanghai China Composite Index was down 38.05 points (-1.14%) to 3,291.53"
2018-02-26,59.86000061035156,60.52999877929688,-0.3292193628632973,George Soros Just Bought These 2 Biotech Stocks. Should You?,"Its once high-flying shares, however, have been in a tailspin over the last few months -- thanks to the FDA approval of Abbott Laboratories ' (NYSE: ABT) competing FreeStyle Libre System and its subsequent coverage by Medicare and Medicaid. In the high-growth biotech space, the fund initiated new, albeit modest, positions in both the diabetes device maker DexCom (NASDAQ: DXCM) and the clinical-stage drugmaker AnaptysBio, Inc. (NASDAQ: ANAB) , according to the latest 13F filings with the U.S. Securities and Exchange Commission. The company is also on track to reportedly launch its own ""no-calibration"" G6 continuous glucose monitoring device later this year, and its G5 system did reportedly outperform Abbott's FreeStyle Libre System in terms of the time required to detect hypoglycemia in people with type 1 diabetes in a head-to-head study earlier this year."
2018-02-23,59.220001220703125,59.709999084472656,1.1192752457631234,"IUSG, MCD, ABT, AMGN: ETF Inflow Alert | Abbott (ABT) Down 6.7% Since Earnings Report: Can It Rebound?","Among the largest underlying components of IUSG, in trading today McDonald's Corp (Symbol: MCD) is up about 0.9%, Abbott Laboratories (Symbol: ABT) is up about 0.2%, and Amgen Inc (Symbol: AMGN) is up by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core S&P U.S. Growth ETF (Symbol: IUSG) where we have detected an approximate $72.6 million dollar inflow -- that's a 2.1% increase week over week in outstanding units (from 61,900,000 to 63,200,000). For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average: Looking at the chart above, IUSG's low point in its 52 week range is $48.59 per share, with $58.35 as the 52 week high point - that compares with a last trade of $56.08. | It has been about a month since the last earnings report for Abbott Laboratories ( ABT ). Will the recent negative trend continue leading up to its next earnings release, or is ABT due for a breakout? Abbott Laboratories Price and Consensus Abbott Laboratories Price and Consensus | Abbott Laboratories Quote VGM Scores At this time, ABT has a strong Growth Score of A, though it is lagging a bit on the momentum front with a B."
2018-02-22,59.209999084472656,58.9900016784668,0.8274195435143449,,
2018-02-21,59.06999969482422,58.9900016784668,-0.3715544830392539,There Are Better Options Than Medtronic PLC Stock,"We could compare it to stocks like Boston ScientificCorporation (NYSE: BSX ) or Abbott Laboratories (NYSE: ABT ). J&J vs. Medtronic Stock Entering the first quarter of fiscal 2018, analysts expect JNJ to grow sales and earnings 6.1% and 11% this year, respectively. Trading MDT Stock Price Despite the favoring of JNJ stock over Medtronic, MDT stock price actually has a pretty decent chart."
2018-02-20,59.68000030517578,59.119998931884766,-0.13542918024499567,,
2018-02-16,59.43999862670898,60.16999816894531,-0.9383400979011879,"Cardiovascular Systems Portfolio Solid, Competition Rife | Abbott Laboratories Jumps After Boosting Quarterly Dividend","Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report PerkinElmer, Inc. (PKI): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report To read this article on Zacks.com click here. Larger competitors in the stent and balloon angioplasty market segments include bigwigs like Abbott Laboratories ABT . The company witnessed year-over-year rise in revenues at both coronary arterial disease (CAD) and coronary arterial disease (PAD) businesses. | Abbott Laboratories ( ABT ) popped Friday after the medical giant announced it raised its dividend to 28 cents, marking the 377th consecutive quarterly dividend to be paid by Abbott since 1924. Its 12-month dividend yield is 1.87% and the firm has a three-year dividend growth of 6.1%, a spokesperson told Investor's Business Daily. Why Biogen May Seek A Merger In The Wake Of Alzheimer's Worries AbbVie Stock Rises After Increasing Dividend By 35% This Biotech Stock May Need Anesthesia After Collapsing Nearly 20% The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2018-02-15,58.720001220703125,59.5,1.2281284641691002,"Noteworthy ETF Outflows: IWB, MDT, UNP, ABT | Did AbbVie, Inc. Just Become the Most Shareholder-Friendly Stock in America? | A Snapshot Of Abbott Labs' Business","Among the largest underlying components of IWB, in trading today Medtronic PLC (Symbol: MDT) is up about 0.9%, Union Pacific Corp (Symbol: UNP) is down about 0.6%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $210.0 million dollar outflow -- that's a 1.0% decrease week over week (from 133,450,000 to 132,050,000). For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $128.86 per share, with $159.31 as the 52 week high point - that compares with a last trade of $150.77. | Management also has high hopes for its hepatitis C drug Mavyret, predicting last month its sales could drive hepatitis C revenue up to $2.5 billion this year from $1.3 billion in 2017. Rova-T, a solid-tumor cancer drug, upadicitinib, a rheumatoid arthritis drug, and risankizumab, a psoriasis drug are the three most exciting potential blockbuster drugs in AbbVie's pipeline. Given the additional clarity into Humira's future, a stable of fast-growing drugs, and multiple blockbusters making their way to market, AbbVie should have plenty of cash flow coming in to support dividend payments and buybacks. | Abbott Labs ( ABT ) struggled to generate significant growth in recent years, which in part prompted the company to make two significant acquisitions. Abbott's Revenue & EBITDA Composition The Medical Devices business is Abbott's largest segment, and accounts for nearly 39% of its revenue and gross profit. Abbott's Past Revenue & Gross Profit Growth Between 2012 and 2016, Abbott's revenue increased from $19 billion to $20.8 billion, growing at a CAGR of just 2.3%."
2018-02-14,57.31999969482422,58.27999877929688,1.3283357681911423,Analysts Anticipate XRLV To Hit $37 | 7 ‘Strong Buy’ Stocks That Look Cheap Right Now,"Below is a twelve month price history chart comparing the stock performance of ABT, BLK, and GD: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of XRLV's underlying holdings with notable upside to their analyst target prices are Abbott Laboratories (Symbol: ABT), BlackRock Inc (Symbol: BLK), and General Dynamics Corp. (Symbol: GD). Although ABT has traded at a recent price of $57.64/share, the average analyst target is 13.48% higher at $65.41/share. | Strong Buy Stock: Abbott Labs (ABT) - 12 analyst buy ratings vs two hold ratings in last three months - 21% upside potential from current share price to average analyst price target Global healthcare giant Abbott Laboratories (NYSE: ABT ) is down in the last week by around 6%. Let's delve in to these seven stock picks now: Strong Buy Stock: Facebook (FB) Source: Shutterstock - 28 analyst buy ratings, two hold ratings and one sell rating in last three months - 28% upside potential from current share price to average analyst price target Social media giant Facebook Inc (NASDAQ: FB ) hasn't escaped the recent pullback. Strong Buy Stock: Amazon (AMZN) - 35 analyst buy ratings vs two hold ratings in last three months - 14% upside potential from current share price to average analyst price target Even shares in one of the world's most exciting companies suffered last week, with shares off by 6.32% at $1,339."
2018-02-13,57.13999938964844,57.63999938964844,1.674806506601129,,
2018-02-12,57.70000076293945,57.40999984741211,0.8750437615345524,,
2018-02-09,56.630001068115234,57.16999816894531,-0.5026012334363963,,
2018-02-08,58.77000045776367,56.27000045776367,0.9535530472276758,,
2018-02-07,58.59999847412109,58.66999816894531,-4.2538709894968925,Vanguard Value ETF Experiences Big Outflow | 5 Dividend Aristocrats Where Analysts See Capital Gains,"Among the largest underlying components of VTV, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.7%, United Technologies Corp (Symbol: UTX) is up about 1.5%, and Qualcomm Inc (Symbol: QCOM) is higher by about 1.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Value ETF (Symbol: VTV) where we have detected an approximate $148.0 million dollar outflow -- that's a 0.4% decrease week over week (from 345,465,467 to 344,067,457). For a complete list of holdings, visit the VTV Holdings page » The chart below shows the one year price performance of VTV, versus its 200 day moving average: Looking at the chart above, VTV's low point in its 52 week range is $93.34 per share, with $113.35 as the 52 week high point - that compares with a last trade of $106.73. | Get the latest Zacks research report on CAH - FREE Get the latest Zacks research report on ABT - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect."
2018-02-06,57.91999816894531,58.86000061035156,0.11945340724733824,"3 Top-Rated Dividend Aristocrats For 2018 | Centene (CNC) Beats Q4 Earnings & Revenues, Ups '18 View","Abbott Labs (ABT) Multinational healthcare stock Abbott Laboratories is a first-class Dividend Aristocrat. For example, four-star Argus Research analyst David Toung has just ramped up his ABT price target from $66 to $80. As a result of the deal, ABT now boasts a big chronic pain management business and a significantly bolstered cardiovascular device offering. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Centene Corporation (CNC): Free Stock Analysis Report To read this article on Zacks.com click here. Among other players in the Medical sector that have reported their fourth-quarter earnings so far, AbbVie Inc. ABBV , UnitedHealth Group Incorporated UNH and Abbott Laboratories ABT have surpassed their respective Zacks Consensus Estimate. Centene reported total revenues of $48.4 billion, up 19% year over year."
2018-02-05,61.59999847412109,58.72999954223633,1.6229324432372767,,
2018-02-02,62.20000076293945,61.68999862670898,-4.659089290546785,How Much Can Abbott's Stock Move In 2018?,"2017 was a good year for Abbott ( ABT ), as the company's stock gained nearly 50%. We have created an interactive valuation calculator dashboard using Trefis' interactive technology where you can modify inputs such as P/E multiple and fundamentals determining Abbott's 2018 earnings (non-GAAP net income). If you have a different view, go to our interactive valuation calculator dashboard and modify the assumptions (blue dots) to come up with your own price estimate for Abbott."
2018-02-01,61.75,62.18000030517578,-0.8199391157151718,"Boston Scientific Tops Fourth-Quarter Sales Views, Earnings In Line","At the same time, rival Abbott Laboratories ( ABT ) ticked up 2 cents to 62.18. Boston Scientific ( BSX ) issued a better-than-expected 2018 outlook on Thursday helped, in part, by stronger sales in its MedSurg unit, which topped the consensus by nearly 3% in the fourth quarter. March-quarter guidance for $2.32 billion to $2.35 billion in sales beat the consensus for $2.295 billion."
2018-01-31,62.65999984741211,62.15999984741211,0.6963567695154352,,
2018-01-30,62.43999862670898,62.43999862670898,-0.7979572314356624,"VTV, GE, AMGN, ABT: ETF Inflow Alert | HCA Healthcare's (HCA) Q4 Earnings, Revenues Beat Estimates (Revised)","Among the largest underlying components of VTV, in trading today General Electric Co (Symbol: GE) is down about 1.1%, Amgen Inc (Symbol: AMGN) is off about 2.2%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Value ETF (Symbol: VTV) where we have detected an approximate $129.9 million dollar inflow -- that's a 0.3% increase week over week in outstanding units (from 344,312,330 to 345,465,467). For a complete list of holdings, visit the VTV Holdings page » The chart below shows the one year price performance of VTV, versus its 200 day moving average: Looking at the chart above, VTV's low point in its 52 week range is $92.85 per share, with $113.46 as the 52 week high point - that compares with a last trade of $111.61. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report HCA Holdings, Inc. (HCA): Free Stock Analysis Report To read this article on Zacks.com click here. Among other players in the Medical sector that have reported their fourth-quarter earnings so far, AbbVie Inc. ABBV , UnitedHealth Group Inc. UNH and Abbott Laboratories ABT have surpassed their respective Zacks Consensus Estimate. For 2017, the company reported revenues of $43.6 billion, up 5% year over year."
2018-01-29,63.09000015258789,63.310001373291016,0.0,"MedTech Stock Q4 Earnings Slated for Jan 30: SYK, ZBH, ALGN","Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. This is evident from the results of MedTech heavyweights AbbottABT and Intuitive SurgicalISRG . Zimmer Biomet Holdings, Inc. Price and Consensus Zimmer Biomet Holdings, Inc. Price and Consensus | Zimmer Biomet Holdings, Inc. Quote Align Technology, Inc ALGN ) is set to report results after the market closes."
2018-01-26,63.150001525878906,63.41999816894531,0.3487101286591149,This Explains Why Senseonics Holdings Inc. Is Falling Today | ABT Crosses Above Average Analyst Target | Boston Scientific's (BSX) Millipede Deal Aids MR Business | Don’t Chase AbbVie Inc Stock After Its Huge Earnings Win,"What happened In response to sharing the pricing details of a convertible note offering and providing investors with a preliminary look at results from its fourth quarter, shares of Senseonics Holdings (NYSEMKT: SENS) , a diabetes company focused on continuous glucose monitoring, fell 11% as of 11:05 a.m. EST on Friday. The notes mature on Feb. 1, 2023, and can be converted into common stock at a price of $3.40 per share. Personally, I think that Senseonics' device does look compelling, but this company is losing money hand-over-fist right now, so I have no interest in buying this stock. | And so with ABT crossing above that average target price of $61.76/share, investors in ABT have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $61.76 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? In recent trading, shares of Abbott Laboratories (Symbol: ABT) have crossed above the average analyst 12-month target price of $61.76, changing hands for $63.22/share. But the whole reason to look at the average ABT price target in the first place is to tap into a ""wisdom of crowds"" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. Apart from Boston Scientific, other major players in this field are Edwards Lifesciences Corporation EW , Medtronic plc MDT and Abbott ABT . Boston Scientific CorporationBSX has recently announced a major investment in Santa Rosa, CA-based Millipede, Inc., to augment its position in the field of mitral regurgitation (MR). | AbbVie has been a phenomenal performer since its late 2012 spinoff from Abbott Laboratories (NYSE: ABT ), gaining 236%. InvestorPlace - Stock Market News, Stock Advice & Trading Tips From a fundamental perspective, it's difficult to find anything wrong with AbbVie Inc (NYSE: ABBV ). ABBV Stock Is Cheap, But Not Cheap Enough AbbVie has a pair of drugs in the pipeline that hopefully will cushion any declines in Humira."
2018-01-25,63.18000030517578,63.220001220703125,0.42754811804044296,,
2018-01-24,61.0,61.720001220703125,0.06331262319425286,"Markets Keep Gaining Amid Strong Corporate Earnings | Plethora of Q4 Earnings Amid New Market Highs | Abbott (ABT) Tops Q4 Earnings and Revenues, Issues Guidance | Abbott (ABT) Beats Earnings and Revenue Estimates in Q4 | Health Care Sector Update for 01/24/2018: JNJ, PFE, ABT, MRK, AMGN, STML, AERI, BSX | Abbott Spikes To Record After Topping Quarterly Expectations | Earnings Reaction History: Abbott Laboratories, 63.6% Follow-Through Indicator, 2.4% Sensitive | Wednesday Sector Leaders: Healthcare, Materials","Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report General Dynamics Corporation (GD): Free Stock Analysis Report Comcast Corporation (CMCSA): Free Stock Analysis Report United Technologies Corporation (UTX): Free Stock Analysis Report General Electric Company (GE): Free Stock Analysis Report Illinois Tool Works Inc. (ITW): Free Stock Analysis Report To read this article on Zacks.com click here. Abbot Labs ABT beat by a penny to 74 cents per share, on revenues of $7.59 billion that easily topped the Zacks consensus estimate of $7.36 billion. For more on ABT's earnings, click here. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report General Dynamics Corporation (GD): Free Stock Analysis Report Comcast Corporation (CMCSA): Free Stock Analysis Report United Technologies Corporation (UTX): Free Stock Analysis Report General Electric Company (GE): Free Stock Analysis Report Illinois Tool Works Inc. (ITW): Free Stock Analysis Report To read this article on Zacks.com click here. Abbot Labs ABT beat by a penny to 74 cents per share, on revenues of $7.59 billion that easily topped the Zacks consensus estimate of $7.36 billion. For more on ABT's earnings, click here. | Abbott ABT reported fourth-quarter 2017 adjusted earnings from continuing operations of 74 cents per share, beating the Zacks Consensus Estimate by a penny. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Amedisys Inc (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. Diagnostics sales rose 51.7% year over year on a reported basis (up 6.7% on a comparable operational basis). | AbbottABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories Price and EPS Surprise Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote Abbott has an impressive track record as the company beat estimates in the last four trailing quarters with an average positive earnings surprise of 4.67%. | Expected movers: - Abbott Laboratories ( ABT ): reports Q4 earnings increase; revenue tops estimates - Stemline Therapeutics ( STML ): prices public offering of 3.7 million shares at a premium - Aerie Pharmaceuticals ( AERI ): prices $75 million share offering Other news: - Boston Scientific ( BSX ): invests in Millipede, has option to acquire remaining shares The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. MRK: flat All rights reserved. | Abbott Laboratories ( ABT ) popped to a record high Wednesday after beating fourth-quarter sales and earnings forecasts - quelling worries that shares would plateau following a big run-up in 2017. Diagnostics and medical device sales benefited from Abbott's acquisitions of Alere and St. Jude Medical, respectively. Why These 3 Biotech Stocks Could Outperform Their Peers In 2018 How Electricity Could Replace Opioids In Treating Chronic Pain The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 62.5% Average next regular session additional gain: 2.1% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 62.5% of the time (5 events) the stock posted additional gains in the following regular session by an average of 2.1%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 66.7% Average next regular session additional loss: 2.7% Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 66.7% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close. Extended-Hours Dollar Volume: $1,821,035 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Within that group, Abbott Laboratories (Symbol: ABT) and McKesson Corp (Symbol: MCK) are two of the day's stand-outs, showing a gain of 4.0% and 2.6%, respectively. Combined, ABT and MCK make up approximately 3.8% of the underlying holdings of XLV. Among healthcare ETFs , one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is up 0.4% on the day, and up 7.54% year-to-date."
2018-01-23,59.52000045776367,59.22999954223633,1.180329870005123,"This Week's Amazing Earnings Charts | Pre-Market Earnings Report for January 24, 2018 : CMCSA, GE, UTX, ABT, GD, ITW, NSC, TEL, PGR, NVS, APH, RCL","Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report United Rentals, Inc. (URI): Free Stock Analysis Report Honeywell International Inc. (HON): Free Stock Analysis Report Illinois Tool Works Inc. (ITW): Free Stock Analysis Report Starbucks Corporation (SBUX): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ABT hasn't missed since early 2007. It's not easy beating the earnings estimate every quarter, or nearly every quarter, for several years. | Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABT is 23.83 vs. an industry ratio of -57.90, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories ( ABT ) is reporting for the quarter ending December 31, 2017. In the past year ABT has beat the expectations every quarter."
2018-01-22,58.880001068115234,59.56999969482422,-0.4872327172328115,"Noteworthy ETF Outflows: IWB, AMGN, GILD, ABT","Among the largest underlying components of IWB, in trading today Amgen Inc (Symbol: AMGN) is up about 1.1%, Gilead Sciences Inc (Symbol: GILD) is up about 0.9%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $109.2 million dollar outflow -- that's a 0.5% decrease week over week (from 135,550,000 to 134,850,000). For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $125.58 per share, with $156.60 as the 52 week high point - that compares with a last trade of $156.50."
2018-01-19,59.22999954223633,59.310001373291016,1.1718726463859275,Can Diagnostics Business Drive Abbott's (ABT) Q4 Earnings?,"Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott 's ABT Diagnostics business has been on a growth trajectory of late on solid contributions from all sub-segments - Core Laboratories Diagnostics, Molecular Diagnostics and Point of Care. Interestingly, the company also continued the initial launch of certain new Alinity systems for the core laboratory, including ""Alinity c"" for clinical chemistry, ""Alinity i"" for immunoassay diagnostics and ""Alinity s"" for blood and plasma screening globally during the last reported third quarter."
2018-01-18,58.77999877929688,59.06999969482422,0.13506978165285816,Can EPD & Medical Devices Drive Abbott's (ABT) Q4 Earnings?,"Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT is slated to report fourth-quarter 2017 results, before the market opens on Jan 24. Abbott Laboratories Price and EPS Surprise Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote Moreover, last September, the company announced the receipt of national reimbursement for FreeStyle Libre in the U.K., marking another milestone for the company."
2018-01-17,58.7599983215332,58.9900016784668,0.49336665796168566,General Electric (GE): Does Breaking Up Make Sense?,"After all, a breakup has worked wonders for the likes of Alcoa (AA), Abbott Labs (ABT) and Mondelez (MDLZ). While announcing on Tuesday that its insurance business, which is part of the slimmed-down GE Capital, would take a $6.2 billion charge for the fourth quarter, CEO John Flannery also shared his vision for a segmented vision. “GE’s sum-of-the-parts valuation is below the current stock price, and that was true before [the] announcement today,” the analysts said in a research note Tuesday."
2018-01-16,58.88999938964844,58.43999862670898,0.391428460693653,5 Soaring ‘Strong Buy’ Stocks Ahead of Earnings Season,'Strong Buy' Stock: Abbott Laboratories (ABT) Source: Phalinn Ooi via Flickr Multinational healthcare stock Abbott Laboratories (NYSE: ABT ) is due to report results on January 24. This is because ABT still trades in line with peers despite a premium growth profile. Upgrading ABT brings Lewis in line with the bullish 'Strong Buy' consensus for ABT.
2018-01-12,58.959999084472656,58.84000015258789,-0.7641378291787866,iShares Edge MSCI USA Momentum Factor ETF Experiences Big Inflow | Abbott's (ABT) Diabetes Care Unit Strong on FreeStyle Libre | 3 of the Best Dividend Aristocrats for Retirement,"Among the largest underlying components of MTUM, in trading today McDonald's Corp (Symbol: MCD) is up about 0.1%, Adobe Systems Inc (Symbol: ADBE) is up about 0.8%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Edge MSCI USA Momentum Factor ETF (Symbol: MTUM) where we have detected an approximate $507.6 million dollar inflow -- that's a 8.7% increase week over week in outstanding units (from 54,000,000 to 58,700,000). For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year price performance of MTUM, versus its 200 day moving average: Looking at the chart above, MTUM's low point in its 52 week range is $76.67 per share, with $108.71 as the 52 week high point - that compares with a last trade of $108.61. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT has been hogging the limelight for developments in the flagship, sensor-based continuous glucose monitoring (CGM) system - FreeStyle Libre System. The company has been witnessing solid growth in the global Diabetes Care business, primarily on the back of solid contributions from FreeStyle Libre. | Dividend Aristocrats for Retirement: AbbVie Inc (ABBV) Source: Black Stripe via Wikimedia (Modified) Dividend Yield: 2.8% AbbVie Inc (NYSE: ABBV ) is the spinoff from Abbott Laboratories (NYSE: ABT ). 7 Stocks With 'Tax Cut' Dividend Increases on Tap I've got three Dividend Aristocrats that not only pay that yummy dividend, but that I think have a pretty decent shot at growing earnings enough that their stock prices should also rise to breach the 10% annual level. Dividend Aristocrats for Retirement: Old Republic International Corporation (ORI) Source: Pictures of Money via Flickr Dividend Yield: 3.8% The first stop for any retired investor, or a Dividend Aristocrats choice, should be an insurance stock like Old Republic International Corporation (NYSE: ORI )."
2018-01-11,58.650001525878906,58.95000076293945,-0.20352600703545093,Miles White's Bold Moves Made Abbott Laboratories A Global Force,"When Miles White was named CEO of Abbott Laboratories ( ABT ) in 1998 at 43, he was the youngest head of a major health care company. It seemed crazy to many, but White perceived that developing new drugs had a completely different business rhythm than what the new Abbott would now focus on: devices, diagnostics, nutritional products and branded generic drugs. White was hired by Abbott, based in the north Chicago suburb of Abbott Park, Ill., in 1984 as a director of sales in diagnostics, and four years later he was offered a chance to head the division's growing Asia-Pacific region - a prestigious position for a 33-year-old."
2018-01-10,58.75,58.83000183105469,0.5115076372643814,"Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for January 11, 2018","Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. The following ETF(s) have ABT as a top-10 holding: First Trust Nasdaq Pharmaceuticals ETF ( FTXH ) iShares U.S. Healthcare ETF ( IYH ) Vanguard Health Care ETF ( VHT ) Vanguard Div Appreciation ETF ( VIG ) AdvisorShares Vice ETF ( ACT )."
2018-01-09,59.09999847412109,58.91999816894531,0.13617332945478725,"Ex-Dividend Reminder: Patterson Companies, AbbVie and Abbott Laboratories","Looking at the universe of stocks we cover at Dividend Channel , on 1/11/18, Patterson Companies Inc (Symbol: PDCO), AbbVie Inc (Symbol: ABBV), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Patterson Companies Inc (Symbol: PDCO) : AbbVie Inc (Symbol: ABBV) : Abbott Laboratories (Symbol: ABT) : In general, dividends are not always predictable, following the ups and downs of company profits over time. Similarly, investors should look for ABBV to open 0.71% lower in price and for ABT to open 0.47% lower, all else being equal."
2018-01-08,58.84999847412109,58.81999969482422,-0.3045690521541947,,
2018-01-05,59.040000915527344,58.9900016784668,-0.05097498738264142,A Look At Johnson & Johnson's Medical Devices Segment,"Johnson & Johnson's ( JNJ ) Medical Devices segment accounts for 35% of the company's value, according to our estimates. Take a look at our interactive dashboard of JNJ's business , which shows how its Medical Devices segment will perform in the coming years, compared to the company's other segments. Medical Devices Revenue Composition Key Factors To Future Growth Changing dynamics in the women's health market - with the rise of sub-specialties, particularly in gynecology - should result in a larger addressable market for the company."
2018-01-04,59.5,58.81999969482422,-0.08468705332861406,This News Explains Why DexCom Is Dropping Today,"Investors are reacting harshly to the news that Abbott Laboratories ' (NYSE: ABT) FreeStyle Libre System has gained coverage by Medicare and Medicaid. Today's news only adds to those fears since DexCom's system was the only continuous glucose monitoring device that had previously secured Medicare coverage . Overall, today's update certainly isn't good news for DexCom's investors but isn't the end of the world either."
2018-01-03,58.9900016784668,58.91999816894531,-1.1428576557576156,Abbott Boosts Diagnostics Arm With Alinity H-Series Launch | Why This Is the Perfect Level to Buy Celgene Corporation Stock,"Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Qiagen N.V. (QGEN): Free Stock Analysis Report Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT has hit the headlines following the announcement of the receipt of CE Mark and commercial launch of Alinity h-series integrated system for hematology testing. Recent Developments in Diagnostics This Illinois-based global medical device company recently signed a $252-million managed equipment service contract with North West London Pathology (NWLP), hosted by Imperial College Healthcare NHS Trust to gain traction in the rapidly growing diagnostics market. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips When investors are looking for high growth and reasonable valuations in the biotech space, Celgene Corporation (NASDAQ: CELG ) is one of the first companies to come to mind. Decaying sentiment and negative analyst commentary wore on the CELG stock price. But it wasn't until mid-October until things really went sour."
2018-01-02,58.20000076293945,58.790000915527344,-0.11867012634284745,"US Stocks Higher as Oil Prices Hold at Two-Year Highs, Manufacturing Activity Rises","In equities, shares in Abbott Laboratories ( ABT ) were 3.5% higher after the manufacturer of a range of healthcare products said it had received a CE mark and launched its Alinity h-series integrated system for hematology testing. US equity benchmarks were in rude health on the first trading day of the new year with oil prices holding close to two-year highs and a closely-watched gauge of US manufacturing activity surpassing expectations. In economic news, the final December manufacturing purchasing managers index (PMI), which provides a numerical indication of manufacturing activity in the US, rose to 55.1 in December, according to research company IHS Markit which produces the gauge, up from 53.9 in November."
2017-12-29,57.59999847412109,57.06999969482422,1.0137459533567401,AbbVie Inc Dividend at Risk Amid Patent Protection Problems,"AbbVie began trading as an independent company in 2013, after it was spun off from fellow pharmaceutical Dividend Aristocrat, Abbott Laboratories (NYSE: ABT ). Source: 2017 AbbVie Strategic Update , page 5 From 2013-2017, revenue and adjusted earnings-per-share rose for AbbVie stock at a compound annual rate of 11% and 16%, respectively, thanks in large part to the success of Humira. Source: 2017 AbbVie Strategic Update , page 11 This is a significant risk for AbbVie, since Humira itself represents two-thirds of the company's revenue."
2017-12-28,57.43999862670898,57.459999084472656,-0.9201367939879187,,
2017-12-27,57.09000015258789,57.470001220703125,0.03481973927899606,iShares Russell 1000 Value ETF Experiences Big Inflow,"Among the largest underlying components of IWD, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.8%, Amgen Inc (Symbol: AMGN) is up about 0.6%, and US Bancorp (Symbol: USB) is higher by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $93.3 million dollar inflow -- that's a 0.2% increase week over week in outstanding units (from 330,200,000 to 330,950,000). For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $111.60 per share, with $125.36 as the 52 week high point - that compares with a last trade of $124.51."
2017-12-26,57.0099983215332,57.0,0.6656175636706648,,
2017-12-22,56.93999862670898,56.93000030517578,-0.01753783867316247,"The Zacks Analyst Blog Highlights: Pfizer, FedEx, Abbott, Biogen and Marathon Petroleum","Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Marathon Petroleum Corporation (MPC): Free Stock Analysis Report FedEx Corporation (FDX): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include Pfizer PFE , FedExFDX , AbbottABT , BiogenBIIB and Marathon PetroleumMPC . Here are highlights from Thursday's Analyst Blog: Top Research Reports for Pfizer, FedEx and Abbott The Zacks Research Daily presents the best research output of our analyst team."
2017-12-21,57.13999938964844,56.93000030517578,-0.017559398971439533,Abbott (ABT) at a 52-Week High: What's Driving the Stock?,"Click to get this free report athenahealth, Inc. (ATHN): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Luminex Corporation (LMNX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Shares of AbbottABT rallied to a new 52-week high of $57.30 on Dec 20, closing the session nominally lower at $57.02. Factors Driving the Stock Alere Acquisition : Abbott's successful closure of the Alere acquisition after a prolonged legal battle has instilled confidence in investors."
2017-12-20,56.7400016784668,57.02000045776367,-0.3675167775915307,,
2017-12-19,56.5099983215332,56.79999923706055,0.4934768611456287,Why 2017 Was a Year to Remember for Johnson & Johnson,"Protecting Remicade A big question among Johnson & Johnson shareholders for 2017 was how autoimmune disease drug Remicade, would fare against biosimilar competition from Pfizer (NYSE: PFE) . Johnson & Johnson's strongest sales growth this year, however, came from its oncology lineup. Johnson & Johnson should also get help from new products next year."
2017-12-18,55.52000045776367,56.400001525878906,0.5131851427021518,,
2017-12-15,55.02999877929688,55.5,1.5850163199920848,"Health Care Sector Update for 12/15/2017: SGRY,ABT,GLYC,ECYT,TTPH,CASC","In other sector news: + Abbott Laboratories ( ABT ) declared a 5.7% increase in its quarterly cash dividend over its most recent distribution to $0.28 per share. Health care stocks were starting to struggle somewhat Friday afternoon, increasingly lagging the broader markets, including a slightly more than 0.6% gain for the NYSE Health Care Index in recent trading. Shares of health care companies in the S&P 500 were up more than 1.4% as a group while the Nasdaq Biotechnology index ( NBI ) raced nearly 1.0% higher today."
2017-12-14,55.04999923706055,54.72999954223633,0.8540818301452325,Medtronic a Top Ranked SAFE Dividend Stock With 2.2% Yield (MDT),"MDT operates in the Medical Instruments & Supplies sector, among companies like 3M Co ( MMM ), and Abbott Laboratories ( ABT ). 25'' list, signifying a stock with above-average ''DividendRank'' statistics including a strong 2.2% yield, as well as a superb track record of at least two decades of dividend growth, according to the most recent ''DividendRank'' report. According to the ETF Finder at ETF Channel , Medtronic PLC is a member of the iShares S&P 1500 Index ETF ( ITOT ), and is also an underlying holding representing 1.01% of the SPDR S&P Dividend ETF ( SDY ), which holds $167,898,987 worth of MDT shares."
2017-12-13,55.66999816894531,55.060001373291016,-0.5812891902980987,"Analysts Take Action on Health Care Stocks | Intersect ENT (XENT) SINUVA Implant Receives FDA Approval | Abbott Laboratories Clears Key Benchmark, Hitting 80-Plus RS Rating","BMO Capital Markets - a Bank of Montreal's subsidiary - raised its rating on shares of Abbott Laboratories ( ABT ) to Outperform from a previous rating of Market Perform. The U.S. health care stock has a market capitalization of $96.85 billion, a price-book (P/B) ratio of 3.02 versus an industry median of 2.94, a price-sales (P/S) ratio of 3.73 versus an industry median of 3.06 and a price-earnings (P/E) ratio of 43.85 versus an industry median of 30.77. The stock has a market capitalization of $110.99 billion, a price-book (P/B) ratio of 2.16 versus an industry median of 2.94, a price-sales (P/S) ratio of 3.80 versus an industry median of 3.06 and a price-earnings (P/E) ratio of 22.47 versus an industry median of 30.77. | A few other major market players engaged in the manufacturing of treatment products for sinusitis include Sanofi SNY , Abbott Laboratories ABT and Eli Lilly And Company LLY . Click to get this free report Sanofi (SNY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intersect ENT, Inc. (XENT): Free Stock Analysis Report To read this article on Zacks.com click here. Market Trends Buoy Optimism Introduction of new technologies and rapid innovations in healthcare market are creating opportunities for companies that are striving to make profits in the sinusitis treatment market. | On Wednesday, Abbott Laboratories ( ABT ) cleared a key performance benchmark, seeing its Relative Strength ( RS ) Rating jump into the 80-plus percentile with an improvement to 83, up from 80 the day before. IBD Stock Rating Upgrades: Rising Relative Strength Why Should You Use IBD's Relative Strength Rating? How Relative Strength Line Can Help You Judge A Stock The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2017-12-12,55.45000076293945,55.70000076293945,-1.0957370499691783,,
2017-12-11,54.77000045776367,54.93999862670898,0.45085662138906574,,
2017-12-08,54.65999984741211,54.63999938964844,0.3103855532672505,Abbott Laboratories (ABT) Chairman and CEO Miles D White Sold $15.1 million of Shares,"Chairman and CEO of Abbott Laboratories ( ABT ) Miles D White sold 276,886 shares of ABT on 12/06/2017 at an average price of $54.41 a share. CEO Recent Trades: Chairman and CEO Miles D White sold 10,644 shares of ABT stock on 12/06/2017 at the average price of $54.94. Chairman and CEO Miles D White sold 71,530 shares of ABT stock on 12/06/2017 at the average price of $54.83."
2017-12-07,54.7599983215332,54.68999862670898,-0.03659066560465569,,
2017-12-06,54.88999938964844,54.65999984741211,-0.12782997985721262,,
2017-12-05,54.63999938964844,54.790000915527344,-0.41901902859139606,,
2017-12-04,56.13999938964844,54.709999084472656,0.2745269537966431,,
2017-12-01,56.29999923706055,55.97999954223633,-2.5472039913122204,,
2017-11-30,55.66999816894531,56.369998931884766,-0.5683831246192501,,
2017-11-29,56.09000015258789,55.58000183105469,1.2574111477696046,"Health Care Sector Update for 11/29/2017: JNJ, PFE, ABT, MRK, AMGN, KOOL, CAPR, RXII | Boston Scientific Again Delays Heart Valve; Can It Catch Up To Rivals?","In sector news, Capricor Therapeutics ( CAPR ) shares rallied 27% after the company said that the US Food and Drug Administration has approved its investigational new drug application to conduct a new clinical trial of CAP-1002, its lead investigational therapy, in boys and young men in advanced stages of Duchenne muscular dystrophy. The randomized, double-blind, placebo-controlled clinical trial will be called the HOPE-2 Trial and is designed to evaluate the safety and efficacy of intravenous, repeat doses of CAP-1002 in boys and young men whose ability to walk has been seriously impaired by the loss of muscle function that occurs as Duchenne muscular dystrophy progresses. In other sector news, (+) RXII (+19.4%) Data show RXI-231 has potential to reduce pigmentation (-) KOOL (-8.3%) Plans registered public offering of shares The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Boston Scientific ( BSX ) dipped Wednesday after announcing another delay for its heart-valve replacement product, called Lotus Edge - a potential competitor to products from Medtronic ( MDT ) and Abbott Laboratories ( ABT ). Canaccord analyst Jason Mills lowered his worldwide transcatheter aortic heart valve replacement sales model for Boston in 2018, 2019, 2020 and 2021 by $70 million, $114 million, $67 million and $9 million, respectively. Medtronic Surges After Topping Quarterly Earnings Views How These Rivals Could Take A Chunk Of Medtronic's Heart-Unit Sales How Electricity Could Replace Opioids In Treating Chronic Pain The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2017-11-28,56.29999923706055,56.02000045776367,-0.9092499913456904,"Health Care Sector Update for 11/28/2017: JNJ, PFE, ABT, MRK, AMGN, EARS, EGLT, AZN","ABT: flat MRK: flat AMGN: flat Health care shares were mostly inactive in pre-market trading Tuesday. In sector news, Auris Medical ( EARS ) shares fell 55% after the company said Tuesday that a phase 3 clinical trial on AM-111 for the treatment of sudden deafness failed to meet its primary endpoint of a statistically significant improvement in hearing from baseline to day 28 compared to placebo for either active treatment groups. In other sector news, (+) EGLT (+9.2%) Study of abuse-deterrent oxycodone meets endpoint in pain reduction (-) AZN (-0.2%) European Medicines Agency accepts variation to Tagrisso drug application The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2017-11-27,56.16999816894531,56.150001525878906,-0.4973335401265165,3 Top Diabetes Stocks to Buy Now,"I think that Abbott Laboratories (NYSE: ABT) , Becton, Dickinson and Company (NYSE: BDX) , and Johnson & Johnson (NYSE: JNJ) will especially stand out over the next few years. Becton, Dickinson and Company Becton, Dickinson and Company's market cap of nearly $52 billion makes it the smallest of these three top diabetes stocks. If you're looking for a growth stock with a solid dividend that's also going to significantly impact how diabetes is managed, I think Abbott Labs is the best option."
2017-11-24,55.84999847412109,56.130001068115234,-0.03560022025683773,"Health Care Sector Update for 11/24/2017: JNJ, PFE, ABT, MRK, AMGN, TEVA, NKTR","MRK: flat AMGN: flat Health care shares were mostly flat in pre-market trading Friday. In sector news, Teva Pharmaceutical Industries ( TEVA ) rose 4.2% after Israel's Calcalist reported that is planning to cut between 20% and 25% of its workforce in Israel and to also cut about 10% of its employee base in the US. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2017-11-22,56.02999877929688,55.79999923706055,0.5013475409921292,"Global In Vitro Diagnostic Market Booms: Stocks in Focus | DexCom-Lily Partnership to Boost CGM Platform, Customer Base","Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Becton, Dickinson and Company (BDX): Free Stock Analysis Report To read this article on Zacks.com click here. On the other hand, Abbott's ABT recent acquisition of Alere should establish the company as the global leader in point-of-care testing, the fastest-growing segment of in vitro diagnostics market. The FDA approvals of Roche Holdings' RHHBY Hemlibra or Cobas Cdiff Nucleic acid test and Thermo Fisher Scientific's TMO slew of advancements in next-generation sequencing (the latest one being the FDA approved Oncomine Dx Target Test) clearly point toward the rapid emergence of in vitro diagnostics (IVD) in the MedTech space. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report To read this article on Zacks.com click here. However, the diabetes market is dominated by many well-established players, Abbott ABT being the most prominent one. Per the agreement, DexCom's flagship continuous glucose monitoring system (CGM) will be added to Lilly's Connected Diabetes Ecosystem."
2017-11-21,55.45000076293945,56.119998931884766,-0.41049356995759956,"Better Buy: AbbVie Inc. vs. Johnson & Johnson | Health Care Sector Update for 11/21/2017: JNJ, PFE, ABT, MRK, AMGN, ARDX, MDT, NVO","AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) co-market fast-growing cancer drug Imbruvica. The case for Johnson & Johnson Johnson & Johnson stands as the largest healthcare company in the world, with three multibillion-dollar business segments. Several of its top drugs experienced year-over-year sales declines of 10% or more in the last quarter, including neuroscience drugs Concerta and Risperdal Consta, cancer drug Velcade, diabetes drug Invokana, and anemia drug Procrit. | ABT: flat MRK: flat In sector news, Ardelyx ( ARDX ) shares rose 21% after the company said that it has decided to discontinue development of RDX7675 after it observed an unexpected side effect of decreased serum bicarbonate in an onset-of-action study of the treatment for hyperkalemia. In other sector news, (+) MDT(+1.4%) Posts fiscal Q2 EPS beat, revenue in line; maintains growth guidance for FY18 (-) NVO (-0.04%) Provides update on research & development, commercial strategies, and market dynamics The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2017-11-20,55.65999984741211,55.290000915527344,1.2082924431501763,"Trade of the Day: Abbott Laboratories (ABT) | Health Care Sector Update for 11/20/2017: JNJ, PFE, ABT, MRK, AMGN, DBVT, EGLT, ACOR","InvestorPlace - Stock Market News, Stock Advice & Trading Tips To receive further updates on this Abbott Laboratories (NYSE: ABT )trade as well as an alert when it's time to take profits, sign up for a risk-free trial of SlingShot Trader today. After experiencing some profit-taking in the aftermath of the company's most recent earnings announcement on Oct. 18, Abbott Laboratories (NYSE: ABT ) has stabilized and completed a bullish ""wedge"" continuation pattern on Thursday by breaking above the down-trending resistance level that started in mid-October. Medical-device companies like ABT have done well this year, but some have been concerned the industry could struggle if Congress fails to extend the two-year moratorium on the medical-device excise tax it put in place at the end of 2015 with the Consolidated Appropriations Act. | AMGN: flat Health care shares were mostly lower in pre-market trading Monday. In sector news, DBV Technologies ( DBVT ) shares were up more than 6% after the company said a phase 3 study of its Viaskin treatment for peanut allergies met its primary objective, showing it was well-tolerated with no new adverse events. In other sector news, (+) EGLT (+9.5%) Wins grant from the Danish Growth Fund's InnoBooster to develop Guardian technology outside of pain management (-) ACOR (-8.7%) Discontinues Tozadenant development program over safety issue."
2017-11-17,55.290000915527344,55.560001373291016,-0.6647483523160099,,
2017-11-16,55.11000061035156,55.540000915527344,0.48833505750195494,How These Rivals Could Take A Chunk Of Medtronic's Heart-Unit Sales,"Medtronic ( MDT ) will overcome Hurricane Maria's impact in fiscal 2018, but the maker of medical devices is expected to face growing competition from Abbott Laboratories ( ABT ) and Boston Scientific ( BSX ) in heart implants, an analyst said Thursday. Despite the mounting competition for its cardiac and vascular group, Novarro sees Medtronic as capable of pulling off its full-year guidance. How Electricity Could Replace Opioids In Treating Chronic Pain Edwards Lifesciences Crashes After Heart Valve Sales Miss Lofty Views Dow Component J&J Pops After Topping Views On Pharma Strength The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2017-11-15,54.77999877929688,54.83000183105469,0.7802582116012757,"Noteworthy ETF Inflows: IVE, MDT, ABT, GS | 3 Stocks for Retirees to Grow Their Nest Eggs","Among the largest underlying components of IVE, in trading today Medtronic PLC (Symbol: MDT) is down about 0.3%, Abbott Laboratories (Symbol: ABT) is off about 0.6%, and Goldman Sachs Group Incorporated (Symbol: GS) is lower by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares S&P 500 Value ETF (Symbol: IVE) where we have detected an approximate $59.8 million dollar inflow -- that's a 0.4% increase week over week in outstanding units (from 130,850,000.0 to 131,400,000.0). For a complete list of holdings, visit the IVE Holdings page » The chart below shows the one year price performance of IVE, versus its 200 day moving average: Looking at the chart above, IVE's low point in its 52 week range is $97.18 per share, with $110.30 as the 52 week high point - that compares with a last trade of $108.25. | Counting the years it was part of Abbott Labs (NYSE: ABT) , AbbVie has raised its dividend for 45 years in a row. A 5% dividend yield and lots of room to grow Matt Frankel (Welltower): Leading healthcare REIT Welltower is an excellent choice for retirees, with an excellent combination of reliable dividends and long-term growth potential. No rust growing on Nucor Rich Smith ( Nucor ): Three months ago, I suggested retirees could "" build their nest egg out of steel "" by investing in steel minimill operator Nucor."
2017-11-14,55.04999923706055,55.0099983215332,0.09127976062807644,,
2017-11-13,54.68999862670898,55.29999923706055,-0.07266288116569944,,
2017-11-10,55.22999954223633,54.79999923706055,1.1153787267671704,7 Things AbbVie's Top Executives Just Said That You'll Want to Know,"AbbVie also increased its dividend for the 45th year in a row (including the years it was part of Abbott Labs (NYSE: ABT) ). Beyond Humira While AbbVie believes Humira will remain a big moneymaker for years to come, it's looking beyond Humira to the next generation of autoimmune-disease drugs. Gonzalez said that potential disruptions by Amazon will ""primarily impact the retail environment"" and won't significantly affect AbbVie's business."
2017-11-09,55.060001373291016,55.45000076293945,-0.7785629345279006,,
2017-11-08,54.97999954223633,55.25,0.7083170721416324,,
2017-11-07,55.150001525878906,55.15999984741211,0.49108850493215106,"Noteworthy ETF Outflows: IVE, MDT, ABT, COST","Among the largest underlying components of IVE, in trading today Medtronic PLC (Symbol: MDT) is up about 0.1%, Abbott Laboratories (Symbol: ABT) is down about 0.3%, and Costco Wholesale Corp (Symbol: COST) is up by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares S&P 500 Value ETF (Symbol: IVE) where we have detected an approximate $109.5 million dollar outflow -- that's a 0.8% decrease week over week (from 131,850,000.0 to 130,850,000.0). For a complete list of holdings, visit the IVE Holdings page » The chart below shows the one year price performance of IVE, versus its 200 day moving average: Looking at the chart above, IVE's low point in its 52 week range is $92.04 per share, with $110.30 as the 52 week high point - that compares with a last trade of $109.61."
2017-11-06,55.31999969482422,55.0099983215332,0.01812932231472642,,
2017-11-03,54.56999969482422,55.470001220703125,-0.5603784797562456,,
2017-11-02,54.04999923706055,54.369998931884766,1.6492606393843694,,
2017-11-01,53.88999938964844,54.0,0.5920438470696666,"If I Could Buy Only 1 Stock, This Would Be It","That's because the biotech wasn't traded as an independent entity until 2013, after being spun off from parent Abbott Labs (NYSE: ABT) . There's at least one alternative on the market that is a growth stock, a dividend stock, and a value stock all rolled into one. Dividend There aren't many healthcare stocks with more attractive dividends than AbbVie."
2017-10-31,54.47999954223633,54.22999954223633,0.2041206375903062,"Notable ETF Outflow Detected - IVE, MDT, ABT, ORCL | HCA Healthcare (HCA) Posts In-Line Q3 Earnings, Keeps View","Among the largest underlying components of IVE, in trading today Medtronic PLC (Symbol: MDT) is trading flat, Abbott Laboratories (Symbol: ABT) is trading flat, and Oracle Corp (Symbol: ORCL) is up by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares S&P 500 Value ETF (Symbol: IVE) where we have detected an approximate $98.1 million dollar outflow -- that's a 0.7% decrease week over week (from 131,700,000.0 to 130,800,000.0). For a complete list of holdings, visit the IVE Holdings page » The chart below shows the one year price performance of IVE, versus its 200 day moving average: Looking at the chart above, IVE's low point in its 52 week range is $92.04 per share, with $110.30 as the 52 week high point - that compares with a last trade of $109.20. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report HCA Holdings, Inc. (HCA): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. ABBV , ABIOMED, Inc. ABMD and Abbott Laboratories ABT have surpassed their respective Zacks Consensus Estimate during the last quarter. HCA Holdings, Inc. Price, Consensus and EPS Surprise HCA Holdings, Inc. Price, Consensus and EPS Surprise | HCA Holdings, Inc. Quote Improvement in revenues was offset by an increase in expenses."
2017-10-30,55.18000030517578,54.290000915527344,-0.45888399798201956,The 3 Best Diabetes Stocks to Buy in 2018,"For decades, insulin pump therapy required users to wear a pager-like device and tubing all day, every day, but a decade ago Insulet introduced the first fully programmable patch pump to market. The company is a leading manufacturer of continuous glucose monitoring (CGM) system that enables people with diabetes to see their blood glucose levels in nearly real time. With Dexcom's stock finally trading at a reasonable valuation, I think this stock stands a great chance of bouncing back in 2018."
2017-10-27,55.4900016784668,55.369998931884766,-1.6129021107760981,"Integra LifeSciences (IART) Misses on Q3 Earnings & Revenues | Align Technology (ALGN) Q3 Earnings Top on Invisalign Sales | Chemed (CHE) Beats on Q3 Earnings & Revenues, View Revised | ResMed (RMD) Q1 Earnings Top on Growth in All Business Lines | Cerner (CERN) Misses on Q3 Earnings, Bookings Decline Y/Y | Stryker (SYK) Earnings and Revenues Beat Estimates in Q3 | How Electricity Could Replace Opioids In Treating Chronic Pain | See Which Of The Latest 13F Filers Holds Abbott Laboratories","Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Integra LifeSciences Holdings Corporation (IART): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Revenue Discussion Total revenue in the reported quarter increased 11.4% year over year to $278.8 million, which lagged the Zacks Consensus Estimate of $286 million. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Revenues Revenues grew 38.3% year over year to $385.3 million in the quarter, surpassing the Zacks Consensus Estimate of $360 million. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Chemed Corp. (CHE): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Quarter in Details Revenues in the quarter increased 6.3% year over year to $417.4 million, beating the Zacks Consensus Estimate of $415 million. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report ResMed Inc. (RMD): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Revenues in Details Revenues in the reported quarter increased 12.5% year over year (up 11% at constant exchange rate or CER) to $523.7 million. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Cerner Corporation (CERN): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. FY17 Guidance Lowered For the fourth quarter, Cerner forecasts revenues between $1.3 billion and $1.35 billion, with the midpoint reflecting growth of 5% on a year-over-year basis. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Stryker CorpSYK reported adjusted earnings of $1.52 per share in the third quarter of 2017, which comfortably beat the Zacks Consensus Estimate by 2 cents. | The leader in the space is Medtronic ( MDT ) with 52.3% of the market, while Abbott Laboratories ( ABT ) and Boston Scientific ( BSX ) on its heels, Matson says. Neuromodulation essentially tricks the brain into thinking a region of the body is no longer in pain, says Dr. Allen Burton, Abbott's medical director for neuromodulation, movement disorders and pain. All About Pain Relief For patients like Swearingen, it's not the specific device maker that matters - though she did a lot of research before settling on a device from Boston Scientific - it's the pain relief. | Looking beyond these particular funds in this one batch of most recent filers, we tallied up the ABT share count in the aggregate among all of the funds which held ABT at the 09/30/2017 reporting period (out of the 838 we looked at in total). We then compared that number to the sum total of ABT shares those same funds held back at the 06/30/2017 period, to see how the aggregate share count held by hedge funds has moved for ABT. The overall top three funds holding ABT on 09/30/2017 were: We'll keep following the latest 13F filings by hedge fund managers and bring you interesting stories derived from a look at the aggregate information across groups of managers between filing periods."
2017-10-26,55.34000015258789,55.47999954223633,-0.2162601242605458,"Health Care Sector Update for 10/26/2017: JNJ, PFE, ABT, MRK, AMGN, INSY, ABMD, THC | Varian Medical (VAR) Misses on Q4 Earnings, Issues FY18 View | Cardiovascular Systems (CSII) Q1 Earnings Top, Revenues Lag | GNC Holdings (GNC) Lags Q3 Earnings & Revenues, Margins Down | McKesson (MCK) Beats Earnings & Revenue Estimates in Q2 | Boston Scientific's (BSX) Q3 Earnings In Line, Guidance Up | Zacks Industry Outlook Highlights: Johnson & Johnson, Abbott Labs, Medtronic and Boston Scientific.","Health care continued to be the lone decliner among sectors ahead of the closing bell, with the NYSE Health Care Index sinking almost 0.9% while shares of health care companies in the S&P 500 were down 1.6% as a group. In company news, Insys Therapeutics ( INSY ) shares fell 20.2% to their lowest level in nearly four years after the company's founder and six former executives were arrested for allegedly offering bribes to doctors to oversubscribe opiods. In other sector news, (+) ABMD, Posts fiscal Q2 results above estimates, issues in-line FY18 guidance; reports first patient in Japan to be treated with the Impella heart pump (-) THC, Company reportedly has taken itself off the auction block after the departure of CEO Trevor Fetter The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Varian Medical Systems, Inc.VAR reported adjusted earnings of $1.09 per share in the fourth quarter of fiscal 2017, missing the Zacks Consensus Estimate of $1.19. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . The company expects revenues in the range of $52.5-$54 million for second-quarter fiscal 2018.The current Zacks Consensus Estimate is pegged at $55.79 million, above the company's guided range. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report GNC Holdings, Inc. (GNC): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Revenues Revenues during the reported quarter dropped 2.9% year over year to $609.5 million. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report McKesson Corporation (MCK): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. McKesson Corporation Price, Consensus and EPS Surprise McKesson Corporation Price, Consensus and EPS Surprise | McKesson Corporation Quote Financial Condition As of Sep 30, McKesson had $2.6 billion in cash and cash equivalents against $2.8 billion as of Mar 31. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Boston Scientific Corporation Price, Consensus and EPS Surprise Boston Scientific Corporation Price, Consensus and EPS Surprise | Boston Scientific Corporation Quote Organic revenue growth in the third quarter (excluding the impact of changes in foreign currency exchange rates and sales from the acquisitions of EndoChoice Holdings and Symetis SA) was 4.3% year over year. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. For Immediate Release Chicago, IL - October 26, 2017 - Today, Zacks Equity Research discusses the MedTech, including Johnson & Johnson JNJ , Abbott LabsABT , MedtronicMDT and Boston ScientificBSX . Emerging Market Openings It has been seen that even considering the dull performance of the U.S. medical device market (that still holds the leading position with almost one-third of the world market share) on rising regulatory and legislative uncertainty, global growth has been strong."
2017-10-25,55.380001068115234,55.4900016784668,0.2529804648760751,"Abaxis (ABAX) Posts In-Line Earnings in Q2, Lags Revenues | Thermo Fisher (TMO) Q3 Earnings & Sales Top, Guidance Up | Walgreens Boots (WBA) Tops Q4 Earnings, Issues 2018 View | Baxter (BAX) Beats on Earnings & Sales in Q3, 2017 View Up | LabCorp (LH) Beats Q3 Earnings Estimates, Raises Guidance | Illumina (ILMN) Tops Q3 Earnings & Revenues, Raises Guidance | Edwards Lifesciences (EW) Q3 Earnings, Sales Lag, View Intact | Anthem's (ANTM) Q3 Earnings Beat Estimates, Improve Y/Y | NuVasive (NUVA) Q3 Earnings Top, Revenues Lag, Guidance Cut","Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report ABAXIS, Inc. (ABAX): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Total Revenue In the fiscal second quarter, Abaxis recorded revenues of $58.9 million, reflecting an increase of 0.5% from a year ago. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report To read this article on Zacks.com click here. A few other stocks worth considering in the broader medical sector are PetMed Express, Inc. PETS , Abbott Labs ABT and Intuitive Surgical, Inc. ISRG . Thermo Fisher Scientific Inc Price, Consensus and EPS Surprise Thermo Fisher Scientific Inc Price, Consensus and EPS Surprise | Thermo Fisher Scientific Inc Quote Quarter in Detail Organic revenues in the third quarter grew 5% year over year while acquisitions increased revenues by 8%. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Total Sales Walgreens Boots recorded total sales of $30.15 billion in the fiscal fourth quarter, up 5.3% year over year and up 6.4% at constant exchange rate (CER). | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, up 11.9% year over year. Baxter International Inc.BAX reported third-quarter 2017 adjusted earnings per share of 64 cents, which beat the Zacks Consensus Estimate by 5 cents and improved from the year-ago figure of 56 cents. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Laboratory Corporation of America Holdings (LH): Free Stock Analysis Report To read this article on Zacks.com click here. A few other top-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Laboratory Corporation of America Holdings Price, Consensus and EPS Surprise Laboratory Corporation of America Holdings Price, Consensus and EPS Surprise | Laboratory Corporation of America Holdings Quote Quarter under Review Currently, LabCorp reports under two operating segments: LabCorp Diagnostics and Covance Drug Development. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Revenues In the reported quarter, Illumina's revenues grew 17.6% year over year to $714 million. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . Edwards Lifesciences Corporation Price, Consensus and EPS Surprise Edwards Lifesciences Corporation Price, Consensus and EPS Surprise | Edwards Lifesciences Corporation Quote Segments Details For the third quarter, the company reported Transcatheter Heart Valve Therapy (THVT) sales of $481.2 million, reflecting 17.3% growth over the prior-year quarter. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Anthem, Inc. (ANTM): Free Stock Analysis Report To read this article on Zacks.com click here. ABT , Johnson & Johnson JNJ and UnitedHealth Group Incorporated UNH beat their respective Zacks Consensus Estimate. Segment Update Commercial & Specialty Business Operating revenues were $10 billion in the third quarter, up 4.1% year over year. | Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report NuVasive, Inc. (NUVA): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the broader medical sector are PetMed Express, Inc. PETS , Abbott ABT and Intuitive Surgical, Inc. ISRG . NuVasive, Inc. Price, Consensus and EPS Surprise NuVasive, Inc. Price, Consensus and EPS Surprise | NuVasive, Inc. Quote However, putting together the impact of hurricanes Harvey and Irma on NuVasive's U.S. results and Maria on the company's international results along with one less selling day, the revenue growth would have been approximately 6% year over year."
2017-10-24,56.0,55.380001068115234,0.19862876170093613,"PetMed (PETS) Tops Q2 Earnings & Sales Estimates, Margins Up | Centene (CNC) Tops Q3 Earnings & Revenues, Raises '17 View","Click to get this free report PetMed Express, Inc. (PETS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO , all three carrying a Zacks Rank #2 (Buy). Net sales in the reported quarter rose 10% year over year to $66.7 million, outpacing the Zacks Consensus Estimate by 5.9%. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Centene Corporation (CNC): Free Stock Analysis Report To read this article on Zacks.com click here. ABT , Johnson & Johnson. Operational Update For the quarter, total revenues grew 10% to $11.9 billion year over year, primarily driven by growth in the Health Insurance Marketplace business in 2017 and expansions and new programs in many states in 2016 and 2017.This was partially offset by the moratorium of the Health Insurer Fee in 2017 and lower membership in the commercial business in California."
2017-10-23,56.209999084472656,56.08000183105469,-1.1071409497942244,"Health Care Sector Update for 10/23/2017: JNJ, PFE, ABT, MRK, AMGN, TIG, AZN","In sector news, Johnson & Johnson ( JNJ ) shares were up 0.4% after it said late Friday that the US Food and Drug Administration has approved Simponi Aria for the treatment of adults with active psoriatic arthritis or active ankylosing spondylitis based on pivotal phase 3 studies involving more than 600 patients that demonstrated the significant efficacy of the drug over placebo. In other sector news, (+) TIG (+1.3%) Gets FDA Orphan Designation for bowel disease drug (-) AZN (-0.4%) Gets FDA approval for type-2 diabetes injectable medicine, Bydureon BCise The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Unauthorized reproduction is strictly prohibited."
2017-10-20,56.16999816894531,56.31999969482422,-0.2312706912209841,"Notable ETF Inflow Detected - ITOT, HON, MDT, ABT | Varian Medical (VAR) Q4 Earnings: Is a Surprise in Store? | Baxter International (BAX) Q3 Earnings: What's in Store?","Among the largest underlying components of ITOT, in trading today Honeywell International Inc (Symbol: HON) is up about 0.2%, Medtronic PLC (Symbol: MDT) is off about 0.1%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core S&P Total U.S. Stock Market ETF (Symbol: ITOT) where we have detected an approximate $76.2 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 200,250,000.0 to 201,550,000.0). For a complete list of holdings, visit the ITOT Holdings page » The chart below shows the one year price performance of ITOT, versus its 200 day moving average: Looking at the chart above, ITOT's low point in its 52 week range is $47.42 per share, with $58.89 as the 52 week high point - that compares with a last trade of $58.82. | Varian Medical Systems, Inc. Price and EPS Surprise Varian Medical Systems, Inc. Price and EPS Surprise | Varian Medical Systems, Inc. Quote Stocks to Consider Here are some companies you may consider as our model shows that they have the right combination of elements to post an earnings beat in the upcoming quarter: Abbott ABT has an Earnings ESP of +0.17% and carries a Zacks Rank #2. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Rank: Varian Medical carries a Zacks Rank #3 which increases the predictive power of ESP. | Baxter International Inc. Price and EPS Surprise Baxter International Inc. Price and EPS Surprise | Baxter International Inc. Quote Stocks to Consider Here are some companies you may consider as our model shows that they have the right combination of elements to post an earnings beat in the upcoming quarter: Abbott ABT has an Earnings ESP of +0.17% and carries a Zacks Rank #2. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Rank: Baxter International carries a Zacks Rank #3, which increases the predictive power of ESP."
2017-10-19,55.900001525878906,56.0,0.2670491913276179,"Company News For Oct 19, 2017 | Varian Medical (VAR) Initiates Halcyon Treatment in Europe | 2 Great Stocks For Retirees | Abbott Laboratories Q3 2017 Earnings Conference Call Transcript (ABT)","Shares of Fogo De Chao IncFOGO tanked 7.5% after the company expects adjusted earnings of 77 cents to 80 cents a share for the year, lower than analysts' expectations of 91 cents Shares of Abbott LaboratoriesABT gained 1.3% after the company reported third quarter earnings per share of 66 cents, ahead of the Zacks Consensus Estimate by a penny Allergan plc's AGN shares slumped 5.3% after a Texas district court judge ruled against the company in a patent lawsuit Shares of Electronic Arts Inc.EA declined 2.4% on news that the company is closing the unit that was working on a coming ""Star Wars"" videogame Want the latest recommendations from Zacks Investment Research? (AGN): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Fogo de Chao, Inc. (FOGO): Free Stock Analysis Report Electronic Arts Inc. (EA): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT continues to lead the emerging market investment trend with about 50% of sales from this region. Strengthening its focus on image-guided volumetric intensity modulated radiotherapy to cancer patients, Varian Medical Systems Inc.VAR announced that it has initiated treatment with its latest Halcyon radiotherapy treatment system in Europe. | Thanks to a recent deal that will delay U.S. entry of Amgen 's biosimilar version of Humira until 2023, global sales will continue to rise from an annualized $17.9 billion based on second-quarter sales to more than $20 billion by the time competition begins diminishing this blockbuster drug's pricing power. By the time the revenue stream responsible for 63% of the company's top line begins drying up, growing sales of more recently launched drugs, and some still in development, could more than offset the losses. The company has increased the payout each year since 2009, and surging sales of recently launched drugs could keep the party going well into your golden years. | Duration: 54 minutes Call participants: Scott Leinenweber-- Vice President of Investor Relations Miles White-- Chairman of the Board and Chief Executive Officer Brian Yoor -- Executive Vice President of Finance and Chief Financial Officer Mike Weinstein -- J.P. Morgan-- Analyst Matt Taylor -- Barclays Capital-- Analyst Bob Hopkins -- Bank of America-- Analyst Rick Wise -- Seful-- Analyst Larry Biegelsen -- Wells Fargo-- Analyst Glen Novarro -- RBC Capital Markets -- Analyst David Lewis -- Morgan Stanley -- Analyst More ABT analysis This article is a transcript of this conference call produced for The Motley Fool. Abbott Laboratories (NYSE: ABT) Q3 2017 Earnings Conference Call Oct. 18, 2017, 9:00 a.m. Unless otherwise noted, our commentary on sales growth refers to comparable operational sales growth, which adjusts the 2016 basis of comparison to include results for St. Jude Medical, and to exclude the impact of exchange, as well as current and historical results for Abbott's medical optics and St. Jude's vascular closure businesses, which were divested during the first quarter of 2017."
2017-10-18,55.18000030517578,55.77000045776367,0.17888814202410971,"Mid-Day Market Update: IBM Surges After Strong Q3 Results; Mobileiron Shares Plunge | Mid-Morning Market Update: Markets Mostly Higher; Abbott Tops Q3 Views | Can Illumina (ILMN) Maintain Balanced Growth in Q3 Earnings? | Abbott (ABT) Beats Earnings and Sales in Q3, Tweaks View | Will Edwards Lifesciences (EW) Gain on THVT in Q3 Earnings? | Morning Movers: Chipotle Drops, Transocean Slips, Electronic Arts Slumps | Abbott Delivers $100 Million Sales Beat On Pharma, Devices Strength | Noteworthy Wednesday Option Activity: BMRN, SALT, ABT | Abbott (ABT) Exceeds Q3 Earnings, '17 Guidance Narrowed | Mid-Afternoon Market Update: Dow Gains 160 Points; Akari Therapeutics Shares Plummet","Top Headline Abbott Laboratories (NYSE: ABT ) posted better-than-expected earnings for its third quarter. Midway through trading Wednesday, the Dow traded up 0.64 percent to 23,145.57 while the NASDAQ climbed 0.13 percent to 6,632.59. The eurozone's STOXX 600 gained 0.29 percent, the Spanish Ibex Index rose 0.55 percent, while Italy's FTSE MIB Index gained 0.08 percent. | Top Headline Abbott Laboratories (NYSE: ABT ) posted better-than-expected earnings for its third quarter. Meanwhile, top gainers in the sector included Interactive Brokers Group, Inc. (NASDAQ: IBKR ), up 6 percent, and Northern Trust Corporation (NASDAQ: NTRS ), up 5 percent. The eurozone's STOXX 600 gained 0.36 percent, the Spanish Ibex Index rose 0.01 percent, while Italy's FTSE MIB Index gained 0.05 percent. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT has an Earnings ESP of +0.17% and a Zacks Rank #2 (Buy). Illumina, Inc. Price and EPS Surprise Illumina, Inc. Price and EPS Surprise | Illumina, Inc. Quote Here are the other factors that might influence Illumina's third-quarter results: Illumina earlier announced that its FDA-approved next-generation sequencing (NGS) -- Extended RAS Panel has met the Current Colorectal Cancer Guidelines. | AbbottABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories Price and EPS Surprise Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote Currently, Abbott Labs has a Zacks Rank #2 (Buy), but that could definitely change following the company's third quarter 2017 earnings report which was just released. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT has an Earnings ESP of +0.17% and a Zacks Rank #2 (Buy). It is worth noting that Edwards Lifesciences has outperformed the Zacks Consensus Estimate in three of the preceding four quarters, with an average positive earnings surprise of 10.8%. | Abbott Laboratories (ABT) has advanced 1% to $55.60 after beating earnings forecasts and offering in-line guidance. Agence France-Presse/Getty Images S&P 500 futures have risen 0.2%, while Dow Jones Industrial Average futures have gained 0.4%. Merck (MRK) has risen 1.6% to $64.25 after getting upgraded to Buy from Neutral at Citigroup. | Abbott Laboratories ( ABT ) delivered a $100 million sales beat in the third quarter, helped by strength in its pharmaceutical and medical devices units, an analyst said Wednesday. RBC analyst Glenn Novarro credited the $100 million sales beat to strong sales from Abbott's established pharmaceuticals, diabetes care, cardiovascular and neuromodulation products. Dow Component J&J Pops After Topping Views On Pharma Strength IBD Rating Upgrades: Johnson & Johnson Shows Improved Relative Price Strength FDA Chief Gottlieb Addresses Opioids, Cancer, New Therapeutics The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in BioMarin Pharmaceutical Inc. (Symbol: BMRN), where a total of 7,906 contracts have traded so far, representing approximately 790,600 underlying shares. Especially high volume was seen for the $100 strike call option expiring January 19, 2018 , with 4,064 contracts trading so far today, representing approximately 406,400 underlying shares of BMRN. Below is a chart showing BMRN's trailing twelve month trading history, with the $100 strike highlighted in orange: Scorpio Bulkers Inc (Symbol: SALT) saw options trading volume of 4,035 contracts, representing approximately 403,500 underlying shares or approximately 64.9% of SALT's average daily trading volume over the past month, of 621,655 shares. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Integra LifeSciences Holdings Corporation (IART): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LabsABT reported third-quarter 2017 adjusted earnings from continuing operations of 66 cents per share, ahead of the Zacks Consensus Estimate by a penny and up 11.9% year over year. Abbott Laboratories Price, Consensus and EPS Surprise Abbott Laboratories price-consensus-eps-surprise-chart | Abbott Laboratories Quote On a comparable operational basis (adjusting the impact of foreign exchange, certain acquisitions and divestments), sales increased 5.6% year over year in the reported quarter. | Top Headline Abbott Laboratories (NYSE: ABT ) posted better-than-expected earnings for its third quarter. Toward the end of trading Wednesday, the Dow traded up 0.70 percent to 23,158.02 while the NASDAQ climbed 0.15 percent to 6,633.65. The eurozone's STOXX 600 gained 0.29 percent, the Spanish Ibex Index rose 0.55 percent, while Italy's FTSE MIB Index gained 0.08 percent."
2017-10-17,54.59000015258789,55.060001373291016,1.0692282517666998,"Will Intuitive Surgical (ISRG) Disappoint in Q3 Earnings? | Henry Schein (HSIC) Inks Distribution Agreement with Terason | What to Expect From Thermo Fisher (TMO) in Q3 Earnings | Phibro Animal Banks on Diverse Portfolio, Competition Rife | Can CR Bard (BCR) Spring a Surprise This Earnings Season? | Can Nutrisystem (NTRI) Surprise Investors in Q3 Earnings? | 5 Must-See Big Cap Earnings Charts | Pre-Market Earnings Report for October 18, 2017 : ABT, USB, ASML, MTB, NTRS, MTG, UNF, UBSH, CTBI, SVU, FCCO | The Zacks Analyst Blog Highlights: AbbVie, American Express, Abbott, United Technologies and VMWare","Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT has an Earnings ESP of +0.17% and a Zacks Rank #2 (Buy). Intuitive Surgical, Inc. Price and Consensus Intuitive Surgical, Inc. Price and Consensus | Intuitive Surgical, Inc. Quote Other Factors at Play We believe that the growing adoption of Intuitive Surgical's da Vinci system among physicians for general surgery, oncology, urology and gynecology procedures is a catalyst for the third quarter. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO . Henry Schein Medical, a subsidiary of Henry Schein, Inc.HSIC , announced an exclusive distribution agreement with Terason to distribute the latter's uSmart 3200T NexGen. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT has an Earnings ESP of +0.17% and a Zacks Rank of 2. Thermo Fisher Scientific Inc Price and EPS Surprise Thermo Fisher Scientific Inc Price and EPS Surprise | Thermo Fisher Scientific Inc Quote Thermo Fisher anticipates realizing total synergies of approximately $80 million by the end of three years following the deal's closure with about $55 million of cost synergies and roughly $25 million of adjusted operating income benefits from revenue-related synergies. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Phibro Animal Health Corporation (PAHC): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO . This NJ-based company is a leading global diversified animal health and mineral nutrition company. | Last quarter, the company reported adjusted earnings of $2.92, exceeding the Zacks Consensus Estimate by 8 cents. Also, the company's earnings surpassed the Zacks Consensus Estimate in all the last four quarters with an average beat of 4.03%. Factors at Play We believe that the growing adoption of the company's flagship Lutonix drug coated-balloon (DCB) will continue to be the key growth catalyst in the to-be-reported quarter. | NutriSystem Inc Price and EPS Surprise NutriSystem Inc Price and EPS Surprise | NutriSystem Inc Quote Stocks that Warrant a Look Here are some companies you may want to consider as our model shows that they have the right combination of elements to post an earnings beat this quarter: Abbott ABT has an Earnings ESP of +0.17% and carries a Zacks Rank #2. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report Henry Schein, Inc. (HSIC): Free Stock Analysis Report NutriSystem Inc (NTRI): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Rank: Nutrisystem currently carries a Zacks Rank #3, which increases the predictive power of ESP. | Abbott Labs ABT hasn't missed in 5 years and shares have finally busted out of the recent narrow trading range. Click to get this free report United Continental Holdings, Inc. (UAL): Free Stock Analysis Report International Business Machines Corporation (IBM): Free Stock Analysis Report eBay Inc. (EBAY): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report United Rentals, Inc. (URI): Free Stock Analysis Report To read this article on Zacks.com click here. Earnings season kicks into high gear this week with over 190 companies reporting, including many big cap Dow and S&P 500 names. | Abbott Laboratories ( ABT ) is reporting for the quarter ending September 30, 2017. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABT is 21.94 vs. an industry ratio of 54.70. | Stocks recently featured in the blog include AbbVie (NYSE: ABBV - Free Report ), American Express (NYSE: AXP - Free Report ), Abbott (NYSE: ABT - Free Report ), United Technologies (NYSE: UTX - Free Report ) and VMWare (NYSE: VMW - Free Report ). Get the full Report on ABBV - FREE Get the full Report on AXP - FREE Get the full Report on ABT - FREE Get the full Report on UTX - FREE Get the full Report on VMW - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Vmware, Inc. (VMW): Free Stock Analysis Report United Technologies Corporation (UTX): Free Stock Analysis Report American Express Company (AXP): Free Stock Analysis Report To read this article on Zacks.com click here."
2017-10-16,54.619998931884766,54.630001068115234,0.8609657801600943,"CHICAGO TRUST Co NA Buys Discover Financial Services, Dominion Energy Inc, DowDuPont Inc, Sells ...","Shares reduced by 8.66% Abbott Laboratories ( ABT ) - 108,584 shares, 2.66% of the total portfolio. CHICAGO TRUST Co NA New Purchases: DFS , DWDP , ITW , AMZN, ENB, KORS, THR, UBNT, Added Positions:D, HOG, MET, MCK, VZ, XOM, MDLZ, GOOG, T, ETN, Reduced Positions:WFC, DUK, ACN, MO, MSFT, AMGN, AET, SHW, AMP, CI, Sold Out:DD, AHL, LQ, SCSC, JLL, NWL, BW, RSYS, For the details of CHICAGO TRUST Co NA's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=CHICAGO+TRUST+Co+NA These are the top 5 holdings of CHICAGO TRUST Co NA Apple Inc ( AAPL ) - 51,659 shares, 3.65% of the total portfolio. New Purchase: Michael Kors Holdings Ltd (KORS) CHICAGO TRUST Co NA initiated holdings in Michael Kors Holdings Ltd."
2017-10-13,54.63999938964844,54.650001525878906,0.01831222340912559,"Spin-Off ETF: Can the Outperformance Continue? | Abbott Banks on FDA Approvals and Buyouts, Competition Rife","Click to get this free report eBay Inc. (EBAY): Free Stock Analysis Report PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Honeywell International Inc. (HON): Free Stock Analysis Report Dean Foods Company (DF): Free Stock Analysis Report GUGG-SPIN-OFF (CSD): ETF Research Reports VANECK-GLB S-O (SPUN): ETF Research Reports To read this article on Zacks.com click here. Abbot LaboratoriesABT cut ties with part of its business and formed a new company called AbbVie ABBV in Jan 2013. ABBV was up 85% while ABT gained 41% in the last three years (as of Oct 12, 2017). | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Qiagen N.V. (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. On Oct 12, we issued an updated research report on AbbottABT - a global healthcare company dedicated toward improving life through the development of products and technologies. Key Stocks A few better-ranked stocks in the medical sector are QIAGEN QGEN , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO ."
2017-10-12,54.2400016784668,54.709999084472656,0.018305520392014604,"DENTSPLY SIRONA Strong on Deal Renewals, Forex Woes Stay | Mazor Projects Higher Q3 Revenues, Clinches Mazor X Orders | MedTech Players Eyeing Emerging Market Growth Opportunities","Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report DENTSPLY SIRONA Inc. (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the broader medical sector are Abbott ABT , IDEXX Laboratories, Inc IDXX and Thermo Fisher Scientific Inc TMO . On Oct 11, we issued an updated research report on New York-based DENTSPLY SIRONA Inc.XRAY - a global leader in the design, development, manufacture and marketing of dental consumables and dental laboratory products. | A few other top-ranked stocks in the broader medical sector are Abbott ABT , IDEXX Laboratories, Inc IDXX and Thermo Fisher Scientific Inc TMO . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Mazor Robotics Ltd. (MZOR): Free Stock Analysis Report To read this article on Zacks.com click here. Factors Behind Mazor X Strength During the third quarter, the company received purchase orders for 19 Mazor X systems in the United States. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Johnson & Johnson Price and Consensus Johnson & Johnson price-consensus-chart | Johnson & Johnson Quote AbbottABT continues to lead the emerging market investment trend with about 50% of sales from this region. Investment in Emerging Market Players Looks Sensible In such a scenario, we believe it will be wise of investors who are keen on MedTech stocks to keep an eye on companies who have turned the emerging markets into a happy hunting ground with their expertise and network."
2017-10-11,55.2599983215332,54.43999862670898,0.8665143647892763,"QIAGEN Banks on Tie-Ups & Product Launches, Competition Rife | Express Scripts (ESRX) to Buy eviCore, Fortify PBM Business | Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for October 12, 2017","Other top-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Qiagen N.V. (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Rank & Other Key Picks QIAGEN currently carries a Zacks Rank #2 (Buy). | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Express Scripts Holding Company (ESRX): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO . Express Scripts' pharmacy benefit management coupled with eviCore's complementary medical benefits management is likely to build a comprehensive patient benefit management (PBM) solution. | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. The following ETF(s) have ABT as a top-10 holding: iShares U.S. Medical Devices ETF ( IHI ) First Trust Nasdaq Pharmaceuticals ETF ( FTXH ) John Hancock Multifactor Healthcare ETF ( JHMH ) SPDR S&P Health Care Equipment ( XHE ) First Trust VL Dividend ( FVD )."
2017-10-10,54.77000045776367,55.400001525878906,-1.4838938105879311,"QIAGEN Partners With CENTOGENE, Boosts Bioinformatics Suite | Pacific Biosciences, Bluebee Team Up for De Novo Sequencing | Illumina (ILMN) Strong on Product Launches, Competition Rife | Ex-Dividend Reminder: Abbott Laboratories, Becton, Dickinson and Pennymac Mortgage Investment Trust | Health Care Sector Update for 10/10/2017: JNJ, PFE, ABT, MRK, AMGN, ANAB, VICL, LLY","Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Qiagen N.V. (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Other top-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO . Notably, this integration of CentoMD phenotype/genotype database is expected to considerably enhance QIAGEN Knowledge Base and QIAGEN Clinical Insight (QCI) bioinformatics solution. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Pacific Biosciences of California, Inc. (PACB): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the medical sector are Abbott ABT , Thermo Fisher Scientific Inc. TMO and IDEXX Laboratories, Inc. IDXX . Pacific Biosciences of California, Inc.PACB recently formed an alliance with genomic data-driven medicine company, Bluebee, to develop an advanced de novo assembly pipeline that integrates both the company's technologies. | Key Picks A few better-ranked stocks in the medical sector are Abbott ABT , IDEXX Laboratories, Inc. IDXX and Thermo Fisher Scientific Inc. TMO , with a Zacks Rank #2 (Buy). Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report To read this article on Zacks.com click here. Along with having global commercial rights to these products, Illumina will be the only provider of the MiSeq FGx Forensic Genomics System, including the MiSeq FGx sequencer, ForenSeq DNA Signature Prep Kit and the ForenSeq Universal Analysis Software. | Looking at the universe of stocks we cover at Dividend Channel , on 10/12/17, Abbott Laboratories (Symbol: ABT), Becton, Dickinson & Co (Symbol: BDXA), and Pennymac Mortgage Investment Trust (Symbol: PMT) will all trade ex-dividend for their respective upcoming dividends. Abbott Laboratories (Symbol: ABT) : Becton, Dickinson & Co (Symbol: BDXA) : Pennymac Mortgage Investment Trust (Symbol: PMT) : In general, dividends are not always predictable, following the ups and downs of company profits over time. As a percentage of ABT's recent stock price of $54.74, this dividend works out to approximately 0.48%, so look for shares of Abbott Laboratories to trade 0.48% lower - all else being equal - when ABT shares open for trading on 10/12/17. | ABT: flat AMGN: flat Health care shares were mostly flat in pre-market trade Tuesday. The company said that after a single dose of ANB020, 75% of patients achieved an Eczema Area Severity Index (EASI) score improvement of 50% relative to enrollment baseline (EASI-50) at day 15, 83% of patients achieved EASI-50 at day 29 and 75% of patients achieved EASI-50 at day 57."
2017-10-09,55.04999923706055,54.65999984741211,1.1502666840418685,,
2017-10-06,54.900001525878906,55.0,-0.7084457675811985,"Abbott (ABT) Hits a 52-Week High: What's Driving the Stock? | Health Care Sector Update for 10/06/2017: JNJ, PFE, ABT, MRK, AMGN, KDMN","Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Luminex Corporation (LMNX): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Orthofix International N.V. (OFIX): Free Stock Analysis Report To read this article on Zacks.com click here. Share price of Abbott ABT scaled a new 52-week high of $55.11 on Oct 6, eventually closing lower at $54.92. The company has gained 6.7% over the past month, much higher than the S&P 500's gain of 2.6%. | Top Health Care Stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Health care shares were inactive in pre-market trade Friday. In sector news, Johnson & Johnson ( JNJ ) reported that its subsidiary, Janssen Research & Development and development partner Bayer have stopped the Phase III NAVIGATE ESUS study early because the treatment was unlikely to show an overall benefit versus aspirin if the study were to be completed. In other sector news, (+) KDMN (+1%) Gets FDA Orphan Designation for graft-vs-host disease treatment The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2017-10-05,54.369998931884766,54.91999816894531,0.18214657803598824,"Health Care Sector Update for 10/05/2017: JNJ, PFE, ABT, MRK, AMGN, DXTR, NBIX, RIGL","MRK: flat In other sector news, (+) NBIX (+3.6%) Gets FDA approval for tardive dyskinesia drug capsulea (-) RIGL (-3%) Prices public sale of 18.1 million shares at $3.35 per share, or 7.5% discount The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2017-10-04,53.66999816894531,54.34000015258789,1.0115858890297036,5 Top Stocks for October,"However, Dexcom's stock was clobbered last week after the FDA approved Abbott Laboratories 's (NYSE: ABT) FreeStyle Libre Flash Glucose Monitoring System. We asked a team of investors to weigh in, and they picked Rigel Pharmaceuticals (NASDAQ: RIGL) , Hanesbrands (NYSE: HBI) , Walt Disney (NYSE: DIS) , Tile Shop Holdings (NASDAQ: TTS) , and Dexcom (NASDAQ: DXCM) . Yet Walt Disney's shares have taken a tumble in recent months, and they now trade at less than 18 times trailing earnings and less than 16 times anticipated forward earnings."
2017-10-03,53.75,53.75,1.2483734050698303,"Analysts Act on Health Care Stocks | Health Care Sector Update for 10/03/2017: JNJ, PFE, ABT, MRK, AMGN, DMPI, RDHL, RIGL","The U.S. global health care company that was originated in 2013 as Abbott Laboratories ' ( ABT ) spinoff and headquartered in Lake Bluff, Illinois, is trading at $90.39 per share, a few below its 52-week high of $90.95 per share. Despite this solid accretion in the market value of AbbVie, Leerink analyst Geoffrey Porges, still sees in the long run more positive development in the share price of the health care stock ""as the company's late-stage pipeline comes to fruition,"" reports The Fly. Concerning expectations on AbbVie's sales and revenue for the next two years, analysts foresee that the company will close the full fiscal 2017 with a 14.5% increase year over year in the EPS to $5.52 and a 18.5% increase year over year in the EPS for full fiscal 2018 to $6.54. | ABT: flat AMGN: flat Health care shares were mostly higher in pre-market trade Tuesday. In sector news, DelMar Pharmaceuticals ( DMPI ) rose nearly 16% after the company said Tuesday it will present data that demonstrate how its lead asset VAL-083 targets the DNA of cancer cells differently than platinum-based chemotherapeutic agents or PARP Inhibitors."
2017-10-02,53.63999938964844,53.68000030517578,0.0,"Abbott Gets FDA Nod for FreeStyle Libre, Boosts Diabetes Arm | Why MannKind Corporation Popped Today | Abbott to Gain from Alere's Takeover Due for Oct 3 Closure","AbbottABT recently announced the receipt of FDA approval for the FreeStyle Libre Flash glucose monitoring system in the United States. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Orthofix International N.V. (OFIX): Free Stock Analysis Report Owens & Minor, Inc. (OMI): Free Stock Analysis Report To read this article on Zacks.com click here. Recently, the company announced the receipt of national reimbursement for FreeStyle Libre in the U.K., marking another milestone for the company. | Castanga believes that the recent approval of Abbott Laboratories (NYSE: ABT) new Libre product will expand the market for Afrezza. Here's what MannKind's CEO Michael Castagna had to say about this labeling change on a special investor call: Second, the company also announced that it was able to exchange 1.3 million shares of its common stock for all of the outstanding Series A and Series B stock purchase warrants that were issued in May 2016. With the warrant restrictions out of the way and the stock price up, MannKind is likely to act quickly on issuing stock to shore up its balance sheet. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Luminex Corporation (LMNX): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report To read this article on Zacks.com click here. Investors keen on the consolidation of Abbott LabsABT with Alere may expect that much-awaited good news to arrive soon. Significantly, Alere develops simple, rapid tests, including Alere i - the molecular test for flu and strep - to deliver reports in less than 15 minutes."
2017-09-29,53.63999938964844,53.36000061035156,0.07457292315902453,Abbott's Ellipse ICD Receives FDA Approval for MRI Scans,"Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott'sABT Ellipse implantable cardioverter defibrillator (ICD) recently gained FDA approval for magnetic resonance (MR) conditional labeling. Continuing with its efforts to expand the MR-conditional labeling enabled devices, the company received FDA approval for MR-conditional labeling for Assurity MRI pacemaker and Tendril MRI pacing lead."
2017-09-28,54.75,53.63999938964844,-0.5219962387824146,"Why DexCom Stock Is Getting Crushed Today | IWD, WMT, SLB, ABT: Large Inflows Detected at ETF | 3 High-Yield Stocks With Virtual Monopolies | Morning Movers: Endo Slumps, Hain Jumps, Philip Morris Rises","This tumble stemmed from the FDA's approval of Abbott Laboratories' (NYSE: ABT) FreeStyle Libre Flash Glucose Monitoring System, which is the first continuous glucose monitoring device to not require a finger-stick blood sample for calibration. So what DexCom's stock has skyrocketed in the last few years because of its dominant position in the rapidly growing glucose-monitoring market. Now what Can Abbott's newly approved CGM device truly disrupt the market and steal a significant chunk of the market share away from DexCom? | Among the largest underlying components of IWD, in trading today Wal-Mart Stores, Inc. (Symbol: WMT) is off about 1%, Schlumberger Ltd (Symbol: SLB) is off about 0.5%, and Abbott Laboratories (Symbol: ABT) is higher by about 4.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $265.9 million dollar inflow -- that's a 0.7% increase week over week in outstanding units (from 309,400,000 to 311,650,000). For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $102.07 per share, with $121.24 as the 52 week high point - that compares with a last trade of $118.10. | However, there are a handful of U.S.-based companies that do, in fact, own a disproportionate share of their respective markets and therefore sport unusually rich free cash flows. And fortunately, some of these titans of industry have also chosen to use their strong free cash flows to reward loyal shareholders with a top-notch dividend yield. Armed with this insight, we asked three of our Motley Fool investors which high-yield stocks with virtual monopolies in their primary markets they think are worth buying right now. | DexCom (DXCM) has plunged 27% to $49.50 after Abbott Laboratories (ABT) announced that it had received FDA approval for a sugar-monitoring system for diabetics that doesn't involve a finger prick, a potential hit to one of DexCom's big businesses. McCormick (MKC) has risen 2.7% to $99.01 after beating earnings forecasts and offering above-consensus full-year guidance. Mallinckrodt (MNK) has gained 3.4% to $36.60 after getting started at Buy at Buy at Goldman Sachs."
2017-09-27,52.84999847412109,52.150001525878906,-2.027398375071347,Abiomed's Latest Regulatory Progress Boosts Impella Line,"Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Teleflex Incorporated (TFX): Free Stock Analysis Report Fresenius Medical Care Corporation (FMS): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, the company faces stiff competition from organizations developing permanent heart assist products like Teleflex Inc. TFX , Abbott Laboratories ABT and Fresenius Medical Care FMS . Abiomed Inc. 's ABMD flagship Impella product line shines bright on the receipt of pre-market approval from the FDA for its Impella RP heart pump."
2017-09-26,52.619998931884766,52.84999847412109,-1.3244975751228185,"FDA Chief Gottlieb Addresses Opioids, Cancer, New Therapies","To cope, companies like Boston Scientific ( BSX ), Abbott Laboratories ( ABT ) and Medtronic (MDT) are working on therapies called neuromodulation, which use electricity to conceal pain from the brain. [ibd-display-video id=2322032 width=50 float=left autostart=true]But last month, the FDA approved its first cellular therapy, a drug called Kymriah from Novartis ( NVS ) to treat a form of acute lymphoblastic leukemia in patients age 25 and younger. In 2005, gene/cell therapy and drugs that biologically copy an existing product - known as biosimilars - didn't exist, Gottlieb told the MedTech Conference in San Jose, Calif. ""Now we have products we're reviewing and approving,"" he said."
2017-09-25,52.459999084472656,52.61000061035156,0.43709530008552355,,
2017-09-22,51.5099983215332,52.5099983215332,0.28593505241463946,Here's Why You Should Add Abbott (ABT) to Your Portfolio Now,"AbbottABT is on a healthy growth trajectory of late. The stock has gained 4.8% over the last three months, ahead of the S&P 500's 2.5% gain and the broader industry 's 1.5% decline. The company's current-year growth rate is also favorable at 13.1% compared with the 4.5% increase of the broader industry."
2017-09-21,51.880001068115234,51.43000030517578,1.9413706709090701,,
2017-09-20,51.38999938964844,51.88999938964844,-0.8673877287485594,,
2017-09-19,52.150001525878906,51.40999984741211,0.9729519477299619,"Here's Why Quidel Corporation Stock Is Popping Today | 3 Value Stocks at 52-Week Highs Still Worth Buying | Health Care Sector Update for 09/19/2017: QDEL,ALR,MDGS,ALDX","Earlier this summer, Quidel agreed to scoop up Alere's Triage MeterPro cardiovascular and toxicology assets, along with its business developing B-type Naturietic Peptide (BNP) assays, which are run on Beckman Coulter analyzers and test for heart failure, for $400 million up front and $40 million in contingent consideration. Quidel stock has risen more than 60% since the original deal with Alere was announced, but investors might want to remain cautious. 10 stocks we like better than Quidel When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | Although AbbVie depends on its rheumatoid arthritis therapy Humira for around two-thirds of its revenue, its next leading treatment, Imbruvica, could become one of the top five cancer drugs on the market, while the biotech has one of the best drug pipeline s in the industry, including two cancer drugs (Rova-T and Veliparib) and an autoimmune-disease drug (ABT-494). Don't overthink this one Brian Stoffel(Apple): In picking out a value stock trading near 52-week highs, it can be tempting to go for a company with an incredibly low P/E, or a sustainable dividend hovering over 3%. This bank stock has paid dividends since the 1800s Matt Frankel (Toronto-Dominion Bank): The banking sector has been one of the hottest areas of the market over the past year, but many banks could have much more room to climb. | The acquisitions are subject to completion of Abbott Laboratories' ( ABT ) purchase of Alere in addition to other regulatory approvals and other customary closing conditions. Health care stocks fell today, with the NYSE Health Care Index declining over 0.5% while shares of health care companies in the S&P 500 were down nearly 0.9% as a group. In company news, Quidel Corp ( QDEL ) jumped to a new record high on Tuesday, with shares of the diagnostics equipment manufacturer topping out at a best-ever $45.55 a share after the company today unveiled its revised agreement to acquire certain assets from rival diagnostics company Alere ( ALR ) for up to $680 million."
2017-09-18,51.88999938964844,52.08000183105469,-1.4189868778806816,"IWB, SLB, ABT, UNP: Large Outflows Detected at ETF","Among the largest underlying components of IWB, in trading today Schlumberger Ltd (Symbol: SLB) is up about 0.5%, Abbott Laboratories (Symbol: ABT) is up about 0.1%, and Union Pacific Corp (Symbol: UNP) is lower by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $55.7 million dollar outflow -- that's a 0.3% decrease week over week (from 138,500,000 to 138,100,000). For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $115.81 per share, with $139.85 as the 52 week high point - that compares with a last trade of $139.76."
2017-09-15,51.75,51.7599983215332,0.3661638921586761,,
2017-09-14,51.93000030517578,51.68999862670898,0.0193204280834843,"Abbott's (ABT) FreeStyle Libre Gets UK Reimbursement Nod | How Safe Is Abbott Labs' Dividend? | Daily Dividend Report: INTC, CSCO, BMY, ABT, KR, KRC, NFG, MFA | Health Care Sector Update for 09/14/2017: JNJ, PFE, ABT, MRK, AMGN, EKSO, RARE, CRIS","Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT recently announced the receipt of national reimbursement for the FreeStyleLibre glucose monitoring system from National Health Service (NHS) Business Services Authority in the U.K. We expect Freestyle Libre to further contribute to Abbott's top line as along with the U.K., Japanese and Canadian developments, the French Health Ministry recently approved national reimbursement for the device. | Abbott Laboratories (NYSE: ABT) has a long history of serving the healthcare community with its products. ABT Dividend data by YCharts . Dividend yield Abbott Labs has a yield of 2%, which matches up well with the S&P 500 's current average dividend yield. | Abbott ( ABT ) declared a quarterly common dividend of 26.5 cents per share. VIDEO: Daily Dividend Report: INTC, CSCO, BMY, ABT, KR, KRC, NFG, MFA The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Cisco ( CSCO ) declared a quarterly dividend of $0.29 per common share to be paid on October 25, 2017 to all shareholders of record as of the close of business on October 5, 2017. | In sector news, Ekso Bionics Holdings ( EKSO ), which is in the field of medical and industrial exoskeletons, and Genesis Rehab Services, a provider of physical, occupational and respiratory therapy, disclosed Thursday a collaboration to study opportunities for incorporating EksoGT in skilled nursing facilities. In other sector news, (+) RARE (+6.8%) Wedbush upgrades shares to outperform (-) CRIS (-5.9%) Prices 20 million shares of common stock The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Unauthorized reproduction is strictly prohibited."
2017-09-13,52.2400016784668,52.0,-0.4621638302645713,,
2017-09-12,52.4900016784668,52.25,-0.45942126867450883,"3 Big Stock Charts for Tuesday: Abbott Laboratories (ABT), Aetna Inc (AET) and Boston Scientific Corporation (BSX)","More From InvestorPlace 7 Stocks to Sell Before They Crash 7 F-Rated Stocks to Sell Before They Get Even Uglier 10 Stocks That Every 20-Year-Old Should Buy The post 3 Big Stock Charts for Tuesday: Abbott Laboratories (ABT), Aetna Inc (AET) and Boston Scientific Corporation (BSX) appeared first on InvestorPlace . Today's three big stock charts look at Abbott Laboratories (NYSE: ABT ), Aetna Inc (NYSE: AET ) and Boston Scientific Corporation (NYSE: BSX ), three stocks leading the group that's pressing to make new 52-week highs. Abbott Laboratories (ABT) Abbott Labs shares have been trading in a bull market trend since crossing above their 20-month moving average in January 2017."
2017-09-11,52.34999847412109,52.45000076293945,-0.45723313162943524,,
2017-09-08,51.290000915527344,52.02000045776367,0.19102634524010925,4 Top MedTech Stocks for Dividend Investors in 2017,"Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Owens & Minor, Inc. (OMI): Free Stock Analysis Report Patterson Companies, Inc. (PDCO): Free Stock Analysis Report Cardinal Health, Inc. (CAH): Free Stock Analysis Report To read this article on Zacks.com click here. Our Choices Abbott LaboratoriesABT Abbott Park, IL-based Abbott Laboratories discovers, develops, manufactures and sells a diversified line of health care products. Dividend Investing to the Rescue As evident from the MedTech story, stocks can be volatile and are risky at times.. With uncertainty ruling the markets, it is not surprising that dividend investing has emerged as one of the most popular investing themes."
2017-09-07,51.400001525878906,51.4900016784668,1.4232784737879207,Abbott (ABT) Hits a 52-Week High: What's Driving the Stock?,"Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH): Free Stock Analysis Report Chemed Corp. (CHE): Free Stock Analysis Report To read this article on Zacks.com click here. Share price of AbbottABT scaled a new 52-week high of $51.42 on Sep 6, eventually closing nominally lower at $51.19. Abbott Laboratories Price and Consensus Abbott Laboratories Price and Consensus | Abbott Laboratories Quote Abbott carries a Zacks Rank #3 (Hold)."
2017-09-06,51.20000076293945,51.18999862670898,0.17509756793018244,,
2017-09-05,50.84000015258789,51.02999877929688,-0.019535422034047685,,
2017-09-01,51.02999877929688,51.18000030517578,0.3737187768267936,"Abbott's AMPLATZER Pivotal Study to Strengthen Vascular Arm | Abbott's (ABT) FreeStyle Libre Gets Japan Reimbursement Nod | Health Care Sector Update for 09/01/2017: JNJ, PFE, ABT, MRK, AMGN, IOVA, APVO, PGNX","Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottABT recently has initiated a U.S. pivotal clinical study to evaluate the safety and effectiveness of a modified version of its AMPLATZER device. Breaking the conventional treatment, Abbott is developing the AMPLATZER Duct Occluder II Additional Sizes (ADO II AS) device to provide physicians with a nonsurgical treatment option for addressing the PDA defect in newborns and pre-term infants. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH): Free Stock Analysis Report To read this article on Zacks.com click here. As a major breakthrough in its diabetics business, AbbottABT recently announced the receipt of national reimbursement for the FreeStyle Libre glucose monitoring system in Japan. Considering the market potential and Abbott's current developments in the diabetes care segment, the recent national reimbursement grant in Japan will accelerate the top line. | ABT: flat MRK: flat Health care shares were mainly firmer in pre-market trade Friday. The company reported data from the first cohort of the study, which showed clinically-meaningful outcomes in the evaluable patients, with a 29% Objective Response Rate including one complete response continuing beyond 15 months post-administration of a single TIL treatment, and 77% of patients had reduction in target tumor size."
2017-08-31,50.29999923706055,50.93999862670898,0.29394773558128223,"Health Care Sector Update for 08/31/2017: JNJ, PFE, ABT, MRK, AMGN, IPXL, INSY","Health care stocks were firmer as Thursday's regular session drew to a close. rose 23.1% after Shanghai Fosun Pharmaceutical Group disclosed in a regulatory filing Thursday it has acquired 3.9 million shares of common stock of the company. In other sector news, (+) MRK (+1.1%) FDA issues alert on safety concerns on Keytruda for multiple myeloma after two halted trials (-) INSY (-4.2%) Sued by Arizona's attorney general for fraudelent marketing scheme The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2017-08-30,50.02000045776367,50.11000061035156,1.272364611045332,"5 Greatest Health-Care Stocks of All Time | Health Care Sector Update for 08/30/2017: JNJ, PFE, ABT, MRK, AMGN, MDCO, OTIC","SEE ALSO: Quiz: Test Your Bull Market IQ Ticker symbol: ABT Lifetime wealth creation: $189.6 billion Lifetime cumulative return: 2,820,670% Current share price: $50.15 Current dividend yield: 2.1% Current analyst ratings: 11 strong buy, 2 buy, 5 hold, 0 sell, 0 strong sell Joining Pfizer and Bristol-Myers Squibb on this distinguished list of top-performing stocks is fellow health-care giant Abbott Laboratories. SEE ALSO: The 30 Greatest Stocks of All Time Ticker symbol: PFE Lifetime wealth creation: $171.6 billion Lifetime cumulative return: 2,588,650% Current share price: $33.50 Current dividend yield: 3.8% Current analyst ratings: 7 strong buy, 0 buy, 7 hold, 0 sell, 1 strong sell It should come as no surprise that many of the top-performing stocks since 1926 are components of the Dow, which dates back to 1896. SEE ALSO: Best Stock in Every State to Buy Now Ticker symbol: BMY Lifetime wealth creation: $177.2 billion Lifetime cumulative return: 3,484,840% Current share price: $58.86 Current dividend yield: 2.7% Current analyst ratings: 5 strong buy, 1 buy, 5 hold, 0 sell, 1 strong sell Add another pharmaceutical maker to the list of the greatest creators of stock market wealth for investors over the 90-year span. | PFE: flat ABT: flat MRK: flat Health care shares were mainly inactive in pre-market trade Wednesday. In sector news, The Medicines Company's ( MDCO ) subsidiary, Rempex Pharmaceuticals, has received approval from the U.S. Food and Drug Administration for Vabomere for adults with complicated urinary tract infections (cUTI), including a type of kidney infection, pyelonephritis, caused by specific bacteria."
2017-08-29,49.90999984741211,50.150001525878906,0.1799283321956099,,
2017-08-28,49.540000915527344,50.2599983215332,0.4808689224615199,,
2017-08-25,49.59000015258789,49.34999847412109,1.453365750302581,,
2017-08-24,49.7400016784668,49.380001068115234,-0.4839719252436407,,
2017-08-23,49.54999923706055,49.63999938964844,-0.7237647732276057,"30 Great Stocks of All Time | Health Care Sector Update for 08/23/2017: JNJ, PFE, ABT, MRK, AMGN, PRTK, NVAX, RARE | How Johnson & Johnson Makes Most of Its Money","Ticker symbol: ABT Lifetime wealth creation: $189.6 billion Lifetime cumulative return: 2,820,670% Current share price: $48.74 Current dividend yield: 2.2% Current analyst ratings: 11 strong buy, 2 buy, 5 hold, 0 sell, 0 strong sell Joining Pfizer and Bristol-Myers Squibb on this distinguished list of top-performing stocks is fellow health-care giant Abbott Laboratories. SEE ALSO: 25 Surprising Stocks Paying Dividends for 25 Years or More Ticker symbol: INTC Lifetime wealth creation: $246.0 billion Lifetime cumulative return: 119,590% Current share price: $35.01 Current dividend yield: 3.1% Current analyst ratings: 12 strong buy, 2 buy, 7 hold, 1 sell, 2 strong sell Intel is an old-timer among publicly traded technology companies. Ticker symbol: CVX Lifetime wealth creation: $330.4 billion Lifetime cumulative return: 945,430% Current share price: $106.48 Current dividend yield: 4.1% Current analyst ratings: 10 strong buy, 2 buy, 5 hold, 0 sell, 2 strong sell Chevron is yet another member of the Dow delivering a disproportionate share of the stock market's total wealth creation over 90 years. | ABT: flat Health care shares were mostly in the red in pre-market trade Wednesday. In sector news, Paratek Pharmaceuticals ( PRTK ) was up 27% after media reports said the company is exploring strategic alternatives, including a potential sale. | Pharmaceutical Around 46% of Johnson & Johnson's total revenue stems from its pharmaceutical segment. In the first half of 2017, the medical devices segment generated $6.7 billion from international sales compared to $6.3 billion in the U.S. Orthopedics and surgical medical devices both contribute around 36% of the segment's total revenue. With the impact of Actelion and its pipeline, combined with solid growth from current products including cancer drugs Darzalex and Imbruvica, Johnson & Johnson's pharmaceutical revenue should grow larger as a percentage of total sales."
2017-08-22,48.95000076293945,49.709999084472656,0.18163502315571317,"Health Care Sector Update for 08/22/2017: JNJ, PFE, ABT, MRK, AMGN, MTBC, PFE, MDT","In other sector news, (+) PFE (+0.4%) Wins Indian patent for pneumonia vaccine (-) MDT (-1.4%) Fiscal Q1 EPS tops Street views while revenues miss The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. All rights reserved. Unauthorized reproduction is strictly prohibited."
2017-08-21,48.77999877929688,48.880001068115234,1.5526012455317584,"Health Care Sector Update for 08/21/2017: JNJ, PFE, ABT, MRK, AMGN, AZN, NVS, TNXP | Better Buy: AbbVie Inc. vs. Pfizer Inc. | Why Is Abbott Laboratories (ABT) Down 3.1% Since the Last Earnings Report?","ABT: flat MRK: flat In sector news, AstraZeneca ( AZN ) was down 0.5% after it its biologics research and development arm MedImmune entered into a five-year strategic research collaboration with Ethris, a German developer of mRNA-based drugs with a focus on pulmonary disease. The collaboration will target the development of RNA therapies for respiratory diseases using Ethris' proprietary SNIM RNA technology, Ethris said in a statement. | AbbVie has several candidates that could prove to be megablockbusters in a few years, including cancer drug Rova-T, autoimmune disease drug ABT-494, and Elagolix, which targets treatment of endometriosis and uterine fibroids. Whether you compare the two drug stocks over five years, three years, one year, or so far in 2017, AbbVie stock has outperformed Pfizer. The case for Pfizer If you like AbbVie's dividend, you'll probably love Pfizer's. | It has been about a month since the last earnings report for Abbott LaboratoriesABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Q2 Earnings Abbott reported second-quarter 2017 adjusted earnings from continuing operations of $0.62 per share, 3.3% higher than the Zacks Consensus Estimate and up 12.7% year over year."
2017-08-18,49.09999847412109,48.7400016784668,0.2050067472752686,,
2017-08-17,49.630001068115234,49.290000915527344,-0.7331910526311557,"Tandem Investment Advisors, Inc. Buys FactSet Research Systems Inc, National Retail Properties ...","Shares added by 18.21% Abbott Laboratories ( ABT ) - 229,576 shares, 4.43% of the total portfolio. Tandem Investment Advisors, Inc. New Purchases: FDS , DG , VRSK , JNJ, KHC, AAPL, Added Positions:NNN, RSG, BRO, WBA, SNI, SJM, BDX, COST, NKE, EXPD, Reduced Positions:GWW, ITT, ATR, TMO, FMC, COP, PYPL, Sold Out:QCOM, For the details of Tandem Investment Advisors, Inc.'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Tandem+Investment+Advisors%2C+Inc. Shares added by 7.97% New Purchase: FactSet Research Systems Inc (FDS) Tandem Investment Advisors, Inc. initiated holdings in FactSet Research Systems Inc."
2017-08-16,49.040000915527344,49.810001373291016,-0.6850698071137531,Abbott-North West London Pathology Expand in Diagnostics,"Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Qiagen N.V. (QGEN): Free Stock Analysis Report Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report To read this article on Zacks.com click here. Illinois-based global medical device company Abbott LaboratoriesABT recently signed a $252-million managed equipment service contract with North West London Pathology (NWLP), hosted by Imperial College Healthcare NHS Trust. Abbott expects this alliance to solidify its footprint in the rapidly growing diagnostics market."
2017-08-15,49.060001373291016,48.81999969482422,1.5701477230598289,,
2017-08-14,48.7400016784668,49.08000183105469,-0.48920030931237873,"VIG, MDT, ABT, CVS: Large Inflows Detected at ETF | Keeley Funds Comments on Abbott Labs","Among the largest underlying components of VIG, in trading today Medtronic PLC (Symbol: MDT) is up about 1.3%, Abbott Laboratories (Symbol: ABT) is up about 1.2%, and CVS Health Corporation (Symbol: CVS) is higher by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $64.9 million dollar inflow -- that's a 0.3% increase week over week in outstanding units (from 265,873,303 to 266,573,385). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $81.24 per share, with $94.53 as the 52 week high point - that compares with a last trade of $93.43. | Abbott Labs ( NYSE:ABT ) is a large, multinational health care products company focusing on pharmaceuticals, diagnostic and nutritional products. The company reported a nice quarter beating estimates for both sales and earnings, and continued to execute well on the integration of recently acquired St. Jude Medical. WMGI 15-Year Financial Data The intrinsic value of WMGI Peter Lynch Chart of WMGI Premium Members This article first appeared on GuruFocus ."
2017-08-11,48.2400016784668,48.540000915527344,0.6975792796045426,,
2017-08-10,48.7400016784668,48.060001373291016,0.6218889440761763,,
2017-08-09,48.7599983215332,48.77000045776367,-1.3951585592090852,,
2017-08-08,49.2400016784668,48.880001068115234,0.02051299543636704,,
2017-08-07,49.2599983215332,49.29999923706055,-0.7311141309505576,,
2017-08-04,49.2400016784668,49.2599983215332,0.08120364776760053,"Noteworthy ETF Inflows: IWD, T, USB, ABT | Health Care Sector Update for 08/04/2017: JNJ, PFE, ABT, MRK, AMGN, MDRX, CFRX | Vanguard Health Care Fund Gains 4 International Stocks in 2nd Quarter","Among the largest underlying components of IWD, in trading today AT&T Inc (Symbol: T) is trading flat, US Bancorp (Symbol: USB) is up about 1%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $187.4 million dollar inflow -- that's a 0.5% increase week over week in outstanding units (from 313,550,000 to 315,150,000). For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $102.07 per share, with $121.24 as the 52 week high point - that compares with a last trade of $117.40. | ABT: flat MRK: flat AMGN: flat Health care shares were mostly flat in pre-market trade Friday. In sector news, Allscripts Healthcare Solutions ( MDRX ) was up 11.8% after it posted Q2 adjusted EPS increased to $0.15 from $0.14 a year earlier, meeting Capital IQ's poll estimate for the quarter. In other sector news, (+) CFRX (+3.7%) Gets US patent for new approach to treat influenza using inhaled antibodies The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other positions the fund added to during the quarter include Abbott Laboratories ( ABT ), Novartis AG ( NOVN ), Teva Pharmaceutical Industries Ltd. ( TEVA ), Baxter International Inc. ( BAX ), Becton, Dickinson and Co. ( BDX ) and Cardinal Health Inc. (CAH). The Japanese clinical testing devices manufacturer has a market cap of 1.36 trillion yen; its shares were trading around 6,640 yen on Friday with a price-earnings (P/E) ratio of 33.42, a price-book (P/B) ratio of 6.47 and a price-sales (P/S) ratio of 5.44. The Japanese manufacturer of pharmaceuticals, medical tools and equipment has a market cap of 1.47 trillion yen; its shares were trading around 4,325 yen on Friday with a P/E ratio of 29.77, a P/B ratio of 3 and a P/S ratio of 3.24."
2017-08-03,49.2599983215332,49.15999984741211,0.04061056536306132,,
2017-08-02,49.13999938964844,49.22999954223633,-0.20300137541292007,"Health Care Sector Update for 08/02/2017: JNJ, PFE, ABT, MRK, AMGN, EYES, OCUL","ABT: flat MRK: flat In sector news, Second Sight Medical Products ( EYES ) rose 7.4% after it said late Tuesday its Q2 loss per share narrowed to $0.12 per share from $0.17 loss per share a year earlier, less than Capital IQ's poll estimate of $0.14 loss per share, helping its shares up over 4% in after-hours trading. In other sector news, (+) OCUL (+2%) Appointed Antony Mattesich as CEO (-) PFE (-0.3%) BMO Capital upgrades shares to outperform from market perform The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2017-08-01,49.209999084472656,49.150001525878906,0.18315049594170235,,
2017-07-31,49.61000061035156,49.18000030517578,-0.12192147878474796,,
2017-07-28,50.15999984741211,49.61000061035156,-0.86676133820901,"USMV, FTXH: Big ETF Outflows | Health Care Sector Update for 07/28/2017: JNJ, PFE, ABT, MRK, AMGN, ABBV, NUVA","Among the largest underlying components of FTXH, in morning trading today Abbott Labs ( ABT ) is down about 1.1%, and Abbvie Incorporated (ABBV) is lower by about 3.1%. Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel, the biggest outflow was seen in the iShares Edge MSCI Min Vol USA ETF ( USMV ), where 4,500,000 units were destroyed, or a 1.6% decrease week over week. And on a percentage change basis, the ETF with the biggest outflow was the First Trust Nasdaq Pharmaceuticals ETF ( FTXH ), which lost 50,000 of its units, representing a 33.3% decline in outstanding units compared to the week prior. | Total revenues of $9.93 billion were up from $9.84 billion in the same period a year ago and exceeded the Street projection of $9.75 billion. The company narrowed and raised its FY revenue range to between $39.40 billion and $40.40 billion from prior guidance of $39.10 billion and $40.30 billion, straddling the Street projection of $40.05 billion. In other sector news, (+) ABBV (+1.8%) Reports Q2 EPS beat and revenues in line with estimates; reaffirms 2017 guidance (-) NUVA (-10.5%) President and COO Jason Hannon resigns The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2017-07-27,50.31999969482422,50.11000061035156,-1.0964897103940539,"Noteworthy ETF Outflows: IWD, T, ABT, USB | Health Care Sector Update for 07/27/2017: JNJ, PFE, ABT, MRK, AMGN, BMY, EW, VAR","Among the largest underlying components of IWD, in trading today AT&T Inc (Symbol: T) is up about 2.7%, Abbott Laboratories (Symbol: ABT) is down about 0.5%, and US Bancorp (Symbol: USB) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $70.2 million dollar outflow -- that's a 0.2% decrease week over week (from 314,150,000 to 313,550,000). For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $102.07 per share, with $121.24 as the 52 week high point - that compares with a last trade of $116.99. | PFE: flat In sector news, Bristol-Myers Squibb Company ( BMY ) was down 6.2% after it reported Q2 adjusted earnings of $0.74 per diluted share compared with an income of $0.69 per share a year ago, beating the $0.73 average estimate from analysts polled by Capital IQ. In other sector news, (+) EW (+2.9%) Reports Q2 EPS and revenues above estimates and raises 2017 guidance (-) VAR (-2.5%) Posts Fiscal Q3 EPS above Street views but revenues fall short; guides Q4 EPS in line The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2017-07-26,50.7400016784668,50.400001525878906,-0.41732727692018684,"MMM a Top Socially Responsible Dividend Stock With 2.4% Yield | The Zacks Analyst Blog Highlights: Oracle, Pfizer, Abbott, Alphabet and Schlumberger | Perkins Capital Management Inc Buys AmerisourceBergen Corp, Pentair PLC, Zagg Inc, Sells ... | Diamond Hill Capital Buys Discover Financial Services, Molson Coors Brewing Co, First Republic ...","MMM operates in the Medical Instruments & Supplies sector, among companies like Medtronic PLC ( MDT ), and Abbott Laboratories ( ABT ). 3M Co (Symbol: MMM) has been named a Top Socially Responsible Dividend Stock by Dividend Channel , signifying a stock with above-average ''DividendRank'' statistics including a strong 2.4% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of social and environmental criteria. According to the ETF Finder at ETF Channel , 3M Co is a member of both the iShares MSCI USA ESG Select ETF ( SUSA ), making up 4.50% of the underlying holdings of the fund, as well as the iShares MSCI KLD 400 Social Index Fund ETF ( DSI ), where MMM makes up 1.21% of the underlying holdings of the fund. | Stocks recently featured in the blog include Oracle (NYSE: ORCL - Free Report ), Pfizer (NYSE: PFE - Free Report ), Abbott (NYSE: ABT - Free Report ), Alphabet (NASDAQ: GOOGL - Free Report ) and Schlumberger (NYSE: SLB - Free Report ). Get the full Report on ABT - FREE Get the full Report on ORCL - FREE Get the full Report on PFE - FREE Get the full Report on GOOGL - FREE Get the full Report on SLB - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Oracle Corporation (ORCL): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Alphabet Inc. (GOOGL): Free Stock Analysis Report Schlumberger N.V. (SLB): Free Stock Analysis Report To read this article on Zacks.com click here. | Shares reduced by 6.31% Abbott Laboratories ( ABT ) - 82,710 shares, 4.46% of the total portfolio. Perkins Capital Management Inc New Purchases: ABC , PNR , ZAGG , VERI, HDP, TEAR, DE, XPO, CTG, CDXS, Added Positions:CYTX, BX, INWK, VG, MRK, ENTL, VCEL, T, DAVE, JBLU, Reduced Positions:CSII, ATRS, NEO, LMAT, BIOS, AXGN, CGNT, RMTI, ARCI, LLY, Sold Out:TCMD, OOMA, STX, SPSC, MMSI, JCI, RIG, EGHT, DRAD, GEOS, For the details of PERKINS CAPITAL MANAGEMENT INC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=PERKINS+CAPITAL+MANAGEMENT+INC These are the top 5 holdings of PERKINS CAPITAL MANAGEMENT INC AxoGen Inc ( AXGN ) - 554,792 shares, 10.31% of the total portfolio. Shares reduced by 1.02% New Purchase: AmerisourceBergen Corp (ABC) Perkins Capital Management Inc initiated holdings in AmerisourceBergen Corp. | Shares reduced by 5.12% Abbott Laboratories ( ABT ) - 11,964,081 shares, 3.14% of the total portfolio. Diamond Hill Capital New Purchases: VRSK , AVT , ENDP , BK, Added Positions:DFS, TAP, FRC, JNPR, PNC, JPM, JCI, VR, TGNA, KEX, Reduced Positions:WFC, WLTW, CSCO, COF, ITW, PFE, C, NWL, AAN, DE, Sold Out:UAM, CARS, ESS, GSOL, NVTR, T, For the details of Diamond Hill Capital's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Diamond+Hill+Capital These are the top 5 holdings of Diamond Hill Capital Citigroup Inc ( C ) - 9,184,967 shares, 3.31% of the total portfolio. Shares added by 12.98% New Purchase: Verisk Analytics Inc (VRSK) Diamond Hill Capital initiated holdings in Verisk Analytics Inc."
2017-07-25,50.97999954223633,50.83000183105469,-0.6700830534898877,"Health Care Sector Update for 07/25/2017: JNJ, PFE, ABT, MRK, AMGN, NVAX, BIIB, LLY | 3 Dividend Stocks That Are Perfect for Retirement | Profit from the Dollar's Dip with These 5 S&P 500 Stocks","ABT: flat In sector news, Novavax ( NVAX ) slumped 19.2% after the company said l;ate Monday topline data were positive from its phase 2 safety and immunogenicity trial of the RSV F Vaccine in older adults, but some investors were skeptical the data were as positive as the company said. The company said new preclinical data on its RSV F Vaccine construct showed the company's construct is a stable prefusogenic RSV F antigen, distinctive from other candidates, that elicits potent neutralizing antibody responses to multiple key epitopes. | It has also been busy on the acquisition front, with buyouts this year of Abbott Labs ' (NYSE: ABT) medical optics business and the purchase of Swiss drugmaker Actelion. We asked three Motley Fool investors to identify stocks that fit that bill, and they chose Lowe's (NYSE: LOW) , Johnson & Johnson (NYSE: JNJ) , and Altria (NYSE: MO) . Moreover, while Lowe's current 2.1% dividend yield slightly trails Home Depot's, Lowe's has only had to use 26% of its free cash flow over the past year to cover it. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Morgan Stanley (MS): Free Stock Analysis Report NVIDIA Corporation (NVDA): Free Stock Analysis Report Micron Technology, Inc. (MU): Free Stock Analysis Report Lam Research Corporation (LRCX): Free Stock Analysis Report Applied Materials, Inc. (AMAT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT discovers, develops, manufactures and sells a diversified line of health care products. By this logic, an 8% decline in the dollar's value by the end of the current year could boost 2018 earnings by 4%."
2017-07-24,50.810001373291016,50.79999923706055,-0.29422854556397027,"Health Care Sector Update for 07/24/2017: JNJ, PFE, ABT, MRK, AMGN, WBMD, BMY, SRPT | Better Buy: Johnson & Johnson vs. AbbVie","In sector news, WebMD Health Corp ( WBMD ) was up 19.8% after it confirmed it has agreed to be bought by KKR's ( KKR ) Internet Brands, in a deal worth approximately $2.8 billion. Internet Brands will pay $66.50 per share in cash, a 30% premium to the share price on Feb. 15, the day before WebMD said it was starting a process to explore and evaluate potential strategic alternatives, and a 20% premium to the closing price on July 21. In other sector news, (+) BMY (+0.7%) Melanoma drug Yervoy secures expanded FDA indication to Include pediatric patients (-) SRPT (-2.1%) To raise $250 million in stock offering The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Just this year, the company acquired Abbott Labs ' (NYSE: ABT) medical optics unit and Swiss drugmaker Actelion. It's been a neck-and-neck race between Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) stocks so far in 2017. Here's how Johnson & Johnson and AbbVie compare."
2017-07-21,50.72999954223633,50.84000015258789,-0.01968536894337994,"Company News for July 21, 2017 | Health Care Sector Update for 07/21/2017: JNJ, PFE, ABT, MRK, AMGN, AEZS, BCLI, RH","• Shares of Abbott Laboratories ABT gained 2.9% after the company reported second-quarter 2017 earnings of 62 cents per share, 3.3% higher than the Zacks Consensus Estimate • Shares of Kinder Morgan Inc KMI soared 4.5% after the company announced a dividend hike and a share-buyback plan • Shares of Philip Morris International Inc. PM declined 1.5% after the company reported second quarter earnings per share of $1.14 that missed the Zacks Consensus Estimate of $1.23 • Shares of Travelers Companies Inc TRV dropped 1.5% after the company posted second-quarter 2017 earnings of $1.92 per share that missed the Zacks Consensus Estimate of $2.07 Want the latest recommendations from Zacks Investment Research? Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report The Travelers Companies, Inc. (TRV): Free Stock Analysis Report Kinder Morgan, Inc. (KMI): Free Stock Analysis Report Philip Morris International Inc (PM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | MRK: flat AMGN: flat Health care shares were mostly mixed in pre-market trade Friday. On July 18, the company said that it has been notified by the U.S. Food and Drug Administration that a new drug application seeking approval of Macrilen (macimorelin) for the evaluation of growth hormone deficiency in adults has been accepted as a complete response to the FDA's Nov. 5, 2014 complete response letter and granted a PDUFA date of Dec. 30. In other sector news, (+) BCLI (+0.5%) Wins $16 million grant to study ALS treatment (-) RH (-1.1%) Deutsche Bank downgrades shares to hold from buy with an $80 price target due to valuation The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2017-07-20,49.68000030517578,50.84999847412109,0.21683542547635778,"Abbott Labs (ABT) Beats on Q2 Earnings and Sales, View Up | Abbott (ABT) Tops Earnings Estimates in Q2, Misses on Sales | Health Care Sector Update for 07/20/2017: JNJ, PFE, ABT, MRK, AMGN, BVXV, GSK, PFE","Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Mesa Laboratories, Inc. (MLAB): Free Stock Analysis Report Insys Therapeutics, Inc. (INSY): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT reported second-quarter 2017 adjusted earnings from continuing operations of 62 cents per share, 3.3% higher than the Zacks Consensus Estimate and up 12.7% year over year. On a comparable operational basis (adjusting the impact of foreign exchange, certain acquisitions and divestments), sales increased 2.9% year over year in the reported quarter. | Abbott LaboratoriesABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Currently, Abbott Labs has a Zacks Rank #2 (Buy), but that could definitely change following the company's second quarter 2017 earnings report which was just released. | MRK: flat AMGN: flat Health care shares were mostly inactive in pre-market trade Thursday. The company said it is considering taking the opportunity to proceed directly to testing the clinical efficacy of the experimental vaccine alone in a pivotal phase 3 clinical trial, with clinical efficacy planned to be assessed by measuring reduction of flu illness rate and severity. In other sector news, (+) GSK (+0.5%) Sells raxibacumab to Emergent Biosolutions for upfront payment of $76 million (-) PFE (-0.6%) Obtains Europe right to Cresemba for life-threatening fungal infections in immunocompromised patients The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2017-07-19,48.79999923706055,49.43000030517578,2.355068763603474,"Medical Product Stocks' Earnings on Jul 20: ABT, ISRG & More | Pre-Market Earnings Report for July 20, 2017 : PM, UNP, ABT, DHR, BK, BBT, TRV, SHW, PPG, BX, KEY, RCI | The Hottest Earnings Charts of the Week | Health Care Sector Update for 07/19/2017: JNJ, PFE, ABT, MRK, AMGN, MDGS, GSK, INO | What To Watch For In Abbott's Q2 Earnings","Click to get this free report athenahealth, Inc. (ATHN): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report ABAXIS, Inc. (ABAX): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is scheduled to report second-quarter 2017 results before the opening bell on Jul 20. Abbott Laboratories Price and EPS Surprise Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote Intuitive Surgical Inc.ISRG is set to report second-quarter results after the closing bell. | Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABT is 19.73 vs. an industry ratio of -5.70, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories ( ABT ) is reporting for the quarter ending June 30, 2017. In the past year ABT has beat the expectations every quarter. | Click to get this free report eBay Inc. (EBAY): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report PPG Industries, Inc. (PPG): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report Snap-On Incorporated (SNA): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ABT hasn't missed in five years. Microsoft MSFT has become an important earnings report again as shares trade at 5-year highs. | In other sector news, Medigus ( MDGS ) American depository shares were 5.8% higher after the medical device company said Wednesday it has signed a five-year commercialization agreement in Spain with Izasa Hospital, SLU, a distributor of medical products in the hospital sector. Izasa Hospital SLU is required to purchase a minimum of EUR1.4 million ($1.6 million) of Medigus Ultrasonic Surgical Endostapler (MUSE) equipment over the course of the agreement. (+) GSK (+0.4%) Said to eye sale of Horlicks business in UK INO (flat) Plans $75 million share offering The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs ( ABT ) will release its Q2 2017 earnings on July 20, and there are a few things to watch out for. First, Abbott's nutritional business has suffered some headwinds in China due to weakness in the country's pediatric nutrition market. The nutritional segment accounts for nearly 30% of Abbott's value, per our estimates, making it the biggest business for the company."
2017-07-18,48.68999862670898,48.7400016784668,1.290985815501382,"UPRO, BMY, ABT, GS: ETF Outflow Alert | Here's Why Quidel Corporation Is Rising Today","Among the largest underlying components of UPRO, in trading today Bristol-Myers Squibb Co. (Symbol: BMY) is down about 0.2%, Abbott Laboratories (Symbol: ABT) is off about 0.5%, and Goldman Sachs Group Incorporated (Symbol: GS) is lower by about 1.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $32.5 million dollar outflow -- that's a 3.5% decrease week over week (from 8,500,000 to 8,200,000). For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $65.51 per share, with $109.05 as the 52 week high point - that compares with a last trade of $108.08. | What happened Shares of Quidel Corporation (NASDAQ: QDEL) , a company focused on diagnostic testing equipment, rose 11% as of 11:45 a.m. EDT on Tuesday in response to the announcement that it is acquiring a few product lines from Alere (NYSE: ALR) . Douglas Bryant, Quidel's CEO, offered up the following commentary on the deal: Traders appear to share Bryant's optimism, which is why Quidel's stock is jumping Tuesday. 10 stocks we like better than Quidel When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen."
2017-07-17,48.90999984741211,48.7599983215332,0.10269676148725615,"3 Big Stock Charts for Monday: Qualcomm, Inc. (QCOM), Abbott Laboratories (ABT) and Microsoft Corporation (MSFT) | Can Abbott Laboratories (ABT) Pull a Surprise in Q2 Earnings?","The earnings season always offers opportunities for those watching the charts, which is why today's three big stock charts will take a look at the technical for Qualcomm, Inc. (NASDAQ: QCOM ), Abbott Laboratories (NYSE: ABT ) and software heavyweight Microsoft Corporation (NASDAQ: MSFT ). The 5 Best (And 5 Worst) Tech Stocks to Buy Now The company will report earnings later this week and a successful report will push ABT stock into new high territory, something that chart watchers should be focusing on. More From InvestorPlace 10 Stocks That Will Rocket Higher on Short Squeeze Power 7 Stocks With Momentum on Their Side 7 Stocks to Buy Before Their Earnings Breakout The post 3 Big Stock Charts for Monday: Qualcomm, Inc. (QCOM), Abbott Laboratories (ABT) and Microsoft Corporation (MSFT) appeared first on InvestorPlace . | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Teleflex Incorporated (TFX): Free Stock Analysis Report Dextera Surgical Inc. (DXTR): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is scheduled to report second-quarter 2017 results before the opening bell on Jul 20. Abbott Laboratories Price and EPS Surprise Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote On a positive note, with a strong market position in several geographies, including China, Latin America and several markets in Southeast Asia, EPD is well positioned for sustained above-market growth in some of the largest and fastest growing pharmaceutical markets in the world."
2017-07-14,48.20000076293945,48.90999984741211,-0.3066888700610843,Abbott Partners Bigfoot Biomedical to Expand in Diabetics,"Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. Illinois-based global medical device company Abbott LaboratoriesABT partnered with Bigfoot Biomedical to solidify its footprint in the rapidly growing diabetes therapeutics market. Leveraged on Abbott's FreeStyle Libre glucose sensing technology, the collaboration will result in innovation and marketing of insulin delivery systems."
2017-07-13,48.43000030517578,48.08000183105469,1.4730271228928447,,
2017-07-12,48.16999816894531,48.43000030517578,-0.7226893906991964,"Edwards Emerges Strong on FDA Nods, International Prospect | LabCorp Diagnostics Strong on Novant Health Deal Extension","Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Mesa Laboratories, Inc. (MLAB): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Other Key Picks Other top-ranked medical stocks are Mesa Laboratories, Inc. MLAB , Abbott Laboratories ABT and Align Technology, Inc. ALGN . Edwards Lifesciences Corporation Price and Consensus Edwards Lifesciences Corporation Price and Consensus | Edwards Lifesciences Corporation Quote We are encouraged by the company's long-term growth strategies and recent progress in its technology pipeline. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Laboratory Corporation of America Holdings (LH): Free Stock Analysis Report Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked medical stocks are Edwards Lifesciences Corporation EW and Abbott Laboratories ABT . The Technical Services Agreement makes the company's diagnostics business - LabCorp Diagnostics - the laboratory management services provider for all Novant Health acute care facilities."
2017-07-11,48.20000076293945,48.150001525878906,0.5397594895448623,"Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for July 12, 2017","Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. The following ETF(s) have ABT as a top-10 holding: iShares U.S. Medical Devices ETF ( IHI ) SPDR S&P Health Care Equipment ( XHE ) First Trust VL Dividend ( FVD ) First Trust CBOE S&P 500 VIX Tail Hedge Fund ( VIXH )."
2017-07-10,48.41999816894531,48.22999954223633,-0.10373285533014107,"Notable ETF Inflow Detected - ITOT, PM, ABT, USB | Investors Look for Gains as Abbott Labs Set to Acquire Alere | Medtronic (MDT) Launches Resolute Onyx DES Device in Japan","Among the largest underlying components of ITOT, in trading today Philip Morris International Inc (Symbol: PM) is up about 0.6%, Abbott Laboratories (Symbol: ABT) is down about 0.3%, and US Bancorp (Symbol: USB) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core S&P Total U.S. Stock Market ETF (Symbol: ITOT) where we have detected an approximate $46.8 million dollar inflow -- that's a 0.5% increase week over week in outstanding units (from 174,000,000 to 174,850,000). For a complete list of holdings, visit the ITOT Holdings page » The chart below shows the one year price performance of ITOT, versus its 200 day moving average: Looking at the chart above, ITOT's low point in its 52 week range is $47.42 per share, with $56.24 as the 52 week high point - that compares with a last trade of $55.42. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Mesa Laboratories, Inc. (MLAB): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT provided some good news for investors as the much-contentious merger of the company with Alere is a step closer to completion. Notably, Alere develops simple, rapid tests, including Alere i, the molecular test for flu and strep, to deliver reports in less than 15 minutes. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Though based in a highly fragmented Coronary Stents market, Medtronic faces strong competition from global leaders like Boston Scientific Corp. BSX , Abbott Laboratories ABT and others. Following the successful launch of its highly innovative and sophisticated Drug Eluting Stent (DES), Resolute Onyx in the U.S. in May 2017, Medtronic is now planning to start selling it in the high-growth Japan market from Jul 10, as per a Cardiovascular Business report released on Jul 7."
2017-07-07,48.16999816894531,48.43999862670898,-0.3923970134117891,"Health Care Sector Update for 07/07/2017: JNJ, PFE, ABT, MRK, AMGN, NVS, DXTR, CNAT, ADXS | Phibro Animal Health & Zydus Cadila Plan to Expand in India","ABT: flat MRK: flat Health care shares were mostly higher in pre-market trade Friday. Dextera Surgical ( DXTR ), the company developing and commercializing the Dextera MicroCutter 5/80 Stapler, said late Thursday it placed a temporary shipping hold on the MicroCutter 5/80 Stapler and reload cartridges in response to six reports that surgeons were unable to clamp the MicroCutter 5/80 Stapler after inserting a MicroCutter 30 Reload into the stapler prior to or during a surgical procedure. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Phibro Animal Health Corporation (PAHC): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report To read this article on Zacks.com click here. A few other top-ranked medical stocks are Inogen, Inc. INGN , Varian Medical Systems, Inc. VAR and Abbott Laboratories ABT . Phibro Animal Health CorporationPAHC recently announced plans to enter into a long-term agreement with global pharmaceutical company Zydus Cadila to expand in the rapidly growing poultry market in India."
2017-07-06,48.83000183105469,47.93999862670898,0.5605158148785881,"Exactech Boosts Knee System Portfolio, Launches New App | Here's Why You Should Add Abbott Laboratories Right Now | Health Care Sector Update for 07/06/2017: JNJ, PFE, ABT, MRK, AMGN, EGLT, TNXP, NVS","Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Exactech, Inc. (EXAC): Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked medical stocks are Inogen, INC. INGN and Abbott Laboratories ABT . The TKA PLUS software can be used in conjunction with Truliant Knee System for enhanced performance in total knee replacement. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. Illinois-based global medical device company Abbott LaboratoriesABT has been gaining investor confidence on consistent positive results. Based upon the promising estimates, solid past performance and a Zacks Rank #2 (Buy), the stock seems to be a lucrative pick for now. | In health care stocks news, Egalet ( EGLT ) fell 28.4% after the company said late Wednesday it is planning to raise funds to market its drugs including morphine sulfate and nasal spray, through the sale of shares and warrants. In other sector news, (+) TNXP (+2.1%) Receives conditional OK of Tonmya as brand name for PTSD treatment (-) NVS (-2.1%) Gets approval in Europe for label update for psoriasis treatment Cosentyx The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. All rights reserved."
2017-07-05,48.720001220703125,49.0,-1.8226565041406368,"Abbott Freestyle Libre System Gets Health Canada License | Health Care Sector Update for 07/05/2017: JNJ, PFE, ABT, MRK, AMGN, MTBC, BGNE, EVHC","Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Mesa Laboratories, Inc. (MLAB): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Global medical device company Abbott LaboratoriesABT has been constantly making efforts to expand its diabetes care business. In this regard, we note that results from the IMPACT clinical trial demonstrated that diabetic patients using the FreeStyle Libre system spent 38% lesser time in hypoglycemia than people using with traditional self-monitoring of blood glucose systems (SMBG). | ABT: flat In health care stocks news, Medical Transcription Billing ( MTBC ) rose 33.6% after it revealed its recent acquisition of a Washington-based revenue cycle management company's client accounts and related business assets, which it says is expected to be accretive to earnings during Q3. Financial terms of the deal were not disclosed."
2017-07-03,48.72999954223633,48.709999084472656,0.5747101237302351,"Health Care Sector Update for 07/03/2017: JNJ, PFE, ABT, MRK, AMGN, OPXA, PTCT. KND","ABT: flat In health care stocks news, Opexa Therapeutics ( OPXA ) rose 10% after the company said in a regulatory filing Monday it entered into an agreement and plan of merger and reorganization with Acer Therapeutics Inc., with Acer becoming a wholly-owned subsidiary of Opexa and the surviving corporation of the merger. Under the merger agreement, each outstanding share of Acer common stock will be converted into the right to receive approximately one share of common stock of Opexa, which amount is subject to adjustment prior to closing of the merger upon the occurrence of specified events, including to account for any additional shares that Acer may issue before closing and for Opexa's net cash balance at closing."
2017-06-30,48.77999877929688,48.61000061035156,-0.04104341873908011,"Health Care Sector Update for 06/30/2017: JNJ, PFE, ABT, MRK, AMGN, SKLN, AMGN. CARA","In health care stocks news, Skyline Medical ( SKLN ) rose 22.9% after the company said late Thursday it expects the full rollout of its Streamway system in Europe by early 2018. The Streamway system, a direct-to-drain fluid disposal system designed specifically for medical applications, has been granted a CE mark, making it available in 32 European countries. (-) CARA (-27.7%) Says new pain reliever effective at higher dosage but shows no success at lower levels The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2017-06-29,48.72999954223633,48.72999954223633,-0.3484997400563075,5 Underfollowed Stocks That Are Projected To Explode | What If St. Jude Medical Acquisition Doesn't Pan Out For Abbott?,"Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Ciena Corporation (CIEN): Free Stock Analysis Report Dave & Buster's Entertainment, Inc. (PLAY): Free Stock Analysis Report CBOE Holdings, Inc. (CBOE): Free Stock Analysis Report Brink's Company (The) (BCO): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT Abbott Laboratories is a global healthcare company focused on improving life throughout the research and development of technologies. CBOE Holdings, Inc.CBOE CBOE Holdings operates as the holding company for Chicago Board Options Exchange, which is an options exchange which operates as an organized marketplace for the trade of listed options on equity securities. | Abbott Labs ( ABT ) acquired St. Jude Medical to create a more integrated offering and compete better against rivals such as Medtronic and Boston Scientific. If price competition reduces our market forecast by 10%, and Abbott's share in the vascular market declines from 40% to 35%, there could be a nearly 10% downside to our price estimate for the company. The agency stated that although St. Jude is a good strategic fit, the acquisition will put stress on Abbott's balance sheet for at least two years, thus increasing default risk."
2017-06-28,48.93000030517578,48.47999954223633,0.0,"Noteworthy ETF Inflows: FVD, ABT, PDCO, AWR | Health Care Sector Update for 06/28/2017: JNJ, PFE, ABT, MRK, AMGN, GMRE, BLUE, FOLD","Among the largest underlying components of FVD, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.3%, Patterson Companies Inc (Symbol: PDCO) is up about 1.2%, and American States Water Co (Symbol: AWR) is up by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the First Trust Value Line Dividend Index Fund (Symbol: FVD) where we have detected an approximate $139.2 million dollar inflow -- that's a 3.8% increase week over week in outstanding units (from 125,137,986 to 129,887,986). For a complete list of holdings, visit the FVD Holdings page » The chart below shows the one year price performance of FVD, versus its 200 day moving average: Looking at the chart above, FVD's low point in its 52 week range is $25.59 per share, with $29.95 as the 52 week high point - that compares with a last trade of $29.47. | ABT: flat On June 5, the company said that it entered into a purchase contract to purchase a 27,280 square-foot cardiac clinic in Lubbock, Texas and that the company was going to enter into a new, 12-year, triple-net lease with the Lubbock Heart Hospital. Since the announcement of the acquisition of the Cardiac Clinic, Surgery Partners has informed that company that, due to legal restrictions on the percentage of lease payments it may guarantee, it was only going to be guaranteeing approximately 52% of the rent payments, a figure which represents Surgery Partners' percentage ownership of the Cardiac Clinic prior to its sale to the company."
2017-06-27,48.95000076293945,48.66999816894531,-0.9196827307026448,,
2017-06-26,49.209999084472656,48.90999984741211,-0.5720175477630094,"How We Earn $5,300 In Dividends From A $10,000 Investment (VZ, PSX, GILD) | How to Find Cheap Stocks With 5%+ Dividends | How to Find Cheap Stocks With 5%+ Dividends | Health Care Sector Update for 06/26/2017: JNJ, PFE, ABT, MRK, AMGN","The fund holds a collection of biotechs - such as Celgene Corporation (NASDAQ: CELG ) and Gilead Sciences, Inc. (NASDAQ: GILD ) - large pharmaceuticals - such as Abbot Laboratories (NYSE: ABT ) and Merck & Co., Inc. (NYSE: MRK ) - and other health care companies, such as UnitedHealth Group Inc (NYSE: UNH ). In a portfolio like mine that earns an average yield of 5.3%, that amount would earn $530 in dividend income during the year. One of Warren Buffett's favorites (the famed investor holds 15.6% of all the shares outstanding), Phillips 66 (NYSE: PSX ) is also an incredible dividend payer, having grown its dividends from 20 cents per share five years ago to the current 63 cents per share. | Even better if we can buy cheap, and with Pfizer, we can: the stock trades at just 15.2 times trailing-twelve-month FCF, well below rivals Johnson & Johnson (NYSE: JNJ ) at 22.9 and Abbott Laboratories (NYSE: ABT ) at 27.6. Beyond the Dividend Yield When it comes to dividends, many people simply dial up a stock in Yahoo Finance or Google Finance, check out its current yield and leave it at that. 10 Best Dividend Stocks for the Market's 10 Sectors Here's How We'll Double Our MoneyandCollect 8.6% Income A 50% gain in 5 years is nice, but we can do a lot better if we zero in on stocks with the same strengths as Pfizer but double the dividend growth. | By Brett Owens Today I'm going to show you 2 easy ways to set yourself up for safe double-digit yearly dividend growth and invite quick 100%+ upside too. It will have you pocketing a nice 5%+ yield in short order. It's a sacred cow for many folks; you calcu | In health care stocks news, Conatus Pharmaceuticals ( CNAT ) was up 2% after it said the U.S. Food and Drug Administration has granted orphan drug designation to its IDN-7314 to treat primary sclerosing cholangitis, a disease affecting bile ducts in the liver which can lead to cirrhosis and liver failure. In other sector news, (+) TGTX (+3.4%) Reports positive results from phase 2 study of TG-1101 to treat MS (-) BMY (-0.7%) Says follow-up data from its phase 3 Eloquent-2 study showed Empliciti plus lenalidomide/dexamethasone (Ld) continued to demonstrate efficacy in patients with relapsed/refractory multiple myeloma, compared to Ld alone The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Unauthorized reproduction is strictly prohibited."
2017-06-23,49.18000030517578,49.08000183105469,-0.6096306495466006,"Health Care Sector Update for 06/23/2017: JNJ, PFE, ABT, MRK, AMGN, CARA, BLCM, NVS","MRK: flat In health care stocks news, Cara Therapeutics ( CARA ) was up 8.2% after it said the U.S. Food and Drug Administration has granted breakthrough therapy designation to I.V. In other sector news, (+) BLCM (+7.3%) Unveils 'encouraging' data on BPX-501 in pediatric leukemias (-) NVS (-1%) Gets European approval for Kisqali as first-line breast cancer treatment The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2017-06-22,48.59999847412109,49.27000045776367,-0.20333158499506915,,
2017-06-21,48.790000915527344,48.56999969482422,1.3786049478979987,"YieldBoost ABT To 5.6% Using Options | Zacks.com featured highlights: Johnson & Johnson, NantKwest, Delek US Holdings, Abbot Labs and Winnebago | Health Care Sector Update for 06/21/2017: JNJ, PFE, ABT, MRK, AMGN, RXII, PSTI, CARA","Shareholders of Abbott Laboratories (Symbol: ABT) looking to boost their income beyond the stock's 2.2% annualized dividend yield can sell the January 2019 covered call at the $52.50 strike and collect the premium based on the $2.59 bid, which annualizes to an additional 3.4% rate of return against the current stock price (at Stock Options Channel we call this the YieldBoost ), for a total of 5.6% annualized rate in the scenario where the stock is not called away. Any upside above $52.50 would be lost if the stock rises there and is called away, but ABT shares would have to advance 8.2% from current levels for that to occur, meaning that in the scenario where the stock is called, the shareholder has earned a 13.6% return from this trading level, in addition to any dividends collected before the stock was called. In the case of Abbott Laboratories, looking at the dividend history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2.2% annualized dividend yield. | Stocks Here are 5 stocks that passed this week's screen: (NYSE: JNJ - Free Report ) Johnson & Johnson (NASDAQ: NK - Free Report ) NantKwest (NYSE: DK - Free Report ) Delek US Holdings (NYSE: ABT - Free Report ) Abbot Labs (NYSE: WGO - Free Report ) Winnebago All of these stocks look good fundamentally. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report NantKwest, Inc. (NK): Free Stock Analysis Report Delek US Holdings, Inc. (DK): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Winnebago Industries, Inc. (WGO): Free Stock Analysis Report To read this article on Zacks.com click here. For Immediate Release Chicago, IL - June 21, 2017 - Stocks in this week's article include Johnson & Johnson (NYSE: JNJ - Free Report ), NantKwest (NASDAQ: NK - Free Report ), Delek US Holdings (NYSE: DK - Free Report ), Abbot Labs (NYSE: ABT - Free Report ) and Winnebago (NYSE: WGO - Free Report ). | PFE: flat ABT: flat In health care stocks news, RXI Pharmaceuticals ( RXII ) rose 15% after the company said it completed enrollment in its phase 1/2 study RXI-109-1501. CR845 in postoperative pain to continue following interim assessment The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2017-06-20,48.88999938964844,48.77000045776367,-0.45091456563820215,"Health Care Sector Update for 06/20/2017: JNJ, PFE, ABT, MRK, AMGN, LPCN, PRXL, MD | How to Uncover Institutional Buying | Health Care Sector Update for 06/20/2017: JNJ, PFE, ABT, MRK, AMGN, EGLT, NVIV, VAR | VHT, LLY, ABT, DHR: Large Inflows Detected at ETF","Top Health Care stocks: JNJ: flat PFE: flat ABT: flat MRK: flat In health care stocks news, Lipocine ( LPCN ) rose 30.1% after it reported late Monday that both the Dosing Validation and the Dosing Flexibility studies evaluating efficacy and tolerability of LPCN 1021 successfully met Food and Drug Administration primary efficacy guidelines. The DF study restored 70% of the subjects' average testosterone levels within the normal range confirming that twice daily dosing is the appropriate dosing regimen for LPCN 1021 and will be the basis for resubmission. | Stocks Here are 5 stocks that passed this week's screen: ( JNJ - Research Report ) Johnson & Johnson ( NK - Research Report ) NantKwest ( DK - Research Report ) Delek US Holdings ( ABT - Research Report ) Abbot Labs ( WGO - Research Report ) Winnebago All of these stocks look good fundamentally. Click to get this free report Winnebago Industries, Inc. (WGO): Free Stock Analysis Report NantKwest, Inc. (NK): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Delek US Holdings, Inc. (DK): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Screen Parameters • Current Price greater than Price from 1 Week Ago • Price from 1 Week Ago greater than Price from 2 Weeks Ago • Price from 2 Week Ago greater than Price from 3 Weeks Ago • Weekly Volume greater than Weekly Volume from 1 Week Ago • Weekly Volume from 1 Wk Ago greater than Weekly Volume from 2 Wks Ago • Weekly Volume from 2 Wks Ago greater than Weekly Volume from 3 Wks Ago • Zacks Rank less than or equal to 3 • Price greater than or equal to $5 • Average 20-day Volume greater than or equal to 100,000 shares The most important elements to this screen are the price and volume items (especially the volume). | In health care stocks news, Egalet ( EGLT ) was down 16.8% after the company said it received a complete response letter ( CRL ) from the U.S. Food and Drug Administration (FDA) regarding the prior approval supplement of Oxaydo (oxycodone HCl, USP) tablets C-II in 10 mg and 15 mg dosage strengths. The FDA has requested more information regarding the effect of food on Oxaydo 15 mg and the intranasal abuse-deterrent properties of Oxaydo 10 mg and 15 mg. Egalet said it will work with the FDA to determine the path forward. In other sector news, (+) NVIV (6.3%) Enrolls new patient in Inspire study evaluating neuro-spinal scaffold (-) VAR (-0.1%) Installs proton therapy device in Danish center The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VHT, in trading today Lilly (Eli) & Co (Symbol: LLY) is up about 1.3%, Abbott Laboratories (Symbol: ABT) is up about 0.7%, and Danaher Corp (Symbol: DHR) is higher by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Health Care ETF (Symbol: VHT) where we have detected an approximate $65.9 million dollar inflow -- that's a 1.0% increase week over week in outstanding units (from 44,174,359 to 44,624,359). For a complete list of holdings, visit the VHT Holdings page » The chart below shows the one year price performance of VHT, versus its 200 day moving average: Looking at the chart above, VHT's low point in its 52 week range is $120.38 per share, with $147.35 as the 52 week high point - that compares with a last trade of $147.30."
2017-06-19,48.34000015258789,48.88999938964844,-0.2454467854016239,"Health Care Sector Update for 06/19/2017: JNJ, PFE, ABT, MRK, AMGN, VRX, MACK, MDT","MRK: flat In health care stocks news, Valeant Pharmaceuticals International ( VRX ) gained 4.7% after the company said that its board elected John Paulson to serve as a director, effective June 14. In other sector news, (+) MACK (+4.3%) Enrolls last patient in Carrie study of MM-141 for metastatic pancreatic cancer (-) MDT (-0.1%) Reports technology in cardiac implants reduces irregular heartbeats The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2017-06-16,48.18000030517578,48.209999084472656,1.137772518254952,"Health Care Sector Update for 06/16/2017: JNJ, PFE, ABT, MRK, AMGN, GSK, PFE, LLY | 2 Solid Medical Device Stocks to Scoop Up Right Away","Top Health Care stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Health care shares were inactive in pre-market trade Friday. In other sector news, PFE (flat) Xeljanz arthritis drug shows similar response rate to AbbVie's Humira LLY (flat) Says long term data show rheumatoid arthritis drug lowers tate of joint damage progression The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Unauthorized reproduction is strictly prohibited. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT : This IL-based medical device major discovers, develops, manufactures and sells a diversified line of health care products. So far, companies in the medical device sector were hopeful about the promised cancellation of major healthcare taxes (the Cadillac tax and the 2.3% MedTech tax) related to Obamacare under Trump's American Health Care Act (AHCA)."
2017-06-15,47.58000183105469,48.119998931884766,0.062263966597883885,"The Zacks Analyst Blog Highlights: United Technologies, Abbott, Delta Air, Equity Residential and Ross Stores | Abbott Laboratories Up on EPD & Buyouts, Pediatric Weak | Health Care Sector Update for 06/15/2017: JNJ, PFE, ABT, MRK, AMGN, CRBP, LNTH | 3 Dividend Stocks for Astute Investors","Stocks recently featured in the blog include United Technologies (NYSE: UTX- Free Report ), Abbott (NYSE: ABT- Free Report ), Delta Air (NYSE: DAL- Free Report ), Equity Residential (NYSE: EQR- Free Report ) and Ross Stores (NASDAQ: ROST- Free Report ). Get the full Report on UTX - FREE Get the full Report on ABT - FREE Get the full Report on DAL - FREE Get the full Report on EQR - FREE Get the full Report on ROST - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Click to get this free report United Technologies Corporation (UTX): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Delta Air Lines, Inc. (DAL): Free Stock Analysis Report Equity Residential (EQR): Free Stock Analysis Report Ross Stores, Inc. (ROST): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Accelerate Diagnostics, Inc. (AXDX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. On Jun 14, we issued an updated research report on Illinois-based Abbott Laboratories ABT . Under the altered terms, Abbott will pay $51 per common share to take over Alere, for a new expected equity value of approximately $5.3 billion, reduced from the originally expected equity value of approximately $5.8 billion. | PFE: flat ABT: flat In health care stocks news, Skyline Medical ( SKLN ) was up 16.6% after it said that its European authorized representative, Emergo Europe BV, has notified the Dutch Competent Authority that the company's Streamway System meets all requirements and can now be affixed with the CE mark and marketed in 32 European countries. In other sector news, (+) CRBP (+2.5%) Plans to commence phase 3 study of anabasum for the treatment of systemic sclerosis in Q4 (-) LNTH (-5.9%) Agrees to sell 3 million shares of its common stock to be offered by certain of its existing stockholders The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company's pipeline is loaded with potential blockbusters, including cancer drugs Rova-T and Veliparib and autoimmune-disease drug ABT-494. AbbVie has increased its dividend payments by 60% since the company was spun off from parent Abbott Labs (NYSE: ABT) in 2013. Read on to find out why Hasbro (NASDAQ: HAS) , AbbVie (NYSE: ABBV) , and Best Buy (NYSE: BBY) could be just what an astute investor is looking for."
2017-06-14,47.459999084472656,47.63999938964844,1.1349245061979607,Johnson & Johnson: The Bear Case From a Bull,"You probably couldn't describe me as a raging bull when it comes to Johnson & Johnson (NYSE: JNJ) stock, but I'm a bull nonetheless. Consumer and medical devices segments still sluggish You know there's a problem when Johnson & Johnson's consumer and medical devices business segments outperform its pharmaceuticals segment. * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them!"
2017-06-13,47.2400016784668,47.459999084472656,0.3792674012812432,"How AbbVie Inc. Makes Most of Its Money | 111 Actions to Take this Week | Health Care Sector Update for 06/13/2017: JNJ, PFE, ABT, MRK, AMGN, CHRS, IMNP","That's a big jump from the $18.8 billion that AbbVie made in 2013, its first year as a standalone company after being spun off by Abbott Laboratories (NYSE: ABT) . Where AbbVie makes its money now The primary source for AbbVie's revenue now is the same as it was when the company was spun off from Abbott: Humira. AbbVie has projected that it will make $7 billion in peak annual sales from the cancer drug -- and that doesn't include the revenue that Johnson & Johnson will make from it. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips During these busy times, it pays to stay on top of the latest profit opportunities and today's blog post should be a great place to start. This Week's Ratings Changes: To stay on top of my latest stock ratings, plug your holdings into Portfolio Grader , my proprietary stock screening tool. More From InvestorPlace 7 Stocks to Buy in Wall Street's Hottest Industry 7 Stocks With More Upside Than Alphabet 10 Stocks to Buy Before They Finally Join the Rally The post 111 Actions to Take this Week appeared first on InvestorPlace . | PFE: flat ABT: flat AMGN: flat Health care shares were mostly flat in pre-market trade Tuesday. In health care stocks news, Merck & Company ( MRK ) was down 1.2% after it said late Monday it accepted an external data monitoring committee's recommendation to pause new enrollment on Keynote-183 and Keynote-185, two studies exploring Keytruda treatment in combination with other therapies in multiple myeloma."
2017-06-12,47.290000915527344,47.16999816894531,0.4657015202989288,"IVE, PFE, ABT, CVS: Large Outflows Detected at ETF | Health Care Sector Update for 06/12/2017: JNJ, PFE, ABT, MRK, AMGN,CHRS, NVO, AZN","Among the largest underlying components of IVE, in trading today Pfizer Inc (Symbol: PFE) is up about 1%, Abbott Laboratories (Symbol: ABT) is trading flat, and CVS Health Corporation (Symbol: CVS) is up by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares S&P 500 Value ETF (Symbol: IVE) where we have detected an approximate $73.9 million dollar outflow -- that's a 0.6% decrease week over week (from 127,050,000 to 126,350,000). For a complete list of holdings, visit the IVE Holdings page » The chart below shows the one year price performance of IVE, versus its 200 day moving average: Looking at the chart above, IVE's low point in its 52 week range is $87.88 per share, with $107.75 as the 52 week high point - that compares with a last trade of $105.95. | ABT: flat In health care stocks news, Coherus BioSciences ( CHRS ) was down 31% after it received a complete response letter from the U.S. Food and Drug Administration for its biologics license application for CHS-1701, a pegfilgrastim (Neulasta) biosimilar candidate, under the 351(k) pathway, that will cause a delay in approval. It said the FDA requested a reanalysis of a subset of subject samples with a revised immunogenicity assay, and requested certain additional manufacturing related process information."
2017-06-09,46.810001373291016,47.290000915527344,-0.25375923928694444,"Health Care Sector Update for 06/09/2017: JNJ, PFE, ABT, MRK, AMGN, ENDP, LXRX, MBOT | Health Care Sector Update for 06/09/2017: JNJ, PFE, ABT, MRK, AMGN, ENZ, BNTC, SNSS | What Traders Can Learn From Professional Horse Betting | Daily Dividend Report: GE, PM, ABT, CL, AMAT, THO, HPP","In health care stocks news, Endo International ( ENDP ) fell 14.9% after the company said it is reviewing a request from the U.S. Food and Drug Administration to voluntarily remove its Opana ER opioid pain killer from the U.S. market, that cited the increase in the misuse and abuse of opioid products. In other sector news, (+) LXRX, (+4.9%) Says phase 3 trial of its drug sotagliflozin to treat patients with type 1 diabetes met its primary endpoint (-) MBOT, (-2.2%) Closes registered direct offering of nearly 3.8 million shares of common stock for total gross proceeds of $10.1 million The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. All rights reserved. | In health care stocks news, Enzo Biochem ( ENZ ) was up 13.7% after the company reported breakeven per share for the three months ended April 30, compared to a net loss per share of $0.04. An analyst had predicted a net loss per share of $0.01 on $27.5 million in revenue. In other sector news, (+) BNTC, (+2.8%) Receives additional AUD636,056 ($478,985) cash refund for 2016 under the Australian Federal Government's research & development tax incentive scheme (-) SNSS, (-1.9%) Files a shelf registration of securities with an aggregate amount of $200 million. | 3: You should bet more on a horse you really like, such as your 'best bet' Professional track gamblers understand that bet size is incredibly important. Sizing your bets based on ""hunches"" leaves you susceptible to accidently betting big on losers and tiny on winners. BMY 15-Year Financial Data The intrinsic value of BMY Peter Lynch Chart of BMY Premium Members This article first appeared on GuruFocus . | Abbott ( ABT ) declared a quarterly common dividend of 26.5 cents per share. VIDEO: Daily Dividend Report: GE, PM, ABT, CL, AMAT, THO, HPP The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. GE ( GE ) declared a $0.24 per share dividend on the outstanding stock of the Company payable July 25, 2017 to shareowners of record at the close of business on June 19, 2017."
2017-06-08,46.560001373291016,46.720001220703125,1.0254209103916148,"Health Care Sector Update for 06/08/2017: JNJ, PFE, ABT, MRK, AMGN, CYTR, TGTX, QGEN | Health Care Sector Update for 06/08/2017: JNJ, PRE, ABT, MRK, AMGN, CHRS, TVTY, AXN","In health care stocks news, CytRx ( CYTR ) rose 16.1% after the biopharmaceutical research and development company said it plans to submit a rolling new drug application (NDA) to the US Food and Drug Administration for aldoxorubicin as a treatment for soft tissue sarcomas ( STS ). Instead, CytRx's completed pharmacokinetic clinical trial, phase 2b and phase 3 trials in STS, along with preclinical safety and efficacy studies, will serve as ""scientific bridges"" between aldoxorubicin and doxorubicin. In other sector news, (+) TGTX, (+4.9%) To present clinical abstracts featuring its two therapies targeting hematological malignancies and autoimmune diseases (-) QGEN, (-0.4%) Says FDA OKs quantiFeron-TB gold plus The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, Coherus BioSciences ( CHRS ) rose 10.1% ahead of the U.S. Food and Drug Administration's June 9 action date on the company's pegfilgrastim, a Neulasta biosimilar. In other sector news, (+) TVTY, (+4.8%) Has reportedly received takeover interest from private equity firms (-) AXN, (-9.6%) Reports an improvement in both Q2 revenue and net income from the year-ago level The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. All rights reserved."
2017-06-07,46.380001068115234,46.560001373291016,0.343642273824959,"Health Care Sector Update for 06/07/2017: JNJ, PFE, ABT, MRK, AMGN, CALA, ALOG, CERS | Health Care Sector Update for 06/07/2017: JNJ, PFE, ABT, MRK, AMGN, KMDA, JAZZ, EXAS","In health care stocks news, Calithera Biosciences ( CALA ) was up 13.6% after it said that the U.S. Food and Drug Administration has granted fast track designation to CB-839 in combination with everolimus, for the treatment of patients with metastatic renal cell carcinoma who have received two or more prior lines of therapy. CB-839 is a first-in-class, oral, selective, potent inhibitor of glutaminase being evaluated in phase 1/2 clinical trials for the treatment of solid tumors including renal cell carcinoma, triple negative breast cancer, non-small cell lung cancer, and melanoma. In other sector news, (+) CERS, (+12.3%) Says the expected shortage of platelet additive solution from Fresenius Kabi could be less disruptive to the blood center production of the company's Intercept platelets than initially anticipated (-) ALOG, (-10.1%) Guides FY17 earnings below Street as fiscal Q3 results beat estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health care stocks news, Kamada ( KMDA ) was down 6.1% following the transfer of full ownership and responsibility for the clinical development of Alpha-1 Antitrypsin (G1-AAT IV) for the treatment of acute Graft-Versus-Host Disease (GvHD) from Shire ( SHPG ). An investigational new drug (IND) application approved by the U.S. Food and Drug Administration for the phase 2/3 study evaluating the drug will be transferred from Shire to Kamada, the company said in a press release. In other sector news, (+) JAZZ, (+4.8%) Says JZP-110 could be an important treatment option for patients suffering from excessive sleepiness as a result of narcolepsy (-) EXAS, (-5%) Prices an offering of 7.0 million common shares at $35 each, equal to a 4.3% discount relative to Tuesday's closing price The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2017-06-06,46.58000183105469,46.36000061035156,0.3880989672928785,"Health Care Sector Update for 06/06/2017: JNJ, PFE, ABT, MRK, AMGN, NOVT, SNOA, EGLT","In health care stocks news, Egalet ( EGLT ) was up 15.3% after the company said one of the largest payers in the United States will provide coverage of its Arymo extended-release tablets, an abuse-deterrent morphine product for the treatment of chronic pain. In other sector news, (+) NOVT, (+5.1%) To acquire privately-held World of Medicine GmbH for EUR115 million ($129.4 million) in cash (-) SNOA, (-7.8%) Reports wider-than-expected Q4 loss and revenue that beat the single analyst estimate on Capital IQ The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. All rights reserved."
2017-06-05,46.56999969482422,46.619998931884766,-0.47230831269837165,"Health Care Sector Update for 06/05/2017: JNJ, PFE, ABT, MRK, AMGN, CLSN, MBOT, LOXO | Abbott Laboratories at 52-Week High on Product Line, Buyouts | Health Care Sector Update for 06/05/2017: JNJ, PFE, ABT, MRK, AMGN, NLNK, RDUS, BPMC","In health care stocks news, Loxo Oncology ( LOXO ) rose 46% to a new 52-week high after the company said data from three ongoing trials of larotrectinib demonstrated a 76% objective response rate in treating tumors.The studies evaluated adults and pediatric patients whose tumors harbor tropomyosin receptor kinase fusions. LOXO-195 was developed to treat patients with TRK fusion cancers who become resistant while receiving another TRK inhibitor, such as Loxo Oncology's larotrectinib. In other sector news, (+) CLSN, (+55.6%) Study shows 86% response rate to ovarian cancer drug combination; (-) MBOT, (-29.1%) Agrees to sell 3.8 million shares of common stock to three institutional investors for $10.1 million. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Accelerate Diagnostics, Inc. (AXDX): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Share price of IL-based Abbott LaboratoriesABT scaled a new 52-week high of $46.55 on Jun 2, eventually closing a bit lower at $46.50. Over the last one year, this Zacks Rank #2 (Buy) company has steadily outshined the Zacks categorized Medical - Products with respect to share price. | In health care stocks news,NewLink Genetics ( NLNK ) fell 11.7% after the company said a phase 2 study of indoximod in combination with the therapeutic cancer vaccine Provenge for patients with metastatic castration resistant prostate cancer didn't show a statistical difference in the primary endpoint of ELISPOT assay immune response to PA2024, the Provenge-related fusion protein, in the 35 of 46 patients who had clinical samples available for testing. In other sector news, (+) RDUS, (+10.8%) Results from a phase 1 study of its elacestrant showed five confirmed partial responses in patients with estrogen receptor positive breast cancer (-) BPMC, (-8.5%) Phase 1 data on BLU-285 foR patients with advanced gastrointestinal stromal tumors showed a 60% objective response rate and an estimated 9-month progression free survival of 87% The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. All rights reserved."
2017-06-02,46.33000183105469,46.5,0.10736361904271985,"Noteworthy ETF Outflows: IVE, CVS, ABT, MDLZ | The Zacks Analyst Blog Highlights: McCormick & Company, S&P Global, Sherwin-Williams, 3M and Abbott Laboratories","Among the largest underlying components of IVE, in trading today CVS Health Corporation (Symbol: CVS) is up about 0.3%, Abbott Laboratories (Symbol: ABT) is up about 0.6%, and Mondelez International Inc (Symbol: MDLZ) is up by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares S&P 500 Value ETF (Symbol: IVE) where we have detected an approximate $160.6 million dollar outflow -- that's a 1.2% decrease week over week (from 128,600,000 to 127,050,000). For a complete list of holdings, visit the IVE Holdings page » The chart below shows the one year price performance of IVE, versus its 200 day moving average: Looking at the chart above, IVE's low point in its 52 week range is $87.88 per share, with $107.75 as the 52 week high point - that compares with a last trade of $104.42. | Stocks recently featured in the blog include McCormick & Company, Incorporated (NYSE: MKC - Free Report ), S&P Global Inc (NYSE: SPGI - Free Report ), Sherwin-Williams Co (NYSE: SHW - Free Report ), 3M Co (NYSE: MMM - Free Report ) and Abbott Laboratories (NYSE: ABT - Free Report ). See these high-potential stocks free >> Get the full Report on MKC - FREE Get the full Report on SPGI - FREE Get the full Report on SHW - FREE Get the full Report on MMM - FREE Get the full Report on ABT - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Click to get this free report McCormick & Company, Incorporated (MKC): Free Stock Analysis Report S&P Global Inc. (SPGI): Free Stock Analysis Report Sherwin-Williams Company (The) (SHW): Free Stock Analysis Report 3M Company (MMM): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here."
2017-06-01,45.52000045776367,46.09999847412109,0.3669289061658614,5 Top High-Yield Dividend Aristocrats to Buy in June | Insider Bets Paying Off At ABT As New 52-Week High Reached,"Click to get this free report J P Morgan Chase & Co (JPM): Free Stock Analysis Report Bank of America Corporation (BAC): Free Stock Analysis Report S&P Global Inc. (SPGI): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report 3M Company (MMM): Free Stock Analysis Report McCormick & Company, Incorporated (MKC): Free Stock Analysis Report Sherwin-Williams Company (The) (SHW): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is engaged in the discovery, development, manufacture and sale of a range of healthcare products. Take a look at the table on the S&P 500's average monthly returns over the past 50 years: Stock Market's Summer Concerns The market isn't void of risks this June. | In trading on Thursday, shares of Abbott Laboratories (Symbol: ABT) touched a new 52-week high of $46.02/share. That means at today's intraday high, any investor who purchased ABT stock any time over the past 52 weeks has an unrealized gain, including company insiders. As summarized by the table below, ABT has seen 3 different instances of insiders buying over the trailing six month period."
2017-05-31,45.20000076293945,45.65999984741211,1.2741608315570505,,
2017-05-30,44.459999084472656,45.0,1.0176970723633711,"3 Big Stock Charts for Tuesday: Boeing Co (BA), Caterpillar Inc. (CAT) and Abbott Laboratories (ABT) | The Zacks Analyst Blog Highlights: Visa, General Electric, GlaxoSmithKline, Morgan Stanley and Abbott Laboratories","Abbott Laboratories (NYSE: ABT ), Boeing Co (NYSE: BA ) and Caterpillar Inc. (NYSE: CAT ) are three of the large-cap companies on our technical radar screens today as all three companies are part of the market's melt-up as stocks continue to push to new highs. More From InvestorPlace 7 Stocks That Will Get Crushed in the Next Crash 7 Stocks to Buy Now for BIG Summer Outperformance 7 Stocks to Sell Thanks to TERRIBLE Seasonality The post 3 Big Stock Charts for Tuesday: Boeing Co (BA), Caterpillar Inc. (CAT) and Abbott Laboratories (ABT) appeared first on InvestorPlace . Abbott Laboratories (ABT) Abbott stock surged on Friday with relatively heavy volume, pushing the stock towards a bullish technical trigger. | Stocks recently featured in the blog include Visa (NYSE: V- Free Report ), General Electric Company (NYSE: GE- Free Report ), GlaxoSmithKline plc (NYSE: GSK- Free Report ), Morgan Stanley (NYSE: MS- Free Report ) and Abbott Laboratories (NYSE: ABT- Free Report ). Get the full Report on V - FREE Get the full Report on GE - FREE Get the full Report on GSK - FREE Get the full Report on MS - FREE Get the full Report on ABT - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Click to get this free report Visa Inc. (V): Free Stock Analysis Report General Electric Company (GE): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Morgan Stanley (MS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here."
2017-05-26,43.91999816894531,44.709999084472656,1.2145769830119841,,
2017-05-25,43.77999877929688,43.95000076293945,1.7987271139868417,"The Zacks Analyst Blog Highlights: Alphabet, Morgan Stanley, Abbott, Waste Management, General Mills and Raytheon","Stocks recently featured in the blog include Alphabet (NASDAQ: GOOGL- Free Report ), Morgan Stanley (NYSE: MS- Free Report ), Abbott (NYSE: ABT- Free Report ), Waste Management (NYSE: WM- Free Report ), General Mills (NYSE: GIS- Free Report ) and Raytheon (NYSE: RTN- Free Report ). Get the full Report on GOOGL - FREE Get the full Report on MS - FREE Get the full Report on ABT - FREE Get the full Report on WM - FREE Get the full Report on GIS - FREE Get the full Report on RTN - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Click to get this free report Alphabet Inc. (GOOGL): Free Stock Analysis Report Morgan Stanley (MS): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Waste Management, Inc. (WM): Free Stock Analysis Report General Mills, Inc. (GIS): Free Stock Analysis Report Raytheon Company (RTN): Free Stock Analysis Report To read this article on Zacks.com click here."
2017-05-24,43.790000915527344,43.52999877929688,0.38830970393485537,Say Congratulations with a Gift That Keeps on GROWING: 5 Great DRIPs to Buy,"Abbott Laboratories (ABT) is a health care company engaged in the discovery, development, manufacture and sale of a diversified line of health care products, including Similac baby formula and Glucerna nutrition drinks. An Astounding Nest Egg at Retirement Let's assume that the graduate or the newlywed (or you on their behalf), invests $1,500 a year for the next five years -- that's $125 a month spread evenly among the five high-quality, dividend-paying companies in the portfolio ($25 in each company every month). 5 Companies for Your Consideration Every year the editors of Moneypaper pick five companies worthy of your consideration for such a gift."
2017-05-23,43.709999084472656,43.68000030517578,-0.5937477296061631,"Edward Owens Buys Abbott Labs, Sells Allergan, Amgen, Aetna","The guru raised its shares in Abbott Laboratories ( ABT ) by 63.66% impacting the portfolio by 0.68%. Vanguard Health Care Fund is the largest shareholder among the gurus with 1.02% of outstanding shares followed by PRIMECAP Management (Trades, Portfolio) with 0.85%, Diamond Hill Capital (Trades, Portfolio) with 0.71%, Jeremy Grantham (Trades, Portfolio) with 0.29%, Mairs and Power (Trades, Portfolio) with 0.25% and Jim Simons (Trades, Portfolio) with 0.18%. Frank Sands (Trades, Portfolio) is another notable shareholder among the gurus with 4.52% of outstanding shares followed by Pioneer Investments (Trades, Portfolio) with 0.27%, Andreas Halvorsen (Trades, Portfolio) with 0.21%, Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) with 0.1%, Manning & Napier Advisors Inc. with 0.03%, Joel Greenblatt (Trades, Portfolio) with 0.03%, John Burbank (Trades, Portfolio) with 0.01% and Ken Fisher (Trades, Portfolio) with 0.01%."
2017-05-22,43.27000045776367,43.72999954223633,-0.06863138852714282,,
2017-05-19,43.150001525878906,43.15999984741211,1.0630900845995286,,
2017-05-18,43.16999816894531,42.97999954223633,0.02317108036996639,"VTV, ABT, MDLZ, AET: Large Outflows Detected at ETF | AbbVie Inc (ABBV) Stock STILL Has Much More Room to Run Higher","Among the largest underlying components of VTV, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.1%, Mondelez International Inc (Symbol: MDLZ) is up about 0.5%, and Aetna Inc. (Symbol: AET) is up by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Value ETF (Symbol: VTV) where we have detected an approximate $134.6 million dollar outflow -- that's a 0.4% decrease week over week (from 320,386,298 to 318,950,101). For a complete list of holdings, visit the VTV Holdings page » The chart below shows the one year price performance of VTV, versus its 200 day moving average: Looking at the chart above, VTV's low point in its 52 week range is $80.43 per share, with $98.50 as the 52 week high point - that compares with a last trade of $93.93. | In late 2012, Abbott Laboratories (NYSE: ABT ) spun off AbbVie with one drug and a lot of its accumulated debt. At the time, it looked like ABBV stock was being set up to fail so ABT could offload a lot of debt. Source: Black Stripe via Wikimedia (Modified) But now it looks like ABT might have some spinoff remorse now that the drug AbbVie was left with is doing about $16 billion a year in revenue."
2017-05-17,43.68999862670898,43.08000183105469,-0.44011729156305923,"The Zacks Analyst Blog Highlights: General Dynamics, EOG Resources, Abbott, Northrop Grumman and Symantec | Abbott Lab Well Poised on Strong EPD, St. Jude Integration","Here are highlights from Tuesday's Analyst Blog: Analyst Reports for Abbott Labs, EOG Resources, General Dynamics & More Today's Research Daily features new research reports on 16 major stocks, including General Dynamics (NYSE: GD- Free Report ), EOG Resources (NYSE: EOG- Free Report ) and Abbott (NYSE: ABT- Free Report ). Get the full Report on GD - FREE Get the full Report on EOG - FREE Get the full Report on ABT - FREE Get the full Report on NOC - FREE Get the full Report on SYMC - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Click to get this free report General Dynamics Corporation (GD): Free Stock Analysis Report EOG Resources, Inc. (EOG): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Northrop Grumman Corporation (NOC): Free Stock Analysis Report Symantec Corporation (SYMC): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Hologic, Inc. (HOLX): Free Stock Analysis Report Luminex Corporation (LMNX): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. On May 17, we issued an updated research report on Abbott LaboratoriesABT . Luminex sports a Zacks Rank #1 (Strong Buy), while Hologic and Edward Lifesciences carry a Zacks Rank #2."
2017-05-16,44.59000015258789,43.68999862670898,-1.3961932131565251,,
2017-05-15,43.91999816894531,44.040000915527344,-2.0183931886052697,,
2017-05-12,43.900001525878906,43.959999084472656,0.27323030870907933,,
2017-05-11,44.38999938964844,43.86000061035156,0.1366686936408912,,
2017-05-10,44.70000076293945,44.5,-1.193959870656066,"IYY, AGN, ABT, MDLZ: Large Outflows Detected at ETF","Among the largest underlying components of IYY, in trading today Allergan PLC (Symbol: AGN) is down about 3.4%, Abbott Laboratories (Symbol: ABT) is down about 0.5%, and Mondelez International Inc (Symbol: MDLZ) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Dow Jones U.S. ETF (Symbol: IYY) where we have detected an approximate $30.0 million dollar outflow -- that's a 2.7% decrease week over week (from 9,300,000 to 9,050,000). For a complete list of holdings, visit the IYY Holdings page » The chart below shows the one year price performance of IYY, versus its 200 day moving average: Looking at the chart above, IYY's low point in its 52 week range is $99.15 per share, with $120.51 as the 52 week high point - that compares with a last trade of $119.86."
2017-05-09,44.650001525878906,44.66999816894531,-0.44742899222783183,7 Stocks to Buy Now for BIG Summer Outperformance,"Stocks to Buy Now: Abbott Laboratories (ABT) Source: Open Grid Scheduler Via Flickr 3-Month Outlook: 12% Abbott Laboratories (NYSE: ABT ) is another embattled biotech name that's on this list of seasonally strong stocks to buy now. Bottom line: The technicians are about get really bullish on ABT. InvestorPlace - Stock Market News, Stock Advice & Trading Tips If you're not looking for stocks to buy right now because you're worried about jumping on the ""sell in May and go away"" bandwagon, you're making a rookie mistake."
2017-05-08,44.70000076293945,44.68000030517578,0.044785313287875925,,
2017-05-05,44.58000183105469,44.63999938964844,-0.04474375262260432,,
2017-05-04,43.75,44.59000015258789,0.13458402003015477,,
2017-05-03,43.61000061035156,43.720001220703125,1.9200003487723212,,
2017-05-02,43.65999984741211,43.59999847412109,0.2522371217886477,,
2017-05-01,43.56999969482422,43.47999954223633,-0.1374287070561665,,
2017-04-28,43.66999816894531,43.63999938964844,-0.20656450130428153,,
2017-04-27,43.959999084472656,43.650001525878906,-0.06869425361736742,,
2017-04-26,43.93000030517578,43.79999923706055,-0.7051809941989873,,
2017-04-25,44.209999084472656,43.7599983215332,-0.29592776510843277,"Health Care Sector Update for 04/25/2017: BIIB, ESRX, JNJ, PFE, ABT, MRK, AMGN","In health care stocks news, Express Scripts Holding Company ( ESRX ) shares fell 12.6%, on track to sink below its 52-week low, after it said it has been notified that Anthem ANTM) has decided to not renew the pharmacy benefit management contract with Express when it expires at the end of 2019. In 2016, Express Scripts revenue attributable to Anthem was $17.08 billion of the group total of $100.29 billion. Express said that Anthem's contribution to its profitability, as a percentage of total EBITDA and adjusted EBITDA, has grown and it expects it will continue to increase and exceed its contribution to its revenues, as a percentage of our total revenues, and that revenues, EBITDA and adjusted EBITDA attributable to Anthem will increase as the contract nears its termination in 2019."
2017-04-24,44.06999969482422,44.130001068115234,-1.0178710071439505,,
2017-04-21,43.93999862670898,43.52999877929688,0.13615015590313803,"The Zacks Analyst Blog Highlights: IBM, Abbott, Dow Chemical, Delta Air Lines and Exelon | Procedure Growth Likely To Remain Strong For Intuitive Surgical","Stocks recently featured in the blog include IBM (NYSE: IBM- Free Report ), Abbott (NYSE: ABT- Free Report ), Dow Chemical (NYSE: DOW- Free Report ), Delta Air Lines (NYSE: DAL- Free Report ) and Exelon (NYSE: EXC- Free Report ). Get the full Report on IBM - FREE Get the full Report on ABT - FREE Get the full Report on DOW - FREE Get the full Report on DAL - FREE Get the full Report on EXC - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Click to get this free report International Business Machines Corporation (IBM): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Dow Chemical Company (The) (DOW): Free Stock Analysis Report Delta Air Lines, Inc. (DAL): Free Stock Analysis Report Exelon Corporation (EXC): Free Stock Analysis Report To read this article on Zacks.com click here. | We think so, considering that the growth in the number of procedures performed using da Vinci surgical systems accelerated to 18% in the first quarter. This is critical because the growth in instruments and accessories revenue closely follows the growth in the number of procedures, and is a recurring source of revenue. While we don't expect such stellar growth in the remaining quarters of the year, we believe that Intuitive has offered an optimistic outlook for da Vinci's adoption."
2017-04-20,43.68999862670898,43.97999954223633,-0.9330902599593535,"Company News for April 20, 2017","• Shares of Ultragenyx Pharmaceutical Inc RARE gained 1.4% after the company declared positive data from a phase III study evaluating its pipeline candidate burosumab (KRN23) in adults with X-linked hypophosphatemia (XLH) • Abbott Laboratories' ABT shares gained 0.4% after the company reported first quarter revenues of $6.33 billion which has surpassed the Zacks Consensus Estimate for revenues of $6.11 billion Want the latest recommendations from Zacks Investment Research? Click to get this free report Facebook, Inc. (FB): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report Lam Research Corporation (LRCX): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2017-04-19,43.77999877929688,43.59000015258789,0.6637695688780928,"Earnings Reaction History: Abbott Laboratories, 50.0% Follow-Through Indicator, 2.4% Sensitive | Granite Investment Advisors, Inc. Buys Abbott Laboratories, Danone SA, AT&T, Sells Corning, ... | The Pressure Is on D.R. Horton, Inc. (DHI) Ahead of Q1 Earnings | 3 Big Stock Charts for Wednesday: Intuitive Surgical, Inc. (ISRG), Abbott Laboratories (ABT) and Huntington Bancshares Incorporated (HBAN) | Abbott Laboratories (ABT) Posts Better-Than-Expected Earnings Results | Abbott (ABT) Tops Q1 Earnings on Strong EPD, Medical Device | 5 Dividend Growth Stocks With Upside To Analyst Targets | Perkins Capital Management Inc Buys LeMaitre Vascular, Abbott Laboratories, ANI ...","Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 42.9% Average next regular session additional gain: 2.4% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 42.9% of the time (3 events) the stock posted additional gains in the following regular session by an average of 2.4%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 66.7% Average next regular session additional loss: 2.7% Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 66.7% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close. Extended-Hours Dollar Volume: $574,475 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Granite Investment Advisors, Inc. New Purchases: BK , VIAB , RIG , XLF, BSV, OEF, PEP, EEM, SNY, SPY, Added Positions:ABT, DANOY, T, MRK, WMT, RDS.B, BRK.B, AAPL, UTX, UL, Reduced Positions:GLW, AIG, GIS, UNH, FAX, KO, WY, TU, NSRGY, BLX, Sold Out:CAT, For the details of Granite Investment Advisors, Inc.'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Granite+Investment+Advisors%2C+Inc. Added: Abbott Laboratories ( ABT ) Granite Investment Advisors, Inc. added to the holdings in Abbott Laboratories by 298.60%. Shares added by 9.76% Abbott Laboratories ( ABT ) - 351,289 shares, 2.82% of the total portfolio. | More From InvestorPlace 3 Reasons Twilio Inc (TWLO) Stock Is Still Dead Money EBay Inc (EBAY) Is a 'Wait-and-See' Stock Before Earnings Abbott Laboratories (ABT) Posts Better-Than-Expected Earnings Results The post The Pressure Is on D.R. Take a look at the iShares U.S. Home Construction ETF (NYSEARCA: ITB ) - which features DHI stock as its top holding, along with heavy weights in LennarCorporation (NYSE: LEN ) and NVR, Inc. (NYSE: NVR ) - and you'll see that it's up 18.5% year-to-date, way ahead of the S&P 500's 5% gain. 10 Stocks That Won't Exist in a Decade In terms of DHI stock itself, it's a question mark heading into earnings and a bit risky to own. | Today's three big stock charts look at three companies who's earnings results hit the tape this morning, Intuitive Surgical, Inc. (NASDAQ: ISRG ), Abbott Laboratories (NYSE: ABT ) and Huntington Bancshares Incorporated (NASDAQ: HBAN ) and the effect of their results on the charts. More From InvestorPlace 10 Hopeless Stocks to Wash From Your Portfolio Forever 7 Top Emerging Markets Stocks to Buy Now Ford Motor Company (F) Stock Has a Secret Weapon The post 3 Big Stock Charts for Wednesday: Intuitive Surgical, Inc. (ISRG), Abbott Laboratories (ABT) and Huntington Bancshares Incorporated (HBAN) appeared first on InvestorPlace . Abbott Laboratories (ABT) Abbott Labs beat expectations with its earnings report, but the stock's reaction is less than ensuring as the stock is trading back into the red. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Abbott Laboratories (NYSE: ABT ) has released its earnings report for the first quarter of 2017. ABT stock remained largely unchanged as of Wednesday morning following the release of its Q1 earnings report. More From InvestorPlace 7 High-Yield Stocks That Could Wreck Your Retirement 7 Energy Stocks That Will Turn 2017 on Its Head 10 Hopeless Stocks to Wash From Your Portfolio Forever The post Abbott Laboratories (ABT) Posts Better-Than-Expected Earnings Results appeared first on InvestorPlace . | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Hologic, Inc. (HOLX): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report Sunshine Heart Inc (SSH): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT reported first-quarter 2017 adjusted earnings from continuing operations of 48 cents per share, 11.6% higher than the Zacks Consensus Estimate and up 17.1% year over year. Abbott Laboratories Price, Consensus and EPS Surprise Abbott Laboratories Price, Consensus and EPS Surprise | Abbott Laboratories Quote Quarter in Detail Abbott Labs operates through four segments - Established Pharmaceuticals Division (EPD), Medical Devices, Nutrition and Diagnostics. | Get the latest Zacks research report on ABT - FREE Get the latest Zacks research report on PPG - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. | Perkins Capital Management Inc New Purchases: LMAT , ANIP , STX , DLX, RIG, BX, SRCI, TCB, VG, INTC, Added Positions:ABT, CYRX, MMSI, JBLU, EDAP, CVS, RMTI, CSII, PFIE, ATRC, Reduced Positions:NVDA, PIP, SNAK, CGNT, GE, XTNT, CEMI, NEO, GSK, USAT, Sold Out:STJ, SVU, SRDX, DTLK, BMY, DLTH, MSTX, For the details of PERKINS CAPITAL MANAGEMENT INC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=PERKINS+CAPITAL+MANAGEMENT+INC These are the top 5 holdings of PERKINS CAPITAL MANAGEMENT INC AxoGen Inc ( AXGN ) - 592,167 shares, 6.44% of the total portfolio. Shares added by 6.66% Abbott Laboratories ( ABT ) - 83,546 shares, 3.86% of the total portfolio. Added: Abbott Laboratories ( ABT ) Perkins Capital Management Inc added to the holdings in Abbott Laboratories by 197.58%."
2017-04-18,43.09000015258789,43.43000030517578,-0.4339849977310641,"High-Yield Healthcare Investments You Can Buy Right Now | Company News for April 18, 2017 | Pre-Market Earnings Report for April 19, 2017 : USB, MS, ABT, BLK, ASML, HBAN, GPC, TXT, SBNY, LAD, UBSH | Abbott Labs: What To Look For In Q1 Earnings","What makes the biotech's dividend even more attractive is that AbbVie has increased its dividend by 60% since 2013, when it was spun off from parent Abbott Laboratories (NYSE: ABT) . Two late-stage candidates for treating autoimmune diseases, risankizumab and ABT-494, also hold significant potential. Here's why AbbVie (NYSE: ABBV) , Pfizer (NYSE: PFE) , and Novo Nordisk (NYSE: NVO) are high-yield healthcare investments you can buy right now. | • Shares of Moneygram International Inc MGI rose 7.8% after Ant Financial hiked its bid for MoneyGram, valuing the company at $1.2 billion • Eli Lilly and Company's LLY shares declined 4.1% after the company's drug to treat rheumatoid arthritis was rejected by Food and Drug Administration • Shares of Ashland Global Holdings Inc. ASH advanced 2% after the company agreed to purchase Pharmachem Laboratories Inc. for $660 million • Alere Inc's ALR shares gained 15.9% after Abbott Laboratories ABT agreed to acquire the company Want the latest recommendations from Zacks Investment Research? Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Ashland Global Holdings Inc. (ASH): Free Stock Analysis Report Moneygram International, Inc. (MGI): Free Stock Analysis Report Alere Inc. (ALR): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Zacks Investment Research reports that the 2017 Price to Earnings ratio for ABT is 17.68 vs. an industry ratio of 16.60, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories ( ABT ) is reporting for the quarter ending March 31, 2017. In the past year ABT has beat the expectations every quarter. | Abbott Labs ( ABT ) will report its Q1 2017 earnings on April 19. Abbott has also obtained CE approval for four new major diagnostics systems, which include ""Alinity s"" for blood and plasma screening, ""Alinity i"" for immunoassay diagnostics, ""Alinity c"" for clinical chemistry diagnostics and ""i-STAT Alinity"" for point of care blood testing. Abbott has also streamlined its established pharma business through sale of its developed markets business and acquisition of CFR Pharmaceuticals and Veropharm."
2017-04-17,42.66999816894531,43.310001373291016,0.7890465337291742,"Company News for April 17, 2017 | Stock Futures Turn Positive; Empire State Manufacturing Index Dives in April | Abbott Laboratories Agrees to Acquire Alere at Lower Price | Alere Inc. Shares Surge After Renewed Commitment From Abbott Laboratories | Midday Update: Market Averages Trade Higher as Bargain-Hunting Overshadows Geopolitical Risks | Close Update: Stocks Rally as Bargain-Hunting Overshadows Geopolitical Tensions | Why Straight Path Communications, Alere, and MoneyGram International Jumped Today","• Shares of Abbott Laboratories ABT fell 1.9% after the company received a warning letter from Food and Drug Administration related to its implantable heart defibrillators • United Continental Holdings, Inc.'s UAL shares declined 1.2% after the company removed a couple from a flight to Costa Rica on Saturday • Shares of Goldman Sachs Group Inc GS fell 1.1% after a U.S. District Court judge in Manhattan rejected the company's bid to shorten a gender bias lawsuit • Pier 1 Imports, Inc.'s PIR shares declined 9.1% after the company's quarterly revenue declined 2.6% year over year, to $528.4 million Want the latest recommendations from Zacks Investment Research? Click to get this free report United Continental Holdings, Inc. (UAL): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Goldman Sachs Group, Inc. (The) (GS): Free Stock Analysis Report Pier 1 Imports, Inc. (PIR): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (+) WPRT (+31.13%) Sold its APU assets for $70 million (+) HTGM (+22.03%) Complete master service agreement with Daiichi Sankyo (+) ALR (+16.76%) To be acquired by Abbott Labs ( ABT ) for $51 per share (+) MGI (+8.00%) Ant Financial raised its bid for Moneygram to $18 per share Most European markets were closed for the Easter holiday, but Asian markets were mixed as bullish Chinese GDP and production data was overshadowed by recent events on the Korean peninsula leaving the Shanghai and Hang Seng lower. (+/-) Large cap tech: Higher (+/-) Chip stocks: Higher (+/-) Software stocks: Flat (+/-) Hardware stocks: Higher (+/-) Internet stocks: Higher (+/-) Oil stocks: Higher (+/-) Biotech stocks: Mixed (+/-) Drug stocks: Flat (+/-) Financial stocks: Higher (+/-) Retail stocks: Flat (+/-) Industrial stocks: Higher (+/-) Airlines: Higher (+/-) Autos: Higher | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report OraSure Technologies, Inc. (OSUR): Free Stock Analysis Report Hill-Rom Holdings Inc (HRC): Free Stock Analysis Report To read this article on Zacks.com click here. Finally the much contentious merger of Abbott LaboratoriesABT with Alere is nearing its close. Against Alere's lawsuit, in December, Abbott filed a lawsuit to terminate its $5.8 billion purchase of the former quoting a substantial loss in the value of Alere's stock since they struck the deal. | What happened Shares of Alere Inc. (NYSE: ALR) popped this morning in response an announcement that Abbott Laboratories (NYSE: ABT) will acquire the point-of-care diagnostics manufacturer. 10 stocks we like better than Alere When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. *Stock Advisor returns as of April 3, 2017 Cory Renauer has no position in any stocks mentioned. | (+) CBLI (+77.64%) FDA completed review of two formulations of entolimod (+) MOCO (+37.30%) To be acquired by AMETEK ( AME ) for $30 per share (+) WPRT (+17.07%) Sold its APU assets for $70 million (+) ALR (+16.19%) To be acquired by Abbott Labs ( ABT ) for $51 per share NYSE Composite Index was up 59.53 points (+0.53%) to 11,384.91 Dow Jones Industrial Index was up 123.25 points (+0.60%) to 20,577.10 S&P 500 was up 13.52 points (+0.58%) to 2,342.45 Nasdaq Composite Index was up 34.49 points (+0.59%) to 5,838.87 FTSE 100 was Closed DAX was Closed CAC 40 was Closed Nikkei 225 was up 19.63 points (+0.11%) to 18,355.26 Hang Seng Index was down 51.84 points (-0.21%) to 24,261.66 Shanghai China Composite Index was down 23.90 points (-0.74%) to 3,222.17 | (+) CBLI (+107.69%) FDA completed review of two formulations of entolimod (+) MOCO (+37.18%) To be acquired by AMETEK ( AME ) for $30 per share (+) WPRT (+19.81%) Sold its APU assets for $70 million (+) ALR (+15.93%) To be acquired by Abbott Labs ( ABT ) for $51 per share Buoyed by bargain-hunting and expectations for upbeat Q1 earnings from Wall Street heavyhitters this week starting with Bank of America ( BAC ) and Johnson & Johnson ( JNJ ) Tuesday, the benchmark averages closed substantially higher on Monday with the Nasdaq Composite in the green for the first time in five sessions. Dow Jones Industrial Index was up 183.67 points (+0.90%) S&P 500 was up 20.06 points (+0.86%) Nasdaq Composite Index was up 51.64 points (+0.89%) | Alere's deal is still on Alere stock jumped 16% after the diagnostic test provider announced an amended merger agreement with Abbott Labs (NYSE: ABT) . Yet today, some market participants believe that Straight Path might get a competing bid from rival Verizon Communications (NYSE: VZ) or another player in the telecommunications space, and that could push shares of Straight Path even higher. Offer from The Motley Fool: The 10 best stocks to buy now Motley Fool co-founders Tom and David Gardner have spent more than a decade beating the market."
2017-04-13,42.400001525878906,42.66999816894531,1.499890395616397,,
2017-04-12,43.31999969482422,43.47999954223633,0.6367845126175606,Will Abbott Lab (ABT) Surprise Estimates in Q1 Earnings? | Market Lower After US Treasury Budget Report,"Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Chemours Company (The) (CC): Free Stock Analysis Report Hill-Rom Holdings Inc (HRC): Free Stock Analysis Report Applied Materials, Inc. (AMAT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is scheduled to report first-quarter 2017 results before the opening bell on Apr 19. Abbott Laboratories Price and EPS Surprise Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote In 2017, the company plans to execute its existing operating model which focuses on portfolio selling in core therapeutic areas which will lead to the creation of unique channel opportunities in differentiated relationships with physicians, retailers and pharmacies that are looking to offer a complete line of solutions to treat prominent local health conditions. | According to the report, the Treasury reported a deficit of $176.2 billion for March, bringing the current deficit for fiscal 2017 to $526.9 billion. Additionally, higher deficits often lead to higher interest rates for Treasury securities, which is what the U.S. is currently seeing from the Federal Reserve with its rate hikes. While higher tax receipts reflect an improved deficit situation when economic conditions are strong, lower tax receipts indicate a slow economic environment."
2017-04-11,43.220001220703125,43.58000183105469,0.36934406403337494,,
2017-04-10,43.83000183105469,43.59000015258789,0.8329490980650783,"XLV, LLY, ABT, AET: ETF Inflow Alert | The Zacks Analyst Blog Highlights: Johnson & Johnson, Verizon, Visa, General Dynamics and Abbott | Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for April 11, 2017","Among the largest underlying components of XLV, in trading today Lilly (Eli) & Co (Symbol: LLY) is up about 0.4%, Abbott Laboratories (Symbol: ABT) is trading flat, and Aetna Inc. (Symbol: AET) is higher by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $89.3 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 212,715,324 to 213,915,324). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $65.96 per share, with $76.75 as the 52 week high point - that compares with a last trade of $74.51. | Get the full Report on JNJ - FREE Get the full Report on VZ - FREE Get the full Report on V - FREE Get the full Report on GD - FREE Get the full Report on ABT - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Verizon Communications Inc. (VZ): Free Stock Analysis Report Visa Inc. (V): Free Stock Analysis Report General Dynamics Corporation (GD): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include Johnson & Johnson (NYSE: JNJ- Free Report ), Verizon (NYSE: VZ- Free Report ), Visa (NYSE: V- Free Report ), General Dynamics (NYSE: GD- Free Report ) and Abbott (NYSE: ABT- Free Report ). | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. The following ETF(s) have ABT as a top-10 holding: iShares U.S. Medical Devices ETF ( IHI ) SPDR S&P Health Care Equipment ( XHE ) First Trust VL Dividend ( FVD ) First Trust Health Care AlphaDEX ( FXH ) First Trust CBOE S&P 500 VIX Tail Hedge Fund ( VIXH )."
2017-04-07,43.619998931884766,43.83000183105469,-0.547573964043847,,
2017-04-06,43.810001373291016,43.66999816894531,0.4814371946635165,Abbott Laboratories Enters Oversold Territory | 4 Big Reasons Mylan N.V. Shares Fell 7% in March,"Abbott Laboratories (Symbol: ABT) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most ""interesting"" ideas that merit further research by investors. But making Abbott Laboratories an even more interesting and timely stock to look at, is the fact that in trading on Thursday, shares of ABT entered into oversold territory, changing hands as low as $43.35 per share. Indeed, ABT's recent annualized dividend of 1.06/share (currently paid in quarterly installments) works out to an annual yield of 2.43% based upon the recent $43.80 share price. | What happened Shares of Mylan (NASDAQ: MYL) , an embattled branded and generic drug developer perhaps best-known for its allergic reaction injectable medication EpiPen, fell 7% in March, according to data from S&P Global Market Intelligence . So what First and foremost, Mylan is dealing with recalls of its EpiPen both outside and within the United States. It was reported on March 22 that 81,000 EpiPens outside the U.S. were being recalled for being ineffective, and the number of recalls has since swelled."
2017-04-05,44.16999816894531,43.79999923706055,-0.31956904806457453,Significant Insider Buying Registered in Holdings of FTXH | Close Update: Stocks Give Back Gains After Minutes Show Fed Considering Balance Sheet Unwinding,"Abbott Laboratories (Symbol: ABT), which makes up 7.93% of the First Trust Nasdaq Pharmaceuticals ETF ( FTXH ), has seen 5 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at ABT: ABT - last trade: $44.18 - Recent Insider Buys: 10 ETFs With Stocks That Insiders Are Buying » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The ETF holds a total of $157,717 worth of ABT, making it the #4 largest holding. | (+) INNL (+20.3%) Agrees to be acquired by Gurnet Point for up to $6.65 per share (+) PNRA (+14.2%) Signs merger deal with JAB Holding (+) NVCN (+12.4%) Ladenburg Thalmann upgrades to buy from neutral with $4 price target (+) NEOT (+12.3%) Gets U.S. patent for LIPO-202 lead clinical asset (+) ALR (+9.5%) Investors anticipate ruling on dispute with would-be acquirer Abbott ( ABT ) Wall Street gave back gains on Wednesday afternoon, with the main indices ending in the red after the release of the Federal Open Market Committee's minutes from its meeting last month that showed most participants could see a change in the reinvestment policy later in 2017. ""Provided that the economy continued to perform about as expected, most participants anticipated that gradual increases in the federal funds rate would continue and judged that a change to the committee's reinvestment policy would likely be appropriate later this year,"" according to the minutes."
2017-04-04,44.52999877929688,44.18000030517578,-0.8376702450146387,,
2017-04-03,44.41999816894531,44.470001220703125,-0.7859835699879336,,
2017-03-31,44.33000183105469,44.40999984741211,0.11256878392392727,"Abbott's St Jude Buyout to Boost Business, Risks Remain","Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report OraSure Technologies, Inc. (OSUR): Free Stock Analysis Report ZELTIQ Aesthetics, Inc. (ZLTQ): Free Stock Analysis Report To read this article on Zacks.com click here. On Mar 31, we updated our research report on medical device major, Abbott LaboratoriesABT . Stocks to Consider Some better-ranked stocks in the medical product industry include Inogen, Inc. INGN , Orasure Technologies, Inc. OSUR and ZELTIQ Aesthetics, Inc. ZLTQ ."
2017-03-30,44.630001068115234,44.54999923706055,0.1804602144216031,,
2017-03-29,44.66999816894531,44.66999816894531,-0.17925572292186828,"Noteworthy ETF Outflows: IYH, MDT, LLY, ABT","Among the largest underlying components of IYH, in trading today Medtronic PLC (Symbol: MDT) is down about 0.1%, Lilly (Eli) & Co (Symbol: LLY) is down about 0.3%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $39.0 million dollar outflow -- that's a 2.1% decrease week over week (from 12,050,000 to 11,800,000). For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $137.30 per share, with $160.58 as the 52 week high point - that compares with a last trade of $156.13."
2017-03-28,44.7400016784668,44.70000076293945,0.0,3 Things You Probably Didn't Know About AbbVie Inc.,"Since its spinoff from Abbott Laboratories (NYSE: ABT) in 2013, AbbVie (NYSE: ABBV) has become one of the hottest big biotech stocks on the market. The company expects to launch risankizumab in 2019 for treating psoriasis and ABT-494 the same year for treating rheumatoid arthritis. One of the fastest-growing dividends You probably already know that AbbVie currently boasts the highest dividend yield of any biotech stock ."
2017-03-27,44.52999877929688,44.70000076293945,-0.08940749670690344,,
2017-03-24,44.7599983215332,44.72999954223633,0.3817695672644151,,
2017-03-23,44.709999084472656,44.77000045776367,-0.06702140398080209,,
2017-03-22,44.93999862670898,44.810001373291016,0.13420124025869978,,
2017-03-21,45.150001525878906,44.79999923706055,-0.2892684855150418,,
2017-03-20,45.18999862670898,44.97999954223633,-0.7751988416163096,"Trump, Biogen and Amgen Hammer Healthcare ETFs | 5 Dividend Aristocrats Where Analysts See Capital Gains | Abbott Laboratories' MitraClip Outcome Positive for DMR","Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc (TMO): Free Stock Analysis Report Affiliated Managers Group, Inc. (AMG): Free Stock Analysis Report ISHARES NDQ BIO (IBB): ETF Research Reports The Medicines Company (MDCO): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Esperion Therapeutics, Inc. (ESPR): Free Stock Analysis Report SPDR-HLTH CR (XLV): ETF Research Reports VIPERS-HLTH CR (VHT): ETF Research Reports ISHARS-US HLTHC (IYH): ETF Research Reports PWRSH-DYN PHARM (PJP): ETF Research Reports BIOSH-BIO PRD (BBP): ETF Research Reports SPDR-SP PHARMA (XPH): ETF Research Reports To read this article on Zacks.com click here. The move dragged down other health care stocks, including Pfizer PFE , Amgen, Celgene CELG , Abbott Laboratories ABT and Thermo Fisher Scientific TMO . Other ETFs - iShares Nasdaq Biotechnology ETF IBB , PowerShares Dynamic Biotechnology & Genome Portfolio PBE , BioShares Biotechnology Products Fund BBP , PowerShares Dynamic Pharmaceuticals Fund PJP , and SPDR S&P Pharmaceuticals ETF XPH tumbled over 2% (see: all the Health care ETFs here ). | Get the latest Zacks research report on PPG - FREE Get the latest Zacks research report on ABT - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. | Global health care major Abbott LaboratoriesABT recently presented one-year positive outcomes from the study of the MitraClip system in transcatheter mitral valve repair (TMVR) procedures in the U.S. MitraClip treats people with degenerative mitral regurgitation (DMR). Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report ResMed Inc. (RMD): Free Stock Analysis Report Bovie Medical Corporation (BVX): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories Price Abbott Laboratories Price | Abbott Laboratories Quote It is said that almost one in 10 people over the age of 75 years suffer moderate to severe MR, which is basically difficult to diagnose."
2017-03-17,45.09999847412109,45.18999862670898,-0.4647025688302009,"IXJ, ABT, TMO, DHR: Large Outflows Detected at ETF | 3 Reasons to Love Abbott Laboratories (ABT) Stock","Among the largest underlying components of IXJ, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.4%, Thermo Fisher Scientific Inc (Symbol: TMO) is down about 0.3%, and Danaher Corp (Symbol: DHR) is up by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Global Healthcare ETF (Symbol: IXJ) where we have detected an approximate $26.0 million dollar outflow -- that's a 1.7% decrease week over week (from 14,600,000 to 14,350,000). For a complete list of holdings, visit the IXJ Holdings page » The chart below shows the one year price performance of IXJ, versus its 200 day moving average: Looking at the chart above, IXJ's low point in its 52 week range is $92.25 per share, with $106.25 as the 52 week high point - that compares with a last trade of $103.75. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Abbott Laboratories (NYSE: ABT ) is up 17% up so far this year and is beginning to look more like its old self. More From InvestorPlace 10 Safe Dividend Stocks to Own During the Next Market Crash 7 IPOs That Were Done the Right Way The post 3 Reasons to Love Abbott Laboratories (ABT) Stock appeared first on InvestorPlace . From early 2011 to the middle of 2015, ABT stock expanded from just $22 per share to over $50."
2017-03-16,45.16999816894531,44.97999954223633,0.19955688610396247,Alere Delays Filing for 2nd Year in a Row,"The filing delay only adds to Alere's problems.The company is currenty in a legal dispute with Abbott Laboratories ( ABT ). According to the company, it needs more time ""to review certain aspects of revenue recognition at its Korean and Japanese locations, including inappropriate conduct at the Company's subsidiary in South Korea, Standard Diagnostics Inc."" The company said some revenue in each of the past four years may have been reported in the wrong quarter. The company expects changes between $5 million and $10 million for 2015 and 2016."
2017-03-15,44.959999084472656,45.31999969482422,-0.4206301403828919,,
2017-03-14,45.18999862670898,44.79999923706055,0.8007131176207963,,
2017-03-13,45.650001525878906,45.52999877929688,-0.8630214682456887,,
2017-03-10,45.77000045776367,45.720001220703125,-0.2628756682822777,,
2017-03-09,45.36000061035156,45.630001068115234,-0.10924019349024461,,
2017-03-08,45.02999877929688,45.36000061035156,0.5952390964078941,,
2017-03-07,44.810001373291016,45.0,0.7328488563193187,,
2017-03-06,44.9900016784668,45.130001068115234,0.4240094195181903,,
2017-03-03,45.41999816894531,45.25,0.31117889403290305,,
2017-03-02,45.5,45.68999862670898,-0.37428043989121984,"IHI, ABT, TMO, DHR: Large Outflows Detected at ETF","Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.2%, Thermo Fisher Scientific Inc (Symbol: TMO) is off about 0.3%, and Danaher Corp (Symbol: DHR) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $136.5 million dollar outflow -- that's a 11.3% decrease week over week (from 7,950,000 to 7,050,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $115.30 per share, with $152.00 as the 52 week high point - that compares with a last trade of $151.06."
2017-03-01,45.369998931884766,45.59000015258789,0.41757939936038957,,
2017-02-28,45.40999984741211,45.08000183105469,0.484904619533756,,
2017-02-27,45.5099983215332,45.459999084472656,-0.7267078120816781,Abbott Labs (ABT) Up 10.8% Since Earnings Report: Can It Continue?,"It has been about a month since the last earnings report for Abbott LaboratoriesABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Recent Earnings Abbott Laboratories reported fourth-quarter 2016 earnings from continuing operations of $0.65 per share, $0.01 higher than the Zacks Consensus Estimate and up 4.8% year over year."
2017-02-24,45.290000915527344,45.68000030517578,-0.1098642911548726,"Acadia Healthcare (ACHC) Tops Q4 Earnings, Gives 2017 View","Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AmerisourceBergen Corporation (Holding Co) (ABC): Free Stock Analysis Report Acadia Healthcare Company, Inc. (ACHC): Free Stock Analysis Report Advanced Accelerator Applications S.A. (AAAP): Free Stock Analysis Report To read this article on Zacks.com click here. Among other medical stocks, Abbott Laboratories ABT , Advanced Accelerator Applications S.A. AAAP and AmerisourceBergen Corporation (Holding Co) ABC have surpassed their respective Zacks Consensus Estimate in the last reported quarter. Acadia Healthcare Company Inc.ACHC reported fourth-quarter 2016 adjusted earnings of 59 cents per share, which surpassed the Zacks Consensus Estimate by 4 cents."
2017-02-23,45.02999877929688,45.400001525878906,0.8611158793656131,,
2017-02-22,44.880001068115234,45.0099983215332,0.8216805609866852,"Noteworthy ETF Outflows: IHI, ABT, TMO, DHR","Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is trading flat, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 0.1%, and Danaher Corp (Symbol: DHR) is up by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $22.4 million dollar outflow -- that's a 1.9% decrease week over week (from 8,100,000 to 7,950,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $112.93 per share, with $149.50 as the 52 week high point - that compares with a last trade of $149.02."
2017-02-21,44.650001525878906,45.0099983215332,0.2896551923442904,,
2017-02-17,44.16999816894531,44.68999862670898,0.8062637925009805,"Daily Dividend Report: MPW, NHI, XRAY, XL, ABT, NKE, FDX","Abbott ( ABT ) declared a quarterly common dividend of 26.5 cents per share. VIDEO: Daily Dividend Report: MPW, NHI, XRAY, XL, ABT, NKE, FDX The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Medical Properties Trust ( MPW ) declared a regular quarterly cash dividend of $0.24 per share of common stock to be paid on April 13, 2017, to stockholders of record on March 16, 2017."
2017-02-16,44.0,44.20000076293945,1.1772707251984051,,
2017-02-15,43.5,44.0,0.4545471884987571,,
2017-02-14,43.0099983215332,43.650001525878906,1.1494252873563218,,
2017-02-13,43.0,43.220001220703125,1.4880335487604095,,
2017-02-10,42.7400016784668,42.7400016784668,0.5116307458212209,Pharmaceutical ETF Experiences Big Inflow,"Among the largest underlying components of PPH, in trading today Novartis (Symbol: NVS) is off about 0.2%, Abbott Laboratories (Symbol: ABT) is trading flat, and GlaxoSmithKline plc (Symbol: GSK) is up by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Pharmaceutical ETF (Symbol: PPH) where we have detected an approximate $66.7 million dollar inflow -- that's a 28.8% increase week over week in outstanding units (from 4,338,138 to 5,588,138). For a complete list of holdings, visit the PPH Holdings page » The chart below shows the one year price performance of PPH, versus its 200 day moving average: Looking at the chart above, PPH's low point in its 52 week range is $50.351 per share, with $62.22 as the 52 week high point - that compares with a last trade of $53.37."
2017-02-09,42.400001525878906,42.540000915527344,0.0,,
2017-02-08,42.65999984741211,42.400001525878906,0.3301872278541987,,
2017-02-07,42.56999969482422,42.88999938964844,-0.6094662973820321,,
2017-02-06,42.56999969482422,42.43000030517578,0.7517023657933576,,
2017-02-03,42.93999862670898,42.77999877929688,-0.32886866490971345,"Mondrian Investment Partners LTD Buys Wells Fargo, Walgreens Boots Alliance, SK Telecom Co, ...","Mondrian Investment Partners LTD New Purchases: SKM , VEDL , AA , AAPL, ARNC, CYD, Added Positions:PHI, WFC, PFE, WBA, CCK, C, INFY, AAC, ECOL, CXW, Reduced Positions:BCE, BAP, ABT, JNJ, MA, MSFT, PG, CAE, YUM, RBA, Sold Out:PAC, CIB, CCU, YUMC, DVMT, CLC, GK, For the details of Mondrian Investment Partners LTD's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Mondrian+Investment+Partners+LTD These are the top 5 holdings of Mondrian Investment Partners LTD CAE Inc ( CAE ) - 14,798,688 shares, 8.03% of the total portfolio. Shares reduced by 28.94% Abbott Laboratories ( ABT ) - 5,158,314 shares, 5.72% of the total portfolio. Reduced: Abbott Laboratories ( ABT ) Mondrian Investment Partners LTD reduced to the holdings in Abbott Laboratories by 26.35%."
2017-02-02,42.33000183105469,42.75,-0.37261260486527853,"Noteworthy ETF Outflows: IWB, PG, CSCO, ABT","Among the largest underlying components of IWB, in trading today Procter & Gamble Co. (Symbol: PG) is up about 0.6%, Cisco Systems Inc (Symbol: CSCO) is up about 1.1%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $25.4 million dollar outflow -- that's a 0.1% decrease week over week (from 134,500,000 to 134,300,000). For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $99.92 per share, with $128.13 as the 52 week high point - that compares with a last trade of $126.80."
2017-02-01,41.5099983215332,42.33000183105469,0.9921997419739963,"After Hours Most Active for Feb 1, 2017 : FB, LOGM, TGI, GE, QQQ, PFE, WFT, BIVVV, CSCO, AAPL, ABT, SYF","Abbott Laboratories ( ABT ) is unchanged at $42.33, with 1,062,372 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the ""buy range"". LogMein, Inc. ( LOGM ) is unchanged at $106.60, with 6,124,848 shares traded."
2017-01-31,40.72999954223633,41.77000045776367,1.9754361423235944,,
2017-01-30,40.86000061035156,41.0099983215332,2.5534027184284156,"Health Care Sector Update for 01/30/2017: JNJ, PFE, ABT, MRK, AMGN, OCRX, CALA, EYEG | Analysts Expect IHI To Hit $156 | After Hours Most Active for Jan 30, 2017 : VREX, ABT, BAC, F, CMCSA, TXN, SWN, SSI, GE, QQQ, YHOO, HBAN","In health care stocks news, Calithera Biosciences ( CALA ) shares surged 52.2% after it and Incyte ( INCY ) said Monday they struck a global collaboration and license agreement for the research, development and commercialization of Calithera's small molecule arginase inhibitor CB-1158 in hematology and oncology. Incyte will also receive worldwide rights to develop and commercialize CB-1158 in hematology and oncology; Calithera will retain certain rights to research, develop and commercialize certain other arginase inhibitors in certain orphan indications. In other sector news, (+) EYEG, (+13.9%) Reports 75% of subjects in pilot trial of its ocular bandage gel achieved complete wound closure by day three (-) OCRX, (-68.3%) Says phase 2b study of intravenously-administered ornithine phenylacetate (OCR-002) did not show statistically significant results in the primary and secondary endpoints The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Similarly, NVRO has 22.55% upside from the recent share price of $83.70 if the average analyst target price of $102.57/share is reached, and analysts on average are expecting ABT to reach a target price of $47.50/share, which is 15.85% above the recent price of $41.00. Three of IHI's underlying holdings with notable upside to their analyst target prices are Omnicell Inc (Symbol: OMCL), Nevro Corp (Symbol: NVRO), and Abbott Laboratories (Symbol: ABT). Below is a twelve month price history chart comparing the stock performance of OMCL, NVRO, and ABT: Combined, OMCL, NVRO, and ABT represent 10.34% of the iShares U.S. Medical Devices ETF. | Abbott Laboratories ( ABT ) is unchanged at $41.01, with 2,916,345 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the ""buy range"". Over the last four weeks they have had 5 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2017."
2017-01-27,41.11000061035156,41.0,0.3671015882061438,"Nutritional Segment Subdues Abbott's Q4'16 Growth, But Future Growth Prospects Remain Strong","Abbott Laboratories ( ABT ) reported its results for Q4 2016 on January 25th. We are in the process of updating our model for Abbott Labs See our complete analysis for Abbott Labs Near-Term Challenges To Continue To Affect Nutritional Segment Growth At $1.7 billion, Abbott's worldwide nutritional sales decreased by 3.7 percent in Q1. New Product Launches In Diagnostics To Drive International Growth Abbott's witnessed 2.9 percent growth from its diagnostics sales, which was primarily led by its growth in Point-of-Care diagnostics and Core Laboratory diagnostics."
2017-01-26,40.459999084472656,40.959999084472656,-0.26757628002531375,,
2017-01-25,39.7599983215332,40.310001373291016,1.2357884609836414,"Abbott Labs (ABT) Tops Q4 Earnings Estimates, Sales In Line | Abbott Laboratories (ABT): Tops Q4 Earnings, Sales in Line | Earnings Reaction History: Abbott Laboratories, 50.0% Follow-Through Indicator, 2.4% Sensitive | Abbott Laboratories Gains Despite Unimpressive Q4 Revenue Results | After Hours Most Active for Jan 25, 2017 : SYMC, EBAY, GE, FTI, SVA, QCOM, MSFT, ABT, BAC, MAT, NOK, KO | 3 Dividend Aristocrats to Buy for Income and Growth","Abbott LaboratoriesABT reported fourth-quarter 2016 earnings from continuing operations of 65 cents per share, a penny higher than the Zacks Consensus Estimate and up 4.8% year over year. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report OraSure Technologies, Inc. (OSUR): Free Stock Analysis Report Neogen Corporation (NEOG): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories Price, Consensus and EPS Surprise Abbott Laboratories Price, Consensus and EPS Surprise | Abbott Laboratories Quote EPD sales were up 10.6% on a reported basis to $979 billion. | Abbott LaboratoriesABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Currently, Abbott Labs has a Zacks Rank #3 (Hold), but that could definitely change following the company's fourth quarter 2016 earnings report which was just released. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 37.5% Average next regular session additional gain: 2.4% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 37.5% of the time (3 events) the stock posted additional gains in the following regular session by an average of 2.4%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 100% Average next regular session additional loss: 2.7% Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 100.0% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close. Extended-Hours Dollar Volume: $626,846 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Abbott Laboratories ABT just released its fourth quarter fiscal 2016 earnings results, posting earnings of $0.65 per share and revenue of $5.33 billion. Currently, ABT has a Zacks Rank #3 (Hold), but it is subject to change following the release of the company's latest earnings report. ABT closed at a gain of $0.56 to $40.32 a shareafter its earnings report was released this morning. | The consensus earnings per share forecast is 0.79 per share, which represents a 78 percent increase over the EPS one Year Ago Abbott Laboratories ( ABT ) is unchanged at $40.31, with 1,072,354 shares traded. The consensus earnings per share forecast is 0.21 per share, which represents a 22 percent increase over the EPS one Year Ago eBay Inc. ( EBAY ) is +2.18 at $32.41, with 1,458,586 shares traded. Smarter Analyst Reports: All Eyes on QUALCOMM, Inc. ( QCOM ) Ahead of Earnings This Evening Microsoft Corporation ( MSFT ) is +0.1 at $63.78, with 1,085,387 shares traded.MSFT is scheduled to provide an earnings report on 1/26/2017, for the fiscal quarter ending Dec2016. | ABBV is a spinoff of the famous Abbott Laboratories (NYSE: ABT ). Dividend Aristocrats to Buy: AbbVie (ABBV) Source: Black Stripe via Wikimedia (Modified) Dividend Yield: 4.2% Long-Term Earnings Growth: 15% The first choice for Dividend Aristocrats is one I frankly didn't expect, but after checking it's financials, I think it may have the best chance for per-share earnings growth in 2017 - AbbVie Inc (NYSE: ABBV ). Dividend Aristocrats to Buy: Cardinal (CAH) Source: Via Wikimedia Dividend Yield: 2.4% Long-Term Earnings Growth: 10% At 2.4%, Cardinal Health Inc (NYSE: CAH ) doesn't have a whopper of a yield as far as Dividend Aristocrats go, but it has a great opportunity for growth going forward."
2017-01-24,40.31999969482422,40.310001373291016,1.383307532636243,"3 Stocks with Great Earnings Charts | Pre-Market Earnings Report for January 25, 2017 : BA, UTX, ABT, ITW, NSC, STT, TEL, FCX, NVS, PGR, APH, HES","Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boeing Company (The) (BA): Free Stock Analysis Report Citrix Systems, Inc. (CTXS): Free Stock Analysis Report Alibaba Group Holding Limited (BABA): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ABT hasn't missed in 5 years but shares still lag. Check it out below: The Best & Worst of Zacks Today you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 ""Strong Buys"" free of charge. | Zacks Investment Research reports that the 2016 Price to Earnings ratio for ABT is 18.34 vs. an industry ratio of 16.90, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories ( ABT ) is reporting for the quarter ending December 31, 2016. In the past year ABT has beat the expectations every quarter."
2017-01-23,40.31999969482422,40.34000015258789,-0.02479742462519558,,
2017-01-20,40.5099983215332,40.459999084472656,0.04960431030518903,"IHI, MDT, ABT, TMO: ETF Inflow Alert | What's in Store for Abbott Labs (ABT) This Earnings Season?","Among the largest underlying components of IHI, in trading today Medtronic PLC (Symbol: MDT) is trading flat, Abbott Laboratories (Symbol: ABT) is up about 0.5%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $139.1 million dollar inflow -- that's a 13.9% increase week over week in outstanding units (from 7,200,000 to 8,200,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $107.22 per share, with $146.91 as the 52 week high point - that compares with a last trade of $139.04. | Click to get this free report Eli Lilly and Co. (LLY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is scheduled to report fourth-quarter and full year 2016 results before the opening bell on Jan 25. The company has a leading position in India, Russia and Latin America At Medical Devices, Vascular is expected to grow in the mid-single digits in the fourth quarter driven by growth from MitraClip and Supera, while Diabetes care sales are expected to increase in the double-digits band, driven by continued consumer uptake of FreeStyle Libre system in Europe."
2017-01-19,40.63999938964844,40.400001525878906,-0.12342443626804508,Insiders Buy the Holdings of XHE ETF,"The table below details the recent insider buying activity observed at ABT: ABT - last trade: $40.76 - Recent Insider Buys: And Endologix Inc. (Symbol: ELGX), the #43 largest holding among components of the SPDR S&P Health Care Equipment ETF ( XHE ), shows 4 directors and officers as recently filing Form 4's indicating purchases. Abbott Laboratories (Symbol: ABT), which makes up 1.78% of the SPDR S&P Health Care Equipment ETF ( XHE ), has seen 4 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $1,387,294 worth of ABT, making it the #25 largest holding."
2017-01-18,41.04999923706055,40.7599983215332,-0.5905459334988622,"After Hours Most Active for Jan 18, 2017 : DHT, NFLX, SQ, NVDA, F, GE, V, ABT, HBAN, MSFT, QQQ, INTC","Abbott Laboratories ( ABT ) is unchanged at $40.76, with 1,426,317 shares traded. ABT is scheduled to provide an earnings report on 1/25/2017, for the fiscal quarter ending Dec2016. The consensus earnings per share forecast is 0.46 per share, which represents a 52 percent increase over the EPS one Year Ago Visa Inc. ( V ) is unchanged at $81.59, with 1,464,663 shares traded."
2017-01-17,40.66999816894531,40.900001525878906,-0.7064577854255516,,
2017-01-13,40.75,40.93000030517578,0.5655356953254527,,
2017-01-12,40.790000915527344,40.720001220703125,0.44171854030866564,,
2017-01-11,41.04999923706055,41.08000183105469,-0.17160993687934017,"Analyst Reports for Facebook, Bank of America & ConocoPhillips","Wednesday, January 11 2017 Today's Research Daily features new research reports on 16 major stocks, including Bank of America (BAC), Facebook (FB) and ConocoPhillips (COP). Bank of America shares have been one of the biggest beneficiaries of the changed macro backdrop following the election, which includes expectations of faster economic growth and overhaul of the country's tax and regulatory systems. No doubt, Bank of America shares have been strong performers since the election - up +34.9% since November 8th vs. +21.8% gain for the Zacks Major Banks industry in that time period, but the analyst still"
2017-01-10,40.810001373291016,41.290000915527344,0.07308792826250247,"Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for January 11, 2017 | Health Care Sector Update for 01/10/2017: IMNP, VRX, JNJ, PFE, ABT, MRK, AMGN","Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. The previous trading day's last sale of ABT was $40.74, representing a -11.03% decrease from the 52 week high of $45.79 and a 13.17% increase over the 52 week low of $36. The following ETF(s) have ABT as a top-10 holding: iShares U.S. Medical Devices ETF ( IHI ) PowerShares Russell Top 200 Pure Value Portfolio ( PXLV ). | ABT: flat MRK: flat AMGN: flat Health care shares were mostly unchanged in pre-market trade Tuesday. In health care stocks news, Immune Pharmaceuticals ( IMNP ) was up 9.8% after it said late Monday it intends to request a hearing before a Nasdaq listing panel to appeal a notification that Immune's securities are subject to delisting. The company agreed to sell its CeraVe, AcneFree and AMBI skincare brands to France-based L'Oreal for $1.3 billion in cash as well all of its outstanding equity interests in Dendreon Pharmaceuticals to China-based Sanpower Group Co., Ltd. for $819.9 million in cash."
2017-01-09,40.790000915527344,40.7400016784668,1.1761811469834307,"Health Care Sector Update for 01/09/2017: ARWR, EXAS, JNJ, PFE, ABT, MRK, AMGN | Oil Sinks Dow Jones Industrial Average as Nasdaq Scores Another High","In health care stocks news, Exact Sciences ( EXAS ) was up 16.6% after the company said Sunday it expects to report revenues between $34.9 million and $35.4 million in Q4, up 142% year-over-year and above the $30.1 million consensus estimate from analysts polled by Capital IQ. For the year the company expects to report revenues between $99.0 million and $99.5 million, up 150% from a year ago and higher than the $94.2 million consensus. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ( CNBC ) Abbott Laboratories ( ABT ) reported today that it has begun releasing updates for its recently acquired St. Jude heart devices, providing extra cybersecurity measures , and allowing doctors to track the performance of devices. After coming within a fraction of a point from the 20,000 level on Friday, the Dow Jones Industrial Average (DJIA) explored a relatively narrow range today, but failed to find its way into positive territory, as falling crude oil prices weighed on stocks. 5 Items on Our Radar Today With questions still looming regarding how closely connected President-elect Donald Trump will remain to his personal businesses, Democratic Senator Elizabeth Warren joined her fellow party members in introducing a bill that would force the incoming president to ""divest all interests that create financial conflicts of interest placing those assets in a true blind trust."""
2017-01-06,39.70000076293945,40.77999877929688,-0.12257719033664913,"Abbott Laboratories (ABT) Shares Cross Above 200 DMA | Notable Friday Option Activity: GS, ABT, ULTA","In trading on Friday, shares of Abbott Laboratories (Symbol: ABT) crossed above their 200 day moving average of $40.78, changing hands as high as $40.99 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $36.00 per share, with $45.79 as the 52 week high point - that compares with a last trade of $40.77. According to the ETF Finder at ETF Channel, ABT makes up 7.98% of the First Trust Nasdaq Pharmaceuticals ETF (Symbol: FTXH) which is trading up by about 0.5% on the day Friday. | Particularly high volume was seen for the $40 strike put option expiring January 20, 2017 , with 10,070 contracts trading so far today, representing approximately 1.0 million underlying shares of ABT. Below is a chart showing ABT's trailing twelve month trading history, with the $40 strike highlighted in orange: And Ulta Salon Cosmetics & Fragrance Inc. (Symbol: ULTA) options are showing a volume of 3,207 contracts thus far today. Below is a chart showing GS's trailing twelve month trading history, with the $245 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) options are showing a volume of 48,714 contracts thus far today."
2017-01-05,39.2400016784668,39.70000076293945,2.7203979738096717,"Health Care Sector Update for 01/05/2017: CTIC, HRTX, JNJ, PFE, ABT, MRK, AMGN","ABT: flat MRK: flat AMGN: flat Health care shares were mostly unchanged in pre-market trade Thursday. In health care stocks news, Heron Therapeutics ( HRTX ) was down 9.4% after providing weak outlook for sales of Sustol, its anti-nausea drug, overshadowed the company's Wednesday release of data from a phase 2 clinical trial of HTX-011 in abdominoplasty, or tummy tucks, which showed the treatment ""produced statistically significant reductions in both pain intensity and need for opioids"" through 96 hours post surgery. And, CTI BioPharma ( CTIC ) was up 20.9% after the U.S. Food and Drug Administration removed the full clinical hold on all clinical trials conducted under the investigational new drug application for pacritinib to treat myelofibrosis."
2017-01-04,39.060001373291016,39.36000061035156,1.172270807330479,"Health Care Sector Update for 01/04/2017: NVLS, JNJ, PFE, ABT, MRK, AMGN | After Hours Most Active for Jan 4, 2017 : CC, IDXX, ABT, MT, STJ, BAC, MSFT, PK, QQQ, EBAY, FOLD, INTC","ABT: flat In health care stocks news, Johnson & Johnson ( JNJ ) was up 0.9% following a Reuters report that said it will only have to pay about half of the more than $1 billion awarded by a jury to plaintiffs in six lawsuits who said they were injured by DePuy's Pinnacle hip implants. The report said the judge cited ""constitutional considerations"" that limit how much plaintiffs may recover in punitive damages but upheld the jury's findings that the implants were defectively designed and that the companies failed to warn consumers about the risks. | Abbott Laboratories ( ABT ) is +0.0852 at $39.45, with 3,504,117 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the ""buy range"". Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2017."
2017-01-03,38.630001068115234,39.04999923706055,0.7680471748925346,"VHT, ABT, TMO, DHR: Large Outflows Detected at ETF | Health Care Sector Update for 01/03/2017: AGN, ITEK, JNJ, PFE, ABT, MRK, AMGN","Among the largest underlying components of VHT, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.7%, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 1.6%, and Danaher Corp (Symbol: DHR) is higher by about 1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Health Care ETF (Symbol: VHT) where we have detected an approximate $19.0 million dollar outflow -- that's a 0.3% decrease week over week (from 43,234,773 to 43,084,773). For a complete list of holdings, visit the VHT Holdings page » The chart below shows the one year price performance of VHT, versus its 200 day moving average: Looking at the chart above, VHT's low point in its 52 week range is $113.02 per share, with $138.99 as the 52 week high point - that compares with a last trade of $128.00. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In health care stocks news, Inotek Pharmaceuticals ( ITEK ) were down 67.7% after the company said that top-line results of a trial of trabodenoson, the company's lead clinical candidate, did not achieve its primary endpoint."
2016-12-30,38.33000183105469,38.40999984741211,1.0872331279637841,"Health Care Sector Update for 12/30/2016: ABT,STJ,MRNS,INNL | Health Care Sector Update for 12/30/2016: CO, JNJ, PFE, ABT, MRK, AMGN | AbbVie's Humira and Imbruvica Drive Performance in 2016","In company news, shares of Abbott Laboratories ( ABT ) and St. Jude Medical ( STJ ) were edging higher shortly before the closing bell late Friday after the medical device companies today said they expect to close their proposed $25 billion merger next Wednesday, Jan. 4. ABT shares were up about 0.1% at $38.36 apiece this afternoon, giving back most of an earlier climb to $38.87 a share. Health care stocks were narrowly mixed in recent trade, with the NYSE Health Care Index climbing about 0.1% while shares of health care companies in the S&P 500 were down nearly 0.2% as a group. | In health care stocks news, Merck & Company ( MRK ) was up 0.7% after it received orphan drug designation for Keytruda as treatment of Merkel cell carcinoma from the U.S. Food and Drug Adminstration, according to the agency's website. Keytruda or pembrolizumab is a cancer drug that works against the growth and spread of cancer cells in the body.It was previously approved by the FDA on an ""accelerated"" basis to treat lung cancer or head and neck cancer. And,China Cord Blood ( CO ) was up 16% after Golden Meditech Holdings, owner of a 65.4% equity stake in the company, said it has agreed to sell its entire holding to Nanjing Yingpeng Huikang Medical Industry Investment Partnership for RMB5.76 billion ($830.4 million). | Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. North Chicago, IL-based AbbVie Inc.ABBV came into existence on Jan 1, 2013, after Abbott Laboratories ABT divested its pharmaceutical division. AbbVie has a presence in the rheumatoid arthritis, cancer, psoriasis, Crohn's disease, HIV, hepatitis C virus (HCV), testosterone, thyroid disease, Parkinson's disease, ulcerative colitis, and chronic kidney disease markets."
2016-12-29,38.29999923706055,38.310001373291016,0.20870861606014343,Abbott to Sell 2 Medical Device Businesses for St. Jude Buyout,"Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ST JUDE MEDICAL (STJ): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report VANDA PHARMACT (VNDA): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT has agreed to divest two medical device businesses in order to settle Federal Trade Commission (FTC) charges in relation to its proposed acquisition of St. Jude Medical STJ . Under the consent order, the companies are required to divest all rights and assets related to St. Jude's vascular closure device business and Abbott Labs' steerable sheath unit to Tokyo-based medical device maker Terumo Corporation."
2016-12-28,38.630001068115234,38.220001220703125,0.026115238719875217,"Abbott Labs to Buy St. Jude Medical for $—5 Billion | ABT, STJ: Abbott Laboratories Gets OK to Buy St. Jude Medical, Inc.","Abbott Labs ( ABT ) agreed Dec. 27 to the conditions imposed by the U.S. Federal Trade Commission for the closing of the deal that will see Abbott purchase St. Jude Medical ( STJ ) for a total consideration of $25 billion. Abbott closed at $38.60 per share Dec. 27, up 18 cents, or 0.47%, from the previous trading day, with 6,633,668 shares traded on the New York Stock Exchange (NYSE) versus an average volume of 7.6 million over the last 10 trading days and an average volume of 8.6 million shares over the last three months. During the third quarter, First Eagle Investment ( Trades , Portfolio ), George Soros (Trades, Portfolio) and Richard Pzena (Trades, Portfolio) reduced their positions in Abbot Labs by 57.24%, 21.26% and 5.81% while Joel Greenblatt (Trades, Portfolio) sold out his position. | InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips The Federal Trade Commission (FTC) has given its approval to Abbott Laboratories' (NYSE: ABT ) deal to acquire St. Jude Medical, Inc. (NYSE: STJ ). More From InvestorPlace 7 Fast-Growing Consumer Stocks to Buy The 10 Best Fidelity Funds for 2017 3 Stocks That Could Get Pounded by Tax Loss Selling The post ABT, STJ: Abbott Laboratories Gets OK to Buy St. Jude Medical, Inc. appeared first on InvestorPlace . This condition was put in place to keep ABT from monopolizing the market for these devices."
2016-12-27,38.47999954223633,38.59999847412109,-1.0613508570428662,"Top Research Reports for 27th December, 2016","Click to access these private picks>> Note: If you want an email notification each time Sheraz publishes a new article, pleaseclick here>>> Today's Must Read Visa's (V) Technological Upgrades to Support Profitability Reynolds (RAI) Boosts Vapor Category; Gets Merger Proposal General Motors (GM) Fined in China on Anti-Competitive Grounds Abbott (ABT) Continues to Reshape Business, Cancels Alere Featured Reports Priceline (PCLN) Appoints Glenn Fogel as its New CEO The Zacks analyst believes that Priceline's appointment of new CEO, strength in international markets, growth opportunities in the domestic market and strong financial position are positives. Click to get this free report VISA INC-A (V): Free Stock Analysis Report REYNOLDS AMER (RAI): Free Stock Analysis Report GENERAL MOTORS (GM): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Tuesday, December 27 2016 Today's Research Daily features new research reports on 17 major stocks, including Visa (V), Reynolds (RAI), General Motors (GM) and Abbott (ABT)."
2016-12-23,38.33000183105469,38.41999816894531,0.31184753979283597,,
2016-12-22,38.150001525878906,38.290000915527344,0.23479346097424555,"Health Care Sector Update for 12/22/2016: STJ,ABT,TKAI,OVAS","In company news, shares of St. Jude Medical ( STJ ) firmed this afternoon following a report earlier Thursday federal regulators are ready to approve Abbott Laboratories' ( ABT ) $25 billion proposed acquisition of the rival medical device manufacturer. Health care stocks were slightly higher in late trade, with the NYSE Health Care Index climbing about 0.1% while shares of health care companies in the S&P 500 also were up 0.1% as a group. The U.S. Federal Trade Commission is poised to sign off on the deal as soon as this week or next, a pair of sources with knowledge of the matter told Reuters."
2016-12-21,38.18999862670898,38.2400016784668,0.36697086251351646,,
2016-12-20,38.400001525878906,38.18999862670898,0.13093232143467248,iShares Russell 3000 ETF Experiences Big Inflow,"Among the largest underlying components of IWV, in trading today Celgene Corp. (Symbol: CELG) is up about 1.9%, Abbott Laboratories (Symbol: ABT) is down about 0.8%, and Thermo Fisher Scientific Inc (Symbol: TMO) is higher by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 3000 ETF (Symbol: IWV) where we have detected an approximate $404.7 million dollar inflow -- that's a 6.0% increase week over week in outstanding units (from 49,950,000 to 52,950,000). For a complete list of holdings, visit the IWV Holdings page » The chart below shows the one year price performance of IWV, versus its 200 day moving average: Looking at the chart above, IWV's low point in its 52 week range is $105.62 per share, with $135.76 as the 52 week high point - that compares with a last trade of $135.40."
2016-12-19,38.22999954223633,38.34000015258789,-0.5468825281905308,"Health Care Sector Update for 12/19/2016: BCLI, JNJ, PFE, ABT, MRK, AMGN","In health care stocks news, Pfizer ( PFE ) rose 1% after it said Monday that Nimenrix, a treatment for infants with invasive meningococcal disease, was approved by the European Commission for an expanded indication in the European Union. The decision was made based on the company's phase 3 trial of the drug, which looked at its impact on 1,000 infants from six weeks of age. And, Brainstorm Cell Therapeutics ( BCLI ) was up 11.2% after it said Monday it has completed an end-of-phase 2 meeting with the U.S. Food and Drug Administration and reached an agreement with the agency to proceed to a phase 3 trial for NurOwn for the treatment of Amyotrophic lateral sclerosis, or Lou Gehrig's disease."
2016-12-16,39.02000045776367,38.09999847412109,0.2877337474985694,,
2016-12-15,38.7599983215332,38.93000030517578,-2.3577703045862872,The Worst Dividend Aristocrats of 2016,"Three of the worst-performing Dividend Aristocrats were Cardinal Health (NYSE: CAH) , Abbott Laboratories (NYSE: ABT) , and VF Corp. (NYSE: VFC) . The Dividend Aristocrats list of top dividend stocks is a great starting point for investors seeking more income from their stock portfolios. Even as the broader stock market made solid gains this year, several members of this elite group of dividend stocks lost ground."
2016-12-14,39.41999816894531,38.81999969482422,0.43860162797822705,First Trust Nasdaq Pharmaceuticals ETF -- Insider Buying Index Registering 10.7%,"The table below details the recent insider buying activity observed at ABT: ABT - last trade: $39.44 - Recent Insider Buys: And Medicines Co (Symbol: MDCO), the #16 largest holding among components of the First Trust Nasdaq Pharmaceuticals ETF (Symbol: FTXH), shows 2 directors and officers as recently filing Form 4's indicating purchases. Abbott Laboratories (Symbol: ABT), which makes up 8.43% of the First Trust Nasdaq Pharmaceuticals ETF (Symbol: FTXH), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $155,137 worth of ABT, making it the #4 largest holding."
2016-12-13,39.310001373291016,39.43999862670898,-1.5220662150962925,,
2016-12-12,39.20000076293945,39.20000076293945,0.3306976567705938,,
2016-12-09,38.81999969482422,39.20000076293945,0.0,"Vanguard Value ETF Experiences Big Inflow | Daily Dividend Report: GE, BMY, ABT, ECL, EIX, VTR, CAG","Among the largest underlying components of VTV, in trading today Intel Corp (Symbol: INTC) is trading flat, Eli Lilly & Co. (Symbol: LLY) is up about 0.9%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Value ETF (Symbol: VTV) where we have detected an approximate $234.2 million dollar inflow -- that's a 0.9% increase week over week in outstanding units (from 282,658,182 to 285,158,182). For a complete list of holdings, visit the VTV Holdings page » The chart below shows the one year price performance of VTV, versus its 200 day moving average: Looking at the chart above, VTV's low point in its 52 week range is $72.48 per share, with $94.00 as the 52 week high point - that compares with a last trade of $93.78. | Abbott ( ABT ) increased the company's quarterly common dividend to 26.5 cents per share from 26 cents per share. VIDEO: Daily Dividend Report: GE, BMY, ABT, ECL, EIX, VTR, CAG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. GE ( GE ) raised the Company's quarterly dividend 4%, or $0.01 per outstanding share of the Company's common stock, to $0.24 per outstanding share of the Company's common stock."
2016-12-08,38.33000183105469,38.68000030517578,0.978879626745332,"Mylan (MYL) Stock Falls on Restructuring Plans, Layoffs","In an 8-K filing, generic drug maker Mylan N.V.MYL revealed restructuring programs in certain locations in an attempt to streamline its operations globally as it focuses on the integration of acquired businesses. We note that Mylan's global workforce comprised nearly 35,000 employees as of Dec 31, 2015. This implies that the layoff could affect up to 3,500 people."
2016-12-07,38.130001068115234,38.47999954223633,0.9131188557302063,,
2016-12-06,38.43999862670898,38.41999816894531,0.9179083774371217,,
2016-12-05,38.11000061035156,38.43000030517578,-0.052030329027556214,3 Beaten-Down Generic Drugmakers to Buy,"Last year, it acquired a portfolio of both branded and generic drugs from pharma giant Abbott Laboratories (NYSE: ABT ). InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips Earlier in November, some of the largest firms in the generic drugs firm space received subpoenas from the U.S. Justice Department. Generic Drugmakers to Buy: Teva (TEVA) Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA ) are down 46% from their 52-week high of over $66 per share."
2016-12-02,37.68000030517578,37.900001525878906,0.8396738118584532,,
2016-12-01,38.119998931884766,37.59999847412109,0.5838673538251148,"Health Care Sector Update for 12/01/2016: JNJ, PFE, ABT, MRK, AMGN, ARDM, HTBX","ABT: flat MRK: flat In health care stocks news, Aradigm ( ARDM ) was 63.4% higher in pre-market trade, coming off a trading halt, after the company reported mixed top-line results from two phase 3 studies of Pulmaquin for patients with non-cystic fibrosis bronchiectasis with chronic lung infections with Pseudomonas aeruginosa. In the key secondary efficacy endpoint, there was a 13% reduction in the frequency of PE's over the 48-week treatment period in the Pulmaquin treatment group as compared to the placebo group."
2016-11-30,38.75,38.06999969482422,-1.3641145654092195,,
2016-11-29,38.86000061035156,38.72999954223633,-1.7548394972278225,The Best Obamacare Stocks of 2016,"In April, Abbott Laboratories (NYSE: ABT) announced that it would acquire St. Jude in a $25 billion deal. Here's why HealthEquity (NASDAQ: HQY) , UnitedHealth Group (NYSE: UNH) , and St. Jude Medical (NYSE: STJ) stand out as three of the best Obamacare stocks of 2016. A leader in health savings accounts HealthEquity is probably the biggest Obamacare stock of the year."
2016-11-28,39.220001220703125,38.7400016784668,-0.33453696879408845,,
2016-11-25,39.08000183105469,39.15999984741211,-1.2238641695476287,,
2016-11-23,38.040000915527344,38.97999954223633,0.20470320524358815,,
2016-11-22,39.41999816894531,38.09999847412109,2.47107940085588,,
2016-11-21,39.84999847412109,39.7599983215332,-3.3485534148606546,,
2016-11-18,40.310001373291016,39.84000015258789,-0.2258473175258221,,
2016-11-17,40.0,40.38999938964844,-1.1659667692657112,,
2016-11-16,39.79999923706055,39.95000076293945,0.9749984741210938,"121,456 shares bought by Abbott Chairman","Miles White, Chairman and Chief Executive Officer at Abbott Laboratories ( ABT ), bought 121,456 shares of the company's common stock on November 10. The shares were purchased at $40.45 for a total of $4,912,895.20 InvestorsKeyhole Trade Alert IK-> The technicals for ABT($40.13 up $0.32) are neutral with a neutral trend. [InvestorsKeyhole, Various news and data services] The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2016-11-15,39.290000915527344,39.810001373291016,0.376888263201848,"Health Care Sector Update for 11/15/2016: ABT,STJ,JNJ,JNP,AGN,TSRO","In company news, Abbott Laboratories ( ABT ) and St. Jude Medical ( STJ ) were advancing ahead of Tuesday's closing bell after the medical device giants were said to be nearing regulatory approval in Europe for their $25 billion merger proposal. ABT shares gained Tuesday, recently adding about 1.5% to $39.79 apiece, easing slightly from an intra-day high of $39.94 a share. Health care stocks turned narrowly higher this afternoon, reversing prior declines, with the NYSE Health Care Index adding about 0.1% while shares of health care companies in the S&P 500 were down almost 0.3% as a group."
2016-11-14,40.11000061035156,39.20000076293945,1.3234931169425566,"IHI, TMO, ABT, DHR: Large Inflows Detected at ETF | Abbott Laboratories (ABT) Chairman and CEO Miles D White Bought $‘.6 million of Shares | Abbott Laboratories (ABT) Chairman and CEO Miles D White Bought $—.– million of Shares","Among the largest underlying components of IHI, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is off about 0.2%, Abbott Laboratories (Symbol: ABT) is down about 0.6%, and Danaher Corp (Symbol: DHR) is lower by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $60.7 million dollar inflow -- that's a 4.9% increase week over week in outstanding units (from 9,200,000 to 9,650,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $107.22 per share, with $146.91 as the 52 week high point - that compares with a last trade of $134.00. | Chairman and CEO of Abbott Laboratories ( ABT ) Miles D White bought 89,578 shares of ABT on --/-…/-…-6 at an average price of $4….5' a share. CEO Recent Trades: Chairman and CEO Miles D White bought 58,-6' shares of ABT stock on --/-…/-…-6 at the average price of $4….67. Chairman and CEO Miles D White bought 48,76- shares of ABT stock on --/-…/-…-6 at the average price of $4….65. | Chairman and CEO of Abbott Laboratories ( ABT ) Miles D White bought 5-,89- shares of ABT on --/-…/-…-6 at an average price of $4….54 a share. CEO Recent Trades: Chairman and CEO Miles D White bought 58,-6' shares of ABT stock on --/-…/-…-6 at the average price of $4….67. Chairman and CEO Miles D White bought 48,76- shares of ABT stock on --/-…/-…-6 at the average price of $4….65."
2016-11-11,40.380001068115234,40.13999938964844,-2.2687604925572034,,
2016-11-10,40.52000045776367,40.61000061035156,-0.5943577813728848,,
2016-11-09,41.5,40.06999969482422,0.2221129110837572,,
2016-11-08,39.619998931884766,39.83000183105469,-3.445783867893449,,
2016-11-07,39.63999938964844,39.86000061035156,0.5300426674189509,,
2016-11-04,38.45000076293945,39.09000015258789,0.5549980426098997,"Notable ETF Outflow Detected - IHI, TMO, ABT, DHR | 10.6% of FTXH Holdings Seeing Recent Insider Buys | Alere Inc. Has Been Left for Dead, With Its Shares Down 13%","Among the largest underlying components of IHI, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is up about 0.3%, Abbott Laboratories (Symbol: ABT) is up about 1.6%, and Danaher Corp (Symbol: DHR) is up by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $59.8 million dollar outflow -- that's a 4.7% decrease week over week (from 9,650,000 to 9,200,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $107.22 per share, with $146.91 as the 52 week high point - that compares with a last trade of $134.13. | The table below details the recent insider buying activity observed at ABT: ABT - last trade: $38.38 - Recent Insider Buys: And Medicines Co (Symbol: MDCO), the #22 largest holding among components of the First Trust Nasdaq Pharmaceuticals ETF (Symbol: FTXH), shows 2 directors and officers as recently filing Form 4's indicating purchases. Abbott Laboratories (Symbol: ABT), which makes up 8.55% of the First Trust Nasdaq Pharmaceuticals ETF (Symbol: FTXH), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $153,507 worth of ABT, making it the #4 largest holding. | Making matters even stranger, Abbott Laboratories (NYSE: ABT) agreed to acquire Alere for $5.8 billion in the weeks before this accounting mess came to a head. According to Alere, only 47 of those claims were specifically identified, and Alere made clear that these 211 claims are out of a pool of 5.8 million claims made over that time period. Given the company's relatively weak third-quarter report, the revoking of its Medicare status for Arriva, its internal control issues with accounting, and the ongoing brouhaha between it and its potential acquirer Abbott, I believe the only true recourse here is to stay as far away from Alere as possible."
2016-11-03,38.86000061035156,38.380001068115234,1.664497729387068,,
2016-11-02,39.04999923706055,38.70000076293945,-1.235202096493188,,
2016-11-01,39.2400016784668,39.04999923706055,-0.8962829217904987,,
2016-10-31,39.43000030517578,39.2400016784668,-0.48420599714325463,,
2016-10-28,40.25,39.540000915527344,-0.4818631124485287,,
2016-10-27,40.09000015258789,40.290000915527344,-1.7639728806774069,,
2016-10-26,40.0,39.959999084472656,0.4988794267354042,,
2016-10-25,40.41999816894531,40.18999862670898,-0.10000228881835936,"Drug Stock Earnings to Watch on Oct 26: BIIB, MDCO & More","Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MEDICINES CO (MDCO): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report EXACT SCIENCES (EXAS): Free Stock Analysis Report To read this article on Zacks.com click here. A couple of other companies that released earnings last week included - Abbott Laboratories ABT and Roche Holding AG RHHBY . Abbott Labs' quarterly earnings beat the Zacks Consensus Estimate for earnings and delivered in-line revenues, while Roche's quarterly sales fell marginally short of expectations."
2016-10-24,40.790000915527344,40.40999984741211,-0.5690241282916334,"The Zacks Analyst Blog Highlights: Abbott, Goldman Sachs, Verizon and Union Pacific | Drug Stocks Q3 Earnings Roster for Oct 25: MRK, LLY & More","Here are highlights from Friday's Analyst Blog: Top Research Reports for Goldman Sachs, Verizon, Abbott Labs and Others Today's Research Daily features new research reports on 16 major stocks, including Abbott (NYSE: ABT - Free Report ), Goldman Sachs (NYSE: GS - Free Report ), Verizon (NYSE: VZ - Free Report ) and Union Pacific (NYSE: UNP - Free Report ). Get the full Report on ABT - FREE Get the full Report on GS - FREE Get the full Report on VZ - FREE Get the full Report on UNP - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report GOLDMAN SACHS (GS): Free Stock Analysis Report VERIZON COMM (VZ): Free Stock Analysis Report UNION PAC CORP (UNP): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT , which also reported last week, beat the Zacks Consensus Estimate for earnings while delivering in-line earnings. LILLY ELI & CO Price and EPS Surprise LILLY ELI & CO Price and EPS Surprise | LILLY ELI & CO Quote The Zacks Consensus Estimate for the quarter is pegged at 96 cents per share."
2016-10-21,40.40999984741211,40.5,-0.9316034802308159,,
2016-10-20,40.0099983215332,40.7400016784668,0.22271752766080324,Dark Cloud And Silver Linings: Abbott Q3'16 Earnings,"Abbott Labs ( ABT ) reported its Q3'16 earnings on October 19th. Over the next quarter and in fiscal 2017 we expect Abbott to report weak performance in nutrition business, due to the weaker performance of its pediatric nutrition business. Drop us a line atcontent@trefis.com See the links below for more information and analysis about Abbott: Leverage to be challenge challenge for Abbott once the deal is done, Part-1 Leverage to be challenge challenge for Abbott once the deal is done, Part-2 Why is Abbott acquiring St. Jude?"
2016-10-19,40.52000045776367,40.0099983215332,1.8245523308125438,"Q3 Earnings Continue, Housing and Permits Mixed | Abbott Labs (ABT) Beats on Q3 Earnings, Narrows 2016 View | Wednesday Sector Laggards: Healthcare, Utilities | Abbott Labs (ABT) Beats on Earnings & Sales in Q3 | Earnings Reaction History: Abbott Laboratories, 44.4% Follow-Through Indicator, 2.5% Sensitive","Click to get this free report SEAGATE TECH (STX): Free Stock Analysis Report US BANCORP (USB): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MORGAN STANLEY (MS): Free Stock Analysis Report HALLIBURTON CO (HAL): Free Stock Analysis Report To read this article on Zacks.com click here. Suburban Chicago-based Abbott Labs ABT beat Q3 earnings estimates by a penny to 58 cents per share, an 8% gain year over year, while bringing sales in-line with $5.3 billion for the quarter. We also have a plethora of new Q3 earnings data: Morgan Stanley MS far surpassed expectations with 81 cents per share (64 cents was the estimate) on $8.9 billion in revenues (as compared to $8.24 billion expected). | Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ST JUDE MEDICAL (STJ): Free Stock Analysis Report INCYTE CORP (INCY): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT reported third-quarter 2016 earnings of 59 cents per share, higher than both the Zacks Consensus Estimate of 58 cents and the year-ago figure of 54 cents. FindTheCompany | Graphiq Quarterly sales came in at $5.3 billion, up 2.9% year over year on a reported basis, and in line with the Zacks Consensus Estimate. | Within that group, Intuitive Surgical Inc (Symbol: ISRG) and Abbott Laboratories (Symbol: ABT) are two large stocks that are lagging, showing a loss of 4.3% and 2.5%, respectively. Combined, ISRG and ABT make up approximately 2.9% of the underlying holdings of XLV. Among healthcare ETFs , one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is down 0.1% on the day, and down 1.53% year-to-date. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. ABBOTT LABS Price and EPS Surprise ABBOTT LABS Price and EPS Surprise | ABBOTT LABS Quote Currently, Abbott Labs has a Zacks Rank #4 (Sell), but that could definitely change following the company's earnings report which was just released. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 37.5% Average next regular session additional gain: 2.4% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 37.5% of the time (3 events) the stock posted additional gains in the following regular session by an average of 2.4%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 100% Average next regular session additional loss: 4.4% Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 100.0% of the time (1 event) the stock dropped further, adding to the extended-hours losses by an average of 4.4% by the following regular session close. Extended-Hours Dollar Volume: $601,876 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session."
2016-10-18,40.59000015258789,41.16999816894531,-1.2586429675934316,"Pharma Boosts Johnson & Johnson Despite Falling Consumer Sales | Without Drugs, Johnson & Johnson Has Nothing (JNJ) | 3 Companies with Perfect Earnings Records | Pre-Market Earnings Report for October 19, 2016 : USB, RAI, MS, ABT, ASML, HAL, BBT, CP, STJ, APH, MTB, NTRS | Your Two Minute Earnings Preview for Abbott Labs (ABT) Stock","Johnson & Johnson paid Abbott Laboratories (NYSE: ABT) $4.325 billion in cash for the division, and investors expect the acquisition to boost earnings modestly within the first year after the deal closes. It surprises many investors to discover that the consumer products division of Johnson & Johnson (NYSE: JNJ) isn't its most important business segment. Looking more closely at Johnson & Johnson's product lines, the company said that Listerine oral care and Aveeno skin care products were among the biggest positive contributors on the consumer front, although lower inventory levels in the U.S. held back growth. | The purchase of Abbott Medical Optics from Abbott Laboratories (NYSE: ABT ), for $4.325 billion, completed during the quarter, will help device sales going forward. InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips Johnson & Johnson (NYSE: JNJ ) shareholders are waking up with a shrug today. Moreover, Johnson & Johnson maintained sales guidance for full-year 2016 of $71.5 billion to $72.2 billion, though it increased its adjusted earnings guidance for full-year 2016 to $6.68 to $6.73 per share. | Click to get this free report US BANCORP (USB): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report CITRIX SYS INC (CTXS): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs (ABT) is in the out-of-favor drug sector. This week's best earnings charts include companies who have perfect earnings surprise track records. | Zacks Investment Research reports that the 2016 Price to Earnings ratio for ABT is 18.45 vs. an industry ratio of 17.00, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories ( ABT ) is reporting for the quarter ending September 30, 2016. In the past year ABT has beat the expectations every quarter. | Make sure to watch the video for a quick guide to ABT heading into the report, but if you want to learn more about trading in earnings season, check out our podcast below: The Best & Worst of Zacks Today you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 ""Strong Buys"" free of charge. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Today's short video takes a closer look at Abbott Labs (ABT) stock ahead of their earnings report."
2016-10-17,40.72999954223633,40.59000015258789,1.4289184877483747,,
2016-10-14,41.16999816894531,40.790000915527344,-0.34372548790053503,"Health Care Sector Update for 10/14/2016: NHTC, EGLT, JNJ, PFE, ABT, MRK, AMGN | 3 Figures That Matter Most When Johnson & Johnson Reports Its 3rd-Quarter Results","ABT: flat AMGN: flat Health care shares were mostly unchanged in pre-market trade Friday. In health care stocks news, Egalet ( EGLT ) shares fell 5.9% after the specialty pharmaceutical company said that the U.S. Food and Drug Administration will not meet the previously announced Oct. 14 prescription drug user fee act (PDUFA) date for Arymo ER. | More recently, J&J announced the acquisition of Abbott Laboratories '(NYSE: ABT) eye-surgery-equipment unit, Abbott Medical Optics, for $4.33 billion. Slated to report its Q3 results before the opening bell on Tuesday, Oct. 18, Johnson & Johnson is projected by Wall Street to earn $1.65 per share on $17.7 billion in sales. Pharmaceuticals growth rate Johnson & Johnson may be made up of three operating segments (pharmaceuticals, medical devices, and consumer health), but it's the company's pharmaceuticals unit that packs the biggest punch."
2016-10-13,40.7400016784668,40.97999954223633,-0.9229955557894635,"Health Care Sector Update for 10/13/2016: FLKS, TGTX, JNJ, PFE, ABT, MRK, AMGN | J&J (JNJ) Likely to Beat Earnings Estimates in Q3 Again | Celgene/Agios Ink Deals with Abbott to Identify IDH Mutations","ABT: flat In health care stocks news, TG Therapeutics ( TGTX ) was down 15.2% after company said it has filed with the U.S. Food and Drug Administration to make changes to its phase 3 trial of TG-1101 in leukemia. And, Flex Pharma ( FLKS ) was down 17% after the company said an exploratory study of FLX-787, a topical treatment being evaluated for nocturnal leg cramps, did not demonstrate a statistically significant reduction on the endpoints of muscle cramp frequency or cramp-free nights. | Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. In Sep 2016, J&J announced its intention to acquire Abbott Laboratories' ABT Abbott Medical Optics for $4.325 billion in cash. Zacks Rank #3 (Hold): Note that stocks with Zacks Ranks #1 (Strong Buy), #2 (Buy) and #3 have a significantly higher chance of beating earnings. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report GERON CORP (GERN): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report AGIOS PHARMACT (AGIO): Free Stock Analysis Report To read this article on Zacks.com click here. Celgene CorporationCELG and Agios Pharmaceuticals, Inc. AGIO announced that they have entered into collaboration agreements with Abbott Laboratories ABT to develop and commercialize diagnostic tests to identify isocitrate dehydrogenase (IDH) mutations in patients with acute myeloid leukemia (AML). CELGENE CORP Price CELGENE CORP Price | CELGENE CORP Quote Agios is developing an IDH1 inhibitor, AG-120, for the treatment of patients with relapsed or refractory AML who have an IDH1 mutation."
2016-10-12,41.04999923706055,40.97999954223633,0.5890963521888674,Can Johnson & Johnson Keep Growing Healthier?,"For instance, in September, J&J bought the Abbott Medical Optics eye-surgery equipment unit of Abbott Laboratories (NYSE: ABT) , paying $4.3 billion to strengthen its overall medical device lineup. As investors prepare for Tuesday's third-quarter financial report from Johnson & Johnson, they want to see whether the company can keep producing the growth in revenue and earnings that they've come to expect. In the Johnson & Johnson earnings report, investors will want to keep a close eye not only on whether the pharmaceutical business continues to take the lead in producing growth but also on the contributions that the medical device and consumer segments are able to make to its overall success."
2016-10-11,43.5,41.15999984741211,-0.1705230112672499,"iShares U.S. Medical Devices ETF Experiences Big Inflow | Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for October 12, 2016 | Pre-Market Most Active for Oct 11, 2016 : AAPL, STJ, ABT, TWTR, MT, ILMN, TVIX, BCS, ABX, SUPN, SQQQ, QQQ","Among the largest underlying components of IHI, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is off about 2.5%, Abbott Laboratories (Symbol: ABT) is off about 4.4%, and Danaher Corp (Symbol: DHR) is lower by about 1.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $50.8 million dollar inflow -- that's a 3.6% increase week over week in outstanding units (from 9,800,000 to 10,150,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $107.22 per share, with $146.9108 as the 52 week high point - that compares with a last trade of $143.50. | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. The following ETF(s) have ABT as a top-10 holding: PowerShares Dynamic Pharmaceuticals ( PJP ) PowerShares Russell Top 200 Pure Value Portfolio ( PXLV ). | Abbott Laboratories ( ABT ) is -0.15 at $43.35, with 948,800 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the ""buy range"". The total Pre-Market volume is currently 6,466,895 shares traded."
2016-10-10,43.150001525878906,43.5,-5.379310695604346,"Ex-Dividend Reminder: Abbott Laboratories, PerkinElmer and Mid-America Apartment Communities","Looking at the universe of stocks we cover at Dividend Channel , on 10/12/16, Abbott Laboratories (Symbol: ABT), PerkinElmer, Inc. (Symbol: PKI), and Mid-America Apartment Communities Inc (Symbol: MAA) will all trade ex-dividend for their respective upcoming dividends. Abbott Laboratories (Symbol: ABT) : PerkinElmer, Inc. (Symbol: PKI) : Mid-America Apartment Communities Inc (Symbol: MAA) : In general, dividends are not always predictable, following the ups and downs of company profits over time. As a percentage of ABT's recent stock price of $43.24, this dividend works out to approximately 0.60%, so look for shares of Abbott Laboratories to trade 0.60% lower - all else being equal - when ABT shares open for trading on 10/12/16."
2016-10-07,43.0,42.970001220703125,0.8111204211920704,Did Pfizer's No-Split Decision Cost Investors a Lot of Money?,"I'd instead look at a similar choice faced by Abbott Labs (NYSE: ABT) . Here's how shares of AbbVie and Abbott have performed since then: ABT data by YCharts . Back in 2011, Abbott announced plans to separate into two companies -- one focused on branded prescription drugs and the other focused on products including medical devices and generic drugs."
2016-10-06,42.68999862670898,42.970001220703125,-0.06976460301598837,,
2016-10-05,42.34000015258789,42.7400016784668,0.655897406890438,,
2016-10-04,42.47999954223633,42.09999847412109,0.9447367133617204,,
2016-10-03,42.060001373291016,42.54999923706055,-0.8945411304381492,Endo International Reports Positive Phase II Data on Xiaflex | J&J's Psoriasis Drug Shows Superior Efficacy Over Humira,"Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report ENDO INTL PLC (ENDP): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. Better-ranked stocks in health care sector include Anika Therapeutics Inc ANIK , ANI Pharmaceuticals, Inc. ANIP and Abbott Laboratories ABT . Endo International plc'sENDP subsidiary Endo Pharmaceuticals Inc. announced positive data from a phase II trial which evaluated the safety and efficacy of Xiaflex (collagenase clostridium histolyticum) injection for the treatment of palmar Dupuytren's disease nodules. | Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks worth considering in the large-cap healthcare sector are Eli Lilly and Co. LLY and Abbott Laboratories ABT . Johnson & JohnsonJNJ subsidiary, Janssen Therapeutics announced that data presented from a phase III trial showed superior efficacy of its pipeline candidate guselkumab, over AbbVie Inc.'s ABBV drug Humira in the treatment of moderate-to-severe plaque psoriasis."
2016-09-30,41.7400016784668,42.290000915527344,1.164997260510529,"Boston Scientific to Buy EndoChoice, Boost Endoscopy Line | Health Care Sector Update for 09/30/2016: JNJ, PFE, ABT, MRK, AMGN, AUPH, THLD","Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report BOSTON SCIENTIF (BSX): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report ENDOCHOICE HLDG (GI): Free Stock Analysis Report To read this article on Zacks.com click here. Two other stocks that warrant a look in the gastrointestinal market are Medtronic plc MDT and Abbott Laboratories ABT . Atlanta, GA-based EndoChoice works on platform technologies, including endoscopic imaging systems, devices and infection control products and pathology services for specialists, which are helpful in treating various gastrointestinal conditions, including colon cancer. | ABT: flat In health care stocks news, Aurinia Pharmaceuticals ( AUPH ) was up 14% after it said late Thursday voclosporin achieved the primary endpoint of complete remission at 24 weeks as well as pre-specified secondary endpoints in its phase 2b AURA-LV study for Lupus Nephritis. And, Threshold Pharmaceuticals ( THLD ) tumbled 57.6% after company said its two phase 2 proof-of-concept clinical trials of tarloxotinib didn't meet the activity thresholds required to move forward, despite more promising results seen in preclinical translational studies."
2016-09-29,42.11000061035156,41.43999862670898,1.3176790008235324,"Noteworthy ETF Inflows: IHI, TMO, ABT, DHR | 7 Healthcare Stocks in Focus on World Heart Day","Among the largest underlying components of IHI, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is off about 0.2%, Abbott Laboratories (Symbol: ABT) is off about 0.5%, and Danaher Corp (Symbol: DHR) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $58.2 million dollar inflow -- that's a 4.2% increase week over week in outstanding units (from 9,450,000 to 9,850,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $107.22 per share, with $146.48 as the 52 week high point - that compares with a last trade of $144.65. | Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BOSTON SCIENTIF (BSX): Free Stock Analysis Report EDWARDS LIFESCI (EW): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Park, IL- based Abbott LaboratoriesABT has a strong presence in the cardiovascular disease device market. ABBOTT LABS Price and Consensus ABBOTT LABS Price and Consensus | ABBOTT LABS Quote Marlborough, MA-based Boston Scientific CorporationBSX also has a strong position in the heart disease device market - the company's offerings in this segment include coronary stents, balloon catheters, rotational atherectomy systems, guide wires, guide catheters, embolic protection devices, crossing and re-entry devices for the treatment of chronically occluded coronary vessels, diagnostic catheters used in percutaneous transluminal coronary angioplasty procedures, and intravascular ultrasound (IVUS) imaging systems."
2016-09-28,42.25,42.290000915527344,-1.591075692071788,Pain Therapeutics (PTIE) Down on CRL for Chronic Pain Drug | Better Buy: Johnson & Johnson vs. AbbVie,"Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report PAIN THERAPEUT (PTIE): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. Some other favorably placed stocks in health care sector include Anika Therapeutics Inc ANIK , ANI Pharmaceuticals, Inc. ANIP and Abbott Laboratories ABT . Pain Therapeutics Inc. 's PTIE shares plunged 51.3% after the company announced that the FDA has issued a complete response letter (CRL) for the new drug application (NDA) for its lead candidate Remoxy ER (oxycodone capsules). | AbbVie has only been around for a few years, but former parent Abbott Labs (NYSE: ABT) had a similar 43-year streak of dividend increases if you adjust for the AbbVie spinoff. Valuation and stock performance Both Johnson & Johnson and AbbVie have seen their stocks rise over the past year. Dividends For dividend investors, both Johnson & Johnson and AbbVie have good track records and are attractive to income investors."
2016-09-27,41.709999084472656,42.33000183105469,0.09467672314164202,,
2016-09-26,42.0099983215332,41.68000030517578,1.4864607053248273,AbbVie (ABBV) HCV Combination Drug Positive in Phase IIIb | J&J's Recent Move: A Visionary Acquisition Or An Optical Illusion?,"Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in health care sector include Anika Therapeutics Inc ANIK , ANI Pharmaceuticals, Inc. ANIP and Abbott Laboratories ABT . AbbVie Inc.ABBV announced positive results from the phase IIIb study, Garnet, on a combination of its hepatitis drugs Viekirax (ombitasvir/paritaprevir/ritonavir tablets) and Exviera (dasabuvir tablets) for the treatment of patients with chronic hepatitis C virus (HCV) infection without liver cirrhosis. | We previously looked at what this divestiture means for Abbott ( ABT ) (Read: Making Sense Of Abbott's Sale ). Johnson & Johnson ( JNJ ) has agreed to acquire Abbott's Medical Optics (AMO) business in an all cash deal valued at $4.3 billion. With this acquisition, the company will be able to broaden its portfolio in the vision-care by adding products in cataract surgery, laser refractive surgery (LASIK) and consumer eye health products such as over-the-counter drops."
2016-09-23,42.25,42.18999862670898,-0.7855225649658589,,
2016-09-22,42.15999984741211,42.220001220703125,-0.14201508471247984,3 Top Dividend Stocks for Your Roth IRA,"A history of dividend payments and increases To make the list of official Dividend Aristocrats, a company needs to have: Made dividend payments for at least 100 consecutive quarters (25 years) Increased said payment at least once per year. That's because the company was spun out of Abbot Labs -- a parent company that has increased its dividend for over 25 consecutive years. Enough free cash flow to make it happen The most important metric for dividend investors to watch is the payout ratio from free cash flow (FCF)."
2016-09-21,41.619998931884766,41.91999816894531,0.14231824835905132,"Bristol-Myers Opdivo's Regulatory Application Validated in EU | The Zacks Analyst Blog Highlights: Abbott Labs, Comcast, Goldman Sachs, Microsoft and Philip Morris | Why Did Abbott’s Stock Plummet Recently?","Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report CAMBREX CORP (CBM): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in health care sector include ANI Pharmaceuticals, Inc. ANIP , Cambrex Corporation CBM and Abbott Laboratories ABT . The company is looking to expand Opdivo's label to include the treatment of locally advanced unresectable or metastatic urothelial carcinoma (mUC) in adults after a failure of prior platinum-containing therapy. | Here are highlights from Tuesday's Analyst Blog: Top Research Reports for Goldman Sachs, Comcast, Abbott Labs Today's Research Daily features new research reports on 16 major stocks, including Abbott Labs ( ABT ), Comcast ( CMCSA ) and Goldman Sachs ( GS ). Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report COMCAST CORP A (CMCSA): Free Stock Analysis Report GOLDMAN SACHS (GS): Free Stock Analysis Report MICROSOFT CORP (MSFT): Free Stock Analysis Report PHILIP MORRIS (PM): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include Abbott Labs ( ABT ), Comcast ( CMCSA ), Goldman Sachs ( GS ), Microsoft ( MSFT ) and Philip Morris ( PM ). | Over the last one month, Abbott 's ( ABT ) stock has declined more than 10%. Our price estimate of $47.50 for Abbott is 14% above the current market price Impending Deals Spooking The Market Abbott is set to acquire St. Jude Medical (subject to regulatory approvals) in a deal valued at about $25 billion. The table below estimates the change in cost of equity in case the two deals go through: The higher cost of equity reflects increased risk as debt increases."
2016-09-20,41.95000076293945,41.58000183105469,0.7208054895713122,,
2016-09-19,42.040000915527344,41.68000030517578,-0.8819998215867486,"Notable ETF Outflow Detected - IHI, ABT, TMO, SYK | J&J (JNJ) to Buy Abbott's Vision Care Unit for $4.3 Billion","Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.9%, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 0.3%, and Stryker Corp. (Symbol: SYK) is up by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $71.4 million dollar outflow -- that's a 5.0% decrease week over week (from 10,000,000 to 9,500,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $107.22 per share, with $145.75 as the 52 week high point - that compares with a last trade of $143.67. | Johnson & JohnsonJNJ entered into a definitive agreement with Abbott Laboratories ABT under which it will acquire Abbott's vision care business, Abbott Medical Optics (AMO) for $4.325 billion in cash. Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ST JUDE MEDICAL (STJ): Free Stock Analysis Report ALERE INC (ALR): Free Stock Analysis Report To read this article on Zacks.com click here. ABBOTT LABS Price ABBOTT LABS Price | ABBOTT LABS Quote While J&J carries a Zacks Rank #2 (Buy), Abbott has a Zacks Rank #3 (Hold)."
2016-09-16,40.95000076293945,41.869998931884766,-0.8563287405129371,The 3 Best Long-Term Dividend Stocks to Buy Now,"Abbott Labs Much like Johnson & Johnson above, Abbott Labs '(NYSE: ABT) place as a diversified healthcare products company makes it a dividend dynamo capable of standing the test of time. Johnson & Johnson The aging Baby Boomer population should serve as a long-term tailwind for the entire healthcare sector, and Johnson & Johnson 's(NYSE: JNJ) formidable competitive position within the industry makes it a fantastic option for long-term dividend investors. Also like Johnson & Johnson, Abbott Labs' streak of 43 consecutive annual dividend increases make it a fairly safe bet that its continued dividend growth will proceed for years to come."
2016-09-15,40.790000915527344,41.119998931884766,2.246637733345121,"Daily Dividend Report: INTC, ABT, KR, HST, LHO","VIDEO: Daily Dividend Report: INTC, ABT, KR, HST, LHO The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Kroger ( KR ) declared a quarterly dividend of 12 cents per share to be paid on December 1, 2016, to shareholders of record as of the close of business on November 15, 2016. LaSalle Hotel Properties ( LHO ) declared a quarterly dividend of $0.45 per common share of beneficial interest for the quarter ending September 30, 2016."
2016-09-14,40.68999862670898,40.810001373291016,0.8090169378540099,,
2016-09-13,41.22999954223633,40.63999938964844,0.2949195149475094,,
2016-09-12,40.84999847412109,41.41999816894531,-1.4309972329334855,,
2016-09-09,41.560001373291016,41.0099983215332,1.3953481422657257,"Notable ETF Outflow Detected - XLV, ABBV, TMO, ABT","Among the largest underlying components of XLV, in trading today AbbVie Inc. (Symbol: ABBV) is off about 0.5%, Thermo Fisher Scientific Inc (Symbol: TMO) is off about 3%, and Abbott Laboratories (Symbol: ABT) is lower by about 1.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $124.1 million dollar outflow -- that's a 1.0% decrease week over week (from 176,265,324 to 174,565,324). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $62.68 per share, with $76.00 as the 52 week high point - that compares with a last trade of $72.30."
2016-09-08,42.119998931884766,41.84999847412109,-1.3233951722419284,"Health Care Sector Update for 09/08/2016: BLRX, APRI, JNJ, PFE, ABT, MRK, AMGN","PFE: flat ABT: flat MRK: flat AMGN: flat Health care shares were mostly unchanged in pre-market trade Thursday. In health care stocks news, Apricus Biosciences ( APRI ) was up 18.8% after it said that Argentina has granted its partner, Ferring Pharmaceuticals, market approval for Vitaros, a topical cream for the treatment of erectile dysfunction. It is not approved in the U.S. And, drug development company BioLineRx ( BLRX ) was up 6.2% after the company said data on its BL-8040 in combination with Cytarabine in relapsed or refractory acute myeloid leukemia show it to be well tolerated at all doses tested."
2016-09-07,42.150001525878906,41.900001525878906,-0.641026744089704,,
2016-09-06,42.09999847412109,42.15999984741211,-0.5931197887300361,,
2016-09-02,42.36000061035156,42.09000015258789,0.14252108186632273,"3 Stocks to Add to Your Social Security Benefits | Health Care Sector Update for 09/02/2016: ALR,ATEC,GMED,ELTP","From the pharmaceutical sector, we have AbbVie (NYSE: ABBV) , which was created when the company was spun out of Abbott Labs (NYSE: ABT) . Typically, the greatest assets of holding these stocks is 1. the compounding effect of reinvested dividends, and 2. downside protection offered by the dividend in market swoons (in 2008, the Aristocrats outperformed the market by over 15 percentage points). But perhaps most important, its dividend is very safe, as only 58% of free cash flow was used to pay the dividend last year. | In company news, Alere ( ALR ) was hanging on to moderate gains this afternoon following reports a state judge in Delaware will fast-track the diagnostics company's lawsuit accusing would-be merger partner Abbott Laboratories ( ABT ) of slow-walking its proposed $5.8 billion buyout offer for Alere. ABT shares were lower just before today's close, sinking about 0.5% to $42.10 each after earlier falling to a session low of $41.89 a share. Health care stocks were trading on the plus side today, with the NYSE Health Care Index climbing about 0.4% although shares of health care companies in the S&P 500 were up just 0.1% as a group this afternoon."
2016-09-01,41.91999816894531,42.29999923706055,-0.6373948391721495,,
2016-08-31,42.869998931884766,42.02000045776367,0.9064911371984323,,
2016-08-30,43.0099983215332,42.83000183105469,-1.982735001863747,"Health Care Sector Update for 08/30/2016: PTLA, RIGL, JNJ, PFE, ABT, MRK, AMGN","MRK: flat AMGN: flat Health care shares were mostly unchanged in pre-market trade Tuesday. In health care stocks news, Rigel Pharmaceuticals ( RIGL ) was up 5.3% as the company said it has met the primary endpoint in a phase 3 study of a treatment for adult chronic/persistent immune thrombocytopenia, a disease in which the immune system attacks and destroys the body's own blood platelets. And, Portola Pharmaceuticals ( PTLA ) was up 2.3% after it reported interim results of a phase 3b/4 study of AndexXa, a drug to reduce bleeding."
2016-08-29,43.0,43.25,-0.4184991804298661,"7 Safe Dividend Stocks That Beat Bear Markets | Abbott Labs Sued by Alere over Pending $5.8B Acquisition | Health Care Sector Update for 08/29/2016: MYL, TNXP, JNJ, PFE, ABT, MRK, AMGN","Read More: Johnson & Johnson - Predictable Income Growth for Retirees Safe Dividend Stocks That Beat Bear Markets: Abbott Laboratories (ABT) Sector: Medical Industry: Pharma Dividend Safety Score: 92 Forward P/E Ratio: 20.1x Dividend Yield: 2.4% Abbott Laboratories ( ABT ) is a Chicago-based healthcare company that manufactures, develops, and sells generic pharmaceutical products in more than 130 countries. Interestingly, about 50% of the company's sales are direct-to-consumer, ""making Abbott one of the most consumer-facing healthcare companies in the world,"" and 70% of ABT's revenue originates in foreign markets. This tactic has clearly worked well for ABT stock, with share prices up more than 80% over the past decade, even considering the stock's -2% return in 2008. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALERE INC (ALR): Free Stock Analysis Report ACTELION LTD (ALIOF): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ' ABT agreement to acquire Alere Inc. ALR came into the spotlight after Alere announced that it has sued Abbott Labs in an attempt to close the pending takeover worth $5.8 billion. Alere filed a complaint against Abbott Labs in the Delaware Chancery Court, seeking to force Abbott Labs to take all the necessary actions to obtain anti-trust approvals and fulfill its obligations under the terms of the merger agreement. | Top Health-care stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Health care shares were unchanged in pre-market trade Monday. In health care stocks news, Tonix Pharmaceuticals Holding ( TNXP ) was up 13% after the company said it received final meeting minutes from an end-of-phase 2/pre-phase 3 meeting with the U.S. Food and Drug Administration that confirm the FDA's acceptance of proposed phase 3 studies and the planned new drug application data package for a post-traumatic stress disorder treatment. The company said the minutes indicated that positive results from two phase 3 efficacy and safety studies and long-term safety exposure studies would support the registration of TNX-102 for the treatment of PTSD."
2016-08-26,42.720001220703125,42.97999954223633,0.5813953488372093,"Health Care Sector Update for 08/26/2016: ALR,ABT,TGTX,ACOR","In company news, Alere ( ALR ) was lower in late trade after the diagnostics products company Friday said it plans to release a redacted version of its complaint against Abbott Laboratories ( ABT ) in a bid to to convince the larger rival to follow through with a proposed $5.8 billion buyout proposal. ABT shares also turned higher again in late trade, rising about 0.5% to $43.06 each. Health care stocks remained mixed late Friday, with the NYSE Health Care Index climbing late to its break-even mark while shares of health care companies in the S&P 500 were ahead over 0.4% as a group."
2016-08-25,43.16999816894531,42.84000015258789,0.6086102858236853,"Analysts Anticipate 12% Gains Ahead For RYH | Health Care Sector Update for 08/25/2016: STJ,ABT,CEMI,PVCT","Similarly, BIIB has 13.52% upside from the recent share price of $309.33 if the average analyst target price of $351.14/share is reached, and analysts on average are expecting ABT to reach a target price of $48.82/share, which is 13.08% above the recent price of $43.17. Three of RYH's underlying holdings with notable upside to their analyst target prices are HCA Holdings Inc (Symbol: HCA), Biogen Inc (Symbol: BIIB), and Abbott Laboratories (Symbol: ABT). Below is a twelve month price history chart comparing the stock performance of HCA, BIIB, and ABT: Combined, HCA, BIIB, and ABT represent 5.59% of the Guggenheim S&P 500 Equal Weight Health Care ETF. | The company in April agreed to be acquired by Abbott Labs ( ABT ). ABT shares - which Block said he holds a long position during a Bloomberg television interview today - was down about 0.9% at $42.78, turning lower again following a mid-day rebound. Health care stocks were ending with large declines again, with the NYSE Health Care Sector index sinking 0.5% while shares of health care companies in the S&P 500 were down over 0.9% as a group today."
2016-08-24,43.959999084472656,43.16999816894531,-0.7644151733942129,,
2016-08-23,44.369998931884766,43.900001525878906,-1.7970903821205586,,
2016-08-22,44.08000183105469,44.16999816894531,-1.0592684636467595,,
2016-08-19,44.16999816894531,44.2400016784668,0.20416591232358325,Edwards Lifesciences Is Taking The Surgery Out Of Heart Surgery,"Transcatheter mitral-valve replacement (TMVR) has lately become a hot area in the cardiac device field, with Medtronic, Boston Scientific ( BSX ) and Abbott Laboratories ( ABT ) all working on devices. ""In less than a decade since the first commercial TAVR cases were performed in Europe in 2007, the technology has proved not only to be an invaluable option for patients too sick or frail to undergo open heart surgery, but also a superior treatment strategy in a large swath of the traditional surgical population,"" wrote Guggenheim analyst Chris Pasquale in his June 9 initiation report on Edwards. ""While we expect some off-label use of CoreValve in intermediate risk patients once the Sapien label is expanded, penetration into this population is likely to accrue disproportionately to Edwards until Medtronic's SURTAVI trial reads out in 2017,"" analyst Pasquale wrote in his report."
2016-08-18,44.68000030517578,44.36000061035156,0.15848655744500773,John Rogers Comments on Abbott Laboratories,"Specifically, Abbott Laboratories ( NYSE:ABT ) offered $ 46.75 in cash and 0.9 shares of Abbott stock for each share of St. Jude. From John Rogers ( Trades , Portfolio)' second quarter 2016 market commentary.About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2016-08-17,45.13999938964844,44.68000030517578,-0.7162034302563548,Better Buy: AbbVie Inc. vs. Eli Lilly & Co.,"Shares of AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) have the benchmark beat when it comes to dividends as well. Eli Lilly has been forced to freeze its dividend, and its shareholders have seen their quarterly payout rise just 4% over the past seven years to $0.51, for a yield of about 2.5% at recent prices. Despite some impressive dividend hikes, AbbVie only requires a sustainable 62% of trailing earnings to make its dividend payments, while Eli Lilly, with a precarious payout ratio of 87%, is struggling to make minor increases."
2016-08-16,45.02000045776367,44.91999816894531,-1.0190498243075825,"Health Care Sector Update for 08/16/2016: REPH, OGXI, JNJ, PFE, ABT, MRK, AMGN","In health care stocks news, OncoGenex Pharmaceuticals ( OGXI ) fell 24.3% after the company said it did not meet its primary endpoint in a phase 3 trial of a drug for prostate cancer. The company said it will begin discussions with the U.S. Food and Drug Administration on early analysis of the phase 3 ENSPIRIT trial investigating custirsen in combination with docetaxel as second-line chemotherapy in patients with non-small cell lung cancer. And, Recro Pharma ( REPH ) late Monday said it plans to offer, subject to market conditions, shares of its common stock in an underwritten public offering."
2016-08-15,45.20000076293945,45.150001525878906,-0.22212858241122926,"See Which Of The Latest 13F Filers Holds Abbott Laboratories | Medtronic Launches MiniMed 630G, Expands in Diabetic Care (revised)","Below, let's take a look at the change in ABT positions, for this latest batch of 13F filers: In terms of shares owned, we count 5 of the above funds having increased existing ABT positions from 03/31/2016 to 06/30/2016, with 1 having decreased their position and 5 new positions. We then compared that number to the sum total of ABT shares those same funds held back at the 03/31/2016 period, to see how the aggregate share count held by hedge funds has moved for ABT. The overall top three funds holding ABT on 06/30/2016 were: We'll keep following the latest 13F filings by hedge fund managers and bring you interesting stories derived from a look at the aggregate information across groups of managers between filing periods. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report BECTON DICKINSO (BDX): Free Stock Analysis Report To read this article on Zacks.com click here. Other major medical device companies that are prominent players in the diabetic space are Becton, Dickinson and Company ( BDX ), DexCom, Inc. ( DXCM ) and Abbott Laboratories ( ABT ), among others. Medical device major Medtronic plc's ( MDT ) MiniMed 630G system with SmartGuard technology - a new insulin pump that facilitates diabetes care - recently won the U.S. FDA (Food and Drug Administration) approval for its commercial launch in the U.S."
2016-08-12,44.81999969482422,45.040000915527344,-0.11061777924026592,,
2016-08-11,44.84999847412109,45.04999923706055,0.49085502499128886,,
2016-08-10,45.08000183105469,44.810001373291016,0.4459325969762579,"Notable ETF Inflow Detected - IHI, MDT, ABT, BDX","Among the largest underlying components of IHI, in trading today Medtronic PLC (Symbol: MDT) is off about 0.5%, Abbott Laboratories (Symbol: ABT) is off about 0.6%, and Becton, Dickinson and Co. (Symbol: BDX) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $58.2 million dollar inflow -- that's a 4.3% increase week over week in outstanding units (from 9,300,000 to 9,700,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $100.01 per share, with $145.75 as the 52 week high point - that compares with a last trade of $144.75."
2016-08-09,45.06999969482422,45.08000183105469,-0.5989362173842551,3 Reasons Behind Abbott Laboratories' 14% Move Higher in July,"What: Shares of Abbott Laboratories (NYSE: ABT) , a diversified healthcare products company that offers everything from generic pharmaceuticals to diagnostic and nutritional products, surged 14% in July, according to data from S&P Global Market Intelligence . Secondly, a filing with the Securities and Exchange Commission last month shows that Abbott CEO Miles White purchased 1,281,500 shares of Abbott's common stock on July 25. In late July, diagnostics company Alere (NYSE: ALR) , which Abbott has agreed to purchase for $5.8 billion, announced that federal investigators had opened a criminal probe into its billing actions."
2016-08-08,45.060001373291016,45.02000045776367,0.022192447965819227,"Health Care Sector Update for 08/08/2016: JNJ, PFE, ABT, MRK, AMGN","In health care stocks news, Allergan ( AGN ) reported Q2 EPS of $3.35 per share, ex one-time items, on revenue of $3.71 billion. The company said that, following the sale of its Actavis generics business to Teva ( TEVA ) it now expects FY16 EPS of $13.75 - $14.20 on revenue of $14.65 billion - $14.9 billion. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2016-08-05,45.0,45.2599983215332,-0.0887725572752734,"Health Care Sector Update for 08/05/2016: JNJ, ABT, PFE, MRK, AMGN, PACB, PETX | 3 Hot Summer Short Squeeze Stocks","In health care stocks news, Aratana Therapeutics ( PETX ) rose 6.7% after it reported that it earned $0.61 per share in Q2, better than the CapIQ mean for a loss of $0.42. Pacific Biosciences of California ( PACB ) was up 15% after it reported late Thursday Q2 sales fell to $20.7 million from $24.9 million in the year-ago period but topped the CapIQ mean for $20.15 million. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | 3 Consumer Stocks to Buy for a Turnaround Among these 15 companies, there are a few that we have identified as a few of our favored short squeeze candidates: Summer Short Squeeze Stocks: Abbott Laboratories (ABT) Click to Enlarge Abbott Laboratories (NYSE: ABT ), and the healthcare sector in general, is making a comeback and beginning to take a leadership role in the market rally as fears over political/regulatory changes have faded. InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips Light volume summer trading actually favors short cover rallies as the thinner volume can make prices even more volatile when a stock starts pressuring the short-sellers to exit their positions. Summer Short Squeeze Stocks: Electronic Arts Inc. (EA) Click to Enlarge Electronic Arts Inc. (NASDAQ: EA ) continues to tear higher and show itself as a relative strength leader against the S&P 500 by gaining 13% year-to-date."
2016-08-04,45.060001373291016,44.810001373291016,0.5777740478515625,"Health Care Sector Update for 08/04/2016: JNJ, PFE, ABT, MRK, AMGN, AMRN, SGMO","ABT: flat MRK: flat AMGN: flat Health care shares were mostly unchanged in pre-market trade Thursday. In health care stocks news, Amarin Corporation ( AMRN ) was down 9.6% after it reported a Q2 adjusted loss per share of $0.09, narrower than the loss of $0.15 reported in the same period a year ago and narrower than the loss of $0.13 expected by analysts polled by Capital IQ. The company increased its guidance on full year product revenue to $112 million to $125 million from prior guidance of $105 million to $120 million."
2016-08-03,45.06999969482422,44.95000076293945,-0.5548157842449283,,
2016-08-02,45.720001220703125,45.06999969482422,-0.2662501280170768,,
2016-08-01,44.75,45.290000915527344,-1.4217005873231907,Zoetis (ZTS): Stock to Beat Earnings Estimates in Q2 Again | What Awaits MNK & Other Drug Stocks this Earnings Season?,"Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report EXELIXIS INC (EXEL): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report INTERCEPT PHARM (ICPT): Free Stock Analysis Report To read this article on Zacks.com click here. The company's companion animal business has been performing well and is expected to drive growth in 2016 and beyond on the back of increasing sales of Apoquel, the launch of Simparica (sales are expected to ramp up in the remainder of the year), introduction of new vaccines in Europe and the U.S. in addition to products acquired from Abbott Laboratories' ABT Animal Health business (acquired in Feb 2015). Factors Likely to Impact Q2 Results At the time of reporting first-quarter 2016 earnings results, Zoetis narrowed or raised its 2016 guidance for a number of factors including muted impact of foreign exchange rates for the balance of the year, strong performance of the International segment (expected to continue for the rest of 2016), continued launch of Apoquel in new markets and a lower tax rate. | Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report SAGENT PHARMA (SGNT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report PROTHENA CP PLC (PRTA): Free Stock Analysis Report To read this article on Zacks.com click here. Bigwigs like Johnson & Johnson JNJ , Novartis AG NVS and Abbott Laboratories ABT were able to beat expectations comfortably. MALLINCKRODT PL Price and EPS Surprise MALLINCKRODT PL Price and EPS Surprise | MALLINCKRODT PL Quote Prothena Corporation plcPRTA is expected to report second-quarter 2016 results."
2016-07-29,44.380001068115234,44.75,1.2067059564856844,What Awaits ACUR & Other Drug Stocks this Earnings Season?,"Click to get this free report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report CYTRX CORP (CYTR): Free Stock Analysis Report ACURA PHARMACT (ACUR): Free Stock Analysis Report NIVALIS THERAPT (NVLS): Free Stock Analysis Report CEMPRA INC (CEMP): Free Stock Analysis Report To read this article on Zacks.com click here. Bigwigs like Johnson & Johnson JNJ , Novartis AG NVS and Abbott Laboratories ABT were able to beat expectations comfortably. CYTRX CORP Price and EPS Surprise CYTRX CORP Price and EPS Surprise | CYTRX CORP Quote Nivalis Therapeutics, Inc. NVLS is expected to report second-quarter 2016 results on Aug 1."
2016-07-28,44.02000045776367,44.45000076293945,0.8337064510586301,"Midday Update: Wall Street Remains Defensive as Ford Disappoints, Oil Trades Lower | Chief Executive Officer at Abbott buys 242,547 shares | Thursday 7/28 Insider Buying Report: ABT, ANCX | Health Care Sector Update for 07/28/2016: JNJ, PFE, ABT, MRK, AMGN, HWAY, ORMP | Why Alere Inc. Climbed 21% Today | Abbott Laboratories (ABT) Chairman and CEO Miles D White Bought $10.5 million of Stocks | Abbott Laboratories (ABT) Chairman and CEO Miles D White Bought $45.5 Million of Stocks | Abbott Laboratories (ABT) Chairman and CEO Miles D White Bought $777,216 of Stocks | Health Care Sector Update for 07/28/2016: JNJ, PFE, ABT, MRK, AMGN, ACOR, BMY","(+) EVOK (+36.59%) Intracoastal Capital discloses 4.99% stake (+) GRPN (+26.19%) Beat Q2 expectations and raised full year revenue guidance (+) ALR (+23.07%) To be sold to Abbott Labs ( ABT ) for $5.8 billion, received DOJ subpoenas seeking records related to Medicare, Medicaid and Tricare billing (+) N (+18.04%) To be acquired by Oracle ( ORCL ) for $9.3 billion (+) OCN (+9.88%) Q2 sales topped estimates (+) ESI (+5.88%) Reported a surprise Q2 profit FTSE 100 was down 29.37 points (-0.44%) to 6,721.06 DAX was down 44.62 points (-0.43%) to 10,274.93 CAC 40 was down 26.38 points (-0.59%) to 4,420.58 Nikkei 225 was down 187.98 points (-1.13%) to 16,476.84 Hang Seng Index was down 44.65 points (-0.20%) to 22,174.34 Shanghai China Composite Index was up 2.32 points (+0.08%) to 2,994.32 NYSE Energy Sector Index was down 44.98 points (-0.43%) to 10,381.60 NYSE Financial Sector Index was down 12.65 points (-0.22%) to 6,098.98 NYSE Healthcare Sector Index was down 14.71 points (-0.11%) to 13,128.83 | Miles White, Charman and Chief Executive Officer at Abbott Laboratories ( ABT ), bought 242,547 shares of the company's common stock on July 25. InvestorsKeyhole Trade Alert IK-> The technicals for ABT ($44.29 up $0.61) are neutral with an upward trend. [InvestorsKeyhole, Various news and data services] The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | At Abbott Laboratories ( ABT ), a filing with the SEC revealed that on Monday, CEO Miles D. White purchased 17,933 shares of ABT, at a cost of $43.34 each, for a total investment of $777,162. White was up about 4.2% on the purchase at the high point of today's trading session, with ABT trading as high as $45.16 at last check today. Before this latest buy, White bought ABT on 4 other occasions during the past year, for a total investment of $30.85M at an average of $43.23 per share. | In health care stocks news, Healthways ( HWAY ) rose 35% after the provider of network-delivered solutions and population health management services said it will sell its Total Population Health Services business as a result of the completion of its strategic assessment that began in October 2015. Healthways signed a definitive agreement to sell its Total Population Health Services business to Sharecare, Inc., the Atlanta-based digital health company helping people manage all their healthcare in one place. And, results from Oramed Pharmaceuticals' ( ORMP ) phase IIb trial of its oral insulin tablet ORMD-0801 indicated a statistically significant lowering of glucose relative to a placebo in adults with type 2 diabetes. | So what: Alere investors have been holding their collective breath awaiting the completion of Abbott Labs '(NYSE: ABT) proposed takeover of Alere. The DOJ has issued a subpoena to the company so that it can investigate its patient-billing records to determine whether Alere inappropriately provided illegal financial incentives to patients and doctors. However, if Abbott Labs questions if its assumptions are based on incorrect data or that those assumptions could be changed by potential outcomes from this investigation, Abbott Labs could still opt to pay a break-up fee and walk away. | GuruFocus has detected 4 Warning Sign with ABT. Chairman and CEO of Abbott Laboratories ( ABT ) Miles D White bought 242,547 shares of ABT on 07/25/2016 at an average price of $43.18 a share. CEO Recent Trades: Chairman and CEO Miles D White bought 17,933 shares of ABT stock on 07/25/2016 at the average price of $43.34. | ABT 15-Year Financial Data The intrinsic value of ABT Peter Lynch Chart of ABT . Chairman and CEO of Abbott Laboratories ( ABT ) Miles D White bought 1,281,500 shares of ABT on 07/25/2016. For the complete insider trading history of ABT, click here . | Chairman and CEO of Abbott Laboratories ( ABT ) Miles D White bought 17,933 shares of ABT on 07/25/2016 at an average price of $43.34 a share. CEO Recent Trades: Chairman and CEO Miles D White bought 17,933 shares of ABT stock on 07/25/2016 at the average price of $43.34. ABT 15-Year Financial Data The intrinsic value of ABT Peter Lynch Chart of ABT Directors and Officers Recent Trades: Executive Vice President Michael J Warmuth sold 26,800 shares of ABT stock on 07/26/2016 at the average price of $43.49. | In health care stocks news, Bristol-Myers Squibb ( BMY ) was down 2% after reporting Q2 adjusted EPS of $0.69, three cents above street view as compiled by Capital IQ, and up from $0.53 reported a year earlier. The company posted Q2 revenues of $4.87 billion, above the street consensus of $4.66 billion, and above the $4.16 billion reported a year earlier. And, Acorda Therapeutics ( ACOR ) was down 6.9% after the company reported non-GAAP earnings of $0.07 per share, down from $0.31 a year ago and missing the $0.24 average estimate compiled by Capital IQ by a large margin."
2016-07-27,43.56999969482422,43.66999816894531,0.9768293973289667,"Watch for Drug Stocks Earnings on Jul 28: BMY, CELG & More","Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report AGENUS INC (AGEN): Free Stock Analysis Report ARIAD PHARMA (ARIA): Free Stock Analysis Report To read this article on Zacks.com click here. Results reported so far have been a mixed bag with companies like Johnson & Johnson JNJ , Novartis AG NVS and Abbott Laboratories ABT surpassing expectations. With the Q2 earnings season shifting into top gear this week, the earnings picture has not been as dismal as was expected - of the 130 S&P 500 companies that have reported so far (Jul 25), 70.8% surpassed earnings estimates while 54.6% topped revenue expectations."
2016-07-26,43.38999938964844,43.59999847412109,0.22951222130252344,S&P 500 Analyst Moves: ABT,"The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories ( ABT ) is now the #84 analyst pick, moving up by 10 spots. VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Looking at the stock price movement year to date, Abbott Laboratories ( ABT ) is lower by about 3.2%."
2016-07-25,43.08000183105469,43.40999984741211,0.48398038125519927,,
2016-07-22,43.04999923706055,43.16999816894531,0.7660120759779987,"Health Care Sector Update for 07/22/2016: ABAX, VRX, AMGN, MRK, ABT, PFE, JNJ | Medical Stocks Reporting Early Next Week: GILD, LLY & More | Recent Product Launches Drive Growth For Abbott Laboratories In Q2'16 | After Hours Most Active for Jul 22, 2016 : NOK, QQQ, SYMC, MSFT, GE, AAPL, KMI, ABT, EA, MS, AA, FB","Top Health Care stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Health care shares were unchanged in pre-market trade Friday. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ANTHEM INC (ANTM): Free Stock Analysis Report CHEMED CORP (CHE): Free Stock Analysis Report EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, Novartis AG NVS and Abbott Laboratories ABT also posted encouraging results, beating on both fronts. GILEAD SCIENCES Price and EPS Surprise GILEAD SCIENCES Price and EPS Surprise | GILEAD SCIENCES Quote Another healthcare company looking up this earnings season is Eli Lilly and CompanyLLY . | Leading healthcare major, Abbott Laboratories ( ABT ) reported its Q2 2016 earnings on July 20, 2016. The foreign currency effects were higher than the company's prior expectations, as the U.S. dollar strengthened relative to other currencies in the quarter due to Brexit. Also, Abbott got FDA approval of its fully dissolving heart stent (Absorb) in Q2, which is likely to drive its vascular market share higher in the coming quarters. | Abbott Laboratories ( ABT ) is unchanged at $43.17, with 513,815 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the ""buy range"". Seeking Alpha Reports: After Farnborough Apple Inc. ( AAPL ) is -0.16 at $98.50, with 769,492 shares traded.AAPL is scheduled to provide an earnings report on 7/26/2016, for the fiscal quarter ending Jun2016."
2016-07-21,42.880001068115234,43.040000915527344,0.2787431684353246,,
2016-07-20,42.79999923706055,42.650001525878906,0.3731339632150389,"Q2 Earnings Season Coming Up Roses | St. Jude Medical (STJ) Meets Q2 Earnings, Withdraws Outlook | Abbott (ABT) Beats on Earnings & Sales in Q2 | Earnings Reaction History: Abbott Laboratories, 50.0% Follow-Through Indicator, 2.8% Sensitive | YieldBoost ABT To 4.7% Using Options | Abbott (ABT) Beats on Earnings & Sales in Q2, Maintains View | Biotech ETFs Rally as Earnings Boost Optimism","Click to get this free report EBAY INC (EBAY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report QUALCOMM INC (QCOM): Free Stock Analysis Report MICROSOFT CORP (MSFT): Free Stock Analysis Report MORGAN STANLEY (MS): Free Stock Analysis Report HALLIBURTON CO (HAL): Free Stock Analysis Report INTEL CORP (INTC): Free Stock Analysis Report UNITED CONT HLD (UAL): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ABT also topped expectations on both top and bottom lines. Let's see how many we can cram into a single column prior to today's opening bell: Morgan Stanley MS outperformed expectations this morning, handily beating earnings and revenue estimates. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ST JUDE MEDICAL (STJ): Free Stock Analysis Report NUVASIVE INC (NUVA): Free Stock Analysis Report NXSTAGE MEDICAL (NXTM): Free Stock Analysis Report To read this article on Zacks.com click here. St. Jude is set to be acquired by Abbott Laboratories ABT . Neuromodulation sales jumped 20% year over year at cc to $140 million, driven by a 19% surge in U.S. sales and 22% increase in international sales. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. ABBOTT LABS Price and EPS Surprise ABBOTT LABS Price and EPS Surprise | ABBOTT LABS Quote Currently, Abbott Labs has a Zacks Rank #3 (Hold). | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 42.9% Average next regular session additional gain: 2.4% Over the prior three fiscal years (12 quarters), when shares of ABT rose in the extended-hours session in reaction to its earnings announcement, history shows that 42.9% of the time (3 events) the stock posted additional gains in the following regular session by an average of 2.4%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 100% Average next regular session additional loss: 4.4% Over that same historical period, when shares of ABT dropped in the extended-hours in reaction to its earnings announcement, history shows that 100.0% of the time (1 event) the stock dropped further, adding to the extended-hours losses by an average of 4.4% by the following regular session close. Extended-Hours Dollar Volume: $517,474 Abbott Laboratories ( ABT ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Shareholders of Abbott Laboratories (Symbol: ABT) looking to boost their income beyond the stock's 2.4% annualized dividend yield can sell the January 2018 covered call at the $50 strike and collect the premium based on the $1.45 bid, which annualizes to an additional 2.3% rate of return against the current stock price (at Stock Options Channel we call this the YieldBoost ), for a total of 4.7% annualized rate in the scenario where the stock is not called away. Any upside above $50 would be lost if the stock rises there and is called away, but ABT shares would have to advance 16.9% from current levels for that to occur, meaning that in the scenario where the stock is called, the shareholder has earned a 20.3% return from this trading level, in addition to any dividends collected before the stock was called. In the case of Abbott Laboratories, looking at the dividend history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2.4% annualized dividend yield. | Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ST JUDE MEDICAL (STJ): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT reported second-quarter 2016 earnings of 55 cents per share, higher than both the Zacks Consensus Estimate of 53 cents and the year-ago figure of 52 cents. In the reported quarter, sales came in at $5.3 billion, up 3.2% year over year on a reported basis, and surpassed the Zacks Consensus Estimate of $5.26 billion. | Fueling the rallying Wednesday, Abbot Laboratories ( ABT ) announced better-than-expected quarterly sales and profit on strong sales in its medical device business, Reuters reports. ABT shares rose 2.6% Wednesday. On Wednesday, the iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB ) , which tracks the Nasdaq Biotechnology Index,rose 2.5%."
2016-07-19,41.93999862670898,41.79999923706055,-0.35046194826040444,"Medical Stocks to Post Earnings This Week: ABT, BIIB, ALIOF | Pre-Market Earnings Report for July 20, 2016 : ABT, MS, ASML, ITW, HAL, STJ, CP, TEL, MTB, APH, NTRS, SBNY","Click to get this free report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ACTELION LTD (ALIOF): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Illinois-based Abbott Laboratories ABT is scheduled to report second-quarter results before the opening bell on Jul 20. Nevertheless, the combination of Abbott Labs' Zacks Rank #3 (Hold) and a 0.00% Earnings ESP makes surprise prediction difficult (read more: Abbott Labs Q2 Earnings: Will the Stock Surprise? | Abbott Laboratories ( ABT ) is reporting for the quarter ending June 30, 2016. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2016 Price to Earnings ratio for ABT is 19.13 vs. an industry ratio of 19.40."
2016-07-18,42.04999923706055,42.09000015258789,-0.3338087606881167,What Can We Expect From Abbott's Q2'16 Earnings?,"Abbott Laboratories ( ABT ) is set to announce its Q2'16 earnings on July 20th. Given the large number of people suffering from the coronary heart disease, we believe that Abbott has a significant opportunity to improve its revenue from the vascular segment going forward. We hope such lean communication sparks thinking, and encourages readers to comment and ask questions on the comment section, or email content@trefis.com 2) Figures mentioned are approximate values to help our readers remember the key concepts more intuitively."
2016-07-15,42.400001525878906,42.09999847412109,0.09512703032843138,"Alere Updates on 10K Filing, Reports Preliminary Q1 Figures | Health Care Sector Update for 07/15/2016: JNJ, PFE, ABT, MRK, AMGN, CYTR, ZIOP | Health Care Sector Update for 07/15/2016: ALR,ARDX,CYTR | The Reason Behind Alere Inc.'s Double-Digit Percentage Gain on Friday | Why is Alere Inc. (ALR) up Today?","Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report BOSTON SCIENTIF (BSX): Free Stock Analysis Report ALERE INC (ALR): Free Stock Analysis Report NUVASIVE INC (NUVA): Free Stock Analysis Report To read this article on Zacks.com click here. The figures will also be eagerly scrutinised by Abbott Laboratories ABT , Alere's current suitor. ALERE INC Price, Consensus and EPS Surprise ALERE INC Price, Consensus and EPS Surprise | ALERE INC Quote As of Dec 31, 2015, cash and cash equivalents are expected to be $502 million, while total debt is estimated to be $3.07 billion. | ABT: flat MRK: flat AMGN: flat Health care shares were mostly unchanged in pre-market trade Friday. In health care stocks news, CytRx ( CYTR ) were lower after the biopharmaceutical company said that it has priced a registered public offering of approximately 28.6 million shares of common stock at a price to the public of $0.70 per share, or a 21% discount from the stock's previous close, for total expected gross proceeds of $20 million. ZIOPHARM Oncology Inc ( ZIOP ) reported late Thursday a brain tumor patient died after being injected by the company's gene therapy. | The company reassured investors that its proposed $5.8 billion acquisition by Abbott Labs ( ABT ) remains on track to close at its expected price. Health care stocks were mostly lower today, with the NYSE Health Care Index decreasing about 0.4% while shares of health care companies in the S&P 500 were down about 0.1% as a group. In company news, Alere ( ALR ) shares were climbing Friday afternoon after analysts at Canaccord Genuity raised their investment call for the diagnostics company to Buy from Hold and increased their price target for the company's stock by $12 to $56 a share. | So what: As a bit of a refresher, it was announced at the beginning of February that Abbott Laboratories (NYSE: ABT) was going to buy Alere for $5.8 billion in an all-cash deal. This delay in filing its results caused Abbott to request a termination of its deal to buy Alere, which Alere's board of directors promptly rejected. Following the release of this information, Canaccord Genuity covering analyst Mark Massaro upgraded Alere to buy from hold, and announced in a note that he and his investment firm felt increasingly confident that the buyout would now go through. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALERE INC (ALR): Free Stock Analysis Report To read this article on Zacks.com click here. Alere Inc. ALR is up 10.5% in afternoon trading on Friday after analysts saw an increased likelihood that the company's $5.8 billion acquisition by Abbott Laboratories ABT would close. Alere also reported preliminary net income of between $10 million to $25 million for 2015, along with between -$8 million and $2 million for Q1 2016."
2016-07-14,42.34000015258789,42.27999877929688,-0.7075543418900876,"Eli Lilly, Boehringer Collaborate for Metastatic Breast Cancer","Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report INNOVIVA INC (INVA): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector include Innoviva, Inc. INVA , Abbott Laboratories ABT and Johnson & Johnson JNJ . Eli Lilly and CompanyLLY announced a clinical trial collaboration with Boehringer Ingelheim under which the safety and tolerability of Eli Lilly's abemaciclib will be evaluated in combination with Boehringer's BI 836845 in a phase Ib study for the treatment of patients with hormone-receptor-positive, human epidermal growth factor receptor 2-negative (HR+, HER2-) metastatic breast cancer (mBC)."
2016-07-13,42.2400016784668,41.970001220703125,-0.14171320990734843,Pfizer (PFE) Gets FDA Nod for Label Expansion of Prevnar 13,"Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Other favorably placed stocks in the healthcare sector include Abbott Laboratories ABT , Roche Holdings RHHBY and Johnson & Johnson JNJ . The vaccine was previously approved for active immunization in the prevention of pneumonia and invasive disease caused by 13 Streptococcus pneumoniae (S. pneumoniae) serotypes - 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F - in adults aged 50 years or older."
2016-07-12,42.34000015258789,42.470001220703125,-0.6392056037756109,"Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for July 13, 2016","Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. The following ETF(s) have ABT as a top-10 holding: iShares U.S. Medical Devices ETF ( IHI ) SPDR S&P Health Care Equipment ( XHE ) Value Line Conservative Equity ETF (VLLV)."
2016-07-11,42.02999877929688,42.119998931884766,0.3070407832941127,Pfizer Reports Positive Data on Kidney Cancer Drug Sutent,"Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report EXELIXIS INC (EXEL): Free Stock Analysis Report To read this article on Zacks.com click here. Other favorably placed stocks in the healthcare sector include Abbott Laboratories ABT and Novartis AG NVS . PFIZER INC Price PFIZER INC Price | PFIZER INC Quote We note that Sutent is approved for advanced RCC, imatinib-resistant or -intolerant gastrointestinal stromal tumors and advanced pancreatic neuroendocrine tumors."
2016-07-08,41.59999847412109,41.88999938964844,0.21413313157700054,Shire (SHPG) Gets EU Nod for Label Expansion of Revestive,Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. A couple of better-ranked stocks in the healthcare sector include Abbott Laboratories ABT and Johnson & Johnson JNJ . Shire plcSHPG announced that the European Commission has granted an extension of the market authorization for its gastrointestinal drug (GI) Revestive for use in the pediatric population.
2016-07-07,40.83000183105469,41.36000061035156,0.6971176109724074,Abbott Laboratories Breaks Above 200-Day Moving Average - Bullish for ABT | Abbott Labs' Absorb Stent Gets Regulatory Approval in U.S. | Medical Device Consolidation Frenzy: Here's How to Play it,"In trading on Thursday, shares of Abbott Laboratories (Symbol: ABT) crossed above their 200 day moving average of $41.23, changing hands as high as $41.52 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $36.00 per share, with $51.74 as the 52 week high point - that compares with a last trade of $41.49. According to the ETF Finder at ETF Channel, ABT makes up 8.15% of the iShares U.S. Medical Devices ETF (Symbol: IHI) which is trading up by about 0.7% on the day Thursday. | Abbott LaboratoriesABT received a major boost when the FDA approved its bioresorbable heart stent, Absorb, for the treatment of coronary artery disease in the U.S. Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ST JUDE MEDICAL (STJ): Free Stock Analysis Report To read this article on Zacks.com click here. ABBOTT LABS Price and Consensus ABBOTT LABS Price and Consensus | ABBOTT LABS Quote The latest approval will strengthen Abbott Labs' vascular division, which recorded only modest growth in the first quarter of 2016. | Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report THERMO FISHER (TMO): Free Stock Analysis Report HEARTWARE INTL (HTWR): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report ST JUDE MEDICAL (STJ): Free Stock Analysis Report NUVASIVE INC (NUVA): Free Stock Analysis Report DENTSPLY SIRONA (XRAY): Free Stock Analysis Report FEI COMPANY (FEIC): Free Stock Analysis Report ZIMMER BIOMET (ZBH): Free Stock Analysis Report LDR HOLDING (LDRH): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT - St. Jude Medical STJ : in April, Abbott announced its decision to consolidate with St. Jude Medical for a deal value of $25 billion. Thermo Fisher - FEI Company FEIC : Thermo Fisher's plan to buy FEI Company for $4.2 billion will enable it to access FEI's industry leading high-performance electron microscopy platform used for protein study, which in turn facilitates life-science research."
2016-07-06,39.27000045776367,40.83000183105469,1.2980621002416068,,
2016-07-05,39.310001373291016,39.43999862670898,3.972501540887056,,
2016-07-01,39.310001373291016,39.540000915527344,0.3306976567705938,,
2016-06-30,38.650001525878906,39.310001373291016,0.5850916667548125,,
2016-06-29,37.95000076293945,38.56999969482422,1.7076321380484107,,
2016-06-28,37.27999877929688,37.560001373291016,1.6337257428733265,,
2016-06-27,37.5099983215332,36.95000076293945,0.7510799441056594,Mylan Launches Generic Version of Glaxo's Avodart in U.S.,"Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. In Feb 2015, Mylan acquired Abbott Laboratories' ABT non-U.S. developed markets' specialty and branded generics business. MYLAN NV Price MYLAN NV Price | MYLAN NV Quote Mylan is a leading generic drug company in terms of both total and new prescriptions."
2016-06-24,38.369998931884766,37.90999984741211,-1.4929287753987304,3 Dividend Aristocrats to Buy at Bargain-Bin Prices,"Dividend Aristocrats to Buy Now: Abbott Laboratories (ABT) Source: Images Money via Flickr (Modified) Dividend Yield: 2.7% AbbottLaboratories ' ( ABT ) roots can be traced back more than 125 years ago. As of this writing, Simply Safe Dividends was long ABT in its Long-term Dividend Growth portfolio . InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips The Dividend Aristocrats Index contains high quality dividend growth stocks in the S&P 500 that have managed to boost their dividend payouts for at least 25 consecutive years."
2016-06-23,39.040000915527344,39.630001068115234,-1.1988509181072857,,
2016-06-22,37.720001220703125,38.7400016784668,1.511270847212584,,
2016-06-21,38.0,37.72999954223633,2.7041368630810942,,
2016-06-20,37.880001068115234,37.75,-0.7105275204307154,Epizyme Offers Early Data on Non-Hodgkin Lymphoma Drug,"Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report EPIZYME INC (EPZM): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the healthcare sector include Pfizer, Inc. PFE , Bristol-Myers Squibb Company BMY and Abbott Laboratories ABT . An Independent Data Monitoring Committee confirmed that futility was surpassed in four of the five cohorts that were being studied - diffuse large B-cell lymphoma (DLBCL) with germinal center B-cell (GCB) subtype and EZH2 mutations; DLBCL with GCB subtype and wild-type EZH2; DLBCL with non-GCB subtype; and follicular lymphoma (FL) with EZH2 mutations."
2016-06-17,37.400001525878906,37.38999938964844,-0.3431918280083162,"Aegerion, QLT Ink Merger Deal to Form Novelion Therapeutics | Abbott Laboratories (ABT) Is in Oversold Territory: What's Next?","Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report AEGERION PHARMA (AEGR): Free Stock Analysis Report QLT INC (QLTI): Free Stock Analysis Report To read this article on Zacks.com click here. A couple of better-ranked stocks in the healthcare sector include Abbott Laboratories ABT and Johnson & Johnson JNJ . Post merger, QLT shareholders, including those who are investing in QLT immediately before closing, are expected to own approximately 67%, while current shareholders of Aegerion will own approximately 33% of Novelion's common shares. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. And for technical investors there is some hope when looking at ABT given that, according to its RSI reading of 29.68, it is now in oversold territory."
2016-06-16,37.36000061035156,37.5,-0.02674367866949893,,
2016-06-15,37.75,37.43000030517578,0.37473069422179567,Shire Buys Global Rights to Pfizer's Gastrointestinal Drug | Novo Nordisk (NVO) Reports Positive Trial Results on Victoza,"Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. A couple of better-ranked stocks in the healthcare sector include Abbott Laboratories ABT and Johnson & Johnson JNJ . PF-00547659 is an investigational biologic which is being evaluated for the treatment of moderate-to-severe inflammatory bowel disease (IBD) in phase I and phase II trials, with phase III trials expected to begin after a consultation with global health authorities. | Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the healthcare sector are Pfizer, Inc. PFE , Bristol-Myers Squibb Co. BMY and Abbott Laboratories ABT . Results from the multicenter, international, randomized, double-blinded, placebo-controlled trial showed that Victoza significantly reduced the risk of the composite primary endpoint of CV death, non-fatal myocardial infarction (heart attack) or non-fatal stroke by 13%, compared to placebo, when added to the standard of care in adults with type II diabetes at high CV risk."
2016-06-14,37.869998931884766,37.65999984741211,-0.8476813107926324,Abbott Labs (ABT) Reports Positive Data on FreeStyle Libre,"Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT announced positive results from the IMPACT trial on FreeStyle Libre. Data also showed that patients using FreeStyle Libre sensor and reader system spent 38% less time in hypoglycemia, as compared to people who managed glucose with traditional self-monitoring of blood glucose (SMBG) systems such as finger pricking."
2016-06-13,38.31999969482422,37.86000061035156,-0.5545262487341842,"Health Care Sector Update for 06/13/2016: JNJ, PFE, ABT, MRK, AMGN, EBIO, CPRX | Health Care Sector Update for 06/13/2016: ABT | Daily Dividend Report: HRB, VET, GE, CL, ABT, AMAT | Health Care Sector Update for 06/13/2016: JNJ, PFE, ABT, MRK, AMGN, BIOS, ANIP","In health care stocks news, Eleven Biotherapeutics ( EBIO ) reported granting an exclusive license to drug giant Hoffmann-La Roche for its Interleukin-6 technology, and that it may receive up to $270 million in payments. Eleven said under the agreement it will grant an exclusive, worldwide license to Roche to develop and commercialize EBI-031, a humanized monoclonal antibody that potently binds IL-6 and inhibits all known forms of IL-6 cytokine signaling, currently being developed for the potential treatment of ocular diseases, and all other IL-6 antagonist antibody technology owned by Eleven. And, Catalyst Pharmaceuticals ( CPRX ) said it reached an agreement with the U.S. Food and Drug Administration on a confirmatory phase 3 study protocol for Firdapse for the symptomatic treatment of Lambert-Eaton myasthenic syndrome. | In health-care stocks news, Abbott Laboratories ( ABT ) said that the results of the IMPACT clinical trial demonstrated that the company's FreeStyle Libre glucose measurement system met its primary endpoint of a reduction in time spent in hypoglycemia (low glucose levels, defined as Shares in the company were unchanged at $38.40 pre-bell. ABT: flat AMGN: flat Health-care shares were mainly unchanged in pre-market trade Friday. | Abbott ( ABT ) declared a quarterly common dividend of 26 cents per share. VIDEO: Daily Dividend Report: HRB, VET, GE, CL, ABT, AMAT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. H&R Block announced a quarterly cash dividend of $0.22 per share, payable on July 1, 2016 to shareholders of record as of June 20, 2016. | In health care stocks news, BioScrip ( BIOS ) signed an agreement to buy Home Solutions, supplier of home infusion and home nursing products and services, for $85 million in cash and stocks. Under the agreement, the consideration will consist of $80 million in cash and $5 million in common shares of BioScrip. And, ANI Pharmaceuticals ( ANIP ) said it received approval from the U.S. Food and Drug Administration of the Prior Approval Supplement for Oxcarbazepine Tablets to treat seizures."
2016-06-10,38.66999816894531,38.400001525878906,-1.2004151569311914,,
2016-06-09,38.869998931884766,38.869998931884766,-0.6982070231470355,7 Medical Stocks to Buy with Market-Beating Yields,"This Zacks Rank #2 (Buy) sports a strong dividend yield of 2.77% and a long-term earnings growth rate of 5.7% We also prefer Abbott Laboratories ABT , another Zacks Rank #2 stock. Click to get this free report DIGIRAD CORP (DRAD): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report KINDRED HLTHCR (KND): Free Stock Analysis Report HEALTHSOUTH CP (HLS): Free Stock Analysis Report To read this article on Zacks.com click here. This Zacks Rank #2 stock has a dividend yield of 3.79% and a long-term earnings growth rate of 8%."
2016-06-08,38.900001525878906,38.90999984741211,0.0,,
2016-06-07,39.119998931884766,38.93000030517578,0.025702625041162448,Merrimack Announces Positive Data on Oncology Candidate | Exelixis Up on Positive Kidney Cancer Data on Cabometyx,"Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MERRIMACK PHAR (MACK): Free Stock Analysis Report To read this article on Zacks.com click here. Other favorably placed stocks in the health care sector include Pfizer Inc. PFE , Johnson & Johnson JNJ and Abbott Laboratories ABT . Data from the phase I study showed positive clinical activity across multiple solid tumor types in a heavily pretreated patient population. | Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report EXELIXIS INC (EXEL): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector include Pfizer Inc. PFE , Johnson & Johnson JNJ and Abbott Laboratories ABT . Trial data also showed that the benefits of Cabometyx in PFS and OS were independent of the presence of bone metastases, prior anti-PD-1/PD-L1 therapy, and the type of prior vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) therapy."
2016-06-06,39.25,39.16999816894531,-0.48568157437787135,Novartis (NVS) Announces Data on Leukemia Drug Tasigna,"Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector include Pfizer Inc. PFE , Johnson & Johnson JNJ and Abbott Laboratories ABT . Last week, Novartis announced that the European Commission has approved Afinitor tablets for the treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin, in adults with progressive disease."
2016-06-03,39.52000045776367,39.18000030517578,-0.2038263211584395,,
2016-06-02,39.5,39.52999877929688,-0.8603242627774258,,
2016-06-01,39.369998931884766,39.5,0.07594627670096736,Novo Nordisk (NVO) Reports Positive Data on Diabetes Drug,"Click to get this free report SANOFI-AVENTIS (SNY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the healthcare sector include Abbott Laboratories ABT , Johnson & Johnson JNJ and Sanofi SNY . Data from the trial showed that treatment with semaglutide, administered once-weekly, significantly improved glycemic control, compared to insulin glargine U100, in adults with type II diabetes."
2016-05-31,39.33000183105469,39.630001068115234,0.33020338237791974,"Noteworthy ETF Inflows: IHI, MDT, TMO, ABT","Among the largest underlying components of IHI, in trading today Medtronic PLC (Symbol: MDT) is off about 2%, Thermo Fisher Scientific Inc (Symbol: TMO) is down about 0.5%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $72.3 million dollar inflow -- that's a 6.7% increase week over week in outstanding units (from 8,150,000 to 8,700,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $100.01 per share, with $131.61 as the 52 week high point - that compares with a last trade of $131.00."
2016-05-27,39.040000915527344,39.29999923706055,0.7627745311307604,Grace Groner and the Power of Dividend Reinvestment Plans,"After graduating in 1931, she became a secretary at Abbott Laboratories ( ABT ) , which was, apparently, the only job she ever had. Here's a chart of ABT from April 1983 through the end of 2010, showing the stock's rise from a split-adjusted 1.30 to 19.91. (ABT is now trading at about 38.)"
2016-05-26,38.650001525878906,38.88999938964844,0.6659792915880651,Seattle Genetics Starts Trial on Acute Myeloid Leukemia Drug,"Click to get this free report SANOFI-AVENTIS (SNY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report SEATTLE GENETIC (SGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the healthcare sector include Abbott Laboratories ABT , Johnson & Johnson JNJ and Sanofi SNY . The randomized, double-blind, placebo-controlled trial will evaluate if vadastuximab talirine, in combination with Vidaza or Dacogen, can extend overall survival compared to Vidaza or Dacogen alone in older patients with newly diagnosed acute myeloid leukemia (AML)."
2016-05-25,38.060001373291016,38.68000030517578,0.6209517575538406,Novo Nordisk IDegLira Recommended by FDA Advisory Committee,"Click to get this free report SANOFI-AVENTIS (SNY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the healthcare sector include Abbott Laboratories ABT , Johnson & Johnson JNJ and Sanofi SNY . Novo NordiskNVO announced that the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted unanimously (16-0) in favor of the approval of IDegLira for the treatment of adults with type II diabetes."
2016-05-24,37.4900016784668,37.97999954223633,1.629003966142408,Novartis Filing for MabThera Biosimilar Accepted in the EU | Exelixis' Kidney Cancer Drug Cabometyx Positive in Phase II,"NovartisNVS announced that the European Medicines Agency (EMA) has accepted its generic arm Sandoz's Marketing Authorisation Application (MAA) for its proposed biosimilar of Roche's RHHBY MabThera (rituximab). Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. We note that MabThera is approved for the treatment of non-Hodgkin's lymphoma, which includes follicular lymphoma and diffuse large B-cell lymphoma, chronic lymphocytic leukemia and autoimmune diseases such as rheumatoid arthritis. | Click to get this free report SANOFI-AVENTIS (SNY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report EXELIXIS INC (EXEL): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the healthcare sector include Abbott Laboratories ABT , Johnson & Johnson JNJ and Sanofi SNY . EXEL announced positive top-line data from the phase II trial, CABOSUN, on Cabometyx in patients suffering from previously untreated advanced renal cell carcinoma (RCC)."
2016-05-23,37.720001220703125,37.369998931884766,1.307009447404139,"Noteworthy ETF Inflows: IHI, TMO, ABT, BDX | Novartis' Cardiovascular Drug Gets Positive Recommendation","Among the largest underlying components of IHI, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is off about 0.5%, Abbott Laboratories (Symbol: ABT) is down about 0.3%, and Becton, Dickinson and Co. (Symbol: BDX) is lower by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $70.5 million dollar inflow -- that's a 7.2% increase week over week in outstanding units (from 7,600,000 to 8,150,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $100.01 per share, with $131.46 as the 52 week high point - that compares with a last trade of $129.18. | Click to get this free report SANOFI-AVENTIS (SNY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the healthcare sector are Abbott Laboratories ABT , Johnson & Johnson JNJ and Sanofi SNY . Novartis AGNVS announced that its cardiovascular drug, Entresto, was given a class I recommendation, as per the updated clinical practice guidelines released simultaneously by the American College of Cardiology (ACC), the American Heart Association (AHA) and the Heart Failure Society of America (HFSA), as well as the European Society of Cardiology."
2016-05-20,37.54999923706055,37.59999847412109,-0.9278957515681521,Merrimack/Baxalta Start Study on Colorectal Cancer Drug,"Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MERRIMACK PHAR (MACK): Free Stock Analysis Report BAXALTA INC (BXLT): Free Stock Analysis Report To read this article on Zacks.com click here. A couple of better-ranked stocks in the health care sector include Pfizer Inc. PFE and Abbott Laboratories ABT . The trial will evaluate the safety and tolerability of MM-151, an oligoclonal EGFR (epidermal growth factor receptor) inhibitor, in combination with Onivyde plus fluorouracil (5-FU) and leucovorin, in patients with RAS wild-type metastatic colorectal cancer."
2016-05-19,37.560001373291016,37.2400016784668,0.13315376318621133,Roche Gets Accelerated Approval for Immunotherapy Drug,"Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. We expect investors to focus on new drug approvals, as Roche's top line could be marred by the entry of biosimilars (expected in the second half of 2017 in Europe) for its key drugs like MabThera and Herceptin. Some better-ranked stocks in the health care sector include Pfizer Inc. PFE , Johnson & Johnson JNJ and Abbott Laboratories ABT ."
2016-05-18,37.75,37.75,-0.8519693373913749,Bear of the Day: AbbVie (ABBV) | Novartis (NVS) to Stop Trial on Breast Cancer Drug Early,"Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report COHERUS BIOSC (CHRS): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. So if you are looking at big Biopharma stocks right now, check out Johnson & Johnson (JNJ), Pfizer (PFE), or Abbott Labs(ABT) , all with a Zacks #2 Rank (Buy). AbbVie (ABBV) was big in the news this week after Federal regulators agreed to review a key patent for the anti-inflammatory drug Humira, knocking the stock down 3.5% on over three times the average volume of 9 million shares. | Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. A couple of better-ranked stocks in the health care sector include Pfizer Inc. PFE and Abbott Laboratories ABT . Recently, Novartis announced that it has split its Pharmaceuticals Division into two business units - Novartis Pharmaceuticals and Novartis Oncology."
2016-05-17,38.220001220703125,37.709999084472656,0.0,"Aegerion (AEGR) Misses Q1 Earnings Estimates, Cuts View","Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report AEGERION PHARMA (AEGR): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector include Pfizer Inc. PFE , Johnson & Johnson JNJ and Abbott Laboratories ABT . The Quarter in Detail Net sales of Juxtapid declined 54.3% year over year to $26.2 million (including $23.6 million from prescriptions written in the U.S.) due to a reduction in patients on therapy in the U.S., along with a delay in timing of a bulk order of Juxtapid from the Brazilian Ministry of Health, which is now shifted to the second quarter."
2016-05-16,37.59999847412109,38.25,-1.3343854524897536,Novartis (NVS) Releases Positive Data on Ultibro Breezhaler | 3 Cheap Stocks Set to Double Their Dividends | Mylan to Buy Renaissance's Topical Business for about $1B | Drug Stocks Reporting Earnings on May 17: AXON & FWP,"Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector include Pfizer Inc. PFE , Johnson & Johnson JNJ and Abbott Laboratories ABT . Results from the study showed consistent superiority of Ultibro Breezhaler over Seretide across exacerbation outcomes, lung function and health-related quality of life in COPD patients. | A Prescription for Dividend Growth AbbVie Inc ( ABBV ) has only been around since 2013, when it was spun off from Abbott Laboratories ( ABT ), but it's hiked its payout by 42% in that time. InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips Plenty of investors judge a stock's dividend by one thing: the current yield. The stock's 1.9% dividend yield is equally unexciting, but the company is the fastest dividend grower of my three picks, nearly tripling its payout in the past five years. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report RETROPHIN INC (RTRX): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. In Feb 2015, Mylan acquired Abbott Laboratories' ABT non-U.S. developed markets' specialty and branded generics business. Mylan N.V.MYL announced an agreement under which it will acquire the non-sterile, topicals-focused specialty and generics business of privately held Renaissance Acquisition Holdings. | Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report FORWARD PHARMA (FWP): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report AXOVANT SCIENC (AXON): Free Stock Analysis Report To read this article on Zacks.com click here. While bigwigs like Johnson & Johnson JNJ and Abbott Laboratories ABT topped estimates, some like Novartis NVS disappointed expectations. As per our Earnings Trend report , 459 S&P 500 members have reported quarterly so far, of which 71% topped earnings estimates and 55.3% surpassed revenue expectations, resulting in a blended beat of 71%."
2016-05-13,37.86000061035156,37.59999847412109,1.728727532598942,"Noteworthy ETF Inflows: IHI, TMO, ABT, BDX | Aegerion Enters into Settlement Agreement with DoJ and SEC","Among the largest underlying components of IHI, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is down about 0.1%, Abbott Laboratories (Symbol: ABT) is down about 0.5%, and Becton, Dickinson and Co. (Symbol: BDX) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $45.4 million dollar inflow -- that's a 4.8% increase week over week in outstanding units (from 7,250,000 to 7,600,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $100.01 per share, with $131.46 as the 52 week high point - that compares with a last trade of $129.73. | Click to get this free report SANOFI-AVENTIS (SNY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report AEGERION PHARMA (AEGR): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the healthcare sector include Acorda Therapeutics ACOR , Abbott Laboratories ABT and Sanofi SNY . As a result of the settlement agreement, Aegerion will pay $40 million to the DoJ and the SEC over a period of five years in following tranches: approximately $3 million upon finalization of the settlement; around $3.7 million per year, payable quarterly, for three years following finalization of the settlement, and roughly $13 million per year, payable quarterly, during the fourth and fifth year after finalization of the settlement."
2016-05-12,38.13999938964844,38.0,-0.6867462547250643,"Health Care Sector Update for 05/12/2016: JNJ, PFE, MRK, ABT, AMGN, AEGR","Health care shares were mostly weaker at the close of regular trading Thursday. In health care stocks news, Aegerion Pharmaceuticals ( AEGR ) said it has reached preliminary agreements to settle an ongoing probe by the Department of Justice and the Securities and Exchange Commission over sales activities and disclosures related to JUXTAPID capsules. It will pay $3 million upon finalization of the settlement, approximately $3.7 million per year, payable quarterly, for three years following finalization of the settlement, and approximately $13 million per year, payable quarterly, in years four and five following finalization of the settlement."
2016-05-11,38.20000076293945,38.0099983215332,-0.36706709986585545,"Catalyst (CPRX) Posts In-Line Q1 Loss, Firdapse in Focus","Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report CATALYST PHARMA (CPRX): Free Stock Analysis Report ARQULE INC (ARQL): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector include ArQule, Inc. ARQL , Shire plc SHPG and Abbott Laboratories ABT . Quarter in Detail Research and development (R&D) expenses were $3.5 million, up 50.9% from the year-ago quarter primarily due to activities related to an expanded access program for Firdapse, including manufacturing of the drug, and increased activities associated with other ongoing studies and trials."
2016-05-10,38.29999923706055,38.09999847412109,-0.4973885801347546,,
2016-05-09,38.11000061035156,37.97999954223633,-0.522195213899461,,
2016-05-06,38.220001220703125,37.970001220703125,-0.3411206140991849,"Drug Stocks' Earnings Previews: FGEN, IRWD, ENTA, FLML","Click to get this free report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report IRONWOOD PHARMA (IRWD): Free Stock Analysis Report FLAMEL TECH (FLML): Free Stock Analysis Report ENANTA PHARMA (ENTA): Free Stock Analysis Report FIBROGEN INC (FGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT followed suit. Johnson & Johnson JNJ kick-started the earnings season on a positive note, wherein its earnings beat estimates and the company raised its outlook for the year."
2016-05-05,38.27999877929688,38.5,-0.6541077760734849,Abbott Laboratories (ABT) Is in Oversold Territory: What's Next?,"Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. And for technical investors there is some hope when looking at ABT given that, according to its RSI reading of 24.52, it is now in oversold territory."
2016-05-04,38.34999847412109,38.09999847412109,0.5747158508847758,"Analysts Forecast 10% Upside For The Holdings of EPS | Zoetis (ZTS) Tops Q1 Earnings & Revenues, Updates Outlook | Abbott Laboratories (ABT) Sees Hammer Chart Pattern: Time to Buy? | After Hours Most Active for May 4, 2016 : FIT, TWTR, PHM, QQQ, AAPL, BAC, TSLA, TLT, WFM, ABT, GT, FCX","Below is a twelve month price history chart comparing the stock performance of ABT, MAN, and CNA: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of EPS's underlying holdings with notable upside to their analyst target prices are Abbott Laboratories (Symbol: ABT), ManpowerGroup (Symbol: MAN), and CNA Financial Corp. (Symbol: CNA). Although ABT has traded at a recent price of $38.27/share, the average analyst target is 25.42% higher at $48.00/share. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ONCOMED PHARMA (OMED): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. Sales of companion animal products grew 32% reflecting increased sales of Apoquel, initial sales of other products into expanded distribution relationships, and the addition of products acquired from Abbott Laboratories' ABT Animal Health business. For 2016, the company expects earnings in the range of $1.83 to $1.90 per share (old guidance: $1.71 to $1.81 per share) on revenues of $4.775 billion and $4.875 billion (old guidance: $4.65 billion and $4.775 billion). | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT has been struggling lately, but the selling pressure may be coming to an end soon. That is because ABT recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom. | The total After hours volume is currently 28,227,887 shares traded. The following are the most active stocks for the after hours session : Fitbit, Inc. ( FIT ) is -1.87 at $15.23, with 2,547,296 shares traded. Investopedia Reports: Garmin's New Niche Device: A ""Semi-Fitness"" Watch Twitter, Inc. ( TWTR ) is +0.01 at $14.85, with 2,050,950 shares traded."
2016-05-03,38.79999923706055,38.54999923706055,-0.6518905083365314,"After Hours Most Active for May 3, 2016 : IRM, QQQ, MU, EMC, BRCD, ABT, CETV, NVAX, FCAU, FDC, ESV","Abbott Laboratories ( ABT ) is -0.1389 at $38.41, with 924,280 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the ""buy range"". The following are the most active stocks for the after hours session : Iron Mountain Incorporated ( IRM ) is unchanged at $36.50, with 7,107,688 shares traded."
2016-05-02,38.84999847412109,38.84999847412109,-0.6443299095769255,Zoetis (ZTS): Stock Likely to Beat on Earnings in Q1 Again?,"Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report GENOCEA BIOSCI (GNCA): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. The top line should also benefit from the addition of products acquired from Abbott Laboratories' ABT Animal Health business (acquired in Feb 2015), the Nov 2015 Pharmaq acquisition as well as from the performance of Apoquel and other key brands. Zacks Rank #3 (Hold): Note that stocks with Zacks Ranks #1 (Strong Buy), #2 (Buy) and #3 have a significantly higher chance of beating earnings."
2016-04-29,40.369998931884766,38.900001525878906,0.0,"Drug Stocks Q1 Earnings Preview: AEGR, AERI, MACK, PRTA | ETF Flows Show Investors Are Riding the Stock Market Rebound","Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report AEGERION PHARMA (AEGR): Free Stock Analysis Report AERIE PHARMACT (AERI): Free Stock Analysis Report PROTHENA CP PLC (PRTA): Free Stock Analysis Report MERRIMACK PHAR (MACK): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT followed suit, while biotech major, Biogen Inc. BIIB reported better-than-expected quarterly earnings. As per our Earnings Trends report , approximately 209 S&P 500 companies (52.4% of the index's total market capitalization) have reported results so far. | The health care sector may continue to attract investors as merger and acquisition activity picks up, with Abbott Laboratories ( ABT ) recently agreeing to acquire St Jude Medical Inc. ( STJ ) for $25 billion and AbbVie Inc. ( ABBV ) buying Stemcentrx for $5.8 billion. Additionally, ETF investors funneled about $1.2 billion into the iShares MSCI USA Minimum Volatility ETF (NYSEArca: USMV ) , which selects U.S. stocks based on variances and correlations along with other risk factors, and $547.2 million into the iShares MSCI EAFE Minimum Volatility ETF (NYSEArca: EFAV ) , which provide a low-volatile option for developed overseas markets. For example, the iShares iBoxx $ Investment Grade Corporate Bond ETF (NYSEArca: LQD ) added $1.0 billion in net inflows this month, Vanguard REIT ETF (NYSEArca: VNQ ) attracted $767.5 million and iShares TIPS Bond ETF (NYSEArca: TIP ) brought in $733.3 million."
2016-04-28,40.08000183105469,40.41999816894531,-3.641311481048457,"Why St. Jude Medical, Inc. Acquired a Higher Price Today | Reaction to the Abbott Deal Makes the Stock a Buy | Mid-Morning Market Update: Markets Mostly Lower; Ford Tops Q1 Expectations | US Stocks Eye Lower Open Amid Lackluster Q1 GDP Growth; Japan Holds Off on More Stimulus | Pre-Market Most Active for Apr 28, 2016 : F, STJ, FB, ABT, TVIX, MDVN, TXTR, SIRI, SRPT, PHI, FE, XIV | US Equities Futures Follow Europe, Asia Lower as Japan Leave Interest Rate Unchanged | 3 Stocks to Watch on Thursday: Marriott International Inc (MAR), St. Jude Medical, Inc. (STJ) and Texas Instruments Incorporated (TXN) | Why Abbott Laboratories (ABT), GNC Holdings Inc (GNC) and Symantec Corporation (SYMC) Are 3 of Today’s Worst Stocks | Why Dreamworks Animation Skg Inc (DWA), St. Jude Medical, Inc. (STJ) and Textura Corp (TXTR) Are 3 of Today’s Best Stocks | Health Care ETFs Can Still Strengthen on Increased M&A Activity","So what: The deal calls for Abbott to pay St. Jude Medical's shareholders $46.75 in cash and 0.8708 shares of Abbott for each share of St. Jude Medical. That values St. Jude Medical's shares at a hair under $85 based on yesterday's closing price, and under $83 per share based on the current price of Abbott, which has fallen 2.3% as of 11:30 a.m. EDT. Now what: In a deal that involves getting shares from the acquiring company, the decision is a little more complicated because the daily changing stock price of the acquiring company will affect the acquired company until the acquisition goes through. | In some cases, such as with Abbott Laboratories (ABT) announced takeover of St. Jude Medical (STJ) this morning, the reason for the acquirer's stock falling initially is fairly clear. Even with that in mind though, this looks like a deal with significant synergies that should, according to Abbott CEO Miles White, be immediately accretive and the big drop in ABT looks like a buying opportunity. That has left ABT, for example trading at around 14x trailing earnings, a discount to the broader market. | St. Jude Medical, Inc. (NYSE: STJ ) shares were also up, gaining 25 percent to $77.62 after Abbott Laboratories (NYSE: ABT ) announced it has entered into an agreement to acquire St. Jude for a total consideration of $25 billion. Meanwhile, top losers in the sector included Ocwen Financial Corp (NYSE: OCN ), down 21 percent, and American Equity Investment Life Holding (NYSE: AEL ), down 12 percent. Equities Trading UP National Holdings Corporation (NASDAQ: NHLD ) shares shot up 45 percent to $3.19 as Fortress Biotech Inc (NASDAQ: FBIO ) announced plans to acquire National Holdings for $3.25 per share in cash. | St. Jude Medical ( STJ ) shares were the most active in pre-market trade, surging over 24% after agreeing to be acquired by Abbot ( ABT ) for $85 per share. ABT fell over 9%. Nikkei down 3.61% Hang Seng up 0.12% Shanghai Composite down 0.27% FTSE-100 down 1.04% DAX-30 down 1.19% | Abbott Laboratories ( ABT ) is -3.68 at $40.15, with 2,393,807 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the ""buy range"". The consensus earnings per share forecast is 0.2 per share, which represents a 3 percent increase over the EPS one Year Ago Textura Corporation ( TXTR ) is +6.11 at $26.00, with 638,107 shares traded. | St. Jude Medical ( STJ ) shares was the most active in pre-market trade, surging 25% after agreeing to be acquired by Abbot ( ABT ) for $85 per share. U.S. stock futures were in the red Thursday, weighed down by the Bank of Japan's decision to leave interest rates unchanged with no additional stimulus. E.T., the first estimate for Q1 GDP is expected to show 0.7% growth from Q4 when GDP grew 1.4%. | Here's why all three will be heavily watched this morning: St. Jude Medical, Inc. (STJ) Medical device maker St. Jude Medical is going to pop this morning, and it has Abbott Laboratories ( ABT ) to thank. The 10 Best Growth Stocks to Buy for Retirement ""St. Jude Medical shareholders will receive $46.75 in cash and 0.8708 shares of Abbott common stock, representing total consideration of approximately $85 per share,"" according to an ABT press release. InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips Technology stocks have had a rough week, but the stock market still managed to post meager gains overall on hump day. | Leading the charge lower were Abbott Laboratories (NYSE: ABT ), GNC Holdings Inc (NYSE: GNC ) and Symantec Corporation (NASDAQ: SYMC ). More From InvestorPlace The 10 Best Stocks of the Past 10 Years Whole Foods Market, Inc.: 365 Is a Really, REALLY Dumb Idea The post Why Abbott Laboratories (ABT), GNC Holdings Inc (GNC) and Symantec Corporation (SYMC) Are 3 of Today's Worst Stocks appeared first on InvestorPlace . Abbott Laboratories (ABT) At another time and in a different situation, an acquisition may have been a big hit with investors. | St. Jude Medical, Inc. Shares of medical device maker St. Jude Medical climbed 25.6% on about 14 times the average daily volume after Abbott Laboratories (NYSE: ABT ) said it will acquire STJ for $19.3 billion in cash and stock. STJ investors will receive $46.75 a share in cash and part of an ABT share for each STJ share they own. ABT's offer values STJ at $85 per share, a 37% premium to where the stock closed yesterday. | About $144 billion in deals for biotechnology, health care and pharmaceutical companies have been announced this year, with Abbott Laboratories ( ABT ) agreeing to acquire St Jude Medical Inc. ( STJ ) for $25 billion and AbbVie Inc. ( ABBV ) buying Stemcentrx for $5.8 billion, Bloomberg reports. ""We are likely see more M&A in health care this year as companies streamline their portfolios and seek to build up those areas of higher future growth,"" Nigel Jones, co-head of health care at Linklaters law firm, told Bloomberg. Trending on ETF Trends How The Fed is Boosting Dividend ETFs 4 Oil ETFs Ignited by Recent Surges ETF Flows Show Investors Are Riding the Stock Market Rebound Water ETFs Are Making a Big Splash Why It's Time to Consider High Dividend ETFs More companies may continue to capitalize on the ongoing low interest rate environment and engage in greater merger and acquisitions, or at least try to squeeze out some deals before the Federal Reserve decides to hike rates again."
2016-04-27,43.93000030517578,43.83000183105469,0.8482942174598153,,
2016-04-26,44.15999984741211,43.880001068115234,-0.2276313986488,,
2016-04-25,44.0099983215332,44.0099983215332,-0.6340552089319893,,
2016-04-22,43.720001220703125,44.08000183105469,0.0,,
2016-04-21,43.77999877929688,43.880001068115234,0.823423147987215,Abbott Earnings Review: Foreign Currency Effects Subdue An Otherwise Strong Operational Growth,"Leading healthcare major, Abbott Laboratories ( ABT ) reported its Q1 2016 earnings on April 20, 2016. Despite a strong operating growth, led by the established pharmaceutical division in key emerging markets, Abbott's key metrics declined year over year due to currency headwinds. We hope such lean communication sparks thinking, and encourages readers to comment and ask questions on the comment section, or email content@trefis.com 2) Figures mentioned are approximate values to help our readers remember the key concepts more intuitively."
2016-04-20,44.47999954223633,43.970001220703125,0.22842003564797342,"See Which Of The Latest 13F Filers Holds Abbott Laboratories | Midday Update: Stocks Regain Momentum As Oil Rebounds; Mostly Positive Earnings Also Lift Markets | Key Morning Earnings for April 20: ABT, DISH, KO, USB | Parade of Mixed Earnings | Health Care Sector Update for 04/20/2016: CARA, AMGN, MRK, ABT, PFE, JNJ, STJ | Close Update: Dow Makes New 2016 High As Oil Shrugs off Supply Pressures | What's Behind Alere Inc.'s Sinking Shares Today","Below, let's take a look at the change in ABT positions, for this latest batch of 13F filers: In terms of shares owned, we count 8 of the above funds having increased existing ABT positions from 12/31/2015 to 03/31/2016, with 8 having decreased their positions and 1 new position. We then compared that number to the sum total of ABT shares those same funds held back at the 12/31/2015 period, to see how the aggregate share count held by hedge funds has moved for ABT. The overall top three funds holding ABT on 03/31/2016 were: We'll keep following the latest 13F filings by hedge fund managers and bring you interesting stories derived from a look at the aggregate information across groups of managers between filing periods. | (-) ALR (-16.62%) Abbott ( ABT ) CEO Mike White would not confirm that Abbott is buying Alere (-) CAMP (-10.15%) Reported in-line Q4 earnings but issued weak FY16 guidance (-) CHKP (-2.88%) Beats Q1 earnings estimates but revenue in-line The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. NYSE Energy Sector Index up 0.83% NYSE Financial Sector Index up 0.32% NYSE Healthcare Sector Index up 0.10% (+) HNSN (+30.56%) To be acquired by Auris Surgical (+) VMW (+12.98%) Reported better-than-expected Q1 earnings and authorized a $1.2 billion share buyback (-) ONCS (12.82%) Reported positive melanoma clinical trial data (+) LXK (+10.07%) To be acquired for $40.50 per share by a group of investors led by Apex Technology and PAG Asia Capital | Abbott Labs ABT Global healthcare company Abbot Labs reported an earnings beat of $0.41 per share (from continuing operations excluding one-time items), topping the Zacks Consensus Estimate of $0.39 per share. INC (YHOO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report COCA COLA CO (KO): Free Stock Analysis Report DISH NETWORK CP (DISH): Free Stock Analysis Report INTEL CORP (INTC): Free Stock Analysis Report To read this article on Zacks.com click here. U.S. Bancorp USB The financial services company reported earnings of $0.76 per share for the first quarter, beating the Zacks Consensus Estimate by a penny. | Click to get this free report US BANCORP (USB): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report COCA COLA CO (KO): Free Stock Analysis Report To read this article on Zacks.com click here. This includes all of this morning's reports from the likes of Coke ( KO ), U.S. Bancorp ( USB ), Abbot Labs ( ABT ) and others. This is weak growth relative to what we have seen from the same group of 71 index members in other recent periods, though the ratio of companies beating estimates compares favorably to other the recent past, likely indicating that estimates may have fallen more than they needed to ahead of the start of this reporting cycle. | In health care stocks news, St. Jude Medical ( STJ ) reported Q1 adjusted net income was $259 million, or $0.90 per diluted share, down from last year's $266 million, or $0.93 per diluted share, but still came in ahead of the Capital IQ consensus of $0.88. Cara Therapeutics ( CARA ) said it received a notice from the U.S. Food and Drug Administration (FDA) for the removal of a clinical hold on its Phase 3 trial for postoperative pain. A subsequent review of safety data from the first 90 patients dosed was completed by Cara, the study's Independent Data Monitoring Committee, and the FDA. | (-) ARGS (-24.70%) CEO Fred Miesowicz announced resignation after Tuesday's close, plans to reduce workforce by 13% (-) ALR (-12.35%) Abbott ( ABT ) CEO Mike White would not confirm that Abbott is buying Alere (-) CAMP (-10.73%) Reported in-line Q4 earnings but issued weak FY16 guidance (-) CHKP (-3.17%) Beats Q1 earnings estimates but revenue in-line The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Quarterly results from Yahoo ( YHOO ), Coca-Cola and Abbot Labs ( ABT ) offset lower-than-expected revenue from Intel ( INTC ) and a miss from EMC ( EMC ) and Angie's List (ANGI). The Dow Jones Industrial Average returned some of its triple-digit gain into the close, but was positive for a third straight day as an unexpected rally in oil coupled with upbeat corporate earnings drove the blue-chip index to its highest level in 10 months. | So what: Abbott Labs inked a deal to acquire Alere for $5.8 billion in February, but since then, Alere has failed to file its annual 10-K financial report with the Securities and Exchange Commission and that's raising doubt that this deal will close as planned. Alere generates $2.5 billion in sales annually from serving the point-of-care market and Abbott anticipates that combining Alere's business with its own $473 million per year in point-of-care sales will lead to significant cost savings. Now what: It would have been nice for White to have said that Abbott Labs is 100% committed to Alere, but his remarks don't necessarily indicate Abbott Labs is suffering buyer's remorse and planning to walk away."
2016-04-19,44.0,43.84999847412109,-1.1465789720814414,"Commit To Buy Abbott Laboratories At $33, Earn 5.3% Using Options | How Will Drug Stocks BIIB, ABT, NVS Perform in Q1 Earnings? | Health Care Sector Update for 04/19/2016: SCMP, AMGN, MRK, ABT, PFE, JNJ","Investors eyeing a purchase of Abbott Laboratories (Symbol: ABT) stock, but tentative about paying the going market price of $43.53/share, might benefit from considering selling puts among the alternative strategies at their disposal. Selling a put does not give an investor access to ABT's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. In the case of Abbott Laboratories, looking at the dividend history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2.4% annualized dividend yield. | Click to get this free report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Earnings releases and guidance of the likes of Abbott LaboratoriesABT , Biogen Inc.BIIB , and Novartis AGNVS have always held investors' attention. As per our Earnings Trends report, the Medical sector is expected to witness earnings growth of 0.9% and revenue growth of 9.1% in the first quarter of 2016. | PFE: flat ABT: flat MRK: flat Health care shares were mostly unchanged in pre-market trade Tuesday. In health care stocks news, Sucampo Pharmaceuticals ( SCMP ) reported that its drug candidate cobiprostone did not meaningfully improve heartburn symptoms in a Phase 2a study."
2016-04-18,43.18000030517578,43.95000076293945,-0.3409125588157122,"Health Care Select Sector SPDR Fund Experiences Big Outflow | Will Currency Woes Hurt Abbott Labs' (ABT) Q1 Earnings? | Health Care Sector Update for 04/18/2016: MDVN, BIIB, AMGN, MRK, ABT, PFE, JNJ","Among the largest underlying components of XLV, in trading today Eli Lilly & Co. (Symbol: LLY) is up about 0.6%, Biogen Inc (Symbol: BIIB) is up about 0.9%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $136.6 million dollar outflow -- that's a 1.1% decrease week over week (from 177,765,324 to 175,815,324). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $56.63 per share, with $77.40 as the 52 week high point - that compares with a last trade of $70.41. | Click to get this free report SANOFI-AVENTIS (SNY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is scheduled to report first-quarter 2016 results before the opening bell on Apr 20. Zacks ESP: The Earnings ESP which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is 0.00%. | In health care stocks news, Biogen ( BIIB ) unveiled new research that it claimed reinforces a ""strong and sustained efficacy"" in newly diagnosed multiple sclerosis patients and further supports its long-term safety profile. ""Data from a post-hoc analysis show that more than half of newly diagnosed patients treated with TECFIDERA were free from relapses and disability progression for six years, reinforcing that early, effective treatment with TECFIDERA improves long-term clinical outcomes,"" the statement added. Medivation said the data from the 40 patient trial demonstrated that combination treatment with talazoparib and low-dose chemotherapy resulted in stable disease or an objective response in 23 of 40 heavily pretreated patients with a variety of advanced cancers (clinical benefit rate of 58%)."
2016-04-15,43.52999877929688,43.40999984741211,1.7832340257565389,"Health Care Sector Update for 04/15/2016: AMGN, MRK, ABT, PFE, JNJ, VRX, MRNS","Top Health-care stocks: JNJ: flat PFE: flat ABT: flat In health care stocks news, Valeant Pharmaceuticals International ( VRX ) rose in pre-market trading after Reuters said late Thursday the company has brought in investment banks to review its options after getting interest from buyout firms and other companies for some of its businesses. Marinus Pharmaceuticals ( MRNS ) has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the intravenous formulation ganaxolone, CNS-selective GABAA modulator, for the treatment of status epilepticus."
2016-04-14,43.380001068115234,43.5099983215332,-0.27566950436452786,,
2016-04-13,42.869998931884766,43.34999847412109,0.2996709318052971,"Health Care Sector Update for 04/13/2016: OCLS, PSTI, AMGN, MRK, ABT, PFE, JNJ","Top Health-care stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Health care shares were unchanged in pre-market trade Wednesday. The patents cover the company's core technology of three-dimensional expansion methods for producing therapeutic cell products derived from placental or fat cells and the use of placenta-derived cells grown with this 3D technology to treat disorders of the hematopoietic system. Oculus Innovative Sciences ( OCLS ) also surged in pre-market trade after the company said it has received a new CE Mark in Europe for its Microcyn-based Sinudox solution, intended for nasal irrigation including the moistening of cuts, abrasions and lacerations located in the nasal cavity."
2016-04-12,42.36000061035156,42.81999969482422,1.1196630608715017,"Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for April 13, 2016 | Health Care Sector Update for 04/12/2016: AMGN, MRK, ABT, PFE, JNJ, CLVS, CBRP","Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. The previous trading day's last sale of ABT was $42.48, representing a -17.9% decrease from the 52 week high of $51.74 and a 18% increase over the 52 week low of $36. The following ETF(s) have ABT as a top-10 holding: iShares U.S. Medical Devices ETF ( IHI ) SPDR S&P Health Care Equipment ( XHE ). | ABT: flat MRK: flat AMGN: flat Health care shares were mostly unchanged in pre-market trade Tuesday. In health care stocks news, Clovis Oncology ( CLVS ) said the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee meets Tuesday morning to discuss the company's New Drug Application for rociletinib. Corbus Pharmaceuticals ( CRBP ) said the U.S. Food and Drug Administration has approved a 12-month open-label extension study of its Phase 2 clinical trial of Resunab for the treatment of scleroderma."
2016-04-11,42.470001220703125,42.47999954223633,1.0859279458089661,Unloved Health Care ETFs May Surprise This Earnings Season,"However, IHI follows a more traditional market cap-weighted index, which tilts toward Medtronic ( MDC ) 14.1%, Abbot Laboratories ( ABT ) 9.5% and Thermo Fisher Scientific ( TMO ) 8.6%. Investors seeking high-quality exposure to the health care industry have a number of options available, including the Health Care Select Sector SPDR (NYSEArca: XLV ) , iShares U.S. Healthcare ETF (NYSEArca: IYH ) and Vanguard Health Care ETF (NYSEArca: VHT ) . Trending on ETF Trends Flatter Yield Curve Ways on Bank ETFs Technical Talk on a big Tech ETF International ETF Strategy to Balance Risk & Opportunity Inverse ETFs Step into the Limelight Gaming ETF Faces Technical Challenges Looking deeper into the health care industry, FactSet projects health care technology will lead the industry, with sales growth of 17% for the first quarter, followed by biotechnology's 12% sales growth."
2016-04-08,42.77999877929688,42.369998931884766,0.02354207969348769,,
2016-04-07,42.66999816894531,42.61000061035156,-0.958391442522746,,
2016-04-06,41.97999954223633,43.04999923706055,-0.14060829896499846,3 Best Dividend Stocks to Buy in April,"Best Dividend Stocks: Abbott Laboratories (ABT) Abbott Laboratories ( ABT ) is a member of the dividend aristocrats list and has been in business for more than 125 years. ABT's stock has a dividend yield of 2.5% and trades for 18 times forward earnings estimates. At the time of this writing, the author was long WFC, CMI and ABT."
2016-04-05,42.0099983215332,42.040000915527344,2.548832078351229,,
2016-04-04,42.34000015258789,42.31999969482422,0.0714177462339057,iShares U.S. Healthcare ETF Experiences Big Outflow,"Among the largest underlying components of IYH, in trading today Eli Lilly & Co. (Symbol: LLY) is down about 0.2%, Abbott Laboratories (Symbol: ABT) is up about 0.4%, and Biogen Inc (Symbol: BIIB) is higher by about 0.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $21.1 million dollar outflow -- that's a 1.2% decrease week over week (from 12,600,000 to 12,450,000). For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $108.00 per share, with $164.98 as the 52 week high point - that compares with a last trade of $143.63."
2016-04-01,41.52999877929688,42.18999862670898,-0.047237736635788403,,
2016-03-31,41.650001525878906,41.83000183105469,1.5892122966810962,,
2016-03-30,41.59999847412109,41.650001525878906,0.4321735860296175,,
2016-03-29,40.75,41.470001220703125,0.12019964805750165,Prepare for Earnings Season with These 49 Trades,"InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips During these busy times it pays to stay on top of the latest profit opportunities. This Week's Ratings Changes To stay on top of my latest stock ratings, plug your holdings into Portfolio Grader , my proprietary stock screening tool. More From InvestorPlace 10 Stocks That Could Derail Your Retirement 7 Low-Risk Healthcare Stocks to Buy Now 7 Best Funds for a New Rollover IRA Portfolio The post Prepare for Earnings Season with These 49 Trades appeared first on InvestorPlace ."
2016-03-28,40.77000045776367,40.880001068115234,1.7668741612346626,,
2016-03-24,40.63999938964844,40.75,0.2698077241022339,"Health Care Sector Update for 03/24/2016: NVIV, JNJ, PFE, ABT, MRK, AMGN","Top Health-care stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Health-care shares were mostly flat in pre-market trade Thursday. In health-care stocks news, InVivo Therapeutics ( NVIV ) was up 4.8% at $7 after the biotechnology firm said a seventh patient was enrolled in the INSPIRE study, a study that is designed to evaluate the benefit of the Neuro-Spinal Scaffold in subjects with complete thoracic AIS A spinal cord injury. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2016-03-23,40.84000015258789,40.77999877929688,0.27067079725296733,"Zacks Industry Outlook Highlights: Bayer, Abbott Laboratories, Roche Holding, Medtronic and DENTSPLY International","For Immediate Release Chicago, IL - March 23, 2016 - Today, Zacks Equity Research discusses the MedTech, part 2, including Bayer AG ( BAYRY ), Abbott Laboratories ( ABT ) , Roche Holding AG ( RHHBY ), Medtronic ( MDT ) and DENTSPLY International Inc. ( XRAY ). Industry: MedTech, part 2 Link: http://www.zacks.com/commentary/75772/lots-happening-in-medtech-should-you-buy-these-stocks In recent years, 2015 can be taken as a case study considering the medley of factors, both domestic and international, that were at play. However, this is not the end of uncertainties as a possible change in the government will likely bring in sectora"
2016-03-22,40.5,41.02999877929688,-0.14691815148586979,,
2016-03-21,40.58000183105469,40.7599983215332,1.3086389612268694,"XLV, GILD, AGN, ABT: Large Outflows Detected at ETF","Among the largest underlying components of XLV, in trading today Gilead Sciences, Inc. (Symbol: GILD) is up about 1.8%, Allergan PLC (Symbol: AGN) is up about 0.5%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $341.5 million dollar outflow -- that's a 2.9% decrease week over week (from 177,215,324 to 172,115,324). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $56.63 per share, with $77.40 as the 52 week high point - that compares with a last trade of $67.03."
2016-03-18,40.36000061035156,40.790000915527344,0.44355959181049026,,
2016-03-17,40.20000076293945,40.290000915527344,1.0654120383375179,,
2016-03-16,40.13999938964844,40.18000030517578,0.22388097233784665,,
2016-03-15,40.15999984741211,39.900001525878906,0.09965350307817754,,
2016-03-14,40.310001373291016,40.5,-0.647406181576361,,
2016-03-11,39.25,40.369998931884766,0.47134363740030893,,
2016-03-10,39.40999984741211,39.02999877929688,2.8535004634006764,,
2016-03-09,39.2599983215332,39.27999877929688,-0.9642249926072516,New Strong Sell Stocks for March 9th,"Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) list today: Abbott LaboratoriesABT Active Power, IncACPW Altisource Residential CorpRESI American Campus Communities, Inc ACC American Tower Corp.AMT View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report AMER TOWER CORP (AMT): Free Stock Analysis Report ACTIVE POWER (ACPW): Free Stock Analysis Report AMER CAMPUS CTY (ACC): Free Stock Analysis Report ALTISOURCE RESI (RESI): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2016-03-08,38.95000076293945,39.16999816894531,0.050943603206190645,,
2016-03-07,39.0,39.18000030517578,0.5648200300298447,,
2016-03-04,38.84999847412109,39.18000030517578,0.4615392440404647,S&P 500 Analyst Moves: ABT,"The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories ( ABT ) is now the #129 analyst pick, moving up by 3 spots. VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Looking at the stock price movement year to date, Abbott Laboratories ( ABT ) is lower by about 13.0%."
2016-03-03,38.560001373291016,38.81999969482422,0.8494255959225242,,
2016-03-02,39.34999847412109,39.34000015258789,0.6742694820371393,,
2016-03-01,38.90999984741211,39.33000183105469,-0.02540869611410916,,
2016-02-29,39.34000015258789,38.7400016784668,1.0794191346431277,New Strong Sell Stocks for February 29th,"Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) list today: Abbott LaboratoriesABT Acceleron Pharma IncXLRN Alliance Fiber Optic Products IncAFOP American Capital Senior Floating Ltd. ACSF American Science & Engineering, Inc.ASEI View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report AMER SCI & ENG (ASEI): Free Stock Analysis Report ALLIANCE FIBER (AFOP): Free Stock Analysis Report AMER CAP SNR FL (ACSF): ETF Research Reports ACCELERON PHARM (XLRN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2016-02-26,39.47999954223633,39.52000045776367,-1.5251613416214596,,
2016-02-25,39.220001220703125,39.630001068115234,0.1013194427334026,,
2016-02-24,38.18000030517578,39.20000076293945,1.045384586055755,New Strong Sell Stocks for February 24th,"Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: Abbott Laboratories ( ABT ) Alliance Fiber Optic Products Inc ( AFOP ) American Capital Senior Floating Ltd ( ACSF ) Arctic Cat Inc ( ACAT ) Bank of Commerce Holdings ( BOCH ) View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALLIANCE FIBER (AFOP): Free Stock Analysis Report AMER CAP SNR FL (ACSF): ETF Research Reports ARCTIC CAT INC (ACAT): Free Stock Analysis Report BANK OF COMMRC (BOCH): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2016-02-23,38.90999984741211,38.38999938964844,2.6715569659788554,,
2016-02-22,38.52999877929688,39.15999984741211,-1.3364185551346306,"UPRO, BIIB, ABT, DHR: Large Outflows Detected at ETF","Among the largest underlying components of UPRO, in trading today Biogen Inc (Symbol: BIIB) is up about 0.8%, Abbott Laboratories (Symbol: ABT) is up about 1.4%, and Danaher Corp. (Symbol: DHR) is higher by about 1.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $69.1 million dollar outflow -- that's a 7.5% decrease week over week (from 18,100,000 to 16,750,000). For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $42.98 per share, with $73.66 as the 52 week high point - that compares with a last trade of $53.15."
2016-02-19,38.31999969482422,38.52999877929688,1.6350923645856492,"Daily Dividend Report: ANTM, EQIX, MDT, ABT, FDX, CCI, K","Abbott ( ABT ) declared a quarterly common dividend of 26 cents per share. VIDEO: Daily Dividend Report: ANTM, EQIX, MDT, ABT, FDX, CCI, K The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The first quarter dividend is payable on March 25, 2016, to shareholders of record at the close of business on March 10, 2016."
2016-02-18,38.34000015258789,38.310001373291016,0.5480143166625009,,
2016-02-17,38.369998931884766,38.45000076293945,-0.07824407714523737,,
2016-02-16,37.130001068115234,37.9900016784668,0.20850099890987345,"Zoetis Tops Q4 Earnings and Revenues, Updates Guidance",Click to get this free report ZOETIS INC (ZTS): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. The addition of Abbott Laboratories' ABT Animal Health business and increased availability of Apoquel also boosted revenues. The company expects revenues to be between $4.65 billion and $4.775 billion.
2016-02-12,36.70000076293945,37.130001068115234,2.316187949399424,,
2016-02-11,36.43999862670898,36.34000015258789,1.171662932525075,"Mylan Q4 Earnings and Revenues Lag, Set To Acquire Meda | Why Earnings Sent Mylan N.V. Shares Tumbling 18% Today","Third-party net sales from the European market increased 65% to $616.4 million driven by net sales from the acquisition of Abbott Lab's ABT non-U.S. developed markets branded generics business and new product sales, partially offset by unfavorable currency translations, lower volumes on existing products and lower pricing. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. Mylan Inc. (MYL) Street EPS & Surprise Percent - Last 5 Quarters | FindTheCompany Revenues also grew 19.6% to $2.5 billion, but fell short of the Zacks Consensus Estimate of $2.7 billion. | So what: The generic drugmaker reported that its ex-currency sales grew 28% to $9.45 billion last year and that its full-year diluted earnings per share advanced 21% to $4.30. Results benefited from both new generic drug launches and the positive impact of Mylan's recent acquisition of Abbott Laboratories ' non-U.S. developed markets generic business. Full-year sales in its specialty drug segment were essentially flat, rising 1% to $1.2 billion as demand for the company's EpiPen remained strong."
2016-02-10,37.58000183105469,37.209999084472656,-0.2744195331769085,New Strong Sell Stocks for February 10th,"Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: Abbott Laboratories ( ABT ) Adeptus Health Inc ( ADPT ) Bancorp Inc ( TBBK ) Bank of Commerce Holdings ( BOCH ) Brookdale Senior Living, Inc. ( BKD ) View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ADEPTUS HEALTH (ADPT): Free Stock Analysis Report BANCORP BNK/THE (TBBK): Free Stock Analysis Report BANK OF COMMRC (BOCH): Free Stock Analysis Report BROOKDALE SENR (BKD): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2016-02-09,36.959999084472656,37.0,-0.984573519302692,,
2016-02-08,37.18999862670898,37.459999084472656,0.10822758798213451,"Vanguard Dividend Appreciation ETF Experiences Big Inflow | Extra Space Storage, Abbott Laboratories, First Data, ServiceMaster Global Holdings and ABM Industries highlighted as Zacks Bull and Bear of the Day | Bear of the Day: Abbott Labs (ABT)","Among the largest underlying components of VIG, in trading today Microsoft Corporation (Symbol: MSFT) is down about 3%, Abbott Laboratories (Symbol: ABT) is down about 1.5%, and Monsanto Co. (Symbol: MON) is lower by about 1.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $245.9 million dollar inflow -- that's a 1.3% increase week over week in outstanding units (from 247,134,771 to 250,435,232). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $47.70 per share, with $83.28 as the 52 week high point - that compares with a last trade of $73.36. | Click to get this free report EXTRA SPACE STG (EXR): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report FIRST DATA CORP (FDC): Free Stock Analysis Report SERVICEMASTR GH (SERV): Free Stock Analysis Report ABM INDUSTRIES (ABM): Free Stock Analysis Report To read this article on Zacks.com click here. For Immediate Release Chicago, IL - February 08, 2016- Zacks Equity Research highlights Extra Space Storage ( EXR ) as the Bull of the Day and Abbott Laboratories ( ABT ) as the Bear of the Day. Bear of the Day : Although many large caps in the health care world have held up pretty well in this uncertain environment, the same cannot be said for Abbott Laboratories ( ABT ) . | Thanks to this, analysts tracking ABT have been racing to slash their earnings estimates for Abbott stock, suggesting that the pain for ABT investors isn't over by a long shot. Recent Estimates There has been total agreement among ABT analysts regarding the company's near term outlook as seven analysts have pushed estimates lower for the current quarter in the last seven days compared to zero higher, while we have seen an 11:0 ratio for the current year in the same time frame too. Click to get this free report ACADIA HEALTHCR (ACHC): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here."
2016-02-05,38.22999954223633,37.40999984741211,0.7260028710239613,,
2016-02-04,37.77999877929688,38.0099983215332,-2.1449115999028114,New Strong Sell Stocks for February 4th,"Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) list today: Abbott Laboratories ( ABT ) AGCO Corporation ( AGCO ) Andersons Inc ( ANDE ) Archer Daniels Midland Company ( ADM ) Bancorp Inc ( TBBK ) View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ADVISORY BOARD (ABCO): Free Stock Analysis Report ANDERSONS INC (ANDE): Free Stock Analysis Report ARCHER DANIELS (ADM): Free Stock Analysis Report BANCORP BNK/THE (TBBK): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2016-02-03,38.22999954223633,38.02000045776367,0.6087865263837934,,
2016-02-02,38.0,37.880001068115234,-0.5493044388887586,"Company News for February 02, 2016 | Abbott Labs to Boost Diagnostics Business with Alere Buyout","Click to get this free report ALERE INC (ALR): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report QUESTAR (STR): Free Stock Analysis Report DOMINION RES VA (D): Free Stock Analysis Report TWITTER INC (TWTR): Free Stock Analysis Report ROPER INDS INC (ROP): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. • Alere Inc.'s ( ALR ) shares surged 45.5% after Abbott Laboratories ( ABT ) agreed to buy the company for around $5.8 billion • Shares of Questar Corporation ( STR ) skyrocketed 22.6% following news that Dominion Resources, Inc. ( D ) will acquire the company in a all cash deal of nearly $4.4 billion • Twitter, Inc.'s ( TWTR ) shares jumped 6.6% on news that Silver Lake Partners and investor Marc Andreessen may offer to acquire the company • Shares of Roper Technologies, Inc. ( ROP ) plunged 6.8% after reporting fourth quarter adjusted earnings of $1.82 per share, missing the Zacks Consensus Estimate of $1.86 Want the latest recommendations from Zacks Investment Research? | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALERE INC (ALR): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. In a bid to strengthen its presence and leadership in the global diagnostics market, Abbott LaboratoriesABT announced a definitive agreement to acquire Alere ALR . Our Take The acquisition should bolster Abbott Labs' diagnostics business, which generated sales of $4.6 billion in 2015, down 1.6% on a reported basis."
2016-02-01,36.16999816894531,38.45000076293945,-0.31578666285464635,"Midday Update: Wall Street Pressured By New Decline For Oil, Disappointing Manufacturing Data | Here's Why Alere's Stock Is Soaring Today | Mid-Morning Market Update: Markets Open Lower; Abbott Laboratories To Buy Alere For $56/Share | Stock Futures Drop on Chinese Manufacturing Data, Supply-Related Oil Sell-off | Health Care Sector Update for 02/01/2016: LIVN, ABT | Close Update: Stocks Trim Early Losses Tied to Lower Oil | Mid-Afternoon Market Update: Roper Technologies Falls Following Weak Results; Questar Shares Spike Higher | Health Care Sector Update for 02/01/2016: ALR,ABT,EYEG,TTHI","(+) ASTI (+69.01%) Reported a 90% increase in Q4 revenue (+) ALR (+45.16%) To be acquired by Abbott Labs ( ABT ) for $56 per share (+) AYA (+24.08%) CEO David Baazov made CAD $21 per share offer for company (+) MGI (+23.21%) Renewed its 17-year-plus relationship with Wal-Mart ( WMT ) for another three years. Nikkei 225 Index up 1.98% Hang Seng Index down 0.45% Shanghai China Composite Index down 1.78% FTSE 100 Index down 0.39% CAC 40 down 0.56% DAX down 0.41% NYSE Energy Sector Index down 3.10% NYSE Financial Sector Index down 1.27% NYSE Healthcare Sector Index down 0.73% | What : Shares of the medical diagnostic company Alere jumped 45% today on a $5.8 billion buyout deal with Abbott Laboratories . Abbott is reportedly paying $56 per share for Alere in an all-cash deal, representing a 50% premium compared to where Alere's shares were trading following Friday's close. This iSecret stock could make this pop look tiny The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. | Top Headline Abbott Laboratories (NYSE: ABT ) announced plans to acquire Alere Inc (NYSE: ALR ) for $5.8 billion. Equities Trading UP Alere Inc (NYSE: ALR ) shares shot up 45 percent to $53.80 as Abbott Laboratories (NYSE: ABT ) announced plans to acquire Alere for $5.8 billion. The eurozone's STOXX 600 fell 0.93 percent, the Spanish Ibex Index dipped 0.69 percent, while Italy's FTSE MIB Index dropped 1.21 percent. | (+) ASTI (+76.06%) Reported a 90% increase in Q4 revenue (+) ALR (+46.32%) To be acquired by Abbott Labs ( ABT ) for $56 per share (+) AYA (+26.33%) CEO David Baazov made CAD $21 per share offer for company (+) STR (+20.89%) To be acquired by Dominion Resources ( D ) for $4.4 billion (+) MSTX (+12.50%) Reported top-line results from a blind Phase 2a study of AIR001 U.S. stock futures were positioned to open lower on Monday as bearish Chinese manufacturing data coupled with another sell-off in oil was fueling losses across Europe and the U.S. Oil was already more than 3% lower, snapping a five-day winning streak, after two OPEC delegates downplayed the potential for a meeting of OPEC and non-OPEC nations to support oil prices , telling Reuters that, ""it's all in the hands of the Russians now."" (-) Large cap tech: Lower (-) Chip stocks: Lower (-) Software stocks: Lower (-) Hardware stocks: Lower (+/-) Internet stocks: Mixed (-) Drug stocks: Lower (-) Financial stocks: Lower (-) Retail stocks: Lower (-) Industrial stocks: Lower (-) Airlines: Lower (-) Autos: Lower | And Abbott Laboratories ( ABT ) shares were slightly higher in recent pre-market trade after saying it has agreed to buy Alere ( ALR ) for $56 per share or a total $5.8 billion. AMGN: flat Health-care shares were mainly unchanged in pre-market trade on Monday. In health-care stocks news, LivaNova ( LIVN ) said the U.S. Food and Drug Administration has approved its stented aortic bioprosthesis CROWN PRT for the treatment of aortic valve disease and it is expected to be launched in the coming months. | (+) EYEG (+110.00%) Initiated by Rodman & Renshaw with a buy rating and a price target of $10 a share (+) ASTI (+55.77%) Reported a 90% increase in Q4 revenue (+) ALR (+45.46%) To be acquired by Abbott Labs ( ABT ) for $56 per share (+) AYA (+20.08%) CEO David Baazov made CAD $21 per share offer for company (+) STR (+22.56%) To be acquired by Dominion Resources ( D ) for $4.4 billion (+) MGI (+16.60%) Renewed its 17-year-plus relationship with Wal-Mart ( WMT ) for another three years. Stocks were mixed at Monday's close with the Dow Industrial Average and S&P 500 closing above their worst levels of the day, but modestly lower as another sell-off in oil and downbeat U.S. and Chinese manufacturing data weighed on Wall Street. Defensive plays bolstered the price of gold to a 3-month high and pushed short-term Treasury yields lower, steepening the yield curve as long-term yields increased disproportionally to yields in shorter-maturing Treasury securities. | Top Headline Abbott Laboratories (NYSE: ABT ) announced plans to acquire Alere Inc (NYSE: ALR ) for $5.8 billion. Toward the end of trading Monday, the Dow traded down 0.53 percent to 16,378.38 while the NASDAQ dipped 0.37 percent to 4,597.08. The eurozone's STOXX 600 fell 0.19 percent, the Spanish Ibex Index dipped 0.31 percent, while Italy's FTSE MIB Index dropped 0.92 percent. | In company news, Alere Inc. ( ALR ) rallied Tuesday after the diagnostics company agreed to a $5.8 billion buyout proposal from Abbott Laboratories ( ABT ), which would pay $56 in cash for each Alere share, a nearly 48% premium over Friday's closing price for the stock. ABT stock has see-sawed between small gains and losses most of today's session, recently rising about 0.2% to $37.92 a share. Health care stocks were trending lower today, with the NYSE Health Care Index dropping nearly 0.5% while shares of health care companies in the S&P 500 were slipping almost 0.9% as a group."
2016-01-29,36.68999862670898,37.84999847412109,6.30357398235009,Weakness Seen in Abbott Laboratories (ABT): Stock Tumbles 9.3%,"Click to get this free report ASTRAZENECA PLC (AZN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT saw a big move last session, as the company's shares fell by over 9% on the day. This continues the recent downtrend for ABT, as the stock is now down nearly 20% in the past one-month time frame."
2016-01-28,38.40999984741211,36.709999084472656,3.161624123277214,"Thursday Sector Laggards: Healthcare, Industrial | New Strong Sell Stocks for January 28th | Abbott Labs (ABT) Beats on Q4 Earnings, Lags on Revenues | Why Abbott Laboratories Is Getting Crushed Today | Abbott Labs (ABT) Tops Earnings in Q4","Within that group, Abbott Laboratories (Symbol: ABT) and Endo International plc (Symbol: ENDP) are two large stocks that are lagging, showing a loss of 8.9% and 6.9%, respectively. Combined, ABT and ENDP make up approximately 2.3% of the underlying holdings of XLV. Among healthcare ETFs , one ETF following the sector is the Health Care Select Sector SPDR ETF (Symbol: XLV), which is down 2.0% on the day, and down 8.90% year-to-date. | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: Abbott Laboratories ( ABT ) Abraxas Petroleum Corp. ( AXAS ) Altra Industrial Motion Corp ( AIMC ) America Movil SAB de CV ( AMX ) Apogee Enterprises Inc ( APOG ) View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ABRAXAS PETE/NV (AXAS): Free Stock Analysis Report ALTRA INDUS MOT (AIMC): Free Stock Analysis Report AMER MOVIL-ADR (AMX): Free Stock Analysis Report APOGEE ENTRPRS (APOG): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT reported fourth-quarter 2015 earnings of 62 cents per share, beating the Zacks Consensus Estimate by a penny but remaining flat year over year. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report CORCEPT THERAPT (CORT): Free Stock Analysis Report To read this article on Zacks.com click here. In the reported quarter, sales came in at $5.2 billion, down 3.1% year over year (on a reported basis) and missing the Zacks Consensus Estimate of $5.3 billion. | What: Investors in Abbott Laboratories are having a rough day as shares of the diversified healthcare giant were down by as much as 10% as of 2:45 p.m. EST on much higher-than-normal trading volume after it released its fourth-quarter results. The company managed to beat on the bottom line, as earnings per share came in at $0.62, which managed to beat expectations by $0.01. The next billion-dollar iSecret The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. We have highlighted some of the key stats from this just-revealed announcement below: Earnings : Abbott Labs beat on earnings in fourth-quarter 2015 by a penny."
2016-01-27,39.95000076293945,40.470001220703125,-4.425932751087974,"Will Currency Volatility Keep Hurting Abbott's (ABT) Earnings? | Pre-Market Earnings Report for January 28, 2016 : MO, BMY, LLY, CELG, BABA, ABT, TMO, TWC, NEE, F, EPD, RTN | Which Of The Latest 13F Filers Holds Abbott Laboratories?","Click to get this free report ASTRAZENECA PLC (AZN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is scheduled to report fourth-quarter 2015 and full-year results before the opening bell on Jan 28, 2016. Zacks ESP : The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is -1.64%. | Abbott Laboratories ( ABT ) is reporting for the quarter ending December 31, 2015. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2015 Price to Earnings ratio for ABT is 18.68 vs. an industry ratio of 61.80. | Looking beyond these particular funds in this one batch of most recent filers, we tallied up the ABT share count in the aggregate among all of the funds which held ABT at the 12/31/2015 reporting period (out of the 623 we looked at in total). We then compared that number to the sum total of ABT shares those same funds held back at the 09/30/2015 period, to see how the aggregate share count held by hedge funds has moved for ABT. The overall top three funds holding ABT on 12/31/2015 were: We'll keep following the latest 13F filings by hedge fund managers and bring you interesting stories derived from a look at the aggregate information across groups of managers between filing periods."
2016-01-26,39.86000061035156,40.15999984741211,1.3016281547760629,"IUSV, C, CSCO, ABT: Large Outflows Detected at ETF","Among the largest underlying components of IUSV, in trading today Citigroup Inc (Symbol: C) is up about 1.7%, Cisco Systems, Inc. (Symbol: CSCO) is up about 1.4%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core U.S. Value ETF (Symbol: IUSV) where we have detected an approximate $69.2 million dollar outflow -- that's a 9.3% decrease week over week (from 6,450,000 to 5,850,000). For a complete list of holdings, visit the IUSV Holdings page » The chart below shows the one year price performance of IUSV, versus its 200 day moving average: Looking at the chart above, IUSV's low point in its 52 week range is $84.01 per share, with $139.04 as the 52 week high point - that compares with a last trade of $116.94."
2016-01-25,40.02999877929688,39.65999984741211,0.7526322941967986,,
2016-01-22,40.20000076293945,40.02999877929688,-0.9243041298220886,,
2016-01-21,40.18000030517578,39.47999954223633,-0.42289049854769295,,
2016-01-20,39.72999954223633,39.959999084472656,-1.742162164317561,,
2016-01-19,41.09999847412109,40.43000030517578,0.5789064809623753,,
2016-01-15,39.84999847412109,40.540000915527344,-1.630165921702344,,
2016-01-14,40.34000015258789,41.09999847412109,1.7314992919117682,,
2016-01-13,41.47999954223633,40.27999877929688,1.8839819500705692,,
2016-01-12,40.9900016784668,41.459999084472656,-2.892962334094447,,
2016-01-11,40.77000045776367,40.72999954223633,1.1466147517938803,,
2016-01-08,41.86000061035156,40.66999816894531,-0.09811360087862478,,
2016-01-07,41.68000030517578,41.540000915527344,-2.8428151554110923,,
2016-01-06,42.310001373291016,42.560001373291016,-0.335891047560891,,
2016-01-05,42.959999084472656,42.91999816894531,0.5908768420835298,"VIG, MDT, MMM, ABT: ETF Outflow Alert","Among the largest underlying components of VIG, in trading today Medtronic PLC (Symbol: MDT) is trading flat, 3M Co (Symbol: MMM) is off about 0.4%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $122.6 million dollar outflow -- that's a 0.6% decrease week over week (from 248,780,110 to 247,181,138). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $47.70 per share, with $83.28 as the 52 week high point - that compares with a last trade of $76.65."
2016-01-04,43.93999862670898,42.93000030517578,-0.09311200274629794,,
2015-12-31,45.11000061035156,44.90999984741211,-2.2985852369127464,,
2015-12-30,45.84999847412109,45.27000045776367,-0.44336235919615175,,
2015-12-29,45.27999877929688,45.81999969482422,-1.2649902631616892,,
2015-12-28,44.91999816894531,45.02999877929688,1.1925815593754792,,
2015-12-24,44.93999862670898,45.09999847412109,0.24488115502109856,,
2015-12-23,44.72999954223633,45.09999847412109,0.356029933915079,,
2015-12-22,44.22999954223633,44.47999954223633,0.8271829547759927,,
2015-12-21,44.04999923706055,44.040000915527344,0.5652272271928666,,
2015-12-18,44.959999084472656,43.70000076293945,-0.022697665621731148,,
2015-12-17,46.09000015258789,45.2599983215332,-2.8024874270256714,Zoetis (ZTS) Declares 14.5% Hike in Quarterly Dividend,"Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report CORCEPT THERAPT (CORT): Free Stock Analysis Report ACHILLION PHARM (ACHN): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. Zoetis acquired Abbott Laboratories' ABT animal health assets for $255 million. The new quarterly dividend comes to about 38 cents per share on a yearly basis, reflecting a forward yield of nearly 0.8% based on the raised dividend and the stock's last closing price of $47.09 (Dec 16, 2015)."
2015-12-16,45.77000045776367,46.04999923706055,-1.8008284406744224,,
2015-12-15,45.20000076293945,45.59000015258789,0.6117517511393876,,
2015-12-14,44.45000076293945,44.810001373291016,0.8628304935078833,,
2015-12-11,44.77000045776367,44.36000061035156,0.8099001218729245,"Daily Dividend Report: ABT, EIX, WPC, GE, LII, FMC, PNY","Abbott ( ABT ) increased the company's quarterly dividend to 26 cents per share from 24 cents per share. Edison International ( EIX ) declared a quarterly common stock dividend of $0.48 per share, payable on January 31, 2016, to shareholders of record on December 31, 2015. FMC Corporation ( FMC ) declared a regular quarterly dividend of 16.5 cents per share, payable on January 21, 2016, to shareholders of record at the close of business on December 31, 2015."
2015-12-10,45.08000183105469,45.310001373291016,-0.9157914746927601,,
2015-12-09,45.38999938964844,44.959999084472656,0.5102030454619152,,
2015-12-08,45.31999969482422,45.54999923706055,-0.9473459153071642,,
2015-12-07,45.56999969482422,45.560001373291016,0.5075011998788589,Health Care Select Sector SPDR Fund Experiences Big Outflow,"Among the largest underlying components of XLV, in trading today Medtronic PLC (Symbol: MDT) is down about 0.3%, Express Scripts Holding Co (Symbol: ESRX) is off about 0.3%, and Abbott Laboratories (Symbol: ABT) is up by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $175.9 million dollar outflow -- that's a 1.3% decrease week over week (from 194,115,324 to 191,665,324). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $56.63 per share, with $77.40 as the 52 week high point - that compares with a last trade of $71.31."
2015-12-04,44.40999984741211,45.29999923706055,-0.021940578451087243,"Zacks Industry Outlook Highlights: Bayer, Abbott Laboratories, Roche Holding, Medtronic and Johnson & Johnson","Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. Chicago, IL - December 04, 2015 - Today, Zacks Equity Research discusses the MedTech (Part 1), including Bayer AG ( BAYRY ), Abbott Laboratories ( ABT ), Roche Holding AG ( RHHBY ), Medtronic plc ( MDT ) and Johnson & Johnson ( JNJ ). Some of the bigger players in this niche are Bayer AG ( BAYRY ), Abbott Laboratories ( ABT ) and Cardinal Health, among others."
2015-12-03,45.36000061035156,44.150001525878906,2.0040517737139782,,
2015-12-02,45.43000030517578,45.220001220703125,-2.6675464466297285,,
2015-12-01,45.220001220703125,45.459999084472656,-0.4622475964384516,Short Iradimed: Don't Underestimate Lingering FDA Risk To The Company's Single-Product Growth Story,"Additionally, the FDA made a further infusion pump recall on October 31, 2013, when it made Abbott ( ABT ) recall its Acclaim Infusion Pumps and Hospira recall its Acclaim Encore Infusion Pumps. By True Intrinsic Value : Please also see the below article from the New York Times: FDA Steps Up Oversight of Infusion Pumps Business Iradimed ( IRMD ) is a single product medical device company focused on non-magnetic intravenous (IV) infusion pump systems which allow for the administration of medication to patients during the course of an MRI procedure. Additionally and more importantly, if the FDA is ultimately not satisfied with the due diligence the company conducts on Iradimed's MRI infusion pump and its compliance procedures, the FDA ultimately reserves the right to block future shipments or even request a recall of Iradimed's products in the field."
2015-11-30,45.43999862670898,44.91999816894531,0.5307338728236317,,
2015-11-27,45.41999816894531,45.41999816894531,-1.1443672391706807,,
2015-11-25,45.380001068115234,45.40999984741211,0.0,,
2015-11-24,45.11000061035156,45.45000076293945,0.06610572629085426,,
2015-11-23,46.02999877929688,45.43999862670898,0.7537134737033666,,
2015-11-20,46.02999877929688,46.0099983215332,-1.2817731223865942,,
2015-11-19,45.720001220703125,45.72999954223633,-0.043450919604791895,,
2015-11-18,44.970001220703125,45.79999923706055,0.021868594195652916,,
2015-11-17,44.88999938964844,44.77000045776367,1.8456704332383038,,
2015-11-16,43.900001525878906,44.880001068115234,-0.2673177400675955,,
2015-11-13,43.45000076293945,43.959999084472656,2.23234512112402,,
2015-11-12,44.810001373291016,44.18999862670898,1.173759062320212,,
2015-11-11,45.86000061035156,45.06999969482422,-1.383625814730706,,
2015-11-10,45.09000015258789,45.7599983215332,-1.722636077220252,,
2015-11-09,45.470001220703125,45.04999923706055,1.4859129888622515,,
2015-11-06,44.88999938964844,45.630001068115234,-0.9236902845108027,,
2015-11-05,45.09000015258789,45.18000030517578,1.6484778091519423,,
2015-11-04,45.720001220703125,45.18000030517578,0.19960113613511524,,
2015-11-03,45.36000061035156,45.5099983215332,-1.1811043331355342,,
2015-11-02,44.880001068115234,45.43000030517578,0.33068278034240106,What's in the Cards for Zoetis (ZTS) this Earnings Season?,"Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALNYLAM PHARMA (ALNY): Free Stock Analysis Report MERRIMACK PHAR (MACK): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. The addition of Abbott Laboratories' ABT Animal Health business, Apoquel and other new products should have driven the top line. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) to likely post an earnings beat."
2015-10-30,45.18999862670898,44.79999923706055,1.2254884669583732,"Mylan Tops Q3 Earnings, Misses Revenues, Updates View","Third-party net sales from the European market increased 79% to $629 million driven by net sales from the acquisition of Abbott Lab's ABT non-U.S. developed markets branded generics business and new product sales, partially offset by unfavorable currency translations. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report To read this article on Zacks.com click here. Adjusted gross margin during the third quarter of 2015 expanded to 58% from 54% in the year-ago quarter on the back of new product introductions, net sales from acquisitions and increased margins on existing products in North America."
2015-10-29,44.93000030517578,45.2400016784668,-0.8630214682456887,,
2015-10-28,43.959999084472656,44.7599983215332,0.6899652151912061,,
2015-10-27,43.540000915527344,43.880001068115234,1.8198345171101673,See Which Of The Latest 13F Filers Holds Abbott Laboratories,"Looking beyond these particular funds in this one batch of most recent filers, we tallied up the ABT share count in the aggregate among all of the funds which held ABT at the 09/30/2015 reporting period (out of the 738 we looked at in total). We then compared that number to the sum total of ABT shares those same funds held back at the 06/30/2015 period, to see how the aggregate share count held by hedge funds has moved for ABT. The overall top three funds holding ABT on 09/30/2015 were: We'll keep following the latest 13F filings by hedge fund managers and bring you interesting stories derived from a look at the aggregate information across groups of managers between filing periods."
2015-10-26,43.58000183105469,43.61000061035156,0.780891468623371,,
2015-10-23,43.52000045776367,43.59999847412109,0.06883611297945876,,
2015-10-22,42.40999984741211,43.5,0.18381896947600715,"Noteworthy ETF Outflows: VIG, ABT, MON, CAT | Company News for October 22, 2015","Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.9%, Monsanto Co. (Symbol: MON) is up about 0.3%, and Caterpillar Inc. (Symbol: CAT) is higher by about 3.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $40.5 million dollar outflow -- that's a 0.2% decrease week over week (from 247,127,192 to 246,602,192). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $47.70 per share, with $83.28 as the 52 week high point - that compares with a last trade of $78.14. | • Shares of Abbott Laboratories ( ABT ) gained 1.1% after the company posted third quarter earnings per share of $0.54, beating the Zacks Consensus Estimate by a cent • Shares of Baker Hughes Incorporated ( BHI ) advanced 2.3% after the company reported third quarter loss per share of $0.05, narrower than the Zacks Consensus Estimate of a loss of $0.15 • Shares of Northern Trust Corporation ( NTRS ) declined 4.3% after the company posted third quarter earnings per share of $0.96, missing the Zacks Consensus Estimate by a cent • Packaging Corporation of America's ( PKG ) shares dropped 5.8% after the company reported third quarter earnings per share of $1.26 that fell short of the Zacks Consensus Estimate of $1.29 Want the latest recommendations from Zacks Investment Research? Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report BAKER-HUGHES (BHI): Free Stock Analysis Report NORTHERN TRUST (NTRS): Free Stock Analysis Report PACKAGING CORP (PKG): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2015-10-21,42.540000915527344,42.20000076293945,2.570148918909754,Abbott (ABT) Posts Higher-Than-Expected Q3 Earnings | Abbott Labs (ABT) Tops Earnings in Q3,"Abbott LaboratoriesABT reported third-quarter 2015 earnings of 54 cents per share, beating the Zacks Consensus Estimate by a penny, but remaining flat year over year. Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. In the reported quarter, sales came in at $5.2 billion, up 1.4% year over year (on a reported basis), surpassing the Zacks Consensus Estimate of $5.1 billion. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >> Want the latest recommendations from Zacks Investment Research?"
2015-10-20,42.08000183105469,41.7400016784668,-0.7992481082993786,"Pre-Market Earnings Report for October 21, 2015 : KO, BA, BIIB, ABT, EMC, GM, TMO, KMB, ITW, BHI, STJ, NLSN","Zacks Investment Research reports that the 2015 Price to Earnings ratio for ABT is 19.51 vs. an industry ratio of 4.50, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories ( ABT ) is reporting for the quarter ending September 30, 2015. In the past year ABT has beat the expectations every quarter."
2015-10-19,42.11000061035156,42.150001525878906,-0.807985118329946,Will Currency Hit Abbott Laboratories (ABT) in Q3 Earnings?,"Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is scheduled to report third-quarter 2015 results before the opening bell on Oct 21, 2015. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) to likely post an earnings beat."
2015-10-16,42.20000076293945,42.220001220703125,0.09499148645823255,,
2015-10-15,41.06999969482422,41.869998931884766,0.04739444882009698,,
2015-10-14,40.970001220703125,40.720001220703125,1.9478919966034611,Abbott Labs Releases Data on Dissolving Heart Stent Absorb,"Click to get this free report SANOFI-AVENTIS (SNY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT has announced results from the phase III trial, ABSORB, on drug-eluting coronary bioresorbable vascular scaffold, Absorb, at the end of one year. This trial, ABSORB China, was conducted to support Absorb's approval in China."
2015-10-13,40.970001220703125,40.91999816894531,-0.610202569077955,,
2015-10-12,41.630001068115234,41.56999969482422,-0.12204796257742057,"Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for October 13, 2015","Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. The following ETF(s) have ABT as a top-10 holding: iShares U.S. Medical Devices ETF ( IHI ) SPDR S&P Health Care Equipment ( XHE ) Direxion S&P 500 Volatility Response Shares ( VSPY )."
2015-10-09,41.06999969482422,41.88999938964844,-0.14413012671520486,Boston Scientific Funds MValve to Boost TMVR Expansion,"Click to get this free report BOSTON SCIENTIF (BSX): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report BAXTER INTL (BAX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Following suit, in September, Abbott Laboratories ABT acquired the remaining equities of Minnesota-based Tendyne (those that it already did not own). Boston Scientific CorporationBSX recently declared that it has closed an additional round of financing with MValve Technologies Ltd., in keeping with its plans to invest toward the development of a unique mitral regurgitation (MR) treatment solution that will work with the Boston Scientific Lotus Valve."
2015-10-08,40.34999847412109,41.15999984741211,1.99659045755376,Roche (RHHBY) Reports Positive Data on Skin Cancer Drugs,"Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report EXELIXIS INC (EXEL): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked health care stocks include Abbott Laboratories ABT and Novo Nordisk A/S NVO . Data from the study showed that Cotellic in combination with Zelboraf, enabled patients with previously untreated BRAF V600 mutation-positive advanced melanoma live significantly longer than Zelboraf alone."
2015-10-07,40.52999877929688,40.630001068115234,2.007438423598767,Express Scripts Includes Praluent and Repatha in Formulary | AmerisourceBergen (ABC) Acquires PharMEDium for $2.6B,"Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the health care sector is Abbott Laboratories ABT , with a Zacks Rank #2 (Buy). Pharmacy benefit manager Express Scripts ESRX announced that it will include two new cholesterol-lowering drugs - Regeneron/Sanofi's REGN / SNY Praluent and Amgen's AMGN Repatha - on its National Preferred Formulary. | Click to get this free report CARDINAL HEALTH (CAH): Free Stock Analysis Report AMERISOURCEBRGN (ABC): Free Stock Analysis Report MCKESSON CORP (MCK): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT also looks attractive in the health care space with the same Zacks Rank as AmerisourceBergen. The acquisition diversified the company's existing pharmaceutical distribution & services businesses into the attractive animal health market, which currently holds huge potential."
2015-10-06,41.25,39.88999938964844,0.24673647133055038,Boston Scientific's Bioabsorbable Stent Wins FDA Approval | Valeant Shares Down 37% since August; More Pain Ahead?,"Click to get this free report BOSTON SCIENTIF (BSX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report NUVASIVE INC (NUVA): Free Stock Analysis Report ICU MEDICAL INC (ICUI): Free Stock Analysis Report ENZYMOTEC LTD (ENZY): Free Stock Analysis Report To read this article on Zacks.com click here. In this respect, the Bioresorbable Vascular Scaffold (BVS) of the renowned healthcare provider Abott Laboratories ABT is worth mentioning. Boston Scientific Corporation 's BSX SYNERGY Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) recently won the U.S. Food and Drug Administration (FDA) approval for treating coronary artery disease (CAD) patients. | Click to get this free report EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are Abbott Laboratories ABT and AbbVie, Inc. ABBV . Last week, all 18 Democratic members of the House of Committee on Oversight and Government Reform requested Chairman Jason Chaffetz to issue a subpoena to compel Valeant to provide documents relating to the massive price hike of two of its drugs."
2015-10-05,41.619998931884766,41.38999938964844,-3.296971176609848,Amicus Therapeutics Plunges on Delay in NDA Submission | Novartis' (NVS) Sandoz Files for Enbrel Biosimilar in the U.S.,"Click to get this free report AMICUS THERAPT (FOLD): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the health care sector is Abbott Laboratories ABT , with a Zacks Rank #2 (Buy). Shares of Amicus TherapeuticsFOLD plunged significantly after the FDA asked for additional data on its lead candidate, galafold (migalastat). | NovartisNVS announced that the FDA has accepted its generic arm, Sandoz's Biologics License Application (BLA) for its proposed biosimilar to Amgen's AMGN blockbuster drug, Enbrel (etanercept). Enbrel, a tumor necrosis factor alpha (TNF-alpha) inhibitor, is approved in the U.S. for moderately to severely active rheumatoid arthritis (RA), chronic moderate-to-severe plaque psoriasis patients who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis. Last month, the division launched Zarxio in the U.S., the biosimilar version of Amgen's another blockbuster drug, Neupogen."
2015-10-02,40.25,41.380001068115234,-0.5526178475226419,"Notable ETF Outflow Detected - VIG, ABT, LMT, TXN","Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.5%, Lockheed Martin Corp. (Symbol: LMT) is down about 1.1%, and Texas Instruments Inc. (Symbol: TXN) is lower by about 2.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $143.7 million dollar outflow -- that's a 0.8% decrease week over week (from 249,326,912 to 247,376,912). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $47.70 per share, with $83.28 as the 52 week high point - that compares with a last trade of $73.03."
2015-10-01,40.34999847412109,40.7599983215332,2.807456069851514,Novartis Announces Positive Data on Arthritis Drug Cosentyx | Celsion Begins Patient Enrollment in Ovarian Cancer Study,"Click to get this free report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked health care stocks are Abbott Laboratories ABT , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . NovartisNVS announced results from a phase III study, FUTURE 1, on Cosentyx for the treatment of psoriatic arthritis. | Click to get this free report CELSION CORP (CLSN): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Other favorably placed stocks in the health care sector include Abbott Laboratories ABT , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . Earlier, Celsion had reported positive safety and encouraging results from a phase I study with GEN-1, when given as monotherapy in patients with peritoneally metastasized ovarian cancer and in combination with PEGylated doxorubicin in patients suffering from platinum-resistant ovarian cancer."
2015-09-30,39.84000015258789,40.220001220703125,1.0161087061132712,Roche Presents Positive Data on Respiratory Drug Esbriet,"Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked health care stocks are Abbott Laboratories ABT , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . Moreover, an ad-hoc analysis of the pooled data from ASCEND and CAPACITY showed that patients, who were hospitalized within the first six months of treatment, showed reduced risk of disease progression or death by more than two-thirds at one year on continued treatment with Esbriet."
2015-09-29,39.2599983215332,39.5,0.9538179384031719,,
2015-09-28,40.7400016784668,39.060001373291016,0.611313521975271,AbbVie Updates on Viekirax and Rheumatoid Arthritis Pipeline | Novo Nordisk's Tresiba & Ryzodeg Gain Entry into the U.S.,"Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report GALAPAGOS -ADR (GLPG): Free Stock Analysis Report To read this article on Zacks.com click here. Additionally, the company announced positive results from two double-blind, placebo-controlled, dose-ranging phase II studies (BALANCE-I and BALANCE-II) on its rheumatoid arthritis candidate, ABT-494. AbbVie stated that both studies achieved impressive levels of ACR20 at week 12 across all doses of ABT-494, except the lowest dose in the BALANCE-II study. | Click to get this free report ASTRAZENECA PLC (AZN): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Other well-ranked stocks in the health care sector include Abbott Laboratories ABT and Eli Lilly and Company LLY . We remind investors that on Mar 26, 2015, Novo Nordisk had announced its decision to submit results from a pre-specified interim analysis of a cardiovascular outcomes study, DEVOTE, to the FDA as part of a Class II resubmission of the new drug applications (NDAs) for Tresiba and Ryzodeg."
2015-09-25,42.22999954223633,40.86000061035156,-4.123711919392847,,
2015-09-24,42.0,41.93999862670898,-3.244136743393903,"Noteworthy ETF Inflows: VIG, ABT, LMT, MON","Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is off about 1.6%, Lockheed Martin Corp. (Symbol: LMT) is off about 1.3%, and Monsanto Co. (Symbol: MON) is lower by about 3.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $103.2 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 247,926,838 to 249,326,912). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $47.70 per share, with $83.28 as the 52 week high point - that compares with a last trade of $72.83."
2015-09-23,42.5,42.20000076293945,-0.14286041259767315,,
2015-09-22,42.83000183105469,42.47999954223633,-0.7058805577895221,,
2015-09-21,43.650001525878906,43.29999923706055,-0.8171895256950088,10 Stocks That Even the Pope Could Love,"AbbVie's former parent, Abbott Labs ( ABT , $43.33) is a top holding in both Ave Maria Growth ( AVEGX ) and Ave Maria Rising Dividend ( AVEDX ) funds. In light of the pope's visit, we've taken a look at the stock holdings of three Catholic values fund families--Ave Maria, LKCM Aquinas and Epiphany FFV (FFV stands for Faith and Family Values)--which all base their investment choices on the ecumenical constraints of the church. Although the stocks aren't cheap--Home Depot sells for 20 times year-ahead earnings, while Lowe's sells for 19 times projected earnings--UBS analyst Michael Lasser says both are attractive because the companies are experiencing growth spurts."
2015-09-18,43.63999938964844,43.33000183105469,-0.8018379761358141,,
2015-09-17,43.84999847412109,44.2400016784668,-0.7103518857227173,"Daily Dividend Report: ORCL, ABT, DHR, A, BEN, BXP, APA, ESS, SLG | Thursday's ETF with Unusual Volume: IHI","Abbott ( ABT ) declared a quarterly common dividend of 24 cents per share. VIDEO: Daily Dividend Report: ORCL, ABT, DHR, A, BEN, BXP, APA, ESS, SLG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Franklin Resources ( BEN ) announced a quarterly cash dividend in the amount of $0.15 per share payable on October 15, 2015 to stockholders of record holding shares of common stock at the close of business on September 30, 2015. | Components of that ETF with the highest volume on Thursday were Boston Scientific ( BSX ), trading up about 0.9% with over 3.1 million shares changing hands so far this session, and Abbott Labs ( ABT ), up about 1.5% on volume of over 2.6 million shares. The iShares U.S. Medical Devices ETF ( IHI ) is seeing unusually high volume in afternoon trading Thursday, with over 978,000 shares traded versus three month average volume of about 77,000. VIDEO: Thursday's ETF with Unusual Volume: IHI The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2015-09-16,43.77999877929688,43.86000061035156,0.8894030055117973,"VIG, ABT, GD, FDX: Large Outflows Detected at ETF","Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.1%, General Dynamics Corp. (Symbol: GD) is down about 0.3%, and FedEx Corp (Symbol: FDX) is lower by about 3.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $56.6 million dollar outflow -- that's a 0.3% decrease week over week (from 248,676,439 to 247,926,838). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $47.70 per share, with $83.28 as the 52 week high point - that compares with a last trade of $75.72."
2015-09-15,43.27999877929688,43.810001373291016,0.1827360285183755,,
2015-09-14,43.59999847412109,43.16999816894531,1.2245901315682612,,
2015-09-11,43.130001068115234,43.40999984741211,-0.9862392665701633,,
2015-09-10,43.02000045776367,43.119998931884766,0.649197246377696,,
2015-09-09,44.36000061035156,43.22999954223633,0.23244647386573275,,
2015-09-08,43.65999984741211,44.040000915527344,-2.5473423186823507,,
2015-09-04,43.5,43.06999969482422,0.8703643367918117,Why September's Volatility Is a Huge Opportunity for Options Trading,"You can see Abbott Laboratories ( ABT ) is currently at the high range of its one-year IV. Let's get started... Two Kinds of Volatility There are two kinds of volatility that traders talk about with regard to options: statistical volatility and implied volatility. If the difference between the stock's SV and the option's IV is significant (let's say the stock's SV is 25% while the option's IV is 70%), the numbers could be telling you the markets expect something to happen that may move that stock significantly, like an upcoming earnings announcement or pending FDA approval for one of its drugs."
2015-09-03,44.52000045776367,44.13999938964844,-0.9885064486799569,,
2015-09-02,44.310001373291016,44.2400016784668,-0.8535513571607959,,
2015-09-01,44.220001220703125,43.56999969482422,-0.15797718947129813,,
2015-08-31,45.90999984741211,45.290000915527344,-1.46992652178984,,
2015-08-28,45.61000061035156,46.02000045776367,-1.3504659855051475,,
2015-08-27,45.59999847412109,45.63999938964844,0.8989253276156646,"Edwards Completes CardiAQ Buyout, Resolves FORTIS Issue | U.S. Stocks Seek to Continue Recovery | Pre-Market Most Active for Aug 27, 2015 : STJ, AAPL, THOR, BAC, XIV, SDRL, RDS/B, QQQ, FB, NFLX, ABT, DB","Click to get this free report MEDTRONIC (MDT): Free Stock Analysis Report EDWARDS LIFESCI (EW): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ICU MEDICAL INC (ICUI): Free Stock Analysis Report To read this article on Zacks.com click here. Apart from Edwards and Medtronic, Abbott Laboratories ABT has also entered the TMVR market. Premium heart valve manufacturer Edwards Lifesciences Corp.EW recently completed the acquisition of California-based CardiAQ Valve Technologies, Inc. - a privately held medical device developer of percutaneous mitral heart valve replacement system. | U.S. stock futures were heading for another bullish open despite a stronger-than-expected upward revision to second quarter GDP that could put a September rate hike back on the table. Led by consumer spending, the economy grew at an annual pace of 3.7%, revised from 2.3% initially and beating the estimated revision to 3.2%. Today's remaining data includes the July pending home sales index (expected +1.0%), and the Kansas City Fed manufacturing index (expected -4.0 from July's -7.0). | The total Pre-Market volume is currently 10,352,943 shares traded. The following are the most active stocks for the pre-market session : St. Jude Medical, Inc. ( STJ ) is +3.02 at $72.36, with 3,091,697 shares traded. As reported by Zacks, the current mean recommendation for AAPL is in the ""buy range""."
2015-08-26,43.86000061035156,43.97999954223633,0.08772130891638555,Will Medtronic's Twelve Buy Expedite Growth in Mitral Valves?,"Click to get this free report MEDTRONIC (MDT): Free Stock Analysis Report EDWARDS LIFESCI (EW): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ICU MEDICAL INC (ICUI): Free Stock Analysis Report To read this article on Zacks.com click here. Following suit, Abbott Laboratories ABT announced that it will acquire the remaining equities of Minnesota-based Tendyne (those that it already did not own), which is focused on developing minimally invasive mitral valve replacement therapies, for a total price of $250 million. In an attempt to enter the billion dollar transcatheter mitral valve replacement (TMVR) market, Medtronic plcMDT recently agreed to purchase California-based medical device startup - Twelve, Inc. - for a total cash-and debt-free amount of $458 million."
2015-08-25,44.869998931884766,42.900001525878906,0.27359537212693114,Abbott Laboratories (ABT) Plunges: Stock Falls by 7.3%,"Abbott Laboratories ( ABT ) saw a big move last session, as the company's shares fell by over 7% on the day. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. This continues the recent downtrend for ABT, as the stock is now down over nearly 14% over the past one month."
2015-08-24,44.5099983215332,43.70000076293945,-4.390455656119869,,
2015-08-21,48.02999877929688,47.130001068115234,-1.8198103552879412,ABT Dividend Yield Pushes Past 2%,"Looking at the universe of stocks we cover at Dividend Channel , in trading on Friday, shares of Abbott Laboratories (Symbol: ABT) were yielding above the 2% mark based on its quarterly dividend (annualized to $0.96), with the stock changing hands as low as $47.50 on the day. Abbott Laboratories (Symbol: ABT) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index. In the case of Abbott Laboratories, looking at the history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2% annual yield."
2015-08-20,49.400001525878906,48.52999877929688,-1.8738241391952477,,
2015-08-19,50.13999938964844,49.84000015258789,-1.7611391087230241,,
2015-08-18,50.310001373291016,50.43999862670898,-0.5983231765305579,,
2015-08-17,50.0099983215332,50.380001068115234,0.2583924664469909,KemPharm (KMPH) Posts Wider-Than-Expected Loss in Q2 | Roche's (RHHBY) Lung Cancer Drug Meets Primary Endpoint,"Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report KEMPHARM INC (KMPH): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are Valeant Pharmaceuticals International, Inc. VRX , Eli Lilly and Company LLY and Abbott Laboratories ABT . KemPharm, Inc. 's KMPH shares gained 25.9% after the company reported positive data from an intranasal human abuse liability study on KP201 in combination with acetaminophen (KP201/APAP). | Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are Eli Lilly and Company LLY and Abbott Laboratories ABT . Atezolizumab enjoys Breakthrough Therapy status for the treatment of patients suffering from PD-L1 expressing NSCLC, whose disease progressed during or after undergoing standard treatments including platinum-based chemotherapy and appropriate targeted therapy for EGFR mutation-positive or ALK-positive disease."
2015-08-14,49.81999969482422,50.22999954223633,0.7398575464912908,"After Hours Most Active for Aug 14, 2015 : CMCSA, DFS, QQQ, ABT, BAX, DG, PRU, AAPL, BAC, TERP, MU, SIRI","Abbott Laboratories ( ABT ) is unchanged at $50.23, with 976,181 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the ""buy range"". Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2015."
2015-08-13,50.02000045776367,49.84000015258789,0.8229623643588744,,
2015-08-12,50.43000030517578,50.09000015258789,-0.3598566643912198,,
2015-08-11,50.18000030517578,50.38999938964844,-0.6742021624635909,"The Zacks Analyst Blog Highlights: Bayer AG, Abbott Laboratories, Xtant Medical Holdings, RTI Surgical, Cogentix Medical and Synergetics USA - Press Releases","Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report XTANT MEDICAL (BONE): Free Stock Analysis Report RTI SURGICAL (RTIX): Free Stock Analysis Report COGENTIX MEDICL (CGNT): Free Stock Analysis Report SYNERGETICS USA (SURG): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include the Bayer AG ( BAYRY ), Abbott Laboratories ( ABT ), Xtant Medical Holdings, Inc. ( BONE ), RTI Surgical Inc. ( RTIX ), Cogentix Medical, Inc. ( CGNT ) and Synergetics USA, Inc. ( SURG ). Some of the bigger players in this niche are Bayer AG ( BAYRY ), Abbott Laboratories ( ABT ) and Cardinal Health among others."
2015-08-10,50.41999816894531,50.65999984741211,0.4184915966431273,,
2015-08-07,50.400001525878906,50.11000061035156,0.476004932928813,"IYH, MDT, LLY, ABT: Large Outflows Detected at ETF","Among the largest underlying components of IYH, in trading today Medtronic PLC (Symbol: MDT) is down about 0.7%, Eli Lilly & Co. (Symbol: LLY) is off about 2.4%, and Abbott Laboratories (Symbol: ABT) is lower by about 1.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $88.4 million dollar outflow -- that's a 3.3% decrease week over week (from 16,500,000 to 15,950,000). For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $124.28 per share, with $164.98 as the 52 week high point - that compares with a last trade of $158.83."
2015-08-06,50.52000045776367,50.31999969482422,-0.5753986244989236,"Mylan Beats on Q2 Earnings, Revenues In Line, Guidance Up - Analyst Blog","Third-party net sales from the European market increased 44% to $571 million driven by net sales from the acquisition of Abbott's ABT non-U.S. developed markets branded generics business and new product sales, partially offset by unfavorable currency translations. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report To read this article on Zacks.com click here. Second Quarter in Details Generics third-party net sales, derived from sales in North America, Europe and rest of the world, climbed 34% to $2.1 billion."
2015-08-05,50.97999954223633,50.47999954223633,-0.3958843252716518,,
2015-08-04,50.75,50.5099983215332,-0.9807767840126321,,
2015-08-03,50.88999938964844,50.5,-0.4729097112646244,,
2015-07-31,51.06999969482422,50.68999862670898,-0.7663576229630835,Will Zoetis (ZTS) Pull a Surprise this Earnings Season? - Analyst Blog,"Click to get this free report MOMENTA PHARMA (MNTA): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report IMMUNE DESIGN (IMDZ): Free Stock Analysis Report To read this article on Zacks.com click here. Zoetis has acquired Abbott Laboratories' ABT animal health assets strengthening its pain and sedation product portfolio and diagnostic business. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) to likely post an earnings beat."
2015-07-30,50.95000076293945,50.77000045776367,-0.7440788533111219,,
2015-07-29,50.97999954223633,51.060001373291016,-0.35328813048166186,,
2015-07-28,51.09000015258789,50.93999862670898,0.15692787715387663,"Notable ETF Outflow Detected - UPRO, ABT, ABBV, ACN | Merck Tops on Q2 Earnings & Revenues, Revises Outlook - Analyst Blog","Among the largest underlying components of UPRO, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.1%, AbbVie Inc. (Symbol: ABBV) is up about 0.7%, and Accenture plc (Symbol: ACN) is higher by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $66.8 million dollar outflow -- that's a 8.3% decrease week over week (from 12,100,000 to 11,100,000). For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $45.74 per share, with $73.66 as the 52 week high point - that compares with a last trade of $67.00. | Merck & Co.MRK reported second quarter 2015 earnings of 86 cents per share, surpassing the Zacks Consensus Estimate of 80 cents and increasing 1.2% from the year-ago period. Merck & Company Inc. - Earnings Surprise | FindTheBest Revenues for the quarter declined 10.5% to $9.785 billion but were above the Zacks Consensus Estimate of $9.709 billion. This was partially offset by the Cubist acquisition."
2015-07-27,50.63999938964844,50.68999862670898,-0.29360251601274506,,
2015-07-24,50.84999847412109,51.04999923706055,0.09873467153074325,,
2015-07-23,51.33000183105469,51.20000076293945,0.39331517982492353,"Company News for July 23, 2015 - Corporate Summary","• Abbott Laboratories's ( ABT ) shares gained 2.5% after announcing second quarter earnings per share of $0.52, beating the Zacks Consensus Estimate by a couple of cents • Shares of Thermo Fisher Scientific, Inc. ( TMO ) rose 2.6% after declaring second quarter adjusted earnings per share of $1.84, ahead of the Zacks Consensus Estimate of $1.78 • Amphenol Corporation's ( APH ) shares jumped 5% after reporting second quarter revenues of $1,351.5 million, higher than the Zacks Consensus Estimate of $1,347 million • Shares of Whirlpool Corp. ( WHR ) surged 7.3% after posting second quarter adjusted earnings per share of $2.70, outpacing the Zacks Consensus Estimate by 3 cents Want the latest recommendations from Zacks Investment Research? Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report THERMO FISHER (TMO): Free Stock Analysis Report AMPHENOL CORP-A (APH): Free Stock Analysis Report WHIRLPOOL CORP (WHR): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2015-07-22,49.869998931884766,50.97999954223633,-0.2532652707535725,"Health Care Sector Update for 07/22/2015: STJ, THOR, ABT | Abbott Laboratories (ABT) Beats on Q2 Earnings, Keeps View - Analyst Blog | Abbott Labs (ABT) Beats on Earnings in Q2 - Tale of the Tape","In notable health-care stocks earnings this morning, Abbott Laboratories ( ABT ) was lower in pre-market trade Wednesday despite beating earnings estimates. In other news, St. Jude Medical ( STJ ) said it has agreed to acquire Thoratec ( THOR ) for $63.5 per share in cash or a total $3.4 billion, a 40.1% premium over the medical device maker's volume-weighted average trading price in the 30 trading days to July 17. THOR shares rose more than 9% in recent pre-market trade to $62.71, an all-time high if it holds into regular trading. | Abbott LaboratoriesABT reported second-quarter 2015 earnings of 52 cents per share, up 6.12% year over year, beating the Zacks Consensus Estimate of 50 cents. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs generated sales of $5.2 billion in the second quarter of 2015, up 2.2% year over year (on a reported basis) and in line with the Zacks Consensus Estimate. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Abbott Labs reports its diversified business in four segments - namely Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition."
2015-07-21,49.90999984741211,49.7599983215332,2.225788317877575,"Dow Jones Industrial Average Today Drops 180 Points as IBM, UTX Slide | Pre-Market Earnings Report for July 22, 2015 : KO, BA, ABT, TMO, EMC, ITW, TEL, ARMH, STJ, NTRS, APH, CHKP","Companies reporting earnings tomorrow include Abbott Laboratories ( ABT ), AutoNation Inc. ( AN ), Boeing Co. (BA), TheCheesecake Factory Inc. (Nasdaq: CAKE), Coca-Cola Co. (KO), Discover Financial Services (DFS), Las Vegas Sands Corp. (LVS), SanDisk Corp. (Nasdaq: SNDK), and Six Flags Entertainment Corp. (SIX). MoneyMorning.com Report - For July 21, 2015, here's how the Dow Jones Industrial Average did today, plus the topstock market news and stocks to watch based on today's market moves... How Did the Stock Market Do Today? Stocks to Watch No.4, LXK: Shares of Lexmark International Inc. (LXK) slumped more than 20.2% after the company reported weak earnings and announced plans to slash 500 jobs. | Zacks Investment Research reports that the 2015 Price to Earnings ratio for ABT is 23.18 vs. an industry ratio of 14.90, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories ( ABT ) is reporting for the quarter ending June 30, 2015. In the past year ABT has beat the expectations every quarter."
2015-07-20,50.0099983215332,50.060001373291016,-0.3005440319324786,Will Abbott Laboratories (ABT) Miss Earnings This Season? - Analyst Blog | Strategy To YieldBoost Abbott Laboratories From 1.9% To 5.3% Using Options,"Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is scheduled to report second-quarter 2015 results before the opening bell on Jul 22. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) to likely post an earnings beat. | Shareholders of Abbott Laboratories (Symbol: ABT) looking to boost their income beyond the stock's 1.9% annualized dividend yield can sell the January 2017 covered call at the $55 strike and collect the premium based on the $2.53 bid, which annualizes to an additional 3.4% rate of return against the current stock price (at Stock Options Channel we call this the YieldBoost ), for a total of 5.3% annualized rate in the scenario where the stock is not called away. Any upside above $55 would be lost if the stock rises there and is called away, but ABT shares would have to climb 9.7% from current levels for that to occur, meaning that in the scenario where the stock is called, the shareholder has earned a 14.7% return from this trading level, in addition to any dividends collected before the stock was called. In the case of Abbott Laboratories, looking at the dividend history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 1.9% annualized dividend yield."
2015-07-17,49.52000045776367,49.900001525878906,0.09998610965016227,,
2015-07-16,49.81999969482422,49.77000045776367,0.7673688703604573,,
2015-07-15,49.84000015258789,49.310001373291016,-0.10035976990530025,,
2015-07-14,49.810001373291016,50.20000076293945,-1.063400436746097,,
2015-07-13,50.0,49.720001220703125,0.7829740592168742,Novo Nordisk Up on Positive Results from Diabetes Study - Analyst Blog,"SUSTAIN1 evaluated the efficacy and safety of semaglutide monotherapy (0.5 mg and 1.0 mg doses) for a treatment period of 30 weeks versus placebo in patients suffering from type II diabetes who were previously on diet and exercise. The study has met its primary objective showing that patients treated with 0.5 mg and 1.0 mg semaglutide achieved superior improvement in HbA1c (1.5% and 1.6%, respectively) from a mean baseline HbA1c of 8.1%, compared to no change in HbA1c in those receiving placebo. Novo Nordisk reported that 74% and 73% of the patients treated with 0.5 mg and 1.0 mg semaglutide, respectively, achieved the treatment target of HbA1c below 7% as set by the American Diabetes Association and the European Association for t"
2015-07-10,49.630001068115234,49.93000030517578,-0.55999755859375,,
2015-07-09,49.79999923706055,49.18999862670898,0.6044715506832443,,
2015-07-08,49.7400016784668,49.25,-1.2249008427647015,"Novartis' Heart Failure Drug Entresto Receives FDA Approval - Analyst Blog | UPRO, MMM, ABT, ABBV: Large Inflows Detected at ETF","Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are Roche Holding RHHBY , Abbott Laboratories ABT and Johnson & Johnson JNJ . The drug can be used along with other heart failure treatments to reduce the risk of cardiovascular death and hospitalization in patients suffering from reduced ejection fraction heart failure, who are classified as NYHA class II-IV. | Among the largest underlying components of UPRO, in trading today 3M Co (Symbol: MMM) is down about 1.1%, Abbott Laboratories (Symbol: ABT) is down about 0.4%, and AbbVie Inc. (Symbol: ABBV) is lower by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $139.9 million dollar inflow -- that's a 18.2% increase week over week in outstanding units (from 11,250,000 to 13,300,000). For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $45.74 per share, with $73.66 as the 52 week high point - that compares with a last trade of $66.14."
2015-07-07,49.959999084472656,50.209999084472656,-0.9851259789541303,,
2015-07-06,49.02000045776367,49.7400016784668,0.5004003294261445,,
2015-07-02,49.79999923706055,49.40999984741211,1.468790726192441,,
2015-07-01,49.400001525878906,49.52000045776367,-0.7831313165125608,Aeterna Zentaris' Endometrial Cancer Study Fully Enrolled - Analyst Blog,"Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report AETERNA ZENTARS (AEZS): Free Stock Analysis Report AVALANCHE BIOT (AAVL): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are Avalanche Biotechnologies, Inc. AAVL , Abbott Laboratories ABT and Roche Holding AG RHHBY . Aeterna Zentaris Inc.AEZS announced that it has completed patient enrolment (n=500) in the open-label, randomized-controlled phase III ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) study on its oncology candidate zoptarelin doxorubicin."
2015-06-30,49.5099983215332,49.08000183105469,0.24291281007734877,Roche's Multiple Sclerosis Studies Meet Primary Endpoint - Analyst Blog | Intercept Pharmaceuticals Files for OCA in U.S. and Europe - Analyst Blog,"Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Another well-ranked stock in the health care sector is Abbott Laboratories ABT , carrying the same Zacks Rank as Roche. Roche Holding AGRHHBY announced that two randomized, double-blind, double-dummy, multi-centre phase III studies (OPERA I and OPERA II) evaluating the efficacy and safety of ocrelizumab (600 mg intravenous infusion) have met their primary and major secondary endpoints. | Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report INTERCEPT PHARM (ICPT): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are Gilead Sciences Inc. GILD , Johnson & Johnson JNJ and Abbott Laboratories ABT . We note that Intercept Pharma is looking to get OCA (in combination with ursodeoxycholic acid (UDCA)) approved for the treatment of primary biliary cirrhosis (PBC) in patients who respond inadequately to UDCA or as monotherapy in those unable to tolerate UDCA."
2015-06-29,49.540000915527344,49.0099983215332,-0.8685043527692846,"Noteworthy ETF Outflows: JKD, ABBV, USB, ABT | Better Dividend Stock: AbbVie or Johnson & Johnson? | Roche's Perjeta Recommended for Pre-Surgery Breast Cancer - Analyst Blog","Among the largest underlying components of JKD, in trading today AbbVie Inc. (Symbol: ABBV) is down about 1.9%, U.S. Bancorp (Symbol: USB) is off about 1.5%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Morningstar Large-Cap ETF (Symbol: JKD) where we have detected an approximate $55.4 million dollar outflow -- that's a 7.9% decrease week over week (from 5,700,000 to 5,250,000). For a complete list of holdings, visit the JKD Holdings page » The chart below shows the one year price performance of JKD, versus its 200 day moving average: Looking at the chart above, JKD's low point in its 52 week range is $107.81 per share, with $126.28 as the 52 week high point - that compares with a last trade of $122.10. | AbbVie is pursuing a high-growth strategy Unlike many of its peers in the large-cap dividend-stock universe, AbbVie is still very much a growth stock as well, reflecting management's strategy of producing double-digit revenue growth over the long term. Because of the drugmaker's various investments in its clinical pipeline and product portfolio -- including its recent $21 billion acquisition of Pharmacyclics -- as a holistic strategy to stave off the pain of the loss of exclusivity for its flagship anti-inflammatory drug Humira in 2017, AbbVie's 12-month trailing payout ratio and cash flows have been heading in the wrong direction for a while now. Johnson & Johnson has provided investors with decades of steady income and growth Despite its massive market cap of $276 billion, J&J also has a long history of generating strong top- and bottom-line growth, as well as regularly increasing its dividend. | Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Other well-ranked stocks in the health care sector are Novo Nordisk A/S NVO , Bayer AG BAYRY and Abbott Laboratories ABT . Roche Holding AG 's RHHBY Perjeta (in combination with Herceptin and chemotherapy) received positive opinion from the EU Committee for Medicinal Products for Human Use (CHMP) as a neoadjuvant (pre-surgery) treatment of patients suffering from HER2-positive, locally advanced, inflammatory or early-stage breast cancer who are at a high risk of recurrence."
2015-06-26,49.470001220703125,49.970001220703125,-1.0698477678631242,,
2015-06-25,49.650001525878906,49.33000183105469,1.0107135388360384,,
2015-06-24,49.59000015258789,49.5,-0.6445109466057647,,
2015-06-23,50.220001220703125,49.880001068115234,-0.18148851040726183,,
2015-06-22,49.959999084472656,50.02999877929688,-0.6770213945110898,,
2015-06-19,49.900001525878906,49.88999938964844,0.14011148139908883,,
2015-06-18,48.68999862670898,49.93999862670898,-0.020044360570372906,S&P 500 Analyst Moves: ABT,"The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories ( ABT ) is now the #116 analyst pick, moving up by 1 spot. VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Looking at the stock price movement year to date, Abbott Laboratories ( ABT ) is showing a gain of 10.4%."
2015-06-17,48.5,48.56999969482422,2.567262343922742,Mylan Inks Deal with Pulmatrix for Respiratory Disease Drug - Analyst Blog,"Meanwhile, Mylan announced that Abbott Laboratories ABT has said that it would support Mylan's offer to acquire Perrigo Company PRGO . Click to get this free report VALEANT PHARMA (VRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report To read this article on Zacks.com click here. As per IMS Health data, global sales of LAMA monotherapies for COPD were approximately $5 billion for the 12 months ending Dec 31, 2014."
2015-06-16,48.06999969482422,48.47999954223633,0.14432926767880155,,
2015-06-15,48.29999923706055,48.06999969482422,0.8529225088725241,,
2015-06-12,48.90999984741211,48.66999816894531,-0.4761895359614203,"Weekly Market Wrap: June 12, 2015 | Daily Dividend Report: ABT, MJN, HST, RL, PF, GGG, THO","In corporate dividend news, Abbott ( ABT ) declared a quarterly common dividend of 24 cents per share. Caterpillar ( CAT ) voted to increase the quarterly cash dividend by 10 percent to seventy-seven cents ($0.77) per share of common stock, payable August 20, 2015, to stockholders of record at the close of business on July 20, 2015. Target Corporation (TGT) has declared a quarterly dividend of 56 cents per common share, a 7.7 percent increase from the prior quarterly dividend of 52 cents. | Abbott ( ABT ) declared a quarterly common dividend of 24 cents per share. VIDEO: Daily Dividend Report: ABT, MJN, HST, RL, PF, GGG, THO The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Pinnacle Foods ( PF ) has declared a quarterly cash dividend of $0.235 per share, payable on July 10, 2015 to all common stockholders of record at the close of business on June 24, 2015."
2015-06-11,48.70000076293945,49.060001373291016,-0.49070063221334415,3 Things AbbVie Inc.'s Management Wants You to Know,"On AbbVie's most recent quarterly investor conference call, CEO Rick Gonzalez had a lot of great information to share with investors. Humira will drive cash flow for years to come Blockbuster drug Humira was responsible for producing 63% of AbbVie's revenue in 2014. Hepatitis C drug Viekira Pak will be a big contributor to revenue for the year AbbVie recently launched a hepatitis C regimen, Viekira Pak, in the United States following FDA approval in mid-December."
2015-06-10,48.36000061035156,48.5,0.7392209542335816,,
2015-06-09,48.52000045776367,48.18000030517578,0.28949418503206203,,
2015-06-08,48.369998931884766,48.43999862670898,-0.700742269950839,,
2015-06-05,48.59000015258789,48.45000076293945,0.14471717256555264,,
2015-06-04,48.97999954223633,48.68000030517578,-0.2881238715966153,,
2015-06-03,48.959999084472656,48.86000061035156,-0.6124933439451182,,
2015-06-02,48.650001525878906,48.93999862670898,-0.20424525324962192,,
2015-06-01,48.77000045776367,48.93999862670898,0.5960885749937949,"Noteworthy ETF Inflows: UPRO, ABT, ACN, ADT","Among the largest underlying components of UPRO, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.3%, Accenture plc (Symbol: ACN) is down about 0.1%, and ADT Corp (Symbol: ADT) is higher by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $43.3 million dollar inflow -- that's a 5.6% increase week over week in outstanding units (from 10,700,000 to 11,300,000). For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $45.74 per share, with $73.66 as the 52 week high point - that compares with a last trade of $70.78."
2015-05-29,49.18000030517578,48.59999847412109,0.34857118587179237,,
2015-05-28,48.880001068115234,49.2599983215332,-1.1793449114591694,,
2015-05-27,48.869998931884766,49.0099983215332,0.7774084392683117,,
2015-05-26,49.09999847412109,48.59999847412109,0.28647307695580126,,
2015-05-22,49.09999847412109,49.02999877929688,-1.0183299705468072,,
2015-05-21,49.060001373291016,49.34000015258789,-0.1425655743372354,,
2015-05-20,49.08000183105469,49.13999938964844,0.5707272145518334,,
2015-05-19,48.77999877929688,49.0099983215332,0.12224440985205379,,
2015-05-18,48.77999877929688,48.84000015258789,0.4715037884214483,,
2015-05-15,48.560001373291016,48.709999084472656,0.12300404836515534,,
2015-05-14,47.380001068115234,48.66999816894531,0.308891488755481,,
2015-05-13,47.20000076293945,47.02999877929688,2.7226616119647837,,
2015-05-12,47.02999877929688,47.130001068115234,-0.3601736883361522,5 Largest Markets for Pharmaceuticals,"4: Germany, total pharmaceutical sales in 2013: $45.8 billion Germany is the leading pharmaceutical market in Europe, but its growth has also slowed to a crawl. It also has a stake in one of China's top drug distributors, Shanghai Pharmaceuticals , as well as a joint venture to develop generic drugs with Zhejiang Hisun Pharmaceuticals. 2: Japan, total pharmaceutical sales in 2013: $94 billion Driven by the needs of a rapidly aging population, the world's third-largest economy is the world's second-largest drug market."
2015-05-11,47.27999877929688,47.33000183105469,0.21263510825854917,,
2015-05-08,47.09999847412109,47.56999969482422,0.10575941846195835,,
2015-05-07,46.43999862670898,46.5,0.9978794818037466,,
2015-05-06,46.84999847412109,46.540000915527344,0.12920192735861585,,
2015-05-05,47.02000045776367,46.84999847412109,-0.661681043095399,,
2015-05-04,46.77999877929688,47.0,-0.3615524925298368,Can Mylan (MYL) Specialty Segment Secure Earnings Beat? - Analyst Blog,Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. We remain positive on Mylan's deal with Abbott ABT . Specialty Segment Could Boost Sales The company expects adjusted earnings per share to be flat in the first quarter with growth expected in the following three quarters of 2015.
2015-05-01,46.709999084472656,46.68999862670898,0.47028906892678757,,
2015-04-30,46.93000030517578,46.41999816894531,-0.04281836470925459,,
2015-04-29,47.27999877929688,47.16999816894531,-1.0867294543235322,,
2015-04-28,47.619998931884766,47.59000015258789,-0.232657811319016,,
2015-04-27,48.27999877929688,47.4900016784668,-0.06299617801290797,,
2015-04-24,48.36000061035156,48.31999969482422,-1.636282354606949,,
2015-04-23,48.34999847412109,48.459999084472656,-0.08271487804485567,"Company News for April 23, 2015 - Corporate Summary | ABT Dividend Yield Pushes Past 2%","Brands, Inc. ( YUM ) gained almost 4% after the company reported first quarter earnings per share of $0.80, beating the Zacks Consensus Estimate of $0.72 • Angie's List, Inc.'s ( ANGI ) shares advanced 5% after the company posted first quarter earnings per share of $0.07, in contrast to the Zacks Consensus Estimate of a loss of $0.01 • Shares of Abbott Laboratories ( ABT ) increased 2.6% after the company reported first quarter earnings per share of $0.47 that came ahead of the Zacks Consensus Estimate of $0.42 • Chipotle Mexican Grill, Inc.'s ( CMG ) shares plunged 7.4% after the company posted first quarter revenues of $1.09 billion that lagged the Zacks Consensus Estimate of $1.10 billion Want the latest recommendations from Zacks Investment Research? BRANDS INC (YUM): Free Stock Analysis Report ANGIES LIST INC (ANGI): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report CHIPOTLE MEXICN (CMG): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Looking at the universe of stocks we cover at Dividend Channel , in trading on Thursday, shares of Abbott Laboratories (Symbol: ABT) were yielding above the 2% mark based on its quarterly dividend (annualized to $0.96), with the stock changing hands as low as $47.83 on the day. Abbott Laboratories (Symbol: ABT) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index. In the case of Abbott Laboratories, looking at the history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2% annual yield."
2015-04-22,47.25,48.34999847412109,0.2275090254872427,"Abbott Labs (ABT) Beats On Earnings in Q1 - Tale of the Tape | Abbott Labs (ABT) Beats on Q1 Earnings, View Reiterated - Analyst Blog","Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ), discovers, develops, manufactures and sells a diversified line of healthcare products. Abbott Labs reports its diversified business in four segments - namely Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT reported first-quarter 2015 earnings of 47 cents per share, up 38.2% from the year-ago quarter and beat the Zacks Consensus Estimate of 42 cents. Abbott Laboratories - Earnings Surprise | FindTheCompany Abbott Labs generated sales of $4.9 billion in the first quarter of 2015, up 3% year over year (on a reported basis)."
2015-04-21,46.93999862670898,47.119998931884766,2.3280390986689667,"Pre-Market Earnings Report for April 22, 2015 : KO, BA, MCD, ABT, TMO, EMC, BK, TEL, TROW, STJ, APH, NLSN","Zacks Investment Research reports that the 2015 Price to Earnings ratio for ABT is 21.69 vs. an industry ratio of 21.10, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories ( ABT ) is reporting for the quarter ending March 31, 2015. In the past year ABT has beat the expectations every quarter."
2015-04-20,46.41999816894531,46.630001068115234,0.3834689187088466,,
2015-04-17,46.290000915527344,46.25,0.45239747404904573,,
2015-04-16,46.61000061035156,46.52000045776367,-0.08641372809721849,"Notable ETF Outflow Detected - SSO, ABT, ABBV, ACN","Among the largest underlying components of SSO, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.4%, AbbVie Inc. (Symbol: ABBV) is up about 1.1%, and Accenture plc (Symbol: ACN) is lower by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares Ultra S&P500 (Symbol: SSO) where we have detected an approximate $60.4 million dollar outflow -- that's a 2.9% decrease week over week (from 15,775,000 to 15,325,000). For a complete list of holdings, visit the SSO Holdings page » The chart below shows the one year price performance of SSO, versus its 200 day moving average: Looking at the chart above, SSO's low point in its 52 week range is $99.04 per share, with $136.10 as the 52 week high point - that compares with a last trade of $133.61."
2015-04-15,46.810001373291016,46.83000183105469,-0.19309193608528424,"Abbott Labs, Sekisui Medical to Offer Coagulation Tests - Analyst Blog","Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT announced that it has entered into an agreement with Sekisui Medical to offer coagulation testing solutions for laboratories on a worldwide basis. Abbott Labs is a diversified company with presence in diagnostics, nutrition, branded generics and medical devices, after having separated its pharmaceutical business into a new company called AbbVie ABBV in Jan 2013."
2015-04-14,46.5099983215332,46.70000076293945,0.04272688993144058,,
2015-04-13,46.77999877929688,46.52999877929688,0.408519561950366,,
2015-04-10,46.97999954223633,47.150001525878906,-0.5344164312176957,"Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for April 13, 2015","Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. The previous trading day's last sale of ABT was $47, representing a -1.84% decrease from the 52 week high of $47.88 and a 28.24% increase over the 52 week low of $36.65. The following ETF(s) have ABT as a top-10 holding: iShares U.S. Medical Devices ETF ( IHI ) SPDR S&P Health Care Equipment ( XHE ) Direxion S&P 500 Volatility Response Shares ( VSPY )."
2015-04-09,46.5,47.0,0.36186033482129265,Bulls coming back to Abbott Labs,"ABT pulled back later that month, only to find support at $45.50 by last week. optionMONSTER's Heat Seeker system detected heavy activity in the April 46 calls yesterday, with large blocks mostly purchased for $0.55 to $0.75. Earnings are due on April 22, after the most recent contracts expire, so the call buyers are looking for a quick move higher before the news."
2015-04-08,46.209999084472656,46.61000061035156,1.0752688172043012,"SSO, ABT, ABBV, ACN: ETF Outflow Alert","Among the largest underlying components of SSO, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.1%, AbbVie Inc. (Symbol: ABBV) is trading flat, and Accenture plc (Symbol: ACN) is higher by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares Ultra S&P500 (Symbol: SSO) where we have detected an approximate $45.6 million dollar outflow -- that's a 2.2% decrease week over week (from 16,125,000 to 15,775,000). For a complete list of holdings, visit the SSO Holdings page » The chart below shows the one year price performance of SSO, versus its 200 day moving average: Looking at the chart above, SSO's low point in its 52 week range is $98.84 per share, with $136.10 as the 52 week high point - that compares with a last trade of $131.47."
2015-04-07,46.29999923706055,46.18999862670898,0.8656168227739991,,
2015-04-06,45.79999923706055,46.29999923706055,-0.2375823156893711,,
2015-04-02,46.11000061035156,46.130001068115234,1.0917030749542216,Is AbbVie Inc. Stock About to Crash?,"Oddly enough, AbbVie's own experimental drug ABT-199 might hurt Imbruvica's pricing structure, if approved. Source: Johnson & Johnson In a surprisingly rich deal, AbbVie's management recently decided to buyout Pharmacyclics for $21 billion, mainly for its top-notch cancer drug Imbruvica, as a means to smooth out the company's transition following Humira's patent expiration. The Pharmacyclics buyout isn't ideal Once you get past the impressive potential of Imbruvica, the Pharmacyclics buyout ends up looking like an accounting maneuver -- i.e., actual net profits probably won't even cover the cost of the acquisition before Pharmacyclics' orally administered BTK-inhibitor Imbruvica loses patent protection in 2026, especially when taking the interest on AbbVie's new debt into account."
2015-04-01,46.33000183105469,45.88999938964844,0.04337553133578105,,
2015-03-31,46.83000183105469,46.33000183105469,-0.9497138441970001,The Single Worst Practice of the Drug Industry,"By keeping the generic drug off the market, companies can continue to control the market for their branded drug. A generic version should have gone on market in 2005, but the FTC said brand-name drug manufacturer Cephalon paid more than $200 million to four different generic-drug manufacturers, which therefore agreed to kept their generic versions off the market until 2012. Looking back to 2005, annual reports by the FTC show as many as 142 generics have been delayed by pay-for-delay tactics, with drug companies raking in an estimated $98 billion in additional branded-drug sales when generic versions were delayed."
2015-03-30,47.0,47.08000183105469,-1.0676916089045114,,
2015-03-27,46.61000061035156,46.77999877929688,0.17021666181848405,,
2015-03-26,46.40999984741211,46.5,0.36472466577819546,,
2015-03-25,47.040000915527344,46.52999877929688,0.1939240527554304,,
2015-03-24,47.310001373291016,47.0,-1.0841881936743671,,
2015-03-23,47.470001220703125,47.470001220703125,-0.6552554730341389,,
2015-03-20,47.65999984741211,47.470001220703125,0.0,,
2015-03-19,47.459999084472656,47.43999862670898,-0.3986542746900599,,
2015-03-18,46.869998931884766,47.38999938964844,-0.04214171544352699,,
2015-03-17,47.43000030517578,47.09000015258789,1.1094526767951887,,
2015-03-16,47.119998931884766,47.83000183105469,-0.7168461952356096,,
2015-03-13,47.209999084472656,46.880001068115234,1.506797358370658,"Noteworthy ETF Inflows: VIG, XOM, MMM, ABT","Among the largest underlying components of VIG, in trading today Exxon Mobil Corp. (Symbol: XOM) is down about 1.7%, 3M Co (Symbol: MMM) is off about 0.5%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $1.6 billion dollar inflow -- that's a 7.5% increase week over week in outstanding units (from 255,720,767 to 275,020,766). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $72.32 per share, with $83.28 as the 52 week high point - that compares with a last trade of $80.74."
2015-03-12,46.470001220703125,47.25,-0.6990002600232162,,
2015-03-11,46.38999938964844,46.29999923706055,1.6784995885676306,,
2015-03-10,46.41999816894531,46.16999816894531,-0.19400766064242167,,
2015-03-09,46.5,46.83000183105469,-0.5385609863449939,Why AbbVie Inc.'s $21 Billion Deal Had To Happen,If you hope to outsmart Wall Street and realize multi-bagger returns you will need to get in early -- check out The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson.
2015-03-06,47.18000030517578,46.5,0.7096813571068549,,
2015-03-05,46.880001068115234,47.43999862670898,-1.441289319154971,"VIG, ABT, OXY, CAT: ETF Outflow Alert","Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.8%, Occidental Petroleum Corp (Symbol: OXY) is down about 1.3%, and Caterpillar Inc. (Symbol: CAT) is lower by about 1.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $41.0 million dollar outflow -- that's a 0.2% decrease week over week (from 256,219,629 to 255,720,767). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $72.32 per share, with $83.28 as the 52 week high point - that compares with a last trade of $82.44."
2015-03-04,46.869998931884766,47.0099983215332,1.194534014152609,,
2015-03-03,47.13999938964844,47.09000015258789,0.298697232427711,"Mylan Beats on Q4 Earnings, 2015 Guidance Encouraging - Analyst Blog",Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALNYLAM PHARMA (ALNY): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report To read this article on Zacks.com click here. The guidance includes contributions from the business acquired from Abbott Laboratories ABT and the pending Famy Care acquisition. The company expects adjusted earnings per share to be flat in the first quarter with growth expected in the following three quarters of 2015.
2015-03-02,47.34000015258789,47.220001220703125,-0.10606541728451167,These Stocks Just Raised Their Dividends,"These are the Dividend Aristocrats, the companies that have raised their distributions at least once annually for a minimum of 25 years in a row. With its latest quarterly dividend raise -- by 8% to $0.33 per share -- it's now lifted its payout for a hard-to-believe 53 consecutive years. The Motley Fool recommends Coca-Cola, owns and recommends shares of Apple and Bank of America, and has the following options: long January 2016 $37 calls on Coca-Cola and short January 2016 $37 puts on Coca-Cola."
2015-02-27,47.47999954223633,47.369998931884766,-0.2534831675073532,Will Mylan (MYL) Beat Earnings on New Product Launches? - Analyst Blog,"Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report AMARIN CORP PLC (AMRN): Free Stock Analysis Report ARATANA THERAP (PETX): Free Stock Analysis Report To read this article on Zacks.com click here. Mylan is set to strengthen its Generics segment further with the impending acquisition of Abbott Laboratories' ( ABT ) branded specialty and generics business that the company had announced last year. Specialty Segment and Product Launches to Boost Sales Mylan expects its fourth quarter adjusted earnings to be in the band of $1.03 to $1.09 per share, much above the year-ago earnings of 78 cents."
2015-02-26,47.31999969482422,47.61000061035156,-0.2316777830920371,,
2015-02-25,47.54999923706055,47.400001525878906,0.6128506284818586,,
2015-02-24,47.27000045776367,47.470001220703125,-0.31545260481251947,,
2015-02-23,47.33000183105469,47.31999969482422,0.4231029426753577,,
2015-02-20,46.52999877929688,47.47999954223633,-0.021132761131452224,"Daily Dividend Report: ABT, STT, APA, IRM, ABBV, CL, CP, LO","Abbott ( ABT ) declared a quarterly common dividend of 24 cents per share. VIDEO: Daily Dividend Report: ABT, STT, APA, IRM, ABBV, CL, CP, LO The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. State Street ( STT ) declared a quarterly cash dividend of $0.30 per share of common stock, payable April 16, 2015 to common shareholders of record as of April 1, 2015."
2015-02-19,46.36000061035156,46.61000061035156,2.0416952242907445,,
2015-02-18,46.2599983215332,46.40999984741211,0.53925797391853,,
2015-02-17,46.04999923706055,46.40999984741211,0.32425752555439075,,
2015-02-13,45.04999923706055,46.09000015258789,0.7817602960171992,,
2015-02-12,45.040000915527344,45.220001220703125,2.308548131276733,,
2015-02-11,44.880001068115234,44.93000030517578,0.39964542965567956,"Zoetis Beats on Q4 Earnings, Provides In-Line 2015 Outlook - Analyst Blog","Click to get this free report ZOETIS INC (ZTS): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ALNYLAM PHARMA (ALNY): Free Stock Analysis Report ACHILLION PHARM (ACHN): Free Stock Analysis Report To read this article on Zacks.com click here. 2015 Outlook Updated The company updated its 2015 guidance to incorporate the expected impact of foreign currency, acquisition of certain assets from Abbott Laboratories ( ABT ) and other changes in its operating assumptions. Sales improved in the U.S. by 14% driven by strong sales of livestock products and improvement in companion animal products sales."
2015-02-10,44.68000030517578,44.91999816894531,0.11140649703787235,Mylan Faces Patent Infringement Lawsuit for Nexavar - Analyst Blog,"Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, we remain positive on Mylan's deal with Abbott Laboratories ( ABT ) to buy the latter's branded specialty and generics business in the developed ex-U.S. markets. Mylan Inc. ( MYL ) announced that it is looking to bring its generic version of Bayer's ( BAYRY ) cancer drug, Nexavar (sorafenib) to market."
2015-02-09,45.209999084472656,44.52000045776367,0.5371483037830902,Will Zoetis (ZTS) Earnings Disappoint Expectation in Q4? - Analyst Blog,"An update on the company's $500 million share repurchase program as well as Abbott Laboratories' (ABT) deal is also expected on the call. As it is, we caution against stocks with Zacks Ranks #4 and 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions. Stocks that Warrant a Look Here are some companies you may want to consider as our model shows that these have the right combination of elements: Acorda Therapeutics, Inc. ( ACOR ) has an Earnings ESP of +106.67% and a Zacks Rank #3 (Hold)."
2015-02-06,45.59000015258789,45.5,-1.5262080085862333,,
2015-02-05,45.2599983215332,45.650001525878906,-0.1974120471302122,,
2015-02-04,45.54999923706055,45.16999816894531,0.8616951365642287,5 Things AbbVie Inc.'s Management Wants You to Know,"Cancer drug ABT-199 was one mentioned. Source: AbbVie By most measures, AbbVie performed well in the fourth quarter of 2014. Under-promised and over-delivered Chairman and CEO Rick Gonzalez spoke only a few seconds before noting that sales and earnings topped the company's projections for the year."
2015-02-03,45.40999984741211,45.83000183105469,-0.8342504379364657,"Should You Buy AbbVie Inc. Stock on This Dip? | Mylan to Buy Famy Care Businesses, Boost Women's Health - Analyst Blog","If ABT-199 can gain a regulatory approval as a treatment for relapsed chronic lymphocytic leukemia, its sales should exceed $2 billion in short order, according to Goldman Sachs. Shares of the Illinois-based drugmaker AbbVie have slumped in a big way of late, perhaps reflecting the dampened expectations for the company's new hepatitis C therapy Viekira Pak. Putting all this doom and gloom aside for the moment, it's important to remember AbbVie has richly rewarded its shareholders, through the market-trouncing performance of its stock, billions in share buybacks, and multiple increases to the dividend, since the company was spun off from Abbott Laboratories in January 2013. | Click to get this free report MYLAN INC (MYL): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report To read this article on Zacks.com click here. The Famy Care acquisition will also complement Mylan's pending acquisition of Abbott's ( ABT ) ex-U.S. developed markets specialty and branded generics business including the women's health care portfolio and sales and marketing capabilities. Mylan, Inc. ( MYL ) announced its intention to acquire certain female health care businesses of Famy Care Limited, a privately held specialty women's health care company focused on generic oral and injectable contraceptives, intra-uterine devices, tubal rings and hormone-replacement therapies."
2015-02-02,44.93000030517578,45.22999954223633,0.9249107796826248,,
2015-01-30,45.400001525878906,44.7599983215332,0.667703616788064,"Best Dividend Stocks for Bear Markets | Company News for January 30, 2015 - Corporate Summary | Zacks Rank #5 Additions for Friday - Tale of the Tape","Share price: $43.41 Market capitalization: $65.4 billion Yield: 2.2% Headquarters: Abbott Park, Ill. Down market total returns: 2000-02 bear market: 26.0% 2007-09 bear market: -11.6% 2011 correction: -2.8% Health care needs are growing steadily, and Abbott Labs ( ABT ), a diagnostics, medical-device and nutritional-formula company, is profiting. Share price: $107.10 Market capitalization: $13.9 billion Yield: 2.8% Headquarters: Oakland, Calif. Down market total returns: 2000-02 bear market: 28.6% 2007-09 bear market: -22.9% 2011 correction: -6.6% During a market downturn, stocks of companies that make essential consumer goods tend to do better than most. Share price: $93.66 Market capitalization: $19.5 billion Yield: 0.9% Headquarters: Dublin, Calif. Down market total returns: 2000-02 bear market: 79.2% 2007-09 bear market: 10.1% 2011 correction: 4.3% A bear market killer, Ross ( ROST ) is the only stock on our list that was in the black in each of the past three downturns, a remarkable accomplishment. | • Shares of Abbott Laboratories ( ABT ) climbed 4.3% after announcing fourth quarter adjusted earnings per share of $0.71, beating the Zacks Consensus Estimate of $0.68 • Baxter International Inc.'s ( BAX ) shares rose 1.7% after declaring fourth quarter adjusted earnings per share of $1.34, outpacing the Zacks Consensus Estimate by 3 cents • Shares of Time Warner Cable Inc. ( TWC ) declined 1% after reporting fourth quarter adjusted earnings per share of $2.03, missing the Zacks Consensus Estimate of $2.09 • Northrop Grumman Corporation's ( NOC ) shares gained 3.8% after posting fourth quarter adjusted earnings of $2.26 per share, higher than the Zacks Consensus Estimate of $2.22 Want the latest recommendations from Zacks Investment Research? Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report BAXTER INTL (BAX): Free Stock Analysis Report TIME WARNER CAB (TWC): Free Stock Analysis Report NORTHROP GRUMMN (NOC): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: Abbott Laboratories ( ABT ) Antero Resources Corp ( AR ) Blackhawk Network Holdings Inc ( HAWK ) Bristow Group Inc ( BRS ) Cameron International Corporation ( CAM ) View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ANTERO RESOURCE (AR): Free Stock Analysis Report BLACKHAWK NETWK (HAWK): Free Stock Analysis Report BRISTOW GROUP (BRS): Free Stock Analysis Report CAMERON INTL (CAM): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2015-01-29,43.790000915527344,45.2599983215332,-1.4096986406066276,"Abbott Labs (ABT) Earnings up Y/Y, Stent Sales Decline - Tale of the Tape | Health Care Sector Update for 01/29/2015: ABT, CAH, ALXN | Abbott Labs' (ABT) Q4 Earnings Up, Guides Below Estimates - Analyst Blog","Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ), discovers, develops, manufactures and sells a diversified line of healthcare products. The sale of branded generics business is expected to positively impact the top line and bottom line as Abbott Labs will now focus primarily on the branded generics pharmaceuticals business in emerging markets. | In health-care stocks news, Abbott Laboratories ( ABT ), a healthcare product developer, reported Q4 results that exceeded Street projections on EPS but missed on total revenues. ABT: flat Shares in the company were down 0.02% at $43.40 during pre-market trading. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) reported fourth-quarter 2014 earnings of 62 cents per share, up 29.2% from the year-ago quarter. Abbott Labs generated sales of $5.4 billion in the fourth quarter of 2014, up 5.6% year over year (on a reported basis)."
2015-01-28,43.93999862670898,43.40999984741211,3.356924812222642,"Zacks Rank #5 Additions for Wednesday - Tale of the Tape | Pre-Market Earnings Report for January 29, 2015 : CELG, COP, EPD, ABT, OXY, CL, F, EMC, DOW, TMO, TWC, PSX","Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: Abbott Laboratories ( ABT ) Baytex Energy Corp ( BTE ) BRS Resources Ltd ( BRS ) Cameron International Corporation ( CAM ) Chart Industries, Inc. ( GTLS ) View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report BAYTEX ENERGY (BTE): Free Stock Analysis Report BRISTOW GROUP (BRS): Free Stock Analysis Report CAMERON INTL (CAM): Free Stock Analysis Report CHART INDUSTRIE (GTLS): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is reporting for the quarter ending December 31, 2014. In the past year ABT has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ABT is 19.33 vs. an industry ratio of 22.60."
2015-01-27,43.880001068115234,43.68000030517578,-1.2061875190289777,3 Stocks to Sell as Greece Concerns Intensify Euro Slide - Analyst Blog,"Click to get this free report PHILIP MORRIS (PM): Free Stock Analysis Report COCA COLA CO (KO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) manufactures and sells health care products worldwide. A slew of incidents -- including Greece's anti-austerity party winning general elections, the European Central Bank's (ECB) aggressive stimulus measures and the Swiss National Bank's (SNB) surprise decision to drop its long-standing exchange rate of the Swiss franc against the euro -- have dragged the currency lower."
2015-01-26,43.7400016784668,44.150001525878906,-0.4557902417299182,,
2015-01-23,44.47999954223633,43.86000061035156,0.9373567253746866,"Notable ETF Outflow Detected - VIG, QCOM, MDT, ABT","Among the largest underlying components of VIG, in trading today Qualcomm, Inc. (Symbol: QCOM) is off about 0.2%, Medtronic, Inc. (Symbol: MDT) is up about 1.8%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $57.0 million dollar outflow -- that's a 0.3% decrease week over week (from 262,818,849 to 262,118,903). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $69.60 per share, with $82.53 as the 52 week high point - that compares with a last trade of $81.25."
2015-01-22,44.34000015258789,44.4900016784668,-1.3938825050931956,,
2015-01-21,43.959999084472656,44.060001373291016,0.33829843338453724,,
2015-01-20,44.66999816894531,44.220001220703125,0.2274847381734403,Can AbbVie Inc. Overcome Humira’s Looming Patent Expiration? | March 20th Options Now Available For Abbott Laboratories (ABT),"Humira's patent expiration should be a nonevent Humira's patent expiration would be a seriously detrimental event if it was accompanied by the typical loss of revenue that has befallen so many former blockbusters. No biosimilar for Humira currently exists in Europe because the drug's patent won't expire in most EU countries until 2018, making it impossible for a similar scenario to play out. Because Humira is the world's best-selling drug, multiple companies are lining up to develop biosimilars once the drug goes off of patent protection. | Below is a chart showing ABT's trailing twelve month trading history, with the $45.00 strike highlighted in red: Considering the fact that the $45.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the March 20th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ABT options chain for the new March 20th contracts and identified one put and one call contract of particular interest."
2015-01-16,43.79999923706055,44.4900016784668,-1.007380717904364,,
2015-01-15,44.5,43.95000076293945,1.5753480671808262,,
2015-01-14,44.290000915527344,44.27999877929688,-1.235953341709094,"DexCom Declares Preliminary Q4 '14 Revenues, Guides '15 - Analyst Blog","Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Nevertheless, the company continues to face stiff competition from Johnson and Johnson ( JNJ ), Abbott Laboratories ( ABT ) and Medtronic ( MDT ), which remains a potent headwind. For 2014, revenues are estimated to soar 64% on a year-over-year basis to $257 million, in line with the current Zacks Consensus Estimate."
2015-01-13,45.34000015258789,44.61000061035156,-0.022583282961629068,,
2015-01-12,45.380001068115234,45.58000183105469,-1.6100563294653223,"Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for January 13, 2015 | Alere (ALR) Closes Alere Health Sale to Optum for $600M - Analyst Blog","Shareholders who purchased ABT stock prior to the ex-dividend date are eligible for the cash dividend payment. The previous trading day's last sale of ABT was $45.2, representing a -2.8% decrease from the 52 week high of $46.50 and a 26.79% increase over the 52 week low of $35.65. The following ETF(s) have ABT as a top-10 holding: iShares Dow Jones US Medical Devices Index Fund ( IHI ) Guggenheim BulletShares 2015 Corporate Bond ETF ( BSCF ) Schwab U.S. Large-Cap Value ETF ( SCHV ) iShares iBonds Mar 2020 Corporate Term ETF ( IBDC ) Schwab Fundamental U.S. Large Company Index ( FNDX ). | Click to get this free report UNITEDHEALTH GP (UNH): Free Stock Analysis Report BECTON DICKINSO (BDX): Free Stock Analysis Report ALERE INC (ALR): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. However, Alere faces significant competition from large diagnostic companies like Becton, Dickinson ( BDX ) and Abbott Laboratories ( ABT ) among others. Alere Health, a subsidiary of Waltham, MA-based Alere, is a $3 billion technology company that provides leading condition management, case management, and wellbeing and wellness services to insurers, employers and health care payers."
2015-01-09,45.75,45.20000076293945,0.4407244562186162,,
2015-01-08,45.18999862670898,45.68000030517578,-1.202184124722507,,
2015-01-07,44.72999954223633,44.7599983215332,1.0843144354007452,Alere's (ALR) Influenza Test Gets CLIA Waiver from the FDA - Analyst Blog,"Click to get this free report BECTON DICKINSO (BDX): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ALERE INC (ALR): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. As such, Alere counters significant competition from large diagnostic companies like Becton, Dickinson ( BDX ), Abbott Laboratories ( ABT ) and Johnson & Johnson ( JNJ ) among others. Global rapid diagnostic tests company, Alere Inc. ( ALR ), has received a waiver from the U.S. Food and Drug Administration (FDA) which makes way for the company's i Influenza A & B test to be used in a greater variety of health care settings."
2015-01-06,44.9900016784668,44.400001525878906,0.06706635279204204,,
2015-01-05,44.79999923706055,44.90999984741211,-1.3114028241307616,,
2015-01-02,45.25,44.900001525878906,0.24553708085906642,"IWV, USB, FOXA, ABT: Large Outflows Detected at ETF","Among the largest underlying components of IWV, in trading today U.S. Bancorp (Symbol: USB) is off about 0.3%, Twenty-First Century Fox Inc (Symbol: FOXA) is down about 0.7%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 3000 ETF (Symbol: IWV) where we have detected an approximate $55.0 million dollar outflow -- that's a 0.9% decrease week over week (from 51,550,000 to 51,100,000). For a complete list of holdings, visit the IWV Holdings page » The chart below shows the one year price performance of IWV, versus its 200 day moving average: Looking at the chart above, IWV's low point in its 52 week range is $104.30 per share, with $124.27 as the 52 week high point - that compares with a last trade of $122.60."
2014-12-31,45.70000076293945,45.02000045776367,-0.7734772908753452,,
2014-12-30,45.61000061035156,45.68999862670898,-1.4879656319989154,"Billionaires Are Gobbling Up These Stocks Right Now | Omnicare (OCR) Faces Another Kickback Allegation - Analyst Blog | Health Care Sector Update for 12/30/2014: NDRM,BGMD,CTSO | Health Care Sector Update for 12/30/2014: XNPT,BGMD,CTSO","AbbVie is also considered a ""dividend aristocrat"" because of Abbott's long history of raising its dividend, a tradition AbbVie extended last quarter by raising its dividend 17%, from $0.42 to $0.49 per share, starting in the first quarter of 2015. Baker Brothers take out a big position in Celladon Billionaires Felix and Julian Baker snapped up 375,000 shares of the clinical-stage biotech Celladon Corp., through their Baker Bros. hedge fund, in the third quarter. George Soros likes Kite Pharma Hedge-fund guru George Soros has never been afraid to dabble on the speculative side of investing, and he proved as much by gobbling up roughly 660,000 shares of Kite Pharma through its IPO . | The U.S. Justice Department has alleged that Omnicare received unauthorized money from Abbott Laboratories ( ABT ) for recommending the latter's prescription drug, Depakote. Click to get this free report OMNICARE INC (OCR): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report AMN HLTHCR SVCS (AHS): Free Stock Analysis Report CATAMARAN CORP (CTRX): Free Stock Analysis Report To read this article on Zacks.com click here. The civil complaint alleges that Omnicare's consultant pharmacists recommended the drug in return for tens of millions of dollars in kickbacks between 1998 and 2008. | In other sector news, (+) BGMD, FDA authorizes first automated version of galectin-3 testing for chronic heart failure with 510(k) clearance for the company's BGM Galectin-3 blood test for use with the Abbott ( ABT ) ARCHITECT immunoassay analyzer. Health care stocks were narrowly lower this afternoon with the NYSE Health Care Sector Index declining about 0.2% and shares of health care companies in the S&P 500 also down about 0.2% as a group. In company news, NeuroDerm Ltd. ( NDRM ) rallied Tuesday, with shares of the recently minted biotech company more than doubling today after Phase IIa testing of its experimental drug combination for Parkinson's disease indicates it could be an effective alternative to current treatments requiring surgery. | In other sector news, (+) BGMD, (+62.5%) FDA authorizes first automated version of galectin-3 testing for chronic heart failure with 510(k) clearance for the company's BGM Galectin-3 blood test for use with the Abbott ( ABT ) ARCHITECT immunoassay analyzer. Health care stocks were narrowly lower this afternoon with the NYSE Health Care Sector Index declining about 0.2% and shares of health care companies in the S&P 500 also down about 0.2% as a group. In company news, shares of XenoPort Inc. ( XNPT ) sprang sharply higher Tuesday after a RBC Capital Markets analyst late yesterday named the biotech company working to develop treatments for neurological disorders as his sleeper pick for the upcoming year."
2014-12-29,45.59000015258789,45.59999847412109,0.17539578006332798,Novartis' Cosentyx Approved in Japan for Psoriatic Arthritis - Analyst Blog,"Click to get this free report ALLERGAN INC (AGN): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader health care sector include AbbVie ( ABBV ), Allergan ( AGN ) and Abbott Inc ( ABT ). Novartis ( NVS ) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Cosentyx (secukinumab) for the treatment of both psoriasis vulgaris and psoriatic arthritis (PsA) in adults who have failed to respond adequately to systemic therapies (except for biologics)."
2014-12-26,45.810001373291016,45.84999847412109,0.021930953059293795,,
2014-12-24,45.7400016784668,45.70000076293945,0.08731084835415626,,
2014-12-23,46.130001068115234,45.720001220703125,-0.08745280730100004,,
2014-12-22,45.93000030517578,46.369998931884766,-0.8887921914562856,,
2014-12-19,45.90999984741211,46.04999923706055,0.957976537743244,,
2014-12-18,44.709999084472656,45.77000045776367,0.3049431281066081,Does China Have an Unfair Competitive Advantage Over U.S. Companies?,"Best Buy is taking a fast boat out of China, selling its stake in a local appliance retailer and essentially ending its presence in the country. Best Buy operated its Chinese stores the way it does here, buying all its products from suppliers and distributors and selling them itself. The Motley Fool recommends Amazon.com, Apple, Facebook, Ford, Google (C shares), Home Depot, McDonald's, Twitter, and Yahoo."
2014-12-17,43.470001220703125,44.2599983215332,2.3708373853649745,Better Big Pharma Spinoff: Zoetis Inc. or AbbVie Inc.?,"We're approaching two years after Abbott Labs spun off its pharmaceutical division AbbVie and a little less since Zoetis , Pfizer 's animal health division, separated from its patent company. Seems like a good time to see which spinoff has performed better. Let's take a look at a couple of metrics."
2014-12-16,43.22999954223633,43.400001525878906,1.8173385752145603,,
2014-12-15,44.15999984741211,43.459999084472656,0.3932500241562199,"Daily Dividend Report: GE, PFE, ABT, BXMT, AES, ZMH","Abbott ( ABT ) increased the company's quarterly common dividend to $0.24 per share from $0.22 per share. VIDEO: Daily Dividend Report: GE, PFE, ABT, BXMT, AES, ZMH The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. GE ( GE ) raised the Company's quarterly dividend 5%, or $0.01 per outstanding share of the Company's common stock, to $0.23 per outstanding share of the Company's common stock."
2014-12-12,44.119998931884766,43.68999862670898,-1.5851466606843185,,
2014-12-11,44.5099983215332,44.459999084472656,-0.9746154025063551,Diamond Hill Adds Two Companies to Portfolio in Third Quarter,"The company added to its existing stakes in 29 companies - Twenty-First Century Fox Inc ( FOX ), Abbott Laboratories ( ABT ), Juniper Networks Inc ( JNPR ), Alere Inc (ALR), Cimarex Energy Co (XEC), Praxair Inc (PX), International Business Machines Corp (IBM), Devon Energy Corp (DVN), TJX Companies (TJX), Willis Group Holdings PLC (WSH), United Technologies Corp (UTX), Pfizer Inc (PFE), Jarden Corp (JAH), Citigroup Inc (C), Boston Scientific Inc (BSX), Parker Hannifin Corp (PH), Whirlpool Corp (WHR), Kimberly-Clark Corp (KMB), Brown & Brown Inc (BRO), Post Holdings Inc (POST), Aircastle Ltd (AYR), Hub Group Inc (HUBG), Live Nation Entertainment Inc (LYV), Fortress Investment Group LLC (FIG), Aaron's Inc (AAN), Molson Coors Brewing C o (TAP), Contango Oil & Gas Co (MCF), State Bank Financial Corp (STBZ) and SunTrust Banks Inc (STI). Dodge & Cox Undervalued Stocks Dodge & Cox Top Growth Companies Dodge & Cox High Yield stocks IVA International Fund Undervalued Stocks IVA International Fund Top Growth Companies IVA International Fund High Yield stocks Diamond Hill Capital Undervalued Stocks Diamond Hill Capital Top Growth Companies Diamond Hill Capital High Yield stocks In the third quarter, Diamond Hill Capital (Trades, Portfolio) bought two stocks that are new to its portfolio - Goodyear Tire & Rubber Co ( GT ) and StrykerCorporation ( SYK ). Diamond Hill's purchase of 2,445,959 shares of Twenty-First Century Fox, a New York-based mass media company, for an average price of $33.42 per share had an impact of 0.63% on the firm's portfolio."
2014-12-10,45.33000183105469,44.369998931884766,-0.11233259704788187,,
2014-12-09,45.33000183105469,45.43999862670898,-2.117809089767658,,
2014-12-08,45.34999847412109,45.709999084472656,0.24265782309969627,,
2014-12-05,45.43000030517578,45.29999923706055,0.7938271719171136,,
2014-12-04,45.65999984741211,45.4900016784668,-0.2861568726435239,This Pet Food Supplier Is Still In the Hunt for Growth,"Data: American Pet Products Association The wave of consolidation washing over the pet supplies industry may claim yet another company in PetSmart, and Petco's acquisition of Drs. As much bite as bark these days Although a lot of the stocks gains PetSmart has made over the year can probably be attributed to the strategic moves it has been forced to undertake, its most recent quarterly performance was a reason for investors to purr with delight. That's why The Motley Fool's chief investment officer just published a brand-new research report that reveals his top stock for the year ahead."
2014-12-03,45.220001220703125,45.68000030517578,-0.37231311763779507,Bulls can't get enough of Abbott Labs | Abbott Labs attracts bullish trades,"We've also had a winning trade recently AbbVie , which was spun off from ABT two years ago. ABT is up 1.04 percent to $45.69 in afternoon trading and is in all-time record territory. Overall ABT calls outnumber puts by a bullish 19-to-1 ratio. | (See our Education section) ABT rose 2.03 percent to $45.22 yesterday and at one point hit an all-time high of $45.62 in the session. The cheap cost of the options lets traders position for profits from a rally at limited risk while also creating the possibility for significant leverage if the stock pushes higher. Overall option volume in Abbott was 8 times greater than its daily average for the last month, with calls accounting for a bullish three-quarters of the total."
2014-12-02,44.68000030517578,45.220001220703125,1.0172469527976358,,
2014-12-01,44.27000045776367,44.31999969482422,1.2085964902394808,,
2014-11-28,44.45000076293945,44.5099983215332,0.11294157791628949,,
2014-11-26,44.15999984741211,44.25,0.13497763231485352,,
2014-11-25,44.310001373291016,44.15999984741211,0.20380469406447443,,
2014-11-24,43.59000015258789,44.31999969482422,-0.33852746835914904,,
2014-11-21,44.150001525878906,43.810001373291016,1.674694975179964,,
2014-11-20,43.29999923706055,43.77999877929688,-0.7701022442515582,,
2014-11-19,43.790000915527344,43.43000030517578,1.1085439969834983,,
2014-11-18,43.79999923706055,43.70000076293945,-0.8221068801665888,"UPRO, ABT, ACT, ADT: ETF Outflow Alert | Zoetis to Buy Abbott's Animal Health Assets for $255 Million - Analyst Blog","Among the largest underlying components of UPRO, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.5%, Actavis plc (Symbol: ACT) is up about 5.4%, and ADT Corp (Symbol: ADT) is lower by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Proshares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $38.8 million dollar outflow -- that's a 4.0% decrease week over week (from 7,550,000 to 7,250,000). For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $79.47 per share, with $131.15 as the 52 week high point - that compares with a last trade of $130.64. | Click to get this free report VALEANT PHARMA (VRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. Zoetis Inc. ( ZTS ) was up 2.5% after the company announced that it has entered into an agreement with Abbott Laboratories ( ABT ) to purchase the latter's animal health assets. Abbott Animal Health - focused on the veterinary surgical suite - is a companion animal health business operating in nearly 20 countries."
2014-11-17,43.709999084472656,43.709999084472656,-0.22830702251812351,,
2014-11-14,44.59000015258789,43.810001373291016,0.0,,
2014-11-13,44.27999877929688,44.59000015258789,-1.749268393423869,,
2014-11-12,44.18999862670898,44.22999954223633,0.7000934549166015,,
2014-11-11,44.119998931884766,44.25,0.09052029140180559,DexCom Scales 52-Week High on Product Pipeline Strength - Analyst Blog,"Click to get this free report MEDTRONIC (MDT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. However, the company continues to face stiff competition from Johnson and Johnson ( JNJ ) Abbott Laboratories ( ABT ) and Medtronic ( MDT ), which remains a headwind. This week, FDA approved a new algorithm designed for DexCom's G4 Platinum Continuous Glucose Monitoring (CGM) system, following which shares of the company shot up around 14%."
2014-11-10,43.34999847412109,44.09000015258789,0.2946533800146691,"DexCom G4 Platinum Software Gains FDA Nod, Shares Surge - Analyst Blog","Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. However, DexCom continues to face stiff competition from Johnson and Johnson ( JNJ ) Abbott Laboratories ( ABT ) and Medtronic ( MDT ), which remains a headwind. The upside was driven by an impressive 60% rise in product revenues to $68 million and a $0.7 million increase in development grant and other revenues to $1.1 million."
2014-11-07,43.77000045776367,43.369998931884766,1.7070396874605827,,
2014-11-06,43.59999847412109,43.68999862670898,-0.9138714226537238,,
2014-11-05,43.93000030517578,43.65999984741211,0.20642237554505993,,
2014-11-04,43.02000045776367,43.61000061035156,-0.6146151966492491,,
2014-11-03,43.560001373291016,43.290000915527344,1.3714554772428307,,
2014-10-31,44.04999923706055,43.59000015258789,-0.6198357420833869,"Mylan Beats, Raises Earnings Guidance; Abbott Deal on Track - Analyst Blog","Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. We remain positive on Mylan's deal with Abbott Laboratories ( ABT ) to buy the latter's branded specialty and generics business in the developed ex-U.S. markets, which is expected to close in the first quarter of 2015. The company expects revenues in the range of $7.7 billion to $7.8 billion (old guidance: $7.8 billion to $8.0 billion)."
2014-10-30,42.70000076293945,43.4900016784668,-1.0442658171163954,,
2014-10-29,42.810001373291016,42.7400016784668,1.8501192070539914,,
2014-10-28,42.220001220703125,42.5,-0.1635124797447245,3 Generics Stocks to Buy Now - Analyst Blog,"Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. On the other hand, Mylan, Inc. ( MYL ) and Abbott Laboratories ( ABT ) have decided to continue with their $5.3 billion deal. Actavis plc ( ACT ) is a specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (OTC) pharmaceutical products."
2014-10-27,42.43000030517578,42.2400016784668,0.6631898891551286,"IYH, GILD, ABT, AGN: Large Inflows Detected at ETF","Among the largest underlying components of IYH, in trading today Gilead Sciences, Inc. (Symbol: GILD) is trading flat, Abbott Laboratories (Symbol: ABT) is down about 0.3%, and Allergan, Inc (Symbol: AGN) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $254.3 million dollar inflow -- that's a 9.2% increase week over week in outstanding units (from 20,150,000 to 22,000,000). The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $109.79 per share, with $137.81 as the 52 week high point - that compares with a last trade of $137.16."
2014-10-24,42.34000015258789,42.459999084472656,-0.4477931306679901,,
2014-10-23,42.0,42.43000030517578,0.2834174101377066,,
2014-10-22,42.5,41.59000015258789,1.0238102504185267,"Abbott Labs' (ABT) Earnings Up Y/Y in Q3, Guidance Updated - Analyst Blog | Amgen Gains as Third Point Suggests Split - Analyst Blog","Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report LANNETT INC (LCI): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) reported third-quarter 2014 earnings of 54 cents per share, up 22.7% from the year-ago quarter. Abbott Labs generated sales of $5.1 billion in the third quarter of 2014, up 5.8% year over year (on a reported basis). | Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report THERAVANCE INC (THRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report To read this article on Zacks.com click here. Last year, Abbott Laboratories ( ABT ) separated its research-based pharmaceuticals business by creating a new company. Third Point also discussed the company's position and even suggested that Amgen split into two, at an investor conference and in its third quarter letter to the investors."
2014-10-21,41.90999984741211,42.38999938964844,-2.1411761115579044,"Pre-Market Earnings Report for October 22, 2014 : BA, BIIB, USB, ABT, DOW, EMC, SPG, TMO, GD, NSC, NOC, BSX","Abbott Laboratories ( ABT ) is reporting for the quarter ending September 30, 2014. In the past year ABT has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ABT is 18.43 vs. an industry ratio of 33.30."
2014-10-20,40.84999847412109,41.459999084472656,1.1453102934477044,Will Abbott Labs (ABT) Miss on Earnings This Quarter? - Analyst Blog,"Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) is scheduled to report third-quarter 2014 results before the opening bell on Oct 22, 2014. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1, 2 or 3 to likely have earnings beat."
2014-10-17,40.34999847412109,40.86000061035156,1.493269603762682,,
2014-10-16,39.34000015258789,39.9900016784668,1.2639458624950664,,
2014-10-15,40.380001068115234,40.0099983215332,1.6522662007060196,,
2014-10-14,41.0,41.060001373291016,-0.9163019732413825,,
2014-10-13,41.470001220703125,40.91999816894531,0.14634481290491616,,
2014-10-10,41.470001220703125,41.540000915527344,-1.3262672668628563,"VGK, RXL: Big ETF Outflows | Notable ETF Inflow Detected - VTV, BRK.B, HPQ, ABT | Amgen, Inc. Gives AbbVie Inc the Highest Form of Flattery","Among the largest underlying components of RXL, in morning trading today Abbott Labs ( ABT ) is up about 1.1%, and Abbvie (ABBV) is lower by about 1.4%. Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel, the biggest outflow was seen in the Vanguard FTSE Europe ETF ( VGK ), where 4,998,080 units were destroyed, or a 2.0% decrease week over week. And on a percentage change basis, the ETF with the biggest outflow was the Proshares Ultra Health Care ( RXL ), which lost 750,000 of its units, representing a 39.0% decline in outstanding units compared to the week prior. | Among the largest underlying components of VTV, in trading today Berkshire Hathaway Inc. (Symbol: BRK.B) is up about 1%, Hewlett-Packard Co (Symbol: HPQ) is down about 1.9%, and Abbott Laboratories (Symbol: ABT) is higher by about 1.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Value ETF (Symbol: VTV) where we have detected an approximate $103.2 million dollar inflow -- that's a 0.7% increase week over week in outstanding units (from 190,661,854 to 191,961,941). The chart below shows the one year price performance of VTV, versus its 200 day moving average: Looking at the chart above, VTV's low point in its 52 week range is $68.68 per share, with $83.89 as the 52 week high point - that compares with a last trade of $79.03. | Amgen released the first data for ABP 501, its biosimilar of Humira, showing that the two drugs performed similarly in patients with plaque psoriasis. Amgen enrolled 350 patients in the ABP 501 trial; to get Humira approved for plaque psoriasis, Abbott Labs , which ran the trials before splitting off its drug division AbbVie, evaluated 1,212 patients in the pivotal trial, and another 147 patients in a second trial. While I'm sure Amgen ran the clinical trial design by the FDA before performing the trials, investors should realize that Amgen and the rest of the companies developing biosimilars are entering uncharted territory that's apt to change as the FDA digs into the data that companies are generating to show equivalence."
2014-10-09,42.18999862670898,41.630001068115234,0.1687959796569109,"Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for October 10, 2014","Shareholders who purchased ABT stock prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. The following ETF(s) have ABT as a top-10 holding: iShares U.S. Medical Devices ETF ( IHI ) Guggenheim BulletShares 2015 Corporate Bond ETF ( BSCF ) Schwab U.S. Large-Cap Value ETF ( SCHV ) iShares iBonds Mar 2020 Corporate Term ETF ( IBDC ) Schwab Fundamental U.S. Large Company Index ETF ( FNDX )."
2014-10-08,41.43999862670898,42.13999938964844,-1.3273230073992666,,
2014-10-07,42.09000015258789,41.459999084472656,1.6891910862378612,S&P 500 Analyst Moves: ABT,"The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories ( ABT ) is now the #163 analyst pick, moving up by 1 spot. VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Looking at the stock price movement year to date, Abbott Laboratories ( ABT ) is showing a gain of 8.9%."
2014-10-06,42.040000915527344,42.36000061035156,-1.4967951195802,,
2014-10-03,41.40999984741211,41.790000915527344,0.7611790862402856,Jazz Pharmaceuticals Uses New Cash To Buy For Growth,"Among those currently pursuing tax inversions areAbbVie ( ABBV ) (withShire ( SHPG ),Mylan ( MYL ) (withAbbott Laboratories' ( ABT ) generic drug unit) andMedtronic (MDT), withCovidien (COV), among others. Just a few years ago, one drug generated all but a small slice of revenue for Jazz Pharmaceuticals. Greener In Ireland Deals to expand the product line began not long after Jazz merged with the Irish drug company Azure Pharma in January 2012 and officially moved to Ireland."
2014-10-02,41.220001220703125,41.209999084472656,0.9176553236306817,"Noteworthy ETF Inflows: UPRO, ABT, ABBV, ACN","Among the largest underlying components of UPRO, in trading today Abbott Laboratories (Symbol: ABT) is trading flat, AbbVie Inc. (Symbol: ABBV) is off about 0.3%, and Accenture plc (Symbol: ACN) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Proshares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $185.8 million dollar inflow -- that's a 25.8% increase week over week in outstanding units (from 6,400,000 to 8,050,000). The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $67.83 per share, with $126.25 as the 52 week high point - that compares with a last trade of $112.43."
2014-10-01,42.04999923706055,41.18000030517578,-0.02426524971921904,,
2014-09-30,41.79999923706055,41.59000015258789,-2.068963014672297,,
2014-09-29,41.66999816894531,41.900001525878906,-0.5023901634105,,
2014-09-26,42.130001068115234,42.0099983215332,0.5519639237829495,3 Reasons AbbVie Inc Stock Could Fall,"Back in early 2013, there was considerable speculation about how Abbott Laboratories' then-new spin-off AbbVie would fare on its own. That speculation was answered by AbbVie's stock performance. Meanwhile, Abbott Labs' shares climbed around 25% -- not bad, but small in comparison to AbbVie's successful run."
2014-09-25,42.41999816894531,42.0,-0.2848391728925247,,
2014-09-24,42.45000076293945,42.630001068115234,-0.9900947361491951,Will New Treasury Rules Contain Tax Inversions? - Analyst Blog,"Click to get this free report MEDTRONIC (MDT): Free Stock Analysis Report COVIDIEN PLC (COV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report BURGER KING WWD (BKW): Free Stock Analysis Report To read this article on Zacks.com click here. Similarly, Abbott Laboratories ( ABT ) lost 2.1%. This involves U.S. companies issuing loans to a newly created overseas parent company born out of a deal involving tax inversion."
2014-09-23,42.709999084472656,42.5,0.42402897983674176,"SSO, MMM, ABT, ABBV: ETF Inflow Alert","Among the largest underlying components of SSO, in trading today 3M Co (Symbol: MMM) is off about 0.2%, Abbott Laboratories (Symbol: ABT) is down about 1.1%, and AbbVie Inc. (Symbol: ABBV) is lower by about 2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Proshares Ultra S&P500 (Symbol: SSO) where we have detected an approximate $153.5 million dollar inflow -- that's a 7.8% increase week over week in outstanding units (from 16,425,000 to 17,700,000). The chart below shows the one year price performance of SSO, versus its 200 day moving average: Looking at the chart above, SSO's low point in its 52 week range is $81.01 per share, with $123.59 as the 52 week high point - that compares with a last trade of $120.14."
2014-09-22,43.59000015258789,43.400001525878906,-0.49168599619334113,Novo Nordisk Reveals Fresh Data on Xultophy for Diabetes - Analyst Blog | Novartis' (NVS) Data on Anti-Cancer Drug LBH589 Published - Analyst Blog | Study Shows Medtronic's CoreValve TAVR Device Has Consistent And Cost Effective Performance,"Click to get this free report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are Allergan Inc. ( AGN ), Abbott Laboratories ( ABT ) and Johnson & Johnson ( JNJ ). Data showed that after four weeks from the initiation of treatment, Xultophy (a once-daily single injection combination of Tresiba and Victoza) led to more rapid and substantial improvement in glycemic control along with a beneficial weight profile in type II diabetes patients (insulin-naive as well as those treated with insulin previously), compared to the individual administration of Tresiba and Victoza. | Click to get this free report ALLERGAN INC (AGN): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Right now, stocks like Allergan Inc. ( AGN ), Abbott Labs ( ABT ) and Johnson & Johnson ( JNJ ) are worth considering. Data from the study, PANORAMA-1 (PANobinostat ORAl in Multiple MyelomA), showed that patients suffering from relapsed or relapsed and refractory multiple myeloma, when treated with LBH589 in combination with Velcade and Decadron showed a statistically significant and clinically relevant four-month improvement in median progression-free survival (PFS) as compared to placebo plus the same combination. | Compared to a mortality rate of about 50% (at one year) for high-risk atrial fibrillation patients not undergoing treatment, patients using the CoreValve TAVR system reported a lower all-cause mortality rate of 36.5% and major stroke rate of 5.1% at the end of two years, consistent with the one-year clinical trial results of the device. Cost Effectiveness Study Results The first-ever cost effectiveness study of the CoreValve TAVR device for high-risk patients revealed that TAVR therapy had significant benefits over SAVR procedures. TAVR patients reported a procedure time of 61 +/- 35 minutes versus 221 +/- 85 minutes for SAVR, hospital length-of-stay of 8.1 days versus 12.5 days for SAVR, ICU time of 3.1 days versus 4.7 days for SAVR, and only 23% TAVR patients required rehabilitation services post discharge compared to 44% for SAVR."
2014-09-19,43.959999084472656,43.59000015258789,-0.4358766369439996,Dividend Aristocrats: Time to Buy AbbVie Inc Stock?,"For example, some companies don't increase their total dividends payouts on a regular basis, don't offer attractive yields at current levels, or simply have weak prospects for growth going forward. Although Shire has impressive product and clinical portfolios in its own right, the main reason AbbVie was interested in acquiring the Dublin-based company was to lower its effective tax rate.AbbVie's effective tax rate for 2013 was 22.6%, whereas Shire's was only 16.4% . Speaking of strong dividends -- Here are the top dividend stocks for the next decade The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term."
2014-09-18,43.4900016784668,43.68999862670898,-0.8416718371030516,,
2014-09-17,42.93999862670898,43.380001068115234,0.45986879862827157,Abbott Labs (ABT) to Initiate New Trial on Absorb - Analyst Blog,"Abbott Labs ( ABT ) recently announced that it will initiate a trial, ABSORB IV, on bioresorbable vascular scaffold (BVS) Absorb. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs plans to consolidate data from the ABSORB IV trial with that from the ABSORB III trial to create a population of more than 5,000 patients studied in the U.S."
2014-09-16,42.709999084472656,42.900001525878906,1.0246913262185635,,
2014-09-15,42.61000061035156,42.720001220703125,0.4448664141398353,"Attunity, Ltd. (ATTU) in Focus: Stock Adds 5.2% in Session - Tale of the Tape | Abbott Labs Presents Positive One-Year Data on Absorb - Analyst Blog | Notable ETF Outflow Detected - SSO, MMM, ABT, ABBV","Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report DTS INC (DTSI): Free Stock Analysis Report RALLY SOFTWARE (RALY): Free Stock Analysis Report SUPPORT.COM INC (SPRT): Free Stock Analysis Report To read this article on Zacks.com click here. Click to get this free report >> Want the latest recommendations from Zacks Investment Research? Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) announced positive one-year results from the randomized, controlled trial ABSORB II, on its drug-eluting coronary bioresorbable vascular scaffold (BVS) Absorb. The trial, conducted in Europe, compared the safety and efficacy of the dissolving Absorb to Abbott Labs' Xience family of drug-eluting stents (DES) in patients suffering from coronary artery disease (CAD). The data from the trial showed that patients treated with Absorb experienced a significantly lower rate of angina (chest pain) compared to those treated with the Xience family of DES. | Among the largest underlying components of SSO, in trading today 3M Co (Symbol: MMM) is up about 0.1%, Abbott Laboratories (Symbol: ABT) is trading flat, and AbbVie Inc. (Symbol: ABBV) is up by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Proshares Ultra S&P500 (Symbol: SSO) where we have detected an approximate $98.4 million dollar outflow -- that's a 4.8% decrease week over week (from 17,250,000 to 16,425,000). The chart below shows the one year price performance of SSO, versus its 200 day moving average: Looking at the chart above, SSO's low point in its 52 week range is $81.01 per share, with $122.33 as the 52 week high point - that compares with a last trade of $119.21."
2014-09-12,42.619998931884766,42.54999923706055,0.25815679130696667,"AbbVie's Humira Positive in Phase III Skin Disease Study - Analyst Blog | Abbott Labs (ABT) to Repurchase Shares for $3B - Analyst Blog | Daily Dividend Report: INTC, ABT, TJX, BXP, RL, SLG, HUN, CBI, DRI, OCR","Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report AKORN INC (AKRX): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector include Allergan Inc. ( AGN ), Akorn, Inc. ( AKRX ) and Abbott Laboratories ( ABT ). AbbVie Inc. ( ABBV ) announced that Humira met the primary endpoint in a pivotal phase III study conducted in patients suffering from moderate-to-severe hidradenitis suppurativa (HS). | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. In an effort to increase shareholder value, Abbott Laboratories ' ( ABT ) board of directors has approved a new share repurchase program. We remind investors that Abbott Labs has returned approximately $35 billion to its shareholders through dividends and share repurchases in the last 10 years. | Abbott ( ABT ) declared a quarterly common dividend of 22 cents per share. VIDEO: Daily Dividend Report: INTC, ABT, TJX, BXP, RL, SLG, HUN, CBI, DRI, OCR The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The TJX Companies ( TJX ) announced the declaration of a quarterly dividend on its common stock of $.175 per share payable December 4, 2014, to shareholders of record on November 13, 2014."
2014-09-11,42.68999862670898,42.560001373291016,-0.16424142791765947,FDA Approves Orexigen Therapeutics Inc.'s Goldilocks Obesity Drug,"Today, Orexigen and Takeda Pharmaceuticals announced that the Food and Drug Administration approved its obesity drug Contrave . In 2011, Orexigen was in a tight race with VIVUS and Arena Pharmaceuticals to gain FDA approval of the first new obesity drug. Many insurers don't cover Qsymia and Belviq, and those that do often put them as a tier 3 drug so patients have to pay large co-pays for the drugs."
2014-09-10,42.97999954223633,42.900001525878906,-0.3045145411099379,,
2014-09-09,42.83000183105469,42.83000183105469,-0.1861284718693588,"ACWI, RXL: Big ETF Inflows","Among the largest underlying components of RXL, in morning trading today Abbott Labs ( ABT ) is trading flat, and Abbvie (ABBV) is up by about 0.4%. Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel, the biggest inflow was seen in the iShares MSCI ACWI ETF ( ACWI ), which added 11,200,000 units, or a 11.5% increase week over week. And on a percentage change basis, the ETF with the biggest increase in inflows was the Proshares Ultra Health Care ( RXL ), which added 375,000 units, for a 33.3% increase in outstanding units."
2014-09-08,42.880001068115234,42.810001373291016,0.0,"Noteworthy ETF Outflows: SSO, MMM, ABT, ABBV","Among the largest underlying components of SSO, in trading today 3M Co (Symbol: MMM) is up about 0.4%, Abbott Laboratories (Symbol: ABT) is off about 0.2%, and AbbVie Inc. (Symbol: ABBV) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Proshares Ultra S&P500 (Symbol: SSO) where we have detected an approximate $447.9 million dollar outflow -- that's a 17.9% decrease week over week (from 20,550,000 to 16,875,000). The chart below shows the one year price performance of SSO, versus its 200 day moving average: Looking at the chart above, SSO's low point in its 52 week range is $80.40 per share, with $122.33 as the 52 week high point - that compares with a last trade of $121.33."
2014-09-05,42.880001068115234,42.95000076293945,-0.16324555289311599,Abbott Labs' FreeStyle Libre Flash Glucose Gets CE Mark - Analyst Blog,Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ( ABT ) received positive news when its FreeStyle Libre Flash Glucose Monitoring System obtained CE Mark (Conformite Europeenne) in Europe. Abbott Labs' glucose system eliminates the need for routine finger pricks and challenges of routine glucose monitoring for people suffering from diabetes.
2014-09-04,42.79999923706055,42.900001525878906,0.16324555289311599,Google's Calico in $500M Joint Venture with AbbVie - Analyst Blog,"Calico, Google's ( GOOGL ) year-old health startup is collaborating with biotechnology drugmaker, AbbVie ( ABBV ), a spin-off from Abbott Laboratories ( ABT ), for a joint venture to formulate treatments for cancer and Alzheimer's. Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report GOOGLE INC-CL A (GOOGL): Free Stock Analysis Report INTEL CORP (INTC): Free Stock Analysis Report APPLE INC (AAPL): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2014-09-03,42.400001525878906,42.7599983215332,0.2336502116845071,,
2014-09-02,42.16999816894531,42.22999954223633,0.8490490157991439,,
2014-08-29,42.40999984741211,42.2400016784668,0.1422845053268265,,
2014-08-28,42.43000030517578,42.34999847412109,-0.4008445403370732,,
2014-08-27,42.72999954223633,42.59999847412109,-0.18855015432308553,,
2014-08-26,42.5,42.79999923706055,-0.30423840278009445,,
2014-08-25,42.40999984741211,42.4900016784668,0.7058805577895221,,
2014-08-22,42.220001220703125,42.11000061035156,0.1886390741394197,PowerTrend Brief: How You Can Use a Technical Analysis of Earnings to Make Smarter Investments,"In its most recent Buyback Quarterly, FactSet found that “dollar-value share repurchases amounted to $154.5 billion over the first quarter and $535.2 billion for the trailing twelve months.” Among the big buyback spenders, FactSet found Apple, IBM (IBM), FedEx (FDX), Boeing (BA), Abbott Laboratories (ABT), Corning (GLW) and eBay (EBAY). Simple calculations show a 6.4% drop in a company’s share count year over year can deliver a 7% increase in its earnings per share, even if its net income is the exact same. Remember, the stock market rewards true growth, not simulated growth, and that means giving a quick check to a company’s outstanding share count, as well as its reported EPS figures, the next time you look at its earnings press release or skim its 10Q filings."
2014-08-21,42.290000915527344,42.31999969482422,-0.2605414665351129,"SSO, SVXY: Big ETF Outflows","Among the largest underlying components of SSO, in morning trading today 3M Company ( MMM ) is off about 0.1%, and Abbott Labs ( ABT ) is higher by about 0.5%. Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel, the biggest outflow was seen in the Proshares Ultra S&P500 ( SSO ), where 3,825,000 units were destroyed, or a 15.5% decrease week over week. And on a percentage change basis, the ETF with the biggest outflow was the Proshares Short VIX Short-Term Futures ETF ( SVXY ), which lost 900,000 of its units, representing a 19.6% decline in outstanding units compared to the week prior."
2014-08-20,42.220001220703125,42.13999938964844,0.07093586816608591,,
2014-08-19,42.29999923706055,42.540000915527344,-0.18948798849266155,,
2014-08-18,42.619998931884766,42.22999954223633,0.5673798647649213,,
2014-08-15,42.36000061035156,42.060001373291016,-0.9150619413945413,,
2014-08-14,42.150001525878906,42.33000183105469,-0.7082134861613664,,
2014-08-13,41.880001068115234,42.15999984741211,0.42704697190880564,,
2014-08-12,41.90999984741211,41.56999969482422,0.6685739545265873,,
2014-08-11,41.91999816894531,42.04999923706055,-0.811262595623429,Bet On This Top Ranked Medical Device ETF - ETF News And Commentary,"Click to get this free report SPDR-SP PHARMA (XPH): ETF Research Reports ISHARS-US MED D (IHI): ETF Research Reports SPDR-HLTH CR (XLV): ETF Research Reports ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. One of the top companies in the space, Abbott Labs ( ABT ) recently signed a deal with Mylan for the sale of its non-U.S. developed markets specialty and branded generics business. About the Zacks ETF Rank The Zacks ETF Rank provides a recommendation for the ETF in the context of our outlook for the underlying industry, sector, style box or asset."
2014-08-08,41.47999954223633,41.68999862670898,0.31011706534744143,"After Hours Most Active for Aug 8, 2014 : F, PPL, QQQ, PVA, CAT, ABT, CMCSA, WMB, MSFT, SIRI, AAPL, CSCO","The total After hours volume is currently 15,617,668 shares traded. The following are the most active stocks for the after hours session : Ford Motor Company ( F ) is -0.05 at $17.04, with 8,105,114 shares traded. Over the last four weeks they have had 6 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2014."
2014-08-07,41.75,41.52999877929688,0.5062658794362354,"Mylan Misses Q2 Earnings and Sales Estimates, Adjusts View - Analyst Blog",Click to get this free report MYLAN INC (MYL): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Mylan's deal with Abbott Laboratories ( ABT ) to buy the latter's branded specialty and generics business in the developed ex-U.S. markets is a prudent move. Mylan 's ( MYL ) second quarter 2014 earnings (excluding special items) of 69 cents per share fell short of the Zacks Consensus Estimate by a penny.
2014-08-06,41.66999816894531,41.77000045776367,-0.5269490316242345,Will Mylan (MYL) Earnings in Q2 Disappoint Expectations? - Analyst Blog,"Click to get this free report MYLAN INC (MYL): Free Stock Analysis Report VIVUS INC (VVUS): Free Stock Analysis Report MYRIAD GENETICS (MYGN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Mylan was also in focus recently when it inked an all-stock deal with Abbott Laboratories ( ABT ) to buy the latter's branded specialty and generics business in the developed ex-U.S. markets (read more: Mylan to Buy Abbott Generic Drug Unit ). Zacks ESP : The Earnings ESP for Mylan is 0.00% since the Most Accurate Estimate stands at $0.70, in line with the Zacks Consensus Estimate."
2014-08-05,42.13999938964844,41.77999877929688,0.2399863048059512,Roche to Acquire Santaris Pharma to Expand RNA Portfolio - Analyst Blog,"Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Investors may consider other large cap pharmas like Allergan ( AGN ), AstraZeneca ( AZN ) and Abbott Labs ( ABT ). Roche expects Santaris Pharma's next-generation antisense technology and LNA expertise to complement its experience in disease biology, chemistry, drug safety, drug formulation, delivery, and development."
2014-08-04,42.119998931884766,42.38999938964844,-0.8542966672182449,,
2014-08-01,42.0,42.02999877929688,0.641026744089687,,
2014-07-31,42.52000045776367,42.119998931884766,0.07142566499257644,,
2014-07-30,42.959999084472656,42.86000061035156,-0.9407373508291449,,
2014-07-29,42.970001220703125,42.75,-0.2327711272164271,,
2014-07-28,42.95000076293945,42.93000030517578,-0.5119879321695888,,
2014-07-25,42.88999938964844,43.040000915527344,-0.04656683913479648,,
2014-07-24,42.93999862670898,42.88999938964844,0.3497354348648215,,
2014-07-23,43.2400016784668,42.970001220703125,-0.11643977331065841,,
2014-07-22,43.0,43.09000015258789,-0.6244228660567562,Abbott Raises Full Year Earnings Guidance On Strong Q2 Results | Tuesday's ETF with Unusual Volume: BSCF,"Healthcare giant Abbott Laboratories ( ABT ) reported a strong set of second quarter 2014 results on Wednesday, July 16. The Diagnostics division was again the star performer for Abbott, as its operational sales increased 5.5% year-over-year (y-o-y) to about $1.2 billion driven by robust growth in Core Laboratory sales in the U.S. and Point of Care sales in international markets. It recently launched a new product, Enovo, in Japan, which is its largest adult nutrition market outside the U.S. Generic Pharma Business Set For Growth Established Pharmaceuticals sales have seen a low-to-mid single-digit decline in the last few years, owing to pricing pressure in developed markets such as Europe and Japan. | Components of that ETF with the highest volume on Tuesday were Bank of America ( BAC ), trading up about 0.1% with over 25.4 million shares changing hands so far this session, and Abbott Labs ( ABT ), up about 0.2% on volume of over 2.8 million shares. The Guggenheim BulletShares 2015 Corporate Bond ETF ( BSCF ) is seeing unusually high volume in afternoon trading Tuesday, with over 2.9 million shares traded versus three month average volume of about 100,000. VIDEO: Tuesday's ETF with Unusual Volume: BSCF The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2014-07-21,42.5,42.959999084472656,0.20930268043695494,,
2014-07-18,41.900001525878906,42.72999954223633,1.0823507869944853,,
2014-07-17,41.02000045776367,41.900001525878906,1.9809021148717287,"#PreMarket Primer: Thursday, July 17: Russia Hit With New Sanctions","Abbott Laboratories (NYSE: ABT ) reported second quarter EPS of $0.54 on revenue of $5.55 billion, compared to last year's EPS of $0.46 on revenue of $5.45 billion. European Markets European markets began the day on a low note; the FTSE was down 0.34 percent, the STOXX 600 was down 0.42 percent, the DAX lost 0.35 percent, the CAC 40 was down 0.46 percent and the MIB fell 0.85 percent. Earnings Notable earnings released on Wednesday included: Bank of America (NYSE: BAC ) reported second quarter EPS of $0.41 on revenue of $21.96 billion, compared to last year's EPS of $0.32 on revenue of $22.73 billion."
2014-07-16,41.56999969482422,41.04999923706055,2.1452975580079023,"Stock Futures Get Boost From Upbeat Earnings, Bullish Chinese GDP; Time Warner Rejects Fox | #PreMarket Primer: Wednesday, July 16: Yellen Hints At Sooner Than Expected Rate Hike","Also, Apple ( AAPL ) and IBM ( IBM ) shares are higher after announcing their collaboration to provide IBM applications on new iPhones and iPads, Abbott Labs ( ABT ) beat earnings estimates, but Yahoo (YHOO) is causing the Nasdaq to underperform after announcing disappointing Q2 results. Shares of Time Warner ( TWX ) are leading the pack higher after the media conglomerate rejected an $80 billion offer from Rupert Murdoch's Twenty-First Century Fox ( FOX ), driving shares of TWX more than 15% higher before the opening bell. (+) Large cap tech: higher (+) Chip stocks: higher (+) Software stocks: higher (+) Hardware stocks: higher (+/-) Internet stocks: mixed (+) Drug stocks: higher (+) Financial stocks: higher (+/-) Retail stocks: mixed (+) Industrial stocks: higher (+) Airlines: higher (+) Autos higher | U.S. employment figures became a lot more important on Tuesday after Federal Reserve Chair Janet Yellen said the US central bank would consider raising its interest rate sooner if the job market improves ahead of expectations. However, Yellen did admit that the bank was open to a sooner than expected rate hike if jobs data improves more quickly than anticipated. Top News In other news around the markets: European policymakers will meet on Wednesday to discuss whether"
2014-07-15,41.7400016784668,41.16999816894531,-1.250903203226186,"Mylan to Buy Abbott Generic Drug Unit - Analyst Blog | Pre-Market Earnings Report for July 16, 2014 : BAC, USB, ABT, BLK, PNC, ASML, SCHW, TSM, STJ, NTRS, TXT, FRC | Will Abbott Laboratories (ABT) Miss This Earnings Season? - Analyst Blog","In a bid to further strengthen its portfolio, enhance geographical reach and save taxes, Mylan ( MYL ) inked an all stock deal with Abbott Laboratories ( ABT ) to buy the latter's branded specialty and generics business in developed ex-U.S. markets for $5.3 billion (based on Mylan's closing price of $50.20 per share last Friday). Deal Structure According to the terms of the deal, Abbott will receive 105 million shares of the merged entity following the closure of the deal and own approximately 21% of the new company. Post merger, the new company will comprise Mylan's existing business and the generic pharmaceuticals business of Abbott in all developed ex-U.S. markets such as Europe, Japan, Canada, Australia and New Zealand. | Abbott Laboratories ( ABT ) is reporting for the quarter ending June 30, 2014. In the past year ABT has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ABT is 18.92 vs. an industry ratio of 26.80. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) is set to report second quarter 2014 results on Jul 16 before market opens. Zacks Rank #3 (Hold): Abbott Labs' Zacks Rank #3 (Hold) has little effect on the predictive power of ESP because the Zacks Rank #3 when combined with a 0.00% ESP makes surprise prediction difficult."
2014-07-14,41.95000076293945,41.81999969482422,-1.3656049032109714,"Futures Higher on Active Merger Market, Citigroup Earnings | Sector Update: Health Care | Close Update: Stocks Rally on Citigroup Earnings Beat, M&A Activity","In M&A activity, Mylan ( MYL ) offered to buy Abbott Laboratories' ( ABT ) specialty and branded generics business outside the U.S. in an all-stock transaction valued at approximately $5.3 billion, while Abbie (ABBV) upped its offer for Shire Plc (SHPG) to more than $53 billion. Nikkei up 0.88% Hang Seng up 0.49% Shanghai Composite up 0.96% FTSE-100 up 0.67% DAX-30 up 0.82% (+) Large cap tech: higher (+) Chip stocks: higher (+) Software stocks: higher (+) Hardware stocks: higher (+) Internet stocks: higher (+) Drug stocks: higher (+) Financial stocks: higher (+) Retail stocks: higher (+) Industrial stocks: higher (+) Airlines: higher (+) Autos higher | In health-care stocks news, Abbott ( ABT ) shares were up about 1% after it said it will sell its developed markets branded generics pharmaceuticals business to Mylan ( MYL ) for equity ownership of a newly formed entity that will combine Mylan's existing business and Abbott's developed markets pharmaceuticals business, and will be a publicly traded company. Abbott will retain its branded generics pharmaceuticals business and products in emerging markets. Finally, Salix Pharmaceuticals ( SLXP ) and Progenics Pharmaceuticals ( PGNX ) have announced the Food and Drug Administration (FDA) has informed Salix that its RELISTOR subcutaneous injection, 20 mg/ml, has been approved on the data submitted in the supplemental NDA (sNDA), for the treatment of opioid-induced constipation (OIC) in patients taking opioids for chronic non-cancer pain. | Health care and industrials were given a shot-in-the arm by M&A deals between Mylan ( MYL ) and Abbott Labs ( ABT ), AbbVie ( ABBV ) and Shire Plc ( SHPG ),and ConAgra Foods (CAG) and Inner Mongolia potato processor TaiMei. Encouraged by upbeat earnings from Citigroup ( C ) and multi-billion dollar deals in the pharmaceutical sector, investors shrugged off geo-political pressures and poured back into equities on Monday, driving the Dow Industrials to another record high. Last week's losses tied to Portugal's banking crisis and worries over Q2 earnings were reversed after Citigroup shares jumped higher on an earnings beat despite a $7 billion judgement levied against the bank by the Justice Department."
2014-07-11,41.09000015258789,41.29999923706055,-0.30989526996643885,"Abbott Labs, Fonterra Collaborate for Dairy Farm Hub in China - Analyst Blog",Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) announced that it has signed an agreement with New Zealand-based Fonterra Co-operative Group Ltd. for the development of a proposed dairy farm hub in China. Abbott Labs expects the development of the first farm to be complete and operational in the first half of 2017 while the remaining farms will commence production in 2018.
2014-07-10,41.02999877929688,41.2400016784668,0.5110710238326205,,
2014-07-09,41.209999084472656,41.27000045776367,0.5118277002627626,,
2014-07-08,41.33000183105469,41.04999923706055,0.14559906484837387,Novo Nordisk Gets FDA Nod for NovoSeven RT - Analyst Blog,"Click to get this free report ALLERGAN INC (AGN): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector include Abbott Laboratories ( ABT ), AbbVie Inc. ( ABBV ) and Allergan Inc. ( AGN ). Novo Nordisk 's ( NVO ) NovoSeven RT (coagulation factor VIIa [recombinant]) received FDA approval for perioperative management and the treatment of bleeding episodes in patients suffering from Glanzmann's thrombasthenia (a rare genetic bleeding disorder) with refractoriness to platelet transfusions (with or without antibodies to platelets)."
2014-07-07,41.68000030517578,41.5099983215332,-0.6774802361217203,Roche's Alectinib Approved in Japan - Analyst Blog,"Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader healthcare sector include Abbott Labs ( ABT ), Allergan ( AGN ) and Shire ( SHPG ). Roche ( RHHBY ) received positive news when the Japanese Ministry of Health, Labour and Welfare (MHLW) approved alectinib for the treatment of patients suffering from non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase fusion gene-positive (ALK+)."
2014-07-03,41.810001373291016,41.88999938964844,-0.40787423799866784,,
2014-07-02,41.22999954223633,41.790000915527344,0.1913370335561052,,
2014-07-01,41.18000030517578,41.18000030517578,1.3582376413013197,,
2014-06-30,40.66999816894531,40.900001525878906,0.0,"IYH, PFE, GILD, ABT: Large Inflows Detected at ETF","Among the largest underlying components of IYH, in trading today Pfizer Inc (Symbol: PFE) is up about 0.1%, Gilead Sciences, Inc. (Symbol: GILD) is up about 1.1%, and Abbott Laboratories (Symbol: ABT) is up by about 1.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $32.1 million dollar inflow -- that's a 1.3% increase week over week in outstanding units (from 19,800,000 to 20,050,000). The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $99.75 per share, with $128.94 as the 52 week high point - that compares with a last trade of $128.70."
2014-06-27,40.5099983215332,40.540000915527344,0.5655356953254527,,
2014-06-26,40.7400016784668,40.619998931884766,0.07406219510552944,,
2014-06-25,40.630001068115234,40.70000076293945,-0.29455753961212755,,
2014-06-24,40.61000061035156,40.45000076293945,0.17228573217821463,Abbott Labs to Buy Russia-Based Veropharm - Analyst Blog,"Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) announced a definitive agreement to acquire Russia-based pharmaceutical manufacturer Veropharm for approximately $395 million - $495 million (13.6 billion rubles - 17 billion rubles). As per the terms of the agreement, Abbott Labs will acquire Limited Liability Company Garden Hills, the holding company that currently owns a controlling interest in Veropharm."
2014-06-23,40.970001220703125,40.72999954223633,-0.3939912460166896,,
2014-06-20,41.209999084472656,40.84999847412109,-0.585798563133843,,
2014-06-19,40.5099983215332,41.0,-0.8735758756355146,,
2014-06-18,39.84000015258789,40.369998931884766,1.209582075460949,,
2014-06-17,39.79999923706055,39.86000061035156,1.3303182160315525,iShares U.S. Medical Devices ETF Experiences Big Outflow | Sector Update: Healthcare Stocks Little Changed Today; Biolase Soars After Legal Fight Ends in CEO Ouster | Sector Update: Healthcare,"Among the largest underlying components of IHI, in trading today Medtronic, Inc. (Symbol: MDT) is up about 1.4%, Abbott Laboratories (Symbol: ABT) is off about 0.3%, and Baxter International Inc. (Symbol: BAX) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $15.0 million dollar outflow -- that's a 2.1% decrease week over week (from 7,150,000 to 7,000,000). The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $76.93 per share, with $101.76 as the 52 week high point - that compares with a last trade of $100.53. | Also today, the company said former Abbott Labs ( ABT ) executive Paul Clark was selected new board chairman. Healthcare stocks were narrowly mixed this afternoon with the NYSE Healthcare Sector Index climbing about 0.1% and shares of healthcare companies in the S&P 500 down about 0.1% as a group. In company news, Biolase Inc. ( BIOL ) jumped to its best share price in nearly two months Tuesday after Federico Pignatelli stepped down as CEO and board chairman at the dental-laser company, less than a week after the Delaware Supreme Court upheld a lower court decision in a shareholder suit seeking to end a board deadlock over his tenure. | Also today, the company said former Abbott Labs ( ABT ) executive Paul Clark was selected new board chairman. Healthcare stocks were narrowly mixed this afternoon with the NYSE Healthcare Sector Index climbing about 0.1% and shares of healthcare companies in the S&P 500 down about 0.1% as a group. In company news, Biolase Inc. ( BIOL ) jumped to its best share price in nearly two months Tuesday after Federico Pignatelli stepped down as CEO and board chairman at the dental-laser company, less than a week after the Delaware Supreme Court upheld a lower court decision in a shareholder suit seeking to end a board deadlock over his tenure."
2014-06-16,39.83000183105469,39.900001525878906,0.15075722221407525,,
2014-06-13,39.77000045776367,39.790000915527344,0.17574615015367973,"Daily Dividend Report: ABT, EQR, RL, GGG, RAS | Weekly Market Wrap: June 13, 2014","VIDEO: Daily Dividend Report: ABT, EQR, RL, GGG, RAS The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. This morning, Abbott Labs ( ABT ) declared its quarterly dividend of 22 cents per share, maintaining the amount paid to shareholders the previous quarter. On the news, shares of ABT were flat, trading just below $40 per share. | In highlights of corporate dividend news, Abbott Labs ( ABT ) declared its quarterly dividend of 22 cents per share, maintaining the amount paid to shareholders the previous quarter. In economic news, the U.S. Census Bureau announced that April 2014 sales of merchant wholesalers, except manufacturers' sales branches and offices, after adjustment for seasonal variations and trading-day differences but not for price changes, were $450.2 billion, up 1.3 percent from the revised March level and were up 7.8 percent from the April 2013 level. Total inventories of merchant wholesalers, except manufacturers' sales branches and offices, after adjustment for seasonal variations but not for price changes, were $530.6 billion at the end of April, up 1.1 percent from the revised March level and were up 6.7 percent from the April 2013 level."
2014-06-12,39.97999954223633,39.810001373291016,0.050290313134174223,,
2014-06-11,40.2400016784668,40.0,-0.4252080312450235,,
2014-06-10,40.02999877929688,40.52999877929688,-0.596425617435365,,
2014-06-09,39.93999862670898,40.130001068115234,1.2490632406878688,,
2014-06-06,40.06999969482422,40.04999923706055,0.47571969939727854,,
2014-06-05,39.7599983215332,40.150001525878906,-0.04991379564760841,,
2014-06-04,39.79999923706055,39.75,0.9808934124991784,,
2014-06-03,39.68000030517578,39.81999969482422,-0.12562622617838926,,
2014-06-02,40.02000045776367,39.79999923706055,0.3528210397472609,,
2014-05-30,39.61000061035156,40.0099983215332,-0.5497281813759848,,
2014-05-29,39.68000030517578,39.59999847412109,1.0098402045394224,,
2014-05-28,39.66999816894531,39.66999816894531,-0.2016175162283437,,
2014-05-27,39.52000045776367,39.58000183105469,0.0,,
2014-05-23,39.65999984741211,39.59999847412109,0.15182533551623076,,
2014-05-22,39.470001220703125,39.650001525878906,-0.1512893936507111,,
2014-05-21,39.54999923706055,39.560001373291016,0.45604332305256184,,
2014-05-20,39.83000183105469,39.540000915527344,0.025289851892326187,"Company News for May 20, 2014 - Corporate Summary","• Campbell Soup Company's (NYSE: CPB ) shares declined 2.4% after forecasting fiscal 2014 sales growth from continuing operations of 3%, lower than the previous forecast of 4% to 5% • Shares of The Valspar Corporation (NYSE: VAL ) rose 1.4% after reporting fiscal second quarter earnings per share of $1.07, beating the Zacks Consensus Estimate of $1.04 • Abbott Laboratories's (NYSE: ABT ) shares increased 1.5% after the company announced it will buy Chile based CFR Pharmaceuticals for about $2.9 billion • Shares of Johnson Controls Inc (NYSE: JCI ) jumped 4.3% after it said it will hive off its automotive-interiors business to form a joint venture with Yanfeng Automotive Trim Systems Co Want the latest recommendations from Zacks Investment Research? Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report CAMPBELL SOUP (CPB): Free Stock Analysis Report JOHNSON CONTROL (JCI): Free Stock Analysis Report VALSPAR CORP (VAL): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2014-05-19,39.619998931884766,39.630001068115234,-0.7280966663206015,Abbott to Buy CFR Pharma - Analyst Blog,"In a move to broaden its presence in the Latin American market, Abbott Labs ( ABT ) announced that it has entered into a definitive agreement to acquire Latin American pharmaceutical company, CFR Pharmaceuticals. Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. The CFR Pharmaceuticals acquisition will double Abbott Labs' branded generics pharmaceutical sales and presence in one of the fast growing markets."
2014-05-16,39.61000061035156,39.060001373291016,0.025245170368794194,Sector Update: Healthcares,"And, Abbott ( ABT ) edged lower in recent pre-market trading on Friday after saying it has signed a definitive agreement to buy Latin American pharmaceutical company CFR Pharmaceuticals for approximately $2.9 billion, plus the assumption of debt of approximately $430 million. ABT closed down to $39.24 Thursday, in a 52-week range of $32.70 - $40.49. In healthcare stocks news, Kamada ( KMDA ) is lower after the company announced preliminary top-line results from the Phase II/III pivotal clinical trial in Europe and Canada of its proprietary inhaled Alpha-1 Antitrypsin ( AAT ) therapy to treat Alpha-1 Antitrypsin Deficiency (AATD or inherited emphysema)."
2014-05-15,39.2599983215332,39.2400016784668,-1.3885363003928146,,
2014-05-14,39.86000061035156,39.93000030517578,-0.05093388670737297,,
2014-05-13,39.380001068115234,39.65999984741211,0.1756138829712912,Abbott's Promising Data on RADICAL Platform - Analyst Blog | Abbott May Be Looking To Divest Part Of Generic Drug Business,"Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottLaboratories ( ABT ) announced positive interim data from the RApid Diagnosis of Infections in the CriticAlly IlL (RADICAL) study. The RADICAL study analyzed samples from more than 180 critically ill patients with suspected severe infections and compared the results of Abbott's technology (IRIDICA) to the current standard of care. | Abbott Laboratories ( ABT ) is reportedly considering divesting a significant part of its generic drug business, according to a recent Reuters report. By divesting a part of its business, the company could be looking to exit from the low-margin, low-growth generic drug market in developed regions to focus on the high-growth opportunity in emerging markets such as India and China. Sales from the Established Pharmaceutical division have dipped in the last two years due to competitive pressures and unfavorable macroeconomic conditions in some developed markets, partially offset by strong sales in emerging markets."
2014-05-12,39.06999969482422,39.27000045776367,0.7110177036627389,,
2014-05-09,38.68000030517578,38.9900016784668,0.5119036716192965,,
2014-05-08,38.68999862670898,38.72999954223633,0.801451320695916,"XLF, HDG: Big ETF Outflows","Among the largest underlying components of HDG, in morning trading today 3M Company ( MMM ) is up about 0.3%, and Abbott Labs ( ABT ) is higher by about 0.5%. Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel, the biggest outflow was seen in the Financial Select Sector SPDR Fund ( XLF ), where 23,350,000 units were destroyed, or a 2.8% decrease week over week. And on a percentage change basis, the ETF with the biggest outflow was the Proshares Hedge Replication ETF ( HDG ), which lost 150,000 of its units, representing a 16.7% decline in outstanding units compared to the week prior."
2014-05-07,38.650001525878906,38.68999862670898,0.10338825781124972,,
2014-05-06,38.7599983215332,38.58000183105469,0.10348537969213309,Tuesday's ETF with Unusual Volume: BSCF,"Abbott Labs ( ABT ) is the component faring the best Tuesday, lower by about 0.3% on the day, while Metlife ( MET ) is lagging other components of the Guggenheim BulletShares 2015 Corporate Bond ETF, trading lower by about 2.3%. The Guggenheim BulletShares 2015 Corporate Bond ETF ( BSCF ) is seeing unusually high volume in afternoon trading Tuesday, with over 470,000 shares traded versus three month average volume of about 121,000. Components of that ETF with the highest volume on Tuesday were Bank of America ( BAC ), trading off about 1.5% with over 44.6 million shares changing hands so far this session, and Astrazeneca ( AZN ), down about 0.8% on volume of over 4.2 million shares."
2014-05-05,38.27000045776367,38.84000015258789,-0.4643872504465981,,
2014-05-02,38.66999816894531,38.560001373291016,1.489416482900996,Medical Devices Face Onslaught Of Pricing Pressure,"In January 2013,Abbott Laboratories ( ABT ) broke into two companies. Makers of medical devices are coming under increasing pressure, owing to a fundamental power shift in American medicine favoring insurance companies, hospitals and their patients. The change, according to Moty Avisar, president of medical systems maker Surgical Theater, is based on patients being forced by soaring medical costs to take control of their health care."
2014-05-01,38.650001525878906,38.66999816894531,-0.28444996344124973,MedTech's Partial Tax Repeal: Is It Enough? - Industry Outlook,"Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ARTHROCARE CORP (ARTC): Free Stock Analysis Report BAXTER INTL (BAX): Free Stock Analysis Report BARD C R INC (BCR): Free Stock Analysis Report BECTON DICKINSO (BDX): Free Stock Analysis Report BOSTON SCIENTIF (BSX): Free Stock Analysis Report CARDINAL HEALTH (CAH): Free Stock Analysis Report CAREFUSION CORP (CFN): Free Stock Analysis Report CARLYLE GROUP (CG): Free Stock Analysis Report COOPER COS (COO): Free Stock Analysis Report COVIDIEN PLC (COV): Free Stock Analysis Report COVANCE INC (CVD): Free Stock Analysis Report QUEST DIAGNOSTC (DGX): Free Stock Analysis Report HAEMONETICS CP (HAE): Free Stock Analysis Report HOLOGIC INC (HOLX): Free Stock Analysis Report HENRY SCHEIN IN (HSIC): Free Stock Analysis Report ILLUMINA INC (ILMN): Free Stock Analysis Report INTUITIVE SURG (ISRG): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report KIMBERLY CLARK (KMB): Free Stock Analysis Report MEAD JOHNSON NU (MJN): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PATTERSON COS (PDCO): Free Stock Analysis Report SMITH & NEPHEW (SNN): Free Stock Analysis Report ST JUDE MEDICAL (STJ): Free Stock Analysis Report STRYKER CORP (SYK): Free Stock Analysis Report THERMO FISHER (TMO): Free Stock Analysis Report VOLCANO CORP (VOLC): Free Stock Analysis Report WRIGHT MEDICAL (WMGI): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report ZIMMER HOLDINGS (ZMH): Free Stock Analysis Report To read this article on Zacks.com click here. Taking a cue from Abbott Laboratories ( ABT ), which separated its research-based pharmaceuticals business by creating a new company AbbVie ( ABBV ) last year, Baxter International revealed in Mar 2014 that it will split its biopharmaceuticals and medical device segments into two independent companies in order to put greater management focus on these two businesses. Against the backdrop of flattening or declining sales growth in developed markets, Boston Scientific achieved 8% international growth in the first quarter of 2014 on the back of 22% growth in emerging markets, which represented 9% of total company sales."
2014-04-30,38.560001373291016,38.7400016784668,0.05173775492095928,,
2014-04-29,38.369998931884766,38.540000915527344,0.4668057540590762,,
2014-04-28,38.27999877929688,38.369998931884766,0.44305965174606665,,
2014-04-25,38.38999938964844,38.02999877929688,0.23511012397565345,,
2014-04-24,38.650001525878906,38.43000030517578,-0.9377458090000043,,
2014-04-23,38.72999954223633,38.59999847412109,-0.5692140026328812,,
2014-04-22,38.75,38.59999847412109,-0.33565987516594487,,
2014-04-21,38.869998931884766,38.709999084472656,-0.3871007119455829,"Noteworthy ETF Outflows: SSO, ABT, ACN, ACE","Among the largest underlying components of SSO, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.7%, Accenture plc (Symbol: ACN) is up about 0.2%, and ACE, Ltd. (Symbol: ACE) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Proshares Ultra S&P500 (Symbol: SSO) where we have detected an approximate $47.0 million dollar outflow -- that's a 1.4% decrease week over week (from 31,500,000 to 31,050,000). The chart below shows the one year price performance of SSO, versus its 200 day moving average: Looking at the chart above, SSO's low point in its 52 week range is $70.11 per share, with $108.35 as the 52 week high point - that compares with a last trade of $104.66."
2014-04-17,38.2599983215332,38.93000030517578,-0.4116281240256549,Abbott Earnings Preview: Emerging Markets & New Products Likely To Drive Sales,"Abbott Labs ( ABT ) is scheduled to release its Q1 2014 earnings on Wednesday, April 16. Nutritionals, the company's largest business segment, continued to be impacted by the supplier recall that was initiated in international markets in August of last year and reported a marginal 1.1% y-o-y increase in operational sales. See our full analysis for Abbott Labs Emerging Markets To Drive Growth In Sales Sales in emerging markets grew 9% y-o-y in the previous quarter driven by strong performance in the Adult Nutrition business, Diagnostics and Established Pharmaceuticals (generic drugs)."
2014-04-16,38.75,38.380001068115234,1.7511814245571795,"Abbott Labs Tops Earnings, Misses Sales Est - Analyst Blog | Prestige Brands Gains on Product Acquisition News - Analyst Blog | Sector Update: Healthcare Shares Higher Pre-Market; St. Jude Q1 Earnings Top Street View | Sector Update: Healthcare","Abbott Laboratories ( ABT ) reported first quarter 2014 earnings of 41 cents per share, above the Zacks Consensus Estimate of 35 cents. ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report BIODEL INC (BIOD): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs generated sales of $5.2 billion in the first quarter of 2014, down 2.5% year over year and short of the Zacks Consensus Estimate of $5.4 billion. | ABBOTT LABS (ABT): Free Stock Analysis Report CENTRAL GARDEN (CENT): Free Stock Analysis Report PRESTIGE BRANDS (PBH): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Some approved oral rehydration therapies include Sanofi 's ( SNY ) Dioralyte and Abbott Laboratories ' ( ABT ) Pedialyte. Prestige Brands Holdings, Inc. 's ( PBH ) shares gained 5.94% immediately after the company announced that it has signed a purchase agreement with Australia-based The Hydration Pharmaceuticals Trust of Victoria to acquire their over-the-counter (OTC) oral rehydration brand, Hydralyte. | And, Abbott Laboratories ( ABT ) reported a Q1 EPS of $0.96, which beat the analyst consensus by $0.01. ABT was up 1.29% at $38.46 in pre-market trade with a 52-week range of $32.70 to $40.49. In healthcare stocks news, St. Jude Medical ( STJ ) reported Q1 earnings that exceeded analysts' expectations by one cent and sales that were in line with estimates while the guidance for Q2 and FY14 straddled the consensus. | And, Abbott Laboratories ( ABT ) reported Q1 EPS of $0.96, which beat the analyst consensus by $0.01. ABT was up 1.29% at $38.46 in pre-market trade with a 52-week range of $32.70 to $40.49. In healthcare stocks news, St. Jude Medical ( STJ ) reported Q1 earnings that exceeded analysts' expectations by one cent and sales that were in line with estimates while the guidance for Q2 and FY14 straddled the consensus."
2014-04-15,37.77000045776367,37.970001220703125,-0.954835953251008,"Will Abbott Labs (ABT) Disappoint This Quarter? - Analyst Blog | Pre-Market Earnings Report for April 16, 2014 : BAC, USB, ABT, PNC, ASML, STJ, GWW, HBAN, FRC, ADTN","ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) is scheduled to report first quarter 2014 results before the opening bell on Apr 16, 2014. Zacks Rank #3 (Hold): Abbott Labs' Zacks Rank #3 (Hold) lowers the predictive power of ESP because the Zacks Rank #3 when combined with a negative ESP makes surprise prediction difficult. | Abbott Laboratories ( ABT ) is reporting for the quarter ending March 31, 2014. In the past year ABT has met analyst expectations twice and beat the expectations the other two quarters. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ABT is 17.15 vs. an industry ratio of 17.70."
2014-04-14,37.18000030517578,37.7400016784668,0.5295227972345515,,
2014-04-11,36.95000076293945,37.02000045776367,1.506189802836173,Notable Two Hundred Day Moving Average Cross - ABT | Abbott Labs Progresses with Absorb - Analyst Blog,"In trading on Friday, shares of Abbott Laboratories (Symbol: ABT) crossed below their 200 day moving average of $36.83, changing hands as low as $36.65 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $32.70 per share, with $40.49 as the 52 week high point - that compares with a last trade of $36.93. According to the ETF Finder at ETF Channel, ABT makes up 10.19% of the iShares U.S. Medical Devices ETF (Symbol: IHI) which is trading lower by about 0.6% on the day Friday. | Abbott Laboratories ( ABT ) announced that it has completed enrollment of three clinical trials on Absorb, a drug-eluting coronary bioresorbable vascular scaffold (BVS) device. The ABSORB III trial (n=2000) will evaluate the potential benefits of Absorb in people with coronary artery disease in the U.S. The primary endpoint of ABSORB III trial is target lesion failure (TLF), a combined measure of the safety and effectiveness of Absorb versus Xience family of drug eluting stents at the end of first year."
2014-04-10,37.81999969482422,37.2599983215332,0.18944436638395926,"Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for April 11, 2014","Shareholders who purchased ABT stock prior to the ex-dividend date are eligible for the cash dividend payment. The previous trading day's last sale of ABT was $37.63, representing a -7.06% decrease from the 52 week high of $40.49 and a 15.08% increase over the 52 week low of $32.70. The following ETF(s) have ABT as a top-10 holding: Vanguard Dividend Appreciation ETF ( VIG ) WisdomTree Low P/E Fund ( EZY ) iShares U.S. Medical Devices ETF ( IHI ) Guggenheim BulletShares 2015 Corporate Bond ETF ( BSCF ) Schwab U.S. Large-Cap Value ETF ( SCHV )."
2014-04-09,37.720001220703125,37.630001068115234,-1.48070168643511,,
2014-04-08,38.20000076293945,37.619998931884766,-0.23860060889524265,,
2014-04-07,38.560001373291016,38.16999816894531,-1.5183293703422873,,
2014-04-04,38.869998931884766,38.630001068115234,-1.01141906238583,,
2014-04-03,38.7400016784668,38.650001525878906,-0.6174372790441803,,
2014-04-02,38.119998931884766,38.58000183105469,-0.2323184013642318,"Noteworthy ETF Inflows: VIG, ABT, CVX, WAG","Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.3%, Chevron Corporation (Symbol: CVX) is off about 0.1%, and Walgreen Co. (Symbol: WAG) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $211.5 million dollar inflow -- that's a 1.1% increase week over week in outstanding units (from 248,416,564 to 251,216,564). The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $64.83 per share, with $75.75 as the 52 week high point - that compares with a last trade of $75.68."
2014-04-01,38.4900016784668,38.470001220703125,1.2067232740270646,,
2014-03-31,38.47999954223633,38.5099983215332,-0.05196273549362071,Abbott's Supera Stent Approved in the U.S. - Analyst Blog,Abbott Laboratories ( ABT ) received a boost for its vascular portfolio when it announced that the U.S. Food and Drug Administration (FDA) approved its Supera peripheral stent system for the treatment of people with blocked blood vessels in the upper leg caused by peripheral artery disease (PAD). ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report LANNETT INC (LCI): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. The continued rollout of Absorb and Xience Xpedition along with new products such as Supera stents will further strengthen Abbott Labs' vascular portfolio in 2014.
2014-03-28,38.58000183105469,38.310001373291016,0.077959406584576,Baxter Hits 52-Week High on Planned Business Split-Up - Analyst Blog,"ABBOTT LABS (ABT): Free Stock Analysis Report BAXTER INTL (BAX): Free Stock Analysis Report MOODYS CORP (MCO): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Recent Split-up in HealthcareIndustry In early 2013, Abbott Laboratories ( ABT ) spun off its drug business into the new company, AbbVie. Baxter International Inc. ( BAX ) revealed that it will split-up its biopharmaceuticals and medical device segments into two independent companies in order to put greater management focus on the two businesses, effectively commercialize product offerings, efficiently allocate resources to high growth areas, and bring flexibility in deciding on growth and investment strategies."
2014-03-27,38.54999923706055,38.45000076293945,-0.6998456323201545,,
2014-03-26,38.54999923706055,38.560001373291016,-0.2593994191962497,Sector Update: Healthcare | Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews | Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook,"Additional details of the partnerships were not disclosed as well as any information on the companies' relationship with Abbott Laboratories ( ABT ), which markets Ensure through its Abbott Nutrition subsidiary. ABT was up 1.1% at $38.83 a share in late trade. Healthcare stocks were higher again with the NYSE Healthcare Sector Index advancing 0.4% and shares of healthcare companies in the S&P 500 also climbing 0.4% as a group. | ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report CUBIST PHARM (CBST): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report CHELSEA THERAP (CHTP): Free Stock Analysis Report FOREST LABS A (FRX): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report HORIZON PHARMA (HZNP): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MANNKIND CORP (MNKD): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report ONCOMED PHARMA (OMED): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report SALIX PHARM-LTD (SLXP): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report VANDA PHARMACT (VNDA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ( ABT ) split into two separate publicly traded companies; while one company deals in diversified medical products, the other, AbbVie ( ABBV ), is focusing on research-based pharmaceuticals. Zacks Industry Rank Within the Zacks Industry classification, pharma and biotech are broadly grouped into the Medical sector (one of 16 Zacks sectors) and further sub-divided into four industries at the expanded level: large-cap pharma, med-biomed/gene, med-drugs and med-generic drugs. | ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report CUBIST PHARM (CBST): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report CHELSEA THERAP (CHTP): Free Stock Analysis Report FOREST LABS A (FRX): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report HORIZON PHARMA (HZNP): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MANNKIND CORP (MNKD): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report ONCOMED PHARMA (OMED): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report SALIX PHARM-LTD (SLXP): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report VANDA PHARMACT (VNDA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ( ABT ) split into two separate publicly traded companies; while one company deals in diversified medical products, the other, AbbVie ( ABBV ), is focusing on research-based pharmaceuticals. Zacks Industry Rank Within the Zacks Industry classification, pharma and biotech are broadly grouped into the Medical sector (one of 16 Zacks sectors) and further sub-divided into four industries at the expanded level: large-cap pharma, med-biomed/gene, med-drugs and med-generic drugs."
2014-03-25,38.4900016784668,38.400001525878906,0.02594587919175123,,
2014-03-24,38.65999984741211,38.43000030517578,-0.23382735428208917,"Noteworthy ETF Inflows: IVE, WMT, ABT, F","Among the largest underlying components of IVE, in trading today Wal-Mart Stores, Inc. (Symbol: WMT) is up about 0.3%, Abbott Laboratories (Symbol: ABT) is up about 0.4%, and Ford Motor Co. (Symbol: F) is lower by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares S&P 500 Value ETF (Symbol: IVE) where we have detected an approximate $43.2 million dollar inflow -- that's a 0.7% increase week over week in outstanding units (from 76,150,000 to 76,650,000). The chart below shows the one year price performance of IVE, versus its 200 day moving average: Looking at the chart above, IVE's low point in its 52 week range is $72.37 per share, with $87.09 as the 52 week high point - that compares with a last trade of $86.22."
2014-03-21,39.209999084472656,38.38999938964844,-0.5949289786448984,,
2014-03-20,39.459999084472656,38.869998931884766,-2.091302509489072,,
2014-03-19,39.72999954223633,39.45000076293945,-1.495185418846229,Sucampo's NDA Gets Delayed - Analyst Blog,ABBOTT LABS (ABT): Free Stock Analysis Report SUCAMPO PHARMAC (SCMP): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report TAKEDA PHARMACT (TKPYY): Get Free Report To read this article on Zacks.com click here. Amitiza is approved for chronic constipation (CC) in Japan where it is marketed in collaboration with Abbott Laboratories ( ABT ). Sucampo Pharma's ( SCMP ) Amitiza was approved by the U.S. Food and Drug Administration (FDA) in 2006 for chronic idiopathic constipation (CIC) in adults.
2014-03-18,39.5,39.72999954223633,-0.7047540461187591,,
2014-03-17,39.04999923706055,39.5099983215332,0.5822773221172863,,
2014-03-14,39.18999862670898,38.970001220703125,1.1779746311392816,,
2014-03-13,39.7400016784668,39.22999954223633,-0.5613610964913851,Proshares Ultra S&P500 Experiences Big Inflow,"Among the largest underlying components of SSO, in trading today Abbott Laboratories (Symbol: ABT) is trading flat, Accenture plc (Symbol: ACN) is trading flat, and ACE, Ltd. (Symbol: ACE) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Proshares Ultra S&P500 (Symbol: SSO) where we have detected an approximate $511.2 million dollar inflow -- that's a 19.1% increase week over week in outstanding units (from 25,500,000 to 30,375,000). The chart below shows the one year price performance of SSO, versus its 200 day moving average: Looking at the chart above, SSO's low point in its 52 week range is $70.11 per share, with $106.77 as the 52 week high point - that compares with a last trade of $104.95."
2014-03-12,39.43999862670898,39.65999984741211,-1.2833470425010436,,
2014-03-11,39.84999847412109,39.709999084472656,0.5578124451407717,,
2014-03-10,39.5,39.81999969482422,-0.3513159222310815,,
2014-03-07,39.84000015258789,39.56999969482422,0.8101258096815664,,
2014-03-06,39.91999816894531,39.72999954223633,-0.6777119897830458,,
2014-03-05,40.4900016784668,39.790000915527344,-0.475948485530715,,
2014-03-04,39.7400016784668,40.119998931884766,-1.728823743941024,"Notable ETF Outflow Detected - SSO, ABT, ACN, ACE","Among the largest underlying components of SSO, in trading today Abbott Laboratories (Symbol: ABT) is up about 1.9%, Accenture plc (Symbol: ACN) is up about 1.7%, and ACE, Ltd. (Symbol: ACE) is higher by about 1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Proshares Ultra S&P500 (Symbol: SSO) where we have detected an approximate $46.0 million dollar outflow -- that's a 2.9% decrease week over week (from 15,600,000 to 15,150,000). The chart below shows the one year price performance of SSO, versus its 200 day moving average: Looking at the chart above, SSO's low point in its 52 week range is $66.94 per share, with $104.97 as the 52 week high point - that compares with a last trade of $104.94."
2014-03-03,39.5,39.33000183105469,0.9562084483349961,,
2014-02-28,39.619998931884766,39.77999877929688,-0.4303751112539557,,
2014-02-27,39.34999847412109,39.790000915527344,0.40383607199785737,,
2014-02-26,39.290000915527344,39.38999938964844,1.1181765145318343,,
2014-02-25,38.9900016784668,39.25,0.25451379941702806,,
2014-02-24,38.869998931884766,38.97999954223633,0.6668333171085594,"SSO, ABT, ACN, ACE: ETF Outflow Alert | Daily Dividend Report: K, ABT, SYY, AGU, PLL","Among the largest underlying components of SSO, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.8%, Accenture plc (Symbol: ACN) is up about 0.6%, and ACE, Ltd. (Symbol: ACE) is up by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Proshares Ultra S&P500 (Symbol: SSO) where we have detected an approximate $75.9 million dollar outflow -- that's a 4.6% decrease week over week (from 16,350,000 to 15,600,000). The chart below shows the one year price performance of SSO, versus its 200 day moving average: Looking at the chart above, SSO's low point in its 52 week range is $65.48 per share, with $102.88 as the 52 week high point - that compares with a last trade of $102.71. | In other dividend news, Abbott Labs ( ABT ) maintained its quarterly dividend of 22 cents per share. VIDEO: Daily Dividend Report: K, ABT, SYY, AGU, PLL The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. This morning, Kellogg ( K ) declared its quarterly dividend of 46 cents per share, maintaining the amount paid to shareholders the prior quarter."
2014-02-21,38.880001068115234,38.81999969482422,0.2829961753905011,,
2014-02-20,38.81999969482422,38.95000076293945,-0.15432451554180032,,
2014-02-19,38.7400016784668,38.7599983215332,0.33488168247607464,,
2014-02-18,38.959999084472656,38.93000030517578,0.05161755859582517,Unilife And The Third Place In Healthcare: Why Trends Matter And Why Success Is Inevitable,"As the patient user interface, the superior functionality and ergonomic design of Unilife's delivery systems - and the benefits they provide to the self-injecting patient in terms of safety, convenience and ease of use - are key differentiators that will drive both patient acceptance and physician preference in writing prescriptions, which in turn will drive market share and revenues for both Unilife and the pharmaceutical companies who choose to use Unilife delivery systems. As product differentiation becomes an increasingly important pillar in the long term success of pharmaceutical companies' injectable drug therapies in theglobal market so too the inherent differentiation of Unilife's unique technology becomes an essential element in Unilife's long term success. As Unilife's unique platform technology becomes increasingly embedded into the drug development, regulatory approval process and product differentiation/life-cycle management strategies of pharmaceutical companies, so too pharmaceutical companies better understand and become more comfortable with the benefits of signing long term commercial Supply Agreements with Unilife."
2014-02-14,38.68000030517578,38.810001373291016,-0.07699892197592707,,
2014-02-13,38.06999969482422,38.720001220703125,0.336093761865454,,
2014-02-12,37.93000030517578,38.2599983215332,1.7073851617794387,Health Care Select Sector SPDR Fund Experiences Big Outflow,"Among the largest underlying components of XLV, in trading today Eli Lilly & Co. (Symbol: LLY) is down about 0.8%, Abbott Laboratories (Symbol: ABT) is up about 0.9%, and Thermo Fisher Scientific Inc (Symbol: TMO) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $51.8 million dollar outflow -- that's a 0.6% decrease week over week (from 156,765,324 to 155,865,324). The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $42.71 per share, with $57.91 as the 52 week high point - that compares with a last trade of $57.75."
2014-02-11,37.04999923706055,37.95000076293945,0.8700184911741,,
2014-02-10,37.16999816894531,37.15999984741211,2.4291539660239683,,
2014-02-07,36.77000045776367,37.18000030517578,-0.026898902409837874,,
2014-02-06,36.40999984741211,36.650001525878906,1.1150390054606087,,
2014-02-05,36.119998931884766,36.34999847412109,0.6591641842147805,,
2014-02-04,35.900001525878906,36.25,0.6367650859294184,,
2014-02-03,36.58000183105469,35.849998474121094,0.9749260703200627,,
2014-01-31,36.02999877929688,36.65999984741211,-1.9956351022209506,Abaxis Misses Q3 Earnings & Revs - Analyst Blog,"Adjusting for prior-year quarter's stocking order from Abbott Laboratories (ABT), worldwide medical sales were up 18%. Segment in Detail On a geographic-region basis, revenues from North America (accounting for 77.9% of total revenues) were down 24% to $31.8 million, while revenues from the international market (representing the rest) increased 13% to $9.0 million. Veterinary market revenues shrunk 19.1% year over year to $32.2 million, while sales in the Medical market declined 12.5% year over year to roughly $7.9 million."
2014-01-30,36.2400016784668,36.52999877929688,1.7485459046899294,,
2014-01-29,36.2599983215332,35.849998474121094,0.8002127135727939,,
2014-01-28,36.540000915527344,36.369998931884766,-1.130722190818825,,
2014-01-27,36.68000030517578,36.29999923706055,-0.4652489857227598,,
2014-01-24,37.20000076293945,36.58000183105469,-1.0359898172127708,,
2014-01-23,37.900001525878906,37.43000030517578,-1.6666637612073394,,
2014-01-22,38.02000045776367,38.06999969482422,-1.2401087118220786,"Sector Update: Healthcare Shares Mixed Pre-Market; Abbott Labs Dips on Q4 Results | Sector Update: Healthcare | Abbott Earnings Preview: Steady Growth Expected Despite Short Term Weakness In Nutritionals | Abbott Posts In-Line Earnings, Misses Sales - Analyst Blog","Among news in this sector, Abbott Labs ( ABT ) is down 0.3% this morning as it reports Q4 EPS of $0.58, in line with the analyst consensus on Capital IQ. MRK: flat AMGN: flat Healthcare shares are generally trading flat in pre-market trade. VIVO reported Q1 earnings of $7.4 million, or $0.18 per diluted share, compared with the prior-year period's $8.47 million or $0.20 per share. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott Labs ( ABT ) is down 0.3% this morning as it reports Q4 EPS of $0.58, in line with the analyst consensus on Capital IQ. VIVO reported Q1 earnings of $7.4 million, or $0.18 per diluted share, compared with the prior-year period's $8.47 million or $0.20 per share. | Abbott Labs ( ABT ) is scheduled to release its Q4 2013 earnings on Wednesday, January 22. In the previous quarter, the company reported a 4.3% year-over-year increase in operational sales as Diagnostics, Abbott's second largest business division, saw an impressive 10.5% revenue increase. See our full analysis for Abbott Labs Nutritionals and Diagnostics To Drive Growth Again Together, the Nutritionals and Diagnostics divisions account for over 50% of Abbott's revenue. | Abbott Laboratories ( ABT ) reported fourth quarter 2013 earnings of 58 cents per share, in line with the Zacks Consensus Estimate. ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report LANNETT INC (LCI): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs generated sales of $5.6 billion in the fourth quarter of 2013, up 0.4% year over year, but fell short of Zacks Consensus Estimate of $5.7 billion."
2014-01-21,39.52000045776367,39.119998931884766,0.1315077234575284,"Two Candidates For An Earnings Straddle | Pre-Market Earnings Report for January 22, 2014 : UTX, USB, ABT, ASML, FCX, GD, NSC, TEL, STJ, PH, MSI, PGR | Earnings Preview: Will Abbott Labs (ABT) Disappoint This Quarter? - Analyst Blog","Abbot Laboratories (ABT) will release earnings tomorrow (Wednesday) and looks to be a decent option for a fairly inexpensive straddle. Now I don't claim to know whether the news from ABT will be good or bad, but I don't have to. The above chart for ABT shows the last earnings release date as a vertical yellow line. | Zacks Investment Research reports that the 2013 Price to Earnings ratio for ABT is 19.60 vs. an industry ratio of 17.00, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories ( ABT ) is reporting for the quarter ending December 31, 2013. In the past year ABT has met analyst expectations once and beat the expectations the other three quarters. | ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) is scheduled to report fourth quarter 2013 results before the opening bell on Jan 22, 2014. Zacks Rank #3(Hold): Abbott Labs' Zacks Rank #3 (Hold) when combined with a 0.00% ESP makes surprise prediction difficult."
2014-01-17,39.86000061035156,39.400001525878906,-1.0121495982936566,Companies Struggling to Meet Expectations - Earnings Preview,"ABBOTT LABS (ABT): Free Stock Analysis Report COACH INC (COH): Free Stock Analysis Report EBAY INC (EBAY): Free Stock Analysis Report FACEBOOK INC-A (FB): Free Stock Analysis Report GOOGLE INC-CL A (GOOG): Free Stock Analysis Report GRAINGER W W (GWW): Free Stock Analysis Report HALLIBURTON CO (HAL): Free Stock Analysis Report INTL BUS MACH (IBM): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report KIMBERLY CLARK (KMB): Free Stock Analysis Report KANSAS CITY SOU (KSU): Free Stock Analysis Report SOUTHWEST AIR (LUV): Free Stock Analysis Report MCDONALDS CORP (MCD): Free Stock Analysis Report MICROSOFT CORP (MSFT): Free Stock Analysis Report NORFOLK SOUTHRN (NSC): Free Stock Analysis Report PROCTER & GAMBL (PG): Free Stock Analysis Report STARBUCKS CORP (SBUX): Free Stock Analysis Report TRAVELERS COS (TRV): Free Stock Analysis Report TEXAS INSTRS (TXN): Free Stock Analysis Report UNION PAC CORP (UNP): Free Stock Analysis Report UTD TECHS CORP (UTX): Free Stock Analysis Report VERIZON COMM (VZ): Free Stock Analysis Report To read this article on Zacks.com click here. Wednesday-1/22 Another busy day on the earnings front and not much on theeconomic calendar Coach ( COH ), Abbott Labs ( ABT ), Norfolk Southern ( NSC ) and United Technology ( UTX ) are the key reports in the morning, while eBay ( EBAY ) will report after the close. Companies Struggling to Meet Expectations The bulk of the 2013 Q4 earnings reports thus far have been from the Finance sector, but the reporting cycle ramps up materially this week, with almost 200 companies including 69 S&P 500 members reporting results."
2014-01-16,39.52999877929688,39.540000915527344,-1.1540368224510147,,
2014-01-15,39.59999847412109,39.52999877929688,0.025302647455936886,,
2014-01-14,39.29999923706055,39.56999969482422,-0.17676691293296362,,
2014-01-13,39.11000061035156,39.11000061035156,0.6870240788937649,,
2014-01-10,39.27000045776367,39.56999969482422,0.0,,
2014-01-09,39.27000045776367,39.27000045776367,0.7639399887025902,Seattle Gentics-AbbVie Deal Expanded - Analyst Blog,"We note that in Mar 2011, Abbott Laboratories ( ABT ) (prior to its spin-off of AbbVie) had entered into a collaboration agreement with Seattle Genetics under which Abbott paid an upfront fee of $8 million for rights to utilize Seattle Genetics' ADC technology with its antibodies to a single oncology target. ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report SEATTLE GENETIC (SGEN): Free Stock Analysis Report WUXI PHARMATECH (WX): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie will pay an upfront fee of $25 million for additional rights of using Seattle Genetics' ADC technology with AbbVie antibodies against oncology targets."
2014-01-08,38.84999847412109,39.20000076293945,0.0,,
2014-01-07,39.22999954223633,38.84999847412109,0.9009068277094306,,
2014-01-06,39.18999862670898,39.150001525878906,-0.9686491780508936,,
2014-01-03,38.369998931884766,38.63999938964844,-0.10205945963675533,,
2014-01-02,38.09000015258789,38.22999954223633,0.7036759585085796,,
2013-12-31,38.380001068115234,38.33000183105469,0.36754893433342695,,
2013-12-30,38.47999954223633,38.40999984741211,-0.1302741940309233,,
2013-12-27,38.52000045776367,38.369998931884766,-0.1819118910003776,,
2013-12-26,38.220001220703125,38.34999847412109,-0.3894120563248165,,
2013-12-24,38.36000061035156,38.18999862670898,0.3401288573155365,,
2013-12-23,37.970001220703125,38.43999862670898,-0.44317513278847465,,
2013-12-20,38.13999938964844,37.84000015258789,1.2378124595623832,,
2013-12-19,38.08000183105469,38.02999877929688,-0.7865737856880238,,
2013-12-18,36.65999984741211,38.119998931884766,-0.13131052876427995,,
2013-12-17,36.45000076293945,36.61000061035156,3.9825397996441074,,
2013-12-16,36.45000076293945,36.52999877929688,0.43895704818417797,,
2013-12-13,36.380001068115234,36.400001525878906,0.21947329131133236,,
2013-12-12,36.56999969482422,36.290000915527344,0.0549765178022521,,
2013-12-11,37.0,36.58000183105469,-0.7656515767937057,,
2013-12-10,37.11000061035156,37.11000061035156,-1.1351301863386825,,
2013-12-09,37.56999969482422,37.20000076293945,0.0,,
2013-12-06,37.27000045776367,37.52999877929688,-0.984825485467699,Dividend Aristocrat Johnson & Johnson Offers Growth,"Johnson & Johnson and rivalAbbott Laboratories ( ABT ) are the only two members of IBD's Medical-Diversified group. Johnson & Johnson has delivered higher adjusted earnings for 29 straight years. In the latest quarters, Johnson & Johnson has reported double-digit gains in its Zytiga prostate cancer treatment, Stelara psoriasis drug and Simponi arthritis medication."
2013-12-05,37.290000915527344,36.91999816894531,0.6976075082903581,,
2013-12-04,37.34999847412109,37.36000061035156,-0.9922304572214805,,
2013-12-03,37.95000076293945,37.59999847412109,0.026779482300129394,Pharma & Biotech Stock Outlook - Dec 2013 - Zacks Analyst Interviews | Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook,"ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report ALKERMES INC (ALKS): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report AUXILIUM PHARMA (AUXL): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BIOLINE RX LTD (BLRX): Get Free Report BRISTOL-MYERS (BMY): Free Stock Analysis Report CUBIST PHARM (CBST): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report FOREST LABS A (FRX): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MEDIVATION INC (MDVN): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PHARMACYCLICS (PCYC): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report PERRIGO COMPANY (PRGO): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Get Free Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report SANTARUS INC (SNTS): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report VANDA PHARMACT (VNDA): Free Stock Analysis Report VIROPHARMA (VPHM): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report XOMA CORP (XOMA): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ( ABT ) split into two separate publicly traded companies; while one company deals in diversified medical products, the other, AbbVie ( ABBV ), is focusing on research-based pharmaceuticals. Zacks Industry Rank Within the Zacks Industry classification, pharma and biotech are broadly grouped into the Medical sector (one of 16 Zacks sectors) and further sub-divided into four industries at the expanded level: large-cap pharma, med-biomed/gene, med-drugs and med-generic drugs. | ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report ALKERMES INC (ALKS): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report AUXILIUM PHARMA (AUXL): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BIOLINE RX LTD (BLRX): Get Free Report BRISTOL-MYERS (BMY): Free Stock Analysis Report CUBIST PHARM (CBST): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report FOREST LABS A (FRX): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MEDIVATION INC (MDVN): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PHARMACYCLICS (PCYC): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report PERRIGO COMPANY (PRGO): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Get Free Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report SANTARUS INC (SNTS): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report VANDA PHARMACT (VNDA): Free Stock Analysis Report VIROPHARMA (VPHM): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report XOMA CORP (XOMA): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ( ABT ) split into two separate publicly traded companies; while one company deals in diversified medical products, the other, AbbVie ( ABBV ), is focusing on research-based pharmaceuticals. Zacks Industry Rank Within the Zacks Industry classification, pharma and biotech are broadly grouped into the Medical sector (one of 16 Zacks sectors) and further sub-divided into four industries at the expanded level: large-cap pharma, med-biomed/gene, med-drugs and med-generic drugs."
2013-12-02,38.2400016784668,38.13999938964844,-0.9222721522582038,,
2013-11-29,38.43999862670898,38.18999862670898,-0.2615122500757403,Abbott Laboratories (ABT): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report,Abbott Laboratories (ABT): Read the Full Research Report Want the latest recommendations from Zacks Investment Research? Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. We expect the sale of the branded generics business to positively impact the top and bottom lines as Abbott now intends to focus on its branded generics pharmaceuticals business in emerging markets.
2013-11-27,38.7400016784668,38.31999969482422,-0.650364227188849,,
2013-11-26,38.290000915527344,38.06999969482422,-1.0841558220066665,,
2013-11-25,38.380001068115234,38.150001525878906,-0.5745657232771446,,
2013-11-22,38.130001068115234,38.25,-0.5992692439693643,,
2013-11-21,38.380001068115234,38.06999969482422,0.31471001448544456,,
2013-11-20,38.75,38.18000030517578,-0.8077159058459589,,
2013-11-19,37.93000030517578,38.709999084472656,-1.4709669543850805,,
2013-11-18,38.040000915527344,37.93999862670898,2.056416485687292,Loss Widens at Apricus - Analyst Blog,"ABBOTT LABS (ABT): Free Stock Analysis Report APPRICUS BIOSCI (APRI): Free Stock Analysis Report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report To read this article on Zacks.com click here. In the 2012 quarter license fees worth $2.5 million and $1.0 million were recognized from Abbott Laboratories ( ABT ) and Takeda Pharmaceutical Co. Ltd. ( TKPYY ), respectively. Revenues in the year-ago quarter comprised license fee and contract service revenues whereas the reported quarter only included contract service revenues."
2013-11-15,37.77000045776367,38.04999923706055,-0.2628871882533186,,
2013-11-14,37.88999938964844,37.7599983215332,0.7413258562439887,,
2013-11-13,37.369998931884766,37.77000045776367,-0.34310126737756225,,
2013-11-12,37.83000183105469,37.470001220703125,1.0703814217602712,,
2013-11-11,38.16999816894531,37.900001525878906,-0.9516272612390878,,
2013-11-08,37.5099983215332,38.119998931884766,-0.7073530417040275,,
2013-11-07,37.61000061035156,37.63999938964844,1.6262347044717997,,
2013-11-06,37.45000076293945,37.560001373291016,0.07976277269354339,,
2013-11-05,36.84999847412109,37.36000061035156,0.2937265904155046,,
2013-11-04,36.97999954223633,36.97999954223633,1.3839949995890468,,
2013-11-01,36.68999862670898,36.959999084472656,0.0,,
2013-10-31,37.0099983215332,36.54999923706055,0.73589661452625,,
2013-10-30,37.33000183105469,36.93999862670898,-1.2429049049835244,,
2013-10-29,37.36000061035156,37.27999877929688,-1.0447446697451486,,
2013-10-28,37.33000183105469,37.27999877929688,-0.21413765992421796,Abbott Labs' Mitra Clip Approved in the U.S. - Analyst Blog,"ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) received positive news when the U.S. Food and Drug Administration (FDA) approved its percutaneous valve repair system, MitraClip. The approval of MitraClip will strengthen Abbott Labs' vascular business which already has drug-eluting stent, Xience Xpedition and BVS Absorb, under its portfolio."
2013-10-25,37.2400016784668,37.25,-0.13394869891543387,,
2013-10-24,37.220001220703125,37.209999084472656,0.026848338030512044,,
2013-10-23,36.90999984741211,37.22999954223633,-0.026873014246182228,,
2013-10-22,36.93999862670898,37.02000045776367,0.866972896632659,,
2013-10-21,37.16999816894531,36.86000061035156,0.2165723714912386,,
2013-10-18,37.16999816894531,37.290000915527344,-0.8339993916188726,The Awful Truth About the Medical Device Tax,"Members of AdvaMed are the most moneyed and powerful in the business and include 3M ( MMM ), Abbott Laboratories ( ABT ), Johnson & Johnson ( JNJ ), Kimberly-Clark ( KMB ), Eli Lilly ( LLY ), Pfizer (PFE), Roche (OTCMKTS:RHHBY), Siemens (SI) and hundreds more . The New York Timescalled the medical device tax a ""distraction from reforms to the industry that are urgently needed to lower health care costs."" That's what AdvaMed, the industry's trade association, has spent on lobbying to ensure medical device companies get out of this tax."
2013-10-17,35.88999938964844,37.16999816894531,0.3228484059552384,"Market Primer: Thursday, October 17: US Debt Deal Kicks The Can","International Business Machines Corp. (NYSE: IBM ) lost 6.09 percent in pre-market trade after gaining 2.98 percent over the past week Abbott Laboratories (NYSE: ABT ) lost 0.33 percent in pre-market trade after gaining 6.50 percent on Wednesday Earnings reports expected on Thursday include: Google Inc. (NASDAQ: GOOG ) is expected to report third quarter EPS of $10.36 on revenue of $14.84 billion, compared to last year's EPS of $9.03 per share on revenue of $11.33 billion. Earnings Notable earnings released on Wednesday included: eBay Inc. (NASDAQ: EBAY ) reported third quarter EPS of $0.64 on revenue of $3.90 billion, compared to last year's EPS of $0.55 per share on revenue of $3.40 billion. UnitedHealth Group Inc. (NYSE: UNH ) is expected to report third quarter EPS of $1.52 on revenue of $30.83 billion, compared to last year's EPS of $1.50 on revenue of $27.30 billion."
2013-10-16,34.349998474121094,35.900001525878906,3.56644971040612,"Abbott Labs Beats Earnings, Reiterates Guidance - Analyst Blog | Mattel beats third quarter earnings and revenue estimates | DC Hijinx Cloud Earnings Season - Ahead of Wall Street | Sector Update: Healthcare Shares Flat to Higher; Isis Pharmaceutical Nabs $10 Mln Milestone Payment | Sector Update: Healthcare","Abbott Laboratories ( ABT ) reported third quarter 2013 earnings of 55 cents per share, beating the Zacks Consensus Estimate of 51 cents. ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs generated sales of $5.4 billion in the third quarter of 2013, up 2.0% year over year, and in line with the Zacks Consensus Estimate. | VisionChina ( VISN ) and Abbot Labs ( ABT ) top the list of other companies with positive news today, while Stanley Black and Decker ( SWK ) and Exelon ( EXC ) top the list of companies with negative news. Mattel beats third quarter earnings and revenue estimates Julian Close 10/16/2013 Shares of Mattel ( MAT ) are trading higher this Wednesday morning, after the company announced its third quarter results. [InvestorsKeyhole, Various news and data services] The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs ( ABT ) posted an earnings beat before the market open today, and announced a raise in quarterly dividend. Mark Vickery Senior Editor ABBOTT LABS (ABT): Free Stock Analysis Report BANK OF AMER CP (BAC): Free Stock Analysis Report EBAY INC (EBAY): Free Stock Analysis Report FACEBOOK INC-A (FB): Free Stock Analysis Report INTL BUS MACH (IBM): Free Stock Analysis Report INTEL CORP (INTC): Free Stock Analysis Report NETFLIX INC (NFLX): Free Stock Analysis Report YAHOO! Click to get this free report The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ABT: flat And, Abbott ( ABT ) is up 0.6% at $33.90 as it reports Q3 EPS of $0.55, vs. the analyst consensus of $0.52 per share on Capital IQ. | And, Abbott ( ABT ) is up 0.6% at $33.90 as it reports Q3 EPS of $0.55, vs. the analyst consensus of $0.52 per share on Capital IQ. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2013-10-15,33.90999984741211,33.709999084472656,4.512381719392412,Earnings Preview: Will Abbott Labs (ABT) Disappoint in Q3? - Analyst Blog,"ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) is scheduled to report third quarter 2013 results before the opening bell on Oct 16, 2013. Negative Zacks ESP : The Earnings ESP for Abbott Labs is -1.92%."
2013-10-14,33.5099983215332,34.0,-0.5897987727496745,3 Ultra Safe Stocks... Just in Case - Investment Ideas,"Learn More>> ABBOTT LABS (ABT): Free Stock Analysis Report DOLLAR TREE INC (DLTR): Free Stock Analysis Report AQUA AMER INC (WTR): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ( ABT ) This large-cap diversified healthcare company derives 70% of its sales from outside of the United States and operates in relatively inelastic, stable businesses like branded generic pharmaceuticals. 3 Ultra Safe Stocks While the ultimate ramifications of a U.S. default are nearly impossible to predict, these 3 stocks should at least hold up much better than the overall market: Dollar Tree ( DLTR ) Dollar Tree is a discount retailer with thousands of stores in all 48 contiguous states."
2013-10-11,33.630001068115234,33.7599983215332,1.462255156700281,,
2013-10-10,33.34000015258789,33.63999938964844,0.38655144005100783,,
2013-10-09,33.029998779296875,33.16999816894531,0.899817743513899,,
2013-10-08,33.54999923706055,33.0099983215332,0.42385526740070234,,
2013-10-07,33.220001220703125,33.5,-1.6095407684267222,,
2013-10-04,33.310001373291016,33.560001373291016,0.8428620379531359,,
2013-10-03,33.790000915527344,33.290000915527344,0.7505253368150795,Valeant Eyes New Growth Platform With Bausch & Lomb | X Factor: 5 Stocks Reaching Their Ex-Dividend Date on October 10,"""Valeant is now stepping into a concentrated market and will face off againstNovartis ( NVS ), Allergan ( AGN ),Abbott ( ABT ) andJohnson & Johnson ( JNJ ), rather than the fragmented group of small companies that it competes with in dermatology,"" he wrote in a report soon after Valeant announced the Bausch & Lomb deal. The Bausch & Lomb deal comes as Valeant continues to build muscle in the dermatology arena through buyouts. Krempa added: ""Ophthalmology is unlikely to be as successful as dermatology for Valeant, as it will be at a severe disadvantage to industry giants Novartis and Johnson & Johnson, but the Bausch & Lomb brand maintains a solid position in the $36 billion industry. | Abbott Laboratories ( ABT ) yields 1.67% annually and has a market cap of $52.12 billion. The gold and resource miner will pay a quarterly dividend of $0.3125 on November 1, and the quarterly yield of the dividend will be 0.93% based on yesterday's closing price of $33.51. The company has paid a quarterly dividend since 1983, and each dividend payment has either increased or remained the same from the prior quarter."
2013-10-02,33.47999954223633,33.900001525878906,-1.4797276900049967,,
2013-10-01,33.16999816894531,33.779998779296875,1.2544862287489855,,
2013-09-30,33.04999923706055,33.189998626708984,1.839013096246301,,
2013-09-27,33.45000076293945,33.13999938964844,0.4235987681701653,,
2013-09-26,33.75,33.65999984741211,-0.9267604371312246,,
2013-09-25,34.31999969482422,33.66999816894531,-0.2666671187789352,"After Hours Most Active for Sep 25, 2013 : MSFT, T, C, QQQ, HBAN, ABT, XOM, BAC, MET, DECK, ATVI, INTC","Abbott Laboratories ( ABT ) is +0.1 at $33.77, with 1,342,425 shares traded. ABT's current last sale is 84.43% of the target price of $40. AT&T Inc. ( T ) is +0.1 at $34.15, with 1,656,177 shares traded."
2013-09-24,35.06999969482422,34.36000061035156,-1.8939438568145812,,
2013-09-23,35.25,35.119998931884766,-2.0245197908497303,,
2013-09-20,35.38999938964844,35.290000915527344,-0.36879735635527483,,
2013-09-19,35.65999984741211,35.34000015258789,-0.2825613897872608,,
2013-09-18,35.0,35.650001525878906,-0.8973631413165626,CE Mark for Abbott Product - Analyst Blog,"ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ( ABT ) recently announced that it has obtained the CE Marking (Conformite Europeenne) in Europe for its glucose monitoring system - FreeStyle Optium Neo Blood Glucose and Ketone Monitoring System. Although growth in the emerging markets is forecasted to be strong, Abbott Labs expects the implementation of Centers for Medicare and Medicaid Services (CMS) competitive bidding for Medicare patients to impact sales in the U.S. in the remainder of the year."
2013-09-17,35.0,34.970001220703125,1.8571472167968748,,
2013-09-16,35.099998474121094,35.0099983215332,-0.08571079799107142,,
2013-09-13,34.900001525878906,34.869998931884766,-0.2564107022803631,,
2013-09-12,34.7599983215332,34.7599983215332,-0.08596731427617052,Abaxis Maintained at Neutral - Analyst Blog,"ABAXIS INC (ABAX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ALERE INC (ALR): Free Stock Analysis Report MWI VET SUPPLY (MWIV): Free Stock Analysis Report To read this article on Zacks.com click here. Although the distribution relationship with MWI Veterinary Supply Inc. ( MWIV ) is yielding positive outcomes, the same with Abbott ( ABT ) in the medical market is yet to pay off. On the positive side, Abaxis remains a strong player in its core veterinary market that continues to record healthy growth."
2013-09-11,34.11000061035156,34.75,0.0,,
2013-09-10,34.040000915527344,34.09000015258789,1.8762807921328888,MedTech Industry Stock Update - Sept 2013 - Zacks Analyst Interviews,"ABBOTT LABS (ABT): Free Stock Analysis Report ATHENAHEALTH IN (ATHN): Free Stock Analysis Report BAXTER INTL (BAX): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report BARD C R INC (BCR): Free Stock Analysis Report BECTON DICKINSO (BDX): Free Stock Analysis Report COVIDIEN PLC (COV): Free Stock Analysis Report QUEST DIAGNOSTC (DGX): Free Stock Analysis Report HAEMONETICS CP (HAE): Free Stock Analysis Report HOLOGIC INC (HOLX): Free Stock Analysis Report HUMANA INC NEW (HUM): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LIFE TECHNOLOGS (LIFE): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report PALL CORP (PLL): Free Stock Analysis Report ST JUDE MEDICAL (STJ): Free Stock Analysis Report STRYKER CORP (SYK): Free Stock Analysis Report THERMO FISHER (TMO): Free Stock Analysis Report ZIMMER HOLDINGS (ZMH): Free Stock Analysis Report To read this article on Zacks.com click here. About the same time, Abbott Labs ( ABT ) completed two significant purchases. Companies like Medtronic, Boston Scientific, Edwards Lifescience ( EW ), Thermo Fisher Scientific, Life Technologies, Smith and Nephew ( SNN ) and many more are all vying to expand their presence in BRIC and other emerging markets."
2013-09-09,33.5,33.79999923706055,0.1468837711979606,,
2013-09-06,33.720001220703125,33.5,0.8955201106284982,,
2013-09-05,33.5,33.7400016784668,-0.6524353877189378,Good News for Abbott Labs - Analyst Blog,ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ALERE INC (ALR): Free Stock Analysis Report EXACTECH INC (EXAC): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ( ABT ) recently announced encouraging initial results from a study on its ARCHITECTSTAT High Sensitive Troponin-I (hsTnI) test. We are encouraged by Abbott Labs traction in its diagnostics business and expect further momentum from new tests.
2013-09-04,33.0099983215332,33.459999084472656,0.7164229207964086,,
2013-09-03,33.68000030517578,32.93000030517578,1.3632256462306664,"After Hours Most Active for Sep 3, 2013 : NOK, VOD, TSN, QQQ, MSFT, ABT, GE, CSCO, TLAB, BAC, VALE, AMAT","Abbott Laboratories ( ABT ) is -0.0901 at $32.84, with 908,236 shares traded. ABT's current last sale is 82.1% of the target price of $40. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Oct 2013."
2013-08-30,33.720001220703125,33.33000183105469,-2.2268408349293978,,
2013-08-29,33.630001068115234,33.72999954223633,-1.1565817779656216,,
2013-08-28,33.970001220703125,33.75,0.29734900667577674,,
2013-08-27,34.31999969482422,34.0099983215332,-0.6476338321973464,,
2013-08-26,34.83000183105469,34.52000045776367,-0.9032674127260168,,
2013-08-23,34.849998474121094,34.84000015258789,-0.8900412201948726,,
2013-08-22,34.66999816894531,34.66999816894531,-0.028689589586718856,Epizyme Wins Orphan Drug Status - Analyst Blog,"ABBOTT LABS (ABT): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report EPIZYME INC (EPZM): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Moreover, in Apr 2013, Epizyme joined forces with Abbott Laboratories ( ABT ) for the development of a molecular companion diagnostic test for use with EPZ-5676. Recently, Epizyme, Inc. ( EPZM ) announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug status to the company's pipeline candidate EPZ-5676."
2013-08-21,34.68000030517578,34.63999938964844,0.0,Profit From The Market's Misunderstanding Of This Spinoff Company | Abbott Acquires OptiMedica - Analyst Blog,"Earlier this year, Abbott Laboratories ( ABT ) completed a split after realizing the company had grown into two distinct units. A 1993 study titled ""Restructuring Through Spinoffs"" found that spinoff companies outperformed the S&P 500index by 30% on average during their first three years. AbbVie ( ABBV ) now trades as the former pharma business of Abbott Labs, while Abbott continues as a health care products and medical devices company. | ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ( ABT ) recently announced that it has completed the previously announced acquisition of privately-held OptiMedica Corporation for $250 million in cash. Hence, the acquisition will further boost the cataract surgery business at Abbott Labs' which currently account for 60% of total sales of the vision care business."
2013-08-20,34.900001525878906,34.709999084472656,-0.11534289266247168,,
2013-08-19,34.849998474121094,34.880001068115234,-0.5444195790804197,,
2013-08-16,34.91999816894531,34.970001220703125,0.08609066085446158,China: Will Tainted Baby Formula Spur Cultural Shift?,"Hackett explains that there was also a ""big baby formula price fixing scandal in China earlier this month,"" which involved Fonterra and five other companies: Abbott Labs ( ABT ), Mead Johnson ( MJN ), Danone (OTCMKTS:DANOY), Biostime (OTCMKTS:BTSDF), and Friesland. This bias, said Global Times , was ""not a product of Chinese groveling before everything foreign, as some critics claim,"" but rather, a ""deep, knee-jerk mistrust of homegrown dairy brands, which have yet to recover from a string of past abuses, the most infamous being the melamine scandal in 2008 that killed six infants and sickened tens of thousands of others."" Per Taiwan's Want China Times , ""the milk-drinking parties were a novelty sparked by recent revelations that wealthy businessmen in Shenzhen have been hiring wet nurses for their own use because they believe in the health benefits of human breast milk."
2013-08-15,35.5099983215332,35.029998779296875,0.14319316832691215,,
2013-08-14,35.90999984741211,35.61000061035156,-1.3517306812860568,,
2013-08-13,35.93000030517578,35.939998626708984,-0.8354197670155841,,
2013-08-12,35.790000915527344,35.900001525878906,0.02782722362449535,,
2013-08-09,35.79999923706055,35.88999938964844,0.3073501188535572,,
2013-08-08,36.20000076293945,35.91999816894531,0.25139707962541374,,
2013-08-07,36.06999969482422,35.93000030517578,-0.7734878124113175,,
2013-08-06,36.25,36.09999847412109,-0.388132494685123,,
2013-08-05,36.63999938964844,36.45000076293945,-0.4137973127694161,,
2013-08-02,36.790000915527344,36.75,-0.5185552125381938,,
2013-08-01,36.88999938964844,36.84000015258789,-0.10872768288097875,,
2013-07-31,36.869998931884766,36.630001068115234,-0.1355360202976229,,
2013-07-30,36.97999954223633,36.880001068115234,-0.6509299450019342,Pharma & Biotech Stock Outlook - July/Aug 2013 - Industry Outlook,"ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ACTAVIS INC (ACT): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report FOREST LABS A (FRX): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MEDIVATION INC (MDVN): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report ONYX PHARMA INC (ONXX): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Get Free Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report WARNER CHIL PLC (WCRX): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ( ABT ) split into two separate publicly traded companies; while one company deals in diversified medical products, the other, AbbVie ( ABBV ), is focusing on research-based pharmaceuticals. Zacks Industry Rank Within the Zacks Industry classification, pharma and biotech are broadly grouped into the Medical sector (one of 16 Zacks sectors) and further sub-divided into four industries at the expanded level: large-cap pharma, med-biomed/gene, med-drugs and med-generic drugs."
2013-07-29,36.619998931884766,36.7400016784668,-0.27041231843954333,,
2013-07-26,36.59000015258789,36.77999877929688,0.32769729678376847,Abaxis Earnings Widely Miss Q1 Estimates - Analyst Blog,"ABAXIS INC (ABAX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ALERE INC (ALR): Free Stock Analysis Report MWI VET SUPPLY (MWIV): Free Stock Analysis Report To read this article on Zacks.com click here. The overall disappointing performance in the Medical business during the quarter was primarily due to decline in Piccolo instrument sales and the transition from a direct sales model to a distribution model with Abbott Point of Care under Abbott Laboratories ( ABT ). Revenues improved 3% year over year to $43.2 million, trailing the Zacks Consensus Estimate of $49 million in the quarter."
2013-07-25,36.41999816894531,36.58000183105469,0.5192638040903464,,
2013-07-24,36.70000076293945,36.45000076293945,0.43932913276697333,,
2013-07-23,35.93000030517578,36.68000030517578,-0.6811988959206128,,
2013-07-22,35.7599983215332,35.79999923706055,2.087392133675994,,
2013-07-19,35.72999954223633,35.869998931884766,0.11185938871606949,,
2013-07-18,35.91999816894531,35.70000076293945,0.39182589264504364,,
2013-07-17,35.880001068115234,35.81999969482422,-0.6124649699900554,,
2013-07-16,35.43000030517578,35.70000076293945,-0.16722790274478516,,
2013-07-15,35.22999954223633,35.47999954223633,0.7620673311826897,,
2013-07-12,35.45000076293945,35.31999969482422,0.7096224900607265,,
2013-07-11,35.02000045776367,35.369998931884766,-0.36671668636786486,Abbott Lab's Xience Xpedition in Japan - Analyst Blog,"ABBOTT LABS (ABT): Free Stock Analysis Report BAXANO SURGICAL (BAXS): Free Stock Analysis Report BOSTON SCIENTIF (BSX): Free Stock Analysis Report LEMAITRE VASCLR (LMAT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) recently announced that it has received approval for the Xience Xpedition Everolimus Eluting Coronary Stent System from the Ministry of Health, Labor and Welfare (MHLW) in Japan. Xience nano and Xience Prime were launched in the US in 2011 while Xience Prime and Xience V were launched in Japan in Apr 2012 and Jan 2010, respectively."
2013-07-10,34.79999923706055,34.7400016784668,0.9994245275445213,,
2013-07-09,35.459999084472656,34.7400016784668,-0.17240678134801538,Roche Seeks Label Expansion for Test - Analyst Blog,ABBOTT LABS (ABT): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Get Free Report SANTARUS INC (SNTS): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Abbott Labs' ( ABT ) RealTime High Risk HPV molecular diagnostic test also enables detection of HPV which is the prime cause of cervical cancer. The FDA had approved the cobas HPV test in Apr 2011 for the screening of patients 21 years of age and above with abnormal Pap test results and to co-test with Pap in women between 30 and 65 years of age to assess the presence or absence of high-risk HPV genotypes.
2013-07-08,34.95000076293945,35.40999984741211,-2.0304495899469277,,
2013-07-05,34.58000183105469,34.91999816894531,1.3161633030933537,Will Earnings Growth Bottom in Q2? - Earnings Trends | Will Earnings Growth Bottom in Q2? - Earnings Trends | Will Earnings Growth Bottom in Q2? - Earnings Trends | Will Earnings Growth Bottom in Q2? - Earnings Outlook | Will Earnings Growth Bottom in Q2? - Earnings Outlook | Will Earnings Growth Bottom in Q2? - Earnings Outlook | Will Earnings Growth Bottom in Q2? - Earnings Outlook,"APPLE INC (AAPL): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report DARDEN RESTRNT (DRI): Free Stock Analysis Report FEDEX CORP (FDX): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report ORACLE CORP (ORCL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report WALGREEN CO (WAG): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | APPLE INC (AAPL): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report DARDEN RESTRNT (DRI): Free Stock Analysis Report FEDEX CORP (FDX): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report ORACLE CORP (ORCL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report WALGREEN CO (WAG): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | APPLE INC (AAPL): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report DARDEN RESTRNT (DRI): Free Stock Analysis Report FEDEX CORP (FDX): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report ORACLE CORP (ORCL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report WALGREEN CO (WAG): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | APPLE INC (AAPL): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report DARDEN RESTRNT (DRI): Free Stock Analysis Report FEDEX CORP (FDX): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report ORACLE CORP (ORCL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report WALGREEN CO (WAG): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | APPLE INC (AAPL): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report DARDEN RESTRNT (DRI): Free Stock Analysis Report FEDEX CORP (FDX): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report ORACLE CORP (ORCL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report WALGREEN CO (WAG): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | APPLE INC (AAPL): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report DARDEN RESTRNT (DRI): Free Stock Analysis Report FEDEX CORP (FDX): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report ORACLE CORP (ORCL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report WALGREEN CO (WAG): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | APPLE INC (AAPL): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report DARDEN RESTRNT (DRI): Free Stock Analysis Report FEDEX CORP (FDX): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report ORACLE CORP (ORCL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report WALGREEN CO (WAG): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2013-07-03,34.720001220703125,34.25,0.9832166567015336,,
2013-07-02,34.970001220703125,34.86000061035156,-1.353690104201001,,
2013-07-01,34.970001220703125,35.029998779296875,-0.31455706752003015,,
2013-06-28,35.29999923706055,34.880001068115234,0.17156864884016626,,
2013-06-27,35.77000045776367,35.36000061035156,-1.1897965383080444,,
2013-06-26,35.40999984741211,35.599998474121094,-1.1462114681721265,,
2013-06-25,35.279998779296875,35.11000061035156,0.5365677140009086,,
2013-06-24,35.290000915527344,34.970001220703125,-0.48185423703889524,,
2013-06-21,35.400001525878906,35.58000183105469,-0.9067715684966764,,
2013-06-20,36.06999969482422,35.16999816894531,0.5084754164323789,,
2013-06-19,37.27000045776367,36.209999084472656,-2.4951525741433533,,
2013-06-18,36.97999954223633,37.5099983215332,-2.8441141944504804,,
2013-06-17,37.06999969482422,36.88999938964844,1.4332038557532762,GE and Three Others Named Top Dividend Growers of Last Week,"Abbott Laboratories ( ABT ) On June 14, Abbott Laboratories declared a dividend of $0.14 per share, making the dividend yield 3.5%. A comparison of the companies' historical dividend growth: General Electric ( GE ) On June 14, General Electric declared a dividend of $0.19 per share, setting the dividend yield for the company at 3.10%. The company's dividend growth history is as follows: � 10-year: 8.9% � 5-year: 9.5% � 3-year: 6.5% Abbott Laboratories has offered a quarterly cash dividend since 1983."
2013-06-14,36.68000030517578,36.810001373291016,-0.4855686718576187,Abbott Progresses with Absorb in Japan - Analyst Blog,"Abbott Labs ( ABT ) recently announced that it has initiated a randomized controlled study in Japan to evaluate Absorb, its bioresorbable vascular scaffold (BVS) device, in patients suffering from coronary artery disease (CAD). ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ATRICURE INC (ATRC): Free Stock Analysis Report BAXANO SURGICAL (BAXS): Free Stock Analysis Report To read this article on Zacks.com click here. We remind investors that Abbott Labs became a diversified medical products company focusing on branded generic pharmaceutical, medical devices, diagnostic and nutritional businesses following the separation of its research-based pharmaceuticals business into a new company, AbbVie Inc ."
2013-06-13,36.33000183105469,36.70000076293945,0.3544194848245146,,
2013-06-12,37.08000183105469,36.43999862670898,1.0184390675380934,Bear of the Day: Covidien (COV) - Bear of the Day,"Kevin Cook is a Senior Stock Strategist withZacks.com ABBOTT LABS (ABT): Free Stock Analysis Report BAXTER INTL (BAX): Free Stock Analysis Report COVIDIEN PLC (COV): Free Stock Analysis Report SPDR-HLTH CR (XLV): ETF Research Reports To read this article on Zacks.com click here. In the wake of its dismal fiscal 2013 second quarter results, analysts covering Covidien PLC ( COV ), the $30 billion medical products maker, slashed earnings estimates for both this year and next by 17% each. Here's a visual of the dramatic drop in analysts estimates since the company's April 26 report, after which it slipped to a Zacks #5 Rank (Strong Sell)... Regulation, Tax, and Cost Headwinds The medical-technology excise tax of 2.3% has started to weigh on the bottom line from the second quarter of fiscal 2013."
2013-06-11,37.13999938964844,36.83000183105469,-1.7260063989794745,,
2013-06-10,37.470001220703125,37.4900016784668,-0.8346730309321214,,
2013-06-07,36.95000076293945,37.5099983215332,0.05337725410219927,,
2013-06-06,36.2400016784668,36.63999938964844,1.515554931071674,,
2013-06-05,36.720001220703125,36.29999923706055,1.1037463925375934,,
2013-06-04,37.060001373291016,36.79999923706055,-1.1437962137260949,,
2013-06-03,36.630001068115234,37.15999984741211,-0.7015707679327049,"After Hours Most Active for Jun 3, 2013 : MMR, BAC, FE, ZNGA, NOK, GNW, MSFT, QQQ, ABT, SIRI, INTC, DTV","Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Jun 2013. Abbott Laboratories ( ABT ) is -0.561 at $36.60, with 908,617 shares traded. ABT's current last sale is 91.5% of the target price of $40."
2013-05-31,37.4900016784668,36.66999816894531,1.4468980721876503,,
2013-05-30,37.720001220703125,37.68000030517578,-2.187259196609936,"Stocks Market News for May 30, 2013 - Market News","Stocks such as Johnson & Johnson (NYSE: JNJ ), Eli Lilly & Co. (NYSE: LLY ), GlaxoSmithKline plc (NYSE: GSK ), Abbott Laboratories (NYSE: ABT ) and Merck & Co., Inc. (NYSE: MRK ) decreased 2.2%, 1.5%, 3.0%, 2.2% and 1.6%, respectively. ABBOTT LABS (ABT): Free Stock Analysis Report CVS CAREMARK CP (CVS): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report COCA COLA CO (KO): Free Stock Analysis Report MICHAEL KORS (KORS): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report PROCTER & GAMBL (PG): Free Stock Analysis Report PHILIP MORRIS (PM): Free Stock Analysis Report WAL-MART STORES (WMT): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks such as The Procter & Gamble Company (NYSE: PG ), The Coca-Cola Company (NYSE: KO ), Philip Morris International Inc. (NYSE: PM ), Wal-Mart Stores, Inc. (NYSE: WMT ) and CVS Caremark Corporation (NYSE: CVS ) lost 2.4%, 2.7%, 1.2%, 1.4% and 1.6%, respectively."
2013-05-29,38.2599983215332,37.720001220703125,-0.10604696244121199,,
2013-05-28,37.97999954223633,38.560001373291016,-1.411388197908417,Vanguard Cuts Fees on Popular Dividend ETF,"Eight of VIG's top-10 holdings are Dow components with PepsiCo and Abbott Labs (NYSE: ABT ) the exceptions. Vanguard, the third-largest U.S. ETF sponsor, lowered the annual expense ratio on its popular Vanguard Dividend Appreciation ETF (NYSE: VIG ) to 0.1 percent from 0.13 percent effective Tuesday. In February, the firm cut fees on eight of its ETFs , including popular global funds such as the Vanguard FTSE Emerging Markets ETF (NYSE: VWO ) and the Vanguard FTSE Europe ETF (NYSE: VGK )."
2013-05-24,37.16999816894531,37.7599983215332,1.5271243761066564,,
2013-05-23,37.4900016784668,37.47999954223633,1.5873020760082315,,
2013-05-22,37.7599983215332,37.720001220703125,-0.02667947661419737,CE Mark for Abbott's Xience Xpedition 48 - Analyst Blog,"ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ATRICURE INC (ATRC): Free Stock Analysis Report TRANS1 INC (TSON): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) recently announced that it received CE Mark in Europe for its drug eluting stent - Xience Xpedition 48 Everolimus Eluting Coronary Stent System. We note that Abbott Labs has been consistently making efforts to innovate its Xience drug-eluting stent franchise (includes Xience V, Prime, nano and Xpedition) over the last three years."
2013-05-21,37.84999847412109,37.720001220703125,-0.10592453021182784,,
2013-05-20,36.95000076293945,37.810001373291016,-0.343453787737518,,
2013-05-17,36.81999969482422,36.59000015258789,2.3274711572242675,,
2013-05-16,37.45000076293945,36.83000183105469,-0.6246592725220992,,
2013-05-15,37.130001068115234,37.65999984741211,-1.6555378351242038,,
2013-05-14,36.41999816894531,37.04999923706055,1.427413854162268,,
2013-05-13,36.04999923706055,36.34999847412109,1.7298218006293726,,
2013-05-10,36.25,36.16999816894531,0.8321754324813716,,
2013-05-09,36.18999862670898,36.18000030517578,-0.22069470635775862,,
2013-05-08,36.0099983215332,36.290000915527344,-0.027627305644098724,,
2013-05-07,35.7400016784668,36.060001373291016,0.7775690281737812,,
2013-05-06,36.75,35.849998474121094,0.8953544482260538,Covidien Provides 2013 Outlook - Analyst Blog,"ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report COVIDIEN PLC (COV): Free Stock Analysis Report CONCEPTUS INC (CPTS): Free Stock Analysis Report To read this article on Zacks.com click here. In Jan 2013, Abbott Laboratories ( ABT ) also divested its research-based pharmaceuticals business into a new company, AbbVie ( ABBV ) for the same reason as Covidien. ABT has also performed well following the divestment, with share price increasing 18%, year-to-date."
2013-05-03,37.25,36.79999923706055,-2.44898374388818,,
2013-05-02,36.95000076293945,37.060001373291016,-1.2080557394347735,,
2013-05-01,36.77000045776367,36.88999938964844,0.29770123973012796,,
2013-04-30,36.70000076293945,36.91999816894531,0.3263500962492615,,
2013-04-29,36.4900016784668,36.72999954223633,0.5994479603063607,Amarin's Performance Issues: Here To Stay?,"Their flagship drug is Vascepa, a drug developed to treat patients with hypertriglyceridemia (high levels of fats in the blood), specifically those with TG's GSK ) Lovaza, Pfizer's ( PFE ) Lipitor, AstraZeneca's ( AZN ) Crestor, and Abbott Laboratories ( ABT ) Tricor. Fortunately for the Amarin faithful, the company is in a unique position to begin and continue a steady upward climb in share price without overcoming the main foundation to the bear argument, something that is extremely rare and could make this stock an extremely long and painful trade for the bears. (click to enlarge) It doesn't take a seasoned trading veteran to recognize that Amarin has had a horrible run over the last twelve months and as I said above, the bears have been correct in shorting this stock (selling borrowed shares of a stock with a promise to buy and return them at a later date, meaning the sellers think the price will go down)."
2013-04-26,36.36000061035156,36.459999084472656,0.6577085577695574,"Earnings Beat for ABAX, Sluggish Overall - Analyst Blog","The overall disappointing performance in the medical business during the quarter was primarily due to the transition from a direct sales model to a distribution model with Abbott Laboratories ( ABT ). ABAXIS INC (ABAX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report CYBERONICS INC (CYBX): Free Stock Analysis Report HEALTH NET INC (HNT): Free Stock Analysis Report To read this article on Zacks.com click here. Revenues soared 17% year over year to $50 million, although missing the Zacks Consensus Estimate of $51 million in the quarter."
2013-04-25,36.619998931884766,36.4900016784668,0.27502330154698773,,
2013-04-24,37.27000045776367,36.52000045776367,-0.3549897793819461,,
2013-04-23,37.11000061035156,37.209999084472656,-2.0123423417983037,Abbott - Epizyme Collaborate - Analyst Blog,"ABBOTT LABS (ABT): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report NUVASIVE INC (NUVA): Free Stock Analysis Report PHARMACYCLICS (PCYC): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories(ABT) recently announced a strategic deal with Epizyme, Inc. for the development of a molecular companion diagnostic test for use with EPZ-5676. In Feb 2013, Abbott Labs collaborated with Johnson & Johnson's ( JNJ ) Janssen Biotech, Inc. and Pharmacyclics, Inc. (PCYC) to use Abbott Labs' proprietary FISH technology for developing a molecular companion diagnostic test that will help identify patients with a genetic subtype of chronic lymphocytic leukemia (CLL)."
2013-04-22,37.0,36.88999938964844,0.26946502957803753,,
2013-04-19,37.04999923706055,37.20000076293945,-0.29729894689611486,S&P Likes The Biggest Dividend ETF | Abbott Labs Recalls Glucose Meter - Analyst Blog,"Eight of the ETF's 10 largest holdings are members of the Dow Jones Industrial Average with Pepsi and Abbott Labs (NYSE: ABT ) being the outliers. Investors have plenty of dividend ETFs from which to choose, but the largest by assets is the Vanguard Dividend Appreciation ETF (NYSE: VIG ). In fact, four of VIG's top-five holdings - PepsiCo (NYSE: PEP ), Procter & Gamble (NYSE: PG ), Coca-Cola (NYSE: KO ) and Wal-Mart (NYSE: WMT ) - are also four of the top six holdings in the Consumer Staples Select Sector SPDR (NYSE: XLP ). | ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report EXACTECH INC (EXAC): Free Stock Analysis Report NUVASIVE INC (NUVA): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) recently announced that the company is initiating a voluntary recall of its FreeStyle InsuLinx Blood Glucose Meters in the US. Abbott Labs decided to recall the its FreeStyle InsuLinx Blood Glucose Meters as it found that the device displayed and stored wrong test results in patients with extremely high blood glucose levels."
2013-04-18,37.45000076293945,36.880001068115234,0.40486242636372854,"Company News for April 18, 2013 - Corporate Summary | Abbott Launches Automated Solution - Analyst Blog","• Intel Corporation (NASDAQ: INTC ) reported first quarter earnings per share of $0.40, missing the Zacks Consensus Estimate of $0.42 • CSX Corporation (NYSE: CSX ) posted first quarter earnings per share of $0.45, beating the Zacks Consensus Estimate of $0.40 • Abbott Laboratories (NYSE: ABT ) reported first quarter earnings per share of $0.42, in line with the Zacks Consensus Estimate • The Bank of New York Mellon Corporation (NYSE: BK ) posted first quarter earnings per share of $0.57 higher than the Zacks Consensus Estimate of $0.52 • Dover Corp. (NYSE: DOV ) reported first quarter earnings per share of $1.10, ahead of the Zacks Consensus Estimate of $1.08 • Mattel, Inc. (NASDAQ: MAT ) posted first quarter earnings per share of $0.11, higher than the Zacks Consensus Estimate of $0.08 • PNC Financial Services (NYSE: PNC ) reported first quarter earnings per share of $1.76, breezing past the Zacks Consensus Estimate of $1.57 • St. Jude Medical, Inc. (NYSE: STJ ) posted first quarter earnings per share of $0.92, in line with the Zacks Consensus Estimate ABBOTT LABS (ABT): Free Stock Analysis Report BANK OF NY MELL (BK): Free Stock Analysis Report CSX CORP (CSX): Free Stock Analysis Report DOVER CORP (DOV): Free Stock Analysis Report INTEL CORP (INTC): Free Stock Analysis Report MATTEL INC (MAT): Free Stock Analysis Report PNC FINL SVC CP (PNC): Free Stock Analysis Report ST JUDE MEDICAL (STJ): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) recently announced that the company has launched ACCELERATOR a3600 - its next-generation track system to increase efficiency in laboratories. Nuvasive ( NUVA ) currently looks attractive with a Zacks Rank #1 (Strong Buy) ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BG MEDICINE INC (BGMD): Free Stock Analysis Report NUVASIVE INC (NUVA): Free Stock Analysis Report To read this article on Zacks.com click here. We note that the diagnostics business is one of the key businesses for Abbott Labs after having separated its proprietary pharmaceutical business into a new company called AbbVie ( ABBV ) on Jan 1, 2013."
2013-04-17,36.84000015258789,37.27999877929688,-1.5220285266009683,Abbott Reports In-Line 1Q Earnings - Analyst Blog,"ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report EXACTECH INC (EXAC): Free Stock Analysis Report NUVASIVE INC (NUVA): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) reported first quarter 2013 earnings of 42 cents per share, in line with the Zacks Consensus Estimate and 5.0% above the year-ago earnings. Abbott Labs generated revenues of $5.4 billion in the first quarter of 2013, up 1.8% year over year and in line with the Zacks Consensus Estimate."
2013-04-16,36.27999877929688,36.400001525878906,1.1943502304195375,"Gold Is Still on the Fritz | Pre-Market Earnings Report for April 17, 2013 : BAC, ABT, PNC, BK, ASML, MAT, DOV, STJ, DGX, TXT, HBAN, FCFS","Earnings releases will play a bigger role tomorrow with Abbott Labs ( ABT ), Mattel ( MAT ), Bank of New York Mellon (BK), Bank of America (BAC), St Jude Medical (STJ), American Express (AXP), SanDisk (SNDK), Steel Dynamics (STLD), eBay (EBAY), and Sallie Mae (SLM) reporting. However, building permits showed a sharp decline to an annualized rate of 902,000, down from 939,000 the month prior, which highlights the weaker NAHB housing conditions survey we received yesterday. Globally, the UK will release employment figures, and Japan will release its trade balance data from March. | Zacks Investment Research reports that the 2013 Price to Earnings ratio for ABT is 17.98 vs. an industry ratio of 15.70, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories ( ABT ) is reporting for the quarter ending March 31, 2013. In the past year ABT has beat the expectations every quarter."
2013-04-15,36.84000015258789,36.130001068115234,0.33076833136638223,,
2013-04-12,37.11000061035156,37.130001068115234,-1.927250492757615,,
2013-04-11,37.02000045776367,37.27000045776367,0.05389506180200087,Abbott's Heart FailureTest in Europe - Analyst Blog,"ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BG MEDICINE INC (BGMD): Free Stock Analysis Report NUVASIVE INC (NUVA): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ( ABT ) recently announced that the company obtained CE Marking (Conformite Europeenne) for its ARCHITECT Galectin-3 assay test. Abbott developed this test in collabration with BG Medicine, Inc. ( BGMD ) to run on the ARCHITECT immunochemistry platform of Abbott.."
2013-04-10,36.72999954223633,37.09999847412109,0.6753106345453086,,
2013-04-09,36.560001373291016,36.65999984741211,1.0073480438225753,,
2013-04-08,36.310001373291016,36.54999923706055,0.27351879202649004,,
2013-04-05,36.369998931884766,36.310001373291016,0.6609690297232249,,
2013-04-04,36.52000045776367,36.650001525878906,-0.16496442220445456,Pharma & Biotech Stock Outlook - Apr 2013 - Zacks Analyst Interviews | Pharma & Biotech Stock Outlook - Apr 2013 - Industry Outlook,"ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ( ABT ) split into two separate publicly traded companies -- while one company deals in diversified medical products, the other, AbbVie is focusing on research-based pharmaceuticals. A Look at Fourth Quarter Results Despite facing challenges like EU austerity measures, genericization and lower-than-expected contributions from new products, companies like Eli Lilly, Bristol-Myers Squibbs, Merck, and Pfizer delivered stronger-than-expected results. | Abbott Labs ( ABT ) split into two separate publicly traded companies -- while one company deals in diversified medical products, the other, AbbVie is focusing on research-based pharmaceuticals. ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. A Look at Fourth Quarter Results Despite facing challenges like EU austerity measures, genericization and lower-than-expected contributions from new products, companies like Eli Lilly, Bristol-Myers Squibbs, Merck, and Pfizer delivered stronger-than-expected results."
2013-04-03,36.130001068115234,36.31999969482422,0.3559722521514861,"Stock Market News for April 3, 2013 - Market News","Stocks such as Johnson & Johnson (NYSE: JNJ ), Pfizer Inc. (NYSE: PFE ), Abbott Laboratories (NYSE: ABT ), Amgen, Inc. (NASDAQ: AMGN ) and Gilead Sciences, Inc. (NASDAQ: GILD ) gained 0.9, 1.4%, 2.3%, 4.0% and 0.5%, respectively. ABBOTT LABS (ABT): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report DOW CHEMICAL (DOW): Free Stock Analysis Report FREEPT MC COP-B (FCX): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MONSANTO CO-NEW (MON): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report PPG INDS INC (PPG): Free Stock Analysis Report PRAXAIR INC (PX): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks such as Monsanto Company (NYSE: MON ), the Dow Chemical Company (NYSE: DOW ), Praxair, Inc. (NYSE: PX ), Freeport-McMoRan Copper & Gold Inc. (NYSE: FCX ) and PPG Industries, Inc. (NYSE: PPG ) declined 1.7%, 1.3%, 0.1%, 1.4% and 0.4%, respectively."
2013-04-02,35.45000076293945,36.119998931884766,0.5258749545863102,Setback for Novartis in India - Analyst Blog,"ABBOTT LABS (ABT): Free Stock Analysis Report FURIEX PHARMACT (FURX): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. Pharma companies that currently look better-positioned include Abbott Laboratories ( ABT ), Furiex Pharmaceuticals ( FURX ) and Novo Nordisk ( NVO ). Novartis ( NVS ) recently suffered a setback when the Indian Supreme Court denied patent for the company's oncology drug, Glivec (imatinib mesylate) under the Indian patent law."
2013-04-01,35.18000030517578,35.310001373291016,1.8899806897768805,Glaxo's Influenza Vaccine Gets CRL - Analyst Blog | Lilly Progresses with Empagliflozin - Analyst Blog | Sanofi Invests in Emerging Markets - Analyst Blog | Abaxis Pinned at Neutral - Analyst Blog | Roche Mulls Bid For Genetic Sequencing Company Life Technologies,"ABBOTT LABS (ABT): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report To read this article on Zacks.com click here. Large-cap pharma companies that currently look better-positioned include Eli Lilly and Company ( LLY ), Abbott Laboratories ( ABT ) and Novo Nordisk ( NVO ). GlaxoSmithKline ( GSK ) recently received a complete response letter (CRL) from the US Food and Drug Administration (FDA) regarding the company's influenza vaccine candidate, Q-Pan H5N1 (pandemic influenza A virus monovalent adjuvanted vaccine). | ABBOTT LABS (ABT): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ( ABT ) is another company that currently holds a Zacks Rank #2. Eli Lilly ( LLY ) and Boehringer Ingelheim recently submitted a New Drug Application (NDA) for their type II diabetes candidate, empagliflozin, in the US. | ABBOTT LABS (ABT): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. However, large cap pharma stocks such as Novo Nordisk ( NVO ), Eli Lilly and Company ( LLY ) and Abbott Laboratories ( ABT ) currently look more attractive. The manufacturing facility is expected to produce pharmaceuticals and consumer healthcare products with an initial capacity of 90 million units per year, which is expandable up to 150 million units. | ABAXIS INC (ABAX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report HENRY SCHEIN IN (HSIC): Free Stock Analysis Report MWI VET SUPPLY (MWIV): Free Stock Analysis Report To read this article on Zacks.com click here. Considering its distribution relationship with MWI Veterinary Supply ( MWIV ) and Abbott Point of Care, a part of Abbott ( ABT ), the company is well poised to expand its foothold in target markets. On Jan 31, Abaxis reported third-quarter fiscal 2013 EPS of 22 cents, a beat of 10% over the Zacks Consensus Estimate. | See Full Analysis for Roche Holdings Here Genetic Sequencing: Holds Key For Growth Genetic sequencing helps in decoding DNA at granular levels, which in turn allows doctors to develop specific treatments targeting a patient's needs. The importance of genetic sequencing for Roche became evident when the drug maker aggressively tried to acquire one of the genetic sequencing market leaders, Illumina, last year. While Illumina would have given Roche ready access to its already well-established same-day gene sequencing machine, what could motivate Roche is that Life Tech's machine can do the job at $1,000 per sequence, at least one-third the price compared with Illumina."
2013-03-28,34.599998474121094,35.31999969482422,0.369531173926989,"What Lessons Does Cyprus Teach Us? - Analyst Blog | Stock Market News for March 28, 2013 - Market News | Bristol-Myers Reaches 52-Week High - Analyst Blog | Sanofi/Transgene Inks Immunotherapy Deal - Analyst Blog","ABBOTT LABS (ABT): Free Stock Analysis Report CITIGROUP INC (C): Free Stock Analysis Report CATERPILLAR INC (CAT): Free Stock Analysis Report FORD MOTOR CO (F): Free Stock Analysis Report FEDEX CORP (FDX): Free Stock Analysis Report GENL ELECTRIC (GE): Free Stock Analysis Report GOLDMAN SACHS (GS): Free Stock Analysis Report COCA COLA CO (KO): Free Stock Analysis Report MCDONALDS CORP (MCD): Free Stock Analysis Report NEWS CORP INC-A (NWSA): Free Stock Analysis Report PHILIP MORRIS (PM): Free Stock Analysis Report To read this article on Zacks.com click here. These include the likes of General Electric Company ( GE ), The Coca-Cola Company ( KO ), Philip Morris International, Inc. ( PM ), McDonald's Corp. ( MCD ), Abbott Laboratories ( ABT ), News Corp. ( NWSA ) and Ford Motor Co. ( F ). Ultimately, uninsured depositors will have to bear the entire burden of rescuing Cyprus's two beleaguered banks - Cyprus Popular Bank and Bank of Cyprus. | Stocks such as Johnson & Johnson (NYSE: JNJ ), Pfizer Inc. (NYSE: PFE ), Abbott Laboratories (NYSE: ABT ), Amgen, Inc. (NASDAQ: AMGN ) and Gilead Sciences, Inc. (NASDAQ: GILD ) gained 0.5%, 0.1%, 0.8%, 1.5% and 4.3%, respectively. ABBOTT LABS (ABT): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BANK OF AMER CP (BAC): Free Stock Analysis Report CITIGROUP INC (C): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report JPMORGAN CHASE (JPM): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report PNC FINL SVC CP (PNC): Free Stock Analysis Report WELLS FARGO-NEW (WFC): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks such as Bank of America Corp (NYSE: BAC ), Wells Fargo & Co (NYSE: WFC ), JPMorgan Chase & Co. (NYSE: JPM ), PNC Financial Services (NYSE: PNC ) and Citigroup Inc. (NYSE: C ) gained 0.4%, 0.9%, 1.8%, 0.1% and 0.8%, respectively. | ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Large cap pharma stocks such as Abbott Laboratories ( ABT ) and Novo Nordisk ( NVO ) appear to be more attractive. Bristol-Myers is looking to strengthen its product portfolio by launching new drugs to make up for the loss of revenues following the genericization of key drugs, especially Plavix. | ABBOTT LABS (ABT): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. However, large cap pharma stocks such as Novo Nordisk ( NVO ), Eli Lilly and Company ( LLY ) and Abbott Laboratories ( ABT ) currently look more attractive. Sanofi and Transgene, a French biopharmaceutical company, will invest €10 million in the platform, which will be located at the Genzyme Polyclonals site at Lyon, Gerland."
2013-03-27,34.130001068115234,34.61000061035156,2.080928475305126,Weekly Healthcare Note: Abbott Labs And Intuitive Surgical,"During the week, Abbott Labs ( ABT ) got conflicting responses relating to the pending approval of MitraClip. While the FDA staff recommended against approving the device seeking more data, an advisory panel to the FDA voted in favor of the device saying benefits outweigh risks. W hile MitraClip is already available in various markets following European CE Mark approval in 2008, it is still an investigational device in the major U.S. market pending FDA approval."
2013-03-26,33.849998474121094,34.349998474121094,1.4063859572648858,,
2013-03-25,33.7599983215332,33.79999923706055,1.477104941030525,FDA Panel Favors Abbott's MitraClip - Analyst Blog,Abbott Laboratories ( ABT ) recently announced that the US Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee has voted in favor of the company's device MitraClip. ABBOTT LABS (ABT): Free Stock Analysis Report AMBEV-PR ADR (ABV): Free Stock Analysis Report FURIEX PHARMACT (FURX): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott expects that the panel's opinion will positively impact FDA's decision when it decides on the approval of the MitraClip for the treatment of significant MR in the US later in 2013.
2013-03-22,33.5,33.689998626708984,0.11848613008321712,,
2013-03-21,33.779998779296875,33.47999954223633,0.5671600797283116,,
2013-03-20,33.65999984741211,33.810001373291016,-0.8880972406796259,,
2013-03-19,33.52000045776367,33.540000915527344,0.44563733380539167,,
2013-03-18,33.939998626708984,33.459999084472656,0.05966723595028921,Weekly Healthcare Note: Boston Scientific And Abbott Labs,"Meanwhile, Abbott Labs' ( ABT ) MitraClip heart valve showed positive results in patients with conditions considered high risk for surgery. During the week, Boston Scientific ( BSX ) released data from a clinical trial called ""Prevail"", where its Watchman devices produced better safety results than what the earlier trial had suggested. See our complete analysis of Boston Scientific Abbott Labs Abbott's MitraClip is used in patients with mitral regurgitation, one of the most common heart valve conditions."
2013-03-15,34.91999816894531,34.13999938964844,-1.414259168114974,Data on Abbott's MitraClip - Analyst Blog,ABBOTT LABS (ABT): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ( ABT ) recently released positive data from the EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) High Surgical Risk cohort. The study evaluated Abbott's MitraClip system for the treatment of mitral regurgitation (MR) - a common form of heart valve insufficiency.
2013-03-14,35.029998779296875,35.13999938964844,-2.233673597355842,Merck Jumps As IMPROVE-IT Study Will Continue,"Merck's ( MRK ) stock jumped Tuesday as investors cheered the Data Safety Monitoring Board's recommendation that the ""IMPROVE-IT"" trial, which is being conducted to prove the efficacy and safety of Merck's blockbuster drug Vytorin, should continue until its projected deadline of September 2014. See our complete analysis for Merck The Cardiovascular Division: Growth Under Pressure Merck has had a decent presence in the cardiovascular drugs market through 2010-11, with drugs like Zetia, Vytorin, Zocor and Cozaar/Hyzaar in its portfolio. Further, the sales of Vyotrin (a combination of Merck's own drugs, Zocor and Zetia) have come under pressure after questions were raised around its efficacy and safety, which we will discuss later in this note."
2013-03-13,34.88999938964844,35.0099983215332,0.31401831054751306,Johnson & Johnson: FDA Rejects Broader Use Of Anticlotting Drug Xarelto | BSX's Stent Tops Abbott - Analyst Blog,"For the second time, the FDA has rejected Johnson & Johnson's ( JNJ ) application to expand the use of Xarelto to prevent heart attacks and strokes in patients who have previously experienced severe chest pain or heart attack (acute coronary syndrome or ACS). While the full details of rejection remain unclear for now, what may have worked against Xarelto is that while it reduced the risk of major heart attacks in ACS patients in clinical trials, some patients witnessed serious bleeding. No Concerns For Pfizer For Now Nonetheless, we don't see any concern for Eliquis as it has exhibited significant safety over Warfarin and Aspirin (ARISTOTLE and AVERROES trials) in reducing the risk of stroke and dangerous blood clots without major bleeding among all non-Aarfarin drugs, including Xarelto and Pradax. | Boston Scientific 's ( BSX ) recently released endpoint data of a clinical trial showed the excellence of the company's Promus Element Everolimus-Eluting Platinum Chromium (PtCr) Coronary Stent System over its major peer Abbott Laboratories ' ( ABT ) Cobalt Chromium (CoCr) Xience V Everolimus-Eluting Coronary Stent System. ABBOTT LABS (ABT): Free Stock Analysis Report BOSTON SCIENTIF (BSX): Free Stock Analysis Report CYBERONICS INC (CYBX): Free Stock Analysis Report GIVEN IMAGING (GIVN): Free Stock Analysis Report To read this article on Zacks.com click here. Moreover, keeping at par with the company's earlier data, the trial result portrayed that unplanned stenting has been significantly reduced with Promus Element compared to Xience V including a significantly lower rate of inadequate lesion coverage."
2013-03-12,34.83000183105469,34.97999954223633,0.3439350357809644,,
2013-03-11,34.59000015258789,34.93000030517578,0.430656627321511,,
2013-03-08,34.5,34.68000030517578,0.9829434839203177,,
2013-03-07,34.29999923706055,34.43000030517578,0.5217400150022645,,
2013-03-06,34.66999816894531,34.27000045776367,0.37901186882468063,,
2013-03-05,34.380001068115234,34.66999816894531,-1.1537286769744552,,
2013-03-04,33.5099983215332,34.310001373291016,0.8435052118105598,,
2013-03-01,33.689998626708984,33.599998474121094,2.387356287164414,"After Hours Most Active for Mar 1, 2013 : CERS, SIRI, ABT, SBGL, ABBV, VOD, BAC, NOK, QQQ, AMD, INTC, HOLX","Abbott Laboratories ( ABT ) is +0.04 at $33.64, with 2,078,381 shares traded. ABT's current last sale is 89.71% of the target price of $37.5. The total After hours volume is currently 28,730,449 shares traded."
2013-02-28,34.310001373291016,33.790000915527344,-0.26714204884692305,,
2013-02-27,34.04999923706055,34.2599983215332,-1.5155943950747601,"Medtronic Earnings Meet Expectations But European Weakness A Concern | After Hours Most Active for Feb 27, 2013 : F, GRPN, JCI, ABT, ABBV, JCP, GTAT, QQQ, BAC, TLAB, ENDP, ACWI","Medtronic ( MDT ) announced its third quarter earnings for fiscal 2013 on Tuesday, registering mid-single digit growth in revenues, in-line with our expectations. The medical device maker's key division, pacemakers & defibrillators along with spinal franchise continued to witness a decline in sales. See our complete analysis of Medtronic here Revenues Grow, But European Weakness A Concern On a quarterly basis, the medical device maker recorded a 1% decline (excluding the currency effect) in revenue from pacemakers & defibrillators division as pricing pressure weighed on growth even as overall procedural volumes were stable during the period. | Abbott Laboratories ( ABT ) is +0.1201 at $34.38, with 2,093,690 shares traded. ABT's current last sale is 91.68% of the target price of $37.5. RTT News Reports: Groupon Q4 Loss Widens, Shares Plunge Johnson Controls, Inc. ( JCI ) is +0.0012 at $31.41, with 4,570,953 shares traded."
2013-02-26,34.369998931884766,34.060001373291016,0.6167374131512168,,
2013-02-25,34.599998474121094,34.27000045776367,-0.9019422991781587,Abbott Explores FISH Technology - Analyst Blog | Weekly Healthcare Notes: Pfizer And Roche Holdings,"Abbott Labs ( ABT ) recently announced its collaboration with Johnson & Johnson's ( JNJ ) Janssen Biotech, Inc. and Pharmacyclics, Inc. to explore Abbott's proprietary FISH (fluorescence in situ hybridization) technology for further use. ABBOTT LABS (ABT): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. Nonetheless, Abbott plans to use its Viysis CLL FISH Probe Kit only for determination of genetic marker status as per the co-development agreement among Janssen, Pharmacyclics and Abbott. | Pfizer ( PFE ) announced that its largest selling drug Lyrica exhibited similar efficacy as Levetiracetam, a conventional treatment, in reducing the most common type of seizures in epilepsy patients. It is also used as an add-on drug to treat seizures in epilepsy patients even as Pfizer has been trying to expand the drug's use as a mono-therapy for epilepsy patients. See Full Analysis For Pfizer here Roche Holdings Roche has been investing heavily in its R&D program focusing mainly on oncology drugs (Read Roche Defends $47 Value With Strong R&D Pipeline ) and has started to reap the fruits now."
2013-02-22,34.18000030517578,34.54999923706055,-0.9537515344234548,"DexCom Reduces Losses in 4Q, Rev Up - Analyst Blog","ABBOTT LABS (ABT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Get Free Report To read this article on Zacks.com click here. Additionally, Medtronic ( MDT ) and Abbott ( ABT ) have gained FDA approval for continuous glucose monitoring systems. DexCom ( DXCM ), a player in the glucose monitoring market, reported fourth quarter 2012 adjusted loss per share of 14 cents, better than the Zacks Consensus Estimate of a loss of 16 cents per share."
2013-02-21,34.470001220703125,34.2599983215332,1.0825012538947747,,
2013-02-20,34.70000076293945,34.52000045776367,-0.609233802532596,Patent Challenge from Perrigo - Analyst Blog | Label Expansion for NVS' Zortress - Analyst Blog,"ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report PERRIGO COMPANY (PRGO): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie came into existence earlier this year following its separation from Abbott Laboratories ( ABT ). Recently, Perrigo Company ( PRGO ) announced that it has filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) seeking approval to market its generic version of AbbVie Inc. 's ( ABBV ) Androgel 1.62%. | ABBOTT LABS (ABT): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. Novartis has also licensed Zortress to Abbott ( ABT ) and sub-licensed to Boston Scientific for use in drug-eluting stents. We note that Zortress is already approved in the US for the prophylaxis of organ rejection in adult patients undergoing kidney transplant."
2013-02-19,35.18000030517578,34.81999969482422,-0.5187328565364946,Weekly Healthcare Notes: Medtronic & Merck | Under The Hood: A New Dividend ETF Diva,"Medtronic In a recently concluded clinical trial, Medtronic's implantable deep brain stimulation devices (DBSs), Kinetra or Soletra, showed strong efficacy in treatment of early-stage patients of Parkinson's disease. With the impressive clinical trial data, Medtronic can now hope for extension of DBSs to millions of early-stage patients. See Full Analysis ForMerck Submit a Post at Trefis Powered by Data and Interactive Charts| Understand What Drives a Stock at Trefis The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top-10 holdings include Abbott Labs (NYSE: ABT ), Altria (NYSE: MO ) and AT&T (NYSE: T ). The ETF tracks the S&P 500 Low Volatility High Dividend Index, which is composed of 50 securities traded on the S&P 500 Index that historically have provided high dividend yields and low volatility, according to PowerShares . As is the case with its low volatility cousin, the PowerShares S&P 500 Low Volatility ETF (NYSE: SPLV ), SPHD devotes a significant portion of its weight to the utilities and consumer staples sectors."
2013-02-15,34.84000015258789,35.08000183105469,-1.0233104241860913,,
2013-02-14,34.279998779296875,34.70000076293945,0.6888681900564507,,
2013-02-13,34.290000915527344,34.459999084472656,1.2252100309181893,,
2013-02-12,34.27000045776367,34.29999923706055,0.49576600876768484,,
2013-02-11,34.41999816894531,34.2599983215332,0.08753655937019093,"Weekly 52 Week Highs: ABBV, ABT, YUM, AET","Abbott Laboratories ( ABT ): Director William A. Osborn Bought 15,000 Shares Director of Abbott Laboratories, William A. Osborn, bought 15,000 shares during the past week at an average price of $34.42. According to GuruFocus Insider Data , these are the largest insider buys during the past week: AbbVie Inc. ( ABBV ), Abbot Laboratories ( ABT ), Yum! Last week, Director William A. Osborn bought 10,000 shares of ABT stock."
2013-02-08,34.38999938964844,34.40999984741211,-0.46484560117282553,Weekly Healthcare Notes: Roche Holdings Strong Pipeline & Merck's Lawsuit Sets Precedent,"Further, an additional analysis suggested that the experimental drug could show superior efficacy compared with Roche's own MabThera/Rituxan as first line treatment for the condition. Meanwhile, Merck ( MRK ) lost an important trial involving its osteoporosis drug Fosamax that has the potential to impact the outcome of about 4,000 other similar trials relating to the drug. See Full Analysis For Roche Holdings Here Merck In a setback, Merck lost a lawsuit for not posting warnings about the risks of its osteoporosis drug Fosamax up front."
2013-02-07,34.2400016784668,34.38999938964844,0.058157772953296744,,
2013-02-06,33.66999816894531,34.099998474121094,0.4380774060416379,"Westport Funds Buys 2 New Holdings, Both Surge","Increases Westport Funds made increases to four other holdings during the quarter, which were Nordson Corp. ( NDSN ), Abbott Laboratories ( ABT ), Air Products & Chemicals international Inc. ( CRL ) and Charles River Laboratories International Inc. Read more about the investing activities at Westport Funds in its portfolio here. New Buy: Core Laboratories N.V. ( CLB ) Westport funds commented in its fourth quarter letter about this company: ""Finally, a new position was established in Core Laboratories N.V., a unique oil service company that provides reservoir management services and production enhancement when it experienced an earnings shortfall relative to expectations for third quarter results. Also check out the Undervalued Stocks, Top Growth Companies and High Yield stocks of Westport Asset Management.About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors."
2013-02-05,33.68000030517578,33.84000015258789,1.277102252926112,Singulair Patent Loss Hits Merck's Earnings But International Growth Helps,"Of the other major drugs, Vyotrin, a combination of Merck's own Zocor and Zetia to prevent cardiovascular events, also weighed on growth as U.S. prescriptions declined due to concerns around its efficacy. A decline in Istentress, due to weak sales in international market owing to timings of tenders, surprised us even as sales grew in the U.S. following FDA's approval for use in children older than 2 years for HIV therapy in January 2012. Further, gross margins are also under pressure though we think this is already factored in Merck's share price and progress on new drugs will drive the stock price going forward."
2013-02-04,33.369998931884766,33.5,0.47505892506634384,Zacks #5 Rank Additions for Monday - Tale of the Tape | AbbVie Provides 2013 Outlook - Analyst Blog,"ABBOTT LABS (ABT): Free Stock Analysis Report ACACIA RES-TECH (ACTG): Free Stock Analysis Report ADOBE SYSTEMS (ADBE): Free Stock Analysis Report AEROPOSTALE INC (ARO): Free Stock Analysis Report ACUITY BRANDS (AYI): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Here are 5 stocks added to the Zacks #5 Rank (""strong sell"") List today: Abbott Laboratories ( ABT ) Acacia Research Corp ( ACTG ) Acuity Brands ( AYI ) Adobe Systems ( ADBE ) Aeropostale, Inc. ( ARO ) View the entire Zacks #5 Rank List . | ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie came into existence earlier this year following its separation from Abbott Laboratories ( ABT ). The company expects 2013 sales from this franchise to decline by roughly $1.2 billion to less than $1 billion."
2013-02-01,33.91999816894531,33.869998931884766,0.3895746846758793,Abbott Spin-Off AbbVie Pays Juicy Dividend,"The former pharmaceuticals arm ofAbbott Laboratories ( ABT ) declared its inaugural dividend last month. The company was recently added to the S&P 500 Dividend Aristocrats index, which tracks the performance of big-cap stocks that have paid increasing dividends for at least 25 years. Although AbbVie has just declared its first-ever dividend, it was added to the Dividend Aristocrats due to the S&P's treatment of spin-offs."
2013-01-31,33.15999984741211,33.880001068115234,-0.14740341910254745,,
2013-01-30,33.400001525878906,33.220001220703125,2.1712944029440813,"Stock Market News for January 30, 2013 - Market News","Stocks such as Abbott Laboratories (NYSE: ABT ), Johnson & Johnson (NYSE: JNJ ), Mylan Inc. (NASDAQ: MYL ), Bristol Myers Squibb Co. (NYSE: BMY ) and Merck & Co. Inc. (NYSE: MRK ) gained 1.0%, 1.1%, 0.1%, 0.4% and 1.7%, respectively. ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report CHEVRON CORP (CVX): Free Stock Analysis Report HESS CORP (HES): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MARATHON OIL CP (MRO): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report VALERO ENERGY (VLO): Free Stock Analysis Report EXXON MOBIL CRP (XOM): Free Stock Analysis Report To read this article on Zacks.com click here. Separately, the S&P Dow Jones Indices released the S&P/Case-Shiller Home Price Indices, which noted that home prices for the 10-City Composite and 20-City Composite slipped 0.2% and 0.1%, respectively in November."
2013-01-29,32.970001220703125,33.33000183105469,-0.5389230447678689,MedTech Industry Stock Outlook - Jan 2013 - Industry Outlook | MedTech Industry Stock Outlook - Jan 2013 - Zacks Analyst Interviews,"ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report (WPI): ETF Research Reports DENTSPLY INTL (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. For example, in early January, Abbott Laboratories ( ABT ) separated its research-based pharmaceuticals business by creating a new company, AbbVie ( ABBV ), to allow the two separate entities to perform in a more focused manner. These are Abbott Laboratories ( ABT ), Patterson Companies Inc. ( PDCO ), a distributor of dental, companion-pet veterinarian, and rehabilitation supplies, MGC Diagnostics Corporation ( MGCD ), a provider of non-invasive cardio respiratory diagnostic systems and Invacare Corporation ( IVC ), which provides medical equipment and supplies for non-acute care environment. | ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. For example, in early January, Abbott Laboratories ( ABT ) separated its research-based pharmaceuticals business by creating a new company, AbbVie ( ABBV ), to allow the two separate entities to perform in a more focused manner. These are Abbott Laboratories ( ABT ), Patterson Companies Inc. ( PDCO ), a distributor of dental, companion-pet veterinarian, and rehabilitation supplies, MGC Diagnostics Corporation ( MGCD ), a provider of non-invasive cardio respiratory diagnostic systems and Invacare Corporation ( IVC ), which provides medical equipment and supplies for non-acute care environment."
2013-01-28,32.810001373291016,33.0,1.0919035396501724,,
2013-01-25,32.83000183105469,32.790000915527344,0.5790875304981022,"Covidien's 1Q Beats, Raises View - Analyst Blog","Additionally, the exit of Abbott Nutrition, a division of Abbott Laboratories ( ABT ), has created opportunities for the nursing care business to gain market share in the U.S. enteral feeding pumps market. ABBOTT LABS (ABT): Free Stock Analysis Report COVIDIEN PLC (COV): Free Stock Analysis Report HANGER ORTHOPED (HGR): Free Stock Analysis Report NXSTAGE MEDICAL (NXTM): Free Stock Analysis Report To read this article on Zacks.com click here. Revenue Revenues for the first quarter of 2013 increased 5% year over year to $3,056 million, primarily led by higher sales in the Medical Devices segment."
2013-01-24,32.650001525878906,32.79999923706055,-0.12184256258403836,"Company News for January 24, 2013 - Corporate Summary | ETF Talk: Here Is to Your Healthcare","• SAP AG (NYSE: SAP ) reported fourth quarter earnings per share of $1.23, missing the Zacks Consensus Estimate of $1.26 • Abbott Laboratories (NYSE: ABT ) posted fourth quarter earnings per share of $1.52, surpassing the Zacks Consensus Estimate of $1.50 • Praxair, Inc. (NYSE: PX ) reported fourth quarter earnings per share of $1.38, in line with the Zacks Consensus Estimate • Baker Hughes Incorporated (NYSE: BHI ) posted fourth quarter earnings per share of $0.62, beating the Zacks Consensus Estimate of $0.61 ABBOTT LABS (ABT): Free Stock Analysis Report BAKER-HUGHES (BHI): Free Stock Analysis Report PRAXAIR INC (PX): Free Stock Analysis Report SAP AG ADR (SAP): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The remaining members of XLV's top five are Merck & Company (MRK), Inc. Common Stock, 8.10%; Abbott Laboratories; (ABT) Common Stock, 5.71%; and Amgen Inc. (AMGN), 4.31%. By Doug Fabian In keeping with our sector theme, the exchange-traded fund (ETF) that we are featuring today focuses on a sector that typically offers slow and steady growth. The Health Care Select Sector SPDR (XLV) covers a wide range of companies investing in various segments of the health-care industry."
2013-01-23,33.0099983215332,32.810001373291016,0.459411038810366,"Abbott Beats on EPS, Guides In-Line - Analyst Blog","Abbott Labs ( ABT ) reported fourth quarter 2012 earnings of $1.51 per share, a penny ahead of the Zacks Consensus Estimate and 4.1% above the year-ago earnings. ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Fourth quarter revenues increased 4.4% to $10.8 billion, narrowly beating the Zacks Consensus Estimate of $10.6 billion."
2013-01-22,32.779998779296875,32.900001525878906,-0.6058677928248326,"Weekly Healthcare Notes: Roche Holdings, Pfizer & JNJ | Pre-Market Earnings Report for January 23, 2013 : MCD, UTX, ABT, PX, GD, NVS, BHI, WLP, APD, COH, MSI, TEL","Roche's Tamiflu became the only oral antiviral drug approved to treat patients of all ages after it received FDA nod for extending the use of Tamiflu for the treatment of infants two weeks of age and older in December 2012. See Full Analysis For Roche Holdings Here Pfizer Pfizer seems more than eager to continue with its approval streak after winning FDA approvals for two of its blockbuster potential drugs (Read Pfizer Secures Coveted FDA Approval For Eliquis and Pfizer Receives Big Boost As FDA Approves Rheumatoid Arthritis Drug ). The drug maker could be mulling to seek an early approval for its experimental advanced breast cancer drug, PD-0332991, following strong efficacy and safety exhibited by the drug in recently concluded mid-stage trials. | Abbott Laboratories ( ABT ) is reporting for the quarter ending December 31, 2012. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2012 Price to Earnings ratio for ABT is 6.47 vs. an industry ratio of 14.50."
2013-01-18,32.79999923706055,32.7400016784668,0.3660852686114874,,
2013-01-17,32.849998474121094,32.779998779296875,-0.18291939021132375,,
2013-01-16,33.150001525878906,32.70000076293945,-0.2130888830310413,,
2013-01-15,33.189998626708984,33.02000045776367,-1.3574683023412688,Zacks #5 Rank Additions for Tuesday - Tale of the Tape,"Here are 5 stocks added to the Zacks #5 Rank (""strong sell"") List today: Abbott Laboratories ( ABT ) Acuity Brands, Inc. ( AYI ) American Midstream Partners LP ( AMID ) America's Car-Mart, Inc. ( CRMT ) Banco Bilbao Vizcaya Argentaria SA (ADR) ( BBVA ) View the entire Zacks #5 Rank List . ABBOTT LABS (ABT): Free Stock Analysis Report AMER MIDSTREAM (AMID): Free Stock Analysis Report ACUITY BRANDS (AYI): Free Stock Analysis Report BANCO BILBAO VZ (BBVA): Free Stock Analysis Report AMERICAS CAR-MT (CRMT): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2013-01-14,33.47999954223633,33.36000061035156,-0.5121969749300017,"Merck, Abbott And JNJ Show Interest In Bausch & Lomb | Weekly Healthcare Notes: Pfizer, Abbott Labs, Merck & JNJ","Abbott Labs ( ABT ) is mulling to throw to bid too since it has appointed a big investment bank to advise the company on the deal. This year could see a major healthcare M&A transaction as Merck ( MRK ), Johnson & Johnson ( JNJ ) and Pfizer ( PFE ), are all rumored to be vying along with other healthcare companies like Sanofi, to acquire private equity firm Warburg Pincus' large eye-care business Bausch & Lomb (B&L). Market wise also, the deal won't help JNJ much since B&L gets a significant chunk of its revenues from the developed markets, and we expect JNJ to rather spend its money on acquisitions in rapidly growing Chinese market. | Abbott Labs ( ABT ) is also said to be in the fray to acquire Bausch & Lomb. Pfizer New year celebrations continue for Pfizer as, after receiving FDA approval for blockbuster potential blood thinner Eliquis (Read Pfizer Secures Coveted FDA Approval For Eliquis ), the drug maker has secured European approval to expand use of its one of the largest selling pneumococcal vaccine, Prevenar 13 (known as Prevnar 13 in the U.S.). See Full Analysis For Pfizer here Merck, Johnson & Johnson And Abbott Labs Merck, Johnson & Johnson and Abbott Labs are said to be considering the acquisition of private equity firm Warburg Pincus owned eye-care company Bausch & Lomb."
2013-01-11,33.880001068115234,33.369998931884766,-0.3584197536603377,,
2013-01-10,33.70000076293945,33.849998474121094,-1.5053191267766406,Pfizer Updates: Europe Approves Expanded Use Of Prevenar 13,"See our complete analysis for Pfizer Drugs like Prevenar (7 & 13) hold the key for future growth for Pfizer as the drug marker has been grappling with the issue of patent cliff and has seen its sales slumping in the last couple of quarters. The vaccine was showing consistent double digit growth rates until Q3, where it surprised the market by posting a decline in revenues (Read Pfizer Earnings Decline As Prevnar And Emerging Markets Disappoint ). While the FDA approved the vaccine for the above age group in December 2011, the CDC is waiting for the efficacy results of an ongoing clinical study (Pfizer expects to complete the trials by 2013) before deciding on broader recommendations."
2013-01-09,33.65999984741211,33.56999969482422,0.4450970557442717,Zacks #5 Rank Additions for Wednesday - Tale of the Tape | Abbott's ABSORB in Phase III Trial - Analyst Blog,"AGILENT TECH (A): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ALTERA CORP (ALTR): Free Stock Analysis Report ALEXANDRIA REAL (ARE): Free Stock Analysis Report AEROPOSTALE INC (ARO): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Here are 5 stocks added to the Zacks #5 Rank (""strong sell"") List today: Abbott Laboratories ( ABT ) Aeropostale, Inc. ( ARO ) Agilent Technologies Inc. ( A ) Alexandria Real Estate Equities Inc. ( ARE ) Altera Corp. ( ALTR ) View the entire Zacks #5 Rank List . | Abbott Laboratories ( ABT ) recently announced that its Absorb Bioresorbable Vascular Scaffold (BVS) device has moved into a phase III study, ABSORB III, in the US. ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report REPLIGEN (RGEN): Free Stock Analysis Report To read this article on Zacks.com click here. The decision to spin off the business was taken back in October 2011 when Abbott decided to separate its business into two publicly traded companies - one in diversified medical products and the other in research-based pharmaceuticals."
2013-01-08,33.290000915527344,33.349998474121094,-0.2673801336776005,"This Stock Could be Perfect for the ""Dividend Decade""","Health care giant Abbott Laboratories ( ABT ) celebrated the New Year by splitting itself in two. Humira is expected to earn $10 billion inrevenue this year and accounts for roughly half of Abbvie's total sales. During the first nine months of 2012, sales of proprietary pharmaceuticals improved 7% to $12.9 billion, fueled by a 29% jump in Androgel sales and a 19% increase in Humira sales.Operating income for this business rose 13% to $5.6 billion andprofit margins were generous even by pharmaceutical industry standards at 43%."
2013-01-07,33.02000045776367,33.34000015258789,0.1802269658868214,"Weekly Healthcare Note: Pfizer, JNJ, Abbott Labs & UnitedHealth | Zacks #5 Rank Additions for Monday - Tale of the Tape","Abbott Labs ( ABT ) started the new year by completing its much touted spin-off into two separate companies. See Full Analysis For Pfizer here Johnson & Johnson Johnson & Johnson also entered 2013 with a major boost as its experimental drug for the treatment of multi-drug resistant TB (MDR-TB), Bedaquilinean was approved by the FDA under its accelerated approval program. However, it will be a long way for the drug to reach its potential peak sales as it will have to wait for approvals from other countries, especially developing countries, where TB is more widespread than the U.S. Read our note Johnson & Johnson Updates: Receives FDA Approval For New Tuberculosis Drug for detail analysis. | AGILENT TECH (A): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report AERCAP HLDGS NV (AER): Free Stock Analysis Report AEROPOSTALE INC (ARO): Free Stock Analysis Report AMERICAS CAR-MT (CRMT): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Here are 5 stocks added to the Zacks #5 Rank (""strong sell"") List today: Abbott Laboratories ( ABT ) AerCap Holdings N.V. ( AER ) Aeropostale, Inc. ( ARO ) Agilent Technologies Inc. ( A ) America's Car-Mart, Inc. ( CRMT ) View the entire Zacks #5 Rank List ."
2013-01-04,33.33000183105469,33.06999969482422,0.9691086928770177,Patent Challenge for Auxilium Pharma - Analyst Blog,"ABBOTT LABS (ABT): Free Stock Analysis Report AUXILIUM PHARMA (AUXL): Free Stock Analysis Report ENDO PHARMACEUT (ENDP): Free Stock Analysis Report IRONWOOD PHARMA (IRWD): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report (XTLS): ETF Research Reports To read this article on Zacks.com click here. Apart from this, the TRT market is highly competitive with the presence of Abbott Labs' ( ABT ) AndroGel, Endo Pharmaceutical's ( ENDP ) Fortesta and Eli Lilly's ( LLY ) Axiron. Auxilium Pharmaceuticals, Inc. ( AUXL ) and Xstelos Holdings, Inc. ( XTLS ) recently received a notice from Upsher-Smith Laboratories, Inc. regarding the filing of a 505(b)(2) new drug application (NDA) for Auxilium Pharma's 1% testosterone gel, Testim."
2013-01-03,32.900001525878906,33.27000045776367,-0.7800843742775194,Abbott Labs Snapshot As AbbVie Begins Trading | Pfizer Secures Coveted FDA Approval For Eliquis | Three Actionable Trading Ideas Right Now | Coronado Amends Ovamed Agreement - Analyst Blog,"Abbott Labs' ( ABT ) split into two separately trading companies: one, Abbott Labs, with diversified medical products, and the other, AbbVie, with research-based proprietary pharmaceuticals, will be effective from today on Jan 2 and AbbVie will begin trading today. See our complete analysis for Abbott Labs here Abbott Labs: A Well Diversified Play Post spin-off, Abbott Labs has a diverse portfolio of healthcare products including: Pharmaceuticals - Generic drugs Nutritionals - Products such as infant formulas, snack bars and meal replacement shakes Vascular - Minimally invasive medical devices for heart diseases, strokes, carotid artery diseases, and other serious vascular conditions Diagnostics - Systems and tests used for screening for drugs of abuse, cancer, therapeutic drug monitoring, fertility, physiological diseases and infectious diseases such as hepatitis and HIV While this business is left with products having relatively lower margins, we expect growth to be fairly stable in the long term. AbbVie: Dependence On Humira Could Hurt AbbVie has the higher-margin proprietary pharmaceuticals and biologics, including primary care and specialty care drugs that prevent and treat conditions such as autoimmune diseases, lipid disorders, kidney diseases, prostate cancer, thyroid diseases and HIV. | Pfizer ( PFE ) has received a major boost as its blockbuster potential blood thinner drug Eliquis has received coveted U.S. FDA nod for patients with atrial fibrillation, which is not caused by a heart valve problem. But, the timing of these pending approvals will matter as J&J has already resubmitted clinical trials data in a bid to convince the U.S. FDA to approve the expanded use of Xarelto by acute coronary syndrome patients (to prevent heart attack and stroke in patients who have previously had severe chest pain or heart attack). However once approved for other indications, we expect Eliquis sales to see strong rise as it has exhibited significant safety over warfarin and aspirin (ARISTOTLE and AVERROES trials) in reducing the risk of stroke, and dangerous blood clots without a major bleeding amongst all non-warfarin drugs, including Xarelto and Pradax. | AbbVie (NYSE: ABBV ) - On Wednesday, Abbott Labs (NYSE: ABT ) completed a planned spinoff of its pharmaceutical division into a separate publicly-traded company known as AbbVie ( ABBV ). Historically, when the stock market moves higher over the course of the first five trading days of January, there is an 86 percent chance that stocks will close the year with a gain. Herbalife (NYSE: HLF ) - In recent weeks, multilevel marketing company Herbalife has been one of the most volatile and talked about stocks on the New York Stock Exchange. | ABBOTT LABS (ABT): Free Stock Analysis Report CORONADO BIOSCI (CNDO): Free Stock Analysis Report REPLIGEN (RGEN): Free Stock Analysis Report TARGACEPT INC (TRGT): Free Stock Analysis Report To read this article on Zacks.com click here. We remind investors that the Crohn's disease market currently has players like Abbott Labs ( ABT ). Although Coronado has the rights to TSO in its licensed territory, Ovamed will be retaining its manufacturing rights outside Coronado's territory."
2013-01-02,32.29999923706055,32.04999923706055,1.1246167620804732,,
2012-12-31,30.76957321166992,31.42690086364746,-0.7739938263315921,,
2012-12-28,31.081443786621094,30.908716201782227,2.1362910933331998,,
2012-12-27,31.172605514526367,31.21099090576172,-0.5557257443530252,,
2012-12-26,31.450889587402344,31.21578788757324,0.12313821896428917,,
2012-12-24,31.6907901763916,31.412506103515625,-0.7475200317490388,,
2012-12-21,31.28775787353516,31.6907901763916,-0.8781228594397349,Myriad Alleviates to Outperform - Analyst Blog,"ABBOTT LABS (ABT): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERIT MEDICAL (MMSI): Free Stock Analysis Report MYRIAD GENETICS (MYGN): Free Stock Analysis Report RESMED INC (RMD): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report THORATEC CORP (THOR): Free Stock Analysis Report To read this article on Zacks.com click here. Also worth mentioning in this context is that the company currently has 13 pipeline candidates and several agreements with pharmaceutical majors like Sanofi ( SNY ), Abbott Laboratories ( ABT ), Eli Lilly ( LLY ) and Johnson & Johnson ( JNJ ) among others to strengthen its presence in the companion diagnostic market. Myriad started fiscal 2013 on a cheery note with 24% year over year growth in earnings per share to 36 cents, beating the Zacks Consensus Estimate of 32 cents."
2012-12-20,31.37891960144043,31.450889587402344,1.2881469630565885,,
2012-12-19,31.657203674316406,31.35013198852539,0.22935775634101285,Positive Data on Actelion Candidate - Analyst Blog,"ABBOTT LABS (ABT): Free Stock Analysis Report (ALIOF): ETF Research Reports AMGEN INC (AMGN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. We note already approved drugs for the treatment of moderate-to-severe plaque psoriasis include Johnson & Johnson 's ( JNJ ) Stelara, Abbott Laboratories ( ABT ) Humira and Pfizer Inc. ( PFE ) and Amgen Inc. 's ( AMGN ) Enbrel. Around 46% of patients treated with ponesimod (20 mg) showed an improvement of at least 75% in PASI, whereas 48.1% treated with ponesimod (40 mg) showed the same at the 16 th week."
2012-12-18,31.24937438964844,31.633214950561523,-0.9699899237788457,Covidien Expands U.S. Kangaroo Biz - Analyst Blog,"Following the announcement made by Abbott Nutrition, a division of Abbott Laboratories ( ABT ), to discontinue sale of all its enteral feeding pumps and sets in North America, the company increased its inventory in the U.S. ABBOTT LABS (ABT): Free Stock Analysis Report COVIDIEN PLC (COV): Free Stock Analysis Report To read this article on Zacks.com click here. ( COV ) is expanding the production of its Kangaroo ePump and the Kangaroo Joey enteral feeding pumps and sets."
2012-12-17,31.46528434753418,31.28296089172364,1.2283143852000828,Weekly Healthcare Note: Pfizer and JNJ | JNJ's Zytiga Inches Towards A Billion Dollar Sales As FDA Approves Expanded Use,"The outcome will certainly help Pfizer gain access to much larger markets as the drug is currently approved in many countries (excluding the U.S.) for preventing blood clots in patients who have knee or hip replacements along with recent European approval for NVAF (irregular heart beat). In a separate event, the U.S. FDA issued a safety notice against Chantix, a smoking-cessation drug and part of cardiovascular franchise in our model, saying patients taking the drug may have a higher rate of heart attacks or strokes than those who are not on the treatment, following separate clinical trials. See Full Analysis For Pfizer here Johnson & Johnson JNJ's blockbuster potential oncology drug Zytiga has secured U.S. FDA approval for expanded use in metastatic castration-resistant prostate cancer (mCCRPC) patients (no longer responsive to reduction of available androgen/testosterone by chemical or surgical means), who have not yet been treated with chemotherapy but have failed hormone treatment. | Johnson & Johnson's ( JNJ ) blockbuster potential oncology drug Zytiga has secured U.S. FDA approval for expanded use in metastatic castration-resistant prostate cancer (mCCRPC) patients (no longer responsive to reduction of androgen/testosterone by chemical or surgical means), who have not yet been treated with chemotherapy but have failed hormone treatment. This lends support to our expectation of exponential growth in sales of Zytiga in the near future even as Xtandi, considered the closest rival of Zytiga, received FDA approval about three months ahead of schedule and shown a little survival advantage over Zytiga. But, the fact that Zytiga had only been approved for use for patients who didn't respond to prior chemotherapy and hormone treatment meant limited eligible patients and consequently revenues."
2012-12-14,31.182201385498047,31.354930877685547,-0.5794432168378857,AstraZeneca's RA Drug Disappoints - Analyst Blog | Meridien Completes Beta Trials - Analyst Blog,"ABBOTT LABS (ABT): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report (RHHBY): ETF Research Reports RIGEL PHARMCTCL (RIGL): Free Stock Analysis Report To read this article on Zacks.com click here. The study enrolled 280 patients with primary objectives to establish superiority of fostamatinib against placebo at 6 weeks and non-inferiority in comparison to Abbott Laboratories' ( ABT ) Humira (adalimumab) at 24 weeks. AstraZeneca ( AZN ) and its partner Rigel Pharmaceuticals ( RIGL ) recently announced top-line data from the phase IIb OSKIRA-4 study evaluating the use of oral fostamatinib for rheumatoid arthritis (RA). | ABBOTT LABS (ABT): Free Stock Analysis Report BECTON DICKINSO (BDX): Free Stock Analysis Report MERIDIAN BIOSCI (VIVO): Free Stock Analysis Report To read this article on Zacks.com click here. However, the company's diagnostics business faces strong competition from Abbott Laboratories ( ABT ), Becton, Dickinson and Company ( BDX ). Diagnostic test kit maker Meridian Bioscience Inc. ( VIVO ), recently announced the successful completion of beta trials for two of its illumigene molecular amplification tests."
2012-12-13,31.67159843444824,31.34053611755371,0.5539361703559248,,
2012-12-12,31.76755714416504,31.67159843444824,-1.0452971534724982,BMY/ABT Present Oncology Data - Analyst Blog,"Bristol-Myers Squibb Company ( BMY ) and partner Abbott Laboratories ( ABT ) recently presented data on their oncology candidate elotuzumab from a phase II study. ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report (RHHBY): ETF Research Reports SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Apart from the above phase II study, Bristol-Myers/Abbott Laboratories are also evaluating elotuzumab in other studies."
2012-12-11,31.345333099365234,31.74836540222168,-0.30206512034062966,Gilead Plans to Split Stock 2-for-1 - Analyst Blog | Myriad Teams Up with Sanofi - Analyst Blog,"ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. Apart from Gilead, companies such as Abbott Laboratories ( ABT ), Johnson & Johnson ( JNJ ) and Bristol-Myers Squibb ( BMY ) are also developing therapies to combat HCV. The action, which will take shape through a stock dividend for stockholders as on record on January 7, 2013, is aimed at increasing the number of authorized shares at Gilead to about 1.52 billion from 759.3 million (as of November 30). | ABBOTT LABS (ABT): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYRIAD GENETICS (MYGN): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Apart from Sanofi, it has agreements with several pharmaceutical majors including Abbott Laboratories ( ABT ), Johnson & Johnson ( JNJ ), Eli Lilly ( LLY ), Merck ( MRK ), Novartis ( NVS ) and AstraZeneca ( AZN ). Myriad RBM, a wholly-owned subsidiary of molecular diagnostic company Myriad Genetics Inc. ( MYGN ), has recently collaborated with global pharmaceutical products maker Sanofi ( SNY ) and Population Health Research Institute (""PHRI"") at Hamilton Health Sciences and McMaster University."
2012-12-10,31.2205867767334,31.345333099365234,1.285780889865889,Weekly Healthcare Note: Pfizer and Merck,"Meanwhile, Merck ( MRK ) announced phase II clinical trials of new type of Alzheimer drug, moving to front-line in quest for a complete cure for Azheimer's disease. While there is still a long way to go for regulatory approval as Pfizer is yet to begin late-stage trials, the drug, if approved as a first-line treatment, could bring multi-billion dollars in revenues for the struggling drug maker. Further, no significant competition is present with the exception of Roche Holdings ( RHHBY ) after competitors either failed late stage clinical trials or saw inconclusive results (Read Pfizer and Johnson & Johnson Dump Alzheimer Drug After Failed Clinical Trials )."
2012-12-07,30.96149444580078,31.441293716430664,0.3995643115996813,,
2012-12-06,30.947099685668945,30.985483169555664,1.5496644435874658,Johnson & Johnson Patent Cliff: A Look At The Pharmaceutical Division | Pharma & Biotech Stock Outlook - Dec 2012 - Industry Outlook | Pharma & Biotech Stock Outlook - Dec 2012 - Zacks Analyst Interviews,"(Read Pfizer Patent Cliff: A Look At The Cardiovascular Drugs Division , Merck Patent Cliff: A Look At The Anti-Infectives Drugs Division and Abbott Patent Cliff: A Look At The Autoimmune and HIV Antiviral Divisons ). J&J also faced a setback with the failure of its trial drug Bapineuzumab for Alzheimers (Read Pfizer and Johnson & Johnson Dump Alzheimer Drug After Failed Clinical Trials), the sales of which could have more than made up for the revenue loss from Invega's patent expiry. Current Drugs Also Hold Promise Further, Zytiga, a prostate cancer drug, continues to hold promise as the drug received a priority review status this August for larger use. | ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ( ABT ) will be splitting into two separate publicly traded companies by year end. Companies that should benefit from this Act include The Medicines Company ( MDCO ), Optimer Pharma ( OPTR ) and Cubist Pharma ( CBST ) among others. | ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ( ABT ) will be splitting into two separate publicly traded companies by year end. Companies that should benefit from this Act include The Medicines Company ( MDCO ), Optimer Pharma ( OPTR ) and Cubist Pharma ( CBST ) among others."
2012-12-05,30.84154319763184,30.966291427612305,0.12402934128426084,,
2012-12-04,30.7983627319336,30.89432144165039,0.4044811544645534,"Weekly Healthcare Summary: Abbott, Pfizer, JNJ, Boston Scientific, Medtronic and Roche Holdings","Below we summarize a few such events related to Abbott Labs ( ABT ), Pfizer ( PFE ), Johnson & Johnson ( JNJ ), Boston Scientific's ( BSX ), Medtronic ( MDT ) and Roche Holdings (RHHBY) which could impact their value going forward. See Full Analysis For Pfizer here Johnson & Johnson An advisory panel to the U.S. FDA has supported early approval for bedaquilinean, Johnson & Johnson's experimental drug for the treatment of tuberculosis (TB) as TB is considered resistant to currently available drugs. See Full Analysis ForJohnson & Johnson here Boston Scientific and Medtronic The U.S. FDA recently raised fresh concerns about the defibrillator leads from St. Jude Medical (STJ), one of its biggest competitors in the Cardiac Rhythm Management (CRDM) market."
2012-12-03,31.23018264770508,30.846342086791992,0.31157081482547117,,
2012-11-30,31.24457550048828,31.187000274658203,-1.229069215646408,,
2012-11-29,31.11503028869629,31.22538375854492,-0.18427270944736746,NVS Discusses Data Readout Plans - Analyst Blog | Gilead Reports Positive HCV Data - Analyst Blog,"ABBOTT LABS (ABT): Free Stock Analysis Report INCYTE CORP (INCY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report (RHHBY): ETF Research Reports To read this article on Zacks.com click here. The hematology market currently has players like Abbott Laboratories ( ABT ). Novartis will also present data from an additional phase II study on Afinitor in combination with Femara and from a phase III trial of Afinitor in combination with Pfizer Inc. 's ( PFE ) Aromasin. | Gilead Sciences ( GILD ) recently presented encouraging top-line data from a phase III study (Positron) which evaluated its candidate sofosbuvir (formerly GS-7977) combined with ribavirin in patients suffering from genotypes 2 or 3 of the chronic hepatitis C virus (HCV). The study evaluated patients, who were unable or unwilling to take interferon, a standard HCV therapy characterized by unpleasant side effects. Data from the study revealed that after 12 weeks of completion of treatment, no traces of the HCV virus were detected in 78% patients in the sofosbuvir arm."
2012-11-28,30.635229110717773,30.98068618774414,0.3546629035058961,3 Retirement Savings Stocks That Consistently Increase Dividends | Abbott's Humira's Label Expanded - Analyst Blog,"Abbott Laboratories ( ABT ) Boasting amarket capitalization of nearly $100 billion, this pharmaceutical kingpin is a leader in its field. This means when stock prices decrease, dividend yields increase. Only invest in companies that historically increase dividends This is perhaps the most important aspect in successful dividend investing. | ABBOTT LABS (ABT): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ( ABT ) recently received approval for yet another indication of Humira (adalimumab). Some time back, Abbott Labs gained FDA approval for Humira for inducing and sustaining clinical remission in adult patients suffering from moderately to severely active ulcerative colitis when certain other medicines have not worked sufficiently."
2012-11-27,30.76957321166992,30.73598861694336,1.1276464614573702,Pfizer Update: Europe Approves Eliquis For Atrial Fibrillation,"Pfizer's ( PFE ) blockbuster potential drug Eliquis (co-developed with Bristol-Myers Squibb ( BMY )) has received the European Medicines Agency's (EMA) approval for expanding the drug's use to prevent heart attack and stroke in adult patients with nonvalvular atrial fibrillation, a type of abnormal/irregular heart beat. The approval will certainly help boost optimism around the drug and could get the stock moving even as the approval was anticipated following a European medical panel's positive opinion to extend the drug (Read European Panel Backs Pfizer's Eliquis For Atrial Fibrillation ). The EMA approval makes the drug's case to receive the U.S. FDA approval stronger as the drug has been delayed two times, citing need for more information on management and verification of data."
2012-11-26,30.74558448791504,30.879928588867188,-0.10914871810383572,The Best Pharma Stock to Profit from the 'Patent Cliff',"Although the two companies haven't yet revealed which medications they intend to imitate, analysts speculate the $9-billion arthritis drug Humira manufactured by Abbott Labs ( ABT ) and the $3-billion cancer medication Rituxan made by Genentech Inc. are among the potential candidates. Now, I'm not saying you should avoid the stocks of big drug companies like Pfizer Inc. ( PFE ) , Johnson & Johnson ( JNJ ) and others simply to avoid near-term bumps in financial performance that may come with patent expirations. You probably haven't heard of Watson, but the firm has three decades of experience bringing generic drugs to market in a timely fashion."
2012-11-23,30.457704544067383,30.932706832885746,0.436954129152933,,
2012-11-21,30.35694694519043,30.38573455810547,1.5595472342018135,3 Bio-Pharmas Trades Offering Good Upside Potential,"It has strategic collaborations with Abbott Laboratories (NYSE: ABT) to develop and commercialize galectin-3 assay kits and related control kits and calibrators. It is also developing CardioSCORE, a cardiovascular diagnostic test designed to identify individuals at high risk for near term cardiovascular events, such as heart attack and stroke; and galectin-3 test for a second indication to identify individuals at risk for developing heart failure, such as patients who have suffered a heart attack, as well as patients suffering from hypertension or diabetes. It offers Vision/Tjet reusable needle-free injectors that deliver precise medication doses through high-speed pressurized liquid penetration of the skin without a needle; The Vibex disposable pressure assisted auto injector devices that are used for the controlled pressure delivery of drugs into the body utilizing a spring power source; disposable pen injection systems, which are needle-based devices designed to deliver multiple drugs by injection through needles from multi-dose drug cartridges."
2012-11-20,30.13143920898437,30.265783309936523,0.09483039571474429,Incyte Progresses on RA Candidate - Analyst Blog,"ABBOTT LABS (ABT): Free Stock Analysis Report INCYTE CORP (INCY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. Our Take Although competition is tough in the RA market, with players like Johnson & Johnson ( JNJ ) and Abbott Laboratories ( ABT ), we believe baricitinib, once launched, will be able to corner a market share of its own as the patient base is quite large. Incyte also stated that baricitinib will now be studied in a phase III study for RA treatment."
2012-11-19,30.34734916687012,30.18901634216309,0.4458602193555171,AUXL Downgraded to Underperform - Analyst Blog | Data Presented by UCB on Cimzia - Analyst Blog,"ABBOTT LABS (ABT): Free Stock Analysis Report (ARUXF): ETF Research Reports AUXILIUM PHARMA (AUXL): Free Stock Analysis Report ENDO PHARMACEUT (ENDP): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Moreover, Testim faces stiff competition from AndroGel, a 1% testosterone gel sold by Abbott ( ABT ) worldwide. In addition to reporting weak results, the company cut its sales guidance for Testim and US sales guidance for Xiaflex. | Currently used products for psoriatic arthritis include Abbott's ( ABT ) Humira and Johnson & Johnson's ( JNJ ) Simponi. ABBOTT LABS (ABT): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report (UCBJF): ETF Research Reports To read this article on Zacks.com click here. UCB ( UCBJF ) recently presented positive data on Cimzia (certolizumab pegol) from a late-stage trial (RAPID-PsA), conducted in patients suffering from psoriatic arthritis."
2012-11-16,30.29936981201172,30.169824600219727,-0.5217352719554218,Oracle Set to Acquire Instantis - Analyst Blog | Gilead Presents Encouraging Data - Analyst Blog,"ABBOTT LABS (ABT): Free Stock Analysis Report SALESFORCE.COM (CRM): Free Stock Analysis Report INTL BUS MACH (IBM): Free Stock Analysis Report ORACLE CORP (ORCL): Free Stock Analysis Report SAP AG ADR (SAP): Free Stock Analysis Report XEROX CORP (XRX): Free Stock Analysis Report To read this article on Zacks.com click here. The simplicity of Instantis has attracted many big names and the company has a significant clientele, which includes Cardinal Healthcare, Abbott Laboratories (ABT) , Credit Suisse Group AG, and Xerox Corp (XRX) . Moreover, the acquisition of Instantis will help Oracle to increase its penetration into the portfolio management market, in which SAP AG (SAP) has significant presence. | ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. While Norvir is marketed by Abbott Labs ( ABT ), Reyataz is marketed by Bristol-Myers Squibb ( BMY ). Gilead Sciences ( GILD ) recently presented encouraging long-term data on its HIV therapy Stribild from two ongoing phase III studies (102 and 103) as a first-line therapy."
2012-11-15,30.625633239746094,30.323360443115234,-0.42755084543255417,Still Neutral on DexCom - Analyst Blog,"ABBOTT LABS (ABT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report EDWARDS LIFESCI (EW): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report (RHHBY): ETF Research Reports To read this article on Zacks.com click here. Additionally, Medtronic ( MDT ) and Abbott ( ABT ) have gained FDA approval for continuous glucose monitoring systems. Last month, the U.S. Food and Drug Administration (FDA) cleared DexCom's new continuous glucose monitoring system, the DexCom G4 Platinum."
2012-11-14,31.05745315551757,30.58245277404785,-0.9869928052248998,,
2012-11-13,31.00947380065918,31.03346443176269,-1.529424769929444,"Stock Market News for November 13, 2012 - Market News","ABBOTT LABS (ABT): Free Stock Analysis Report DUKE ENERGY CP (DUK): Free Stock Analysis Report ENDO PHARMACEUT (ENDP): Free Stock Analysis Report EXELON CORP (EXC): Free Stock Analysis Report GENON ENERGY (GEN): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report NEXTERA ENERGY (NEE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report XCEL ENERGY INC (XEL): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks such as Abbott Laboratories (NYSE: ABT ), Sanofi SA (NYSE: SNY ), Watson Pharmaceuticals, Inc. (NYSE: WPI ), Mylan Inc. (NASDAQ: MYL ) and Endo Health Solutions Inc (NASDAQ: ENDP ) rose 0.1%, 0.3%, 0.2%, 0.6% and 3.0%, respectively. Apprehension about this week's ""fiscal cliff"" discussion between top U.S. leaders and President Barack Obama led to benchmarks ending flat."
2012-11-12,31.172605514526367,31.12462615966797,0.07736548919769833,,
2012-11-09,30.78396797180176,31.110231399536133,-0.15391512536877985,,
2012-11-08,31.014272689819336,30.457704544067383,1.0598485160627442,The Stock is Not the Company | 5 Dividend Stocks Investors Mostly Dislike,"For example, just look at this monthly chart of Abbott Laboratories ( ABT ), a conservative blue chip growth stock: The bars represent the stock itself, while the generally smoothly rising line is the earnings line (depicting the company's 12-month earnings per share totals). As you can see, back in the late 1990s, ABT was trading around 50 per share, even as earnings totaled about $1.60. Now fast forward to mid-2011, and you see ABT was still hovering at 50 per share ... even though earnings by then were up to $4.50 per share! | Abbott Laboratories ( ABT ) has a market capitalization of $101.72 billion. Financial Analysis: The total debt represents 27.62 percent of the company's assets and the total debt in relation to the equity amounts to 74.92 percent. Financial Analysis: The total debt represents 9.85 percent of the company's assets and the total debt in relation to the equity amounts to 18.00 percent."
2012-11-07,30.88472557067871,30.956695556640625,-1.794554885482292,Why Teva Pharmaceutical Is An Attractive Buying Opportunity,"It is from the latter facility that Teva acquired Copaxone, its top selling drug for the treatment of multiple sclerosis or MS. During the last 3 years Teva's stock has been under heavy pressure due to a number of concerns. This remunerative franchise is threatened by a number of elements: Immediate generic threat due to patent challenges Medium-term generic threat following patent expiration in 2015 Immediate threat from recently-launched competing branded drugs Because Copaxone clearly represents such a significant share of Teva's revenue and profit, it is important to quantify the magnitude of these threats and its impact on the bottom line. Future growth rates are likely to moderate given Teva's intention to avoid large acquisitions, Copaxone's slowdown, and generics uncertainty, but we would expect Teva's earnings to maintain at least a low double-digit pace for the next 5-10 years."
2012-11-06,31.2205867767334,31.100635528564453,0.23302776577118367,,
2012-11-05,31.081443786621094,31.20619201660156,-0.3842056173599431,DexCom Continues to Incur Loss - Analyst Blog | Donald Yacktman Buys 4 New Stocks in Q3,"ABBOTT LABS (ABT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report (RHHBY): ETF Research Reports To read this article on Zacks.com click here. Additionally, Medtronic ( MDT ) and Abbott ( ABT ) have gained FDA approval for continuous glucose monitoring systems. DexCom ( DXCM ), a player in the glucose monitoring market, reported third quarter 2012 loss per share of 25 cents, higher than the Zacks Consensus Estimate of a loss of 22 cents per share and the year-ago loss of 20 cents a share. | Abbott Laboratories ( ABT ) Yacktman purchased 3,000 shares of his smallest new position, Abbott Laboratories, for $66 per share on average, which is a 0.0012% weighting of his portfolio. ABT data by GuruFocus.com See more of Donald Yacktman's portfolio updates here. Donald Yacktman of Yacktman Asset Management reported his third quarter portfolio on Monday, which his largest new buys were WellPoint Inc. ( WLP ), CH Robinson Worldwide ( CHRW ), Liberty Ventures ( LVNTA ) and Abbott Laboratories ( ABR )."
2012-11-02,31.609224319458008,31.167808532714844,0.4013591866480883,,
2012-11-01,31.551647186279297,31.402910232543945,-1.3964777568788276,,
2012-10-31,31.57563781738281,31.42690086364746,-0.47140788833374137,,
2012-10-26,31.58043670654297,31.41730308532715,-0.471049720659851,,
2012-10-25,31.638011932373047,31.561243057250977,-0.5165654380644509,,
2012-10-24,31.422101974487305,31.4556884765625,-0.24264759519708598,,
2012-10-23,31.24457550048828,31.35972785949707,0.10688814549219325,,
2012-10-22,31.5036678314209,31.57563781738281,0.3685515234700164,,
2012-10-19,32.32892227172852,31.73876953125,0.22844954545302057,What Moves Biotech Stocks? Ed Arce Has Answers. | Wells Fargo Analysts Upgrade Abbott Laboratories to “Outperform” (ABT) | BIIB's BG-12 Review Period Extended - Analyst Blog | Pipeline Setback at Abbott - Analyst Blog,"But increasingly, companies are focusing one or more of their development programs on rare diseases that qualify for the FDA's orphan indication, with the candidate drug being entitled to marketing exclusivity. TLSR: You have alluded to a very interesting point regarding orphan indications-incentives from the FDA for developing these products and the pricing models available to companies for focusing on rare diseases. Normally this percentage would be considered small-and perhaps even insignificant-but for a company the size of Ligand, with a $336M market cap, and for the market opportunity that we see in Kyprolis, specifically for patients who have come to the end of the line and have no therapeutic alternatives left, we see this as one of the key value drivers, especially starting next year. | Analysts at Wells Fargo upgraded pharmaceutical company Abbott Laboratories ( ABT ) from ""Market Perform"" to ""Outperform"" on Friday. Biegelsen went on to say, ""Looking at 2013, we believe ABT management has set performance targets for each company's first year that should be at least achievable if not beatable. For the new ABT, we expect the management team, including current CEO Miles White, to build an earnings track record of beats and raises as was done for the current ABT. | Meanwhile, Biogen and partner Abbott Labs ( ABT ) moved another MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010, with results due in 2014. ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Biogen Idec 's ( BIIB ) shares were down 2.74% after the company announced that the US Food and Drug Administration (FDA) has extended its review period for the company's oral multiple sclerosis (MS) candidate, BG-12 (dimethyl fumarate), by three months. | Abbott Laboratories ( ABT ) and its partner Reata Pharmaceuticals, Inc. recently announced the discontinuation of the pivotal phase III BEACON (Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type II diabetes: the Occurrence of renal eveNts) study with bardoxolone methyl. ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. The study was being conducted to evaluate the safety and efficacy of bardoxolone methyl in patients with stage 4 chronic kidney disease (CKD) and type II diabetes."
2012-10-18,31.70518493652344,31.9738712310791,-1.8254636994027118,"Pharmaceutical Stocks Are All-of-a-Sudden Hot Again: Read About Drugs and Dividends | Company News for October 18, 2012 - Corporate Summary","MRK PE Ratio TTM data by YCharts Shares of Merck ( MRK ), Pfizer ( PFE ), Eli Lilly & Co. ( LLY ) and Abbott Laboratories ( ABT ) have been trading at 52-week highs lately, with particularly strong gains in the past five months, as seen in a stock chart . MRK data by YCharts Dividends remain the key reason for drug company popularity on Wall Street, especially as more investors worry about a slumping market generally. MRK Dividend Yield data by YCharts Despite their big yields, none of these companies pay big portions of their income or cash on dividends. | • CSX Corporation (NYSE: CSX ) reported third quarter earnings per share of $0.44, in line with the Zacks Consensus Estimate • Abbott Laboratories (NYSE: ABT ) posted third quarter earnings per share of $1.30, beating the Zacks Consensus Estimate of $1.28 • PepsiCo, Inc. (NYSE: PEP ) reported third quarter earnings per share of $1.20, ahead of the Zacks Consensus Estimate of $1.16 • Halliburton Company (NYSE: HAL ) posted third quarter earnings per share of $0.67, in line with the Zacks Consensus Estimate • M&T Bank Corporation (NYSE: MTB ) reported third quarter earnings per share of $2.17, breezing past the Zacks Consensus Estimate of $1.84 by 33 cents • Dover Corporation (NYSE: DOV ) posted third quarter earnings per share of $1.30, higher than the Zacks Consensus Estimate of $1.27 ABBOTT LABS (ABT): Free Stock Analysis Report CSX CORP (CSX): Free Stock Analysis Report DOVER CORP (DOV): Free Stock Analysis Report HALLIBURTON CO (HAL): Free Stock Analysis Report M&T BANK CORP (MTB): Free Stock Analysis Report PEPSICO INC (PEP): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
2012-10-17,34.44484329223633,33.12539291381836,0.8474522230152387,"Abbott’s Q3 Earnings Rise on Lower Costs; Adjusted Net Beats, but Revenue Misses (ABT) | Market Wrap-Up for Oct.17 (MTB, SWK, ABT, INTC, IBM, more)","Diversified health care products maker Abbott Laboratories ( ABT ) on Wednesday posted mixed third quarter earnings, as profit beat estimates but its revenue fell short of analysts' view. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $72.13. Looking ahead, ABT narrowed its full-year earnings outlook to a range of $5.06 to $5.08 per share. | On the flip side, investors were not as pleased with the earnings results from companies such as IBM Corp ( IBM ), Intel Corp ( INTC ), Stanley Black & Decker ( SWK ), and Abbott Labs ( ABT ). Wrong Person for the Job Yesterday was a big day for fans of the Philadelphia Eagles football team, which decided to shake things up mid-season, firing their defensive coordinator Juan Castillo. An Important Note Regarding the Best Dividend Stocks List We want to make sure everyone understands that the stocks on our Best Dividend Stocks List are the names we currently like for new investor capital, regardless of what date the stock was first recommended on."
2012-10-16,34.59357833862305,34.60797500610352,-3.8306180324976693,"Stock Market News for October 16, 2012 - Market News | Pre-Market Earnings Report for October 17, 2012 : ABT, PEP, BAC, USB, HAL, BLK, BK, ASML, STJ, MTB, SWK, NTRS | Abbott Reports Encouraging HCV Data - Analyst Blog","ABBOTT LABS (ABT): Free Stock Analysis Report BANK OF AMER CP (BAC): Free Stock Analysis Report BIG LOTS INC (BIG): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report CITIGROUP INC (C): Free Stock Analysis Report GOLDMAN SACHS (GS): Free Stock Analysis Report JPMORGAN CHASE (JPM): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MORGAN STANLEY (MS): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report PRICESMART INC (PSMT): Free Stock Analysis Report SEARS HLDG CP (SHLD): Free Stock Analysis Report TARGET CORP (TGT): Free Stock Analysis Report WELLS FARGO-NEW (WFC): Free Stock Analysis Report WAL-MART STORES (WMT): Free Stock Analysis Report To read this article on Zacks.com click here. Whereas, Abbott Laboratories's (NYSE: ABT ) experimental hepatitis C candidate showed positive signs. The U.S. Census Bureau released its retail sales data, which revealed that the retail sales rose 1.1% to $412.9 billion in September, beating the consensus estimates of 0.8%. | Abbott Laboratories ( ABT ) is reporting for the quarter ending September 30, 2012. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2012 Price to Earnings ratio for ABT is 14.24 vs. an industry ratio of 14.50. | Abbott Laboratories ( ABT ) recently announced promising data from the phase IIb Aviator trial evaluating the combination of ABT-450/r, ABT-267, ABT-333 and ribavirin for the treatment of patients suffering from hepatitis C (HCV). ABT-450/r (protease), ABT-267 (polymerase) and ABT-333 (NS5A) are also being evaluated in other clinical studies. The combination regimen demonstrated impressive sustained virological response in genotype 1 (GT1) HCV patients at 12 weeks post treatment in treatment-naïve (99%) and null responders (93%)."
2012-10-15,33.346099853515625,34.5695915222168,0.04161658947089108,Abbott Labs Eyes Russian Pharmaceutical Market,"Abbott Labs ( ABT ) may be looking to acquire the manufacturing facilities of Russian drug maker Petrovax Pharm, according to a local newspaper. See our complete analysis for Abbott Labs Russia: A Key Market For Growth Abbott's management has oftentimes reiterated its intention to tap the high potential emerging markets as they are expected to grow at a faster pace than developed markets going forward. Abbott's revenue from Russia is a meager $430 million in a market worth more than $16 billion even as most of the drugs sold in the country are from international companies."
2012-10-12,33.39887619018555,33.24054336547852,3.6690697685060196,,
2012-10-11,33.66276931762695,33.307716369628906,-0.47406632428414214,FDA Nod for Dexcom G4 Platinum - Analyst Blog,"DexCom ( DXCM ), a provider of continuous glucose monitoring systems, recently announced that the U.S. Food and Drug Administration (FDA) has cleared its new continuous glucose monitoring system, the DexCom G4 Platinum. Clinical data validates the improved performance of G4 Platinum over the company's Seven Plus with a 19% increase in overall accuracy for glucose monitoring. The inbuilt features of the G4 Platinum make it the most innovative system for continuous glucose monitoring in the market."
2012-10-10,34.07539749145508,33.763526916503906,-1.0547348159265355,,
2012-10-09,34.104183197021484,34.017818450927734,-0.9152367922615667,Alexandria Pens New Lease Deals - Analyst Blog,"ABBOTT LABS (ABT): Free Stock Analysis Report ALEXANDRIA REAL (ARE): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report QUEST DIAGNOSTC (DGX): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report THERMO FISHER (TMO): Free Stock Analysis Report To read this article on Zacks.com click here. It has around 100 client tenants in the area including the likes of Abbott Laboratories (ABT) , Biogen Idec Inc. (BIIB) , Quest Diagnostics Inc. (DGX) , Thermo Fisher Scientific Inc. (TMO) and others. The 400 Technology square comprises of rentable space of around 194,776 square feet and is one of the seven facilities located at the company's state-of-the-art laboratory/office park-like community known as Alexandria Technology Square."
2012-10-08,34.29130554199219,34.219337463378906,-0.25323798431065414,,
2012-10-05,34.15696334838867,34.35847854614258,-0.20987267027541756,,
2012-10-04,33.557212829589844,33.960243225097656,0.5899681294807273,,
2012-10-03,32.99104690551758,33.504432678222656,1.2010246427630342,,
2012-10-02,33.307716369628906,32.88549041748047,1.556136651787237,,
2012-10-01,32.86150360107422,33.14458465576172,-1.267652058348369,Novartis Progresses with AIN457 - Analyst Blog | Why Barron's Article on Opko Health is Myopic,"We note already approved drugs for the treatment of moderate-to-severe plaque psoriasis include Johnson & Johnson 's ( JNJ ) Stelara, Abbott Laboratories ( ABT ) Humira and Pfizer Inc. and Amgen Inc. 's ( PFE / AMGN ) Enbrel. ABBOTT LABS (ABT): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Switzerland-based pharmaceutical company, Novartis AG ( NVS ) recently announced phase II data on its pipeline candidate, AIN457 (secukinumab), which is being developed for the treatment of moderate-to-severe plaque psoriasis on the hands, feet and nails. | Alpert's Article Is Superficial The depth of Alpert's analysis reflects the self-evidently brief amount of time he spent reflecting on Opko Health. Alpert's article in Barron's began and ended with the same, superficial perspective: If Opko Health's shares traded like a traditional company, they would trade at a lower price per share. Conclusion * Alpert failed to reflect on the implications of Opko Health's corporate structure as a holding company, which would have fundamentally altered his entire perspective on the valuation of long-term opportunities to serve human health versus his near-term revenue estimates."
2012-09-28,33.26933288574219,32.89508819580078,0.8614367075955901,,
2012-09-27,33.24534225463867,33.259735107421875,-1.1248938811808622,,
2012-09-26,33.37968444824219,33.19736099243164,0.04329283985998042,Ex-US Launch for Abbott's Absorb - Analyst Blog,"Abbott Labs ( ABT ) recently announced the launch of Absorb, the world's first drug eluting bioresorbable vascular scaffold (BVS), in Europe and parts of Asia Pacific and Latin America. ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. The launch of Absorb should boost the performance of Abbott Labs' vascular devices segment which posted sales of $766 million in the second quarter of 2012."
2012-09-25,33.49003982543945,33.37968444824219,-0.5462108429852106,,
2012-09-24,33.394081115722656,33.39887619018555,-0.3295170079595973,,
2012-09-21,33.538021087646484,33.4036750793457,0.01435905496627964,Myriad Remains Neutral - Analyst Blog,"ABBOTT LABS (ABT): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MYRIAD GENETICS (MYGN): Free Stock Analysis Report To read this article on Zacks.com click here. The company has agreements with several pharmaceutical companies including Abbott Laboratories ( ABT ), Johnson & Johnson ( JNJ ), and AstraZeneca ( AZN ), among others. While Myriad markets several molecular diagnostic products, the company's flagship product is Bracanalysis (representing 81.7% of total revenues during the last reported quarter), which studies BRCA1 and BRCA2 genes to assess a woman's risk of developing hereditary breast and ovarian cancers."
2012-09-20,33.173370361328125,33.518829345703125,-0.4005782212065778,FDA Clears Meridian Ilumigene GAS - Analyst Blog,"ABBOTT LABS (ABT): Free Stock Analysis Report BECTON DICKINSO (BDX): Free Stock Analysis Report MERIDIAN BIOSCI (VIVO): Free Stock Analysis Report To read this article on Zacks.com click here. The company's diagnostics business faces strong competition from Abbott Laboratories ( ABT ), Becton, Dickinson and Company ( BDX ). Diagnostic test kit maker Meridian Bioscience ( VIVO ) won the approval of the U.S. Food and Drug Administration (FDA) for its new illumigene GAS (Group A Streptococcus) test."
2012-09-19,33.134986877441406,33.274131774902344,1.041374393413215,Celgene's Drug Pipeline News Soothes Investor Worries,"The bigger prizes are psoriasis and rheumatoid arthritis, two markets already inhabited by some of the world's top-selling drugs, includingAbbott Laboratories ' ( ABT ) Humira,Johnson & Johnson 's ( JNJ ) Remicade andAmgen 's ( AMGN ) Enbrel. The biotech earlier this month reported positive trial results for its immunology drug candidate apremilast, one of several Celgene is hoping will fill out a portfolio still dominated by its blockbuster cancer drug Revlimid. Though the idea of a cancer-causing cancer drug might sound odd, it wasn't a total shock since the traditional myeloma treatment, thalidomide (which Celgene also makes), has long been known to increase the risk of cancer."
2012-09-18,33.00544357299805,33.063018798828125,0.4199334617985577,Neutral on Auxilium Pharma - Analyst Blog,"ABBOTT LABS (ABT): Free Stock Analysis Report AUXILIUM PHARMA (AUXL): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report To read this article on Zacks.com click here. While pleased with Testim's performance, we note that the product faces stiff competition from Abbott's ( ABT ) AndroGel worldwide. Auxilium Pharma's second marketed product, Xiaflex, is an injectable enzyme (clostridial collagenase for injection) that received approval in February 2010 from the FDA for the treatment of Dupuytren's Contracture (DC), a condition that affects the connective tissue in the palm known as palmar fascia."
2012-09-17,32.70316696166992,33.16377639770508,0.17444160598156833,,
2012-09-14,33.19736099243164,32.75594711303711,1.4084551400634018,"Apricus, Takeda Ink Marketing Deal - Analyst Blog | Amgen Bounces Back On Strong 2012 Performance","ABBOTT LABS (ABT): Free Stock Analysis Report APPRICUS BIOSCI (APRI): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report (TKPYY): ETF Research Reports WARNER CHIL PLC (WCRX): Free Stock Analysis Report To read this article on Zacks.com click here. The company has a marketing agreement with Abbott Laboratories ( ABT ) in Canada. Apricus Biosciences, Inc. ( APRI ) and Takeda Pharmaceuticals ( TKPYY ) recently signed an exclusive licensing agreement to market Apricus' Vitaros in the UK. | While Enbrel faces increasing competition from products made byAbbott Labs ( ABT ),Merck ( MRK ) andJohnson & Johnson ( JNJ ), it still managed to post an 11% rise in second-quarter sales. Top Seller The company's top-selling drug during the second quarter was its Enbrel treatment for inflammatory conditions, which notched $1.06 billion in sales. ""(Amgen management) said that over the last year, Enbrel has been increasing its share among bio-naive patients, or those who are new to biologics,"" Zacks Equity Research noted in a report."
2012-09-13,32.46806716918945,33.23574447631836,-1.3296655703902642,Abbott-Astellas Collaborate - Analyst Blog,"ABBOTT LABS (ABT): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report VICAL INC (VICL): Free Stock Analysis Report VIROPHARMA (VPHM): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) recently announced that it is collaborating with Astellas Pharma Global Development for a phase III study being conducted with ASP0113 (TransVax). Under the collaboration, patients will be monitored for CMV viral load using Abbott Labs' RealTime CMV assay, which is performed on the Abbott m2000 System."
2012-09-12,32.304935455322266,32.54963302612305,2.364407166982188,,
2012-09-11,32.27134704589844,32.304935455322266,0.7574618780439851,Profiling 7 Companies That Have Raised Dividends For 25 Years,"Abbott Labs ( ABT ) Abbott ( ABT ) is often thought of as a rather sleepy healthcare company, but it actually has a pretty interesting history of continual reinvention. Rather, the most successful dividend stock investments are those where the company's underlying fundamentals continue to improve and where ongoing free cash flow growth can continue to support higher payouts. Dividends have grown nearly 12% a year for the past decade at Johnson & Johnson, outpacing the 7% or so growth in free cash flow."
2012-09-10,32.05064010620117,32.237762451171875,0.10408121289779591,,
2012-09-07,32.0986213684082,31.997861862182617,0.583833409724939,,
2012-09-06,31.652406692504883,32.10821533203125,-0.31390602440251375,,
2012-09-05,31.5036678314209,31.546850204467773,1.4400441772230237,Perrigo Cut to Neutral - Analyst Blog,"We have downgraded Perrigo Company ( PRGO ) to Neutral from Outperform following the disappointing revenue numbers put out by the company in the fourth quarter of fiscal 2012 (ended June 30, 2012). Perrigo's fourth quarter fiscal 2012 revenues of $832 million fell short of the Zacks Consensus Estimate of $854 million, primarily due to weakness in the Consumer HealthCare (CHC) segment. Total revenues were, however, up 18% year over year aided by the inclusion of $58 million of net sales from Paddock Laboratories (acquired by Perrigo in 2011) and $10 million from CanAm Care (whose assets were acquired by Perrigo in January 2012)."
2012-09-04,31.311748504638672,31.40770721435547,0.13707093814583102,"JNJ Updates: Strikes Cancer Deal, Zytiga Gets FDA Priority Review Status","See our complete analysis for Johnson & Johnson More About the Genmab Deal Daratumumab is in an experimental drug for a type of bone marrow cancer multiple myeloma. Zytiga Holds Promise Zytiga is used in the treatment of prostate cancer, one of the most prevalent cancers in men, with around 218,000 Americans diagnosed with the cancer each year. After demonstrating encouraging results in its clinical trials recently, the company filed applications with the U.S. FDA and the EU's European Medicines Agency (EMA) to extend the use of its metastatic prostate cancer drug, Zytiga, to patients who have not yet been treated with chemotherapy but have failed hormone treatment."
2012-08-31,31.42690086364746,31.44609260559082,0.3064623162215968,,
2012-08-30,31.35972785949707,31.37891960144043,0.06106787947888014,Bio-Rad's New Digital Biology Center - Analyst Blog,"ABBOTT LABS (ABT): Free Stock Analysis Report BIO-RAD LABS -A (BIO): Free Stock Analysis Report LIFE TECHNOLOGS (LIFE): Free Stock Analysis Report (RHHBY): ETF Research Reports To read this article on Zacks.com click here. In the Clinical Diagnostics market, the company competes with Roche ( RHHBY ) and Abbott Laboratories ( ABT ). Bio-Rad Laboratories, Inc. ( BIO ), a worldwide provider of life science research and clinical diagnostic products, recently inaugurated its Digital Biology Center for the development of products based on the droplet partitioning technology acquired by the company last year."
2012-08-29,31.58043670654297,31.479677200317383,0.061198687786275845,Pfizer Could Acquire India's Stride Acrolab's Injectables Unit,"Pfizer ( PFE ) is vying to acquire Indian company Stride Acrolab's specialty injectables unit, Agila. The reason for the gold rush is a huge generic injectable market, which could zoom by high single digit growth to $17 billion by 2020 as more and more injectable drugs are set to lose patent protection in the next few years. We currently have a $25 price estimate for Pfizer , which is 5% above the current market price."
2012-08-28,31.450889587402344,31.537254333496094,-0.3190567222419383,,
2012-08-27,31.566041946411133,31.532455444335938,0.27460191818657936,DexCom Remains Neutral - Analyst Blog,"ABBOTT LABS (ABT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. However, we note that competition in the glucose monitoring market is intense and DexCom faces stiff challenges from much larger players such as Johnson & Johnson ( JNJ ), Medtronic ( MDT ) and Abbott Labs ( ABT ). San Diego, California-based DexCom is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and by healthcare providers for the treatment of diabetic and non-diabetic patients."
2012-08-24,31.23018264770508,31.59003257751465,-0.10640073954224057,,
2012-08-23,31.47488021850586,31.345333099365234,1.15225048110953,,
2012-08-22,31.23977851867676,31.44609260559082,-0.4115889186591945,FDA Extends PFE Drug Review Period - Analyst Blog,"ABBOTT LABS (ABT): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. The rheumatoid arthritis market currently has treatments like Abbott 's ( ABT ) Humira and Johnson & Johnson 's ( JNJ ) Remicade and Simponi among others. The US Food and Drug Administration (FDA) recently extended its review period for Pfizer's ( PFE ) rheumatoid arthritis (RA) candidate, tofacitinib."
2012-08-21,31.537254333496094,31.33094024658203,0.6604210935449292,Everything You Need To Know About The Apple Dividend | Agilent Wins Patent in US - Analyst Blog,"Companies like Coca-Cola ( KO ), Abbott Labs ( ABT ), and 3M ( MMM ), for instance, have excellent records of steadily (if slowly) increasing their payouts over time and sharing their success with shareholders. At the current rate, the dividend will send almost $2.5 billion of cash flowing out of the company each quarter; a relative pittance for a company that has been generating over $10 billion in quarterly free cash flow with pretty solid regularity. Accordingly, whether you measure dividend coverage by earnings, operating income, or free cash flow, Apple will not be putting itself under any appreciable financial strain in paying this dividend. | AGILENT TECH (A): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report GENOMIC HEALTH (GHDX): Free Stock Analysis Report LIFE TECHNOLOGS (LIFE): Free Stock Analysis Report To read this article on Zacks.com click here. In the health care sector, major players such as Abbott Laboratories ( ABT ), Genomic Health Inc. ( GHDX ), Life Technologies Corporation ( LIFE ) and others have all increased focus on the genetic testing market. Agilent Technologies Inc. ( A ) has won the patent for comparative genomic hybridization (CGH) methods in the U.S. CGH methods facilitate the basic and clinical study of genetics and cancer."
2012-08-20,31.657203674316406,31.537254333496094,-0.654191657689534,"Market Wrap-Up for Aug.20 (AET, LOW, HD, SWK, PSA, WM, more)","Apparently Mr. Murray was tipped off about a planned acquisition of Advanced Medical Optics by Abbott Laboratories ( ABT ) in early 2009, and decided he needed to make out on the last-minute investment advice. My Reaction to Barron's Weekend's Piece on Waste Management/MLP's This past weekend's Barron's magazine had an article on the lack of potential upside for Waste Management ( WM ), digging into the company's headwinds and recent inability to beat analyst estimates. We of course will keep our subscribers updated of any moves we make, and yes, we will even consider stocks like Waste Management and their attractive yields as candidates that can use a break as well."
2012-08-17,31.94988250732422,31.628416061401367,-0.37890061944298575,,
2012-08-16,31.82513427734375,31.87311363220215,-1.0061584603610305,,
2012-08-15,31.781951904296875,31.868316650390625,0.1507593163324211,,
2012-08-14,31.74836540222168,31.74836540222168,0.27174147879216193,,
2012-08-13,31.599628448486328,31.66200256347656,0.0,,
2012-08-10,31.51806259155273,31.71957778930664,0.19738876073151626,"Abbott Labs Shows Slow Growth, Solid Dividends","Abbott Laboratories ( ABT ) shows many of the classic traits you'd want to see in a high-quality income stock: a broad array of enviable niches in its industry, a solid but unspectacular stock uptrend and a history of rising dividends. Big-cap Abbott Labs produces generic drugs, research-based drugs, diagnostic systems and nutrients. Abbott Labs' Q2 report, released July 18, showed results that pretty much met consensus estimates: Earnings of $1.23 a share beat the Street's consensus estimate by a penny, and reflected a 10% gain from a year ago."
2012-08-09,31.51326370239257,31.532455444335938,0.6393641651308816,Pharma & Biotech Stock Outlook - Aug. 2012 - Industry Outlook | Pharma & Biotech Stock Outlook - Aug. 2012 - Zacks Analyst Interviews,"ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. With most of the big pharma companies already facing or likely to face patent challenges for their blockbuster products, the companies have been looking toward M&A and in-licensing activities to make up for the loss of revenues resulting from the loss of patent exclusivity of key products. Companies that should benefit from this Act include The Medicines Company ( MDCO ), Optimer Pharma ( OPTR ) and Cubist Pharma ( CBST ) among others. | ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. With most of the big pharma companies already facing or likely to face patent challenges for their blockbuster products, the companies have been looking toward M&A and in-licensing activities to make up for the loss of revenues resulting from the loss of patent exclusivity of key products. Companies that should benefit from this Act include The Medicines Company ( MDCO ), Optimer Pharma ( OPTR ) and Cubist Pharma ( CBST ) among others."
2012-08-08,31.633214950561523,31.618820190429688,0.06090052152201992,,
2012-08-07,31.84432601928711,31.68119430541992,-0.04550520759376819,"DexCom Misses on EPS, Losses Climb - Analyst Blog","ABBOTT LABS (ABT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. However, we note that competition in the glucose monitoring market is intense and DexCom faces stiff challenges from much larger players such as Johnson & Johnson ( JNJ ), Medtronic ( MDT ) and Abbott Labs ( ABT ). DexCom ( DXCM ), a player in the glucose monitoring market, reported second-quarter 2012 loss per share of 21 cents, higher than the Zacks Consensus Estimate of a loss of 20 cents per share and the year-ago loss of 11 cents a share."
2012-08-06,32.00265884399414,31.84432601928711,-0.5122787455711492,,
2012-08-03,32.08902359008789,31.94988250732422,-0.4947489690743155,,
2012-08-02,31.954679489135746,31.82993125915528,-0.4336095873189851,,
2012-08-01,31.87311363220215,31.71478080749512,-0.39039111633987217,,
2012-07-31,31.98346710205078,31.81553840637207,-0.49675982878265257,,
2012-07-30,31.74356842041016,31.954679489135746,-0.525048441880597,,
2012-07-27,31.11503028869629,31.85392189025879,0.665051470992933,"Amgen Beats, Raises Guidance - Analyst Blog","ABBOTT LABS (ABT): Free Stock Analysis Report AFFYMAX INC (AFFY): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Enbrel's competitors include Abbott Labs' ( ABT ) Humira, Merck / Johnson & Johnson's ( MRK / JNJ ) Remicade and Johnson & Johnson's Stelara among others. The Quarter in Detail Second quarter total product sales increased 8% to $4,200 million (US: $3,255 million, ex-US: $945 million)."
2012-07-26,31.081443786621094,31.01906967163086,2.374709568677265,,
2012-07-25,30.80315971374512,30.7647762298584,-0.2006795933240499,,
2012-07-24,30.956695556640625,30.67841148376465,-0.12460891753775069,,
2012-07-23,30.66881561279297,31.014272689819336,-0.8989463115234886,"Earnings are Up, but Will it Spark a Stock Market Rally?","News and company press releases typically try to frame the earnings into positive headlines as shown below: ""Abbott ( ABT ) Reports Strong Second Quarter Results"" - Abbott Investor's Relations Press Release , July 18, 2012 (Even though earnings were a self-proclaimed ""strong"", the price stalled out that day at $65.93 with a popular candlestick pattern and as of today (7/23) was down 2.5% to $64.27, evidently ""strong"" earnings weren't enough to drive price higher.) ""Groupon Earnings Top Forecast; Shares Jump"" - CNBC, May 2012 (After popping above $14.00 on the earnings announcement after hours, Groupon (NasdaqGS: GRPN) finished the next day selling from the get go ending the day at $12.25, slightly ahead of its pre-earnings share price of $11.75. In a recent ETF Profit Strategy Update, shown in the chart below, key price levels are identified as important support and resistances that will help traders know if earnings are going to be a catalyst or a drag on stock prices."
2012-07-20,31.470081329345703,31.21578788757324,1.1264115360303177,,
2012-07-19,31.73397254943848,31.57084083557129,-0.8080482510076549,"Company News for July 19, 2012 - Corporate Summary | Dutch Approval for Hologic's HPV HR - Analyst Blog","Inc. (NASDAQ: YHOO ) reported second quarter earnings per share of $0.27, higher than the Zacks Consensus Estimate of $0.23 • Abbott Laboratories (NYSE: ABT ) posted second quarter earnings per share of $1.23, beating the Zacks Consensus Estimate of $1.22 by a penny • Bank of America Corp. (NYSE: BAC ) reported second quarter earnings per share of $0.19, surpassing the Zacks Consensus Estimate of $0.15 • U.S. Bancorp. (NYSE: USB ) posted second quarter earnings per share of $0.71, beating the Zacks Consensus Estimate of $0.69 ABBOTT LABS (ABT): Free Stock Analysis Report BANK OF AMER CP (BAC): Free Stock Analysis Report US BANCORP (USB): Free Stock Analysis Report YAHOO! Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABBOTT LABS (ABT): Free Stock Analysis Report HOLOGIC INC (HOLX): Free Stock Analysis Report QIAGEN NV (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. The company faces stiff competition from players such as Qiagen ( QGEN ) and Abbott Laboratories ( ABT ). Hologic ( HOLX ), a prominent player in the field of women's health, recently got the Netherlands Society for Pathology's (""NVVP"") approval for its Human Papillomavirus (""HPV) high-risk test Cervista HPV HR for the use in the national cervical screening programme of Netherlands."
2012-07-18,31.642810821533203,31.633214950561523,-0.5140601719909081,"Abbott Labs Q2 Profit Falls 11%, but Adjusted Net Beats View; Outlook Reaffirmed (ABT)","Medical device maker Abbott Laboratories ( ABT ) on Wednesday posted lower second quarter earnings due to special items, but its adjusted profit beat Wall Street's view and the company reiterated its full-year outlook. Looking ahead, ABT affirmed its previously-announced full-year 2012 earnings outlook of $5 to $5.10 per share. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011."
2012-07-17,31.41730308532715,31.887508392333984,-0.030325595996514996,"Pre-Market Earnings Report for July 18, 2012 : ABT, BAC, BK, ERIC, BLK, ASML, DOV, CHKP, APH, FRC, HBI, FCFS","Abbott Laboratories ( ABT ) is reporting for the quarter ending June 30, 2012. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2012 Price to Earnings ratio for ABT is 12.97 vs. an industry ratio of 13.50."
2012-07-16,31.30694961547852,31.41730308532715,1.4966443992019047,,
2012-07-13,31.302152633666992,31.402910232543945,0.35248873238697526,,
2012-07-12,31.09583854675293,31.24937438964844,0.3218871240458505,,
2012-07-11,31.311748504638672,31.27336311340332,0.4937504504490804,,
2012-07-10,31.51806259155273,31.50846672058105,-0.1225910179677924,,
2012-07-09,31.110231399536133,31.479677200317383,-0.03044562445361572,"After Hours Most Active for Jul 9, 2012 : PG, ABT, XOM, COP, VRSN, AA, HSH, MAKO, QQQ, INTC, MSFT, ASML","Abbott Laboratories ( ABT ) is unchanged at $65.61, with 3,005,464 shares traded., following a 52-week high recorded in today's regular session. RTT News Reports: Stocks Close Modestly Lower But Well Off Worst Levels - U.S. Commentary Hillshire Brands Company (The) (HSH) is unchanged at $28.77, with 1,428,000 shares traded. Microsoft Corporation ( MSFT ) is unchanged at $30.00, with 433,216 shares traded."
2012-07-06,30.89432144165039,31.06705093383789,1.1875379390034322,Setback for Chelsea Therapeutics - Analyst Blog,"ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report CHELSEA THERAP (CHTP): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. The candidates, on approval, would have to compete with big players such as Abbott Labs ( ABT ), Johnson & Johnson ( JNJ ) and Bristol-Myers Squibb ( BMY ) among others in the RA space. Chelsea Therapeutics International, Ltd. ( CHTP ) recently suffered a setback when the US Food and Drug Administration (FDA), in a written statement, informed the company that it has to conduct a new trial with its candidate, Northera (droxidopa), before it can be considered for approval."
2012-07-05,31.06705093383789,31.06705093383789,0.5590978669453266,"After Hours Most Active for Jul 5, 2012 : PG, ROSE, ABT, SXCI, BAC, COP, SAN, TWX, VIAB, ORCL, EZPW, QQQ","Abbott Laboratories ( ABT ) is +0.08 at $64.83, with 3,019,400 shares traded. ABT's current last sale is 99.74% of the target price of $65. The total After hours volume is currently 19,459,828 shares traded."
2012-07-03,30.932706832885746,31.10543441772461,0.0,,
2012-07-02,30.8127555847168,31.00947380065918,0.5583978982894259,Gilead Seeks FDA OK for Cobicistat - Analyst Blog,"ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. The new drug application (NDA) included data from a phase III study (114) which showed that cobicistat was non-inferior to Abbott Laboratories ' ( ABT ) HIV therapy Norvir over 48 weeks. Cobicistat acts as a ""boosting"" agent whose addition causes blood levels of protease inhibitors -- such as Bristol-Myers Squibb 's ( BMY ) HIV drug Reyataz and Johnson & Johnson 's ( JNJ ) Prezista -- to increase, thereby enabling the HIV therapy to be dosed once daily."
2012-06-29,30.33295631408692,30.932706832885746,0.6384311049413314,,
2012-06-28,30.064268112182617,30.18421745300293,1.9772240878489464,Recognition for Hologic's Selenia - Analyst Blog,"ABBOTT LABS (ABT): Free Stock Analysis Report HOLOGIC INC (HOLX): Free Stock Analysis Report QIAGEN NV (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. The company also faces stiff competition from players such as Qiagen ( QGEN ) and Abbott Laboratories ( ABT ), among others. In a major achievement, Hologic ( HOLX ), a prominent player in the field of women's health, has won an award for its Selenia Dimensions (3D/2D) mammography systems in the digital mammography category in the KLAS annual survey."
2012-06-27,29.987499237060547,30.16502571105957,0.3989764206889398,,
2012-06-26,29.81477165222168,29.91552925109864,0.5920015957170061,,
2012-06-25,29.70921516418457,29.80517578125,0.33794523081464606,,
2012-06-22,29.88194465637207,29.90113639831543,0.32299950212455747,,
2012-06-21,30.14583396911621,29.86275291442871,0.06422521078883968,,
2012-06-20,30.15542984008789,30.14103507995605,-0.9390387241484536,,
2012-06-19,30.12664222717285,30.16502571105957,-0.04773521786349551,,
2012-06-18,29.977903366088867,30.083459854125977,0.1274071089545406,Vermillion Presents Positive Data - Analyst Blog,"ABBOTT LABS (ABT): Free Stock Analysis Report GENMARK DIAGNST (GNMK): Free Stock Analysis Report (VRML): ETF Research Reports To read this article on Zacks.com click here. It competes with Abbott Laboratories ( ABT ), GenMark Diagnostics ( GNMK ), among others. Leading developer of diagnostics tests, Vermillion, Inc. ( VRML ) reported that it had presented the results for the intended use of Peripheral Artery Disease (PAD) multi-marker at the Society for Vascular Medicine's 23 rd Annual Scientific Sessions in Minneapolis, Minnesota."
2012-06-15,29.944318771362305,29.987499237060547,0.3521143114915612,,
2012-06-14,29.55088233947754,29.81477165222168,0.1442025314649618,Echo Therapeutics to Join Russell Microcap Index - Analyst Blog,"Its competitors such as Abbott Laboratories ( ABT ) and DexCom Inc. ( DXCM ) are already a part of the family of Russell Indexes, being listed on the Russell 1000 Index and Russell 2000 Index respectively. ABBOTT LABS (ABT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report ECHO THERAPEUT (ECTE): Free Stock Analysis Report To read this article on Zacks.com click here. Membership in the Russell Microcap Index for its equity indexes depends on the market capitalization, objectives and style attributes of the company."
2012-06-13,29.613256454467773,29.51249885559082,0.8929997748040378,,
2012-06-12,29.517295837402344,29.72840881347656,-0.3402449137327204,,
2012-06-11,29.781185150146484,29.51249885559082,0.7152178750964949,,
2012-06-08,29.33017349243164,29.69002342224121,-0.9022014845985484,New Lease Agreements for Alexandria - Analyst Blog,"ABBOTT LABS (ABT): Free Stock Analysis Report ALEXANDRIA REAL (ARE): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report QUEST DIAGNOSTC (DGX): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report LIFE TECHNOLOGS (LIFE): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report SYNTA PHARMACT (SNTA): Free Stock Analysis Report THERMO FISHER (TMO): Free Stock Analysis Report To read this article on Zacks.com click here. The company has around 100 client tenants in the area including the likes of GlaxoSmithKline plc ( GSK ), Abbott Laboratories ( ABT ), Biogen Idec Inc. ( BIIB ), Novartis AG ( NVS ), Quest Diagnostics Inc. ( DGX ), Thermo Fisher Scientific Inc. ( TMO ) and others. Alexandria Real Estate Equities, Inc. ( ARE ), a real estate investment trust (REIT), recently entered into long-term agreements with six prestigious life science and technologies companies, to lease a total of 187,000 square feet of space at 'Alexandria Park at 128' located in the midst of Route 128 submarket of Greater Boston."
2012-06-07,29.440528869628903,29.36375999450684,1.2268932875641734,Abbott Presents Data on Humira - Analyst Blog,"ABBOTT LABS (ABT): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ( ABT ) recently presented phase III data on its blockbuster drug, Humira, from two studies. Abbott Labs said that 39.3% of patients in the Humira arm achieved the primary endpoint compared to 19.8% of patients on placebo."
2012-06-06,29.02790069580078,29.28699111938477,-0.2607591577651943,BMY Presents Positive Data - Analyst Blog | Elagolix Enters Phase 3 - Analyst Blog,"Bristol-Myers Squibb Company ( BMY ) recently presented encouraging data from a late-stage study (AMPLE: n=646), which evaluated the efficacy of the subcutaneous formulation of its rheumatoid arthritis (RA) drug Orencia versus Abbott Laboratories ' ( ABT ) anti-inflammatory drug Humira. ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report DOCTOR REDDYS (RDY): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Even though pleased with the positive data on Orencia, we believe that investor focus will remain on how Bristol-Myers fares following the US loss of exclusivity of its blockbuster blood thinner Plavix on May 17, 2012. | Elagolix Enters Phase 3 By Jason Napodano, CFA On June 5, 2012, Abbott Labs (NYSE:ABT) and Neurocrine Biosciences (NASDAQ:NBIX)announced that they had initiated a pivotal phase 3 clinical study designed to evaluate the safety and efficacy of elagolix in female patients with endometriosis. For additional information, please visit: http://scr.zacks.com ABBOTT LABS (ABT): Free Stock Analysis Report NEUROCRINE BIOS (NBIX): Free Stock Analysis Report To read this article on Zacks.com click here. In total, Neurocrine has presented data from 12 phase 1 programs and 6 phase 2 programs (2 phase 2a and 4 phase 2b) on roughly 1,000 patients."
2012-06-05,28.807191848754883,28.93194007873535,0.89255653138385,LabCorp to Acquire Medtox Scientific - Analyst Blog,"The company, to its advantage has other significant collaborations or agreements with leading companies and academic institutions such as Abbott ( ABT ) for lung cancer (Xalkori), Duke University (joint venture in biomarker development and lung cancer), John Hopkins (melanoma), and Roche ( RHHBY ) for melanoma (Zelboraf). ABBOTT LABS (ABT): Free Stock Analysis Report QUEST DIAGNOSTC (DGX): Free Stock Analysis Report LABORATORY CP (LH): Free Stock Analysis Report MEDTOX SCIENTIF (MTOX): Free Stock Analysis Report (RHHBY): ETF Research Reports To read this article on Zacks.com click here. The company exited the first quarter of fiscal 2012 with cash and short-term investment of $129.9 million ($159.3 million at the end of 2011) and $460 million of borrowings outstanding under the $1 billion revolving credit facility."
2012-06-04,29.04709243774414,28.89355659484864,0.43304543752625674,,
2012-06-01,29.33976936340332,29.03749656677246,-0.5285755991742375,,
2012-05-31,29.69002342224121,29.646841049194336,-1.030249395920257,,
2012-05-30,29.694822311401367,29.646841049194336,-0.14544405180403625,,
2012-05-29,29.963510513305664,29.81477165222168,-0.16158124033834942,Auxilium Pharma Sues Watson - Analyst Blog,"ABBOTT LABS (ABT): Free Stock Analysis Report AUXILIUM PHARMA (AUXL): Free Stock Analysis Report ENDO PHARMACEUT (ENDP): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report To read this article on Zacks.com click here. However, the product faces stiff competition from Abbott Labs' ( ABT ) AndroGel. Auxilium Pharmaceuticals, Inc. ( AUXL ) and FCB I LLC recently filed a patent infringement lawsuit against Watson Pharmaceuticals ( WPI ) and its subsidiary, Watson Laboratories, Inc. which is looking to launch a generic version of Auxilium Pharma's 1% testosterone gel, Testim."
2012-05-25,29.82916641235352,29.867549896240234,-0.4963999829657312,Gen-Probe Remains Neutral - Analyst Blog,"ABBOTT LABS (ABT): Free Stock Analysis Report BECTON DICKINSO (BDX): Free Stock Analysis Report GEN-PROBE INC (GPRO): Free Stock Analysis Report HOLOGIC INC (HOLX): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. Gen-Probe competes with more established firms in the molecular diagnostic industry such as Roche ( RHHBY ), Becton, Dickinson ( BDX ) and Abbott Labs ( ABT ). Product sales increased 9% as healthy sales across Blood Screening and Clinical Diagnostics franchises were partially offset by lower revenues from the Research Products and Services and Collaborative Research businesses."
2012-05-24,29.55088233947754,29.949115753173828,0.12867769536737364,Gilead Drug Up for European Review - Analyst Blog,"The MAA was filed on the basis of pharmacokinetic data from a study which revealed that the addition of cobicistat boosted the exposure of HIV therapies Reyataz and Prezista similar to Abbott Laboratories ' ( ABT ) HIV therapy Norvir. ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. Cobicistat acts as a ""boosting"" agent whose addition causes blood levels of protease inhibitors -- such as Bristol-Myers ' ( BMY ) HIV drug Reyataz and Johnson & Johnson 's ( JNJ ) Prezista -- to increase, thereby enabling the HIV therapy to be dosed once daily."
2012-05-23,29.574871063232425,29.44532585144043,1.3476193675756412,"Zacks' Voice of the People highlights opportunities with Johnson & Johnson, Disney, Abbott Labs and Church & Dwight - Press Releases","Contact: Brent Billock People & Picks Manager Company: Zacks.com Phone: 312-265-9307 Email: pandp@zacks.com Visit: www.Zacks.com ABBOTT LABS (ABT): Free Stock Analysis Report CHURCH & DWIGHT (CHD): Free Stock Analysis Report DISNEY WALT (DIS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. The most recent picks by «RobMarketsBlind» are: A buy rating on Disney ( DIS ), a buy rating on Abbott Labs ( ABT ) and a buy rating on Church & Dwight ( CHD ). About the Zacks Community In 2008, Zacks Investment Research launched PeopleAndPicks.com, a stock-picking website where members of the Zacks community can test their strategies and share ideas with other members."
2012-05-22,29.65163993835449,29.74280166625977,-0.43802460377603053,Auxilium-Glaxo to Drive Testim Sales - Analyst Blog | RobMarketsBlind's Latest Purchase - Voice of the People,"ABBOTT LABS (ABT): Free Stock Analysis Report AUXILIUM PHARMA (AUXL): Free Stock Analysis Report ENDO PHARMACEUT (ENDP): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. The testosterone therapy market, while lucrative, has several players like Abbott Labs' ( ABT ) AndroGel franchise (1% and 1.62%), Endo Pharmaceutical's ( ENDP ) Fortesta, and Eli Lilly / Acrux's ( LLY ) Axiron . The companies have settled on a baseline revenue forecast for the co-promotion period - once Testim sales exceed this forecast, Glaxo will be compensated by the amount that Testim net sales exceed the baseline. | ABBOTT LABS (ABT): Free Stock Analysis Report CHURCH & DWIGHT (CHD): Free Stock Analysis Report DISNEY WALT (DIS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. The most recent picks by «RobMarketsBlind» are: A buy rating on Disney ( DIS ), a buy rating on Abbott Labs ( ABT ) and a buy rating on Church & Dwight ( CHD ). About the Zacks Community In 2008, Zacks Investment Research launched PeopleAndPicks.com, a stock-picking website where members of the Zacks community can test their strategies and share ideas with other members."
2012-05-21,29.555679321289062,29.65643882751465,0.30744244869695236,,
2012-05-18,29.87714576721192,29.54128646850586,0.34091419496830344,,
2012-05-17,29.949115753173828,29.857954025268555,-1.1241344850104253,,
2012-05-16,29.86275291442871,30.011489868164062,-0.3043887126971776,,
2012-05-15,29.646841049194336,29.694822311401367,0.49806846060560844,"The Zacks Analyst Blog Highlights: Gilead Sciences, Abbott Labs, Alliance Data Systems Corporation, Blue Nile and Bristol-Myers Squibb - Press Releases | Panel Votes in Favor of Pfizer Drug - Analyst Blog","9339 support@zacks.com http://www.zacks.com ABBOTT LABS (ABT): Free Stock Analysis Report ALLIANCE DATA (ADS): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report BLUE NILE INC (NILE): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include Gilead Sciences ( GILD ), Abbott Labs ( ABT ), Alliance Data Systems Corporation ( ADS ), Blue Nile ( NILE ) and Bristol-MyersSquibb ( BMY ). While Norvir is marketed by Abbott Labs ( ABT ), Reyataz is marketed by Bristol-MyersSquibb ( BMY ). | The rheumatoid arthritis market currently has players like products like Abbott's ( ABT ) Humira and Johnson & Johnson's ( JNJ ) Remicade and Simponi among others. ABBOTT LABS (ABT): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Pfizer Inc. ( PFE ) recently received a boost with the U.S. Food and Drug Administration's (FDA) Arthritis Advisory Committee voting 8-2 in favor of the company's rheumatoid arthritis candidate, tofacitinib."
2012-05-14,29.488508224487305,29.59406471252441,0.1618427478577356,"Zacks Bull and Bear of the Day Highlights: Eastman Chemical, Kirkland's, Biogen Idec, Abbott, Novartis - Press Releases | Good News for Gilead - Analyst Blog","In addition, Zacks Equity Research provides analysis on Biogen Idec ( BIIB ), Abbott ( ABT ) and Novartis ( NVS ) Full analysis of all these stocks is available at http://at.zacks.com/?id=2678 . 9339 support@zacks.com http://www.zacks.com ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report EASTMAN CHEM CO (EMN): Free Stock Analysis Report KIRKLANDS INC (KIRK): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, Biogen and partner Abbott ( ABT ) moved their MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010. | ABBOTT LABS (ABT): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. While Norvir is marketed by Abbott Labs ( ABT ), Reyataz is marketed by Bristol-MyersSquibb ( BMY ). GileadSciences ( GILD ) received some encouraging news recently when an advisory panel of the U.S. Food and Drug Administration (FDA) recommended the approval of the company's HIV combination pill Quad."
2012-05-11,29.77638816833496,29.76679229736328,0.357958046685629,Standard Review for Biogen's BG-12 - Analyst Blog | FDA Approves Gen-Probe's PANTHER - Analyst Blog,"ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, Biogen and partner Abbott ( ABT ) moved their MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010. Biogen is the market leader in therapies for the treatment of multiple sclerosis (MS). | ABBOTT LABS (ABT): Free Stock Analysis Report BECTON DICKINSO (BDX): Free Stock Analysis Report GEN-PROBE INC (GPRO): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. Gen-Probe competes with more established firms in the molecular diagnostic industry such as Roche ( RHHBY ), Becton, Dickinson ( BDX ) and Abbott Labs ( ABT ). Gen-Probe Inc. ( GPRO ), a leading diagnostic devices company, recently announced the approval of the U.S. Food and Drug Administration (""FDA"") for its PANTHER system, an immunoassay instrument for molecular diagnosis."
2012-05-10,29.55088233947754,29.8531551361084,-0.03222644370912723,,
2012-05-09,29.78598403930664,29.378154754638672,1.0228892428942735,,
2012-05-08,29.857954025268555,30.03548049926757,-1.3691986275483892,,
2012-05-07,29.69961929321289,29.992298126220703,0.5945701230860528,"DexCom Misses on EPS, Losses Mount - Analyst Blog","ABBOTT LABS (ABT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. However, we note that competition in the glucose monitoring market is intense and DexCom faces stiff challenges from much larger players such as Johnson & Johnson ( JNJ ), Medtronic ( MDT ) and Abbott Labs ( ABT ). DexCom ( DXCM ), a player in the glucose monitoring market, reported first-quarter 2012 loss per share of 21 cents, higher than the Zacks Consensus Estimate of a loss of 19 cents per share."
2012-05-04,30.160228729248047,29.944318771362305,0.9854632482602125,,
2012-05-03,30.021085739135746,30.25139045715332,-0.7158763941215152,,
2012-05-02,29.7907829284668,30.05946922302246,0.7671432006782731,,
2012-05-01,29.7571964263916,29.857954025268555,0.9019108198694414,,
2012-04-30,29.622852325439453,29.77638816833496,0.3385990986287653,,
2012-04-27,29.78598403930664,29.74280166625977,0.5183020230757949,,
2012-04-26,29.536487579345703,29.68042755126953,-0.14497547903700767,"The Zacks Analyst Blog Highlights: St. Jude Medical, Abbott Laboratories, Medtronic, Boston Scientific and Big Lots - Press Releases | Pharma & Biotech Stock Outlook - April 2012 - Industry Outlook","Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513 Here are highlights from Wednesday's Analyst Blog: St. Jude's Alliance with Abbott Labs St. Jude Medical Inc. ( STJ ) recently disclosed its decision to build on its mutual agreement with Abbott Laboratories ( ABT ) by revealing the long-term Choice Alliance joint venture. 9339 support@zacks.com http://www.zacks.com ABBOTT LABS ( ABT ): Free Stock Analysis Report BIG LOTS INC ( BIG ): Free Stock Analysis Report BOSTON SCIENTIF ( BSX ): Free Stock Analysis Report MEDTRONIC ( MDT ): Free Stock Analysis Report ST JUDE MEDICAL (STJ): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include St. Jude Medical Inc. ( STJ ), Abbott Laboratories ( ABT ), Medtronic ( MDT ), Boston Scientific ( BSX ) and Big Lots Inc . | ABBOTT LABS ( ABT ): Free Stock Analysis Report BRISTOL-MYERS ( BMY ): Free Stock Analysis Report CELGENE CORP ( CELG ): Free Stock Analysis Report GILEAD SCIENCES ( GILD ): Free Stock Analysis Report GLAXOSMITHKLINE ( GSK ): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. With most of the big pharma companies already facing or likely to face patent challenges for their blockbuster products, the companies have been looking toward M&A and in-licensing activities to make up for the loss of revenues that will arise with key products losing patent exclusivity. We would also avoid companies like Eli Lilly ( LLY ), which are facing patent expirations on key products and whose new products may not be enough to make up for the loss of revenues that will take place once generics enter the market."
2012-04-25,29.19103240966797,29.555679321289062,0.4873293465824371,Amgen Beats but Maintains Outlook - Analyst Blog | St. Jude's Alliance with Abbott - Analyst Blog,"ABBOTT LABS ( ABT ): Free Stock Analysis Report AFFYMAX INC ( AFFY ): Free Stock Analysis Report AMGEN INC ( AMGN ): Free Stock Analysis Report ASTRAZENECA PLC ( AZN ): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Enbrel's competitors include Abbott Labs' ( ABT ) Humira, Merck / Johnson & Johnson's ( MRK / JNJ ) Remicade and Johnson & Johnson's Stelara among others. First quarter 2012 Prolia sales came in at $88 million, up slightly from fourth quarter 2011 sales of $81 million. | ABBOTT LABS ( ABT ): Free Stock Analysis Report BOSTON SCIENTIF ( BSX ): Free Stock Analysis Report MEDTRONIC ( MDT ): Free Stock Analysis Report ST JUDE MEDICAL ( STJ ): Free Stock Analysis Report To read this article on Zacks.com click here. St. Jude Medical Inc. ( STJ ) recently disclosed its decision to build on its mutual agreement with Abbott Laboratories ( ABT ) by revealing the long-term Choice Alliance joint venture. This initiative provides St. Jude Medical the opportunity to incorporate Abbott's drug-eluting stents with its cardiovascular, cardiac rhythm management and electrophysiology offerings."
2012-04-24,28.740020751953125,29.13825416564941,1.249174426254016,,
2012-04-23,28.57209014892578,28.72562599182129,1.3856406616172057,,
2012-04-20,28.490524291992188,28.730424880981445,0.5373630073797043,Patent Challenge for Auxilium Pharma - Analyst Blog,"ABBOTT LABS ( ABT ): Free Stock Analysis Report AUXILIUM PHARMA ( AUXL ): Free Stock Analysis Report ENDO PHARMACEUT ( ENDP ): Free Stock Analysis Report LILLY ELI & CO ( LLY ): Free Stock Analysis Report To read this article on Zacks.com click here. However, Testim faces stiff competition from Abbott Labs' ( ABT ) AndroGel. Auxilium Pharmaceuticals, Inc. ( AUXL ) and FCB I LLC (""FCB"") recently announced that Watson Laboratories, Inc. is seeking US Food and Drug Administration (FDA) approval for its generic version of Auxilium Pharma's 1% testosterone gel, Testim."
2012-04-19,28.701635360717773,28.552898406982425,0.8420364136882047,,
2012-04-18,29.032697677612305,29.00870704650879,-0.5182176968874584,"Ahead of Wall Street - April 18, 2012 - Ahead of Wall Street | Market May Take a Breather - Analyst Blog | Abbott Beats, Raises Outlook - Analyst Blog","Sheraz Mian Director of Research ABBOTT LABS ( ABT ): Free Stock Analysis Report BERKSHIRE HTH-B (BRK.B): Free Stock Analysis Report EBAY INC ( EBAY ): Free Stock Analysis Report HALLIBURTON CO ( HAL ): Free Stock Analysis Report INTL BUS MACH ( IBM ): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report YAHOO! Of this morning's major earnings releases, we got positive earnings and revenue surprises from Halliburton ( HAL ) and Abbot Labs ( ABT ). On the earnings front, the first quarter reporting season is off to a fairly good start, both relative to expectations as well as relative to where we were at this stage in the preceding quarter. | ABBOTT LABS ( ABT ): Free Stock Analysis Report BERKSHIRE HTH-B (BRK.B): Free Stock Analysis Report EBAY INC ( EBAY ): Free Stock Analysis Report HALLIBURTON CO ( HAL ): Free Stock Analysis Report INTL BUS MACH ( IBM ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report YAHOO! Of this morning's major earnings releases, we got positive earnings and revenue surprises from Halliburton ( HAL ) and Abbot Labs ( ABT ). On the earnings front, the first quarter reporting season is off to a fairly good start, both relative to expectations as well as relative to where we were at this stage in the preceding quarter. | Abbott Labs ( ABT ) reported first quarter earnings of $1.03 per share, three cents above the Zacks Consensus Estimate of $1.00 and 13.2% above the year-earlier earnings. ABBOTT LABS ( ABT ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs provided an update on its intention to split into two separate publicly traded companies: the company said that it expects to complete the separation by year end."
2012-04-17,28.768808364868164,28.994314193725582,-0.08263314477323022,Earnings Preview: Abbott Labs - Analyst Blog,"ABBOTT LABS ( ABT ): Free Stock Analysis Report AMGEN INC ( AMGN ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) is set to release its first quarter 2012 results on April 18, 2012 before the opening bell. Fourth Quarter 2011 Flashback Abbott Labs reported fourth quarter earnings of $1.45 per share, a penny above the Zacks Consensus Estimate and at the higher end of the guidance range provided by the company."
2012-04-16,28.65365600585937,28.71603012084961,0.7838552991051276,,
2012-04-13,28.68244361877441,28.59128189086914,0.21768291968565223,Biogen's Fampyra Launched in Canada - Analyst Blog,"ABBOTT LABS ( ABT ): Free Stock Analysis Report ACORDA THERAPT ( ACOR ): Free Stock Analysis Report BAYER A G -ADR ( BAYRY ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. Besides BG-12, Biogen is developing other multiple sclerosis candidates like daclizumab, in partnership with Abbott Labs ( ABT ), and PEGylated interferon. The company has been working on consolidating its position in the multiple sclerosis market and has an impressive late-stage pipeline of multiple sclerosis drugs including BG-12 (new drug application filed in the US in Feb 2012)."
2012-04-12,28.69683837890625,28.65365600585937,-0.3178311064319463,,
2012-04-11,28.71603012084961,28.624868392944336,-0.1504778069162489,,
2012-04-10,29.267799377441406,28.85517120361328,-0.3174593685882938,,
2012-04-09,29.176637649536133,29.253406524658203,-1.40983668948532,,
2012-04-05,29.45492172241211,29.411739349365234,0.2631176218596622,,
2012-04-04,29.32537651062012,29.488508224487305,-0.14660494926393824,,
2012-04-03,29.34456825256348,29.3349723815918,0.5562817371095172,,
2012-04-02,29.3349723815918,29.382951736450195,-0.03270067185548526,Myriad Inks Deal with Cephalon - Analyst Blog,"Over the recent past, the company has entered into similar agreements with players such as Abbott ( ABT ), Astra Zeneca ( AZN ) and BioMarin Pharmaceuticals ( BMRN ) to provide companion diagnostic tests for clinical trial enrollment. ABBOTT LABS ( ABT ): Free Stock Analysis Report ASTRAZENECA PLC ( AZN ): Free Stock Analysis Report BIOMARIN PHARMA ( BMRN ): Free Stock Analysis Report MYRIAD GENETICS ( MYGN ): Free Stock Analysis Report TEVA PHARM ADR ( TEVA ): Free Stock Analysis Report To read this article on Zacks.com click here. The recent agreement with Cephalon is another attempt by Myriad Genetics ( MYGN ) to establish itself as a strong player in the companion diagnostic market."
2012-03-30,29.29658889770508,29.40694236755371,0.16355684346409255,5 Safe Stocks to Own Before the Next Market Crash,"Abbott Labs ( ABT ) While many health care-related companies tend to focus on one core strengths such as insurance, hospital ownership, niche drug development or specialized medical devices, Abbott plays the field by selling hundreds of products to a range of customers. Any sell-off in the stock would simply boost the yield , making it newly attractive to a fresh base of investors (whose buying would presumably push shares back up.) The fact that the stock's current market value of $15.7 billion is actually lower than the book value of $18.8 billion just underscores the relative safety of this stock."
2012-03-29,29.13825416564941,29.258203506469727,0.3766768555682388,,
2012-03-28,29.450124740600582,29.32537651062012,0.4116558944760743,"Stock Market News for March 28, 2012 - Market News","This included the likes of Abbott Laboratories (NYSE: ABT ), American Express Company (NYSE: AXP ), Big Lots, Inc. (NYSE: BIG ), The Coca-Cola Company (NYSE: KO ), The Walt Disney Company (NYSE: DIS ), EMC Corporation (NYSE: EMC ), Fortune Brands Home & Security (NYSE: FBHS ), The Home Depot, Inc. (NYSE: HD ), International Business Machines (NYSE: IBM ), Lockheed Martin Corporation (NYSE: LMT ), Lowe's Companies, Inc. (NYSE: LOW ), Pfizer, Inc. (NYSE: PFE ) and Western Digital Corporation (NYSE: WDC ) and they hit 52-week highs of $61.49, $59.18, $47.22, $71.98, $44.50, $29.79, $21.95, $50.35, $208.66, $91.09, $31.49, $22.80 and $43.10, respectively. APPLE INC ( AAPL ): Free Stock Analysis Report ABBOTT LABS ( ABT ): Free Stock Analysis Report AMER EXPRESS CO ( AXP ): Free Stock Analysis Report BIG LOTS INC ( BIG ): Free Stock Analysis Report DISNEY WALT ( DIS ): Free Stock Analysis Report EMC CORP -MASS (EMC): Free Stock Analysis Report FORTUNE BRD H&S (FBHS): Free Stock Analysis Report HOME DEPOT (HD): Free Stock Analysis Report INTL BUS MACH (IBM): Free Stock Analysis Report COCA COLA CO (KO): Free Stock Analysis Report LOCKHEED MARTIN (LMT): Free Stock Analysis Report LOWES COS (LOW): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report WESTERN DIGITAL (WDC): Free Stock Analysis Report To read this article on Zacks.com click here. Amidst the absence of any positive catalysts, disappointing consumer confidence data dragged the benchmarks marginally lower on Tuesday."
2012-03-27,29.234214782714844,29.42613410949707,-0.42359151643415965,The Right Stocks for Today's Market,"Companies such as Abbott Labs ( ABT ) , Watson Pharmaceuticals ( WPI ) , Amgen (Nasdaq: AMGN) , Gilead Sciences (Nasdaq: GILD) and Baxter International ( BAX ) all have a beta below 0.5, largely due to the fact that they have a high degree of recurring revenue and rarely tend to deliver quarterly results far from the consensus forecasts. StreetAuthority LLC owns shares of ABT, GILD in one or more if its ""real money"" portfolios. Beta measures how a stock moves in relation to the broader market, and those with a beta of less than 1.0 means that they are fairly decoupled from the broader market."
2012-03-26,29.080678939819336,29.263002395629883,0.6564887348905355,,
2012-03-23,28.81678771972656,28.97991943359375,0.626957356077738,,
2012-03-22,28.8791618347168,28.84077835083008,0.5660995786685796,Abbott Unveils Pharma Co. Name - Analyst Blog,"Abbott Labs ( ABT ) recently zeroed in on a name for its research-based pharmaceutical company that will be launched later this year. ABBOTT LABS ( ABT ): Free Stock Analysis Report To read this article on Zacks.com click here. The diversified medical products company will retain the company name and will include Abbott Labs' branded generic pharmaceutical, devices, diagnostic and nutritional businesses."
2012-03-21,28.90794944763184,28.975122451782227,-0.1329106575405399,Watson's Generic Boniva Approved - Analyst Blog,"ABBOTT LABS ( ABT ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report WATSON PHARMA ( WPI ): Free Stock Analysis Report To read this article on Zacks.com click here. Earlier during the week, Watson Pharma filed an ANDA with the FDA to market a generic version of Abbott Laboratories' ( ABT ) cholesterol drug, Niaspan. Watson Pharmaceuticals Inc. ( WPI ) recently announced that the US Food and Drug Administration (FDA) has approved the company's abbreviated new drug application (ANDA) for a generic version of Roche Holding Ltd. 's ( RHHBY ) drug, Boniva."
2012-03-20,28.730424880981445,28.97991943359375,0.2323686232815449,"Watson Files ANDA, Attracts Lawsuit - Analyst Blog","Watson Pharmaceuticals Inc. ( WPI ) recently confirmed that it has filed an abbreviated new drug application (ANDA) with the US Food and Drug Administration (FDA) to market a generic version of Abbott Laboratories' ( ABT ) cholesterol drug, Niaspan. ABBOTT LABS ( ABT ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report WATSON PHARMA ( WPI ): Free Stock Analysis Report To read this article on Zacks.com click here. We expect new generic product launches over regular intervals to help drive the company's Global Generic segment's sales, which climbed 46% during 2011 to $3.32 billion, driven by the generic launch of Pfizer Inc. 's ( PFE ) Lipitor and Johnson & Johnson 's ( JNJ ) Concerta."
2012-03-19,28.634464263916016,28.89355659484864,0.868398409163317,"Abbott Laboratories Now Rated a “Buy” at Deutsche Bank (ABT) | Market Wrap-Up for Mar. 19 (AAPL, UPS, ABT, COF, APA, more) | Biogen Inks Deal with MAKScientific - Analyst Blog","The firm said it boosted its rating on ABT to ""Buy"" with a $70 price target, suggesting an 18% upside to the stock's Friday closing price of $59.42. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. Abbott Laboratories ( ABT ) is a ""Recommended"" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars. | Meanwhile, Wall Street analyst upgrades helped some stocks come of the gate strongly this week, including Devon Energy ( DVN ), Abbott Labs ( ABT ), Capital One Financial ( COF ), and U.S. Steel ( X ). It is a big dividend-centric news day with Apple ( AAPL ) announcing it will join the ever-expanding list of big brands paying dividends. Teams get seeded according to the their rankings and usually the best teams in the country (1 through 3 seeds) playing the smaller schools (lowest seeds 14-16). | ABBOTT LABS ( ABT ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report ISIS PHARMACEUT ( ISIS ): Free Stock Analysis Report To read this article on Zacks.com click here. Besides BG-12, Biogen is developing other multiple sclerosis candidates like daclizumab, in partnership with Abbott Labs ( ABT ), and PEGylated interferon. Terms of the Agreement Per the terms of the agreement, Biogen has the option to gain an exclusive global license to certain discovery-stage MAKScientific drug candidates for all indications."
2012-03-16,28.44254493713379,28.509716033935547,0.9048268846402755,,
2012-03-15,28.25062370300293,28.36097717285156,0.23616415813080466,,
2012-03-14,28.22183609008789,28.303401947021484,0.39062312750602785,,
2012-03-13,28.044309616088867,28.274614334106445,0.2890168331827333,Watson Ups Generic Count - Analyst Blog,"ABBOTT LABS ( ABT ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report WATSON PHARMA ( WPI ): Free Stock Analysis Report To read this article on Zacks.com click here. Watson Pharmaceuticals Inc. ( WPI ) recently announced the launch of an authorized generic version of Abbott Laboratories' ( ABT ) drug Prometrium. According to the agreement, Abbott Labs will manufacture and supply all dosages of the authorized generic product to Watson Pharma, who will then market and distribute the same in the US."
2012-03-12,27.732440948486328,27.93875312805176,0.8212172849691175,,
2012-03-09,27.588499069213867,27.80441093444824,0.7439380469561372,,
2012-03-08,27.39657974243164,27.583702087402344,0.7826154829688017,"Abbott Laboratories’ Target Raised at Jefferies; Break-up Potential is Strong (ABT) | Abbott, Galapagos Team Up - Analyst Blog | Market Wrap-Up for Mar.8 (COH, MCD, WSM, MW, JPM, ABT, more)","The firm maintained its ""Buy"" rating on ABT and lifted its price target $65 to $76, suggesting a 35% upside to the stock's Wednesday closing price of $56.26. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. Abbott Laboratories ( ABT ) is a ""Recommended"" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars. | Abbott Laboratories ( ABT ) recently signed a deal to expand its pharma portfolio. ABBOTT LABS ( ABT ): Free Stock Analysis Report To read this article on Zacks.com click here. Once the phase II RA studies are done, Abbott Labs will pay a one-time license fee of $200 million, provided the studies meet certain pre-determined criteria. | Today's rally was being tied to the confidence seen earlier in the Asian and European markets that Greece is going to see its troubles subside - and more importantly, the rest of Europe as well. Earnings results however didn't lift stocks like Williams-Sonoma ( WSM ) ( report here ) and Men's Wearhouse ( MW ) ( read more ), which both ended in the red. Wall Street analyst upgrades helped boost stocks like J.P. Morgan ( JPM ) ( read more ) and Abbott Lab"
2012-03-07,27.08470916748047,26.993547439575195,0.6830135247900645,,
2012-03-06,27.42057037353516,27.03672981262207,-0.336580050912002,,
2012-03-05,27.47334861755371,27.48294448852539,-1.399827048395578,,
2012-03-02,27.48294448852539,27.535722732543945,0.03492792635240882,BSX Unveils Promus Element in Japan - Analyst Blog,"Under an agreement with Abbott Laboratories ( ABT ), Boston Scientific markets its everolimus eluting stent Xience under the brand name Promus in Japan until the second quarter of 2012. ABBOTT LABS ( ABT ): Free Stock Analysis Report BOSTON SCIENTIF ( BSX ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report To read this article on Zacks.com click here. However, global sales of coronary stent system at $381 million, during the most recent quarter, declined 6.8% year over year due to disappointing performance from both drug-eluting stents (""DES"") that declined 5.6% to $356 million and bare-metal stents that dropped 21.8% to $25 million."
2012-03-01,27.156679153442383,27.50213623046875,0.19203999062251326,,
2012-02-29,27.42057037353516,27.16147804260254,1.2720888112808042,Meridian's Legionella Test Cleared - Analyst Blog,"ABBOTT LABS ( ABT ): Free Stock Analysis Report BECTON DICKINSO ( BDX ): Free Stock Analysis Report SIEMENS AG-ADR ( SI ): Free Stock Analysis Report THERMO FISHER ( TMO ): Free Stock Analysis Report MERIDIAN BIOSCI ( VIVO ): Free Stock Analysis Report To read this article on Zacks.com click here. The company's diagnostics business faces strong competition from Abbott Laboratories ( ABT ), Becton, Dickinson and Company ( BDX ), Thermo Fisher ( TMO ) and Siemens ( SI ). Diagnostic test kit maker Meridian Bioscience ( VIVO ) has won the approval of the U.S. Food and Drug Administration (FDA) for its new test for detection of Legionnaire's disease (legionellosis), a potentially fatal form of pneumonia."
2012-02-28,27.19986152648925,27.3677921295166,-0.9448830837694118,,
2012-02-27,27.051124572753903,27.156679153442383,0.6173950660146101,Auxilium Misses 4Q Estimates - Analyst Blog,"However, Testim faces significant competition in the form of Abbott's ( ABT ) AndroGel. ABBOTT LABS ( ABT ): Free Stock Analysis Report AUXILIUM PHARMA ( AUXL ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report To read this article on Zacks.com click here. Auxilium Pharma expects Testim revenues of $215 - $225 million in 2012, up from $207.9 million in 2011."
2012-02-24,27.02713394165039,27.20466041564941,0.3902040390394545,"DexCom's EPS Misses, Sales Beat - Analyst Blog","ABBOTT LABS ( ABT ): Free Stock Analysis Report DEXCOM INC ( DXCM ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report MEDTRONIC ( MDT ): Free Stock Analysis Report To read this article on Zacks.com click here. However, we note that competition in the glucose monitoring market is intense and DexCom faces stiff challenges from much larger players such as Johnson & Johnson ( JNJ ), Medtronic ( MDT ) and Abbott Labs ( ABT ). DexCom ( DXCM ), a player in the glucose monitoring market, reported fourth-quarter 2011 loss per share of 18 cents, higher than both the Zacks Consensus Estimate of a loss of 17 cents and the year-ago loss of 16 cents per share."
2012-02-23,26.95036506652832,27.00794219970703,0.6568453554205436,,
2012-02-22,26.90718460083008,26.979154586791992,0.21364138495556148,,
2012-02-21,27.051124572753903,26.9455680847168,0.26747497751842175,,
2012-02-17,26.969558715820312,27.041528701782227,-0.39021108994270637,FDA Nod for Gen-Probe's PROGENSA - Analyst Blog,"It competes with larger, more established players in the molecular diagnostic industry such as Roche ( RHHBY ), Becton Dickinson ( BDX ), and Abbott Labs ( ABT ). ABBOTT LABS ( ABT ): Free Stock Analysis Report BECTON DICKINSO ( BDX ): Free Stock Analysis Report GEN-PROBE INC ( GPRO ): Free Stock Analysis Report To read this article on Zacks.com click here. ( GPRO ) has secured the approval of the U.S. Food and Drug Administration (""FDA"") for its PROGENSA PCA3 assay, a novel molecular test designed to aid the diagnosis of prostate cancer."
2012-02-16,26.643293380737305,26.79682922363281,0.2668563721055493,,
2012-02-15,26.532939910888672,26.609708786010746,0.5762645056729674,"Gen-Probe's EPS Trounces, Net Slips - Analyst Blog","However, Gen-Probe competes with more established firms such as Roche ( RHHBY ), Becton Dickinson ( BDX ), and Abbott Labs ( ABT ) in the maturing molecular diagnostic industry. ABBOTT LABS ( ABT ): Free Stock Analysis Report BECTON DICKINSO ( BDX ): Free Stock Analysis Report GEN-PROBE INC ( GPRO ): Free Stock Analysis Report NOVARTIS AG-ADR ( NVS ): Free Stock Analysis Report To read this article on Zacks.com click here. For the fiscal, sales rose 6% year over year to $576.2 million, just missing the Zacks Consensus Estimate of $577 million."
2012-02-14,26.46576881408692,26.42738342285156,0.289334221461713,,
2012-02-13,26.4753646850586,26.46576881408692,-0.1450378846161871,,
2012-02-10,26.417787551879883,26.4417781829834,-0.03624452802002432,,
2012-02-09,26.619304656982425,26.513748168945312,0.09081241590122659,,
2012-02-08,26.78243637084961,26.662485122680664,-0.3965411170476414,How to Earn 12.9% Yields From Stocks Paying 5.4%,"Her passing was of interest because her three shares of Abbott Laboratories (NYSE: ABT ) grew into thousands of shares through decades of stock splits and dividend reinvestment. Neither ABT nor IBM had a particularly juicy yield at the time these women bought their shares. But there's something else to this story, and it's something that can help you earn larger dividends soon -- helpful if you don't have a lifetime to invest as Aunt Lillian and Grace Groner did."
2012-02-07,26.50415229797364,26.72965812683105,-0.4478728018168727,,
2012-02-06,26.26425170898437,26.576122283935547,0.850832074620444,,
2012-02-03,26.28344345092773,26.388999938964844,1.1874336965956351,How to Stop “Off-Label” Marketing and Sales of Prescription Drugs,"If physicians and patients have made a choice to use a product ""off-label"" and private payers (insurance companies, employers, or PBMs) choose to pay for the unapproved use then they should assume the same liabilities as stated above. Physicians have the choice to prescribe, patients have the choice to take, and payers have the choice to reimburse for the unapproved use if they want to assume the liabilities with the inability to sue the pharmaceutical company. While preserving physician, patient, and payer choice these recommendations remove a major financial incentive (reimbursement) for pharmaceutical companies and increase the legal consequences for individuals who inappropriately promote for off-label uses of prescription drugs."
2012-02-02,26.02435111999512,26.125110626220703,0.40160829091588107,,
2012-02-01,26.03394889831543,26.03394889831543,0.38717394243949654,,
2012-01-31,26.18268585205078,25.981170654296875,0.0,,
2012-01-30,26.21147346496582,26.134706497192383,-0.7696505961710662,Q4 Preview: Pfizer (PFE) May Suffer Same Ailment as Peers: Strong Dollar Syndrome,"Competitors like Abbott ( ABT ), Bristol Myers-Squibb ( BMY ), and -- to a lesser extent -- Johnson & Johnson ( JNJ ) have all signaled warnings following quarterly reports. Pfizer Inc. ( PFE ) is trading lower Monday afternoon heading into its fourth-quarter report, which are expected out before the market opens on Tuesday. On average, Pfizer has beat earnings views by 4.6 percent over the last 5 quarters."
2012-01-27,26.33142471313477,26.398595809936523,-0.2928754382161842,Amgen Misses; 2012 Outlook Strong - Analyst Blog,"Total revenue increased 3% to $3,973 million in the fourth quarter of 2011. Full year 2011 earnings came in at $5.26 per share, 2.7% above the year-ago period but 3 cents below the Zacks Consensus Estimate. The Quarter in Detail Fourth quarter total product sales increased 4% to $3,907 million."
2012-01-26,26.600112915039062,26.32662582397461,0.2550986037920221,"The Zacks Analyst Blog Highlights: The Boeing, Lockheed Martin, Abbott Labs, Bristol-Myers Squibb and Biogen - Press Releases","Abbott Beats, Guides In-Line Abbott Labs ( ABT ) reported fourth quarter earnings of $1.45 per share, a penny above the Zacks Consensus Estimate and at the higher end of the guidance range provided by the company. 9339 support@zacks.com http://www.zacks.com ABBOTT LABS ( ABT ): Free Stock Analysis Report BOEING CO ( BA ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report LOCKHEED MARTIN (LMT): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include The Boeing Company ( BA ), Lockheed Martin Corporation ( LMT ), Abbott Labs ( ABT ), Bristol-Myers Squibb ( BMY ) and Biogen ( BIIB )."
2012-01-25,26.49935340881348,26.49935340881348,-1.0281425944994018,"Focus Moves Toward the Fed - Analyst Blog | Abbott Labs Q4 Profit Rises, but Revenue Misses (ABT) | Ahead of Wall Street - January 25, 2012 - Ahead of Wall Street","APPLE INC ( AAPL ): Free Stock Analysis Report ABBOTT LABS ( ABT ): Free Stock Analysis Report AUTOMATIC DATA ( ADP ): Free Stock Analysis Report BOEING CO ( BA ): Free Stock Analysis Report DOVER CORP ( DOV ): Free Stock Analysis Report UTD TECHS CORP (UTX): Free Stock Analysis Report To read this article on Zacks.com click here. Dover ( DOV ) and Abbott Labs ( ABT ) beat on earnings, but modestly missed revenue expectations. In this morning's key earnings releases, Boeing ( BA ) came out ahead of expectations on both the bottom- and top-lines, but the company's full-year 2012 earnings guidance came in below current expectations. | Looking ahead, ABT forecast 2012 adjusted earnings of $4.95 to $5.05 per share, while analysts are looking for $5.02 per share for the year. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. Healthcare products maker Abbott Laboratories ( ABT ) on Wednesday posted higher-than-expected fourth quarter earnings, but revenue totals missed Wall Street's view. | Sheraz Mian Director of Research APPLE INC ( AAPL ): Free Stock Analysis Report ABBOTT LABS ( ABT ): Free Stock Analysis Report AUTOMATIC DATA ( ADP ): Free Stock Analysis Report BOEING CO ( BA ): Free Stock Analysis Report DOVER CORP ( DOV ): Free Stock Analysis Report UTD TECHS CORP (UTX): Free Stock Analysis Report To read this article on Zacks.com click here. Dover ( DOV ) and Abbot Labs ( ABT ) beat on earnings, but modestly missed expectations. The prospect of an even longer timeframe for lower interest rates, as many in the markets are hoping to come out of today's Fed releases, has the potential to put stocks out of the slumber of the last two trading sessions."
2012-01-24,26.7248592376709,26.859203338623047,0.0,,
2012-01-23,26.80642509460449,26.73445510864257,0.5026933902902632,,
2012-01-20,26.691274642944336,26.75364875793457,-0.26848035763039324,Earnings Season in Full Swing - Earnings Preview | Neutral on Biogen - Analyst Blog,"APPLE INC ( AAPL ): Free Stock Analysis Report ABBOTT LABS ( ABT ): Free Stock Analysis Report BOEING CO ( BA ): Free Stock Analysis Report BRISTOL-MYERS ( BMY ): Free Stock Analysis Report CATERPILLAR INC (CAT): Free Stock Analysis Report COLGATE PALMOLI (CL): Free Stock Analysis Report CONOCOPHILLIPS (COP): Free Stock Analysis Report CSX CORP (CSX): Free Stock Analysis Report CHEVRON CORP (CVX): Free Stock Analysis Report DU PONT ( EI ) DE (DD): Free Stock Analysis Report AT&T INC (T): Free Stock Analysis Report To read this article on Zacks.com click here. They.include: Abbott Labs ( ABT ), Apple ( AAPL ), Automatic Data Processing ( ADP ), AT&T ( T ), Boeing ( BA ), Bristol Myers ( BMY ), Caterpillar ( CAT ), CSX ( CSX ), Chevron ( CVX ), Colgate Palmolive ( CL ), Conoco Phillips (COP - Analyst Report) and DuPont ( DD ) - and that is just in the first four letters of the alphabet! Potential Positive or Negative Surprises The best indicators of firms likely to report positive surprises are a recent history of positive surprises and rising estimates going into the report. | ABBOTT LABS ( ABT ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report NOVARTIS AG-ADR ( NVS ): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Other interesting candidates in the MS pipeline daclizumab, which is being developed in collaboration with Abbott Labs ( ABT ), and PEGylated interferon. The most promising candidate in the company's MS pipeline in BG-12, which could become a leader in the oral MS market once launched."
2012-01-19,26.523344039916992,26.595314025878903,0.23368728479485548,Meridian Intros HyperPAGE II Marker - Analyst Blog,"ABBOTT LABS ( ABT ): Free Stock Analysis Report BECTON DICKINSO ( BDX ): Free Stock Analysis Report SIEMENS AG-ADR ( SI ): Free Stock Analysis Report THERMO FISHER ( TMO ): Free Stock Analysis Report MERIDIAN BIOSCI ( VIVO ): Free Stock Analysis Report To read this article on Zacks.com click here. The company's diagnostics business faces strong competition from Abbott Laboratories ( ABT ), Becton, Dickinson and Company ( BDX ), Thermo Fisher ( TMO ) and Siemens ( SI ). Bioline, a fully owned subsidiary of diagnostic test kits maker Meridian Bioscience ( VIVO ), has broadened its HyperPAGE line of prestained molecular weight protein markers with the launch of the new HyperPAGE II protein marker."
2012-01-18,26.600112915039062,26.56172752380371,0.2713458222070242,,
2012-01-17,26.825618743896484,26.72965812683105,-0.14430536952213233,,
2012-01-13,26.40339469909668,26.595314025878903,-0.35772005105107496,,
2012-01-12,26.700870513916016,26.46576881408692,0.7268736803331921,Qiagen Expands with New Deals - Analyst Blog,"ABBOTT LABS ( ABT ): Free Stock Analysis Report ASTRAZENECA PLC ( AZN ): Free Stock Analysis Report BIOMARIN PHARMA ( BMRN ): Free Stock Analysis Report LABORATORY CP ( LH ): Free Stock Analysis Report MYRIAD GENETICS (MYGN): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report QIAGEN NV (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Myriad also has agreements with Abbott Laboratories ( ABT ) and AstraZeneca ( AZN ). In an attempt to expand its companion diagnostic portfolio for several types of new anti-cancer drugs, Qiagen ( QGEN ) recently entered into two different agreements with US biotech companies, namely Insight Genetics, Inc. and Personal Genome Diagnostics Inc."
2012-01-11,26.700870513916016,26.59051513671875,-0.8805020035079517,,
2012-01-10,26.96475982666016,26.92157745361328,-0.413302544348696,,
2012-01-09,26.868799209594727,26.79682922363281,-0.1601437332446921,,
2012-01-06,27.10390281677246,26.80162811279297,-0.2678570984899744,,
2012-01-05,27.11349868774414,27.04632568359375,-1.115244199416323,FDA OKs Meridian's GDH Test - Analyst Blog,"ABBOTT LABS ( ABT ): Free Stock Analysis Report BECTON DICKINSO ( BDX ): Free Stock Analysis Report SIEMENS AG-ADR ( SI ): Free Stock Analysis Report THERMO FISHER ( TMO ): Free Stock Analysis Report MERIDIAN BIOSCI ( VIVO ): Free Stock Analysis Report To read this article on Zacks.com click here. Meridian's diagnostics business faces strong competition from Abbott Laboratories ( ABT ), Becton, Dickinson and Company ( BDX ), Thermo Fisher ( TMO ) and Siemens ( SI ). Diagnostic test kit maker Meridian Bioscience ( VIVO ) recently won the approval of the U.S. Food and Drug Administration (""FDA"") for its new C. difficile(Clostridium difficile) test dubbed ImmunoCard C. difficile GDH."
2012-01-04,27.219053268432617,27.108699798583984,-0.24774745938912784,,
2012-01-03,27.147083282470703,27.214256286621094,-0.40542728933417976,,
2011-12-30,26.90238571166992,26.979154586791992,0.24744096244683966,,
2011-12-29,26.777637481689453,27.02713394165039,0.28536084474014695,Ring in Generics in 2012 and Beyond - Analyst Blog,"Important among these are: Forest Laboratories ' ( FRX ) depression drug Lexapro (March 2012), Bristol-Myers Squibb/Sanofi 's ( BMY / SNY ) hypertension drug Avapro (March 2012) and blood thinner Plavix (May 2012), Swiss drug maker Novartis ' ( NVS ) hypertension drug Diovan (September 2012), Merck 's ( MRK ) asthma drug Singulair (August 2012), Pfizer's erectile dysfunction drug Viagra (2012), Abbott Laboratories ' ( ABT ) dyslipidemia drug TriCor (mid-2012), Eli Lily's depression drug Cymbalta (2013) and diabetes product Humalog (2013), Teva's multiple sclerosis drug Copaxone (2014), Forest's Alzheimer's drug Namenda (early 2015) and Pfizer's central nervous system drug Lyrica (2018). ABBOTT LABS ( ABT ): Free Stock Analysis Report BRISTOL-MYERS ( BMY ): Free Stock Analysis Report FOREST LABS A ( FRX ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report LILLY ELI & CO ( LLY ): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report DOCTOR REDDYS (RDY): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report To read this article on Zacks.com click here. While Teva and Dr. Reddy's have launched their generic version of Zyprexa, India's largest generic maker Ranbaxy Laboratories Ltd. has launched a generic of Lipitor in partnership with Teva."
2011-12-28,26.868799209594727,26.787233352661133,0.931734400137216,Pharma & Biotech Stock Review & Outlook - Industry Outlook | More Generic Launches for Mylan - Analyst Blog | Pharma & Biotech Stock Review & Outlook - Industry Outlook,"ABBOTT LABS ( ABT ): Free Stock Analysis Report BRISTOL-MYERS ( BMY ): Free Stock Analysis Report CELGENE CORP ( CELG ): Free Stock Analysis Report GILEAD SCIENCES ( GILD ): Free Stock Analysis Report GLAXOSMITHKLINE ( GSK ): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. 2012 will see Abbott Labs ( ABT ) splitting into two separate publicly traded companies. With most of the big pharma companies already facing or likely to face patent challenges for their blockbuster products, the companies have been looking towards M&As and in-licensing activities to make up for the loss of revenues that will arise with key products losing patent exclusivity. | Generic maker, Mylan Inc. ( MYL ) received final approval from the US Food & Drug Administration (FDA) to launch its generic versions of Abbott Laboratories ' ( ABT ) hypertension tablets Teveten and UCB Pharma 's ( UCBJF ) partial onset seizures medicine Keppra. ABBOTT LABS ( ABT ): Free Stock Analysis Report MYLAN INC ( MYL ): Free Stock Analysis Report NOVARTIS AG-ADR ( NVS ): Free Stock Analysis Report TEVA PHARM ADR ( TEVA ): Free Stock Analysis Report WATSON PHARMA ( WPI ): Free Stock Analysis Report To read this article on Zacks.com click here. Mylan was the first company to have filed abbreviated new drug applications (ANDAs) to market generic versions of these drugs. | ABBOTT LABS ( ABT ): Free Stock Analysis Report BRISTOL-MYERS ( BMY ): Free Stock Analysis Report CELGENE CORP ( CELG ): Free Stock Analysis Report GILEAD SCIENCES ( GILD ): Free Stock Analysis Report GLAXOSMITHKLINE ( GSK ): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report To read this article on Zacks.com click here. 2012 will see Abbott Labs ( ABT ) splitting into two separate publicly traded companies. With most of the big pharma companies already facing or likely to face patent challenges for their blockbuster products, the companies have been looking towards M&As and in-licensing activities to make up for the loss of revenues that will arise with key products losing patent exclusivity."
2011-12-27,26.78243637084961,26.979154586791992,-0.303570905038685,,
2011-12-23,26.79682922363281,26.878395080566406,0.7345045582055177,Teva Provides In-Line 2012 Outlook - Analyst Blog,"However, we were disappointed to hear that new product launches do not include the generic version of Abbott Laboratories' ( ABT ) TriCor. ABBOTT LABS ( ABT ): Free Stock Analysis Report FOREST LABS A ( FRX ): Free Stock Analysis Report PROCTER & GAMBL ( PG ): Free Stock Analysis Report TEVA PHARM ADR ( TEVA ): Free Stock Analysis Report To read this article on Zacks.com click here. Teva expects to generate $11 billion sales in the US with the EU and Rest of the World (RoW) generating sales of $6.6 billion and $4.4 billion, respectively."
2011-12-22,26.604909896850582,26.700870513916016,0.3043862251495871,,
2011-12-21,26.26425170898437,26.600112915039062,0.3606876228390941,UCB Launches RA Drug Study - Analyst Blog,"Abbott Labs ( ABT ) markets Humira as a treatment for RA, psoriatic arthritis (PA), ankylosing spondylitis (AS), CD, plaque psoriasis, and juvenile idiopathic arthritis. ABBOTT LABS ( ABT ): Free Stock Analysis Report To read this article on Zacks.com click here. The study is designed to evaluate the short- (12 weeks) and long-term (104 weeks) efficacy of Cimzia plus methotrexate ( MTX ) compared with Humira (adalimumab) plus MTX in the treatment of patients with moderate to severe rheumatoid arthritis ( RA )."
2011-12-20,26.24026107788086,26.32182884216309,1.2787769846867596,,
2011-12-19,26.302635192871094,26.077129364013672,0.31084966738759845,,
2011-12-16,26.360212326049805,26.33622169494629,-0.8573507072726371,,
2011-12-15,26.2210693359375,26.33622169494629,-0.09101076579647843,,
2011-12-14,25.97637176513672,26.0195541381836,0.4391596602468308,FDA Clears Meridian illumigene GBS - Analyst Blog,"ABBOTT LABS ( ABT ): Free Stock Analysis Report BECTON DICKINSO ( BDX ): Free Stock Analysis Report SIEMENS AG-ADR ( SI ): Free Stock Analysis Report THERMO FISHER ( TMO ): Free Stock Analysis Report MERIDIAN BIOSCI ( VIVO ): Free Stock Analysis Report Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Its diagnostics business faces stro ng competition from Abbott Laboratories ( ABT ), Becton, Dickinson and Company ( BDX ), Thermo Fisher ( TMO ) and Siemens ( SI ). The company feels that the novel illumigene GBS test will provide hospitals and laboratories a simple, highly sensitive and economical test, helping them in early detection and proper management of GBS."
2011-12-13,26.077129364013672,26.077129364013672,0.1662371228642401,,
2011-12-12,26.0195541381836,26.03874588012696,0.0,,
2011-12-09,26.04834175109864,26.18268585205078,0.07375891931674404,,
2011-12-08,26.187484741210938,25.99556350708008,0.5157491491621539,"The Zacks Analyst Blog Highlights: Pfizer, Bristol - Myers Squibb, Eli Lilly, Forest Laboratories and Abbott Laboratories - Press Releases","Stocks recently featured in the blog include Pfizer ( PFE ), Bristol - Myers Squibb ( BMY ), Eli Lilly ( LLY ), Forest Laboratories ( FRX ) and Abbott Laboratories ( ABT ). For Immediate Release Chicago, IL - December 8, 2011 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets."
2011-12-07,26.09632110595703,26.245059967041016,-0.7328738747819932,Emerging Markets: The Way Forward - Analyst Blog,"ABBOTT LABS ( ABT ): Free Stock Analysis Report ASTRAZENECA PLC ( AZN ): Free Stock Analysis Report BRISTOL-MYERS ( BMY ): Free Stock Analysis Report FOREST LABS A ( FRX ): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. For example, pharma giant Abbott Laboratories ( ABT ) is leaving no stone unturned to expand its overall presence in emerging markets. M&A Activity: Emerging Markets in Focus With sales in the once dominant markets (US and EU) being impacted by the headwinds mentioned above, many leading players in the pharma space are increasing their exposure to emerging markets through mergers and acquisitions (M&A)."
2011-12-06,26.144302368164062,26.168291091918945,0.5699610319786861,,
2011-12-05,26.125110626220703,26.057937622070312,0.09175507312099442,Good News for Mylan - Analyst Blog,"( MYL ) recently announced that its Indian subsidiary Mylan Laboratories has received tentative approval from the US Food & Drug Administration (FDA) for a fixed-dose combination of generic versions of Bristol Myers Squibb 's ( BMY ) drug Reyataz and AbbottLabs ' ( ABT ) Norvir for the treatment of HIV/AIDS. ABBOTT LABS ( ABT ): Free Stock Analysis Report BRISTOL-MYERS ( BMY ): Free Stock Analysis Report MYLAN INC ( MYL ): Free Stock Analysis Report NOVARTIS AG-ADR ( NVS ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report WARNER CHIL PLC (WCRX): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In a separate development, Mylan announced that Warner Chilcott Company ( WCRX ) filed a patent infringement lawsuit in connection with the abbreviated new drug application (ANDA) filed by Mylan and partner Famy Care Ltd. with the FDA for the generic version of Warner Chilcott's oral contraceptive Generess Fe."
2011-12-02,26.187484741210938,25.981170654296875,-0.2571204582114643,,
2011-12-01,26.000362396240234,26.158695220947266,-0.7878346811574021,,
2011-11-30,25.9859676361084,26.1730899810791,0.6089639147873065,,
2011-11-29,25.635713577270508,25.45339012145996,0.7200899639030188,,
2011-11-28,25.280662536621094,25.525360107421875,-0.7112088191381614,,
2011-11-25,25.045560836791992,24.97359085083008,0.9679238842981941,,
2011-11-23,25.18950080871582,25.117530822753903,-0.28735625618806837,FDA Approves BSX Promus Element - Analyst Blog,"Under the current agreement, Boston Scientific will market Abbott Laboratories ' ( ABT ) everolimus eluting stent, Xience, under the brand name Promus in the US and Japan till the second quarter of 2012. In a major breakthrough, Boston Scientific ( BSX ) received approval from the US Food and Drug Administration (FDA) for Promus Element stent, the company's next generation drug-eluting stent ( DES ) technology. The approval grants Boston Scientific the green signal to switch to the high margin, internally manufactured Promus Element stent from Promus in the US."
2011-11-22,25.280662536621094,25.280662536621094,-0.2857142208114552,,
2011-11-21,25.314247131347656,25.31904602050781,0.0,,
2011-11-18,25.7172794342041,25.678895950317383,0.018957265982483193,,
2011-11-17,25.71248245239257,25.626117706298828,-0.14925172775339735,,
2011-11-16,26.04354476928711,25.79884529113769,-0.3358864561352635,,
2011-11-15,26.120311737060547,26.149099349975582,-0.9395782345189402,,
2011-11-14,26.158695220947266,26.02435111999512,0.11021159779724407,,
2011-11-11,26.077129364013672,26.163494110107425,-0.5135734019507414,,
2011-11-10,25.54935073852539,25.885210037231445,0.3311896217109562,,
2011-11-09,25.74606704711914,25.400611877441406,1.3145512077519006,Biotech Update: Pharmasset’s Hepatitis C Drug Shows 100% Cure Rate in Ph2 Trial,"Bizmology also reports that other hepatitis C therapies are currently being developed by Inhibitex (INHX), Achillion (ACHN), Roche, and Abbott Labs (ABT), but none of these drugs including PSI-7977 will hit the market until at least 2013. Abbott Laboratories (ABT): Engages in the discovery, development, manufacture, and sale of health care products worldwide. (By Alexander Crawford) The landscape of treatment options for hepatitis C is looking brighter – biotech company Pharmasset Inc (VRUS) just released clinical results showing that their experimental drug cured all 40 patients of hepatitis C in a Phase II trial."
2011-11-08,25.77485656738281,26.03394889831543,-1.3417784123901328,,
2011-11-07,25.48697662353516,25.731674194335938,1.0052134732749325,,
2011-11-04,25.707683563232425,25.58773422241211,0.9600886539630569,,
2011-11-03,25.48697662353516,25.83243179321289,-0.4665894557371543,,
2011-11-02,25.56854248046875,25.371824264526367,1.355418395757192,Medical Devices: Venture Capitalists Lobby to Change FDA Approval Process,"Abbott Laboratories (ABT): Engages in the discovery, development, manufacture, and sale of health care products worldwide. Paulsen’s campaign committee took in $74,000 from people with a stake in device regulation, much of it from executives affiliated with venture capital funds and their spouses.” The device industry is lobbying for change because they argue the FDA experiences high personnel turnover, cumbersome bureaucracy, and a system that requires start-up firms to run new and costly tests that often duplicate past efforts. Boston Scientific Corporation (BSX): Develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide."
2011-11-01,25.40541076660156,25.314247131347656,-0.7693759473878948,,
2011-10-31,25.69329071044922,25.846826553344727,-0.3588355098503196,,
2011-10-28,26.00995826721192,26.01475524902344,0.5975717342935222,,
2011-10-27,25.96677589416504,25.971574783325195,0.018442866236994107,,
2011-10-26,25.659704208374023,25.741270065307617,0.018480881799556034,,
2011-10-25,25.664501190185547,25.42460250854492,0.3178752813018585,,
2011-10-24,25.7028865814209,25.645309448242188,-0.9347490522526465,,
2011-10-21,26.187484741210938,25.84202766418457,-0.22401037718592295,,
2011-10-20,25.669300079345703,25.933189392089844,-1.319168604546146,"Stocks in Red at Session's Half; Investors Again Eying Europe, Overshadows Data | Mid-Day Update: Stocks Lower, Despite Positive Philly Fed Index Surprise | J&J Third-Quarter Earnings Fall: These 4 Other Drugmakers Reporting Soon","In other company news: Abbott Laboratories ( ABT ) are higher on a Bloomberg report that the breakup of the drug maker into two separate firms will result in a $54 billion target for acquisitive drug makers. In earnings news: --Shares of The New York Times Co. (NYT) are higher after the media company reported Q3 EPS, excluding items, of $0.05 per share, ahead of the analyst consensus of $0.04 per share on Thomson Reuters. --Shares of Nokia (NOK) are higher after the mobile phone company reported a $93.1 million Q3 loss, which was less than analysts had expected, The New York Times reports. | In other company news: Abbott Laboratories ( ABT ) are higher on a Bloomberg report that the breakup of the drug maker into two separate firms will result in a $54 billion target for acquisitive drug makers. In earnings news: --Shares of The New York Times Co. (NYT) are higher after the media company reported Q3 EPS, excluding items, of $0.05 per share, ahead of the analyst consensus of $0.04 per share on Thomson Reuters. --Shares of Nokia (NOK) are higher after the mobile phone company reported a $93.1 million Q3 loss, which was less than analysts had expected, The New York Times reports. | Abbott Laboratories (ABT): Engages in the discovery, development, manufacture, and sale of health care products worldwide. Among 17 analysts surveyed, the average EPS estimate for this quarter is $1.17 vs. year-ago EPS at $1.05. Among 16 analysts surveyed, the average EPS estimate for this quarter is $1.12 vs. year-ago EPS at $1.21 3."
2011-10-19,26.643293380737305,25.54935073852539,1.0280347026542962,"Abbott Labs’ Adjusted Q3 Net Beats View; Will Split into Two Companies in 2012 (ABT) | Market Wrap-Up for Oct.19 (AAPL, ABT, TRV, AEM, BLK, INTC, GG, more) | Thinking Beyond Today","Diversified healthcare products maker Abbott Laboratories ( ABT ) on Wednesday posted better-than-expected third quarter earnings and announced it would split into two separate publicly-traded companies next year. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. Abbott Laboratories ( ABT ) is a ""Recommended"" dividend stock, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars. | A name we currently like, Abbott Labs ( ABT ), was up following their results as well as news the company will be splitting itself into two separate publicly-traded companies by the end of 2012. Speaking of BlackRock, company executives were participating along with other market titans in a Senate hearing today regarding ETFs and the effects they are having on market prices (especially leveraged ETFs). Dangers of Good News Already Built In The negative reaction to Apple's ( AAPL ) surprise earnings miss from last night caught many investors off guard. | One that isn't: Abbott (ABT). Builder confidence in the market for newly built, single-family homes rose four points to 18 on the National Association of Home Builders/Wells Fargo Housing Market Index (HMI) for October, which was released today (October 17). Several stocks in the home building group include Beazer Homes (BZH), Pulte Homes (PHM), Centex (CTX), B.R."
2011-10-18,24.925609588623047,25.16071128845215,-4.105883708065978,,
2011-10-17,25.146318435668945,24.96879196166992,0.9432134407513568,,
2011-10-14,25.14151954650879,25.299854278564453,-0.7059740154535445,,
2011-10-13,25.203893661499023,25.02157020568848,0.6297739154658646,,
2011-10-12,25.079145431518555,25.107934951782227,-0.7233940051455505,,
2011-10-11,25.21828842163086,25.285459518432617,0.11479466213186937,Update: Top unusual option activity,"Similar activity also appeared in Abbott Laboratories (ABT), where total option volume was 1,658 percent above average. Accenture (ACN): Option volume 2,761 percent above average. Dynegy (DYN): Option volume 2,606 percent above average."
2011-10-10,25.045560836791992,25.2470760345459,0.26635866668945757,,
2011-10-07,24.75288200378418,24.72409439086914,0.8045944711203269,,
2011-10-06,24.5561637878418,24.5561637878418,-0.11630004502359789,,
2011-10-05,24.301870346069336,24.5225772857666,0.0,,
2011-10-04,23.846059799194336,24.229900360107425,0.9081891087159202,,
2011-10-03,24.417022705078125,24.06196975708008,1.6096603134663694,,
2011-09-30,24.71449851989746,24.53697204589844,-1.454120562881736,,
2011-09-29,24.685710906982425,24.87763023376465,-0.7183090276183214,,
2011-09-28,24.671316146850582,24.426618576049805,0.7774510829580284,,
2011-09-27,24.273082733154297,24.56575965881348,-0.9918302264227382,5 Companies that Haven't Lost a Dime in the Past Decade | Abbott Labs Cut to a “Neutral” at JPMorgan (ABT),"Abbott Labs ( ABT ) 2002 sales: $15.3 billion 2011E sales: $39 billion This provider of medical devices, hospital supplies and pharmaceuticals has been expanding through the ups and downs of the economy . Analysts think the stock is quite a bargain, trading for slightly less than book value : ""This has historically represented a bottom for the stock and provided investors with an excellent entry point, in which the stock has produced returns ranging from 20%-130% over the next two years,"" note analysts at Citigroup. Cisco Systems (Nasdaq: CSCO) Fiscal (July) 2003 sales: $18.9 billion Fiscal 2011 sales: $43 billion What a wild ride this stock has been on. | The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. Abbott Laboratories ( ABT ) is a ""Recommended"" dividend stock, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars. Healthcare products maker Abbott Laboratories ( ABT ) on Tuesday caught a downgrade from analysts at JPMorgan."
2011-09-26,24.5417709350586,24.34984970092773,1.205767429200163,,
2011-09-23,24.34025382995605,24.450607299804688,-0.7820186841394776,,
2011-09-22,24.35464859008789,24.32106208801269,0.4533784677003741,,
2011-09-21,25.371824264526367,24.824851989746094,-0.13790591948375822,,
2011-09-20,25.06475257873535,25.31904602050781,-2.155825568857589,Abbott Labs Started as a “Buy” at Jefferies (ABT),"The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. Abbott Laboratories ( ABT ) is a ""Recommended"" dividend stock, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars. Healthcare products maker Abbott Laboratories ( ABT ) on Tuesday saw its coverage started with a ""Buy"" rating by analysts at Jefferies & Co."
2011-09-19,24.66651725769043,24.944801330566406,1.01454598833023,,
2011-09-16,24.748083114624023,25.03116607666016,1.1281855073772697,,
2011-09-15,24.642528533935547,24.60894203186035,1.1438581352947625,,
2011-09-14,24.39303207397461,24.431415557861328,-0.1362948693716349,Rumor Roundup: Crazy Day in Europe,"Abbott Laboratories (ABT): Engages in the discovery, development, manufacture, and sale of health care products worldwide. Business Insider reported ""markets seem to think something big might happen -- all the big European markets are rallying, making up early morning losses."" The EPS estimate for the company's current year increased from 4.63 to 4.64 over the last 30 days, an increase of 0.22%."
2011-09-13,24.27787971496582,24.26828384399414,0.15735429597401637,,
2011-09-12,24.018787384033203,24.234697341918945,-0.03952516069912161,,
2011-09-09,24.5225772857666,24.196313858032227,0.8989211421608698,Sanofi Expresses Optimistic Earnings Outlook After Genzyme Acquisition,"Abbott Laboratories (ABT): Engages in the discovery, development, manufacture, and sale of health care products worldwide. Offers a good dividend, and appears to have good liquidity to back it up--dividend yield at 3.48%, current ratio at 2.51, and quick ratio at 2.2. Offers a good dividend, and appears to have good liquidity to back it up--dividend yield at 4.21%, current ratio at 1.98, and quick ratio at 1.7."
2011-09-08,24.944801330566406,24.680912017822266,-1.3304614108556398,Stocks Choppy Ahead of Obama's Address to Congress; Commodities Mixed,"Shares of Pfizer ( PFE ) are higher after the company said its experimental pill to treat rheumatoid arthritis showed the medicine was as effective as Abbott's ( ABT ) injectable Humira drug, but more patients taking it had serious side effects. New data released this morning showed a rise in jobless claims and set the tone for Obama's speech, which will outline a new spending to boost hiring in the sluggish economy. Oil prices have turned lower, slipping below $89 a barrel, despite a new Energy Information Administration report that U.S. stockpiles fell sharply last week by 4 million barrels, three times as much as analysts predicted."
2011-09-07,24.86803436279297,25.09354019165039,-1.0578930224662915,,
2011-09-06,23.87005043029785,24.60894203186035,0.9068100259456733,,
2011-09-02,24.78646850585937,24.48899269104004,3.09547566193927,,
2011-09-01,25.14151954650879,24.920812606811523,-1.200154087093976,,
2011-08-31,24.94960021972656,25.194297790527344,-0.8778583939168207,,
2011-08-30,24.49378967285156,24.824851989746094,0.9807675018668761,,
2011-08-29,24.26828384399414,24.57055854797364,1.351617374511376,,
2011-08-26,23.798080444335938,24.06196975708008,1.245554510251476,,
2011-08-25,24.58495140075684,23.961212158203125,1.1088680591755506,,
2011-08-24,24.124343872070312,24.5225772857666,-2.5370773868380025,"Abbott Labs’ Rating, Target Cut at Morgan Keegan (ABT)","The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. Abbott Laboratories ( ABT ) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars. Medical device maker Abbott Laboratories ( ABT ) on Wednesday caught a downgrade from analysts at Morgan Keegan."
2011-08-23,23.706918716430664,24.234697341918945,1.6507533461141686,,
2011-08-22,23.93242454528809,23.692523956298828,2.2262641206193163,,
2011-08-19,23.289491653442383,23.548583984375,-1.0024082120693196,,
2011-08-18,23.64934158325196,23.447826385498047,1.1124859863324719,,
2011-08-17,24.04277801513672,24.06196975708008,-0.8520964401673778,,
2011-08-16,23.87484741210937,24.02358627319336,0.079823312976896,,
2011-08-15,23.99479866027832,23.94681739807129,0.6229939756957243,,
2011-08-12,24.009191513061523,23.81247329711914,-0.19996526283198537,,
2011-08-11,22.502620697021484,23.692523956298828,-0.8193454404133675,,
2011-08-10,23.28469467163086,22.497821807861328,5.287843026367338,"Stocks Down, But Off Lows; Crude Futures Find Feet After Two-Day Decline | Mid-Day Update: Stocks Off Lows; Job Ads Rise, But Banking Concerns Weigh","In company news: Abbott Laboratories ( ABT ) said that it has received U.S. Food and Drug Administration approval for its RX Herculink Elite Renal Stent System for the treatment of renal artery stenosis, or the narrowing of the main arteries supplying blood to the kidneys, in patients with uncontrolled hypertension. Shares of Walt Disney Co. ( DIS ) are down sharply after the company said late yesterday that Q3 EPS was $0.78, excluding charges, compared to expectations of $0.73 per share. Apple ( AAPL ) shares are down after Reuters reported a court in Germany temporarily halted Samsung Electronics from selling its Galaxy tablet in most of the European Union, handing Apple a victory in its intellectual property fight against the Korean firm. | In company news: Abbott Laboratories ( ABT ) said that it has received U.S. Food and Drug Administration approval for its RX Herculink Elite Renal Stent System for the treatment of renal artery stenosis, or the narrowing of the main arteries supplying blood to the kidneys, in patients with uncontrolled hypertension. (-) BAC (-6.9%) reportedly selling part of mortgage business: WSJ (-) M (-2.1%) beats with Q2 results and sees FY EPS beating Street. Apple ( AAPL ) shares are down after Reuters reported a court in Germany temporarily halted Samsung Electronics from selling its Galaxy tablet in most of the European Union, handing Apple a victory in its intellectual property fight against the Korean firm."
2011-08-09,23.27509880065918,23.299087524414062,-3.379356589666712,Stocks Rally; All Eyes Turn to Fed Statement This Afternoon | Mid-Day Update: Stocks Surge Ahead of FOMC Statement,"In company news: Shares of Biogen Idec ( BIIB ) and Abbott Laboratories ( ABT ) are mixed after the companies announced positive top-line results from the first trial for their drug Daclizumab HYP in relapsing-remitting multiple sclerosis. Before the market opened, productivity data eased and revealed a sharp rise in a key inflation measure within the report -- unit labor costs jumped 2.2%. Meanwhile, shares of Pfizer ( PFE ) are higher after Bloomberg reported that Nestle may be putting together a bid for the drug makers baby-food division. | In company news: Shares of Biogen Idec ( BIIB ) and Abbott Laboratories ( ABT ) are mixed after the companies announced positive top-line results from the first trial for their drug Daclizumab HYP in relapsing-remitting multiple sclerosis. Before the market opened, productivity data eased and revealed a sharp rise in a key inflation measure within the report -- unit labor costs jumped 2.2%. Ford ( F ) is up 9.21% to $10.85, after the company said its July sales totaled 180,865 vehicles, up 9% versus a year ago - driven by 13% higher Ford brand sales and 40% higher sales for Lincoln."
2011-08-08,23.65414047241211,23.05918884277344,0.103066044790338,,
2011-08-05,23.64454460144043,24.1003532409668,-2.5152113657757385,,
2011-08-04,23.92762565612793,23.399845123291016,1.9277539373653354,,
2011-08-03,24.02358627319336,24.12914276123047,-2.2057371693365155,,
2011-08-02,24.124343872070312,24.0859603881836,0.43938688768918,,
2011-08-01,24.767276763916016,24.215505599975582,-0.15910685111378176,,
2011-07-29,24.652124404907227,24.623336791992188,-2.2278233057270174,,
2011-07-28,24.87283134460449,24.767276763916016,-0.11677538390690836,,
2011-07-27,24.930408477783203,24.86803436279297,-0.4243770209593381,,
2011-07-26,25.275863647460938,25.03596305847168,-0.2501929121852104,These Tiny Companies Could Cure Cancer and Make You Wealthy,"It may well be the case that the next miracle drug will come from Pfizer ( PFE ) , Abbott Labs ( ABT ) or Eli Lilly ( LLY ) -- and more power to them. Shares of biotechnology company Clinical Data (Nasdaq: CLDA) rose 68% on January 24, 2011, following news the Food and Drug Administration (FDA) approved its antidepressant drug. I've found a total of 39 companies with cancer drugs in phase III of trials -- this is the step before FDA approval."
2011-07-25,25.285459518432617,25.22788429260254,-0.9491291468228694,,
2011-07-22,25.395814895629883,25.40541076660156,-0.22770092743660397,,
2011-07-21,25.32864189147949,25.35742950439453,0.037785245368627235,,
2011-07-20,25.525360107421875,25.14151954650879,0.11365636198886256,Abbott Labs’ Q2 Profit Surges 50% on Higher Sales (ABT),"The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.8, 2011, when the stock was trading at $46.32. Healthcare products maker Abbott Laboratories ( ABT ) on Wednesday posted better-than-expected second quarter profit and boosted its full-year earnings outlook. Abbott Laboratories ( ABT ) is a ""Recommended"" dividend stock, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars."
2011-07-19,25.242277145385746,25.37662124633789,-1.5037615896415057,,
2011-07-18,25.395814895629883,25.20869255065918,0.5322186274177043,,
2011-07-15,25.56854248046875,25.448591232299805,-0.7368235504146124,,
2011-07-14,25.304651260375977,25.50616836547852,-0.46913604191781155,,
2011-07-13,25.46298599243164,25.31904602050781,0.7963638898991429,,
2011-07-12,25.46298599243164,25.56854248046875,-0.5652910148346896,Abbott Labs’ Estimates Boosted at UBS (ABT) | Update: Top unusual option activity,"The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. Abbott Laboratories ( ABT ) is a ""Recommended"" dividend stock, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars. Medical products maker Abbott Laboratories ( ABT ) on Tuesday saw its earnings estimates raised by analysts at UBS. | Abbott Laboratories (ABT): Option volume 4,239 percent above average. Two Harbors Investment (TWO): Option volume 4,451 percent above average. Mohawk Industries (MHK): Option volume 4,390 percent above average."
2011-07-11,25.400611877441406,25.515764236450195,0.41454874172449335,,
2011-07-08,25.54935073852539,25.58773422241211,0.4533448232050555,,
2011-07-07,25.664501190185547,25.688491821289062,0.1502327173772013,,
2011-07-06,25.55894660949707,25.5637435913086,0.09347787796744698,,
2011-07-05,25.47738075256348,25.50616836547852,0.018768307962066418,,
2011-07-01,25.213489532470703,25.47738075256348,0.11299282761687546,,
2011-06-30,25.304651260375977,25.2470760345459,1.04662712296499,,
2011-06-29,25.09354019165039,25.0263671875,-0.22752823280451198,,
2011-06-28,25.0263671875,25.069549560546875,-0.2676904240587852,,
2011-06-27,24.87283134460449,24.901620864868164,0.17254750848714248,,
2011-06-24,24.89202308654785,24.82965087890625,0.11574685593612793,"Stocks Slump, But Off Lows, as Investors Eye Revised GDP Data; Commodities in Red | Mid-Day Update: Stocks Lower; Earnings, GDP Data Disappoint","Shares of Abbott Laboratories ( ABT ) are down even as new data showed that an experimental drug from Abbott and Reata Pharmaceuticals reversed declining kidney function in diabetics, the companies said in a statement. Stocks are lower for the second session in a row after new data showed the US economy grew slower than analysts had expected, and reports from two tech names failed to inspire investor confidence. EPS was $0.07 per share, vs. expectations of $0.16 per share. | Shares of Abbott Laboratories ( ABT ) are down even as new data showed that an experimental drug from Abbott and Reata Pharmaceuticals reversed declining kidney function in diabetics, the companies said in a statement. In earnings, Oracle (ORCL) is down after the company reported a rise in fiscal Q4 profit that topped analyst expectations. EPS was $0.07 per share, vs. expectations of $0.16 per share."
2011-06-23,24.834447860717773,24.911216735839844,-0.2505710661794652,,
2011-06-22,24.99278259277344,24.98798370361328,0.30912253637617826,,
2011-06-21,25.055156707763672,25.07434844970703,-0.019201099926934032,,
2011-06-20,24.80086135864257,24.95919609069824,0.07659797209495225,Mid-Day Update: Stocks Shake Off Greece Worries to Sit Higher at Session's Half; Commodities Mixed | US Indexes Gains Despite Greece Worries; Commodities Mixed at the Session's Half,"Abbott Laboratories ( ABT ) shares are higher as the company said the U.S. Food and Drug Administration approved a new 45 mg for six-month administration formulation of Lupron Depot, a medication used for the palliative treatment of advanced prostate cancer. In deal news: The PNC Financial Services Group, Inc. (PNC) and Royal Bank of Canada (RY have signed a definitive agreement for PNC to acquire RBC Bank ( USA ), the U.S. retail banking subsidiary of Royal Bank of Canada, for $3.45 billion, or $112 million discount to tangible book value. Whole Foods (WFMI) shares are higher after it was reportedly upgraded by BMO Capital Markets to Outperform from Market Perform. | Abbott Laboratories ( ABT ) shares are higher as the company said the U.S. Food and Drug Administration approved a new 45 mg for six-month administration formulation of Lupron Depot, a medication used for the palliative treatment of advanced prostate cancer. In deal news: The PNC Financial Services Group, Inc. (PNC) and Royal Bank of Canada (RY have signed a definitive agreement for PNC to acquire RBC Bank ( USA ), the U.S. retail banking subsidiary of Royal Bank of Canada, for $3.45 billion, or $112 million discount to tangible book value. Whole Foods (WFMI) shares are higher after it was reportedly upgraded by BMO Capital Markets to Outperform from Market Perform."
2011-06-17,24.853639602661133,24.79606437683105,0.6384243263409533,Abbott Labs Started as an “Outperform” at Morgan Keegan (ABT),"The firm also set a $61 price target on ABT shares, which suggests a 19% upside to the stock's Thursday closing price of $51.31. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. Abbott Laboratories ( ABT ) is a ""Recommended"" dividend stock, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars."
2011-06-16,24.61853790283203,24.61853790283203,-0.23165712044813336,,
2011-06-15,24.53217315673828,24.61853790283203,0.0,,
2011-06-14,24.820053100585938,24.60894203186035,0.3520468632842178,,
2011-06-13,24.58495140075684,24.661720275878903,-0.8505665474204893,,
2011-06-10,24.63772964477539,24.42181968688965,0.31225961715628975,,
2011-06-09,24.738487243652344,24.72409439086914,-0.8763386927233673,Mid-Day Update: Stocks Rally Despite Disappointing Jobs Data; Trade Deficit Narrows,"Shares of Abbott Laboratories ( ABT ) are higher after the company reported on the interim efficacy and safety results from its long-term, 54-week, Phase III study of its investigational treatment of Parkinson's disease.The treatment is for patients with levodopa-carbidopa intestinal gel, or LCIG. The study showed that patients treated for 12 weeks with LCIG showed decreased ""off"" times, when re-emergence of the disease results in loss of mobility, and increased ""on"" times, periods wherein the disease is manageable, without dyskinesias, the company said. Shares of Microsoft (MSFT) have turned higher at mid-day, following a Wall Street Journal reported that the US Supreme Court upheld a patent-infringement verdict worth $290 million against the company, rejecting the software firm's effort to make it more difficult to sue it for patent claims."
2011-06-08,24.589750289916992,24.72409439086914,-0.05818000365764561,,
2011-06-07,24.613740921020508,24.652124404907227,0.5463418675188261,,
2011-06-06,24.51298141479492,24.47939682006836,0.1559433164177765,,
2011-06-03,24.431415557861328,24.5081844329834,-0.13700738461086914,,
2011-06-02,24.89202308654785,24.589750289916992,0.31422196941580116,,
2011-06-01,25.055156707763672,24.911216735839844,-1.2143359966358607,,
2011-05-31,24.911216735839844,25.069549560546875,-0.574492403311237,Will Corporate Tax Reform Help or Hurt Your Stocks?,"According to the angry-about-corporate-taxes organization Pay Up Now, for example, Abbott Labs ( ABT ) paid the equivalent of a U.S. tax rate of 15% between 2008 and 2010, while Caterpillar ( CAT ) paid 5%. A 25% solution One reform that many have suggested, and which is currently being considered, involves lowering the corporate tax rate from its current 35% rate, while eliminating many corporate tax breaks. Getting territorial Another reform on the table would make our corporate tax system ""territorial,"" like those of many other nations."
2011-05-27,25.00717544555664,24.73369026184082,0.6355884836377235,,
2011-05-26,25.391016006469727,25.01677131652832,-1.0936268444680108,,
2011-05-25,25.57813835144043,25.41500663757324,-1.4739256193846173,,
2011-05-24,25.630916595458984,25.58773422241211,-0.6377779009002987,,
2011-05-23,25.41020774841309,25.54935073852539,-0.1684776776751152,,
2011-05-20,25.621320724487305,25.674097061157227,0.5475869835066218,,
2011-05-19,25.894805908203125,25.630916595458984,0.2059860115621653,,
2011-05-18,25.73647117614746,25.82283592224121,-1.0190820262550957,,
2011-05-17,25.86121940612793,25.669300079345703,0.3355733795151869,,
2011-05-16,25.659704208374023,25.90920066833496,-0.7421124416768624,,
2011-05-13,25.635713577270508,25.664501190185547,0.9723278878620687,,
2011-05-12,25.45339012145996,25.68369483947754,0.11229495456901631,,
2011-05-11,25.381420135498047,25.45339012145996,0.9048096026446644,,
2011-05-10,25.31904602050781,25.352632522583008,0.28355381841403743,Mid-Day Update: China Trade Data Supporting Stock Advance Through Session's Half; Import Price Log Increase | US Indexes Sitting Higher as Chinese Trade Data Eases Slowdown Concerns; Deal News Continues,"Elsewhere in company news: Shares of Abbot Laboratories ( ABT ) near the flatline as Reuters reports that the drugmaker's Humira, to treat ulcerative colitis--a bowel disease--met the main goal of a late-stage trial. Goldman Sachs (GS) shares are higher as Bloomberg reports the fifth-largest US bank cut its estimated losses due to legal claims by 21 percent for the first quarter. --Independent energy company, Carrizo Oil & Gas (CRZO) reported an increase in Q1 revenues to $44.06 million compared to Q1 2010's $38.96 million. | Elsewhere in company news: Shares of Abbot Laboratories ( ABT ) are near the flatline as Reuters reports that the drugmaker's Humira, to treat ulcerative colitis--a bowel disease--met the main goal of a late-stage trial. Wal-Mart Stores (WMT) shares are higher as Reuters reports South Africa's government may demand local procurement targets in the retailer's acquisition attempt for retailer Massmart--potentially derailing the deal. --Independent energy company, Carrizo Oil & Gas (CRZO) reported an increase in Q1 revenues to $44.06 million compared to Q1 2010's $38.96 million."
2011-05-09,25.194297790527344,25.26626777648925,0.13265311042127975,,
2011-05-06,25.309450149536133,25.1990966796875,0.2856598209653874,,
2011-05-05,25.352632522583008,25.223085403442383,-0.43601686009229784,,
2011-05-04,25.36702537536621,25.400611877441406,-0.5109809366945628,,
2011-05-03,25.09354019165039,25.35742950439453,0.13240220947549883,,
2011-05-02,25.055156707763672,25.232681274414062,1.051622492198,,
2011-04-29,25.10313606262207,24.96879196166992,0.7085350481778558,,
2011-04-28,24.97359085083008,25.088741302490234,-0.5351685965331915,,
2011-04-27,24.834447860717773,25.03596305847168,0.46108888524665365,,
2011-04-26,24.55136680603028,24.83924674987793,0.8114341775749951,,
2011-04-25,24.709699630737305,24.623336791992188,1.1725617808656599,,
2011-04-21,24.33545684814453,24.853639602661133,-0.34950986873870077,,
2011-04-20,24.86323547363281,24.37384033203125,2.12933234724176,Abbott Labs’ Profit Falls 14% on Items; Adjusted Net Beats View (ABT),"Healthcare products maker Abbott Laboratories ( ABT ) on Wednesday said its first quarter profit fell 14% from last year due to one-time costs, but its adjusted results edged out analyst expectations. Shares of Abbott Labs ( ABT ) have a 3.76% dividend yield, based on last night's closing stock price of $51.09. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011."
2011-04-19,24.49858856201172,24.51298141479492,-1.9683485768397166,,
2011-04-18,24.748083114624023,24.604143142700195,0.058749722445306844,,
2011-04-15,24.671316146850582,24.901620864868164,-0.5816206906092528,"Stocks Higher Ahead Next Week's Earnings; Economic Data Supports | Mid-Day Update: Stocks Firmer Following Data Deluge, Corporate Earnings","It will compete with rheumatoid arthritis drugs by Abbott Laboratories ( ABT ), Amgen ( AMGN ) and Johnson & Johnson ( JNJ ) Reuters reported. Stocks are seeing some support as the week draws to a close, supported by economic data showing a rise in consumer sentiment and tame inflation, excluding gas and food, which seemed to encourage market bulls. Shares of Merck & Co. (MRK) are higher after the drug maker announced a tender offer for all outstanding shares of Inspire Pharmaceuticals (ISPH) for $5.00 per share in cash without interest and less any applicable withholding taxes. | It will compete with rheumatoid arthritis drugs by Abbott Laboratories ( ABT ), Amgen ( AMGN ) and Johnson & Johnson (JNJ) Reuters reported. Stocks are seeing some support as the week draws to a close, supported by economic data showing a rise in consumer sentiment and tame inflation, excluding gas and food, which seemed to encourage market bulls. Shares of Merck & Co. (MRK) are higher after the drug maker announced a tender offer for all outstanding shares of Inspire Pharmaceuticals (ISPH) for $5.00 per share in cash without interest and less any applicable withholding taxes."
2011-04-14,24.196313858032227,24.46980094909668,0.9334918195962612,,
2011-04-13,24.25868797302246,24.205909729003903,1.1302841113282476,,
2011-04-12,24.38343620300293,24.484193801879883,-0.21756429728290225,Why More Stocks are Likely to Pay Dividends,"To learn more about Dividend Aristocrats like CB, XOM, ABT, JNJ and MHP, check out Dick Davis Dividend Digest, where top income-generating stocks are recommended each and every month. Abbott Laboratories ( ABT ) is definitely an income investor favorite; I see it recommended by one of our contributors at least once every month. She wrote: ""Abbott Laboratories (ABT 47.86 NYSE - yield 3.70%) is a global, broad-based health care company."
2011-04-11,24.229900360107425,24.426618576049805,0.41322149199194647,,
2011-04-08,24.24909210205078,24.225101470947266,0.8118820672752741,,
2011-04-07,24.253889083862305,24.225101470947266,-0.09893414154456819,Abbott Labs Started as a “Hold” at Deutsche Bank (ABT),"Healthcare products maker Abbott Laboratories ( ABT ) on Thursday saw its coverage initiated with a ""Hold"" rating by analysts at Deutsche Bank. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. Abbott Laboratories ( ABT ) is a ""Recommended"" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars."
2011-04-06,24.009191513061523,24.31626319885254,-0.11869277053053458,,
2011-04-05,24.157930374145508,23.98520278930664,1.2789755357816273,,
2011-04-04,23.989999771118164,24.10994911193848,-0.7149933051538433,,
2011-04-01,23.582170486450195,23.687725067138672,0.4999972570434304,,
2011-03-31,23.51979637145996,23.534189224243164,0.4476033312927067,,
2011-03-30,23.318279266357425,23.49100875854492,0.06119463177269722,Abbott Labs’ Price Target Upped at Morgan Stanley (ABT),"Healthcare products maker Abbott Laboratories ( ABT ) on Wednesday saw its price target boosted by analysts at Morgan Stanley. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. Abbott Laboratories ( ABT ) is a ""Recommended"" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars."
2011-03-29,23.039995193481445,23.212724685668945,0.7407471632638833,,
2011-03-28,23.0927734375,23.06878471374512,0.7496941329066302,,
2011-03-25,23.14075469970703,23.0447940826416,-0.10387978654796111,,
2011-03-24,23.09757232666016,23.08317756652832,-0.4146823139983614,,
2011-03-23,23.006410598754883,23.02560234069824,-0.06232152854966698,,
2011-03-22,23.006410598754883,23.011207580566406,0.08341910556179714,,
2011-03-21,23.0927734375,23.0447940826416,0.02085063113575419,,
2011-03-18,22.824085235595703,22.987218856811523,-0.20776783260032985,,
2011-03-17,22.64176177978516,22.67534828186035,0.7147433052931401,,
2011-03-16,22.80009651184082,22.41145706176757,0.14833873088965277,,
2011-03-15,22.8096923828125,22.86247062683105,-1.704551776223475,,
2011-03-14,23.17913818359375,23.135955810546875,0.23138516352075164,,
2011-03-11,23.18873405456543,23.251108169555664,-0.1862984408861223,,
2011-03-10,23.419038772583008,23.270299911499023,0.26898456312216873,,
2011-03-09,23.38545227050781,23.543785095214844,-0.6351194108705905,,
2011-03-08,23.2655029296875,23.366260528564453,0.6770569278521661,,
2011-03-07,23.46221923828125,23.270299911499023,0.4330772439412144,,
2011-03-04,23.15994644165039,23.361461639404297,-0.8179930672077627,,
2011-03-03,22.992015838623047,23.19832992553711,0.8701021751566113,,
2011-03-02,22.665752410888672,22.87686347961425,0.8973292657857629,,
2011-03-01,23.12156105041504,22.79050064086914,0.9314099302706609,,
2011-02-28,22.96802520751953,23.0783805847168,-1.4318255105009694,,
2011-02-25,22.68494415283203,22.8576717376709,0.4804739467158882,,
2011-02-24,22.32509422302246,22.646560668945312,0.7614194845496393,7 Health Care Stocks to Sell,"Abbott Laboratories : The first big pharma stock worth selling is Abbott Laboratories (NYSE: ABT ), which has dropped -14% in the last year, compared to gains by the broader markets. The stock may have rebounded in October, but has since dropped -10%, putting it right above its 52-week low of $44.59 Bristol-Myers Squibb : Global pharmaceutical company Bristol-Myers Squibb (NYSE: BMY ) has watched its stock price fall -6% since the start of October. Johnson & Johnson : Consumer staple Johnson & Johnson (NYSE: JNJ ) is in the midst of its second large stock swoon of the past calendar year, down -5% since November."
2011-02-23,22.48822593688965,22.296306610107425,1.4399332101870526,,
2011-02-22,22.296306610107425,22.536205291748047,-0.8534213740150967,,
2011-02-18,22.243528366088867,22.493024826049805,1.075957044526244,,
2011-02-17,22.18115425109864,22.224336624145508,1.1216586498988383,,
2011-02-16,22.44024658203125,22.19554710388184,0.1946804596281506,How to Earn 13.0% Yields From Stocks Paying 6.2%,"Her passing was of interest because her threeshares of Abbott Laboratories ( ABT ) grew into more than 100,000shares through decades ofdividend reinvestment.In total, her estate became worth roughly $7 million . And it's something that can help you earn larger dividends soon -- helpful if you don't have a lifetime to invest as Aunt Lillian and Grace did. It's nothing to sneeze at, but thanks to the company's commitment to dividend growth, $5,000 invested just five years ago -- plus reinvested dividends -- is now earning 13.0%, or about $650 every year."
2011-02-15,22.08999252319336,22.43065071105957,-1.0904491501682096,,
2011-02-14,21.93645668029785,22.06120491027832,1.5421380858709541,,
2011-02-11,21.76372718811035,21.85968780517578,0.5686799458934994,,
2011-02-10,21.806909561157227,21.826101303100582,0.4409199593250439,,
2011-02-09,21.811708450317383,21.8500919342041,0.08800761928017724,,
2011-02-08,21.874082565307617,21.883678436279297,0.1759765126796394,,
2011-02-07,22.14756774902344,21.922061920166016,0.04386867857442752,,
2011-02-04,22.085193634033203,22.12837600708008,-1.0181968124575158,,
2011-02-03,21.95564842224121,22.07080078125,0.19552635019841835,,
2011-02-02,21.72054672241211,21.94125366210937,0.5244771495436181,,
2011-02-01,21.677364349365234,21.70135307312012,1.0161205540444707,,
2011-01-31,21.99883079528809,21.667768478393555,0.11066254812287092,,
2011-01-28,22.243528366088867,21.826101303100582,-1.5049086925358086,,
2011-01-27,22.39226531982422,22.253124237060547,-1.8766225219226853,,
2011-01-26,23.10236930847168,22.43065071105957,-0.6213801094991855,"Stocks Higher Ahead of Fed Meeting; Generally Positive Home Sales Data Supports | Mid-Day Update: Stocks Higher Amid Heavy Earnings Week; Investors Await Fed Meeting | Market Wrap-Up for Jan.26 (ROK, BA, COP, ABT, DD, more)","In company news: Abbott Laboratories ( ABT ) announced today that it plans to restructure its pharmaceutical business and cut 1,900 jobs or 2% of its workforce. Shares of WellPoint ( WLP ) are higher as the healthcare company reported Q4 adjusted EPS of $1.33 compared to $1.16 a year earlier and above the Street view for $1.23. Shares of computer maker Dell Inc. (DELL) are trending higher as Bloomberg reported comments made by company founder Michael Dell regarding Hewlett-Packard's (HPQ) acquisition of storage company 3Par. | (-) ABT (-1.9%) beats with earnings. In company news: Abbott Laboratories ( ABT ) announced today that it plans to restructure its pharmaceutical business and cut 1,900 jobs or 2% of its workforce. Shares of WellPoint ( WLP ) are higher as the healthcare company reported Q4 adjusted EPS of $1.33 compared to $1.16 a year earlier and above the Street view for $1.23. | As for earnings movers to the downside today, sellers were active in names like Boeing ( BA ), Abbott Labs ( ABT ), and Altera Corp ( ALTR ). The job of putting capital to work never stops and neither does our job in finding the best dividend stocks for your investment portfolio. Fear of losing, fear having an opinion others may not like, fear the stock you buy may go down, etc."
2011-01-25,23.10716819763184,23.011207580566406,-2.9075744935208396,,
2011-01-24,22.982419967651367,23.11196517944336,-0.4152850589249957,,
2011-01-21,23.08317756652832,22.992015838623047,0.5636708926837645,,
2011-01-20,22.72332763671875,23.011207580566406,-0.3949271179954972,,
2011-01-19,22.680145263671875,22.708934783935547,1.2668916650326754,,
2011-01-18,22.47863006591797,22.646560668945312,0.1269371070113283,,
2011-01-14,22.718530654907227,22.497821807861328,0.7470677818661183,Stocks Turn Positive at Mid-Day as Industrial Production Buoys Investors | Mid-Day Update: Stocks Turn Positive as Dec. Industrial Production Jumps; China Tempers Gains | The Top 20 Most Undervalued Healthcare Stocks By Target Price,"In company news: Shares of Abbott Laboratories ( ABT ) are down after a Wall Street Journal report that it withdrew its U.S. and European applications for an experimental drug called briakinumab. Sales rose 0.6% last month to $381 billion, less than analysts expected, although a 13.5% gain over the recession low in Dec. 2008. Shares of Citigroup (C) are higher following news that the bank will sell warrants this quarter in bank, Bloomberg reports. | In company news: Shares of Abbott Laboratories ( ABT ) are down after a Wall Street Journal report that it withdrew its U.S. and European applications for an experimental drug called briakinumab. The report offset disappointing data on US business inventory and consumer sentiment, Inventories rose less than expected, showing that demand for goods could be stabilizing and consumer sentiment unexpectedly declined in a preliminary sampling by Thomson Reuters and the University of Michigan. Shares of Citigroup (C) are higher following news that the bank will sell warrants this quarter in bank, Bloomberg reports. | Abbott Laboratories (ABT): Drug Manufacturers Industry. Price at time of writing $4.12 vs. target price of $6.75 (discount of 38.96%). China Medical Technologies Inc. (CMED): Medical Instruments & Supplies Industry."
2011-01-13,22.93444061279297,22.728126525878903,-0.9714926127857881,,
2011-01-12,22.94403648376465,22.82888412475586,-0.899581944889394,,
2011-01-11,23.11676406860352,22.953632354736328,-0.5018836118495175,,
2011-01-10,23.1743392944336,23.001611709594727,-0.7056857671907096,,
2011-01-07,23.09757232666016,23.20792579650879,-0.7453398461304263,,
2011-01-06,23.270299911499023,23.11196517944336,0.4777708595862033,,
2011-01-05,23.135955810546875,23.15994644165039,-0.6804155196015454,,
2011-01-04,23.049591064453125,23.15994644165039,0.10369414300393474,"Stocks Slip Despite Positive Economic News; Investors Look to Fed Minutes This Afternoon | Mid-Day Update: Stocks Lower After Europe Inflation Overshadows Upbeat Retail Sales, Factory Orders; Fed Meeting Minutes on Tap","Meanwhile, shares of Ford Motor ( F ) are just higher after the automaker reported that December sales jumped about 7%, Shares of Abbott Laboratories ( ABT ) are higher even as copyright protection for the company's HIV drug Kaletra was rejected in India, which will allow other generic drug companies to manufacture copies, Bloomberg reports. In company news: General Motors ( GM ) shares are higher after it reported a 7.5% increase in December domestic sales, lifting sales on the year to 2.22 million, up from 2.08 million last year. American International Group (AIG) shares are down after the firm received a proposal from a local Taiwan company to buy a stake in AIG's Taiwan unit, Reuters reported. | Meanwhile, shares of Ford Motor ( F ) are just higher after the automaker reported that December sales jumped about 7%, Shares of Abbott Laboratories ( ABT ) are higher even as copyright protection for the company's HIV drug Kaletra was rejected in India, which will allow other generic drug companies to manufacture copies, Bloomberg reports. In company news: General Motors ( GM ) shares are higher after it reported a 7.5% increase in December domestic sales, lifting sales on the year to 2.22 million, up from 2.08 million last year. American International Group (AIG) shares are down after the firm received a proposal from a local Taiwan company to buy a stake in AIG's Taiwan unit, Reuters reported."
2011-01-03,23.16954231262207,22.94403648376465,0.4787736879525586,,
2010-12-31,22.76171112060547,22.987218856811523,-0.9732856429130802,Stocks Mixed as 2010 Comes to a Close; Market Near Two-Year Highs,"Abbott Laboratories ( ABT ) is up on speculation the medical technology company will again soon raise its dividend. According to Seeking Alpha, ABT raised its dividend 10% to $0.44 a share in April 2010, following an 11% increase in 2009. In fact, ABT has increased its dividend for 38 consecutive years and there's little evidence the string will snap in 2011."
2010-12-30,22.776105880737305,22.824085235595703,0.9907327925004265,,
2010-12-29,22.71373176574707,22.75211524963379,0.21065653237490684,,
2010-12-28,22.804893493652344,22.737722396850582,0.1689880125493165,,
2010-12-27,22.92964172363281,22.73292350769043,-0.2945468560090324,,
2010-12-23,22.900854110717773,22.93923759460449,-0.8579210190607925,,
2010-12-22,23.08797645568848,22.953632354736328,0.16760721543897106,,
2010-12-21,23.11676406860352,23.03039932250977,-0.581879062506805,,
2010-12-20,23.299087524414062,23.15994644165039,-0.37360223012808247,,
2010-12-17,23.3278751373291,23.222320556640625,-0.5971954164208028,,
2010-12-16,23.11196517944336,23.299087524414062,-0.45248262032905373,,
2010-12-15,23.07358169555664,23.08797645568848,0.8096340727318883,,
2010-12-14,22.785701751708984,23.05438995361328,0.06238632702009823,,
2010-12-13,22.87686347961425,22.78090476989746,1.179196519080851,,
2010-12-10,22.66095352172852,22.84807586669922,-0.41945745666707906,,
2010-12-09,22.48342704772949,22.61297416687012,0.8257478874014581,,
2010-12-08,22.517013549804688,22.42105484008789,0.5761893810299464,,
2010-12-07,22.6225700378418,22.497821807861328,-0.4261609094143358,,
2010-12-06,22.79050064086914,22.512216567993164,-0.5514326169475894,,
2010-12-03,22.824085235595703,22.728126525878903,-1.2210529170076356,,
2010-12-02,22.6225700378418,22.84327888488769,-0.4204274069531879,,
2010-12-01,22.497821807861328,22.55539894104004,0.9756134987169963,,
2010-11-30,22.11398124694824,22.31549835205078,0.25592314522907267,,
2010-11-29,22.435447692871094,22.3059024810791,0.911265605465557,Abbott Laboratories’ Price Target Slashed at Goldman Sachs (ABT),"Healthcare products maker Abbott Laboratories ( ABT ) on Monday saw its price target cut by analysts at Goldman Sachs. The firm said it now expected ABT shares to reach $54, which implies a smaller 15% upside to the stock's Friday closing price of $46.80. The Bottom Line Shares of Abbott Labs ( ABT ) have a 3.76% dividend yield, based on Friday's closing stock price of $46.80."
2010-11-26,22.56019592285156,22.454639434814453,-0.5774130900590649,,
2010-11-24,22.65135765075684,22.531408309936523,-0.4678881708211855,,
2010-11-23,22.63216590881348,22.526609420776367,-0.5295459224551524,,
2010-11-22,22.814489364624023,22.670549392700195,-0.466400292673742,,
2010-11-19,22.8576717376709,22.74251937866211,-0.6309147210062933,,
2010-11-18,22.996814727783203,22.84807586669922,-0.5037799139402752,,
2010-11-17,22.94883346557617,22.93444061279297,-0.6467802730274993,,
2010-11-16,23.049591064453125,22.86726760864257,-0.06271714335628091,,
2010-11-15,23.457422256469727,23.10716819763184,-0.7910051649104161,,
2010-11-12,23.77888870239257,23.308683395385746,-1.4931481175058972,,
2010-11-11,23.88444328308105,23.88444328308105,-1.9774065680349242,,
2010-11-10,23.92762565612793,24.07156562805176,0.0,,
2010-11-09,24.220304489135746,24.01399040222168,0.601563957880494,5 Famous Pharma Stocks to Sell Now,"Here are five famous pharmaceutical stocks that you should sell immediately: Abbott Laboratories ( ABT ) Abbott Laboratories (NYSE: ABT ) is engaged in the discovery, development, manufacture and sale of a variety of health-care products. Since January, ABT stock has dropped 6.6%, compared to gains of 9.5% and 9.3% for the S&P 500 and Dow Jones, respectively. While the stock regained slightly in September, ABT has lost 3.5% since October."
2010-11-08,24.436214447021484,24.205909729003903,-0.8518228456071237,,
2010-11-05,24.40262794494629,24.431415557861328,-0.9424729780338515,,
2010-11-04,24.64732551574707,24.41222381591797,0.11796931453442452,,
2010-11-03,24.40262794494629,24.48899269104004,-0.953862923905866,,
2010-11-02,24.369041442871094,24.41222381591797,0.3539157597640457,,
2010-11-01,24.748083114624023,24.27787971496582,0.17720177114109487,,
2010-10-29,24.844043731689453,24.623336791992188,-1.8999588674419505,,
2010-10-28,24.87283134460449,24.82965087890625,-0.8883696312921321,,
2010-10-27,25.11273193359375,24.77687263488769,-0.17360494710066657,,
2010-10-26,25.136722564697266,25.280662536621094,-1.3374064581829637,Stocks Trending Higher as Indexes Move Into Positive Territory; Consumer Confidence Provides Lift | Mid-Day Update: Consumer Confidence Rise Lifts Stocks Off Lows; Indexes Just Higher,"Abbott Laboratories ( ABT ) filed suit against Anchen Pharmaceuticals, a generic drug maker, in federal court in Delaware, saying it had infringed on a U.S. patent for Zemplar, a drug used to treat people with kidney disease. --Hospira Inc. ( HSP ) is higher on reported Q3 earnings of $71.4 million, or 42 cents per share, down from $116.2 million, or 71 cents per share, last year. --Ford ( F ) is just higher after it reported Q3 net income of $0.43 per share and pre-tax operating profit of $0.48, vs. Street estimates of $0.38 per share. | Abbott Laboratories ( ABT ) filed suit against Anchen Pharmaceuticals, a generic drug maker, in federal court in Delaware, saying it had infringed on a U.S. patent for Zemplar, a drug used to treat people with kidney disease. --Hospira Inc. ( HSP ) is higher on reported Q3 earnings of $71.4 million, or 42 cents per share, down from $116.2 million, or 71 cents per share, last year. Ex items, the company reported earning 74 cents a share, ahead of the Street's consensus for 70 cents."
2010-10-25,25.35742950439453,25.194297790527344,0.5726282396336806,,
2010-10-22,25.40541076660156,25.21828842163086,-0.6433290639294342,,
2010-10-21,25.275863647460938,25.352632522583008,-0.7365452449865294,My Top 10 Super Companies,"In my opinion, the following companies should be included in your portfolio: Abbott Laboratories ( ABT ) produces a wide range of drugs, diagnostic products, medical testing products, test analysis and nutritional products. ABT shares are undervalued at 12.1 times current EPS. Don't include companies paying really low dividends, because I am referring to companies paying dividends yielding more than 1% per year (calculated by dividing the annual dividend by the current stock price)."
2010-10-20,25.03596305847168,25.15111541748047,0.30372404358884114,Major Indexes in Positive Territory as Earnings Season Presses On; Fed Beige Book on Tap | Mid-Day Update: Stocks In Strong Advance; Eyes Ahead to Fed's Beige Book,"Abbott Labs ( ABT ) reports Q3 adjusted EPS at $1.05, just topping the Thomson Reuters mean analyst estimate for $1.04. ABT sees adjusted 2010 EPS at $4.16 to $4.18. Shares of Altera ( ALTR ) are lower even after the company reported third quarter earnings results that beat Street expectations. | Abbott Labs ( ABT ) reports Q3 adjusted EPS at $1.05, just topping the Thomson Reuters mean analyst estimate for $1.04. ABT sees adjusted 2010 EPS at $4.16 to $4.18. Shares of Altera ( ALTR ) are lower even after the company reported third quarter earnings results that beat Street expectations."
2010-10-19,25.534955978393555,25.36702537536621,0.4599477908632868,,
2010-10-18,25.515764236450195,25.750865936279297,-0.657649863071777,,
2010-10-15,25.60692596435547,25.51096534729004,0.9213978372368336,,
2010-10-14,25.5301570892334,25.5301570892334,-0.3747447749058427,,
2010-10-13,25.621320724487305,25.515764236450195,0.0,,
2010-10-12,25.33344078063965,25.674097061157227,-0.4119869118855567,,
2010-10-11,25.381420135498047,25.33823776245117,1.3446901408588559,,
2010-10-08,25.213489532470703,25.33823776245117,-0.17013379399714668,,
2010-10-07,25.52056121826172,25.22788429260254,0.4947678099844554,,
2010-10-06,25.41500663757324,25.41980361938477,-1.1468279367216627,,
2010-10-05,25.31904602050781,25.4677848815918,0.018874603811587218,,
2010-10-04,25.223085403442383,25.194297790527344,0.5874583938254097,,
2010-10-01,25.20869255065918,25.22788429260254,-0.11413200429123632,,
2010-09-30,25.155914306640625,25.06475257873535,0.07613144515445143,,
2010-09-29,25.13192367553711,25.184701919555664,-0.36238685978195073,,
2010-09-28,25.05035781860352,25.13192367553711,0.2100047919130358,,
2010-09-27,24.925609588623047,24.99757957458496,0.3256075522921901,,
2010-09-24,24.944801330566406,24.920812606811523,0.28873912072651486,,
2010-09-23,24.73369026184082,24.757680892944336,-0.0961672271387784,,
2010-09-22,25.05035781860352,24.944801330566406,0.09699576104310004,,
2010-09-21,25.12232780456543,25.02157020568848,-0.4213771667513745,,
2010-09-20,24.757680892944336,25.07434844970703,-0.4010679251571548,,
2010-09-17,24.844043731689453,24.77687263488769,1.2790679310069872,,
2010-09-16,24.66651725769043,24.76247787475586,-0.27037102947972297,9 Stocks that Have Consistently Raised Dividends for 25 Years or More,"[ Read my colleague Tom Hutchinson's take on JNJ ] Abbott Labs ( ABT ) Yield: 3.4% Drug manufacturer Abbott Labs has grown dividends for 38 years running. I used this list of 42 companies as my starting point and then looked at nine companies that were raising payments the fastest: Pitney Bowes ( PBI ) Yield: 7.0% Pitney Bowes yields 7.0% and has recorded 28 consecutive years of dividend growth. The company last increased the dividend by +3% to a $1.96 annual payment in 2009, meaning a dividend increase is likely in the next quarter if Eli Lilly wants to maintain its track record."
2010-09-15,24.642528533935547,24.78646850585937,0.38903188505670155,,
2010-09-14,24.671316146850582,24.66651725769043,0.5841120229427876,,
2010-09-13,24.84884262084961,24.685710906982425,-0.019451289633631078,,
2010-09-10,24.589750289916992,24.728891372680664,-0.6564962254230186,,
2010-09-09,24.445810317993164,24.51298141479492,0.5658499217079344,,
2010-09-08,24.225101470947266,24.205909729003903,0.27477549701968135,,
2010-09-07,24.229900360107425,24.225101470947266,-0.0792225451207263,,
2010-09-03,24.441011428833008,24.34505271911621,-0.019805649585174466,,
2010-09-02,24.09075736999512,24.282678604125977,-0.3926134971795586,,
2010-09-01,23.855655670166016,24.11954689025879,0.7966591966506311,,
2010-08-31,23.60615921020508,23.67333221435547,1.1061998200401464,,
2010-08-30,23.93722152709961,23.745302200317383,0.2845571088131431,The 20 Highest Paid CEOs in America,"Miles White, Abbott Labs ( ABT ) Total 2009 Compensation: $21.9 Million At least we can say Miles White delivers more for his shareholders than William Weldon does for his. Starting at the top, here are the 20 highest paid executives in America: Larry Ellison, Oracle (Nasdaq: ORCL) 2009 Total Compensation: $84.5 million Ellison is usually somewhere toward the top of this list in any given year. Samuel Palmisano, IBM ( IBM ) 2009 Total Compensation: $21.2 Million IBM is up only +5% in the past year and shareholders have been grumbling that the company could commit more cash to its dividend than it does."
2010-08-27,23.77888870239257,23.913232803344727,-0.8017610839459895,,
2010-08-26,24.01399040222168,23.750099182128903,0.5649721592693194,,
2010-08-25,23.5965633392334,23.903636932373047,-1.0989061612532451,,
2010-08-24,23.64934158325196,23.740503311157227,1.3013487969626707,,
2010-08-23,23.774089813232425,23.88444328308105,0.38547258317679944,,
2010-08-20,23.52939224243164,23.67333221435547,0.4641753720775634,,
2010-08-19,24.066768646240234,23.66373634338379,0.6117453882393721,,
2010-08-18,24.292274475097656,24.1003532409668,-1.6746423617588893,,
2010-08-17,24.229900360107425,24.32106208801269,-0.7900504925036843,,
2010-08-16,24.01399040222168,24.15313148498535,0.37623649519977703,,
2010-08-13,24.047576904296875,24.018787384033203,0.5794167501241239,,
2010-08-12,23.94681739807129,24.177122116088867,-0.1197190069429727,,
2010-08-11,24.484193801879883,24.177122116088867,0.9617341385671033,,
2010-08-10,24.311466217041016,24.6953067779541,-1.254162943961989,,
2010-08-09,24.292274475097656,24.41222381591797,1.578845790238824,,
2010-08-06,23.85085868835449,24.263486862182617,0.49377566906414716,,
2010-08-05,23.95641326904297,23.980403900146484,1.7300348772331622,,
2010-08-04,23.980403900146484,24.07636451721192,0.1001428337125778,,
2010-08-03,23.94681739807129,23.989999771118164,0.4001626388988828,,
2010-08-02,23.85085868835449,23.90843391418457,0.18032614659830734,,
2010-07-30,23.375856399536133,23.548583984375,0.24139686785446252,,
2010-07-29,23.721311569213867,23.5006046295166,0.7389144675028666,,
2010-07-28,23.65893745422364,23.61575508117676,-0.9304162590390019,,
2010-07-27,23.750099182128903,23.63974571228028,-0.18252033985224284,,
2010-07-26,23.42383575439453,23.62535285949707,-0.4646442484402725,,
2010-07-23,23.5006046295166,23.47661399841309,0.8603078813201316,,
2010-07-22,23.51979637145996,23.514997482299805,-0.1020851653892343,,
2010-07-21,22.900854110717773,23.356664657592773,-0.02040361695469205,"Opening View: DJIA, SPX Bulls Optimistic Ahead of Bernanke Testimony","Earnings Preview On the earnings front Abbott Laboratories ( ABT ), The Coca-Cola Co. ( KO ), Wells Fargo & Co. ( WFC ), Baidu Inc. ( BIDU ), CA Inc. ( CA ), eBay Inc. ( EBAY ), Netflix Inc. ( NFLX ), QUALCOMM Inc. ( QCOM ), Starbucks Corp. ( SBUX ), Western Digital Corp. ( WDC ), and Xilinx Inc. ( XLNX ) are scheduled to release their quarterly earnings report today. In earnings news, Apple Inc. ( AAPL ) said that strong demand for iPhones and iPads lifted third-quarter earnings to $3.25 billion, or $3.51 per share, compared with earnings of $1.83 billion, or $2.01 per share, last year. Looking ahead to the fourth quarter, Apple said it expects revenue of $18 billion with earnings of $3.44 per share, versus Wall Street's view for earnings of $3.82 per share on revenue of $17.03 billion."
2010-07-20,22.61297416687012,22.776105880737305,1.990364833867385,,
2010-07-19,22.747318267822266,22.747318267822266,0.7214075984139469,,
2010-07-16,22.987218856811523,22.58418655395508,0.0,,
2010-07-15,22.963228225708008,23.039995193481445,-1.7532886660493776,,
2010-07-14,22.804893493652344,22.95842933654785,0.3343039010843198,,
2010-07-13,22.92484474182129,22.87206649780273,0.6732583203611275,,
2010-07-12,23.0783805847168,22.94403648376465,-0.23022290712519441,,
2010-07-09,23.10716819763184,23.0447940826416,-0.5821210048035983,,
2010-07-08,22.982419967651367,23.0783805847168,-0.2699340501473928,,
2010-07-07,22.42585182189941,22.891258239746094,0.4175392199798867,,
2010-07-06,22.445043563842773,22.4018611907959,2.0753121065047,,
2010-07-02,22.301103591918945,22.291507720947266,-0.1923915760022781,,
2010-07-01,22.33469009399414,22.291507720947266,-0.043028682110408466,,
2010-06-30,22.38746833801269,22.445043563842773,-0.19334216353638528,,
2010-06-29,22.550600051879883,22.38266944885254,0.25717613515201315,,
2010-06-28,22.670549392700195,22.63696479797364,-0.7446835234583684,,
2010-06-25,22.84807586669922,22.64176177978516,-0.14814195344277573,,
2010-06-24,22.73292350769043,22.77130889892578,-0.9029823260292965,,
2010-06-23,23.049591064453125,22.81928825378418,0.16885373859796776,,
2010-06-22,23.18393516540528,23.02560234069824,-0.9991622412083321,,
2010-06-21,23.58696746826172,23.1743392944336,-0.6829419750246013,,
2010-06-18,23.44302749633789,23.399845123291016,-1.7493905241669765,,
2010-06-17,23.43343162536621,23.33267402648925,-0.1842013496491469,"Thursday Winners: Neurocrine Biosciences, Pier One and Winnebago","On Wednesday, the company secured an impressive agreement with Abbott Labs (NYSE: ABT ) . Among the biggest winners in Thursday's early trading are Neurocrine Biosciences, (Nasdaq: NBIX ) , Pier One (NYSE: PIR ) and Winnebago (NYSE: WGO ) . Winnebago (NYSE: WGO ) just announced that it doubled the amount of mobile homes and campers it made in its fiscal third quarter compared with a year earlier."
2010-06-16,22.92964172363281,23.409442901611328,-0.4299737250940754,"Wednesday Winners: Neurocrine Biosciences, Sunoco and Ener1","Abbott Labs (NYSE: ABT ) has announced a wide-ranging partnership that will net Neurocrine $75 million now, and up to $500 million more down the road. Among the biggest winners in Wednesday's early trading are Neurocrine Biosciences (Nasdaq: NBIX ) , Sunoco (NYSE: SUN ) and Ener1 (NYSE: HEV ) . ------------------------------------ Good Call, Bad Timing In late May, we suggested that investors had been too harsh in dumping shares of advanced battery makers A123 Systems (Nasdaq: AONE ) and Ener1 (NYSE: HEV ) ."
2010-06-15,22.8096923828125,23.11196517944336,2.0924931307758037,,
2010-06-14,22.76171112060547,22.708934783935547,1.3251945337878699,,
2010-06-11,22.59378242492676,22.646560668945312,-0.2318645394903773,,
2010-06-10,22.253124237060547,22.646560668945312,0.233596318783362,,
2010-06-09,22.25792121887207,22.00362777709961,1.768005371711057,,
2010-06-08,22.10918426513672,22.21953773498535,-1.1424851371872515,,
2010-06-07,22.233932495117188,22.18115425109864,0.49912954058031783,Abbott Labs Downgraded at Goldman Sachs (ABT),"Healthcare products maker Abbott Laboratories ( ABT ) saw its rating cut on Monday by analysts at Goldman Sachs. The firm lowered its rating on ABT to ""Neutral"" from ""Buy,"" but maintained its $69 price target on the stock. The Bottom Line We had removed shares of ABT from our recommended list back on Apr.27, when the stock was trading at $50.37."
2010-06-04,22.56979179382324,22.32509422302246,-0.2373770093533308,,
2010-06-03,22.910449981689453,22.900854110717773,-1.0841817817200468,,
2010-06-02,22.550600051879883,22.78090476989746,-0.04188425360195423,,
2010-06-01,22.76171112060547,22.521812438964844,1.0212797774238351,,
2010-05-28,22.920045852661133,22.81928825378418,-1.0539571492208781,,
2010-05-27,22.95842933654785,22.96802520751953,-0.4396047002901378,,
2010-05-26,22.81928825378418,22.63216590881348,0.04179672237596795,,
2010-05-25,22.56019592285156,22.66095352172852,-0.8200183234885453,,
2010-05-24,22.56979179382324,22.81928825378418,0.4466166837447602,,
2010-05-21,21.821304321289062,22.521812438964844,1.1054442249184668,5 Booming Blue Chip Stocks to Buy Now,"HSP stock was spun off from drug stock Abbott Laboratories (NYSE: ABT ) and makes specialty injectable pharmaceuticals (primarily generics) and other drug delivery-related equipment. NEXT - Blue Chip Stock to Buy #1 5 Top Small Cap Stocks Blue Chip Stock to Buy #1 - AmerisourceBergen Corp. AmerisourceBergen Corp. (NYSE: ABC ) is a Pennsylvania-based company that acts as an intermediary between pharmaceutical companies and health care providers such as hospitals and drugstores that dispense drugs. NEXT - Blue Chip Stock to Buy #2 5 Top Small Cap Stocks Blue Chip Stock to Buy #2 - Hospira, Inc. Illinois health care company Hospira, Inc. (NYSE: HSP ) is another great blue chip stock to buy."
2010-05-20,22.776105880737305,22.301103591918945,3.2102027787237226,,
2010-05-19,22.96802520751953,23.001611709594727,-2.085528980702924,,
2010-05-18,23.371057510375977,23.05438995361328,0.14623156223374129,,
2010-05-17,23.308683395385746,23.236713409423828,-1.3549560460501429,,
2010-05-14,23.236713409423828,23.270299911499023,-0.30876898853997475,,
2010-05-13,23.56297874450684,23.32307815551757,0.14454067356003128,,
2010-05-12,23.7836856842041,23.582170486450195,-1.0181250494282084,,
2010-05-11,23.692523956298828,23.702119827270508,-0.8472833034778215,,
2010-05-10,23.89403915405273,23.84126281738281,0.04050168310214394,,
2010-05-07,23.51979637145996,23.375856399536133,-0.22087658068045954,,
2010-05-06,24.057172775268555,23.51020050048828,-0.611994975001109,,
2010-05-05,24.09555625915528,24.06196975708008,-2.2736348942157334,,
2010-05-04,24.30666732788086,24.08116149902344,-0.1393887807111215,,
2010-05-03,24.685710906982425,24.407426834106445,-0.9277529733529237,,
2010-04-30,24.397829055786133,24.54656791687012,-1.1273083198801725,,
2010-04-29,24.234697341918945,24.34984970092773,0.6096397377975454,,
2010-04-28,23.961212158203125,24.11954689025879,0.47515492924933533,,
2010-04-27,24.124343872070312,23.87964630126953,0.6607960023485628,,
2010-04-26,24.5081844329834,24.167526245117188,-1.0143180353355727,,
2010-04-23,24.484193801879883,24.56575965881348,-1.3899772494275389,,
2010-04-22,24.75288200378418,24.52737617492676,0.3331367885485971,,
2010-04-21,25.33344078063965,24.844043731689453,-0.9110285776942796,"Abbott Laboratories Q1 Profit Surges 30%, Beating View (ABT)","Healthcare products maker Abbott Laboratories ( ABT ) said Wednesday that its first quarter profit fell 30% from last year, despite sharply higher revenue, as adjusted results beat analysts expectations. The Bottom Line We have been recommending shares of ABT since Oct.14, when the stock was trading at $49.65. Abbott Laboratories ( ABT ) is a ""recommended"" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars."
2010-04-20,25.44379425048828,25.458187103271484,-1.931822262865307,Medicated Gains,"One name that stands to benefit is Abbott Laboratories ( ABT ), a leading pharmaceutical company that also offers nutritional, diagnostic and vascular products. A diverse product line and strong international business are reason enough to invest in the company, but analysts forecast that health care reform could expand the company's US revenues by as much as 20 percent over the next decade. Its most recent acquisition, STARLIMS Technologies, provides entrée into the medical information technology field, and last year's acquisitions of Advanced Medical Optics and Visiogen give Abbott a strong presence in the eye-care market, especially the rapidly growing field of LASIK vision corrective surgery."
2010-04-19,25.07434844970703,25.38621711730957,0.05656724245412776,,
2010-04-16,25.06475257873535,25.07434844970703,1.2437757584332483,,
2010-04-15,25.09833717346192,25.12232780456543,0.038284323539745264,,
2010-04-14,25.15111541748047,25.09833717346192,0.09558653602309299,,
2010-04-13,25.0263671875,25.08394432067871,-0.20984454622583365,,
2010-04-12,25.429399490356445,25.27106666564941,0.2300658851016506,,
2010-04-09,25.117530822753903,25.299854278564453,-0.6226369001245158,,
2010-04-08,25.232681274414062,25.08394432067871,0.7258812862504148,,
2010-04-07,25.285459518432617,25.18950080871582,-0.5894615483696963,,
2010-04-06,25.36702537536621,25.352632522583008,-0.37950154572767325,,
2010-04-05,25.42460250854492,25.395814895629883,-0.056738433341025275,,
2010-04-01,25.33344078063965,25.41020774841309,-0.11322738636861804,,
2010-03-31,25.21828842163086,25.275863647460938,0.30302621913130723,,
2010-03-30,25.44379425048828,25.194297790527344,0.22830742859096362,,
2010-03-29,25.4677848815918,25.48697662353516,-0.9805788299681347,,
2010-03-26,25.765260696411133,25.381420135498047,0.07535693438824054,,
2010-03-25,26.04354476928711,25.678895950317383,-1.4897600510851863,,
2010-03-24,26.02915000915528,25.846826553344727,-1.400150487193868,,
2010-03-23,25.96197891235352,26.07233238220215,-0.7004587385543709,,
2010-03-22,25.621320724487305,25.846826553344727,0.4250580058676484,,
2010-03-19,25.650108337402344,25.650108337402344,0.8801491198769354,,
2010-03-18,26.120311737060547,25.79884529113769,0.0,,
2010-03-17,26.312231063842773,26.149099349975582,-1.2307144308187778,,
2010-03-16,26.312231063842773,26.235464096069336,-0.6199843467145596,,
2010-03-15,26.105918884277344,26.29303932189941,-0.2917539283809636,2 Things Investors Don't Want to See Happen,"Stocks making large moves included: Aeropostale ( ARO ), up 4.2% on better earnings; Citigroup, off 5% on a ""neutral"" rating by Oppenheimer; Pall Corp. ( PLL ), down 4.8% after missing analysts' estimates; Abbott Labs ( ABT ), down 1.8% on a rating cut by Citi; and SuperValu ( SVU ), up 6.6% on rumors that it was the target of a leveraged buyout. The Dow Jones Industrial Average ( DJI ) gained 13 points to 10,625, the S&P 500 ( SPX ) fell fractionally to 1,150, and the Nasdaq ( NASD ) fell a point to 2,368. Meanwhile, lots of other important indices have broken to new highs, including the Dow Jones Transportation Average ( DJT ), technology and financial indices, the Russell 2000 ( RUT ) and the S&P MidCap 400 Index ( MID )."
2010-03-12,26.408191680908203,26.158695220947266,0.7167739946313963,,
2010-03-11,26.408191680908203,26.64809226989746,-0.9447691950119815,Why the Market is Stuck,"And Facet Biotech ( FACT ) received an offer from Abbott Labs ( ABT ) to acquire the company for $27 a share. Today's Trading Landscape Earnings to be reported before the opening include: Chemspec International, China Sunergy, Delek US Holdings, Imax, Jackson Hewitt, Metalico, NGP Capital Resources, Piedmont Natural Gas, Smithfield Foods, Stewart Enterprises, Sun Communities and The Buckle. Earnings to be reported after the close: Aeropostale, Air Methods, Clear Channel Outdoor Holdings, GMX Resources, Goldcorp, HQ Sustainable Maritime Industries, Kodiak Oil & Gas, National Semiconductor, NPS Pharmaceuticals, Obagi Medical Products, Optimer Pharmaceuticals, Pacific Sunwear, Pall Corp, PowerSecure, Quiksilver, SeaChange, Shuffle Master, Smith & Wesson, Ulta Salon and Zumiez."
2010-03-10,26.29783821105957,26.40339469909668,0.908432473862623,,
2010-03-09,26.000362396240234,26.29303932189941,0.40138846086868674,,
2010-03-08,26.08672523498535,26.110715866088867,1.1256647934318735,,
2010-03-05,25.97637176513672,26.06273651123047,0.0919649012569097,,
2010-03-04,26.144302368164062,25.94758415222168,0.3324742457284255,,
2010-03-03,26.197080612182617,25.94758415222168,-0.752432454200525,,
2010-03-02,26.01475524902344,26.187484741210938,-0.9523826858971163,,
2010-03-01,26.08672523498535,26.04834175109864,0.6639673928663252,,
2010-02-26,25.99556350708008,26.04354476928711,-0.1471379927566949,,
2010-02-25,25.894805908203125,25.96677589416504,0.18457481098249573,Comparing Dividend Aristocrats to Dividend Champions,"Abbott Laboratories ( ABT ) Yes Yes (37 years) ABM Industries ( ABM ) Yes (43) Aflac ( AFL ) Yes Yes (27) Air Products & Chemicals ( APD ) Yes Yes (27) American States Water ( AWR ) Yes (55) Archer Daniels Midland ( ADM ) Yes Yes (34) Yes Yes (37) Walgreen ( WAG ) Yes Yes (34) Wal-Mart ( WMT ) Yes Yes (35) Washington REIT ( WRE ) Yes (38) Wesco Financial ( WSC ) Yes (38) Weyco ( WEYS ) Yes (28) WGL Holdings ( WGL ) Yes (33) W. W. Grainger ( GWW ) Yes Yes (38) Author's Disclosure: Long PG, EMR, MMM, JNJ, CB, ABT, PEP, CTL, MCD, T, SHW See also Productivity: Cyclical or Structural? So even if a company declares a decreased dividend early in the year, the company will remain on the DA list for the rest of the year."
2010-02-24,26.000362396240234,26.067533493041992,0.27793213132026195,,
2010-02-23,26.0195541381836,25.894805908203125,0.25834677139527507,,
2010-02-22,26.144302368164062,26.101119995117188,-0.47944030600204746,,
2010-02-19,26.33142471313477,26.091524124145508,-0.1651693452698826,,
2010-02-18,26.24026107788086,26.374605178833008,-0.9110809293565987,,
2010-02-17,26.28824234008789,26.26905059814453,0.5119769980695555,,
2010-02-16,26.02435111999512,26.19228172302246,-0.07300504040961762,,
2010-02-12,25.525360107421875,25.87561416625977,0.6452825749738489,,
2010-02-11,25.55894660949707,25.688491821289062,1.3721806758606812,,
2010-02-10,25.55414772033692,25.55414772033692,0.5068487906456066,,
2010-02-09,25.73647117614746,25.59733009338379,0.0,,
2010-02-08,25.837230682373047,25.59733009338379,-0.5406377658046131,,
2010-02-05,25.731674194335938,25.894805908203125,-0.928507361870347,,
2010-02-04,26.26905059814453,25.82283592224121,0.633972405507513,,
2010-02-03,26.08672523498535,26.2210693359375,-1.6986326713110746,,
2010-02-02,25.56854248046875,26.120311737060547,0.5149902862164442,,
2010-02-01,25.482177734375,25.59253120422364,2.158000429681439,,
2010-01-29,25.94758415222168,25.400611877441406,0.43306137724553684,,
2010-01-28,25.95718002319336,25.885210037231445,-2.1079892122960535,,
2010-01-27,25.95718002319336,25.86121940612793,-0.2772642709940262,,
2010-01-26,26.18268585205078,26.139503479003903,-0.3696881440113548,,
2010-01-25,26.27384757995605,26.245059967041016,-0.16492720911401934,,
2010-01-22,26.547334671020508,26.153898239135746,-0.10956755696869146,,
2010-01-21,26.969558715820312,26.65768814086914,-1.482018578363136,,
2010-01-20,26.979154586791992,26.98395156860352,-1.1563799698666517,,
2010-01-19,26.652889251708984,26.96475982666016,0.017780326644762316,,
2010-01-15,26.56172752380371,26.624101638793945,1.1701192017341169,,
2010-01-14,26.49455642700196,26.556930541992188,0.23482702672232755,,
2010-01-13,26.32182884216309,26.52814292907715,0.23542237878969968,,
2010-01-12,26.48496055603028,26.47056579589844,0.7838136481747001,,
2010-01-11,26.532939910888672,26.547334671020508,-0.0543506949968328,,
2010-01-08,26.27384757995605,26.41299057006836,0.054252412963587834,,
2010-01-07,26.057937622070312,26.27864646911621,0.5295874145911483,,
2010-01-06,25.88041114807129,26.06273651123047,0.8469927676047719,,
2010-01-05,26.134706497192383,25.91879653930664,0.7044917567809478,,
2010-01-04,26.000362396240234,26.129907608032227,-0.8261426540563489,,
2009-12-31,26.134706497192383,25.904401779174805,0.49824386990361713,,
2009-12-30,25.86601829528809,26.168291091918945,-0.8812217502512204,,
2009-12-29,26.21147346496582,26.03394889831543,1.1686096916042146,,
2009-12-28,25.9859676361084,26.163494110107425,-0.6772780892599168,,
2009-12-24,25.942785263061523,25.981170654296875,0.6831628380555198,,
2009-12-23,26.01475524902344,25.952381134033203,0.14796171978498535,,
2009-12-22,25.92839241027832,25.96677589416504,-0.23976437369165474,,
2009-12-21,25.707683563232425,25.87081527709961,0.14803649713162736,,
2009-12-18,25.789249420166016,25.59253120422364,0.6345640340014833,,
2009-12-17,25.79404830932617,25.707683563232425,-0.7627915521595252,,
2009-12-16,26.02915000915528,25.85162353515625,-0.33482431705967075,,
2009-12-15,25.80364418029785,25.904401779174805,-0.6820294705612318,,
2009-12-14,25.80364418029785,25.80364418029785,0.3904781749931497,,
2009-12-11,25.90920066833496,25.79884529113769,0.0,,
2009-12-10,25.7028865814209,25.942785263061523,-0.4259312304147633,,
2009-12-09,25.669300079345703,25.72207832336425,0.9333530725456868,,
2009-12-08,25.678895950317383,25.544551849365234,0.20560842662404555,,
2009-12-07,25.83243179321289,25.74606704711914,-0.5231693029640863,,
2009-12-04,26.18268585205078,25.80364418029785,-0.3343268136159025,,
2009-12-03,26.105918884277344,26.02435111999512,-1.4476806309893564,,
2009-12-02,26.144302368164062,26.120311737060547,-0.31244931329097303,,
2009-12-01,26.31702995300293,26.139503479003903,-0.0917623685867749,,
2009-11-30,26.00515937805176,26.144302368164062,-0.6745688032276231,,
2009-11-27,25.664501190185547,25.94758415222168,0.5350591707187813,,
2009-11-25,26.05314064025879,26.105918884277344,1.1030136917073128,,
2009-11-24,25.534955978393555,26.02435111999512,0.20257920051680356,,
2009-11-23,25.77485656738281,25.49177360534668,1.916569356985258,,
2009-11-20,25.54935073852539,25.73647117614746,-1.098291124515358,,
2009-11-19,25.37662124633789,25.41020774841309,0.7323882298892037,,
2009-11-18,25.57813835144043,25.515764236450195,0.1323521431366508,,
2009-11-17,25.72687530517578,25.57813835144043,-0.24385713351465152,,
2009-11-16,25.68369483947754,25.731674194335938,-0.5781384329461432,,
2009-11-13,25.621320724487305,25.40541076660156,0.186808615965375,,
2009-11-12,25.61652183532715,25.53975486755371,-0.8426964410128635,,
2009-11-11,25.630916595458984,25.55414772033692,-0.2996775607044746,,
2009-11-10,25.04076194763184,25.33344078063965,-0.29951669826612565,,
2009-11-09,24.844043731689453,25.117530822753903,1.1688096137804953,"Three Core Biotech Holdings: Isis, Ligand and Vical","Together with the $200M sale of Ibis Biosciences to Abbott ( ABT ), Isis has almost as much cash as India has gold. Michael Steinberg submits: Isis ( ISIS ), Ligand ( LGND ) and Vical ( VICL ) have been my core biotech holdings since the mid 1990s and I have been steadily adding to these positions each time the market has lost faith. Isis and Vical have maintained consistent management throughout the years, whereas Ligand radically changed direction a few years ago when Daniel Loeb's Third Point hedge fund took a stake."
2009-11-06,24.685710906982425,24.72409439086914,1.1008155275286653,,
2009-11-05,24.48899269104004,24.767276763916016,0.15548867128577737,,
2009-11-04,24.229900360107425,24.426618576049805,1.1363639018839444,The Entry Point Market Investors May Be Missing,"However, investors may be ignoring the ability of companies to manage the cost items of the income statement as well as the ability of companies to manage working capital accounts on their balance sheets, in essence enhancing their ability to generate cash and profits. But assuming gross margins remain level with 2009 and SG&A increases by about 3% as work weeks and worker demand slightly increases, Company X - despite sales levels 14% below 2008 levels - can generate a higher EPS in 2010. One thing investors should note is that PE contraction likely occurred in 2007 and 2008 such that Company X's 2008 EPS of $0.90 may have been valued at 6.0x EPS, making Company X worth $5.40 early in 2008."
2009-11-03,24.41222381591797,24.196313858032227,0.8118820672752741,,
2009-11-02,24.388233184814453,24.426618576049805,-0.8844337964202929,,
2009-10-30,24.388233184814453,24.263486862182617,0.15739307945953446,,
2009-10-29,24.47939682006836,24.40262794494629,-0.5115020907275494,,
2009-10-28,24.53217315673828,24.47939682006836,-0.3136060732474205,,
2009-10-27,24.2394962310791,24.57535552978516,-0.2151311110219591,,
2009-10-26,24.652124404907227,24.417022705078125,1.3855869590038354,,
2009-10-23,24.940004348754883,24.61853790283203,-0.9536772408235229,,
2009-10-22,24.52737617492676,25.03116607666016,-1.2889590612236625,,
2009-10-21,24.906417846679688,24.5417709350586,2.0539901950392894,,
2009-10-20,24.940004348754883,24.88242721557617,-1.4640680721964932,,
2009-10-19,24.690507888793945,25.059953689575195,-0.23086256270676633,,
2009-10-16,24.767276763916016,24.67611312866211,1.496307011768385,,
2009-10-15,24.671316146850582,24.906417846679688,-0.36808098089623054,,
2009-10-14,24.33545684814453,24.56575965881348,0.9529353781926913,,
2009-10-13,23.87964630126953,23.82206916809082,0.9463673195291109,,
2009-10-12,24.196313858032227,23.989999771118164,-0.2411138442014944,,
2009-10-09,24.01399040222168,24.028383255004883,-0.8526674274626105,,
2009-10-08,24.148334503173828,24.04277801513672,0.05993528165094776,,
2009-10-07,24.03318214416504,24.009191513061523,-0.43711705262007217,,
2009-10-06,24.229900360107425,24.07636451721192,-0.09982294878641469,,
2009-10-05,23.95641326904297,24.148334503173828,-0.6336627085280492,,
2009-10-02,23.22711753845215,23.913232803344727,0.8011267462098111,,
2009-10-01,23.730907440185547,23.356664657592773,2.9539406418240426,,
2009-09-30,23.582170486450195,23.735706329345703,-1.5770268521592083,,
2009-09-29,23.5006046295166,23.55817985534668,0.6510674790674005,,
2009-09-28,23.582170486450195,23.308683395385746,0.24499465753218974,,
2009-09-25,22.435447692871094,22.708934783935547,-1.159719760407929,,
2009-09-24,22.209941864013672,22.521812438964844,1.2189954700630028,,
2009-09-23,22.48822593688965,22.133174896240234,1.404193567280289,,
2009-09-22,22.39226531982422,22.42105484008789,-1.5788308141594616,,
2009-09-21,21.979637145996094,22.320295333862305,0.1285690386947321,,
2009-09-18,22.296306610107425,22.056406021118164,1.5498808538259545,,
2009-09-17,22.42585182189941,22.243528366088867,-1.0759655990759875,,
2009-09-16,22.68494415283203,22.41625595092773,-0.8130057099213501,,
2009-09-15,22.71373176574707,22.59378242492676,-1.1844340461854603,,
2009-09-14,22.464235305786133,22.708934783935547,-0.5280917378851671,,
2009-09-11,22.497821807861328,22.46903419494629,1.0892846999621064,,
2009-09-10,22.24832534790039,22.48822593688965,-0.12795733365165118,,
2009-09-09,22.066001892089844,22.243528366088867,1.0782860518169184,,
2009-09-08,21.912466049194336,22.027618408203125,0.8045248743618689,,
2009-09-04,21.6629695892334,21.893274307250977,0.5255107241251056,,
2009-09-03,21.70135307312012,21.619787216186523,1.0631262582395016,,
2009-09-02,21.63898086547852,21.590999603271484,-0.375856089059382,,
2009-09-01,21.629383087158203,21.648576736450195,-0.2217353141782251,,
2009-08-31,21.96044540405273,21.70135307312012,0.08873877361480476,,
2009-08-28,22.377872467041016,22.03241539001465,-1.1798136429637052,,
2009-08-27,22.1523666381836,22.36347770690918,-1.5437440602772652,,
2009-08-26,21.98443603515625,22.10438537597656,0.952995552004321,,
2009-08-25,22.08039665222168,22.03241539001465,0.5456102700496517,,
2009-08-24,21.94125366210937,22.10918426513672,-0.21730253746235798,,
2009-08-21,21.86928367614746,21.778121948242188,0.7653646670032752,,
2009-08-20,21.68216133117676,21.72534370422364,-0.41684825737892056,,
2009-08-19,21.17837142944336,21.67256546020508,0.19916083266471526,,
2009-08-18,21.495040893554688,21.26953315734864,2.33348457603622,,
2009-08-17,21.1112003326416,21.47584724426269,-1.0491151764855042,,
2009-08-14,21.35110092163086,21.28392791748047,1.7272675445994534,,
2009-08-13,21.12079620361328,21.26473617553711,-0.31461143103088174,,
2009-08-12,21.317514419555664,21.115997314453125,0.6815082657688981,,
2009-08-11,21.36069679260254,21.447059631347656,-0.9453123902553898,,
2009-08-10,20.967260360717773,21.36069679260254,0.4043072170521406,,
2009-08-07,21.09200859069824,21.03443145751953,1.876432233473239,,
2009-08-06,21.192766189575195,20.93367385864257,-0.27298079711620926,,
2009-08-05,21.279130935668945,21.1112003326416,-1.2225507921663987,,
2009-08-04,21.427867889404297,21.25514030456543,-0.7891798003171814,,
2009-08-03,21.629383087158203,21.504636764526367,-0.8060885279411206,,
2009-07-31,21.94605255126953,21.58620262145996,-0.5767447094036645,,
2009-07-30,22.06120491027832,21.92686080932617,-1.6397023062297997,,
2009-07-29,21.77332305908203,21.922061920166016,-0.6089608500465948,,
2009-07-28,21.571807861328125,21.797313690185547,0.6831243016069741,,
2009-07-27,21.65337371826172,21.60539436340332,1.0453728788382506,,
2009-07-24,21.08241271972656,21.59579849243164,-0.22157911964514926,,
2009-07-23,21.307918548583984,21.03443145751953,2.4351376644131095,,
2009-07-22,21.59579849243164,21.21675682067871,-1.2834997958194638,,
2009-07-21,21.68696022033692,21.590999603271484,-1.7551639587939607,,
2009-07-20,21.40387725830078,21.59579849243164,-0.4424807169399879,,
2009-07-17,21.36069679260254,21.336706161499023,0.8966657387106306,,
2009-07-16,21.65337371826172,21.562211990356445,-0.11231202491401807,,
2009-07-15,21.92686080932617,21.72534370422364,-0.42100473160166607,,
2009-07-14,22.296306610107425,22.3059024810791,-0.919042205151487,,
2009-07-13,21.677364349365234,22.14277076721192,0.043037939599046005,,
2009-07-10,21.97484016418457,21.787717819213867,2.1469695777859408,,
2009-07-09,22.26751708984375,22.037214279174805,-0.8515299477612686,,
2009-07-08,21.830900192260746,22.21953773498535,-1.0342545589601762,,
2009-07-07,21.792516708374023,21.754131317138672,1.7802176699171637,,
2009-07-06,21.893274307250977,22.07080078125,-0.17614024001459885,,
2009-07-02,22.214740753173828,22.20514488220215,0.8108721953035015,,
2009-07-01,22.550600051879883,22.377872467041016,-0.0431959619889272,,
2009-06-30,22.66095352172852,22.56979179382324,-0.765955604026014,,
2009-06-29,22.833681106567383,22.94403648376465,-0.4022854899634733,,
2009-06-26,22.972824096679688,22.756914138793945,0.48330086017328766,,
2009-06-25,22.44024658203125,23.039995193481445,-0.9398494367827773,,
2009-06-24,22.646560668945312,22.545801162719727,2.6726471532199496,,
2009-06-23,22.502620697021484,22.48342704772949,-0.4449218921076834,,
2009-06-22,22.63696479797364,22.41145706176757,-0.08529517317303523,,
2009-06-19,22.953632354736328,22.82888412475586,-0.9961924587445369,,
2009-06-18,22.10438537597656,22.86726760864257,-0.5434792544053612,,
2009-06-17,21.48064613342285,22.03241539001465,3.451270956826179,,
2009-06-16,21.447059631347656,21.46145439147949,2.5686809100833816,,
2009-06-15,21.902870178222656,21.46145439147949,0.06711763933734105,,
2009-06-12,21.336706161499023,21.792516708374023,-2.0153330734802672,,
2009-06-11,21.211957931518555,21.3798885345459,2.13627419070656,,
2009-06-10,21.39908027648925,21.18317031860352,0.7916789368029907,,
2009-06-09,21.55261611938477,21.279130935668945,-1.008968400024872,,
2009-06-08,21.418272018432617,21.46145439147949,-1.2689187345096675,,
2009-06-05,21.54781723022461,21.581403732299805,0.20161464477483798,,
2009-06-04,21.677364349365234,21.47105026245117,0.1558696257553379,,
2009-06-03,21.581403732299805,21.648576736450195,-0.9517489469152528,,
2009-06-02,21.504636764526367,21.6629695892334,0.31125410090844163,,
2009-06-01,21.734939575195312,21.581403732299805,0.7362729556456122,,
2009-05-29,21.442262649536133,21.619787216186523,-0.7064010569908755,,
2009-05-28,21.21675682067871,21.39908027648925,0.82791900067613,,
2009-05-27,21.35110092163086,21.298322677612305,0.8593370671658919,,
2009-05-26,21.22635269165039,21.384685516357425,-0.2471921434509492,,
2009-05-22,20.890491485595703,21.08241271972656,0.745925722648134,,
2009-05-21,20.63619804382324,20.784936904907227,0.918701382699341,,
2009-05-20,20.74175453186035,20.66978454589844,0.7207667845022837,,
2009-05-19,20.746551513671875,20.573823928833008,-0.3469811864341615,,
2009-05-18,20.91448211669922,20.72735977172852,-0.8325604605904773,,
2009-05-15,21.375089645385746,20.784936904907227,-0.8947022638504221,,
2009-05-14,21.816505432128903,21.41347312927246,-2.760936914273554,,
2009-05-13,21.6629695892334,21.830900192260746,-1.8473733298409056,,
2009-05-12,21.619787216186523,21.787717819213867,0.7751965968267325,,
2009-05-11,21.571807861328125,21.52862548828125,0.7767449390140887,,
2009-05-08,21.6629695892334,21.55741310119629,-0.20017966655584868,,
2009-05-07,20.746551513671875,21.408676147460938,-0.4872669354139308,,
2009-05-06,20.93367385864257,20.597814559936523,3.1914924914279155,,
2009-05-05,20.72735977172852,20.981653213500977,-1.6043973025183365,,
2009-05-04,20.329126358032227,20.71776390075684,1.2268491721714883,,
2009-05-01,20.122812271118164,19.921295166015625,1.9117277146101195,,
2009-04-30,20.63139915466309,20.07962989807129,-1.0014360934618078,,
2009-04-29,20.69377326965332,20.44907569885254,-2.674415110945542,,
2009-04-28,20.6553897857666,20.63619804382324,-1.1824695651789203,,
2009-04-27,20.63139915466309,20.70816802978516,-0.09291396648727367,,
2009-04-24,20.90488624572754,20.67458152770996,0.37209728020176025,,
2009-04-23,20.425085067749023,20.804128646850582,-1.10167888650744,,
2009-04-22,21.17357444763184,20.39150047302246,1.855774787934981,,
2009-04-21,21.221553802490234,21.288726806640625,-3.693632251576916,,
2009-04-20,21.072816848754883,21.15438270568848,0.3165319786457306,,
2009-04-17,20.573823928833008,21.058422088623047,0.3870667007596411,,
2009-04-16,20.63139915466309,20.48266220092773,2.3554112325755017,,
2009-04-15,20.82811737060547,20.4682674407959,-0.720925190872192,,
2009-04-14,21.365493774414062,21.45185852050781,-1.727712223849013,,
2009-04-13,21.04402732849121,21.29352378845215,0.40422536921272234,,
2009-04-09,21.331907272338867,21.125593185424805,1.185592738815482,,
2009-04-08,20.765743255615234,20.952865600585938,-0.9671619339054152,,
2009-04-07,20.68417739868164,20.593015670776367,0.9011107508521452,,
2009-04-06,21.04402732849121,20.804128646850582,-0.4407317059226337,,
2009-04-03,21.85489082336425,21.16877555847168,-1.1399846516823,,
2009-04-02,22.78090476989746,21.77332305908203,-3.1394129141980005,,
2009-04-01,22.60817527770996,22.40666007995605,-4.422922271932069,,
2009-03-31,23.155147552490234,22.886459350585938,-0.8913377363656115,,
2009-03-30,22.4018611907959,22.97762107849121,-1.1603821625200599,,
2009-03-27,22.08999252319336,22.358680725097656,2.5701430911993643,,
2009-03-26,22.281911849975582,22.286710739135746,1.2163345081361527,,
2009-03-25,22.493024826049805,22.085193634033203,0.0215371517151416,,
2009-03-24,23.203128814697266,22.291507720947266,-1.8131451646480237,,
2009-03-23,23.16474342346192,23.39504814147949,-3.928871407948067,,
2009-03-20,23.03039932250977,22.8096923828125,0.9942036214582382,,
2009-03-19,23.5006046295166,22.804893493652344,-0.9583287575980135,,
2009-03-18,23.467018127441406,23.33267402648925,-2.9603967507731666,,
2009-03-17,22.992015838623047,23.57737159729004,-0.5724804925047501,,
2009-03-16,22.68494415283203,22.95842933654785,2.5459088179805645,,
2009-03-13,22.521812438964844,22.47863006591797,1.2055801498708028,,
2009-03-12,21.28392791748047,22.38266944885254,-0.19173578131822755,,
2009-03-11,22.69454002380371,21.336706161499023,5.162306204155461,,
2009-03-10,22.69454002380371,22.541004180908203,-5.98308606775238,,
2009-03-09,22.286710739135746,22.38266944885254,-0.676532076589647,,
2009-03-06,22.233932495117188,22.497821807861328,0.430564702167057,,
2009-03-05,22.262720108032227,22.08999252319336,1.1868764682185375,,
2009-03-04,22.310699462890625,22.63696479797364,-0.7758602003739351,,
2009-03-03,22.718530654907227,21.98443603515625,1.462371610651167,,
2009-03-02,22.4018611907959,22.56979179382324,-3.2312592345949596,,
2009-02-27,23.668533325195312,22.71373176574707,0.7496279063470704,,
2009-02-26,25.74606704711914,24.26828384399414,-4.03405460883311,,
2009-02-25,26.19228172302246,25.72687530517578,-5.739840576117651,,
2009-02-24,25.818038940429688,26.26425170898437,-1.7768838269542484,,
2009-02-23,25.640512466430664,25.621320724487305,1.7282984566885065,,
2009-02-20,25.90920066833496,25.923593521118164,-0.07484929159854267,,
2009-02-19,25.73647117614746,26.129907608032227,0.05555112628693872,,
2009-02-18,25.9859676361084,26.00515937805176,1.5287116450113882,,
2009-02-17,26.187484741210938,25.87561416625977,0.07385425169503922,,
2009-02-13,26.90238571166992,26.360212326049805,-1.1909145839439144,,
2009-02-12,26.523344039916992,26.93117332458496,-2.0153357082562593,,
2009-02-11,26.91678047180176,26.7248592376709,1.537623928770805,,
2009-02-10,27.38218688964844,26.768041610717773,-0.7130170502074763,,
2009-02-09,27.44455909729004,27.468549728393555,-2.242864243844742,,
2009-02-06,27.099103927612305,27.42057037353516,0.08741488984563259,,
2009-02-05,26.79203224182129,27.12309455871582,1.186262271924426,,
2009-02-04,27.42057037353516,26.825618743896484,1.2356745240764389,,
2009-02-03,26.816022872924805,27.33900451660156,-2.1697274036753456,,
2009-02-02,25.83243179321289,26.662485122680664,1.9502580459266778,,
2009-01-30,26.398595809936523,26.600112915039062,3.213221798521726,,
2009-01-29,26.19228172302246,26.585718154907227,0.7633629703390789,,
2009-01-28,26.24985885620117,26.369808197021484,1.502108277718101,,
2009-01-27,25.87081527709961,26.09632110595703,0.4569523267816721,,
2009-01-26,25.50136947631836,25.933189392089844,0.8716610838972503,,
2009-01-23,25.170307159423828,25.33823776245117,1.6933204946992766,,
2009-01-22,24.78166961669922,25.4341983795166,0.6671774085381653,,
2009-01-21,24.133939743041992,25.10313606262207,2.6331105728956774,,
2009-01-20,24.201112747192383,23.60615921020508,4.015905939516175,,
2009-01-16,23.77888870239257,23.951616287231445,-2.458372650886984,,
2009-01-15,23.750099182128903,23.61575508117676,0.7263904844362843,,
2009-01-14,23.93242454528809,23.735706329345703,-0.5656570101956898,,
2009-01-13,23.745302200317383,24.018787384033203,-0.8219736181352216,,
2009-01-12,24.623336791992188,24.018787384033203,1.1517443804617693,,
2009-01-09,24.5561637878418,24.55136680603028,-2.455188803475211,,
2009-01-08,24.32585906982422,24.56575965881348,-0.01953473617851888,,
2009-01-07,24.167526245117188,24.29707145690918,0.9861957528433338,,
2009-01-06,25.35742950439453,24.431415557861328,0.5360300863153734,,
2009-01-05,25.525360107421875,25.25667190551757,-3.651844704419751,,
2009-01-02,25.68369483947754,25.698087692260746,-1.0526323655123633,,
2008-12-31,25.54935073852539,25.60692596435547,0.05603887163884189,,
2008-12-30,25.18950080871582,25.50616836547852,0.225349076065802,,
2008-12-29,25.51096534729004,25.03116607666016,1.2571410571706476,,
2008-12-26,25.33823776245117,25.194297790527344,-1.8807570160446596,,
2008-12-24,25.23748016357422,25.26147079467773,-0.5680741228860429,,
2008-12-23,25.50136947631836,25.170307159423828,0.09505953426419429,,
2008-12-22,25.136722564697266,25.290258407592773,-1.2982138751488213,,
2008-12-19,25.429399490356445,25.079145431518555,0.6108029497494553,,
2008-12-18,25.117530822753903,24.944801330566406,-1.3773587495478097,,
2008-12-17,25.2470760345459,24.9783878326416,-0.6876850013896321,,
2008-12-16,24.96399307250977,25.50616836547852,-1.0642349297663116,,
2008-12-15,24.42181968688965,24.77687263488769,2.1718292077471806,,
2008-12-12,24.01399040222168,24.34984970092773,1.4538349416634428,,
2008-12-11,24.719295501708984,24.484193801879883,1.3985984548198152,,
2008-12-10,24.86803436279297,24.719295501708984,-0.9510857613755523,,
2008-12-09,25.400611877441406,24.935205459594727,-0.5981126570523174,,
2008-12-08,25.765260696411133,25.391016006469727,-1.832264593043181,,
2008-12-05,24.728891372680664,25.309450149536133,-1.4525166050174496,,
2008-12-04,25.13192367553711,24.96399307250977,2.3476943147432934,,
2008-12-03,24.55136680603028,25.50136947631836,-0.6681963752372857,,
2008-12-02,24.431415557861328,24.935205459594727,3.869449215571738,,
2008-12-01,24.51778030395508,24.06196975708008,2.0620577655038628,,
2008-11-28,24.49378967285156,25.136722564697266,-1.8591020117815111,,
2008-11-26,24.196313858032227,24.64732551574707,2.6248812471772016,,
2008-11-25,24.661720275878903,24.57535552978516,1.8639684555303682,,
2008-11-24,24.925609588623047,24.36424446105957,-0.3501975739227502,,
2008-11-21,24.292274475097656,24.719295501708984,-2.2521620808010407,,
2008-11-20,26.03394889831543,24.157930374145508,1.757847035069002,,
2008-11-19,27.108699798583984,26.158695220947266,-7.206046733430105,,
2008-11-18,26.768041610717773,27.14228630065918,-3.504426935615488,,
2008-11-17,26.06273651123047,26.54253578186035,1.3981026157384662,,
2008-11-14,27.00794219970703,26.417787551879883,1.8409397279642397,,
2008-11-13,26.23066520690918,27.415771484375,-2.185115191166064,,
2008-11-12,26.47056579589844,26.149099349975582,4.518018388468708,,
2008-11-11,26.25945472717285,26.47056579589844,-1.2144298251934955,,
2008-11-10,26.868799209594727,26.57132339477539,0.803943078479597,,
2008-11-07,25.90920066833496,26.532939910888672,-1.1071422005085687,,
2008-11-06,26.26425170898437,25.78445243835449,2.4074044218431503,,
2008-11-05,26.80162811279297,26.4753646850586,-1.8268149267917464,,
2008-11-04,27.319812774658203,27.06551742553711,-1.2173268965650472,,
2008-11-03,26.44657516479492,26.868799209594727,-0.9308092673203733,,
2008-10-31,26.08672523498535,26.46096992492676,1.596516910673044,,
2008-10-30,26.6768798828125,26.17788887023925,1.4346173640818047,,
2008-10-29,26.35541343688965,25.990766525268555,-1.870499903906459,,
2008-10-28,26.03394889831543,26.388999938964844,-1.383575000613338,,
2008-10-27,25.74606704711914,25.51096534729004,1.363800175056763,,
2008-10-24,24.896821975708008,26.05314064025879,-0.9131557818086561,,
2008-10-23,26.000362396240234,26.398595809936523,4.644442835631828,,
2008-10-22,26.379404067993164,25.84202766418457,1.5316456271927785,,
2008-10-21,27.694055557250977,26.864002227783203,-2.0371059271221634,,
2008-10-20,26.830415725708008,27.612489700317383,-2.997225623931578,,
2008-10-17,26.158695220947266,26.609708786010746,2.914878332876586,,
2008-10-16,25.923593521118164,26.57132339477539,1.7241439653393686,,
2008-10-15,26.91678047180176,25.85162353515625,2.49861144107805,,
2008-10-14,27.14228630065918,26.28344345092773,-3.95722266175696,,
2008-10-13,25.309450149536133,26.00995826721192,-3.1642244143250045,,
2008-10-10,23.01600646972656,23.726110458374023,2.767772960443501,,
2008-10-09,26.556930541992188,24.10994911193848,3.0852615095563136,,
2008-10-08,26.350616455078125,26.52814292907715,-9.214097337734518,,
2008-10-07,27.295822143554688,26.81122398376465,0.6737089976686738,,
2008-10-06,27.6364803314209,27.060720443725582,-1.7753565261432007,,
2008-10-03,28.538503646850582,28.073097229003903,-2.0833329019857643,,
2008-10-02,27.770824432373047,28.26021957397461,-1.6308017533289292,,
2008-10-01,27.47334861755371,27.96754264831543,1.7622636403659089,,
2008-09-30,28.236230850219727,27.62688446044922,1.79881250604435,,
2008-09-29,28.25062370300293,27.54051971435547,-2.15803020241197,,
2008-09-26,28.245826721191406,28.500120162963867,-2.5135869427618323,,
2008-09-25,28.25542259216309,28.466533660888672,0.9002867725648034,,
2008-09-24,28.0922908782959,28.236230850219727,0.7471524024706537,,
2008-09-23,27.574106216430664,28.073097229003903,0.5123824630302264,,
2008-09-22,28.001127243041992,27.415771484375,1.8096362168790927,,
2008-09-19,28.303401947021484,28.169057846069336,-2.0904721213052144,,
2008-09-18,27.70845031738281,27.866783142089844,-0.4746570790451788,,
2008-09-17,28.41375541687012,27.468549728393555,0.5714243232423042,,
2008-09-16,27.588499069213867,28.69683837890625,-3.326577830382,,
2008-09-15,27.94355201721192,28.058704376220703,4.017396187127787,,
2008-09-12,28.30820083618164,28.351381301879883,0.41208919659839055,,
2008-09-11,27.75642967224121,28.456937789916992,0.15253694838511891,,
2008-09-10,27.578903198242188,27.780420303344727,2.523768820225279,,
2008-09-09,28.0922908782959,27.578903198242188,0.7306929635816093,,
2008-09-08,27.905168533325195,28.029916763305664,-1.8275037884160392,,
2008-09-05,26.969558715820312,27.35339736938477,0.44704345659654643,,
2008-09-04,27.59809684753418,27.14228630065918,1.4232292697444002,,
2008-09-03,28.21224021911621,27.79481315612793,-1.6516013745191473,,
2008-09-02,27.88597679138184,28.312997817993164,-1.4795955930697011,,
2008-08-29,28.053905487060547,27.554914474487305,1.5313109876190365,,
2008-08-28,27.80920791625977,28.18824958801269,-1.7786864392317656,,
2008-08-27,27.61728858947754,27.694055557250977,1.3630077954550466,,
2008-08-26,27.751632690429688,27.622085571289062,0.27796706952139566,,
2008-08-25,28.00592613220215,27.713247299194336,-0.4668090003414469,,
2008-08-22,27.89557266235352,28.058704376220703,-1.045060361961323,,
2008-08-21,27.80441093444824,27.847591400146484,0.5847942820236074,,
2008-08-20,28.14506721496582,27.991531372070312,0.15530077511819307,,
2008-08-19,28.140270233154297,28.24102783203125,-0.5455159929902987,,
2008-08-18,28.66325187683105,28.28900718688965,0.3580548375766575,,
2008-08-15,28.1546630859375,28.605676651000977,-1.305660263355919,,
2008-08-14,27.905168533325195,28.16426086425781,1.6019142679378953,,
2008-08-13,28.26981544494629,28.044309616088867,0.9284743456152137,,
2008-08-12,28.077896118164062,28.25062370300293,-0.7976911957440276,,
2008-08-11,28.341785430908203,28.26021957397461,0.6151728181910567,,
2008-08-08,27.90036964416504,28.322593688964844,-0.2877936435318641,,
2008-08-07,28.140270233154297,28.001127243041992,1.5133277809030992,,
2008-08-06,28.039512634277344,28.20264434814453,-0.49446216741859583,,
2008-08-05,27.578903198242188,28.169057846069336,0.5817922586420584,,
2008-08-04,26.90238571166992,27.47334861755371,2.139877150244189,,
2008-08-01,27.031932830810547,26.90238571166992,2.1223504562129447,,
2008-07-31,27.15188217163086,27.031932830810547,-0.4792373521769516,,
2008-07-30,26.91678047180176,27.276630401611328,-0.44177173450479745,,
2008-07-29,27.310216903686523,26.840011596679688,1.336898111520241,,
2008-07-28,27.43496322631836,26.969558715820312,-1.7217194160891645,,
2008-07-25,27.48294448852539,27.55011558532715,-1.696391960356573,,
2008-07-24,27.30061912536621,27.329408645629883,0.24441011708116983,,
2008-07-23,27.751632690429688,27.34380149841309,0.10545372664066163,,
2008-07-22,27.10390281677246,27.679662704467773,-1.4695754897233162,,
2008-07-21,27.4973373413086,27.243043899536133,2.124269303898995,,
2008-07-18,27.713247299194336,27.62688446044922,-0.9247929667373611,,
2008-07-17,27.39657974243164,27.588499069213867,-0.31163016665906157,,
2008-07-16,27.97233963012696,27.334205627441406,0.7005229433255976,,
2008-07-15,27.06551742553711,27.75642967224121,-2.2813036418243207,,
2008-07-14,27.276630401611328,26.97435569763184,2.5527398417744847,,
2008-07-11,27.25743865966797,27.07511329650879,-1.1081819840973912,,
2008-07-10,27.305418014526367,27.51652908325196,-0.6689013059358404,,
2008-07-09,27.276630401611328,27.305418014526367,0.7731471776527385,,
2008-07-08,26.144302368164062,27.526126861572266,0.10553947643525087,,
2008-07-07,26.32662582397461,26.000362396240234,5.285375275841561,,
2008-07-03,26.365009307861328,26.26905059814453,-1.2392907086378684,,
2008-07-02,26.081928253173828,26.02435111999512,-0.3639623585802588,,
2008-07-01,25.285459518432617,26.00995826721192,-0.22075489442273505,,
2008-06-30,25.41500663757324,25.41500663757324,2.865278158188734,,
2008-06-27,25.280662536621094,25.429399490356445,0.0,,
2008-06-26,25.84202766418457,25.304651260375977,0.5883427838170538,,
2008-06-25,25.83243179321289,25.68369483947754,-2.0794668699831313,,
2008-06-24,25.904401779174805,25.789249420166016,-0.5757760435640833,,
2008-06-23,25.654905319213867,26.04834175109864,-0.4445281539038007,,
2008-06-20,25.72687530517578,25.59733009338379,1.5335719504297458,,
2008-06-19,25.482177734375,25.97637176513672,-0.5035404037812942,,
2008-06-18,25.59253120422364,25.482177734375,1.93937125748503,,
2008-06-17,26.149099349975582,25.7028865814209,-0.4311940423869751,,
2008-06-16,25.741270065307617,26.067533493041992,-1.7064173514454166,,
2008-06-13,25.99556350708008,25.96197891235352,1.2674721445624835,,
2008-06-12,25.789249420166016,25.87561416625977,-0.12919356303784485,,
2008-06-11,25.90920066833496,25.669300079345703,0.33488662150136195,,
2008-06-10,26.149099349975582,26.0195541381836,-0.9259281753236539,,
2008-06-09,26.49935340881348,26.28344345092773,-0.49540984206824124,,
2008-06-06,26.66728401184082,26.27384757995605,-0.8147744382847443,,
2008-06-05,26.4897575378418,26.73925399780273,-1.4753524645032294,,
2008-06-04,26.73925399780273,26.868799209594727,0.9418601117979791,,
2008-06-03,26.844810485839844,26.73925399780273,0.48447578905021427,,
2008-06-02,26.79203224182129,26.71526336669922,-0.3932100325043907,,
2008-05-30,26.878395080566406,27.03672981262207,-0.2865362150551505,,
2008-05-29,25.99556350708008,26.849607467651367,0.5890780739737809,,
2008-05-28,26.30743408203125,25.95718002319336,3.285345056431188,,
2008-05-27,26.04834175109864,26.19228172302246,-1.3313881458212014,,
2008-05-23,26.245059967041016,26.03394889831543,0.5525878510778909,,
2008-05-22,26.02915000915528,26.31702995300293,-0.8043840211860926,,
2008-05-21,26.33142471313477,26.081928253173828,1.105990567292411,,
2008-05-20,26.43697929382324,26.235464096069336,-0.9475235870411751,,
2008-05-19,26.235464096069336,26.41299057006836,-0.7622474395211442,,
2008-05-16,26.33142471313477,26.24985885620117,0.6766660324702276,,
2008-05-15,26.374605178833008,26.32662582397461,-0.3097662121294704,,
2008-05-14,26.168291091918945,26.30743408203125,-0.18191496908891877,,
2008-05-13,25.438995361328125,26.101119995117188,0.531723640735843,,
2008-05-12,24.95439720153809,25.32384490966797,2.60279395622522,,
2008-05-09,24.580154418945312,24.844043731689453,1.480491414583671,,
2008-05-08,24.748083114624023,24.604143142700195,1.0735868792620207,,
2008-05-07,25.194297790527344,24.60894203186035,-0.5816206906092528,,
2008-05-06,25.707683563232425,25.22788429260254,-2.323366039148258,,
2008-05-05,25.54935073852539,25.429399490356445,-1.8663652423204071,,
2008-05-02,25.894805908203125,25.51096534729004,-0.46948843982979593,,
2008-05-01,25.22788429260254,25.7028865814209,-1.482307155627262,,
2008-04-30,25.765260696411133,25.309450149536133,1.8828463112843838,,
2008-04-29,25.58293533325196,25.659704208374023,-1.7690895979891648,,
2008-04-28,24.81525611877441,24.76247787475586,0.30007844730108524,,
2008-04-25,24.36424446105957,24.604143142700195,-0.21268466368405056,,
2008-04-24,24.244293212890625,24.201112747192383,0.9846341922239608,,
2008-04-23,24.378637313842773,24.25868797302246,-0.17810568994143022,,
2008-04-22,24.253889083862305,24.2394962310791,-0.49202643804952295,,
2008-04-21,24.253889083862305,24.244293212890625,-0.059342453218274305,,
2008-04-18,24.60894203186035,24.33545684814453,-0.03956425684351153,,
2008-04-17,24.73369026184082,24.436214447021484,-1.1113244257382071,,
2008-04-16,25.213489532470703,24.63772964477539,-1.202715048462793,,
2008-04-15,25.14151954650879,24.906417846679688,-2.2835390831317945,,
2008-04-14,25.37662124633789,25.175106048583984,-0.9351133267589163,,
2008-04-11,25.818038940429688,25.33344078063965,-0.7940978264905418,,
2008-04-10,25.933189392089844,25.86601829528809,-1.8769750905874725,,
2008-04-09,25.87081527709961,25.846826553344727,-0.25901594973984504,,
2008-04-08,26.149099349975582,25.90920066833496,-0.09272503977142618,,
2008-04-07,26.45137405395508,26.32662582397461,-0.9174261737655047,,
2008-04-04,26.153898239135746,26.312231063842773,-0.47161342063369904,,
2008-04-03,25.96197891235352,26.163494110107425,0.605389006485099,,
2008-04-02,26.532939910888672,26.05314064025879,0.7761935191235327,,
2008-04-01,26.48496055603028,26.49935340881348,-1.8083155211646231,,
2008-03-31,25.818038940429688,26.46096992492676,0.05434349336768224,,
2008-03-28,25.770057678222656,25.46298599243164,2.4902394251574154,,
2008-03-27,26.03394889831543,25.69329071044922,-1.191583230527694,,
2008-03-26,25.86121940612793,25.923593521118164,-1.308515235997309,,
2008-03-25,26.55213165283203,26.163494110107425,0.24118783422662024,,
2008-03-24,26.768041610717773,26.595314025878903,-1.4636773717682061,,
2008-03-20,26.235464096069336,26.70566749572754,-0.6452753897756629,,
2008-03-19,25.894805908203125,26.09632110595703,1.7922434988624816,,
2008-03-18,25.645309448242188,25.82283592224121,0.7782070213936956,,
2008-03-17,24.11474800109864,25.21828842163086,0.6922375975119757,,
2008-03-14,25.429399490356445,24.652124404907227,4.576205484220459,,
2008-03-13,24.589750289916992,25.213489532470703,-3.0566002384129582,,
2008-03-12,24.49858856201172,24.632932662963867,2.5365822556135296,,
2008-03-11,24.34984970092773,24.40262794494629,0.5483748609112389,,
2008-03-10,24.56096267700196,24.27787971496582,0.21674977327086906,,
2008-03-07,25.03116607666016,24.48899269104004,-1.152572746267837,,
2008-03-06,25.34783363342285,24.99278259277344,-2.1659933219238243,,
2008-03-05,25.47738075256348,25.41980361938477,-1.4007155237962878,,
2008-03-04,25.352632522583008,25.544551849365234,-0.22599314167300205,,
2008-03-03,25.60692596435547,25.53975486755371,0.756999599987391,,
2008-02-29,25.96677589416504,25.69329071044922,-0.26231612843829505,,
2008-02-28,26.03394889831543,26.01475524902344,-1.0532119383264475,,
2008-02-27,26.44657516479492,26.168291091918945,-0.07372546272928496,,
2008-02-26,26.537738800048828,26.662485122680664,-1.0522499459454338,,
2008-02-25,26.27864646911621,26.614505767822266,0.4700714087652653,,
2008-02-22,26.43218231201172,26.168291091918945,1.278069245692585,,
2008-02-21,26.72006225585937,26.32182884216309,-0.9983709138267102,,
2008-02-20,26.556930541992188,26.681678771972656,-1.4903910398223508,,
2008-02-19,27.012739181518555,26.662485122680664,0.46973888711730116,,
2008-02-15,26.523344039916992,26.652889251708984,-1.2966254791277358,,
2008-02-14,27.099103927612305,26.57132339477539,0.48841960348977775,,
2008-02-13,27.099103927612305,27.118295669555664,-1.9475940394440072,,
2008-02-12,26.873598098754883,26.844810485839844,0.07082057766420896,,
2008-02-11,27.30061912536621,27.031932830810547,-0.10712228712080375,,
2008-02-08,27.780420303344727,27.25263977050781,-0.9841765614246301,,
2008-02-07,27.679662704467773,27.87638092041016,-1.8998291857138443,,
2008-02-06,27.64607620239257,27.698854446411133,0.7106958565309183,,
2008-02-05,27.837995529174805,27.51173210144043,0.1909068166931921,,
2008-02-04,27.622085571289062,27.85239028930664,-1.1720076159666168,,
2008-02-01,27.19986152648925,27.612489700317383,0.8337701996584986,,
2008-01-31,26.49455642700196,26.95516395568848,1.517023068026593,,
2008-01-30,27.243043899536133,26.844810485839844,1.738498736355862,,
2008-01-29,27.19506454467773,26.988750457763672,-1.4617801709854816,,
2008-01-28,26.604909896850582,27.079912185668945,-0.7586453291004822,,
2008-01-25,27.49254035949707,26.619304656982425,1.785393337771057,,
2008-01-24,27.90996551513672,27.37738800048828,-3.1762641469142845,,
2008-01-23,27.468549728393555,27.81400680541992,-1.9081983973057899,,
2008-01-22,27.003143310546875,27.583702087402344,1.257645854776502,,
2008-01-18,28.807191848754883,28.514514923095703,2.1499673951984484,,
2008-01-17,29.16224479675293,28.66805076599121,-1.015985616355139,,
2008-01-16,28.44254493713379,29.02790069580078,-1.694636452735438,,
2008-01-15,28.3753719329834,28.62966537475586,2.058028773307019,,
2008-01-14,29.20062828063965,28.754413604736328,0.89617659417134,,
2008-01-11,28.634464263916016,29.02790069580078,-1.528099572429973,,
2008-01-10,28.538503646850582,28.84077835083008,1.373996133675035,,
2008-01-09,28.26021957397461,28.807191848754883,1.0591820360310213,,
2008-01-08,27.670066833496094,28.312997817993164,1.9354848724671303,,
2008-01-07,26.878395080566406,27.588499069213867,2.3235613718098,,
2008-01-04,26.4417781829834,26.768041610717773,2.6419136504205927,,
2008-01-03,26.81122398376465,26.614505767822266,1.2338936718875502,,
2008-01-02,26.94076919555664,26.777637481689453,-0.7337159096559865,,
2007-12-31,27.319812774658203,26.94076919555664,-0.6055198820904227,,
2007-12-28,27.38698387145996,27.458953857421875,-1.3874311007473759,,
2007-12-27,27.670066833496094,27.33900451660156,0.2627890179499253,,
2007-12-26,27.90036964416504,27.770824432373047,-1.1964637414383335,,
2007-12-24,27.89557266235352,27.99633026123047,-0.4643136038847597,,
2007-12-21,28.13547134399414,27.9531478881836,0.36119566390163066,,
2007-12-20,27.602893829345703,27.6364803314209,-0.6480199090372053,,
2007-12-19,27.62688446044922,27.458953857421875,0.12167746716283859,,
2007-12-18,27.46375274658203,27.679662704467773,-0.6078521205232317,,
2007-12-17,27.564510345458984,27.23824691772461,0.7861633472964215,,
2007-12-14,27.83319854736328,27.593297958374023,-1.183635855110062,,
2007-12-13,27.76602554321289,28.010723114013672,-0.8619224577477973,,
2007-12-12,28.068300247192383,27.88117790222168,0.8812841089552154,,
2007-12-11,28.245826721191406,27.87158203125,-0.6666678898356896,,
2007-12-10,27.95794677734375,28.26021957397461,-1.3249556957050561,,
2007-12-07,27.89557266235352,27.933956146240234,1.0811695116173976,,
2007-12-06,27.89557266235352,27.90036964416504,0.13759704577965393,,
2007-12-05,27.80441093444824,27.905168533325195,0.01719621199242722,,
2007-12-04,27.137487411499023,27.588499069213867,0.3623799084055515,,
2007-12-03,27.51652908325196,27.35339736938477,1.661950684217492,,
2007-11-30,27.83319854736328,27.593297958374023,-0.592849895325213,,
2007-11-29,27.089508056640625,27.34860038757324,-0.8619224577477973,,
2007-11-28,26.90238571166992,27.070316314697266,0.9564305501262164,,
2007-11-27,26.101119995117188,26.825618743896484,0.6242219735720357,,
2007-11-26,26.57132339477539,26.02915000915528,2.7757381634000033,,
2007-11-23,26.48496055603028,26.624101638793945,-2.040445549380184,,
2007-11-21,26.393798828125,26.25945472717285,0.5253588445763577,,
2007-11-20,26.398595809936523,26.66728401184082,-0.5089987304479738,,
2007-11-19,26.32182884216309,26.302635192871094,1.0178124769922865,,
2007-11-16,26.302635192871094,26.4897575378418,-0.07291913266015461,,
2007-11-15,26.00515937805176,26.139503479003903,0.7114205234516698,,
2007-11-14,26.614505767822266,26.057937622070312,0.5166055666073985,,
2007-11-13,26.398595809936523,26.4417781829834,-2.0912210454227584,,
2007-11-12,25.96677589416504,26.23066520690918,0.16357829544335462,,
2007-11-09,25.58293533325196,25.96677589416504,1.016257520069863,,
2007-11-08,25.81324005126953,25.87081527709961,1.5003773254047745,,
2007-11-07,25.72687530517578,25.789249420166016,0.22304532757501122,,
2007-11-06,25.93798828125,26.07233238220215,0.24244730170432252,,
2007-11-05,26.149099349975582,25.91879653930664,0.5179434098567421,,
2007-11-02,26.70566749572754,25.933189392089844,-0.8807294185799819,,
2007-11-01,26.17788887023925,25.96677589416504,-2.8925624261639555,,
2007-10-31,26.2210693359375,26.206676483154297,-0.8064553147149264,,
2007-10-30,26.02915000915528,26.2210693359375,-0.054890411213996085,,
2007-10-29,25.971574783325195,26.125110626220703,0.7373246022813473,,
2007-10-26,26.03874588012696,25.942785263061523,0.5911687842436264,,
2007-10-25,25.36702537536621,25.846826553344727,-0.36853010320545015,,
2007-10-24,24.95439720153809,25.362228393554688,1.8914365041966967,,
2007-10-23,24.35944557189941,24.86323547363281,1.6343059250153353,,
2007-10-22,24.42181968688965,24.77687263488769,2.0681501155123203,,
2007-10-19,24.728891372680664,24.661720275878903,1.4538349416634428,,
2007-10-18,24.613740921020508,24.7912654876709,-0.2716300370665581,,
2007-10-17,24.99757957458496,24.56575965881348,0.7212417129928509,,
2007-10-16,25.00237846374512,24.935205459594727,-1.7274469093420235,,
2007-10-15,25.290258407592773,24.911216735839844,-0.2686664560645655,,
2007-10-12,25.56854248046875,25.25667190551757,-1.498765515338237,,
2007-10-11,25.57333946228028,25.602127075195312,-1.2197432653402518,,
2007-10-10,26.46096992492676,26.02435111999512,0.11256884521277563,,
2007-10-09,26.398595809936523,26.32182884216309,-1.650048377555265,,
2007-10-08,26.42738342285156,26.360212326049805,-0.2907994361750809,,
2007-10-05,26.820819854736328,26.388999938964844,-0.2541723322622697,,
2007-10-04,26.74405288696289,26.64809226989746,-1.6100175837661004,,
2007-10-03,26.40339469909668,26.643293380737305,-0.35881105033339306,,
2007-10-02,26.43697929382324,26.609708786010746,0.9085902944473746,,
2007-10-01,25.698087692260746,26.4897575378418,0.6533631935319621,,
2007-09-28,25.86601829528809,25.72687530517578,3.0806566428655877,,
2007-09-27,26.05314064025879,25.933189392089844,-0.5379374147340465,,
2007-09-26,26.02915000915528,25.90920066833496,-0.4604099360811412,,
2007-09-25,25.789249420166016,26.077129364013672,-0.46082696045829236,,
2007-09-24,26.00995826721192,25.84202766418457,1.1162788771298915,,
2007-09-21,26.04354476928711,26.120311737060547,-0.645639648099873,,
2007-09-20,25.80364418029785,25.760461807250977,0.29476389813097953,,
2007-09-19,25.81324005126953,25.885210037231445,-0.16734990121994678,,
2007-09-18,25.107934951782227,25.7172794342041,0.2788103539848903,,
2007-09-17,24.906417846679688,24.944801330566406,2.426900036152205,,
2007-09-14,24.920812606811523,24.99757957458496,0.15411081642892982,,
2007-09-13,25.285459518432617,25.0263671875,0.3080435978739114,,
2007-09-12,24.911216735839844,25.069549560546875,-1.0246692599900897,,
2007-09-11,24.901620864868164,24.930408477783203,0.6355884836377235,,
2007-09-10,24.944801330566406,24.79606437683105,0.11560537794410547,,
2007-09-07,25.01677131652832,24.88242721557617,-0.5962643348580152,,
2007-09-06,24.925609588623047,25.381420135498047,-0.5370161450985973,,
2007-09-05,24.589750289916992,24.81525611877441,1.8286836486560734,,
2007-09-04,24.86323547363281,24.748083114624023,0.9170724639277317,,
2007-08-31,24.709699630737305,24.906417846679688,-0.46314309789207986,,
2007-08-30,24.748083114624023,24.661720275878903,0.7961173906690383,,
2007-08-29,24.397829055786133,24.70490264892578,-0.34896779013194607,,
2007-08-28,24.84884262084961,24.369041442871094,1.2586103150305643,,
2007-08-27,25.10313606262207,24.95439720153809,-1.9308793785668503,,
2007-08-24,25.069549560546875,25.203893661499023,-0.5925110739667669,,
2007-08-23,25.1990966796875,25.0263671875,0.53588557954616,,
2007-08-22,25.184701919555664,25.01677131652832,-0.6854590638034016,,
2007-08-21,24.901620864868164,25.12232780456543,-0.6667960715347889,,
2007-08-20,25.26626777648925,25.136722564697266,0.8863155571075478,,
2007-08-17,25.52056121826172,25.299854278564453,-0.5127200144396847,,
2007-08-16,25.069549560546875,24.88242721557617,-0.86482008686915,,
2007-08-15,25.127126693725582,25.117530822753903,-0.74641287239237,,
2007-08-14,25.981170654296875,25.175106048583984,-0.03818928876605634,,
2007-08-13,26.4897575378418,25.856422424316406,-3.1024953280139447,,
2007-08-10,26.33142471313477,26.49455642700196,-2.390867914214189,,
2007-08-09,27.305418014526367,26.35541343688965,0.6195324242589004,,
2007-08-08,26.868799209594727,27.012739181518555,-3.4791797625340153,,
2007-08-07,26.225868225097656,26.05314064025879,0.5357141969799224,,
2007-08-06,25.00717544555664,25.48697662353516,-0.6586153158261132,,
2007-08-03,24.5417709350586,24.51298141479492,1.918654024014423,,
2007-08-02,24.5561637878418,24.57055854797364,-0.1173082429131302,,
2007-08-01,24.215505599975582,24.445810317993164,0.05861974311706862,,
2007-07-31,24.613740921020508,24.32106208801269,0.9510630164906154,,
2007-07-30,24.685710906982425,24.38343620300293,-1.1890871604887328,,
2007-07-27,24.51778030395508,24.00439453125,-1.2244926026983345,,
2007-07-26,24.89202308654785,24.51298141479492,-2.0939325107757205,,
2007-07-25,25.314247131347656,25.09354019165039,-1.522743532878109,,
2007-07-24,25.525360107421875,25.194297790527344,-0.8718684721377918,,
2007-07-23,25.59733009338379,25.87081527709961,-1.2969937172336699,,
2007-07-20,26.05314064025879,25.36702537536621,1.0684129271220704,,
2007-07-19,26.21147346496582,26.06273651123047,-2.6335222857253298,,
2007-07-18,25.90920066833496,25.765260696411133,-0.5674497999288477,,
2007-07-17,25.669300079345703,25.61652183532715,-0.5555554328611341,,
2007-07-16,25.54935073852539,25.698087692260746,-0.20560842662407328,,
2007-07-13,25.69329071044922,25.544551849365234,0.5821555125120164,,
2007-07-12,24.901620864868164,25.79404830932617,-0.5789015613461054,,
2007-07-11,25.36702537536621,25.5301570892334,3.5838126734836906,,
2007-07-10,25.611724853515625,25.391016006469727,0.6430857045840459,,
2007-07-09,25.90920066833496,25.770057678222656,-0.8617492508147204,,
2007-07-06,26.067533493041992,25.90920066833496,-0.5370408446539182,,
2007-07-05,26.120311737060547,26.0195541381836,-0.6073947301124359,,
2007-07-03,26.077129364013672,26.06273651123047,-0.38574424337358537,,
2007-07-02,25.904401779174805,26.06273651123047,-0.055193394112870414,,
2007-06-29,25.760461807250977,25.69329071044922,0.6112271319963595,,
2007-06-28,25.894805908203125,25.77485656738281,-0.2607526887691536,,
2007-06-27,25.755664825439453,25.894805908203125,-0.46321776361458544,,
2007-06-26,26.6289005279541,25.894805908203125,0.5402348714611284,,
2007-06-25,25.53975486755371,25.933189392089844,-2.7567590294625544,,
2007-06-22,25.760461807250977,25.362228393554688,1.5404788596305639,,
2007-06-21,25.99556350708008,25.81324005126953,-1.5459094509873867,,
2007-06-20,26.35541343688965,26.04354476928711,-0.701363737550422,,
2007-06-19,26.081928253173828,26.235464096069336,-1.1833192006239475,,
2007-06-18,26.25465583801269,26.168291091918945,0.5886675302728989,,
2007-06-15,26.134706497192383,26.25465583801269,-0.3289502122084709,,
2007-06-14,26.00515937805176,26.000362396240234,0.4589657084275844,,
2007-06-13,25.789249420166016,26.000362396240234,-0.018446269610543596,,
2007-06-12,25.755664825439453,25.59253120422364,0.8186084543784281,,
2007-06-11,25.96197891235352,25.93798828125,-0.6333892847319649,,
2007-06-08,25.90920066833496,26.04834175109864,-0.09240678911461439,,
2007-06-07,26.1730899810791,25.89960479736328,0.5370334829886545,,
2007-06-06,26.45137405395508,26.26425170898437,-1.0449098058866058,,
2007-06-05,26.768041610717773,26.624101638793945,-0.7074201309505552,,
2007-06-04,26.63849639892578,26.68647575378418,-0.537730679057953,,
2007-06-01,27.03672981262207,27.012739181518555,0.18011284923849247,,
2007-05-31,26.80162811279297,27.03672981262207,-0.08873347949172324,,
2007-05-30,27.156679153442383,26.79203224182129,0.8771918587919019,,
2007-05-29,26.95036506652832,27.1806697845459,-1.3427522178273077,,
2007-05-25,26.42258644104004,27.04632568359375,0.854551385293147,,
2007-05-24,27.415771484375,27.089508056640625,2.360629016941763,,
2007-05-23,27.684459686279297,27.449357986450195,-1.19005743799813,,
2007-05-22,28.015522003173828,27.679662704467773,-0.8492190293517644,,
2007-05-21,28.42815017700196,28.130674362182617,-1.1988329136541014,,
2007-05-18,28.298603057861328,28.514514923095703,-1.046412844195531,,
2007-05-17,28.30820083618164,28.26021957397461,0.7629771151349991,,
2007-05-16,28.30820083618164,28.351381301879883,-0.16949597922063922,,
2007-05-15,28.001127243041992,28.1546630859375,0.15253694838511891,,
2007-05-14,27.75642967224121,27.80441093444824,0.5483202214070149,,
2007-05-11,27.51652908325196,27.751632690429688,0.17286539649951102,,
2007-05-10,28.1546630859375,27.50693321228028,0.8544086591241771,,
2007-05-09,28.11627960205078,28.1546630859375,-2.300613122878189,,
2007-05-08,28.25542259216309,28.23143196105957,0.13651693762470296,,
2007-05-07,28.21703720092773,28.284210205078125,-0.08490629020063994,,
2007-05-04,27.60769271850586,27.97233963012696,0.23805831800152866,,
2007-05-03,27.52132797241211,27.545318603515625,1.3208163222443883,,
2007-05-02,27.38218688964844,27.43976211547852,0.08717105194765412,,
2007-05-01,27.137487411499023,27.35339736938477,0.2102652577097261,,
2007-04-30,27.315013885498047,27.16627693176269,0.7956151378784528,,
2007-04-27,27.156679153442383,27.233448028564453,-0.5445245400893676,,
2007-04-26,26.868799209594727,27.305418014526367,0.28268874367261904,,
2007-04-25,27.468549728393555,27.61728858947754,1.6250030435886618,,
2007-04-24,27.38698387145996,27.43016624450684,0.5414878563109458,,
2007-04-23,27.588499069213867,27.449357986450195,0.15767480365692627,,
2007-04-20,27.79481315612793,27.75642967224121,-0.5043445183973058,,
2007-04-19,27.72764205932617,27.46375274658203,-0.13809585144937855,,
2007-04-18,27.49254035949707,27.84279441833496,-0.9517192705370277,,
2007-04-17,28.140270233154297,28.30820083618164,1.273996706953631,,
2007-04-16,28.20744132995605,28.25062370300293,0.596762581297074,,
2007-04-13,27.559711456298828,28.063501358032227,0.15308858588680022,,
2007-04-12,27.25263977050781,27.545318603515625,1.8279941084733533,,
2007-04-11,27.228649139404297,27.34860038757324,1.0739467276287358,,
2007-04-10,27.449357986450195,27.37738800048828,0.4405332323128463,,
2007-04-09,27.372589111328125,27.449357986450195,-0.2621918734763871,,
2007-04-05,27.04632568359375,27.35819625854492,0.2804589467581624,,
2007-04-04,27.16147804260254,27.00794219970703,1.1530977575277384,,
2007-04-03,26.873598098754883,27.19026565551757,-0.5652705742106089,,
2007-04-02,26.77284049987793,26.777637481689453,1.1783593532916612,,
2007-03-30,26.6289005279541,26.77284049987793,0.01791734355398453,,
2007-03-29,26.398595809936523,26.777637481689453,0.5405404243886258,,
2007-03-28,26.98395156860352,26.75364875793457,1.4358402790888487,,
2007-03-27,27.25263977050781,27.156679153442383,-0.8534806701065671,,
2007-03-26,26.42738342285156,27.46375274658203,-0.35211494326238646,,
2007-03-23,26.21147346496582,25.84202766418457,3.921573722029293,,
2007-03-22,25.94758415222168,26.149099349975582,-1.4094812383403403,,
2007-03-21,26.05314064025879,26.235464096069336,0.7766241225838691,,
2007-03-20,25.544551849365234,26.139503479003903,0.699813731972146,,
2007-03-19,25.438995361328125,25.515764236450195,2.329074446665043,,
2007-03-16,25.640512466430664,25.371824264526367,0.30177636353821147,,
2007-03-15,25.750865936279297,25.731674194335938,-1.0479049599966912,,
2007-03-14,26.00515937805176,25.79884529113769,-0.0745285303835975,,
2007-03-13,25.90920066833496,25.96197891235352,-0.7933582867721155,,
2007-03-12,26.120311737060547,26.091524124145508,0.20370464027113502,,
2007-03-09,25.885210037231445,26.09632110595703,-0.1102115977972577,,
2007-03-08,25.280662536621094,25.621320724487305,0.8155663733148728,,
2007-03-07,25.26147079467773,25.280662536621094,1.3475049847793343,,
2007-03-06,25.429399490356445,25.36702537536621,0.07597238537435588,,
2007-03-05,25.33344078063965,25.309450149536133,-0.24528347597782804,,
2007-03-02,25.68369483947754,25.4341983795166,-0.0946994579664432,,
2007-03-01,25.789249420166016,25.80364418029785,-0.9714196556230879,,
2007-02-28,25.7028865814209,26.206676483154297,0.05581690221887533,,
2007-02-27,25.94758415222168,25.83243179321289,1.9600518414050756,,
2007-02-26,25.741270065307617,26.134706497192383,-0.44378836323739024,,
2007-02-23,25.58293533325196,25.71248245239257,1.5284266506143116,,
2007-02-22,25.290258407592773,25.72687530517578,0.5063809819048761,,
2007-02-21,25.18950080871582,25.290258407592773,1.7264232359599947,,
2007-02-20,25.184701919555664,25.22788429260254,0.39999839473631005,,
2007-02-16,25.203893661499023,25.184701919555664,0.17146271250224457,,
2007-02-15,25.22788429260254,25.33344078063965,-0.0761459407864282,,
2007-02-14,25.285459518432617,25.285459518432617,0.418411971502744,,
2007-02-13,25.25667190551757,25.290258407592773,0.0,,
2007-02-12,25.11273193359375,25.295055389404297,0.13298071179308907,,
2007-02-09,25.117530822753903,25.079145431518555,0.7260199977153801,,
2007-02-08,25.14151954650879,25.01677131652832,-0.1528231079170202,,
2007-02-07,25.18950080871582,25.165510177612305,-0.49618412980050597,,
2007-02-06,25.285459518432617,25.170307159423828,-0.09524059760332616,,
2007-02-05,25.14151954650879,25.18950080871582,-0.4554093981358938,,
2007-02-02,25.213489532470703,25.27106666564941,0.1908447185074541,,
2007-02-01,25.18950080871582,25.36702537536621,0.2283584471897783,,
2007-01-31,25.309450149536133,25.429399490356445,0.704756191869294,,
2007-01-30,25.309450149536133,25.52056121826172,0.47393104200847647,,
2007-01-29,24.906417846679688,25.26626777648925,0.8341195382684168,,
2007-01-26,25.285459518432617,25.213489532470703,1.444808049173299,,
2007-01-25,25.47738075256348,25.232681274414062,-0.28462993092709793,,
2007-01-24,25.611724853515625,25.69329071044922,-0.9604577508415831,,
2007-01-23,25.47738075256348,25.611724853515625,0.318470768369189,,
2007-01-22,25.525360107421875,25.58293533325196,0.5273073486513227,,
2007-01-19,25.59253120422364,25.678895950317383,0.22556087588101992,,
2007-01-18,24.94960021972656,25.32864189147949,0.33746074354493616,,
2007-01-17,24.29707145690918,24.73369026184082,1.519229440210581,,
2007-01-16,24.234697341918945,24.282678604125977,1.7970017732630184,,
2007-01-12,24.02358627319336,24.205909729003903,0.19798581154152764,,
2007-01-11,24.201112747192383,24.157930374145508,0.7589352136570399,,
2007-01-10,24.09555625915528,24.177122116088867,-0.17843135354131462,,
2007-01-09,24.06196975708008,24.2394962310791,0.33850995617748025,,
2007-01-08,23.903636932373047,24.028383255004883,0.7377886174376221,,
2007-01-05,23.94202041625977,23.94202041625977,0.5218717259836313,,
2007-01-04,23.53898811340332,23.94202041625977,0.0,,
2007-01-03,23.428634643554688,23.495805740356445,1.712190434502826,,
2006-12-29,23.41423988342285,23.371057510375977,0.2867051273951931,,
2006-12-28,23.390249252319336,23.47661399841309,-0.18442782367429264,,
2006-12-27,23.270299911499023,23.51020050048828,0.36923397079742437,,
2006-12-26,22.891258239746094,23.14075469970703,1.0309303700495536,,
2006-12-22,23.0447940826416,22.900854110717773,1.0899202540458732,,
2006-12-21,22.963228225708008,23.03039932250977,-0.6246094949151676,,
2006-12-20,23.08797645568848,23.006410598754883,0.2925159134487953,,
2006-12-19,23.12156105041504,23.155147552490234,-0.3532828313912321,,
2006-12-18,23.1743392944336,23.0927734375,0.14526052977981097,,
2006-12-15,23.0783805847168,23.255905151367188,-0.35196626707365375,,
2006-12-14,23.08797645568848,23.0783805847168,0.7692245389520493,,
2006-12-13,23.03039932250977,23.011207580566406,-0.04156220009188129,,
2006-12-12,23.006410598754883,23.02560234069824,-0.08333221528037092,,
2006-12-11,22.982419967651367,22.94403648376465,0.08341910556179714,,
2006-12-08,23.12156105041504,23.011207580566406,-0.16701236832650768,,
2006-12-07,23.18393516540528,23.049591064453125,-0.4772751701669898,,
2006-12-06,23.30388641357422,23.03519821166992,-0.5794706549758722,,
2006-12-05,23.126359939575195,23.16954231262207,-1.1529759334382652,,
2006-12-04,23.03039932250977,23.0783805847168,0.18672360526992735,,
2006-12-01,22.502620697021484,22.34428596496582,0.20833882007479854,,
2006-11-30,22.512216567993164,22.38746833801269,-0.7036279648824268,,
2006-11-29,22.358680725097656,22.44024658203125,-0.5541357049568971,,
2006-11-28,22.253124237060547,22.262720108032227,0.3648062152523871,,
2006-11-27,22.4018611907959,22.25792121887207,0.04312145507954627,,
2006-11-24,22.5889835357666,22.526609420776367,-0.6425357727998411,,
2006-11-22,22.73292350769043,22.814489364624023,-0.2761262581446987,,
2006-11-21,22.886459350585938,22.785701751708984,0.35880056036787544,,
2006-11-20,22.766510009765625,22.91524887084961,-0.44024983215402225,,
2006-11-17,22.69454002380371,22.87206649780273,0.6533230654157501,,
2006-11-16,22.74251937866211,22.785701751708984,0.7822431025824581,,
2006-11-15,22.358680725097656,22.545801162719727,0.1898750632148096,,
2006-11-14,21.835697174072266,22.15716361999512,0.8369028563122121,,
2006-11-13,21.99883079528809,21.902870178222656,1.4722060090875633,,
2006-11-10,21.95084953308105,22.056406021118164,-0.4362078055802264,,
2006-11-09,22.689741134643555,21.99403190612793,0.4808765504862758,,
2006-11-08,22.79050064086914,22.68494415283203,-3.066184071414503,,
2006-11-07,22.718530654907227,22.963228225708008,-0.46316002311866655,,
2006-11-06,22.56019592285156,22.776105880737305,1.0770836130105372,,
2006-11-03,22.747318267822266,22.8576717376709,0.9570393742327713,,
2006-11-02,22.766510009765625,22.77130889892578,0.4851273831462402,,
2006-11-01,22.646560668945312,22.75211524963379,0.021078721148290982,,
2006-10-31,22.79050064086914,22.795297622680664,0.4660954139196114,,
2006-10-30,22.814489364624023,22.59378242492676,0.021048163386640284,,
2006-10-27,22.766510009765625,22.87206649780273,-0.9673981134089663,,
2006-10-26,23.16474342346192,22.97762107849121,0.46364808656147866,,
2006-10-25,23.01600646972656,23.16474342346192,-0.8077894132044964,,
2006-10-24,23.279895782470703,23.08797645568848,0.6462326726011269,,
2006-10-23,23.270299911499023,23.428634643554688,-0.8243994241878627,,
2006-10-20,23.10236930847168,23.40464401245117,0.6804155196015454,,
2006-10-19,23.0447940826416,22.992015838623047,1.3084143013359413,,
2006-10-18,22.86247062683105,22.95842933654785,-0.2290245850289879,,
2006-10-17,22.63216590881348,22.64176177978516,0.4197215221533614,,
2006-10-16,22.454639434814453,22.63216590881348,0.04239926046116,,
2006-10-13,22.358680725097656,22.517013549804688,0.7906004214157355,,
2006-10-12,22.454639434814453,22.286710739135746,0.7081492269322599,,
2006-10-11,22.190750122070312,22.296306610107425,-0.7478574579930458,,
2006-10-10,22.502620697021484,22.33469009399414,0.47567787234073416,,
2006-10-09,22.25792121887207,22.40666007995605,-0.7462713134100489,,
2006-10-06,22.214740753173828,22.16196250915528,0.668251359241347,,
2006-10-05,22.61777114868164,22.23872947692871,-0.2375820839187922,,
2006-10-04,22.766510009765625,22.61777114868164,-1.675857754777148,,
2006-10-03,22.910449981689453,22.84327888488769,-0.6533230654157501,,
2006-10-02,22.910449981689453,23.145551681518555,-0.29318977521369516,,
2006-09-29,23.10236930847168,23.299087524414062,1.0261767010992806,,
2006-09-28,23.246309280395508,23.18873405456543,0.851506671526742,,
2006-09-27,23.06398582458496,23.20792579650879,-0.2476746959511267,,
2006-09-26,23.05918884277344,23.06398582458496,0.6240897519560383,,
2006-09-25,23.16474342346192,23.006410598754883,0.02080290787428639,,
2006-09-22,23.03519821166992,22.982419967651367,-0.6835077851398703,,
2006-09-21,23.270299911499023,23.126359939575195,-0.22911999077921116,,
2006-09-20,23.678129196166992,23.29429054260254,-0.6185565827310209,,
2006-09-19,23.231916427612305,23.58696746826172,-1.621068330122081,,
2006-09-18,23.60615921020508,23.45262336730957,1.5282899357687858,,
2006-09-15,23.65414047241211,23.740503311157227,-0.6504058603024965,,
2006-09-14,23.49100875854492,23.582170486450195,0.365106645265096,,
2006-09-13,23.41423988342285,23.5965633392334,0.3880707246006056,,
2006-09-12,23.270299911499023,23.41423988342285,0.7786862042855845,,
2006-09-11,23.347068786621094,23.33747291564941,0.6185565827310209,,
2006-09-08,22.982419967651367,23.46221923828125,-0.04110096671828071,,
2006-09-07,22.886459350585938,22.982419967651367,2.0876795015721523,,
2006-09-06,23.126359939575195,22.996814727783203,0.419289919840628,,
2006-09-05,23.30388641357422,23.19832992553711,-0.5601625683007154,,
2006-09-01,23.41423988342285,23.20792579650879,-0.45295658485369233,,
2006-08-31,23.18873405456543,23.366260528564453,-0.8811479165724773,,
2006-08-30,23.46221923828125,23.11676406860352,0.7655720816034448,,
2006-08-29,23.41423988342285,23.49100875854492,-1.472389146863319,,
2006-08-28,23.505401611328125,23.49100875854492,0.3278725916548702,,
2006-08-25,23.289491653442383,23.409442901611328,-0.06123210750107,,
2006-08-24,23.428634643554688,23.42383575439453,0.5150445100042169,,
2006-08-23,23.5006046295166,23.51020050048828,-0.020483008221208673,,
2006-08-22,23.270299911499023,23.48141288757324,0.04083244292203163,,
2006-08-21,23.3278751373291,23.351865768432617,0.9072206928020453,,
2006-08-18,23.57257461547852,23.51020050048828,0.10284104729764258,,
2006-08-17,23.55338287353516,23.57257461547852,-0.26460459244566803,,
2006-08-16,23.51020050048828,23.64454460144043,0.0814818917792205,,
2006-08-15,23.19832992553711,23.347068786621094,0.5714289886611484,,
2006-08-14,22.747318267822266,23.011207580566406,0.6411619351971116,,
2006-08-11,22.79050064086914,22.747318267822266,1.1600897725048813,,
2006-08-10,22.58418655395508,22.896055221557617,-0.18947531573500437,,
2006-08-09,22.910449981689453,22.70413589477539,1.3809160974536812,,
2006-08-08,22.776105880737305,22.87206649780273,-0.9005239402934179,,
2006-08-07,22.665752410888672,22.71373176574707,0.42132143909018266,,
2006-08-04,22.83847999572754,22.665752410888672,0.21168216253588415,,
2006-08-03,22.6225700378418,22.656156539916992,-0.7563007033356853,,
2006-08-02,22.69454002380371,22.6225700378418,0.1484645732956516,,
2006-08-01,22.766510009765625,22.795297622680664,-0.3171246735400809,,
2006-07-31,22.886459350585938,22.920045852661133,0.12644719327947368,,
2006-07-28,22.814489364624023,22.94403648376465,0.14675272203839357,,
2006-07-27,22.550600051879883,22.656156539916992,0.5678282650564154,,
2006-07-26,22.79050064086914,22.59857940673828,0.4680872694929015,,
2006-07-25,22.814489364624023,23.06878471374512,-0.8421106545886754,,
2006-07-24,22.02281951904297,22.81928825378418,1.1146221379620522,,
2006-07-21,22.23872947692871,22.47383117675781,3.616561149459134,,
2006-07-20,22.051607131958008,22.17155838012696,1.0571723536319881,,
2006-07-19,21.447059631347656,22.20514488220215,0.5439569435967079,,
2006-07-18,21.35110092163086,21.447059631347656,3.5346815082588403,,
2006-07-17,21.06321907043457,21.341503143310547,0.44943213967754164,,
2006-07-14,21.048826217651367,21.115997314453125,1.3211849145441903,,
2006-07-13,21.06321907043457,21.106401443481445,0.31912039230685796,,
2006-07-12,21.35110092163086,21.16397857666016,0.20501316965120506,,
2006-07-11,20.981653213500977,21.3798885345459,-0.8764060722560933,,
2006-07-10,21.17837142944336,20.94326972961425,1.8980168864323383,,
2006-07-07,21.06321907043457,21.01523971557617,-1.110102826425346,,
2006-07-06,20.967260360717773,21.00564384460449,-0.2277873799724578,,
2006-07-05,20.823320388793945,20.9240779876709,0.18306389688672334,,
2006-07-03,20.962461471557617,20.909683227539062,0.48386903239108664,,
2006-06-30,20.63139915466309,20.9240779876709,-0.25177503171641125,,
2006-06-29,20.338722229003903,20.583419799804688,1.418608746860767,,
2006-06-28,20.113216400146484,20.24276161193848,1.203111818164444,,
2006-06-27,20.1995792388916,19.978872299194336,0.6440800377957067,,
2006-06-26,20.103620529174805,20.16599464416504,-1.092631371609582,,
2006-06-23,20.03165054321289,20.127609252929688,0.310263093653781,,
2006-06-22,20.281145095825195,20.17079162597656,0.47903546195452945,,
2006-06-21,20.27154922485352,20.281145095825195,-0.5441185363411865,,
2006-06-20,20.24756050109864,20.257156372070312,0.04733664341702761,,
2006-06-19,20.612207412719727,20.30513572692871,0.04739272650229595,,
2006-06-16,20.497055053710938,20.52584457397461,-1.4897564324019108,,
2006-06-15,20.434682846069336,20.66018867492676,0.14045686167223134,,
2006-06-14,20.24756050109864,20.48745918273925,1.1035445499992287,,
2006-06-13,20.497055053710938,20.367509841918945,1.1848275826986359,,
2006-06-12,20.63139915466309,20.497055053710938,-0.632018655619205,,
2006-06-09,20.736955642700195,20.63139915466309,-0.6511633066911395,,
2006-06-08,20.39150047302246,20.712966918945312,-0.5090259624211702,,
2006-06-07,20.38190460205078,20.578622817993164,1.5764727384732926,,
2006-06-06,20.3723087310791,20.26195335388184,0.9651611063010738,,
2006-06-05,20.63139915466309,20.3723087310791,-0.5416930336860091,,
2006-06-02,20.67938041687012,20.69377326965332,-1.2558063640847574,,
2006-06-01,20.511449813842773,20.736955642700195,0.06960001940608417,,
2006-05-31,20.4202880859375,20.48745918273925,1.0994143802805807,,
2006-05-30,20.39150047302246,20.41069221496582,0.32894294399307866,,
2006-05-26,20.46347045898437,20.47306632995605,0.09411637936477336,,
2006-05-25,20.34351921081543,20.39150047302246,0.04689268612043601,,
2006-05-24,19.959680557250977,20.22356986999512,0.23585527022051567,,
2006-05-23,20.055639266967773,20.02685165405273,1.3221119044827505,,
2006-05-22,20.055639266967773,20.03165054321289,-0.14353874504741745,,
2006-05-19,20.27154922485352,20.065235137939453,-0.11961086572988448,,
2006-05-18,19.95488166809082,20.132408142089844,-1.017751946955879,,
2006-05-17,20.63139915466309,20.07003402709961,0.8896393221058285,,
2006-05-16,20.497055053710938,20.4682674407959,-2.7209261153604354,,
2006-05-15,19.99326515197754,20.29553985595703,-0.14044755619577232,,
2006-05-12,20.151599884033203,19.873315811157227,1.5118826348861487,,
2006-05-11,20.00765991210937,20.161195755004883,-1.380952750538038,,
2006-05-10,20.27154922485352,20.05084228515625,0.7673853092764028,,
2006-05-09,20.29553985595703,20.27154922485352,-1.088752207584983,,
2006-05-08,20.300338745117188,20.377105712890625,-0.1182064200990962,,
2006-05-05,20.151599884033203,20.521045684814453,0.378156092552407,,
2006-05-04,20.362712860107425,20.405893325805664,1.8333323552834853,,
2006-05-03,20.1995792388916,20.27154922485352,0.21205654666394402,,
2006-05-02,20.300338745117188,20.22356986999512,0.3562944807451681,,
2006-05-01,20.511449813842773,20.30513572692871,-0.3781654882016778,,
2006-04-28,20.07962989807129,20.50665283203125,-1.0058483860795895,,
2006-04-27,19.638214111328125,20.16599464416504,2.1266474338801324,,
2006-04-26,19.863719940185547,19.724578857421875,2.6875179680033567,,
2006-04-25,19.73897171020508,19.76775932312012,-0.7004784762504669,,
2006-04-24,20.065235137939453,19.73897171020508,0.14584150247378802,,
2006-04-21,20.17559051513672,20.151599884033203,-1.626013477995435,,
2006-04-20,19.834932327270508,20.108417510986328,-0.11890918922802618,,
2006-04-19,19.75816345214844,19.834932327270508,1.3788057312391884,,
2006-04-18,19.705385208129883,19.99806404113769,0.3885425652439329,,
2006-04-17,19.854124069213867,19.734174728393555,1.485273339833306,,
2006-04-13,19.897306442260746,19.911699295043945,-0.6041532751692025,,
2006-04-12,19.887710571289062,19.978872299194336,0.07233568435489325,,
2006-04-11,20.15639877319336,19.887710571289062,0.45838221336989526,,
2006-04-10,20.20437812805176,20.23796463012696,-1.333016899137925,,
2006-04-07,20.569026947021484,20.19478225708008,0.1662337829075143,,
2006-04-06,20.4682674407959,20.569026947021484,-1.819457434254543,,
2006-04-05,20.386701583862305,20.4682674407959,0.49227178859681714,,
2006-04-04,20.607410430908203,20.434682846069336,0.4000934462010255,,
2006-04-03,20.30513572692871,20.583419799804688,-0.8381819026606091,,
2006-03-31,20.45867156982422,20.377105712890625,1.3705107743107359,,
2006-03-30,20.583419799804688,20.45867156982422,-0.3986859882627979,,
2006-03-29,20.64579391479492,20.593015670776367,-0.6060617292645047,,
2006-03-28,20.74175453186035,20.612207412719727,-0.25563678605127355,,
2006-03-27,21.39908027648925,20.852108001708984,-0.6245716529989509,,
2006-03-24,20.967260360717773,21.048826217651367,-2.5560550627085314,,
2006-03-23,21.01523971557617,21.05362319946289,0.38901532928168164,,
2006-03-22,21.10160446166992,21.1591796875,0.1826459483984523,,
2006-03-21,21.336706161499023,21.08241271972656,0.27284762130132995,,
2006-03-20,21.54302024841309,21.23114967346192,-1.1918120812448727,,
2006-03-17,21.68696022033692,21.677364349365234,-1.44766412209143,,
2006-03-16,21.614990234375,21.590999603271484,-0.04424719220302842,,
2006-03-15,21.590999603271484,21.71095085144043,-0.11099070988874456,,
2006-03-14,21.39908027648925,21.667768478393555,0.555561346732507,,
2006-03-13,21.48544311523437,21.55741310119629,1.2556063084613334,,
2006-03-10,20.722562789916992,21.072816848754883,0.33497091763905446,,
2006-03-09,20.861703872680664,20.722562789916992,1.6902062857221223,,
2006-03-08,20.847309112548828,20.861703872680664,-0.6669689283907598,,
2006-03-07,20.86650276184082,20.88569450378418,0.06904852829745378,,
2006-03-06,21.01523971557617,20.957664489746094,0.09197392664407507,,
2006-03-03,20.784936904907227,21.00564384460449,-0.27396892259763617,,
2006-03-02,21.01523971557617,20.842512130737305,1.061860041755307,,
2006-03-01,21.19756317138672,21.1112003326416,-0.8219158438190007,,
2006-02-28,21.1447868347168,21.19756317138672,-0.407418711513468,,
2006-02-27,21.03443145751953,21.327110290527344,0.24959502823299648,,
2006-02-24,20.82811737060547,21.08720970153809,1.3914273537599406,,
2006-02-23,20.991249084472656,20.83771324157715,1.243954632684543,,
2006-02-22,21.115997314453125,21.06321907043457,-0.7314278549011127,,
2006-02-21,21.23114967346192,21.106401443481445,-0.24994435845296264,,
2006-02-17,21.18317031860352,21.27433204650879,-0.5875717137278067,,
2006-02-16,21.1112003326416,21.28392791748047,0.4303497849196335,,
2006-02-15,20.890491485595703,21.18317031860352,0.818179838745598,,
2006-02-14,20.62660217285156,20.981653213500977,1.4010145869934287,,
2006-02-13,20.44907569885254,20.54983329772949,1.7213258765262405,,
2006-02-10,20.29553985595703,20.377105712890625,0.49272446520701857,,
2006-02-09,20.24756050109864,20.22356986999512,0.40189055089191433,,
2006-02-08,20.27154922485352,20.18038749694824,-0.11848652632606006,,
2006-02-07,20.24756050109864,20.20437812805176,-0.44970281695842745,,
2006-02-06,20.290742874145508,20.35311508178711,-0.21327197933072214,,
2006-02-03,20.1995792388916,20.386701583862305,0.30739243027457763,,
2006-02-02,20.53544044494629,20.35311508178711,0.9263675384407213,,
2006-02-01,20.511449813842773,20.67938041687012,-0.8878570861334968,,
2006-01-31,20.27154922485352,20.703369140625,0.8187163976776243,,
2006-01-30,20.367509841918945,20.602611541748047,2.130177180745795,,
2006-01-27,21.01523971557617,20.63139915466309,1.1542977106864196,,
2006-01-26,20.511449813842773,20.784936904907227,-1.8264867120624952,,
2006-01-25,19.79654884338379,20.2331657409668,1.3333386647290142,,
2006-01-24,19.451091766357425,19.220787048339844,2.2055202704128565,,
2006-01-23,19.431900024414062,19.43669891357422,-1.1840194924992145,,
2006-01-20,19.959680557250977,19.35993003845215,0.024695933769353327,,
2006-01-19,19.695789337158203,19.930892944335938,-3.004810207651094,,
2006-01-18,19.705385208129883,19.7773551940918,1.1936744608360854,,
2006-01-17,19.58543586730957,19.705385208129883,0.36523003839693957,,
2006-01-13,19.902103424072266,19.7629623413086,0.6124415184475024,,
2006-01-12,19.78695106506348,19.834932327270508,-0.6991275233519736,,
2006-01-11,19.94528579711914,19.878114700317383,0.2424894166324849,,
2006-01-10,20.34351921081543,20.151599884033203,-0.33677680773799634,,
2006-01-09,20.39150047302246,20.348318099975582,-0.94339295376286,,
2006-01-06,19.220787048339844,19.61902236938477,-0.2117665303934252,,
2006-01-05,19.048059463500977,19.24957656860352,2.0718991373421525,,
2006-01-04,18.89452362060547,19.0048770904541,1.0579403402676295,,
2006-01-03,18.976089477539062,18.976089477539062,0.5840500245705404,,
2005-12-30,18.937705993652344,18.918514251708984,0.0,,
2005-12-29,19.33593940734864,19.096040725708008,-0.10134142936738051,,
2005-12-28,19.47987937927246,19.35993003845215,-1.2406880089283814,,
2005-12-27,19.67180061340332,19.383920669555664,-0.6157601825191199,,
2005-12-23,19.32634353637696,19.60462760925293,-1.4634143030684754,,
2005-12-22,19.407909393310547,19.54705238342285,1.4399209677307556,,
2005-12-21,19.201595306396484,19.369525909423828,0.7169396110240706,,
2005-12-20,19.32154655456543,19.191999435424805,0.8745658907382674,,
2005-12-19,19.67180061340332,19.398313522338867,-0.6704800714310041,,
2005-12-16,18.90411949157715,19.2735652923584,-1.3902494054261283,,
2005-12-15,19.086444854736328,18.832149505615234,1.9543137195353584,,
2005-12-14,18.89452362060547,18.937705993652344,-1.3323348117289113,,
2005-12-13,18.673816680908203,18.937705993652344,0.22854438626747042,,
2005-12-12,18.61623954772949,18.79376602172852,1.4131514582872424,,
2005-12-09,18.44831085205078,18.70740127563477,0.9536108167488766,,
2005-12-08,18.23240089416504,18.37154197692871,1.404412716490987,,
2005-12-07,18.25638961791992,18.23240089416504,0.7631528265057047,,
2005-12-06,18.43871307373047,18.170026779174805,-0.1313990567517942,,
2005-12-05,18.481895446777344,18.323562622070312,-1.4571857237610575,,
2005-12-02,18.424320220947266,18.501087188720703,-0.8566914858001725,,
2005-12-01,18.01169204711914,18.054874420166016,0.4166610591481058,,
2005-11-30,18.30916786193848,18.09325790405273,0.23974634328584227,,
2005-11-29,18.678613662719727,18.30916786193848,-1.1792450618937624,,
2005-11-28,18.71220016479492,18.688209533691406,-1.9779080367116109,,
2005-11-25,18.77937126159668,18.70260429382324,-0.12820849976074958,,
2005-11-23,18.822553634643555,18.70740127563477,-0.4087834821734819,,
2005-11-22,19.16801071166992,18.86573600769043,-0.6117786207119296,,
2005-11-21,19.58543586730957,19.369525909423828,-1.5769748281466525,,
2005-11-18,19.911699295043945,19.62381935119629,-1.102400576369718,,
2005-11-17,19.47028350830078,19.60462760925293,-1.4457829017100015,,
2005-11-16,19.71977996826172,19.47028350830078,0.6899956073822624,,
2005-11-15,19.78215408325196,19.897306442260746,-1.2652091471735138,,
2005-11-14,20.900087356567383,19.441495895385746,0.5821022246827823,,
2005-11-11,20.823320388793945,20.981653213500977,-6.978877342937552,,
2005-11-10,20.54983329772949,20.53544044494629,0.7603630052786295,,
2005-11-09,20.348318099975582,20.48745918273925,-0.07003878121381067,,
2005-11-08,20.29553985595703,20.40109634399414,0.6837964792964156,,
2005-11-07,20.425085067749023,20.415489196777344,0.520096970991028,,
2005-11-04,20.607410430908203,20.425085067749023,-0.04698081275965631,,
2005-11-03,20.42988395690918,20.530641555786133,-0.8847563053614801,,
2005-11-02,20.357913970947266,20.45867156982422,0.49318732837382534,,
2005-11-01,20.607410430908203,20.52584457397461,0.49493086089637706,,
2005-10-31,20.823320388793945,20.6553897857666,-0.39580837780207695,,
2005-10-28,20.362712860107425,20.511449813842773,-0.806454493768993,,
2005-10-27,20.63619804382324,20.362712860107425,0.7304378093291216,,
2005-10-26,20.83771324157715,20.63619804382324,-1.325269233872622,,
2005-10-25,20.621803283691406,20.765743255615234,-0.9670696367575969,,
2005-10-24,20.64579391479492,20.583419799804688,0.6979989574319233,,
2005-10-21,20.852108001708984,20.511449813842773,-0.30211536183906734,,
2005-10-20,20.991249084472656,20.756147384643555,-1.6336870489942381,,
2005-10-19,20.27154922485352,21.08720970153809,-1.1199986188673623,,
2005-10-18,20.29553985595703,20.34351921081543,4.0236711444064,,
2005-10-17,20.34351921081543,20.415489196777344,0.23640344232733387,,
2005-10-14,20.30513572692871,20.45867156982422,0.35377352962437264,,
2005-10-13,20.065235137939453,20.425085067749023,0.7561429037476872,,
2005-10-12,20.17559051513672,20.1995792388916,1.7934000141825608,,
2005-10-11,20.18038749694824,20.35311508178711,0.11889973548424912,,
2005-10-10,20.45867156982422,20.23796463012696,0.8559180782083166,,
2005-10-07,20.6409969329834,20.48745918273925,-1.0787940895575696,,
2005-10-06,20.63139915466309,20.6409969329834,-0.7438485202175541,,
2005-10-05,21.125593185424805,20.765743255615234,0.04652024929748725,,
2005-10-04,20.63139915466309,21.115997314453125,-1.7033837897524309,,
2005-10-03,20.34351921081543,20.38190460205078,2.348838080041251,,
2005-09-30,20.127609252929688,20.34351921081543,0.18868609131769273,,
2005-09-29,20.103620529174805,20.19478225708008,1.072705432486053,,
2005-09-28,20.63139915466309,20.122812271118164,0.45345925512760815,,
2005-09-27,20.583419799804688,20.501853942871094,-2.4651109686372146,,
2005-09-26,20.85690689086914,20.4682674407959,-0.3962697050679971,,
2005-09-23,21.10160446166992,21.21675682067871,-1.8633609101615305,,
2005-09-22,20.67938041687012,21.068017959594727,0.5457042814822992,,
2005-09-21,20.50665283203125,20.67938041687012,1.879348098879972,,
2005-09-20,20.78013801574707,20.67458152770996,0.8423002342394535,,
2005-09-19,20.871299743652344,20.78013801574707,-0.5079681759433902,,
2005-09-16,20.991249084472656,20.986452102661133,-0.43678031088120783,,
2005-09-15,21.1112003326416,20.967260360717773,-0.022852293316226673,,
2005-09-14,21.427867889404297,21.039230346679688,-0.6818180380831866,,
2005-09-13,21.734939575195312,21.427867889404297,-1.8137014131806546,,
2005-09-12,21.69175720214844,21.70135307312012,-1.412802113981751,,
2005-09-09,21.782920837402344,21.864486694335938,0.04423740724301152,,
2005-09-08,21.97484016418457,21.778121948242188,0.37444866802959303,,
2005-09-07,21.734939575195312,21.91726493835449,-0.8951974825418828,,
2005-09-06,21.533424377441406,21.734939575195312,0.8388583852666991,,
2005-09-02,21.68696022033692,21.533424377441406,0.9358251350166824,,
2005-09-01,21.744535446166992,21.658172607421875,-0.7079638701579618,,
2005-08-31,21.51902961730957,21.65337371826172,-0.39717030956548094,,
2005-08-30,21.65337371826172,21.41347312927246,0.6243037132310285,,
2005-08-29,21.327110290527344,21.65337371826172,-1.1079132153292761,,
2005-08-26,21.54781723022461,21.46145439147949,1.5298060697856861,,
2005-08-25,21.54302024841309,21.64377784729004,-0.40079622832507433,,
2005-08-24,21.806909561157227,21.55261611938477,0.46770414600697235,,
2005-08-23,21.99883079528809,21.92686080932617,-1.1661140752626793,,
2005-08-22,21.99403190612793,22.051607131958008,-0.3271536866283655,,
2005-08-19,22.18115425109864,21.989234924316406,0.261776585920277,,
2005-08-18,22.046810150146484,22.08039665222168,-0.8652359773961169,,
2005-08-17,22.16196250915528,22.11398124694824,0.15234177573290417,,
2005-08-16,22.43065071105957,22.08039665222168,-0.21650276769135615,,
2005-08-15,22.310699462890625,22.41625595092773,-1.5614975390134167,,
2005-08-12,22.38266944885254,22.329891204833984,0.47312047841744215,,
2005-08-11,22.42585182189941,22.445043563842773,-0.2357995954823896,,
2005-08-10,22.497821807861328,22.358680725097656,0.08557865313558215,,
2005-08-09,22.262720108032227,22.358680725097656,-0.6184646849458659,,
2005-08-08,22.38266944885254,22.253124237060547,0.43103725241017515,,
2005-08-05,22.502620697021484,22.3059024810791,-0.5787746277896866,,
2005-08-04,22.59857940673828,22.56499481201172,-0.8742013589929152,,
2005-08-03,22.550600051879883,22.708934783935547,-0.14861374302381367,,
2005-08-02,22.646560668945312,22.68494415283203,0.7021309042393522,,
2005-08-01,22.47863006591797,22.56019592285156,0.16948924142531321,,
2005-07-29,22.47383117675781,22.37307357788086,0.36285955458317765,,
2005-07-28,22.286710739135746,22.464235305786133,-0.4483329881962982,,
2005-07-27,22.06120491027832,22.190750122070312,0.7965489781255682,,
2005-07-26,21.8980712890625,21.94605255126953,0.5872082341778034,,
2005-07-25,22.15716361999512,21.826101303100582,0.21911181845040667,,
2005-07-22,22.262720108032227,22.08999252319336,-1.4941547689605013,,
2005-07-21,22.497821807861328,22.291507720947266,-0.7758602003739351,,
2005-07-20,22.310699462890625,22.47863006591797,-0.9170402747254889,,
2005-07-19,22.358680725097656,22.23872947692871,0.7526908930249482,,
2005-07-18,22.526609420776367,22.26751708984375,-0.5364862517773682,,
2005-07-15,22.262720108032227,22.48822593688965,-1.1501612430570909,,
2005-07-14,22.84327888488769,22.368276596069336,1.0129302608267576,,
2005-07-13,23.51020050048828,22.86247062683105,-2.0793962688631384,,
2005-07-12,23.855655670166016,23.98520278930664,-2.755101444769803,,
2005-07-11,23.798080444335938,23.82206916809082,0.5430457285759585,,
2005-07-08,23.5006046295166,23.678129196166992,0.10080108692376594,,
2005-07-07,23.438230514526367,23.495805740356445,0.7554042521417553,,
2005-07-06,23.48620986938477,23.57737159729004,0.24564664040826203,,
2005-07-05,23.47181510925293,23.48620986938477,0.3881500182969194,,
2005-07-01,23.62055397033692,23.524593353271484,0.06132785242571575,,
2005-06-30,23.51020050048828,23.514997482299805,-0.4062589606744436,,
2005-06-29,23.692523956298828,23.62055397033692,0.02040383199379269,,
2005-06-28,23.582170486450195,23.750099182128903,-0.3037666484780454,,
2005-06-27,23.51020050048828,23.505401611328125,0.7121002529228408,,
2005-06-24,23.49100875854492,23.51979637145996,-0.020411944849456225,,
2005-06-23,23.855655670166016,23.548583984375,0.12254736785013987,,
2005-06-22,23.759695053100582,23.855655670166016,-1.2872070675258813,,
2005-06-21,23.750099182128903,23.726110458374023,0.4038798345305809,,
2005-06-20,23.57737159729004,23.697322845458984,-0.10100473084731332,,
2005-06-17,23.764493942260746,23.716514587402344,0.5087558113675927,,
2005-06-16,23.51979637145996,23.548583984375,-0.20189512545470029,,
2005-06-15,23.53898811340332,23.51979637145996,0.1223973730910839,,
2005-06-14,23.390249252319336,23.51979637145996,-0.08153172027149042,,
2005-06-13,23.375856399536133,23.438230514526367,0.5538509561961138,,
2005-06-10,23.534189224243164,23.46221923828125,0.2668313576373275,,
2005-06-09,23.27509880065918,23.5006046295166,-0.3058103479841828,,
2005-06-08,23.51020050048828,23.347068786621094,0.9688716288114544,,
2005-06-07,23.2655029296875,23.39504814147949,-0.6938763191908952,,
2005-06-06,23.342269897460938,23.246309280395508,0.5568124281838969,,
2005-06-03,23.05438995361328,23.15994644165039,-0.4111023370347878,,
2005-06-02,23.06398582458496,23.155147552490234,0.4578585173994841,,
2005-06-01,23.10236930847168,23.18873405456543,0.3952557402636797,,
2005-05-31,23.10236930847168,23.145551681518555,0.3738350164027544,,
2005-05-27,23.222320556640625,23.03039932250977,0.1869175082013772,,
2005-05-26,23.241512298583984,23.135955810546875,-0.8264515755983495,,
2005-05-25,23.255905151367188,23.145551681518555,-0.4541722013654874,,
2005-05-24,23.222320556640625,23.351865768432617,-0.4745180595223801,,
2005-05-23,23.60615921020508,23.366260528564453,0.5578478321148986,,
2005-05-20,23.5965633392334,23.45262336730957,-1.0162546117918199,,
2005-05-19,23.702119827270508,23.52939224243164,-0.6100039647913594,,
2005-05-18,23.702119827270508,23.678129196166992,-0.7287431930039237,,
2005-05-17,23.6301498413086,23.706918716430664,-0.10121723828226187,,
2005-05-16,23.46221923828125,23.735706329345703,0.32487680204152214,,
2005-05-13,23.438230514526367,23.39504814147949,1.16564885992638,,
2005-05-12,23.692523956298828,23.56777572631836,-0.18423904918980685,,
2005-05-11,23.52939224243164,23.63494873046875,-0.5265299307518628,,
2005-05-10,23.447826385498047,23.438230514526367,0.4486154463724502,,
2005-05-09,23.49100875854492,23.543785095214844,-0.04092435185213806,,
2005-05-06,23.67333221435547,23.51979637145996,0.22466611465004838,,
2005-05-05,23.745302200317383,23.601362228393555,-0.6485603357621278,,
2005-05-04,23.65414047241211,23.85085868835449,-0.6061829439336603,,
2005-05-03,23.678129196166992,23.63494873046875,0.8316438983348909,,
2005-05-02,23.51020050048828,23.692523956298828,-0.18236434703309343,,
2005-04-29,23.193532943725582,23.58696746826172,0.7755078728773931,,
2005-04-28,23.10716819763184,23.07358169555664,1.6963113187228773,,
2005-04-27,22.996814727783203,23.255905151367188,-0.14535100877761825,,
2005-04-26,22.80009651184082,23.001611709594727,1.1266361304853614,,
2005-04-25,22.83847999572754,22.920045852661133,0.8838348453887156,,
2005-04-22,22.982419967651367,22.824085235595703,0.35714223078266377,,
2005-04-21,22.910449981689453,23.0783805847168,-0.6889384680922472,,
2005-04-20,22.93444061279297,22.69454002380371,0.7329869258856165,,
2005-04-19,23.342269897460938,23.11196517944336,-1.0460276447965329,,
2005-04-18,23.702119827270508,23.5006046295166,-0.9866423403947941,,
2005-04-15,23.16954231262207,23.92762565612793,-0.8501990506437853,,
2005-04-14,22.987218856811523,23.16954231262207,3.271896066297686,,
2005-04-13,22.79050064086914,23.049591064453125,0.7931514331779252,,
2005-04-12,22.886459350585938,22.982419967651367,1.1368351563079295,,
2005-04-11,23.03039932250977,22.910449981689453,0.419289919840628,,
2005-04-08,23.19832992553711,22.963228225708008,-0.5208304864391922,,
2005-04-07,22.84327888488769,23.19832992553711,-1.013442349443861,,
2005-04-06,22.69454002380371,22.84327888488769,1.5542910561946817,,
2005-04-05,22.3059024810791,22.646560668945312,0.6553949140540963,,
2005-04-04,22.243528366088867,22.15716361999512,1.527210962009598,,
2005-04-01,22.46903419494629,22.16196250915528,-0.3882690941488082,,
2005-03-31,22.43065071105957,22.368276596069336,-1.3666439025673598,,
2005-03-30,22.14277076721192,22.43065071105957,-0.2780753701428752,,
2005-03-29,21.830900192260746,21.95084953308105,1.3001080437229184,,
2005-03-28,21.5670108795166,21.677364349365234,0.5494475251315039,,
2005-03-24,21.35110092163086,21.562211990356445,0.5116771650235578,,
2005-03-23,20.93847274780273,21.39908027648925,0.9887596405471941,,
2005-03-22,20.794532775878903,20.99604797363281,2.1998143524333966,,
2005-03-21,21.29352378845215,21.048826217651367,0.969077785617085,,
2005-03-18,21.25993728637696,21.336706161499023,-1.1491642869062613,,
2005-03-17,21.23114967346192,21.365493774414062,0.36109643263743546,,
2005-03-16,21.797313690185547,21.792516708374023,0.6327688468046835,,
2005-03-15,22.12837600708008,21.90766716003418,-0.022007215566582985,,
2005-03-14,22.07080078125,22.12837600708008,-0.9974019194869298,,
2005-03-11,22.1667594909668,22.07080078125,0.2608660483175312,,
2005-03-10,21.99403190612793,22.209941864013672,-0.4328946220393859,,
2005-03-09,22.1667594909668,22.02281951904297,0.9816752053796276,,
2005-03-08,22.38266944885254,22.310699462890625,-0.6493505376033372,,
2005-03-07,22.349084854125977,22.38266944885254,-0.3215433535592139,,
2005-03-04,22.13797187805176,22.26751708984375,0.15027279616043107,,
2005-03-03,22.09958839416504,22.075597763061523,0.5851719954546675,,
2005-03-02,21.88847541809082,22.09958839416504,-0.1085569137108901,,
2005-03-01,22.066001892089844,22.051607131958008,0.9644937440445666,,
2005-02-28,22.200345993041992,22.066001892089844,-0.06523501720987403,,
2005-02-25,22.190750122070312,22.200345993041992,-0.6051441765558717,,
2005-02-24,21.86928367614746,22.243528366088867,0.04324266155444604,,
2005-02-23,21.830900192260746,21.94605255126953,1.711280056006544,,
2005-02-22,22.07080078125,21.802112579345703,0.527474167325487,,
2005-02-18,22.339487075805664,22.262720108032227,-1.2173921760580517,,
2005-02-17,22.46903419494629,22.339487075805664,-0.3436380052636859,,
2005-02-16,22.48822593688965,22.46903419494629,-0.5765584671626099,,
2005-02-15,22.38266944885254,22.48822593688965,-0.08534128924717567,,
2005-02-14,22.1187801361084,22.3059024810791,0.4715991909647792,,
2005-02-11,21.6629695892334,22.1667594909668,0.8459885392378859,,
2005-02-10,21.787717819213867,21.581403732299805,2.3255809858302534,,
2005-02-09,21.73014259338379,21.667768478393555,-0.9469283961999954,,
2005-02-08,21.782920837402344,21.72534370422364,-0.2870396028106392,,
2005-02-07,21.830900192260746,21.874082565307617,-0.2643223725986327,,
2005-02-04,21.811708450317383,21.840496063232425,0.19780390486224655,,
2005-02-03,21.94125366210937,21.90766716003418,0.13198238450974586,,
2005-02-02,21.85489082336425,21.8980712890625,-0.15307467199648994,,
2005-02-01,21.600595474243164,21.85489082336425,0.1975780435017624,,
2005-01-31,21.72054672241211,21.600595474243164,1.1772608279448211,,
2005-01-28,21.782920837402344,21.72054672241211,-0.5522478310602326,,
2005-01-27,21.97004127502441,21.811708450317383,-0.28634412921858926,,
2005-01-26,22.056406021118164,22.018022537231445,-0.7206760457342463,,
2005-01-25,22.042011260986328,22.027618408203125,-0.17402419891059331,,
2005-01-24,22.066001892089844,22.037214279174805,-0.06529736607420225,,
2005-01-21,21.87887954711914,22.06120491027832,-0.13046139058548148,,
2005-01-20,22.094789505004883,21.95084953308105,0.8333395810627195,,
2005-01-19,22.094789505004883,22.094789505004883,-0.6514656855691093,,
2005-01-18,22.094789505004883,22.08999252319336,0.0,,
2005-01-14,21.95084953308105,22.190750122070312,-0.02171091881385352,,
2005-01-13,22.521812438964844,22.085193634033203,1.09289888132903,,
2005-01-12,22.526609420776367,22.517013549804688,-1.9386486150477358,,
2005-01-11,23.03039932250977,22.5889835357666,-0.04259793736570664,,
2005-01-10,22.785701751708984,23.011207580566406,-1.9166657970699212,,
2005-01-07,22.454639434814453,22.79050064086914,0.9896812980118481,,
2005-01-06,22.018022537231445,22.40666007995605,1.4957319044453532,,
2005-01-05,22.262720108032227,21.912466049194336,1.765088313754961,,
2005-01-04,22.39706420898437,22.1667594909668,-1.5732761187233428,,
2005-01-03,22.310699462890625,22.39226531982422,-1.028280831222453,,
2004-12-31,22.497821807861328,22.38266944885254,0.36559076540501206,,
2004-12-30,22.536205291748047,22.512216567993164,-0.5118378125323751,,
2004-12-29,22.243528366088867,22.47383117675781,-0.10644526638061212,,
2004-12-28,22.12837600708008,22.243528366088867,1.0353699596510393,,
2004-12-27,22.26751708984375,22.075597763061523,0.5203832354075235,,
2004-12-23,22.31549835205078,22.272315979003903,-0.8618802267351184,,
2004-12-22,22.08039665222168,22.310699462890625,-0.19350844137841142,,
2004-12-21,22.272315979003903,22.1187801361084,1.0430193546626019,,
2004-12-20,22.502620697021484,22.272315979003903,-0.6893573305993073,,
2004-12-17,22.17635536193848,22.545801162719727,-1.0234573168984957,,
2004-12-16,21.375089645385746,22.16196250915528,1.6659446277422587,,
2004-12-15,21.20716094970703,21.279130935668945,3.6812611166727787,,
2004-12-14,21.1112003326416,21.346302032470703,0.3393664344444384,,
2004-12-13,21.01523971557617,21.058422088623047,1.113634924233054,,
2004-12-10,20.617006301879883,20.986452102661133,0.2054812299612859,,
2004-12-09,20.45387458801269,21.09680557250977,1.79194687808561,,
2004-12-08,21.06321907043457,21.04402732849121,3.143321240826797,,
2004-12-07,20.91448211669922,20.89529037475586,-0.09111495198897637,,
2004-12-06,20.76094627380371,20.91448211669922,-0.09176293171531932,,
2004-12-03,21.00084686279297,20.83771324157715,0.7395416416507001,,
2004-12-02,20.63139915466309,20.952865600585938,-0.7767954420202112,,
2004-12-01,20.122812271118164,20.75135040283203,1.5581417601054481,,
2004-11-30,19.9644775390625,20.132408142089844,3.1235103883366957,,
2004-11-29,20.434682846069336,20.357913970947266,0.841146995701594,,
2004-11-26,20.281145095825195,20.434682846069336,-0.3756793080683266,,
2004-11-24,20.319530487060547,20.338722229003903,0.7570467521370173,,
2004-11-23,20.607410430908203,20.27154922485352,0.09444973128477108,,
2004-11-22,20.588218688964844,20.569026947021484,-1.6298079139091617,,
2004-11-19,20.63139915466309,20.511449813842773,-0.09321710747926934,,
2004-11-18,20.847309112548828,20.80892562866211,-0.5813921776274936,,
2004-11-17,21.23114967346192,20.94326972961425,-0.18411720994540345,,
2004-11-16,21.346302032470703,21.202362060546875,-1.3559319597633883,,
2004-11-15,21.25514030456543,21.346302032470703,-0.6743087008929011,,
2004-11-12,21.375089645385746,21.19756317138672,0.42889261891013086,,
2004-11-11,21.619787216186523,21.734939575195312,-0.8305297285026815,,
2004-11-10,21.590999603271484,21.614990234375,0.5326248489743489,,
2004-11-09,21.54302024841309,21.590999603271484,0.11111403614624932,,
2004-11-08,21.447059631347656,21.571807861328125,0.22271415198585795,,
2004-11-05,21.375089645385746,21.327110290527344,0.5816565632993953,,
2004-11-04,20.9240779876709,21.327110290527344,-0.22446387666383108,,
2004-11-03,20.621803283691406,20.9240779876709,1.9261651724578936,,
2004-11-02,20.415489196777344,20.300338745117188,1.4658015102808386,,
2004-11-01,20.39150047302246,20.50665283203125,-0.5640347412215484,,
2004-10-29,20.425085067749023,20.45387458801269,0.5647076298339756,,
2004-10-28,20.27154922485352,20.49225807189941,0.14095177654425856,,
2004-10-27,19.599830627441406,20.357913970947266,1.0887616165778575,,
2004-10-26,19.45589065551757,19.66220474243164,3.8678055842200956,,
2004-10-25,19.60462760925293,19.49907112121582,1.0604196465072147,,
2004-10-22,19.71977996826172,19.60462760925293,-0.5384263865705318,,
2004-10-21,19.83972930908203,19.71977996826172,-0.5839434273309473,,
2004-10-20,19.887710571289062,19.863719940185547,-0.6045916199340649,,
2004-10-19,19.79654884338379,19.854124069213867,-0.1206304316302237,,
2004-10-18,19.887710571289062,19.83972930908203,0.2908346615643583,,
2004-10-15,20.00765991210937,19.844528198242188,-0.2412608632604474,,
2004-10-14,19.83972930908203,19.676597595214844,-0.8153462952878894,,
2004-10-13,20.00765991210937,19.743770599365234,-0.8222476795210644,,
2004-10-12,19.7293758392334,19.9164981842041,-1.3189414149548873,,
2004-10-11,19.59503173828125,19.75336647033692,0.948445336008024,,
2004-10-08,19.71977996826172,19.590234756469727,0.8080350885390262,,
2004-10-07,20.25235748291016,19.83013343811035,-0.656930310584046,,
2004-10-06,20.319530487060547,20.24756050109864,-2.084814299550557,,
2004-10-05,20.24756050109864,20.28594398498535,-0.3541911857054835,,
2004-10-04,20.24756050109864,20.24756050109864,0.18957090600928908,,
2004-10-01,20.367509841918945,20.24276161193848,0.0,,
2004-09-30,20.348318099975582,20.32432746887207,-0.6124864107035675,,
2004-09-29,20.34351921081543,20.300338745117188,-0.11789982339395835,,
2004-09-28,20.29553985595703,20.396297454833984,-0.2122566172095029,,
2004-09-27,20.2331657409668,20.357913970947266,0.4964519278228479,,
2004-09-24,20.276348114013672,20.31473159790039,0.6165531957655201,,
2004-09-23,20.21397399902344,20.329126358032227,0.18930176021287887,,
2004-09-22,20.43947982788086,20.15639877319336,0.5696670976936482,,
2004-09-21,20.39150047302246,20.65059280395508,-1.384971912550132,,
2004-09-20,20.511449813842773,20.434682846069336,1.2705898287151287,,
2004-09-17,20.573823928833008,20.593015670776367,-0.3742639768039653,,
2004-09-16,20.44907569885254,20.48266220092773,0.09328232811627825,,
2004-09-15,20.55942916870117,20.396297454833984,0.16424459750558018,,
2004-09-14,20.55942916870117,20.602611541748047,-0.7934642179439932,,
2004-09-13,20.27154922485352,20.607410430908203,0.21003682880757035,,
2004-09-10,20.055639266967773,20.300338745117188,1.656810746575344,,
2004-09-09,20.20917510986328,20.151599884033203,1.2201031086176408,,
2004-09-08,20.24756050109864,20.2331657409668,-0.2848964666646784,,
2004-09-07,20.47306632995605,20.18998336791992,-0.07109379982372901,,
2004-09-03,20.47306632995605,20.47306632995605,-1.3827091529612627,,
2004-09-02,20.18038749694824,20.43947982788086,0.0,,
2004-09-01,20.00286293029785,20.18038749694824,1.2838818430607528,,
2004-08-31,19.83972930908203,20.00286293029785,0.8874957913224257,,
2004-08-30,19.9164981842041,19.7773551940918,0.822257293304615,,
2004-08-27,19.75816345214844,19.9164981842041,-0.6986318017625022,,
2004-08-26,19.83972930908203,19.7773551940918,0.8013636107380399,,
2004-08-25,19.67180061340332,19.887710571289062,-0.31438994967374795,,
2004-08-24,19.743770599365234,19.67180061340332,1.0975607273013566,,
2004-08-23,19.71498107910156,19.61422348022461,-0.36451996643552936,,
2004-08-20,19.532657623291016,19.676597595214844,-0.5110712430952089,,
2004-08-19,19.441495895385746,19.532657623291016,0.7369195462280159,,
2004-08-18,19.191999435424805,19.475082397460938,0.46890284778398283,,
2004-08-17,19.383920669555664,19.191999435424805,1.4750050560840218,,
2004-08-16,19.048059463500977,19.191999435424805,-0.99010534247744,,
2004-08-13,19.01447486877441,18.995281219482425,0.7556673801845241,,
2004-08-12,18.9425048828125,19.01447486877441,-0.10094230539863562,,
2004-08-11,18.664220809936523,19.086444854736328,0.37993911791049634,,
2004-08-10,18.568260192871094,18.73619079589844,2.262210938776611,,
2004-08-09,18.424320220947266,18.405128479003903,0.9043960030882207,,
2004-08-06,18.5346736907959,18.563461303710938,-0.10416526478704573,,
2004-08-05,18.688209533691406,18.573057174682617,0.1553176138694832,,
2004-08-04,18.58265495300293,18.77457427978516,-0.6161765192175875,,
2004-08-03,18.76497840881348,18.79376602172852,1.0327874422013967,,
2004-08-02,18.880130767822266,18.83694839477539,0.1534113830981984,,
2004-07-30,18.78896713256836,18.880130767822266,-0.2287186120578755,,
2004-07-29,18.73619079589844,18.78417015075684,0.48519769400141916,,
2004-07-28,18.71220016479492,18.73619079589844,0.25607849205347355,,
2004-07-27,18.54906845092773,18.803361892700195,0.1282084997608065,,
2004-07-26,18.54426956176757,18.47709846496582,1.3709229789366917,,
2004-07-23,18.84174537658692,18.5346736907959,-0.3622202350867262,,
2004-07-22,18.568260192871094,18.84174537658692,-1.6297411925149743,,
2004-07-21,18.932907104492188,18.597047805786133,1.472863805629062,,
2004-07-20,18.77457427978516,18.889726638793945,-1.773944681883353,,
2004-07-19,18.86093711853028,18.77457427978516,0.6133420512909932,,
2004-07-16,19.23038482666016,18.76017951965332,-0.45789261796685576,,
2004-07-15,19.23998069763184,19.08164596557617,-2.445116471902151,,
2004-07-14,19.16801071166992,19.08164596557617,-0.8229464184190157,,
2004-07-13,19.19679832458496,19.32634353637696,-0.45056707966658843,,
2004-07-12,19.23998069763184,19.383920669555664,0.6748271748320307,,
2004-07-09,19.599830627441406,19.144020080566406,0.748129502757461,,
2004-07-08,18.9904842376709,19.32634353637696,-2.3255841111036286,,
2004-07-07,19.07205009460449,18.9904842376709,1.7685662698364846,,
2004-07-06,19.31195068359375,19.09124183654785,-0.42767220371692133,,
2004-07-02,19.475082397460938,19.475082397460938,-1.1428614885258543,,
2004-07-01,19.57583999633789,19.53745651245117,0.0,,
2004-06-30,19.81574058532715,19.55664825439453,-0.19607579492835459,,
2004-06-29,19.56144523620605,19.81574058532715,-1.3075076846962048,,
2004-06-28,19.57583999633789,19.56624412536621,1.2999824197571304,,
2004-06-25,20.108417510986328,19.4606876373291,-0.049018948732084115,,
2004-06-24,19.950084686279297,20.108417510986328,-3.2211877105860585,,
2004-06-23,20.161195755004883,20.127609252929688,0.793644875181532,,
2004-06-22,20.38190460205078,20.161195755004883,-0.16658983169119662,,
2004-06-21,20.63139915466309,20.4202880859375,-1.0828666474265178,,
2004-06-18,20.71776390075684,20.63139915466309,-1.0232513420102891,,
2004-06-17,20.511449813842773,20.71776390075684,-0.4168632604727917,,
2004-06-16,20.573823928833008,20.55463218688965,1.0058483860796068,,
2004-06-15,20.511449813842773,20.63139915466309,-0.09328232811627825,,
2004-06-14,20.34351921081543,20.434682846069336,0.5847921132291907,,
2004-06-10,20.39150047302246,20.48745918273925,0.4481212631364194,,
2004-06-09,20.49225807189941,20.425085067749023,0.470581896823832,,
2004-06-08,20.22356986999512,20.48745918273925,-0.3277969851575311,,
2004-06-07,20.127609252929688,20.300338745117188,1.304860192540248,,
2004-06-04,19.79174995422364,20.02685165405273,0.8581719270129325,,
2004-06-03,19.590234756469727,19.743770599365234,1.187877273979602,,
2004-06-02,19.79174995422364,19.76775932312012,0.7837366157381151,,
2004-06-01,19.70058822631836,19.676597595214844,-0.12121531021262463,,
2004-05-28,19.9644775390625,19.77255821228028,-0.1217762171764299,,
2004-05-27,19.81574058532715,19.93568992614746,-0.9613040281505493,,
2004-05-26,19.46548652648925,19.69099235534668,0.6053235320870658,,
2004-05-25,19.019271850585938,19.48947525024414,1.1584905856350085,,
2004-05-24,19.24957656860352,18.976089477539062,2.472247115200245,,
2004-05-21,19.35993003845215,19.16801071166992,-1.4207434126656069,,
2004-05-20,19.494274139404297,19.31674766540528,-0.9913224190430716,,
2004-05-19,19.911699295043945,19.590234756469727,-0.9106595748552512,,
2004-05-18,19.902103424072266,19.667001724243164,-1.614450548950545,,
2004-05-17,19.62381935119629,19.71018409729004,-1.1812907149539686,,
2004-05-14,19.67180061340332,19.743770599365234,0.4401016160418594,,
2004-05-13,19.58543586730957,19.67180061340332,0.36585357576711885,,
2004-05-12,19.4462947845459,19.7773551940918,0.4409641259906963,,
2004-05-11,19.35033416748047,19.638214111328125,1.7024343877014447,,
2004-05-10,19.887710571289062,19.57104110717773,1.4877259553039541,,
2004-05-07,20.14680290222168,19.911699295043945,-1.5922871713976585,,
2004-05-06,20.137205123901367,20.14680290222168,-1.1669524356730985,,
2004-05-05,19.911699295043945,20.137205123901367,0.04766191862901893,,
2004-05-04,20.30513572692871,20.046043395996094,1.132529301070505,,
2004-05-03,19.84932518005371,20.30513572692871,-1.275994085520977,,
2004-04-30,19.931198120117188,19.760616302490234,2.2963528620763247,,
2004-04-29,19.823463439941406,19.931198120117188,-0.855853303945534,,
2004-04-28,19.836929321289062,19.81897354125977,0.5434705216986022,,
2004-04-27,19.751638412475582,19.94017791748047,-0.09051693303168205,,
2004-04-26,19.769594192504883,19.751638412475582,0.9545512178159384,,
2004-04-23,19.751638412475582,19.706748962402344,-0.09082523320639473,,
2004-04-22,19.24438095092773,19.863862991333008,-0.22726950107027802,,
2004-04-21,19.32967185974121,19.35660552978516,3.2190281515676036,,
2004-04-20,19.863862991333008,19.40598487854004,0.13933847526943718,,
2004-04-19,19.67083740234375,19.841419219970703,-2.3050809049214136,,
2004-04-16,19.751638412475582,19.80999565124512,0.8671812701101813,,
2004-04-15,18.786500930786133,19.73817253112793,0.29545517972159013,,
2004-04-14,17.978479385375977,18.835880279541016,5.065720348073214,,
2004-04-13,18.38249015808105,18.068260192871094,4.769040116165022,,
2004-04-12,18.51716041564941,18.49471664428711,-1.7093982507686536,,
2004-04-08,19.437408447265625,18.99748611450196,-0.12120525425341797,,
2004-04-07,19.40149688720703,19.19051170349121,-2.2632766809278593,,
2004-04-06,19.23540306091309,19.388029098510746,-1.0874685852458108,,
2004-04-05,19.046863555908203,19.253358840942383,0.7934642030340238,,
2004-04-02,19.051353454589844,19.01992988586425,1.0841432471443642,,
2004-04-01,18.51716041564941,18.786500930786133,-0.16494139799827445,,
2004-03-31,18.42289161682129,18.449825286865234,1.454545454545474,,
2004-03-30,18.27026557922364,18.38698005676269,0.14619675675317512,,
2004-03-29,18.13559532165528,18.2119083404541,0.6388220085414401,,
2004-03-26,17.776473999023438,18.01888084411621,0.4207913633124437,,
2004-03-25,17.686695098876953,17.870744705200195,1.3636385095609524,,
2004-03-24,17.938079833984375,17.664249420166016,1.040610500120674,,
2004-03-23,17.866254806518555,17.97399139404297,-1.5265313587220033,,
2004-03-22,17.956035614013672,17.780963897705078,0.6030171890591534,,
2004-03-19,18.04581451416016,18.0503044128418,-0.9750020554200737,,
2004-03-18,18.126617431640625,17.996437072753906,0.024880554314228923,,
2004-03-17,18.67427635192871,18.238842010498047,-0.7181723748385869,,
2004-03-16,18.5844955444336,18.65632057189941,-2.331733413518279,,
2004-03-15,18.49471664428711,18.27026557922364,0.3864782194065126,,
2004-03-12,18.67427635192871,18.602453231811523,-1.2135955872176114,,
2004-03-11,18.60694122314453,18.63836479187012,-0.38460992417395323,,
2004-03-10,18.988506317138672,18.60694122314453,0.1688808942251228,,
2004-03-09,19.302738189697266,19.033397674560547,-2.0094529165242823,,
2004-03-08,19.563100814819336,19.370073318481445,-1.395348745290851,,
2004-03-05,19.504743576049805,19.563100814819336,-0.9866917221612919,,
2004-03-04,19.616968154907227,19.58554458618164,0.2991951088308029,,
2004-03-03,19.58105659484864,19.72021484375,-0.16018565395756768,,
2004-03-02,19.3835391998291,19.576566696166992,0.7106779362354207,,
2004-03-01,19.21295738220215,19.482297897338867,0.9958320528977107,,
2004-02-27,19.21295738220215,19.21295738220215,1.4018691124887486,,
2004-02-26,19.428430557250977,19.32518196105957,0.0,,
2004-02-25,19.52718734741211,19.52718734741211,-0.531430451302575,,
2004-02-24,19.50923156738281,19.549633026123047,0.0,,
2004-02-23,19.52718734741211,19.625946044921875,0.20708892916000096,,
2004-02-20,19.52718734741211,19.47332000732422,0.5057497311452479,,
2004-02-19,19.99404525756836,19.45536422729492,-0.2758581619028177,,
2004-02-18,20.097291946411133,20.016490936279297,-2.6942073168986838,,
2004-02-17,19.935688018798828,20.20054054260254,-0.4020492429890036,,
2004-02-13,19.64839172363281,19.890798568725582,1.3285346538025775,,
2004-02-12,19.908754348754883,19.64839172363281,1.2337235968336782,,
2004-02-11,19.87284278869629,20.020978927612305,-1.3077795856090677,,
2004-02-10,19.863862991333008,19.796527862548828,0.7454199708170376,,
2004-02-09,19.976089477539062,19.91324234008789,-0.3389830508474576,,
2004-02-06,19.953643798828125,19.91773223876953,-0.3146118138979936,,
2004-02-05,19.841419219970703,20.00751304626465,-0.1799749480378257,,
2004-02-04,19.863862991333008,19.86835289001465,0.8371065822084403,,
2004-02-03,19.616968154907227,19.863862991333008,0.022603351038011366,,
2004-02-02,19.35660552978516,19.51820945739746,1.2585779539231192,,
2004-01-30,19.64390182495117,19.33864974975586,0.834877413623125,,
2004-01-29,19.52718734741211,19.639413833618164,-1.5539279208145185,,
2004-01-28,19.51820945739746,19.66185760498047,0.5747191554493268,,
2004-01-27,19.55861091613769,19.47780990600586,0.7359699049062348,,
2004-01-26,19.298248291015625,19.69777107238769,-0.4131224373667762,,
2004-01-23,19.428430557250977,19.289270401000977,2.0702541253864277,,
2004-01-22,19.549633026123047,19.33864974975586,-0.7162707035955788,,
2004-01-21,19.414962768554688,19.616968154907227,-1.079218602647235,,
2004-01-20,19.45985221862793,19.428430557250977,1.040462393673583,,
2004-01-16,19.63043594360352,19.414962768554688,-0.16146916751441082,,
2004-01-15,19.863862991333008,20.1780948638916,-1.0976484458514664,,
2004-01-14,19.94466590881348,19.976089477539062,1.5819273053569654,,
2004-01-13,19.836929321289062,19.94466590881348,0.15755374830167707,,
2004-01-12,20.16911697387696,19.94915580749512,0.5431112133307565,,
2004-01-09,20.31725311279297,20.16911697387696,-1.090584018461161,,
2004-01-08,20.424989700317383,20.43396759033203,-0.7291149945005758,,
2004-01-07,20.8514461517334,21.053451538085938,0.043955420033866315,,
2004-01-06,20.8514461517334,20.8334903717041,0.9687835792422781,,
2004-01-05,21.14323234558105,20.98611640930176,-0.08611287628989799,,
2004-01-02,20.91878128051757,20.98611640930176,-0.7431027276779045,,
2003-12-31,20.96367073059082,20.91878128051757,0.32188839245095996,,
2003-12-30,21.00856208801269,20.90531349182129,-0.21412972303435987,,
2003-12-29,20.98162651062012,21.16567611694336,-0.4914596047023869,,
2003-12-26,21.00856208801269,21.026517868041992,0.8771941785832454,,
2003-12-24,20.873891830444336,21.03549575805664,0.0854688671888965,,
2003-12-23,20.6943302154541,20.878379821777344,0.7741916501483791,,
2003-12-22,20.77513313293457,20.78411102294922,0.8893721343336722,,
2003-12-19,20.91878128051757,20.82900047302246,0.04321459678357438,,
2003-12-18,20.53721618652344,20.90531349182129,-0.429187562559996,,
2003-12-17,20.49232482910156,20.46988105773925,1.792342749643908,,
2003-12-16,20.53721618652344,20.604551315307617,-0.10952281671055397,,
2003-12-15,20.57761573791504,20.49232482910156,0.3278688220089029,,
2003-12-12,20.63597297668457,20.57312774658203,-0.4144839222375427,,
2003-12-11,20.46988105773925,20.541704177856445,-0.30454212250396123,,
2003-12-10,20.50130271911621,20.362144470214844,0.35087219077924114,,
2003-12-09,20.299297332763672,20.451923370361328,-0.6787775918825423,,
2003-12-08,20.18258285522461,20.339698791503903,0.751878427591251,,
2003-12-05,20.37112236022949,20.18258285522461,0.7784728912366197,,
2003-12-04,20.36663246154785,20.357654571533203,-0.9255234035261829,,
2003-12-03,20.424989700317383,20.326231002807617,-0.04408136706742595,,
2003-12-02,20.214006423950195,20.31725311279297,-0.4835189586814383,,
2003-12-01,19.953643798828125,20.1960506439209,0.51076806189417,,
2003-11-28,19.953643798828125,19.841419219970703,1.2148500170530756,,
2003-11-26,19.96711158752441,20.020978927612305,-0.5624264920676434,,
2003-11-25,20.012001037597656,19.95813369750977,0.26978033278258867,,
2003-11-24,19.60350227355957,20.012001037597656,-0.26917518136583896,,
2003-11-21,19.54514503479004,19.60350227355957,2.0838050177852807,,
2003-11-20,19.899776458740234,19.54514503479004,0.298576647375378,,
2003-11-19,20.088314056396484,19.91324234008789,-1.7820874756331078,,
2003-11-18,19.976089477539062,19.78754997253418,-0.8715102512689348,,
2003-11-17,19.841419219970703,19.823463439941406,-0.9438258935357441,,
2003-11-14,20.020978927612305,19.841419219970703,-0.0904964500282525,,
2003-11-13,18.764057159423828,19.688793182373047,-0.8968577824831455,,
2003-11-12,18.728145599365234,18.777523040771484,4.928230686425887,,
2003-11-11,18.50818252563477,18.705699920654297,0.2636536604452903,,
2003-11-10,18.67876625061035,18.571029663085938,1.0671895781552625,,
2003-11-07,19.00197410583496,18.63387489318848,-0.5767864219666737,,
2003-11-06,17.933589935302734,18.966062545776367,-1.937163005255586,,
2003-11-05,18.777523040771484,18.992996215820312,5.757199836721949,,
2003-11-04,19.05584144592285,18.777523040771484,1.1475058482472527,,
2003-11-03,19.14562225341797,19.21295738220215,-1.4605411466147333,,
2003-10-31,19.23540306091309,19.132156372070312,0.3516998710875469,,
2003-10-30,19.25784683227539,19.27580451965332,-0.536753446318873,,
2003-10-29,19.05584144592285,19.253358840942383,0.09324867693844835,,
2003-10-28,18.62938690185547,19.05584144592285,1.036518883619236,,
2003-10-27,18.74610137939453,18.597963333129883,2.2891496446665585,,
2003-10-24,18.5844955444336,18.74610137939453,-0.7902338905916717,,
2003-10-23,18.440847396850582,18.68325424194336,0.8695734278853445,,
2003-10-22,19.07828712463379,18.41391372680664,1.3145103360823667,,
2003-10-21,19.033397674560547,19.07828712463379,-3.482353491626158,,
2003-10-20,18.759567260742188,18.966062545776367,0.2358457004932968,,
2003-10-17,18.97055053710937,18.75507926940918,1.1007465266339522,,
2003-10-16,18.81343650817871,18.966062545776367,-1.1358197922548223,,
2003-10-15,18.94361686706543,18.82241439819336,0.8112608110235765,,
2003-10-14,18.799968719482425,18.898727416992188,-0.6398063776447453,,
2003-10-13,18.853836059570312,18.85832595825196,0.5253130948426438,,
2003-10-10,18.94361686706543,18.759567260742188,0.023814244843656802,,
2003-10-09,19.18153381347656,18.94361686706543,-0.9715652909092721,,
2003-10-08,19.033397674560547,18.831392288208008,-1.2403437010025424,,
2003-10-07,18.988506317138672,18.94361686706543,-1.0613206838132387,,
2003-10-06,19.13664436340332,19.186023712158203,-0.23640327113421136,,
2003-10-03,19.3610954284668,19.13664436340332,0.25803556682756384,,
2003-10-02,19.20846939086914,19.370073318481445,-1.1592890799632525,,
2003-10-01,18.92117118835449,19.2039794921875,0.8413160066211421,,
2003-09-30,19.07828712463379,19.100732803344727,1.494665953908143,,
2003-09-29,19.00197410583496,19.100732803344727,0.11765038739749206,,
2003-09-26,18.898727416992188,18.99748611450196,0.5197286185093771,,
2003-09-25,18.764057159423828,18.898727416992188,0.5225679768309532,,
2003-09-24,19.23540306091309,18.898727416992188,0.7177033006463863,,
2003-09-23,19.168067932128903,19.31620407104492,-1.7502915995820065,,
2003-09-22,19.168067932128903,19.17255592346192,0.7728277019913654,,
2003-09-19,19.796527862548828,19.50923156738281,0.023413895176653893,,
2003-09-18,19.72919273376465,19.80101776123047,-1.4512458808977697,,
2003-09-17,19.751638412475582,19.774084091186523,0.3640545684512401,,
2003-09-16,19.60799026489257,19.72021484375,0.11363957886533531,,
2003-09-15,19.77857208251953,19.634923934936523,0.5723410576063127,,
2003-09-12,19.482297897338867,19.77857208251953,-0.7262816900213198,,
2003-09-11,19.432918548583984,19.55861091613769,1.5207353195288777,,
2003-09-10,18.99748611450196,19.428430557250977,0.6468012884398479,,
2003-09-09,19.20846939086914,18.99748611450196,2.2684287813220174,,
2003-09-08,18.87179374694824,19.21295738220215,-1.098386717202322,,
2003-09-05,18.49471664428711,18.853836059570312,1.8077965445604738,,
2003-09-04,18.74161148071289,18.49471664428711,1.9417405640228214,,
2003-09-03,18.62938690185547,18.74161148071289,-1.3173618324115952,,
2003-09-02,18.202930450439453,18.47227096557617,0.6024061846407003,,
2003-08-29,17.879722595214844,18.09070587158203,1.4796546955449847,,
2003-08-28,17.88421058654785,17.875232696533203,1.1800142605325041,,
2003-08-27,17.911144256591797,17.821365356445312,-0.050200091142974065,,
2003-08-26,17.76300811767578,17.933589935302734,-0.5012460335326887,,
2003-08-25,17.475711822509766,17.77198600769043,0.96032055210969,,
2003-08-22,17.866254806518555,17.49815559387207,1.695348310785516,,
2003-08-21,17.52509117126465,17.327573776245117,-2.060304281075082,,
2003-08-20,17.596914291381836,17.50713348388672,-1.1270548785697299,,
2003-08-19,17.911144256591797,17.745052337646484,-0.510207676234962,,
2003-08-18,17.956035614013672,17.861766815185547,-0.9273104865100178,,
2003-08-15,17.754030227661133,17.812387466430664,-0.5249978383566667,,
2003-08-14,17.677717208862305,17.776473999023438,0.32869854349244887,,
2003-08-13,17.776473999023438,17.6956729888916,0.5586512613270193,,
2003-08-12,17.888700485229492,17.76300811767578,-0.4545390167716882,,
2003-08-11,17.911144256591797,17.776473999023438,-0.702635541678915,,
2003-08-08,18.08621597290039,17.911144256591797,-0.7518796992481203,,
2003-08-07,17.332063674926758,17.915634155273438,-0.9679842183180478,,
2003-08-06,16.954986572265625,17.327573776245117,3.3669994023325427,,
2003-08-05,17.30512809753418,16.99089813232422,2.197508104128831,,
2003-08-04,17.300640106201172,17.282684326171875,-1.8158199317503798,,
2003-08-01,17.619359970092773,17.300640106201172,-0.10378679585884731,,
2003-07-31,17.888700485229492,17.619359970092773,-1.8089185102784604,,
2003-07-30,17.529579162597656,17.63282585144043,-1.505646066124872,,
2003-07-29,17.731584548950195,17.466733932495117,0.5889855534185774,,
2003-07-28,18.059282302856445,17.664249420166016,-1.4936658126854134,,
2003-07-25,17.96052360534668,18.059282302856445,-2.187422933346289,,
2003-07-24,18.22537612915039,17.96052360534668,0.5498653584930346,,
2003-07-23,18.404935836791992,18.315155029296875,-1.453207450572695,,
2003-07-22,18.544095993041992,18.602453231811523,-0.4878083156130476,,
2003-07-21,18.580007553100582,18.53960609436035,0.314694438550295,,
2003-07-18,18.328622817993164,18.5844955444336,-0.21744586822564954,,
2003-07-17,19.037885665893555,18.87628173828125,1.3960281085016772,,
2003-07-16,19.347627639770508,19.033397674560547,-0.8488543867127993,,
2003-07-15,19.796527862548828,19.370073318481445,-1.6241265909213467,,
2003-07-14,19.86835289001465,19.769594192504883,-2.1541885881622287,,
2003-07-11,19.49127578735352,19.760616302490234,-0.4970653483782209,,
2003-07-10,19.302738189697266,19.549633026123047,1.3818516451933371,,
2003-07-09,19.84590721130371,19.60799026489257,1.2790663894387795,,
2003-07-08,20.19156074523925,19.976089477539062,-1.1988212172816601,,
2003-07-07,19.85488510131836,20.19156074523925,-1.0671352770537652,,
2003-07-03,19.80999565124512,19.85039710998535,1.6956816531692553,,
2003-07-02,19.482297897338867,19.83244132995605,0.20394481377733906,,
2003-07-01,19.59452247619629,19.549633026123047,1.7972388804557333,,
2003-06-30,19.66185760498047,19.64390182495117,-0.22909182975892647,,
2003-06-27,20.11973762512207,19.572078704833984,-0.09132290747926136,,
2003-06-26,19.886308670043945,20.11973762512207,-2.721998320714996,,
2003-06-25,20.06587028503418,19.91324234008789,1.173817418562724,,
2003-06-24,19.976089477539062,19.94466590881348,-0.760634563954718,,
2003-06-23,20.40254592895508,19.908754348754883,-0.157305906948979,,
2003-06-20,20.604551315307617,20.474369049072266,-2.4202449141379705,,
2003-06-19,20.80655670166016,20.46988105773925,-0.6318131574097224,,
2003-06-18,20.873891830444336,20.64944076538086,-1.6181228290120955,,
2003-06-17,20.873891830444336,20.873891830444336,-1.0752717647799497,,
2003-06-16,20.474369049072266,20.748199462890625,0.0,,
2003-06-13,20.58210563659668,20.46988105773925,1.3374302922939996,,
2003-06-12,20.57761573791504,20.52823638916016,-0.5452531477531843,,
2003-06-11,20.429479598999023,20.46988105773925,-0.23996632741030308,,
2003-06-10,20.37112236022949,20.50579261779785,0.19776058682477063,,
2003-06-09,20.299297332763672,20.151161193847656,0.6610841326606504,,
2003-06-06,20.357654571533203,20.294809341430664,-0.7297599344826556,,
2003-06-05,19.931198120117188,20.30827522277832,-0.30870565114322,,
2003-06-04,20.30827522277832,20.04791259765625,1.891893805824633,,
2003-06-03,19.751638412475582,19.774084091186523,-1.2820518841011197,,
2003-06-02,20.110759735107425,19.72021484375,0.11363957886533531,,
2003-05-30,19.841419219970703,19.99853515625,-1.941969853459339,,
2003-05-29,20.46988105773925,19.67083740234375,0.7918583571943141,,
2003-05-28,19.27580451965332,19.549633026123047,-3.903509029396135,,
2003-05-27,18.88974952697754,19.27580451965332,1.4205814662134342,,
2003-05-23,18.80894660949707,18.88974952697754,2.0437274307127993,,
2003-05-22,18.593475341796875,18.831392288208008,0.42959831381343544,,
2003-05-21,18.404935836791992,18.5844955444336,1.2795722264804987,,
2003-05-20,18.404935836791992,18.404935836791992,0.9756062679809169,,
2003-05-19,19.280292510986328,18.512672424316406,0.0,,
2003-05-16,19.751638412475582,19.32518196105957,-3.981371580501257,,
2003-05-15,19.58554458618164,19.715726852416992,-2.159094058478979,,
2003-05-14,19.51820945739746,19.347627639770508,0.6646854554516712,,
2003-05-13,19.423940658569336,19.513721466064453,-0.8739624297980987,,
2003-05-12,19.280292510986328,19.40149688720703,0.46221726617306275,,
2003-05-09,19.347627639770508,19.47332000732422,0.6286438660183098,,
2003-05-08,19.100732803344727,19.23540306091309,0.6496526080300449,,
2003-05-07,19.033397674560547,19.168067932128903,0.7050528320294646,,
2003-05-06,18.80894660949707,19.033397674560547,0.7075471225421405,,
2003-05-05,18.99748611450196,18.63836479187012,1.1933207623128987,,
2003-05-02,18.50369453430176,18.992996215820312,-1.8903623377711005,,
2003-05-01,18.23435401916504,18.50369453430176,2.644345866234951,,
2003-04-30,18.13559532165528,18.238842010498047,1.4771047817412923,,
2003-04-29,18.126617431640625,18.23435401916504,0.5693041061601211,,
2003-04-28,17.641803741455078,18.0323486328125,0.5943557198727889,,
2003-04-25,17.991947174072266,17.727096557617188,2.213746944932345,,
2003-04-24,17.866254806518555,17.920124053955078,-1.4720508786105573,,
2003-04-23,17.686695098876953,17.911144256591797,0.3015139323820071,,
2003-04-22,17.43979835510254,17.821365356445312,1.2690282523674845,,
2003-04-21,17.794431686401367,17.484689712524414,2.187909479074536,,
2003-04-17,17.36348533630371,17.794431686401367,-1.7406679760031907,,
2003-04-16,17.870744705200195,17.36348533630371,2.4819115618258407,,
2003-04-15,17.956035614013672,17.75851821899414,-2.8384903777897814,,
2003-04-14,17.655271530151367,18.01888084411621,-1.100005587343456,,
2003-04-11,17.924612045288086,17.561002731323242,2.0594943178521956,,
2003-04-10,18.05479431152344,18.005414962768555,-2.028547747901898,,
2003-04-09,18.13559532165528,18.0503044128418,-0.2734971548436311,,
2003-04-08,18.09070587158203,17.924612045288086,-0.47029561092839495,,
2003-04-07,18.36004638671875,18.0323486328125,-0.9181168909216278,,
2003-04-04,17.776473999023438,18.036836624145508,-1.7848416447536826,,
2003-04-03,18.081727981567383,17.677717208862305,1.464647179954661,,
2003-04-02,17.798919677734375,18.113149642944336,-2.2343593107745514,,
2003-04-01,16.887651443481445,17.466733932495117,1.7654440319939648,,
2003-03-31,16.833782196044922,16.883161544799805,3.429029139733903,,
2003-03-28,17.125568389892578,17.152502059936523,0.29333484406424387,,
2003-03-27,17.206371307373047,17.291662216186523,0.1572716854165344,,
2003-03-26,17.394908905029297,17.43979835510254,0.49569375953736877,,
2003-03-25,17.215349197387695,17.49815559387207,0.258060851702785,,
2003-03-24,17.23779296875,17.215349197387695,1.6427572466975509,,
2003-03-21,17.269216537475586,17.63731575012207,-0.1302009567175594,,
2003-03-20,16.865205764770508,16.937030792236328,2.131533945663832,,
2003-03-19,16.744003295898438,17.11210060119629,0.42587697101125566,,
2003-03-18,16.497106552124023,16.784404754638672,2.1983829003904916,,
2003-03-17,15.801310539245604,16.40732765197754,1.741506618793454,,
2003-03-14,15.891091346740724,15.79682159423828,3.835233230982803,,
2003-03-13,16.160430908203125,16.106563568115234,-0.5932239041705576,,
2003-03-12,15.554415702819824,15.689085960388184,-0.333328612299238,,
2003-03-11,15.518503189086914,15.608283996582031,0.8658008127167728,,
2003-03-10,15.733975410461426,15.491569519042969,0.5785403811255057,,
2003-03-07,15.576860427856444,15.913536071777344,-1.54065253754803,,
2003-03-06,15.859667778015137,15.81028938293457,2.1613831970838984,,
2003-03-05,16.093095779418945,16.13349723815918,-0.3113457089499399,,
2003-03-04,15.724997520446776,15.918025016784668,0.2510483954982905,,
2003-03-03,15.989849090576172,15.724997520446776,1.227520043083658,,
2003-02-28,15.913536071777344,15.989849090576172,-1.6563731691845052,,
2003-02-27,15.554415702819824,15.949448585510254,0.47954784187889743,,
2003-02-26,15.689085960388184,15.576860427856444,2.5396832014642317,,
2003-02-25,15.329964637756348,15.576860427856444,-0.7153095649745764,,
2003-02-24,15.823756217956545,15.433212280273438,1.610543767935468,,
2003-02-21,15.927002906799316,15.747443199157717,-2.4680861630054958,,
2003-02-20,16.27265739440918,15.801310539245604,-1.1273916925383674,,
2003-02-19,16.564441680908203,16.07065200805664,-2.8965573583913673,,
2003-02-18,16.295101165771484,16.429771423339844,-2.981022133819899,,
2003-02-14,15.711530685424805,16.07513999938965,0.8264462809917356,,
2003-02-13,15.509525299072266,15.657662391662598,2.3142831926755236,,
2003-02-12,16.160430908203125,15.895580291748049,0.9551362129645139,,
2003-02-11,16.3848819732666,16.236743927001953,-1.6388833810157668,,
2003-02-10,16.770936965942383,16.582399368286133,-0.9041142103211296,,
2003-02-07,16.7215576171875,16.766447067260742,-1.124192393299928,,
2003-02-06,16.550975799560547,16.564441680908203,0.2684525634567793,,
2003-02-05,16.833782196044922,16.555463790893555,0.08136004493471491,,
2003-02-04,16.85622787475586,16.699111938476562,-1.6533325779678782,,
2003-02-03,17.03578758239746,17.013343811035156,-0.9320942825802447,,
2003-01-31,17.04476547241211,17.11210060119629,-0.13174484157982294,,
2003-01-30,17.43979835510254,17.04476547241211,0.395048725622921,,
2003-01-29,16.833782196044922,17.139036178588867,-2.2651229942395,,
2003-01-28,16.73502540588379,16.92356300354004,1.8133416423533408,,
2003-01-27,16.7215576171875,16.59137725830078,1.126604788959346,,
2003-01-24,17.06272315979004,16.766447067260742,-0.7785181372871086,,
2003-01-23,17.161479949951172,17.18392562866211,-1.73639394928179,,
2003-01-22,17.215349197387695,17.161479949951172,0.13079104352536544,,
2003-01-21,17.23779296875,17.24228286743164,-0.3129140560488759,,
2003-01-17,17.664249420166016,17.0582332611084,0.02604683029770841,,
2003-01-16,17.0582332611084,17.596914291381836,-3.430749558856272,,
2003-01-15,17.493667602539062,17.03578758239746,3.1578946191431987,,
2003-01-14,17.282684326171875,17.534069061279297,-2.617404369082353,,
2003-01-13,17.888700485229492,17.70016098022461,1.4545468190189628,,
2003-01-10,17.947057723999023,17.857276916503906,-1.0539586436731827,,
2003-01-09,17.920124053955078,17.947057723999023,-0.5002536286215941,,
2003-01-08,17.619359970092773,17.888700485229492,0.15029845754890794,,
2003-01-07,18.24781990051269,17.44877815246582,1.5286623100606336,,
2003-01-06,18.036836624145508,18.27026557922364,-4.378834032795455,,
2003-01-03,17.911144256591797,18.15355110168457,1.2941790178752632,,
2003-01-02,17.956035614013672,17.978479385375977,1.3533855884364339,,
2002-12-31,16.65422248840332,17.956035614013672,0.12499290959742022,,
2002-12-30,16.510574340820312,16.65422248840332,7.816715109437447,,
2002-12-27,16.568931579589844,16.510574340820312,0.8700372538092506,,
2002-12-26,16.80236053466797,16.45221710205078,-0.3522088222116725,,
2002-12-24,16.946008682250977,16.92356300354004,-2.083894295058981,,
2002-12-23,17.37246322631836,17.11659049987793,-0.13245407300213888,,
2002-12-20,18.131107330322266,17.37246322631836,-1.47286382539464,,
2002-12-19,18.23435401916504,18.131107330322266,-4.184212746538421,,
2002-12-18,18.51716041564941,18.30168914794922,-0.5662207102826732,,
2002-12-17,18.391469955444336,18.40942573547364,-1.1636301833735292,,
2002-12-16,18.22537612915039,18.38698005676269,0.09763102173346737,,
2002-12-13,18.27026557922364,18.171506881713867,0.8866973524558727,,
2002-12-12,18.42289161682129,18.33760070800781,-0.5405433056325024,,
2002-12-11,17.956035614013672,18.41840362548828,-0.46296157295743956,,
2002-12-10,18.33760070800781,18.216398239135746,2.575000525805135,,
2002-12-09,19.168067932128903,18.69672203063965,-0.6609505289268053,,
2002-12-06,18.62938690185547,19.27580451965332,-2.4590162303170855,,
2002-12-05,18.94361686706543,18.62938690185547,3.4698813289098047,,
2002-12-04,18.93463897705078,18.966062545776367,-1.6587643606552658,,
2002-12-03,19.01095199584961,18.93463897705078,0.16595810864771188,,
2002-12-02,19.751638412475582,18.87628173828125,-0.40141608276896634,,
2002-11-29,19.482297897338867,19.65287971496582,-4.431818039162955,,
2002-11-27,19.46434211730957,19.572078704833984,0.8755733975829069,,
2002-11-26,19.370073318481445,19.46434211730957,0.553507469582567,,
2002-11-25,19.52718734741211,19.65287971496582,0.4866723903320536,,
2002-11-22,20.357654571533203,19.66185760498047,0.6436788120966568,,
2002-11-21,20.49232482910156,20.24991798400879,-3.417864096808533,,
2002-11-20,19.976089477539062,20.290319442749023,-1.182915296894587,,
2002-11-19,19.98506736755371,19.94915580749512,1.573030425015258,,
2002-11-18,20.222984313964844,19.99404525756836,-0.17969196399554585,,
2002-11-15,19.52718734741211,20.1780948638916,-1.1320735497895436,,
2002-11-14,19.52718734741211,19.73368263244629,3.3333398451044993,,
2002-11-13,19.53616714477539,19.293760299682617,1.0574758226076322,,
2002-11-12,19.79203987121582,19.500253677368164,-1.240810663096732,,
2002-11-11,20.3352108001709,19.79203987121582,-1.4742603377229955,,
2002-11-08,20.46988105773925,20.600061416625977,-2.6710858042863923,,
2002-11-07,20.43396759033203,20.49232482910156,0.6359605047021379,,
2002-11-06,19.751638412475582,20.44743537902832,0.28558936736856916,,
2002-11-05,19.14562225341797,19.504743576049805,3.5227303782214685,,
2002-11-04,18.80894660949707,18.8852596282959,1.8757359665744155,,
2002-11-01,18.53960609436035,18.73263359069824,0.4057272338701622,,
2002-10-31,18.74161148071289,18.79548072814941,1.04116287776257,,
2002-10-30,18.79548072814941,18.903215408325195,0.2874312461975699,,
2002-10-29,19.19051170349121,18.79548072814941,0.5731945978611438,,
2002-10-28,19.639413833618164,19.114198684692383,-2.05847025574589,,
2002-10-25,19.05584144592285,19.33864974975586,-2.6742913682420277,,
2002-10-24,19.59452247619629,19.05584144592285,1.4841029436331552,,
2002-10-23,19.033397674560547,19.374561309814453,-2.7491408934707904,,
2002-10-22,19.280292510986328,19.21295738220215,1.792447365873593,,
2002-10-21,19.437408447265625,19.59452247619629,-0.34924329465339116,,
2002-10-18,19.706748962402344,19.751638412475582,0.8083074930329316,,
2002-10-17,19.953643798828125,19.841419219970703,0.2277871918847765,,
2002-10-16,19.841419219970703,19.52718734741211,-0.5624264920676434,,
2002-10-15,19.931198120117188,19.80999565124512,-1.5837167143886282,,
2002-10-14,19.07828712463379,19.428430557250977,-0.6081042802426077,,
2002-10-11,18.315155029296875,18.624897003173828,1.8352980554794358,,
2002-10-10,18.000925064086914,18.09519386291504,1.691178553397395,,
2002-10-09,17.43979835510254,18.09070587158203,0.5236886354035091,,
2002-10-08,17.866254806518555,17.71811866760254,3.73231102347608,,
2002-10-07,18.18048477172852,17.754030227661133,-0.8291392937145826,,
2002-10-04,18.80894660949707,18.35555648803711,-2.3456720182211126,,
2002-10-03,18.853836059570312,19.028907775878903,-2.410502463923385,,
2002-10-02,18.82241439819336,18.69672203063965,0.9285734518717362,,
2002-10-01,18.171506881713867,18.853836059570312,-0.6677802586568029,,
2002-09-30,18.108661651611328,18.13559532165528,3.7549399854289387,,
2002-09-27,18.62938690185547,18.113149642944336,0.14873363124301256,,
2002-09-26,18.853836059570312,18.80894660949707,-2.7710909737975116,,
2002-09-25,19.07828712463379,19.66185760498047,-0.23809186592802714,,
2002-09-24,18.51716041564941,18.898727416992188,3.058820094982093,,
2002-09-23,18.76854515075684,18.71916580200196,2.0606129275647644,,
2002-09-20,18.29271125793457,18.764057159423828,-0.2630963047921061,,
2002-09-19,17.77198600769043,18.000925064086914,2.5766869374533465,,
2002-09-18,17.776473999023438,18.14457321166992,1.2882018717402552,,
2002-09-17,17.50713348388672,17.32308578491211,2.070709931939836,,
2002-09-16,16.896629333496094,17.1973934173584,-1.0512726092138607,,
2002-09-13,17.156991958618164,16.887651443481445,1.7800241570433584,,
2002-09-12,17.50713348388672,17.156991958618164,-1.5698586080028192,,
2002-09-11,17.50713348388672,17.332063674926758,-1.9999934631835605,,
2002-09-10,17.013343811035156,17.125568389892578,-0.999991284244747,,
2002-09-09,16.811338424682617,17.026809692382812,0.659626820593792,,
2002-09-06,17.071701049804688,16.833782196044922,1.2817020409501585,,
2002-09-05,17.10312271118164,16.96845245361328,-1.3936446817201475,,
2002-09-04,17.125568389892578,17.417354583740234,-0.7874015748031495,,
2002-09-03,17.731584548950195,17.18392562866211,1.7038044355938982,,
2002-08-30,18.000925064086914,17.969501495361328,-3.08860676707266,,
2002-08-29,17.619359970092773,18.16701889038086,-0.17456641041341883,,
2002-08-28,18.24781990051269,17.88421058654785,3.108279308769933,,
2002-08-27,18.449825286865234,18.29719924926757,-1.9926178357044406,,
2002-08-26,18.36004638671875,18.48573875427246,-0.8272492298684292,,
2002-08-23,18.62938690185547,18.193952560424805,0.6845972221760507,,
2002-08-22,18.13559532165528,18.737123489379883,-2.33735196828885,,
2002-08-21,17.543046951293945,18.15355110168457,3.3168371760387254,,
2002-08-20,17.95154571533203,17.552024841308594,3.480034865583001,,
2002-08-19,17.933589935302734,17.956035614013672,-2.2255513834790017,,
2002-08-16,18.068260192871094,17.933589935302734,0.12515998632684583,,
2002-08-15,17.812387466430664,18.09070587158203,-0.7453415886798779,,
2002-08-14,17.76749610900879,17.96052360534668,1.562499163438297,,
2002-08-13,18.02337074279785,17.740562438964844,1.0864079842967767,,
2002-08-12,18.104171752929688,18.28822135925293,-1.5691199380449863,,
2002-08-09,18.29271125793457,18.104171752929688,1.016614340799427,,
2002-08-08,17.789941787719727,18.29271125793457,-1.030681031075165,,
2002-08-07,17.089656829833984,17.8931884765625,2.826144549623552,,
2002-08-06,16.609333038330078,17.089656829833984,4.701859462302155,,
2002-08-05,17.978479385375977,16.99089813232422,2.891890904923408,,
2002-08-02,17.915634155273438,18.009902954101562,-5.493130046666097,,
2002-08-01,18.51716041564941,17.915634155273438,0.5261817584077934,,
2002-07-31,18.24781990051269,18.588985443115234,-3.248480041613751,,
2002-07-30,17.798919677734375,18.13559532165528,1.8696235740081872,,
2002-07-29,17.664249420166016,17.798919677734375,1.8915510043121955,,
2002-07-26,17.0582332611084,17.350019454956055,0.7623887908569493,,
2002-07-25,16.946008682250977,16.887651443481445,1.7105299791679411,,
2002-07-24,13.579251289367676,15.015734672546388,-0.34437158544981655,,
2002-07-23,14.230157852172852,13.915926933288574,10.57851683106752,,
2002-07-22,14.427674293518066,14.364828109741213,-2.2082040280129176,,
2002-07-19,14.40971851348877,14.427674293518066,-0.4355946946008384,,
2002-07-18,15.419745445251465,14.845151901245115,0.12460881878080185,,
2002-07-17,15.374855041503906,15.531970024108888,-3.7263490895259648,,
2002-07-16,15.464634895324709,15.083069801330566,1.0218957003552593,,
2002-07-15,15.217740058898926,15.487080574035645,-2.4673398148539394,,
2002-07-12,14.34238338470459,14.881064414978027,1.7699113935069197,,
2002-07-11,15.065113067626951,14.20771312713623,3.7558682948603437,,
2002-07-10,15.895580291748049,15.217740058898926,-5.691294427342642,,
2002-07-09,16.609333038330078,15.895580291748049,-4.264331470811503,,
2002-07-08,16.699111938476562,16.609333038330078,-4.297299265026906,,
2002-07-05,16.70808982849121,16.820316314697266,-0.5376267940310291,,
2002-07-03,16.609333038330078,16.65422248840332,0.6716895070475514,,
2002-07-02,16.85622787475586,16.510574340820312,0.27026642171391746,,
2002-07-01,17.094144821166992,16.744003295898438,-2.0505983693611713,,
2002-06-28,17.641803741455078,16.9011173248291,-2.048312617750778,,
2002-06-27,16.99089813232422,17.5744686126709,-4.198473282442748,,
2002-06-26,17.10761260986328,17.03578758239746,3.4346064334084256,,
2002-06-25,17.22881507873535,17.10761260986328,-0.4198424941210679,,
2002-06-24,16.27265739440918,16.70808982849121,-0.7034869683038408,,
2002-06-21,16.609333038330078,16.218788146972656,2.675853264333049,,
2002-06-20,16.7215576171875,16.91009521484375,-2.351358061495573,,
2002-06-19,17.50713348388672,16.9011173248291,1.1275121730433704,,
2002-06-18,16.941518783569336,17.394908905029297,-3.4615384615384617,,
2002-06-17,16.57341957092285,16.954986572265625,2.6762070582460384,,
2002-06-14,16.048206329345703,16.497106552124023,2.302282879582749,,
2002-06-13,16.58688735961914,16.13798713684082,2.7971987246790486,,
2002-06-12,17.192903518676758,16.618310928344727,-2.7063560090916763,,
2002-06-11,18.5844955444336,17.192903518676758,-3.3420334715881337,,
2002-06-10,20.362144470214844,20.50130271911621,-7.487919284274845,,
2002-06-07,19.774084091186523,20.362144470214844,0.683416469738361,,
2002-06-06,20.13320541381836,20.088314056396484,2.9738943979227024,,
2002-06-05,19.94017791748047,20.222984313964844,-0.22297173499786557,,
2002-06-04,20.38907814025879,20.05240249633789,1.41827418819796,,
2002-06-03,21.412572860717773,20.38907814025879,-1.651254861082332,,
2002-05-31,20.96367073059082,21.322792053222656,-4.779877351108174,,
2002-05-30,21.031005859375,20.98162651062012,1.7130650793317188,,
2002-05-29,20.99958229064941,21.14323234558105,-0.23479309113913546,,
2002-05-28,21.09834098815918,20.995094299316406,0.6840614872401742,,
2002-05-24,21.547243118286133,21.053451538085938,-0.4893592766403652,,
2002-05-23,21.322792053222656,21.43501663208008,-2.291669414455799,,
2002-05-22,21.031005859375,21.3676815032959,0.5263127763817599,,
2002-05-21,21.147720336914062,20.932247161865234,1.6008537402923046,,
2002-05-20,21.25545692443848,21.10283088684082,-1.0188955197819238,,
2002-05-17,20.24542999267578,21.3676815032959,-0.7180557827584402,,
2002-05-16,20.53721618652344,20.53721618652344,5.543233762019951,,
2002-05-15,21.771692276000977,21.053451538085938,0.0,,
2002-05-14,22.84905433654785,23.226131439208984,-3.298966055600366,,
2002-05-13,22.893945693969727,22.90292358398437,1.6502963190821642,,
2002-05-10,23.567296981811523,23.00617027282715,0.03921512759161329,,
2002-05-09,23.657075881958008,23.410181045532227,-2.3809548859906777,,
2002-05-08,23.365291595458984,23.52240562438965,-1.043640548213631,,
2002-05-07,23.45507049560547,23.19919776916504,0.6724248584220494,,
2002-05-06,24.128421783447266,23.42364883422852,-1.0909058085686414,,
2002-05-03,24.195756912231445,23.98477363586425,-2.9209243586011886,,
2002-05-02,24.667102813720703,24.24064826965332,-0.8719846092541056,,
2002-05-01,24.28553771972656,24.68954849243164,-1.7288392045383374,,
2002-04-30,24.05659866333008,24.218202590942383,1.6635858648372173,,
2002-04-29,24.29451560974121,23.85459327697754,0.6717654888537381,,
2002-04-26,24.079042434692383,24.29451560974121,-1.8107886562977165,,
2002-04-25,24.132911682128903,23.96681785583496,0.8948577404323215,,
2002-04-24,24.61323547363281,24.08802032470703,-0.6882461117070217,,
2002-04-23,24.63568115234375,24.50101089477539,-2.133872848567268,,
2002-04-22,24.599767684936523,24.41571807861328,-0.5466471851765597,,
2002-04-19,24.653636932373047,24.57732391357422,-0.7481761969481668,,
2002-04-18,24.37531852722168,24.541410446166992,-0.3095406126412951,,
2002-04-17,24.27655982971192,24.465097427368164,0.6813938400838768,,
2002-04-16,24.128421783447266,24.388784408569336,0.7766240314885677,,
2002-04-15,24.03864288330078,24.128421783447266,1.0790702660075595,,
2002-04-12,24.10597801208496,24.10148811340332,0.3734774071162403,,
2002-04-11,24.393274307250977,24.15984535217285,-0.0186256648844105,,
2002-04-10,23.52689552307129,24.50101089477539,-0.9569398193039527,,
2002-04-09,23.724411010742188,23.63912010192871,4.140433108774808,,
2002-04-08,23.477516174316406,23.32040023803711,-0.3595069600457421,,
2002-04-05,23.589740753173828,23.30244445800781,-0.669218732990061,,
2002-04-04,23.881526947021484,23.701967239379883,-1.217886615084422,,
2002-04-03,24.02517509460449,23.769302368164062,-0.7518769969773492,,
2002-04-02,23.61218643188477,24.007219314575195,-1.0650191952103165,,
2002-04-01,23.61218643188477,23.89948272705078,1.6730042507075609,,
2002-03-28,23.342845916748047,23.61218643188477,1.2167288954573934,,
2002-03-27,23.607696533203125,23.30244445800781,1.1538460909921682,,
2002-03-26,23.45956039428711,23.71992301940918,-1.293019311587614,,
2002-03-25,24.03864288330078,23.52689552307129,1.1098359080312263,,
2002-03-22,23.544851303100582,24.10597801208496,-2.1288529586043894,,
2002-03-21,23.410181045532227,23.50444984436035,2.383224687898049,,
2002-03-20,23.701967239379883,23.25306510925293,0.4026829123823285,,
2002-03-19,24.37531852722168,23.96232986450196,-1.8939446063410297,,
2002-03-18,24.352872848510746,24.02068519592285,-1.6942903218208418,,
2002-03-15,24.729949951171875,24.245136260986328,-1.3640594054520696,,
2002-03-14,24.91399955749512,24.61772346496582,-1.9604313439484866,,
2002-03-13,24.77483940124512,24.91399955749512,-1.1891952227323885,,
2002-03-12,24.330427169799805,24.77483940124512,0.5616995290916241,,
2002-03-11,24.195756912231445,24.541410446166992,1.8265697858233403,,
2002-03-08,24.57732391357422,24.28104782104492,1.4285708655008515,,
2002-03-07,25.13844871520996,24.397762298583984,-1.2054855669850417,,
2002-03-06,25.01275634765625,25.14742660522461,-2.9464284969096997,,
2002-03-05,25.654685974121094,24.69852638244629,0.5384063063524716,,
2002-03-04,25.80731201171875,25.753442764282227,-3.7270368175206707,,
2002-03-01,25.564905166625977,25.80731201171875,-0.20873637445101662,,
2002-02-28,25.403301239013672,25.38534545898437,0.9482016205920704,,
2002-02-27,25.250675201416016,25.313520431518555,-0.07068286070522381,,
2002-02-26,25.484102249145508,25.3584098815918,0.24888534505015852,,
2002-02-25,25.86117935180664,25.484102249145508,-0.4932187381955819,,
2002-02-22,25.45716857910156,25.86117935180664,-1.4580816192931687,,
2002-02-21,25.847713470458984,25.654685974121094,1.587021633807086,,
2002-02-20,25.63224029541016,25.847713470458984,-0.746787512011456,,
2002-02-19,25.76691055297852,25.403301239013672,0.840633407636274,,
2002-02-15,25.259653091430664,25.73997688293457,-1.4111482756818745,,
2002-02-14,25.124982833862305,25.259653091430664,1.9015454795254336,,
2002-02-13,25.13844871520996,25.124982833862305,0.5360013913595871,,
2002-02-12,24.927465438842773,25.19680595397949,-0.053566874790920364,,
2002-02-11,24.57732391357422,24.99480056762696,1.0804969955630555,,
2002-02-08,24.71199417114257,24.81972885131836,1.6986253488003482,,
2002-02-07,25.21476173400879,24.94991111755371,0.4359610941540101,,
2002-02-06,25.38534545898437,25.102537155151367,-1.0503792153540632,,
2002-02-05,25.41227912902832,25.58735084533692,-1.1140612771645888,,
2002-02-04,25.67264175415039,25.41227912902832,0.6889256780932227,,
2002-02-01,25.72202110290528,25.78486633300781,-1.01416374526388,,
2002-01-31,25.452680587768555,25.901580810546875,0.24432461917010903,,
2002-01-30,25.237207412719727,25.35392189025879,1.7636658002695487,,
2002-01-29,25.52001571655273,25.237207412719727,0.4624698590076079,,
2002-01-28,25.58735084533692,25.52001571655273,-1.108182326273294,,
2002-01-25,25.6771297454834,25.69508552551269,-0.2631578751204,,
2002-01-24,25.6771297454834,25.73997688293457,0.06992907777183212,,
2002-01-23,25.80282211303711,25.762420654296875,0.2447592004017765,,
2002-01-22,25.704065322875977,25.80282211303711,-0.15657767419099933,,
2002-01-18,25.704065322875977,25.77140045166016,0.38420689070238917,,
2002-01-17,25.36289978027344,25.76691055297852,0.26196295386884444,,
2002-01-16,25.0037784576416,25.36289978027344,1.5929202741214412,,
2002-01-15,25.250675201416016,25.035202026367188,1.4362682153828057,,
2002-01-14,25.13844871520996,25.08906936645508,-0.8533362903370787,,
2002-01-11,24.75688362121582,25.08458137512207,-0.1964295781107702,,
2002-01-10,24.57732391357422,24.79728507995605,1.3236631836222876,,
2002-01-09,24.62221336364746,24.57283401489257,0.8949760647470101,,
2002-01-08,24.981334686279297,24.707504272460938,-0.20054796872077388,,
2002-01-07,25.09355926513672,24.86910820007324,-1.096140047187941,,
2002-01-04,25.1608943939209,25.04417991638184,-0.8944568711514637,,
2002-01-03,25.04866981506348,25.08906936645508,-0.46387253056973293,,
2002-01-02,24.75688362121582,25.066625595092773,0.16128421864264642,,
2001-12-31,25.250675201416016,25.02622413635254,1.251134749494539,,
2001-12-28,25.4975700378418,25.35392189025879,-0.8888913396299585,,
2001-12-27,25.309032440185547,25.36289978027344,-0.5633797548935774,,
2001-12-26,25.47512435913086,25.484102249145508,0.21283840152800113,,
2001-12-24,25.36289978027344,25.34494400024414,0.03524179072920034,,
2001-12-21,24.95888900756836,25.403301239013672,-0.07079545393017693,,
2001-12-20,24.801773071289062,24.95888900756836,1.7805769772466717,,
2001-12-19,24.28553771972656,24.60874557495117,0.6334867101141928,,
2001-12-18,24.13739967346192,24.17331314086914,1.3308655503315268,,
2001-12-17,24.263092041015625,24.24064826965332,0.14878764031365332,,
2001-12-14,23.9713077545166,24.42020797729492,-0.09250169485556309,,
2001-12-13,23.809701919555664,23.877037048339844,1.8726563747600975,,
2001-12-12,24.24064826965332,23.809701919555664,0.2828054253332555,,
2001-12-11,25.116004943847656,24.30349349975586,-1.777783932606929,,
2001-12-10,24.75239372253418,24.91399955749512,-3.235034576192928,,
2001-12-07,24.78381729125977,24.75239372253418,0.6528897236060758,,
2001-12-06,24.70301628112793,24.653636932373047,-0.12679067294718677,,
2001-12-05,24.667102813720703,24.761371612548828,-0.19989198158204902,,
2001-12-04,24.86910820007324,24.729949951171875,0.38216404877385685,,
2001-12-03,24.57732391357422,24.896041870117188,-0.5595626822716298,,
2001-11-30,24.55487823486328,24.68954849243164,1.296796826471977,,
2001-11-29,24.24064826965332,24.4875431060791,0.5484460410687482,,
2001-11-28,24.141889572143555,24.28104782104492,1.0185158155810008,,
2001-11-27,23.926416397094727,24.141889572143555,0.5764182148440165,,
2001-11-26,24.330427169799805,24.263092041015625,0.9005660165430875,,
2001-11-23,24.3259391784668,24.218202590942383,-0.2767527602957977,,
2001-11-21,23.535873413085938,24.128421783447266,-0.44288767941911783,,
2001-11-20,23.477516174316406,23.764812469482425,2.51763917982271,,
2001-11-19,23.32937812805176,23.40120315551757,1.223708219527547,,
2001-11-16,23.814191818237305,23.356313705444336,0.3078737335884905,,
2001-11-15,23.432626724243164,23.746856689453125,-1.9227111139766586,,
2001-11-14,23.73787879943848,23.42364883422852,1.340993346191367,,
2001-11-13,24.065576553344727,23.84561538696289,-1.3237491347263683,,
2001-11-12,23.769302368164062,24.065576553344727,-0.914007465785252,,
2001-11-09,24.029664993286133,23.881526947021484,1.2464572186076668,,
2001-11-08,24.11495590209961,24.029664993286133,-0.6164798648089271,,
2001-11-07,24.24064826965332,24.11495590209961,-0.3536846974124077,,
2001-11-06,24.24064826965332,24.352872848510746,-0.5185190022787642,,
2001-11-05,24.66261482238769,24.150867462158203,0.46296030373873504,,
2001-11-02,24.204734802246094,24.44265365600586,-2.074992306837415,,
2001-11-01,23.692989349365234,24.204734802246094,0.9829434435186946,,
2001-10-31,24.016197204589844,23.78276824951172,2.1599024307777763,,
2001-10-30,24.330427169799805,24.141889572143555,-0.9719646832076868,,
2001-10-29,24.397762298583984,24.254114151000977,-0.7749045930861119,,
2001-10-26,24.24064826965332,24.37531852722168,-0.5887759124177752,,
2001-10-25,24.14637756347656,24.4875431060791,0.5555555118422804,,
2001-10-24,24.17780113220215,24.3483829498291,1.4129056903284092,,
2001-10-23,24.50101089477539,24.17780113220215,0.7055307333128696,,
2001-10-22,23.567296981811523,24.50101089477539,-1.3191690904564415,,
2001-10-19,23.59423065185547,23.814191818237305,3.9619049808065703,,
2001-10-18,23.791746139526367,23.59423065185547,0.9322667461697379,,
2001-10-17,23.814191818237305,23.890504837036133,-0.8301849158635587,,
2001-10-16,23.926416397094727,24.007219314575195,0.32045185232944307,,
2001-10-15,23.275510787963867,23.791746139526367,0.33771424913544623,,
2001-10-12,22.87150001525879,23.30244445800781,2.2179335021487625,,
2001-10-11,23.634632110595703,22.90292358398437,1.8841984236342784,,
2001-10-10,23.18572998046875,23.634632110595703,-3.0959167174144318,,
2001-10-09,23.23510932922364,22.907411575317383,1.936113853241198,,
2001-10-08,23.073505401611328,23.23959922790528,-1.4103559800947427,,
2001-10-05,23.12737274169922,23.3338680267334,0.719846522680309,,
2001-10-04,23.095951080322266,23.19021987915039,0.8928609718900913,,
2001-10-03,23.97579574584961,23.095951080322266,0.40816157992489843,,
2001-10-02,23.553829193115234,23.9713077545166,-3.6697203915730365,,
2001-10-01,23.230621337890625,23.69747734069824,1.772444548096646,,
2001-09-28,23.073505401611328,23.275510787963867,2.0096578391820357,,
2001-09-27,22.31037330627441,22.88945579528809,0.8754863330754767,,
2001-09-26,22.13081359863281,22.40015411376953,2.5955750765085672,,
2001-09-25,21.075897216796875,21.749248504638672,1.2170384696266274,,
2001-09-24,21.47990798950196,21.210567474365234,3.194887889779399,,
2001-09-21,21.22852325439453,21.12078666687012,-1.2539183839537986,,
2001-09-20,21.861473083496094,21.76720428466797,-0.5075086299378261,,
2001-09-19,22.66949462890625,22.26548385620117,-0.43120972895139187,,
2001-09-18,22.71438407897949,22.629093170166016,-1.7821781178567642,,
2001-09-17,21.547243118286133,22.68296241760254,-0.3754929410232327,,
2001-09-10,21.95125389099121,22.234060287475582,5.270833456891637,,
2001-09-07,22.5393123626709,21.95125389099121,1.2883382329263438,,
2001-09-06,22.826610565185547,22.42708778381348,-2.609034660052969,,
2001-09-05,22.60215950012207,23.1767520904541,-1.7502501312280099,,
2001-09-04,22.53482437133789,22.71438407897949,2.5422021746591423,,
2001-08-31,22.58869171142578,22.31037330627441,0.7968098827074974,,
2001-08-30,22.893945693969727,22.58869171142578,-1.2321138767438757,,
2001-08-29,23.275510787963867,22.893945693969727,-1.3333393318232136,,
2001-08-28,23.163286209106445,23.073505401611328,-1.639341441183125,,
2001-08-27,23.544851303100582,23.369779586791992,-0.38759961209571653,,
2001-08-24,23.47302627563477,23.567296981811523,-0.7435668803121102,,
2001-08-23,23.657075881958008,23.47302627563477,0.40161291973931873,,
2001-08-22,23.675031661987305,23.769302368164062,-0.7779896688905812,,
2001-08-21,23.89948272705078,23.675031661987305,0.3981861883974547,,
2001-08-20,23.45507049560547,23.78725814819336,-0.9391461213904442,,
2001-08-17,23.62116432189941,23.47302627563477,1.4162722412202051,,
2001-08-16,23.791746139526367,23.77828025817871,-0.6271411698673174,,
2001-08-15,23.58525276184082,23.859081268310547,-0.05659896196221065,,
2001-08-14,23.567296981811523,23.47302627563477,1.1610157806439143,,
2001-08-13,23.275510787963867,23.589740753173828,-0.40000644218770337,,
2001-08-10,23.14981842041016,23.46853828430176,1.3500454107003064,,
2001-08-09,23.28448867797852,23.14981842041016,1.3767704700897374,,
2001-08-08,23.607696533203125,23.28448867797852,-0.5783689709953769,,
2001-08-07,23.19021987915039,23.607696533203125,-1.3690783205808708,,
2001-08-06,23.558319091796875,23.21266365051269,1.8002272347062767,,
2001-08-03,23.342845916748047,23.45956039428711,-1.467233039578542,,
2001-08-02,23.939884185791016,23.342845916748047,0.5000010622326136,,
2001-08-01,23.948862075805664,23.83663749694824,-2.493906254556267,,
2001-07-31,23.342845916748047,24.05659866333008,-0.46860088175462955,,
2001-07-30,23.297956466674805,23.47302627563477,3.0576937753332416,,
2001-07-27,23.163286209106445,23.136350631713867,0.7514384757752588,,
2001-07-26,23.05105972290039,23.275510787963867,-0.11628564768149624,,
2001-07-25,22.93883514404297,23.11839485168457,0.9737125657632677,,
2001-07-24,22.74580764770508,23.01963806152344,0.7827760499348276,,
2001-07-23,23.37875747680664,23.077993392944336,1.203872019228947,,
2001-07-20,23.31142234802246,23.46853828430176,-1.2864844684782057,,
2001-07-19,23.158796310424805,23.163286209106445,0.6739869147994257,,
2001-07-18,22.48993492126465,23.140840530395508,0.019387444068582792,,
2001-07-17,22.445043563842773,22.51237869262696,2.8942085044248667,,
2001-07-16,22.498912811279297,22.33281898498535,0.29999999150217055,,
2001-07-13,22.099390029907227,22.26548385620117,-0.7382304544541286,,
2001-07-12,22.445043563842773,21.996143341064453,0.751576518940867,,
2001-07-11,22.04103279113769,22.52584648132324,-1.9999971107272154,,
2001-07-10,21.27790260314941,21.72680282592773,2.1995960660268237,,
2001-07-09,21.322792053222656,21.50235176086425,2.1097014642405454,,
2001-07-06,21.906362533569336,21.23750114440918,0.8421022312340959,,
2001-07-05,22.121835708618164,21.969209671020508,-3.0532745367250826,,
2001-07-03,22.22957229614257,22.117345809936523,-0.6899338717093745,,
2001-07-02,22.01858901977539,22.1622371673584,-0.5048522063806054,,
2001-06-29,22.93883514404297,21.547243118286133,0.6523948807709439,,
2001-06-28,22.40015411376953,22.718873977661133,-6.066533095592787,,
2001-06-27,23.10492897033692,22.445043563842773,1.4228467459323517,,
2001-06-26,22.961280822753903,23.10492897033692,-2.856037373416453,,
2001-06-25,23.410181045532227,23.279998779296875,0.6256103424364189,,
2001-06-22,23.45507049560547,23.35182380676269,-0.5560925222327425,,
2001-06-21,23.45507049560547,23.791746139526367,-0.44018920711460335,,
2001-06-20,23.410181045532227,23.45507049560547,1.4354066596558634,,
2001-06-19,22.893945693969727,23.01963806152344,0.1917518279159538,,
2001-06-18,22.66949462890625,22.93883514404297,0.5490201175187636,,
2001-06-15,22.557270050048828,22.696428298950195,1.1881187452378323,,
2001-06-14,22.570735931396484,22.66949462890625,0.6169108610776506,,
2001-06-13,22.66949462890625,22.79518699645996,0.43755196024596477,,
2001-06-12,22.87150001525879,22.768253326416016,0.5544559753592323,,
2001-06-11,23.11839485168457,22.620115280151367,-0.451420714749326,,
2001-06-08,22.93883514404297,23.12737274169922,-2.155338096480755,,
2001-06-07,22.781719207763672,23.18572998046875,0.8219144366849495,,
2001-06-06,23.499961853027344,23.208175659179688,1.7733989652870326,,
2001-06-05,22.98372459411621,23.724411010742188,-1.241645393607596,,
2001-06-04,22.98372459411621,23.271020889282227,3.2226561608538886,,
2001-06-01,22.920879364013672,23.172264099121094,1.249998858929779,,
2001-05-31,23.10941696166992,23.3338680267334,1.0967499593497356,,
2001-05-30,23.163286209106445,23.10941696166992,0.9712536903711697,,
2001-05-29,22.98372459411621,23.05105972290039,-0.2325630610018917,,
2001-05-25,23.11390686035156,23.073505401611328,0.29296874189580807,,
2001-05-24,23.275510787963867,23.3159122467041,-0.17479285948639633,,
2001-05-23,23.903972625732425,23.746856689453125,0.17357925722139944,,
2001-05-22,23.746856689453125,23.769302368164062,-0.6572796025969609,,
2001-05-21,23.800724029541016,23.90846061706543,0.09452063068585609,,
2001-05-18,24.10597801208496,23.800724029541016,0.4526609669129956,,
2001-05-17,24.150867462158203,24.10597801208496,-1.2662999293823027,,
2001-05-16,23.11839485168457,24.150867462158203,-0.18587096361478156,,
2001-05-15,22.66949462890625,23.11839485168457,4.466022044771847,,
2001-05-14,22.11285781860352,22.3777084350586,1.980195104155168,,
2001-05-11,21.996143341064453,22.11285781860352,1.1977222420896823,,
2001-05-10,21.713335037231445,21.59213256835937,0.5306133703955846,,
2001-05-09,21.547243118286133,21.70884704589844,-0.558193702921501,,
2001-05-08,21.053451538085938,21.412572860717773,0.7499981632228514,,
2001-05-07,20.76166534423828,21.09834098815918,1.705759846465941,,
2001-05-04,20.357654571533203,20.914291381835938,1.6216215719628275,,
2001-05-03,20.3352108001709,20.564149856567383,2.734287529768279,,
2001-05-02,20.020978927612305,20.36663246154785,1.1258258330646878,,
2001-05-01,20.76166534423828,20.559659957885746,1.7264567091613707,,
2001-04-30,20.64944076538086,20.82002258300781,-0.9729729431776795,,
2001-04-27,20.290319442749023,20.64046287536621,0.8260844425042876,,
2001-04-26,19.886308670043945,20.137693405151367,1.7256674228572348,,
2001-04-25,19.94466590881348,20.429479598999023,1.2641095905651873,,
2001-04-24,20.17360496520996,19.94466590881348,2.4307937390483225,,
2001-04-23,20.38010025024414,19.99404525756836,-1.134844549555192,,
2001-04-20,19.99853515625,20.24094009399414,-1.894274257415179,,
2001-04-19,21.09385299682617,20.52374839782715,1.2121134665624924,,
2001-04-18,20.932247161865234,21.048961639404297,-2.702704902157037,,
2001-04-17,20.78411102294922,21.14323234558105,0.5575821680134523,,
2001-04-16,20.82900047302246,20.89184761047364,1.7278647243334149,,
2001-04-12,20.64944076538086,20.50130271911621,0.3017290125494886,,
2001-04-11,21.322792053222656,21.09385299682617,-0.7173949548939088,,
2001-04-10,22.22059440612793,21.64151191711425,-1.0736823574747887,,
2001-04-09,21.22403335571289,21.735780715942383,-2.6060620991037995,,
2001-04-06,21.09834098815918,21.22403335571289,2.411169223364157,,
2001-04-05,20.8514461517334,21.14323234558105,0.5957452655839247,,
2001-04-04,19.976089477539062,20.3935661315918,1.399357108012368,,
2001-04-03,20.76166534423828,20.164627075195312,2.0898817785239947,,
2001-04-02,20.98611640930176,20.82900047302246,-2.8756762000725398,,
2001-03-30,20.873891830444336,21.183631896972656,-0.7486660857826049,,
2001-03-29,20.24542999267578,20.873891830444336,1.483863522165847,,
2001-03-28,19.886308670043945,20.438457489013672,3.104215805719682,,
2001-03-27,19.863862991333008,20.101781845092773,2.776527449769824,,
2001-03-26,19.751638412475582,19.863862991333008,1.1977471545367298,,
2001-03-23,19.12317657470703,19.51820945739746,0.5681785810059273,,
2001-03-22,19.549633026123047,19.51820945739746,2.065728364464896,,
2001-03-21,19.751638412475582,19.751638412475582,-0.1607373840910284,,
2001-03-20,20.110759735107425,19.437408447265625,0.0,,
2001-03-19,19.774084091186523,20.088314056396484,-3.348214074012971,,
2001-03-16,20.424989700317383,20.20054054260254,1.589099974294212,,
2001-03-15,20.77513313293457,20.77513313293457,-1.0988948391555666,,
2001-03-14,21.322792053222656,20.77513313293457,0.0,,
2001-03-13,21.16567611694336,21.49337387084961,-2.5684203031249586,,
2001-03-12,21.210567474365234,21.183631896972656,1.5482508193722397,,
2001-03-09,21.776182174682617,21.43950653076172,-0.12699130952121884,,
2001-03-08,21.210567474365234,21.771692276000977,-1.5460728663095205,,
2001-03-07,21.5068416595459,21.15669822692871,2.6454964126438814,,
2001-03-06,22.13081359863281,21.55622100830078,-1.6280560305412157,,
2001-03-05,22.26548385620117,21.982675552368164,-2.596346436931378,,
2001-03-02,22.33281898498535,22.30139541625977,-1.270164644341377,,
2001-03-01,21.95125389099121,22.368730545043945,-0.14070578706032977,,
2001-02-28,21.92431831359864,21.99165344238281,1.901835112134832,,
2001-02-27,22.08592414855957,21.8255615234375,0.30712530178146596,,
2001-02-26,22.108367919921875,22.08592414855957,-1.1788622625467589,,
2001-02-23,22.22059440612793,21.95125389099121,-0.10151708820659068,,
2001-02-22,22.26548385620117,22.42259979248047,-1.2121211080763925,,
2001-02-21,21.92880821228028,22.445043563842773,0.7056479764554588,,
2001-02-20,21.68191337585449,21.848005294799805,2.354142307074388,,
2001-02-16,21.68191337585449,21.771692276000977,0.7660390301636391,,
2001-02-15,21.39012718200684,21.524797439575195,0.41407277388382113,,
2001-02-14,21.5068416595459,21.282390594482425,0.6295907285751863,,
2001-02-13,21.79413795471192,21.394615173339844,-1.043626342800778,,
2001-02-12,21.95125389099121,22.22059440612793,-1.8331662495772176,,
2001-02-09,21.95125389099121,21.72680282592773,1.2269937584169441,,
2001-02-08,21.327280044555664,21.67742347717285,-1.0224976950204872,,
2001-02-07,21.174654006958008,21.3497257232666,1.6417631872685547,,
2001-02-06,20.797576904296875,21.174654006958008,0.8267984744924995,,
2001-02-05,20.33072090148925,20.797576904296875,1.813081900820989,,
2001-02-02,20.64944076538086,20.429479598999023,2.296308158819034,,
2001-02-01,20.155649185180664,20.64944076538086,-1.0652160941356077,,
2001-01-31,20.1780948638916,20.137693405151367,2.4498917185126095,,
2001-01-30,20.58210563659668,20.222984313964844,-0.20022434730709973,,
2001-01-29,21.075897216796875,20.40254592895508,-1.7448230466434331,,
2001-01-26,20.59332847595215,20.73361015319824,-3.1948878897793827,,
2001-01-25,19.807750701904297,20.481101989746094,0.681199629335802,,
2001-01-24,19.38690757751465,19.414962768554688,3.399433373205073,,
2001-01-23,19.94803237915039,19.751638412475582,0.14471204821019562,,
2001-01-22,20.088314056396484,19.83580780029297,-0.9845280122969847,,
2001-01-19,19.976089477539062,19.77969551086425,-1.2569808267364928,,
2001-01-18,20.20054054260254,20.22859573364257,-0.9831452091543513,,
2001-01-17,20.20054054260254,19.863862991333008,0.1388833679022802,,
2001-01-16,19.52718734741211,20.20054054260254,-1.6666759513661775,,
2001-01-12,19.05023193359375,19.55524444580078,3.448285629725714,,
2001-01-11,19.218568801879883,18.881893157958984,2.6509520407280553,,
2001-01-10,19.61135673522949,19.10634422302246,-1.7518247450765752,,
2001-01-09,19.218568801879883,19.52718734741211,-2.575102370657673,,
2001-01-08,19.07828712463379,19.10634422302246,1.6058352144413517,,
2001-01-05,19.38690757751465,19.302738189697266,0.14706298424686506,,
2001-01-04,20.481101989746094,19.19051170349121,-0.43415582129769,,
2001-01-03,21.715579986572266,21.12639808654785,-6.301371317329603,,
2001-01-02,21.603355407714844,21.603355407714844,-2.7131759795903774,,
2000-12-29,21.743637084960938,21.743637084960938,0.0,,
2000-12-28,21.827804565429688,21.771692276000977,0.0,,
2000-12-27,21.91197395324707,21.79974937438965,-0.25706794863639254,,
2000-12-26,21.09834098815918,21.631410598754883,-0.5121609723381022,,
2000-12-22,21.631410598754883,21.266679763793945,2.526594915187278,,
2000-12-21,21.88391876220703,21.603355407714844,-1.6861167388775453,,
2000-12-20,22.445043563842773,21.91197395324707,-1.2820526229365887,,
2000-12-19,22.02419853210449,22.585325241088867,-2.3749992245701717,,
2000-12-18,21.51918601989746,22.24864959716797,2.5477735689969783,,
2000-12-15,20.424989700317383,21.0141716003418,3.389828855961457,,
2000-12-14,22.61338233947754,21.603355407714844,2.8846129602467427,,
2000-12-13,22.75366401672364,23.258676528930664,-4.466500926751814,,
2000-12-12,22.445043563842773,22.52921295166016,2.2194777589923396,,
2000-12-11,22.41698837280273,22.473100662231445,0.3750021138429721,,
2000-12-08,22.92200088500977,22.30476188659668,0.2503114535081455,,
2000-12-07,22.69754981994629,22.92200088500977,-2.6927797512508755,,
2000-12-06,24.016197204589844,22.97811317443848,0.988877948694866,,
2000-12-05,24.549266815185547,24.128421783447266,-4.322432986821789,,
2000-12-04,23.258676528930664,24.26870346069336,-1.714287578959211,,
2000-12-01,24.465097427368164,23.735633850097656,4.342581275019486,,
2000-11-30,25.11039352416992,24.717605590820312,-2.9816499992944436,,
2000-11-29,24.68954849243164,25.02622413635254,-1.5642444351639857,,
2000-11-28,23.791746139526367,24.57732391357422,1.363636293406108,,
2000-11-27,23.791746139526367,23.791746139526367,3.3018920487838157,,
2000-11-24,24.016197204589844,23.81980323791504,0.0,,
2000-11-22,23.735633850097656,24.04425430297852,-0.8177563042215149,,
2000-11-21,23.342845916748047,24.184534072875977,1.300241041928582,,
2000-11-20,23.623409271240234,23.65146446228028,3.605764948840426,,
2000-11-17,23.735633850097656,23.39895820617676,0.11876012779493814,,
2000-11-16,23.903972625732425,23.735633850097656,-1.4184396593205355,,
2000-11-15,22.781719207763672,23.903972625732425,-0.7042292855270169,,
2000-11-14,22.72560691833496,22.837831497192383,4.926113818426426,,
2000-11-13,23.51118278503418,23.00617027282715,0.4938243421207791,,
2000-11-10,23.342845916748047,23.59535217285156,-2.1479672750810823,,
2000-11-09,23.567296981811523,23.51118278503418,1.081728667550102,,
2000-11-08,23.735633850097656,23.567296981811523,-0.2381019631595888,,
2000-11-07,23.59535217285156,23.48312759399414,-0.7092158117590789,,
2000-11-06,23.37090301513672,23.623409271240234,-0.4756215462914012,,
2000-11-03,24.016197204589844,23.679521560668945,1.080430037042103,,
2000-11-02,23.567296981811523,24.016197204589844,-1.4018690846548962,,
2000-11-01,23.230621337890625,23.735633850097656,1.9047590528721514,,
2000-10-31,24.24064826965332,23.707578659057617,2.1739087597425715,,
2000-10-30,23.286733627319336,24.24064826965332,-2.1990732453432313,,
2000-10-27,22.61338233947754,23.20256423950196,4.0963866276843515,,
2000-10-26,23.11839485168457,22.92200088500977,2.6054567652882734,,
2000-10-25,22.388931274414062,23.09033966064453,-0.8495138522149192,,
2000-10-24,22.22059440612793,22.108367919921875,3.1328354964045744,,
2000-10-23,22.02419853210449,22.136425018310547,-0.5050561841635758,,
2000-10-20,21.603355407714844,21.91197395324707,0.5095599099439039,,
2000-10-19,22.388931274414062,21.88391876220703,1.4285676447373301,,
2000-10-18,23.11839485168457,22.893945693969727,-2.255634742084168,,
2000-10-17,23.00617027282715,23.11839485168457,-0.970868259473857,,
2000-10-16,22.557270050048828,22.64143753051757,0.48780208755549204,,
2000-10-13,22.02419853210449,22.557270050048828,0.3731279551204411,,
2000-10-12,22.52921295166016,22.33281898498535,2.4203900866916253,,
2000-10-11,22.108367919921875,22.473100662231445,-0.8717302601568961,,
2000-10-10,20.98611640930176,22.02419853210449,1.6497497401466221,,
2000-10-09,21.715579986572266,21.40696144104004,4.9465184627614756,,
2000-10-06,21.603355407714844,21.51918601989746,-1.4211849083609993,,
2000-10-05,21.322792053222656,21.378904342651367,-0.3896125681815373,,
2000-10-04,21.659467697143555,21.266679763793945,0.2631563881908716,,
2000-10-03,21.46307373046875,21.659467697143555,-1.8134699284480114,,
2000-10-02,21.51918601989746,21.51918601989746,0.9150318781974174,,
2000-09-29,20.873891830444336,21.35084724426269,0.0,,
2000-09-28,20.76166534423828,20.95805931091309,2.284937651745046,,
2000-09-27,20.64944076538086,20.98611640930176,0.9459451514052601,,
2000-09-26,21.210567474365234,20.873891830444336,1.6304346822086555,,
2000-09-25,21.547243118286133,21.547243118286133,-1.5873014445643638,,
2000-09-22,21.09834098815918,21.771692276000977,0.0,,
2000-09-21,19.723583221435547,20.64944076538086,3.19148926552896,,
2000-09-20,19.52718734741211,19.723583221435547,4.694165018347642,,
2000-09-19,19.667469024658203,19.52718734741211,1.0057560801221348,,
2000-09-18,20.172483444213867,19.863862991333008,-0.7132675641701267,,
2000-09-15,19.55524444580078,21.547243118286133,-1.529908073710091,,
2000-09-14,19.751638412475582,19.751638412475582,10.186518905485254,,
2000-09-13,20.032201766967773,19.863862991333008,0.0,,
2000-09-12,19.976089477539062,20.144426345825195,-0.8403408551542693,,
2000-09-11,19.723583221435547,20.172483444213867,0.8426918014930264,,
2000-09-08,19.38690757751465,19.807750701904297,2.275956745478461,,
2000-09-07,19.07828712463379,19.38690757751465,2.170759429821347,,
2000-09-06,19.10634422302246,19.02217483520508,1.6176528367809824,,
2000-09-05,19.218568801879883,19.16245651245117,-0.4405310970790433,,
2000-09-01,19.751638412475582,19.414962768554688,-0.2919691367612442,,
2000-08-31,19.751638412475582,19.646427154541016,-1.7045453996780486,,
2000-08-30,19.1343994140625,19.330793380737305,-0.532671040940649,,
2000-08-29,19.302738189697266,19.10634422302246,1.026392114144269,,
2000-08-28,19.07828712463379,19.414962768554688,-1.0174409700051206,,
2000-08-25,18.23659896850586,18.7977237701416,1.764705823544214,,
2000-08-24,18.657442092895508,18.37688064575196,3.076915836142421,,
2000-08-23,18.68549919128418,18.68549919128418,-1.5037508665262398,,
2000-08-22,18.82578086853028,18.881893157958984,0.0,,
2000-08-21,18.966062545776367,18.76966857910156,0.29806088693246585,,
2000-08-18,18.208541870117188,18.04020500183105,-1.0355020511020303,,
2000-08-17,18.48910522460937,18.37688064575196,-0.9244939517227414,,
2000-08-16,18.34882354736328,18.32076644897461,-0.6069767979255051,,
2000-08-15,17.89992332458496,18.04020500183105,-0.15290952205327446,,
2000-08-14,18.09631729125977,18.04020500183105,0.7836998779398004,,
2000-08-11,18.37688064575196,18.37688064575196,-0.31007573820458695,,
2000-08-10,17.647415161132812,18.208541870117188,0.0,,
2000-08-09,17.98409080505371,17.759641647338867,3.1796538125323703,,
2000-08-08,18.012147903442383,18.04020500183105,-1.2480428404630346,,
2000-08-07,18.62938690185547,18.15242958068848,0.15576764380946598,,
2000-08-04,18.909950256347656,18.853836059570312,-2.5602416423027003,,
2000-08-03,19.19051170349121,19.2746810913086,-0.2967442855039105,,
2000-08-02,18.909950256347656,19.19051170349121,0.43859897598289416,,
2000-08-01,18.7977237701416,18.93800544738769,1.4836709951120912,,
2000-07-31,18.853836059570312,18.62938690185547,0.7462694896544566,,
2000-07-28,17.87186622619629,18.62938690185547,-1.1904694461417686,,
2000-07-27,17.89992332458496,17.956035614013672,4.238621003937565,,
2000-07-26,17.927978515625,17.89992332458496,0.31347782005100844,,
2000-07-25,17.98409080505371,17.843809127807617,-0.15648831247531764,,
2000-07-24,17.956035614013672,18.29271125793457,-0.7800320781669607,,
2000-07-21,18.404935836791992,18.124372482299805,1.8749998672209254,,
2000-07-20,18.57327461242676,18.461048126220703,-1.5243919184512087,,
2000-07-19,18.881893157958984,18.461048126220703,-0.6042364017542239,,
2000-07-18,19.16245651245117,18.82578086853028,-2.2288285831174144,,
2000-07-17,18.657442092895508,19.07828712463379,-1.7569545099926327,,
2000-07-14,19.583301544189453,19.07828712463379,2.2556416342759715,,
2000-07-13,20.20054054260254,19.583301544189453,-2.5788012221335914,,
2000-07-12,19.302738189697266,19.89192008972168,-3.055556840725827,,
2000-07-11,19.2746810913086,19.302738189697266,3.0523229100153615,,
2000-07-10,19.49913215637207,19.302738189697266,0.1455645271418595,,
2000-07-07,19.667469024658203,19.44301986694336,-1.0071933719913049,,
2000-07-06,19.976089477539062,19.667469024658203,-1.1412203442824256,,
2000-07-05,19.94803237915039,20.0041446685791,-1.5449492916412366,,
2000-07-03,19.807750701904297,19.89192008972168,0.28129235185801726,,
2000-06-30,18.404935836791992,20.0041446685791,0.42493157897676315,,
2000-06-29,19.38690757751465,18.7977237701416,8.68902149927763,,
2000-06-28,18.7977237701416,19.092315673828125,-3.039080910750278,,
2000-06-27,18.37688064575196,18.657442092895508,1.567167957614393,,
2000-06-26,18.124372482299805,18.432992935180664,1.5267087627758131,,
2000-06-23,18.404935836791992,18.15242958068848,1.7027924866488866,,
2000-06-22,18.432992935180664,18.32076644897461,-1.371948581307982,,
2000-06-21,18.76966857910156,18.657442092895508,-0.6088348571536777,,
2000-06-20,18.93800544738769,18.76966857910156,-0.5979140533733549,,
2000-06-19,19.10634422302246,19.10634422302246,-0.888883830738116,,
2000-06-16,19.246625900268555,19.05023193359375,0.0,,
2000-06-15,18.881893157958984,19.246625900268555,-1.020407253159445,,
2000-06-14,18.57327461242676,18.853836059570312,1.9316534589956107,,
2000-06-13,18.04020500183105,18.432992935180664,1.510565331090495,,
2000-06-12,18.34882354736328,18.09631729125977,2.177291961536721,,
2000-06-09,18.29271125793457,18.32076644897461,-1.3761441187317818,,
2000-06-08,18.37688064575196,18.23659896850586,0.15336814015401876,,
2000-06-07,17.98409080505371,18.04020500183105,-0.7633595709211327,,
2000-06-06,17.5913028717041,18.04020500183105,0.31202131587086707,,
2000-06-05,17.451021194458008,17.843809127807617,2.5518412899877703,,
2000-06-02,18.461048126220703,17.563247680664062,2.2508019958989487,,
2000-06-01,18.29271125793457,18.34882354736328,-4.863214912925076,,
2000-05-31,18.6013298034668,18.2646541595459,0.30674670713108154,,
2000-05-30,18.71355628967285,18.461048126220703,-1.809954704733822,,
2000-05-26,19.19051170349121,18.71355628967285,-1.349332855516597,,
2000-05-25,19.218568801879883,19.19051170349121,-2.485371006191512,,
2000-05-24,19.2746810913086,19.513160705566406,-0.14598953063522316,,
2000-05-23,19.19051170349121,19.19051170349121,1.2372687938548637,,
2000-05-22,18.68549919128418,19.19051170349121,0.0,,
2000-05-19,18.09631729125977,18.657442092895508,2.7026974609412284,,
2000-05-18,17.50713348388672,18.208541870117188,3.1007679220277207,,
2000-05-17,17.226572036743164,17.310739517211914,4.006414795866117,,
2000-05-16,17.47907829284668,17.338796615600586,0.4885909993539411,,
2000-05-15,16.805727005004883,17.47907829284668,-0.8025690765599699,,
2000-05-12,16.805727005004883,16.609333038330078,4.0066775310658524,,
2000-05-11,17.451021194458008,16.974063873291016,-1.1686133341111453,,
2000-05-10,17.17045783996582,17.310739517211914,-2.7331198320844483,,
2000-05-09,17.14240264892578,17.50713348388672,0.8169943897452474,,
2000-05-08,17.0582332611084,17.42296600341797,2.1276529459176663,,
2000-05-05,16.609333038330078,17.03017807006836,2.1381624739599263,,
2000-05-04,16.77766990661621,16.7215576171875,2.533786460703021,,
2000-05-03,17.03017807006836,16.889896392822266,-0.33444625946886264,,
2000-05-02,16.889896392822266,17.14240264892578,-0.8237240777455397,,
2000-05-01,17.11434555053711,17.08629035949707,1.4950136473946858,,
2000-04-28,17.394908905029297,17.254627227783203,-0.1639279220884879,,
2000-04-27,17.282684326171875,17.50713348388672,-0.8064524971759688,,
2000-04-26,17.310739517211914,17.50713348388672,1.2986938456947408,,
2000-04-25,17.956035614013672,17.843809127807617,1.13452095145636,,
2000-04-24,17.394908905029297,17.98409080505371,-0.62500703729095,,
2000-04-20,17.310739517211914,17.619359970092773,3.387093909149861,,
2000-04-19,17.254627227783203,17.226572036743164,1.782826508214746,,
2000-04-18,16.917951583862305,17.14240264892578,-0.16259517328119913,,
2000-04-17,16.609333038330078,16.917951583862305,1.3267035548061028,,
2000-04-14,17.42296600341797,16.525163650512695,1.858103181024874,,
2000-04-13,17.619359970092773,17.5913028717041,-5.152982292045718,,
2000-04-12,17.394908905029297,17.787696838378906,-0.15924016783978642,,
2000-04-11,16.581275939941406,17.08629035949707,2.2580626060999074,,
2000-04-10,16.27265739440918,16.637388229370117,3.045690943114771,,
2000-04-07,16.974063873291016,16.440994262695312,2.2413722978414614,,
2000-04-06,16.66544532775879,16.974063873291016,-3.140494901957435,,
2000-04-05,17.338796615600586,16.66544532775879,1.8518469771592379,,
2000-04-04,16.69350242614746,17.703529357910156,-3.883494932029764,,
2000-04-03,15.964037895202637,16.609333038330078,6.050419534373232,,
2000-03-31,15.935980796813965,15.795700073242188,4.042179975790207,,
2000-03-30,15.879868507385254,15.935980796813965,-0.880276685573211,,
2000-03-29,15.318742752075195,15.655418395996094,0.3533548744601681,,
2000-03-28,14.841785430908203,15.206517219543455,2.197802060977163,,
2000-03-27,15.038179397583008,14.92595386505127,2.457465716191353,,
2000-03-24,15.206517219543455,15.09429168701172,-0.7462707390615089,,
2000-03-23,15.374855041503906,15.178461074829102,-0.7380094397124819,,
2000-03-22,15.038179397583008,15.402911186218262,-1.2773711761486255,,
2000-03-21,15.430967330932615,15.12234878540039,2.4253719748407505,,
2000-03-20,15.374855041503906,15.206517219543455,-1.9999948085793307,,
2000-03-17,15.487080574035645,15.038179397583008,-1.094890465672871,,
2000-03-16,15.038179397583008,15.487080574035645,-2.898552598772084,,
2000-03-15,13.88787078857422,14.589278221130373,2.985076614558713,,
2000-03-14,13.859814643859863,13.972040176391602,5.050503732603934,,
2000-03-13,13.467026710510254,13.71953296661377,0.8097188556663427,,
2000-03-10,14.112321853637695,13.88787078857422,1.8749963264456049,,
2000-03-09,13.579251289367676,14.028152465820312,-1.5904616362304593,,
2000-03-08,13.523138999938965,13.915926933288574,3.3057873875868156,,
2000-03-07,14.000096321105955,13.298688888549805,2.9045618280739567,,
2000-03-06,14.448997497558594,14.028152465820312,-5.0100186203629065,,
2000-03-03,14.70150375366211,14.561222076416016,-2.9126244350820207,,
2000-03-02,15.178461074829102,15.038179397583008,-0.9541995131698683,,
2000-03-01,14.86984157562256,15.178461074829102,-0.9242154165334131,,
2000-02-29,14.86984157562256,14.813729286193848,2.075472678286555,,
2000-02-28,15.038179397583008,14.86984157562256,-0.37735633660484,,
2000-02-25,14.3087158203125,14.392884254455566,-1.1194029377485903,,
2000-02-24,14.47705364227295,14.252602577209473,0.5882319224173969,,
2000-02-23,14.53316593170166,14.420940399169922,-1.5503918864269468,,
2000-02-22,15.010123252868652,14.982067108154297,-0.7722029257708889,,
2000-02-18,15.262629508972168,14.645391464233398,-0.18691481903050686,,
2000-02-17,15.68347454071045,15.374855041503906,-4.0441133972093395,,
2000-02-16,15.599305152893066,15.571249008178713,-1.9678005559638108,,
2000-02-15,15.795700073242188,15.767642974853516,-0.17985509251449167,,
2000-02-14,15.599305152893066,15.73958683013916,-0.17762491221392848,,
2000-02-11,15.795700073242188,15.262629508972168,0.8992815761417228,,
2000-02-10,16.160430908203125,15.767642974853516,-3.374782768717149,,
2000-02-09,15.571249008178713,16.188488006591797,-2.430553588458016,,
2000-02-08,15.34679889678955,15.318742752075195,3.963965884103984,,
2000-02-07,15.487080574035645,15.178461074829102,-0.1828143113299323,,
2000-02-04,15.178461074829102,15.459024429321287,-1.9927545267889213,,
2000-02-03,14.813729286193848,14.92595386505127,1.8484308330668144,,
2000-02-02,14.70150375366211,14.841785430908203,0.7575714169558461,,
2000-02-01,14.53316593170166,14.75761604309082,0.9541995131698683,,
2000-01-31,14.3087158203125,14.617335319519045,1.5443992894869518,,
2000-01-28,14.000096321105955,14.3087158203125,2.1568637121748675,,
2000-01-27,13.354801177978516,13.831758499145508,2.2044098278187056,,
2000-01-26,13.382857322692873,13.32674503326416,3.571429591579948,,
2000-01-25,13.467026710510254,13.298688888549805,-0.41928482143768314,,
2000-01-24,13.747589111328123,13.467026710510254,-1.2499999114806168,,
2000-01-21,14.14037799835205,14.000096321105955,-2.040811654653569,,
2000-01-20,14.673447608947754,14.392884254455566,-0.9920645492110908,,
2000-01-19,14.75761604309082,14.841785430908203,-1.9120479519830238,,
2000-01-18,15.178461074829102,15.150404930114746,0.5703454241634711,,
2000-01-14,15.487080574035645,15.487080574035645,-0.1848418266913885,,
2000-01-13,15.29068660736084,15.150404930114746,0.0,,
2000-01-12,15.627362251281738,15.29068660736084,-0.9174321653977463,,
2000-01-11,15.430967330932615,15.599305152893066,-2.154398410347752,,
2000-01-10,16.160430908203125,15.823756217956545,1.09090906843542,,
2000-01-07,15.487080574035645,15.935980796813965,-2.0833274320407034,,
2000-01-06,15.262629508972168,15.767642974853516,2.898546440901904,,
2000-01-05,15.066235542297363,15.234573364257812,3.3088234604952866,,
2000-01-04,15.459024429321287,15.262629508972168,1.1173184003917436,,
2000-01-03,15.823756217956545,15.711530685424805,-1.2704224723043656,,
1999-12-31,16.35682487487793,16.30071258544922,-0.7092218243629684,,
1999-12-30,16.3848819732666,16.469051361083984,-0.34305123309654373,,
1999-12-29,16.7215576171875,16.32876968383789,0.513701520430313,,
1999-12-28,16.749614715576172,16.637388229370117,-2.348991298190286,,
1999-12-27,16.609333038330078,16.69350242614746,-0.6700242848075219,,
1999-12-23,16.66544532775879,16.637388229370117,0.5067595888597181,,
1999-12-22,16.805727005004883,16.833782196044922,-0.16835492743742397,,
1999-12-21,16.805727005004883,16.917951583862305,0.16693827664631228,,
1999-12-20,16.609333038330078,16.812740325927734,0.6677758053787288,,
1999-12-17,17.89992332458496,16.7215576171875,1.2246565658491189,,
1999-12-16,15.879868507385254,17.731584548950195,-6.58307684356957,,
1999-12-15,14.982067108154297,15.795700073242188,11.660776918296039,,
1999-12-14,14.813729286193848,14.95401096343994,5.430712325704737,,
1999-12-13,15.543192863464355,15.234573364257812,0.9469707089681475,,
1999-12-10,15.879868507385254,15.655418395996094,-1.9855605081757706,,
1999-12-09,15.767642974853516,15.795700073242188,-1.4134255033961718,,
1999-12-08,16.160430908203125,15.957023620605469,0.177940979722954,,
1999-12-07,16.412939071655273,16.076263427734375,-1.2586749001501287,,
1999-12-06,16.66544532775879,16.32876968383789,-2.0512818724973436,,
1999-12-03,17.03017807006836,16.805727005004883,-2.0202019045966617,,
1999-12-02,16.917951583862305,16.868852615356445,-1.3179607643560922,,
1999-12-01,17.0582332611084,16.805727005004883,-0.29021816419367163,,
1999-11-30,17.0582332611084,17.0582332611084,-1.4802603073743432,,
1999-11-29,16.917951583862305,17.451021194458008,0.0,,
1999-11-26,17.0582332611084,17.0582332611084,3.1509110778174088,,
1999-11-24,17.14240264892578,17.282684326171875,0.0,,
1999-11-23,17.254627227783203,17.03017807006836,0.8183314796592088,,
1999-11-22,17.0582332611084,17.451021194458008,-1.3008056027628245,,
1999-11-19,17.03017807006836,16.833782196044922,2.3026296295592283,,
1999-11-18,17.282684326171875,17.0582332611084,-1.1532226686966707,,
1999-11-17,16.974063873291016,16.749614715576172,-1.2987048818775284,,
1999-11-16,16.833782196044922,17.03017807006836,-1.3223065459769974,,
1999-11-15,16.35682487487793,16.440994262695312,1.1666770529416763,,
1999-11-12,16.3848819732666,16.35682487487793,0.5145826800814909,,
1999-11-11,17.11434555053711,16.3848819732666,-0.17123772044528326,,
1999-11-10,16.469051361083984,16.609333038330078,-4.262293145340954,,
1999-11-09,17.50713348388672,16.609333038330078,0.8517896639607084,,
1999-11-08,17.310739517211914,17.451021194458008,-5.128197865075751,,
1999-11-05,17.002120971679688,17.254627227783203,0.8103736822254931,,
1999-11-04,16.805727005004883,17.002120971679688,1.4851456269727377,,
1999-11-03,16.946008682250977,16.525163650512695,1.1686133341111453,,
1999-11-02,17.53519058227539,17.0582332611084,-2.48344633612202,,
1999-11-01,18.18048477172852,18.09631729125977,-2.7200007831628685,,
1999-10-29,17.956035614013672,18.124372482299805,-0.46295509457280404,,
1999-10-28,17.50713348388672,17.87186622619629,0.9374946224474816,,
1999-10-27,17.0582332611084,16.946008682250977,2.083337872789194,,
1999-10-26,17.563247680664062,16.889896392822266,-0.6578909851894582,,
1999-10-25,17.338796615600586,17.50713348388672,-3.8338654677352793,,
1999-10-22,17.50713348388672,17.53519058227539,0.9708682327738459,,
1999-10-21,17.282684326171875,17.42296600341797,0.16026094971227114,,
1999-10-20,17.50713348388672,17.47907829284668,0.8116891716506067,,
1999-10-19,17.0582332611084,17.394908905029297,-0.16025005501820502,,
1999-10-18,16.946008682250977,16.7215576171875,1.9736841369644993,,
1999-10-15,16.609333038330078,16.861839294433594,-1.3245069636873468,,
1999-10-14,17.0582332611084,17.226572036743164,1.520267282983585,,
1999-10-13,17.89992332458496,17.366853713989258,0.9868476591803119,,
1999-10-12,18.404935836791992,18.15242958068848,-2.978055273921478,,
1999-10-11,18.404935836791992,18.6013298034668,-1.371948581307982,,
1999-10-08,17.254627227783203,18.32076644897461,1.067072270266822,,
1999-10-07,16.69350242614746,17.002120971679688,6.17885977550834,,
1999-10-06,16.27265739440918,16.32876968383789,1.8487345414634464,,
1999-10-05,16.861839294433594,16.27265739440918,0.3448256057304415,,
1999-10-04,16.69350242614746,16.889896392822266,-3.494173380118229,,
1999-10-01,16.581275939941406,16.609333038330078,1.1764695128757867,,
1999-09-30,16.833782196044922,16.469051361083984,0.1692095257946176,,
1999-09-29,16.3848819732666,16.833782196044922,-2.166660057218933,,
1999-09-28,18.29271125793457,17.956035614013672,2.739722040785775,,
1999-09-27,18.04020500183105,18.2646541595459,-1.8404906696095333,,
1999-09-24,18.18048477172852,17.89992332458496,1.244160793583366,,
1999-09-23,19.19051170349121,18.18048477172852,-1.5432011338874971,,
1999-09-22,19.302738189697266,18.966062545776367,-5.263157894736824,,
1999-09-21,19.55524444580078,19.302738189697266,-1.744185931613564,,
1999-09-20,19.302738189697266,19.639413833618164,-1.2912457157125328,,
1999-09-17,19.52718734741211,19.44301986694336,1.744185931613564,,
1999-09-16,19.38690757751465,19.302738189697266,-0.431027157016059,,
1999-09-15,19.94803237915039,19.583301544189453,-0.43415582129769,,
1999-09-14,20.144426345825195,19.695526123046875,-1.8284050678710189,,
1999-09-13,20.50915908813477,20.28470802307129,-2.228409064978671,,
1999-09-10,20.25665283203125,20.481101989746094,-1.0943942854942919,,
1999-09-09,20.20054054260254,20.25665283203125,1.1080268767796073,,
1999-09-08,20.22859573364257,20.20054054260254,0.2777761778719299,,
1999-09-07,20.172483444213867,20.172483444213867,-0.13869074951838017,,
1999-09-03,20.088314056396484,20.088314056396484,0.0,,
1999-09-02,19.639413833618164,19.695526123046875,0.0,,
1999-09-01,19.38690757751465,19.751638412475582,0.28571264857538464,,
1999-08-31,19.583301544189453,19.4710750579834,1.8813254950673857,,
1999-08-30,19.358850479125977,19.695526123046875,-0.5730723491787998,,
1999-08-27,19.83580780029297,19.4710750579834,1.739130349107892,,
1999-08-26,20.424989700317383,19.83580780029297,-1.8387592074983874,,
1999-08-25,20.0041446685791,20.424989700317383,-2.8846129602467254,,
1999-08-24,19.583301544189453,19.83580780029297,2.103789183245164,,
1999-08-23,19.2746810913086,19.583301544189453,1.289395741232594,,
1999-08-20,18.966062545776367,19.302738189697266,1.6011702160925316,,
1999-08-19,18.7977237701416,18.966062545776367,1.7751478099805917,,
1999-08-18,18.82578086853028,18.7977237701416,0.8955274462653598,,
1999-08-17,18.853836059570312,18.93800544738769,-0.14903550925518336,,
1999-08-16,18.404935836791992,18.71355628967285,0.4464311005539608,,
1999-08-13,18.62938690185547,18.34882354736328,1.6768352555944166,,
1999-08-12,18.74161148071289,18.51716041564941,-1.5060256999882462,,
1999-08-11,18.853836059570312,18.74161148071289,-1.197608142151832,,
1999-08-10,18.76966857910156,18.71355628967285,-0.5952347230708843,,
1999-08-09,18.71355628967285,18.76966857910156,-0.29895194575349976,,
1999-08-06,18.74161148071289,18.62938690185547,0.29984834822482764,,
1999-08-05,18.881893157958984,18.74161148071289,-0.5987989825363358,,
1999-08-04,19.330793380737305,18.994117736816406,-0.7429428610391382,,
1999-08-03,19.358850479125977,19.2746810913086,-1.741654557522652,,
1999-08-02,19.1343994140625,19.44301986694336,-0.4347850504250387,,
1999-07-30,19.49913215637207,19.2746810913086,1.6129090137736126,,
1999-07-29,19.55524444580078,19.4710750579834,-1.1510823315801861,,
1999-07-28,19.414962768554688,19.52718734741211,-0.43041848978501024,,
1999-07-27,19.414962768554688,19.44301986694336,0.578031388446367,,
1999-07-26,19.1343994140625,19.358850479125977,0.14451275917002718,,
1999-07-23,19.330793380737305,19.246625900268555,1.1730238310930212,,
1999-07-22,19.330793380737305,19.330793380737305,-0.4354062392111695,,
1999-07-21,19.414962768554688,19.414962768554688,0.0,,
1999-07-20,18.7977237701416,18.966062545776367,0.0,,
1999-07-19,18.82578086853028,18.74161148071289,0.8955274462653598,,
1999-07-16,18.853836059570312,18.82578086853028,-0.44709639618768693,,
1999-07-15,18.853836059570312,18.7977237701416,-0.148803622516867,,
1999-07-14,18.68549919128418,18.74161148071289,-0.29761736153544216,,
1999-07-13,18.71355628967285,18.62938690185547,0.3002985837000513,,
1999-07-12,19.1343994140625,18.7977237701416,-0.4497776185055324,,
1999-07-09,19.19051170349121,18.93800544738769,-1.7595307625566987,,
1999-07-08,19.4710750579834,19.246625900268555,-1.315786988929442,,
1999-07-07,19.94803237915039,19.55524444580078,-1.1527312028044217,,
1999-07-06,20.0041446685791,19.976089477539062,-1.9690560245939337,,
1999-07-02,20.424989700317383,20.368877410888672,-0.1402468913559993,,
1999-07-01,20.144426345825195,20.396934509277344,-0.27472370978889166,,
1999-06-30,20.060258865356445,20.368877410888672,1.2534889756465026,,
1999-06-29,19.751638412475582,19.976089477539062,1.53845744266642,,
1999-06-28,19.667469024658203,19.77969551086425,1.1363668186721754,,
1999-06-25,19.723583221435547,19.639413833618164,0.5706198701283982,,
1999-06-24,19.751638412475582,19.52718734741211,-0.4267449117760089,,
1999-06-23,19.52718734741211,19.667469024658203,-1.1363668186721392,,
1999-06-22,19.07828712463379,19.52718734741211,0.718391618569097,,
1999-06-21,19.83580780029297,19.83580780029297,2.3529377655644073,,
1999-06-18,19.83580780029297,20.060258865356445,0.0,,
1999-06-17,19.667469024658203,20.032201766967773,1.1315448673593294,,
1999-06-16,19.414962768554688,19.751638412475582,1.8544976064397738,,
1999-06-15,19.49913215637207,19.414962768554688,1.7341039894559536,,
1999-06-14,19.44301986694336,19.38690757751465,-0.43165709705638006,,
1999-06-11,19.583301544189453,19.38690757751465,-0.2885986323766091,,
1999-06-10,19.83580780029297,19.583301544189453,-1.0028644364773958,,
1999-06-09,20.0041446685791,20.060258865356445,-1.2729819659766324,,
1999-06-08,20.0041446685791,20.144426345825195,0.28051285224648176,,
1999-06-07,20.31276512145996,20.172483444213867,0.7012630610817212,,
1999-06-04,20.20054054260254,20.20054054260254,-0.6906084740668292,,
1999-06-03,20.28470802307129,19.751638412475582,0.0,,
1999-06-02,20.20054054260254,20.368877410888672,-2.6279382971123244,,
1999-06-01,20.31276512145996,20.144426345825195,0.8333285336157896,,
1999-05-28,19.77969551086425,20.28470802307129,-0.8287339248407872,,
1999-05-27,19.751638412475582,19.751638412475582,2.553186483227984,,
1999-05-26,20.11637115478516,19.976089477539062,0.0,,
1999-05-25,20.3408203125,20.0041446685791,-0.697350810276375,,
1999-05-24,21.04222869873047,20.22859573364257,-1.655172400859379,,
1999-05-21,21.378904342651367,21.15445327758789,-3.866667246787344,,
1999-05-20,21.46307373046875,21.378904342651367,-1.0498716934510621,,
1999-05-19,21.43501663208008,21.79974937438965,-0.3921590582708424,,
1999-05-18,21.827804565429688,21.43501663208008,1.7015743377763484,,
1999-05-17,21.743637084960938,22.108367919921875,-1.7994843786153978,,
1999-05-14,22.36087417602539,21.91197395324707,1.6774141029662644,,
1999-05-13,22.41698837280273,22.41698837280273,-2.007525373313073,,
1999-05-12,21.35084724426269,22.33281898498535,0.0,,
1999-05-11,21.07028579711914,21.35084724426269,4.599216740621528,,
1999-05-10,21.0141716003418,20.90194702148437,1.3315502686817435,,
1999-05-07,21.210567474365234,21.04222869873047,-0.534042364323339,,
1999-05-06,21.266679763793945,21.210567474365234,-0.7936552185047254,,
1999-05-05,21.547243118286133,21.547243118286133,-0.2638507282375168,,
1999-05-04,21.547243118286133,21.18251037597656,0.0,,
1999-05-03,22.108367919921875,21.6875228881836,-1.6927118718034158,,
1999-04-30,21.378904342651367,21.715579986572266,-1.9035554015683365,,
1999-04-29,22.86588859558105,22.72560691833496,1.5748030793571746,,
1999-04-28,23.342845916748047,22.92200088500977,-0.613497597785027,,
1999-04-27,23.258676528930664,23.230621337890625,-1.8028865599302502,,
1999-04-26,23.735633850097656,23.42701530456543,-0.12062247396210261,,
1999-04-23,23.45507049560547,23.763690948486328,-1.3002330061261744,,
1999-04-22,23.00617027282715,23.48312759399414,1.3157941816405214,,
1999-04-21,22.809776306152344,23.53923988342285,2.0731713080048437,,
1999-04-20,21.35084724426269,22.837831497192383,3.1980303860926247,,
1999-04-19,22.27670669555664,21.35084724426269,6.964521060536683,,
1999-04-16,22.41698837280273,22.02419853210449,-4.156177409646565,,
1999-04-15,22.893945693969727,22.41698837280273,-1.752197191549566,,
1999-04-14,23.567296981811523,23.11839485168457,-2.0833338540355952,,
1999-04-13,23.59535217285156,23.735633850097656,-1.9047671460728028,,
1999-04-12,22.66949462890625,23.567296981811523,0.5945309746531487,,
1999-04-09,23.09033966064453,22.86588859558105,3.960398622033994,,
1999-04-08,21.88391876220703,23.09033966064453,-0.9720561427948042,,
1999-04-07,21.57529830932617,21.771692276000977,5.512819306023737,,
1999-04-06,21.40696144104004,21.659467697143555,0.9102723116922777,,
1999-04-05,21.322792053222656,21.659467697143555,1.1795520667376314,,
1999-04-01,20.90194702148437,21.35084724426269,1.5789472742619295,,
1999-03-31,21.603355407714844,21.0141716003418,2.1476478833139883,,
1999-03-30,20.873891830444336,21.49112892150879,-2.7272791483245142,,
1999-03-29,21.12639808654785,21.51918601989746,2.9569813625469674,,
1999-03-26,21.210567474365234,21.0141716003418,1.8592281170717668,,
1999-03-25,21.18251037597656,21.210567474365234,-0.9259340857371919,,
1999-03-24,20.930004119873047,21.18251037597656,0.13245407598381473,,
1999-03-23,21.79974937438965,20.76166534423828,1.2064319464885211,,
1999-03-22,21.547243118286133,21.79974937438965,-4.761908095011902,,
1999-03-19,22.22059440612793,21.547243118286133,1.1718726832818136,,
1999-03-18,21.996143341064453,22.22059440612793,-3.030302770190981,,
1999-03-17,22.64143753051757,22.136425018310547,1.0204109947058326,,
1999-03-16,22.86588859558105,22.809776306152344,-2.23047901232568,,
1999-03-15,22.30476188659668,22.75366401672364,-0.24539737082227966,,
1999-03-12,22.837831497192383,22.36087417602539,2.012584274198028,,
1999-03-11,22.388931274414062,22.72560691833496,-2.0884527553573897,,
1999-03-10,22.33281898498535,22.30476188659668,1.5037593344424143,,
1999-03-09,22.22059440612793,22.30476188659668,-0.1256316921188276,,
1999-03-08,22.27670669555664,22.41698837280273,0.37878140850065894,,
1999-03-05,21.996143341064453,22.19253730773925,0.6297235904895722,,
1999-03-04,21.09834098815918,21.743637084960938,0.8928563686350915,,
1999-03-03,20.31276512145996,21.09834098815918,3.058515819627293,,
1999-03-02,20.73361015319824,20.59332847595215,3.8673999428530594,,
1999-03-01,20.45304679870605,20.621383666992188,-0.6765906960223771,,
1999-02-26,21.07028579711914,20.78972244262696,0.8230405471755244,,
1999-02-25,20.64944076538086,20.76166534423828,-1.331559320996684,,
1999-02-24,21.18251037597656,20.53721618652344,0.5434751484677894,,
1999-02-23,21.266679763793945,21.18251037597656,-3.046353704067847,,
1999-02-22,20.76166534423828,21.210567474365234,-0.3957805767155195,,
1999-02-19,20.396934509277344,20.64944076538086,2.1621682205350217,,
1999-02-18,20.22859573364257,20.64944076538086,1.2379617926834332,,
1999-02-17,20.70555305480957,20.20054054260254,2.0804461035244914,,
1999-02-16,20.396934509277344,21.07028579711914,-2.439019672018492,,
1999-02-12,20.396934509277344,20.20054054260254,3.301237681258082,,
1999-02-11,20.11637115478516,20.59332847595215,-0.9628602111041581,,
1999-02-10,19.89192008972168,20.20054054260254,2.370990858624782,,
1999-02-09,20.25665283203125,19.89192008972168,1.551486490438528,,
1999-02-08,20.64944076538086,20.25665283203125,-1.8005577986350694,,
1999-02-05,20.817777633666992,20.56527137756348,-1.9021722564425332,,
1999-02-04,20.64944076538086,20.481101989746094,-1.212935696340387,,
1999-02-03,20.53721618652344,20.930004119873047,-0.8152219595069541,,
1999-02-02,20.53721618652344,20.70555305480957,1.912566580505463,,
1999-02-01,21.07028579711914,20.56527137756348,0.8196674113826207,,
1999-01-29,20.621383666992188,20.845834732055664,-2.3968085882570667,,
1999-01-28,20.53721618652344,20.663469314575195,1.0884384321055345,,
1999-01-27,20.56527137756348,20.53721618652344,0.6147528803567924,,
1999-01-26,19.639413833618164,20.45304679870605,-0.1364202325608356,,
1999-01-25,19.91997718811035,19.49913215637207,4.142857683945405,,
1999-01-22,19.751638412475582,19.863862991333008,-2.112678281526704,,
1999-01-21,21.04222869873047,20.20054054260254,0.5681785810059273,,
1999-01-20,20.98611640930176,21.04222869873047,-3.999995286519773,,
1999-01-19,21.23862266540528,20.817777633666992,0.267378148173411,,
1999-01-15,21.547243118286133,21.378904342651367,-1.9815081155134675,,
1999-01-14,21.322792053222656,21.294734954833984,-0.7812543568133058,,
1999-01-13,20.3408203125,21.57529830932617,-0.1315826666537857,,
1999-01-12,20.70555305480957,20.90194702148437,6.06896859546784,,
1999-01-11,21.49112892150879,21.09834098815918,0.9485086737597764,,
1999-01-08,21.51918601989746,21.378904342651367,-1.827674733999193,,
1999-01-07,21.603355407714844,21.46307373046875,-0.6518911873171409,,
1999-01-06,21.91197395324707,21.743637084960938,-0.6493513373204854,,
1999-01-05,22.108367919921875,21.91197395324707,-0.7682414585071532,,
1999-01-04,22.136425018310547,21.88391876220703,-0.8883241286112028,,
1998-12-31,21.88391876220703,21.996143341064453,-1.1406821828486329,,
1998-12-30,21.91197395324707,21.827804565429688,0.5128175628728382,,
1998-12-29,21.09834098815918,21.96808624267578,-0.38412508155117625,,
1998-12-28,21.659467697143555,21.07028579711914,4.122339547951758,,
1998-12-24,21.631410598754883,21.49112892150879,-2.720204892672017,,
1998-12-23,21.547243118286133,21.715579986572266,-0.6485091511053304,,
1998-12-22,20.90194702148437,21.23862266540528,0.7812455048751606,,
1998-12-21,21.09834098815918,20.78972244262696,1.6107381937905216,,
1998-12-18,21.23862266540528,21.12639808654785,-1.462762146584997,,
1998-12-17,20.78972244262696,21.40696144104004,-0.528398571910348,,
1998-12-16,20.873891830444336,20.70555305480957,2.968962188487425,,
1998-12-15,21.210567474365234,21.09834098815918,-0.8064561079560901,,
1998-12-14,21.88391876220703,21.43501663208008,-0.5291064764848461,,
1998-12-11,21.743637084960938,21.940031051635746,-2.051287683000323,,
1998-12-10,22.136425018310547,21.603355407714844,0.9032250028245956,,
1998-12-09,22.24864959716797,22.164480209350582,-2.4081106599406406,,
1998-12-08,22.164480209350582,22.27670669555664,-0.3783123440808753,,
1998-12-07,22.33281898498535,22.33281898498535,0.5063348436148436,,
1998-12-04,21.715579986572266,22.33281898498535,0.0,,
1998-12-03,21.603355407714844,21.49112892150879,2.84237860004086,,
1998-12-02,21.43501663208008,21.940031051635746,-0.5194863672241263,,
1998-12-01,21.547243118286133,21.49112892150879,2.356025321668513,,
1998-11-30,22.164480209350582,21.547243118286133,-0.2604240202298653,,
1998-11-27,21.940031051635746,22.136425018310547,-2.7848029154505247,,
1998-11-25,21.88391876220703,21.91197395324707,0.8951398756573725,,
1998-11-24,22.30476188659668,21.940031051635746,0.12820003284096293,,
1998-11-23,22.136425018310547,22.30476188659668,-1.6352151025656414,,
1998-11-20,21.771692276000977,22.08031272888184,0.7604519164539437,,
1998-11-19,21.266679763793945,21.88391876220703,1.4175308421985024,,
1998-11-18,21.18251037597656,21.23862266540528,2.902375948049595,,
1998-11-17,21.547243118286133,21.18251037597656,0.26489914761169897,,
1998-11-16,20.930004119873047,21.715579986572266,-1.6927118718034158,,
1998-11-13,20.6774959564209,20.621383666992188,3.753347883736507,,
1998-11-12,20.73361015319824,20.53721618652344,-0.27136888115935826,,
1998-11-11,21.09834098815918,20.621383666992188,-0.9472251345697414,,
1998-11-10,20.90194702148437,21.322792053222656,-2.2606389831061615,,
1998-11-09,21.266679763793945,20.90194702148437,2.0134250235430846,,
1998-11-06,20.78972244262696,21.23862266540528,-1.7150431866215585,,
1998-11-05,20.424989700317383,20.90194702148437,2.1592410577733423,,
1998-11-04,21.09834098815918,20.481101989746094,2.335165540668925,,
1998-11-03,21.12639808654785,21.0141716003418,-2.9255333334478437,,
1998-11-02,21.210567474365234,21.12639808654785,-0.5312144822146039,,
1998-10-30,21.40696144104004,21.09834098815918,-0.3968276092523627,,
1998-10-29,20.56527137756348,21.18251037597656,-1.4416826681865846,,
1998-10-28,20.20054054260254,20.64944076538086,3.001365686263109,,
1998-10-27,20.6774959564209,20.172483444213867,2.222218865042738,,
1998-10-26,20.873891830444336,20.45304679870605,-2.4423291547070125,,
1998-10-23,20.64944076538086,21.0141716003418,-2.0161311324057314,,
1998-10-22,20.032201766967773,20.621383666992188,1.766298850922968,,
1998-10-21,20.20054054260254,20.144426345825195,2.9411739502142464,,
1998-10-20,20.76166534423828,20.172483444213867,-0.27778561993922896,,
1998-10-19,20.172483444213867,20.11637115478516,-2.837835454215729,,
1998-10-16,20.31276512145996,20.11637115478516,-0.2781625256200284,,
1998-10-15,19.330793380737305,19.89192008972168,-0.9668499857132475,,
1998-10-14,19.246625900268555,19.667469024658203,2.902760884835306,,
1998-10-13,19.583301544189453,19.52718734741211,2.186581308175041,,
1998-10-12,19.218568801879883,19.2746810913086,-0.28654104442360157,,
1998-10-09,18.68549919128418,18.82578086853028,0.29196913676126274,,
1998-10-08,18.012147903442383,18.18048477172852,0.7507515630705495,,
1998-10-07,19.16245651245117,18.76966857910156,0.9345740951525539,,
1998-10-06,19.302738189697266,19.2746810913086,-2.0497786027297074,,
1998-10-05,18.76966857910156,19.38690757751465,-0.1453529448150527,,
1998-10-02,18.62938690185547,18.881893157958984,3.2884917270213974,,
1998-10-01,19.07828712463379,18.966062545776367,1.3554190346348234,,
1998-09-30,19.751638412475582,19.49913215637207,-0.5882319420201936,,
1998-09-29,20.144426345825195,20.032201766967773,-1.2784066355934474,,
1998-09-28,20.088314056396484,20.032201766967773,-0.5570998991524011,,
1998-09-25,19.4710750579834,19.863862991333008,-0.2793280176284568,,
1998-09-24,19.89192008972168,19.91997718811035,2.0172894007131936,,
1998-09-23,19.89192008972168,20.45304679870605,0.14104771315248352,,
1998-09-22,19.976089477539062,19.695526123046875,2.8208775545720712,,
1998-09-21,19.07828712463379,19.751638412475582,-1.4044958839799473,,
1998-09-18,19.38690757751465,19.246625900268555,3.5294116470884087,,
1998-09-17,18.68549919128418,19.10634422302246,-0.7235897560516328,,
1998-09-16,19.52718734741211,19.358850479125977,2.2522546892115343,,
1998-09-15,19.10634422302246,19.723583221435547,-0.8620640816888668,,
1998-09-14,18.853836059570312,19.218568801879883,3.2305447405754104,,
1998-09-11,18.29271125793457,18.432992935180664,1.934528024732823,,
1998-09-10,17.787696838378906,18.29271125793457,0.7668719812392258,,
1998-09-09,18.6013298034668,18.23659896850586,2.8391220299304862,,
1998-09-08,18.29271125793457,18.657442092895508,-1.9607782820611288,,
1998-09-04,18.04020500183105,17.787696838378906,1.9938588097635521,,
1998-09-03,17.47907829284668,18.012147903442383,-1.3996967519300125,,
1998-09-02,17.647415161132812,17.47907829284668,3.049758126055549,,
1998-09-01,17.394908905029297,17.731584548950195,-0.9538896589053047,,
1998-08-31,18.432992935180664,17.282684326171875,1.9354838002259223,,
1998-08-28,19.02217483520508,18.6013298034668,-6.240487440394685,,
1998-08-27,19.330793380737305,19.07828712463379,-2.2123917763567547,,
1998-08-26,19.02217483520508,19.751638412475582,-1.3062384514188246,,
1998-08-25,19.19051170349121,19.414962768554688,3.8348063961669303,,
1998-08-24,19.414962768554688,19.414962768554688,1.1695939562812365,,
1998-08-21,19.1343994140625,19.4710750579834,0.0,,
1998-08-20,19.07828712463379,19.302738189697266,1.7595307625566987,,
1998-08-19,18.966062545776367,19.2746810913086,1.1764738815240203,,
1998-08-18,18.93800544738769,19.1343994140625,1.627214635548912,,
1998-08-17,18.32076644897461,18.966062545776367,1.037036171630729,,
1998-08-14,18.461048126220703,18.29271125793457,3.522211249179885,,
1998-08-13,18.57327461242676,18.57327461242676,-0.911848921768638,,
1998-08-12,18.51716041564941,18.57327461242676,0.0,,
1998-08-11,17.89992332458496,18.32076644897461,0.30303888672869655,,
1998-08-10,18.068260192871094,18.15242958068848,2.3510889781948627,,
1998-08-07,18.068260192871094,18.15242958068848,0.46584113201223293,,
1998-08-06,18.37688064575196,18.18048477172852,0.46584113201223293,,
1998-08-05,18.18048477172852,18.23659896850586,-1.0687117025426205,,
1998-08-04,19.330793380737305,18.23659896850586,0.30865071796435445,,
1998-08-03,18.57327461242676,19.02217483520508,-5.660369911779126,,
1998-07-31,19.2746810913086,18.68549919128418,2.4169147990628215,,
1998-07-30,18.994117736816406,19.330793380737305,-3.056766009426205,,
1998-07-29,19.1343994140625,19.218568801879883,1.7725258345025319,,
1998-07-28,19.246625900268555,19.1343994140625,0.43988518268059124,,
1998-07-27,19.44301986694336,19.55524444580078,-0.5830969375493954,,
1998-07-24,19.330793380737305,19.583301544189453,0.5771972647532182,,
1998-07-23,19.667469024658203,19.52718734741211,1.3062483183114826,,
1998-07-22,19.358850479125977,20.032201766967773,-0.7132675641701267,,
1998-07-21,20.032201766967773,19.4710750579834,3.478260698215784,,
1998-07-20,19.94803237915039,20.060258865356445,-2.801123488630433,,
1998-07-17,20.0041446685791,20.144426345825195,0.5625942653038472,,
1998-07-16,19.807750701904297,20.0041446685791,0.7012630610817212,,
1998-07-15,20.088314056396484,19.751638412475582,0.9915005980761035,,
1998-07-14,19.77969551086425,20.22859573364257,-1.6759776005876328,,
1998-07-13,19.695526123046875,20.0041446685791,2.269500167642905,,
1998-07-10,19.358850479125977,19.695526123046875,1.5669474560067433,,
1998-07-09,19.302738189697266,19.2746810913086,1.739130349107892,,
1998-07-08,19.05023193359375,19.218568801879883,-0.1453529448150527,,
1998-07-07,19.07828712463379,19.07828712463379,0.883647342840391,,
1998-07-06,19.10634422302246,19.19051170349121,0.0,,
1998-07-02,18.404935836791992,18.74161148071289,0.44052111427643603,,
1998-07-01,18.51716041564941,18.6013298034668,1.8292682294924072,,
1998-06-30,18.909950256347656,18.404935836791992,0.4545480296549996,,
1998-06-29,19.07828712463379,18.994117736816406,-2.6706279641647486,,
1998-06-26,18.57327461242676,18.966062545776367,-0.44117895525696177,,
1998-06-25,18.71355628967285,18.68549919128418,2.1148017328446995,,
1998-06-24,18.23659896850586,18.657442092895508,-0.14992927028068573,,
1998-06-23,18.068260192871094,18.29271125793457,2.3076842623804676,,
1998-06-22,17.731584548950195,18.012147903442383,1.2422394999161825,,
1998-06-19,18.404935836791992,17.956035614013672,1.5822802170762473,,
1998-06-18,17.89992332458496,18.34882354736328,-2.4390208515748037,,
1998-06-17,17.563247680664062,17.927978515625,2.507833216032666,,
1998-06-16,17.310739517211914,17.50713348388672,2.076670793423253,,
1998-06-15,17.03017807006836,17.310739517211914,1.13452095145636,,
1998-06-12,16.7215576171875,17.226572036743164,1.6474369556749358,,
1998-06-11,16.833782196044922,16.7215576171875,3.0201398166195803,,
1998-06-10,16.581275939941406,16.833782196044922,-0.6666628898393905,,
1998-06-09,16.609333038330078,16.69350242614746,1.5228397200439325,,
1998-06-08,16.833782196044922,16.69350242614746,0.5067595888597181,,
1998-06-05,16.497106552124023,16.833782196044922,-0.8333229470583237,,
1998-06-04,16.188488006591797,16.3848819732666,2.0408163265306123,,
1998-06-03,16.525163650512695,16.32876968383789,1.2131705357216496,,
1998-06-02,16.440994262695312,16.412939071655273,-1.1884539894932389,,
1998-06-01,16.609333038330078,16.440994262695312,-0.17064169351178726,,
1998-05-29,16.833782196044922,16.651416778564453,-1.0135191777194361,,
1998-05-28,16.7215576171875,16.805727005004883,-1.0833300286094665,,
1998-05-27,16.763641357421875,16.7215576171875,0.5033585371907463,,
1998-05-26,16.833782196044922,16.805727005004883,-0.2510417595860997,,
1998-05-22,16.917951583862305,16.917951583862305,-0.16666005721893323,,
1998-05-21,17.156431198120117,16.889896392822266,0.0,,
1998-05-20,16.90392303466797,17.156431198120117,-1.5535562275157586,,
1998-05-19,17.002120971679688,16.847810745239258,1.4937843891875497,,
1998-05-18,16.749614715576172,16.90392303466797,-0.9075939801714336,,
1998-05-15,16.32876968383789,16.707529067993164,0.9212648870561726,,
1998-05-14,16.426965713500977,16.27265739440918,2.319583113050869,,
1998-05-13,16.45502281188965,16.469051361083984,-0.9393598415133607,,
1998-05-12,16.244600296020508,16.45502281188965,0.08525390304654909,,
1998-05-11,16.286685943603516,16.244600296020508,1.2953382172209462,,
1998-05-08,16.048206329345703,16.30071258544922,-0.2584052257699281,,
1998-05-07,15.837783813476562,16.006122589111328,1.5734235398119443,,
1998-05-06,16.076263427734375,15.865840911865234,1.0628935059179436,,
1998-05-05,16.17445945739746,16.076263427734375,-1.3089018901377596,,
1998-05-04,16.51113510131836,16.27265739440918,-0.6071054796095553,,
1998-05-01,16.426965713500977,16.35682487487793,-1.4443447131029654,,
1998-04-30,15.935980796813965,16.412939071655273,-0.42698596835445757,,
1998-04-29,15.935980796813965,15.851812362670898,2.9929646685861058,,
1998-04-28,16.02014923095703,15.753615379333496,-0.5281660113439266,,
1998-04-27,15.851812362670898,16.02014923095703,-1.6637413783168151,,
1998-04-24,16.160430908203125,16.11834716796875,1.0619408332295541,,
1998-04-23,16.160430908203125,16.188488006591797,-0.2604122406972023,,
1998-04-22,16.314741134643555,16.21654510498047,0.17361602885496039,,
1998-04-21,16.3848819732666,16.314741134643555,-0.6018853063783616,,
1998-04-20,16.7215576171875,16.398910522460938,-0.42808266020767144,,
1998-04-17,16.21654510498047,16.805727005004883,-1.929527751618814,,
1998-04-16,16.497106552124023,16.160430908203125,3.633214696535225,,
1998-04-15,16.833782196044922,16.609333038330078,-2.0408163265306123,,
1998-04-14,16.805727005004883,16.87586784362793,-1.333325779678781,,
1998-04-13,17.03017807006836,16.81975555419922,0.4173627157108905,,
1998-04-09,17.198514938354492,17.14240264892578,-1.2355861166183095,,
1998-04-08,17.282684326171875,16.98809242248535,-0.3262624106199696,,
1998-04-07,17.38088035583496,17.240598678588867,-1.7045494677028317,,
1998-04-06,17.801725387573242,17.32476806640625,-0.8071034054325079,,
1998-04-03,17.50713348388672,17.549219131469727,-2.679275804916861,,
1998-04-02,17.03017807006836,17.366853713989258,0.24039142456840668,,
1998-04-01,17.08629035949707,17.0582332611084,1.9769355466260665,,
1998-03-31,16.791698455810547,16.90392303466797,-0.16420824999662317,,
1998-03-30,16.917951583862305,16.637388229370117,0.6683336956815589,,
1998-03-27,17.11434555053711,16.861839294433594,-1.6583766249798897,,
1998-03-26,16.749614715576172,16.917951583862305,-1.4754070224764806,,
1998-03-25,17.226572036743164,16.735586166381836,1.0050193460843566,,
1998-03-24,17.38088035583496,17.226572036743164,-2.8501658328429302,,
1998-03-23,17.338796615600586,17.32476806640625,-0.8878049669100554,,
1998-03-20,17.29671287536621,17.451021194458008,-0.08090843618128463,,
1998-03-19,17.32476806640625,17.282684326171875,0.8921251118850513,,
1998-03-18,17.47907829284668,17.338796615600586,-0.2429108434414072,,
1998-03-17,17.549219131469727,17.53519058227539,-0.8025690765599699,,
1998-03-16,17.394908905029297,17.493106842041016,-0.0799383100139172,,
1998-03-13,17.577274322509766,17.47907829284668,0.5645211340159838,,
1998-03-12,17.32476806640625,17.521162033081055,-0.558653337607267,,
1998-03-11,17.338796615600586,17.42296600341797,1.1336022850177383,,
1998-03-10,17.0582332611084,17.254627227783203,0.4854396166205178,,
1998-03-09,17.0582332611084,16.974063873291016,1.1513148147796142,,
1998-03-06,16.847810745239258,17.03017807006836,-0.49342382959015596,,
1998-03-05,16.609333038330078,16.77766990661621,1.0824393007894733,,
1998-03-04,16.805727005004883,16.66544532775879,1.0135076941238672,,
1998-03-03,16.791698455810547,16.847810745239258,-0.834725431421781,,
1998-03-02,16.749614715576172,16.87586784362793,0.33416684784077944,,
1998-02-27,16.637388229370117,16.791698455810547,0.7537673564177552,,
1998-02-26,16.679473876953125,16.7215576171875,0.9274906873184854,,
1998-02-25,16.889896392822266,16.77766990661621,0.2523085592797039,,
1998-02-24,16.81975555419922,16.791698455810547,-0.6644592932716141,,
1998-02-23,16.81975555419922,16.81975555419922,-0.1668103813890871,,
1998-02-20,16.581275939941406,16.66544532775879,0.0,,
1998-02-19,16.623361587524414,16.553220748901367,0.5076170743569463,,
1998-02-18,16.98809242248535,16.805727005004883,-0.42194136398793447,,
1998-02-17,16.81975555419922,16.889896392822266,-1.0734896711480733,,
1998-02-13,16.525163650512695,16.623361587524414,0.41701461354196384,,
1998-02-12,16.32876968383789,16.581275939941406,0.5942327657897182,,
1998-02-11,16.51113510131836,16.426965713500977,1.5463887420339126,,
1998-02-10,16.048206329345703,16.51113510131836,-0.5097734789333906,,
1998-02-09,16.146404266357422,16.090290069580078,2.8846137846953406,,
1998-02-06,15.879868507385254,16.11834716796875,-0.34753370379969395,,
1998-02-05,15.753615379333496,15.851812362670898,1.5017672247889633,,
1998-02-04,15.613333702087402,15.795700073242188,0.6233298260297939,,
1998-02-03,15.935980796813965,15.809727668762209,1.1680168670858802,,
1998-02-02,16.06223487854004,15.978065490722656,-0.7922520092205274,,
1998-01-30,16.02014923095703,15.89389705657959,-0.5240204022283188,,
1998-01-29,15.73958683013916,16.132375717163086,-0.7880836349106792,,
1998-01-28,15.978065490722656,15.921953201293944,2.4955476357980926,,
1998-01-27,15.557221412658691,15.90792465209961,-0.3511832484432686,,
1998-01-26,15.68347454071045,15.529165267944336,2.2542794123605883,,
1998-01-23,15.711530685424805,15.68347454071045,-0.9838972376023202,,
1998-01-22,15.72555923461914,15.767642974853516,-0.17857040969523394,,
1998-01-21,16.034177780151367,15.865840911865234,0.2676136320909304,,
1998-01-20,15.935980796813965,16.034177780151367,-1.0498628030338808,,
1998-01-16,15.599305152893066,15.72555923461914,0.6161966721058963,,
1998-01-15,15.711530685424805,15.585277557373049,0.809357086669075,,
1998-01-14,15.669445991516112,15.711530685424805,-0.8035698785789084,,
1998-01-13,15.487080574035645,15.669445991516112,0.2685780590550492,,
1998-01-12,14.897897720336914,15.613333702087402,1.1775325672819557,,
1998-01-09,15.262629508972168,15.09429168701172,4.8022613336501605,,
1998-01-08,15.318742752075195,15.262629508972168,-1.1029411534984173,,
1998-01-07,14.86984157562256,15.066235542297363,-0.3663044938555797,,
1998-01-06,15.052207946777344,14.96803855895996,1.3207535915968924,,
1998-01-05,15.192489624023438,15.220545768737791,-0.5591829990324119,,
1998-01-02,14.729559898376465,15.13637638092041,0.18467114612992286,,
1997-12-31,15.024151802062988,14.70150375366211,2.761905212040896,,
1997-12-30,14.92595386505127,15.024151802062988,-2.147529209313338,,
1997-12-29,14.645391464233398,14.785673141479492,0.6579005797522037,,
1997-12-26,14.53316593170166,14.645391464233398,0.957855429052109,,
1997-12-24,14.645391464233398,14.47705364227295,0.7722029257708889,,
1997-12-23,14.75761604309082,14.561222076416016,-1.1494252125083824,,
1997-12-22,14.519137382507324,14.827756881713867,-1.3307973733789602,,
1997-12-19,14.434968948364258,14.505109786987305,2.12560492456231,,
1997-12-18,14.982067108154297,14.645391464233398,0.4859091756549646,,
1997-12-17,15.332770347595217,15.12234878540039,-2.247190868192386,,
1997-12-16,15.220545768737791,15.402911186218262,-1.372364924436688,,
1997-12-15,14.95401096343994,15.178461074829102,1.1981529457047435,,
1997-12-12,14.982067108154297,14.95401096343994,1.500935848836175,,
1997-12-11,15.164432525634766,14.996094703674316,-0.18726484477623995,,
1997-12-10,15.164432525634766,15.206517219543455,-1.1100832271559253,,
1997-12-09,15.09429168701172,15.388883590698242,0.27752237901119886,,
1997-12-08,15.262629508972168,15.09429168701172,1.9516775599348661,,
1997-12-05,15.150404930114746,15.262629508972168,-1.1029411534984173,,
1997-12-04,15.276658058166504,15.164432525634766,0.7407364976387592,,
1997-12-03,15.12234878540039,15.318742752075195,-0.7346209629385887,,
1997-12-02,15.024151802062988,15.09429168701172,1.2987001520849053,,
1997-12-01,14.617335319519045,15.09429168701172,0.46684755234635766,,
1997-11-28,14.813729286193848,14.617335319519045,3.2629501688709235,,
1997-11-26,14.799700736999512,14.785673141479492,-1.3257564174460705,,
1997-11-25,14.70150375366211,14.799700736999512,-0.09478296736737586,,
1997-11-24,14.673447608947754,14.603306770324709,0.6679383618355483,,
1997-11-21,14.687475204467772,14.785673141479492,-0.47801198799574385,,
1997-11-20,14.603306770324709,14.687475204467772,0.6685828275090451,,
1997-11-19,14.32274341583252,14.603306770324709,0.5763655825823026,,
1997-11-18,14.491081237792969,14.420940399169922,1.9588660241029763,,
1997-11-17,14.561222076416016,14.547194480895996,-0.48402764067127346,,
1997-11-14,14.224546432495115,14.463025093078612,-0.09633529003543756,,
1997-11-13,13.972040176391602,14.266631126403809,1.6765291021069468,,
1997-11-12,13.803702354431152,14.084264755249023,2.1084318846289465,,
1997-11-11,14.056208610534668,14.042181015014648,2.032515578893276,,
1997-11-10,14.112321853637695,14.070237159729004,-0.09979643806300874,,
1997-11-07,13.747589111328123,14.014123916625977,-0.29821240151097705,,
1997-11-06,14.028152465820312,14.028152465820312,1.9387748872871573,,
1997-11-05,14.14037799835205,14.3087158203125,0.0,,
1997-11-04,13.92995548248291,14.168434143066406,1.1904761101865005,,
1997-11-03,14.028152465820312,13.972040176391602,1.711984369823622,,
1997-10-31,13.66342067718506,13.76161766052246,-0.39999771577496684,,
1997-10-30,13.467026710510254,13.509110450744627,0.7186852081731363,,
1997-10-29,13.76161766052246,13.66342067718506,0.3124946667071599,,
1997-10-28,13.018125534057615,13.747589111328123,-0.7135569797080872,,
1997-10-27,13.691476821899414,13.074237823486328,5.603445560285218,,
1997-10-24,14.196490287780762,13.803702354431152,-4.508198833786993,,
1997-10-23,13.831758499145508,13.859814643859863,-2.7667960558370597,,
1997-10-22,14.280659675598145,14.252602577209473,0.20283859580174646,,
1997-10-21,14.210518836975098,14.294687271118164,-0.19646920398652176,,
1997-10-20,14.3087158203125,14.266631126403809,0.5922967001321875,,
1997-10-17,14.210518836975098,14.336771965026855,-0.2941192937031318,,
1997-10-16,14.294687271118164,14.266631126403809,0.8884484057207901,,
1997-10-15,14.420940399169922,14.266631126403809,-0.19626973421826283,,
1997-10-14,14.519137382507324,14.547194480895996,-1.0700361314508686,,
1997-10-13,14.448997497558594,14.406912803649902,0.19324218546533697,,
1997-10-10,14.364828109741213,14.392884254455566,-0.2912637635642358,,
1997-10-09,14.53316593170166,14.575250625610352,0.19531138486319927,,
1997-10-08,14.70150375366211,14.715532302856444,0.2895769174209366,,
1997-10-07,14.589278221130373,14.785673141479492,0.09542254608369354,,
1997-10-06,14.547194480895996,14.589278221130373,1.3461592641688802,,
1997-10-03,14.589278221130373,14.434968948364258,0.28929110894642235,,
1997-10-02,14.434968948364258,14.47705364227295,-1.0576895609723949,,
1997-10-01,14.392884254455566,14.378856658935549,0.2915468267319021,,
1997-09-30,14.434968948364258,14.350799560546877,-0.0974620185365228,,
1997-09-29,14.15440559387207,14.463025093078612,-0.5830936534637918,,
1997-09-26,14.196490287780762,14.266631126403809,2.18037767223622,,
1997-09-25,14.364828109741213,14.09829330444336,0.4940716839247139,,
1997-09-24,14.463025093078612,14.168434143066406,-1.855468114631377,,
1997-09-23,14.491081237792969,14.448997497558594,-2.0368556931646613,,
1997-09-22,14.491081237792969,14.547194480895996,-0.2904113195129977,,
1997-09-19,14.463025093078612,14.463025093078612,0.3872260612043435,,
1997-09-18,14.32274341583252,14.3087158203125,0.0,,
1997-09-17,14.182461738586426,14.168434143066406,-0.09793930612841442,,
1997-09-16,14.014123916625977,14.238574981689451,-0.09890804416453636,,
1997-09-15,13.915926933288574,13.8738431930542,1.6016061110833486,,
1997-09-12,13.467026710510254,13.915926933288574,-0.30241420809493924,,
1997-09-11,13.382857322692873,13.354801177978516,3.3333283762478843,,
1997-09-10,13.579251289367676,13.382857322692873,-0.2096424107188482,,
1997-09-09,13.467026710510254,13.621335983276367,-1.4462797873736681,,
1997-09-08,13.859814643859863,13.649392127990724,1.145830301544465,,
1997-09-05,14.056208610534668,13.88787078857422,-1.5182202740522195,,
1997-09-04,14.14037799835205,14.042181015014648,-1.1976047497920865,,
1997-09-03,14.028152465820312,14.070237159729004,-0.6944438355809613,,
1997-09-02,13.579251289367676,13.958011627197266,0.3000016859756197,,
1997-08-29,13.424942016601562,13.452998161315918,2.789257888806821,,
1997-08-28,13.523138999938965,13.502097129821776,0.20898522079023252,,
1997-08-27,13.396885871887209,13.523138999938965,-0.1555990078729816,,
1997-08-26,13.354801177978516,13.452998161315918,0.9424065358106306,,
1997-08-25,13.66342067718506,13.354801177978516,0.7352934875535616,,
1997-08-22,13.410913467407228,13.621335983276367,-2.2587279312996063,,
1997-08-21,13.943984031677246,13.70550537109375,1.5690393975066073,,
1997-08-20,13.915926933288574,13.915926933288574,-1.7102620028948123,,
1997-08-19,14.028152465820312,13.845786094665527,0.0,,
1997-08-18,13.831758499145508,14.014123916625977,-1.300002773701826,,
1997-08-15,14.168434143066406,13.607308387756348,1.3184543201194183,,
1997-08-14,14.182461738586426,14.280659675598145,-3.960393573799799,,
1997-08-13,14.406912803649902,14.09829330444336,0.6923899307589896,,
1997-08-12,14.392884254455566,14.350799560546877,-2.1421626091077344,,
1997-08-11,14.364828109741213,14.392884254455566,-0.29239930763468475,,
1997-08-08,14.252602577209473,14.350799560546877,0.19531138486319927,,
1997-08-07,14.252602577209473,14.3087158203125,0.6889758049833322,,
1997-08-06,14.196490287780762,14.196490287780762,0.39370523943995217,,
1997-08-05,14.14037799835205,14.238574981689451,0.0,,
1997-08-04,14.252602577209473,14.196490287780762,0.6944438355809488,,
1997-08-01,14.687475204467772,14.336771965026855,-0.393698548210675,,
1997-07-31,14.575250625610352,14.687475204467772,-2.387770767669014,,
1997-07-30,14.448997497558594,14.589278221130373,0.7699667178293931,,
1997-07-29,14.266631126403809,14.392884254455566,0.9708682114138504,,
1997-07-28,14.364828109741213,14.168434143066406,0.8849540366828175,,
1997-07-25,14.364828109741213,14.280659675598145,-1.3671863329963965,,
1997-07-24,14.336771965026855,14.266631126403809,-0.5859341545896473,,
1997-07-23,14.252602577209473,14.392884254455566,-0.489237317815674,,
1997-07-22,13.972040176391602,14.168434143066406,0.9842530617559646,,
1997-07-21,13.915926933288574,13.88787078857422,1.4056212564192978,,
1997-07-18,14.084264755249023,13.92995548248291,-0.2016117564345643,,
1997-07-17,14.420940399169922,14.084264755249023,-1.0956146838165919,,
1997-07-16,14.364828109741213,14.519137382507324,-2.3346302987305716,,
1997-07-15,14.3087158203125,14.561222076416016,1.0742159362246029,,
1997-07-14,14.392884254455566,14.420940399169922,1.7647024322410572,,
1997-07-11,14.70150375366211,14.406912803649902,0.1949306630856161,,
1997-07-10,15.038179397583008,14.813729286193848,-2.0038150855066448,,
1997-07-09,15.234573364257812,14.91192626953125,-1.4925351364356954,,
1997-07-08,15.052207946777344,15.192489624023438,-2.1178610454791755,,
1997-07-07,15.374855041503906,15.052207946777344,0.931967441202723,,
1997-07-03,15.038179397583008,15.374855041503906,-2.098537474698704,,
1997-07-02,14.813729286193848,14.92595386505127,2.2388058754972042,,
1997-07-01,14.897897720336914,14.771644592285156,0.7575714169558461,,
1997-06-30,15.178461074829102,14.982067108154297,-0.8474559996435699,,
1997-06-27,14.813729286193848,15.206517219543455,-1.29389906991619,,
1997-06-26,15.052207946777344,14.785673141479492,2.651512834892153,,
1997-06-25,15.220545768737791,15.052207946777344,-1.7707356039744075,,
1997-06-24,14.813729286193848,15.262629508972168,-1.1059907083371778,,
1997-06-23,14.813729286193848,14.561222076416016,3.030298543370088,,
1997-06-20,14.95401096343994,14.982067108154297,-1.7045485636973574,,
1997-06-19,14.645391464233398,14.982067108154297,0.18761618393185503,,
1997-06-18,14.448997497558594,14.53316593170166,2.2988504250167647,,
1997-06-17,14.75761604309082,14.673447608947754,0.5825209268483029,,
1997-06-16,14.95401096343994,14.841785430908203,-0.5703389619116168,,
1997-06-13,14.897897720336914,14.897897720336914,-0.7504711131087787,,
1997-06-12,14.813729286193848,14.92595386505127,0.0,,
1997-06-11,14.505109786987305,14.729559898376465,0.7575714169558461,,
1997-06-10,14.645391464233398,14.505109786987305,1.547386505068144,,
1997-06-09,14.364828109741213,14.589278221130373,-0.957855429052109,,
1997-06-06,14.056208610534668,14.364828109741213,1.5624977178595958,,
1997-06-05,14.168434143066406,14.056208610534668,2.1956098387387657,,
1997-06-04,14.168434143066406,14.112321853637695,-0.7920814071515304,,
1997-06-03,14.028152465820312,14.196490287780762,-0.396037338086302,,
1997-06-02,14.252602577209473,14.056208610534668,1.1999999456136896,,
1997-05-30,13.943984031677246,14.14037799835205,-1.3779516099666396,,
1997-05-29,14.196490287780762,14.14037799835205,1.4084494519546686,,
1997-05-28,14.364828109741213,14.168434143066406,-0.3952546600691021,,
1997-05-27,14.224546432495115,14.364828109741213,-1.3671863329963965,,
1997-05-23,14.3087158203125,14.364828109741213,0.9861943782308046,,
1997-05-22,14.252602577209473,14.224546432495115,0.3921546149449436,,
1997-05-21,14.53316593170166,14.224546432495115,-0.19684927410534994,,
1997-05-20,14.673447608947754,14.589278221130373,-2.1235531243288372,,
1997-05-19,14.813729286193848,14.841785430908203,-0.5736169853228985,,
1997-05-16,15.010123252868652,14.86984157562256,0.18939285423896152,,
1997-05-15,14.561222076416016,15.066235542297363,-0.9345804486933984,,
1997-05-14,14.561222076416016,14.561222076416016,3.4682079789119435,,
1997-05-13,14.364828109741213,14.392884254455566,0.0,,
1997-05-12,14.112321853637695,14.3087158203125,0.19531138486319927,,
1997-05-09,14.084264755249023,14.084264755249023,1.3916488633950814,,
1997-05-08,14.000096321105955,14.028152465820312,0.0,,
1997-05-07,14.196490287780762,14.056208610534668,0.2003996549085236,,
1997-05-06,14.14037799835205,14.196490287780762,-0.9881433678494278,,
1997-05-05,13.943984031677246,14.196490287780762,0.39682312195084446,,
1997-05-02,13.71953296661377,13.88787078857422,1.8108616269918592,,
1997-05-01,13.691476821899414,13.691476821899414,1.2269938223851933,,
1997-04-30,13.49508285522461,13.691476821899414,0.0,,
1997-04-29,13.523138999938965,13.607308387756348,1.4553001917937165,,
1997-04-28,13.158407211303713,13.270631790161133,0.6224101358254375,,
1997-04-25,13.298688888549805,13.214519500732422,0.8528735815457491,,
1997-04-24,13.438970565795898,13.32674503326416,-0.6329149326130398,,
1997-04-23,13.55119514465332,13.438970565795898,-0.835075365202215,,
1997-04-22,13.214519500732422,13.523138999938965,-0.8281526290446827,,
1997-04-21,13.018125534057615,13.186463356018066,2.3354575941216598,,
1997-04-18,13.130351066589355,13.018125534057615,1.2931033851229259,,
1997-04-17,13.130351066589355,13.130351066589355,-0.8547032136657938,,
1997-04-16,12.68144989013672,13.074237823486328,0.0,,
1997-04-15,12.56922435760498,12.68144989013672,3.0973424707147026,,
1997-04-14,12.260604858398438,12.34477424621582,0.892859649401025,,
1997-04-11,12.541168212890623,12.064210891723633,0.6865027361168671,,
1997-04-10,12.485055923461914,12.709506034851074,-3.8031331138413638,,
1997-04-09,12.793675422668455,12.45699977874756,1.797750148378379,,
1997-04-08,12.625337600708008,12.68144989013672,-2.631578751203557,,
1997-04-07,12.821731567382812,12.653393745422363,0.4444418929880024,,
1997-04-04,12.45699977874756,12.821731567382812,-1.3129102030858577,,
1997-04-03,12.45699977874756,12.541168212890623,2.927926427818582,,
1997-04-02,12.45699977874756,12.541168212890623,0.6756717960825495,,
1997-04-01,12.541168212890623,12.485055923461914,0.6756717960825495,,
1997-03-31,12.962013244628906,12.597280502319336,-0.4474247412695838,,
1997-03-27,13.382857322692873,13.018125534057615,-2.8138587380375135,,
1997-03-26,13.242575645446776,13.298688888549805,-2.725365591522774,,
1997-03-25,13.354801177978516,13.242575645446776,0.42373360443912333,,
1997-03-24,13.018125534057615,13.354801177978516,-0.8403384748010705,,
1997-03-21,13.130351066589355,12.962013244628906,2.586206770245838,,
1997-03-20,13.214519500732422,13.046181678771973,-1.2820511889342456,,
1997-03-19,13.382857322692873,13.186463356018066,-1.2738853043511646,,
1997-03-18,13.410913467407228,13.354801177978516,-1.4675040011208043,,
1997-03-17,12.821731567382812,13.438970565795898,-0.41840766152942055,,
1997-03-14,13.186463356018066,12.990069389343262,4.814006557299011,,
1997-03-13,13.130351066589355,13.130351066589355,-1.489360424948013,,
1997-03-12,13.214519500732422,13.270631790161133,0.0,,
1997-03-11,13.382857322692873,13.270631790161133,0.4246260291613394,,
1997-03-10,13.410913467407228,13.49508285522461,-0.8385767689642996,,
1997-03-07,12.962013244628906,13.242575645446776,0.6276186034749932,,
1997-03-06,13.354801177978516,12.90590000152588,2.164497100279746,,
1997-03-05,12.625337600708008,13.214519500732422,-3.3613467581445797,,
1997-03-04,12.793675422668455,12.541168212890623,4.666662537335823,,
1997-03-03,12.400886535644531,12.793675422668455,-1.9736877905345909,,
1997-02-28,12.793675422668455,12.625337600708008,3.167425860198865,,
1997-02-27,12.90590000152588,12.90590000152588,-1.3157893756017784,,
1997-02-26,13.102293968200684,12.990069389343262,0.0,,
1997-02-25,13.074237823486328,13.130351066589355,-0.8565261864051543,,
1997-02-24,12.793675422668455,13.046181678771973,0.42918940178850434,,
1997-02-21,12.933956146240234,12.90590000152588,1.9736803362707995,,
1997-02-20,13.074237823486328,13.018125534057615,-0.21691850812799704,,
1997-02-19,13.382857322692873,13.214519500732422,-0.42918210748708885,,
1997-02-18,13.102293968200684,13.382857322692873,-1.2578615904019694,,
1997-02-14,13.102293968200684,13.074237823486328,2.1413300233769568,,
1997-02-13,12.877843856811523,13.130351066589355,-0.21413154660128858,,
1997-02-12,12.625337600708008,12.765618324279783,1.9607879438938258,,
1997-02-11,12.56922435760498,12.56922435760498,1.1111047324699568,,
1997-02-10,12.51311206817627,12.541168212890623,0.0,,
1997-02-07,12.34477424621582,12.45699977874756,0.22421396501120563,,
1997-02-06,12.12032413482666,12.260604858398438,0.9090934373801269,,
1997-02-05,12.28866195678711,12.148380279541016,1.157400759346801,,
1997-02-04,12.008098602294922,12.28866195678711,-1.1415537162580605,,
1997-02-03,12.176436424255373,12.176436424255373,2.3364511217335253,,
1997-01-31,12.232548713684082,12.232548713684082,0.0,,
1997-01-30,12.008098602294922,12.176436424255373,0.0,,
1997-01-29,11.980042457580566,11.92392921447754,1.4018690846549111,,
1997-01-28,12.176436424255373,12.036154747009276,-0.4683893508868076,,
1997-01-27,12.064210891723633,12.036154747009276,-1.152074977919297,,
1997-01-24,12.232548713684082,12.232548713684082,-0.2325568159091491,,
1997-01-23,12.653393745422363,12.176436424255373,0.0,,
1997-01-22,12.372830390930176,12.625337600708008,-3.7694023497809823,,
1997-01-21,12.148380279541016,12.372830390930176,2.0408201017847203,,
1997-01-20,12.260604858398438,12.400886535644531,1.8475723201318837,,
1997-01-17,12.485055923461914,12.372830390930176,1.1441660412863046,,
1997-01-16,12.12032413482666,12.428942680358888,-0.8988788934524842,,
1997-01-15,11.951986312866213,11.951986312866213,2.5462895389525166,,
1997-01-14,11.867816925048828,11.980042457580566,0.0,,
1997-01-13,11.867816925048828,11.75559139251709,0.9456291181478312,,
1997-01-10,11.47502899169922,11.839760780334473,-0.9456291181478312,,
1997-01-09,11.559197425842283,11.615310668945312,3.1784825023020944,,
1997-01-08,11.671422958374023,11.503085136413574,0.48544238008756324,,
1997-01-07,11.334747314453123,11.671422958374023,-1.4423076137401913,,
1997-01-06,11.671422958374023,11.418915748596191,2.9702968630945974,,
1997-01-03,11.390859603881836,11.559197425842283,-2.1634655061203394,,
1997-01-02,11.47502899169922,11.30669116973877,1.4778324710725117,,
1996-12-31,11.671422958374023,11.390859603881836,-1.4669925634368577,,
1996-12-30,11.867816925048828,11.727535247802734,-2.403848746573687,,
1996-12-27,11.867816925048828,11.867816925048828,-1.1820343887341906,,
1996-12-26,11.839760780334473,11.867816925048828,0.0,,
1996-12-24,11.727535247802734,11.839760780334473,0.23696546944559876,,
1996-12-23,11.839760780334473,11.783648490905762,0.9569404837454214,,
1996-12-20,12.064210891723633,11.839760780334473,-0.47393093889119753,,
1996-12-19,11.503085136413574,11.75559139251709,-1.8604624322601893,,
1996-12-18,11.47502899169922,11.36280345916748,2.1951176845957163,,
1996-12-17,11.278635025024414,11.390859603881836,-0.9779978125800073,,
1996-12-16,11.559197425842283,11.30669116973877,0.9950191544315794,,
1996-12-13,11.418915748596191,11.53114128112793,-2.1844618341667825,,
1996-12-12,11.671422958374023,11.47502899169922,0.9828037530230045,,
1996-12-11,11.783648490905762,11.727535247802734,-1.6826908541935237,,
1996-12-10,12.036154747009276,12.092267036437988,-0.4761958331185263,,
1996-12-09,11.951986312866213,12.092267036437988,0.4661978065931348,,
1996-12-06,11.53114128112793,11.839760780334473,1.1737021771917906,,
1996-12-05,11.92392921447754,11.867816925048828,2.6764002944932703,,
1996-12-04,12.092267036437988,11.951986312866213,-0.4705855630255126,,
1996-12-03,12.34477424621582,12.12032413482666,-1.1600862199706927,,
1996-12-02,12.428942680358888,12.400886535644531,-1.8181791494321036,,
1996-11-29,12.541168212890623,12.485055923461914,-0.22573235258936056,,
1996-11-27,12.56922435760498,12.51311206817627,-0.4474247412695838,,
1996-11-26,12.793675422668455,12.597280502319336,-0.44642603101248907,,
1996-11-25,12.485055923461914,12.73756217956543,-1.5350938167552481,,
1996-11-22,12.34477424621582,12.51311206817627,2.0224679621098525,,
1996-11-21,12.148380279541016,12.28866195678711,1.363636293406108,,
1996-11-20,11.980042457580566,12.092267036437988,1.1547356439141188,,
1996-11-19,11.951986312866213,12.064210891723633,0.936762780722951,,
1996-11-18,11.92392921447754,11.951986312866213,0.9389617417534296,,
1996-11-15,12.204492568969728,12.008098602294922,0.23530077949981543,,
1996-11-14,11.75559139251709,12.008098602294922,-1.6091940370724118,,
1996-11-13,11.727535247802734,11.783648490905762,2.1479753875977954,,
1996-11-12,12.008098602294922,11.783648490905762,0.4784743078349792,,
1996-11-11,11.980042457580566,11.951986312866213,-1.8691561322311634,,
1996-11-08,11.783648490905762,11.980042457580566,-0.23419069518072294,,
1996-11-07,11.75559139251709,11.839760780334473,1.666665182913214,,
1996-11-06,11.418915748596191,11.811704635620115,0.7159945000381693,,
1996-11-05,11.30669116973877,11.446972846984863,3.4398089597273045,,
1996-11-04,11.166409492492676,11.278635025024414,1.2406961076423813,,
1996-11-01,11.390859603881836,11.222521781921388,1.005027915259502,,
1996-10-31,11.166409492492676,11.390859603881836,-1.4778324710725117,,
1996-10-30,11.390859603881836,11.222521781921388,2.0100472899552977,,
1996-10-29,11.194465637207031,11.36280345916748,-1.4778324710725117,,
1996-10-28,11.194465637207031,11.166409492492676,1.5037593344424143,,
1996-10-25,11.418915748596191,11.222521781921388,-0.2506251358805846,,
1996-10-24,11.334747314453123,11.446972846984863,-1.7199003040104486,,
1996-10-23,11.30669116973877,11.390859603881836,0.990101758939429,,
1996-10-22,11.58725357055664,11.418915748596191,0.74441260382467,,
1996-10-21,11.783648490905762,11.671422958374023,-1.4527844837036947,,
1996-10-18,11.75559139251709,11.867816925048828,-0.9523835730364014,,
1996-10-17,11.47502899169922,11.69947910308838,0.9546566292119884,,
1996-10-16,11.53114128112793,11.47502899169922,1.9559873142936925,,
1996-10-15,11.783648490905762,11.503085136413574,-0.48661522793536083,,
1996-10-14,11.250577926635742,11.615310668945312,-2.3809548859906777,,
1996-10-11,10.998071670532228,11.30669116973877,3.2419022799359096,,
1996-10-10,10.998071670532228,10.970015525817873,2.8061237319760637,,
1996-10-09,11.36280345916748,11.082240104675291,-0.255100580854805,,
1996-10-08,11.222521781921388,11.36280345916748,-2.4691384965022123,,
1996-10-07,11.250577926635742,11.30669116973877,1.2500013809024177,,
1996-10-04,11.13835334777832,11.30669116973877,0.4987587612737586,,
1996-10-03,11.082240104675291,11.110297203063965,1.5113349047597437,,
1996-10-02,11.110297203063965,11.054183959960938,0.2531717245219866,,
1996-10-01,11.026127815246582,11.082240104675291,-0.5050561841635758,,
1996-09-30,11.054183959960938,11.054183959960938,0.5089029473349552,,
1996-09-27,10.970015525817873,11.054183959960938,0.0,,
1996-09-26,10.857789993286133,10.941959381103516,0.7672590247933074,,
1996-09-25,10.829733848571776,10.857789993286133,0.7751981560651715,,
1996-09-24,10.661396026611328,10.773621559143066,0.2590658746249548,,
1996-09-23,10.661396026611328,10.689452171325684,1.0526344978801863,,
1996-09-20,10.885846138000488,10.689452171325684,0.2631563881908716,,
1996-09-19,10.689452171325684,10.857789993286133,-1.8041221985420999,,
1996-09-18,10.689452171325684,10.661396026611328,1.5748030793571746,,
1996-09-17,10.801677703857422,10.745564460754396,-0.2624656929530562,,
1996-09-16,10.773621559143066,10.801677703857422,-0.5194863672241099,,
1996-09-13,10.71750831604004,10.71750831604004,0.26041516829172023,,
1996-09-12,10.521114349365234,10.577226638793944,0.0,,
1996-09-11,10.49305820465088,10.49305820465088,0.533330287699939,,
1996-09-10,10.521114349365234,10.54917049407959,0.0,,
1996-09-09,10.49305820465088,10.54917049407959,0.2666651438499779,,
1996-09-06,10.352776527404783,10.436945915222168,0.534756296346839,,
1996-09-05,10.26860809326172,10.38083267211914,0.8130126985217948,,
1996-09-04,10.15638256072998,10.296664237976074,1.0928898818435,,
1996-09-03,10.016100883483888,10.212494850158691,1.3812169481336585,,
1996-08-30,10.184438705444336,10.10027027130127,1.960782633476146,,
1996-08-29,10.296664237976074,10.15638256072998,-0.8264415602803143,,
1996-08-28,10.38083267211914,10.26860809326172,-1.3623992586716385,,
1996-08-27,10.38083267211914,10.408888816833496,-1.0810749233906167,,
1996-08-26,10.54917049407959,10.436945915222168,0.2702687308476584,,
1996-08-23,10.633339881896973,10.49305820465088,-1.063823728324465,,
1996-08-22,10.605283737182615,10.689452171325684,-1.3192626099060225,,
1996-08-21,10.633339881896973,10.54917049407959,0.7936462260596552,,
1996-08-20,10.605283737182615,10.661396026611328,-0.7915611534310057,,
1996-08-19,10.633339881896973,10.661396026611328,0.5290974840397757,,
1996-08-16,10.38083267211914,10.605283737182615,0.2638507282375168,,
1996-08-15,10.296664237976074,10.38083267211914,2.162168220535005,,
1996-08-14,10.296664237976074,10.296664237976074,0.8174339980188637,,
1996-08-13,10.296664237976074,10.32472038269043,0.0,,
1996-08-12,10.408888816833496,10.408888816833496,0.2724779993396213,,
1996-08-09,10.26860809326172,10.436945915222168,0.0,,
1996-08-08,10.10027027130127,10.296664237976074,1.6393441100445838,,
1996-08-07,10.26860809326172,10.15638256072998,1.9444426871708083,,
1996-08-06,10.15638256072998,10.296664237976074,-1.0928991691228596,,
1996-08-05,10.15638256072998,10.212494850158691,1.3812169481336585,,
1996-08-02,10.072213172912598,10.15638256072998,0.5524830232928714,,
1996-08-01,9.847763061523438,9.988044738769531,0.8356593170976685,,
1996-07-31,9.847763061523438,9.847763061523438,1.4245029695545126,,
1996-07-30,9.959988594055176,9.931931495666504,0.0,,
1996-07-29,9.903875350952148,9.875819206237791,-0.28169809758033587,,
1996-07-26,9.903875350952148,10.016100883483888,-0.2832845095496881,,
1996-07-25,9.875819206237791,9.903875350952148,1.1331476675032144,,
1996-07-24,9.623312950134276,9.819706916809082,0.28408929050297266,,
1996-07-23,9.931931495666504,9.791650772094728,2.040814506318909,,
1996-07-22,9.931931495666504,9.959988594055176,-1.4124213767783516,,
1996-07-19,10.044157028198242,9.959988594055176,0.28249387745891863,,
1996-07-18,9.651369094848633,10.128326416015623,-0.8379840528853704,,
1996-07-17,9.819706916809082,9.623312950134276,4.941861786443996,,
1996-07-16,9.791650772094728,9.7355375289917,-1.9999982518686492,,
1996-07-15,9.931931495666504,9.763593673706056,-0.5730723491788179,,
1996-07-12,9.763593673706056,9.931931495666504,-1.69491525423727,,
1996-07-11,9.51108741760254,9.763593673706056,1.7241379310344644,,
1996-07-10,9.370805740356444,9.539143562316896,2.6548621100484517,,
1996-07-09,9.51108741760254,9.34274959564209,1.796407124688187,,
1996-07-08,9.539143562316896,9.454975128173828,-1.7699114156905087,,
1996-07-05,9.651369094848633,9.595255851745604,-0.8823479130303088,,
1996-07-03,9.707481384277344,9.791650772094728,-0.5814018980268745,,
1996-07-02,9.7355375289917,9.7355375289917,0.8670569067864395,,
1996-07-01,9.819706916809082,9.7355375289917,0.0,,
1996-06-28,9.847763061523438,9.763593673706056,-0.8571476575670925,,
1996-06-27,9.707481384277344,9.819706916809082,-0.8547056554015032,,
1996-06-26,9.7355375289917,9.7355375289917,1.1560726010096047,,
1996-06-25,9.763593673706056,9.763593673706056,0.0,,
1996-06-24,9.707481384277344,9.707481384277344,0.0,,
1996-06-21,9.595255851745604,9.679425239562988,0.0,,
1996-06-20,9.679425239562988,9.595255851745604,0.877197951965733,,
1996-06-19,9.679425239562988,9.679425239562988,-0.8695701008501691,,
1996-06-18,9.651369094848633,9.707481384277344,0.0,,
1996-06-17,9.651369094848633,9.651369094848633,0.581392016793354,,
1996-06-14,9.763593673706056,9.623312950134276,0.0,,
1996-06-13,9.595255851745604,9.7355375289917,-1.4367734694814809,,
1996-06-12,9.651369094848633,9.595255851745604,1.4619899605967772,,
1996-06-11,9.7355375289917,9.707481384277344,-0.5814018980268745,,
1996-06-10,9.7355375289917,9.7355375289917,-0.2881828007011054,,
1996-06-07,9.56719970703125,9.791650772094728,0.0,,
1996-06-06,9.847763061523438,9.791650772094728,2.346047662186061,,
1996-06-05,9.56719970703125,9.847763061523438,-0.5697973141529733,,
1996-06-04,9.56719970703125,9.595255851745604,2.9325545936497206,,
1996-06-03,9.595255851745604,9.56719970703125,0.2932534657318202,,
1996-05-31,9.623312950134276,9.679425239562988,-0.29239600431550367,,
1996-05-30,9.483031272888184,9.623312950134276,0.5830870275078165,,
1996-05-29,9.51108741760254,9.454975128173828,1.4792915177571415,,
1996-05-28,9.623312950134276,9.51108741760254,-0.589967129571993,,
1996-05-24,9.34274959564209,9.595255851745604,-1.1661839650571566,,
1996-05-23,9.370805740356444,9.28663730621338,2.7026974609412093,,
1996-05-22,9.28663730621338,9.3988618850708,-0.8981984738044658,,
1996-05-21,9.314693450927734,9.28663730621338,1.208452264872392,,
1996-05-20,9.28663730621338,9.314693450927734,-0.30120309232033105,,
1996-05-17,9.230524063110352,9.258580207824709,0.30211306621808365,,
1996-05-16,9.090242385864258,9.17441177368164,0.3039496405895652,,
1996-05-15,9.11829948425293,9.202467918395996,0.9259311715193652,,
1996-05-14,9.17441177368164,9.090242385864258,0.9230716131711089,,
1996-05-13,9.034130096435549,9.17441177368164,-0.9174363424458123,,
1996-05-10,8.978017807006836,9.006073951721191,1.5527967358079187,,
1996-05-09,8.893848419189453,8.921904563903809,0.3124982074824939,,
1996-05-08,8.809679985046387,8.837736129760742,0.3154556204693264,,
1996-05-07,8.94996166229248,8.865792274475098,0.3184695103792438,,
1996-05-06,8.921904563903809,8.893848419189453,-0.9404441157776234,,
1996-05-03,9.006073951721191,8.837736129760742,-0.31446362728273136,,
1996-05-02,9.034130096435549,9.006073951721191,-1.8691587795398616,,
1996-05-01,9.11829948425293,9.146355628967283,-0.31055723589177564,,
1996-04-30,9.17441177368164,9.11829948425293,0.30769053772368343,,
1996-04-29,9.11829948425293,9.230524063110352,-0.6116172983392634,,
1996-04-26,9.202467918395996,9.11829948425293,1.2307621508948117,,
1996-04-25,9.090242385864258,9.202467918395996,-0.9146289331235951,,
1996-04-24,9.34274959564209,9.090242385864258,1.2345713982968607,,
1996-04-23,9.28663730621338,9.370805740356444,-2.7027076685819944,,
1996-04-22,9.3988618850708,9.28663730621338,0.9063391986542703,,
1996-04-19,9.230524063110352,9.34274959564209,-1.194023066087163,,
1996-04-18,9.17441177368164,9.202467918395996,1.2158088941043543,,
1996-04-17,9.146355628967283,9.146355628967283,0.3058086491696317,,
1996-04-16,9.258580207824709,9.202467918395996,0.0,,
1996-04-15,9.370805740356444,9.258580207824709,-0.6060571725812831,,
1996-04-12,9.230524063110352,9.314693450927734,-1.1976081421517755,,
1996-04-11,9.146355628967283,9.258580207824709,0.9118592535148083,,
1996-04-10,9.426918029785156,9.258580207824709,1.2269868285243652,,
1996-04-09,9.623312950134276,9.483031272888184,-1.785714285714267,,
1996-04-08,9.258580207824709,9.679425239562988,-1.4577274788110741,,
1996-04-04,9.370805740356444,9.426918029785156,4.5454596956735385,,
1996-04-03,9.370805740356444,9.370805740356444,0.5987989825363549,,
1996-04-02,9.3988618850708,9.370805740356444,0.0,,
1996-04-01,9.28663730621338,9.3988618850708,-0.2985057665218144,,
1996-03-29,9.202467918395996,9.146355628967283,1.208452264872392,,
1996-03-28,9.006073951721191,9.11829948425293,-0.609752622082416,,
1996-03-27,9.258580207824709,9.090242385864258,1.2461093827715055,,
1996-03-26,9.146355628967283,9.202467918395996,-1.8181818181818372,,
1996-03-25,9.202467918395996,9.11829948425293,0.6134934142621826,,
1996-03-22,9.202467918395996,9.202467918395996,-0.9146289331235951,,
1996-03-21,9.146355628967283,9.258580207824709,0.0,,
1996-03-20,9.258580207824709,9.090242385864258,1.2269868285243652,,
1996-03-19,9.11829948425293,9.28663730621338,-1.8181818181818372,,
1996-03-18,9.28663730621338,9.090242385864258,1.8461536852476288,,
1996-03-15,9.146355628967283,9.202467918395996,-2.114812002162737,,
1996-03-14,9.370805740356444,9.454975128173828,0.6134934142621826,,
1996-03-13,9.3988618850708,9.314693450927734,0.8982086508836643,,
1996-03-12,9.426918029785156,9.51108741760254,-0.8955172995653864,,
1996-03-11,9.426918029785156,9.483031272888184,0.8928622011079782,,
1996-03-08,9.7355375289917,9.56719970703125,0.5952448395725172,,
1996-03-07,9.7355375289917,9.847763061523438,-1.729106600012088,,
1996-03-06,9.763593673706056,9.679425239562988,1.1527409986098773,,
1996-03-05,9.763593673706056,9.707481384277344,-0.8620640816888849,,
1996-03-04,9.56719970703125,9.847763061523438,-0.5747093877925961,,
1996-03-01,9.56719970703125,9.483031272888184,2.9325545936497206,,
1996-02-29,9.202467918395996,9.370805740356444,-0.8797603971955164,,
1996-02-28,9.146355628967283,9.28663730621338,1.8292682294923879,,
1996-02-27,9.230524063110352,9.11829948425293,1.5337439624784908,,
1996-02-26,9.3988618850708,9.202467918395996,-1.215798562358184,,
1996-02-23,9.454975128173828,9.370805740356444,-2.0895505123525417,,
1996-02-22,9.34274959564209,9.370805740356444,-0.8902126835487658,,
1996-02-21,9.539143562316896,9.202467918395996,0.3002985837000323,,
1996-02-20,9.51108741760254,9.595255851745604,-3.5294116470884456,,
1996-02-16,9.791650772094728,9.707481384277344,0.8849506943579243,,
1996-02-15,9.595255851745604,9.875819206237791,-0.859603653934016,,
1996-02-14,9.791650772094728,9.623312950134276,2.923979921193518,,
1996-02-13,9.903875350952148,9.819706916809082,-1.719197568199629,,
1996-02-12,9.791650772094728,9.931931495666504,-0.8498535286490105,,
1996-02-09,9.819706916809082,9.763593673706056,1.4326565237759732,,
1996-02-08,9.707481384277344,9.763593673706056,-0.5714350089916899,,
1996-02-07,9.595255851745604,9.7355375289917,0.5780313884463854,,
1996-02-06,9.679425239562988,9.56719970703125,1.4619899605967772,,
1996-02-05,9.679425239562988,9.7355375289917,-1.1594235169360645,,
1996-02-02,9.623312950134276,9.679425239562988,0.5797068321718276,,
1996-02-01,9.595255851745604,9.651369094848633,0.5830870275078165,,
1996-01-31,9.454975128173828,9.539143562316896,0.5848019476502109,,
1996-01-30,9.258580207824709,9.426918029785156,0.8902025970672734,,
1996-01-29,9.006073951721191,9.006073951721191,1.8181818181817986,,
1996-01-26,8.893848419189453,9.034130096435549,0.0,,
1996-01-25,8.865792274475098,8.893848419189453,1.577288825199926,,
1996-01-24,8.865792274475098,8.921904563903809,0.3164538920580174,,
1996-01-23,8.641342163085938,8.837736129760742,0.6329077841160348,,
1996-01-22,8.75356674194336,8.697454452514648,2.2727252661485844,,
1996-01-19,8.725510597229004,8.75356674194336,-0.6410220094609523,,
1996-01-18,8.75356674194336,8.781623840332031,0.32154158088198725,,
1996-01-17,8.893848419189453,8.697454452514648,0.3205218994245423,,
1996-01-16,9.062186241149902,8.978017807006836,-2.208200066138559,,
1996-01-15,9.090242385864258,9.034130096435549,-0.928787291535362,,
1996-01-12,9.202467918395996,9.090242385864258,-0.6172804535549716,,
1996-01-11,9.062186241149902,9.11829948425293,-1.2195156074100104,,
1996-01-10,9.28663730621338,9.006073951721191,0.6192020513573899,,
1996-01-09,9.51108741760254,9.437439918518066,-3.0211512008170454,,
1996-01-08,9.314693450927734,9.51108741760254,-0.774333110935056,,
1996-01-05,9.51108741760254,9.34274959564209,2.1084318846289656,,
1996-01-04,9.483031272888184,9.539143562316896,-1.7699114156905087,,
1996-01-03,9.3988618850708,9.3988618850708,0.5917125844468819,,
1996-01-02,9.258580207824709,9.370805740356444,0.0,,
1995-12-29,9.34274959564209,9.34274959564209,1.2121246456005157,,
1995-12-28,9.090242385864258,9.28663730621338,0.0,,
1995-12-27,9.17441177368164,9.034130096435549,2.1605025698162454,,
1995-12-26,9.146355628967283,9.17441177368164,-1.5290536407850561,,
1995-12-22,9.090242385864258,9.146355628967283,0.30674670713110097,,
1995-12-21,9.11829948425293,9.006073951721191,0.6172909447418501,,
1995-12-20,9.034130096435549,9.090242385864258,-1.2307726098002034,,
1995-12-19,9.230524063110352,9.062186241149902,0.6211144717834922,,
1995-12-18,9.28663730621338,9.28663730621338,-1.8237081752834463,,
1995-12-15,9.370805740356444,9.314693450927734,0.0,,
1995-12-14,9.3988618850708,9.370805740356444,-0.5987989825363169,,
1995-12-13,9.370805740356444,9.370805740356444,-0.2985057665218144,,
1995-12-12,9.426918029785156,9.34274959564209,0.0,,
1995-12-11,9.3988618850708,9.34274959564209,-0.8928520846063265,,
1995-12-08,9.258580207824709,9.314693450927734,-0.5970115330435909,,
1995-12-07,9.483031272888184,9.230524063110352,0.6060674730192709,,
1995-12-06,9.11829948425293,9.370805740356444,-2.6627267432908885,,
1995-12-05,9.034130096435549,9.062186241149902,2.7692252984186987,,
1995-12-04,8.893848419189453,8.893848419189453,0.31055723589173634,,
1995-12-01,9.090242385864258,8.837736129760742,0.0,,
1995-11-30,9.202467918395996,9.11829948425293,-2.7777725321843385,,
1995-11-29,9.17441177368164,9.146355628967283,-0.9146289331235951,,
1995-11-28,9.17441177368164,9.146355628967283,-0.305808649169651,,
1995-11-27,9.230524063110352,9.202467918395996,-0.305808649169651,,
1995-11-24,9.11829948425293,9.146355628967283,-0.303949640589546,,
1995-11-22,9.258580207824709,9.146355628967283,0.30769053772368343,,
1995-11-21,9.17441177368164,9.258580207824709,-1.2121143451625662,,
1995-11-20,9.11829948425293,9.146355628967283,0.9174259475089144,,
1995-11-17,9.034130096435549,9.090242385864258,0.30769053772368343,,
1995-11-16,8.921904563903809,9.034130096435549,0.6211144717834922,,
1995-11-15,8.865792274475098,8.921904563903809,1.257865198264746,,
1995-11-14,8.75356674194336,8.809679985046387,0.6329077841160348,,
1995-11-13,8.781623840332031,8.75356674194336,0.6410329041550185,,
1995-11-10,8.837736129760742,8.809679985046387,-0.3194978388827349,,
1995-11-09,8.94996166229248,8.893848419189453,-0.31745850184276786,,
1995-11-08,8.865792274475098,8.94996166229248,-0.6269662957266151,,
1995-11-07,8.865792274475098,8.809679985046387,0.9493724329602127,,
1995-11-06,8.809679985046387,8.865792274475098,-0.6329077841160348,,
1995-11-03,8.781623840332031,8.837736129760742,0.6369390207584876,,
1995-11-02,8.865792274475098,8.75356674194336,0.638973957993962,,
1995-11-01,8.921904563903809,8.865792274475098,-1.2658263250182302,,
1995-10-31,8.865792274475098,8.921904563903809,-0.6289272545654627,,
1995-10-30,8.865792274475098,8.837736129760742,0.6329077841160348,,
1995-10-27,8.893848419189453,8.809679985046387,-0.3164538920580174,,
1995-10-26,9.034130096435549,8.893848419189453,-0.9463668614079792,,
1995-10-25,9.090242385864258,9.034130096435549,-1.552796735807958,,
1995-10-24,9.090242385864258,9.062186241149902,-0.6172804535549716,,
1995-10-23,9.034130096435549,9.090242385864258,-0.3086402267774956,,
1995-10-20,9.11829948425293,9.062186241149902,0.6211144717834922,,
1995-10-19,8.837736129760742,9.146355628967283,-0.6153915343527977,,
1995-10-18,8.865792274475098,8.809679985046387,3.492065102139412,,
1995-10-17,8.978017807006836,8.865792274475098,-0.6329077841160348,,
1995-10-16,9.034130096435549,8.94996166229248,-1.2500034522559378,,
1995-10-13,8.978017807006836,9.006073951721191,-0.9316717076752875,,
1995-10-12,8.893848419189453,8.921904563903809,0.3124982074824939,,
1995-10-11,9.034130096435549,8.809679985046387,0.3154556204693264,,
1995-10-10,9.7355375289917,9.062186241149902,-2.484468443483226,,
1995-10-09,9.903875350952148,9.847763061523438,-6.916426400048352,,
1995-10-06,9.763593673706056,9.903875350952148,-0.5665690190993403,,
1995-10-05,9.959988594055176,9.847763061523438,1.4367832371381755,,
1995-10-04,9.791650772094728,10.016100883483888,-1.126763665158436,,
1995-10-03,9.595255851745604,9.763593673706056,2.292260177709989,,
1995-10-02,9.483031272888184,9.595255851745604,1.7543859649123181,,
1995-09-29,9.595255851745604,9.56719970703125,1.1834251688937076,,
1995-09-28,9.679425239562988,9.595255851745604,-0.29239600431550367,,
1995-09-27,9.707481384277344,9.679425239562988,-0.8695701008501691,,
1995-09-26,9.651369094848633,9.763593673706056,-0.2890156942231835,,
1995-09-25,9.539143562316896,9.595255851745604,1.1627840335867263,,
1995-09-22,9.483031272888184,9.51108741760254,0.5882319420201562,,
1995-09-21,9.454975128173828,9.539143562316896,0.29585629222345033,,
1995-09-20,9.539143562316896,9.454975128173828,0.8902025970672734,,
1995-09-19,9.483031272888184,9.483031272888184,-0.8823479130303088,,
1995-09-18,8.94996166229248,9.28663730621338,0.0,,
1995-09-15,9.3988618850708,8.978017807006836,3.761755151861318,,
1995-09-14,8.921904563903809,9.090242385864258,-4.477606791226879,,
1995-09-13,8.837736129760742,8.921904563903809,1.8867924528301887,,
1995-09-12,8.809679985046387,8.837736129760742,0.9523755055283036,,
1995-09-11,8.837736129760742,8.781623840332031,0.3184695103792438,,
1995-09-08,8.921904563903809,8.809679985046387,-0.6349170036855357,,
1995-09-07,8.781623840332031,8.809679985046387,-1.2578545091309254,,
1995-09-06,8.697454452514648,8.75356674194336,0.319486978996981,,
1995-09-05,8.669398307800293,8.641342163085938,0.6451576117479695,,
1995-09-01,8.697454452514648,8.641342163085938,-0.3236227442579486,,
1995-08-31,8.75356674194336,8.697454452514648,-0.6451576117479695,,
1995-08-30,8.725510597229004,8.697454452514648,-0.6410220094609523,,
1995-08-29,8.58522891998291,8.669398307800293,-0.32154158088198725,,
1995-08-28,8.641342163085938,8.613286018371582,0.9803977110205043,,
1995-08-25,8.501060485839844,8.501060485839844,-0.3246734614236852,,
1995-08-24,8.473004341125488,8.473004341125488,0.0,,
1995-08-23,8.388834953308105,8.444948196411133,0.0,,
1995-08-22,8.388834953308105,8.416891098022461,0.6689038873139267,,
1995-08-21,8.388834953308105,8.388834953308105,0.33444625946886264,,
1995-08-18,8.248553276062012,8.304666519165039,0.0,,
1995-08-17,8.220497131347656,8.248553276062012,0.6802798166543053,,
1995-08-16,8.473004341125488,8.276610374450684,0.34129498819928406,,
1995-08-15,8.613286018371582,8.5291166305542,-2.3178787448693465,,
1995-08-14,8.58522891998291,8.697454452514648,-0.9772041429699995,,
1995-08-11,8.725510597229004,8.58522891998291,1.3071932452554997,,
1995-08-10,8.697454452514648,8.697454452514648,-1.607718834134974,,
1995-08-09,8.697454452514648,8.641342163085938,0.0,,
1995-08-08,8.669398307800293,8.669398307800293,-0.6451576117479695,,
1995-08-07,8.697454452514648,8.613286018371582,0.0,,
1995-08-04,8.697454452514648,8.669398307800293,-0.9677364176219542,,
1995-08-03,8.697454452514648,8.669398307800293,-0.32257880587398474,,
1995-08-02,8.865792274475098,8.725510597229004,-0.32257880587398474,,
1995-08-01,8.94996166229248,8.837736129760742,-1.5822802170762473,,
1995-07-31,8.94996166229248,8.978017807006836,-1.253921935828632,,
1995-07-28,8.865792274475098,8.978017807006836,0.31347782005100844,,
1995-07-27,8.809679985046387,8.94996166229248,1.2658263250182302,,
1995-07-26,8.697454452514648,8.725510597229004,1.5923583771965482,,
1995-07-25,8.58522891998291,8.697454452514648,0.32257880587398474,,
1995-07-24,8.641342163085938,8.613286018371582,1.3071932452554997,,
1995-07-21,8.613286018371582,8.613286018371582,-0.3246734614236852,,
1995-07-20,8.837736129760742,8.613286018371582,0.0,,
1995-07-19,8.75356674194336,8.725510597229004,-2.539678805676636,,
1995-07-18,8.725510597229004,8.75356674194336,-0.32051100473047617,,
1995-07-17,8.669398307800293,8.725510597229004,0.32154158088198725,,
1995-07-14,8.613286018371582,8.641342163085938,0.6472454885158972,,
1995-07-13,8.58522891998291,8.641342163085938,0.3257310236129803,,
1995-07-12,8.557172775268555,8.473004341125488,0.653602176785509,,
1995-07-11,8.613286018371582,8.58522891998291,-0.9836009667389811,,
1995-07-10,8.641342163085938,8.58522891998291,-0.3257420957440389,,
1995-07-07,8.697454452514648,8.5291166305542,-0.6493579590301579,,
1995-07-06,8.781623840332031,8.893848419189453,-1.9354838002259223,,
1995-07-05,9.11829948425293,8.94996166229248,1.277947915987924,,
1995-07-03,9.034130096435549,9.11829948425293,-1.8461536852476095,,
1995-06-30,9.202467918395996,9.090242385864258,0.9316822640244067,,
1995-06-29,9.146355628967283,9.146355628967283,-1.2195156074100104,,
1995-06-28,9.11829948425293,9.146355628967283,0.0,,
1995-06-27,9.202467918395996,9.062186241149902,0.30769053772368343,,
1995-06-26,9.34274959564209,9.202467918395996,-1.5243919184512087,,
1995-06-23,9.426918029785156,9.426918029785156,-1.5015031261410228,,
1995-06-22,9.230524063110352,9.51108741760254,0.0,,
1995-06-21,9.202467918395996,9.258580207824709,3.03951706938782,,
1995-06-20,9.17441177368164,9.202467918395996,0.609752622082416,,
1995-06-19,9.090242385864258,9.17441177368164,0.3058086491696317,,
1995-06-16,9.034130096435549,9.090242385864258,0.9259311715193652,,
1995-06-15,8.94996166229248,8.978017807006836,0.6211144717834922,,
1995-06-14,9.062186241149902,8.978017807006836,0.31347782005100844,,
1995-06-13,8.978017807006836,9.090242385864258,-0.928787291535362,,
1995-06-12,8.809679985046387,8.94996166229248,1.2499928299299756,,
1995-06-09,8.893848419189453,8.809679985046387,1.5923583771965482,,
1995-06-08,8.893848419189453,8.94996166229248,-0.9463668614079792,,
1995-06-07,8.893848419189453,8.865792274475098,0.6309219637919269,,
1995-06-06,8.809679985046387,8.921904563903809,-0.3154556204693264,,
1995-06-05,8.921904563903809,8.781623840332031,1.2738780415169753,,
1995-06-02,8.809679985046387,8.893848419189453,-1.5723181364136567,,
1995-06-01,8.94996166229248,8.978017807006836,0.9554085311377315,,
1995-05-31,8.809679985046387,8.978017807006836,0.31347782005100844,,
1995-05-30,8.669398307800293,8.809679985046387,1.910827887575792,,
1995-05-26,8.725510597229004,8.669398307800293,1.618124721756933,,
1995-05-25,8.58522891998291,8.725510597229004,-0.6430831617639745,,
1995-05-24,8.865792274475098,8.5291166305542,1.6339887794904948,,
1995-05-23,8.557172775268555,8.725510597229004,-3.7974682182685293,,
1995-05-22,8.5291166305542,8.557172775268555,1.9672130782139803,,
1995-05-19,8.444948196411133,8.501060485839844,0.3289454925947291,,
1995-05-18,8.669398307800293,8.501060485839844,0.664448000433645,,
1995-05-17,8.75356674194336,8.697454452514648,-1.941747466014882,,
1995-05-16,8.557172775268555,8.697454452514648,-0.6410220094609523,,
1995-05-15,8.473004341125488,8.5291166305542,1.6393460893009866,,
1995-05-12,8.978017807006836,8.613286018371582,0.662247854121333,,
1995-05-11,8.978017807006836,9.090242385864258,-4.062497941924345,,
1995-05-10,8.94996166229248,8.978017807006836,1.2499928299299756,,
1995-05-09,9.11829948425293,8.893848419189453,0.31347782005100844,,
1995-05-08,9.006073951721191,9.090242385864258,-2.461545219600407,,
1995-05-05,8.921904563903809,9.034130096435549,0.9345740951525343,,
1995-05-04,9.146355628967283,8.921904563903809,1.257865198264746,,
1995-05-03,8.978017807006836,9.062186241149902,-2.4539945106947214,,
1995-05-02,8.809679985046387,8.978017807006836,0.9374946224474816,,
1995-05-01,8.781623840332031,8.865792274475098,1.910827887575792,,
1995-04-28,8.697454452514648,8.837736129760742,0.9584609369909428,,
1995-04-27,8.725510597229004,8.75356674194336,1.6129049943519376,,
1995-04-26,8.669398307800293,8.75356674194336,0.32154158088198725,,
1995-04-25,8.669398307800293,8.557172775268555,0.9708682327738459,,
1995-04-24,8.416891098022461,8.697454452514648,-1.2945019774989843,,
1995-04-21,8.444948196411133,8.36077880859375,3.3333371101606097,,
1995-04-20,8.332722663879395,8.304666519165039,-0.9966832934884367,,
1995-04-19,8.473004341125488,8.332722663879395,-0.3366984099443628,,
1995-04-18,8.473004341125488,8.473004341125488,-1.655630890748013,,
1995-04-17,8.75356674194336,8.5291166305542,0.0,,
1995-04-13,8.669398307800293,8.75356674194336,-2.5640989325378754,,
1995-04-12,8.58522891998291,8.641342163085938,0.9708682327738459,,
1995-04-11,8.5291166305542,8.58522891998291,0.653602176785509,,
1995-04-10,8.304666519165039,8.416891098022461,0.6578909851894582,,
1995-04-07,8.501060485839844,8.36077880859375,1.3513435921651562,,
1995-04-06,8.501060485839844,8.557172775268555,-1.6501667936578024,,
1995-04-05,8.388834953308105,8.473004341125488,0.6600622301438365,,
1995-04-04,8.1924409866333,8.416891098022461,1.0033501467827892,,
1995-04-03,8.024103164672852,8.164384841918945,2.739722040785775,,
1995-03-31,8.108272552490234,8.024103164672852,1.7482536598445282,,
1995-03-30,8.304666519165039,8.1924409866333,-1.038068062864173,,
1995-03-29,8.332722663879395,8.248553276062012,-1.351355075760725,,
1995-03-28,8.444948196411133,8.388834953308105,-1.0101066747635734,,
1995-03-27,8.473004341125488,8.444948196411133,-0.6644592932716141,,
1995-03-24,8.557172775268555,8.473004341125488,-0.3311239270606665,,
1995-03-23,8.501060485839844,8.5291166305542,-0.9836009667389811,,
1995-03-22,8.5291166305542,8.5291166305542,0.33003111507191824,,
1995-03-21,8.416891098022461,8.473004341125488,0.0,,
1995-03-20,8.276610374450684,8.473004341125488,0.6666742203212191,,
1995-03-17,8.248553276062012,8.276610374450684,2.372879207665243,,
1995-03-16,8.248553276062012,8.276610374450684,0.34014568918522853,,
1995-03-15,8.36077880859375,8.248553276062012,0.34014568918522853,,
1995-03-14,8.220497131347656,8.388834953308105,-1.342285630333691,,
1995-03-13,7.967990398406982,8.164384841918945,2.047781530371414,,
1995-03-10,7.827709197998047,7.967990398406982,2.4647926728328824,,
1995-03-09,7.771596431732178,7.827709197998047,1.7921105250666793,,
1995-03-08,7.855765342712402,7.827709197998047,0.7220236763292971,,
1995-03-07,7.855765342712402,7.799652576446533,-0.3571408193904679,,
1995-03-06,7.883821487426758,7.883821487426758,-0.7142877086816698,,
1995-03-03,7.855765342712402,7.939934253692627,0.0,,
1995-03-02,7.967990398406982,7.883821487426758,1.0714285280721376,,
1995-03-01,7.939934253692627,7.939934253692627,-1.0563380070971504,,
1995-02-28,7.911878108978271,7.967990398406982,0.0,,
1995-02-27,7.967990398406982,7.883821487426758,0.7092157975112953,,
1995-02-24,7.911878108978271,8.024103164672852,-1.0563380070971504,,
1995-02-23,7.855765342712402,7.939934253692627,1.4184376218742527,,
1995-02-22,7.659371376037598,7.799652576446533,1.0714285280721376,,
1995-02-21,7.715483665466309,7.659371376037598,1.8314975671215834,,
1995-02-17,7.743540287017822,7.743540287017822,-0.7272685921151467,,
1995-02-16,7.771596431732178,7.771596431732178,0.0,,
1995-02-15,7.771596431732178,7.771596431732178,0.0,,
1995-02-14,7.827709197998047,7.771596431732178,0.0,,
1995-02-13,7.771596431732178,7.799652576446533,-0.7168478650205873,,
1995-02-10,7.855765342712402,7.799652576446533,0.3610087703447843,,
1995-02-09,7.827709197998047,7.855765342712402,-0.7142877086816698,,
1995-02-08,7.996047019958496,7.855765342712402,0.35842088668203065,,
1995-02-07,8.024103164672852,8.024103164672852,-1.7543878480947437,,
1995-02-06,7.799652576446533,7.996047019958496,0.0,,
1995-02-03,7.855765342712402,7.771596431732178,2.5179896359106655,,
1995-02-02,7.883821487426758,7.799652576446533,-1.0714285280721376,,
1995-02-01,8.024103164672852,7.911878108978271,-1.0676156368387908,,
1995-01-31,7.799652576446533,7.939934253692627,-1.3985993623395352,,
1995-01-30,7.659371376037598,7.743540287017822,1.7985631522834455,,
1995-01-27,7.519089698791504,7.687427520751953,1.0989010304885816,,
1995-01-26,7.519089698791504,7.462976932525635,2.2388058754972042,,
1995-01-25,7.406864643096924,7.519089698791504,-0.7462707390615089,,
1995-01-24,7.37880802154541,7.434920787811279,1.515149271685044,,
1995-01-23,7.1824140548706055,7.37880802154541,0.7604584114673435,,
1995-01-20,7.1824140548706055,7.210470199584961,2.7343726659927685,,
1995-01-19,7.210470199584961,7.210470199584961,0.39062276972642335,,
1995-01-18,7.238526821136475,7.15435791015625,0.0,,
1995-01-17,7.15435791015625,7.238526821136475,-1.1627906210757093,,
1995-01-16,7.070188999176025,7.1824140548706055,1.1764705098236603,,
1995-01-13,7.098245143890381,7.098245143890381,1.5872992321373447,,
1995-01-12,7.014076232910156,7.070188999176025,0.0,,
1995-01-11,6.957963466644287,7.014076232910156,0.8000022298387229,,
1995-01-10,7.126301288604736,7.014076232910156,0.806453878852161,,
1995-01-09,7.15435791015625,7.126301288604736,-1.574800884071977,,
1995-01-06,7.2946391105651855,7.1824140548706055,-0.392161279933798,,
1995-01-05,7.322695732116699,7.2946391105651855,-1.5384593260006378,,
1995-01-04,7.37880802154541,7.350751876831055,-0.3831460786832887,,
1995-01-03,7.2946391105651855,7.350751876831055,-0.38022597460774454,,
1994-12-30,7.406864643096924,7.322695732116699,0.7692329314084675,,
1994-12-29,7.406864643096924,7.406864643096924,-1.136363563207121,,
1994-12-28,7.462976932525635,7.406864643096924,0.0,,
1994-12-27,7.462976932525635,7.462976932525635,-0.7518754236551193,,
1994-12-23,7.575202465057373,7.519089698791504,0.0,,
1994-12-22,7.406864643096924,7.547145843505859,-0.74074279235049,,
1994-12-21,7.2946391105651855,7.434920787811279,1.893934980162967,,
1994-12-20,7.26658296585083,7.26658296585083,1.9230790601130203,,
1994-12-19,7.238526821136475,7.26658296585083,0.0,,
1994-12-16,7.1824140548706055,7.26658296585083,0.38759467786223595,,
1994-12-15,7.1824140548706055,7.15435791015625,1.1718749481331727,,
1994-12-14,7.070188999176025,7.210470199584961,-0.39062276972642335,,
1994-12-13,7.1824140548706055,7.098245143890381,1.9841223540881894,,
1994-12-12,7.070188999176025,7.210470199584961,-1.1718749481331727,,
1994-12-09,7.014076232910156,7.098245143890381,1.9841223540881894,,
1994-12-08,7.210470199584961,7.070188999176025,1.1999999456136896,,
1994-12-07,7.238526821136475,7.238526821136475,-1.9455208401944468,,
1994-12-06,7.1824140548706055,7.2946391105651855,0.0,,
1994-12-05,7.070188999176025,7.1824140548706055,1.562497717859596,,
1994-12-02,7.070188999176025,7.014076232910156,1.5872992321373447,,
1994-12-01,7.15435791015625,7.098245143890381,-0.7936529882356559,,
1994-11-30,7.1824140548706055,7.15435791015625,-0.7843158948787291,,
1994-11-29,7.098245143890381,7.1824140548706055,-0.39062276972642335,,
1994-11-28,7.098245143890381,7.15435791015625,1.185770697883979,,
1994-11-25,7.042132377624512,7.070188999176025,0.7905160378148769,,
1994-11-23,6.957963466644287,7.014076232910156,0.39841087964577393,,
1994-11-22,7.1824140548706055,7.014076232910156,0.806453878852161,,
1994-11-21,7.2946391105651855,7.1824140548706055,-2.3437498962663454,,
1994-11-18,7.350751876831055,7.2946391105651855,-1.5384593260006378,,
1994-11-17,7.238526821136475,7.37880802154541,-0.763360907919254,,
1994-11-16,7.2946391105651855,7.26658296585083,1.937979976800181,,
1994-11-15,7.322695732116699,7.2946391105651855,-0.3846131972960852,,
1994-11-14,7.238526821136475,7.2946391105651855,-0.3831460786832887,,
1994-11-11,7.1824140548706055,7.238526821136475,0.7751893557244719,,
1994-11-10,7.210470199584961,7.210470199584961,0.7812521784067492,,
1994-11-09,7.126301288604736,7.1824140548706055,0.0,,
1994-11-08,6.986020088195801,6.986020088195801,0.787403787650627,,
1994-11-07,6.929907321929932,6.957963466644287,0.0,,
1994-11-04,7.042132377624512,6.957963466644287,0.4048559874036241,,
1994-11-03,7.014076232910156,7.042132377624512,-1.1952190965290672,,
1994-11-02,6.957963466644287,6.929907321929932,0.39999771577496684,,
1994-11-01,6.929907321929932,6.986020088195801,-0.40322351286915414,,
1994-10-31,7.098245143890381,6.957963466644287,0.8097188556663427,,
1994-10-28,6.929907321929932,7.070188999176025,-1.9762867356988556,,
1994-10-27,6.789625644683838,6.929907321929932,2.02429369873631,,
1994-10-26,6.929907321929932,6.761569499969482,2.0661179951199804,,
1994-10-25,6.817682266235352,6.845738410949707,-2.4291496861399335,,
1994-10-24,6.957963466644287,6.873794555664063,0.41152027358775345,,
1994-10-21,7.014076232910156,6.957963466644287,-1.2096773917213024,,
1994-10-20,7.014076232910156,7.014076232910156,-0.8000022298387229,,
1994-10-19,6.957963466644287,7.070188999176025,0.0,,
1994-10-18,6.986020088195801,6.986020088195801,1.612907757704322,,
1994-10-17,7.126301288604736,7.070188999176025,0.0,,
1994-10-14,7.070188999176025,7.1824140548706055,-0.78739709642135,,
1994-10-13,7.126301288604736,7.070188999176025,1.5872992321373447,,
1994-10-12,7.042132377624512,7.042132377624512,-0.78739709642135,,
1994-10-11,6.957963466644287,7.014076232910156,0.0,,
1994-10-10,6.986020088195801,6.929907321929932,0.806453878852161,,
1994-10-07,6.845738410949707,6.957963466644287,-0.8032150717785975,,
1994-10-06,6.901851177215576,6.873794555664063,1.639341864349899,,
1994-10-05,6.845738410949707,6.845738410949707,-0.40650864284256716,,
1994-10-04,7.126301288604736,6.901851177215576,0.0,,
1994-10-03,7.042132377624512,7.098245143890381,-3.149601768143954,,
1994-09-30,7.014076232910156,7.042132377624512,0.7968149880874206,,
1994-09-29,7.15435791015625,7.014076232910156,0.39999771577496684,,
1994-09-28,7.042132377624512,7.15435791015625,-1.9607864047023895,,
1994-09-27,6.957963466644287,6.986020088195801,1.5936299761748411,,
1994-09-26,6.957963466644287,6.929907321929932,0.40323036598300693,,
1994-09-23,7.014076232910156,6.873794555664063,-0.40322351286915414,,
1994-09-22,6.873794555664063,7.070188999176025,-2.0000021754524,,
1994-09-21,6.733513355255127,6.817682266235352,2.85714741576225,,
1994-09-20,6.845738410949707,6.705456733703613,1.2499999114806168,,
1994-09-19,6.873794555664063,6.873794555664063,-2.0491825545322366,,
1994-09-16,6.901851177215576,6.845738410949707,0.0,,
1994-09-15,6.845738410949707,6.901851177215576,-0.8130103768552541,,
1994-09-14,6.761569499969482,6.817682266235352,0.8196744149048582,,
1994-09-13,6.733513355255127,6.733513355255127,0.8298778303783225,,
1994-09-12,6.733513355255127,6.705456733703613,0.0,,
1994-09-09,6.789625644683838,6.705456733703613,-0.41667135819396667,,
1994-09-08,6.817682266235352,6.929907321929932,-1.2396693924668356,,
1994-09-07,6.677400588989258,6.789625644683838,1.6460880884751103,,
1994-09-06,6.677400588989258,6.649344444274902,1.6806698085424783,,
1994-09-02,6.733513355255127,6.649344444274902,-0.4201656668707105,,
1994-09-01,6.677400588989258,6.705456733703613,-1.2499999114806168,,
1994-08-31,6.649344444274902,6.733513355255127,0.4201656668707105,,
1994-08-30,6.817682266235352,6.761569499969482,1.265822694035563,,
1994-08-29,6.845738410949707,6.817682266235352,-0.8230475412996034,,
1994-08-26,6.873794555664063,6.901851177215576,-0.40983372472252044,,
1994-08-25,6.845738410949707,6.817682266235352,0.4081678805543278,,
1994-08-24,6.789625644683838,6.817682266235352,-0.40983372472252044,,
1994-08-23,6.817682266235352,6.761569499969482,0.4132278128394536,,
1994-08-22,6.761569499969482,6.845738410949707,-0.8230475412996034,,
1994-08-19,6.845738410949707,6.789625644683838,1.244813219484093,,
1994-08-18,6.817682266235352,6.789625644683838,-0.8196744149048582,,
1994-08-17,6.845738410949707,6.986020088195801,-0.4115272677118499,,
1994-08-16,6.537118911743164,6.789625644683838,2.0491825545322366,,
1994-08-15,6.45295000076294,6.509062767028809,3.862660850287965,,
1994-08-12,6.340724945068359,6.424893856048584,0.8695676591207737,,
1994-08-11,6.368781089782715,6.368781089782715,1.3274335617678679,,
1994-08-10,6.200443267822266,6.3968377113342285,0.0,,
1994-08-09,6.0882182121276855,6.17238712310791,3.167425860198879,,
1994-08-08,6.228499889373779,6.0882182121276855,1.3824884070771437,,
1994-08-05,6.17238712310791,6.17238712310791,-2.252254631736019,,
1994-08-04,6.256556034088135,6.200443267822266,0.0,,
1994-08-03,6.424893856048584,6.256556034088135,-0.8968634814448253,,
1994-08-02,6.340724945068359,6.45295000076294,-2.6200872066076397,,
1994-08-01,6.256556034088135,6.312668800354004,1.7699089089468627,,
1994-07-29,6.28461217880249,6.312668800354004,0.8968634814448253,,
1994-07-28,6.28461217880249,6.28461217880249,0.4464336183885218,,
1994-07-27,6.17238712310791,6.28461217880249,0.0,,
1994-07-26,6.340724945068359,6.228499889373779,1.8181791494321036,,
1994-07-25,6.256556034088135,6.3968377113342285,-1.769908908946849,,
1994-07-22,6.28461217880249,6.228499889373779,2.2421548929120902,,
1994-07-21,6.256556034088135,6.28461217880249,-0.8928520620249781,,
1994-07-20,6.200443267822266,6.256556034088135,0.44842793002243975,,
1994-07-19,6.200443267822266,6.200443267822266,0.9049799158242633,,
1994-07-18,6.228499889373779,6.200443267822266,0.0,,
1994-07-15,6.17238712310791,6.228499889373779,-0.4504555197854313,,
1994-07-14,6.200443267822266,6.228499889373779,0.9090934373801126,,
1994-07-13,6.116274356842041,6.144330978393555,0.45249380309817405,,
1994-07-12,6.28461217880249,6.032105445861816,0.4587207818780695,,
1994-07-11,6.677400588989258,6.509062767028809,-4.017857041240499,,
1994-07-08,6.677400588989258,6.733513355255127,-2.5210082833435354,,
1994-07-07,6.677400588989258,6.705456733703613,0.8403384748010572,,
1994-07-06,6.705456733703613,6.705456733703613,0.4201656668707105,,
1994-07-05,6.537118911743164,6.705456733703613,0.0,,
1994-07-01,6.565175533294678,6.509062767028809,2.57510723352531,,
1994-06-30,6.677400588989258,6.509062767028809,-0.8547032136657803,,
1994-06-29,6.649344444274902,6.649344444274902,-2.5210082833435354,,
1994-06-28,6.565175533294678,6.649344444274902,0.0,,
1994-06-27,6.424893856048584,6.565175533294678,1.2820511889342456,,
1994-06-24,6.565175533294678,6.45295000076294,2.1834084794105735,,
1994-06-23,6.677400588989258,6.593231678009033,-1.709406427331547,,
1994-06-22,6.677400588989258,6.705456733703613,-1.2605041416717677,,
1994-06-21,6.649344444274902,6.705456733703613,0.4201656668707105,,
1994-06-20,6.593231678009033,6.621287822723389,0.843877015230031,,
1994-06-17,6.817682266235352,6.705456733703613,0.4255294836359765,,
1994-06-16,6.845738410949707,6.817682266235352,-1.646095082599207,,
1994-06-15,6.845738410949707,6.873794555664063,-0.40983372472252044,,
1994-06-14,6.845738410949707,6.817682266235352,0.40983372472253343,,
1994-06-13,6.789625644683838,6.873794555664063,-0.40983372472252044,,
1994-06-10,6.845738410949707,6.789625644683838,1.2396693924668487,,
1994-06-09,7.014076232910156,6.901851177215576,-0.8196744149048582,,
1994-06-08,6.901851177215576,6.957963466644287,-1.5999976613886566,,
1994-06-07,6.761569499969482,6.873794555664063,0.813003468025348,,
1994-06-06,6.957963466644287,6.817682266235352,1.6597486085898765,,
1994-06-03,6.929907321929932,7.014076232910156,-2.0161244174596233,,
1994-06-02,6.873794555664063,6.929907321929932,1.2145748430699668,,
1994-06-01,6.649344444274902,6.817682266235352,0.816328824079138,,
1994-05-31,6.845738410949707,6.705456733703613,2.531645388071126,,
1994-05-27,6.789625644683838,6.901851177215576,-2.0491825545322366,,
1994-05-26,6.677400588989258,6.817682266235352,1.6528972053062894,,
1994-05-25,6.565175533294678,6.677400588989258,2.100842616472825,,
1994-05-24,6.509062767028809,6.565175533294678,1.7093991642027109,,
1994-05-23,6.677400588989258,6.509062767028809,0.8620713653293427,,
1994-05-20,6.705456733703613,6.649344444274902,-2.5210082833435354,,
1994-05-19,6.677400588989258,6.677400588989258,-0.8368153230588147,,
1994-05-18,6.705456733703613,6.677400588989258,0.0,,
1994-05-17,6.677400588989258,6.705456733703613,-0.41840766152940734,,
1994-05-16,6.424893856048584,6.649344444274902,0.4201656668707105,,
1994-05-13,6.509062767028809,6.481006622314453,3.493452082714393,,
1994-05-12,6.509062767028809,6.45295000076294,-0.4310320197935694,,
1994-05-11,6.3968377113342285,6.340724945068359,-0.8620713653293289,,
1994-05-10,6.312668800354004,6.368781089782715,-0.8771954018224632,,
1994-05-09,6.200443267822266,6.200443267822266,0.8888837859759767,,
1994-05-06,6.28461217880249,6.256556034088135,0.0,,
1994-05-05,6.45295000076294,6.3968377113342285,-0.44642603101248907,,
1994-05-04,6.481006622314453,6.424893856048584,-0.8695602696763123,,
1994-05-03,6.45295000076294,6.481006622314453,-0.8658032545850189,,
1994-05-02,6.368781089782715,6.45295000076294,0.43478752428262446,,
1994-04-29,6.368781089782715,6.368781089782715,1.3215858701008847,,
1994-04-28,6.312668800354004,6.45295000076294,0.0,,
1994-04-26,6.340724945068359,6.312668800354004,2.2222170185939376,,
1994-04-25,6.228499889373779,6.340724945068359,-0.44247534717898085,,
1994-04-22,6.312668800354004,6.312668800354004,1.8017991119505874,,
1994-04-21,6.228499889373779,6.340724945068359,0.0,,
1994-04-20,6.28461217880249,6.228499889373779,1.8017991119505874,,
1994-04-19,6.200443267822266,6.228499889373779,-0.8928520620249781,,
1994-04-18,6.144330978393555,6.116274356842041,0.45249380309817405,,
1994-04-15,6.116274356842041,6.116274356842041,-0.45662614286525827,,
1994-04-14,6.116274356842041,6.0882182121276855,0.0,,
1994-04-13,6.004049301147461,6.0882182121276855,-0.4587129856751788,,
1994-04-12,6.06016206741333,5.891824245452881,1.4018690846548962,,
1994-04-11,5.891824245452881,6.004049301147461,-2.7777775592114016,,
1994-04-08,5.9759931564331055,5.919880390167236,1.9047590528721514,,
1994-04-07,5.947936534881592,6.032105445861816,-0.9389697209653634,,
1994-04-06,6.116274356842041,6.004049301147461,1.4150943018073106,,
1994-04-05,5.9759931564331055,6.0882182121276855,-1.8348597389036059,,
1994-04-04,5.807655334472656,5.863767623901367,1.8779314627188082,,
1994-03-31,6.0882182121276855,5.9759931564331055,0.9661780218885186,,
1994-03-30,6.200443267822266,6.17238712310791,-1.8433152653928961,,
1994-03-29,6.116274356842041,6.228499889373779,-0.45248611272608924,,
1994-03-28,6.0882182121276855,6.144330978393555,1.8348675351064965,,
1994-03-25,6.116274356842041,6.06016206741333,0.9216615487613917,,
1994-03-24,6.228499889373779,6.116274356842041,-0.9174259713503576,,
1994-03-23,6.424893856048584,6.312668800354004,-1.8018067676809666,,
1994-03-22,6.312668800354004,6.3968377113342285,-1.7467223305008863,,
1994-03-21,6.312668800354004,6.368781089782715,1.3333332326179468,,
1994-03-18,6.17238712310791,6.340724945068359,0.8888837859759767,,
1994-03-17,6.340724945068359,6.368781089782715,2.727272586812216,,
1994-03-16,6.3968377113342285,6.340724945068359,0.44247534717898085,,
1994-03-15,6.340724945068359,6.3968377113342285,-0.8771954018224632,,
1994-03-14,6.312668800354004,6.340724945068359,0.884958214588887,,
1994-03-11,6.228499889373779,6.312668800354004,0.44444189298798836,,
1994-03-10,6.312668800354004,6.28461217880249,1.3513512478955354,,
1994-03-09,6.144330978393555,6.312668800354004,-0.4444494466419703,,
1994-03-08,6.116274356842041,6.200443267822266,2.7397258147779895,,
1994-03-07,6.032105445861816,6.144330978393555,1.376146753228427,,
1994-03-04,5.9759931564331055,5.9759931564331055,1.8604703372473033,,
1994-03-03,6.0882182121276855,6.004049301147461,0.0,,
1994-03-02,6.0882182121276855,6.0882182121276855,-1.3824884070771437,,
1994-03-01,6.228499889373779,6.256556034088135,0.0,,
1994-02-28,6.17238712310791,6.200443267822266,0.45044786405505205,,
1994-02-25,6.116274356842041,6.17238712310791,0.4545428560259955,,
1994-02-24,6.256556034088135,6.0882182121276855,0.9174337675532482,,
1994-02-23,6.340724945068359,6.312668800354004,-2.6905828229345303,,
1994-02-22,6.368781089782715,6.368781089782715,-0.44247534717898085,,
1994-02-18,6.368781089782715,6.340724945068359,0.0,,
1994-02-17,6.481006622314453,6.368781089782715,-0.4405261276661758,,
1994-02-16,6.593231678009033,6.45295000076294,-1.7316065091700379,,
1994-02-15,6.649344444274902,6.593231678009033,-2.1276618826240594,,
1994-02-14,6.537118911743164,6.649344444274902,-0.8438841864205475,,
1994-02-11,6.424893856048584,6.509062767028809,1.7167430185511594,,
1994-02-10,6.537118911743164,6.3968377113342285,1.3100436033038199,,
1994-02-09,6.593231678009033,6.565175533294678,-2.1459178317368055,,
1994-02-08,6.593231678009033,6.565175533294678,-0.4255294836359765,,
1994-02-07,6.45295000076294,6.621287822723389,-0.4255294836359765,,
1994-02-04,6.705456733703613,6.509062767028809,2.60869558791786,,
1994-02-03,6.733513355255127,6.733513355255127,-2.9288678530676426,,
1994-02-02,6.677400588989258,6.761569499969482,0.0,,
1994-02-01,6.677400588989258,6.677400588989258,1.2605041416717677,,
1994-01-31,6.565175533294678,6.621287822723389,0.0,,
1994-01-28,6.593231678009033,6.565175533294678,0.8546959505369304,,
1994-01-27,6.368781089782715,6.509062767028809,-0.4255294836359765,,
1994-01-26,6.340724945068359,6.3968377113342285,2.202645612535566,,
1994-01-25,6.340724945068359,6.368781089782715,0.884958214588887,,
1994-01-24,6.424893856048584,6.340724945068359,0.44247534717898085,,
1994-01-21,6.593231678009033,6.45295000076294,-1.3100436033038199,,
1994-01-20,6.481006622314453,6.593231678009033,-2.1276618826240594,,
1994-01-19,6.705456733703613,6.537118911743164,1.7315991517148461,,
1994-01-18,6.649344444274902,6.677400588989258,-2.510460191538235,,
1994-01-17,6.677400588989258,6.677400588989258,0.4219385076150155,,
1994-01-14,6.593231678009033,6.649344444274902,0.0,,
1994-01-13,6.621287822723389,6.565175533294678,0.8510661994940482,,
1994-01-12,6.761569499969482,6.649344444274902,-0.8474528057236984,,
1994-01-11,6.705456733703613,6.761569499969482,-1.6597486085898636,,
1994-01-10,6.705456733703613,6.733513355255127,0.8368224342397103,,
1994-01-07,6.649344444274902,6.677400588989258,0.41841477271030286,,
1994-01-06,6.733513355255127,6.677400588989258,0.4219385076150155,,
1994-01-05,6.677400588989258,6.761569499969482,-0.8333356348372918,,
1994-01-04,6.481006622314453,6.621287822723389,1.2605041416717677,,
1994-01-03,6.621287822723389,6.481006622314453,2.16449710027976,,
1993-12-31,6.677400588989258,6.649344444274902,-2.1186392158865064,,
1993-12-30,6.705456733703613,6.565175533294678,-0.4201656668707105,,
1993-12-29,6.705456733703613,6.677400588989258,-2.0920454188279325,,
1993-12-28,6.705456733703613,6.677400588989258,-0.41840766152940734,,
1993-12-27,6.705456733703613,6.733513355255127,-0.41840766152940734,,
1993-12-23,6.649344444274902,6.649344444274902,0.41841477271030286,,
1993-12-22,6.45295000076294,6.593231678009033,0.0,,
1993-12-21,6.45295000076294,6.481006622314453,2.1739154530797102,,
1993-12-20,6.340724945068359,6.481006622314453,0.43478752428262446,,
1993-12-17,6.28461217880249,6.3968377113342285,2.212391776356755,,
1993-12-16,6.3968377113342285,6.312668800354004,1.7857192988020216,,
1993-12-15,6.340724945068359,6.368781089782715,-1.315789375601792,,
1993-12-14,6.481006622314453,6.424893856048584,0.44247534717898085,,
1993-12-13,6.368781089782715,6.3968377113342285,-0.8658032545850189,,
1993-12-10,6.593231678009033,6.3968377113342285,0.440533614768519,,
1993-12-09,6.677400588989258,6.565175533294678,-2.978720849896026,,
1993-12-08,6.677400588989258,6.705456733703613,-1.6806698085424783,,
1993-12-07,6.733513355255127,6.677400588989258,0.4201656668707105,,
1993-12-06,6.677400588989258,6.733513355255127,-0.8333356348372918,,
1993-12-03,6.621287822723389,6.677400588989258,0.8403384748010572,,
1993-12-02,6.565175533294678,6.621287822723389,0.847460007300959,,
1993-12-01,6.565175533294678,6.537118911743164,0.8546959505369304,,
1993-11-30,6.509062767028809,6.565175533294678,-0.4273552383973151,,
1993-11-29,6.593231678009033,6.565175533294678,0.8620713653293427,,
1993-11-26,6.509062767028809,6.565175533294678,-0.4255294836359765,,
1993-11-24,6.45295000076294,6.537118911743164,0.8620713653293427,,
1993-11-23,6.424893856048584,6.424893856048584,1.304347793958923,,
1993-11-22,6.509062767028809,6.368781089782715,0.0,,
1993-11-19,6.45295000076294,6.509062767028809,-2.1551747504522547,,
1993-11-18,6.3968377113342285,6.481006622314453,0.8695676591207737,,
1993-11-17,6.621287822723389,6.481006622314453,1.315789375601792,,
1993-11-16,6.509062767028809,6.593231678009033,-2.1186392158865064,,
1993-11-15,6.509062767028809,6.481006622314453,1.293103385122912,,
1993-11-12,6.45295000076294,6.537118911743164,-0.4310320197935694,,
1993-11-11,6.312668800354004,6.45295000076294,1.304347793958923,,
1993-11-10,6.228499889373779,6.340724945068359,2.2222170185939376,,
1993-11-09,6.340724945068359,6.256556034088135,1.8017991119505874,,
1993-11-08,6.312668800354004,6.28461217880249,-1.3274335617678679,,
1993-11-05,6.28461217880249,6.256556034088135,-0.4444494466419703,,
1993-11-04,6.3968377113342285,6.28461217880249,-0.44642603101248907,,
1993-11-03,6.509062767028809,6.45295000076294,-1.7543908036449265,,
1993-11-02,6.424893856048584,6.481006622314453,-0.8620713653293289,,
1993-11-01,6.368781089782715,6.3968377113342285,0.8733648761067535,,
1993-10-29,6.28461217880249,6.368781089782715,0.440533614768519,,
1993-10-28,6.228499889373779,6.28461217880249,1.3392856804134998,,
1993-10-27,6.144330978393555,6.144330978393555,0.9008957281101041,,
1993-10-26,6.312668800354004,6.256556034088135,0.0,,
1993-10-25,6.28461217880249,6.256556034088135,-0.8888913396299585,,
1993-10-22,6.481006622314453,6.228499889373779,-0.44642603101248907,,
1993-10-21,6.312668800354004,6.509062767028809,-3.896103609449798,,
1993-10-20,6.228499889373779,6.28461217880249,3.111108358223882,,
1993-10-19,6.312668800354004,6.228499889373779,0.9008957281101041,,
1993-10-18,6.17238712310791,6.312668800354004,-1.3333332326179468,,
1993-10-15,6.144330978393555,6.116274356842041,2.2727297307862204,,
1993-10-14,5.919880390167236,6.06016206741333,-0.45662614286525827,,
1993-10-13,5.9759931564331055,5.891824245452881,2.3696708041449264,,
1993-10-12,6.0882182121276855,5.9759931564331055,-1.4084505918420858,,
1993-10-11,5.9759931564331055,6.032105445861816,-1.8433152653928961,,
1993-10-08,5.919880390167236,5.919880390167236,0.9389617417534446,,
1993-10-07,6.032105445861816,5.947936534881592,0.0,,
1993-10-06,6.0882182121276855,6.032105445861816,-1.3953488004419206,,
1993-10-05,6.116274356842041,6.06016206741333,-0.9216615487613917,,
1993-10-04,6.116274356842041,6.06016206741333,-0.9174259713503576,,
1993-10-01,6.0882182121276855,6.17238712310791,-0.9174259713503576,,
1993-09-30,6.116274356842041,6.144330978393555,1.3824884070771437,,
1993-09-29,6.0882182121276855,6.144330978393555,0.4587207818780695,,
1993-09-28,6.144330978393555,6.032105445861816,0.9216615487613917,,
1993-09-27,6.116274356842041,6.144330978393555,-1.8264890502542528,,
1993-09-24,6.0882182121276855,6.116274356842041,0.4587207818780695,,
1993-09-23,5.863767623901367,6.06016206741333,0.4608268583157522,,
1993-09-22,5.891824245452881,5.835711479187012,3.349287627146706,,
1993-09-21,5.807655334472656,5.863767623901367,-0.9523835730364014,,
1993-09-20,5.891824245452881,5.779598712921143,0.9661780218885186,,
1993-09-17,5.751542568206787,5.919880390167236,-1.9047671460728028,,
1993-09-16,6.032105445861816,5.947936534881592,2.926829106524956,,
1993-09-15,6.032105445861816,6.06016206741333,-1.3953488004419206,,
1993-09-14,5.723486423492432,5.9759931564331055,0.4651215368053829,,
1993-09-13,5.891824245452881,5.807655334472656,4.411764338327826,,
1993-09-10,5.835711479187012,5.891824245452881,-1.4285713129542763,,
1993-09-09,5.723486423492432,5.891824245452881,0.9615411328334957,,
1993-09-08,5.835711479187012,5.779598712921143,2.941176225551884,,
1993-09-07,5.863767623901367,5.891824245452881,-0.9615411328334957,,
1993-09-03,6.004049301147461,6.004049301147461,0.4784743078349792,,
1993-09-02,5.9759931564331055,6.032105445861816,0.0,,
1993-09-01,5.835711479187012,5.835711479187012,0.9389617417534446,,
1993-08-31,5.891824245452881,5.835711479187012,0.0,,
1993-08-30,5.863767623901367,5.863767623901367,-0.9523835730364014,,
1993-08-27,5.919880390167236,5.863767623901367,0.0,,
1993-08-26,5.807655334472656,5.919880390167236,-0.9478699326268645,,
1993-08-25,5.835711479187012,5.779598712921143,1.9323642542704418,,
1993-08-24,5.835711479187012,5.807655334472656,-0.9615411328334957,,
1993-08-23,5.835711479187012,5.835711479187012,-0.48076648090669566,,
1993-08-20,5.891824245452881,5.835711479187012,0.0,,
1993-08-19,5.863767623901367,5.919880390167236,-0.9523835730364014,,
1993-08-18,5.695429801940918,5.807655334472656,0.9569404837454214,,
1993-08-17,5.583204746246338,5.639317512512207,1.9704488762813561,,
1993-08-16,5.386810779571533,5.583204746246338,1.005027915259502,,
1993-08-13,5.302641868591309,5.386810779571533,3.6458300599603732,,
1993-08-12,5.218472957611084,5.24652910232544,1.5873014445643638,,
1993-08-11,5.330698013305664,5.162360191345215,0.5376313136477364,,
1993-08-10,5.386810779571533,5.330698013305664,-3.157894548523859,,
1993-08-09,5.555148601531982,5.442923069000244,-1.041669525105026,,
1993-08-06,5.555148601531982,5.527091979980469,-2.0202075692590666,,
1993-08-05,5.555148601531982,5.555148601531982,-0.5050561841635758,,
1993-08-04,5.611260890960693,5.611260890960693,0.0,,
1993-08-03,5.555148601531982,5.611260890960693,0.0,,
1993-08-02,5.611260890960693,5.583204746246338,1.0100952009319148,,
1993-07-30,5.583204746246338,5.611260890960693,-0.49999715321652116,,
1993-07-29,5.6673736572265625,5.583204746246338,0.5025096873478979,,
1993-07-28,5.751542568206787,5.6673736572265625,-1.4851484315472905,,
1993-07-27,5.751542568206787,5.723486423492432,-1.463414553262478,,
1993-07-26,5.751542568206787,5.751542568206787,-0.48780208755549204,,
1993-07-23,5.723486423492432,5.807655334472656,0.0,,
1993-07-22,5.779598712921143,5.751542568206787,1.470588112775942,,
1993-07-21,5.779598712921143,5.863767623901367,-0.4854341297369285,,
1993-07-20,5.639317512512207,5.751542568206787,1.4563106395614047,,
1993-07-19,5.583204746246338,5.611260890960693,1.9900467644458981,,
1993-07-16,5.6673736572265625,5.583204746246338,0.5025096873478979,,
1993-07-15,5.779598712921143,5.6673736572265625,-1.4851484315472905,,
1993-07-14,5.807655334472656,5.807655334472656,-1.9417447692983332,,
1993-07-13,5.779598712921143,5.807655334472656,0.0,,
1993-07-12,5.723486423492432,5.723486423492432,0.4854423800875478,,
1993-07-09,5.723486423492432,5.6673736572265625,0.0,,
1993-07-08,5.695429801940918,5.779598712921143,-0.9803948522626095,,
1993-07-07,5.6673736572265625,5.695429801940918,1.4778324710725272,,
1993-07-06,5.611260890960693,5.555148601531982,0.4950466726078774,,
1993-07-02,5.6673736572265625,5.6673736572265625,-0.9999943064330423,,
1993-07-01,5.751542568206787,5.723486423492432,0.0,,
1993-06-30,5.807655334472656,5.751542568206787,-0.48780208755549204,,
1993-06-29,5.807655334472656,5.835711479187012,-0.9661862323819232,,
1993-06-28,5.919880390167236,5.863767623901367,0.4830890109442593,,
1993-06-25,5.891824245452881,5.947936534881592,-0.9478699326268645,,
1993-06-24,5.779598712921143,5.835711479187012,0.95237547983575,,
1993-06-23,5.807655334472656,5.751542568206787,0.9708765098244763,,
1993-06-22,5.891824245452881,5.835711479187012,-0.9661862323819232,,
1993-06-21,5.891824245452881,5.863767623901367,-0.9523835730364014,,
1993-06-18,6.004049301147461,5.863767623901367,-0.4761958331185263,,
1993-06-17,6.06016206741333,6.06016206741333,-2.3364511217335253,,
1993-06-16,5.863767623901367,6.0882182121276855,0.0,,
1993-06-15,5.9759931564331055,5.863767623901367,3.8277538030571483,,
1993-06-14,5.835711479187012,5.947936534881592,-1.8779394419307267,,
1993-06-11,5.919880390167236,5.835711479187012,1.9230740946468867,,
1993-06-10,5.835711479187012,5.863767623901367,-1.421800871518062,,
1993-06-09,5.807655334472656,5.807655334472656,0.48076648090669566,,
1993-06-08,5.835711479187012,5.779598712921143,0.0,,
1993-06-07,5.863767623901367,5.835711479187012,-0.9615411328334957,,
1993-06-04,6.032105445861816,5.807655334472656,-0.47846617591044216,,
1993-06-03,6.144330978393555,6.06016206741333,-3.7209248645203785,,
1993-06-02,6.0882182121276855,6.17238712310791,-1.3698629073889947,,
1993-06-01,6.032105445861816,6.0882182121276855,1.3824884070771437,,
1993-05-28,6.144330978393555,6.0882182121276855,0.9302351686236516,,
1993-05-27,6.256556034088135,6.17238712310791,-0.9132445251271264,,
1993-05-26,6.228499889373779,6.256556034088135,-1.3452914114672652,,
1993-05-25,6.256556034088135,6.256556034088135,0.45044786405505205,,
1993-05-24,6.28461217880249,6.312668800354004,0.0,,
1993-05-21,6.17238712310791,6.28461217880249,0.4464336183885218,,
1993-05-20,6.312668800354004,6.312668800354004,1.8181791494321036,,
1993-05-19,6.340724945068359,6.28461217880249,0.0,,
1993-05-18,6.368781089782715,6.312668800354004,-0.884958214588887,,
1993-05-17,6.228499889373779,6.312668800354004,-0.8810522553323517,,
1993-05-14,5.863767623901367,6.06016206741333,1.3513512478955354,,
1993-05-13,6.004049301147461,5.891824245452881,3.349287627146706,,
1993-05-12,6.144330978393555,6.116274356842041,-1.8691561322311634,,
1993-05-11,6.17238712310791,6.17238712310791,-0.45662614286525827,,
1993-05-10,6.200443267822266,6.144330978393555,0.0,,
1993-05-07,6.144330978393555,6.200443267822266,-0.9049722254521785,,
1993-05-06,6.28461217880249,6.200443267822266,0.9132367645237364,,
1993-05-05,6.17238712310791,6.28461217880249,-1.3392856804134998,,
1993-05-04,6.368781089782715,6.28461217880249,1.8181791494321036,,
1993-05-03,6.28461217880249,6.424893856048584,-1.321585870100871,,
1993-04-30,6.0882182121276855,6.256556034088135,2.232145329814511,,
1993-04-29,6.116274356842041,6.0882182121276855,2.7649768141542874,,
1993-04-28,6.312668800354004,6.17238712310791,-0.4587129856751788,,
1993-04-27,5.9759931564331055,6.340724945068359,-2.2222245722479053,,
1993-04-26,5.807655334472656,5.9759931564331055,6.103283238245065,,
1993-04-23,5.723486423492432,5.779598712921143,2.898550486652365,,
1993-04-22,6.144330978393555,5.779598712921143,0.9803865210266648,,
1993-04-21,6.116274356842041,6.144330978393555,-5.936077772421236,,
1993-04-20,5.863767623901367,6.06016206741333,0.4587207818780695,,
1993-04-19,5.6673736572265625,5.863767623901367,3.349287627146706,,
1993-04-16,5.751542568206787,5.6673736572265625,3.4653435357024587,,
1993-04-15,5.583204746246338,5.723486423492432,-1.463414553262478,,
1993-04-14,5.499035835266113,5.583204746246338,2.512565517866902,,
1993-04-13,5.779598712921143,5.583204746246338,1.5306121564154427,,
1993-04-12,5.499035835266113,5.6673736572265625,-3.3980554088597383,,
1993-04-08,5.24652910232544,5.330698013305664,3.0612243128308854,,
1993-04-07,5.555148601531982,5.527091979980469,1.6042779776617877,,
1993-04-06,5.723486423492432,5.611260890960693,-0.5050561841635758,,
1993-04-05,5.611260890960693,5.695429801940918,-1.960789704525219,,
1993-04-02,5.583204746246338,5.611260890960693,1.4999999575106944,,
1993-04-01,5.835711479187012,5.639317512512207,0.5025096873478979,,
1993-03-31,6.032105445861816,5.779598712921143,-3.365381708387078,,
1993-03-30,5.527091979980469,5.835711479187012,-4.186046401325761,,
1993-03-29,5.414866924285889,5.499035835266113,5.583759060359142,,
1993-03-26,5.555148601531982,5.330698013305664,1.554404053823073,,
1993-03-25,5.35875415802002,5.470979690551758,-4.040406554820515,,
1993-03-24,5.330698013305664,5.386810779571533,2.0942467077684164,,
1993-03-23,5.583204746246338,5.555148601531982,1.0526344978801863,,
1993-03-22,5.35875415802002,5.555148601531982,-0.5025096873478979,,
1993-03-19,5.723486423492432,5.35875415802002,3.6649272894527933,,
1993-03-18,5.723486423492432,5.723486423492432,-6.372554042853029,,
1993-03-17,5.779598712921143,5.723486423492432,0.0,,
1993-03-16,5.863767623901367,5.835711479187012,-0.970868259473857,,
1993-03-15,5.947936534881592,5.947936534881592,-0.47846617591044216,,
1993-03-12,5.807655334472656,5.9759931564331055,0.0,,
1993-03-11,5.919880390167236,5.891824245452881,2.898550486652365,,
1993-03-10,5.695429801940918,5.919880390167236,-0.47393093889119753,,
1993-03-09,5.863767623901367,5.6673736572265625,3.940889380285732,,
1993-03-08,5.695429801940918,5.919880390167236,-3.349279495222169,,
1993-03-05,5.751542568206787,5.723486423492432,3.940889380285732,,
1993-03-04,5.807655334472656,5.723486423492432,-0.48780208755549204,,
1993-03-03,5.779598712921143,5.751542568206787,-1.4492752433261824,,
1993-03-02,5.835711479187012,5.835711479187012,-0.4854341297369285,,
1993-03-01,5.863767623901367,5.807655334472656,0.0,,
1993-02-26,5.919880390167236,5.863767623901367,-0.9569323518208843,,
1993-02-25,5.779598712921143,5.919880390167236,-0.9478699326268645,,
1993-02-24,5.499035835266113,5.835711479187012,2.427187149385881,,
1993-02-23,5.274585247039795,5.442923069000244,6.122448625661771,,
1993-02-22,5.470979690551758,5.218472957611084,3.19148926552896,,
1993-02-19,5.611260890960693,5.442923069000244,-4.6153842131190235,,
1993-02-18,5.835711479187012,5.611260890960693,-2.9999999150213887,,
1993-02-17,5.891824245452881,5.779598712921143,-3.8461563603138784,,
1993-02-16,6.144330978393555,5.9759931564331055,-1.9047671460728028,,
1993-02-12,6.28461217880249,6.28461217880249,-2.7397258147779895,,
1993-02-11,6.144330978393555,6.228499889373779,0.0,,
1993-02-10,6.17238712310791,6.17238712310791,1.3698629073889947,,
1993-02-09,5.947936534881592,6.144330978393555,0.0,,
1993-02-08,6.17238712310791,5.9759931564331055,3.3018920487838157,,
1993-02-05,6.116274356842041,6.17238712310791,-3.1818154428382117,,
1993-02-04,6.256556034088135,6.144330978393555,0.9174337675532482,,
1993-02-03,5.891824245452881,6.200443267822266,-1.7937193414897048,,
1993-02-02,6.144330978393555,5.863767623901367,5.238089418698579,,
1993-02-01,6.256556034088135,6.17238712310791,-4.566214865032242,,
1993-01-29,6.0882182121276855,6.17238712310791,-1.3452914114672652,,
1993-01-28,6.144330978393555,6.06016206741333,1.3824884070771437,,
1993-01-27,6.228499889373779,6.116274356842041,-1.3698629073889947,,
1993-01-26,6.3968377113342285,6.200443267822266,-1.8018067676809666,,
1993-01-25,6.28461217880249,6.340724945068359,-3.0701801792467185,,
1993-01-22,6.256556034088135,6.256556034088135,0.8928596494010108,,
1993-01-21,6.144330978393555,6.228499889373779,0.0,,
1993-01-20,6.06016206741333,6.116274356842041,1.3698629073889947,,
1993-01-19,6.17238712310791,6.004049301147461,0.9259206074774408,,
1993-01-18,6.340724945068359,6.200443267822266,-2.727272586812216,,
1993-01-15,6.340724945068359,6.312668800354004,-2.212391776356755,,
1993-01-14,6.424893856048584,6.228499889373779,-0.44247534717898085,,
1993-01-13,6.340724945068359,6.3968377113342285,-3.056765933804706,,
1993-01-12,6.368781089782715,6.312668800354004,0.884958214588887,,
1993-01-11,6.509062767028809,6.424893856048584,-0.8810522553323517,,
1993-01-08,6.368781089782715,6.481006622314453,-1.293103385122912,,
1993-01-07,6.45295000076294,6.368781089782715,1.7621194848693895,,
1993-01-06,6.649344444274902,6.509062767028809,-1.3043477939589507,,
1993-01-05,6.817682266235352,6.677400588989258,-2.1097068804561103,,
1993-01-04,6.845738410949707,6.817682266235352,-2.05761535618696,,
1992-12-31,6.986020088195801,6.817682266235352,-0.40983372472252044,,
1992-12-30,6.929907321929932,6.929907321929932,-2.4096383897447953,,
1992-12-29,7.042132377624512,6.901851177215576,0.0,,
1992-12-28,7.014076232910156,7.042132377624512,-1.9920273134123607,,
1992-12-24,7.014076232910156,7.014076232910156,0.39999771577496684,,
1992-12-23,7.1824140548706055,7.042132377624512,0.0,,
1992-12-22,7.37880802154541,7.238526821136475,-1.953127126539922,,
1992-12-21,7.238526821136475,7.406864643096924,-1.901136335290577,,
1992-12-18,7.2946391105651855,7.322695732116699,2.3255812421514186,,
1992-12-17,7.014076232910156,7.1824140548706055,0.3846197341123824,,
1992-12-16,7.126301288604736,6.986020088195801,2.3999998912273792,,
1992-12-15,7.126301288604736,7.070188999176025,-1.968499432282652,,
1992-12-14,6.986020088195801,7.126301288604736,-0.78739709642135,,
1992-12-11,6.957963466644287,7.014076232910156,2.008027441059998,,
1992-12-10,7.098245143890381,6.929907321929932,0.806453878852161,,
1992-12-09,7.070188999176025,7.126301288604736,-2.371541395767958,,
1992-12-08,7.070188999176025,7.098245143890381,0.7936462439016889,,
1992-12-07,6.986020088195801,7.042132377624512,0.39682312195084446,,
1992-12-04,6.957963466644287,6.957963466644287,0.8032082461876002,,
1992-12-03,6.901851177215576,6.901851177215576,0.0,,
1992-12-02,7.014076232910156,6.901851177215576,0.0,,
1992-12-01,6.873794555664063,6.929907321929932,-1.5999976613886566,,
1992-11-30,6.986020088195801,6.901851177215576,0.816328824079138,,
1992-11-27,6.986020088195801,6.986020088195801,-1.2048191948723976,,
1992-11-25,7.014076232910156,6.986020088195801,0.0,,
1992-11-24,6.986020088195801,7.014076232910156,-0.39999771577496684,,
1992-11-23,7.126301288604736,6.986020088195801,0.4016041230938001,,
1992-11-20,7.070188999176025,7.126301288604736,-1.968499432282652,,
1992-11-19,6.986020088195801,7.014076232910156,0.7936462439016889,,
1992-11-18,6.929907321929932,7.014076232910156,0.4016041230938001,,
1992-11-17,6.789625644683838,6.929907321929932,1.2145748430699668,,
1992-11-16,6.705456733703613,6.761569499969482,2.0661179951199804,,
1992-11-13,6.677400588989258,6.705456733703613,0.8368224342397103,,
1992-11-12,6.649344444274902,6.649344444274902,0.4201656668707105,,
1992-11-11,6.368781089782715,6.593231678009033,0.0,,
1992-11-10,6.312668800354004,6.340724945068359,3.524231482636436,,
1992-11-09,6.28461217880249,6.340724945068359,0.44444189298798836,,
1992-11-06,6.368781089782715,6.28461217880249,0.8928596494010108,,
1992-11-05,6.312668800354004,6.340724945068359,-1.321585870100871,,
1992-11-04,6.481006622314453,6.340724945068359,0.44444189298798836,,
1992-11-03,6.677400588989258,6.537118911743164,-2.1645044577349513,,
1992-11-02,6.481006622314453,6.677400588989258,-2.100842616472825,,
1992-10-30,6.509062767028809,6.509062767028809,3.030300354864779,,
1992-10-29,6.45295000076294,6.509062767028809,0.0,,
1992-10-28,6.481006622314453,6.424893856048584,0.8695676591207737,,
1992-10-27,6.537118911743164,6.481006622314453,-0.8658032545850189,,
1992-10-26,6.481006622314453,6.537118911743164,-0.8583642149741505,,
1992-10-23,6.537118911743164,6.481006622314453,0.8657958971298273,,
1992-10-22,6.565175533294678,6.593231678009033,-0.8583642149741505,,
1992-10-21,6.509062767028809,6.565175533294678,0.4273479752684652,,
1992-10-20,6.649344444274902,6.481006622314453,0.8620713653293427,,
1992-10-19,6.565175533294678,6.621287822723389,-2.531645388071126,,
1992-10-16,6.621287822723389,6.621287822723389,0.8546959505369304,,
1992-10-15,6.424893856048584,6.621287822723389,0.0,,
1992-10-14,6.424893856048584,6.481006622314453,3.056765933804706,,
1992-10-13,6.481006622314453,6.424893856048584,0.8733648761067535,,
1992-10-12,6.340724945068359,6.481006622314453,-0.8658032545850189,,
1992-10-09,6.368781089782715,6.424893856048584,2.212391776356755,,
1992-10-08,6.144330978393555,6.3968377113342285,0.8810597424346948,,
1992-10-07,6.228499889373779,6.200443267822266,4.109588722166984,,
1992-10-06,6.17238712310791,6.200443267822266,-0.4504555197854313,,
1992-10-05,6.144330978393555,6.17238712310791,0.4545428560259955,,
1992-10-02,6.3968377113342285,6.256556034088135,0.4566183822618682,,
1992-10-01,6.3968377113342285,6.368781089782715,-2.1929847774242552,,
1992-09-30,6.340724945068359,6.340724945068359,-0.4386014280431343,,
1992-09-29,6.340724945068359,6.368781089782715,0.0,,
1992-09-28,6.28461217880249,6.340724945068359,0.44247534717898085,,
1992-09-25,6.537118911743164,6.368781089782715,0.8928596494010108,,
1992-09-24,6.621287822723389,6.565175533294678,-2.57510723352531,,
1992-09-23,6.593231678009033,6.565175533294678,-0.8474528057236984,,
1992-09-22,6.621287822723389,6.593231678009033,-0.4255294836359765,,
1992-09-21,6.677400588989258,6.649344444274902,-0.4237264028618492,,
1992-09-18,6.733513355255127,6.705456733703613,-0.4201656668707105,,
1992-09-17,6.733513355255127,6.677400588989258,-0.41667135819396667,,
1992-09-16,6.621287822723389,6.677400588989258,-0.8333356348372918,,
1992-09-15,6.873794555664063,6.733513355255127,0.847460007300959,,
1992-09-14,6.957963466644287,6.929907321929932,-2.040811654653594,,
1992-09-11,6.789625644683838,6.817682266235352,-0.40322351286915414,,
1992-09-10,6.845738410949707,6.789625644683838,0.4132278128394536,,
1992-09-09,6.817682266235352,6.789625644683838,-0.8196744149048582,,
1992-09-08,6.986020088195801,6.789625644683838,-0.4115272677118499,,
1992-09-04,6.901851177215576,6.986020088195801,-2.811249338429593,,
1992-09-03,6.986020088195801,6.929907321929932,1.219512110867928,,
1992-09-02,7.042132377624512,6.986020088195801,-0.8032150717785975,,
1992-09-01,6.845738410949707,7.070188999176025,-0.7968082168832933,,
1992-08-31,6.873794555664063,6.845738410949707,3.2786906941596152,,
1992-08-28,6.957963466644287,6.929907321929932,-0.40816094352482296,,
1992-08-27,7.070188999176025,6.986020088195801,-0.40322351286915414,,
1992-08-26,6.817682266235352,7.014076232910156,-1.1904761101865005,,
1992-08-25,6.705456733703613,6.789625644683838,2.880655903362467,,
1992-08-24,6.649344444274902,6.733513355255127,1.2552300957691176,,
1992-08-21,6.957963466644287,6.733513355255127,1.265822694035563,,
1992-08-20,6.873794555664063,6.845738410949707,-3.2258018091809384,,
1992-08-19,6.957963466644287,6.901851177215576,-0.40816094352482296,,
1992-08-18,6.957963466644287,6.957963466644287,-0.8064470257383083,,
1992-08-17,6.817682266235352,6.901851177215576,0.0,,
1992-08-14,6.761569499969482,6.789625644683838,1.234567814887357,,
1992-08-13,6.873794555664063,6.789625644683838,0.4149353891057705,,
1992-08-12,6.817682266235352,6.817682266235352,-1.2244897676039739,,
1992-08-11,6.986020088195801,6.873794555664063,0.0,,
1992-08-10,6.789625644683838,6.986020088195801,-1.6064301435571822,,
1992-08-07,6.873794555664063,6.845738410949707,2.892566597773125,,
1992-08-06,6.873794555664063,6.873794555664063,-0.40816094352482296,,
1992-08-05,6.901851177215576,6.873794555664063,0.0,,
1992-08-04,6.957963466644287,6.873794555664063,-0.40650864284256716,,
1992-08-03,6.817682266235352,6.957963466644287,-1.2096773917213024,,
1992-07-31,6.761569499969482,6.817682266235352,2.057608362062864,,
1992-07-30,6.845738410949707,6.789625644683838,0.8298778303783225,,
1992-07-29,6.957963466644287,6.901851177215576,-0.8196744149048582,,
1992-07-28,6.733513355255127,6.873794555664063,-0.8064470257383083,,
1992-07-27,6.677400588989258,6.733513355255127,2.0833284647672805,,
1992-07-24,6.537118911743164,6.649344444274902,0.8403384748010572,,
1992-07-23,6.509062767028809,6.621287822723389,1.7167430185511594,,
1992-07-22,6.621287822723389,6.537118911743164,1.7241354049164814,,
1992-07-21,6.649344444274902,6.649344444274902,-1.2711864101628083,,
1992-07-20,6.537118911743164,6.593231678009033,0.0,,
1992-07-17,6.705456733703613,6.705456733703613,0.8583715092755797,,
1992-07-16,6.733513355255127,6.761569499969482,0.0,,
1992-07-15,6.845738410949707,6.789625644683838,0.41666427664332517,,
1992-07-14,6.649344444274902,6.845738410949707,-0.8196744149048582,,
1992-07-13,6.565175533294678,6.621287822723389,2.9535838956861418,,
1992-07-10,6.649344444274902,6.537118911743164,0.8546959505369304,,
1992-07-09,6.677400588989258,6.593231678009033,-1.687768372841095,,
1992-07-08,6.705456733703613,6.649344444274902,-1.2605041416717677,,
1992-07-07,6.817682266235352,6.705456733703613,-0.8368153230588147,,
1992-07-06,6.733513355255127,6.817682266235352,-1.646095082599207,,
1992-07-02,6.873794555664063,6.733513355255127,1.2499999114806168,,
1992-07-01,6.649344444274902,6.817682266235352,-2.040811654653594,,
1992-06-30,6.649344444274902,6.677400588989258,2.531645388071126,,
1992-06-29,6.509062767028809,6.621287822723389,0.4219385076150155,,
1992-06-26,6.312668800354004,6.45295000076294,1.7241354049164814,,
1992-06-25,6.3968377113342285,6.28461217880249,2.2222170185939376,,
1992-06-24,6.368781089782715,6.3968377113342285,-1.7543908036449265,,
1992-06-23,6.537118911743164,6.3968377113342285,0.440533614768519,,
1992-06-22,6.256556034088135,6.565175533294678,-2.1459178317368055,,
1992-06-19,6.17238712310791,6.228499889373779,4.932737715846621,,
1992-06-18,6.116274356842041,6.228499889373779,0.9090934373801126,,
1992-06-17,6.116274356842041,6.144330978393555,1.8348675351064965,,
1992-06-16,6.200443267822266,6.0882182121276855,0.4587207818780695,,
1992-06-15,6.228499889373779,6.17238712310791,-1.8099521412764417,,
1992-06-12,6.0882182121276855,6.228499889373779,-0.9009033838404833,,
1992-06-11,6.0882182121276855,6.06016206741333,2.3041499558385357,,
1992-06-10,6.228499889373779,6.0882182121276855,-0.4608268583157522,,
1992-06-09,6.312668800354004,6.228499889373779,-2.252254631736019,,
1992-06-08,6.0882182121276855,6.228499889373779,-1.3333332326179468,,
1992-06-05,7.15435791015625,7.15435791015625,2.3041499558385357,,
1992-06-04,7.070188999176025,7.126301288604736,0.0,,
1992-06-03,7.406864643096924,7.070188999176025,0.7936462439016889,,
1992-06-02,7.547145843505859,7.350751876831055,-4.545454252828484,,
1992-06-01,7.462976932525635,7.575202465057373,-2.6022283224299563,,
1992-05-29,7.533117771148682,7.477005481719971,1.503763626048871,,
1992-05-28,7.392836570739746,7.519089698791504,-0.7448747136758848,,
1992-05-27,7.2946391105651855,7.364779949188232,1.707776532643202,,
1992-05-26,7.364779949188232,7.322695732116699,0.9615395300565102,,
1992-05-22,7.406864643096924,7.392836570739746,-0.5714253156494085,,
1992-05-21,7.322695732116699,7.392836570739746,-0.18939285423896152,,
1992-05-20,7.448948860168457,7.37880802154541,0.957855429052109,,
1992-05-19,7.37880802154541,7.434920787811279,-0.9416206224492814,,
1992-05-18,7.3086676597595215,7.364779949188232,0.7604584114673435,,
1992-05-15,7.26658296585083,7.322695732116699,0.7677499106664429,,
1992-05-14,7.350751876831055,7.2946391105651855,0.7722029257708889,,
1992-05-13,7.448948860168457,7.420892715454102,-0.763360907919254,,
1992-05-12,7.533117771148682,7.477005481719971,-0.37664568841892926,,
1992-05-11,7.406864643096924,7.533117771148682,-0.7448747136758848,,
1992-05-08,7.37880802154541,7.392836570739746,1.7045421259240054,,
1992-05-07,7.37880802154541,7.406864643096924,0.19011944955572663,,
1992-05-06,7.477005481719971,7.37880802154541,0.38023243685959895,,
1992-05-05,7.589230537414551,7.491033554077148,-1.3133260422857376,,
1992-05-04,7.364779949188232,7.589230537414551,-1.29389906991619,,
1992-05-01,7.406864643096924,7.350751876831055,3.047621107146018,,
1992-04-30,7.364779949188232,7.406864643096924,-0.757577854729198,,
1992-04-29,7.224498748779297,7.336723804473877,0.5714317902102439,,
1992-04-28,7.042132377624512,7.15435791015625,1.5533957385423096,,
1992-04-27,7.014076232910156,7.014076232910156,1.5936299761748411,,
1992-04-24,7.042132377624512,6.957963466644287,0.0,,
1992-04-23,7.126301288604736,7.028104305267334,-1.1952190965290672,,
1992-04-22,7.070188999176025,7.112273216247559,-1.3779516099666396,,
1992-04-21,7.084217071533203,7.042132377624512,0.5952346829262667,,
1992-04-20,7.224498748779297,7.098245143890381,-0.5940627381083795,,
1992-04-16,7.392836570739746,7.280611038208008,-1.7475759811052458,,
1992-04-15,7.603258609771728,7.448948860168457,-1.5180307512263687,,
1992-04-14,7.37880802154541,7.547145843505859,-2.029521255596269,,
1992-04-13,7.280611038208008,7.364779949188232,2.281368772150176,,
1992-04-10,7.26658296585083,7.3086676597595215,1.1560693263039812,,
1992-04-09,7.014076232910156,7.15435791015625,0.5791538348418732,,
1992-04-08,6.705456733703613,7.0000481605529785,2.0000021754524124,,
1992-04-07,6.817682266235352,6.733513355255127,4.393308890782359,,
1992-04-06,6.845738410949707,6.789625644683838,-1.234567814887357,,
1992-04-03,6.803654193878174,6.817682266235352,-0.8196744149048582,,
1992-04-02,6.915879249572754,6.77559757232666,0.20618438206045192,,
1992-04-01,6.859766483306885,6.915879249572754,-2.0283997476497295,,
1992-03-31,6.845738410949707,6.845738410949707,0.8179981986619882,,
1992-03-30,6.831710338592529,6.845738410949707,0.0,,
1992-03-27,6.901851177215576,6.817682266235352,0.2053376337976853,,
1992-03-26,6.887823104858398,6.887823104858398,-1.219512110867928,,
1992-03-25,7.014076232910156,6.845738410949707,0.0,,
1992-03-24,6.873794555664063,6.957963466644287,-2.3999998912273792,,
1992-03-23,6.77559757232666,6.845738410949707,1.2244897676039481,,
1992-03-20,6.747541427612305,6.77559757232666,1.035197823871959,,
1992-03-19,6.719485282897949,6.733513355255127,0.4157980357044426,,
1992-03-18,6.789625644683838,6.747541427612305,0.20876706721690697,,
1992-03-17,6.66337251663208,6.747541427612305,-0.6198311847205367,,
1992-03-16,6.705456733703613,6.635315895080566,1.2631578194095434,,
1992-03-13,6.747541427612305,6.705456733703613,-1.0460262650044139,,
1992-03-12,6.733513355255127,6.705456733703613,-0.6237041203848313,,
1992-03-11,6.733513355255127,6.719485282897949,-0.41667135819396667,,
1992-03-10,6.77559757232666,6.719485282897949,-0.20833213832166259,,
1992-03-09,6.719485282897949,6.761569499969482,-0.8281526290446827,,
1992-03-06,6.887823104858398,6.705456733703613,0.626301201650721,,
1992-03-05,6.873794555664063,6.859766483306885,-2.647663396380652,,
1992-03-04,7.070188999176025,6.957963466644287,-0.20408047176241795,,
1992-03-03,7.112273216247559,7.042132377624512,-1.5873059764713118,,
1992-03-02,7.140329837799072,7.098245143890381,-0.9861943782307795,,
1992-02-28,7.15435791015625,7.140329837799072,-0.5893942557934206,,
1992-02-27,7.224498748779297,7.098245143890381,-0.1960773074724656,,
1992-02-26,7.042132377624512,7.224498748779297,-1.7475759811052458,,
1992-02-25,7.098245143890381,7.028104305267334,2.589647018483085,,
1992-02-24,6.943935394287109,7.070188999176025,-0.9881433678494278,,
1992-02-21,6.873794555664063,6.915879249572754,1.8181851892341474,,
1992-02-20,6.957963466644287,7.014076232910156,0.6122483523167329,,
1992-02-19,7.042132377624512,6.957963466644287,0.806453878852161,,
1992-02-18,7.350751876831055,7.084217071533203,-1.1952190965290672,,
1992-02-14,7.112273216247559,7.2946391105651855,-3.6259529605120617,,
1992-02-13,7.26658296585083,7.15435791015625,2.5641013607438907,,
1992-02-12,7.210470199584961,7.280611038208008,-1.5443992894869518,,
1992-02-11,7.252554893493652,7.252554893493652,0.9727637266579955,,
1992-02-10,7.322695732116699,7.280611038208008,0.0,,
1992-02-07,7.364779949188232,7.336723804473877,-0.5747158621395622,,
1992-02-06,7.37880802154541,7.364779949188232,-0.380950210432939,,
1992-02-05,7.280611038208008,7.406864643096924,-0.19011298730387227,,
1992-02-04,7.168385982513428,7.210470199584961,1.7341072641615953,,
1992-02-03,7.1824140548706055,7.140329837799072,0.5870807902112625,,
1992-01-31,6.901851177215576,7.168385982513428,-0.5859341545896349,,
1992-01-30,6.901851177215576,6.957963466644287,3.8617871996101205,,
1992-01-29,6.873794555664063,6.929907321929932,0.813003468025348,,
1992-01-28,6.943935394287109,6.901851177215576,0.816328824079138,,
1992-01-27,7.126301288604736,6.986020088195801,-0.6060571517724169,,
1992-01-24,7.098245143890381,7.140329837799072,-1.968499432282652,,
1992-01-23,7.26658296585083,7.070188999176025,0.5928887077803258,,
1992-01-22,6.915879249572754,7.112273216247559,-2.702700397115872,,
1992-01-21,6.986020088195801,6.957963466644287,2.8397541308567154,,
1992-01-20,6.986020088195801,7.028104305267334,-0.40161094868479735,,
1992-01-17,7.014076232910156,7.028104305267334,0.6024061846407003,,
1992-01-16,7.070188999176025,6.986020088195801,0.19999885788748342,,
1992-01-15,7.406864643096924,7.15435791015625,-1.1904761101865005,,
1992-01-14,7.2946391105651855,7.280611038208008,-3.4090906896213626,,
1992-01-13,7.336723804473877,7.2946391105651855,-0.1923065986480426,,
1992-01-10,7.322695732116699,7.392836570739746,-0.5736169853229106,,
1992-01-09,7.462976932525635,7.350751876831055,0.957855429052109,,
1992-01-08,7.519089698791504,7.462976932525635,-1.5037572366795546,,
1992-01-07,7.575202465057373,7.617286682128906,-0.7462707390615089,,
1992-01-06,7.575202465057373,7.64534330368042,0.5555523732290694,,
1992-01-03,7.519089698791504,7.575202465057373,0.9259269167601799,,
1992-01-02,7.519089698791504,7.547145843505859,0.7462707390615089,,
1991-12-31,7.547145843505859,7.729512214660644,0.37313219868709313,,
1991-12-30,7.603258609771728,7.589230537414551,2.4163620915277026,,
1991-12-27,7.519089698791504,7.631314754486084,-0.18450079205707842,,
1991-12-26,7.238526821136475,7.505061626434326,1.4925351364356954,,
1991-12-24,7.2946391105651855,7.26658296585083,3.682169202158246,,
1991-12-23,7.070188999176025,7.3086676597595215,-0.3846131972960852,,
1991-12-20,7.070188999176025,7.070188999176025,3.3730167695840785,,
1991-12-19,6.859766483306885,6.929907321929932,0.0,,
1991-12-18,6.831710338592529,6.859766483306885,1.0224960105235843,,
1991-12-17,6.817682266235352,6.887823104858398,0.4106752675953706,,
1991-12-16,6.691428661346436,6.803654193878174,1.02880767809348,,
1991-12-13,6.719485282897949,6.677400588989258,1.6771535379285594,,
1991-12-12,6.649344444274902,6.705456733703613,-0.6263082979853081,,
1991-12-11,6.691428661346436,6.579203605651856,0.843877015230031,,
1991-12-10,6.761569499969482,6.691428661346436,-1.6771464118396262,,
1991-12-09,6.733513355255127,6.789625644683838,-1.0373455249311947,,
1991-12-06,6.593231678009033,6.747541427612305,0.8333285532866503,,
1991-12-05,6.649344444274902,6.635315895080566,2.340426624442061,,
1991-12-04,6.677400588989258,6.705456733703613,-0.21097642499802433,,
1991-12-03,6.677400588989258,6.705456733703613,0.4201656668707105,,
1991-12-02,6.3968377113342285,6.705456733703613,0.4201656668707105,,
1991-11-29,6.45295000076294,6.466978073120117,4.824556074364033,,
1991-11-27,6.537118911743164,6.481006622314453,0.21739006741906092,,
1991-11-26,6.607259750366211,6.537118911743164,-0.8583642149741505,,
1991-11-25,6.579203605651856,6.565175533294678,-1.061572289770495,,
1991-11-22,6.579203605651856,6.579203605651856,-0.21321839538645412,,
1991-11-21,6.481006622314453,6.607259750366211,0.0,,
1991-11-20,6.607259750366211,6.509062767028809,1.948048125997303,,
1991-11-19,6.537118911743164,6.523090839385986,-1.4861983189318344,,
1991-11-18,6.466978073120117,6.607259750366211,-0.21459105374353762,,
1991-11-15,6.803654193878174,6.424893856048584,2.1691998281109397,,
1991-11-14,6.873794555664063,6.803654193878174,-5.567013358356642,,
1991-11-13,6.817682266235352,6.859766483306885,-1.0204023588120381,,
1991-11-12,6.77559757232666,6.887823104858398,0.6172804103816302,,
1991-11-11,6.635315895080566,6.77559757232666,1.6563193332215769,,
1991-11-08,6.66337251663208,6.649344444274902,2.1141672749913654,,
1991-11-07,6.677400588989258,6.635315895080566,-0.2105251105526973,,
1991-11-06,6.677400588989258,6.677400588989258,-0.6302556413657019,,
1991-11-05,6.677400588989258,6.649344444274902,0.0,,
1991-11-04,6.761569499969482,6.66337251663208,-0.4201656668707105,,
1991-11-01,6.677400588989258,6.789625644683838,-1.4522809140369783,,
1991-10-31,6.565175533294678,6.607259750366211,1.6806698085424783,,
1991-10-30,6.579203605651856,6.565175533294678,0.6410219629026979,,
1991-10-29,6.579203605651856,6.565175533294678,-0.21321839538645412,,
1991-10-28,6.368781089782715,6.579203605651856,-0.21321839538645412,,
1991-10-25,6.382809162139893,6.354753017425537,3.3039684188033625,,
1991-10-24,6.424893856048584,6.382809162139893,-0.43955794387168234,,
1991-10-23,6.3968377113342285,6.45295000076294,-0.6550255125082205,,
1991-10-22,6.242527961730957,6.368781089782715,0.8771879475586717,,
1991-10-21,6.28461217880249,6.228499889373779,2.0224679621098525,,
1991-10-18,6.326696872711182,6.2705841064453125,-0.8928520620249781,,
1991-10-17,6.228499889373779,6.326696872711182,-0.8869204166853519,,
1991-10-16,6.186415195465088,6.242527961730957,1.5765751799230614,,
1991-10-15,6.130302429199219,6.186415195465088,0.9070320127721503,,
1991-10-14,5.990021228790283,6.116274356842041,0.915334388701586,,
1991-10-11,6.018077373504639,6.004049301147461,2.1077242171519868,,
1991-10-10,5.990021228790283,6.004049301147461,-0.23309890329655997,,
1991-10-09,5.990021228790283,5.990021228790283,0.23419069518073776,,
1991-10-08,6.004049301147461,5.990021228790283,0.0,,
1991-10-07,5.947936534881592,6.004049301147461,-0.23364352378813358,,
1991-10-04,6.074190139770508,5.947936534881592,0.9433988734882526,,
1991-10-03,6.116274356842041,6.06016206741333,-2.078525729088982,,
1991-10-02,6.102246284484863,6.130302429199219,-0.9174259713503576,,
1991-10-01,6.046133518218994,6.116274356842041,0.45976749227065816,,
1991-09-30,6.032105445861816,6.046133518218994,1.1600941066168884,,
1991-09-27,6.032105445861816,6.032105445861816,0.23255681590913438,,
1991-09-26,6.004049301147461,6.032105445861816,0.0,,
1991-09-25,6.018077373504639,6.004049301147461,0.46728704757626716,,
1991-09-24,5.9759931564331055,6.004049301147461,-0.23309890329655997,,
1991-09-23,5.990021228790283,5.9759931564331055,0.4694808708767223,,
1991-09-20,6.018077373504639,6.06016206741333,-0.23419069518073776,,
1991-09-19,5.947936534881592,5.9759931564331055,0.6993046333032323,,
1991-09-18,5.9619646072387695,5.9759931564331055,0.47170344516919444,,
1991-09-17,5.9759931564331055,6.018077373504639,0.23530077949981548,,
1991-09-16,5.919880390167236,5.9759931564331055,0.7042213063150835,,
1991-09-13,6.004049301147461,5.919880390167236,0.9478699326268645,,
1991-09-12,6.06016206741333,6.032105445861816,-1.4018690846548962,,
1991-09-11,6.06016206741333,6.046133518218994,-0.46296817212826014,,
1991-09-10,6.0882182121276855,6.046133518218994,-0.2314880202588999,,
1991-09-09,6.0882182121276855,6.102246284484863,-0.6912481196035156,,
1991-09-06,6.074190139770508,6.116274356842041,0.2304134291578761,,
1991-09-05,6.046133518218994,6.06016206741333,0.692836676217765,,
1991-09-04,6.06016206741333,6.018077373504639,0.23202513064032232,,
1991-09-03,6.116274356842041,6.018077373504639,-0.6944483239976202,,
1991-08-30,6.144330978393555,6.0882182121276855,-1.6055032460660166,,
1991-08-29,6.17238712310791,6.158359050750732,-0.9132445251271264,,
1991-08-28,6.116274356842041,6.158359050750732,-0.22727142801299774,,
1991-08-27,6.116274356842041,6.116274356842041,0.6880772747156588,,
1991-08-26,6.116274356842041,6.130302429199219,0.0,,
1991-08-23,6.116274356842041,6.144330978393555,0.2293564928375894,,
1991-08-22,6.102246284484863,6.144330978393555,0.4587207818780695,,
1991-08-21,6.018077373504639,6.102246284484863,0.6896590525310811,,
1991-08-20,5.933908462524414,5.919880390167236,1.3986013431929123,,
1991-08-19,5.723486423492432,5.877795696258545,-0.23640527058635966,,
1991-08-16,6.144330978393555,6.032105445861816,2.696071264059273,,
1991-08-15,6.0882182121276855,6.130302429199219,-1.8264890502542528,,
1991-08-14,6.116274356842041,6.06016206741333,0.6912402874736282,,
1991-08-13,6.102246284484863,6.06016206741333,-0.9174259713503576,,
1991-08-12,6.032105445861816,6.074190139770508,-0.6896512384059872,,
1991-08-09,6.046133518218994,6.06016206741333,0.6976783527145173,,
1991-08-08,6.130302429199219,6.06016206741333,0.23202513064032232,,
1991-08-07,6.17238712310791,6.144330978393555,-1.1441582629235942,,
1991-08-06,6.06016206741333,6.186415195465088,-0.4545428560259955,,
1991-08-05,6.0882182121276855,6.074190139770508,2.0833292352137813,,
1991-08-02,6.074190139770508,6.0882182121276855,-0.2304134291578761,,
1991-08-01,6.074190139770508,6.046133518218994,0.230945558739255,,
1991-07-31,5.919880390167236,6.046133518218994,-0.4618989676963536,,
1991-07-30,5.919880390167236,5.919880390167236,2.1326972798548582,,
1991-07-29,5.821683406829834,5.919880390167236,0.0,,
1991-07-26,5.779598712921143,5.835711479187012,1.6867455077031572,,
1991-07-25,5.751542568206787,5.807655334472656,0.9708765098244763,,
1991-07-24,5.751542568206787,5.765570640563965,0.975612465706986,,
1991-07-23,5.807655334472656,5.737514495849609,0.24390104377774602,,
1991-07-22,5.807655334472656,5.821683406829834,-1.207730737854053,,
1991-07-19,5.863767623901367,5.779598712921143,0.24154450547212966,,
1991-07-18,5.751542568206787,5.8497395515441895,-1.4354066596558634,,
1991-07-17,5.737514495849609,5.765570640563965,1.707315597040224,,
1991-07-16,5.79362678527832,5.765570640563965,0.4889947508568503,,
1991-07-15,5.751542568206787,5.79362678527832,-0.484258751109866,,
1991-07-12,5.723486423492432,5.765570640563965,0.731703131333238,,
1991-07-11,5.737514495849609,5.709457874298096,0.7352898907699986,,
1991-07-10,5.821683406829834,5.723486423492432,-0.4890030617231418,,
1991-07-09,5.821683406829834,5.79362678527832,-1.6867455077031572,,
1991-07-08,5.807655334472656,5.8497395515441895,-0.4819331384217568,,
1991-07-05,5.8497395515441895,5.8497395515441895,0.724633516416389,,
1991-07-03,5.933908462524414,5.877795696258545,0.0,,
1991-07-02,5.835711479187012,5.9759931564331055,-0.9456291181478312,,
1991-07-01,5.8497395515441895,5.891824245452881,2.403848746573687,,
1991-06-28,5.835711479187012,5.807655334472656,0.7194285068227024,,
1991-06-27,5.835711479187012,5.877795696258545,-0.48076648090669566,,
1991-06-26,5.737514495849609,5.821683406829834,0.7211497213600434,,
1991-06-25,5.723486423492432,5.737514495849609,1.4669925634368424,,
1991-06-24,5.765570640563965,5.695429801940918,0.2450966302566662,,
1991-06-21,5.779598712921143,5.807655334472656,-1.2165463402627912,,
1991-06-20,5.583204746246338,5.79362678527832,0.4854423800875478,,
1991-06-19,5.583204746246338,5.583204746246338,3.768839736236647,,
1991-06-18,5.6673736572265625,5.597232818603516,0.0,,
1991-06-17,5.695429801940918,5.68140172958374,-1.2376250952433518,,
1991-06-14,5.68140172958374,5.765570640563965,-0.2463040164659246,,
1991-06-13,5.695429801940918,5.653345584869385,1.4814814193114878,,
1991-06-12,5.611260890960693,5.68140172958374,-0.7389120493977737,,
1991-06-11,5.513063907623291,5.611260890960693,1.2500013809024337,,
1991-06-10,5.541120052337647,5.513063907623291,1.7811689648947957,,
1991-06-07,5.597232818603516,5.555148601531982,-0.5063262381857299,,
1991-06-06,5.639317512512207,5.611260890960693,-0.7518754076417538,,
1991-06-05,5.653345584869385,5.68140172958374,-0.497518032798529,,
1991-06-04,5.611260890960693,5.6673736572265625,0.49627506921644665,,
1991-06-03,5.723486423492432,5.653345584869385,1.000002804294173,,
1991-05-31,5.863767623901367,5.765570640563965,-1.2254914825192758,,
1991-05-30,5.919880390167236,5.891824245452881,-1.6746397476110846,,
1991-05-29,5.947936534881592,5.947936534881592,-0.47393093889119753,,
1991-05-28,5.835711479187012,5.9759931564331055,0.0,,
1991-05-24,5.821683406829834,5.821683406829834,2.403848746573687,,
1991-05-23,5.891824245452881,5.807655334472656,0.0,,
1991-05-22,5.821683406829834,5.877795696258545,-1.4285713129542763,,
1991-05-21,5.709457874298096,5.807655334472656,0.9638498954251203,,
1991-05-20,5.653345584869385,5.695429801940918,1.7199086557168557,,
1991-05-17,5.583204746246338,5.653345584869385,0.74441260382467,,
1991-05-16,5.56917667388916,5.625288963317871,1.256282758933451,,
1991-05-15,5.597232818603516,5.513063907623291,1.0075508951222707,,
1991-05-14,5.653345584869385,5.597232818603516,-1.5037593344424143,,
1991-05-13,5.723486423492432,5.709457874298096,-0.992558573034158,,
1991-05-10,5.8497395515441895,5.709457874298096,-0.2451049614926109,,
1991-05-09,5.751542568206787,5.8497395515441895,-2.398084154175083,,
1991-05-08,5.723486423492432,5.737514495849609,1.707315597040224,,
1991-05-07,5.779598712921143,5.709457874298096,0.2450966302566662,,
1991-05-06,5.695429801940918,5.737514495849609,-1.2135935746929405,,
1991-05-03,5.751542568206787,5.723486423492432,0.7389204216747535,,
1991-05-02,5.779598712921143,5.751542568206787,-0.48780208755549204,,
1991-05-01,5.68140172958374,5.765570640563965,-0.4854341297369285,,
1991-04-30,5.695429801940918,5.68140172958374,1.4814814193114878,,
1991-04-29,5.779598712921143,5.653345584869385,-0.2463040164659246,,
1991-04-26,5.6673736572265625,5.765570640563965,-2.1844618341667976,,
1991-04-25,5.765570640563965,5.765570640563965,1.7326717678512293,,
1991-04-24,5.891824245452881,5.765570640563965,0.0,,
1991-04-23,5.807655334472656,5.8497395515441895,-2.1428610160317403,,
1991-04-22,5.723486423492432,5.737514495849609,0.724633516416389,,
1991-04-19,5.891824245452881,5.751542568206787,0.2450966302566662,,
1991-04-18,5.947936534881592,5.919880390167236,-2.3809548859906777,,
1991-04-17,5.947936534881592,6.004049301147461,-0.4716954283190581,,
1991-04-16,5.807655334472656,5.891824245452881,0.9433988734882526,,
1991-04-15,5.6673736572265625,5.79362678527832,1.4492752433261824,,
1991-04-12,5.709457874298096,5.6673736572265625,2.227718440459107,,
1991-04-11,5.470979690551758,5.6673736572265625,-0.7370965509874599,,
1991-04-10,5.513063907623291,5.442923069000244,3.589740371618854,,
1991-04-09,5.527091979980469,5.485007762908936,-1.2722660175598244,,
1991-04-08,5.597232818603516,5.611260890960693,-0.7614169842652235,,
1991-04-05,5.583204746246338,5.611260890960693,0.2506251358805846,,
1991-04-04,5.653345584869385,5.583204746246338,0.5025096873478979,,
1991-04-03,5.611260890960693,5.541120052337647,-1.2406961076423813,,
1991-04-02,5.302641868591309,5.597232818603516,-1.250001380902418,,
1991-04-01,5.330698013305664,5.274585247039795,5.55555055975273,,
1991-03-28,5.428894996643066,5.386810779571533,-1.0526344978801863,,
1991-03-27,5.56917667388916,5.414866924285889,-0.7751893727463102,,
1991-03-26,5.428894996643066,5.541120052337647,-2.77078208573892,,
1991-03-25,5.35875415802002,5.400838851928711,2.0671804439757047,,
1991-03-22,5.288613319396973,5.288613319396973,0.7853447399841195,,
1991-03-21,5.330698013305664,5.274585247039795,0.0,,
1991-03-20,5.274585247039795,5.302641868591309,-1.0526344978801863,,
1991-03-19,5.400838851928711,5.330698013305664,0.5319209044400149,,
1991-03-18,5.35875415802002,5.456951141357422,-1.2987026746409709,,
1991-03-15,5.456951141357422,5.386810779571533,1.8324591955844411,,
1991-03-14,5.316669940948486,5.470979690551758,-1.2853397431819629,,
1991-03-13,5.274585247039795,5.302641868591309,2.902375948049595,,
1991-03-12,5.344726085662842,5.260557174682617,0.5319209044400149,,
1991-03-11,5.344726085662842,5.35875415802002,-1.5748030793571746,,
1991-03-08,5.204444408416748,5.316669940948486,0.2624656929530728,,
1991-03-07,5.204444408416748,5.176388263702393,2.1563403069546587,,
1991-03-06,5.218472957611084,5.204444408416748,-0.5390804956813915,,
1991-03-05,5.106247425079346,5.106247425079346,-0.2688247943083706,,
1991-03-04,5.148332118988037,5.092219352722168,0.0,,
1991-03-01,5.148332118988037,5.092219352722168,-1.0899212593320173,,
1991-02-28,5.35875415802002,5.204444408416748,-1.0899212593320173,,
1991-02-27,5.162360191345215,5.330698013305664,-2.8795825494686906,,
1991-02-26,5.274585247039795,5.148332118988037,3.2608693644172764,,
1991-02-25,5.330698013305664,5.330698013305664,-2.393612429007829,,
1991-02-22,5.232501029968262,5.260557174682617,0.0,,
1991-02-21,5.19041633605957,5.176388263702393,0.5361899511088227,,
1991-02-20,5.260557174682617,5.19041633605957,-0.2702687308476584,,
1991-02-19,5.162360191345215,5.260557174682617,-1.3333347836349418,,
1991-02-15,5.19041633605957,5.274585247039795,1.9021722564425332,,
1991-02-14,5.162360191345215,5.134304046630859,1.6216215719628275,,
1991-02-13,5.218472957611084,5.204444408416748,-0.5434751484677894,,
1991-02-12,5.232501029968262,5.24652910232544,-0.2688247943083706,,
1991-02-11,5.036106586456299,5.260557174682617,0.26809497555442835,,
1991-02-08,5.036106586456299,5.022078514099121,4.456827598326409,,
1991-02-07,5.036106586456299,5.050135135650635,-0.27854994957620055,,
1991-02-06,4.994022369384766,5.036106586456299,0.27855941794526734,,
1991-02-05,4.853740692138672,4.994022369384766,0.8426918014930264,,
1991-02-04,4.86776876449585,4.839712619781494,2.8901765904655767,,
1991-02-01,4.825684547424316,4.825684547424316,-0.5763656014022108,,
1991-01-31,4.9379096031188965,4.881796836853027,0.0,,
1991-01-30,4.86776876449585,4.965965747833252,-1.1363668186721572,,
1991-01-29,4.979994297027588,4.86776876449585,2.0172894007131936,,
1991-01-28,4.909853458404541,4.979994297027588,-2.253527330316872,,
1991-01-25,4.909853458404541,4.951937675476074,1.4285729547178616,,
1991-01-24,4.797627925872803,4.923881530761719,0.8571379457261539,,
1991-01-23,4.713459014892578,4.797627925872803,2.631583916877995,,
1991-01-22,4.727487564086914,4.6994309425354,1.7857142857142856,,
1991-01-21,4.713459014892578,4.741515636444092,-0.5934784845263288,,
1991-01-18,4.7555437088012695,4.797627925872803,0.5952448395725172,,
1991-01-17,4.685402870178223,4.769571781158447,0.8849506943579617,,
1991-01-16,4.460952281951904,4.573177814483643,1.796407124688149,,
1991-01-15,4.460952281951904,4.47498083114624,2.515730396529452,,
1991-01-14,4.460952281951904,4.460952281951904,0.31447431641653206,,
1991-01-11,4.573177814483643,4.573177814483643,0.0,,
1991-01-10,4.559149742126465,4.559149742126465,0.0,,
1991-01-09,4.6292901039123535,4.531093120574951,0.0,,
1991-01-08,4.503036975860596,4.559149742126465,-2.1212104044724502,,
1991-01-07,4.47498083114624,4.503036975860596,1.2461093827715055,,
1991-01-04,4.601233959197998,4.573177814483643,0.6269556401020169,,
1991-01-03,4.825684547424316,4.671374797821045,-0.6097526220823968,,
1991-01-02,5.036106586456299,4.853740692138672,-3.1976758548304507,,
1990-12-31,4.9379096031188965,5.050135135650635,-3.6211682812287407,,
1990-12-28,4.9379096031188965,4.965965747833252,2.2727336373443143,,
1990-12-27,4.895825386047363,4.9379096031188965,0.5681785810059092,,
1990-12-26,4.895825386047363,4.909853458404541,0.859593914265595,,
1990-12-24,4.86776876449585,4.909853458404541,0.28653130475519833,,
1990-12-21,5.036106586456299,4.895825386047363,0.8645581979087719,,
1990-12-20,4.965965747833252,4.951937675476074,-2.7855089641310724,,
1990-12-19,5.036106586456299,5.050135135650635,-0.2824842753556739,,
1990-12-18,4.979994297027588,5.036106586456299,0.27855941794526734,,
1990-12-17,4.979994297027588,4.979994297027588,1.1267540901041335,,
1990-12-14,5.07819128036499,5.022078514099121,0.0,,
1990-12-13,5.134304046630859,5.0641632080078125,-1.1049754364872229,,
1990-12-12,5.008050441741943,5.106247425079346,-1.366121639583722,,
1990-12-11,5.0641632080078125,5.036106586456299,1.960782633476164,,
1990-12-10,5.022078514099121,5.092219352722168,-0.554022854301942,,
1990-12-07,5.022078514099121,5.036106586456299,1.3966495829591583,,
1990-12-06,5.036106586456299,5.050135135650635,0.2793280176284568,,
1990-12-05,4.9379096031188965,4.994022369384766,0.27855941794526734,,
1990-12-04,4.9379096031188965,5.022078514099121,1.1363668186721572,,
1990-12-03,4.965965747833252,4.9379096031188965,1.7045453996780664,,
1990-11-30,4.727487564086914,4.895825386047363,-0.5649685507113478,,
1990-11-29,4.783599853515625,4.741515636444092,3.5608305612320033,,
1990-11-28,4.797627925872803,4.797627925872803,-0.8797603971955164,,
1990-11-27,4.741515636444092,4.769571781158447,0.0,,
1990-11-26,4.727487564086914,4.727487564086914,0.5917125844468631,,
1990-11-23,4.727487564086914,4.7555437088012695,0.0,,
1990-11-21,4.685402870178223,4.7555437088012695,0.5934683980448364,,
1990-11-20,4.7555437088012695,4.685402870178223,1.4970076334199809,,
1990-11-19,4.797627925872803,4.741515636444092,-1.4749278509045034,,
1990-11-16,4.811656475067139,4.741515636444092,-1.1695840172620886,,
1990-11-15,4.769571781158447,4.825684547424316,-1.4577274788110923,,
1990-11-14,4.713459014892578,4.811656475067139,1.1764738815240203,,
1990-11-13,4.741515636444092,4.727487564086914,2.0833417637513607,,
1990-11-12,4.685402870178223,4.741515636444092,-0.29585629222343157,,
1990-11-09,4.573177814483643,4.6292901039123535,1.197608142151813,,
1990-11-08,4.489008903503418,4.559149742126465,1.2269868285243262,,
1990-11-07,4.573177814483643,4.503036975860596,1.5625016597384318,,
1990-11-06,4.58720588684082,4.559149742126465,-1.5337439624784517,,
1990-11-05,4.601233959197998,4.601233959197998,-0.6116172983392634,,
1990-11-02,4.545121192932129,4.559149742126465,0.0,,
1990-11-01,4.573177814483643,4.559149742126465,0.30865071796437404,,
1990-10-31,4.615262031555176,4.601233959197998,-0.30674670713108154,,
1990-10-30,4.601233959197998,4.601233959197998,-0.303949640589546,,
1990-10-29,4.797627925872803,4.6292901039123535,0.0,,
1990-10-26,4.825684547424316,4.811656475067139,-3.508771929824561,,
1990-10-25,4.895825386047363,4.895825386047363,-0.290696008396677,,
1990-10-24,4.853740692138672,4.895825386047363,0.0,,
1990-10-23,5.008050441741943,4.895825386047363,0.8670569067864213,,
1990-10-22,4.825684547424316,5.008050441741943,-2.2408930780566374,,
1990-10-19,4.881796836853027,4.853740692138672,3.779067871623805,,
1990-10-18,4.601233959197998,4.797627925872803,-0.574709387792578,,
1990-10-17,4.531093120574951,4.58720588684082,4.268289081067211,,
1990-10-16,4.601233959197998,4.559149742126465,1.2383935790476313,,
1990-10-15,4.573177814483643,4.615262031555176,-0.9146289331235951,,
1990-10-12,4.559149742126465,4.545121192932129,0.9202401213932445,,
1990-10-11,4.517065048217773,4.489008903503418,-0.3077009966290948,,
1990-10-10,4.489008903503418,4.489008903503418,-0.6211144717835121,,
1990-10-09,4.545121192932129,4.517065048217773,0.0,,
1990-10-08,4.615262031555176,4.6433186531066895,-0.6172804535549912,,
1990-10-05,4.404839992523193,4.531093120574951,0.6079096129252625,,
1990-10-04,4.6292901039123535,4.559149742126465,2.866236418713523,,
1990-10-03,4.685402870178223,4.6292901039123535,-1.51514293145316,,
1990-10-02,4.685402870178223,4.671374797821045,-1.197608142151813,,
1990-10-01,4.489008903503418,4.657346725463867,-0.2993994912681679,,
1990-09-28,4.180389404296875,4.390811920166016,3.7499997344418508,,
1990-09-27,4.418868064880371,4.2645583152771,5.0335625588576685,,
1990-09-26,4.460952281951904,4.362755298614502,-3.492065102139432,,
1990-09-25,4.320671081542969,4.446924209594727,-2.20125608011292,,
1990-09-24,4.2645583152771,4.320671081542969,2.9220721889959544,,
1990-09-21,4.390811920166016,4.348727226257324,1.315793151775041,,
1990-09-20,4.489008903503418,4.446924209594727,-0.9584717968766969,,
1990-09-19,4.713459014892578,4.615262031555176,-0.9375052447734438,,
1990-09-18,4.517065048217773,4.671374797821045,-2.083331647249728,,
1990-09-17,4.460952281951904,4.531093120574951,3.4161507075076334,,
1990-09-14,4.460952281951904,4.517065048217773,1.5723288255474575,,
1990-09-13,4.573177814483643,4.517065048217773,1.257865198264726,,
1990-09-12,4.601233959197998,4.573177814483643,-1.2269972553473703,,
1990-09-11,4.559149742126465,4.545121192932129,-0.6097526220823968,,
1990-09-10,4.6292901039123535,4.545121192932129,-0.3077009966290948,,
1990-09-07,4.390811920166016,4.573177814483643,-1.8181818181818181,,
1990-09-06,4.545121192932129,4.418868064880371,4.153352446732261,,
1990-09-05,4.489008903503418,4.545121192932129,-2.7777725321843385,,
1990-09-04,4.404839992523193,4.489008903503418,1.2499928299299756,,
1990-08-31,4.517065048217773,4.489008903503418,1.910827887575792,,
1990-08-30,4.58720588684082,4.503036975860596,-0.6211144717835121,,
1990-08-29,4.432896137237549,4.573177814483643,-1.8348622899547071,,
1990-08-28,4.432896137237549,4.517065048217773,3.1645604341524947,,
1990-08-27,4.348727226257324,4.404839992523193,1.8987341091342647,,
1990-08-24,4.124276638031006,4.180389404296875,1.290326188477953,,
1990-08-23,3.927882671356201,4.012051582336426,1.360548071592459,,
1990-08-22,4.292614459991455,4.082192420959473,2.1428570561442752,,
1990-08-21,4.292614459991455,4.278586387634277,-4.901955230155966,,
1990-08-20,4.503036975860596,4.404839992523193,-0.3267955342349953,,
1990-08-17,4.404839992523193,4.503036975860596,-2.18068347792404,,
1990-08-16,4.517065048217773,4.489008903503418,2.229297397955036,,
1990-08-15,4.713459014892578,4.615262031555176,-0.6211144717835121,,
1990-08-14,4.671374797821045,4.685402870178223,-2.083331647249728,,
1990-08-13,4.489008903503418,4.6433186531066895,0.3002985837000513,,
1990-08-10,4.601233959197998,4.517065048217773,3.437501526959357,,
1990-08-09,4.559149742126465,4.615262031555176,-1.8292682294924072,,
1990-08-08,4.545121192932129,4.545121192932129,1.2307621508948117,,
1990-08-07,4.37678337097168,4.460952281951904,0.0,,
1990-08-06,4.292614459991455,4.292614459991455,1.9230769230769231,,
1990-08-03,4.573177814483643,4.545121192932129,0.0,,
1990-08-02,4.7555437088012695,4.657346725463867,-0.6135038410852071,,
1990-08-01,4.853740692138672,4.825684547424316,-2.064894980476478,,
1990-07-31,4.769571781158447,4.881796836853027,-0.578031388446367,,
1990-07-30,4.727487564086914,4.741515636444092,2.3529377655644073,,
1990-07-27,4.839712619781494,4.797627925872803,0.2967341990224182,,
1990-07-26,4.825684547424316,4.825684547424316,-0.8695701008501507,,
1990-07-25,4.769571781158447,4.881796836853027,0.0,,
1990-07-24,4.923881530761719,4.797627925872803,2.3529377655644073,,
1990-07-23,4.965965747833252,4.895825386047363,-2.5641072820325297,,
1990-07-20,4.951937675476074,4.994022369384766,-1.4124213767783695,,
1990-07-19,4.965965747833252,4.979994297027588,0.8498631579535263,,
1990-07-18,4.965965747833252,4.994022369384766,0.28249387745891863,,
1990-07-17,5.050135135650635,5.036106586456299,0.5649781528145925,,
1990-07-16,4.909853458404541,4.979994297027588,-0.27778561993922896,,
1990-07-13,4.923881530761719,4.895825386047363,1.4285729547178616,,
1990-07-12,4.923881530761719,4.895825386047363,-0.5697973141529913,,
1990-07-11,4.825684547424316,4.909853458404541,-0.5697973141529913,,
1990-07-10,4.741515636444092,4.797627925872803,1.744185931613564,,
1990-07-09,4.6994309425354,4.713459014892578,1.1834251688937263,,
1990-07-06,4.601233959197998,4.671374797821045,0.29850576652179545,,
1990-07-05,4.657346725463867,4.6292901039123535,1.5243919184512087,,
1990-07-03,4.615262031555176,4.685402870178223,-0.6024164230271961,,
1990-07-02,4.601233959197998,4.601233959197998,1.5197585346939002,,
1990-06-29,4.713459014892578,4.601233959197998,0.0,,
1990-06-28,4.615262031555176,4.713459014892578,-2.38094900878517,,
1990-06-27,4.503036975860596,4.58720588684082,2.1276578158729924,,
1990-06-26,4.545121192932129,4.517065048217773,1.8691587795398616,,
1990-06-25,4.489008903503418,4.489008903503418,-0.6172804535549912,,
1990-06-22,4.573177814483643,4.503036975860596,0.0,,
1990-06-21,4.545121192932129,4.573177814483643,-1.5337439624784517,,
1990-06-20,4.432896137237549,4.489008903503418,0.6172909447418695,,
1990-06-19,4.348727226257324,4.37678337097168,1.2658263250182302,,
1990-06-18,4.3346991539001465,4.37678337097168,0.6451576117479695,,
1990-06-15,4.292614459991455,4.3346991539001465,0.9708682327738459,,
1990-06-14,4.348727226257324,4.320671081542969,0.9803977110205043,,
1990-06-13,4.390811920166016,4.320671081542969,-0.6451576117479695,,
1990-06-12,4.292614459991455,4.37678337097168,-1.5974457548706589,,
1990-06-11,4.166361331939697,4.236502170562744,1.9607843137254901,,
1990-06-08,4.278586387634277,4.194417476654053,1.683503494652299,,
1990-06-07,4.37678337097168,4.278586387634277,-1.9672130782139803,,
1990-06-06,4.2645583152771,4.348727226257324,-2.243587927807399,,
1990-06-05,4.2645583152771,4.250530242919922,1.9736841369644993,,
1990-06-04,4.292614459991455,4.278586387634277,-0.3289454925947291,,
1990-06-01,4.2645583152771,4.2645583152771,-0.3267955342349953,,
1990-05-31,4.145318984985352,4.201431751251221,0.0,,
1990-05-30,4.180389404296875,4.159347057342529,1.353641697276221,,
1990-05-29,4.124276638031006,4.173375606536865,-0.5033585371907463,,
1990-05-25,4.09622049331665,4.103234767913818,1.1904867887159962,,
1990-05-24,4.09622049331665,4.124276638031006,0.17123772044528326,,
1990-05-23,4.040107727050781,4.09622049331665,0.6849275999700596,,
1990-05-22,4.026079654693604,4.040107727050781,1.3888928230839683,,
1990-05-21,3.983995199203491,4.012051582336426,0.34843007491972783,,
1990-05-18,4.005037307739258,3.991009473800659,0.704227332867866,,
1990-05-17,3.9699671268463135,4.005037307739258,-0.3502547632076114,,
1990-05-16,3.991009473800659,3.9699671268463135,0.8833871861504203,,
1990-05-15,4.005037307739258,3.991009473800659,-0.5272437234860023,,
1990-05-14,3.9769811630249023,4.005037307739258,-0.3502547632076114,,
1990-05-11,3.941910743713379,3.9769811630249023,0.7054633543452816,,
1990-05-10,3.885798215866089,3.913854598999024,0.8896807054156235,,
1990-05-09,3.8577418327331534,3.885798215866089,0.7220236763293085,,
1990-05-08,3.850727796554565,3.871770143508911,0.7272747723778583,,
1990-05-07,3.82267165184021,3.843713760375977,0.5464511662749512,,
1990-05-04,3.815657377243042,3.82267165184021,0.550455557061447,,
1990-05-03,3.82267165184021,3.7946152687072754,0.18382873260586227,,
1990-05-02,3.801629304885864,3.808643341064453,-0.7339469797106012,,
1990-05-01,3.759544849395752,3.7946152687072754,0.18450079205710176,,
1990-04-30,3.71746039390564,3.745516777038574,0.9328368384050555,,
1990-04-27,3.808643341064453,3.766558885574341,0.7547190866896504,,
1990-04-26,3.7735729217529297,3.808643341064453,-1.1049723411053343,,
1990-04-25,3.745516777038574,3.759544849395752,0.9293690631856732,,
1990-04-24,3.759544849395752,3.7314884662628174,0.3745296895524562,,
1990-04-23,3.745516777038574,3.724474430084229,-0.7462707390615089,,
1990-04-20,3.7946152687072754,3.759544849395752,-0.5618008997674968,,
1990-04-19,3.829685688018799,3.787601232528688,-0.9242154165334131,,
1990-04-18,3.9068405628204346,3.843713760375977,-1.0989010304885467,,
1990-04-17,3.8787841796875,3.8928122520446777,-1.6158018590573076,,
1990-04-16,3.8998262882232666,3.885798215866089,0.3616615853658537,,
1990-04-12,3.8787841796875,3.885798215866089,-0.3597101850290061,,
1990-04-11,3.850727796554565,3.885798215866089,0.18083079268292684,,
1990-04-10,3.808643341064453,3.850727796554565,0.910747816111622,,
1990-04-09,3.801629304885864,3.82267165184021,1.1049723411053225,,
1990-04-06,3.766558885574341,3.7946152687072754,0.5535086476554268,,
1990-04-05,3.745516777038574,3.7735729217529297,0.7448810435538011,,
1990-04-04,3.759544849395752,3.745516777038574,0.7490593791049124,,
1990-04-03,3.689404010772705,3.759544849395752,-0.37313219868709313,,
1990-04-02,3.6753759384155273,3.6683619022369385,1.9011427975424315,,
1990-03-30,3.696418285369873,3.689404010772705,-0.19083860525061425,,
1990-03-29,3.703432321548462,3.689404010772705,-0.18975868139517393,,
1990-03-28,3.640305519104004,3.6753759384155273,-0.3787921462512749,,
1990-03-27,3.577178955078125,3.640305519104004,0.9633921968218588,,
1990-03-26,3.584192991256714,3.5912070274353027,1.7647024322410572,,
1990-03-23,3.55613660812378,3.577178955078125,0.19569359673708747,,
1990-03-22,3.570164918899536,3.5421085357666016,0.5917193087091998,,
1990-03-21,3.55613660812378,3.55613660812378,-0.7858567816968701,,
1990-03-20,3.640305519104004,3.584192991256714,0.0,,
1990-03-19,3.626277446746826,3.640305519104004,-1.5414235852682259,,
1990-03-16,3.6753759384155273,3.640305519104004,0.386844982580207,,
1990-03-15,3.563150644302368,3.5912070274353027,-0.9541995131698683,,
1990-03-14,3.5421085357666016,3.570164918899536,0.787403787650627,,
1990-03-13,3.598221063613892,3.563150644302368,0.7920814071515304,,
1990-03-12,3.612249374389648,3.619263410568237,-0.9746599414406386,,
1990-03-09,3.619263410568237,3.626277446746826,0.19417364228276765,,
1990-03-08,3.619263410568237,3.633291482925415,0.19379733893113027,,
1990-03-07,3.6543338298797607,3.633291482925415,0.38759467786224827,,
1990-03-06,3.619263410568237,3.6473195552825928,-0.5758189572691027,,
1990-03-05,3.626277446746826,3.612249374389648,0.7751893557244843,,
1990-03-02,3.633291482925415,3.6473195552825928,-0.3868449825802192,,
1990-03-01,3.5912070274353027,3.619263410568237,0.3860981818580314,,
1990-02-28,3.55613660812378,3.598221063613892,0.781252178406737,,
1990-02-27,3.55613660812378,3.563150644302368,1.183431912991544,,
1990-02-26,3.514052152633667,3.563150644302368,0.19723753476075231,,
1990-02-23,3.55613660812378,3.5350944995880127,1.3972044106375445,,
1990-02-22,3.584192991256714,3.5912070274353027,-0.5917126042823568,,
1990-02-21,3.563150644302368,3.577178955078125,0.19569359673708747,,
1990-02-20,3.6473195552825928,3.612249374389648,0.39370523943995217,,
1990-02-16,3.696418285369873,3.6683619022369385,-0.9615329932402251,,
1990-02-15,3.633291482925415,3.689404010772705,-0.7590153756131843,,
1990-02-14,3.605235099792481,3.640305519104004,1.5443992894869518,,
1990-02-13,3.563150644302368,3.612249374389648,0.972763726657983,,
1990-02-12,3.584192991256714,3.570164918899536,1.3779583011959042,,
1990-02-09,3.619263410568237,3.598221063613892,-0.39138719347417494,,
1990-02-08,3.633291482925415,3.619263410568237,-0.5813986042823308,,
1990-02-07,3.619263410568237,3.633291482925415,-0.3860981818580436,,
1990-02-06,3.6613478660583496,3.633291482925415,0.38759467786224827,,
1990-02-05,3.689404010772705,3.6753759384155273,-0.7662856455958356,,
1990-02-02,3.6473195552825928,3.689404010772705,-0.38022597460774454,,
1990-02-01,3.6473195552825928,3.6613478660583496,1.1538461287045527,,
1990-01-31,3.605235099792481,3.6473195552825928,0.3846197341123824,,
1990-01-30,3.605235099792481,3.612249374389648,1.1673151493652734,,
1990-01-29,3.6473195552825928,3.619263410568237,0.19455803582880976,,
1990-01-26,3.605235099792481,3.626277446746826,-0.7692263945921824,,
1990-01-25,3.710446357727051,3.5912070274353027,0.5836608812434027,,
1990-01-24,3.6473195552825928,3.71746039390564,-3.2136114848670605,,
1990-01-23,3.752530813217163,3.703432321548462,1.9230790601130323,,
1990-01-22,3.815657377243042,3.738502740859986,-1.308410086754424,,
1990-01-19,3.7735729217529297,3.815657377243042,-2.0220535743909838,,
1990-01-18,3.696418285369873,3.7735729217529297,1.1152416122003257,,
1990-01-17,3.738502740859986,3.696418285369873,2.0872809954552087,,
1990-01-16,3.6683619022369385,3.738502740859986,-1.1257034809724886,,
1990-01-15,3.7314884662628174,3.696418285369873,1.9120479519830358,,
1990-01-12,3.7946152687072754,3.745516777038574,-0.939844279568899,,
1990-01-11,3.7946152687072754,3.82267165184021,-1.29389906991619,,
1990-01-10,3.815657377243042,3.787601232528688,0.7393735898420246,,
1990-01-09,3.843713760375977,3.836699724197388,-0.7352899367140183,,
1990-01-08,3.815657377243042,3.850727796554565,-0.18248071047576606,,
1990-01-05,3.8787841796875,3.850727796554565,0.9191186693199038,,
1990-01-04,3.9068405628204346,3.8928122520446777,-0.7233293174665733,,
1990-01-03,3.8928122520446777,3.8998262882232666,-0.3590704701199654,,
1990-01-02,3.829685688018799,3.885798215866089,0.18017915389843894,,
1989-12-29,3.787601232528688,3.815657377243042,1.4651992988050824,,
1989-12-28,3.7946152687072754,3.7805871963500977,0.7407364976387238,,
1989-12-27,3.7805871963500977,3.7805871963500977,-0.369683653382777,,
1989-12-26,3.766558885574341,3.7735729217529297,0.0,,
1989-12-22,3.745516777038574,3.7735729217529297,0.1862186784189712,,
1989-12-21,3.689404010772705,3.745516777038574,0.7490593791049124,,
1989-12-20,3.6473195552825928,3.6683619022369385,1.520916822934687,,
1989-12-19,3.6473195552825928,3.640305519104004,0.5769263327604249,,
1989-12-18,3.6473195552825928,3.6543338298797607,-0.1923065986480426,,
1989-12-15,3.619263410568237,3.6613478660583496,0.1923131354643398,,
1989-12-14,3.605235099792481,3.6613478660583496,1.1627906210757217,,
1989-12-13,3.633291482925415,3.605235099792481,1.556424607901398,,
1989-12-12,3.6543338298797607,3.640305519104004,-0.7722029257708767,,
1989-12-11,3.759544849395752,3.6473195552825928,-0.38388147960249197,,
1989-12-08,3.7735729217529297,3.766558885574341,-2.985076614558713,,
1989-12-07,3.836699724197388,3.766558885574341,-0.18587254901465247,,
1989-12-06,3.885798215866089,3.836699724197388,-1.8281555416151392,,
1989-12-05,3.927882671356201,3.885798215866089,-1.263536831846462,,
1989-12-04,3.9068405628204346,3.920868635177612,-1.0714285280721376,,
1989-12-01,3.8928122520446777,3.927882671356201,0.35906436752694393,,
1989-11-30,3.8787841796875,3.885798215866089,0.9009018940767796,,
1989-11-29,3.9068405628204346,3.871770143508911,0.18083079268292684,,
1989-11-28,3.8998262882232666,3.920868635177612,-0.8976670214103983,,
1989-11-27,3.927882671356201,3.93489670753479,0.5395713911127054,,
1989-11-24,3.7946152687072754,3.885798215866089,0.17857040969523394,,
1989-11-22,3.696418285369873,3.7805871963500977,2.4029563131409915,,
1989-11-21,3.710446357727051,3.696418285369873,2.2770396768503827,,
1989-11-20,3.71746039390564,3.724474430084229,-0.37806967153598914,,
1989-11-17,3.682389974594116,3.710446357727051,0.18867816830241402,,
1989-11-16,3.6683619022369385,3.6683619022369385,0.7619068954267134,,
1989-11-15,3.6613478660583496,3.6683619022369385,0.0,,
1989-11-14,3.71746039390564,3.682389974594116,0.19156978345627337,,
1989-11-13,3.759544849395752,3.724474430084229,-0.9433972549920884,,
1989-11-10,3.6683619022369385,3.745516777038574,-0.9328368384050437,,
1989-11-09,3.6613478660583496,3.6753759384155273,2.1032514473173247,,
1989-11-08,3.612249374389648,3.6543338298797607,0.38313956691254675,,
1989-11-07,3.563150644302368,3.598221063613892,1.165048453976787,,
1989-11-06,3.626277446746826,3.563150644302368,0.9842530617559772,,
1989-11-03,3.6473195552825928,3.626277446746826,-1.7408155711055635,,
1989-11-02,3.6473195552825928,3.6613478660583496,-0.5769197959441278,,
1989-11-01,3.6613478660583496,3.682389974594116,0.3846197341123824,,
1989-10-31,3.6613478660583496,3.6613478660583496,0.5747093503688202,,
1989-10-30,3.626277446746826,3.640305519104004,0.0,,
1989-10-27,3.6753759384155273,3.626277446746826,0.386844982580207,,
1989-10-26,3.703432321548462,3.689404010772705,-1.3358767236710967,,
1989-10-25,3.738502740859986,3.710446357727051,-0.3787921462512749,,
1989-10-24,3.787601232528688,3.759544849395752,-0.7504711131088022,,
1989-10-23,3.759544849395752,3.787601232528688,-0.740742792350525,,
1989-10-20,3.766558885574341,3.766558885574341,0.7462707390615444,,
1989-10-19,3.7314884662628174,3.787601232528688,0.0,,
1989-10-18,3.619263410568237,3.71746039390564,1.5037636260489067,,
1989-10-17,3.5912070274353027,3.6473195552825928,2.7131759200136796,,
1989-10-16,3.478981733322144,3.6473195552825928,1.562497717859596,,
1989-10-13,3.766558885574341,3.450925588607788,4.838709566885247,,
1989-10-12,3.787601232528688,3.759544849395752,-8.379884837999118,,
1989-10-11,3.829685688018799,3.787601232528688,-0.740742792350525,,
1989-10-10,3.787601232528688,3.82267165184021,-1.0989010304885467,,
1989-10-09,3.766558885574341,3.7946152687072754,0.9259269167601444,,
1989-10-06,3.759544849395752,3.759544849395752,0.7448810435538011,,
1989-10-05,3.689404010772705,3.738502740859986,0.0,,
1989-10-04,3.6683619022369385,3.703432321548462,1.3308038356308267,,
1989-10-03,3.619263410568237,3.6473195552825928,0.9560239759915119,,
1989-10-02,3.584192991256714,3.619263410568237,0.7751893557244843,,
1989-09-29,3.598221063613892,3.577178955078125,0.9784746356313354,,
1989-09-28,3.5000240802764893,3.5912070274353027,-0.5847919892568606,,
1989-09-27,3.443911552429199,3.4859960079193115,2.6052091376357147,,
1989-09-26,3.478981733322144,3.443911552429199,1.221995827983085,,
1989-09-25,3.521066188812256,3.464953660964966,-1.008058782172898,,
1989-09-22,3.4719676971435547,3.507038116455078,-1.593623204970714,,
1989-09-21,3.507038116455078,3.478981733322144,1.0101021199124764,,
1989-09-20,3.577178955078125,3.5350944995880127,-0.8000022298387102,,
1989-09-19,3.619263410568237,3.598221063613892,-1.1764705098236603,,
1989-09-18,3.5350944995880127,3.619263410568237,-0.5813986042823308,,
1989-09-15,3.4859960079193115,3.528080463409424,2.3809522203729885,,
1989-09-14,3.4930100440979004,3.5000240802764893,1.2072433644360734,,
1989-09-13,3.5350944995880127,3.4859960079193115,0.20080206154690006,,
1989-09-12,3.521066188812256,3.5350944995880127,-1.3888876711619227,,
1989-09-11,3.528080463409424,3.4930100440979004,0.39841087964577393,,
1989-09-08,3.464953660964966,3.528080463409424,-0.9940368332085179,,
1989-09-07,3.5000240802764893,3.464953660964966,1.8218657050344973,,
1989-09-06,3.577178955078125,3.4930100440979004,-1.002005086455091,,
1989-09-05,3.584192991256714,3.5912070274353027,-2.3529410196473206,,
1989-09-01,3.5491225719451904,3.5912070274353027,0.19569359673708747,,
1989-08-31,3.5491225719451904,3.5491225719451904,1.185770697883979,,
1989-08-30,3.5350944995880127,3.5421085357666016,0.0,,
1989-08-29,3.584192991256714,3.55613660812378,0.19841156097542223,,
1989-08-28,3.521066188812256,3.584192991256714,-0.7827810388942356,,
1989-08-25,3.55613660812378,3.5350944995880127,1.7928320303956646,,
1989-08-24,3.5350944995880127,3.570164918899536,-0.5917126042823568,,
1989-08-23,3.514052152633667,3.5000240802764893,0.9920645492110781,,
1989-08-22,3.4859960079193115,3.507038116455078,-0.3991993216908905,,
1989-08-21,3.5350944995880127,3.4859960079193115,0.6036182625557859,,
1989-08-18,3.55613660812378,3.577178955078125,-1.3888876711619227,,
1989-08-17,3.521066188812256,3.55613660812378,0.5917193087091998,,
1989-08-16,3.4930100440979004,3.514052152633667,0.9960170423082692,,
1989-08-15,3.4719676971435547,3.478981733322144,0.6024061846407003,,
1989-08-14,3.4930100440979004,3.4719676971435547,0.2020190505908184,,
1989-08-11,3.5912070274353027,3.507038116455078,-0.6024130102316975,,
1989-08-10,3.521066188812256,3.563150644302368,-2.3437498962663454,,
1989-08-09,3.570164918899536,3.5350944995880127,1.1952190965290672,,
1989-08-08,3.584192991256714,3.570164918899536,-0.9823193076003196,,
1989-08-07,3.55613660812378,3.577178955078125,-0.39138719347417494,,
1989-08-04,3.55613660812378,3.563150644302368,0.5917193087091998,,
1989-08-03,3.619263410568237,3.584192991256714,0.19723753476075231,,
1989-08-02,3.640305519104004,3.626277446746826,-0.9689932821445791,,
1989-08-01,3.696418285369873,3.6543338298797607,-0.38535425896424463,,
1989-07-31,3.6473195552825928,3.689404010772705,-1.1385198384251913,,
1989-07-28,3.619263410568237,3.6613478660583496,1.1538461287045527,,
1989-07-27,3.584192991256714,3.640305519104004,1.1627906210757217,,
1989-07-26,3.464953660964966,3.528080463409424,1.5655554258426103,,
1989-07-25,3.4859960079193115,3.443911552429199,1.8218657050344973,,
1989-07-24,3.464953660964966,3.478981733322144,-1.2072433644360734,,
1989-07-21,3.450925588607788,3.521066188812256,0.40485598740363693,,
1989-07-20,3.514052152633667,3.457939624786377,2.032515578893276,,
1989-07-19,3.4930100440979004,3.521066188812256,-1.5968040714829896,,
1989-07-18,3.4719676971435547,3.4930100440979004,0.8032082461876002,,
1989-07-17,3.450925588607788,3.4719676971435547,0.6060640187308652,,
1989-07-14,3.422869205474853,3.4368972778320312,0.609752601019011,,
1989-07-13,3.394812822341919,3.422869205474853,0.40983372472253343,,
1989-07-12,3.3667566776275635,3.380784749984741,0.8264486026531315,,
1989-07-11,3.338700294494629,3.3667566776275635,0.41666427664332517,,
1989-07-10,3.338700294494629,3.33168625831604,0.8403384748010572,,
1989-07-07,3.3106439113616943,3.3597426414489746,-0.21008283343535525,,
1989-07-06,3.3106439113616943,3.317657947540283,1.4830568131709936,,
1989-07-05,3.268559455871582,3.2966158390045166,0.2118632014309246,,
1989-07-03,3.2475173473358154,3.282587766647339,0.8583715092755797,,
1989-06-30,3.268559455871582,3.2545313835144043,1.0799147644367277,,
1989-06-29,3.3106439113616943,3.268559455871582,-0.42918210748707525,,
1989-06-28,3.352728366851806,3.324672222137451,-1.2711864101628083,,
1989-06-27,3.338700294494629,3.3667566776275635,-0.8368153230588016,,
1989-06-26,3.268559455871582,3.3106439113616943,0.8403384748010572,,
1989-06-23,3.275573492050171,3.2545313835144043,1.287553616762655,,
1989-06-22,3.212446928024292,3.2545313835144043,-0.6423946398038658,,
1989-06-21,3.2475173473358154,3.219460964202881,1.3100436033038199,,
1989-06-20,3.219460964202881,3.2334890365600586,-0.8639332798622723,,
1989-06-19,3.177376508712769,3.2264750003814697,0.43572736284600366,,
1989-06-16,3.100221633911133,3.1843905448913574,1.5452525545545654,,
1989-06-15,3.1843905448913574,3.142306089401245,2.714932057100705,,
1989-06-14,3.2264750003814697,3.1984188556671143,-1.321585870100871,,
1989-06-13,3.338700294494629,3.2545313835144043,-0.8695602696762987,,
1989-06-12,3.3667566776275635,3.3597426414489746,-2.5210082833435354,,
1989-06-09,3.38779878616333,3.380784749984741,-0.20833213832166259,,
1989-06-08,3.380784749984741,3.394812822341919,-0.20703815726117067,,
1989-06-07,3.394812822341919,3.408841133117676,0.4149353891057705,,
1989-06-06,3.38779878616333,3.38779878616333,0.4132278128394536,,
1989-06-05,3.408841133117676,3.380784749984741,0.0,,
1989-06-02,3.3597426414489746,3.422869205474853,-0.8230475412996034,,
1989-06-01,3.317657947540283,3.3457143306732178,1.8789107012867365,,
1989-05-31,3.2545313835144043,3.324672222137451,0.8456683472669513,,
1989-05-30,3.2966158390045166,3.2545313835144043,2.1551747504522547,,
1989-05-26,3.2475173473358154,3.2966158390045166,-1.2765956831300247,,
1989-05-25,3.2405033111572266,3.2405033111572266,1.5118777335856384,,
1989-05-24,3.289601802825928,3.268559455871582,0.0,,
1989-05-23,3.324672222137451,3.289601802825928,-0.6396624338018585,,
1989-05-22,3.338700294494629,3.338700294494629,-1.0548534402280418,,
1989-05-19,3.324672222137451,3.3106439113616943,0.0,,
1989-05-18,3.38779878616333,3.352728366851806,-0.4219456788055321,,
1989-05-17,3.3667566776275635,3.4158551692962646,-1.0351978238719721,,
1989-05-16,3.338700294494629,3.3667566776275635,1.4583320498022796,,
1989-05-15,3.261545419692993,3.352728366851806,0.8403384748010572,,
1989-05-12,3.219460964202881,3.2545313835144043,2.795697604217206,,
1989-05-11,3.163348436355591,3.177376508712769,1.0893258126584138,,
1989-05-10,3.1282780170440674,3.135292053222656,0.4434564398899903,,
1989-05-09,3.1142499446868896,3.135292053222656,0.22421396501120563,,
1989-05-08,3.1212639808654785,3.100221633911133,0.6756717960825639,,
1989-05-05,3.149320125579834,3.1212639808654785,-0.6741610797210105,,
1989-05-04,3.135292053222656,3.135292053222656,-0.8908635386562977,,
1989-05-03,3.086193561553955,3.135292053222656,0.0,,
1989-05-02,3.100221633911133,3.093207597732544,1.5909077214190912,,
1989-05-01,3.086193561553955,3.086193561553955,-0.22624305636304462,,
1989-04-28,3.1142499446868896,3.100221633911133,0.0,,
1989-04-27,3.0441091060638428,3.1142499446868896,-0.4504555197854313,,
1989-04-26,3.037095069885254,3.030081033706665,2.3041499558385357,,
1989-04-25,3.0651512145996094,3.023066759109497,-0.230945558739255,,
1989-04-24,3.0651512145996094,3.0651512145996094,-1.3729976938710236,,
1989-04-21,3.051123142242432,3.079179525375366,0.0,,
1989-04-20,3.086193561553955,3.0441091060638428,0.9195427986663954,,
1989-04-19,3.1142499446868896,3.0721654891967773,-1.363636293406108,,
1989-04-18,3.093207597732544,3.100221633911133,-1.3513512478955354,,
1989-04-17,3.1212639808654785,3.093207597732544,0.22675607624041988,,
1989-04-14,3.086193561553955,3.1142499446868896,-0.8988788934524842,,
1989-04-13,3.051123142242432,3.0441091060638428,0.9090934373801126,,
1989-04-12,3.086193561553955,3.0721654891967773,-0.22988374613534363,,
1989-04-11,3.0651512145996094,3.079179525375366,-0.4545428560259955,,
1989-04-10,3.0441091060638428,3.0721654891967773,0.45767108353214825,,
1989-04-07,3.037095069885254,3.079179525375366,0.9216615487613917,,
1989-04-06,2.9950106143951416,3.037095069885254,1.3856812026533736,,
1989-04-05,3.037095069885254,3.016052722930908,1.4051521316097735,,
1989-04-04,3.023066759109497,3.030081033706665,-0.6928445264356086,,
1989-04-03,3.086193561553955,3.030081033706665,0.23202513064032232,,
1989-03-31,3.030081033706665,3.0721654891967773,-1.8181791494321036,,
1989-03-30,3.0020246505737305,3.037095069885254,1.3888887796057008,,
1989-03-29,3.016052722930908,3.016052722930908,1.1682255608667627,,
1989-03-28,2.973968267440796,3.016052722930908,0.0,,
1989-03-27,2.89681339263916,2.959940195083618,1.4150943018073106,,
1989-03-23,2.903827667236328,2.89681339263916,2.1791808407425903,,
1989-03-22,2.931883811950684,2.903827667236328,-0.2415527159655343,,
1989-03-21,2.903827667236328,2.931883811950684,-0.9569323518208992,,
1989-03-20,2.8757712841033936,2.89681339263916,0.9661780218885339,,
1989-03-17,2.833686828613281,2.8687572479248047,0.731703131333238,,
1989-03-16,2.9950106143951416,2.9809823036193848,1.2376250952433676,,
1989-03-15,2.966954231262207,2.9879965782165527,-0.46838935088682243,,
1989-03-14,2.9388978481292725,2.9459121227264404,0.7092238475614715,,
1989-03-13,2.9248697757720947,2.931883811950684,0.2386702416905317,,
1989-03-10,2.9248697757720947,2.917855739593506,0.23980678513243467,,
1989-03-09,2.917855739593506,2.9248697757720947,-0.2398067851324195,,
1989-03-08,2.89681339263916,2.903827667236328,0.24038324045334783,,
1989-03-07,2.910841703414917,2.89681339263916,0.24213760592902983,,
1989-03-06,2.889799356460572,2.910841703414917,-0.4819331384217568,,
1989-03-03,2.8757712841033936,2.889799356460572,0.7281594449559811,,
1989-03-02,2.903827667236328,2.8827853202819824,0.4878020875555229,,
1989-03-01,2.889799356460572,2.917855739593506,-0.7246417269097937,,
1989-02-28,2.854728937149048,2.8687572479248047,0.9708765098244452,,
1989-02-27,2.833686828613281,2.847714900970459,0.491406052364698,,
1989-02-24,2.889799356460572,2.8266727924346924,0.4950466726078931,,
1989-02-23,2.847714900970459,2.8827853202819824,-2.184461834166828,,
1989-02-22,2.9459121227264404,2.854728937149048,1.2315284546066028,,
1989-02-21,2.903827667236328,2.959940195083618,-3.0952445890681415,,
1989-02-17,2.854728937149048,2.903827667236328,1.9323642542704418,,
1989-02-16,2.833686828613281,2.833686828613281,1.7199086557168557,,
1989-02-15,2.728475570678711,2.798616409301758,0.0,,
1989-02-14,2.728475570678711,2.721461534500122,2.5706969626852576,,
1989-02-13,2.728475570678711,2.714447498321533,-0.25706794863639254,,
1989-02-10,2.735489845275879,2.735489845275879,-0.5141358972727851,,
1989-02-09,2.8056304454803467,2.777574300765991,0.0,,
1989-02-08,2.833686828613281,2.8266727924346924,-0.9999943064330423,,
1989-02-07,2.777574300765991,2.8196587562561035,-0.24752333630392304,,
1989-02-06,2.8126444816589355,2.777574300765991,1.5151513850954905,,
1989-02-03,2.756531953811645,2.8056304454803467,-1.2468757115104527,,
1989-02-02,2.728475570678711,2.7635459899902344,1.781168964894812,,
1989-02-01,2.735489845275879,2.714447498321533,1.2853484813426288,,
1989-01-31,2.7495179176330566,2.7495179176330566,-0.7692350600637504,,
1989-01-30,2.742503881454468,2.756531953811645,0.0,,
1989-01-27,2.756531953811645,2.735489845275879,0.51150601652885,,
1989-01-26,2.714447498321533,2.728475570678711,-0.763354421002441,,
1989-01-25,2.7074334621429443,2.714447498321533,0.5167929151642068,,
1989-01-24,2.616250514984131,2.672363042831421,0.2590658746249383,,
1989-01-23,2.62326455116272,2.616250514984131,2.144768917422665,,
1989-01-20,2.637292623519897,2.62326455116272,-0.2673781481734449,,
1989-01-19,2.6302785873413086,2.6443066596984863,-0.5319118641621989,,
1989-01-18,2.6443066596984863,2.6443066596984863,0.5333302876999558,,
1989-01-17,2.672363042831421,2.6443066596984863,0.0,,
1989-01-16,2.6443066596984863,2.672363042831421,-1.0498716934510621,,
1989-01-13,2.6513209342956543,2.672363042831421,1.0610109470485418,,
1989-01-12,2.637292623519897,2.6513209342956543,0.7936462260596383,,
1989-01-11,2.62326455116272,2.6513209342956543,0.5319209044400318,,
1989-01-10,2.62326455116272,2.62326455116272,1.069521681314932,,
1989-01-09,2.6443066596984863,2.62326455116272,0.0,,
1989-01-06,2.714447498321533,2.6793770790100098,-0.795751448062588,,
1989-01-05,2.7074334621429443,2.714447498321533,-1.2919910712293783,,
1989-01-04,2.6793770790100098,2.721461534500122,0.2590658746249383,,
1989-01-03,2.7004194259643555,2.6793770790100098,1.5706805816843774,,
1988-12-30,2.6793770790100098,2.7004194259643555,-0.7792251363630746,,
1988-12-29,2.62326455116272,2.6934053897857666,0.7853447399841361,,
1988-12-28,2.6443066596984863,2.637292623519897,2.6737996589767365,,
1988-12-27,2.637292623519897,2.637292623519897,-0.26525048268755175,,
1988-12-23,2.616250514984131,2.6443066596984863,0.0,,
1988-12-22,2.6443066596984863,2.616250514984131,1.0723799022176455,,
1988-12-21,2.637292623519897,2.658334970474243,-1.0610019307501397,,
1988-12-20,2.637292623519897,2.637292623519897,0.7978768365211482,,
1988-12-19,2.602222204208374,2.637292623519897,0.0,,
1988-12-16,2.616250514984131,2.609236478805542,1.3477104013180081,,
1988-12-15,2.6443066596984863,2.595208168029785,-0.26809497555441136,,
1988-12-14,2.6443066596984863,2.6513209342956543,-1.8567623951111465,,
1988-12-13,2.6443066596984863,2.6513209342956543,0.2652594989859369,,
1988-12-12,2.672363042831421,2.6513209342956543,0.2652594989859369,,
1988-12-09,2.6443066596984863,2.665349006652832,-0.7873970788591687,,
1988-12-08,2.637292623519897,2.6513209342956543,0.7957604643610068,,
1988-12-07,2.62326455116272,2.6513209342956543,0.5319209044400318,,
1988-12-06,2.595208168029785,2.6302785873413086,1.069521681314932,,
1988-12-05,2.5811800956726074,2.609236478805542,1.3513528411151694,,
1988-12-02,2.546109676361084,2.5811800956726074,1.0869595337408489,,
1988-12-01,2.5811800956726074,2.5671520233154297,1.3774119645013212,,
1988-11-30,2.5671520233154297,2.5811800956726074,-0.5434751484677894,,
1988-11-29,2.5250675678253174,2.5671520233154297,0.5464449409217588,,
1988-11-28,2.504025220870972,2.5250675678253174,1.6666665092988784,,
1988-11-25,2.5110392570495605,2.489997148513794,0.8403408551542514,,
1988-11-23,2.497011184692383,2.5250675678253174,-0.8379840528853704,,
1988-11-22,2.489997148513794,2.489997148513794,1.1235986168156051,,
1988-11-21,2.504025220870972,2.489997148513794,0.0,,
1988-11-18,2.5110392570495605,2.5180532932281494,-0.560220889160965,,
1988-11-17,2.504025220870972,2.497011184692383,0.2793280176284568,,
1988-11-16,2.5110392570495605,2.504025220870972,-0.2801104445804914,,
1988-11-15,2.5320816040039062,2.5110392570495605,-0.2793280176284391,,
1988-11-14,2.5110392570495605,2.5320816040039062,-0.8310295734968437,,
1988-11-11,2.5250675678253174,2.5250675678253174,0.8379935477022448,,
1988-11-10,2.5601377487182617,2.5601377487182617,0.0,,
1988-11-09,2.5811800956726074,2.5741660594940186,0.0,,
1988-11-08,2.62326455116272,2.609236478805542,-0.2717375742338947,,
1988-11-07,2.595208168029785,2.616250514984131,-0.5347562963468727,,
1988-11-04,2.665349006652832,2.6513209342956543,0.8108153794198525,,
1988-11-03,2.6793770790100098,2.6793770790100098,-0.5263127763817432,,
1988-11-02,2.7074334621429443,2.7074334621429443,0.0,,
1988-11-01,2.686391115188598,2.714447498321533,0.0,,
1988-10-31,2.7074334621429443,2.6934053897857666,1.0443893658785168,,
1988-10-28,2.7074334621429443,2.721461534500122,-0.5181317492498766,,
1988-10-27,2.728475570678711,2.714447498321533,0.5181317492498766,,
1988-10-26,2.728475570678711,2.728475570678711,-0.5141358972727851,,
1988-10-25,2.7004194259643555,2.721461534500122,0.0,,
1988-10-24,2.721461534500122,2.7074334621429443,0.7792163074168446,,
1988-10-21,2.7074334621429443,2.721461534500122,-0.5154609822458656,,
1988-10-20,2.714447498321533,2.735489845275879,0.5181317492498766,,
1988-10-19,2.721461534500122,2.7004194259643555,0.7751981560651715,,
1988-10-18,2.7074334621429443,2.721461534500122,-0.7731914733687983,,
1988-10-17,2.714447498321533,2.7074334621429443,0.5181317492498766,,
1988-10-14,2.6934053897857666,2.721461534500122,-0.2583964575821034,,
1988-10-13,2.609236478805542,2.6793770790100098,1.041660673166881,,
1988-10-12,2.609236478805542,2.62326455116272,2.688165705723108,,
1988-10-11,2.616250514984131,2.637292623519897,0.5376313136477364,,
1988-10-10,2.5811800956726074,2.609236478805542,0.804284926663217,,
1988-10-07,2.5741660594940186,2.602222204208374,1.0869595337408489,,
1988-10-06,2.616250514984131,2.5671520233154297,1.0899119973584852,,
1988-10-05,2.6443066596984863,2.6302785873413086,-1.8766739418682534,,
1988-10-04,2.7004194259643555,2.665349006652832,-0.5305009653750699,,
1988-10-03,2.7004194259643555,2.721461534500122,-1.2987026746409709,,
1988-09-30,2.721461534500122,2.7074334621429443,0.7792163074168446,,
1988-09-29,2.7074334621429443,2.735489845275879,-0.5154609822458656,,
1988-09-28,2.7074334621429443,2.7074334621429443,1.0362723045731963,,
1988-09-27,2.728475570678711,2.728475570678711,0.0,,
1988-09-26,2.6934053897857666,2.714447498321533,0.0,,
1988-09-23,2.721461534500122,2.6934053897857666,0.7812455048751606,,
1988-09-22,2.7495179176330566,2.756531953811645,-1.0309219644917311,,
1988-09-21,2.728475570678711,2.7495179176330566,0.25510058085478887,,
1988-09-20,2.7074334621429443,2.721461534500122,0.7712125840698437,,
1988-09-19,2.714447498321533,2.721461534500122,0.5181317492498766,,
1988-09-16,2.7074334621429443,2.735489845275879,0.2583964575821034,,
1988-09-15,2.735489845275879,2.714447498321533,1.0362723045731963,,
1988-09-14,2.742503881454468,2.735489845275879,-0.7692350600637504,,
1988-09-13,2.735489845275879,2.7074334621429443,-0.2557530082644574,,
1988-09-12,2.742503881454468,2.735489845275879,-1.0256438415001696,,
1988-09-09,2.7495179176330566,2.721461534500122,-0.2557530082644574,,
1988-09-08,2.735489845275879,2.756531953811645,-1.0204109947058326,,
1988-09-07,2.714447498321533,2.735489845275879,0.7692263443092411,,
1988-09-06,2.658334970474243,2.6793770790100098,0.7751981560651715,,
1988-09-02,2.62326455116272,2.6443066596984863,0.7915521847125504,,
1988-09-01,2.609236478805542,2.5811800956726074,0.8021344445202669,,
1988-08-31,2.6302785873413086,2.616250514984131,-1.0752717647799497,,
1988-08-30,2.609236478805542,2.62326455116272,-0.5333302876999558,,
1988-08-29,2.5741660594940186,2.595208168029785,0.5376313136477364,,
1988-08-26,2.553123712539673,2.5671520233154297,0.8174339980188637,,
1988-08-25,2.546109676361084,2.553123712539673,0.5494567578866921,,
1988-08-24,2.5320816040039062,2.5811800956726074,0.27548052009343804,,
1988-08-23,2.5180532932281494,2.539095640182495,1.9390564502764513,,
1988-08-22,2.5601377487182617,2.5250675678253174,0.8356593170976685,,
1988-08-19,2.5741660594940186,2.5601377487182617,-1.3698552318328299,,
1988-08-18,2.5180532932281494,2.5601377487182617,-0.5449652606527746,,
1988-08-17,2.5250675678253174,2.5250675678253174,1.67130916582627,,
1988-08-16,2.475968837738037,2.5250675678253174,0.0,,
1988-08-15,2.5180532932281494,2.475968837738037,1.9830108254567227,,
1988-08-12,2.5180532932281494,2.5250675678253174,-1.67130916582627,,
1988-08-11,2.5180532932281494,2.5320816040039062,0.27855941794526734,,
1988-08-10,2.553123712539673,2.5180532932281494,0.5571093675214679,,
1988-08-09,2.5741660594940186,2.5601377487182617,-1.3736278872533672,,
1988-08-08,2.602222204208374,2.5601377487182617,-0.5449652606527746,,
1988-08-05,2.602222204208374,2.602222204208374,-1.6172506491587209,,
1988-08-04,2.6513209342956543,2.616250514984131,0.0,,
1988-08-03,2.5881941318511963,2.6443066596984863,-1.3227527025444843,,
1988-08-02,2.5881941318511963,2.595208168029785,2.1680185097690394,,
1988-08-01,2.546109676361084,2.5741660594940186,0.2710011622494524,,
1988-07-29,2.497011184692383,2.5320816040039062,1.1019314444078832,,
1988-07-28,2.4479126930236816,2.482982873916626,1.4044958839799473,,
1988-07-27,2.475968837738037,2.4408984184265137,1.4326565237759916,,
1988-07-26,2.475968837738037,2.475968837738037,-1.4164321770528665,,
1988-07-25,2.4549267292022705,2.468954801559448,0.0,,
1988-07-22,2.489997148513794,2.46194076538086,0.5714252971507511,,
1988-07-21,2.504025220870972,2.497011184692383,-1.126763665158418,,
1988-07-20,2.5180532932281494,2.5180532932281494,-0.2801104445804914,,
1988-07-19,2.5320816040039062,2.504025220870972,0.0,,
1988-07-18,2.5250675678253174,2.5250675678253174,-1.108036292691728,,
1988-07-15,2.546109676361084,2.5320816040039062,0.0,,
1988-07-14,2.546109676361084,2.546109676361084,-0.5509610401868761,,
1988-07-13,2.5320816040039062,2.546109676361084,0.0,,
1988-07-12,2.5601377487182617,2.5320816040039062,0.5540134383898037,,
1988-07-11,2.546109676361084,2.553123712539673,-1.095884185466264,,
1988-07-08,2.5671520233154297,2.553123712539673,0.27548052009343804,,
1988-07-07,2.539095640182495,2.5671520233154297,-0.5464542282010837,,
1988-07-06,2.5671520233154297,2.5601377487182617,1.1049754364872229,,
1988-07-05,2.489997148513794,2.5671520233154297,-0.27323175774020436,,
1988-07-01,2.5110392570495605,2.497011184692383,3.098592897894972,,
1988-06-30,2.5180532932281494,2.5250675678253174,-0.5586560352569137,,
1988-06-29,2.5320816040039062,2.5110392570495605,0.27855941794526734,,
1988-06-28,2.5320816040039062,2.5250675678253174,-0.8310295734968437,,
1988-06-27,2.482982873916626,2.5180532932281494,-0.27700671919490183,,
1988-06-24,2.5250675678253174,2.497011184692383,1.4124309788816143,,
1988-06-23,2.539095640182495,2.5250675678253174,-1.1111141535550186,,
1988-06-22,2.546109676361084,2.539095640182495,-0.5524830232928714,,
1988-06-21,2.5180532932281494,2.5110392570495605,-0.27548052009343804,,
1988-06-20,2.5250675678253174,2.5110392570495605,-0.27854994957620055,,
1988-06-17,2.5180532932281494,2.5250675678253174,-0.5555617978111589,,
1988-06-16,2.539095640182495,2.5320816040039062,0.27855941794526734,,
1988-06-15,2.5320816040039062,2.5601377487182617,-0.2762415116464357,,
1988-06-14,2.5811800956726074,2.5320816040039062,1.1080268767796073,,
1988-06-13,2.5250675678253174,2.5250675678253174,-1.9021722564425332,,
1988-06-10,2.539095640182495,2.5180532932281494,0.0,,
1988-06-09,2.546109676361084,2.5250675678253174,-0.8287339248407872,,
1988-06-08,2.504025220870972,2.539095640182495,-0.8264415602803143,,
1988-06-07,2.489997148513794,2.489997148513794,1.4005617443151988,,
1988-06-06,2.5110392570495605,2.5110392570495605,0.0,,
1988-06-03,2.546109676361084,2.5320816040039062,0.0,,
1988-06-02,2.728475570678711,2.637292623519897,-0.5509610401868761,,
1988-06-01,2.62326455116272,2.742503881454468,-3.3419008085944517,,
1988-05-31,2.5320816040039062,2.602222204208374,4.545455784811986,,
1988-05-27,2.539095640182495,2.5320816040039062,2.7700766078611565,,
1988-05-26,2.46194076538086,2.553123712539673,-0.2762415116464357,,
1988-05-25,2.468954801559448,2.475968837738037,3.7037019103384936,,
1988-05-24,2.433884382247925,2.4549267292022705,0.28408929050297266,,
1988-05-23,2.4408984184265137,2.419856309890747,0.8645581979087719,,
1988-05-20,2.468954801559448,2.4549267292022705,-0.8620640816888668,,
1988-05-19,2.4408984184265137,2.4408984184265137,-0.5681785810058914,,
1988-05-18,2.497011184692383,2.4479126930236816,0.0,,
1988-05-17,2.553123712539673,2.497011184692383,-1.9662904183086316,,
1988-05-16,2.482982873916626,2.5250675678253174,-2.197799016620042,,
1988-05-13,2.426870346069336,2.4549267292022705,1.694924856340533,,
1988-05-12,2.419856309890747,2.412842273712158,1.1560726010096047,,
1988-05-11,2.4549267292022705,2.419856309890747,-0.2898534160859138,,
1988-05-10,2.5110392570495605,2.468954801559448,-1.4285729547178616,,
1988-05-09,2.482982873916626,2.504025220870972,-1.6759776005876328,,
1988-05-06,2.546109676361084,2.482982873916626,0.8474624281702844,,
1988-05-05,2.553123712539673,2.5320816040039062,-2.4793434089092043,,
1988-05-04,2.5811800956726074,2.5601377487182617,-0.8241711293666749,,
1988-05-03,2.602222204208374,2.5811800956726074,-0.8152219595069541,,
1988-05-02,2.5741660594940186,2.595208168029785,-0.8086207435220873,,
1988-04-29,2.602222204208374,2.5601377487182617,0.8174339980188637,,
1988-04-28,2.62326455116272,2.609236478805542,-1.6172506491587209,,
1988-04-27,2.6934053897857666,2.6443066596984863,-0.5347562963468727,,
1988-04-26,2.686391115188598,2.7074334621429443,-1.8229238819183318,,
1988-04-25,2.609236478805542,2.658334970474243,0.7832942431716191,,
1988-04-22,2.5811800956726074,2.595208168029785,1.881718735251529,,
1988-04-21,2.5881941318511963,2.539095640182495,0.5434751484677894,,
1988-04-20,2.62326455116272,2.5741660594940186,-1.8970173475195873,,
1988-04-19,2.686391115188598,2.609236478805542,-1.8716561258352495,,
1988-04-18,2.6934053897857666,2.665349006652832,-2.8720552248267674,,
1988-04-15,2.6934053897857666,2.6793770790100098,-1.041669525105026,,
1988-04-14,2.7495179176330566,2.7074334621429443,-0.5208391885215856,,
1988-04-13,2.8266727924346924,2.8196587562561035,-1.5306121564154427,,
1988-04-12,2.8126444816589355,2.8266727924346924,-0.24813753460822333,,
1988-04-11,2.8126444816589355,2.8126444816589355,0.4987587612737586,,
1988-04-08,2.7495179176330566,2.833686828613281,0.0,,
1988-04-07,2.665349006652832,2.742503881454468,3.0612243128308694,,
1988-04-06,2.6302785873413086,2.672363042831421,2.894738160333004,,
1988-04-05,2.5881941318511963,2.6302785873413086,1.5999999274849197,,
1988-04-04,2.5881941318511963,2.595208168029785,1.626016185270135,,
1988-03-31,2.616250514984131,2.6302785873413086,0.2710011622494524,,
1988-03-30,2.665349006652832,2.6302785873413086,0.5361899511088227,,
1988-03-29,2.62326455116272,2.637292623519897,-1.3157908860710579,,
1988-03-28,2.595208168029785,2.609236478805542,0.534756296346822,,
1988-03-25,2.6793770790100098,2.602222204208374,0.5405466485721939,,
1988-03-24,2.6934053897857666,2.686391115188598,-2.8795825494686746,,
1988-03-23,2.777574300765991,2.714447498321533,-0.26042402022988187,,
1988-03-22,2.777574300765991,2.7635459899902344,-2.272731369492045,,
1988-03-21,2.7635459899902344,2.791602373123169,-0.5050561841635758,,
1988-03-18,2.798616409301758,2.8196587562561035,1.015231272957166,,
1988-03-17,2.7495179176330566,2.7705600261688232,0.7518839268006605,,
1988-03-16,2.714447498321533,2.721461534500122,0.7653017425644151,,
1988-03-15,2.728475570678711,2.728475570678711,0.2583964575821034,,
1988-03-14,2.7074334621429443,2.721461534500122,0.0,,
1988-03-11,2.756531953811645,2.6934053897857666,0.5181317492498766,,
1988-03-10,2.8126444816589355,2.7635459899902344,-2.290071912229751,,
1988-03-09,2.8126444816589355,2.8196587562561035,-1.7456344727842112,,
1988-03-08,2.8757712841033936,2.8196587562561035,0.24938361897166808,,
1988-03-07,2.89681339263916,2.889799356460572,-1.9512166408179699,,
1988-03-04,2.889799356460572,2.89681339263916,-0.24212937555490233,,
1988-03-03,2.910841703414917,2.903827667236328,0.24271706486843342,,
1988-03-02,2.917855739593506,2.89681339263916,-0.24096247385628008,,
1988-03-01,2.917855739593506,2.903827667236328,-0.7211578923801478,,
1988-02-29,2.8056304454803467,2.917855739593506,-0.48076648090669566,,
1988-02-26,2.833686828613281,2.798616409301758,4.000002719315562,,
1988-02-25,2.84070086479187,2.8196587562561035,-1.2376250952433363,,
1988-02-24,2.798616409301758,2.833686828613281,-0.7407365131811685,,
1988-02-23,2.777574300765991,2.798616409301758,1.2531341985618139,,
1988-02-22,2.7074334621429443,2.777574300765991,0.7575714006989361,,
1988-02-19,2.6513209342956543,2.714447498321533,2.5906763583962698,,
1988-02-18,2.672363042831421,2.6513209342956543,2.380947670624002,,
1988-02-17,2.7074334621429443,2.7074334621429443,-0.7873970788591687,,
1988-02-16,2.6934053897857666,2.728475570678711,0.0,,
1988-02-12,2.665349006652832,2.7074334621429443,1.3020758414586011,,
1988-02-11,2.637292623519897,2.665349006652832,1.5789472742619295,,
1988-02-10,2.595208168029785,2.672363042831421,1.0638327686022644,,
1988-02-09,2.609236478805542,2.609236478805542,2.972974413077997,,
1988-02-08,2.5811800956726074,2.616250514984131,0.0,,
1988-02-05,2.609236478805542,2.616250514984131,1.3586971079747436,,
1988-02-04,2.6793770790100098,2.6302785873413086,0.2688156568238597,,
1988-02-03,2.686391115188598,2.665349006652832,-1.8324591955844578,,
1988-02-02,2.7004194259643555,2.721461534500122,-0.7832853681206765,,
1988-02-01,2.721461534500122,2.721461534500122,0.7792163074168446,,
1988-01-29,2.6513209342956543,2.735489845275879,0.0,,
1988-01-28,2.595208168029785,2.6513209342956543,3.1746028891287277,,
1988-01-27,2.5881941318511963,2.5811800956726074,2.1621682205350217,,
1988-01-26,2.5881941318511963,2.5741660594940186,-0.2710011622494524,,
1988-01-25,2.5601377487182617,2.5811800956726074,-0.5420023244989048,,
1988-01-22,2.665349006652832,2.616250514984131,0.8219224518243442,,
1988-01-21,2.7074334621429443,2.6793770790100098,-1.842103662452801,,
1988-01-20,2.6934053897857666,2.672363042831421,-1.0362723045731963,,
1988-01-19,2.637292623519897,2.721461534500122,-0.7812543568133058,,
1988-01-18,2.7495179176330566,2.686391115188598,3.1914892655289773,,
1988-01-15,2.8056304454803467,2.742503881454468,-2.2959225702664865,,
1988-01-14,2.609236478805542,2.658334970474243,-2.2499956873354603,,
1988-01-13,2.5811800956726074,2.609236478805542,1.881718735251529,,
1988-01-12,2.616250514984131,2.6302785873413086,1.0869595337408489,,
1988-01-11,2.6443066596984863,2.62326455116272,0.5361899511088227,,
1988-01-08,2.756531953811645,2.658334970474243,-0.795751448062588,,
1988-01-07,2.7074334621429443,2.7635459899902344,-3.562337929789576,,
1988-01-06,2.7705600261688232,2.78458833694458,2.0725358030729497,,
1988-01-05,2.8056304454803467,2.791602373123169,0.5063348436148275,,
1988-01-04,2.6934053897857666,2.728475570678711,-0.49999715321652116,,
1987-12-31,2.665349006652832,2.7074334621429443,1.3020758414586011,,
1987-12-30,2.616250514984131,2.6793770790100098,1.5789472742619295,,
1987-12-29,2.62326455116272,2.616250514984131,2.412863892977076,,
1987-12-28,2.6513209342956543,2.62326455116272,-0.2673781481734449,,
1987-12-24,2.7074334621429443,2.6934053897857666,-1.058203960524588,,
1987-12-23,2.62326455116272,2.735489845275879,-0.5181317492498766,,
1987-12-22,2.686391115188598,2.616250514984131,4.278077636638542,,
1987-12-21,2.672363042831421,2.6934053897857666,-2.6109601021198694,,
1987-12-18,2.616250514984131,2.672363042831421,0.7874060004980058,,
1987-12-17,2.665349006652832,2.637292623519897,2.144768917422665,,
1987-12-16,2.602222204208374,2.658334970474243,-1.052634497880203,,
1987-12-15,2.5811800956726074,2.616250514984131,2.1563403069546587,,
1987-12-14,2.504025220870972,2.5811800956726074,1.3586971079747436,,
1987-12-11,2.5250675678253174,2.5180532932281494,3.0812339332108887,,
1987-12-10,2.504025220870972,2.539095640182495,-0.27778561993922896,,
1987-12-09,2.553123712539673,2.5811800956726074,1.4005617443151988,,
1987-12-08,2.46194076538086,2.5601377487182617,1.0989041774644754,,
1987-12-07,2.3988139629364014,2.468954801559448,3.988600567414989,,
1987-12-04,2.4058282375335693,2.412842273712158,2.923979921193499,,
1987-12-03,2.504025220870972,2.419856309890747,0.291543513753899,,
1987-12-02,2.468954801559448,2.5180532932281494,-3.3613443777913976,,
1987-12-01,2.482982873916626,2.4479126930236816,1.9886346901810392,,
1987-11-30,2.468954801559448,2.419856309890747,-1.4124213767783695,,
1987-11-27,2.609236478805542,2.595208168029785,-1.9886346901810033,,
1987-11-25,2.665349006652832,2.616250514984131,-0.5376404511322302,,
1987-11-24,2.616250514984131,2.6934053897857666,-1.842103662452801,,
1987-11-23,2.5881941318511963,2.595208168029785,2.9490629570732727,,
1987-11-20,2.539095640182495,2.602222204208374,0.2710011622494524,,
1987-11-19,2.5601377487182617,2.5671520233154297,2.4861829947194014,,
1987-11-18,2.602222204208374,2.5811800956726074,0.27398035909121216,,
1987-11-17,2.637292623519897,2.5881941318511963,-0.8086207435220873,,
1987-11-16,2.735489845275879,2.6793770790100098,-1.8617005648455796,,
1987-11-13,2.742503881454468,2.672363042831421,-2.0512876830003393,,
1987-11-12,2.7495179176330566,2.742503881454468,-2.557547469571806,,
1987-11-11,2.637292623519897,2.6793770790100098,-0.25510058085478887,,
1987-11-10,2.504025220870972,2.546109676361084,1.595744632764497,,
1987-11-09,2.609236478805542,2.5811800956726074,1.6806721888956724,,
1987-11-06,2.7705600261688232,2.6934053897857666,-1.0752717647799497,,
1987-11-05,2.714447498321533,2.78458833694458,-2.7848029154505403,,
1987-11-04,2.7635459899902344,2.7635459899902344,2.5839821424587566,,
1987-11-03,2.777574300765991,2.84070086479187,0.0,,
1987-11-02,2.8056304454803467,2.847714900970459,2.2727227857944268,,
1987-10-30,2.917855739593506,2.791602373123169,1.4999999575106944,,
1987-10-29,2.6513209342956543,2.721461534500122,-4.326922841220574,,
1987-10-28,2.539095640182495,2.658334970474243,2.6454964126438814,,
1987-10-27,2.602222204208374,2.616250514984131,4.696133867693847,,
1987-10-26,2.468954801559448,2.433884382247925,0.5390896577959379,,
1987-10-23,2.4408984184265137,2.62326455116272,-1.420456109175094,,
1987-10-22,2.497011184692383,2.5811800956726074,7.4712708795872755,,
1987-10-21,2.7495179176330566,2.7074334621429443,3.370786302288579,,
1987-10-20,2.5811800956726074,2.595208168029785,-1.5306121564154427,,
1987-10-19,2.665349006652832,2.609236478805542,0.5434751484677894,,
1987-10-16,3.037095069885254,2.917855739593506,-2.1052600506436727,,
1987-10-15,3.1072356700897217,3.0581371784210205,-3.9260980492208657,,
1987-10-14,3.2264750003814697,3.1142499446868896,-1.5801341411378511,,
1987-10-13,3.261545419692993,3.2405033111572266,-3.478255857594173,,
1987-10-12,3.261545419692993,3.205432891845703,-0.6451576117479695,,
1987-10-09,3.2264750003814697,3.2966158390045166,-1.7204276079825946,,
1987-10-08,3.212446928024292,3.212446928024292,2.1739154530797244,,
1987-10-07,3.2264750003814697,3.282587766647339,0.0,,
1987-10-06,3.4158551692962646,3.1984188556671143,1.7391353182415754,,
1987-10-05,3.457939624786377,3.422869205474853,-6.365501546540882,,
1987-10-02,3.3737707138061523,3.4158551692962646,-1.0141998738248776,,
1987-10-01,3.303629875183105,3.3597426414489746,1.2474011739414952,,
1987-09-30,3.3106439113616943,3.3106439113616943,1.6985185503796643,,
1987-09-29,3.282587766647339,3.352728366851806,0.0,,
1987-09-28,3.275573492050171,3.275573492050171,2.1367471394711623,,
1987-09-25,3.261545419692993,3.261545419692993,0.0,,
1987-09-24,3.282587766647339,3.289601802825928,0.0,,
1987-09-23,3.33168625831604,3.289601802825928,0.2136739876342461,,
1987-09-22,3.268559455871582,3.33168625831604,-1.2631578194095303,,
1987-09-21,3.380784749984741,3.2475173473358154,1.9313340722946968,,
1987-09-18,3.3667566776275635,3.3597426414489746,-3.9419073530051647,,
1987-09-17,3.380784749984741,3.33168625831604,-0.20833213832166259,,
1987-09-16,3.422869205474853,3.3597426414489746,-1.4522809140369783,,
1987-09-15,3.528080463409424,3.464953660964966,-1.8442587267111465,,
1987-09-14,3.55613660812378,3.5350944995880127,-1.789267651323754,,
1987-09-11,3.38779878616333,3.528080463409424,-0.5917126042823568,,
1987-09-10,3.422869205474853,3.408841133117676,4.140791295487836,,
1987-09-09,3.408841133117676,3.3737707138061523,-0.4098337247225075,,
1987-09-08,3.450925588607788,3.394812822341919,-1.02880767809348,,
1987-09-04,3.4719676971435547,3.450925588607788,-1.6260207537105082,,
1987-09-03,3.478981733322144,3.4298832416534424,-0.6060571517724169,,
1987-09-02,3.422869205474853,3.4368972778320312,-1.4112891481559047,,
1987-09-01,3.5491225719451904,3.4930100440979004,0.40983372472253343,,
1987-08-31,3.4368972778320312,3.521066188812256,-1.5810253579530809,,
1987-08-28,3.521066188812256,3.422869205474853,2.448979535207922,,
1987-08-27,3.5491225719451904,3.521066188812256,-2.7888423014997934,,
1987-08-26,3.6473195552825928,3.5912070274353027,-0.7905160378148769,,
1987-08-25,3.612249374389648,3.6613478660583496,-1.5384593260006378,,
1987-08-24,3.6473195552825928,3.605235099792481,1.3592220962595545,,
1987-08-21,3.6543338298797607,3.6543338298797607,-1.1538461287045405,,
1987-08-20,3.598221063613892,3.6543338298797607,0.0,,
1987-08-19,3.605235099792481,3.612249374389648,1.5594585567100079,,
1987-08-18,3.612249374389648,3.633291482925415,0.19455803582880976,,
1987-08-17,3.619263410568237,3.612249374389648,0.5825209268483152,,
1987-08-14,3.6613478660583496,3.626277446746826,-0.193797338931118,,
1987-08-13,3.703432321548462,3.6753759384155273,-0.957855429052109,,
1987-08-12,3.703432321548462,3.703432321548462,-0.757577854729198,,
1987-08-11,3.633291482925415,3.689404010772705,0.0,,
1987-08-10,3.5350944995880127,3.619263410568237,1.5443992894869518,,
1987-08-07,3.478981733322144,3.514052152633667,2.3809522203729885,,
1987-08-06,3.464953660964966,3.464953660964966,1.0080656352867252,,
1987-08-05,3.478981733322144,3.443911552429199,0.0,,
1987-08-04,3.5350944995880127,3.4719676971435547,-1.008058782172898,,
1987-08-03,3.507038116455078,3.5491225719451904,-1.7857175374467342,,
1987-07-31,3.563150644302368,3.5350944995880127,1.1999999456136896,,
1987-07-30,3.584192991256714,3.55613660812378,-0.78739709642135,,
1987-07-29,3.4930100440979004,3.584192991256714,-0.7827810388942356,,
1987-07-28,3.4930100440979004,3.4859960079193115,2.610440451291695,,
1987-07-27,3.4859960079193115,3.4930100440979004,-0.20080206154690006,,
1987-07-24,3.4719676971435547,3.507038116455078,0.20120608751859528,,
1987-07-23,3.507038116455078,3.457939624786377,1.0101021199124764,,
1987-07-22,3.4930100440979004,3.4930100440979004,-1.399998803501173,,
1987-07-21,3.507038116455078,3.478981733322144,0.0,,
1987-07-20,3.577178955078125,3.507038116455078,-0.8000022298387102,,
1987-07-17,3.5350944995880127,3.5912070274353027,-1.9607864047023895,,
1987-07-16,3.4368972778320312,3.507038116455078,1.5872992321373447,,
1987-07-15,3.4158551692962646,3.422869205474853,2.040818591683112,,
1987-07-14,3.422869205474853,3.408841133117676,0.2053376337976723,,
1987-07-13,3.464953660964966,3.4158551692962646,-0.4098337247225075,,
1987-07-10,3.528080463409424,3.478981733322144,-1.417002836771779,,
1987-07-09,3.514052152633667,3.514052152633667,-1.3916556211371776,,
1987-07-08,3.5000240802764893,3.584192991256714,0.0,,
1987-07-07,3.464953660964966,3.5350944995880127,2.4048094827272037,,
1987-07-06,3.4930100440979004,3.457939624786377,2.02429369873631,,
1987-07-02,3.514052152633667,3.464953660964966,-1.0040171333254977,,
1987-07-01,3.443911552429199,3.5000240802764893,-1.3972044106375445,,
1987-06-30,3.5421085357666016,3.5000240802764893,1.629325463010526,,
1987-06-29,3.577178955078125,3.5421085357666016,-1.1881187452378323,,
1987-06-26,3.605235099792481,3.584192991256714,-0.9803932023511948,,
1987-06-25,3.6473195552825928,3.626277446746826,-0.583654268121883,,
1987-06-24,3.626277446746826,3.633291482925415,-0.5769197959441278,,
1987-06-23,3.696418285369873,3.6613478660583496,0.1934224912901035,,
1987-06-22,3.6473195552825928,3.703432321548462,-0.9487676070191878,,
1987-06-19,3.6683619022369385,3.6543338298797607,1.538465862816935,,
1987-06-18,3.605235099792481,3.6543338298797607,-0.3824069906686013,,
1987-06-17,3.6613478660583496,3.626277446746826,1.3618731851941077,,
1987-06-16,3.633291482925415,3.6683619022369385,-0.957855429052109,,
1987-06-15,3.5491225719451904,3.640305519104004,0.9652520166999046,,
1987-06-12,3.5491225719451904,3.5350944995880127,2.5691687258025087,,
1987-06-11,3.5000240802764893,3.507038116455078,-0.3952546600691021,,
1987-06-10,3.528080463409424,3.5000240802764893,0.20039965490851092,,
1987-06-09,3.514052152633667,3.4930100440979004,-0.795230818115236,,
1987-06-08,3.4719676971435547,3.5000240802764893,-0.5987989825363358,,
1987-06-05,3.464953660964966,3.5000240802764893,0.8080830693216708,,
1987-06-04,3.450925588607788,3.4719676971435547,1.012146849368155,,
1987-06-03,3.352728366851806,3.443911552429199,0.609752601019011,,
1987-06-02,3.3737707138061523,3.317657947540283,2.719671133483848,,
1987-06-01,3.401827096939087,3.3667566776275635,-1.6632062764741051,,
1987-05-29,3.478981733322144,3.3737707138061523,-1.0309289188471475,,
1987-05-28,3.38779878616333,3.443911552429199,-3.024190052746374,,
1987-05-27,3.380784749984741,3.38779878616333,1.6563193332215769,,
1987-05-26,3.282587766647339,3.394812822341919,0.20746769455288525,,
1987-05-22,3.1984188556671143,3.268559455871582,3.4187983284054217,,
1987-05-21,3.1843905448913574,3.1843905448913574,2.19297732316045,,
1987-05-20,3.086193561553955,3.1282780170440674,0.0,,
1987-05-19,3.275573492050171,3.0441091060638428,1.363636293406108,,
1987-05-18,3.289601802825928,3.282587766647339,-7.066377431252666,,
1987-05-15,3.408841133117676,3.303629875183105,-0.21321839538645412,,
1987-05-14,3.394812822341919,3.4719676971435547,-3.0864230342804535,,
1987-05-13,3.3737707138061523,3.380784749984741,2.272728390026826,,
1987-05-12,3.352728366851806,3.380784749984741,0.2078990178522213,,
1987-05-11,3.422869205474853,3.380784749984741,0.8368224342397236,,
1987-05-08,3.4298832416534424,3.3667566776275635,-1.2295081396273657,,
1987-05-07,3.4368972778320312,3.4298832416534424,-1.8404872579699683,,
1987-05-06,3.443911552429199,3.4719676971435547,-0.20408047176240507,,
1987-05-05,3.352728366851806,3.443911552429199,0.8146592700548819,,
1987-05-04,3.303629875183105,3.338700294494629,2.719671133483848,,
1987-05-01,3.324672222137451,3.317657947540283,1.0615722897705084,,
1987-04-30,3.3457143306732178,3.352728366851806,-0.21097642499802433,,
1987-04-29,3.324672222137451,3.33168625831604,0.2096424107188217,,
1987-04-28,3.282587766647339,3.3106439113616943,0.21096925380750775,,
1987-04-27,3.1984188556671143,3.275573492050171,0.8546959505369304,,
1987-04-24,3.338700294494629,3.268559455871582,2.4122743100501145,,
1987-04-23,3.4368972778320312,3.352728366851806,-2.100842616472825,,
1987-04-22,3.514052152633667,3.457939624786377,-2.448979535207935,,
1987-04-21,3.401827096939087,3.528080463409424,-1.5968040714829896,,
1987-04-20,3.457939624786377,3.422869205474853,3.711339902722799,,
1987-04-16,3.450925588607788,3.443911552429199,-1.0141998738248776,,
1987-04-15,3.3667566776275635,3.394812822341919,-0.203250867006337,,
1987-04-14,3.268559455871582,3.282587766647339,0.8333285532866503,,
1987-04-13,3.4930100440979004,3.324672222137451,0.42918940178850434,,
1987-04-10,3.4719676971435547,3.478981733322144,-4.8192767794895905,,
1987-04-09,3.450925588607788,3.450925588607788,0.2020190505908184,,
1987-04-08,3.5350944995880127,3.584192991256714,0.0,,
1987-04-07,3.633291482925415,3.507038116455078,1.3888876711619227,,
1987-04-06,3.6543338298797607,3.633291482925415,-3.474903322886761,,
1987-04-03,3.5912070274353027,3.6613478660583496,-0.5758189572691027,,
1987-04-02,3.633291482925415,3.598221063613892,1.953127126539922,,
1987-04-01,3.338700294494629,3.5350944995880127,-0.9652520166998922,,
1987-03-31,3.3737707138061523,3.380784749984741,5.882355041488128,,
1987-03-30,3.2545313835144043,3.38779878616333,0.2078990178522213,,
1987-03-27,3.6613478660583496,3.457939624786377,4.094826165265521,,
1987-03-26,3.7314884662628174,3.6473195552825928,-5.555556279085638,,
1987-03-25,3.738502740859986,3.689404010772705,-2.25563904970399,,
1987-03-24,3.689404010772705,3.752530813217163,-1.3133260422857496,,
1987-03-23,3.5912070274353027,3.703432321548462,1.7110298102385593,,
1987-03-20,3.5491225719451904,3.584192991256714,3.1250020746730947,,
1987-03-19,3.507038116455078,3.528080463409424,0.9881433678494278,,
1987-03-18,3.443911552429199,3.4719676971435547,0.6000033719512394,,
1987-03-17,3.3667566776275635,3.4368972778320312,0.8146592700548819,,
1987-03-16,3.422869205474853,3.3737707138061523,2.083328464767267,,
1987-03-13,3.464953660964966,3.457939624786377,-1.434425001988626,,
1987-03-12,3.507038116455078,3.5000240802764893,-0.20242799370181205,,
1987-03-11,3.507038116455078,3.5000240802764893,-0.19999885788748342,,
1987-03-10,3.4368972778320312,3.4719676971435547,-0.19999885788748342,,
1987-03-09,3.464953660964966,3.4298832416534424,1.020409295841556,,
1987-03-06,3.521066188812256,3.5000240802764893,-1.012146849368155,,
1987-03-05,3.507038116455078,3.528080463409424,-0.5976061626624699,,
1987-03-04,3.457939624786377,3.478981733322144,0.6000033719512394,,
1987-03-03,3.408841133117676,3.4368972778320312,0.6085157874052523,,
1987-03-02,3.394812822341919,3.394812822341919,0.8230405471755069,,
1987-02-27,3.457939624786377,3.380784749984741,0.0,,
1987-02-26,3.478981733322144,3.443911552429199,-2.231238343451476,,
1987-02-25,3.394812822341919,3.4719676971435547,-1.008058782172898,,
1987-02-24,3.324672222137451,3.394812822341919,2.272728390026826,,
1987-02-23,3.422869205474853,3.3106439113616943,2.1096997092655942,,
1987-02-20,3.443911552429199,3.422869205474853,-3.278690694159603,,
1987-02-19,3.4719676971435547,3.4368972778320312,-0.6110013754419363,,
1987-02-18,3.507038116455078,3.457939624786377,-1.0101021199124764,,
1987-02-17,3.352728366851806,3.443911552429199,-1.399998803501173,,
1987-02-13,3.2405033111572266,3.324672222137451,2.719671133483848,,
1987-02-12,3.282587766647339,3.2405033111572266,2.5974024062998655,,
1987-02-11,3.219460964202881,3.268559455871582,-1.2820511889342456,,
1987-02-10,3.282587766647339,3.219460964202881,1.5250531755044174,,
1987-02-09,3.282587766647339,3.275573492050171,-1.9230804149657932,,
1987-02-06,3.317657947540283,3.2966158390045166,-0.21368125076308248,,
1987-02-05,3.289601802825928,3.324672222137451,-0.6342458706861945,,
1987-02-04,3.1072356700897217,3.2545313835144043,1.066099224574713,,
1987-02-03,3.093207597732544,3.0651512145996094,4.74041009642598,,
1987-02-02,3.051123142242432,3.0721654891967773,-0.9070320127721503,,
1987-01-30,3.0721654891967773,3.051123142242432,0.6896590525310664,,
1987-01-29,3.086193561553955,3.0651512145996094,-0.6849353339961779,,
1987-01-28,3.051123142242432,3.0721654891967773,-0.6818220093671149,,
1987-01-27,2.9879965782165527,3.037095069885254,0.6896590525310664,,
1987-01-26,2.931883811950684,2.966954231262207,1.6431910272804466,,
1987-01-23,3.0020246505737305,2.9809823036193848,1.1961735717006272,,
1987-01-22,2.931883811950684,2.959940195083618,-0.7009385132904956,,
1987-01-21,2.9388978481292725,2.917855739593506,0.9569404837454061,,
1987-01-20,2.9459121227264404,2.9388978481292725,-0.7159863875214566,,
1987-01-19,2.8757712841033936,2.9248697757720947,-0.2381019631595888,,
1987-01-16,2.917855739593506,2.889799356460572,1.707315597040224,,
1987-01-15,2.861743211746216,2.8687572479248047,-0.9615411328334652,,
1987-01-14,2.833686828613281,2.84070086479187,0.2450966302566662,,
1987-01-13,2.847714900970459,2.854728937149048,0.2475233363039544,,
1987-01-12,2.7635459899902344,2.84070086479187,0.2463040164659246,,
1987-01-09,2.7635459899902344,2.7635459899902344,2.791879530179571,,
1987-01-08,2.742503881454468,2.78458833694458,0.0,,
1987-01-07,2.721461534500122,2.735489845275879,1.53452674305032,,
1987-01-06,2.728475570678711,2.7074334621429443,0.5154697429274361,,
1987-01-05,2.6934053897857666,2.728475570678711,-0.7712038459091777,,
1987-01-02,2.5741660594940186,2.665349006652832,1.3020758414586011,,
1986-12-31,2.637292623519897,2.5601377487182617,3.5422325153621412,,
1986-12-30,2.6443066596984863,2.62326455116272,-2.9255333334478273,,
1986-12-29,2.6934053897857666,2.6513209342956543,-0.795751448062588,,
1986-12-26,2.6793770790100098,2.6934053897857666,-1.5624998616884664,,
1986-12-24,2.665349006652832,2.6793770790100098,0.5235661260840556,,
1986-12-23,2.7004194259643555,2.665349006652832,0.5263127763817432,,
1986-12-22,2.6934053897857666,2.6934053897857666,-1.2987026746409709,,
1986-12-19,2.672363042831421,2.6934053897857666,0.0,,
1986-12-18,2.6793770790100098,2.665349006652832,0.7874060004980058,,
1986-12-17,2.742503881454468,2.686391115188598,-0.523557227800161,,
1986-12-16,2.728475570678711,2.742503881454468,-2.04604145304294,,
1986-12-15,2.7004194259643555,2.721461534500122,0.5141446354334676,,
1986-12-12,2.742503881454468,2.714447498321533,0.7792163074168446,,
1986-12-11,2.7495179176330566,2.735489845275879,-1.02302072652147,,
1986-12-10,2.7495179176330566,2.742503881454468,-0.51020116170961,,
1986-12-09,2.728475570678711,2.735489845275879,-0.25510058085478887,,
1986-12-08,2.728475570678711,2.728475570678711,0.2570766867970587,,
1986-12-05,2.742503881454468,2.728475570678711,0.0,,
1986-12-04,2.7074334621429443,2.735489845275879,-0.5115147099925875,,
1986-12-03,2.7074334621429443,2.714447498321533,1.0362723045731963,,
1986-12-02,2.637292623519897,2.6934053897857666,0.2590658746249383,,
1986-12-01,2.637292623519897,2.602222204208374,2.127665537204512,,
1986-11-28,2.6513209342956543,2.6443066596984863,-1.329788700683347,,
1986-11-26,2.6793770790100098,2.665349006652832,-0.2645577344649666,,
1986-11-25,2.672363042831421,2.686391115188598,-0.523557227800161,,
1986-11-24,2.672363042831421,2.665349006652832,0.5249313859060958,,
1986-11-21,2.5811800956726074,2.672363042831421,-0.2624656929530562,,
1986-11-20,2.5110392570495605,2.5881941318511963,3.5326069386511714,,
1986-11-19,2.4479126930236816,2.489997148513794,3.0726271835467736,,
1986-11-18,2.546109676361084,2.468954801559448,1.719197568199593,,
1986-11-17,2.5601377487182617,2.546109676361084,-3.0303044490960978,,
1986-11-14,2.5671520233154297,2.5741660594940186,-0.547942092733132,,
1986-11-13,2.6443066596984863,2.5811800956726074,0.2732224704608794,,
1986-11-12,2.6934053897857666,2.6302785873413086,-2.3872633604862163,,
1986-11-11,2.7004194259643555,2.6934053897857666,-2.3437542185017723,,
1986-11-10,2.5320816040039062,2.686391115188598,-0.25973876913894817,,
1986-11-07,2.5110392570495605,2.546109676361084,6.094176070024238,,
1986-11-06,2.5180532932281494,2.5110392570495605,1.3966495829591583,,
1986-11-05,2.504025220870972,2.5110392570495605,-0.27854994957620055,,
1986-11-04,2.4479126930236816,2.5180532932281494,0.2801104445804559,,
1986-11-03,2.426870346069336,2.4479126930236816,2.8653227872203866,,
1986-10-31,2.433884382247925,2.412842273712158,0.8670569067864213,,
1986-10-30,2.4549267292022705,2.433884382247925,-0.8645484021033162,,
1986-10-29,2.3988139629364014,2.4058282375335693,-0.8571476575670925,,
1986-10-28,2.46194076538086,2.412842273712158,0.2924059433346701,,
1986-10-27,2.489997148513794,2.468954801559448,-1.9943002837075217,,
1986-10-24,2.5110392570495605,2.482982873916626,-0.8450751426324205,,
1986-10-23,2.475968837738037,2.5110392570495605,-1.1173215653307016,,
1986-10-22,2.468954801559448,2.468954801559448,1.4164321770528665,,
1986-10-21,2.426870346069336,2.4549267292022705,0.0,,
1986-10-20,2.4408984184265137,2.433884382247925,1.1560726010096047,,
1986-10-17,2.482982873916626,2.468954801559448,-0.287354693896289,,
1986-10-16,2.4408984184265137,2.497011184692383,-0.5649685507113658,,
1986-10-15,2.356729507446289,2.384785890579224,2.29885708648381,,
1986-10-14,2.412842273712158,2.370757818222046,1.1904795626434201,,
1986-10-13,2.468954801559448,2.433884382247925,-1.744185931613564,,
1986-10-10,2.489997148513794,2.468954801559448,-1.420456109175094,,
1986-10-09,2.504025220870972,2.489997148513794,-0.8450751426324205,,
1986-10-08,2.497011184692383,2.497011184692383,-0.560220889160965,,
1986-10-07,2.5320816040039062,2.5320816040039062,0.0,,
1986-10-06,2.497011184692383,2.5320816040039062,0.0,,
1986-10-03,2.468954801559448,2.504025220870972,1.4044958839799473,,
1986-10-02,2.412842273712158,2.468954801559448,1.420456109175148,,
1986-10-01,2.3497154712677,2.412842273712158,2.3255779484068992,,
1986-09-30,2.356729507446289,2.3497154712677,2.686572192096106,,
1986-09-29,2.3286733627319336,2.342701435089112,-0.29761736153544216,,
1986-09-26,2.3988139629364014,2.370757818222046,0.6024061846407384,,
1986-09-25,2.475968837738037,2.384785890579224,-1.1695840172620886,,
1986-09-24,2.5110392570495605,2.475968837738037,-3.6827178827547256,,
1986-09-23,2.497011184692383,2.504025220870972,-1.3966495829591583,,
1986-09-22,2.363743782043457,2.482982873916626,0.2808972671643599,,
1986-09-19,2.3497154712677,2.356729507446289,5.044501556344095,,
1986-09-18,2.370757818222046,2.363743782043457,0.29850576652179545,,
1986-09-17,2.3497154712677,2.3988139629364014,-0.29585629222343157,,
1986-09-16,2.363743782043457,2.3497154712677,2.0895505123525417,,
1986-09-15,2.384785890579224,2.363743782043457,-0.5934784845263288,,
1986-09-12,2.426870346069336,2.370757818222046,-0.8823479130303088,,
1986-09-11,2.5320816040039062,2.4058282375335693,-2.312135377902339,,
1986-09-10,2.637292623519897,2.539095640182495,-4.986149193244648,,
1986-09-09,2.609236478805542,2.6443066596984863,-3.7234011296911764,,
1986-09-08,2.616250514984131,2.609236478805542,1.3440782841192986,,
1986-09-05,2.6934053897857666,2.62326455116272,-0.26809497555441136,,
1986-09-04,2.6934053897857666,2.721461534500122,-2.604169386793476,,
1986-09-03,2.7004194259643555,2.7074334621429443,1.041660673166881,,
1986-09-02,2.78458833694458,2.728475570678711,0.25973876913894817,,
1986-08-29,2.714447498321533,2.78458833694458,-2.0151189143972172,,
1986-08-28,2.735489845275879,2.735489845275879,2.5839821424587566,,
1986-08-27,2.8266727924346924,2.7495179176330566,0.0,,
1986-08-26,2.742503881454468,2.8126444816589355,-2.729529749892986,,
1986-08-25,2.791602373123169,2.742503881454468,2.557538776108085,,
1986-08-22,2.8056304454803467,2.791602373123169,-1.7587924462813331,,
1986-08-21,2.8687572479248047,2.8126444816589355,-0.49999715321652116,,
1986-08-20,2.833686828613281,2.854728937149048,-1.9559956251599842,,
1986-08-19,2.854728937149048,2.861743211746216,0.7425700089118319,,
1986-08-18,2.8687572479248047,2.847714900970459,0.24570720203554466,,
1986-08-15,2.917855739593506,2.8827853202819824,-0.7335004371515669,,
1986-08-14,2.9388978481292725,2.910841703414917,-1.2019243732868434,,
1986-08-13,2.903827667236328,2.9459121227264404,-0.9546485166952754,,
1986-08-12,2.910841703414917,2.917855739593506,1.4492752433261824,,
1986-08-11,2.854728937149048,2.89681339263916,0.24096247385628008,,
1986-08-08,2.889799356460572,2.8687572479248047,1.474201453681311,,
1986-08-07,2.917855739593506,2.903827667236328,-0.7281511946054232,,
1986-08-06,2.903827667236328,2.931883811950684,-0.48076648090669566,,
1986-08-05,2.9248697757720947,2.889799356460572,0.9661780218885339,,
1986-08-04,2.8757712841033936,2.917855739593506,-1.199042077087511,,
1986-08-01,2.8266727924346924,2.889799356460572,1.463414553262478,,
1986-07-31,2.7495179176330566,2.8196587562561035,2.233246246075306,,
1986-07-30,2.728475570678711,2.7635459899902344,2.5510231511212753,,
1986-07-29,2.7635459899902344,2.721461534500122,1.2853484813426288,,
1986-07-28,2.8196587562561035,2.777574300765991,-1.5228425958006588,,
1986-07-25,2.798616409301758,2.8196587562561035,-1.4925371872301083,,
1986-07-24,2.8056304454803467,2.8056304454803467,0.7518839268006605,,
1986-07-23,2.833686828613281,2.791602373123169,0.0,,
1986-07-22,2.8266727924346924,2.8266727924346924,-1.485148431547275,,
1986-07-21,2.8196587562561035,2.833686828613281,0.0,,
1986-07-18,2.798616409301758,2.833686828613281,0.49750957721577393,,
1986-07-17,2.714447498321533,2.777574300765991,1.2531341985618139,,
1986-07-16,2.672363042831421,2.7004194259643555,2.325585684876653,,
1986-07-15,2.7495179176330566,2.6793770790100098,1.0498716934510621,,
1986-07-14,2.861743211746216,2.7495179176330566,-2.5510231511212753,,
1986-07-11,2.8266727924346924,2.861743211746216,-3.9215710778144937,,
1986-07-10,2.903827667236328,2.84070086479187,1.2406961076423813,,
1986-07-09,2.861743211746216,2.861743211746216,-2.173916970235976,,
1986-07-08,2.7495179176330566,2.7495179176330566,0.0,,
1986-07-07,3.0581371784210205,2.8687572479248047,0.0,,
1986-07-03,3.0581371784210205,3.0441091060638428,-6.192656491426477,,
1986-07-02,3.037095069885254,3.0441091060638428,-0.4587129856751788,,
1986-07-01,3.030081033706665,3.051123142242432,0.230945558739255,,
1986-06-30,3.00903868675232,3.016052722930908,0.6944404556080952,,
1986-06-27,2.917855739593506,2.973968267440796,0.2330989032965452,,
1986-06-26,2.910841703414917,2.903827667236328,1.9230740946468867,,
1986-06-25,2.854728937149048,2.910841703414917,-0.24096247385628008,,
1986-06-24,2.8056304454803467,2.847714900970459,1.965607506046009,,
1986-06-23,2.791602373123169,2.7705600261688232,1.4999999575106944,,
1986-06-20,2.728475570678711,2.861743211746216,-0.7537730715855531,,
1986-06-19,2.735489845275879,2.728475570678711,4.884325976734123,,
1986-06-18,2.7705600261688232,2.742503881454468,-0.25641749719091234,,
1986-06-17,2.8056304454803467,2.78458833694458,-1.012652476371412,,
1986-06-16,2.777574300765991,2.791602373123169,-0.7499957298247818,,
1986-06-13,2.721461534500122,2.777574300765991,0.5050476004659574,,
1986-06-12,2.665349006652832,2.728475570678711,2.0618614503466035,,
1986-06-11,2.595208168029785,2.6513209342956543,2.368416438834544,,
1986-06-10,2.602222204208374,2.616250514984131,2.1621682205350217,,
1986-06-09,2.637292623519897,2.595208168029785,0.5390896577959379,,
1986-06-06,2.602222204208374,2.6302785873413086,-1.5957446327644633,,
1986-06-05,2.5811800956726074,2.616250514984131,1.0781701534773294,,
1986-06-04,2.602222204208374,2.5671520233154297,1.3586971079747436,,
1986-06-03,2.5741660594940186,2.5881941318511963,-1.3477012392034786,,
1986-06-02,2.5811800956726074,2.5811800956726074,0.5449559986792426,,
1986-05-30,2.598715305328369,2.595208168029785,0.0,,
1986-05-29,2.5706589221954346,2.5846869945526123,-0.1349565799452137,,
1986-05-28,2.5741660594940186,2.5776729583740234,0.5456994794625364,,
1986-05-27,2.5180532932281494,2.5636448860168457,0.13623436868304462,,
1986-05-23,2.507532358169556,2.5250675678253174,1.8105888747989036,,
1986-05-22,2.409335136413574,2.507532358169556,0.6993014306926669,,
1986-05-21,2.3917999267578125,2.4023211002349854,4.075697908185317,,
1986-05-20,2.384785890579224,2.3988139629364014,0.43988518268059124,,
1986-05-19,2.3812789916992188,2.3917999267578125,0.5882319420201748,,
1986-05-16,2.367250680923462,2.3812789916992188,0.4418186653167542,,
1986-05-15,2.423363447189331,2.370757818222046,0.592599292031227,,
1986-05-14,2.4058282375335693,2.423363447189331,-2.1707692681548982,,
1986-05-13,2.384785890579224,2.3988139629364014,0.7288637394055462,,
1986-05-12,2.409335136413574,2.384785890579224,0.5882319420201748,,
1986-05-09,2.416349172592163,2.412842273712158,-1.0189220031420378,,
1986-05-08,2.426870346069336,2.423363447189331,-0.14513212410617052,,
1986-05-07,2.437391519546509,2.426870346069336,-0.1445029350531563,,
1986-05-06,2.4514195919036865,2.437391519546509,-0.43165709705638006,,
1986-05-05,2.388293027877808,2.4514195919036865,-0.572242809982767,,
1986-05-02,2.412842273712158,2.4023211002349854,2.6431666168691006,,
1986-05-01,2.3988139629364014,2.4058282375335693,-0.43604895321176645,,
1986-04-30,2.472461938858032,2.419856309890747,0.2924059433346701,,
1986-04-29,2.507532358169556,2.482982873916626,-2.1276618313316455,,
1986-04-28,2.5320816040039062,2.5250675678253174,-0.9790296094464248,,
1986-04-25,2.5180532932281494,2.5426025390625,-0.27700671919490183,,
1986-04-24,2.4584336280822754,2.5250675678253174,0.9749295577012352,,
1986-04-23,2.4549267292022705,2.465447902679444,2.7104225626388145,,
1986-04-22,2.556630849838257,2.475968837738037,0.4285738287835644,,
1986-04-21,2.556630849838257,2.5426025390625,-3.1550120779197646,,
1986-04-18,2.5601377487182617,2.556630849838257,-0.5487030236157999,,
1986-04-17,2.5110392570495605,2.546109676361084,-0.1369808668209599,,
1986-04-16,2.4408984184265137,2.5180532932281494,1.3966495829591583,,
1986-04-15,2.3777718544006348,2.426870346069336,3.1609211681726763,,
1986-04-14,2.3777718544006348,2.388293027877808,2.064894980476478,,
1986-04-11,2.384785890579224,2.370757818222046,0.4424803606662831,,
1986-04-10,2.342701435089112,2.374264717102051,-0.588231942020212,,
1986-04-09,2.304124116897583,2.304124116897583,1.3473027992462878,,
1986-04-08,2.297110080718994,2.3181521892547607,0.0,,
1986-04-07,2.3146450519561768,2.290095806121826,0.9160252576655113,,
1986-04-04,2.346208572387696,2.3216593265533447,-1.0606052022362251,,
1986-04-03,2.342701435089112,2.353222608566284,-1.046336891070521,,
1986-04-02,2.3356873989105225,2.3286733627319336,0.4491043254417845,,
1986-04-01,2.412842273712158,2.3391945362091064,-0.3002985837000513,,
1986-03-31,2.3953070640563965,2.419856309890747,-3.0523229100153615,,
1986-03-27,2.363743782043457,2.3988139629364014,1.0248893013648535,,
1986-03-26,2.290095806121826,2.3497154712677,1.4836709951120912,,
1986-03-25,2.2865889072418213,2.2795748710632324,2.6033699108351818,,
1986-03-24,2.2164480686187744,2.2865889072418213,-0.30674670713108154,,
1986-03-21,2.2585325241088867,2.209434032440185,3.1645604341524947,,
1986-03-20,2.244504451751709,2.251518487930298,-2.17391120759147,,
1986-03-19,2.244504451751709,2.244504451751709,0.3124982074824939,,
1986-03-18,2.174363613128662,2.251518487930298,0.0,,
1986-03-17,2.1463072299957275,2.174363613128662,3.54838879457786,,
1986-03-14,2.135786294937134,2.1533215045928955,1.3071932452554997,,
1986-03-13,2.07616662979126,2.125265121459961,0.8210189239124162,,
1986-03-12,2.1042227745056152,2.07616662979126,2.3648627698845703,,
1986-03-11,2.07616662979126,2.1042227745056152,-1.3333257796787596,,
1986-03-10,2.07616662979126,2.07616662979126,1.3513435921651344,,
1986-03-07,2.072659492492676,2.0831806659698486,0.0,,
1986-03-06,2.055124282836914,2.07616662979126,0.5076170743569463,,
1986-03-05,2.006025791168213,2.048110246658325,1.0238965657735835,,
1986-03-04,1.9919975996017456,2.0130398273468018,2.0979020147893683,,
1986-03-03,1.9814765453338623,1.9884905815124512,1.0563380070971504,,
1986-02-28,1.9499131441116333,1.9814765453338623,0.3539802777431847,,
1986-02-27,1.879772424697876,1.9218568801879885,1.6187080597689425,,
1986-02-26,1.8622372150421145,1.869251370429993,2.238805875497216,,
1986-02-25,1.876265406608581,1.85873019695282,0.3766520898208875,,
1986-02-24,1.872758388519287,1.869251370429993,-0.934580448693375,,
1986-02-21,1.879772424697876,1.879772424697876,-0.18726484477621624,,
1986-02-20,1.876265406608581,1.879772424697876,0.0,,
1986-02-19,1.900814652442932,1.872758388519287,0.18691481903053056,,
1986-02-18,1.872758388519287,1.907828688621521,-1.476012607940854,,
1986-02-14,1.8657442331314087,1.869251370429993,1.8726548132011054,,
1986-02-13,1.8867864608764648,1.869251370429993,0.1879752452831079,,
1986-02-12,1.9043216705322263,1.8867864608764648,-0.9293627450732506,,
1986-02-11,1.9148428440094,1.911335825920105,-0.920811327576853,,
1986-02-10,1.932378053665161,1.932378053665161,-0.18314913415828518,,
1986-02-07,1.9288709163665767,1.9218568801879885,0.0,,
1986-02-06,1.9428991079330444,1.9253638982772827,-0.3636342960575389,,
1986-02-05,1.9428991079330444,1.935885071754456,-0.9025280615016892,,
1986-02-04,1.9464061260223389,1.935885071754456,-0.3610087703447615,,
1986-02-03,1.932378053665161,1.9428991079330444,-0.540537461695294,,
1986-01-31,1.8902935981750488,1.9288709163665767,0.5444614860910956,,
1986-01-30,1.907828688621521,1.893800616264344,2.040810921053305,,
1986-01-29,1.85873019695282,1.907828688621521,-0.7352899367140183,,
1986-01-28,1.792096495628357,1.85873019695282,2.641507183193797,,
1986-01-27,1.8166457414627075,1.7885894775390625,3.7181982938424056,,
1986-01-24,1.820152759552002,1.8166457414627075,-1.5443992894869518,,
1986-01-23,1.841194987297058,1.820152759552002,-0.19267712948212232,,
1986-01-22,1.869251370429993,1.8447020053863523,-1.1428571058596524,,
1986-01-21,1.872758388519287,1.869251370429993,-1.3133260422857613,,
1986-01-20,1.8622372150421145,1.869251370429993,-0.18726484477621624,,
1986-01-17,1.9148428440094,1.85873019695282,0.3766520898208875,,
1986-01-16,1.907828688621521,1.907828688621521,-2.930404823149266,,
1986-01-15,1.911335825920105,1.9218568801879885,0.0,,
1986-01-14,1.893800616264344,1.911335825920105,0.550455557061447,,
1986-01-13,1.869251370429993,1.893800616264344,0.9259269167601444,,
1986-01-10,1.8482091426849363,1.872758388519287,1.3133196649043435,,
1986-01-09,1.8447020053863523,1.8447020053863523,1.328272069831207,,
1986-01-08,1.9709553718566888,1.879772424697876,0.0,,
1986-01-07,1.9148428440094,1.977969527244568,-4.626332410201465,,
1986-01-06,1.9148428440094,1.9183498620986936,3.2967030914657207,,
1986-01-03,1.900814652442932,1.9183498620986936,0.18314913415820402,,
1986-01-02,1.911335825920105,1.907828688621521,0.9225102317695953,,
1985-12-31,1.8867864608764648,1.9183498620986936,-0.18349142264916582,,
1985-12-30,1.837687969207764,1.869251370429993,1.672865577356682,,
1985-12-27,1.8271669149398804,1.837687969207764,1.7175604210891218,,
1985-12-26,1.8271669149398804,1.8306739330291748,0.5758124329998444,,
1985-12-24,1.837687969207764,1.8271669149398804,0.19193747766661073,,
1985-12-23,1.872758388519287,1.8447020053863523,-0.5725158157518548,,
1985-12-20,1.8657442331314087,1.869251370429993,-1.4981314890874853,,
1985-12-19,1.8447020053863523,1.8657442331314087,0.1879752452831079,,
1985-12-18,1.9604343175888064,1.85873019695282,1.1406843860751001,,
1985-12-17,1.9639413356781008,1.956927299499512,-5.1878361709702725,,
1985-12-16,1.9148428440094,1.967448353767395,-0.3571408193904678,,
1985-12-13,1.8552231788635247,1.8973076343536377,2.7472494634518787,,
1985-12-12,1.8166457414627075,1.851716160774231,2.268430880423407,,
1985-12-11,1.7780683040618896,1.813138723373413,1.9305040333998091,,
1985-12-10,1.753519058227539,1.7780683040618896,1.972388756461559,,
1985-12-09,1.7184486389160156,1.7289698123931885,1.399998803501173,,
1985-12-06,1.7114346027374268,1.7184486389160156,0.6122483523167459,,
1985-12-05,1.764040231704712,1.732476830482483,0.40983372472252044,,
1985-12-04,1.7149416208267212,1.753519058227539,-1.789267651323754,,
1985-12-03,1.725462794303894,1.7219557762145996,2.2494898329087647,,
1985-12-02,1.7500120401382446,1.7184486389160156,-0.203250867006337,,
1985-11-29,1.764040231704712,1.7465050220489502,-1.803610518001671,,
1985-11-27,1.7429980039596558,1.764040231704712,-0.9940368332085179,,
1985-11-26,1.7465050220489502,1.7465050220489502,1.2072433644360734,,
1985-11-25,1.7359838485717771,1.725462794303894,0.0,,
1985-11-22,1.7570260763168335,1.7429980039596558,-0.6060571517724043,,
1985-11-21,1.7675472497940063,1.760533094406128,-0.798398643381781,,
1985-11-20,1.7465050220489502,1.764040231704712,-0.39682986628481143,,
1985-11-19,1.732476830482483,1.7465050220489502,1.0040171333254977,,
1985-11-18,1.7394908666610718,1.732476830482483,0.8097188556663427,,
1985-11-15,1.7219557762145996,1.7394908666610718,-0.40322351286915414,,
1985-11-14,1.7184486389160156,1.725462794303894,1.0183240875686026,,
1985-11-13,1.7219557762145996,1.7184486389160156,0.40816788055434083,,
1985-11-12,1.6974064111709597,1.7184486389160156,-0.20367174041448238,,
1985-11-11,1.676364183425903,1.7079275846481323,1.2396693924668225,,
1985-11-08,1.6798713207244873,1.6728571653366089,1.8828486992441378,,
1985-11-07,1.6798713207244873,1.6798713207244873,-0.417541230768401,,
1985-11-06,1.6518149375915527,1.6728571653366089,0.0,,
1985-11-05,1.634279727935791,1.6483079195022583,1.2738853043511646,,
1985-11-04,1.6518149375915527,1.634279727935791,0.8583715092755797,,
1985-11-01,1.627265691757202,1.6588289737701416,-1.061572289770495,,
1985-10-31,1.6307727098464966,1.634279727935791,1.9396514148132802,,
1985-10-30,1.6132375001907349,1.6377867460250854,0.21505253724932316,,
1985-10-29,1.5851812362670898,1.606223464012146,1.5217378613780117,,
1985-10-28,1.5711530447006226,1.5851812362670898,1.3274335617678679,,
1985-10-25,1.5851812362670898,1.5816742181777954,0.8928596494010108,,
1985-10-24,1.6167445182800293,1.5921952724456787,-0.22123767358949042,,
1985-10-23,1.6167445182800293,1.6097304821014404,-1.5184369303114915,,
1985-10-22,1.606223464012146,1.6132375001907349,-0.43383701625602145,,
1985-10-21,1.6027164459228516,1.5992094278335571,0.43667872719706624,,
1985-10-18,1.5886882543563845,1.6097304821014404,-0.21881712752220972,,
1985-10-17,1.5816742181777954,1.5921952724456787,1.3245032615653496,,
1985-10-16,1.5711530447006226,1.578167200088501,0.6651846598349643,,
1985-10-15,1.5711530447006226,1.5711530447006226,0.4464336183885218,,
1985-10-14,1.5536178350448608,1.574660062789917,0.0,,
1985-10-11,1.532575607299805,1.5571249723434448,1.3544017885485047,,
1985-10-10,1.5290685892105105,1.5290685892105105,1.6018371248184382,,
1985-10-09,1.5010123252868652,1.5115333795547483,0.0,,
1985-10-08,1.5045193433761597,1.5045193433761597,0.7009305713643859,,
1985-10-07,1.5430967807769775,1.5290685892105105,0.0,,
1985-10-04,1.5851812362670898,1.546603798866272,-0.9090934373800982,,
1985-10-03,1.5851812362670898,1.5816742181777954,-2.4336294499462454,,
1985-10-02,1.6237586736679075,1.5921952724456787,-0.22123767358949042,,
1985-10-01,1.5851812362670898,1.6132375001907349,-1.9438480442989865,,
1985-09-30,1.5921952724456787,1.5921952724456787,1.769908908946849,,
1985-09-26,1.578167200088501,1.578167200088501,0.0,,
1985-09-25,1.5711530447006226,1.5851812362670898,0.0,,
1985-09-24,1.6027164459228516,1.578167200088501,0.8928596494010108,,
1985-09-23,1.5851812362670898,1.606223464012146,-1.5317273306080676,,
1985-09-20,1.5711530447006226,1.5606319904327393,1.3274335617678679,,
1985-09-19,1.5290685892105105,1.567646026611328,-0.6696390465187335,,
1985-09-18,1.5150405168533323,1.539589762687683,2.5229370136192353,,
1985-09-17,1.539589762687683,1.5220545530319214,1.620368931475076,,
1985-09-16,1.532575607299805,1.539589762687683,-1.1389533810065262,,
1985-09-13,1.5641390085220337,1.5430967807769775,0.45767108353213376,,
1985-09-12,1.5711530447006226,1.5641390085220337,-1.3452914114672652,,
1985-09-11,1.574660062789917,1.5711530447006226,-0.44642603101248907,,
1985-09-10,1.606223464012146,1.578167200088501,-0.22271588466407444,,
1985-09-09,1.5921952724456787,1.6097304821014404,-1.7467223305008863,,
1985-09-06,1.5851812362670898,1.5851812362670898,1.101322806267783,,
1985-09-05,1.606223464012146,1.5851812362670898,0.0,,
1985-09-04,1.6097304821014404,1.5957022905349731,-1.3100436033038199,,
1985-09-03,1.6237586736679075,1.6167445182800293,-0.871462131235412,,
1985-08-30,1.6412938833236694,1.6237586736679075,-0.43197031071334785,,
1985-08-29,1.634279727935791,1.6412938833236694,-1.0683772013000266,,
1985-08-28,1.6202516555786133,1.6412938833236694,0.42918940178850434,,
1985-08-27,1.6097304821014404,1.6167445182800293,1.2987012031499328,,
1985-08-26,1.5992094278335571,1.6097304821014404,0.43572736284600366,,
1985-08-23,1.5886882543563845,1.6027164459228516,0.6578909606689933,,
1985-08-22,1.606223464012146,1.5886882543563845,0.8830046755869179,,
1985-08-21,1.5606319904327393,1.5992094278335571,-1.091704239705273,,
1985-08-20,1.5536178350448608,1.5571249723434448,2.4719112280993896,,
1985-08-19,1.546603798866272,1.5536178350448608,0.22574002560177328,,
1985-08-16,1.5571249723434448,1.5430967807769775,0.45351215248083976,,
1985-08-15,1.5816742181777954,1.5571249723434448,-0.9009033838404833,,
1985-08-14,1.5536178350448608,1.5711530447006226,-1.5521050765203164,,
1985-08-13,1.5571249723434448,1.5571249723434448,1.1286694359591585,,
1985-08-12,1.546603798866272,1.5536178350448608,0.0,,
1985-08-09,1.578167200088501,1.5536178350448608,0.45351215248083976,,
1985-08-08,1.546603798866272,1.5501108169555664,-1.555561732765923,,
1985-08-07,1.5150405168533323,1.532575607299805,0.22675607624041988,,
1985-08-06,1.5571249723434448,1.518547534942627,1.1574007593468305,,
1985-08-05,1.5641390085220337,1.5571249723434448,-2.477478563763545,,
1985-08-02,1.5921952724456787,1.5711530447006226,-0.44842793002243975,,
1985-08-01,1.5851812362670898,1.5921952724456787,-1.321585870100871,,
1985-07-31,1.536082744598389,1.5571249723434448,0.44247534717898085,,
1985-07-30,1.508026361465454,1.5220545530319214,1.36986290738898,,
1985-07-29,1.5536178350448608,1.5010123252868652,0.9302351686236516,,
1985-07-26,1.5957022905349731,1.5536178350448608,-3.386000634865048,,
1985-07-25,1.6167445182800293,1.5886882543563845,-2.6373626045246272,,
1985-07-24,1.66584312915802,1.6132375001907349,-1.7353554384394885,,
1985-07-23,1.6693501472473145,1.6728571653366089,-3.157898126570539,,
1985-07-22,1.676364183425903,1.6728571653366089,0.21008283343535525,,
1985-07-19,1.6623361110687256,1.6728571653366089,-0.20920383076469046,,
1985-07-18,1.6588289737701416,1.6623361110687256,0.6329077614225233,,
1985-07-17,1.6728571653366089,1.66584312915802,0.21142247658075672,,
1985-07-16,1.6307727098464966,1.66584312915802,-0.41928482143766993,,
1985-07-15,1.6623361110687256,1.6377867460250854,2.1505399924692505,,
1985-07-12,1.66584312915802,1.6623361110687256,-1.4767991190335874,,
1985-07-11,1.6553219556808472,1.6553219556808472,-0.2105251105526973,,
1985-07-10,1.5851812362670898,1.6553219556808472,0.0,,
1985-07-09,1.5816742181777954,1.5816742181777954,4.424776032482584,,
1985-07-08,1.6237586736679075,1.5992094278335571,0.0,,
1985-07-05,1.6132375001907349,1.6202516555786133,-1.5118777335856248,,
1985-07-03,1.6027164459228516,1.5992094278335571,0.4347875242826382,,
1985-07-02,1.6237586736679075,1.6097304821014404,-0.21881712752220972,,
1985-07-01,1.5957022905349731,1.627265691757202,-0.8639332798622588,,
1985-06-28,1.5992094278335571,1.6097304821014404,1.97802568871709,,
1985-06-27,1.6167445182800293,1.5992094278335571,0.6578909606689933,,
1985-06-26,1.6167445182800293,1.6202516555786133,-1.0845925406400538,,
1985-06-25,1.627265691757202,1.6237586736679075,0.2169258815434269,,
1985-06-24,1.5921952724456787,1.6202516555786133,-0.2155160098967847,,
1985-06-21,1.5921952724456787,1.6027164459228516,1.7621194848693895,,
1985-06-20,1.5921952724456787,1.578167200088501,0.660796678601607,,
1985-06-19,1.5816742181777954,1.5957022905349731,-0.8810522553323517,,
1985-06-18,1.567646026611328,1.5816742181777954,0.8869128797799525,,
1985-06-17,1.5571249723434448,1.5711530447006226,0.8948570868891417,,
1985-06-14,1.5290685892105105,1.546603798866272,0.9008957281101041,,
1985-06-13,1.5501108169555664,1.5220545530319214,1.1467902603908229,,
1985-06-12,1.578167200088501,1.546603798866272,-1.8099521412764417,,
1985-06-11,1.5851812362670898,1.5816742181777954,-2.0000036257539113,,
1985-06-10,1.5886882543563845,1.5816742181777954,-0.22123767358949042,,
1985-06-07,1.5957022905349731,1.5851812362670898,-0.4414985859784456,,
1985-06-06,1.5886882543563845,1.5957022905349731,-0.6593369158075235,,
1985-06-05,1.5921952724456787,1.5886882543563845,0.4414985859784177,,
1985-06-04,1.536082744598389,1.5711530447006226,-0.220263063833074,,
1985-06-03,1.5290685892105105,1.536082744598389,2.283099671912716,,
1985-05-31,1.5010123252868652,1.518547534942627,0.45872078187806936,,
1985-05-30,1.486984133720398,1.5045193433761597,1.1682255608667627,,
1985-05-29,1.508026361465454,1.4904911518096924,1.1792465876477816,,
1985-05-28,1.5220545530319214,1.5115333795547483,-1.162791984532786,,
1985-05-24,1.5150405168533323,1.518547534942627,-0.6912481196035303,,
1985-05-23,1.5115333795547483,1.508026361465454,0.23148015186937484,,
1985-05-22,1.5115333795547483,1.5045193433761597,-0.23201724399412685,,
1985-05-21,1.518547534942627,1.508026361465454,-0.46403448798826835,,
1985-05-20,1.518547534942627,1.518547534942627,-0.6928445264356086,,
1985-05-17,1.4729560613632202,1.5010123252868652,0.0,,
1985-05-16,1.458927869796753,1.4694489240646362,1.9047590528721514,,
1985-05-15,1.4659419059753418,1.4624348878860474,0.7211497213600434,,
1985-05-14,1.4939982891082764,1.4694489240646362,-0.23923308795522108,,
1985-05-13,1.4904911518096924,1.4904911518096924,-1.6431990064923658,,
1985-05-10,1.479970097541809,1.4904911518096924,0.0,,
1985-05-09,1.451913833618164,1.4694489240646362,0.7108964083367962,,
1985-05-08,1.44840669631958,1.451913833618164,1.2077225273606482,,
1985-05-07,1.4448996782302856,1.458927869796753,0.24213760592902983,,
1985-05-06,1.4413926601409912,1.4413926601409912,0.9708765098244763,,
1985-05-03,1.427364468574524,1.4378856420516968,0.0,,
1985-05-02,1.4098293781280518,1.4238574504852295,0.7371049026938512,,
1985-05-01,1.427364468574524,1.4028152227401731,0.9950191544315794,,
1985-04-30,1.3958011865615845,1.430871605873108,-1.7199003040104799,,
1985-04-29,1.427364468574524,1.399308204650879,2.512565517866902,,
1985-04-26,1.4343786239624023,1.4238574504852295,-1.9655991543396176,,
1985-04-25,1.430871605873108,1.4378856420516968,-0.7335004371515669,,
1985-04-24,1.4378856420516968,1.430871605873108,0.4901932605133324,,
1985-04-23,1.4238574504852295,1.4343786239624023,-0.48780208755549204,,
1985-04-22,1.44840669631958,1.420350432395935,0.7389204216747535,,
1985-04-19,1.4343786239624023,1.4448996782302856,-1.9370432348135607,,
1985-04-18,1.4448996782302856,1.430871605873108,0.7334921262852755,,
1985-04-17,1.4448996782302856,1.4448996782302856,-0.970868259473857,,
1985-04-16,1.427364468574524,1.4378856420516968,0.0,,
1985-04-15,1.427364468574524,1.4238574504852295,0.7371049026938512,,
1985-04-12,1.4238574504852295,1.427364468574524,-0.24569885032915328,,
1985-04-11,1.458927869796753,1.4238574504852295,0.2463040164659246,,
1985-04-10,1.458927869796753,1.4554208517074585,-2.403848746573687,,
1985-04-09,1.458927869796753,1.4624348878860474,-0.24038324045334783,,
1985-04-08,1.4659419059753418,1.4729560613632202,0.24038324045334783,,
1985-04-04,1.4554208517074585,1.4624348878860474,0.4784743078349792,,
1985-04-03,1.4834771156311035,1.458927869796753,0.48192494771256017,,
1985-04-02,1.5045193433761597,1.486984133720398,-1.65484492990691,,
1985-04-01,1.4904911518096924,1.5115333795547483,-1.1655024398963523,,
1985-03-29,1.4694489240646362,1.486984133720398,1.411764687063545,,
1985-03-28,1.4764630794525146,1.4659419059753418,1.1933187583858071,,
1985-03-27,1.4624348878860474,1.4764630794525146,-0.7125930626774761,,
1985-03-26,1.427364468574524,1.44840669631958,0.9592352919551218,,
1985-03-25,1.4238574504852295,1.420350432395935,1.474201453681311,,
1985-03-22,1.4413926601409912,1.4238574504852295,-0.2463040164659246,,
1985-03-21,1.458927869796753,1.4343786239624023,-1.2165463402627912,,
1985-03-20,1.4448996782302856,1.458927869796753,-1.682690854193539,,
1985-03-19,1.399308204650879,1.4378856420516968,0.9708765098244763,,
1985-03-18,1.3747589588165283,1.3887871503829956,2.756893533004244,,
1985-03-15,1.3887871503829956,1.3817729949951172,1.0204109947058326,,
1985-03-14,1.3887871503829956,1.39229416847229,-0.5050561841635758,,
1985-03-13,1.3958011865615845,1.3852800130844116,0.2525238002329787,,
1985-03-12,1.371251940727234,1.39229416847229,-0.7537730715855531,,
1985-03-11,1.3677449226379397,1.3642377853393557,1.53452674305032,,
1985-03-08,1.3782659769058228,1.3677449226379397,-0.2564174971909123,,
1985-03-07,1.3747589588165283,1.3642377853393557,-0.7633544210024409,,
1985-03-06,1.3958011865615845,1.371251940727234,-0.7653104138510115,,
1985-03-05,1.3852800130844116,1.399308204650879,-1.7587924462813331,,
1985-03-04,1.3887871503829956,1.3852800130844116,1.0126610818005415,,
1985-03-01,1.343195557594299,1.360730767250061,-0.252532383930597,,
1985-02-28,1.332674503326416,1.343195557594299,1.3054844885854144,,
1985-02-27,1.332674503326416,1.3361815214157104,0.7894691645725982,,
1985-02-26,1.3291674852371216,1.3396885395050049,0.2631563881908716,,
1985-02-25,1.3291674852371216,1.332674503326416,0.7915521847125504,,
1985-02-22,1.343195557594299,1.3361815214157104,0.2638507282375168,,
1985-02-21,1.3502097129821775,1.3502097129821775,-0.5221902454137788,,
1985-02-20,1.360730767250061,1.360730767250061,0.0,,
1985-02-19,1.360730767250061,1.3572237491607666,0.0,,
1985-02-15,1.360730767250061,1.3642377853393557,-0.2577304911229328,,
1985-02-14,1.3537167310714722,1.3642377853393557,0.2577304911229491,,
1985-02-13,1.294097065925598,1.3361815214157104,0.7771976238748314,,
1985-02-12,1.301111102104187,1.294097065925598,3.252032370540287,,
1985-02-11,1.332674503326416,1.3081252574920654,-0.5390804956814086,,
1985-02-08,1.3291674852371216,1.3291674852371216,-1.842103662452801,,
1985-02-07,1.3361815214157104,1.3291674852371216,0.0,,
1985-02-06,1.3396885395050049,1.3361815214157104,-0.5249313859061124,,
1985-02-05,1.3291674852371216,1.332674503326416,-0.2617786139000805,,
1985-02-04,1.304618239402771,1.3221533298492432,0.2638507282375168,,
1985-02-01,1.3186463117599487,1.3081252574920654,1.3440782841192986,,
1985-01-31,1.3151392936706543,1.3256604671478271,-0.7978677962433487,,
1985-01-30,1.3186463117599487,1.31163227558136,0.8000044959349859,,
1985-01-29,1.273054838180542,1.301111102104187,-0.5319118641622157,,
1985-01-28,1.2695478200912476,1.2835760116577148,2.2038535247816355,,
1985-01-25,1.2625337839126587,1.2695478200912476,1.1049754364872229,,
1985-01-24,1.2625337839126587,1.2590266466140747,0.5555523557438597,,
1985-01-23,1.2485055923461914,1.2555196285247805,-0.27778561993922896,,
1985-01-22,1.2695478200912476,1.2485055923461914,0.5617945343287021,,
1985-01-21,1.2309703826904297,1.2590266466140747,-1.657458459780094,,
1985-01-18,1.2379844188690186,1.2309703826904297,2.2791989407839996,,
1985-01-17,1.234477400779724,1.241491436958313,-0.5665690190993403,,
1985-01-16,1.202914118766785,1.2309703826904297,0.5681785810059273,,
1985-01-15,1.199406981468201,1.199406981468201,2.3323580200727707,,
1985-01-14,1.153815507888794,1.1923929452896118,0.0,,
1985-01-11,1.1643366813659668,1.1573225259780884,3.343466709977347,,
1985-01-10,1.1222522258758545,1.1678436994552612,-0.6024164230271961,,
1985-01-09,1.1292662620544434,1.1222522258758545,4.062497941924345,,
1985-01-08,1.1362802982330322,1.1327732801437378,-0.6211144717835121,,
1985-01-07,1.1292662620544434,1.1397874355316162,-0.3086402267774956,,
1985-01-04,1.1222522258758545,1.125759243965149,0.9316822640244267,,
1985-01-03,1.1397874355316162,1.125759243965149,0.3124982074824939,,
1985-01-02,1.1643366813659668,1.1397874355316162,-1.2307726098002034,,
1984-12-31,1.1573225259780884,1.1713507175445557,-2.1084318846289465,,
1984-12-28,1.1678436994552612,1.1503084897994995,1.212124645600554,,
1984-12-27,1.1643366813659668,1.1608296632766724,-1.5015031261410228,,
1984-12-26,1.1608296632766724,1.1713507175445557,-0.30120309232035014,,
1984-12-24,1.1608296632766724,1.1678436994552612,0.9063391986543086,,
1984-12-21,1.1783647537231443,1.1573225259780884,0.6042261324362057,,
1984-12-20,1.1818718910217283,1.1783647537231443,-1.7857142857142672,,
1984-12-19,1.1888859272003174,1.1888859272003174,-0.2967442855039106,,
1984-12-18,1.1573225259780884,1.1678436994552612,0.0,,
1984-12-17,1.1573225259780884,1.1608296632766724,0.9090960593099221,,
1984-12-14,1.1327732801437378,1.1397874355316162,0.30303888672865814,,
1984-12-13,1.1292662620544434,1.1222522258758545,0.6192020513573899,,
1984-12-12,1.115238070487976,1.11874520778656,-0.6211144717835121,,
1984-12-11,1.097702980041504,1.115238070487976,0.31447431641653206,,
1984-12-10,1.09419584274292,1.09419584274292,1.5974348949849047,,
1984-12-07,1.1047170162200928,1.1012099981307983,0.0,,
1984-12-06,1.1047170162200928,1.1047170162200928,-0.31745850184276786,,
1984-12-05,1.11874520778656,1.1047170162200928,0.0,,
1984-12-04,1.11874520778656,1.1222522258758545,-1.253921935828632,,
1984-12-03,1.153815507888794,1.1222522258758545,0.31347782005100844,,
1984-11-30,1.153815507888794,1.1573225259780884,-2.735557097052084,,
1984-11-29,1.1573225259780884,1.1573225259780884,0.303949640589546,,
1984-11-28,1.1783647537231443,1.1608296632766724,0.0,,
1984-11-27,1.1643366813659668,1.1783647537231443,-1.4880868076771923,,
1984-11-26,1.17485773563385,1.1608296632766724,1.2048123692813815,,
1984-11-23,1.1573225259780884,1.17485773563385,-1.1940230660871818,,
1984-11-21,1.1503084897994995,1.1397874355316162,1.515153231891186,,
1984-11-20,1.1713507175445557,1.153815507888794,-0.9146289331235951,,
1984-11-19,1.1713507175445557,1.1643366813659668,-1.4970076334199809,,
1984-11-16,1.185378909111023,1.1678436994552612,-0.5987989825363358,,
1984-11-15,1.1958999633789062,1.1888859272003174,-1.4792915177571602,,
1984-11-14,1.185378909111023,1.1888859272003174,-0.5865069314636776,,
1984-11-13,1.206421136856079,1.185378909111023,0.29585629222343157,,
1984-11-12,1.206421136856079,1.202914118766785,-1.744185931613564,,
1984-11-09,1.2204492092132568,1.206421136856079,-0.2906960083966586,,
1984-11-08,1.1958999633789062,1.199406981468201,-1.149418775585156,,
1984-11-07,1.199406981468201,1.1923929452896118,0.2932534657318574,,
1984-11-06,1.17485773563385,1.202914118766785,-0.5847920086310626,,
1984-11-05,1.1608296632766724,1.1678436994552612,2.38806642557433,,
1984-11-02,1.1503084897994995,1.146801471710205,0.6042261324362057,,
1984-11-01,1.153815507888794,1.1362802982330322,-0.3048763110411984,,
1984-10-31,1.1678436994552612,1.153815507888794,-1.5197585346939002,,
1984-10-30,1.1573225259780884,1.1678436994552612,-1.2012045424409714,,
1984-10-29,1.125759243965149,1.146801471710205,0.9090960593099221,,
1984-10-26,1.1397874355316162,1.1327732801437378,1.8691587795398616,,
1984-10-25,1.153815507888794,1.146801471710205,-0.6153915343527977,,
1984-10-24,1.1573225259780884,1.1503084897994995,-0.607899281179092,,
1984-10-23,1.1783647537231443,1.1643366813659668,-0.606057172581264,,
1984-10-22,1.185378909111023,1.1713507175445557,-1.19046944614175,,
1984-10-19,1.1888859272003174,1.185378909111023,-1.1834352255337286,,
1984-10-18,1.1432944536209106,1.1888859272003174,-0.29498356478598725,,
1984-10-17,1.115238070487976,1.1432944536209106,3.9877280463501483,,
1984-10-16,1.1292662620544434,1.1117310523986816,2.515730396529452,,
1984-10-15,1.1117310523986816,1.125759243965149,-1.5527967358079386,,
1984-10-12,1.087181806564331,1.1047170162200928,1.2618332047305798,,
1984-10-11,1.066139578819275,1.0801677703857422,1.6129049943519376,,
1984-10-10,1.0766607522964478,1.066139578819275,1.315793151775041,,
1984-10-09,1.0801677703857422,1.0801677703857422,-0.9772041429699995,,
1984-10-08,1.0836747884750366,1.0801677703857422,0.0,,
1984-10-05,1.1012099981307983,1.087181806564331,-0.3236227442579486,,
1984-10-04,1.1222522258758545,1.1047170162200928,-1.2738888668173043,,
1984-10-03,1.1362802982330322,1.125759243965149,-1.5625016597384318,,
1984-10-02,1.1432944536209106,1.1362802982330322,-0.9259206803324868,,
1984-10-01,1.1503084897994995,1.1432944536209106,-0.6135038410852071,,
1984-09-28,1.1783647537231443,1.1678436994552612,-0.6097526220823968,,
1984-09-27,1.199406981468201,1.1783647537231443,-0.8928520846063078,,
1984-09-26,1.2099281549453735,1.199406981468201,-1.7543859649123175,,
1984-09-25,1.213435173034668,1.202914118766785,-0.8695701008501323,,
1984-09-24,1.213435173034668,1.213435173034668,-0.8670470826695322,,
1984-09-21,1.234477400779724,1.2204492092132568,0.0,,
1984-09-20,1.2590266466140747,1.2520126104354858,-1.1363668186721392,,
1984-09-19,1.2835760116577148,1.2590266466140747,-0.5570998991524011,,
1984-09-18,1.332674503326416,1.2870830297470093,-1.9125758677848055,,
1984-09-17,1.301111102104187,1.3361815214157104,-3.4210509367147304,,
1984-09-14,1.3151392936706543,1.3081252574920654,2.6954208026360504,,
1984-09-13,1.2905900478363037,1.3151392936706543,-0.5333302876999558,,
1984-09-12,1.3151392936706543,1.2976040840148926,1.9021722564425332,,
1984-09-11,1.31163227558136,1.31163227558136,-1.3333347836349418,,
1984-09-10,1.2625337839126587,1.2905900478363037,0.0,,
1984-09-07,1.3081252574920654,1.2765618562698364,2.222218865042738,,
1984-09-06,1.294097065925598,1.304618239402771,-2.41287300596445,,
1984-09-05,1.301111102104187,1.2905900478363037,0.8130126985217948,,
1984-09-04,1.3186463117599487,1.3081252574920654,-0.8086207435220873,,
1984-08-31,1.3221533298492432,1.3256604671478271,-0.7978677962433487,,
1984-08-30,1.3396885395050049,1.3186463117599487,0.2652594989859369,,
1984-08-29,1.3361815214157104,1.3467026948928833,-1.5706805816843774,,
1984-08-28,1.301111102104187,1.3361815214157104,0.7874060004980058,,
1984-08-27,1.3151392936706543,1.301111102104187,2.6954208026360504,,
1984-08-24,1.3151392936706543,1.3186463117599487,-1.0666696397849638,,
1984-08-23,1.304618239402771,1.3081252574920654,0.2666651438499779,,
1984-08-22,1.3256604671478271,1.301111102104187,0.2688156568238597,,
1984-08-21,1.3186463117599487,1.332674503326416,-1.8518591790293304,,
1984-08-20,1.2835760116577148,1.3081252574920654,1.0638327686022475,,
1984-08-17,1.2905900478363037,1.2835760116577148,1.9125665805054808,,
1984-08-16,1.2835760116577148,1.2835760116577148,-0.5434751484677894,,
1984-08-15,1.301111102104187,1.2800688743591309,0.0,,
1984-08-14,1.2976040840148926,1.304618239402771,-1.6172506491587209,,
1984-08-13,1.31163227558136,1.3081252574920654,0.5405466485721939,,
1984-08-10,1.343195557594299,1.3186463117599487,-0.2673781481734449,,
1984-08-09,1.2905900478363037,1.3221533298492432,-1.8276747339991766,,
1984-08-08,1.3221533298492432,1.2870830297470093,2.4456474049103227,,
1984-08-07,1.2976040840148926,1.3256604671478271,-2.6525138431737516,,
1984-08-06,1.3256604671478271,1.3186463117599487,2.1621682205350217,,
1984-08-03,1.301111102104187,1.294097065925598,-0.5291064764848461,,
1984-08-02,1.2555196285247805,1.2835760116577148,-0.5390804956814086,,
1984-08-01,1.2274633646011353,1.2379844188690186,2.2346431306613854,,
1984-07-31,1.213435173034668,1.2204492092132568,0.8571379457261539,,
1984-07-30,1.213435173034668,1.2204492092132568,0.578031388446367,,
1984-07-27,1.2204492092132568,1.2169421911239624,0.578031388446367,,
1984-07-26,1.1818718910217283,1.2204492092132568,-0.287354693896289,,
1984-07-25,1.1503084897994995,1.1818718910217283,3.264086275728112,,
1984-07-24,1.1292662620544434,1.153815507888794,2.7439075258612,,
1984-07-23,1.1222522258758545,1.1432944536209106,2.173911207591451,,
1984-07-20,1.1222522258758545,1.1222522258758545,1.8749998672209254,,
1984-07-19,1.1362802982330322,1.125759243965149,0.0,,
1984-07-18,1.1783647537231443,1.1397874355316162,-0.9259206803324868,,
1984-07-17,1.1713507175445557,1.17485773563385,-3.2738010933914783,,
1984-07-16,1.17485773563385,1.1783647537231443,0.2993994912681679,,
1984-07-13,1.185378909111023,1.17485773563385,0.29850576652177657,,
1984-07-12,1.206421136856079,1.1818718910217283,-0.8875789333102969,,
1984-07-11,1.2169421911239624,1.2099281549453735,-2.0348819400102593,,
1984-07-10,1.213435173034668,1.2239563465118408,-0.5763656014022108,,
1984-07-09,1.1888859272003174,1.2169421911239624,0.8670569067864213,,
1984-07-06,1.202914118766785,1.202914118766785,2.359878545262465,,
1984-07-05,1.2099281549453735,1.2099281549453735,0.0,,
1984-07-03,1.199406981468201,1.213435173034668,0.0,,
1984-07-02,1.2204492092132568,1.2099281549453735,1.1695939562812179,,
1984-06-29,1.244998574256897,1.2239563465118408,-0.8620640816888668,,
1984-06-28,1.2309703826904297,1.2485055923461914,-1.690140710210503,,
1984-06-27,1.2309703826904297,1.234477400779724,1.4245029695545126,,
1984-06-26,1.2309703826904297,1.2520126104354858,0.2848986570764776,,
1984-06-25,1.2520126104354858,1.2520126104354858,1.7094016266310081,,
1984-06-22,1.2379844188690186,1.2555196285247805,0.0,,
1984-06-21,1.2485055923461914,1.2590266466140747,1.4164321770528847,,
1984-06-20,1.2204492092132568,1.2555196285247805,0.8426918014930264,,
1984-06-19,1.234477400779724,1.2379844188690186,2.8735664742764055,,
1984-06-18,1.202914118766785,1.2274633646011353,0.28408929050297266,,
1984-06-15,1.213435173034668,1.1958999633789062,2.0408145063188714,,
1984-06-14,1.202914118766785,1.206421136856079,-1.4450882952327884,,
1984-06-13,1.2099281549453735,1.202914118766785,0.2915435137538805,,
1984-06-12,1.2099281549453735,1.2099281549453735,-0.5797068321718093,,
1984-06-11,1.2274633646011353,1.2169421911239624,0.0,,
1984-06-08,1.2204492092132568,1.2239563465118408,-0.8571476575670925,,
1984-06-07,1.2099281549453735,1.234477400779724,0.28736446155303785,,
1984-06-06,1.1783647537231443,1.2099281549453735,2.0289837651937876,,
1984-06-05,1.17485773563385,1.1923929452896118,2.6785764868222643,,
1984-06-04,1.1643366813659668,1.17485773563385,1.4925389793089507,,
1984-06-01,1.1082240343093872,1.1432944536209106,0.9036092769610503,,
1984-05-31,1.0906888246536257,1.1082240343093872,3.1645604341524947,,
1984-05-30,1.1047170162200928,1.1012099981307983,1.6077188341349535,,
1984-05-29,1.1292662620544434,1.1047170162200928,-0.31745850184276786,,
1984-05-25,1.1292662620544434,1.125759243965149,-2.173911207591451,,
1984-05-24,1.153815507888794,1.125759243965149,-0.31055723589175604,,
1984-05-23,1.1608296632766724,1.1608296632766724,-2.431607456462538,,
1984-05-22,1.1643366813659668,1.1643366813659668,0.0,,
1984-05-21,1.1818718910217283,1.1713507175445557,0.0,,
1984-05-18,1.199406981468201,1.1818718910217283,-0.8902126835487283,,
1984-05-17,1.1923929452896118,1.206421136856079,-1.4619800215776473,,
1984-05-16,1.2099281549453735,1.199406981468201,1.1764738815240203,,
1984-05-15,1.213435173034668,1.206421136856079,-0.8695701008501323,,
1984-05-14,1.199406981468201,1.2099281549453735,-0.578031388446367,,
1984-05-11,1.206421136856079,1.206421136856079,0.8771979519656957,,
1984-05-10,1.213435173034668,1.206421136856079,0.0,,
1984-05-09,1.2309703826904297,1.2169421911239624,-0.578031388446367,,
1984-05-08,1.2204492092132568,1.2274633646011353,-1.1396043124780169,,
1984-05-07,1.199406981468201,1.2204492092132568,0.5747191554493268,,
1984-05-04,1.2309703826904297,1.199406981468201,1.754385964912262,,
1984-05-03,1.234477400779724,1.2274633646011353,-2.5641072820325115,,
1984-05-02,1.2239563465118408,1.2379844188690186,-0.5681785810058914,,
1984-05-01,1.241491436958313,1.2204492092132568,1.1461252190207933,,
1984-04-30,1.241491436958313,1.241491436958313,-1.694915254237288,,
1984-04-27,1.234477400779724,1.234477400779724,0.0,,
1984-04-26,1.2099281549453735,1.2379844188690186,0.0,,
1984-04-25,1.206421136856079,1.213435173034668,2.3188371812797195,,
1984-04-24,1.2204492092132568,1.2099281549453735,0.581392016793354,,
1984-04-23,1.2204492092132568,1.2239563465118408,-0.8620640816888668,,
1984-04-19,1.213435173034668,1.2204492092132568,0.28736446155303785,,
1984-04-18,1.241491436958313,1.2274633646011353,0.578031388446367,,
1984-04-17,1.206421136856079,1.2309703826904297,-1.1299371014226955,,
1984-04-16,1.1783647537231443,1.202914118766785,2.034881940010241,,
1984-04-13,1.1643366813659668,1.1818718910217283,2.0833417637513985,,
1984-04-12,1.17485773563385,1.1713507175445557,1.506025699988227,,
1984-04-11,1.1678436994552612,1.1678436994552612,-0.29850576652179545,,
1984-04-10,1.153815507888794,1.17485773563385,0.0,,
1984-04-09,1.1292662620544434,1.146801471710205,1.8237081752834463,,
1984-04-06,1.1222522258758545,1.1362802982330322,1.5527967358079386,,
1984-04-05,1.1432944536209106,1.1222522258758545,1.2499928299299756,,
1984-04-04,1.1678436994552612,1.1503084897994995,-1.8404906696095333,,
1984-04-03,1.1643366813659668,1.1608296632766724,-1.5015031261410228,,
1984-04-02,1.1678436994552612,1.1573225259780884,-0.30120309232035014,,
1984-03-30,1.1362802982330322,1.153815507888794,-0.90090595874092,,
1984-03-29,1.1362802982330322,1.1292662620544434,1.5432116250743562,,
1984-03-28,1.1117310523986816,1.125759243965149,-0.6172804535549912,,
1984-03-27,1.1047170162200928,1.1082240343093872,1.2618332047305798,,
1984-03-26,1.125759243965149,1.0906888246536257,0.31745850184276786,,
1984-03-23,1.1432944536209106,1.125759243965149,-3.1152681623113474,,
1984-03-22,1.1678436994552612,1.1432944536209106,-1.5337439624784517,,
1984-03-21,1.1573225259780884,1.1678436994552612,-2.1021002935411257,,
1984-03-20,1.153815507888794,1.1608296632766724,0.9090960593099221,,
1984-03-19,1.1608296632766724,1.1503084897994995,0.6079096129252625,,
1984-03-16,1.199406981468201,1.1643366813659668,-0.9063494679723079,,
1984-03-15,1.1783647537231443,1.1713507175445557,-2.923969982174387,,
1984-03-14,1.1643366813659668,1.1783647537231443,-0.5952347230708656,,
1984-03-13,1.1678436994552612,1.1678436994552612,1.2048123692813815,,
1984-03-12,1.125759243965149,1.1643366813659668,0.0,,
1984-03-09,1.1362802982330322,1.1327732801437378,3.4267928606955453,,
1984-03-08,1.1432944536209106,1.146801471710205,-0.3086402267774956,,
1984-03-07,1.1292662620544434,1.1432944536209106,0.30674670713108154,,
1984-03-06,1.1327732801437378,1.1292662620544434,1.2422394999161825,,
1984-03-05,1.125759243965149,1.125759243965149,-0.30959576384512066,,
1984-03-02,1.185378909111023,1.1327732801437378,0.0,,
1984-03-01,1.1783647537231443,1.1783647537231443,-4.43787455327148,,
1984-02-29,1.1958999633789062,1.185378909111023,0.0,,
1984-02-28,1.2204492092132568,1.185378909111023,-0.8797603971955164,,
1984-02-27,1.1923929452896118,1.2204492092132568,-2.8735567066196386,,
1984-02-24,1.1783647537231443,1.1923929452896118,2.3529377655644073,,
1984-02-23,1.1818718910217283,1.1643366813659668,1.1904795626434204,,
1984-02-22,1.199406981468201,1.185378909111023,-1.483681081593565,,
1984-02-21,1.2520126104354858,1.2204492092132568,-1.1695840172621068,,
1984-02-17,1.2765618562698364,1.2625337839126587,-2.5210130440499596,,
1984-02-16,1.2905900478363037,1.2765618562698364,-1.0988948391555666,,
1984-02-15,1.2765618562698364,1.2835760116577148,-1.0869595337408489,,
1984-02-14,1.2485055923461914,1.273054838180542,0.5494567578866921,,
1984-02-13,1.2485055923461914,1.2485055923461914,1.9662904183086316,,
1984-02-10,1.241491436958313,1.2485055923461914,0.0,,
1984-02-09,1.2274633646011353,1.2379844188690186,0.5649781528145925,,
1984-02-08,1.2660408020019531,1.2309703826904297,0.8571379457261539,,
1984-02-07,1.2590266466140747,1.2590266466140747,-2.770086023773295,,
1984-02-06,1.2625337839126587,1.2800688743591309,0.0,,
1984-02-03,1.2905900478363037,1.2800688743591309,1.3888808893596494,,
1984-02-02,1.241491436958313,1.2835760116577148,-0.8152219595069541,,
1984-02-01,1.2555196285247805,1.241491436958313,3.3898401105778206,,
1984-01-31,1.2274633646011353,1.2239563465118408,-1.1173215653307191,,
1984-01-30,1.2379844188690186,1.2239563465118408,-0.28571264857538464,,
1984-01-27,1.2274633646011353,1.2309703826904297,-1.1331380381986806,,
1984-01-26,1.2520126104354858,1.234477400779724,0.28571264857538464,,
1984-01-25,1.2660408020019531,1.2485055923461914,-1.4005617443152345,,
1984-01-24,1.273054838180542,1.2555196285247805,-1.3850430118866475,,
1984-01-23,1.301111102104187,1.2660408020019531,-1.3774119645013037,,
1984-01-20,1.3081252574920654,1.2976040840148926,-2.695411640521504,,
1984-01-19,1.301111102104187,1.3081252574920654,-0.804294039650608,,
1984-01-18,1.2800688743591309,1.3081252574920654,0.5390896577959379,,
1984-01-17,1.2765618562698364,1.2765618562698364,2.19178699638182,,
1984-01-16,1.2555196285247805,1.2765618562698364,0.0,,
1984-01-13,1.2625337839126587,1.2520126104354858,1.6759776005875975,,
1984-01-12,1.2835760116577148,1.273054838180542,-0.8333379756830888,,
1984-01-11,1.3186463117599487,1.2905900478363037,-0.8196766986619631,,
1984-01-10,1.3256604671478271,1.31163227558136,-2.127656496926712,,
1984-01-09,1.31163227558136,1.3256604671478271,-1.058203960524588,,
1984-01-06,1.3467026948928833,1.343195557594299,1.069521681314932,,
1984-01-05,1.3396885395050049,1.3467026948928833,-0.26042402022988187,,
1984-01-04,1.294097065925598,1.332674503326416,0.5235661260840556,,
1984-01-03,1.2765618562698364,1.2905900478363037,2.981031208290835,,
1983-12-30,1.2765618562698364,1.2695478200912476,1.0989041774644754,,
1983-12-29,1.2520126104354858,1.273054838180542,-0.5494474195777833,,
1983-12-28,1.2695478200912476,1.2590266466140747,1.6806721888956906,,
1983-12-27,1.2485055923461914,1.2695478200912476,-0.8287339248407872,,
1983-12-23,1.2800688743591309,1.2765618562698364,1.6853931511442894,,
1983-12-22,1.2870830297470093,1.2800688743591309,-0.273971046366566,,
1983-12-21,1.2905900478363037,1.2870830297470093,-0.5449652606527746,,
1983-12-20,1.2870830297470093,1.2870830297470093,-0.2717375742338947,,
1983-12-19,1.2695478200912476,1.2835760116577148,0.0,,
1983-12-16,1.2169421911239624,1.2520126104354858,1.1049754364872229,,
1983-12-15,1.2485055923461914,1.2169421911239624,2.8818475986219654,,
1983-12-14,1.2660408020019531,1.2485055923461914,-2.5280945007955524,,
1983-12-13,1.2625337839126587,1.2660408020019531,-1.3850430118866475,,
1983-12-12,1.241491436958313,1.241491436958313,0.2777761778719299,,
1983-12-09,1.2520126104354858,1.2485055923461914,0.0,,
1983-12-08,1.2695478200912476,1.2590266466140747,-0.2801104445804737,,
1983-12-07,1.2520126104354858,1.2660408020019531,-0.8287339248407872,,
1983-12-06,1.241491436958313,1.2485055923461914,1.1204512997347431,,
1983-12-05,1.2169421911239624,1.2274633646011353,0.5649781528145925,,
1983-12-02,1.206421136856079,1.2204492092132568,0.8645581979087719,,
1983-12-01,1.2555196285247805,1.185378909111023,1.162784033586708,,
1983-11-30,1.2625337839126587,1.2590266466140747,-5.586588837019776,,
1983-11-29,1.2590266466140747,1.2660408020019531,-0.27778561993922896,,
1983-11-28,1.2590266466140747,1.2555196285247805,0.5571093675214679,,
1983-11-25,1.2695478200912476,1.2625337839126587,-0.2785499495761829,,
1983-11-23,1.2800688743591309,1.2695478200912476,-0.5524830232928714,,
1983-11-22,1.3186463117599487,1.2765618562698364,-0.8219131390996979,,
1983-11-21,1.31163227558136,1.3151392936706543,-3.19148926552896,,
1983-11-18,1.343195557594299,1.3151392936706543,0.267378148173411,,
1983-11-17,1.3747589588165283,1.343195557594299,-2.088769856706074,,
1983-11-16,1.4133363962173462,1.3817729949951172,-2.2959225702664865,,
1983-11-15,1.399308204650879,1.4063222408294678,-2.233254680676539,,
1983-11-14,1.3817729949951172,1.39229416847229,0.5012502717611692,,
1983-11-11,1.3782659769058228,1.3817729949951172,0.7614256115354194,,
1983-11-10,1.3887871503829956,1.3782659769058228,0.25445147366748566,,
1983-11-09,1.3958011865615845,1.3887871503829956,-0.7575799843965545,,
1983-11-08,1.3782659769058228,1.39229416847229,-0.5025096873478979,,
1983-11-07,1.39229416847229,1.3782659769058228,1.0178145438923387,,
1983-11-04,1.4028152227401731,1.39229416847229,-1.0075594571986086,,
1983-11-03,1.4168434143066406,1.4028152227401731,-0.749995729824766,,
1983-11-02,1.427364468574524,1.4378856420516968,-0.9901017589394289,,
1983-11-01,1.430871605873108,1.427364468574524,0.7371049026938512,,
1983-10-31,1.427364468574524,1.420350432395935,-0.2451049614926109,,
1983-10-28,1.4238574504852295,1.420350432395935,-0.49139770065830657,,
1983-10-27,1.44840669631958,1.430871605873108,-0.2463040164659246,,
1983-10-26,1.451913833618164,1.4378856420516968,-1.2106468777746648,,
1983-10-25,1.4378856420516968,1.4448996782302856,-0.9661862323819232,,
1983-10-24,1.4343786239624023,1.4378856420516968,0.48780208755549204,,
1983-10-21,1.44840669631958,1.4378856420516968,0.24449737542842515,,
1983-10-20,1.4448996782302856,1.44840669631958,-0.7263881266647989,,
1983-10-19,1.44840669631958,1.4413926601409912,0.24271706486846426,,
1983-10-18,1.4729560613632202,1.44840669631958,-0.484258751109866,,
1983-10-17,1.4659419059753418,1.4729560613632202,-1.6666732761138652,,
1983-10-14,1.4448996782302856,1.4554208517074585,0.4784743078349792,,
1983-10-13,1.44840669631958,1.4378856420516968,0.7281594449560119,,
1983-10-12,1.4448996782302856,1.44840669631958,-0.7263881266647989,,
1983-10-11,1.4834771156311035,1.44840669631958,0.24271706486846426,,
1983-10-10,1.4624348878860474,1.486984133720398,-2.3640687774683813,,
1983-10-07,1.458927869796753,1.4624348878860474,1.6786556473523804,,
1983-10-06,1.4098293781280518,1.451913833618164,0.24038324045334783,,
1983-10-05,1.3887871503829956,1.4028152227401731,2.9850743744602166,,
1983-10-04,1.39229416847229,1.3887871503829956,1.0100952009318989,,
1983-10-03,1.3537167310714722,1.3747589588165283,-0.2518877237805677,,
1983-09-30,1.3677449226379397,1.3572237491607666,1.554404053823073,,
1983-09-29,1.4098293781280518,1.3642377853393557,-0.7692350600637666,,
1983-09-28,1.4168434143066406,1.4063222408294678,-3.2338376186508353,,
1983-09-27,1.4238574504852295,1.4098293781280518,-0.7425784226354745,,
1983-09-26,1.427364468574524,1.427364468574524,-0.9852160658636984,,
1983-09-23,1.4133363962173462,1.4168434143066406,0.0,,
1983-09-22,1.3852800130844116,1.427364468574524,0.24813753460822333,,
1983-09-21,1.3958011865615845,1.3852800130844116,3.037974639972511,,
1983-09-20,1.3642377853393557,1.3958011865615845,-0.7537730715855531,,
1983-09-19,1.3256604671478271,1.3537167310714722,2.3136290140488485,,
1983-09-16,1.3151392936706543,1.3151392936706543,2.1163989286041227,,
1983-09-15,1.332674503326416,1.31163227558136,0.0,,
1983-09-14,1.3221533298492432,1.3291674852371216,-1.5789472742619128,,
1983-09-13,1.343195557594299,1.3221533298492432,0.5305099816734719,,
1983-09-12,1.3747589588165283,1.343195557594299,-1.5665796112922787,,
1983-09-09,1.3502097129821775,1.360730767250061,-2.2959225702664865,,
1983-09-08,1.371251940727234,1.3502097129821775,0.7792163074168612,,
1983-09-07,1.371251940727234,1.3677449226379397,-1.5345267430503686,,
1983-09-06,1.3502097129821775,1.371251940727234,-0.25575300826444125,,
1983-09-02,1.332674503326416,1.3396885395050049,1.558441443779952,,
1983-09-01,1.3186463117599487,1.3361815214157104,0.5263127763817432,,
1983-08-31,1.301111102104187,1.3186463117599487,1.3297887006833635,,
1983-08-30,1.3081252574920654,1.3081252574920654,1.3477104013180252,,
1983-08-29,1.31163227558136,1.3081252574920654,0.0,,
1983-08-26,1.3221533298492432,1.3186463117599487,-0.2673781481734449,,
1983-08-25,1.3502097129821775,1.3291674852371216,-0.2652504826875349,,
1983-08-24,1.3396885395050049,1.3467026948928833,-1.558441443779903,,
1983-08-23,1.3361815214157104,1.3467026948928833,0.5235661260840556,,
1983-08-22,1.3467026948928833,1.343195557594299,0.7874060004980058,,
1983-08-19,1.343195557594299,1.3396885395050049,-0.26042402022988187,,
1983-08-18,1.332674503326416,1.3361815214157104,-0.2610951227068811,,
1983-08-17,1.3256604671478271,1.332674503326416,0.2631563881908716,,
1983-08-16,1.332674503326416,1.3256604671478271,0.5290974840397589,,
1983-08-15,1.3467026948928833,1.3396885395050049,-0.5263127763817432,,
1983-08-12,1.3291674852371216,1.3151392936706543,-0.5208391885215856,,
1983-08-11,1.3467026948928833,1.3361815214157104,-1.0554118816685225,,
1983-08-10,1.304618239402771,1.332674503326416,-0.7812543568133058,,
1983-08-09,1.31163227558136,1.301111102104187,2.1505343920753885,,
1983-08-08,1.332674503326416,1.3186463117599487,-0.8021435331415379,,
1983-08-05,1.3291674852371216,1.3396885395050049,-1.0526344978801863,,
1983-08-04,1.332674503326416,1.3291674852371216,0.7915521847125504,,
1983-08-03,1.3396885395050049,1.332674503326416,-0.2631563881908716,,
1983-08-02,1.3467026948928833,1.3291674852371216,-0.523557227800161,,
1983-08-01,1.3572237491607666,1.343195557594299,-1.3020846933967463,,
1983-07-29,1.3502097129821775,1.3642377853393557,-1.0335946136472913,,
1983-07-28,1.3887871503829956,1.3537167310714722,1.0389550765558258,,
1983-07-27,1.4133363962173462,1.3887871503829956,-2.525255169725024,,
1983-07-26,1.4028152227401731,1.420350432395935,-1.7369711768588278,,
1983-07-25,1.3887871503829956,1.3958011865615845,1.2500013809024497,,
1983-07-22,1.3870335817337036,1.3887871503829956,0.5050476004659574,,
1983-07-21,1.3817729949951172,1.39229416847229,0.12642582504023753,,
1983-07-20,1.3677449226379397,1.3747589588165283,0.7614256115354194,,
1983-07-19,1.3291674852371216,1.3572237491607666,0.5128175628728219,,
1983-07-18,1.3221533298492432,1.3221533298492432,2.1108147946185896,,
1983-07-15,1.332674503326416,1.3256604671478271,0.0,,
1983-07-14,1.2905900478363037,1.304618239402771,-0.5263127763817432,,
1983-07-13,1.2625337839126587,1.2590266466140747,1.0869595337408489,,
1983-07-12,1.2976040840148926,1.273054838180542,-0.27778561993922896,,
1983-07-11,1.332674503326416,1.2976040840148926,-1.8918903028104859,,
1983-07-08,1.3467026948928833,1.3291674852371216,-2.6315817721421157,,
1983-07-07,1.3467026948928833,1.3396885395050049,-1.3020846933967463,,
1983-07-06,1.343195557594299,1.3537167310714722,-0.5208391885215856,,
1983-07-05,1.360730767250061,1.3396885395050049,0.7832942431716191,,
1983-07-01,1.3467026948928833,1.3642377853393557,-1.546391707419167,,
1983-06-30,1.3361815214157104,1.3502097129821775,1.3020758414586175,,
1983-06-29,1.3361815214157104,1.3291674852371216,1.0498716934510455,,
1983-06-28,1.3361815214157104,1.3361815214157104,-0.5249313859061124,,
1983-06-27,1.3572237491607666,1.332674503326416,0.0,,
1983-06-24,1.2835760116577148,1.3572237491607666,-1.808783986393585,,
1983-06-23,1.2976040840148926,1.2765618562698364,5.737699741516441,,
1983-06-22,1.301111102104187,1.2976040840148926,-1.6216215719628275,,
1983-06-21,1.304618239402771,1.2976040840148926,-0.26954024784069575,,
1983-06-20,1.3396885395050049,1.3256604671478271,-0.5376404511322302,,
1983-06-17,1.31163227558136,1.332674503326416,-1.047114455600322,,
1983-06-16,1.31163227558136,1.31163227558136,1.6042779776617877,,
1983-06-15,1.213435173034668,1.2625337839126587,0.0,,
1983-06-14,1.202914118766785,1.213435173034668,4.046249191475181,,
1983-06-13,1.199406981468201,1.185378909111023,0.8746305412616784,,
1983-06-10,1.234477400779724,1.199406981468201,-1.1695840172621068,,
1983-06-09,1.2274633646011353,1.2379844188690186,-2.840912218350188,,
1983-06-08,1.2309703826904297,1.2274633646011353,0.8571379457261539,,
1983-06-07,1.2204492092132568,1.2379844188690186,-0.28489865707649564,,
1983-06-06,1.206421136856079,1.213435173034668,1.436783237138194,,
1983-06-03,1.1888859272003174,1.202914118766785,0.581392016793354,,
1983-06-02,1.206421136856079,1.1888859272003174,1.1799442861185347,,
1983-06-01,1.213435173034668,1.199406981468201,-1.453489923216887,,
1983-05-31,1.2169421911239624,1.2169421911239624,-1.1560726010095865,,
1983-05-27,1.2274633646011353,1.2274633646011353,0.0,,
1983-05-26,1.2309703826904297,1.234477400779724,0.0,,
1983-05-25,1.2309703826904297,1.2309703826904297,0.2848986570764776,,
1983-05-24,1.234477400779724,1.2309703826904297,0.0,,
1983-05-23,1.206421136856079,1.234477400779724,-0.2840892905029367,,
1983-05-20,1.2485055923461914,1.2485055923461914,2.3255779484068992,,
1983-05-19,1.2765618562698364,1.2520126104354858,0.0,,
1983-05-18,1.2765618562698364,1.2765618562698364,-1.9230753068311506,,
1983-05-17,1.2625337839126587,1.2695478200912476,0.0,,
1983-05-16,1.2625337839126587,1.2590266466140747,0.5555523557438597,,
1983-05-13,1.2765618562698364,1.273054838180542,-0.27778561993922896,,
1983-05-12,1.273054838180542,1.273054838180542,-0.27472370978889166,,
1983-05-11,1.2660408020019531,1.2765618562698364,0.0,,
1983-05-10,1.2765618562698364,1.2765618562698364,0.8310201575847056,,
1983-05-09,1.2870830297470093,1.2765618562698364,0.0,,
1983-05-06,1.2625337839126587,1.2800688743591309,-0.817443259992396,,
1983-05-05,1.2625337839126587,1.2590266466140747,1.3888808893596494,,
1983-05-04,1.2660408020019531,1.2555196285247805,-0.27778561993922896,,
1983-05-03,1.2625337839126587,1.2695478200912476,-0.8310295734968263,,
1983-05-02,1.2800688743591309,1.2695478200912476,0.5555523557438597,,
1983-04-29,1.31163227558136,1.304618239402771,-0.8219131390996979,,
1983-04-28,1.31163227558136,1.3151392936706543,-0.5347562963468727,,
1983-04-27,1.3186463117599487,1.3081252574920654,0.267378148173411,,
1983-04-26,1.3081252574920654,1.3256604671478271,-0.7978677962433487,,
1983-04-25,1.304618239402771,1.304618239402771,1.3404839907594308,,
1983-04-22,1.2870830297470093,1.301111102104187,0.0,,
1983-04-21,1.2835760116577148,1.2835760116577148,1.0899119973584852,,
1983-04-20,1.2520126104354858,1.2835760116577148,0.0,,
1983-04-19,1.2520126104354858,1.2485055923461914,2.5210130440499596,,
1983-04-18,1.2590266466140747,1.2520126104354858,-0.2801104445804737,,
1983-04-15,1.2555196285247805,1.2590266466140747,-0.5570998991524011,,
1983-04-14,1.2485055923461914,1.2485055923461914,0.27932801762843906,,
1983-04-13,1.2099281549453735,1.2239563465118408,0.0,,
1983-04-12,1.202914118766785,1.206421136856079,1.1594235169360645,,
1983-04-11,1.1923929452896118,1.1958999633789062,0.2915435137538805,,
1983-04-08,1.199406981468201,1.1923929452896118,0.2941159710100968,,
1983-04-07,1.1888859272003174,1.199406981468201,-0.5847920086310626,,
1983-04-06,1.202914118766785,1.1888859272003174,0.8849506943579805,,
1983-04-05,0.0,1.202914118766785,-1.1661839650572114,,
1983-04-04,0.0,1.199406981468201,inf,,
1983-03-31,0.0,1.206421136856079,inf,,
1983-03-30,0.0,1.206421136856079,inf,,
1983-03-29,0.0,1.213435173034668,inf,,
1983-03-28,0.0,1.206421136856079,inf,,
1983-03-25,0.0,1.2274633646011353,inf,,
1983-03-24,0.0,1.2274633646011353,inf,,
1983-03-23,0.0,1.2204492092132568,inf,,
1983-03-22,0.0,1.1888859272003174,inf,,
1983-03-21,0.0,1.1958999633789062,inf,,
1983-03-18,0.0,1.185378909111023,inf,,
1983-03-17,0.0,1.1923929452896118,inf,,
1983-03-16,0.0,1.1923929452896118,inf,,
1983-03-15,0.0,1.1888859272003174,inf,,
1983-03-14,0.0,1.206421136856079,inf,,
1983-03-11,0.0,1.206421136856079,inf,,
1983-03-10,0.0,1.206421136856079,inf,,
1983-03-09,0.0,1.244998574256897,inf,,
1983-03-08,0.0,1.2309703826904297,inf,,
1983-03-07,0.0,1.234477400779724,inf,,
1983-03-04,0.0,1.234477400779724,inf,,
1983-03-03,0.0,1.199406981468201,inf,,
1983-03-02,0.0,1.1713507175445557,inf,,
1983-03-01,0.0,1.1327732801437378,inf,,
1983-02-28,0.0,1.125759243965149,inf,,
1983-02-25,0.0,1.1292662620544434,inf,,
1983-02-24,0.0,1.1362802982330322,inf,,
1983-02-23,0.0,1.115238070487976,inf,,
1983-02-22,0.0,1.097702980041504,inf,,
1983-02-18,0.0,1.097702980041504,inf,,
1983-02-17,0.0,1.0836747884750366,inf,,
1983-02-16,0.0,1.0906888246536257,inf,,
1983-02-15,0.0,1.0836747884750366,inf,,
1983-02-14,0.0,1.097702980041504,inf,,
1983-02-11,0.0,1.059125542640686,inf,,
1983-02-10,0.0,1.0450973510742188,inf,,
1983-02-09,0.0,1.027562141418457,inf,,
1983-02-08,0.0,1.0486043691635132,inf,,
1983-02-07,0.0,1.0731536149978638,inf,,
1983-02-04,0.0,1.115238070487976,inf,,
1983-02-03,0.0,1.115238070487976,inf,,
1983-02-02,0.0,1.11874520778656,inf,,
1983-02-01,0.0,1.097702980041504,inf,,
1983-01-31,0.0,1.1327732801437378,inf,,
1983-01-28,0.0,1.1503084897994995,inf,,
1983-01-27,0.0,1.1678436994552612,inf,,
1983-01-26,0.0,1.1362802982330322,inf,,
1983-01-25,0.0,1.115238070487976,inf,,
1983-01-24,0.0,1.1012099981307983,inf,,
1983-01-21,0.0,1.115238070487976,inf,,
1983-01-20,0.0,1.1573225259780884,inf,,
1983-01-19,0.0,1.1362802982330322,inf,,
1983-01-18,0.0,1.1222522258758545,inf,,
1983-01-17,0.0,1.1327732801437378,inf,,
1983-01-14,0.0,1.1432944536209106,inf,,
1983-01-13,0.0,1.1503084897994995,inf,,
1983-01-12,0.0,1.146801471710205,inf,,
1983-01-11,0.0,1.1292662620544434,inf,,
1983-01-10,0.0,1.125759243965149,inf,,
1983-01-07,0.0,1.09419584274292,inf,,
1983-01-06,0.0,1.0906888246536257,inf,,
1983-01-05,0.0,1.0696465969085691,inf,,
1983-01-04,0.0,1.0626325607299805,inf,,
1983-01-03,0.0,1.03808331489563,inf,,
1982-12-31,0.0,1.087181806564331,inf,,
1982-12-30,0.0,1.0836747884750366,inf,,
1982-12-29,0.0,1.09419584274292,inf,,
1982-12-28,0.0,1.097702980041504,inf,,
1982-12-27,0.0,1.1047170162200928,inf,,
1982-12-23,0.0,1.1082240343093872,inf,,
1982-12-22,0.0,1.09419584274292,inf,,
1982-12-21,0.0,1.087181806564331,inf,,
1982-12-20,0.0,1.0766607522964478,inf,,
1982-12-17,0.0,1.087181806564331,inf,,
1982-12-16,0.0,1.0836747884750366,inf,,
1982-12-15,0.0,1.09419584274292,inf,,
1982-12-14,0.0,1.125759243965149,inf,,
1982-12-13,0.0,1.11874520778656,inf,,
1982-12-10,0.0,1.087181806564331,inf,,
1982-12-09,0.0,1.0696465969085691,inf,,
1982-12-08,0.0,1.0626325607299805,inf,,
1982-12-07,0.0,1.066139578819275,inf,,
1982-12-06,0.0,1.059125542640686,inf,,
1982-12-03,0.0,1.0556185245513916,inf,,
1982-12-02,0.0,1.0801677703857422,inf,,
1982-12-01,0.0,1.097702980041504,inf,,
1982-11-30,0.0,1.0731536149978638,inf,,
1982-11-29,0.0,1.0450973510742188,inf,,
1982-11-26,0.0,1.0345762968063354,inf,,
1982-11-24,0.0,1.0170410871505735,inf,,
1982-11-23,0.0,0.9644354581832886,inf,,
1982-11-22,0.0,1.0030128955841064,inf,,
1982-11-19,0.0,1.0450973510742188,inf,,
1982-11-18,0.0,1.0521113872528076,inf,,
1982-11-17,0.0,1.0556185245513916,inf,,
1982-11-16,0.0,1.03808331489563,inf,,
1982-11-15,0.0,1.0731536149978638,inf,,
1982-11-12,0.0,1.0836747884750366,inf,,
1982-11-11,0.0,1.087181806564331,inf,,
1982-11-10,0.0,1.066139578819275,inf,,
1982-11-09,0.0,1.1117310523986816,inf,,
1982-11-08,0.0,1.115238070487976,inf,,
1982-11-05,0.0,1.11874520778656,inf,,
1982-11-04,0.0,1.11874520778656,inf,,
1982-11-03,0.0,1.1012099981307983,inf,,
1982-11-02,0.0,1.087181806564331,inf,,
1982-11-01,0.0,1.0626325607299805,inf,,
1982-10-29,0.0,1.0450973510742188,inf,,
1982-10-28,0.0,1.0415903329849243,inf,,
1982-10-27,0.0,1.0415903329849243,inf,,
1982-10-26,0.0,1.0415903329849243,inf,,
1982-10-25,0.0,1.0345762968063354,inf,,
1982-10-22,0.0,1.0521113872528076,inf,,
1982-10-21,0.0,1.0836747884750366,inf,,
1982-10-20,0.0,1.0801677703857422,inf,,
1982-10-19,0.0,1.059125542640686,inf,,
1982-10-18,0.0,1.0801677703857422,inf,,
1982-10-15,0.0,1.0626325607299805,inf,,
1982-10-14,0.0,1.03808331489563,inf,,
1982-10-13,0.0,1.0731536149978638,inf,,
1982-10-12,0.0,1.0801677703857422,inf,,
1982-10-11,0.0,1.0731536149978638,inf,,
1982-10-08,0.0,1.066139578819275,inf,,
1982-10-07,0.0,1.0486043691635132,inf,,
1982-10-06,0.0,1.0240551233291626,inf,,
1982-10-05,0.0,0.9924917817115784,inf,,
1982-10-04,0.0,0.988984763622284,inf,,
1982-10-01,0.0,0.9854776859283448,inf,,
1982-09-30,0.0,0.978463649749756,inf,,
1982-09-29,0.0,0.988984763622284,inf,,
1982-09-28,0.0,1.0240551233291626,inf,,
1982-09-27,0.0,1.027562141418457,inf,,
1982-09-24,0.0,1.0345762968063354,inf,,
1982-09-23,0.0,1.03808331489563,inf,,
1982-09-22,0.0,1.0310691595077517,inf,,
1982-09-21,0.0,1.03808331489563,inf,,
1982-09-20,0.0,1.0065199136734009,inf,,
1982-09-17,0.0,0.9959987998008728,inf,,
1982-09-16,0.0,1.0240551233291626,inf,,
1982-09-15,0.0,1.0521113872528076,inf,,
1982-09-14,0.0,1.0170410871505735,inf,,
1982-09-13,0.0,1.0030128955841064,inf,,
1982-09-10,0.0,0.9749565720558168,inf,,
1982-09-09,0.0,0.999505877494812,inf,,
1982-09-08,0.0,1.0240551233291626,inf,,
1982-09-07,0.0,1.0030128955841064,inf,,
1982-09-03,0.0,1.0170410871505735,inf,,
1982-09-02,0.0,0.9959987998008728,inf,,
1982-09-01,0.0,0.9749565720558168,inf,,
1982-08-31,0.0,0.9819706678390504,inf,,
1982-08-30,0.0,0.9539143443107604,inf,,
1982-08-27,0.0,0.92936509847641,inf,,
1982-08-26,0.0,0.9363791942596436,inf,,
1982-08-25,0.0,0.9258580803871156,inf,,
1982-08-24,0.0,0.9048158526420592,inf,,
1982-08-23,0.0,0.8872806429862976,inf,,
1982-08-20,0.0,0.8837736248970032,inf,,
1982-08-19,0.0,0.862731397151947,inf,,
1982-08-18,0.0,0.8487032055854797,inf,,
1982-08-17,0.0,0.8487032055854797,inf,,
1982-08-16,0.0,0.8171398639678955,inf,,
1982-08-13,0.0,0.8136328458786011,inf,,
1982-08-12,0.0,0.803111732006073,inf,,
1982-08-11,0.0,0.8066187500953674,inf,,
1982-08-10,0.0,0.8136328458786011,inf,,
1982-08-09,0.0,0.803111732006073,inf,,
1982-08-06,0.0,0.8136328458786011,inf,,
1982-08-05,0.0,0.8311680555343628,inf,,
1982-08-04,0.0,0.8241539597511292,inf,,
1982-08-03,0.0,0.852210283279419,inf,,
1982-08-02,0.0,0.8732525110244751,inf,,
1982-07-30,0.0,0.8451961874961853,inf,,
1982-07-29,0.0,0.8416891694068909,inf,,
1982-07-28,0.0,0.852210283279419,inf,,
1982-07-27,0.0,0.8557173013687134,inf,,
1982-07-26,0.0,0.8451961874961853,inf,,
1982-07-23,0.0,0.8662384152412415,inf,,
1982-07-22,0.0,0.9048158526420592,inf,,
1982-07-21,0.0,0.890787661075592,inf,,
1982-07-20,0.0,0.90130877494812,inf,,
1982-07-19,0.0,0.8942947387695312,inf,,
1982-07-16,0.0,0.8872806429862976,inf,,
1982-07-15,0.0,0.8592243194580078,inf,,
1982-07-14,0.0,0.8487032055854797,inf,,
1982-07-13,0.0,0.8487032055854797,inf,,
1982-07-12,0.0,0.8311680555343628,inf,,
1982-07-09,0.0,0.7996047139167786,inf,,
1982-07-08,0.0,0.7996047139167786,inf,,
1982-07-07,0.0,0.7996047139167786,inf,,
1982-07-06,0.0,0.7890836000442505,inf,,
1982-07-02,0.0,0.7960976362228394,inf,,
1982-07-01,0.0,0.7960976362228394,inf,,
1982-06-30,0.0,0.803111732006073,inf,,
1982-06-29,0.0,0.8101258277893066,inf,,
1982-06-28,0.0,0.8101258277893066,inf,,
1982-06-25,0.0,0.7996047139167786,inf,,
1982-06-24,0.0,0.8171398639678955,inf,,
1982-06-23,0.0,0.8311680555343628,inf,,
1982-06-22,0.0,0.7855765223503113,inf,,
1982-06-21,0.0,0.7820695042610168,inf,,
1982-06-18,0.0,0.7785624861717224,inf,,
1982-06-17,0.0,0.7820695042610168,inf,,
1982-06-16,0.0,0.7890836000442505,inf,,
1982-06-15,0.0,0.7925906181335449,inf,,
1982-06-14,0.0,0.7855765223503113,inf,,
1982-06-11,0.0,0.803111732006073,inf,,
1982-06-10,0.0,0.8101258277893066,inf,,
1982-06-09,0.0,0.7996047139167786,inf,,
1982-06-08,0.0,0.8066187500953674,inf,,
1982-06-07,0.0,0.8066187500953674,inf,,
1982-06-04,0.0,0.8171398639678955,inf,,
1982-06-03,0.0,0.8311680555343628,inf,,
1982-06-02,0.0,0.8241539597511292,inf,,
1982-06-01,0.0,0.8101258277893066,inf,,
1982-05-28,0.0,0.8101258277893066,inf,,
1982-05-27,0.0,0.8136328458786011,inf,,
1982-05-26,0.0,0.8171398639678955,inf,,
1982-05-25,0.0,0.8276609778404236,inf,,
1982-05-24,0.0,0.8311680555343628,inf,,
1982-05-21,0.0,0.8416891694068909,inf,,
1982-05-20,0.0,0.8487032055854797,inf,,
1982-05-19,0.0,0.8557173013687134,inf,,
1982-05-18,0.0,0.8697454333305359,inf,,
1982-05-17,0.0,0.8662384152412415,inf,,
1982-05-14,0.0,0.8767595291137695,inf,,
1982-05-13,0.0,0.8837736248970032,inf,,
1982-05-12,0.0,0.8767595291137695,inf,,
1982-05-11,0.0,0.8837736248970032,inf,,
1982-05-10,0.0,0.8767595291137695,inf,,
1982-05-07,0.0,0.890787661075592,inf,,
1982-05-06,0.0,0.890787661075592,inf,,
1982-05-05,0.0,0.8837736248970032,inf,,
1982-05-04,0.0,0.880266547203064,inf,,
1982-05-03,0.0,0.862731397151947,inf,,
1982-04-30,0.0,0.8557173013687134,inf,,
1982-04-29,0.0,0.8451961874961853,inf,,
1982-04-28,0.0,0.8487032055854797,inf,,
1982-04-27,0.0,0.852210283279419,inf,,
1982-04-26,0.0,0.8732525110244751,inf,,
1982-04-23,0.0,0.8662384152412415,inf,,
1982-04-22,0.0,0.8557173013687134,inf,,
1982-04-21,0.0,0.8416891694068909,inf,,
1982-04-20,0.0,0.8487032055854797,inf,,
1982-04-19,0.0,0.8557173013687134,inf,,
1982-04-16,0.0,0.8346750736236572,inf,,
1982-04-15,0.0,0.8311680555343628,inf,,
1982-04-14,0.0,0.8241539597511292,inf,,
1982-04-13,0.0,0.8276609778404236,inf,,
1982-04-12,0.0,0.8311680555343628,inf,,
1982-04-08,0.0,0.8276609778404236,inf,,
1982-04-07,0.0,0.8276609778404236,inf,,
1982-04-06,0.0,0.8171398639678955,inf,,
1982-04-05,0.0,0.8136328458786011,inf,,
1982-04-02,0.0,0.8241539597511292,inf,,
1982-04-01,0.0,0.8101258277893066,inf,,
1982-03-31,0.0,0.8136328458786011,inf,,
1982-03-30,0.0,0.8311680555343628,inf,,
1982-03-29,0.0,0.8346750736236572,inf,,
1982-03-26,0.0,0.8206469416618347,inf,,
1982-03-25,0.0,0.8451961874961853,inf,,
1982-03-24,0.0,0.8241539597511292,inf,,
1982-03-23,0.0,0.8171398639678955,inf,,
1982-03-22,0.0,0.7855765223503113,inf,,
1982-03-19,0.0,0.7785624861717224,inf,,
1982-03-18,0.0,0.7750554084777832,inf,,
1982-03-17,0.0,0.7680413722991943,inf,,
1982-03-16,0.0,0.7680413722991943,inf,,
1982-03-15,0.0,0.7575202584266663,inf,,
1982-03-12,0.0,0.7610272765159607,inf,,
1982-03-11,0.0,0.7715483903884888,inf,,
1982-03-10,0.0,0.7645342946052551,inf,,
1982-03-09,0.0,0.7785624861717224,inf,,
1982-03-08,0.0,0.7715483903884888,inf,,
1982-03-05,0.0,0.7925906181335449,inf,,
1982-03-04,0.0,0.7925906181335449,inf,,
1982-03-03,0.0,0.8171398639678955,inf,,
1982-03-02,0.0,0.8206469416618347,inf,,
1982-03-01,0.0,0.8136328458786011,inf,,
1982-02-26,0.0,0.8066187500953674,inf,,
1982-02-25,0.0,0.8101258277893066,inf,,
1982-02-24,0.0,0.8101258277893066,inf,,
1982-02-23,0.0,0.7996047139167786,inf,,
1982-02-22,0.0,0.7996047139167786,inf,,
1982-02-19,0.0,0.8136328458786011,inf,,
1982-02-18,0.0,0.8276609778404236,inf,,
1982-02-17,0.0,0.8276609778404236,inf,,
1982-02-16,0.0,0.8311680555343628,inf,,
1982-02-12,0.0,0.8241539597511292,inf,,
1982-02-11,0.0,0.8066187500953674,inf,,
1982-02-10,0.0,0.8101258277893066,inf,,
1982-02-09,0.0,0.8171398639678955,inf,,
1982-02-08,0.0,0.8276609778404236,inf,,
1982-02-05,0.0,0.8171398639678955,inf,,
1982-02-04,0.0,0.803111732006073,inf,,
1982-02-03,0.0,0.803111732006073,inf,,
1982-02-02,0.0,0.8066187500953674,inf,,
1982-02-01,0.0,0.7785624861717224,inf,,
1982-01-29,0.0,0.8136328458786011,inf,,
1982-01-28,0.0,0.7855765223503113,inf,,
1982-01-27,0.0,0.754013180732727,inf,,
1982-01-26,0.0,0.7399850487709045,inf,,
1982-01-25,0.0,0.7329709529876709,inf,,
1982-01-22,0.0,0.7364780306816101,inf,,
1982-01-21,0.0,0.7469991445541382,inf,,
1982-01-20,0.0,0.743492066860199,inf,,
1982-01-19,0.0,0.7645342946052551,inf,,
1982-01-18,0.0,0.7645342946052551,inf,,
1982-01-15,0.0,0.7469991445541382,inf,,
1982-01-14,0.0,0.7399850487709045,inf,,
1982-01-13,0.0,0.725956916809082,inf,,
1982-01-12,0.0,0.7119287252426147,inf,,
1982-01-11,0.0,0.7364780306816101,inf,,
1982-01-08,0.0,0.7399850487709045,inf,,
1982-01-07,0.0,0.7399850487709045,inf,,
1982-01-06,0.0,0.7329709529876709,inf,,
1982-01-05,0.0,0.754013180732727,inf,,
1982-01-04,0.0,0.7575202584266663,inf,,
1981-12-31,0.0,0.7575202584266663,inf,,
1981-12-30,0.0,0.7680413722991943,inf,,
1981-12-29,0.0,0.754013180732727,inf,,
1981-12-28,0.0,0.7715483903884888,inf,,
1981-12-24,0.0,0.7820695042610168,inf,,
1981-12-23,0.0,0.7890836000442505,inf,,
1981-12-22,0.0,0.7820695042610168,inf,,
1981-12-21,0.0,0.7820695042610168,inf,,
1981-12-18,0.0,0.7855765223503113,inf,,
1981-12-17,0.0,0.7855765223503113,inf,,
1981-12-16,0.0,0.7890836000442505,inf,,
1981-12-15,0.0,0.7960976362228394,inf,,
1981-12-14,0.0,0.7925906181335449,inf,,
1981-12-11,0.0,0.803111732006073,inf,,
1981-12-10,0.0,0.7925906181335449,inf,,
1981-12-09,0.0,0.7996047139167786,inf,,
1981-12-08,0.0,0.8066187500953674,inf,,
1981-12-07,0.0,0.8066187500953674,inf,,
1981-12-04,0.0,0.8136328458786011,inf,,
1981-12-03,0.0,0.7960976362228394,inf,,
1981-12-02,0.0,0.803111732006073,inf,,
1981-12-01,0.0,0.8241539597511292,inf,,
1981-11-30,0.0,0.8311680555343628,inf,,
1981-11-27,0.0,0.8136328458786011,inf,,
1981-11-25,0.0,0.8136328458786011,inf,,
1981-11-24,0.0,0.8276609778404236,inf,,
1981-11-23,0.0,0.8276609778404236,inf,,
1981-11-20,0.0,0.803111732006073,inf,,
1981-11-19,0.0,0.8066187500953674,inf,,
1981-11-18,0.0,0.8066187500953674,inf,,
1981-11-17,0.0,0.8136328458786011,inf,,
1981-11-16,0.0,0.7750554084777832,inf,,
1981-11-13,0.0,0.7820695042610168,inf,,
1981-11-12,0.0,0.7925906181335449,inf,,
1981-11-11,0.0,0.8066187500953674,inf,,
1981-11-10,0.0,0.7996047139167786,inf,,
1981-11-09,0.0,0.8066187500953674,inf,,
1981-11-06,0.0,0.7996047139167786,inf,,
1981-11-05,0.0,0.8171398639678955,inf,,
1981-11-04,0.0,0.8066187500953674,inf,,
1981-11-03,0.0,0.8136328458786011,inf,,
1981-11-02,0.0,0.8066187500953674,inf,,
1981-10-30,0.0,0.7890836000442505,inf,,
1981-10-29,0.0,0.7750554084777832,inf,,
1981-10-28,0.0,0.743492066860199,inf,,
1981-10-27,0.0,0.7119287252426147,inf,,
1981-10-26,0.0,0.715435802936554,inf,,
1981-10-23,0.0,0.7294639348983765,inf,,
1981-10-22,0.0,0.7364780306816101,inf,,
1981-10-21,0.0,0.7364780306816101,inf,,
1981-10-20,0.0,0.7505061626434326,inf,,
1981-10-19,0.0,0.7469991445541382,inf,,
1981-10-16,0.0,0.754013180732727,inf,,
1981-10-15,0.0,0.7645342946052551,inf,,
1981-10-14,0.0,0.7610272765159607,inf,,
1981-10-13,0.0,0.7820695042610168,inf,,
1981-10-12,0.0,0.7855765223503113,inf,,
1981-10-09,0.0,0.7645342946052551,inf,,
1981-10-08,0.0,0.7890836000442505,inf,,
1981-10-07,0.0,0.7715483903884888,inf,,
1981-10-06,0.0,0.7610272765159607,inf,,
1981-10-05,0.0,0.7715483903884888,inf,,
1981-10-02,0.0,0.7785624861717224,inf,,
1981-10-01,0.0,0.7364780306816101,inf,,
1981-09-30,0.0,0.7294639348983765,inf,,
1981-09-29,0.0,0.7224498391151428,inf,,
1981-09-28,0.0,0.7014076113700867,inf,,
1981-09-25,0.0,0.6803653836250305,inf,,
1981-09-24,0.0,0.6838724613189697,inf,,
1981-09-23,0.0,0.7014076113700867,inf,,
1981-09-22,0.0,0.7119287252426147,inf,,
1981-09-21,0.0,0.7189428210258484,inf,,
1981-09-18,0.0,0.7119287252426147,inf,,
1981-09-17,0.0,0.7119287252426147,inf,,
1981-09-16,0.0,0.7189428210258484,inf,,
1981-09-15,0.0,0.715435802936554,inf,,
1981-09-14,0.0,0.7084217071533203,inf,,
1981-09-11,0.0,0.7119287252426147,inf,,
1981-09-10,0.0,0.7014076113700867,inf,,
1981-09-09,0.0,0.6838724613189697,inf,,
1981-09-08,0.0,0.6733513474464417,inf,,
1981-09-04,0.0,0.6733513474464417,inf,,
1981-09-03,0.0,0.6873794794082642,inf,,
1981-09-02,0.0,0.7119287252426147,inf,,
1981-09-01,0.0,0.7294639348983765,inf,,
1981-08-31,0.0,0.7329709529876709,inf,,
1981-08-28,0.0,0.743492066860199,inf,,
1981-08-27,0.0,0.7399850487709045,inf,,
1981-08-26,0.0,0.7364780306816101,inf,,
1981-08-25,0.0,0.754013180732727,inf,,
1981-08-24,0.0,0.7680413722991943,inf,,
1981-08-21,0.0,0.7575202584266663,inf,,
1981-08-20,0.0,0.754013180732727,inf,,
1981-08-19,0.0,0.7575202584266663,inf,,
1981-08-18,0.0,0.7329709529876709,inf,,
1981-08-17,0.0,0.7294639348983765,inf,,
1981-08-14,0.0,0.7750554084777832,inf,,
1981-08-13,0.0,0.7925906181335449,inf,,
1981-08-12,0.0,0.7925906181335449,inf,,
1981-08-11,0.0,0.7996047139167786,inf,,
1981-08-10,0.0,0.7960976362228394,inf,,
1981-08-07,0.0,0.7890836000442505,inf,,
1981-08-06,0.0,0.7855765223503113,inf,,
1981-08-05,0.0,0.7785624861717224,inf,,
1981-08-04,0.0,0.7750554084777832,inf,,
1981-08-03,0.0,0.7645342946052551,inf,,
1981-07-31,0.0,0.7785624861717224,inf,,
1981-07-30,0.0,0.7645342946052551,inf,,
1981-07-29,0.0,0.7575202584266663,inf,,
1981-07-28,0.0,0.7645342946052551,inf,,
1981-07-27,0.0,0.7680413722991943,inf,,
1981-07-24,0.0,0.7364780306816101,inf,,
1981-07-23,0.0,0.7399850487709045,inf,,
1981-07-22,0.0,0.7715483903884888,inf,,
1981-07-21,0.0,0.7890836000442505,inf,,
1981-07-20,0.0,0.8136328458786011,inf,,
1981-07-17,0.0,0.8136328458786011,inf,,
1981-07-16,0.0,0.8066187500953674,inf,,
1981-07-15,0.0,0.8171398639678955,inf,,
1981-07-14,0.0,0.7960976362228394,inf,,
1981-07-13,0.0,0.7820695042610168,inf,,
1981-07-10,0.0,0.7960976362228394,inf,,
1981-07-09,0.0,0.7960976362228394,inf,,
1981-07-08,0.0,0.7925906181335449,inf,,
1981-07-07,0.0,0.8101258277893066,inf,,
1981-07-06,0.0,0.8101258277893066,inf,,
1981-07-02,0.0,0.8346750736236572,inf,,
1981-07-01,0.0,0.8592243194580078,inf,,
1981-06-30,0.0,0.8837736248970032,inf,,
1981-06-29,0.0,0.880266547203064,inf,,
1981-06-26,0.0,0.8872806429862976,inf,,
1981-06-25,0.0,0.8837736248970032,inf,,
1981-06-24,0.0,0.880266547203064,inf,,
1981-06-23,0.0,0.8697454333305359,inf,,
1981-06-22,0.0,0.862731397151947,inf,,
1981-06-19,0.0,0.862731397151947,inf,,
1981-06-18,0.0,0.8837736248970032,inf,,
1981-06-17,0.0,0.8767595291137695,inf,,
1981-06-16,0.0,0.8451961874961853,inf,,
1981-06-15,0.0,0.8381820917129517,inf,,
1981-06-12,0.0,0.862731397151947,inf,,
1981-06-11,0.0,0.8557173013687134,inf,,
1981-06-10,0.0,0.8311680555343628,inf,,
1981-06-09,0.0,0.8136328458786011,inf,,
1981-06-08,0.0,0.8066187500953674,inf,,
1981-06-05,0.0,0.7855765223503113,inf,,
1981-06-04,0.0,0.7820695042610168,inf,,
1981-06-03,0.0,0.7785624861717224,inf,,
1981-06-02,0.0,0.7890836000442505,inf,,
1981-06-01,0.0,0.7925906181335449,inf,,
1981-05-29,0.0,0.7820695042610168,inf,,
1981-05-28,0.0,0.7838230133056641,inf,,
1981-05-27,0.0,0.7890836000442505,inf,,
1981-05-26,0.0,0.7908371090888977,inf,,
1981-05-22,0.0,0.7908371090888977,inf,,
1981-05-21,0.0,0.7908371090888977,inf,,
1981-05-20,0.0,0.7855765223503113,inf,,
1981-05-19,0.0,0.7943441271781921,inf,,
1981-05-18,0.0,0.803111732006073,inf,,
1981-05-15,0.0,0.7908371090888977,inf,,
1981-05-14,0.0,0.7855765223503113,inf,,
1981-05-13,0.0,0.7838230133056641,inf,,
1981-05-12,0.0,0.7803159952163696,inf,,
1981-05-11,0.0,0.7855765223503113,inf,,
1981-05-08,0.0,0.7996047139167786,inf,,
1981-05-07,0.0,0.7960976362228394,inf,,
1981-05-06,0.0,0.7855765223503113,inf,,
1981-05-05,0.0,0.7908371090888977,inf,,
1981-05-04,0.0,0.803111732006073,inf,,
1981-05-01,0.0,0.803111732006073,inf,,
1981-04-30,0.0,0.8101258277893066,inf,,
1981-04-29,0.0,0.8171398639678955,inf,,
1981-04-28,0.0,0.8206469416618347,inf,,
1981-04-27,0.0,0.8276609778404236,inf,,
1981-04-24,0.0,0.8276609778404236,inf,,
1981-04-23,0.0,0.8276609778404236,inf,,
1981-04-22,0.0,0.8259074687957764,inf,,
1981-04-21,0.0,0.8259074687957764,inf,,
1981-04-20,0.0,0.8276609778404236,inf,,
1981-04-16,0.0,0.8346750736236572,inf,,
1981-04-15,0.0,0.8346750736236572,inf,,
1981-04-14,0.0,0.8346750736236572,inf,,
1981-04-13,0.0,0.83292156457901,inf,,
1981-04-10,0.0,0.8381820917129517,inf,,
1981-04-09,0.0,0.83292156457901,inf,,
1981-04-08,0.0,0.8101258277893066,inf,,
1981-04-07,0.0,0.8101258277893066,inf,,
1981-04-06,0.0,0.8171398639678955,inf,,
1981-04-03,0.0,0.8276609778404236,inf,,
1981-04-02,0.0,0.8381820917129517,inf,,
1981-04-01,0.0,0.8416891694068909,inf,,
1981-03-31,0.0,0.8416891694068909,inf,,
1981-03-30,0.0,0.8381820917129517,inf,,
1981-03-27,0.0,0.8259074687957764,inf,,
1981-03-26,0.0,0.8276609778404236,inf,,
1981-03-25,0.0,0.8416891694068909,inf,,
1981-03-24,0.0,0.8364285826683044,inf,,
1981-03-23,0.0,0.852210283279419,inf,,
1981-03-20,0.0,0.8399356603622437,inf,,
1981-03-19,0.0,0.8259074687957764,inf,,
1981-03-18,0.0,0.8311680555343628,inf,,
1981-03-17,0.0,0.8276609778404236,inf,,
1981-03-16,0.0,0.8381820917129517,inf,,
1981-03-13,0.0,0.8416891694068909,inf,,
1981-03-12,0.0,0.8364285826683044,inf,,
1981-03-11,0.0,0.8224004507064819,inf,,
1981-03-10,0.0,0.8241539597511292,inf,,
1981-03-09,0.0,0.8224004507064819,inf,,
1981-03-06,0.0,0.8206469416618347,inf,,
1981-03-05,0.0,0.8171398639678955,inf,,
1981-03-04,0.0,0.8346750736236572,inf,,
1981-03-03,0.0,0.8346750736236572,inf,,
1981-03-02,0.0,0.8539637923240662,inf,,
1981-02-27,0.0,0.8399356603622437,inf,,
1981-02-26,0.0,0.8346750736236572,inf,,
1981-02-25,0.0,0.8066187500953674,inf,,
1981-02-24,0.0,0.8101258277893066,inf,,
1981-02-23,0.0,0.8066187500953674,inf,,
1981-02-20,0.0,0.8206469416618347,inf,,
1981-02-19,0.0,0.8171398639678955,inf,,
1981-02-18,0.0,0.8276609778404236,inf,,
1981-02-17,0.0,0.8083722591400146,inf,,
1981-02-13,0.0,0.8048652410507202,inf,,
1981-02-12,0.0,0.8013582229614258,inf,,
1981-02-11,0.0,0.8118793368339539,inf,,
1981-02-10,0.0,0.8101258277893066,inf,,
1981-02-09,0.0,0.8048652410507202,inf,,
1981-02-06,0.0,0.8048652410507202,inf,,
1981-02-05,0.0,0.7925906181335449,inf,,
1981-02-04,0.0,0.773301899433136,inf,,
1981-02-03,0.0,0.7820695042610168,inf,,
1981-02-02,0.0,0.7662878036499023,inf,,
1981-01-30,0.0,0.7715483903884888,inf,,
1981-01-29,0.0,0.7715483903884888,inf,,
1981-01-28,0.0,0.7645342946052551,inf,,
1981-01-27,0.0,0.7645342946052551,inf,,
1981-01-26,0.0,0.7610272765159607,inf,,
1981-01-23,0.0,0.7592737674713135,inf,,
1981-01-22,0.0,0.7697948813438416,inf,,
1981-01-21,0.0,0.7908371090888977,inf,,
1981-01-20,0.0,0.7820695042610168,inf,,
1981-01-19,0.0,0.7978511452674866,inf,,
1981-01-16,0.0,0.7908371090888977,inf,,
1981-01-15,0.0,0.7820695042610168,inf,,
1981-01-14,0.0,0.7978511452674866,inf,,
1981-01-13,0.0,0.803111732006073,inf,,
1981-01-12,0.0,0.8136328458786011,inf,,
1981-01-09,0.0,0.8276609778404236,inf,,
1981-01-08,0.0,0.8381820917129517,inf,,
1981-01-07,0.0,0.83292156457901,inf,,
1981-01-06,0.0,0.8259074687957764,inf,,
1981-01-05,0.0,0.8013582229614258,inf,,
1981-01-02,0.0,0.7978511452674866,inf,,
1980-12-31,0.0,0.7925906181335449,inf,,
1980-12-30,0.0,0.7680413722991943,inf,,
1980-12-29,0.0,0.7715483903884888,inf,,
1980-12-26,0.0,0.7575202584266663,inf,,
1980-12-24,0.0,0.754013180732727,inf,,
1980-12-23,0.0,0.7557666897773743,inf,,
1980-12-22,0.0,0.7277104258537292,inf,,
1980-12-19,0.0,0.7049146890640259,inf,,
1980-12-18,0.0,0.7049146890640259,inf,,
1980-12-17,0.0,0.7084217071533203,inf,,
1980-12-16,0.0,0.7101752161979675,inf,,
1980-12-15,0.0,0.7119287252426147,inf,,
1980-12-12,0.0,0.696147084236145,inf,,
1980-12-11,0.0,0.6856259703636169,inf,,
1980-12-10,0.0,0.6908864974975586,inf,,
1980-12-09,0.0,0.7189428210258484,inf,,
1980-12-08,0.0,0.7224498391151428,inf,,
1980-12-05,0.0,0.743492066860199,inf,,
1980-12-04,0.0,0.754013180732727,inf,,
1980-12-03,0.0,0.7347244620323181,inf,,
1980-12-02,0.0,0.7294639348983765,inf,,
1980-12-01,0.0,0.7312174439430237,inf,,
1980-11-28,0.0,0.7505061626434326,inf,,
1980-11-26,0.0,0.7505061626434326,inf,,
1980-11-25,0.0,0.7522596716880798,inf,,
1980-11-24,0.0,0.715435802936554,inf,,
1980-11-21,0.0,0.7119287252426147,inf,,
1980-11-20,0.0,0.715435802936554,inf,,
1980-11-19,0.0,0.7189428210258484,inf,,
1980-11-18,0.0,0.7171893119812012,inf,,
1980-11-17,0.0,0.715435802936554,inf,,
1980-11-14,0.0,0.7084217071533203,inf,,
1980-11-13,0.0,0.7014076113700867,inf,,
1980-11-12,0.0,0.6891329884529114,inf,,
1980-11-11,0.0,0.6733513474464417,inf,,
1980-11-10,0.0,0.6733513474464417,inf,,
1980-11-07,0.0,0.6751048564910889,inf,,
1980-11-06,0.0,0.6926400065422058,inf,,
1980-11-05,0.0,0.7066681981086731,inf,,
1980-11-03,0.0,0.6979005932807922,inf,,
1980-10-31,0.0,0.6979005932807922,inf,,
1980-10-30,0.0,0.6680907607078552,inf,,
1980-10-29,0.0,0.696147084236145,inf,,
1980-10-28,0.0,0.6926400065422058,inf,,
1980-10-27,0.0,0.6943935751914978,inf,,
1980-10-24,0.0,0.715435802936554,inf,,
1980-10-23,0.0,0.713682234287262,inf,,
1980-10-22,0.0,0.715435802936554,inf,,
1980-10-21,0.0,0.7049146890640259,inf,,
1980-10-20,0.0,0.7189428210258484,inf,,
1980-10-17,0.0,0.715435802936554,inf,,
1980-10-16,0.0,0.7084217071533203,inf,,
1980-10-15,0.0,0.7294639348983765,inf,,
1980-10-14,0.0,0.7329709529876709,inf,,
1980-10-13,0.0,0.7399850487709045,inf,,
1980-10-10,0.0,0.7364780306816101,inf,,
1980-10-09,0.0,0.7505061626434326,inf,,
1980-10-08,0.0,0.7592737674713135,inf,,
1980-10-07,0.0,0.754013180732727,inf,,
1980-10-06,0.0,0.7452455759048462,inf,,
1980-10-03,0.0,0.743492066860199,inf,,
1980-10-02,0.0,0.7364780306816101,inf,,
1980-10-01,0.0,0.7294639348983765,inf,,
1980-09-30,0.0,0.7224498391151428,inf,,
1980-09-29,0.0,0.7189428210258484,inf,,
1980-09-26,0.0,0.7294639348983765,inf,,
1980-09-25,0.0,0.7329709529876709,inf,,
1980-09-24,0.0,0.743492066860199,inf,,
1980-09-23,0.0,0.7487526535987854,inf,,
1980-09-22,0.0,0.7715483903884888,inf,,
1980-09-19,0.0,0.7680413722991943,inf,,
1980-09-18,0.0,0.7557666897773743,inf,,
1980-09-17,0.0,0.7505061626434326,inf,,
1980-09-16,0.0,0.7171893119812012,inf,,
1980-09-15,0.0,0.6926400065422058,inf,,
1980-09-12,0.0,0.696147084236145,inf,,
1980-09-11,0.0,0.7014076113700867,inf,,
1980-09-10,0.0,0.7014076113700867,inf,,
1980-09-09,0.0,0.6926400065422058,inf,,
1980-09-08,0.0,0.6856259703636169,inf,,
1980-09-05,0.0,0.6856259703636169,inf,,
1980-09-04,0.0,0.6908864974975586,inf,,
1980-09-03,0.0,0.6979005932807922,inf,,
1980-09-02,0.0,0.6751048564910889,inf,,
1980-08-29,0.0,0.6715977787971497,inf,,
1980-08-28,0.0,0.6803653836250305,inf,,
1980-08-27,0.0,0.6873794794082642,inf,,
1980-08-26,0.0,0.7014076113700867,inf,,
1980-08-25,0.0,0.6943935751914978,inf,,
1980-08-22,0.0,0.7014076113700867,inf,,
1980-08-21,0.0,0.6733513474464417,inf,,
1980-08-20,0.0,0.6733513474464417,inf,,
1980-08-19,0.0,0.6751048564910889,inf,,
1980-08-18,0.0,0.6786118745803833,inf,,
1980-08-15,0.0,0.6891329884529114,inf,,
1980-08-14,0.0,0.6891329884529114,inf,,
1980-08-13,0.0,0.6943935751914978,inf,,
1980-08-12,0.0,0.7031611204147339,inf,,
1980-08-11,0.0,0.6996541023254395,inf,,
1980-08-08,0.0,0.6891329884529114,inf,,
1980-08-07,0.0,0.6908864974975586,inf,,
1980-08-06,0.0,0.6803653836250305,inf,,
1980-08-05,0.0,0.6803653836250305,inf,,
1980-08-04,0.0,0.6786118745803833,inf,,
1980-08-01,0.0,0.6768583655357361,inf,,
1980-07-31,0.0,0.6751048564910889,inf,,
1980-07-30,0.0,0.6751048564910889,inf,,
1980-07-29,0.0,0.6558161377906799,inf,,
1980-07-28,0.0,0.6400344371795654,inf,,
1980-07-25,0.0,0.6382809281349182,inf,,
1980-07-24,0.0,0.6400344371795654,inf,,
1980-07-23,0.0,0.6347739100456238,inf,,
1980-07-22,0.0,0.6400344371795654,inf,,
1980-07-21,0.0,0.6277598142623901,inf,,
1980-07-18,0.0,0.606717586517334,inf,,
1980-07-17,0.0,0.6032105684280396,inf,,
1980-07-16,0.0,0.5961964726448059,inf,,
1980-07-15,0.0,0.5979499816894531,inf,,
1980-07-14,0.0,0.5944429636001587,inf,,
1980-07-11,0.0,0.5926894545555115,inf,,
1980-07-10,0.0,0.5961964726448059,inf,,
1980-07-09,0.0,0.6032105684280396,inf,,
1980-07-08,0.0,0.6119781732559204,inf,,
1980-07-07,0.0,0.6172387003898621,inf,,
1980-07-03,0.0,0.6172387003898621,inf,,
1980-07-02,0.0,0.6189922094345093,inf,,
1980-07-01,0.0,0.5979499816894531,inf,,
1980-06-30,0.0,0.5909359455108643,inf,,
1980-06-27,0.0,0.6119781732559204,inf,,
1980-06-26,0.0,0.6207457184791565,inf,,
1980-06-25,0.0,0.6295133233070374,inf,,
1980-06-24,0.0,0.6260063052177429,inf,,
1980-06-23,0.0,0.6154851913452148,inf,,
1980-06-20,0.0,0.6242527961730957,inf,,
1980-06-19,0.0,0.6312668919563293,inf,,
1980-06-18,0.0,0.6330204010009766,inf,,
1980-06-17,0.0,0.6347739100456238,inf,,
1980-06-16,0.0,0.6260063052177429,inf,,
1980-06-13,0.0,0.6312668919563293,inf,,
1980-06-12,0.0,0.6312668919563293,inf,,
1980-06-11,0.0,0.6435415148735046,inf,,
1980-06-10,0.0,0.6242527961730957,inf,,
1980-06-09,0.0,0.606717586517334,inf,,
1980-06-06,0.0,0.606717586517334,inf,,
1980-06-05,0.0,0.5961964726448059,inf,,
1980-06-04,0.0,0.6014570593833923,inf,,
1980-06-03,0.0,0.5979499816894531,inf,,
1980-06-02,0.0,0.5944429636001587,inf,,
1980-05-30,0.0,0.5979499816894531,inf,,
1980-05-29,0.0,0.5997034907341003,inf,,
1980-05-28,0.0,0.6032105684280396,inf,,
1980-05-27,0.0,0.5961964726448059,inf,,
1980-05-23,0.0,0.5944429636001587,inf,,
1980-05-22,0.0,0.5751542448997498,inf,,
1980-05-21,0.0,0.5681401491165161,inf,,
1980-05-20,0.0,0.5663866400718689,inf,,
1980-05-19,0.0,0.5663866400718689,inf,,
1980-05-16,0.0,0.5698937177658081,inf,,
1980-05-15,0.0,0.5751542448997498,inf,,
1980-05-14,0.0,0.5663866400718689,inf,,
1980-05-13,0.0,0.5611261129379272,inf,,
1980-05-12,0.0,0.5663866400718689,inf,,
1980-05-09,0.0,0.5646331310272217,inf,,
1980-05-08,0.0,0.5611261129379272,inf,,
1980-05-07,0.0,0.5734007358551025,inf,,
1980-05-06,0.0,0.5716472268104553,inf,,
1980-05-05,0.0,0.5663866400718689,inf,,
1980-05-02,0.0,0.5681401491165161,inf,,
1980-05-01,0.0,0.5663866400718689,inf,,
1980-04-30,0.0,0.5628796219825745,inf,,
1980-04-29,0.0,0.557619035243988,inf,,
1980-04-28,0.0,0.5558655261993408,inf,,
1980-04-25,0.0,0.5506049990653992,inf,,
1980-04-24,0.0,0.557619035243988,inf,,
1980-04-23,0.0,0.5506049990653992,inf,,
1980-04-22,0.0,0.5541120171546936,inf,,
1980-04-21,0.0,0.5365768074989319,inf,,
1980-04-18,0.0,0.5278092622756958,inf,,
1980-04-17,0.0,0.5313162803649902,inf,,
1980-04-16,0.0,0.5365768074989319,inf,,
1980-04-15,0.0,0.5453444123268127,inf,,
1980-04-14,0.0,0.5400838851928711,inf,,
1980-04-11,0.0,0.5541120171546936,inf,,
1980-04-10,0.0,0.54709792137146,inf,,
1980-04-09,0.0,0.5243021845817566,inf,,
1980-04-08,0.0,0.5172881484031677,inf,,
1980-04-07,0.0,0.5190416574478149,inf,,
1980-04-03,0.0,0.5190416574478149,inf,,
1980-04-02,0.0,0.5190416574478149,inf,,
1980-04-01,0.0,0.5155345797538757,inf,,
1980-03-31,0.0,0.5137810707092285,inf,,
1980-03-28,0.0,0.5067670345306396,inf,,
1980-03-27,0.0,0.4909853339195251,inf,,
1980-03-26,0.0,0.4874782860279083,inf,,
1980-03-25,0.0,0.4874782860279083,inf,,
1980-03-24,0.0,0.4892318248748779,inf,,
1980-03-21,0.0,0.5050134658813477,inf,,
1980-03-20,0.0,0.499752938747406,inf,,
1980-03-19,0.0,0.5120275616645813,inf,,
1980-03-18,0.0,0.5050134658813477,inf,,
1980-03-17,0.0,0.5015064477920532,inf,,